PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	SIEGAL, G; TURCHI, JJ; JESSEE, CB; MALLABER, LM; BAMBARA, RA; MYERS, TW				SIEGAL, G; TURCHI, JJ; JESSEE, CB; MALLABER, LM; BAMBARA, RA; MYERS, TW			STRUCTURAL RELATIONSHIPS BETWEEN 2 FORMS OF DNA POLYMERASE-EPSILON FROM CALF THYMUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; DELTA; ALPHA; PURIFICATION; SUBUNIT; IDENTIFICATION; INHIBITOR; PROTEINS; ENZYMES	We previously reported purification of two forms of DNA polymerase-epsilon from calf thymus (Crute, J. J., Wahl, A. F., and Bambara, R. A. (1986) Biochemistry 25, 26-36). We have now used the "polymerase trap" photolabeling method to identify the polypeptides containing the polymerase active site in each enzyme preparation. The molecular mass of these polypeptides are 210 and 145 kDa for the polymerases now designated-epsilon and epsilon*, respectively. Renaturation of polymerase activity from denaturing gel electrophoresis corroborates the polymerase trap results. Photolabeling of polymerase fractions suggests that the smaller subunit is derived by proteolysis of the larger subunit during purification. Native sedimentation coefficient measurements of polymerase-containing column fractions further suggest a precursor/product relationship between the two polymerases. Response of polymerization activity to a battery of inhibitors normally used to distinguish mammalian nuclear DNA polymerases was found to be essentially identical for polymerases epsilon, epsilon*, and the epsilon*-generated in fractions initially containing epsilon. These latter results demonstrate that the loss of the protease-sensitive domain of the active site subunit does not affect catalytic function as measured in a standard DNA polymerase assay. The sole apparent functional difference observed here between the epsilon and epsilon* forms is evidence that only the full-length epsilon-form can be directly photocrosslinked to dATP, independent of DNA synthesis. Photolabeling of the post-microsomal supernatant fraction from thymus glands obtained from fetal calves reveals the presence of both the epsilon and epsilon*-polypeptide.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, CTR CANC, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester			Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992; Siegal, Gregg/0000-0003-3806-4811	NCI NIH HHS [CA 46148, T32-CA09363] Funding Source: Medline; NIGMS NIH HHS [GM 24441] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009363, R01CA046148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; BUDD M, 1987, P NATL ACAD SCI USA, V84, P2838, DOI 10.1073/pnas.84.9.2838; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; CRUTE JJ, 1986, BIOCHEMISTRY-US, V25, P26, DOI 10.1021/bi00349a005; FOCHER F, 1989, NUCLEIC ACIDS RES, V17, P1805, DOI 10.1093/nar/17.5.1805; FOCHER F, 1988, NUCLEIC ACIDS RES, V16, P6279, DOI 10.1093/nar/16.14.6279; FRY M, 1986, ANIMAL CELL DNA POLY; GOULIAN M, 1990, J BIOL CHEM, V265, P16402; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HAMATAKE RK, 1990, J BIOL CHEM, V265, P4072; HSI KL, 1990, NUCLEIC ACIDS RES, V18, P6231, DOI 10.1093/nar/18.21.6231; INSDORF NF, 1989, J BIOL CHEM, V264, P21491; KESTI T, 1991, J BIOL CHEM, V266, P6336; KHAN NN, 1984, NUCLEIC ACIDS RES, V12, P3695, DOI 10.1093/nar/12.8.3695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee M Y, 1981, Prog Nucleic Acid Res Mol Biol, V26, P83; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; MARCH SC, 1974, ANAL BIOCHEM, V60, P149, DOI 10.1016/0003-2697(74)90139-0; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MYERS TW, 1990, UCLA SYM BI, V133, P165; NISHIDA C, 1988, J BIOL CHEM, V263, P501; SABATINO RD, 1988, BIOCHEMISTRY-US, V27, P2998, DOI 10.1021/bi00408a050; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TALANIAN RV, 1989, BIOCHEMISTRY-US, V28, P8270, DOI 10.1021/bi00447a002; TAN CK, 1986, J BIOL CHEM, V261, P2310; VANDERZEIJST B, 1976, HDB BIOCH MOL BIOL P, P426; WAHL AF, 1984, BIOCHEMISTRY-US, V23, P1895, DOI 10.1021/bi00304a001; WAHL AF, 1986, BIOCHEMISTRY-US, V25, P7821, DOI 10.1021/bi00372a006	30	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3991	3999						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740447				2022-12-25	WOS:A1992HE60700068
J	TARENTINO, AL; QUINONES, G; SCHRADER, WP; CHANGCHIEN, LM; PLUMMER, TH				TARENTINO, AL; QUINONES, G; SCHRADER, WP; CHANGCHIEN, LM; PLUMMER, TH			MULTIPLE ENDOGLYCOSIDASE-(ENDO)-F ACTIVITIES EXPRESSED BY FLAVOBACTERIUM-MENINGOSEPTICUM - ENDO-F1 - MOLECULAR-CLONING, PRIMARY SEQUENCE, AND STRUCTURAL RELATIONSHIP TO ENDO-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; PEPTIDE-N-4-(N-ACETYL-BETA-D-GLUCOSAMINYL)ASPARAGINE AMIDASE; SECRETION	A full-length insert for the endo-beta-N-acetylglucosaminidase (Endo) F1 gene was located on a 2,200-base pair EcoRI fragment of genomic DNA and cloned into the plasmid vector Bluescript. Transformed Escherichia coli cells expressed Endo F1 activity very well, but the enzyme apparently was not processed and secreted into the medium as it normally is in Flavobacterium meningosepticum. DNA sequencing revealed an open reading frame of 1,017 nucleotides encoding a putative 50-amino acid signal sequence, and a mature protein (31,667 Da) of 289 amino acids. The deduced amino acid sequence was verified by direct Edman microsequencing of 88% of the purified protein as tryptic and V8 protease peptides. Alignment of Endo F1 (289 amino acids) with the established amino acid sequence of Streptomyces plicatus Endo H (271 amino acids) revealed a 32% structural identity over the entire sequence and a high degree of conservative replacements. Potential catalytic domains identified in other proteins that hydrolyze the beta-1, 4 glycosidic linkage between N-acetylglucosamine residues are also conserved for amino acid identity and relative spacing in Endo F1.			TARENTINO, AL (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DIV CLIN SCI,ALBANY,NY 12201, USA.				PHS HHS [30471] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAHMSEN L, 1985, EMBO J, V4, P3901, DOI 10.1002/j.1460-2075.1985.tb04164.x; BARSOMIAN GD, 1990, J BIOL CHEM, V265, P6967; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; SCHMITZ GG, 1991, ANAL BIOCHEM, V192, P222, DOI 10.1016/0003-2697(91)90212-C; TARENTINO AL, 1990, J BIOL CHEM, V265, P6961; TARENTINO AL, 1987, METHOD ENZYMOL, V138, P770; TRIMBLE RB, 1991, J BIOL CHEM, V266, P1646; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; YOUNG PM, 1990, J CHROMATOGR, V512, P273, DOI 10.1016/S0021-9673(01)89494-2	12	59	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3868	3872						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740434				2022-12-25	WOS:A1992HE60700051
J	WRIGHT, BE; BUTLER, MH; ALBE, KR				WRIGHT, BE; BUTLER, MH; ALBE, KR			SYSTEMS-ANALYSIS OF THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM .1. THE BASIS FOR MODEL CONSTRUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; 2 CELL-TYPES; CARBOHYDRATE-METABOLISM; PURIFICATION; GLUCOSE; DIFFERENTIATION; TREHALOSE; ENZYME	A steady-state model of the tricarboxylic acid cycle was constructed using a dynamic systems analysis computer program, METASIM. The model was based on radioactive tracer analyses which provided flux relationships and compartmented metabolite concentrations. Ten of the enzymes modeled were purified and characterized from Dictyostelium discoideum. Although experimentally determined enzyme mechanisms and constants were used in the model, V(max) values were found to be unreliable, i.e. they did not reflect enzyme activity in vivo. This value was therefore calculated as the only unknown in each enzyme kinetic equation and called V(vivo), to distinguish it from V(max) determined in vitro.			WRIGHT, BE (corresponding author), UNIV MONTANA, DIV BIOL SCI, MISSOULA, MT 59812 USA.				NATIONAL INSTITUTE ON AGING [R01AG003884] Funding Source: NIH RePORTER; NIA NIH HHS [AG03884] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ackrell B A, 1978, Methods Enzymol, V53, P466; ALBE KR, 1990, J THEOR BIOL, V143, P163, DOI 10.1016/S0022-5193(05)80266-8; BLOCH W, 1971, J BIOL CHEM, V246, P780; BUTLER MH, 1989, EXP MYCOL, V13, P294, DOI 10.1016/0147-5975(89)90051-0; BUTLER MH, 1985, CURR TOP CELL REGUL, V26, P337; BUTLER MH, 1989, BIOCHIM BIOPHYS ACTA, V991, P337, DOI 10.1016/0304-4165(89)90125-6; CHIEW YY, 1985, J BIOL CHEM, V260, P5325; DIMOND RL, 1976, J BIOL CHEM, V251, P2680; DIMOND RL, 1976, DEV BIOL, V50, P169, DOI 10.1016/0012-1606(76)90075-0; EMYANITOFF RG, 1982, J GEN MICROBIOL, V128, P1767; EMYANITOFF RG, 1979, J BACTERIOL, V140, P1008, DOI 10.1128/JB.140.3.1008-1012.1979; EMYANITOFF RG, 1982, EXP MYCOL, V6, P274, DOI 10.1016/0147-5975(82)90120-7; GEZELIUS K, 1965, J GEN MICROBIOL, V38, P309, DOI 10.1099/00221287-38-3-309; GUSTAFSON GL, 1972, CRIT REV MICROBIOL, V1, P453; HECKERT LL, 1989, J GEN MICROBIOL, V135, P155; KELLEHER JK, 1979, J BACTERIOL, V138, P467, DOI 10.1128/JB.138.2.467-474.1979; KELLY PJ, 1979, BIOCHEM J, V184, P589, DOI 10.1042/bj1840589; KELLY PJ, 1979, BIOCHEM J, V184, P581, DOI 10.1042/bj1840581; KOMUNIECKI P R, 1979, Abstracts of the Annual Meeting of the American Society for Microbiology, P103; KOMUNIECKI R, 1979, BIOCHIM BIOPHYS ACTA, V571, P1, DOI 10.1016/0005-2744(79)90219-5; LANDRIDGE WHR, 1977, ARCH BIOCHEM BIOPHYS, V178, P581; MARSHALL R, 1970, BIOCHEMISTRY-US, V9, P3087, DOI 10.1021/bi00817a023; OWEN TG, 1974, BIOCHEM J, V143, P541, DOI 10.1042/bj1430541; PALMER TN, 1983, TRENDS BIOCHEM SCI, V8, P161, DOI 10.1016/0968-0004(83)90162-7; PANNBACK.RG, 1967, BIOCHEMISTRY-US, V6, P1287, DOI 10.1021/bi00857a009; PARK D J M, 1973, Computer Programs in Biomedicine, V3, P10, DOI 10.1016/0010-468X(73)90010-X; PORTER JS, 1977, ARCH BIOCHEM BIOPHYS, V181, P155, DOI 10.1016/0003-9861(77)90493-3; RANDALL DD, 1977, BIOCHIM BIOPHYS ACTA, V485, P336, DOI 10.1016/0005-2744(77)90169-3; RAVAL DN, 1962, BIOCHEMISTRY-US, V1, P263, DOI 10.1021/bi00908a012; SARGENT D, 1971, J BIOL CHEM, V246, P5340; SHERWOOD P, 1979, COMPUT PROG BIOMED, V10, P66, DOI 10.1016/0010-468X(79)90053-9; SRERE PA, 1967, SCIENCE, V158, P936, DOI 10.1126/science.158.3803.936; THOMAS E, 1969, ENZYME HDB; WALSH J, 1978, J GEN MICROBIOL, V108, P57, DOI 10.1099/00221287-108-1-57; WILSON JB, 1978, J CELL PHYSIOL, V94, P37, DOI 10.1002/jcp.1040940106; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0; Wright B.E., 1987, Basic Life Sciences, V42, P111; WRIGHT BE, 1960, P NATL ACAD SCI USA, V46, P798, DOI 10.1073/pnas.46.6.798; WRIGHT BE, 1967, BIOCHEMISTRY-US, V6, P2074, DOI 10.1021/bi00859a026; WRIGHT BE, 1981, CURR TOP CELL REGUL, V19, P103; WRIGHT BE, 1968, J CELL PHYSIOL, V72, P145, DOI 10.1002/jcp.1040720411; WRIGHT BE, 1982, J BIOL CHEM, V257, P7587; WRIGHT BE, 1971, J BIOL CHEM, V246, P5335; WRIGHT BE, 1964, BIOCHIM BIOPHYS ACTA, V90, P423, DOI 10.1016/0304-4165(64)90214-4; WRIGHT BE, 1984, J THEOR BIOL, V110, P445, DOI 10.1016/S0022-5193(84)80186-1; WRIGHT BE, 1975, J BIOL CHEM, V250, P2219; WRIGHT BE, 1968, J BACTERIOL, V95, P983, DOI 10.1128/JB.95.3.983-985.1968; WRIGHT BE, 1977, EUR J BIOCHEM, V74, P217, DOI 10.1111/j.1432-1033.1977.tb11384.x; WRIGHT BE, 1979, ARCH BIOCHEM BIOPHYS, V192, P489, DOI 10.1016/0003-9861(79)90119-X; WRIGHT BE, 1988, J BIOL CHEM, V263, P14906	50	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3101	3105						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737766				2022-12-25	WOS:A1992HD15400045
J	ANDROLEWICZ, MJ; BROWNING, JL; WARE, CF				ANDROLEWICZ, MJ; BROWNING, JL; WARE, CF			LYMPHOTOXIN IS EXPRESSED AS A HETEROMERIC COMPLEX WITH A DISTINCT 33-KDA GLYCOPROTEIN ON THE SURFACE OF AN ACTIVATED HUMAN T-CELL HYBRIDOMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; STIMULATING FACTOR CSF-1; MOLECULAR-CLONING; GROWTH-FACTOR; ENDOPLASMIC-RETICULUM; FACTOR TNF; PROTEIN; RECEPTOR; PRECURSOR; CDNA	We characterized the membrane-associated form of lymphotoxin (surface LT) on the activated II-23.D7 T cell hybridoma. Antibodies to rLT precipitated both surface LT and a distinct 33-kDa glycoprotein (p33). Because p33 and surface LT were antigenically unrelated, their coprecipitation suggested a physical association of p33 and surface LT on the membrane. Pulse-chase analysis indicated that LT and p33 associate with each other early in the LT biosynthetic pathway, precluding the possibility that LT is secreted and bound to p33 or a surface receptor. Furthermore, no p33 was associated with the secreted form of LT. Isoelectric focusing of surface LT and p33 under nondenaturing and denaturing conditions confirmed that surface LT and p33 existed as a complex. Treatment of cells with a high concentration of salt or with acid indicated that surface LT is a peripheral membrane protein. Although secreted LT is a homologous trimer, protein cross-linking studies revealed that surface LT existed as a monomer associated with a dimer of p33. Together the results demonstrate a novel mechanism for stable membrane expression of LT by activated T cells.	UNIV CALIF RIVERSIDE,DIV BIOMED SCI,RIVERSIDE,CA 92521; BIOGEN INC,DEPT CELL BIOL,CAMBRIDGE,MA 02142	University of California System; University of California Riverside; Biogen				Browning, Jeffrey/0000-0001-9168-5233				ABE Y, 1991, JPN J CANCER RES, V82, P23, DOI 10.1111/j.1349-7006.1991.tb01740.x; AGGARWAL BB, 1990, TUMOR NECROSIS FACTOR : STRUCTURE, MECHANISM OF ACTION, ROLE IN DISEASE AND THERAPY, P49; AGGARWAL BB, 1985, J BIOL CHEM, V260, P2334; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDREWS JS, 1990, J IMMUNOL, V144, P2582; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BEUTLER B, 1990, PEPTIDE GROWTH FACTO, V2, P39; BROWNING J, 1989, J IMMUNOL, V143, P1859; BROWNING JL, 1991, J IMMUNOL, V147, P1230; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; HAINS JM, 1989, ARCH BIOCHEM BIOPHYS, V274, P417, DOI 10.1016/0003-9861(89)90454-2; HISERODT JC, 1977, CELL IMMUNOL, V34, P326, DOI 10.1016/0008-8749(77)90255-6; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LANTZ M, 1991, MOL IMMUNOL, V28, P9, DOI 10.1016/0161-5890(91)90081-T; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; TEIXIDO J, 1987, NATURE, V326, P883, DOI 10.1038/326883a0; WARE CF, 1986, LYMPHOKINE RES, V5, P313; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	31	99	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2542	2547						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733951				2022-12-25	WOS:A1992HB53200067
J	NILSON, BHK; SOLOMON, A; BJORCK, L; AKERSTROM, B				NILSON, BHK; SOLOMON, A; BJORCK, L; AKERSTROM, B			PROTEIN-L FROM PEPTOSTREPTOCOCCUS-MAGNUS BINDS TO THE KAPPA-LIGHT CHAIN VARIABLE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-C; IMMUNOGLOBULIN; PURIFICATION; AFFINITY	Protein L is an immunoglobulin light chain-binding protein expressed by some strains of the anaerobic bacterial species Peptostreptococcus magnus. The major variable region subgroups of human kappa and lambda-light chains were tested for protein L binding; V(kappa-I), V(kappa-III), and V(kappa-IV) bound protein L, whereas no binding occurred with proteins of the V(kappa-II) subgroup or with any lambda-light chain subgroups. Studies of the protein L binding capacity of naturally occurring V(L) fragments, and V(L)- and C(L)-related trypsin- and pepsin-derived peptides prepared from a kappa-I light chain, localized the site of interaction to the V(L) domain. The affinity constant for the binding to an isolated V(kappa-I) fragment was comparable to that for the native protein (K(a) 0.9 x 10(9) M-1 and K(a) 1.5 x 10(9) M-1, respectively). No binding occurred with C(L)-related fragments. Extensive reduction and alkylation of the V(kappa) fragment or the native kappa-chain resulted in complete loss of protein L binding. Although it is possible, from comparative amino acid sequence data, to identify certain V(L)-framework region residues that account for the selective binding of protein L by kappa-I, kappa-III, and kappa-IV proteins, our studies indicate that this interaction is essentially dependent upon the tertiary structural integrity of the kappa-chain V(L) domain.	UNIV TENNESSEE,GRAD SCH MED,DEPT MED,HUMAN IMMUNOL & CANC PROGRAM,KNOXVILLE,TN 37920	University of Tennessee System; University of Tennessee Health Science Center	NILSON, BHK (corresponding author), UNIV LUND,DEPT MED & PHYSIOL CHEM,POB 94,S-22100 LUND,SWEDEN.				NCI NIH HHS [CA10056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA010056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERSTROM B, 1989, J BIOL CHEM, V264, P19740; Atherton E., 1987, PEPTIDES ANAL SYNTHE, V9, P1; BJORCK L, 1988, J IMMUNOL, V140, P1194; BJORCK L, 1984, J IMMUNOL, V133, P969; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; EDMUNDSON AB, 1975, BIOCHEMISTRY-US, V14, P3953, DOI 10.1021/bi00689a005; ELBASHIR MI, 1990, J IMMUNOL METHODS, V135, P171, DOI 10.1016/0022-1759(90)90270-6; ENDRESEN C, 1979, ACTA PATH MICRO IM C, V87, P185; ERNTELL M, 1985, SCAND J IMMUNOL, V21, P151, DOI 10.1111/j.1365-3083.1985.tb01414.x; ERNTELL M, 1986, ACTA PATH MICROBIO B, V94, P151; FORSGREN A, 1966, J IMMUNOL, V97, P822; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KASTERN W, 1990, INFECT IMMUN, V58, P1217, DOI 10.1128/IAI.58.5.1217-1222.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MYHRE EB, 1985, MOL IMMUNOL, V22, P879, DOI 10.1016/0161-5890(85)90073-2; PATELLA V, 1990, J IMMUNOL, V145, P3054; PAUL WE, 1989, FUNDAMENTAL IMMUNOLO, P209; REIS KJ, 1984, J IMMUNOL, V132, P3091; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEON BK, 1972, J BIOL CHEM, V247, P2151; SOLOMON A, 1985, METHOD ENZYMOL, V116, P101; SOLOMON A, 1976, NEW ENGL J MED, V294, P17, DOI 10.1056/NEJM197601012940105; STEVENS FJ, 1981, J MOL BIOL, V147, P185, DOI 10.1016/0022-2836(81)90086-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	25	168	187	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2234	2239						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733930				2022-12-25	WOS:A1992HB53200020
J	SARNESTO, A; KOHLIN, T; HINDSGAUL, O; VOGELE, K; BLASZCZYKTHURIN, M; THURIN, J				SARNESTO, A; KOHLIN, T; HINDSGAUL, O; VOGELE, K; BLASZCZYKTHURIN, M; THURIN, J			PURIFICATION OF THE BETA-N-ACETYLGLUCOSAMINIDE ALPHA-1-]3-FUCOSYL-TRANSFERASE FROM HUMAN SERUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP ANTIGENS; TRIFUCOSYLATED TYPE-2 CHAIN; HUMAN AMNIOTIC-FLUID; FUCOSYL-TRANSFERASE; AFFINITY-CHROMATOGRAPHY; CARBOHYDRATE ANTIGENS; HUMAN ADENOCARCINOMA; MONOCLONAL-ANTIBODY; EMBRYONIC ANTIGEN; SIALYL COMPOUNDS	A beta-N-Acetylglucosaminide alpha-1 --> 3-fucosyltransferase was purified from human serum by ammonium sulfate precipitation, hydrophobic chromatography on phenyl-Sepharose, ion-exchange chromatography on sulfopropyl-Sepharose, affinity chromatography on GDP-hexanolamine-Sepharose, and finally high pressure liquid chromatography gel filtration. Gel filtration chromatography of the native enzyme revealed a M(r) of 45,000. Upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis, the purified protein also appeared as a single molecular species of M(r) 45,000. In contrast to the multisubunit beta-galactoside alpha-1 --> 2-fucosyltransferases with an apparent M(r) of 150,000, present in human serum, the native beta-N-acetylglucosaminide alpha-1 --> 3-fucosyltransferase is a monomer with a M(r) of 45,000. The enzyme is glycosylated, as revealed by wheat germ agglutinin binding properties. The alpha-1 --> 3 linkage formed by the enzyme between alpha-L-fucose and the penultimate beta-N-acetylglucosamine by the purified enzyme was confirmed by H-1 NMR homonuclear cross-irradiation analysis of the oligosaccharide product. The specificity of the purified enzyme is restricted to type 2 structures, as revealed by its reactivity with different substrates and from the K(m) values calculated from the initial rate data using various oligosaccharide acceptors. The enzyme has the ability to utilize the N-acetyl-beta-lactosamine determinant (Gal-beta-1 --> 4GlcNAc) and the sialylated (NeuAc-alpha-2 --> 3Gal-beta-1 --> 4GlcNAc) and fucosylated (Fuc-alpha-1 --> 2Gal-beta-1 --> 4GlcNAc) derivatives of N-acetyl-beta-lactosamine and thus is distinct from both the human Lewis gene-encoded enzyme and the alpha-1 --> 3-fucosyltransferase of the myeloid cell type.	WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA; UNIV ALBERTA, DEPT CHEM, EDMONTON T6G 2G2, ALBERTA, CANADA	The Wistar Institute; University of Alberta					NCI NIH HHS [CA50542, CA45363] Funding Source: Medline; NIAID NIH HHS [AI28679] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045363, R01CA050542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI028679] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; BETTERIDGE A, 1985, BIOCHEM SOC T, V13, P1126, DOI 10.1042/bst0131126; BLASZCZYK M, 1985, P NATL ACAD SCI USA, V82, P3552, DOI 10.1073/pnas.82.11.3552; BLASZCZYKTHURIN M, 1987, J BIOL CHEM, V262, P372; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAILLARD T, 1988, EXP CLIN IMMUNOGENET, V5, P15; CHESTER MA, 1969, BIOCHEM BIOPH RES CO, V34, P835, DOI 10.1016/0006-291X(69)90256-3; CORDONCARDO C, 1986, INT J CANCER, V37, P667, DOI 10.1002/ijc.2910370505; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; EPPENBERGERCASTORI S, 1989, GLYCOCONJUGATE J, V6, P101, DOI 10.1007/BF01047893; FOSTER CS, 1991, J BIOL CHEM, V266, P3526; FOSTER CS, 1987, BIOCHEM SOC T, V15, P398, DOI 10.1042/bst0150398; FUKUSHI Y, 1984, J EXP MED, V160, P506, DOI 10.1084/jem.160.2.506; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; GREENWELL P, 1985, 8 P INT S GLYC HOUST, P751; HAKOMORI S, 1982, BIOCHEM BIOPH RES CO, V109, P36, DOI 10.1016/0006-291X(82)91562-5; HAKOMORI S, 1984, J BIOL CHEM, V259, P4672; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HANISCH FG, 1988, CARBOHYD RES, V178, P23, DOI 10.1016/0008-6215(88)80099-5; HINDSGAUL O, 1982, CARBOHYD RES, V109, P109, DOI 10.1016/0008-6215(82)84034-2; HOLMES EH, 1985, J BIOL CHEM, V260, P7619; HOLMES EH, 1987, J BIOL CHEM, V262, P11331; IUPAC - Abbreviated Terminology of Oligosaccharide Chains - Recommendations - IUB-IUPAC, 1980, J BIOL CHEM, V257, P3347; JOHNSON PH, 1987, BIOCHEM SOC T, V15, P396, DOI 10.1042/bst0150396; JOHNSON PH, 1981, BIOCHEM BIOPH RES CO, V100, P1611, DOI 10.1016/0006-291X(81)90703-8; JOHNSON PH, 1985, BIOCHEM SOC T, V13, P1119, DOI 10.1042/bst0131119; JOHNSON PH, 1982, BIOCHEM SOC T, V10, P445; JOHNSON PH, 1987, 9 P INT S GLYC LILL; KHARE DP, 1985, CARBOHYD RES, V136, P285, DOI 10.1016/0008-6215(85)85204-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMED R, 1973, BIOCHIM BIOPHYS ACTA, V304, P231, DOI 10.1016/0304-4165(73)90239-0; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MITSAKOS A, 1989, BIOL CHEM H-S, V370, P239, DOI 10.1515/bchm3.1989.370.1.239; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MURAMATSU H, 1983, FEBS LETT, V163, P181, DOI 10.1016/0014-5793(83)80814-X; NUNEZ HA, 1981, CAN J CHEM, V59, P2086, DOI 10.1139/v81-304; ORNTOFT TF, 1989, INT J CANCER, V43, P774, DOI 10.1002/ijc.2910430505; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; SADLER JE, 1982, METHOD ENZYMOL, V83, P458; SAKAMOTO J, 1986, CANCER RES, V46, P1553; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SCHENKELBRUNNER H, 1972, EUR J BIOCHEM, V30, P269, DOI 10.1111/j.1432-1033.1972.tb02095.x; SCUDDER PR, 1981, BIOCHIM BIOPHYS ACTA, V660, P128, DOI 10.1016/0005-2744(81)90117-0; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; WATKINS WM, 1988, BIOCHIMIE, V70, P1597, DOI 10.1016/0300-9084(88)90295-7; YANG HJ, 1971, J BIOL CHEM, V246, P1192	48	39	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2745	2752						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733970				2022-12-25	WOS:A1992HB53200095
J	SHINOHARA, M; MIYAZAKI, A; SHICHIRI, M; MORINO, Y; HORIUCHI, S				SHINOHARA, M; MIYAZAKI, A; SHICHIRI, M; MORINO, Y; HORIUCHI, S			EXPOSURE OF RAT PERITONEAL-MACROPHAGES TO ACETYLATED LOW-DENSITY-LIPOPROTEIN RESULTS IN RELEASE OF PLASMA-MEMBRANE CHOLESTEROL - AN EFFICIENT SUBSTRATE FOR ESTERIFICATION BY ACYL-COA-CHOLESTEROL ACYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; COENZYME-A; J774 MACROPHAGES; HUMAN FIBROBLASTS; CULTURED-CELLS; ACCUMULATION; TRANSFERASE; INHIBITION; 25-HYDROXYCHOLESTEROL; BIOSYNTHESIS	In J774 macrophages and murine macrophages stimulated with acetylated low density lipoprotein (acetyl-LDL), the plasma membrane free cholesterol (FC) became accessible to acyl-CoA:cholesterol acyltransferase (ACAT) as substrate, the result being an accumulation of cholesteryl esters (CE) (Tabas, I., Rosoff, W. J., and Boykow, G. C (1988) J. Biol. Chem. 263, 1266-1272). As the route of delivery of FC to ACAT was not well characterized, we examined this route in the present study. In foam cells derived from rat peritoneal macrophages by preincubation with acetyl-LDL, esterification of the exogenously labeled [H-3]FC was low (1.3% of total labeled cholesterol). In contrast, when cells were first labeled with exogenous [H-3]FC and then chased with acetyl-LDL, the esterification was more extensive (9.2% of the total labeled cholesterol). During this experiment a significant portion of cellular [H-3]FC was released into the medium (up to 33.4% of the total labeled cholesterol). In experiments using a two-compartment chamber in which cells in the lower and upper chambers were separated by filter paper yet the cells in both compartments could communicate without direct contact, [H-3]FC released into the medium was biologically active and could serve as an efficient substrate for ACAT. Thus, when acetyl-LDL is not included in culture medium, FC delivery from the macrophage plasma membrane to ACAT is not enhanced, whereas in the presence of acetyl-LDL, plasma membrane FC released and bound to acetyl-LDL may re-enter the cells, possibly through the scavenger receptor. This would provide a significant route for CE synthesis in macrophages.	KUMAMOTO UNIV, SCH MED, DEPT BIOCHEM, HONJO 2-2-1, KUMAMOTO 860, JAPAN; KUMAMOTO UNIV, SCH MED, DEPT METAB MED, KUMAMOTO 860, JAPAN	Kumamoto University; Kumamoto University								BROWN MS, 1975, J BIOL CHEM, V250, P4025; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1974, J BIOL CHEM, V249, P7306; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; DEGRELLA RF, 1982, J BIOL CHEM, V257, P4256; DREVON CA, 1980, J BIOL CHEM, V255, P9128; FIELD FJ, 1983, J LIPID RES, V24, P1049; FREEMAN DA, 1987, J BIOL CHEM, V262, P13061; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, J BIOL CHEM, V254, P5403; GOODMAN DS, 1965, PHYSIOL REV, V45, P747, DOI 10.1152/physrev.1965.45.4.747; HAGA Y, 1989, BIOCHEM BIOPH RES CO, V160, P874, DOI 10.1016/0006-291X(89)92516-3; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; HORIUCHI S, 1985, J BIOL CHEM, V260, P53; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; KOO C, 1986, J BIOL CHEM, V261, P1194; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1984, J BIOL CHEM, V259, P4624; LISCUM L, 1987, J BIOL CHEM, V262, P17002; MILLER SC, 1984, J LIPID RES, V25, P991; MURAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P729, DOI 10.1093/jb/101.3.729; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SLOTTE JP, 1984, BIOCHEM J, V222, P821, DOI 10.1042/bj2220821; SLOTTE JP, 1983, BIOCHIM BIOPHYS ACTA, V750, P434, DOI 10.1016/0005-2760(83)90182-0; SOKOL J, 1988, J BIOL CHEM, V263, P3411; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TABAS I, 1985, P NATL ACAD SCI USA, V82, P416, DOI 10.1073/pnas.82.2.416; TABAS I, 1986, J BIOL CHEM, V261, P3147; TAKATA K, 1988, J BIOL CHEM, V263, P14819	31	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1603	1608						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730705				2022-12-25	WOS:A1992HA48500034
J	BLANK, RS; MCQUINN, TC; YIN, KC; THOMPSON, MM; TAKEYASU, K; SCHWARTZ, RJ; OWENS, GK				BLANK, RS; MCQUINN, TC; YIN, KC; THOMPSON, MM; TAKEYASU, K; SCHWARTZ, RJ; OWENS, GK			ELEMENTS OF THE SMOOTH-MUSCLE ALPHA-ACTIN PROMOTER REQUIRED IN CIS FOR TRANSCRIPTIONAL ACTIVATION IN SMOOTH-MUSCLE - EVIDENCE FOR CELL TYPE-SPECIFIC REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS GENE; II INDUCES HYPERTROPHY; PROTEIN-BINDING SITE; MYOSIN HEAVY-CHAINS; MAMMALIAN-CELLS; EXPRESSION; DIFFERENTIATION; SEQUENCES; INVIVO; GROWTH	To assess the role of cis-acting elements within the smooth muscle alpha-actin gene in smooth muscle cells (SMC), we transfected chicken smooth muscle alpha-actin promoter-chloramphenicol acetyltransferase gene fusion plasmids into SMC derived from rat and chicken aortas. In marked contrast to effects in chicken skeletal myoblasts and fibroblasts, p122CAT (positions -122 to +19), containing two conserved CArG elements, elicited a modest increase in chloramphenicol acetyltransferase reporter activity in chicken SMC. Addition of upstream sequences between -122 and -151 (p151CAT) increased activity in adult chicken SMC. Addition of sequence between positions -151 and -257 (p257CAT) resulted in a 7-fold increase in chloramphenicol acetyltransferase activity over that of p151CAT in rat SMC, but not in chicken SMC. A genomic clone encoding the rat smooth muscle a-actin gene was isolated, and the 5'-flanking region was partially characterized. Comparison of primary sequence between rat and chicken promoters showed a conserved E box motif at position -214 in the chicken gene and at position -213 in the rat gene. Results of these studies demonstrate that regions upstream of the conserved CArG elements exert potent regulatory effects on transcription and that SMC require different cis-acting elements than other cell types to transcriptionally regulate this gene.	UNIV VIRGINIA,SCH MED,DEPT PHYSIOL,BOX 449,JORDAN HALL,CHARLOTTESVILLE,VA 22908; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	University of Virginia; Baylor College of Medicine; Baylor College of Medicine					NHLBI NIH HHS [P01-HL19242, HL38401, R01 HL38854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019242, R01HL038401, R01HL038854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLANK RS, 1988, J CELL BIOL, V107, P299, DOI 10.1083/jcb.107.1.299; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CARROLL SL, 1986, J BIOL CHEM, V261, P8955; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CLOWES AW, 1988, J CELL BIOL, V107, P1939, DOI 10.1083/jcb.107.5.1939; CORJAY MH, 1989, J BIOL CHEM, V264, P10501; FRANKE WW, 1980, J CELL BIOL, V87, P594, DOI 10.1083/jcb.87.3.594; FYRBERG EA, 1983, CELL, V33, P115, DOI 10.1016/0092-8674(83)90340-9; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GUO LH, 1983, METHOD ENZYMOL, V100, P60; HAYWARD LJ, 1986, J CELL BIOL, V102, P1485, DOI 10.1083/jcb.102.4.1485; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KOCHER O, 1984, LAB INVEST, V50, P645; MCHUGH KM, 1988, MOL CELL BIOL, V8, P5224, DOI 10.1128/MCB.8.12.5224; MCHUGH KM, 1988, NUCLEIC ACIDS RES, V16, P4167, DOI 10.1093/nar/16.9.4167; Miller J.H., 1972, EXPT MOL GENETICS; MIN BH, 1990, J BIOL CHEM, V265, P16667; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MONICAL PL, 1988, BIOPHYS J, V53, pA580; ORDAHL CP, 1983, NATURE, V303, P348, DOI 10.1038/303348a0; OWENS GK, 1986, J BIOL CHEM, V261, P3373; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; QUITSCHKE WW, 1989, MOL CELL BIOL, V9, P3218, DOI 10.1128/MCB.9.8.3218; REDDY S, 1990, J BIOL CHEM, V265, P1683; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SABORIO JL, 1979, J BIOL CHEM, V254, P1119; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; STOFLET E S, 1990, Journal of Cell Biology, V111, p370A; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VANDEKERCKHOVE J, 1981, EUR J BIOCHEM, V113, P595, DOI 10.1111/j.1432-1033.1981.tb05104.x; VANDEKERCKHOVE J, 1979, DIFFERENTIATION, V14, P123, DOI 10.1111/j.1432-0436.1979.tb01021.x; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WOODCOCKMITCHELL J, 1988, DIFFERENTIATION, V39, P161, DOI 10.1111/j.1432-0436.1988.tb00091.x	45	126	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					984	989						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730687				2022-12-25	WOS:A1992GY96000050
J	CAO, XM; GUY, GR; SUKHATME, VP; TAN, YH				CAO, XM; GUY, GR; SUKHATME, VP; TAN, YH			REGULATION OF THE EGR-1 GENE BY TUMOR-NECROSIS-FACTOR AND INTERFERONS IN PRIMARY HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER-ENCODING GENE; SERUM GROWTH-FACTORS; CAP-BINDING-PROTEIN; INDUCIBLE GENE; LYMPHOCYTES-B; JUN ENCODES; C-JUN; CELL; EXPRESSION; INDUCTION	Treatment of quiescent primary human fibroblasts with tumor necrosis factor (TNF) alpha, TNF-beta, interleukin-1, interferon (IFN) alpha, IFN-beta, or IFN-gamma induced Egr-1 mRNA. In primary human fibroblasts TNF-alpha and TNF-beta were mildly mitogenic and IFN-alpha and IFN-gamma were growth inhibitory. However, in HeLa cells TNF but not IFN induced the expression of Egr-1 mRNA, while both cytokines inhibited HeLa cell division. Kinetic measurements of Egr-1 gene expression showed that TNF-alpha, TNF-beta, and IFN-gamma increased the cellular concentration of Egr-1 mRNA within 30 min. A maximum induction of Egr-1 mRNA was detected at approximately 60 min which dropped to basal level by 180 min. Induction was inhibited by H7 and staurosporine but not by HA1004, indicating the involvement of a functional protein kinase C. The Egr-1 message was translated and the cellular Egr-1 protein detected within 60 min of cytokine treatment. Despite similar Egr-1 mRNA induction, the amount of Egr-1 protein translated in IFN-alpha- and IFN-gamma-treated cells was lower than in those treated with TNF-alpha and TNF-beta, and highest in the EGF-treated primary human fibroblasts. Indeed, the level of Egr-1 protein translated in these cells correlated proportionally with both the phosphorylation of cap-binding protein (eukaryotic initiation factor) and the amount of cellular DNA synthesis in the variously treated fibroblasts. These results suggest that both growth stimulatory and inhibitory cytokines can regulate Egr-1 gene expression at the transcriptional and translational level. However, the combination of these regulatory controls may determine the cellular concentration of the Egr-1 gene product and hence, its effect on cell proliferation.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SIGNAL TRANSDUCT LAB, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of Chicago			Sukhatme, Vikas/W-2776-2019					ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, ONCOGENE HDB, V1, P307; GUY GR, 1991, J BIOL CHEM, V266, P14343; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; JAMIESON GA, 1989, J CELL PHYSIOL, V139, P262, DOI 10.1002/jcp.1041390207; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; LIU JW, 1991, J BIOL CHEM, V266, P5929; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PFEFFER LM, 1991, TRENDS BIOCHEM SCI, V16, P321, DOI 10.1016/0968-0004(91)90132-F; PORTER A G, 1990, FEMS (Federation of European Microbiological Societies) Microbiology Immunology, V64, P193, DOI 10.1016/0378-1097(90)90609-T; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RYCHLIK W, 1990, J BIOL CHEM, V265, P19467; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SEOW HF, 1989, BIO-TECHNOL, V7, P363, DOI 10.1038/nbt0489-363; SEYFERT VL, 1990, SCIENCE, V250, P797, DOI 10.1126/science.2237429; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SEYFERT VL, 1990, J IMMUNOL, V145, P3647; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	44	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1345	1349						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730654				2022-12-25	WOS:A1992GY96000104
J	ENDO, T; OHBAYASHI, H; KANAZAWA, K; KOCHIBE, N; KOBATA, A				ENDO, T; OHBAYASHI, H; KANAZAWA, K; KOCHIBE, N; KOBATA, A			CARBOHYDRATE BINDING-SPECIFICITY OF IMMOBILIZED PSATHYRELLA-VELUTINA LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SUGAR CHAINS; IMMUNOGLOBULIN-G; COLUMN CHROMATOGRAPHY; OLIGOSACCHARIDES; BOVINE; GLYCOPEPTIDES; CHORIOCARCINOMA; GLYCOSYLATION; PURIFICATION; ELUCIDATION	The carbohydrate binding specificity of Psathyrella velutina lectin (PVL) was thoroughly investigated by analyzing the behavior of various complex-type oligosaccharides and human milk oligosaccharides on a PVL-Affi-Gel 10 column. Basically, the lectin interacts with the nonreducing terminal beta-N-acetylglucosamine residue, but does not show any affinity for the nonreducing terminal N-acetylgalactosamine or N-acetylneuraminic acid residue. Substitution of the terminal N-acetylglucosamine residues of oligosaccharides by galactose completely abolishes their affinity to the column. GlcNAc-beta-1 --> 3Gal-beta-1 --> 4sorbitol binds to the column, but GlcNAc-beta-1 --> 6Gal-beta-1 --> 4sorbitol is only retarded in the column. The behavior of degalactosylated N-linked oligosaccharides is quite interesting. Although all degalactosylated monoantennary sugar chain isomers are retarded in the column, those with the GlcNAc-beta-1 --> 2Man group interact more strongly with the column than those with the GlcNAc-beta-1 --> 4Man group or the GlcNAc-beta-1 --> 6Man group. The degalactosylated bi- and triantennary sugar chains bind to the column, but the tetraantennary ones are only retarded in the column. These results indicated that the binding affinity is not simply determined by the number of terminal N-acetylglucosamine residues. Addition of the bisecting N-acetylglucosamine residue reduces the affinity of oligosaccharides to the column, but addition of an alpha-fucosyl residue at the C-6 position of the proximal N-acetylglucosamine residue does not affect the behavior of oligosaccharides in the column. These results indicated that the binding specificity of PVL is quite different from those of other N-acetylglucosamine-binding lectins from higher plants, which interact preferentially with the GlcNAc-beta-1 --> 4 residue.	GUNMA UNIV,FAC EDUC,MAEBASHI,GUNMA 371,JAPAN	Gunma University	ENDO, T (corresponding author), UNIV TOKYO,INST MED SCI,DEPT BIOCHEM,MINATO KU,TOKYO 108,JAPAN.							BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; EBISU S, 1978, CARBOHYD RES, V61, P129, DOI 10.1016/S0008-6215(00)84473-0; ENDO T, 1988, JPN J CANCER RES, V79, P160, DOI 10.1111/j.1349-7006.1988.tb01572.x; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; GREEN ED, 1988, J BIOL CHEM, V263, P25; HARA T, 1989, J BIOCHEM-TOKYO, V106, P236, DOI 10.1093/oxfordjournals.jbchem.a122838; KATOH H, 1990, CARBOHYD RES, V195, P273, DOI 10.1016/0008-6215(90)84171-P; KOBATA A, 1984, PURE APPL CHEM, V56, P821, DOI 10.1351/pac198456070821; KOBATA A, 1990, Glycobiology, V1, P5, DOI 10.1093/glycob/1.1.5; KOBATA A, 1972, J BIOL CHEM, V247, P1525; KOBATA A, 1972, METHOD ENZYMOL, V28, P262; KOCHIBE N, 1989, J BIOL CHEM, V264, P173; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; LIANG CJ, 1979, J BIOL CHEM, V254, P6414; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERKLE RK, 1987, METHOD ENZYMOL, V138, P232; MIZUOCHI T, 1987, ARCH BIOCHEM BIOPHYS, V257, P387, DOI 10.1016/0003-9861(87)90581-9; MIZUOCHI T, 1983, J BIOL CHEM, V258, P4126; MIZUOCHI T, 1979, J BIOL CHEM, V254, P6419; MORI E, 1991, BIOCHEMISTRY-US, V30, P2078, DOI 10.1021/bi00222a012; OGATA S, 1975, J BIOCHEM, V78, P687, DOI 10.1093/oxfordjournals.jbchem.a130956; OHBAYASHI H, 1989, ARCH BIOCHEM BIOPHYS, V269, P463, DOI 10.1016/0003-9861(89)90130-6; OHKURA T, 1985, BIOCHEMISTRY-US, V24, P503, DOI 10.1021/bi00323a038; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; RADEMACHER TW, 1983, BIOCHEM SOC T, V11, P132, DOI 10.1042/bst0110132; ROTHMAN RJ, 1989, BIOCHEMISTRY-US, V28, P1377, DOI 10.1021/bi00429a065; TAI T, 1975, BIOCHEM BIOPH RES CO, V65, P968, DOI 10.1016/S0006-291X(75)80480-3; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V105, P742, DOI 10.1093/oxfordjournals.jbchem.a122738; TAKAMOTO M, 1989, J BIOCHEM-TOKYO, V106, P228, DOI 10.1093/oxfordjournals.jbchem.a122837; TANIGUCHI T, 1985, BIOCHEMISTRY-US, V24, P5551, DOI 10.1021/bi00341a040; YAMAMOTO K, 1981, BIOCHEMISTRY-US, V20, P5894, DOI 10.1021/bi00523a037; YAMASHITA K, 1983, J BIOL CHEM, V258, P3099; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YAMASHITA K, 1981, BIOCHEM BIOPH RES CO, V100, P226, DOI 10.1016/S0006-291X(81)80086-1; YAMASHITA K, 1983, CANCER RES, V43, P5059; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809	37	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					707	713						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730662				2022-12-25	WOS:A1992GY96000008
J	SEGARINI, PR; ZIMAN, JM; KANE, CJM; DASCH Jr				SEGARINI, PR; ZIMAN, JM; KANE, CJM; DASCH, JR			2 NOVEL PATTERNS OF TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) BINDING TO CELL-SURFACE PROTEINS ARE DEPENDENT UPON THE BINDING OF TGF-BETA-1 AND INDICATE A MECHANISM OF POSITIVE COOPERATIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR; DIFFERENTIATION; PROTEOGLYCAN; EXPRESSION; FORMS	Three isoforms of the transforming growth factor beta (TGF-beta) family, TGF-beta-1, TGF-beta-2, and TGF-beta-3, bind specifically and with high-affinity to several cell surface components known as type I, type II, and type III proteins. The type I and II proteins may serve as biological receptors, whereas the type III protein does not appear to be associated with TGF-beta-mediated cell responses, and its function remains unknown. Binding data on confluent monolayers of rat skeletal myoblasts of the L6 cell line reveals two novel patterns of TGF-beta-1 binding. Saturation of the type I receptor with native TGF-beta-2 induces a 7-fold increase in binding of radiolabeled TGF-beta-1 at the type II protein. No induction of type II receptor binding was observed on subconfluent cells indicating a density-dependent phenomenon. The data suggest that the type I and type II proteins may interact during ligand binding in a manner which may be indicative of a regulatory role that is activated by the phase of cell growth or differentiation. A second observation is the binding of TGF-beta to a glycoprotein of 180 kDa and referred to here as the "type VI" binding protein. This protein is not related to previously described TGF-beta binding proteins, and its distribution appears universal among cell types. The level of TGF-beta-1 binding to this protein is dependent on the presence of TGF-beta-2. It is not known whether this protein transmits biological information or whether it serves as an accessory protein of a TGF-beta receptor complex.	CELTRIX LABS, DEPT IMMUNOL, PALO ALTO, CA 94303 USA; STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University	SEGARINI, PR (corresponding author), CELTRIX LABS, DEPT CELLULAR & MOLEC BIOL, 2500 FABER PL, PALO ALTO, CA 94303 USA.				NATIONAL CANCER INSTITUTE [F32CA008795] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08795-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BENTZ H, 1989, J BIOL CHEM, V264, P20805; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEIFETZ S, 1986, J BIOL CHEM, V261, P9972; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FROLIK CA, 1984, J BIOL CHEM, V259, P995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, J BIOL CHEM, V265, P18518; MACKAY K, 1991, J BIOL CHEM, V266, P9907; MADISEN L, 1989, DNA-J MOLEC CELL BIO, V8, P205, DOI 10.1089/dna.1.1989.8.205; Madisen L, 1990, GROWTH FACTORS, V3, P129, DOI 10.3109/08977199009108275; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; OGRADY P, 1991, J BIOL CHEM, V266, P8583; SEGARINI PR, 1988, J BIOL CHEM, V263, P8366; SEGARINI PR, 1989, MOL ENDOCRINOL, V3, P261, DOI 10.1210/mend-3-2-261; SEGARINI PR, 1987, J BIOL CHEM, V262, P14655; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x	24	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1048	1053						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730634				2022-12-25	WOS:A1992GY96000060
J	WATTS, JD; WILSON, GM; ETTEHADIEH, E; CLARKLEWIS, I; KUBANEK, CA; ASTELL, CR; MARTH, JD; AEBERSOLD, R				WATTS, JD; WILSON, GM; ETTEHADIEH, E; CLARKLEWIS, I; KUBANEK, CA; ASTELL, CR; MARTH, JD; AEBERSOLD, R			PURIFICATION AND INITIAL CHARACTERIZATION OF THE LYMPHOCYTE-SPECIFIC PROTEIN-TYROSYL KINASE P56LCK FROM A BACULOVIRUS EXPRESSION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; T-CELLS; SIGNAL TRANSDUCTION; TRANSGENIC MICE; HUMAN PLATELETS; ZETA-CHAIN; CD8; PHOSPHORYLATION; ACTIVATION; PP60C-SRC	A baculovirus expression system has been used to express large quantities of the lymphocyte-specific protein-tyrosyl kinase p56lck. A series of chromatographic steps, including the novel application of metalchelate affinity chromatography for protein kinase purification, were employed to obtain p56lck in a highly active form. Recombinant p56lck was purified to apparent homogeneity as determined by polyacrylamide gel electrophoretic analyses and was found to migrate in SDS gels as two related species, both with apparent molecular masses close to 56 kDa. p56lck phosphorylated all assayed substrates exclusively on tyrosyl residues, and underwent autophosphorylation at one principal site, also on a tyrosyl residue. p56lck displayed a high affinity for a synthetic peptide corresponding to the cytoplasmic domain (residues 52-164) of the T-cell receptor zeta-chain (TCR-zeta) (K(m) approximately 6.5-mu-M) but a low affinity for a peptide corresponding to its own autophosphorylation site (K(m) approximately 900-mu-M). p56lck was also found to be highly active for a purified protein-tyrosyl kinase (V(max) > 400 pmol.min-1.mu-g-1 using the TCR-zeta (52-164) as a substrate). A variety of agents were tested for their ability to inhibit p56lck, with zinc ions (I50 approximately 1.7 mM) and staurosporine (I50 approximately 500 nM) proving the most potent.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia	WATTS, JD (corresponding author), UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z3,BC,CANADA.							ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AEBERSOLD J, 1991, IN PRESS ANAL BIOCH; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; AZUMA K, 1991, J BIOL CHEM, V266, P4831; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; FEDER D, 1990, J BIOL CHEM, V265, P8205; FOWLKES BJ, 1988, NATURE, V334, P620, DOI 10.1038/334620a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HERRERA R, 1986, J BIOL CHEM, V261, P1980; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; NORMENT AM, 1988, NATURE, V336, P79, DOI 10.1038/336079a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; OKADA M, 1989, J BIOL CHEM, V264, P20886; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PORATH J, 1975, NATURE, V246, P417; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; RATNOFSKY SE, 1987, J EXP MED, V166, P1747, DOI 10.1084/jem.166.6.1747; REUTER C, 1990, EUR J BIOCHEM, V190, P343, DOI 10.1111/j.1432-1033.1990.tb15581.x; ROSENSTEIN Y, 1989, J EXP MED, V169, P149, DOI 10.1084/jem.169.1.149; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, NATURE, V324, P674, DOI 10.1038/324674a0; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SMITH CD, 1988, BIOCHEM BIOPH RES CO, V156, P1250, DOI 10.1016/S0006-291X(88)80767-8; SUMMERS MD, 1987, TEXAS A M B, V1555; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; TONKS NK, 1989, P NATL ACAD SCI USA, V265, P10674; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, ONCOGENES, P121; VORONOVA AF, 1985, MOL CELL BIOL, V4, P2705; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WETTENHALL EH, 1991, METHODS ENZYMOLOGY B, V201, P186; YU G, 1987, J BIOL CHEM, V262, P17543; ZUNIGAPFLUCKER JC, 1989, NATURE, V338, P76, DOI 10.1038/338076a0	57	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					901	907						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730679				2022-12-25	WOS:A1992GY96000036
J	WEIS, M; KASS, GEN; ORRENIUS, S; MOLDEUS, P				WEIS, M; KASS, GEN; ORRENIUS, S; MOLDEUS, P			N-ACETYL-PARA-BENZOQUINONE IMINE INDUCES CA2+ RELEASE FROM MITOCHONDRIA BY STIMULATING PYRIDINE-NUCLEOTIDE HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; INNER MEMBRANE-PERMEABILITY; INDUCED CA-2+ RELEASE; HEART-MITOCHONDRIA; CA-2+-DEPENDENT PORE; OXIDATIVE STRESS; INTRACELLULAR CALCIUM; ISOLATED HEPATOCYTES; INORGANIC-PHOSPHATE; ADP/ATP CARRIER	The mechanism of N-acetyl-p-benzoquinone imine (NAPQI)-induced release of Ca2+ from rat liver mitochondria was investigated. The addition of NAPQI or 3,5-Me2-NAPQI (a dimethylated analogue of NAPQI with only oxidizing properties) to mitochondria resulted in the rapid and extensive oxidation of NADH and NADPH. High-performance liquid chromatographic analysis of mitochondrial pyridine nucleotides revealed that the formation of NAD+ and NADP+ was followed by a time-dependent net loss of total pyridine nucleotides as a result of their hydrolysis, with the formation of nicotinamide. Preincubation of the mitochondria with cyclosporin A completely prevented the quinone imine-stimulated release of sequestered Ca2+ from mitochondria. Cyclosporin A did not affect the ability of NAPQI or 3,5-Me2-NAPQI to oxidize NAD(P)H but prevented the quinone imine-induced hydrolysis of the pyridine nucleotides. Although there was no detectable change in total protein-bound ADP-ribose content during quinone imine-induced Ca2+ release from mitochondria, meta-iodobenzylguanidine, a competitive inhibitor of protein mono(ADP-ribosylation), prevented Ca2+ release by NAPQI and 3,5-Me2-NAPQI; meta-iodobenzylguanidine did not inhibit the quinone imine-induced NAD(P)H oxidation and only partially blocked hydrolysis of the oxidized pyridine nucleotides. It is concluded that NAPQI causes the oxidation of mitochondrial NADH and NADPH, and stimulates Ca2+ release as a result of the further hydrolysis of the oxidized pyridine nucleotides and protein mono(ADP-ribosylation).	KAROLINSKA INST,DEPT TOXICOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN	Karolinska Institutet			Kass, George/T-8520-2017	Kass, George/0000-0002-3343-5276				BLACK M, 1984, ANNU REV MED, V35, P577, DOI 10.1146/annurev.me.35.020184.003045; BOOBIS AR, 1990, BIOCHEM PHARMACOL, V39, P1277, DOI 10.1016/0006-2952(90)90003-4; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CROMPTON M, 1976, EUR J BIOCHEM, V69, P453, DOI 10.1111/j.1432-1033.1976.tb10930.x; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; CROMPTON M, 1990, BIOCHEM J, V266, P33, DOI 10.1042/bj2660033; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; FREI B, 1988, BIOCHEMISTRY-US, V27, P529, DOI 10.1021/bi00402a004; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HARRIS EJ, 1979, BIOCHEM J, V182, P455, DOI 10.1042/bj1820455; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; JACOBSON MK, 1984, METHOD ENZYMOL, V106, P483; JONES DP, 1981, J CHROMATOGR, V225, P446, DOI 10.1016/S0378-4347(00)80293-5; KASS GEN, 1991, REGULATION HEPATIC F, P344; KUN E, 1975, P NATL ACAD SCI USA, V72, P1436, DOI 10.1073/pnas.72.4.1436; LEQUOC K, 1988, ARCH BIOCHEM BIOPHYS, V265, P249, DOI 10.1016/0003-9861(88)90125-7; LOESBERG C, 1990, BIOCHIM BIOPHYS ACTA, V1037, P92, DOI 10.1016/0167-4838(90)90106-P; LOTSCHER HR, 1980, J BIOL CHEM, V255, P9325; MCGUINNESS O, 1990, EUR J BIOCHEM, V194, P671, DOI 10.1111/j.1432-1033.1990.tb15667.x; MITCHELL JR, 1973, J PHARMACOL EXP THER, V187, P185; MOORE GA, 1988, ARCH BIOCHEM BIOPHYS, V267, P539, DOI 10.1016/0003-9861(88)90061-6; MOORE M, 1985, J BIOL CHEM, V260, P3035; NICOTERA P, 1989, CHEM RES TOXICOL, V2, P46, DOI 10.1021/tx00007a008; NOVGORODOV SA, 1990, FEBS LETT, V277, P123, DOI 10.1016/0014-5793(90)80824-3; PAYNE DM, 1985, BIOCHEMISTRY-US, V24, P7540, DOI 10.1021/bi00347a006; POUNDS JG, 1988, TOXICOL APPL PHARM, V94, P331, DOI 10.1016/0041-008X(88)90275-X; REED DJ, 1990, ENVIRON HEALTH PERSP, V84, P113, DOI 10.2307/3430712; RICHTER C, 1990, BIOCHEM PHARMACOL, V40, P779, DOI 10.1016/0006-2952(90)90315-C; RICHTER C, 1990, FREE RADICAL RES COM, V8, P329, DOI 10.3109/10715769009053366; RICHTER C, 1988, FREE RADICAL BIO MED, V4, P365, DOI 10.1016/0891-5849(88)90088-3; RICHTER C, 1983, P NATL ACAD SCI USA, V80, P3183; ROTTENBERG H, 1990, FEBS LETT, V274, P65, DOI 10.1016/0014-5793(90)81330-Q; RUNDGREN M, 1988, MOL PHARMACOL, V34, P566; TIRMENSTEIN MA, 1989, J BIOL CHEM, V264, P9814; TRUMP BF, 1989, TOXICOL APPL PHARM, V97, P6, DOI 10.1016/0041-008X(89)90051-3; TSOKOSKUHN JO, 1989, BIOCHEM PHARMACOL, V38, P3061, DOI 10.1016/0006-2952(89)90016-6; WEIS M, 1990, CHEM-BIOL INTERACT, V76, P227, DOI 10.1016/0009-2797(90)90090-A	42	55	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					804	809						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730671				2022-12-25	WOS:A1992GY96000022
J	CASTANHO, MARB; COUTINHO, A; PRIETO, MJE				CASTANHO, MARB; COUTINHO, A; PRIETO, MJE			ABSORPTION AND FLUORESCENCE-SPECTRA OF POLYENE ANTIBIOTICS IN THE PRESENCE OF CHOLESTEROL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPHOTERICIN-B; BIOLOGICAL PROPERTIES; VISUAL PIGMENTS; FILIPIN-III; FATTY-ACIDS; STEROL; MEMBRANES; PROBES; SPECTROSCOPY; BINDING	The alterations in the absorption and fluorescence spectra observed for the polyene antibiotics filipin and nystatin in the presence of cholesterol are due to an exciton interaction (polyene aggregates) and cannot be attributed to a specific sterol-antibiotic complex. Filipin and nystatin molecules partition into the sterol aggregates, these structures being very efficient to induce exciton interaction; the observed splitting profile indicates that the chromophores are in a stacked arrangement (parallel transition dipoles). For filipin incorporated in lipid bilayers, the sterol is able to induce the same type of aggregate, at variance with nystatin.	Univ Tecn Lisboa, INST SUPER TECN, CTR QUIM FIS MOLEC, P-1096 LISBON, PORTUGAL	Universidade de Lisboa; Instituto Superior Tecnico			Prieto, Manuel/N-4448-2013; Coutinho, Ana/L-3755-2014	Prieto, Manuel/0000-0003-3012-6598; Coutinho, Ana/0000-0003-1653-0703; Castanho, Miguel/0000-0001-7891-7562; FCCN, Bogus/0000-0003-1034-3552				BECKER RS, 1988, PHOTOCHEM PHOTOBIOL, V48, P369, DOI 10.1111/j.1751-1097.1988.tb02836.x; BERGY ME, 1968, BIOCHEMISTRY-US, V7, P653, DOI 10.1021/bi00842a021; BITTMAN R, 1972, P NATL ACAD SCI USA, V69, P3795, DOI 10.1073/pnas.69.12.3795; BITTMAN R, 1974, BIOCHEMISTRY-US, V13, P1364, DOI 10.1021/bi00704a009; CANTOR CR, 1980, BIOPHYSICAL CHEM, V2, P390; CHALPIN DB, 1983, BIOCHIM BIOPHYS ACTA, V731, P465, DOI 10.1016/0005-2736(83)90042-1; CHIHARA K, 1979, PHOTOCHEM PHOTOBIOL, V29, P1001, DOI 10.1111/j.1751-1097.1979.tb07804.x; DAS PK, 1980, PHOTOCHEM PHOTOBIOL, V32, P739, DOI 10.1111/j.1751-1097.1980.tb04051.x; DEKRUIJFF B, 1974, BIOCHIM BIOPHYS ACTA, V339, P44, DOI 10.1016/0005-2736(74)90331-9; DEKRUIJFF B, 1974, BIOCHIM BIOPHYS ACTA, V339, P57, DOI 10.1016/0005-2736(74)90332-0; DRABIKOWSKI W, 1973, BIOCHIM BIOPHYS ACTA, V291, P61, DOI 10.1016/0005-2736(73)90060-6; EATON DF, 1988, J PHOTOCH PHOTOBIO B, V2, P523, DOI 10.1016/1011-1344(88)85081-4; ELIAS PM, 1979, J HISTOCHEM CYTOCHEM, V27, P1247, DOI 10.1177/27.9.479568; ERNST C, 1981, BIOPOLYMERS, V20, P1575, DOI 10.1002/bip.1981.360200802; HEMENGER RP, 1983, BIOPOLYMERS, V22, P911, DOI 10.1002/bip.360220312; HOUDSON B, 1974, ANNU REV PHYS CHEM, V25, P437; Israelachvili J. N., 1985, INTERMOLECULAR SURFA, P229; KINSKY SC, 1966, FED PROC, V25, P1503; LAMPEN JO, 1960, J BACTERIOL, V80, P200, DOI 10.1128/JB.80.2.200-206.1960; MAZERSKI J, 1982, BIOCHIM BIOPHYS ACTA, V719, P11, DOI 10.1016/0304-4165(82)90300-2; MEDOFF G, 1983, ANNU REV PHARMACOL, V23, P303, DOI 10.1146/annurev.pa.23.040183.001511; MILHAUD J, 1988, BIOCHIM BIOPHYS ACTA, V943, P315, DOI 10.1016/0005-2736(88)90563-9; MILLER RG, 1984, CELL BIOL INT REP, V8, P519, DOI 10.1016/0309-1651(84)90050-X; NECKERS DC, 1989, J PHOTOCH PHOTOBIO A, V47, P1, DOI 10.1016/1010-6030(89)85002-6; NORMAN AW, 1972, J BIOL CHEM, V247, P1918; NORMAN AW, 1972, BIOCHIM BIOPHYS ACTA, V290, P1, DOI 10.1016/0005-2736(72)90046-6; PETERSEN NO, 1985, CAN J CHEM, V63, P77, DOI 10.1139/v85-014; PHILLIPS D, 1984, TIME CORRELATED SING, P171; SCHROEDER F, 1973, BIOCHEMISTRY-US, V12, P4785, DOI 10.1021/bi00747a034; SCHROEDER F, 1972, BIOCHEMISTRY-US, V11, P3105, DOI 10.1021/bi00766a026; SEVERS NJ, 1983, BIOCHIM BIOPHYS ACTA, V737, P373, DOI 10.1016/0304-4157(83)90007-2; SKLAR LA, 1977, BIOCHEMISTRY-US, V16, P819, DOI 10.1021/bi00624a002; SKLAR LA, 1979, BIOCHEMISTRY-US, V18, P1707, DOI 10.1021/bi00576a012; SKLAR LA, 1977, BIOCHEMISTRY-US, V16, P813, DOI 10.1021/bi00624a001; SUZUKI H, 1967, ELECTRONIC ABSORPTIO, pCH4; TANCREDE P, 1990, BIOCHIM BIOPHYS ACTA, V1030, P289, DOI 10.1016/0005-2736(90)90305-8; WEETE JD, 1973, PHYTOCHEMISTRY, V12, P1843, DOI 10.1016/S0031-9422(00)91502-4; ZUCKER M, 1985, REV SCI INSTRUM, V56, P14	38	67	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					204	209						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730589				2022-12-25	WOS:A1992GY43900037
J	DAVIDOFF, AM; PENCE, JC; SHORTER, NA; IGLEHART, JD; MARKS, JR				DAVIDOFF, AM; PENCE, JC; SHORTER, NA; IGLEHART, JD; MARKS, JR			EXPRESSION OF P53 IN HUMAN NEUROBLASTOMA-DERIVED AND NEUROEPITHELIOMA-DERIVED CELL-LINES	ONCOGENE			English	Article							NEURO-BLASTOMA CELLS; TUMOR-ANTIGEN; TRANSFORMED-CELLS; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; HOST PROTEIN; T-ANTIGEN; GENE	Overexpression of the nuclear phosphoprotein p53 has been detected in many different transformed human cell lines and primary adult tumors. Elevated steady-state levels of p53 appear to be the result of an increase in the stability of the protein and, in adult cancers, high levels of the protein are associated with mutation of the p53 gene. In this study, overexpression of p53 was detected in 4 out of 5 human neuroblastoma-derived cell lines. The protein expressed by each of these four lines had a significantly prolonged half-life relative to the p53 protein in immortalized rodent fibroblasts and normal bovine adrenal medullary cells. However, no mutations were detected in the highly conserved regions of the p53 gene in these four neuroblastoma lines and the protein being expressed was not recognized by the mutant-specific anti-p53 monoclonal antibody, PAb 240. Upon retinoic acid-induced differentiation of the LA-N-5 neuroblastoma cell line, the level of p53 protein declined, as did the level of p53 mRNA, but the half-life of the protein remained unchanged. The high level of protein observed in the undifferentiated cell lines appears to result from expression of a stable wild-type p53 protein and increased transcription. In contrast, p53 protein was undetectable in two neuroepithelioma-derived cell lines; the p53 gene in one of these lines contained a nonsense mutation, while the other transcribed truncated p53 mRNA.	DUKE UNIV,MED CTR,DEPT SURG,BOX 3873,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710	Duke University; Duke University					NATIONAL CANCER INSTITUTE [F32CA008899] Funding Source: NIH RePORTER; NCI NIH HHS [1 F32 CA08899-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BRODEUR GM, 1981, CANCER RES, V41, P4678; CHANDRASEKARAN K, 1981, P NATL ACAD SCI-BIOL, V78, P6953, DOI 10.1073/pnas.78.11.6953; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crawford L V, 1984, Mol Biol Med, V2, P261; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P569; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVITSKY K, 1983, INT J CANCER, V32, P597, DOI 10.1002/ijc.2910320513; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MARKS JR, 1989, J VIROL, V63, P790, DOI 10.1128/JVI.63.2.790-797.1989; MARKS JR, 1991, CANCER RES, V51, P2979; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PENCE JC, 1990, CANCER RES, V50, P5177; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHOHAT O, 1987, ONCOGENE, V1, P277; SIDELL N, 1988, CANCER RES, V48, P2226; SIDELL N, 1985, ADV NEUROBLASTOMA RE, P39; SOUSSI T, 1987, ONCOGENE, V1, P71; WILSON SP, 1983, METHOD ENZYMOL, V103, P305	39	133	134	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					127	133						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741160				2022-12-25	WOS:A1992HC22700017
J	KUMBLA, L; BHADRA, S; SUBBIAH, MTR				KUMBLA, L; BHADRA, S; SUBBIAH, MTR			MULTIFUNCTIONAL ROLE FOR FETUIN (FETAL PROTEIN) IN LIPID TRANSPORT	FASEB JOURNAL			English	Article						LIPID METABOLISM; CHOLESTEROL; FATTY ACID INCORPORATION	CHOLESTEROL	Recent studies from this laboratory have shown that fetuin 1) is nearly 50-fold more efficient than albumin in incorporating exogenous fatty acids into cultured cells, (JBC, 265: 5883, 1990), and 2) is associated with a lipoprotein-like particle (FASEB J. 3: 2075-2080, 1989). In the present study, this lipid-containing fraction (FLP) was isolated by ultracentrifugation, and its effect on cholesterol efflux from cultured human skin fibroblasts and Hep-G2 cells prelabeled with [C-14]cholesterol was investigated. FLP fraction caused a significant efflux of [C-14]cholesterol from cells, the same in magnitude as HDL. This effect of fetuin supranatant fraction increased proportionately with concentration and time. Similar results were observed with Hep-G2 cells. This ability to induce efflux of cholesterol was confirmed by a decrease in cholesterol mass of cells after 24 h incubation with FLP. The ultracentrifugal bottom (infranatant) fraction of fetuin (FI) was ineffective in this regard. However, FI was more effective in the incorporation of exogenous fatty acids into cellular triglycerides. These studies suggest that the fetuin molecule is a multifunctional protein (delivery of fatty acids to cells and cholesterol efflux from cells) which may play a role in lipid transport during fetal life.	UNIV CINCINNATI,MED CTR,DEPT INTERNAL MED,LIPID RES LAB,CINCINNATI,OH 45267	University of Cincinnati					NHLBI NIH HHS [HL-07460] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007460] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVIRAM M, 1989, ARTERIOSCLEROSIS, V9, P67, DOI 10.1161/01.ATV.9.1.67; CARDIN AD, 1984, METHODS PHARM, V6; CAYATTE AJ, 1990, J BIOL CHEM, V265, P5883; DZIEGIELEWSKA KM, 1983, COMP BIOCHEM PHYS A, V76, P241, DOI 10.1016/0300-9629(83)90321-3; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRIEDMAN M, 1957, P SOC EXP BIOL MED, V95, P586; GLICK JM, 1983, J BIOL CHEM, V258, P3425; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; KUMBLA L, 1989, FASEB J, V3, P2075, DOI 10.1096/fasebj.3.9.2472993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PEDERSEN KO, 1947, J PHYS COLLOID CHEM, V51, P164, DOI 10.1021/j150451a012; PUCK TT, 1968, P NATL ACAD SCI USA, V59, P192, DOI 10.1073/pnas.59.1.192; SPIRO RG, 1960, J BIOL CHEM, V235, P2860; SUBBIAH MTR, 1983, J CLIN INVEST, V71, P1509, DOI 10.1172/JCI110906; SUBBIAH MTR, 1991, P SOC EXP BIOL MED, V198, P495	16	20	21	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1991	5	14					2971	2975		10.1096/fasebj.5.14.1721594	http://dx.doi.org/10.1096/fasebj.5.14.1721594			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1721594				2022-12-25	WOS:A1991GP26900013
J	HORISBERGER, JD; JAUNIN, P; REUBEN, MA; LASATER, LS; CHOW, DC; FORTE, JG; SACHS, G; ROSSIER, BC; GEERING, K				HORISBERGER, JD; JAUNIN, P; REUBEN, MA; LASATER, LS; CHOW, DC; FORTE, JG; SACHS, G; ROSSIER, BC; GEERING, K			THE H,K-ATPASE BETA-SUBUNIT CAN ACT AS A SURROGATE FOR THE BETA-SUBUNIT OF NA,K-PUMPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TISSUE-SPECIFIC EXPRESSION; GASTRIC H+/K+-ATPASE; ALPHA-SUBUNITS; K+-ATPASE; NA,K-ATPASE; CLONING; ALDOSTERONE; MATURATION; TRANSPORT; KIDNEY	Na,K-ATPase and H,K-ATPase are the only members of the P-type ATPases in which a glycosylated beta-subunit is part of the purified active enzyme. In this study, we have followed the synthesis and the posttranslational processing of the beta-subunit of H,K-ATPase (beta-HK) in Xenopus oocytes injected with beta-HK cRNA and have tested whether it can act as a surrogate for the beta-subunit of Na,K-ATPase (beta-NaK) to support the functional expression of Na,K-pumps. In Xenopus oocytes, beta-HK is processed from an Endo H-sensitive 51-kDa coreglycosylated form to an Endo H-resistant 71-kDa fully glycosylated form. Similar to beta-NaK, beta-HK can stabilize and increase the trypsin resistance of alpha-subunits of Na,K-ATPase (alpha-NaK). Finally, expression of beta-HK together with alpha-NaK leads to an increased number of ouabain binding sites at the plasma membrane accompanied by an increased Rb+ uptake and Na,K-pump current. Our data suggest that beta-HK, similar to alpha-NaK, can assemble to alpha-NaK, support the structural maturation and the intracellular transport of catalytic alpha-NaK, and ultimately form active alpha-NaK-beta-HK complexes with Na,K-pump transport properties.	UNIV LAUSANNE,INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND; UNIV CALIF LOS ANGELES,DEPT PHYSIOL & MED,LOS ANGELES,CA 90024; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,LIFE SCI ADDIT,BERKELEY,CA 94720	University of Lausanne; University of California System; University of California Los Angeles; University of California System; University of California Berkeley			Horisberger, Jean-Daniel/A-2538-2009					ACKERMANN U, 1990, FEBS LETT, V269, P105, DOI 10.1016/0014-5793(90)81130-G; BALDWIN GS, 1990, FEBS LETT, V272, P159, DOI 10.1016/0014-5793(90)80473-V; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CHOW D, 1989, FASEB Journal, V3, pA873; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; FORTE JG, 1989, HDB PHYSL, V3, P207; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GEERING K, 1982, J BIOL CHEM, V257, P338; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; GEERING K, 1985, J BIOL CHEM, V260, P5154; GEERING K, 1991, FEBS LETT, V286, P189; GIRARDET M, 1981, BIOCHEMISTRY-US, V20, P6684, DOI 10.1021/bi00526a025; GLOOR S, 1990, J CELL BIOL, V110, P165, DOI 10.1083/jcb.110.1.165; GOOD PJ, 1988, J VIROL, V62, P944, DOI 10.1128/JVI.62.3.944-953.1988; HALL K, 1990, BIOCHEMISTRY-US, V29, P701, DOI 10.1021/bi00455a016; HORISBERGER JD, 1991, IN PRESS P NATL ACAD; JAUNIN P, 1991, SODIUM PUMP RECENT D; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINVASALLO P, 1989, J BIOL CHEM, V264, P4613; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLER RP, 1990, BIOCHEMISTRY-US, V29, P1524, DOI 10.1021/bi00458a025; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SMOLKA A, 1983, AM J PHYSIOL, V245, pG589, DOI 10.1152/ajpgi.1983.245.4.G589; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; VERREY F, 1987, J CELL BIOL, V104, P1231, DOI 10.1083/jcb.104.5.1231; WALLMARK B, 1990, J INTERN MED, V228, P3, DOI 10.1111/j.1365-2796.1990.tb01465.x; ZAMOFING D, 1988, J MEMBRANE BIOL, V104, P69, DOI 10.1007/BF01871903	32	102	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19131	19134						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717460				2022-12-25	WOS:A1991GK66700002
J	BERNSTROM, K; KAYGANICH, K; MURPHY, RC; FITZPATRICK, FA				BERNSTROM, K; KAYGANICH, K; MURPHY, RC; FITZPATRICK, FA			INCORPORATION AND DISTRIBUTION OF EPOXYEICOSATRIENOIC ACIDS INTO CELLULAR PHOSPHOLIPIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST ATOM BOMBARDMENT; ARACHIDONIC-ACID; RETICULOCYTE LIPOXYGENASE; RABBIT RETICULOCYTES; EPOXIDE HYDROLASE; MASS-SPECTROMETRY; FATTY-ACIDS; METABOLISM; OXYGENATION; EPOXYGENASE	The different regioisomers of epoxyeicosatrienoic acids derived from cytochrome P-450 monooxygenase are readily esterified into phospholipids of mastocytoma cells. Incorporation of 14, 15-epoxyeicosatrienoic acid was concentration-dependent, with K(m) = 1.1-mu-M and V(max) = 36 pmol/min/10(7) cells. Half-maximal incorporation occurred in 30 min, reaching a steady-state concentration of 470 pmol/10(6) cells. This was slightly lower than the values for arachidonic acid (665 pmol/10(6) cells) or 5-hydroxyeicosatetraenoic acid (554 pmol/10(6) cells). The distribution of 14,15-epoxyeicosatrienoic acid was preferential in the order phosphatidylethanolamine > phosphatidylcholine > phosphatidylinositol > phosphatidyl serine >> neutral lipids plus fatty acids. This contrasted with 5(S)-hydroxyeicosatetraenoic acid, which was distributed primarily into phosphatidylcholine. Fast atom bombardment/tandem mass spectrometry facilitated identification of molecular species containing epoxyeicosatrienoic acids without relying on radioisotopes. Phosphatidylethanolamine plasmalogens with 16:1 or 18:2 at the sn-1 position, or an 18:0 acyl group, and phosphatidylcholine with 16:0 alkyl ether or an acyl group at the sn-1 position incorporated all possible epoxyeicosatrienoic acid regioisomers. Under basal conditions, cells eliminated 14,15-cis-epoxyeicosatrienoic acid slowly with a half-life of 34.9 +/- 7 h. Cells stimulated with calcium ionophore A23187 eliminated 14,15-epoxyeicosatrienoic acid rapidly. It was notable that its rate of release from phosphatidylcholine and phosphatidylinositol exceeded that for arachidonic acid. A coenzyme A-independent transacylase also catalyzed the transfer of epoxyeicosatrienoic acids from mastocytoma cell membranes into 1-palmitoyl-2-lysophosphatidylcholine. The cellular incorporation, release, and distribution of epoxyeicosatrienoic acids is distinctive and contrasts with most other eicosanoids, suggesting that these compounds may have both autocoid and nonautocoid functions.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL C236, 4200 E 9TH AVE, DENVER, CO 80262 USA; NATL JEWISH CTR IMMUNOL & RESP MED, DENVER, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health					NIGMS NIH HHS [GM 41026] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041026] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLOU LR, 1987, P NATL ACAD SCI USA, V84, P6990, DOI 10.1073/pnas.84.20.6990; BERNSTROM K, 1991, ANAL BIOCHEM, V198, P203, DOI 10.1016/0003-2697(91)90530-7; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRASH AR, 1987, BIOCHEMISTRY-US, V26, P5465, DOI 10.1021/bi00391a038; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; CAPDEVILA JH, 1987, BIOCHEM BIOPH RES CO, V146, P638, DOI 10.1016/0006-291X(87)90576-6; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; CHACOS N, 1983, ARCH BIOCHEM BIOPHYS, V223, P639, DOI 10.1016/0003-9861(83)90628-8; CHILTON FH, 1989, BIOCHEM J, V258, P327, DOI 10.1042/bj2580327; Dollery C T, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P91; FALCK JR, 1987, J LIPID RES, V28, P840; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; FALCK JR, 1984, J AM CHEM SOC, V106, P3334, DOI 10.1021/ja00323a046; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; JURGENS G, 1990, ANNU REP MED CHEM, V25, P169; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1991, J BIOL CHEM, V266, P7561; KUHN H, 1990, J BIOL CHEM, V265, P18351; KUHN H, 1990, J BIOL CHEM, V265, P1454; LANIADOSCHWARTZMAN M, 1988, J BIOL CHEM, V263, P2536; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; MOORE SA, 1988, J CELL PHYSIOL, V137, P75, DOI 10.1002/jcp.1041370109; MUNSTER H, 1986, BIOMED ENVIRON MASS, V13, P423, DOI 10.1002/bms.1200130808; NIETO ML, 1991, J BIOL CHEM, V266, P18699; OLIW EH, 1981, J BIOL CHEM, V256, P9924; OLIW EH, 1985, J CHROMATOGR, V339, P175, DOI 10.1016/S0378-4347(00)84640-X; OLIW EH, 1982, J BIOL CHEM, V257, P3771; PATTON GM, 1990, METHOD ENZYMOL, V187, P195; PAWLOWSKI NA, 1982, J EXP MED, V155, P1653, DOI 10.1084/jem.155.6.1653; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RICHARDS CF, 1989, PROSTAGLANDINS, V38, P565, DOI 10.1016/0090-6980(89)90150-0; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SEVANIAN A, 1981, LIPIDS, V16, P781, DOI 10.1007/BF02535029; SEVANIAN A, 1988, BIOCHIM BIOPHYS ACTA, V961, P316, DOI 10.1016/0005-2760(88)90079-3; SEVANIAN A, 1985, Journal of Free Radicals in Biology and Medicine, V1, P263, DOI 10.1016/0748-5514(85)90130-8; SHEN XY, 1988, BIOCHEMISTRY-US, V27, P996, DOI 10.1021/bi00403a024; SHERMAN WR, 1985, BIOMED MASS SPECTROM, V12, P409, DOI 10.1002/bms.1200120810; SMILEY PL, 1991, J BIOL CHEM, V266, P11104; SPEARMAN ME, 1985, ARCH BIOCHEM BIOPHYS, V242, P225, DOI 10.1016/0003-9861(85)90496-5; STENSON WF, 1983, PROSTAGLANDINS, V26, P253, DOI 10.1016/0090-6980(83)90093-X; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TOTO R, 1987, BIOCHIM BIOPHYS ACTA, V919, P132, DOI 10.1016/0005-2760(87)90199-8; TURK J, 1985, BIOCHIM BIOPHYS ACTA, V835, P1, DOI 10.1016/0005-2760(85)90023-2; UEMURA Y, 1991, J BIOL CHEM, V266, P8268; VENABLE ME, 1991, J BIOL CHEM, V266, P18691	46	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3686	3690						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740420				2022-12-25	WOS:A1992HE60700024
J	EIPPER, BA; GREEN, CBR; CAMPBELL, TA; STOFFERS, DA; KEUTMANN, HT; MAINS, RE; OUAFIK, L				EIPPER, BA; GREEN, CBR; CAMPBELL, TA; STOFFERS, DA; KEUTMANN, HT; MAINS, RE; OUAFIK, L			ALTERNATIVE SPLICING AND ENDOPROTEOLYTIC PROCESSING GENERATE TISSUE-SPECIFIC FORMS OF PITUITARY PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PEPTIDE AMIDATION; ENZYME; RAT; EXPRESSION; GLYCINE; DOMAIN; INTERMEDIATE; PRECURSOR; PRODUCT	The pituitary is a rich source of peptidylglycine alpha-amidating monooxygenase (PAM). This bifunctional protein contains peptidylglycine alpha-hydroxylating monooxygenase (PHM) and peptidyl-alpha-hydroxyglycine a-amidating lyase (PAL) catalytic domains necessary for the two-step formation of alpha-amidated peptides from their peptidylglycine precursors. In addition to the four forms of PAM mRNA identified previously, three novel forms of PAM mRNA were identified by examining anterior and neurointermediate pituitary cDNA libraries. None of the PAM cDNAs found in pituitary cDNA libraries contained exon A, the 315-nucleotide (nt) segment situated between the PHM and PAL domains and present in rPAM-1 but absent from rPAM-2. Although mRNAs of the rPAM-3a and -3b type encode bifunctional PAM precursors, the proteins differ significantly. rPAM-3b lacks a 54-nt segment encoding an 18-amino acid peptide predicted to occur in the cytoplasmic domain of this integral membrane protein; rPAM-3a lacks a 204-nt segment including the transmembrane domain and encodes a soluble protein. rPAM-5 is identical to rPAM-1 through nt 1217 in the PHM domain; alternative splicing generates a novel 3'-region encoding a COOH-terminal pentapeptide followed by 1.1 kb of 3'-untranslated region. The soluble rPAM-5 protein lacks PAL, transmembrane, and cytoplasmic domains. These three forms of PAM mRNA can be generated by alternative splicing. The major forms of PAM mRNA in both lobes of the pituitary are rPAM-3b and rPAM-2. Despite the fact that anterior and neurointermediate pituitary contain a similar distribution of forms of PAM mRNA, the distribution of PAM proteins in the two lobes of the pituitary is quite different. Although integral membrane proteins similar to rPAM-2 and rPAM-3b are major components of anterior pituitary granules, the PAM proteins in the neurointermediate lobe have undergone more extensive endoproteolytic processing, and a 75-kDa protein containing both PHM and PAL domains predominates. The bifunctional PAM precursor undergoes tissue-specific endoproteolytic cleavage reminiscent of the processing of prohormones.			EIPPER, BA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,RM 902,WOOD BASIC SCI BLDG,725 N WOLFE ST,BALTIMORE,MD 21205, USA.		Stoffers, Doris/H-6157-2012	Ouafik, L'Houcine/0000-0002-4848-1232	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032949, R37DK032949, R56DK032949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00266, DA-00097] Funding Source: Medline; NIDDK NIH HHS [DK-32949] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUDRY GA, 1989, BIOCHEM BIOPH RES CO, V163, P959, DOI 10.1016/0006-291X(89)92315-2; BERTELSEN AH, 1990, ARCH BIOCHEM BIOPHYS, V279, P87, DOI 10.1016/0003-9861(90)90466-C; BOND RW, 1990, P NATL ACAD SCI USA, V87, P8771, DOI 10.1073/pnas.87.22.8771; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; BRADBURY AF, 1987, EUR J BIOCHEM, V169, P579, DOI 10.1111/j.1432-1033.1987.tb13648.x; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; EIPPER BA, 1986, J BIOL CHEM, V261, P8686; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GRUNFELD C, 1987, ENDOCRINOLOGY, V121, P948, DOI 10.1210/endo-121-3-948; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; KATAPODIS AG, 1990, BIOCHEMISTRY-US, V26, P6115; KATO I, 1990, FEBS LETT, V269, P319, DOI 10.1016/0014-5793(90)81184-P; KATO I, 1990, BIOCHEM BIOPH RES CO, V172, P197, DOI 10.1016/S0006-291X(05)80193-7; MAINS RE, 1990, TRENDS ENDOCRIN MET, V1, P388, DOI 10.1016/1043-2760(90)90097-M; MAY V, 1988, J BIOL CHEM, V263, P7550; MAY V, 1990, ENDOCRINOLOGY, V127, P358, DOI 10.1210/endo-127-1-358; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; NEEDLEMAN P, 1989, ANNU REV PHARMACOL, V29, P23, DOI 10.1146/annurev.pa.29.040189.000323; OHALLORAN DJ, 1991, MOL CELL ENDOCRINOL, V75, pC7, DOI 10.1016/0303-7207(91)90237-M; OUAFIK L, 1990, MOL ENDOCRINOL, V4, P1497, DOI 10.1210/mend-4-10-1497; OUAFIK L, 1989, J BIOL CHEM, V264, P5839; OUAFIK LH, 1991, ENDOCRINOLOGY, V128, P106; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; SAKATA J, 1986, BIOCHEM BIOPH RES CO, V140, P230, DOI 10.1016/0006-291X(86)91080-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; STOFFERS DA, 1989, ICSU SHORT REPORTS, V9, P120; SUZUKI K, 1990, EMBO J, V9, P4259, DOI 10.1002/j.1460-2075.1990.tb07874.x; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; THIELE EA, 1989, ENDOCRINOLOGY, V125, P2279, DOI 10.1210/endo-125-5-2279; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088	36	97	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4008	4015						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740449				2022-12-25	WOS:A1992HE60700070
J	RAWLINGS, DJ; KASLOW, DC				RAWLINGS, DJ; KASLOW, DC			A NOVEL 40-KDA MEMBRANE-ASSOCIATED EF-HAND CALCIUM-BINDING PROTEIN IN PLASMODIUM-FALCIPARUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSION-BLOCKING ANTIBODIES; AMINO-ACID-SEQUENCE; GEL-ELECTROPHORESIS; SEXUAL STAGES; ANTIGENS; DNA; NITROCELLULOSE; EXPRESSION; IMMUNITY; VACCINE	A 40-kDa sexual stage radiolabeled surface protein of Plasmodium falciparum, Pfs40, was previously identified as a potential target antigen of transmission blocking immunity by an immunogenetic approach. Synthetic oligonucleotide "guessmers," based on micro-sequenced tryptic peptides of Pfs40 purified by two-dimensional gel electrophoresis, were used to clone the full length cDNA and genomic DNA encoding Pfs40. The deduced amino acid sequence predicted an integral membrane protein containing five EF-hand calcium-binding domains. The biological activity of one or more of these domains was confirmed by binding of Ca-45 to both native and recombinant Pfs40. Antisera to recombinant Pfs40 immunoprecipitated the native radiolabeled 40-kDa surface protein. The predicted noncytosolic membrane-associated localization of Pfs40 is unique within the EF-hand calcium-binding protein superfamily.	NIAID,PARASIT DIS LAB,MALARIA SECT,BLDG 4,ROOM B1-37,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BAIROCH A, 1990, FEBS LETT, V269, P454, DOI 10.1016/0014-5793(90)81214-9; BURKOT TR, 1984, T ROY SOC TROP MED H, V78, P339, DOI 10.1016/0035-9203(84)90114-7; CARTER R, 1988, PROG ALLERGY, V41, P193; CESBRONDELAUW MF, 1989, P NATL ACAD SCI USA, V86, P7537, DOI 10.1073/pnas.86.19.7537; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GOOD MF, 1988, SCIENCE, V242, P574, DOI 10.1126/science.2902690; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HYDE JE, 1989, MOL BIOCHEM PARASIT, V32, P247, DOI 10.1016/0166-6851(89)90074-1; Ifediba T, 1981, NATURE, V294, P364, DOI 10.1038/294364a0; KASLOW DC, 1990, J BIOL CHEM, V265, P12337; KASLOW DC, 1990, IMMUNOL LETT, V25, P83, DOI 10.1016/0165-2478(90)90096-9; KAWAMOTO F, 1990, MOL BIOCHEM PARASIT, V42, P101, DOI 10.1016/0166-6851(90)90117-5; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KOBAYASHI T, 1984, EUR J BIOCHEM, V144, P401, DOI 10.1111/j.1432-1033.1984.tb08478.x; KOCH GLE, 1990, BIOESSAYS, V12, P527, DOI 10.1002/bies.950121105; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MOOS M, 1988, J BIOL CHEM, V263, P6005; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; QUAKYI IA, 1987, J IMMUNOL, V139, P4213; RENER J, 1983, J EXP MED, V158, P976, DOI 10.1084/jem.158.3.976; RIGAUD G, 1987, NUCLEIC ACIDS RES, V15, P857, DOI 10.1093/nar/15.2.857; ROBSON KJH, 1991, MOL BIOCHEM PARASIT, V46, P19, DOI 10.1016/0166-6851(91)90195-C; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAUL A, 1990, MOL BIOCHEM PARASIT, V42, P55, DOI 10.1016/0166-6851(90)90112-Y; SINGH L, 1984, NUCLEIC ACIDS RES, V12, P5627, DOI 10.1093/nar/12.14.5627; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANABE K, 1990, BLOOD CELLS, V16, P437; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; URDAL DL, 1984, J CHROMATOGR, V296, P171, DOI 10.1016/S0021-9673(01)96410-6; VERMEULEN AN, 1985, J EXP MED, V162, P1460, DOI 10.1084/jem.162.5.1460; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3; [No title captured]	43	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3976	3982						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740445				2022-12-25	WOS:A1992HE60700066
J	WOLLE, D; KIM, CH; DEAN, D; HOWARD, JB				WOLLE, D; KIM, CH; DEAN, D; HOWARD, JB			IONIC INTERACTIONS IN THE NITROGENASE COMPLEX - PROPERTIES OF FE-PROTEIN CONTAINING SUBSTITUTIONS FOR ARG-100	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII NITROGENASE; BACTERIUM RHODOSPIRILLUM-RUBRUM; OXIDIZED IRON PROTEIN; DINITROGENASE REDUCTASE; KLEBSIELLA-PNEUMONIAE; CLOSTRIDIUM-PASTEURIANUM; COVALENT MODIFICATION; DIRECTED MUTAGENESIS; SUBSTRATE REDUCTION; CROSS-LINKING	A series of Azotobacter vinelandii strains have been constructed in which the nitrogenase Fe-protein (Av2) was altered by substitutions for Arg- 100. This invariant residue is a likely partner in a salt bridge with the MoFe-protein and, in some species, is the site of reversible regulation by ADP-ribosylation (Pope, M. R., Murrell, S. A., and Ludden, P. W. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 3173-3177). Although we find that arginine is the optimum amino acid, other residues in this position could support diazotrophic growth. These results were surprising because Klebsiella pneumoniae Fe-protein substituted by His-100 had been reported to be inactive (Lowery, R. G., Chang, C. L., Davis, L. C., McKenna, M.-C., Stevens, P. J., and Ludden, P. W. (1989) Biochemistry 28, 1206-1212). Two altered Fe-proteins (Av2-R100Y, the tyrosyl form, and Av2-R100H, the histidyl form) were isolated and, in contrast to this earlier report, we found that both had some activity in acetylene reduction. However, both altered proteins exhibited a decreased maximum velocity (35 and 3% of wild type, respectively) and were strongly inhibited by excess MoFe-protein. These adverse activity parameters were also manifest in the increased sensitivity of the altered proteins to inhibition by salts. Indeed, the salt sensitivity of Av2-R100H is so significant that its activity is masked in the normal assay and is easily missed. In addition, for Av2-R100H, substrate reduction is substantially uncoupled from MgATP hydrolysis. These results suggest that substitutions for Arg-100 may decrease the affinity of the Fe-protein for the MoFe-protein prior to electron transfer but increase affinity after electron transfer. Hence, the role of Arg-100 may be to provide the optimum balance in stabilities of these two complexes for maximum efficiency in substrate reduction.	VIRGINIA POLYTECH INST & STATE UNIV,DEPT ANAEROB MICROBIOL,BLACKSBURG,VA 24061	Virginia Polytechnic Institute & State University	WOLLE, D (corresponding author), UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455, USA.				NIGMS NIH HHS [GM 34321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034321] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON GL, 1984, BIOCHEMISTRY-US, V23, P2118, DOI 10.1021/bi00305a002; BRIGLE KE, 1987, P NATL ACAD SCI USA, V84, P7066, DOI 10.1073/pnas.84.20.7066; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURNS A, 1985, BIOCHEMISTRY-US, V24, P3932, DOI 10.1021/bi00336a019; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; DEITS TL, 1989, J BIOL CHEM, V264, P6619; DEITS TL, 1990, J BIOL CHEM, V265, P3859; Eady R. R., 1980, Methods in Enzymology, V69, P753, DOI 10.1016/S0076-6879(80)69072-7; EMERICH DW, 1978, J BACTERIOL, V134, P936, DOI 10.1128/JB.134.3.936-943.1978; GEORGIADIS MM, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P111; GOTTO JW, 1985, ARCH MICROBIOL, V141, P40, DOI 10.1007/BF00446737; GUTH JH, 1983, BIOCHEM J, V213, P741, DOI 10.1042/bj2130741; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HOOVER T R, 1988, Biofactors, V1, P199; HOWARD JB, 1989, J BIOL CHEM, V264, P11270; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; LI JG, 1982, BIOCHEMISTRY-US, V21, P4393, DOI 10.1021/bi00261a031; LINDAHL PA, 1987, J BIOL CHEM, V262, P14945; LJONES T, 1978, BIOCHEMISTRY-US, V17, P1866, DOI 10.1021/bi00603a010; LOWE D, 1984, MOLYBDENUM ENZYMES, P222; LOWERY RG, 1986, J BACTERIOL, V166, P513, DOI 10.1128/jb.166.2.513-518.1986; LOWERY RG, 1988, J BIOL CHEM, V263, P16714; LOWERY RG, 1989, BIOCHEMISTRY-US, V28, P1206, DOI 10.1021/bi00429a038; MURRELL SA, 1988, BIOCHEM J, V251, P609, DOI 10.1042/bj2510609; ORMEJOHNSON WH, 1985, ANNU REV BIOPHYS BIO, V14, P419, DOI 10.1146/annurev.biophys.14.1.419; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; POPE MR, 1985, P NATL ACAD SCI USA, V82, P3173, DOI 10.1073/pnas.82.10.3173; RUBINSON JF, 1983, BIOCHEMISTRY-US, V22, P6260, DOI 10.1021/bi00295a034; SAARI LL, 1984, J BIOL CHEM, V259, P5502; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SMITH BE, 1976, BIOCHEM J, V157, P439, DOI 10.1042/bj1570439; THORNELEY RNF, 1984, BIOCHEM J, V224, P903, DOI 10.1042/bj2240903; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WATT GD, 1980, BIOCHEMISTRY-US, V19, P4926, DOI 10.1021/bi00562a035; WILLING A, 1990, J BIOL CHEM, V265, P6596; WILLING AH, 1989, J BIOL CHEM, V264, P8499; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	40	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3667	3673						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740419				2022-12-25	WOS:A1992HE60700021
J	ELICH, TD; EDELMAN, M; MATTOO, AK				ELICH, TD; EDELMAN, M; MATTOO, AK			IDENTIFICATION, CHARACTERIZATION, AND RESOLUTION OF THE INVIVO PHOSPHORYLATED FORM OF THE D1 PHOTOSYSTEM-II REACTION CENTER PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOLIZED 32-KILODALTON PROTEIN; PHOTOSYNTHETIC ELECTRON-TRANSPORT; REDOX STATE; POLYPEPTIDE; INHIBITION; THYLAKOIDS; BINDING; KINASE; PHOSPHOPROTEINS; CHLOROPLASTS	The chloroplast-encoded D1 protein of oxygenic photosynthetic organisms is a component of the photosystem II reaction center. Previously, we detected an electrophoretic variant of D1 which was generated in vivo in granal-localized reaction centers in a light dependent manner (Callahan, F. E., Ghirardi, M. L., Sopory, S. K., Mehta, A. M., Edelman, M., and Mattoo, A. K. (1990) J. Biol Chem. 265, 15357-15360). In the present study, we identify this modified form as phosphorylated D1. The in vivo phosphorylation occurs on a threonine residue(s) localized within 1 kDa from the N terminus and is identical to the phosphorylation of D1 catalyzed in vitro by a redox-regulated thylakoid-bound protein kinase. While virtually all of the D1 protein present in thylakoids can be phosphorylated in vitro, the steady-state level of phosphorylated D1 in vivo varies with light intensity and did not exceed 20% of the total D1 under the conditions of this study.	USDA ARS,BELTSVILLE AGR RES CTR,BELTSVILLE AGR RES CTR W,PLANT MOLEC BIOL LAB,BLDG 006,BELTSVILLE,MD 20705; WEIZMANN INST SCI,DEPT PLANT GENET,IL-76100 REHOVOT,ISRAEL	United States Department of Agriculture (USDA); Weizmann Institute of Science			Mattoo, Autar/G-9863-2011					AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALLEN JF, 1981, NATURE, V291, P25, DOI 10.1038/291025a0; ALLEN JF, 1986, FEBS LETT, V202, P175, DOI 10.1016/0014-5793(86)80682-2; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; AVNI A, 1991, PLANT MOL BIOL, V17, P919, DOI 10.1007/BF00037073; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; BENNETT J, 1980, EUR J BIOCHEM, V104, P85, DOI 10.1111/j.1432-1033.1980.tb04403.x; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; CALLAHAN FE, 1989, PLANT PHYSIOL, V91, P629, DOI 10.1104/pp.91.2.629; CALLAHAN FE, 1990, J BIOL CHEM, V265, P15357; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COUGHLAN SJ, 1987, BIOCHEMISTRY-US, V26, P6515, DOI 10.1021/bi00394a034; Edelman M., 1978, CHLOROPLAST DEV, P641; FARCHAUS J, 1985, BIOCHIM BIOPHYS ACTA, V809, P17, DOI 10.1016/0005-2728(85)90162-8; GIRDI MT, 1991, BIOCHEM BIOPH RES CO, V176, P1298; GREBANIER AE, 1978, J CELL BIOL, V78, P734, DOI 10.1083/jcb.78.3.734; HABASH DZ, 1990, J EXP BOT, V41, P761, DOI 10.1093/jxb/41.7.761; HAWORTH P, 1982, PHOTOCHEM PHOTOBIOL, V36, P743, DOI 10.1111/j.1751-1097.1982.tb09498.x; HODGES M, 1987, BIOCHIM BIOPHYS ACTA, V894, P138, DOI 10.1016/0005-2728(87)90183-6; HODGES M, 1985, FEBS LETT, V181, P83, DOI 10.1016/0014-5793(85)81118-2; HORTON P, 1984, BIOCHIM BIOPHYS ACTA, V767, P563, DOI 10.1016/0005-2728(84)90056-2; HORTON P, 1985, PLANTA, V165, P37, DOI 10.1007/BF00392209; JURSINIC PA, 1983, BIOCHIM BIOPHYS ACTA, V723, P37, DOI 10.1016/0005-2728(83)90006-3; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; MARDER JB, 1984, J BIOL CHEM, V259, P3900; MARDER JB, 1986, METHOD ENZYMOL, V118, P384; MARDER JB, 1988, BIOCHIM BIOPHYS ACTA, V932, P362, DOI 10.1016/0005-2728(88)90172-7; MATTOO AK, 1984, P NATL ACAD SCI-BIOL, V81, P1380, DOI 10.1073/pnas.81.5.1380; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MICHEL H, 1987, PLANT MEMBRANES STRU, P85; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; OHAD I, 1990, J BIOL CHEM, V265, P1972; PACKHAM NK, 1987, BIOCHIM BIOPHYS ACTA, V893, P259, DOI 10.1016/0005-2728(87)90047-8; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; POSNER HB, 1967, METHODS DEV BIOL, P301; REISFELD A, 1982, EUR J BIOCHEM, V124, P125, DOI 10.1111/j.1432-1033.1982.tb05914.x; RUTHERFORD AW, 1989, TRENDS BIOCHEM SCI, V14, P227, DOI 10.1016/0968-0004(89)90032-7; SHOCHAT S, 1982, BIOCHIM BIOPHYS ACTA, V681, P21, DOI 10.1016/0005-2728(82)90274-2; VERMAAS WFJ, 1984, ARCH BIOCHEM BIOPHYS, V231, P226, DOI 10.1016/0003-9861(84)90382-5; WILLIAMS WP, 1987, PHOTOSYNTH RES, V13, P19, DOI 10.1007/BF00032263	42	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3523	3529						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737803				2022-12-25	WOS:A1992HD15400106
J	GRIGORIEV, M; PRASEUTH, D; ROBIN, P; HEMAR, A; SAISONBEHMOARAS, T; DAUTRYVARSAT, A; THUONG, NT; HELENE, C; HARELBELLAN, A				GRIGORIEV, M; PRASEUTH, D; ROBIN, P; HEMAR, A; SAISONBEHMOARAS, T; DAUTRYVARSAT, A; THUONG, NT; HELENE, C; HARELBELLAN, A			A TRIPLE HELIX-FORMING OLIGONUCLEOTIDE-INTERCALATOR CONJUGATE ACTS AS A TRANSCRIPTIONAL REPRESSOR VIA INHIBITION OF NF KAPPA-B BINDING TO INTERLEUKIN-2 RECEPTOR ALPHA-REGULATORY SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE NUCLEAR PROTEINS; PRIMARY HUMAN-LYMPHOCYTES; DOUBLE-STRANDED DNA; C-MYC GENE; MAJOR GROOVE; CHAIN GENE; DUPLEX DNA; RNA GENES; HTLV-I; EXPRESSION	Oligonucleotide-directed triplex formation within upstream regulatory sequences is envisioned as a potential tool for gene inhibition. However, this approach requires that triple helix-forming oligonucleotides are chemically modified, so that the triplex is stable under physiological conditions. Here, we have compared several chemical modifications of an oligonucleotide, targeted to a natural 15-base pair homopyrimidine . homopurine sequence located in the upstream regulatory region of the gene encoding the interleukin-2 receptor alpha-chain (p55, IL-2 R-alpha). Methylation of the cytosines strongly stabilized the triplex. Further attachment of an intercalating agent (acridine) dramatically increased the stability of the triplex, as assessed by T(m) measurements or by band shift assays. Furthermore, the acridine-derivatized oligonucleotide was more efficient in competing away high affinity DNA-binding proteins, as assessed by restriction enzyme inhibition assays. Using a novel footprinting assay, we have further shown that the interaction of the methylcytosine-substituted, acridine-derivatized oligonucleotide with a plasmidic target, harboring the IL-2 R-alpha regulatory region, remains highly sequence specific, occurs at physiological pH and is independent of the superhelicity of the plasmid. Acridine derivatization did not impair the exquisite target specificity of triplex formation, since the derivatized oligonucleotide inhibited the binding of nuclear proteins to the overlapping NF kappa-B enhancer sequence on an IL-2 R-alpha target and not on the related human immunodeficiency virus long terminal repeat target. Finally, the oligonucleotide inhibited the NF kappa-B-dependent tax-induced transcriptional activation of the IL-2 R-alpha chloramphenicol acetyltransferase construct in live cells, whereas it did not have any effect on a human immunodeficiency virus long terminal repeat chloramphenicol acetyltransferase construct. We conclude that this modified oligonucleotide acts as a transcriptional repressor for the IL-2 R-alpha gene via triple helix formation with regulatory sequences.	INST GUSTAVE ROUSSY, IMMUNOBIOL LAB,CNRS,URA 1156,PAVILLON RECH 1, 39 RUE CAMILLE DESMOULINS, F-94805 VILLEJUIF, FRANCE; MUSEUM NATL HIST NAT, INSERM, U201, BIOPHYS LAB, F-75231 PARIS 05, FRANCE; INST PASTEUR, UNITE GENET SOMAT, F-75724 PARIS, FRANCE; CNRS, CTR BIOPHYS MOLEC, F-45071 ORLEANS, FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)			Harel-Bellan, Annick/M-9795-2015	Grigoriev, Michel/0000-0002-0252-2254; Harel-Bellan, Annick/0000-0002-2339-153X				BIRG F, 1990, NUCLEIC ACIDS RES, V18, P2901, DOI 10.1093/nar/18.10.2901; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOHNLEIN E, 1989, J BIOL CHEM, V264, P8475; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; CANN AJ, 1988, ONCOGENE, V3, P123; CHENG HL, 1982, NATURE, V296, P410, DOI 10.1038/296410a0; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; CRABTREE GR, 1982, CELL, V31, P159, DOI 10.1016/0092-8674(82)90415-9; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUKOVICH M, 1987, NATURE, V327, P518, DOI 10.1038/327518a0; EVANS T, 1986, J BIOL CHEM, V261, P4771; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FRANCOIS JC, 1989, BIOCHEMISTRY-US, V28, P9617, DOI 10.1021/bi00451a011; FRANCOIS JC, 1988, NUCLEIC ACIDS RES, V16, P11431, DOI 10.1093/nar/16.24.11431; FRANCOIS JC, 1989, P NATL ACAD SCI USA, V86, P9702, DOI 10.1073/pnas.86.24.9702; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE WC, 1985, J EXP MED, V162, P363, DOI 10.1084/jem.162.1.363; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HARELBELLAN A, 1989, BIOCHEM BIOPH RES CO, V162, P238, DOI 10.1016/0006-291X(89)91987-6; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HTUN H, 1984, P NATL ACAD SCI-BIOL, V81, P7288, DOI 10.1073/pnas.81.23.7288; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1985, EMBO J, V4, P1839, DOI 10.1002/j.1460-2075.1985.tb03858.x; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JOHNSTON BH, 1988, SCIENCE, V241, P1800, DOI 10.1126/science.2845572; KEDES LH, 1979, ANNU REV BIOCHEM, V48, P837, DOI 10.1146/annurev.bi.48.070179.004201; KEHRL JH, 1988, J CLIN INVEST, V81, P200, DOI 10.1172/JCI113295; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MCINTYRE P, 1988, ANAL BIOCHEM, V174, P209, DOI 10.1016/0003-2697(88)90537-4; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; PERROUAULT L, 1990, NATURE, V344, P358, DOI 10.1038/344358a0; POMERANTZ JL, 1989, J IMMUNOL, V143, P4275; PRASEUTH D, 1988, P NATL ACAD SCI USA, V85, P1349, DOI 10.1073/pnas.85.5.1349; PULLEYBLANK DE, 1985, CELL, V42, P271, DOI 10.1016/S0092-8674(85)80122-7; RAJAGOPAL P, 1989, NATURE, V339, P637, DOI 10.1038/339637a0; RICHARDS JE, 1983, NATURE, V306, P483, DOI 10.1038/306483a0; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUN JS, 1989, P NATL ACAD SCI USA, V86, P9198, DOI 10.1073/pnas.86.23.9198; THUONG NT, 1988, TETRAHEDRON LETT, V29, P5905, DOI 10.1016/S0040-4039(00)82222-4; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; TROUCHE D, 1991, BLOOD, V77, P55; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; VLASSOV VV, 1988, GENE, V72, P313, DOI 10.1016/0378-1119(88)90158-8; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0	60	194	230	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3389	3395						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737792				2022-12-25	WOS:A1992HD15400088
J	HUTCHISON, KA; CZAR, MJ; PRATT, WB				HUTCHISON, KA; CZAR, MJ; PRATT, WB			EVIDENCE THAT THE HORMONE-BINDING DOMAIN OF THE MOUSE GLUCOCORTICOID RECEPTOR DIRECTLY REPRESSES DNA-BINDING ACTIVITY IN A MAJOR PORTION OF RECEPTORS THAT ARE MISFOLDED AFTER REMOVAL OF HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TWO-DIMENSIONAL ELECTROPHORESIS; CALF THYMUS DNA; STEROID-BINDING; MONOCLONAL-ANTIBODY; FUNCTIONAL DOMAINS; SULFHYDRYL-GROUPS; TRANSFORMATION; PHOSPHORYLATION; ACTIVATION	After dissociation of cytosolic heteromeric glucocorticoid receptor complexes by steroid, salt, and other methods, only 35-60% of the dissociated receptors can bind to DNA-cellulose. The DNA-binding and non-DNA-binding forms of the dissociated receptors have the same Mr and are phosphorylated to the same extent (Tienrungroj, W., Sanchez, E. R., Housley, P. R., Harrison, R. W., and Pratt, W. B. (1987) J. Biol. Chem. 262, 17347-17349). The basis for the different DNA-binding activities is unknown, but the DNA-binding fraction of the receptor has a more basic pl than the non-DNA-binding fraction (Smith, A. C., Elsasser, M. S., and Harmon, J. M. (1986) J. Biol. Chem. 261, 13285-13292). We have separated the non-DNA-binding state of the receptor from the DNA-binding state and then cleaved it with trypsin and chymotrypsin. We find that the 15-kDa tryptic fragment derived from the non-DNA-binding state of the dissociated receptor is fully competent in binding DNA, whereas the 42-kDa chymotryptic fragment containing both the hormone-binding and DNA-binding domains does not bind DNA. Trypsin cleavage of the molybdate-stabilized untransformed receptor also yields a 15-kDa fragment that is fully competent in binding DNA. Reducing agents do not restore DNA-binding to the non-DNA-binding fraction of the receptor and the hormone-binding domain can be separated from the DNA-binding domain on nonreducing gel electrophoresis. These results argue that the two domains are not linked by disulfide bridges, and they are consistent with the proposal that there are two least energy states of folding after dissociation of hsp90. A significant portion of the receptors is ''misfolded'' in such a manner that the steroid binding domain is directly preventing DNA-binding activity.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan					NIDDK NIH HHS [DK31578] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CARLSTEDTDUKE J, 1987, P NATL ACAD SCI USA, V84, P4437, DOI 10.1073/pnas.84.13.4437; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P989, DOI 10.1021/bi00456a022; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P996, DOI 10.1021/bi00456a023; CHAKRABORTI PK, 1991, BIOCHEM BIOPH RES CO, V176, P1339; DALMAN FC, 1988, J BIOL CHEM, V263, P12259; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DENIS M, 1988, J BIOL CHEM, V263, P18520; EISEN LP, 1985, J BIOL CHEM, V260, P1805; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; HARMON JM, 1989, CANCER RES, V49, pS2238; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; MENDEL DB, 1985, J BIOL CHEM, V260, P8736; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; MESHINCHI S, 1990, J BIOL CHEM, V265, P11643; MOUDGIL VK, 1987, J BIOL CHEM, V262, P5180; PELEG S, 1988, BIOCHEMISTRY-US, V27, P358, DOI 10.1021/bi00401a054; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; PRATT WB, 1988, J BIOL CHEM, V263, P267; RUSCONI S, 1987, EMBO J, V6, P1309, DOI 10.1002/j.1460-2075.1987.tb02369.x; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SMITH AC, 1985, BIOCHEMISTRY-US, V24, P4946, DOI 10.1021/bi00339a033; SMITH AC, 1986, J BIOL CHEM, V261, P3285; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P17342; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P6992; WRANGE O, 1984, J BIOL CHEM, V259, P4534	27	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3190	3195						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737773				2022-12-25	WOS:A1992HD15400059
J	MAKAARU, CK; DAMIAN, RT; SMITH, DF; CUMMINGS, RD				MAKAARU, CK; DAMIAN, RT; SMITH, DF; CUMMINGS, RD			THE HUMAN BLOOD FLUKE SCHISTOSOMA-MANSONI SYNTHESIZES A NOVEL TYPE OF GLYCOSPHINGOLIPID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; GLYCOLIPID-LECTIN INTERACTIONS; CELL-LINES; SURFACE ANTIGENS; HAMSTER CELLS; MEMBRANE; BINDING; GLYCOPROTEINS; TEGUMENT; DIFFERENTIATION	Previous studies have shown that the glycoprotein oligosaccharides synthesized by adult Schistosoma mansoni, the organism responsible for human schistosomiasis, are unusual in that they contain terminal beta-GalNAc residues and lack sialic acid. These observations and other studies indicating that schistosome glycoproteins and glycolipids are antigenic in infected animals led us to investigate the structures of the glycosphingolipids synthesized by these organisms and to determine whether they are structurally related to those synthesized by their vertebrate hosts. For our studies, adult schistosomes were metabolically radiolabeled with either [H-3]galactose or [H-3]glucosamine, and the newly synthesized glycosphingolipids were isolated and characterized. The major glycosphingolipids synthesized by adult schistosomes were found to be galactosylceramide and glucosylceramide. The adult worms synthesized no lactosylceramide (Gal-beta-1-4Glc-ceramide), a common constituent of vertebrate cells; however, another disaccharide-containing glycosphingolipid cleavable by ceramide glycanase was found. The results of compositional and methylation analyses and exoglycosidase treatments demonstrated that this ceramide-disaccharide has the structure GalNAc-beta-1-4Glc-ceramide. We also found that extracts of adult schistosomes are unable to transfer Gal from UDP-Gal to glucosylceramide, whereas extracts of Chinese hamster ovary cells, as a control, are able to do so, confirming that schistosomes are unable to synthesize lactosylceramide. Low levels of higher molecular weight glycosphingolipids were also found to be synthesized by adult schistosomes, and although their levels were too small to allow definitive characterization, compositional analyses indicated that they also contained GalNAc. We have tentatively designated the new disaccharide structure GalNAc-beta-1,4Glc- the "schistocore", which may represent a new type of glycosphingolipid core series.	UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA; UNIV GEORGIA, DEPT ZOOL, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI026725, R01AI026725, R22AI018906] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26725, AI18906] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALVING CR, 1974, P SOC EXP BIOL MED, V146, P458, DOI 10.3181/00379727-146-38125; ARTZT K, 1973, P NATL ACAD SCI USA, V70, P2988, DOI 10.1073/pnas.70.10.2988; BENNETT JL, 1977, J PARASITOL, V63, P250, DOI 10.2307/3280054; BERN PL, 1978, CELL, V14, P775; BLANCHARD D, 1985, BIOCHEM J, V232, P813, DOI 10.1042/bj2320813; BOSSHARDT SC, 1986, J PARASITOL, V72, P583, DOI 10.2307/3281514; CINANU I, 1984, CARBOHYD RES, V131, P209; CLARK GF, 1991, CARBOHYD RES, V213, P155, DOI 10.1016/S0008-6215(00)90606-2; COULONMORELEC MJ, 1981, DEV BIOL, V83, P278, DOI 10.1016/0012-1606(81)90474-7; CRITCHLEY DR, 1973, BIOCHIM BIOPHYS ACTA, V296, P145, DOI 10.1016/0005-2760(73)90054-4; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1989, METHOD CELL BIOL, V32, P141; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DAMIAN RT, 1972, AM J TROP MED HYG, V21, P951, DOI 10.4269/ajtmh.1972.21.951; DEAN DA, 1972, CLIN EXP IMMUNOL, V12, P525; DEAN DA, 1974, J PARASITOL, V60, P260, DOI 10.2307/3278461; DONALD ASR, 1986, BIOCHEM J, V236, P821, DOI 10.1042/bj2360821; DYER CA, 1990, J CELL BIOL, V111, P625, DOI 10.1083/jcb.111.2.625; ESSELMAN WJ, 1972, METHOD ENZYMOL, V28, P140; GOLDRING OL, 1976, CLIN EXP IMMUNOL, V26, P181; GREEN ED, 1985, J BIOL CHEM, V260, P5623; GUNNARSSON A, 1987, GLYCOCONJUGATE J, V4, P239, DOI 10.1007/BF01048429; HAKOMORI SI, 1970, P NATL ACAD SCI USA, V67, P1741, DOI 10.1073/pnas.67.4.1741; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HOCKLEY D J, 1973, International Journal for Parasitology, V3, P13, DOI 10.1016/0020-7519(73)90004-0; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KAYSER S G, 1970, Biochemical and Biophysical Research Communications, V41, P1572, DOI 10.1016/0006-291X(70)90567-X; KIJIMOTO S, 1971, BIOCHEM BIOPH RES CO, V44, P557, DOI 10.1016/S0006-291X(71)80119-5; LI SC, 1986, BIOCHEM BIOPH RES CO, V141, P346, DOI 10.1016/S0006-291X(86)80375-8; Lindberg B, 1972, METHODS ENZYMOL, V28, P178; LINDER E, 1982, PARASITOLOGY, V85, P503, DOI 10.1017/S0031182000056286; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALONEY MD, 1990, INT J PARASITOL, V20, P1091, DOI 10.1016/0020-7519(90)90055-R; MARCHASE RB, 1977, J CELL BIOL, V75, P237, DOI 10.1083/jcb.75.1.237; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; MOSKAL JR, 1974, BIOCHEM BIOPH RES CO, V61, P751, DOI 10.1016/0006-291X(74)91021-3; MUCHMORE AV, 1987, J IMMUNOL, V138, P2541; NAKATA N, 1991, GLYCOCONJUGATE J, V8, P250; NYAME K, 1987, J BIOL CHEM, V262, P7990; NYAME K, 1988, MOL BIOCHEM PARASIT, V28, P265, DOI 10.1016/0166-6851(88)90011-4; NYAME K, 1989, J BIOL CHEM, V264, P3235; ROGERS MV, 1987, MOL BIOCHEM PARASIT, V22, P273, DOI 10.1016/0166-6851(87)90058-2; SAKIYAMA H, 1972, P NATL ACAD SCI USA, V69, P872, DOI 10.1073/pnas.69.4.872; SAMUELSON JC, 1982, J CELL BIOL, V94, P363, DOI 10.1083/jcb.94.2.363; SAMUELSSON BE, 1987, METHOD ENZYMOL, V138, P567; SAUNDERS N, 1987, MOL BIOCHEM PARASIT, V25, P123, DOI 10.1016/0166-6851(87)90001-6; SHERBLOM AP, 1988, J BIOL CHEM, V263, P5418; SIMPSON AJG, 1980, PARASITOLOGY, V81, P1; SMITH DF, 1983, BIOCHEM BIOPH RES CO, V115, P360, DOI 10.1016/0006-291X(83)91012-4; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SVENNERHOLM L, 1956, J NEUROCHEM, V1, P42, DOI 10.1111/j.1471-4159.1956.tb12053.x; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; Tilley CA, 1991, GLYCOCONJUGATE J, V8, P249; TORRES BV, 1988, ARCH BIOCHEM BIOPHYS, V262, P1, DOI 10.1016/0003-9861(88)90161-0; VANCE DE, 1967, J LIPID RES, V8, P621; VIAL HJ, 1985, MOL BIOCHEM PARASIT, V17, P203, DOI 10.1016/0166-6851(85)90019-2; WATANABE K, 1979, J BIOL CHEM, V254, P3221; WEIGANDT H, 1985, NEW COMPREHENSIVE BI, V10, P2; WEISS JB, 1986, J IMMUNOL, V136, P4275; WHEATER PR, 1976, PARASITOLOGY, V72, P99, DOI 10.1017/S0031182000043237; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WILSON RA, 1977, PARASITOLOGY, V74, P61, DOI 10.1017/S0031182000047533	64	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2251	2257						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733932				2022-12-25	WOS:A1992HB53200023
J	ROBINSON, BS; JOHNSON, DW; POULOS, A				ROBINSON, BS; JOHNSON, DW; POULOS, A			NOVEL MOLECULAR-SPECIES OF SPHINGOMYELIN CONTAINING 2-HYDROXYLATED POLYENOIC VERY-LONG-CHAIN FATTY-ACIDS IN MAMMALIAN TESTES AND SPERMATOZOA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM ACROSOME REACTION; PROTEIN KINASE-C; LIPID-COMPOSITION; MOUSE TESTIS; RAT SERTOLI; DIPOLYUNSATURATED PHOSPHATIDYLCHOLINES; ZELLWEGERS SYNDROME; ARACHIDONIC-ACID; GERMINAL CELLS; LEYDIG-CELLS	Polyenoic very-long-chain fatty acids (VLCFA) have been shown to be localized in unusual molecular species of sphingomyelin in the testes and spermatozoa of the ram, bull, rat, and boar and in the spermatozoa of man. The composition of polyenoic VLCFA-sphingomyelin was comparable in the testes and spermatozoa of each mammalian species; however, the sphingolipid was more concentrated in spermatozoa. The composition of testicular and spermatozoan polyenoic VLCFA-sphingomyelin differed considerably between animal types. Human spermatozoa mainly contained n-6 polyenoic VLCFA with two to four double bonds and even-carbon chain lengths up to 32. In ram and bull testes and spermatozoa, n-3 and n-6, tetra-, penta-, and hexaenoic VLCFA with even-carbon chain lengths up to 34 predominated. In rat and boar testes and spermatozoa, the polyenoic VLCFA were mainly n-6 derivatives with three to five double bonds and even- and odd-carbon chain lengths up to 34. The testes and spermatozoa of the latter two animal species contained 2-hydroxylated, in addition to non-hydroxylated, polyenoic VLCFA in sphingomyelin. This is the first time that 2-hydroxylated polyenoic VLCFA have been recognized in biological systems. Non-hydroxylated polyenoic VLCFA were initially observed in the sphingomyelin of rat testes 25 days after birth, followed by 2-hydroxylated derivatives at 30 days. The total amount of polyenoic VLCFA associated with rat testicular sphingomyelin increased dramatically from 25 to 40 days of postnatal life and then remained constant to 60 days (sexual maturity). The ratio of 2-hydroxylated to non-hydroxylated polyenoic VLCFA increased during this period. Polyenoic VLCFA-sphingomyelin seems to occur exclusively in the testes and spermatozoa of mammals, and it is postulated that this lipid plays a role in reproduction.			ROBINSON, BS (corresponding author), ADELAIDE CHILDRENS HOSP INC,DEPT CHEM PATHOL,72 KING WILLIAM RD,ADELAIDE,SA 5006,AUSTRALIA.							AITKEN RJ, 1985, J REPROD FERTIL, V73, P139; ARVIDSON GA, 1968, EUR J BIOCHEM, V4, P478, DOI 10.1111/j.1432-1033.1968.tb00237.x; AVELDANO MI, 1987, J BIOL CHEM, V262, P1180; AVELDANO MI, 1987, J BIOL CHEM, V262, P1172; BARENHOLZ U, 1982, NEW COMPR BIOCH, V4, P129; BECKMAN JK, 1980, LIPIDS, V15, P389, DOI 10.1007/BF02534061; BECKMAN JK, 1978, BIOCHIM BIOPHYS ACTA, V530, P367, DOI 10.1016/0005-2760(78)90156-X; BECKMAN JK, 1979, LIPIDS, V14, P262, DOI 10.1007/BF02533912; BERNHARD KARL, 1963, HELV CHIM ACTA, V46, P1798, DOI 10.1002/hlca.19630460542; BILINSKA B, 1988, FOLIA HISTOCHEM CYTO, V26, P53; BLACKSHAW A. W., 1954, AUSTRALIAN VET JOUR, V30, P249, DOI 10.1111/j.1751-0813.1954.tb06519.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOREK C, 1991, P NATL ACAD SCI USA, V88, P1953, DOI 10.1073/pnas.88.5.1953; BRIDGES RB, 1970, J BIOL CHEM, V245, P46; CARBALLEIRA NM, 1989, LIPIDS, V24, P89, DOI 10.1007/BF02535272; CARBALLEIRA NM, 1989, LIPIDS, V24, P229, DOI 10.1007/BF02535240; CARPENTER MP, 1971, BIOCHIM BIOPHYS ACTA, V231, P52, DOI 10.1016/0005-2760(71)90255-4; CHRISTENSEN AK, 1965, ENDOCRINOLOGY, V76, P646, DOI 10.1210/endo-76-4-646; CLERMONT Y, 1972, PHYSIOL REV, V52, P198, DOI 10.1152/physrev.1972.52.1.198; CONIGLIO JG, 1989, LIPIDS, V24, P84, DOI 10.1007/BF02535270; CONIGLIO JG, 1977, FUNCTION BIOSYNTHESI, P575; CONIGLIO JG, 1971, TESTES, V4, P425; DIDOLKAR AK, 1980, J REPROD FERTIL, V58, P275, DOI 10.1530/jrf.0.0580275; DIX CJ, 1984, BIOCHEM J, V219, P529, DOI 10.1042/bj2190529; EASTON C, 1988, J LIPID RES, V29, P109; FELLENBERG AJ, 1987, BIOMED ENVIRON MASS, V14, P127, DOI 10.1002/bms.1200140306; FOLCH J, 1957, J BIOL CHEM, V226, P497; GROGAN WM, 1983, LIPIDS, V18, P275, DOI 10.1007/BF02534702; GROGAN WM, 1984, LIPIDS, V19, P341, DOI 10.1007/BF02534785; GROGAN WM, 1981, LIPIDS, V16, P401, DOI 10.1007/BF02535006; GROGAN WM, 1982, LIPIDS, V17, P605, DOI 10.1007/BF02535366; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JONES R, 1986, J REPROD FERTIL, V77, P435, DOI 10.1530/jrf.0.0770435; JOYCE CL, 1987, J ANDROL, V8, P74; KIM MY, 1991, J BIOL CHEM, V266, P484; LEAT WMF, 1983, Q J EXP PHYSIOL CMS, V68, P221, DOI 10.1113/expphysiol.1983.sp002714; LEE VWK, 1975, J REPROD FERTIL, V42, P121, DOI 10.1530/jrf.0.0420121; MACDONALD ML, 1984, J NUTR, V114, P719, DOI 10.1093/jn/114.4.719; MARZOUKI ZMH, 1982, BIOL REPROD, V27, P312, DOI 10.1095/biolreprod27.2.312; MEAD JF, 1964, J BIOL CHEM, V239, P77; MEIZEL S, 1984, J EXP ZOOL, V231, P283, DOI 10.1002/jez.1402310213; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; MIZUMURA K, 1987, PFLUG ARCH EUR J PHY, V408, P565, DOI 10.1007/BF00581157; OLIW EH, 1989, BIOCHIM BIOPHYS ACTA, V1002, P283, DOI 10.1016/0005-2760(89)90342-1; POULOS A, 1973, COMP BIOCHEM PHYSIOL, V46, P541, DOI 10.1016/0305-0491(73)90094-1; POULOS A, 1988, BIOCHEM J, V253, P645, DOI 10.1042/bj2530645; POULOS A, 1987, BIOCHEM J, V248, P961, DOI 10.1042/bj2480961; POULOS A, 1975, BIOCHIM BIOPHYS ACTA, V388, P12, DOI 10.1016/0005-2760(75)90057-0; POULOS A, 1986, BIOCHEM J, V235, P607, DOI 10.1042/bj2350607; POULOS A, 1986, BIOCHEM J, V240, P891, DOI 10.1042/bj2400891; ROBINSON BS, 1990, BIOCHEM J, V265, P763, DOI 10.1042/bj2650763; ROBINSON BS, 1990, BIOCHEM J, V267, P561, DOI 10.1042/bj2670561; ROSENTHAL MD, 1984, BIOCHIM BIOPHYS ACTA, V795, P171, DOI 10.1016/0005-2760(84)90063-8; ROTSTEIN NP, 1988, BIOCHEM J, V249, P191, DOI 10.1042/bj2490191; SAMUELSSON B, 1968, BIOCHIM BIOPHYS ACTA, V164, P421, DOI 10.1016/0005-2760(68)90166-5; SHARP P, 1987, BIOCHEM J, V248, P61, DOI 10.1042/bj2480061; STREET JM, 1989, BIOCHEM J, V260, P647, DOI 10.1042/bj2600647; Sweely CC, 1985, BIOCH LIPIDS MEMBRAN, P361	59	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1746	1751						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730716				2022-12-25	WOS:A1992HA48500055
J	SANO, M; HAYAKAWA, K; KATO, I				SANO, M; HAYAKAWA, K; KATO, I			PURIFICATION AND CHARACTERIZATION OF ALPHA-L-FUCOSIDASE FROM STREPTOMYCES SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARINE GASTROPOD; ALMOND EMULSIN; CANCER; SERUM; LIVER; GLYCOPROTEINS; PROTEINS; ANTIGEN; ENZYMES; FUCOSE	Streptomyces sp. 142, isolated from a soil sample, produced alpha-fucosidase when cultured in the presence Of L-fucose. The enzyme was purified 700-fold with an overall recovery of 17% from a cell-free extract by cation exchange chromatography and gel filtration chromatography. The apparent molecular weight of the purified enzyme was 40,000 by gel filtration chromatography. The enzyme had a pH optimum of 6.0 and was stable at pH 4.5-7.0. Substrate specificity studies with oligosaccharides labeled with 2-aminopyridine as the substrate showed that the enzyme specifically hydrolyzed terminal alpha-1-3 and alpha-1-4 fucosidic linkages in the oligosaccharides but did not hydrolyze alpha-1-2 or alpha-1-6 fucosidic linkages or a synthetic substrate, p-nitrophenyl alpha-L-fucoside. The purified enzyme released L-fucose from a fucosylated glycoprotein, alpha-1-acid glycoprotein. Thus, the substrate specificities of the Streptomyces alpha-fucosidase resembled those of alpha-fucosidases I and III isolated from almond emulsin rather than those of other microbial alpha-fucosidases.			SANO, M (corresponding author), TAKARA SHUZO CO LTD,BIOTECHNOL RES LABS,3-4-1 SETA,OTSU,SHIGA 52021,JAPAN.							AMINOFF D, 1970, J BIOL CHEM, V245, P1659; BAHL OP, 1970, J BIOL CHEM, V245, P299; CARLSEN RB, 1972, J BIOL CHEM, V247, P23; HASE S, 1981, J BIOCHEM-TOKYO, V90, P407, DOI 10.1093/oxfordjournals.jbchem.a133487; IIJIMA Y, 1971, J BIOCHEM-TOKYO, V70, P75, DOI 10.1093/oxfordjournals.jbchem.a129628; IIJIMA Y, 1971, ARCH BIOCHEM BIOPHYS, V145, P50, DOI 10.1016/0003-9861(71)90008-7; IMBER MJ, 1982, J BIOL CHEM, V257, P8205; KANNAGI R, 1986, CANCER RES, V46, P2619; KOCHIBE N, 1973, J BIOCHEM-TOKYO, V74, P1141, DOI 10.1093/oxfordjournals.jbchem.a130341; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGNANI JL, 1983, CANCER RES, V43, P5489; MEGA T, 1982, ANAL BIOCHEM, V119, P17, DOI 10.1016/0003-2697(82)90659-5; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OGATAARAKAWA M, 1977, ARCH BIOCHEM BIOPHYS, V181, P353, DOI 10.1016/0003-9861(77)90514-8; OPHEIM DJ, 1977, J BIOL CHEM, V252, P739; SAKAI T, 1990, CLIN CHEM, V36, P474; SCUDDER P, 1990, J BIOL CHEM, V265, P16472; SHI ZR, 1984, CANCER RES, V44, P1142; SUZUKI J, 1991, AGR BIOL CHEM TOKYO, V55, P283, DOI 10.1080/00021369.1991.10870520; TSUJI Y, 1990, J BIOCHEM-TOKYO, V108, P235, DOI 10.1093/oxfordjournals.jbchem.a123186; TSUJI Y, 1990, J BIOCHEM-TOKYO, V107, P324, DOI 10.1093/oxfordjournals.jbchem.a123046; WATKINS WM, 1959, BIOCHEM J, V71, P261, DOI 10.1042/bj0710261; WIEDERSCHAIN GY, 1971, BIOCHEM BIOPH RES CO, V44, P1008, DOI 10.1016/0006-291X(71)90812-6; YAMASHITA K, 1989, J BIOL CHEM, V264, P2415	26	49	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1522	1527						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730698				2022-12-25	WOS:A1992HA48500023
J	DEMEL, VSJ; MARTIN, PD; DOSCHER, MS; EDWARDS, BFP				DEMEL, VSJ; MARTIN, PD; DOSCHER, MS; EDWARDS, BFP			STRUCTURAL-CHANGES THAT ACCOMPANY THE REDUCED CATALYTIC EFFICIENCY OF 2 SEMISYNTHETIC RIBONUCLEASE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PANCREATIC RIBONUCLEASE; X-RAY REFINEMENT; COOH-TERMINAL PEPTIDES; ACTIVE-SITE; CRYSTAL-STRUCTURE; STAPHYLOCOCCAL NUCLEASE; RNASE-A; RESOLUTION; RESIDUES; COMPLEX	The structures of two catalytically defective semisynthetic RNases obtained by replacing aspartic acid 121 with asparagine or alanine have been determined and refined at a resolution of 2.0 angstrom (R = 0.186 and 0.172, respectively). When these structures are compared with the refined 1.8-angstrom structure (R = 0.204) of the fully active aspartic acid-containing enzyme (Martin, P. D., Doscher, M. S., and Edwards, B. F. P. (1987) J. Biol. Chem. 262, 15930-15938), numerous and widespread changes, much greater in number and magnitude than the small structural variations noted previously between the semisynthetic complex and RNase A, are found to have occurred. These changes include the movement of the loop containing residues 65-72 away from the active site, a more or less generalized relocation of crystallographically bound water molecules, and a number of rearrangements in the hydrogen bonding network at the active site. Most changes are far removed from the immediate site of the modifications and are distributed essentially throughout the molecule. The details of many of these changes are unique to each analog. In the asparagine analog, a destabilization in the positioning of active site residue His-119 also appears to have occurred.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,DETROIT,MI 48201	Wayne State University					NIGMS NIH HHS [GM 40630] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1956, J BIOL CHEM, V2221, P405; BEINTEMA JJ, 1988, PROG BIOPHYS MOL BIO, V51, P165, DOI 10.1016/0079-6107(88)90001-6; BEINTEMA JJ, 1989, FEBS LETT, V254, P1, DOI 10.1016/0014-5793(89)80996-2; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Blackburn P, 1982, ENZYMES, VXV, P317; BORKAKOTI N, 1982, ACTA CRYSTALLOGR B, V38, P2210, DOI 10.1107/S0567740882008346; BORKAKOTI N, 1983, J MOL BIOL, V169, P743, DOI 10.1016/S0022-2836(83)80168-5; BORKAKOTI N, 1983, EUR J BIOCHEM, V132, P89, DOI 10.1111/j.1432-1033.1983.tb07329.x; BORKAKOTI N, 1984, J CRYST SPECTROSC, V14, P467, DOI 10.1007/BF01160695; BROOKS C, 1986, ANN NY ACAD SCI, V471, P295, DOI 10.1111/j.1749-6632.1986.tb48046.x; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1985, P NATL ACAD SCI USA, V82, P8458, DOI 10.1073/pnas.82.24.8458; CAMPBELL RL, 1987, BIOCHEMISTRY-US, V26, P8579, DOI 10.1021/bi00400a013; CEDERHOLM MT, 1991, P NATL ACAD SCI USA, V88, P8116, DOI 10.1073/pnas.88.18.8116; DOSCHER MS, 1983, J MOL BIOL, V166, P685, DOI 10.1016/S0022-2836(83)80293-9; DOSCHER MS, 1983, BIOCHEMISTRY-US, V22, P4125, DOI 10.1021/bi00286a021; FINDLAY D, 1962, BIOCHEM J, V85, P152, DOI 10.1042/bj0850152; GUTTE B, 1972, J BIOL CHEM, V247, P4763; HARRIS GW, 1987, BIOCHIM BIOPHYS ACTA, V912, P348, DOI 10.1016/0167-4838(87)90039-2; HERRIES DG, 1962, BIOCHEM J, V85, P127, DOI 10.1042/bj0850127; HIBLER DW, 1987, BIOCHEMISTRY-US, V26, P6278, DOI 10.1021/bi00393a048; HODGES RS, 1974, INT J PEPT PROT RES, V6, P397; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; HOWLIN B, 1987, J MOL BIOL, V196, P159, DOI 10.1016/0022-2836(87)90518-3; HUMMEL CF, 1987, BIOCHEMISTRY-US, V26, P135, DOI 10.1021/bi00375a020; IRIE M, 1988, AGR BIOL CHEM TOKYO, V52, P1291; KUNDROT CE, 1987, J MOL BIOL, V193, P157, DOI 10.1016/0022-2836(87)90634-6; Kunitz M, 1939, SCIENCE, V90, P112, DOI 10.1126/science.90.2327.112; LIN MC, 1972, J BIOL CHEM, V247, P4768; LIN MC, 1970, J BIOL CHEM, V245, P5169; LINDQUIST RN, 1973, J AM CHEM SOC, V95, P8762, DOI 10.1021/ja00807a043; LOLL PJ, 1990, BIOCHEMISTRY-US, V29, P6866, DOI 10.1021/bi00481a016; MARKLEY JL, 1984, ANNU REV BIOPHYS BIO, V13, P493; MARTIN PD, 1987, J BIOL CHEM, V262, P15930; MERRIFIELD RB, 1975, P INT S MACROMOLECUL, P417; NACHMAN J, 1990, BIOCHEMISTRY-US, V29, P928, DOI 10.1021/bi00456a012; NISHIKAWA K, 1972, J PHYS SOC JPN, V32, P1331, DOI 10.1143/JPSJ.32.1331; OKADA Y, 1984, CHEM PHARM BULL, V32, P4585; PALMER RA, 1984, BIOCHIM BIOPHYS ACTA, V785, P81, DOI 10.1016/0167-4838(84)90237-1; RICHARDS FM, 1973, ATLAS MOL STRUCTURES, V1, P7; RICO M, 1989, EUR J BIOCHEM, V183, P623, DOI 10.1111/j.1432-1033.1989.tb21092.x; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; SASAKI DM, 1979, J MOL BIOL, V135, P301, DOI 10.1016/0022-2836(79)90355-3; SASAKI DM, 1985, ARCH BIOCHEM BIOPHYS, V241, P132, DOI 10.1016/0003-9861(85)90369-8; STERN MS, 1984, FEBS LETT, V171, P253, DOI 10.1016/0014-5793(84)80498-6; STERN MS, 1988, THESIS WAYNE STATE U; WILDE JA, 1988, BIOCHEMISTRY-US, V27, P4127, DOI 10.1021/bi00411a033; WLODAWER A, 1983, BIOCHEMISTRY-US, V22, P2720, DOI 10.1021/bi00280a021; WLODAWER A, 1981, P NATL ACAD SCI-BIOL, V78, P2853, DOI 10.1073/pnas.78.5.2853; WLODAWER A, 1983, P NATL ACAD SCI-BIOL, V80, P3628, DOI 10.1073/pnas.80.12.3628; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; WLODAWER A, 1982, J BIOL CHEM, V257, P1325; WODAK SY, 1977, J MOL BIOL, V116, P855, DOI 10.1016/0022-2836(77)90275-3; WYCKOFF HW, 1971, ENZYMES, V4, P647	54	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					247	256						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730593				2022-12-25	WOS:A1992GY43900043
J	KONDO, N; KONDO, J				KONDO, N; KONDO, J			IDENTIFICATION OF NOVEL BLOOD PROTEINS SPECIFIC FOR MAMMALIAN HIBERNATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT APOPROTEIN; AMINO-ACID SEQUENCE; BINDING GLOBULIN; MYOCARDIUM; CHIPMUNKS; HOMOLOGY; RYANODINE	Mammalian hibernation is a unique physiological adaptation that allows the sustainment of life under extremely low body temperatures. In the chipmunk, we found four proteins related specifically to hibernation. These proteins started to diminish in concentration in the blood before and disappeared during hibernation. These proteins reappeared in the blood as hibernation ceased and remained during nonhibernation. The complete or partial amino acid sequences of the four proteins showed that three (27-, 25-, and 20-kDa) were previously unknown, whereas another (55-kDa) is highly homologous with alpha-1-antitrypsin. The three novel proteins are homologous, indicating that they are a family. In the NH2-terminal regions of these proteins, a collagen-like amino acid sequence is present, whereas in their COOH-terminal regions, two sequences, Ser-Ala-Phe-Ala-Val-Lys and Val-Trp-Leu-Glu, are conserved. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions and gel permeation chromatography under denaturating conditions revealed that the four proteins form a 140-kDa complex in the plasma fraction. The novel proteins were detected in blood of another hibernator, the ground squirrel, but not in rodent nonhibernators, namely tree squirrels and rats. The present finding is the first identification of a hibernation-specific protein. The presence of specific proteins in hibernators suggests the involvement of genetic factors in the control of hibernation. These proteins provide valuable tools for understanding molecular mechanisms of mammalian hibernation.	MITSUBISHI KASEI CORP,RES CTR,YOKOHAMA,KANAGAWA 224,JAPAN		KONDO, N (corresponding author), MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN.							BELKE DD, 1987, J THERM BIOL, V12, P53, DOI 10.1016/0306-4565(87)90035-0; BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; BOEDTKER H, 1956, J AM CHEM SOC, V78, P4267, DOI 10.1021/ja01598a024; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; FLINK IL, 1986, P NATL ACAD SCI USA, V83, P7708, DOI 10.1073/pnas.83.20.7708; HAMMOND GL, 1987, P NATL ACAD SCI USA, V84, P5153, DOI 10.1073/pnas.84.15.5153; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KONDO N, 1986, CIRC RES, V59, P221, DOI 10.1161/01.RES.59.2.221; KONDO N, 1988, BRIT J PHARMACOL, V95, P1287, DOI 10.1111/j.1476-5381.1988.tb11766.x; KONDO N, 1987, EXPERIENTIA, V43, P873, DOI 10.1007/BF01951645; KONDO N, 1984, SCIENCE, V225, P641, DOI 10.1126/science.6740332; KONDO N, 1986, EXPERIENTIA, V42, P1220, DOI 10.1007/BF01946394; KRUMAN II, 1988, COMP BIOCHEM PHYS B, V89, P271, DOI 10.1016/0305-0491(88)90222-2; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Lyman C.P., 1982, P1; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; REID KBM, 1983, BIOCHEM SOC T, V11, P1; RICQUIER D, 1989, LIVING COLD, P499; ROSENBERRY TL, 1977, BIOCHEMISTRY-US, V16, P3550, DOI 10.1021/bi00635a008; SHIMOMURA T, 1991, CYTOTECHNOLOGY, V6, P1, DOI 10.1007/BF00353697; Shivatcheva T.M., 1989, P87; Wang L.C.H., 1982, P206	25	89	99	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					473	478						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730610				2022-12-25	WOS:A1992GY43900076
J	ROQUEMORE, EP; DELL, A; MORRIS, HR; PANICO, M; REASON, AJ; SAVOY, LA; WISTOW, GJ; ZIGLER, JS; EARLES, BJ; HART, GW				ROQUEMORE, EP; DELL, A; MORRIS, HR; PANICO, M; REASON, AJ; SAVOY, LA; WISTOW, GJ; ZIGLER, JS; EARLES, BJ; HART, GW			VERTEBRATE LENS ALPHA-CRYSTALLINS ARE MODIFIED BY O-LINKED N-ACETYLGLUCOSAMINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; NON-LENTICULAR TISSUES; B-CRYSTALLIN; HEAT-SHOCK; EYE LENS; A-CHAIN; PROTEINS; PHOSPHORYLATION; GLYCOPROTEINS; GLCNAC	Crystallins are structural proteins responsible for establishing the remarkable optical properties of the lens. Yet many of these highly conserved proteins are also expressed in nonocular tissues, where they have alternative functions apparently unrelated to their structural role in the lens. Here we report that lens alpha-crystallins, some of which function as heat-shock proteins in other tissues, are modified with O-linked N-acetylglucosamine (O-GlcNAc). An in vitro enzymatic assay that transfers [H-3]Gal to terminal GlcNAc moieties labels alpha-A and alpha-B crystallins in lens homogenates from man, rhesus monkey, rat, cow, and rhea (an ostrich-like bird). O-Linkage of the saccharide is demonstrated by sensitivity to base-catalyzed beta-elimination and resistance to peptide:N-glycosidase F treatment. Chromatographic analyses of the beta-elimination products and fast atom bombardment-mass spectrometry of [H-3]Gal-labeled tryptic peptides confirm the saccharide structure. Isoelectric focusing of [H-3]Gal-labeled bovine lens proteins reveals the presence of O-GlcNAc on all four alpha-crystallin subunits, A1, A2, B1, and B2. Electrospray mass spectrometry of bovine alpha-crystallin demonstrates the presence of a single O-GlcNAc substitution on alpha-A2. Gas-phase protein sequencing and fast atom bombardment-mass spectrometry of the major radiolabeled tryptic peptide from bovine alpha-crystallin reveal that GlcNAc is attached to the alpha-A subunits at serine 162. This post-translational modification may play an important role in the molecular organization of lens alpha-crystallin.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, 725 N WOLFE ST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AZ, ENGLAND; M SCAN LTD, ASCOT SL5 7PZ, BERKS, ENGLAND; NEI, MOLEC & DEV BIOL LAB, BETHESDA, MD 20892 USA; NEI, MECH OCULAR DIS LAB, BETHESDA, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Imperial College London; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013563, R37HD013563] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042486] Funding Source: NIH RePORTER; NCI NIH HHS [CA42486] Funding Source: Medline; NICHD NIH HHS [HD13563] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; ARTERBURN LM, 1990, J BIOL CHEM, V265, P7419; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BLOEMENDAL H, 1977, SCIENCE, V197, P127, DOI 10.1126/science.877544; BLOEMENDAL H, 1972, EUR J BIOCHEM, V24, P401, DOI 10.1111/j.1432-1033.1972.tb19699.x; CAHNMANN HJ, 1965, J BIOL CHEM, V240, P2762; CHIESA R, 1988, EXP EYE RES, V46, P199, DOI 10.1016/S0014-4835(88)80077-0; CHIESA R, 1989, BIOCHEM BIOPH RES CO, V162, P1494, DOI 10.1016/0006-291X(89)90843-7; CHIESA R, 1990, FEBS LETT, V268, P222, DOI 10.1016/0014-5793(90)81013-E; DASGUPTA S, 1991, IN PRESS EXP EYE RES; de Jong W W, 1974, Eur J Biochem, V48, P271; DEJONG WW, 1984, EUR J BIOCHEM, V141, P131; DONG DLY, 1991, GLYCOCONJUGATE J, V8, P211; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; EDINGTON BV, 1990, MOL CELL BIOL, V10, P4886, DOI 10.1128/MCB.10.9.4886; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOENDERS HJ, 1967, BIOCHIM BIOPHYS ACTA, V147, P183, DOI 10.1016/0005-2795(67)90105-5; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HOLT GD, 1986, J BIOL CHEM, V261, P8049; HUNT E, 1973, BIOCHEM J, V135, P833, DOI 10.1042/bj1350833; ISACSSON U, 1974, ANAL CHIM ACTA, V68, P339, DOI 10.1016/S0003-2670(01)82590-3; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; KIM YJ, 1984, MOL CELL BIOL, V4, P468, DOI 10.1128/MCB.4.3.468; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI LK, 1974, EXP EYE RES, V18, P381; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P113, DOI 10.1007/BF00221052; NAGINENI CN, 1989, FEBS LETT, V249, P89, DOI 10.1016/0014-5793(89)80022-5; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OSHANNESSY DJ, 1987, ANAL BIOCHEM, V163, P204, DOI 10.1016/0003-2697(87)90114-X; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PLUMMER TH, 1981, J BIOL CHEM, V256, P243; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REASON AJ, 1991, IN PRESS GLYCOBIOLOG; ROLLET E, 1986, BIOCHEM BIOPH RES CO, V141, P426, DOI 10.1016/S0006-291X(86)80190-5; SMITH JB, 1991, ANAL BIOCHEM, V193, P118, DOI 10.1016/0003-2697(91)90050-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; STAUFFER J, 1974, INVEST OPHTH VISUAL, V13, P135; STROUS G, 1971, FEBS LETT, V19, P33, DOI 10.1016/0014-5793(71)80599-9; SWIEDLER SJ, 1983, J IMMUNOL, V131, P352; TARENTINO AL, 1982, J BIOL CHEM, V257, P776; TORRES CR, 1984, J BIOL CHEM, V259, P3308; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VANDEROU.FJ, 1973, EUR J BIOCHEM, V39, P207; VANKLEEF FS, 1974, EUR J BIOCHEM, V48, P563; VANKLEEF FSM, 1975, NATURE, V258, P264, DOI 10.1038/258264a0; VANKLEEF FSM, 1976, EUR J BIOCHEM, V66, P477; VOORTER CEM, 1986, EUR J BIOCHEM, V160, P203; VOORTER CEM, 1987, FEBS LETT, V221, P249, DOI 10.1016/0014-5793(87)80935-3; WAGNER BJ, 1978, EXP EYE RES, V26, P255, DOI 10.1016/0014-4835(78)90073-8; WALLENFELS B, 1979, P NATL ACAD SCI USA, V76, P3223, DOI 10.1073/pnas.76.7.3223; WHITEHEAD TP, 1979, CLIN CHEM, V25, P1531; WHITEHEART SW, 1989, METHOD ENZYMOL, V179, P82; WISTOW G, 1991, CURR EYE RES, V10, P313, DOI 10.3109/02713689108996337; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZIGLER JS, 1976, COMP BIOCHEM PHYS B, V53, P349, DOI 10.1016/0305-0491(76)90340-0	66	96	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					555	563						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730617				2022-12-25	WOS:A1992GY43900087
J	GIL, G; ESSER, V				GIL, G; ESSER, V			CHOLESTEROL-MEDIATED SUPPRESSION OF ALPHA-1-INHIBITOR-III, A PLASMA ALPHA-MACROGLOBULIN FAMILY PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; COENZYME-A SYNTHASE; MESSENGER-RNA; GROWTH-FACTOR; NUCLEOTIDE-SEQUENCE; APOLIPOPROTEIN-E; DNA-POLYMERASE; RAT-LIVER; ALPHA-2-MACROGLOBULIN; BINDING	Using differential hybridization techniques we have isolated a hamster cDNA encoding a cholesterol-regulated protein. By sequence homology we concluded that the isolated cDNA encodes alpha-1-inhibitor III (alpha-1-I3), a protein of the alpha-macroglobulin (alpha-M) family. When hamsters were fed diets rich in cholesterol, cholic acid, or chenodeoxycholic acid, the amount of alpha-1-I3 RNA was reduced between 5- and 10-fold. Drugs that lower plasma cholesterol levels, such as colestipol and mevinolin, increased alpha-1-I3 RNA between 2- and 3-fold. Additionally, plasma alpha-1-I3 protein levels, as measured by immunoblotting techniques using an anti-human alpha-2-M antibody, correlate well with alpha-1-I3 RNA levels in those hamsters. Plasma alpha-1-I3 protein was inversely proportional to plasma cholesterol levels in those hamsters. The observed suppression of alpha-1-I3 expression by cholesterol mimics the cholesterol-mediated regulation of other genes that maintain cholesterol homeostasis, such as 3-hydroxy-3-methylglutaryl coenzyme A synthase, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and low density lipoprotein receptor. We hypothesize that alpha-1-I3 may play a role in the onset of atherosclerosis and may provide a link between cholesterol and the clotting system. Furthermore, the availability of another sterol-regulated gene, like alpha-1-I3, should help elucidate the molecular mechanisms of cholesterol-mediated regulation of gene transcription.	UNIV TEXAS,HLTH SCI CTR,SW MED SCH,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	GIL, G (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,55 LAKE AVE N,WORCESTER,MA 01655, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32520] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1988, J BIOL CHEM, V263, P4013; ALLAIN CC, 1974, CLIN CHEM, V20, P470; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P737; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BORTH W, 1989, J BIOL CHEM, V264, P5818; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CUMMINGS HS, 1983, CHEM BIOL ALPHA2 MAC, P143; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GADDYKURTEN D, 1989, ENDOCRINOLOGY, V125, P2985; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GIL G, 1986, J BIOL CHEM, V261, P3710; GIL G, 1986, J BIOL CHEM, V261, P3717; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARPEL PC, 1983, CHEM BIOL ALPHA 2 MA, P1; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; JORIS I, 1977, ADV EXP MED BIOL, V104, P227; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; Koj A, 1985, ACUTE PHASE RESPONSE, P139; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LONBERGHOLM K, 1987, J BIOL CHEM, V262, P438; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MA PTS, 1986, P NATL ACAD SCI USA, V83, P8370, DOI 10.1073/pnas.83.21.8370; OCONNERMCCOURT DM, 1987, J BIOL CHEM, V262, P14090; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RINDERKNECHT, 1972, NATURE-NEW BIOL, V239, P116; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFER EJ, 1986, CLIN NUTR, V5, P99; SCHOENFIELD LJ, 1973, J LAB CLIN MED, V82, P858; SHI DL, 1990, J BIOL CHEM, V265, P2881; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255	43	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20512	20518						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1718965				2022-12-25	WOS:A1991GM03900095
J	PIMPLIKAR, SW; HUTTNER, WB				PIMPLIKAR, SW; HUTTNER, WB			CHROMOGRANIN-B (SECRETOGRANIN-I), A SECRETORY PROTEIN OF THE REGULATED PATHWAY, IS ALSO PRESENT IN A TIGHTLY MEMBRANE-ASSOCIATED FORM IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ANTERIOR-PITUITARY; GRANULES; CALCIUM; ISLET	Chromogranin B (CgB, also called secretogranin I) is a secretory protein sorted to secretory granules in a wide variety of endocrine cells and neurons. Unexpectedly, after stimulation of regulated secretion in the neuroendocrine cell line PC12, a fraction of the exocytosed CgB was not released into the medium but remained associated with the plasma membrane. The addition of exogenous CgB to unstimulated cells did not result in the appearance of cell surface CgB, suggesting that the presence of cell surface CgB could not be accounted for by adsorption of released CgB to the cell surface. Upon further incubation of stimulated PC12 cells, the surface CgB was internalized by the cells and largely degraded. The surface CgB was not released by exposure to pH 11, yet it partitioned in the aqueous phase upon Triton X-114 phase separation. Subcellular fractionation and differential extraction studies showed that the membrane-associated CgB constituted at least 10% of the total cellular CgB. These observations suggest that (a) the appearance of CgB at the cell surface is due to fusion of secretory granules with the plasma membrane and (b) a fraction of CgB is present in tight association with the secretory granule membrane. We propose a model in which membrane-associated CgB, by virtue of its ability to interact in a homophilic manner with soluble CgB, plays a key role in the sorting and targeting of CgB to the regulated pathway.	EUROPEAN MOLEC BIOL LAB, PROGRAM CELL BIOL, POSTFACH 102209, W-6900 HEIDELBERG, GERMANY; UNIV HEIDELBERG, INST NEUROBIOL, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL); Ruprecht Karls University Heidelberg			Huttner, Wieland B./P-4080-2018					BASSETTI M, 1990, J HISTOCHEM CYTOCHEM, V38, P1353, DOI 10.1177/38.9.2387987; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; EHRHART M, 1986, J HISTOCHEM CYTOCHEM, V34, P1673, DOI 10.1177/34.12.2878021; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; HEUMANN R, 1983, EXP CELL RES, V145, P179, DOI 10.1016/S0014-4827(83)80019-6; HORTSCH M, 1986, J CELL BIOL, V103, P241, DOI 10.1083/jcb.103.1.241; Huttner WB, 1989, CURR OPIN CELL BIOL, V1, P648, DOI 10.1016/0955-0674(89)90029-X; HUTTNER WB, 1988, INT CONGR SER, V799, P325; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; KAPLAN DR, 1983, J CELL BIOL, V97, P433, DOI 10.1083/jcb.97.2.433; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON LI, 1989, EUR J CELL BIOL, V48, P45; OTTIGER HP, 1990, J NEUROSCI, V10, P3135; PATZAK A, 1986, J CELL BIOL, V102, P510, DOI 10.1083/jcb.102.2.510; PATZAK A, 1987, EXP CELL RES, V171, P346, DOI 10.1016/0014-4827(87)90167-4; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; SETTLEMAN J, 1985, J BIOL CHEM, V260, P1641; STINCHCOMBE J C, 1990, Cell Biology International Reports, V14, P236, DOI 10.1016/0309-1651(90)91046-7; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; TAYLOR CS, 1989, J BIOL CHEM, V264, P14; THORNER MO, 1982, ENDOCRINOLOGY, V110, P1831, DOI 10.1210/endo-110-5-1831; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X	28	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4110	4118						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740454				2022-12-25	WOS:A1992HE60700081
J	SALVO, JL; BELFORT, M				SALVO, JL; BELFORT, M			THE P2 ELEMENT OF THE TD INTRON IS DISPENSABLE DESPITE ITS NORMAL ROLE IN SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GROUP-I INTRON; CATALYTIC ACTIVITY; RNA ENZYME; TETRAHYMENA; BACTERIOPHAGE-T4; SEQUENCES; DELETION; SITE	The P2 region of group I introns has been proposed to be involved in the correct positioning of the P1 5'-splice site duplex in the catalytic core (Michel, F., and Westhof, E. (1990) J. Mol. Biol. 216, 585-610). The behavior of DELTA-P2 deletion mutants of the td intron is consistent with this hypothesis. The DELTA-P2 mutants are capable of site-specific hydrolysis, indicating that the conformation of the ribozyme is not grossly altered, but they are incapable of transesterification reactions at the splice sites, as would be predicted if P1 is not appropriately aligned within the catalytic core. Nevertheless, the function of the P2 element can be bypassed in specific pseudorevertants isolated by genetic selection from the DELTA-P2 mutants. These results, together with phylogenetic data, support the existence of alternate strategies to create a functional P1-core interaction.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,MOLEC GENET PROGRAM,ALBANY,NY 12201; SUNY ALBANY,SCH PUBL HLTH,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany				Belfort, Marlene/0000-0002-1592-5618	NIGMS NIH HHS [GM44844, GM39422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044844, R01GM039422, R37GM039422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUDRY AA, 1990, BIOCHEMISTRY-US, V29, P6534, DOI 10.1021/bi00479a027; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BELFORT M, 1990, METHOD ENZYMOL, V181, P521; BELLPEDERSEN D, 1991, J BACTERIOL, V173, P1193, DOI 10.1128/jb.173.3.1193-1200.1991; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; BURKE JM, 1988, GENE AMST, V73, P2273; CECH TR, 1988, GENE AMST, V73, P2259; CHANDRY PS, 1987, GENE DEV, V1, P1028, DOI 10.1101/gad.1.9.1028; COX EC, 1982, GENETICS, V100, P7; DOUDNA JA, 1987, COLD SPRING HARB SYM, V52, P173, DOI 10.1101/SQB.1987.052.01.022; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SCHROEDER R, 1991, BIOCHEMISTRY-US, V30, P3295, DOI 10.1021/bi00227a018; SHUB DA, 1988, P NATL ACAD SCI USA, V85, P1151, DOI 10.1073/pnas.85.4.1151; SZOSTAK JW, 1986, NATURE, V322, P83, DOI 10.1038/322083a0; WILLIAMSON CL, 1989, NUCLEIC ACIDS RES, V17, P675, DOI 10.1093/nar/17.2.675; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7	22	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2845	2848						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737742				2022-12-25	WOS:A1992HD15400003
J	LITERSKY, JM; JOHNSON, GVW				LITERSKY, JM; JOHNSON, GVW			PHOSPHORYLATION BY CAMP-DEPENDENT PROTEIN-KINASE INHIBITS THE DEGRADATION OF TAU BY CALPAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; PAIRED HELICAL FILAMENTS; ACTIN-BINDING-PROTEIN; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; CYCLIC-AMP; RAT-BRAIN; ALUMINUM; PROTEOLYSIS; ELECTROPHORESIS	The effects of cAMP-dependent protein kinase (cAMP-PK) phosphorylation on the degradation of the microtubule-associated protein tau by calpain were studied. Purified bovine brain tau that had been phosphorylated by cAMP-PK had a slower migration pattern on sodium dodecyl sulfate-polyacrylamide gels and a more acidic, less heterogeneous pattern on two-dimensional, nonequilibrium pH gradient electrophoresis (NEPHGE) gels compared with untreated tau. Phosphorylation of tau by cAMP-PK significantly inhibited its proteolysis by calpain compared with untreated tau. To our knowledge this is the first demonstration that phosphorylation of tau by a specific kinase results in increased resistance to hydrolysis by calpain. Tau dephosphorylated by alkaline phosphatase migrated more rapidly on sodium dodecyl sulfate-polyacrylamide gels and also showed an altered two-dimensional NEPHGE pattern. Dephosphorylation of tau had no effect on its susceptibility to calpain proteolysis, indicating that regulation of the susceptibility to calpain hydrolysis is due to the phosphorylation of a specific site(s). These results suggest a role for phosphorylation in regulating the degradation of tau. Abnormal phosphorylation could result in a protease-resistant tau population which may contribute to the formation of paired helical filaments in Alzheimer's disease.	UNIV ALABAMA,DEPT PSYCHIAT,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NIA NIH HHS [AG-06569] Funding Source: Medline; NINDS NIH HHS [NS-27538] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027538, R29NS027538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAKER AC, 1988, AGE, V11, P60, DOI 10.1007/BF02431774; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BAUDIER J, 1987, J BIOL CHEM, V262, P17577; BAUDIER J, 1987, J BIOL CHEM, V262, P17584; BILLINGS PC, 1979, NUCLEIC ACIDS RES, V6, P2151, DOI 10.1093/nar/6.6.2151; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; CHEN M, 1989, J BIOL CHEM, V264, P14282; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; DANIELSSON E, 1988, NEUROBIOL AGING, V9, P153, DOI 10.1016/S0197-4580(88)80045-9; DELACOURTE A, 1986, J NEUROL SCI, V76, P173, DOI 10.1016/0022-510X(86)90167-X; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FLAMENT S, 1990, BRAIN RES, V516, P15, DOI 10.1016/0006-8993(90)90891-E; FLAMENT S, 1989, FEBS LETT, V247, P213, DOI 10.1016/0014-5793(89)81337-7; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; GRUNDKEIQBAL I, 1986, J BIOL CHEM, V261, P6084; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; HOSHI M, 1987, FEBS LETT, V217, P237, DOI 10.1016/0014-5793(87)80670-1; JOHNSON GVW, 1989, J NEUROCHEM, V53, P258, DOI 10.1111/j.1471-4159.1989.tb07322.x; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; JOHNSON GVW, 1987, BRAIN RES, V403, P1, DOI 10.1016/0006-8993(87)90115-6; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P420, DOI 10.1002/jnr.490250320; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LICHTENBERG B, 1988, NATURE, V334, P359, DOI 10.1038/334359a0; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTYN CN, 1989, LANCET, V1, P59; MCLACHLAN DRC, 1989, CAN J NEUROL SCI, V16, P490; NESTLER EJ, 1984, PROTEIN PHOSPHORYLAT, P2; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; PERLMUTTER LS, 1990, J COMP NEUROL, V296, P269, DOI 10.1002/cne.902960207; PIERRE M, 1983, BIOCHEM BIOPH RES CO, V115, P212, DOI 10.1016/0006-291X(83)90991-9; REED J, 1985, BIOCHEMISTRY-US, V24, P2967, DOI 10.1021/bi00333a024; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SIMAN R, 1989, J NEUROSCI, V9, P1579; SINGER HS, 1990, BRAIN RES, V528, P73, DOI 10.1016/0006-8993(90)90196-I; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VITTO A, 1986, J NEUROCHEM, V47, P1039; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040; ZHANG Z, 1988, BIOCHEM BIOPH RES CO, V151, P355, DOI 10.1016/0006-291X(88)90601-8	49	212	216	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1563	1568						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730702				2022-12-25	WOS:A1992HA48500028
J	CALLANDER, NS; RAO, LVM; NORDFANG, O; SANDSET, PM; WARNCRAMER, B; RAPAPORT, SI				CALLANDER, NS; RAO, LVM; NORDFANG, O; SANDSET, PM; WARNCRAMER, B; RAPAPORT, SI			MECHANISMS OF BINDING OF RECOMBINANT EXTRINSIC PATHWAY INHIBITOR (REPI) TO CULTURED-CELL SURFACES - EVIDENCE THAT REPI CAN BIND TO AND INHIBIT FACTOR-VIIA-TISSUE FACTOR COMPLEXES IN THE ABSENCE OF FACTOR-XA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION INHIBITOR; BLOOD-COAGULATION; FACTOR ANTIBODY; PROTEIN; PURIFICATION; DOMAINS; PLASMA; EPI	Extrinsic pathway inhibitor plays a key role in modulating tissue factor-dependent blood coagulation. We have studied binding of radioiodinated recombinant extrinsic pathway inhibitor (rEPI) to cultured cell surfaces. rEPI in the absence of added reactants bound to a limited extent to three cell lines studied. Binding of rEPI to two cell lines possessing surface tissue factor, but not to a cell line lacking surface tissue factor, was markedly increased in the presence of both factor VIIa and factor Xa, and calcium ions. Moreover, some increased tissue factor-dependent binding was also demonstrated with factor VIIa alone. Binding isotherms of rEPI to factor VIIa-tissue factor obtained with an ovarian carcinoma cell line were hyperbolic. Scatchard plots indicated the following: a K(d) value of 4.5 +/- 1.5 nM and 335,000 +/- 84,000 sites/cell when factor Xa was present; a K(d) value of 11.9 +/- 3.5 nM and 236,000 +/- 68,000 sites/cell when factor Xa was absent. In functional studies, high concentrations of rEPI, e.g. 27-67.5 nM, were found to inhibit factor VIIa-tissue factor-catalyzed release of activation peptide from tritiated factor IX in the absence of factor Xa. Whereas factor Xa was thus shown not to be required for rEPI to inhibit factor VIIa-tissue factor catalytic activity, its presence markedly enhanced rEPI's inhibitory function. Since the local concentration of extrinsic pathway inhibitor achieved at a site of tissue injury is unknown, the physiologic significance of the observation of extrinsic pathway inhibitor-induced inhibition of factor VIIa-tissue factor activity in the absence of factor Xa is not clear. However, factor Xa-independent inhibition could play a significant role when large doses of rEPI are administered in experimental studies of thrombosis.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT PATHOL,LA JOLLA,CA 92093; NOVO NORDISK AS,DK-2820 GENTOFRE,DENMARK	University of California System; University of California San Diego; University of California System; University of California San Diego; Novo Nordisk			Sandset, Per Morten/J-8141-2019	Sandset, Per Morten/0000-0001-5556-8099	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL027234, R01HL042813] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09290] Funding Source: Medline; NHLBI NIH HHS [HL-42813, HL-27234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMUS FE, 1989, THROMB HAEMOSTASIS, V62, P1067; BAJAJ SP, 1981, PREP BIOCHEM, V11, P397, DOI 10.1080/00327488108065531; BROZE GJ, 1988, BLOOD, V71, P335; BROZE GJ, 1990, BIOCHEMISTRY-US, V29, P7539, DOI 10.1021/bi00485a001; BROZE GJ, 1987, BLOOD, V69, P150; BROZE GJ, 1987, P NATL ACAD SCI USA, V84, P1886, DOI 10.1073/pnas.84.7.1886; DAY KC, 1990, BLOOD, V76, P1538; FLECK RA, 1990, THROMB RES, V57, P765, DOI 10.1016/0049-3848(90)90034-A; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUNAKOSHI T, 1987, BIOCHEMISTRY-US, V26, P5572, DOI 10.1021/bi00391a053; GEMMELL CH, 1990, BLOOD, V76, P2266; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GIRARD TJ, 1990, SCIENCE, V248, P1421, DOI 10.1126/science.1972598; HASKEL EJ, 1990, CIRCULATION S, V82, pA604; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; NOVOTNY WF, 1988, BLOOD, V72, P2020; NOVOTNY WF, 1991, BLOOD, V78, P387; NOVOTNY WF, 1989, J BIOL CHEM, V264, P18832; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1987, BLOOD, V69, P645; RAO LVM, 1988, THROMB RES, V51, P373, DOI 10.1016/0049-3848(88)90373-8; RAO LVM, 1990, BLOOD S, V76, pA1730; RAPAPORT SI, 1989, BLOOD, V73, P359; SANDERS NL, 1985, BLOOD, V66, P204; SANDSET PM, 1991, P NATL ACAD SCI USA, V88, P708, DOI 10.1073/pnas.88.3.708; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; VANLENTEN L, 1971, J BIOL CHEM, V246, P1889; WARNCRAMER BJ, 1988, THROMB HAEMOSTASIS, V60, P453; WUN TC, 1988, J BIOL CHEM, V263, P6001; ZUR M, 1980, J BIOL CHEM, V255, P5703	32	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					876	882						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730676				2022-12-25	WOS:A1992GY96000032
J	HEATH, WF; BELAGAJE, RM; BROOKE, GS; CHANCE, RE; HOFFMANN, JA; LONG, HB; REAMS, SG; ROUNDTREE, C; SHAW, WN; SLIEKER, LJ; SUNDELL, KL; DIMARCHI, RD				HEATH, WF; BELAGAJE, RM; BROOKE, GS; CHANCE, RE; HOFFMANN, JA; LONG, HB; REAMS, SG; ROUNDTREE, C; SHAW, WN; SLIEKER, LJ; SUNDELL, KL; DIMARCHI, RD			(A-C-B) HUMAN PROINSULIN, A NOVEL INSULIN AGONIST AND INTERMEDIATE IN THE SYNTHESIS OF BIOSYNTHETIC HUMAN INSULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BIOLOGICAL-ACTIVITY; METABOLISM; CONVERSION; PROTEINS; BINDING; INVITRO; SYSTEM	The hormone insulin is synthesized in the beta-cell of the pancreas as the precursor, proinsulin, where the carboxyl terminus of the B-chain is connected to the amino terminus of the A-chain by a connecting or C-peptide. Proinsulin is a weak insulin agonist that possesses a longer in vivo half-life than does insulin. A form of proinsulin clipped at the Arg65-Gly66 bond has been shown to be more potent than the parent molecule with protracted in vivo activity, presumably as a result of freeing the amino terminal residue of the A-chain. To generate a more active proinsulin-like molecule, we have constructed an "inverted" proinsulin molecule where the carboxyl terminus of the A-chain is connected to the amino terminus of the B-chain by the C-peptide, leaving the critical Gly1 residue free. Transformation of Escherichia coli with a plasmid coding for A-C-B human proinsulin led to the stable production of the protein. By a process of cell disruption, sulfitolysis, anion-exchange chromatography, refolding, and reversed-phase high-performance liquid chromatography, two forms of the inverted proinsulin differing at their amino termini as Gly1 and Met0-Gly1 were identified and purified to homogeneity. Both proteins were shown by a number of analytical techniques to be of the inverted sequence, with insulin-like disulfide bonding. Biological analyses by in vitro techniques revealed A-C-B human proinsulin to be intermediate in potency when compared to human insulin and proinsulin. The time to maximal lowering of blood glucose in the fasted normal rat appeared comparable to that of proinsulin. Additionally, we were able to generate fully active, native insulin from A-C-B human proinsulin by proteolytic transformation. The results of this study lend themselves to the generation of novel insulin-like peptides while providing a simplified route to the biosynthetic production of insulin.			HEATH, WF (corresponding author), ELI LILLY & CO,LILLY RES LAB,LILLY CORP CTR,MC797 88-4,DROP 1543,INDIANAPOLIS,IN 46285, USA.							BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BROSSEAU R, 1982, GENE, V17, P279; Brown E L, 1979, Methods Enzymol, V68, P109; Chance R. E., 1981, PEPTIDES SYNTHESIS S, P721; CHANCE RE, 1970, 7 P C INT DIAB FED, V231, P292; DANNER DB, 1982, ANAL BIOCHEM, V125, P139, DOI 10.1016/0003-2697(82)90394-3; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; FRANK BH, 1982, PEPTIDES SYNTHESIS S, P729; GAIT MJ, 1980, NUCLEIC ACIDS RES, V8, P1081, DOI 10.1093/nar/8.5.1081; GLIEMANN J, 1974, DIABETOLOGIA, V10, P105, DOI 10.1007/BF01219665; GRAPPUSO PA, 1988, J CLIN ENDOCR METAB, V67, P194; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KASHIWAGI A, 1983, J CLIN INVEST, V72, P1246, DOI 10.1172/JCI111080; KEMMLER W, 1971, J BIOL CHEM, V246, P6786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANIATIS T, 1982, MOL CLONING LABORATO, P368; MAURER R, 1980, J MOL BIOL, V139, P147, DOI 10.1016/0022-2836(80)90302-2; PEAVY DE, 1985, J BIOL CHEM, V260, P3989; REVERS RR, 1984, DIABETES, V33, P762, DOI 10.2337/diabetes.33.8.762; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONER BE, 1987, METHOD ENZYMOL, V153, P401; SCHONER BE, 1986, P NATL ACAD SCI USA, V83, P8506, DOI 10.1073/pnas.83.22.8506; SIEBER P, 1978, H-S Z PHYSIOL CHEM, V359, P113; SONKSEN PH, 1973, CLIN SCI MOL MED, V45, P633; TOREN P, 1988, ANAL BIOCHEM, V169, P287, DOI 10.1016/0003-2697(88)90287-4; WENSINK PC, 1974, CELL, V3, P315, DOI 10.1016/0092-8674(74)90045-2	26	32	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					419	425						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730606				2022-12-25	WOS:A1992GY43900068
J	POULIN, R; LU, L; ACKERMANN, B; BEY, P; PEGG, AE				POULIN, R; LU, L; ACKERMANN, B; BEY, P; PEGG, AE			MECHANISM OF THE IRREVERSIBLE INACTIVATION OF MOUSE ORNITHINE DECARBOXYLASE BY ALPHA-DIFLUOROMETHYLORNITHINE - CHARACTERIZATION OF SEQUENCES AT THE INHIBITOR AND COENZYME BINDING-SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-PHOSPHATE-DEPENDENT HISTIDINE-DECARBOXYLASE; AMINO-ACID SEQUENCE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; POLYAMINE METABOLISM; COMPLEMENTARY-DNA; ALANINE RACEMASE; MESSENGER-RNA; ACTIVE-SITE; PURIFICATION	Mouse ornithine decarboxylase (ODC) was expressed in Escherichia coli and the purified recombinant enzyme used for determination of the binding site for pyridoxal 5'-phosphate and of the residues modified in the inactivation of the enzyme by the enzyme-activated irreversible inhibitor, alpha-difluoromethylornithine (DFMO). The pyridoxal 5'-phosphate binding lysine in mouse ODC was identified as lysine 69 of the mouse sequence by reduction of the purified holoenzyme form with NaB[H-3]4 followed by digestion of the carboxymethylated protein with endoproteinase Lys-C, radioactive peptide mapping using reversed-phase high pressure liquid chromatography and gas-phase peptide sequencing. This lysine is contained in the sequence PFYAVKC, which is found in all known ODCs from eukaryotes. The preceding amino acids do not conform to the consensus sequence of SXHK, which contains the pyridoxal 5'-phosphate binding lysine in a number of other decarboxylases including ODCs from E. coli. Using a similar procedure to analyze ODC labeled by reaction with [5-C-14]DFMO, it was found that lysine 69 and cysteine 360 formed covalent adducts with the inhibitor. Cysteine 360, which was the major adduct accounting for about 90% of the total labeling, is contained within the sequence -WGPTCDGL(I)D-, which is present in all known eukaryote ODCs. These results provide strong evidence that these two peptides form essential parts of the catalytic site of ODC. Analysis by fast atom bombardment-mass spectrometry of tryptic peptides containing the DFMO-cysteine adduct indicated that the adduct formed in the enzyme was probably the cyclic imine S-((2-(1-pyrroline))methyl)cysteine, This is readily oxidized to S-((2-pyrrole)methyl)cysteine or converted to S-((2-pyrrolidine)methyl)cysteine by NaBH4 reduction. This adduct is consistent with spectral evidence showing that inactivation of the enzyme with DFMO does not entail the formation of a stable adduct between the pyridoxal 5'-phosphate, the enzyme, and the inhibitor.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL & PHARMACOL,HERSHEY,PA 17033; MARION MERRELL DOW RES INST,CINCINNATI,OH 45215	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Dow Chemical Company					NCI NIH HHS [CA-18138, CA-37606] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA037606, R37CA018138, R01CA018138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBAUM D, 1975, BIOCHEMISTRY-US, V14, P3675, DOI 10.1021/bi00687a025; BADET B, 1984, BIOCHEMISTRY-US, V23, P5188, DOI 10.1021/bi00317a016; BARROSO L, 1990, EMBL M33766 GENB EMB; BASSEZ T, 1990, DEVELOPMENT, V110, P955; BEY P, 1989, ENZYMES AS TARGETS FOR DRUG DESIGN, P59; Bey P., 1987, INHIBITION POLYAMINE, P1; BHATTACHARJEE MK, 1990, J BIOL CHEM, V265, P6664; BLANKENSHIP DT, 1989, ANAL BIOCHEM, V178, P227, DOI 10.1016/0003-2697(89)90629-5; BOEKER EA, 1972, ENZYMES, V6, P217; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P2413; DEBIASE D, 1991, BIOCHEMISTRY-US, V30, P2239, DOI 10.1021/bi00222a029; DEBIASE D, 1991, BIOCHIMIE PARIS, V71, P491; Drapeau G R, 1977, Methods Enzymol, V47, P189; DUFFAUD GD, 1987, METHOD ENZYMOL, V153, P492; FARACI WS, 1989, BIOCHEMISTRY-US, V28, P431, DOI 10.1021/bi00428a004; FONZI WA, 1987, J BIOL CHEM, V262, P10127; FUTAKI S, 1990, J BIOL CHEM, V265, P22306; GRENS A, 1989, NUCLEIC ACIDS RES, V17, P10497, DOI 10.1093/nar/17.24.10497; GUIRARD BM, 1980, J BIOL CHEM, V255, P5960; GUPTA M, 1985, J BIOL CHEM, V260, P2941; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HAYASHI H, 1986, J BIOL CHEM, V261, P1003; HAYASHI H, 1990, ANNU REV BIOCHEM, V59, P87, DOI 10.1146/annurev.biochem.59.1.87; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P1; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; HICKOK NJ, 1986, P NATL ACAD SCI USA, V83, P594, DOI 10.1073/pnas.83.3.594; JOSEPH DR, 1990, P NATL ACAD SCI USA, V87, P733, DOI 10.1073/pnas.87.2.733; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KALLEN RG, 1985, BIOCHEMISTRY-US, V2, P37; KASHIGAWA K, 1990, 1990 INT S POL MOL M, P220; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIKOS JJ, 1982, BIOCHEMISTRY-US, V21, P4377, DOI 10.1021/bi00261a029; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MACRAE M, 1987, MOL CELL BIOL, V7, P564, DOI 10.1128/MCB.7.1.564; MCCANN PP, 1987, INHIBITION POLYAMINE, P1; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; OLEARY MH, 1978, BIOCHEMISTRY-US, V17, P1010, DOI 10.1021/bi00599a011; Pegg  A., 1981, POLYAMINES BIOL MED, P3; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PEGG AE, 1987, BIOCHEM J, V241, P305, DOI 10.1042/bj2410305; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; PILZ RB, 1990, J BIOL CHEM, V265, P8880; SEELY JE, 1982, BIOCHEM J, V206, P311, DOI 10.1042/bj2060311; SEELY JE, 1983, METHOD ENZYMOL, V94, P158; SJOERDSMA A, 1984, CLIN PHARMACOL THER, V35, P287, DOI 10.1038/clpt.1984.33; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TANASE S, 1985, J BIOL CHEM, V260, P6738; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; VANKRANEN HJ, 1987, GENE, V60, P145, DOI 10.1016/0378-1119(87)90222-8; WALSH CT, 1984, ANNU REV BIOCHEM, V53, P493, DOI 10.1146/annurev.bi.53.070184.002425; WEN L, 1989, J BIOL CHEM, V264, P9016; YIP WK, 1990, P NATL ACAD SCI USA, V87, P7930, DOI 10.1073/pnas.87.20.7930	56	187	191	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					150	158						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730582				2022-12-25	WOS:A1992GY43900029
J	DESTEFANO, JJ; BUISER, RG; MALLABER, LM; BAMBARA, RA; FAY, PJ				DESTEFANO, JJ; BUISER, RG; MALLABER, LM; BAMBARA, RA; FAY, PJ			HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE DISPLAYS A PARTIALLY PROCESSIVE 3' TO 5' ENDONUCLEASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; RNASE-H ACTIVITY; PLUS-STRAND DNA; RIBONUCLEASE-H; TUMOR-VIRUSES; POLYMERASE; INITIATION; RETROVIRUS; MECHANISM; PRIMER	We have examined the ribonuclease H (RNase H) activity of human immunodeficiency virus reverse transcriptase (HIV-RT) using a natural sequence 83-nucleotide-long RNA template to which was hybridized a DNA oligomer. This substrate configuration allowed for the simultaneous electrophoretic resolution of 5'-, 3'-, and internally derived RNase H cleavage products. Assays performed in the presence of excess challenger RNA to sequester the RT permitted the analysis of products resulting from a single round of binding of RT to substrate. Substrate cleavage was highly sensitive to ionic strength, showing greatest activity at low KCl concentrations. The increase in cleavage correlated with an increase in the half-life of the enzyme on the RNA-DNA hybrid from approximately 31 s to 6.2 min at 80 and 5 mM KCl respectively. Internally derived cleavage products generated in challenged reactions were primarily 2-9 nucleotides in length. These lengths indicate that the products were generated by an endo- rather than an exonuclease activity. The directionality and processivity of the endonuclease were also determined by examination of cleavage products from challenged reactions. Although the lengths of 5'-derived products markedly decreased with time, no change in the size distribution of 3'-derived products was observed, indicating that cleavage proceeded processively in the 3' to 5' direction. The 5'-derived products were shortened more in reactions performed under conditions allowing multiple versus single enzyme-binding events, suggesting that the endonuclease action of a single enzyme is not processive enough to generate the maximum possible amount of cleavage on each substrate. Therefore, HIV-RT displays a partially processive 3' to 5' endonuclease activity.	UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027054] Funding Source: NIH RePORTER; NCI NIH HHS [CA 11198] Funding Source: Medline; NIAID NIH HHS [AI 27054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHAMPOUX JJ, 1984, J VIROL, V49, P686, DOI 10.1128/JVI.49.3.686-691.1984; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; FINSTON WI, 1984, J VIROL, V51, P26, DOI 10.1128/JVI.51.1.26-33.1984; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GERARD GF, 1981, BIOCHEMISTRY-US, V20, P256, DOI 10.1021/bi00505a005; GRANDGENETT DP, 1974, J BIOL CHEM, V249, P5148; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HANSEN J, 1987, J BIOL CHEM, V262, P12393; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KELLER W, 1972, P NATL ACAD SCI USA, V69, P3360, DOI 10.1073/pnas.69.11.3360; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; LEIS JP, 1973, P NATL ACAD SCI USA, V70, P466, DOI 10.1073/pnas.70.2.466; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MATSON SW, 1981, BIOCHIM BIOPHYS ACTA, V652, P29, DOI 10.1016/0005-2787(81)90205-7; MITRA SW, 1982, J BIOL CHEM, V257, P5983; MIZRAHI V, 1989, BIOCHEMISTRY-US, V28, P9088, DOI 10.1021/bi00449a020; MOELLING K, 1976, J VIROL, V18, P418, DOI 10.1128/JVI.18.2.418-425.1976; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; RESNICK R, 1984, J VIROL, V51, P813, DOI 10.1128/JVI.51.3.813-821.1984; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SMITH JK, 1984, J VIROL, V52, P314, DOI 10.1128/JVI.52.2.314-319.1984; SMITH JK, 1984, J VIROL, V49, P200, DOI 10.1128/JVI.49.1.200-204.1984; STARNES MC, 1989, J BIOL CHEM, V264, P7073; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VERMA IM, 1975, J VIROL, V15, P843, DOI 10.1128/JVI.15.4.843-854.1975; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WATSON KF, 1979, BIOCHEMISTRY-US, V18, P3210, DOI 10.1021/bi00582a004	32	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24295	24301						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722202				2022-12-25	WOS:A1991GW84500012
J	GREENSPAN, DS; CHENG, W; HOFFMAN, GG				GREENSPAN, DS; CHENG, W; HOFFMAN, GG			THE PRO-ALPHA-1(V) COLLAGEN CHAIN - COMPLETE PRIMARY STRUCTURE, DISTRIBUTION OF EXPRESSION, AND COMPARISON WITH THE PRO-ALPHA-1(XI) COLLAGEN CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; MOLECULAR-CLONING; MESSENGER-RNA; XI COLLAGEN; PROCOLLAGEN; GENE; CDNA; SEQUENCE; REGION; REVEALS	We have isolated overlapping cDNA clones from human and hamster libraries which comprise the entire coding sequences for the prepro-alpha-1(V) collagen chains of both species. The translated polypeptide has a signal peptide of 36 amino acids, a central triple helical domain of 338 uninterrupted Gly-X-Y triplets, and 266 amino acids which comprise the C-telopeptide and propeptide. The N-propeptide and telopeptide are comprised of 522 residues in humans and 524 residues in hamsters. The cDNA-derived pro-alpha-1(V) amino acid sequences exhibit a variety of structural features characteristic of fibrillar collagens. Pro-alpha-1(V) is found to be unique among fibrillar collagen chains, however, in lacking potential cross-linking lysyl residues in either telopeptide, and in possessing potential N-asparaginyl-linked carbohydrate attachment sites in its N-propeptide. Of particular interest is the strong homology found between the pro-alpha-1(V) and pro-alpha-1(XI) collagen chains in most domains, with the notable exception of a subdomain in the globular region of the N-propeptide. RNase protection analysis of RNA with a variety of pro-alpha-1(V) cDNA-derived riboprobes indicates a broad distribution of expression of the pro-alpha-1(V) chain in tissues and suggests that transcripts encoding the pro-alpha-1(V) chain and the putative pro-alpha-1'(V) chain are not products of the same gene.			GREENSPAN, DS (corresponding author), UNIV WISCONSIN,DEPT PATHOL & LAB MED,MADISON,WI 53706, USA.			Greenspan, Daniel/0000-0001-8096-7446	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038544] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38544] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERNARD M, 1988, J BIOL CHEM, V263, P17159; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET W, 1987, J BIOL CHEM, V262, P16032; DION AS, 1987, J MOL BIOL, V193, P127, DOI 10.1016/0022-2836(87)90632-2; Eyre D, 1987, STRUCTURE FUNCTION C, P261; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; FESSLER LI, 1981, J BIOL CHEM, V256, P9646; FESSLER LI, 1985, J BIOL CHEM, V260, P3286; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GREENSPAN DS, 1985, MOL CELL BIOL, V5, P1894, DOI 10.1128/MCB.5.8.1894; GREENSPAN DS, 1991, GENE EXPRESSION, V1, P29; GREENSPAN DS, 1989, J BIOL CHEM, V264, P20683; HARALSON MA, 1980, P NATL ACAD SCI-BIOL, V77, P5206, DOI 10.1073/pnas.77.9.5206; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; KIMURA T, 1989, J BIOL CHEM, V264, P13910; KOHNO K, 1984, J BIOL CHEM, V259, P3668; KUHN K, 1987, STRUCTURE FUNCTION C, P1; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; Lee S. A., UNPUB; LEE ST, 1990, J BIOL CHEM, V265, P21992; LEE ST, 1988, J BIOL CHEM, V263, P13414; LOIDL HR, 1984, NUCLEIC ACIDS RES, V12, P9383, DOI 10.1093/nar/12.24.9383; Maniatis T., 1982, MOL CLONING; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MYERS JC, 1985, J BIOL CHEM, V260, P1216; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; NIYIBIZI C, 1984, J BIOL CHEM, V259, P4170; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SANDELL LJ, 1984, J BIOL CHEM, V259, P7826; SEYER JM, 1989, ARCH BIOCHEM BIOPHYS, V271, P120, DOI 10.1016/0003-9861(89)90262-2; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TOMAN PD, 1988, NUCLEIC ACIDS RES, V16, P7201, DOI 10.1093/nar/16.14.7201; UCKER DS, 1983, MOL CELL BIOL, V3, P551, DOI 10.1128/MCB.3.4.551; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WEIL D, 1987, NUCLEIC ACIDS RES, V15, P181, DOI 10.1093/nar/15.1.181; WOODBURY D, 1989, J BIOL CHEM, V264, P2735; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423	45	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24727	24733						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722213				2022-12-25	WOS:A1991GW84500075
J	HEVEL, JM; WHITE, KA; MARLETTA, MA				HEVEL, JM; WHITE, KA; MARLETTA, MA			PURIFICATION OF THE INDUCIBLE MURINE MACROPHAGE NITRIC-OXIDE SYNTHASE - IDENTIFICATION AS A FLAVOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							L-ARGININE; RELAXING FACTOR; NITRATE; OXIDATION; COFACTOR; RELEASE	The synthesis of nitric oxide (.NO) from L-arginine has been demonstrated in a number of cell types and functions either as a cell signaling agent or as a key component of the cell-mediated immune response. Both constitutive and inducible activities have been described. Herein we report the purification of inducible .NO synthase (EC 1.14.23) from activated murine macrophages using a two-column procedure. Crude 100,000 x g supernatant was passed through a 2'-5'-ADP-Sepharose 4B affinity column followed by a DEAE-Bio-Gel A anion exchange column. The .NO synthase ran as a band of M(r) = 130,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Gel filtration experiments using a Superose 6 HR 10/30 column estimated the native molecular weight to be 260 +/- 30 kDa, indicating that the native enzyme exists as a dimer. Activity was dependent upon L-arginine (K(m) = 16 +/- 1-mu-M at 37-degrees-C and pH 7.5) and NADPH. Both (6R)-tetrahydro-L-biopterin and FAD enhanced activity, whereas Mg2+ and FMN had no effect on activity. Fluorescence studies demonstrated the presence of one bound FAD and one bound FMN per sub unit.	UNIV MICHIGAN,COLL PHARM,INTERDEPT PROGRAM MED CHEM,428 CHURCH ST,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Hevel, Joan/0000-0002-9559-4635	NATIONAL CANCER INSTITUTE [R01CA050414] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50414] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6368; KWON NS, 1989, J BIOL CHEM, V264, P20496; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; MARLETTA M A, 1990, Biofactors, V2, P219; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MOORE EG, 1978, J BIOL CHEM, V253, P6413; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; YUI Y, 1991, J BIOL CHEM, V266, P12544; YUI Y, 1991, J BIOL CHEM, V266, P3369	20	422	437	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22789	22791						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1720773				2022-12-25	WOS:A1991GT48300004
J	BAECKSTROM, D; HANSSON, GC; NILSSON, O; JOHANSSON, C; GENDLER, SJ; LINDHOLM, L				BAECKSTROM, D; HANSSON, GC; NILSSON, O; JOHANSSON, C; GENDLER, SJ; LINDHOLM, L			PURIFICATION AND CHARACTERIZATION OF A MEMBRANE-BOUND AND A SECRETED MUCIN-TYPE GLYCOPROTEIN CARRYING THE CARCINOMA-ASSOCIATED SIALYL-LE(A) EPITOPE ON DISTINCT CORE PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; N-FUCOPENTAOSE-II; MONOCLONAL-ANTIBODIES; HUMAN-MILK; CANCER; ANTIGEN; GANGLIOSIDES; EXPRESSION; ADENOCARCINOMA; BIOSYNTHESIS	Two mucin-type glycoproteins detected by the monoclonal antibody C50, which reacts with the carcinoma-associated sialyl-Lewis a and sialyl-lactotetraose epitopes, were found in secreted and solubilized materials from the colon carcinoma cell line COLO 205. The larger glycoprotein (H-CanAg; heavy cancer antigen) was predominantly found in extracts of cells grown in vitro or as nude mice xenografts whereas the smaller species (L-CanAg; light cancer antigen) was the major component in spent culture medium and serum from grafted mice. Using detergent in the extraction buffer doubled the yield of H-CanAg, suggesting that this glycoprotein is membrane bound whereas the yield of L-CanAg was relatively unaffected. The two glycoproteins were purified from xenograft extracts and spent culture medium using perchloric acid precipitation, monoclonal antibody affinity purification, ion exchange chromatography, and gel filtration. Both glycoproteins were unaffected by reduction and alkylation in guanidine HCI. Using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, relative molecular masses were estimated to be 600-800 kDa for H-CanAg and 150-300 kDa for L-CanAg. Carbohydrate analysis revealed that the CanAg glycoproteins were highly glycosylated (81-89% carbohydrate by weight), carrying carbohydrate chains with average lengths of 13-18 sugars which were rich in fucose and sialic acid (2-3 residues/chain for each sugar). L-CanAg isolated from spent medium was glycosylated to a higher degree than its counterpart from xenograft extract. Immunochemical studies of the intact glycoproteins showed that both H-CanAg and L-CanAg expressed the monoclonal antibody-defined, sialic acid-containing carbohydrate epitopes CA2O3 and CA242 as well as the Lewis a blood group antigen whereas only H-CanAg appeared to carry the sialyl-Lewis x epitope. The amino acid compositions were typical of mucins, containing high amounts of serine, threonine (more than 25% together), and proline (11-18%). Significant differences in amino acid composition between H-CanAg and L-CanAg were found. A rabbit antiserum against the cytoplasmic C-terminal part of the MUC1 gene product, core protein of the carcinoma-associated Polymorphic epithelial mucin (PEM) and DU-PAN-2, reacted with H-CanAg. After deglycosylation with trifluoromethanesulfonic acid, H-CanAg but not L-CanAg was recognized by the monoclonal antibodies SM-3 and HMFG-2, directed to the tandem repeat of the PEM apoprotein. However, these antibodies which react with PEM from mammary carcinomas without prior deglycosylation were unable to recognize intact H-CanAg, probably as a consequence of a more extensive glycosylation of this glycoprotein. Comparison of amino acid compositions confirmed that H-CanAg apoprotein is closely related to the MUC1 protein whereas L-CanAg is not. These findings show that colon carcinoma cells can express two, mucins with several carcinoma-associated carbohydrate epitopes in common but differing in core protein structure and cellular localization.	PHARMACIA CANAG,S-40242 GOTHENBURG,SWEDEN; DEPT MED MICROBIOL & IMMUNOL,S-41346 GOTHENBURG,SWEDEN; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	BAECKSTROM, D (corresponding author), GOTHENBURG UNIV,DEPT MED BIOCHEM,BOX 33031,S-40033 GOTHENBURG,SWEDEN.		Hansson, Gunnar C./AAF-7324-2019; Hansson, Gunnar C/A-1236-2009	Hansson, Gunnar C./0000-0002-1900-1869; Hansson, Gunnar C/0000-0002-1900-1869				BURCHELL J, 1983, J IMMUNOL, V131, P508; BURCHELL J, 1987, CANCER RES, V47, P5476; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GOLD DV, 1988, TUMOR BIOL, V9, P137, DOI 10.1159/000217554; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HANISCH FG, 1985, EUR J BIOCHEM, V149, P323, DOI 10.1111/j.1432-1033.1985.tb08929.x; HANSSON GC, 1985, J BIOL CHEM, V260, P9388; HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HIGASHI H, 1985, CANCER RES, V45, P3796; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; HILKENS J, 1989, CANCER RES, V49, P786; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V270, P630, DOI 10.1016/0003-9861(89)90546-8; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; JOHANSSON C, 1991, TUMOR BIOL, V12, P159, DOI 10.1159/000217701; JOHANSSON C, 1991, INT J CANCER, V48, P757, DOI 10.1002/ijc.2910480521; KJELDSEN T, 1988, CANCER RES, V48, P2214; KLUG TL, 1988, CANCER RES, V48, P1505; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAN MS, 1990, J BIOL CHEM, V265, P15294; LAN MS, 1987, INT J CANCER, V39, P68, DOI 10.1002/ijc.2910390112; LAN MS, 1987, J BIOL CHEM, V262, P12863; LARSON LN, 1988, INT J CANCER, V42, P877, DOI 10.1002/ijc.2910420615; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LINDHOLM L, 1983, INT ARCH ALLER A IMM, V71, P178, DOI 10.1159/000233384; MAGNANI JL, 1982, J BIOL CHEM, V257, P4365; MANSSON JE, 1985, BIOCHIM BIOPHYS ACTA, V834, P110, DOI 10.1016/0005-2760(85)90182-1; MANSSON JE, 1986, FEBS LETT, V201, P109, DOI 10.1016/0014-5793(86)80580-4; MARTENSSON S, 1988, SCAND J CLIN LAB INV, V48, P633, DOI 10.3109/00365518809085783; Neutra M.R., 1987, PHYSL GASTROINTESTIN, V2, P975; NILSSON LA, 1987, J DERMATOL SURG ONC, V13, P49, DOI 10.1111/j.1524-4725.1987.tb00496.x; NILSSON O, 1985, FEBS LETT, V182, P398, DOI 10.1016/0014-5793(85)80341-0; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SHEER DG, 1988, CANCER RES, V48, P6811; SOJAR HT, 1987, METHOD ENZYMOL, V138, P341; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; YOUNG H, 1971, J BIOL CHEM, V246, P1192; 1989, CYTOGENET CELL GENET, V51, P1	44	144	163	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21537	21547						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1718981				2022-12-25	WOS:A1991GP80400037
J	WEI, XY; PEREZREYES, E; LACERDA, AE; SCHUSTER, G; BROWN, AM; BIRNBAUMER, L				WEI, XY; PEREZREYES, E; LACERDA, AE; SCHUSTER, G; BROWN, AM; BIRNBAUMER, L			HETEROLOGOUS REGULATION OF THE CARDIAC CA2+ CHANNEL-ALPHA-1 SUBUNIT BY SKELETAL-MUSCLE BETA-SUBUNIT AND GAMMA-SUBUNITS - IMPLICATIONS FOR THE STRUCTURE OF CARDIAC L-TYPE CA2+ CHANNELS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; AMINO-ACID-SEQUENCE; DIHYDROPYRIDINE RECEPTOR; XENOPUS OOCYTES; MESSENGER-RNA; COMPLEMENTARY-DNA; RAT-HEART; EXPRESSION; PROTEIN; PHOSPHORYLATION	High threshold L-type Ca" channels of skeletal muscle are thought to consist of a complex of alpha-1, alpha-2-delta, beta, and gamma-subunits. Expression of the cloned alpha-1 subunit from skeletal and cardiac muscle has established that this protein is the dihydropyridine-sensitive ion-conducting subunit. However, the kinetics of the skeletal muscle alpha-1 alone expressed in mouse L-cells were abnormally slow and were accelerated to within the normal range by coexpression with the skeletal muscle beta-subunit. The kinetics of cardiac muscle alpha-1 were also slowed but to a lesser extent and were not altered by coexpression with skeletal muscle alpha-2. We show here that coexpression of the skeletal muscle beta-subunit with the cardiac alpha-1 subunit in Xenopus laevis oocytes produced: 1) an increase in the peak voltage-sensitive current, 2) a shift of the peak current-voltage relationship to more hyperpolarized potentials, and 3) an increase in the rate of activation. Coexpression of the skeletal muscle gamma-subunit did not have a significant effect on currents elicited by alpha-1. However, when gamma was coexpressed with beta and alpha-1, both peak currents and rates of activation at more negative potentials were increased. These results indicate that rather than simply amplifying expression of alpha-1, heterologous skeletal muscle-beta and gamma-subunits can modulate the biophysical properties of cardiac alpha-1.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DIV NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	WEI, XY (corresponding author), BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037044, F32HL007831] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07831, HL-37044] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOSSE E, 1990, FEBS LETT, V267, P153, DOI 10.1016/0014-5793(90)80312-7; CURTIS BM, 1984, BIOCHEMISTRY-US, V23, P2113, DOI 10.1021/bi00305a001; DEJONGH KS, 1989, P NATL ACAD SCI USA, V86, P8585; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; FLOCKERZI V, 1986, EUR J BIOCHEM, V161, P217, DOI 10.1111/j.1432-1033.1986.tb10145.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAMILTON SL, 1989, BIOCHEMISTRY-US, V28, P7820, DOI 10.1021/bi00445a044; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KIM HS, 1990, J BIOL CHEM, V265, P11858; KRAFTE DS, 1988, J NEUROSCI, V8, P2859; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LORY P, 1990, J PHYSIOL-LONDON, V429, P95, DOI 10.1113/jphysiol.1990.sp018246; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MOORMAN JR, 1987, AM J PHYSIOL, V253, pH985, DOI 10.1152/ajpheart.1987.253.4.H985; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NUNOKI K, 1989, P NATL ACAD SCI USA, V86, P6816, DOI 10.1073/pnas.86.17.6816; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PRAGNELL M, 1991, BIOPHYS J, V59, P390; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SANFORD J, 1991, J BIOL CHEM, V266, P9570; SHARP AH, 1989, J BIOL CHEM, V264, P2816; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; VANDAELE S, 1987, BIOCHEMISTRY-US, V26, P5, DOI 10.1021/bi00375a002; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YATANI A, 1988, J BIOL CHEM, V263, P9887	31	203	211	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21943	21947						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1718988				2022-12-25	WOS:A1991GP80400093
J	WATANABE, S; KUSAMAEGUCHI, K; KOBAYASHI, H; IGARASHI, K				WATANABE, S; KUSAMAEGUCHI, K; KOBAYASHI, H; IGARASHI, K			ESTIMATION OF POLYAMINE BINDING TO MACROMOLECULES AND ATP IN BOVINE LYMPHOCYTES AND RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NEUROSPORA-CRASSA; TRANSFER-RNA; DNA; SPERMIDINE; GROWTH; PROTEIN; INHIBITION; MECHANISM; SYSTEM	To estimate the polyamine distribution in bovine lymphocytes and rat liver, the binding constants (K) for DNA, RNA, phospholipid, and ATP were determined under the conditions of 10 mM Tris-HCL, pH 7.5, 2 mM Mg2+, and 150 mM K+. The binding constants of spermine for calf thymus DNA, Escherichia coli 16 S rRNA, phospholipid in rat liver microsomes and ATP were 1.15 x 10(2), 6.69 x 10(2), 2.22 x 10(2), and 5.95 x 10(2) M-1, respectively. From these binding constants and experimentally determined cellular concentrations of macromolecules, ATP, and polyamines, spermine distribution in the cells was estimated. In bovine lymphocytes, the mols of spermine bound to DNA, RNA, phospholipid, and ATP were 0.79, 3.7, 0.23, and 4.3 per 100 mol of phosphate of macromolecules or ATP, respectively. In rat liver, they were 0.19, 1.0, 0.05, and 0.97/100 mol of phosphate of macromolecules or ATP, respectively. The binding constants of spermidine for macromolecules and ATP were smaller than those of spermine, but a similar tendency was observed with spermidine distribution among macromolecules and ATP in the above two cells. The amount of polyamine bound to DNA and phospholipid was significantly lower than that to RNA. When either the Mg2+ or K+ concentration increased, the amount of free spermine and that bound to RNA and ATP increased, but the amount of spermine bound to DNA and phospholipid decreased. The results indicate that most polyamines exist as a polyamine-RNA complex in cells. Under the conditions that globin synthesis is stimulated by spermine in a rabbit reticulocyte cell-free system, the amount of spermine bound to RNA was very close to the value estimated in the cells.	CHIBA UNIV,FAC PHARMACEUT SCI,1-33 YAYOI CHO,CHIBA 260,JAPAN	Chiba University				Igarashi, Kazuei/0000-0003-3751-3187				BEHE M, 1981, P NATL ACAD SCI-BIOL, V78, P1619, DOI 10.1073/pnas.78.3.1619; BLOOMFIELD VA, 1981, POLYAMINES BIOL MED, P183; BRAUNLIN WH, 1982, BIOPOLYMERS, V21, P1301, DOI 10.1002/bip.360210704; BRAY GA, 1960, ANAL BIOCHEM, V1, P279, DOI 10.1016/0003-2697(60)90025-7; Cohen S, 1978, ADV ENVIRON PSYCHOL, P1; COHEN SS, 1969, P NATL ACAD SCI USA, V64, P669, DOI 10.1073/pnas.64.2.669; DAVIS RH, 1989, ARCH BIOCHEM BIOPHYS, V271, P315, DOI 10.1016/0003-9861(89)90281-6; FALVEY AK, 1970, J MOL BIOL, V53, P1, DOI 10.1016/0022-2836(70)90042-2; FEUERSTEIN BG, 1986, P NATL ACAD SCI USA, V83, P5948, DOI 10.1073/pnas.83.16.5948; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; IGARASHI K, 1989, J BIOCHEM-TOKYO, V106, P294, DOI 10.1093/oxfordjournals.jbchem.a122847; IGARASHI K, 1986, J BACTERIOL, V166, P128, DOI 10.1128/jb.166.1.128-134.1986; IGARASHI K, 1982, ARCH BIOCHEM BIOPHYS, V219, P438, DOI 10.1016/0003-9861(82)90175-8; IGARASHI K, 1984, CANCER RES, V44, P5326; IGARASHI K, 1978, EUR J BIOCHEM, V82, P301, DOI 10.1111/j.1432-1033.1978.tb12024.x; IGARASHI K, 1969, P NATL ACAD SCI USA, V62, P498, DOI 10.1073/pnas.62.2.498; IGARASHI K, 1981, BIOCHEM BIOPH RES CO, V103, P659, DOI 10.1016/0006-291X(81)90501-5; ITO K, 1990, ARCH BIOCHEM BIOPHYS, V279, P138; JAIN S, 1989, BIOCHEMISTRY-US, V28, P2360, DOI 10.1021/bi00432a002; JENKINS WT, 1985, ANAL BIOCHEM, V145, P362, DOI 10.1016/0003-2697(85)90375-6; KAKINUMA Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P171, DOI 10.1016/0003-9861(87)90483-8; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; KASHIWAGI K, 1989, ARCH BIOCHEM BIOPHYS, V268, P379, DOI 10.1016/0003-9861(89)90598-5; KIMMICH GA, 1975, ANAL BIOCHEM, V69, P187, DOI 10.1016/0003-2697(75)90580-1; KITADA M, 1979, BIOCHEM BIOPH RES CO, V87, P388, DOI 10.1016/0006-291X(79)91808-4; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LABORATO, P86; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCMAHON ME, 1982, BIOCHEMISTRY-US, V21, P5280, DOI 10.1021/bi00264a025; McMurray W. C., 1973, FORM FUNCTION PHOSPH, P205; MORGAN JE, 1986, ARCH BIOCHEM BIOPHYS, V246, P225, DOI 10.1016/0003-9861(86)90467-4; MORRISON WR, 1964, ANAL BIOCHEM, V7, P218, DOI 10.1016/0003-2697(64)90231-3; OGASAWARA T, 1989, J BIOCHEM-TOKYO, V105, P164, DOI 10.1093/oxfordjournals.jbchem.a122633; PAULUS TJ, 1983, J BIOL CHEM, V258, P8608; PEGG AE, 1988, CANCER RES, V48, P759; QUIGLEY GJ, 1978, P NATL ACAD SCI USA, V75, P64, DOI 10.1073/pnas.75.1.64; RUBIN RL, 1977, J BACTERIOL, V129, P916, DOI 10.1128/JB.129.2.916-925.1977; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMIDT G, 1945, J BIOL CHEM, V161, P83; SCHNEIDER WC, 1945, J BIOL CHEM, V161, P293; SCHREIER AA, 1975, J MOL BIOL, V93, P323, DOI 10.1016/0022-2836(75)90136-9; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TONINELLO A, 1988, J BIOL CHEM, V263, P19407; Traub P, 1971, METHOD ENZYMOL, V20, P391; [No title captured]	47	298	300	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20803	20809						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1718969				2022-12-25	WOS:A1991GN00100035
J	ALI, S; PELLEGRINI, I; KELLY, PA				ALI, S; PELLEGRINI, I; KELLY, PA			A PROLACTIN-DEPENDENT IMMUNE CELL-LINE (NB2) EXPRESSES A MUTANT FORM OF PROLACTIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NODE LYMPHOMA-CELLS; COLONY-STIMULATING FACTOR; SENSITIVE NA+/H+ EXCHANGE; GROWTH-HORMONE RECEPTOR; MYC GENE-EXPRESSION; MOLECULAR-CLONING; C-MYC; ORNITHINE DECARBOXYLASE; ERYTHROPOIETIN RECEPTOR; PROTEIN-PHOSPHORYLATION	The Nb2 cell line is a pre-T rat lymphoma that is dependent on prolactin (PRL) for mitogenesis. Two forms of PRL receptor (PRL-R), which differ in the length of their cytoplasmic domains have been identified in different tissues and species. In the present study we have cloned the cDNA and characterized the mitogenic form of PRL-R in Nb2 cells. Polymerase chain reaction amplification of first strand cDNA prepared from Nb2-11C (PRL-dependent) and Nb2-Sp (PRL-independent) cell lines was performed using oligonucleotide primers specific for the binding domain, the short form of the PRL-R, and the cytoplasmic domain of the long form of the PRL-R. These studies indicate that both cell lines express a novel form of PRL-R. A cDNA was isolated from an Nb2-Sp cDNA library, which contains 1446 base pairs identical to the nucleotide sequence of the long form of the rat PRL-R. However, the cDNA sequence is missing 594 base pairs in the cytoplasmic domain compared with the long form of the PRL-R. The cDNA encodes a protein of 393 amino acids, lacking 198 amino acids in the cytoplasmic domain. Scatchard analysis of I-125-labeled ovine prolactin (oPRL) binding to microsomes prepared from transiently transfected COS-7 cells with either PRL-R long form cDNA or Nb2 PRL-R cDNA indicates that the long form of PRL-R binds oPRL with high affinity (K(a) = 8.8 x 10(9) M-1), while the Nb2 PRL-R showed a 3.3-fold increased affinity for PRL (K(a) = 29.1 x 10(9) M-1). In addition, immunoblot analysis of these microsomes using I-125-labeled monoclonal antibody (U6) to the PRL-R demonstrates a M(r) of approximately 82,000 for the long form and approximately 62,000 for the Nb2 form of PRL-R. Polymerase chain reaction amplification of genomic DNA prepared from PRL-dependent and -independent cell lines suggests that this form of PRL-R results from a deletion in the PRL-R gene. The identification of a modified long form of PRL-R in the Nb2 cell line should help localize domains of the PRL-R involved in signal transduction and further the investigation of prolactin's role in immune cell proliferation.	MCGILL UNIV, ROYAL VICTORIA HOSP, MOLEC ENDOCRINOL LAB, MONTREAL H3A 1A1, QUEBEC, CANADA	McGill University; Royal Victoria Hospital			Kelly, Paul/A-7951-2008					AMSELEM S, 1991, TRENDS ENDOCRIN MET, V2, P35, DOI 10.1016/1043-2760(91)90059-V; ANDREWS GK, 1987, BIOCHIM BIOPHYS ACTA, V909, P231, DOI 10.1016/0167-4781(87)90082-0; ARDEN KC, 1990, CYTOGENET CELL GENET, V53, P161, DOI 10.1159/000132919; ASHKENAZI A, 1987, FEBS LETT, V210, P51, DOI 10.1016/0014-5793(87)81296-6; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BERNTON EW, 1988, SCIENCE, V239, P401, DOI 10.1126/science.3122324; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; BROWN TR, 1990, MOL ENDOCRINOL, V4, P1759, DOI 10.1210/mend-4-12-1759; BUCKLEY AR, 1986, IMMUNOPHARMACOLOGY, V12, P37, DOI 10.1016/0162-3109(86)90050-0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN HW, 1972, JNCI-J NATL CANCER I, V49, P1145; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVENGER CV, 1990, ENDOCRINOLOGY, V127, P3151, DOI 10.1210/endo-127-6-3151; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; COOKE NE, 1980, J BIOL CHEM, V255, P6502; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DETOLEDO SM, 1987, MOL ENDOCRINOL, V1, P430, DOI 10.1210/mend-1-6-430; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ELBERG G, 1990, J BIOL CHEM, V265, P14770; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ELSHOLTZ HP, 1986, BIOCHEM CELL BIOL, V64, P381, DOI 10.1139/o86-053; FLEMING WH, 1985, ENDOCRINOLOGY, V117, P2547, DOI 10.1210/endo-117-6-2547; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GERTLER A, 1986, MOL CELL ENDOCRINOL, V48, P221, DOI 10.1016/0303-7207(86)90045-6; GERTLER A, 1985, ENDOCRINOLOGY, V116, P1636, DOI 10.1210/endo-116-4-1636; GODOWSKI PJ, 1989, P NATL ACAD SCI USA, V86, P8083, DOI 10.1073/pnas.86.20.8083; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOUT PW, 1980, CANCER RES, V40, P2433; GUYETTE WA, 1979, CELL, V17, P1013, DOI 10.1016/0092-8674(79)90340-4; HARTMANN DP, 1989, FASEB J, V3, P2194, DOI 10.1096/fasebj.3.10.2787766; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KO KWS, 1986, J BIOL CHEM, V261, P7846; KORNBERG LJ, 1989, BIOCHIM BIOPHYS ACTA, V1011, P205, DOI 10.1016/0167-4889(89)90211-5; LARSEN JL, 1988, ENDOCRINOLOGY, V123, P438, DOI 10.1210/endo-123-1-438; LAWSON DM, 1982, LIFE SCI, V31, P3063, DOI 10.1016/0024-3205(82)90076-5; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MEEKER TC, 1990, BLOOD, V76, P285; MONTGOMERY DW, 1987, BIOCHEM BIOPH RES CO, V145, P692, DOI 10.1016/0006-291X(87)91020-5; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MUKHERJEE P, 1990, ENDOCRINOLOGY, V126, P88, DOI 10.1210/endo-126-1-88; MURPHY PR, 1988, ENDOCRINOLOGY, V122, P2476, DOI 10.1210/endo-122-6-2476; NAGY E, 1978, ACTA ENDOCRINOL-COP, V89, P530; NAGY E, 1983, IMMUNOPHARMACOLOGY, V6, P231, DOI 10.1016/0162-3109(83)90023-1; OFENSTEIN JP, 1987, P SOC EXP BIOL MED, V185, P147, DOI 10.3181/00379727-185-42529; OKAMURA H, 1989, J BIOL CHEM, V264, P5904; OKAMURA H, 1989, ENDOCRINOLOGY, V124, P2499, DOI 10.1210/endo-124-5-2499; RAYHEL EJ, 1988, BIOCHEM J, V249, P333, DOI 10.1042/bj2490333; RICHARDS JF, 1982, MOL CELL ENDOCRINOL, V26, P41, DOI 10.1016/0303-7207(82)90005-3; ROSEN JM, 1986, ANN NY ACAD SCI, V478, P63; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; RUSSELL DH, 1987, J IMMUNOL, V138, P276; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; THOREAU E, 1991, FEBS LETT, V282, P26, DOI 10.1016/0014-5793(91)80437-8; TOO CKL, 1989, ENDOCRINOLOGY, V124, P2185, DOI 10.1210/endo-124-5-2185; TOO CKL, 1987, ENDOCRINOLOGY, V121, P1503, DOI 10.1210/endo-121-4-1503; TOO CKL, 1987, ENDOCRINOLOGY, V121, P1512, DOI 10.1210/endo-121-4-1512; TOO CKL, 1990, ENDOCRINOLOGY, V126, P1368, DOI 10.1210/endo-126-3-1368; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YULEE LY, 1990, MOL CELL ENDOCRINOL, V68, P21; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087; ZHANG R, 1990, BIOCHEM BIOPH RES CO, V168, P415, DOI 10.1016/0006-291X(90)92337-Y	83	187	194	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20110	20117						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1718958				2022-12-25	WOS:A1991GM03900038
J	SIEGALL, CB; EPSTEIN, S; SPEIR, E; HLA, T; FOROUGH, R; MACIAG, T; FITZGERALD, DJ; PASTAN, I				SIEGALL, CB; EPSTEIN, S; SPEIR, E; HLA, T; FOROUGH, R; MACIAG, T; FITZGERALD, DJ; PASTAN, I			CYTOTOXIC ACTIVITY OF CHIMERIC PROTEINS COMPOSED OF ACIDIC FIBROBLAST GROWTH-FACTOR AND PSEUDOMONAS EXOTOXIN ON A VARIETY OF CELL-TYPES	FASEB JOURNAL			English	Note						AFGF; TOXIN; CYTOTOXICITY; CHIMERIC; ANTIANGIOGENIC	RECOMBINANT FUSION PROTEIN; CYTO-TOXIC ACTIVITY; ENDOTHELIAL-CELLS; RECEPTOR-BINDING; ANIMAL TOXICITY; DOMAIN-I; SEQUENCE; FAMILY; ALPHA; GENE	Chimeric proteins composed of acidic fibroblast growth factor (acidic FGF) and several forms of Pseudomonas exotoxin (PE) that cannot bind to the PE receptor have been produced in Escherichia coli by expressing chimeric genes in which DNA encoding acidic FGF is fused to various mutant forms of PE. These acidic FGF-PE fusion proteins were found to be cytotoxic to a variety of tumor cell lines including hepatocellular (PLC/PRF/5 and HEPG2), prostatic (LNCaP), colon (HT29), and breast (MCF-7) carcinomas at concentrations of 1-70 ng/ml. The cytotoxic effects of acidic FGF-PE were FGF-receptor specific as demonstrated by competition with excess acidic FGF and by showing that acidic FGF-PE bound to the FGF receptor with the same affinity as acidic FGF. Furthermore, the cell-killing activity of acidic FGF-PE was toxin-mediated, as an acidic FGF-PE mutant, which does not possess ADP-ribosylation activity, failed to kill cells. These findings demonstrate that acidic FGF-PE is a potent cytotoxic molecule that can be targeted to FGF receptor-bearing cells. Because acidic FGF is a potent angiogenic molecule, cytotoxic acidic FGF-PE chimeras may have utility as anti-angiogenic agents. These molecules could be helpful in determining the functional role of FGF receptors in cellular processes.	NCI,DIV CANC BIOL,MOLEC BIOL LAB,9000 ROCKVILLE PIKE,BLDG 37,ROOM 4E16,BETHESDA,MD 20892; NHLBI,CARDIOL BRANCH,BETHESDA,MD 20892; AMER RED CROSS,JEROME H HOLLAND LABS BIOMED SCI,MOLEC BIOL LAB,ROCKVILLE,MD 20855	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); American Red Cross			Hla, Timothy/G-5873-2012; pastan, ira/P-9319-2019	Hla, Timothy/0000-0001-8355-4065; pastan, ira/0000-0002-9223-0270	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, R01HL035627] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 35627, HL-32348] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDHARY VK, 1990, J BIOL CHEM, V265, P16306; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; CHAUDRY GJ, 1989, J BIOL CHEM, V264, P15151; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; EDWARDS GM, 1989, MOL CELL BIOL, V9, P2860, DOI 10.1128/MCB.9.7.2860; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL R, 1988, BIOCHEM BIOPH RES CO, V151, P957, DOI 10.1016/S0006-291X(88)80459-5; Gospodarowicz Denis, 1989, Critical Reviews in Oncogenesis, V1, P1; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JINNO Y, 1988, J BIOL CHEM, V263, P13203; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KONDO T, 1988, J BIOL CHEM, V263, P9470; LAPPI DA, 1989, BIOCHEM BIOPH RES CO, V160, P917, DOI 10.1016/0006-291X(89)92522-9; LORBERBOUMGALSKI H, 1988, J BIOL CHEM, V263, P18650; LORBERBOUMGALSKI H, 1990, J BIOL CHEM, V265, P16311; LORBERBOUMGALSKI H, 1988, P NATL ACAD SCI USA, V85, P1922, DOI 10.1073/pnas.85.6.1922; MARICS I, 1989, ONCOGENE, V4, P335; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OGATA M, 1989, P NATL ACAD SCI USA, V86, P4215, DOI 10.1073/pnas.86.11.4215; OGATA M, 1990, J BIOL CHEM, V265, P20678; PASTAN I, 1989, J BIOL CHEM, V264, P15157; PRIOR TI, 1991, CANCER RES, V51, P174; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SEETHARAM S, 1991, IN PRESS J BIOL CHEM; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; SIEGALL CB, 1990, J BIOL CHEM, V265, P16318; SIEGALL CB, 1988, P NATL ACAD SCI USA, V85, P9738, DOI 10.1073/pnas.85.24.9738; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SIEGALL CB, 1991, BIOCHEMISTRY-US, V30, P7154, DOI 10.1021/bi00243a016; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	43	33	35	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2843	2849		10.1096/fasebj.5.13.1717336	http://dx.doi.org/10.1096/fasebj.5.13.1717336			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1717336				2022-12-25	WOS:A1991GJ47100013
J	BRENNAN, CA; PLATT, T				BRENNAN, CA; PLATT, T			MUTATIONS IN AN RNP1 CONSENSUS SEQUENCE OF RHO PROTEIN REDUCE RNA-BINDING AFFINITY BUT FACILITATE HELICASE TURNOVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; DEPENDENT TRANSCRIPTION TERMINATION; REPRESSOR-OPERATOR INTERACTION; CRO MESSENGER-RNA; ESCHERICHIA-COLI; NUCLEAR RIBONUCLEOPROTEIN; ATPASE ACTIVITY; 3' END; U1 RNA; DOMAIN	Escherichia coli rho protein facilitates transcription termination by a mechanism that involves rho binding to the nascent RNA, activation of rho's RNA-dependent ATPase activity, and release of the mRNA from the DNA template. The initial step, formation of a rho-RNA complex, is mediated primarily by an RNA binding domain included within the amino-terminal 151 amino acids of rho protein. We have now identified one specific portion of this region that is involved in RNA binding, by photocross-linking and by site-directed mutagenesis. UV irradiation of rho-RNA complexes results in covalent attachment of the RNA to a single peptide in rho that apparently spans amino acids 45-100. Within this peptide is a ribonucleoprotein (RNP1) consensus sequence, Gly-Phe-Gly-Phe, that is present in many RNA-binding proteins. Mutagenesis of the phenylalanine residues in this consensus to leucine or alanine results in mutant proteins that are defective for RNA binding and have altered ATPase and RNA-DNA helicase activities. The weakened affinity but inceased salt sensitivity of RNA binding by the mutant proteins suggests that they have lost more than just a set of nonionic interactions and are consistent with a change in the conformation of the RNA binding site. Whatever the changes, they appear localized primarily to the RNA binding domain because the mutants retain much of their RNA-dependent ATPase activity. We infer that the Phe residues themselves do not play a substantial role in the activation of ATP hydrolysis. Our results indicate that several different components of RNA interaction are required for rho activity and support a role for the RNP1 consensus region of rho in at least one specific aspect of RNA binding.	UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035658] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35658] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; BRENNAN CA, 1990, J BIOL CHEM, V265, P5440; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1990, J BACTERIOL, V172, P2477, DOI 10.1128/jb.172.5.2477-2484.1990; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; GALLOWAY JL, 1988, J BIOL CHEM, V263, P1761; GALLOWAY JL, 1986, REGULATION GENE EXPR, P155; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LOWERY C, 1977, J BIOL CHEM, V252, P1375; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MOSSING MC, 1985, J MOL BIOL, V186, P295, DOI 10.1016/0022-2836(85)90106-8; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEINMETZ EJ, 1990, J BIOL CHEM, V265, P18408; WITHERELL GW, 1989, BIOCHEMISTRY-US, V28, P71, DOI 10.1021/bi00427a011; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913	37	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17296	17305						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1716628				2022-12-25	WOS:A1991GF44500051
J	HYMAN, MR; ARP, DJ				HYMAN, MR; ARP, DJ			14C2H2-LABELING AND 14CO2-LABELING STUDIES OF THE DENOVO SYNTHESIS OF POLYPEPTIDES BY NITROSOMONAS-EUROPAEA DURING RECOVERY FROM ACETYLENE AND LIGHT INACTIVATION OF AMMONIA MONOOXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOCOCCUS-CAPSULATUS; METHANE MONOOXYGENASE; NITRIFYING BACTERIA; MONO-OXYGENASE; OXIDATION; TRICHLOROETHYLENE; INHIBITORS; STATE	Incubation of cells of the nitrifying bacterium Nitrosomonas europaea with (C2H2)-C-14 results in the covalent attachment of C-14 label to a membrane-bound polypeptide of an approximate M(r) of 28,000 (Hyman, M. R., and Wood, P. M. (1985) Biochem. J. 227, 719-725). A labeling procedure using (C2H2)-C-14 generated from (BaCO3)-C-14 has been used to investigate the correlation between the extent of covalent modification of this polypeptide by C-14 from (C2H2)-C-14 and the level of ammonia oxidizing activity in whole cells. The time-dependent inactivation of ammonia monooxygenase by (C2H2)-C-14 resulted in a progressive and saturable incorporation of C-14 into a 27-kDa polypeptide. In contrast, the specific, time-dependent and complete inactivation of ammonia monooxygenase by light resulted in concomitant decrease in the ability of cells to incorporate C-14 from (C2H2)-C-14 into this polypeptide. The (C2H2)-C-14 labeling procedure was also used to investigate the recovery of ammonia monooxygenase activity after complete inactivation of pre-existing ammonia monooxygenase by either C2H2 or light. The recovery of ammonia monooxygenase activity was closely correlated with a recovery of ability of cells to incorporate C-14 label from (C2H2)-C-14 into the 27-kDa polypeptide. This recovery process was energy (NH4+)-dependent and was inhibited by chloramphenicol and rifampicin, implying that de novo protein synthesis was required. Additional polypeptides labeled with C-14 from (CO2)-C-14 were also identified during recovery from C2H2 or light inactivation of ammonia monooxygenase.	OREGON STATE UNIV, NITROGEN FIXAT RES LAB, CORVALLIS, OR 97331 USA	Oregon State University				Hyman, Michael/0000-0002-5965-6579				ARCIERO D, 1989, BIOCHEM BIOPH RES CO, V159, P640, DOI 10.1016/0006-291X(89)90042-9; Ator M. A., 1990, ENZYMES, V19, P214; BEDARD C, 1989, MICROBIOL REV, V53, P68; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CONCANNO.PW, 1973, J AM CHEM SOC, V95, P3284, DOI 10.1021/ja00791a035; FOX BG, 1990, BIOCHEMISTRY-US, V29, P6419, DOI 10.1021/bi00479a013; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HOOPER AB, 1974, J BACTERIOL, V119, P899, DOI 10.1128/JB.119.3.899-906.1974; HOOPER AB, 1973, J BACTERIOL, V115, P480, DOI 10.1128/JB.115.2.480-485.1973; Hucklesby DP., 1971, METHODS ENZYMOLOGY, P491; HYMAN MR, 1987, APPL ENVIRON MICROB, V53, P298, DOI 10.1128/AEM.53.2.298-303.1987; HYMAN MR, 1983, BIOCHEM J, V212, P31, DOI 10.1042/bj2120031; HYMAN MR, 1984, ARCH MICROBIOL, V137, P155, DOI 10.1007/BF00414458; HYMAN MR, 1985, BIOCHEM J, V227, P719, DOI 10.1042/bj2270719; HYMAN MR, 1990, ANAL BIOCHEM, V190, P348, DOI 10.1016/0003-2697(90)90206-O; HYMAN MR, 1990, J BACTERIOL, V172, P4775, DOI 10.1128/jb.172.9.4775-4782.1990; HYNES RK, 1978, FEMS MICROBIOL LETT, V4, P319, DOI 10.1016/0378-1097(78)90146-5; HYNES RK, 1982, CAN J MICROBIOL, V28, P334, DOI 10.1139/m82-049; MILLER RE, 1982, BIOCHEMISTRY-US, V21, P1090, DOI 10.1021/bi00534a041; OLDENHUIS R, 1991, APPL ENVIRON MICROB, V57, P7, DOI 10.1128/AEM.57.1.7-14.1991; OLSON RJ, 1981, J MAR RES, V39, P227; PRIOR SD, 1985, FEMS MICROBIOL LETT, V29, P105; RASCHE ME, 1990, J BACTERIOL, V172, P5368, DOI 10.1128/jb.172.9.5368-5373.1990; SHEARS JH, 1985, BIOCHEM J, V226, P499, DOI 10.1042/bj2260499; STIRLING DI, 1977, ARCH MICROBIOL, V114, P71, DOI 10.1007/BF00429633; VANNELLI T, 1990, APPL ENVIRON MICROB, V55, P2819; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WOOD PM, 1986, NITRIFICATION, P39	28	154	167	0	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1534	1545						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730700				2022-12-25	WOS:A1992HA48500025
J	PIKULEVA, IA; LAPKO, AG; CHASHCHIN, VL				PIKULEVA, IA; LAPKO, AG; CHASHCHIN, VL			FUNCTIONAL RECONSTITUTION OF CYTOCHROME-P-450SCC WITH HEMIN ACTIVATED WITH WOODWARDS REAGENT-K - FORMATION OF A HEMEPROTEIN CROSS-LINK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ADRENOCORTICAL MITOCHONDRIA; SELECTIVE CHEMICAL MODIFICATION; CRYSTAL-STRUCTURE; CHOLESTEROL; TETRANITROMETHANE; CHAIN; IDENTIFICATION; ADRENODOXIN; RESIDUES	In order to evaluate structure-function relationships of heme moiety in cytochrome P-450scc, we carried out the reconstitution of apoprotein with Fe-protoporphyrin IX, one carboxyl group of which was converted to reactive enol ester by Woodward's reagent K (N-ethyl-5-phenylisoxazolium-3'-sulfonate). Woodward's reagent K can be used as a cross-linking reagent, since amino groups can apparently react with the enol ester. Treatment of cytochrome P-450scc with H2O2 was used to obtain the apoprotein. Functional reconstitution of the hemin derivative with apocytochrome P-450scc was achieved. The reconstituted hemeprotein was purified, and the resulting preparation contained no P-420 form and had the same cholesterol-hydroxylating activity as a control preparation. 30% of the reconstituted hemin was covalently bound to protein. Heme-linked peptide (Gly177-Phe194) was isolated. Its possible role in the active site formation of cytochrome P-450scc, is discussed.			PIKULEVA, IA (corresponding author), ACAD SCI BESSR,INST BIOORGAN CHEM,ZHODINSKAYA 5-2,MINSK 220067,BELORUSSIA,USSR.		Chashchin, Valerii/I-5713-2014	Chashchin, Valerii/0000-0002-2600-0522; Pikuleva, Irina/0000-0001-9742-6232				ADAMOVICH TB, 1989, BIOCHIM BIOPHYS ACTA, V996, P247, DOI 10.1016/0167-4838(89)90254-9; AKHREM AA, 1989, ANAL BIOCHEM, V179, P86, DOI 10.1016/0003-2697(89)90205-4; BORNHEIM LM, 1986, ARCH BIOCHEM BIOPHYS, V246, P63, DOI 10.1016/0003-9861(86)90449-2; BURSTEIN S, 1976, STEROIDS, V28, P115, DOI 10.1016/0039-128X(76)90131-8; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CHASHCHIN VL, 1986, BIOCHIM BIOPHYS ACTA, V871, P217, DOI 10.1016/0167-4838(86)90176-7; DOLPHIN D, 1980, J MOL CATAL, V7, P201, DOI 10.1016/0304-5102(80)85018-8; Fuhrhop J. H., 1975, PORPHYRINS METALLOPO, P804; GUNSALUS IC, 1979, ADV ENZYMOL, V47, P1; IKARIYAMA Y, 1983, ENZYME MICROB TECH, V5, P215, DOI 10.1016/0141-0229(83)90098-4; KOBAYASHI K, 1987, J BIOL CHEM, V262, P5445; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Makino R., 1982, OXYGENASES OXYGEN ME, P467; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OMURA T, 1964, J BIOL CHEM, V239, P2370; PIKULEVA IA, 1989, BIOORG KHIM+, V15, P1480; PIKULEVA IA, 1987, BIOORG KHIM+, V13, P739; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; SATO R, 1978, CYTOCHROME P450; STONE D, 1954, ARCH BIOCHEM BIOPHYS, V51, P457, DOI 10.1016/0003-9861(54)90501-9; TSUBAKI M, 1989, BIOCHEMISTRY-US, V28, P6899, DOI 10.1021/bi00443a019; TURKO IV, 1989, BIOCHIM BIOPHYS ACTA, V996, P37, DOI 10.1016/0167-4838(89)90091-5; ULLRICH V, 1979, TOP CURR CHEM, V83, P68; USANOV SA, 1984, BIOORG KHIM+, V10, P32; USANOV SA, 1984, BIOCHIM BIOPHYS ACTA, V790, P259, DOI 10.1016/0167-4838(84)90030-X; UVAROV VY, 1990, FEBS LETT, V260, P309, DOI 10.1016/0014-5793(90)80131-2; WAGNER GC, 1981, J BIOL CHEM, V256, P6262; WHITE RE, 1980, ANNU REV BIOCHEM, V49, P315, DOI 10.1146/annurev.bi.49.070180.001531; YU CA, 1974, J BIOL CHEM, V249, P107	30	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1438	1442						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730693				2022-12-25	WOS:A1992HA48500010
J	READ, LK; MYLER, PJ; STUART, K				READ, LK; MYLER, PJ; STUART, K			EXTENSIVE EDITING OF BOTH PROCESSED AND PREPROCESSED MAXICIRCLE CR6 TRANSCRIPTS IN TRYPANOSOMA-BRUCEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUG INITIATION CODONS; KINETOPLAST DNA; MITOCHONDRIAL-DNA; BLOOD-STREAM; LIFE-CYCLE; SEQUENCE; OXIDASE; GENE; ORGANIZATION; PROTEIN	Transcripts from several genes encoded in the Trypanosoma brucei maxicircle genome are altered by posttranscriptional uridine insertion and deletion through a process called RNA editing. We find that transcripts from the CR6 gene are extensively edited by addition of 132 uridines and deletion of 28 uridines to produce a fully edited mRNA 47% larger than unedited mRNA. Two open reading frames (ORFs) and their initiation and termination codons are created by editing of CR6 mRNA. Both ORFs specify small, hydrophobic proteins with no homology to proteins in three databases. Both unedited and edited CR6 transcripts are more abundant in bloodstream form than in procyclic form parasites. cDNA clones spanning both CR6 and the downstream NADH dehydrogenase subunit 5 (ND5) gene were isolated, indicating that mature CR6 and ND5 transcripts arise from a common precursor. Sequencing of these cDNAs revealed 37 nucleotides of overlap between the 3' end of CR6 and the 5' end of ND5. In addition, the CR6 portion of many of these molecules was extensively edited, indicating that RNA editing can precede precursor processing. These results provide the first clear demonstration of polycistronic transcription of maxicircle genes, and suggest new mechanisms by which both RNA editing and precursor processing may regulate maxicircle gene expression.	SEATTLE BIOMED RES INST,4 NICKERSON ST,SEATTLE,WA 98109	Center for Infectious Disease Research			Myler, Peter John/AAR-9535-2021	Myler, Peter/0000-0002-0056-0513	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI014102, F32AI008491, R01AI014102] Funding Source: NIH RePORTER; NIAID NIH HHS [1 F32 AI08491-01, AI14102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BHAT GJ, 1991, NUCLEIC ACIDS RES, V19, P398, DOI 10.1093/nar/19.2.398; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BIENEN EJ, 1991, MOL BIOCHEM PARASIT, V45, P185, DOI 10.1016/0166-6851(91)90085-K; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKSON AB, 1989, J BIOL CHEM, V264, P17770; FEAGIN JE, 1985, NUCLEIC ACIDS RES, V13, P4577, DOI 10.1093/nar/13.12.4577; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; Fourney R.M., 1988, FOCUS, V10, P5; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; JASMER DP, 1985, MOL CELL BIOL, V5, P3041, DOI 10.1128/MCB.5.11.3041; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; RAGAN CI, 1987, CURR TOP BIOENERG, V15, P1; ROHRER SP, 1987, CELL, V49, P625, DOI 10.1016/0092-8674(87)90538-1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SIMPSON L, 1970, J PROTOZOOL, V17, P511, DOI 10.1111/j.1550-7408.1970.tb04719.x; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; STUART K, 1991, TRENDS BIOCHEM SCI, V16, P68, DOI 10.1016/0968-0004(91)90027-S; STUART K, 1984, J PARASITOL, V70, P747, DOI 10.2307/3281757; STUART K, 1980, AM J TROP MED HYG, V29, P1075, DOI 10.4269/ajtmh.1980.29.1075; STUART KD, 1982, MOL CELL BIOL, V2, P845, DOI 10.1128/MCB.2.7.845; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x	33	102	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1123	1128						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730639				2022-12-25	WOS:A1992GY96000072
J	TIPPER, J; KAUFMAN, S				TIPPER, J; KAUFMAN, S			PHENYLALANINE-INDUCED PHOSPHORYLATION AND ACTIVATION OF RAT HEPATIC PHENYLALANINE-HYDROXYLASE INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE ACTIVATION; PYRUVATE-KINASE; PROTEIN-KINASE; LIVER; GLUCAGON; 4-MONO-OXYGENASE; STIMULATION; INVITRO; ENZYME; ASSAY	Rats were given intraperitoneal injections of 2 mCi of carrier-free P-32(i) and substances known to activate liver phenylalanine hydroxylase. After 30 min, these animals were anesthetized and their livers removed for analysis of enzyme activity, P-32(i) incorporation into immunoprecipitated phenylalanine hydroxylase and [gamma-P-32]ATP specific activity. Following glucagon treatment, rat liver phenylalanine hydroxylase activity was stimulated more than 6-fold when assayed in the presence of the natural cofactor, tetrahydrobiopterin (BH4). Glucagon injection also resulted in an incorporation of 0.41 mol of P-32(i)/mol of hydroxylase subunit (approximately 50,000 Da). In vivo stimulation of phenylalanine hydroxylase activity and P-32(i) incorporation by glucagon had been previously observed in this laboratory (Donlon, J., and Kaufman, S. (1978) J. Biol. Chem. 253, 6657-6659). However, we show for the first time in the present study that in vivo treatment with phenylalanine alone results in a 4-fold increase in the BH4-dependent activity of phenylalanine hydroxylase concomitant with a significant incorporation of phosphate into phenylalanine hydroxylase (0.51 mol of P-32(i)/mol of hydroxylase subunit). It is further demonstrated in vivo that the combined treatment with phenylalanine and glucagon results in a greater than 10-fold stimulation of BH4-dependent activity and the greatest level of P-32(i) incorporation (0.75 mol of P-32(i)/mol of hydroxylase subunit). Phenylalanine did not produce an elevation in plasma glucagon in these animals. A model is, thereby, proposed with respect to the ligand binding effects of phenylalanine on the state of phosphorylation and activation of phenylalanine hydroxylase. The significance of these regulatory roles are considered in light of the probable physiological environment of the enzyme.			TIPPER, J (corresponding author), NIMH,NEUROCHEM LAB,BETHESDA,MD 20892, USA.							ABITA JP, 1976, J BIOL CHEM, V251, P5310; ABITA JP, 1980, BIOCHEM BIOPH RES CO, V93, P912; AYLING JE, 1975, CHEM BIOL PTERIDINES, P305; BERGLUND L, 1977, J BIOL CHEM, V252, P613; BRUMM AF, 1956, J BIOL CHEM, V220, P713; BUCHER NLR, 1966, BIOCHIM BIOPHYS ACTA, V129, P445, DOI 10.1016/0005-2787(66)90060-8; DHONDT JL, 1978, BIOCHIMIE, V60, P787, DOI 10.1016/S0300-9084(78)80023-6; DONLON J, 1978, J BIOL CHEM, V253, P6657; DOSKELAND AP, 1987, BIOCHEM J, V242, P867, DOI 10.1042/bj2420867; DOSKELAND AP, 1984, J BIOL CHEM, V259, P1242; ENGSTROM L, 1974, LIPMANN S ENERGY BIO, P192; FISHER DB, 1973, J BIOL CHEM, V248, P4345; GUTTLER F, 1978, SCAND J CLIN LAB INV, V38, P255, DOI 10.3109/00365517809108420; HURLBERT RB, 1954, J BIOL CHEM, V209, P23; JUENGLING E, 1980, ANAL BIOCHEM, V102, P358, DOI 10.1016/0003-2697(80)90167-0; KAUFMAN S, 1983, ADV HUM GENET, V13, P217; KAUFMAN S, 1970, J BIOL CHEM, V245, P4745; KAUFMAN S, 1963, P NATL ACAD SCI USA, V50, P1085, DOI 10.1073/pnas.50.6.1085; KAUFMAN S, 1970, J BIOL CHEM, V245, P4751; KAUFMAN S, 1987, ENZYMES B, V18, P217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGSTROM O, 1974, BIOCHIM BIOPHYS ACTA, V358, P289, DOI 10.1016/0005-2744(74)90459-8; MILSTEIN S, 1976, P NATL ACAD SCI USA, V73, P1591, DOI 10.1073/pnas.73.5.1591; MILSTIEN S, 1975, J BIOL CHEM, V250, P4782; NIELSEN KH, 1969, EUR J BIOCHEM, V7, P360, DOI 10.1111/j.1432-1033.1969.tb19617.x; O'Neill R R, 1989, Appl Theor Electrophor, V1, P163; PARNIAK MA, 1981, J BIOL CHEM, V256, P6876; PHILLIPS RS, 1984, J BIOL CHEM, V259, P2474; ROCHA DM, 1972, J CLIN INVEST, V51, P2346, DOI 10.1172/JCI107046; SHIMAN R, 1980, J BIOL CHEM, V255, P4793; SHIMAN R, 1982, J BIOL CHEM, V257, P1213; SHIMAN R, 1980, J BIOL CHEM, V255, P29; SHIMAN R, 1979, J BIOL CHEM, V254, P11330; SULLIVAN PT, 1973, BIOCHIM BIOPHYS ACTA, V293, P343, DOI 10.1016/0005-2744(73)90342-2; TOURIAN A, 1971, BIOCHIM BIOPHYS ACTA, V242, P4345	35	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					889	896						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730677				2022-12-25	WOS:A1992GY96000034
J	KO, YH; CREMO, CR; MCFADDEN, BA				KO, YH; CREMO, CR; MCFADDEN, BA			VANADATE-DEPENDENT PHOTOMODIFICATION OF SERINE-319 AND SERINE-321 IN THE ACTIVE-SITE OF ISOCITRATE LYASE FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBFRAGMENT-1 HEAVY-CHAIN; SKELETAL MYOSIN; CLEAVAGE; CDNA	Vanadate was used as a substrate analogue to modify and subsequently localize active site serine residues of isocitrate lyase from Escherichia coli. Irradiation of the enzyme on ice with UV light in the presence of vanadate resulted in inactivation. Inactivation was prevented by the substrates glyoxylate or D(S)-isocitrate and to a much lesser extent by succinate. Reduction of photoinactivated isocitrate lyase by NaBH, partially restored enzyme activity. The photomodified enzyme was labeled by reduction with NaB[H-3]4 in the presence and absence of the substrates succinate plus glyoxylate. Highly differential labeling of serine residues 319 and 321 in the absence of substrates suggests their importance in the action of isocitrate lyase. These residues are highly conserved in all five known sequences of this enzyme.	WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Washington State University								ATOMI H, 1990, J BIOCHEM-TOKYO, V107, P262, DOI 10.1093/oxfordjournals.jbchem.a123036; BEECHING JR, 1987, PLANT MOL BIOL, V8, P471, DOI 10.1007/BF00017992; CHASTEEN ND, 1983, STRUCT BOND, V53, P105; COLE D G, 1991, Biophysical Journal, V59, p435A; COMAI L, 1989, PLANT CELL, V1, P293, DOI 10.1105/tpc.1.3.293; CONDER MJ, 1988, PREP BIOCHEM, V18, P431, DOI 10.1080/00327488808062542; CREMO CR, 1988, BIOCHEMISTRY-US, V27, P8415, DOI 10.1021/bi00422a018; CREMO CR, 1989, J BIOL CHEM, V264, P6608; CREMO CR, 1991, METHOD ENZYMOL, V196, P442; GIBBONS IR, 1991, METHOD ENZYMOL, V196, P428; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; GRAMMER JC, 1988, BIOCHEMISTRY-US, V27, P8408, DOI 10.1021/bi00422a017; JAMEEL S, 1984, PHYTOCHEMISTRY, V23, P2753, DOI 10.1016/0031-9422(84)83009-5; KO YH, 1990, ARCH BIOCHEM BIOPHYS, V278, P373, DOI 10.1016/0003-9861(90)90273-2; KO YH, 1990, CURR MICROBIOL, V21, P313, DOI 10.1007/BF02092097; KO YH, 1991, BIOCHEMISTRY-US, V30, P7451, DOI 10.1021/bi00244a012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUOKA M, 1988, J BACTERIOL, V170, P4528, DOI 10.1128/jb.170.10.4528-4536.1988; MOCZ G, 1989, EUR J BIOCHEM, V179, P373, DOI 10.1111/j.1432-1033.1989.tb14563.x; MOGEL SN, 1989, BIOCHEMISTRY-US, V28, P5428, DOI 10.1021/bi00439a017; NIMMO HG, 1989, BIOCHEM J, V261, P431, DOI 10.1042/bj2610431; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; TURLEY RB, 1990, BIOCHIM BIOPHYS ACTA, V1049, P223, DOI 10.1016/0167-4781(90)90045-4	23	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					91	95						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730628				2022-12-25	WOS:A1992GY43900020
J	OLSEN, LJ; KEEGSTRA, K				OLSEN, LJ; KEEGSTRA, K			THE BINDING OF PRECURSOR PROTEINS TO CHLOROPLASTS REQUIRES NUCLEOSIDE TRIPHOSPHATES IN THE INTERMEMBRANE SPACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER ENVELOPE MEMBRANE; HEAT-SHOCK PROTEIN; PEA-CHLOROPLASTS; INNER MEMBRANE; IMPORT; TRANSLOCATION; TRANSPORT; ATP; MITOCHONDRIA; BIOGENESIS	Protein import into chloroplasts is initiated by a binding interaction between a precursor protein and the surface of the outer envelope. The binding step was previously shown to be energy-dependent (Olsen, L. J., Theg, S. M., Selman, B. R., and Keegstra, K. (1989) J. Biol. Chem. 264, 6724-6729). We took advantage of the broad nucleotide specificity of the energy requirement for binding to investigate the site of the nucleoside triphosphate (NTP) requirement. GTP supported precursor binding to chloroplasts. It was not converted to ATP, as determined by direct ATP measurements, and was not transported across the inner envelope. Thus, GTP supported binding from either the intermembrane space or outside the outer membrane. To distinguish between an intermembrane space and an external NTP requirement, we experimentally manipulated the NTP levels inside and outside chloroplasts. Internally generated ATP was able to support binding in the presence of an external membrane-impermeant ATP trap. Therefore, since GTP supported binding from either the intermembrane space or outside the chloroplast, and ATP supported binding from either the intermembrane space or the stroma, we concluded that the site of NTP utilization for precursor binding to chloroplasts was the intermembrane space between the two envelope membranes.	UNIV WISCONSIN,DEPT BOT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; CASHMORE AR, 1983, GENETIC ENG PLANTS A, P29; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1986, J BIOL CHEM, V261, P4804; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; DARROW RA, 1962, METHOD ENZYMOL, V5, P226, DOI 10.1016/S0076-6879(62)05209-X; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; Ellis R J, 1983, Subcell Biochem, V9, P237; FLUGGE UI, 1990, J CELL SCI, V96, P351; FLUGGE UI, 1990, J BIOENERG BIOMEMBR, V22, P769; FLUGGE UI, 1986, EUR J BIOCHEM, V160, P563, DOI 10.1111/j.1432-1033.1986.tb10075.x; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; GELI V, 1990, J BIOENERG BIOMEMBR, V22, P725; GROSSMAN A, 1980, NATURE, V285, P625, DOI 10.1038/285625a0; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Heldt H. W., 1980, METHOD ENZYMOL, V69, P604; HELDT HW, 1969, FEBS LETT, V5, P11, DOI 10.1016/0014-5793(69)80280-2; HINZ G, 1988, EUR J BIOCHEM, V175, P649, DOI 10.1111/j.1432-1033.1988.tb14241.x; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; LIEBECQ C, 1963, B SOC CHIM BIOL, V45, P573; LUBBEN TH, 1986, P NATL ACAD SCI USA, V83, P5502, DOI 10.1073/pnas.83.15.5502; MARSHALL JS, 1990, P NATL ACAD SCI USA, V87, P374, DOI 10.1073/pnas.87.1.374; MISHKIND ML, 1988, PHOTOSYNTH RES, V19, P153, DOI 10.1007/BF00114573; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PFALLER R, 1989, J BIOL CHEM, V264, P34; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1990, J BIOL CHEM, V265, P16324; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; ROBINSON SP, 1977, BIOCHIM BIOPHYS ACTA, V461, P131, DOI 10.1016/0005-2728(77)90075-5; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SOLL J, 1988, PLANTA, V176, P488, DOI 10.1007/BF00397655; SOLL J, 1988, PLANT PHYSIOL, V87, P898, DOI 10.1104/pp.87.4.898; SOLL J, 1988, EUR J BIOCHEM, V175, P649; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; THEG SM, 1989, J BIOL CHEM, V264, P6730; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; WOLDEGIORGIS G, 1985, BIOCHIM BIOPHYS ACTA, V810, P340, DOI 10.1016/0005-2728(85)90219-1	48	146	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					433	439						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730608				2022-12-25	WOS:A1992GY43900070
J	SHATOS, MA; DOHERTY, JM; ORFEO, T; HOAK, JC; COLLEN, D; STUMP, DC				SHATOS, MA; DOHERTY, JM; ORFEO, T; HOAK, JC; COLLEN, D; STUMP, DC			MODULATION OF THE FIBRINOLYTIC RESPONSE OF CULTURED HUMAN VASCULAR ENDOTHELIUM BY EXTRACELLULARLY GENERATED OXYGEN RADICALS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; LINKED IMMUNOSORBENT-ASSAY; HYDROGEN-PEROXIDE; T-PA; CELLS; INJURY; ENZYME; GENE; RNA; PURIFICATION	Clinical and experimental data indicate that activated oxygen species interfere with vascular endothelial cell function. Here, the impact of extracellular oxidant injury on the fibrinolytic response of cultured human umbilical vein endothelial (HUVE) cells was investigated at the protein and mRNA levels. Xanthine (50-mu-M) and xanthine oxidase (100 milliunits), which produces the superoxide anion radical (O2-) and hydrogen peroxide (H2O2), was used to sublethally injure HUVE cells. Following a 15-min exposure, washed cells were incubated for up to 24 h in serum-free culture medium. Tissue-type plasminogen activator (t-PA) antigen, plasminogen activator inhibitor-1 (PAI-1) antigen, and PAI-1 activity were determined in 1.25 ml of conditioned medium and t-PA and PAI-1 mRNA in the cell extracts of 2 x 10(6) HUVE cells. Control cells secreted 3.9 +/- 1.3 ng/ml (mean +/- S.D., n = 12) within 24 h. Treatment with xanthine/xanthine oxidase for 15 min induced a 2.8 +/- 0.4-fold increase (n = 12, p < 0.05) of t-PA antigen secretion after 24 h. The t-PA antigen was recovered predominantly in complex with PAI-1. The oxidant injury caused a 3.0 +/- 0.8-fold increase (n = 9, p < 0.05) in t-PA mRNA within 2 h. Total protein synthesis was unaltered by xanthine/xanthine oxidase. The oxidant scavengers superoxide dismutase and catalase, in combination, abolished the effect of xanthine/xanthine oxidase on t-PA secretion and t-PA mRNA synthesis. Xanthine/xanthine oxidase treatment of HUVE cells did not affect the PAI-1 secretion in conditioned medium nor the PAI-1 mRNA levels in cell extracts. Thus extracellular oxidant injury induces t-PA but not PAI-1 synthesis in HUVE cells.	UNIV VERMONT, COLL MED, DEPT MED, BURLINGTON, VT 05405 USA; UNIV VERMONT, COLL MED, DEPT BIOCHEM, BURLINGTON, VT 05405 USA; CATHOLIC UNIV LEUVEN, CTR THROMBOSIS & VASC RES, B-3000 LOUVAIN, BELGIUM	University of Vermont; University of Vermont; KU Leuven	SHATOS, MA (corresponding author), UNIV VERMONT, COLL MED, DEPT SURG, GIVEN BLDG D313, BURLINGTON, VT 05405 USA.				PHS HHS [35058] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASTRUP T, 1952, ARCH BIOCHEM BIOPHYS, V40, P346, DOI 10.1016/0003-9861(52)90121-5; Beckman J.S., 1986, PHYSL OXYGEN RADICAL, P39; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V2, P1464; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITIGAN BE, 1986, J BIOL CHEM, V261, P4426; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOPRA J, 1987, LAB INVEST, V57, P578; COLLEN D, 1988, SEMIN THROMB HEMOST, V14, P95, DOI 10.1055/s-2007-1002761; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; CRUTCHLEY DJ, 1986, J BIOL CHEM, V261, P154; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DECLERCK PJ, 1988, BLOOD, V71, P220; ERICKSON LA, 1985, CLIN HAEMATOL, V14, P513; FREEMAN BA, 1986, J BIOL CHEM, V261, P6590; FREEMAN BA, 1982, LAB INVEST, V47, P412; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; HANSS M, 1987, J LAB CLIN MED, V109, P97; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; HOLVOET P, 1985, THROMB HAEMOSTASIS, V54, P684; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JUHANVAGUE I, 1987, THROMB HAEMOSTASIS, V57, P67; KNUDSEN BS, 1987, J CLIN INVEST, V80, P1082, DOI 10.1172/JCI113164; KRUITHOF EKO, 1988, BIOCHEM BIOPH RES CO, V156, P383, DOI 10.1016/S0006-291X(88)80852-0; KRUITHOF EKO, 1986, J BIOL CHEM, V261, P1207; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1955, METHOD ENZYMOL, V2, P26, DOI 10.1016/S0076-6879(55)02167-8; LEVIN EG, 1987, BLOOD, V70, P1090; LEVIN EG, 1982, J CELL BIOL, V94, P631, DOI 10.1083/jcb.94.3.631; LOSKUTOFF DJ, 1983, P NATL ACAD SCI-BIOL, V80, P2956, DOI 10.1073/pnas.80.10.2956; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; Patterson Jr MK, 1973, TISSUE CULTURE METHO, P406; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; POUMAY Y, 1988, J CELL PHYSIOL, V136, P289, DOI 10.1002/jcp.1041360211; ROTMAN B, 1966, P NATL ACAD SCI USA, V55, P134, DOI 10.1073/pnas.55.1.134; SHASBY DM, 1985, BLOOD, V65, P605; SHASBY DM, 1988, BLOOD, V72, P491; SHATOS MA, 1991, ARTERIOSCLER THROMB, V11, P594, DOI 10.1161/01.ATV.11.3.594; SHATOS MA, 1990, J BIOL CHEM, V265, P20443; STUMP DC, 1990, SEMIN THROMB HEMOST, V16, P260, DOI 10.1055/s-2007-1002678; STUMP DC, 1986, J BIOL CHEM, V261, P1267; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VERHEIJEN JH, 1984, THROMB HAEMOSTASIS, V51, P392; WEISS SJ, 1982, LAB INVEST, V47, P5; WEISS SJ, 1981, J CLIN INVEST, V68, P714, DOI 10.1172/JCI110307	47	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					597	601						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730619				2022-12-25	WOS:A1992GY43900093
J	JIANG, JX; CHUNG, LA; LONDON, E				JIANG, JX; CHUNG, LA; LONDON, E			SELF-TRANSLOCATION OF DIPHTHERIA-TOXIN ACROSS MODEL MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANAR LIPID BILAYERS; ALTERED FRAGMENT-B; LOW-PH; PROTEIN TRANSLOCATION; UNILAMELLAR VESICLES; STRUCTURAL GENE; PLASMA-MEMBRANE; A-FRAGMENT; ENTRY; CELLS	To understand the mechanism of diphtheria toxin membrane translocation, the toxin was entrapped within lipid vesicles, and its low pH-induced translocation across the lipid bilayer was measured. Proteolysis and resistance to guanidinium chloride denaturation were used to demonstrate that the toxin molecules were entrapped. Low pH-induced movement of entrapped toxin to the outer (trans) face of the bilayer was assayed by the binding of external streptavidin to biotin-labeled entrapped toxin. Complete translocation was quantified by the amount of protein released into the external medium. Using whole toxin, it was found that the A fragment was efficiently translocated, but the B fragment was not. This was true both in the low temperature (A domain folded) and high temperature (A domain unfolded) toxin conformations previously identified [Jiang J. X., Abrams, F. S., and London, E. (1991) Biochemistry 30, 3857-3864]. Remarkably, even isolated fragment A appeared to self-translocate under some conditions. Toxin-induced translocation may partly result from formation of a nonspecific toxin-induced pore. This idea is supported by the toxin-induced release of fluorescent dextrans coentrapped within the vesicles. However, low pH-induced exposure of entrapped toxin on the outside of the membrane was conformation dependent. Exposure was greatest for the high temperature conformation. This suggests the existence of a more specific translocation process. The nature and relationship of these processes, and their relative roles in translocation in vivo are discussed.			JIANG, JX (corresponding author), SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA.			Jiang, Jean/0000-0002-2185-5716	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031986] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31986] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHA P, 1983, J BIOL CHEM, V258, P1565; Bangham AD, 1967, CHEM PHYS LIPIDS, V1, P225, DOI [10.1016/0009-3084(67)90030-8, DOI 10.1016/0009-3084(67)90030-8]; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; BLEWITT MG, 1984, BIOCHEM BIOPH RES CO, V120, P286, DOI 10.1016/0006-291X(84)91446-3; BLOK MC, 1976, BIOCHIM BIOPHYS ACTA, V433, P1, DOI 10.1016/0005-2736(76)90172-3; BOQUET P, 1976, P NATL ACAD SCI USA, V73, P4449, DOI 10.1073/pnas.73.12.4449; CABIAUX V, 1984, BIOCHIM BIOPHYS ACTA, V775, P31, DOI 10.1016/0005-2736(84)90231-1; CABIAUX V, 1985, BIOSCIENCE REP, V5, P243, DOI 10.1007/BF01119594; CHANG MP, 1989, J BIOL CHEM, V264, P15261; CHANG MP, 1989, SCIENCE, V246, P1165, DOI 10.1126/science.2531465; CHUNG LA, 1988, BIOCHEMISTRY-US, V27, P1245, DOI 10.1021/bi00404a026; COLLIER RJ, 1984, SCI AM, V251, P56, DOI 10.1038/scientificamerican0784-56; COLLIER RJ, 1982, ADP RIBOSYLATION REA, P573; COLLINS CM, 1971, J BIOL CHEM, V259, P15159; COLOMBATTI M, 1986, J BIOL CHEM, V261, P3030; DEFRISEQUERTAIN F, 1989, BIOCHEMISTRY-US, V28, P3406, DOI 10.1021/bi00434a040; DELEERS M, 1983, FEBS LETT, V160, P82, DOI 10.1016/0014-5793(83)80941-7; DONOVAN JJ, 1985, J BIOL CHEM, V260, P8817; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; EILERS M, 1988, CELL, V52, P481, DOI 10.1016/0092-8674(88)90458-8; GONZALEZ JE, 1988, J BIOL CHEM, V263, P15257; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HU VW, 1984, J BIOL CHEM, V259, P2226; HUDSON TH, 1985, J BIOL CHEM, V260, P2675; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; JIANG GS, 1989, J BIOL CHEM, V264, P17170; JIANG JX, 1991, BIOCHEMISTRY-US, V30, P3857, DOI 10.1021/bi00230a008; JIANG JX, 1990, J BIOL CHEM, V265, P8636; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KANDEL J, 1974, J BIOL CHEM, V249, P2088; LIU G, 1988, J BIOL CHEM, V263, P14790; MALINSKI JA, 1989, BIOCHEMISTRY-US, V28, P61, DOI 10.1021/bi00427a010; MARNELL MH, 1984, INFECT IMMUN, V44, P145, DOI 10.1128/IAI.44.1.145-150.1984; MCKEEVER B, 1982, J BIOL CHEM, V257, P6923; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P840; MISLER S, 1984, BIOPHYS J, V45, P107, DOI 10.1016/S0006-3495(84)84128-4; MONTECUCCO C, 1985, BIOCHEM J, V231, P123, DOI 10.1042/bj2310123; MOSKAUG JO, 1989, J BIOL CHEM, V264, P15709; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; MURPHY JR, 1985, CURR TOP MICROBIOL, V118, P235; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PAPINI E, 1987, EUR J BIOCHEM, V169, P629, DOI 10.1111/j.1432-1033.1987.tb13654.x; PAPINI E, 1987, EUR J BIOCHEM, V169, P637, DOI 10.1111/j.1432-1033.1987.tb13655.x; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SHIVER JW, 1987, BIOCHIM BIOPHYS ACTA, V903, P48, DOI 10.1016/0005-2736(87)90154-4; STENMARK H, 1989, EMBO J, V8, P2849, DOI 10.1002/j.1460-2075.1989.tb08432.x; STENMARK H, 1988, J BIOL CHEM, V263, P13449; WARD WHJ, 1987, TRENDS BIOCHEM SCI, V12, P182, DOI 10.1016/0968-0004(87)90088-0; WILLIAMS DP, 1990, J BIOL CHEM, V265, P11885; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; ZALMAN LS, 1984, P NATL ACAD SCI-BIOL, V81, P3341, DOI 10.1073/pnas.81.11.3341; ZHAO JM, 1986, P NATL ACAD SCI USA, V83, P2002, DOI 10.1073/pnas.83.7.2002; ZHAO JM, 1988, J BIOL CHEM, V263, P15369; ZHAO JM, 1988, BIOCHEMISTRY-US, V27, P3398, DOI 10.1021/bi00409a041	61	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24003	24010						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721061				2022-12-25	WOS:A1991GV31900073
J	DEAK, SB; SCHOLZ, PM; AMENTA, PS; CONSTANTINOU, CD; LEVIMINZI, SA; GONZALEZLAVIN, L; MACKENZIE, JW				DEAK, SB; SCHOLZ, PM; AMENTA, PS; CONSTANTINOU, CD; LEVIMINZI, SA; GONZALEZLAVIN, L; MACKENZIE, JW			THE SUBSTITUTION OF ARGININE FOR GLYCINE-85 OF THE ALPHA-1(I) PROCOLLAGEN CHAIN RESULTS IN MILD OSTEOGENESIS IMPERFECTA - THE MUTATION PROVIDES DIRECT EVIDENCE FOR 3 DISCRETE DOMAINS OF COOPERATIVE MELTING OF INTACT TYPE-I COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC REGURGITATION; TRIPLE HELIX; EXPRESSION; STABILITY; MOLECULES; VARIANT; DEFECT; CDNA	We report a case of mild osteogenesis imperfecta in a 56-year-old male undergoing aortic valve replacement surgery. The primary defect in this patient was the substitution of arginine for glycine 85 in one of the two chains of alpha-1(I) procollagen. The thermal stability of the type I collagen synthesized by the patient's cultured skin fibroblasts was examined by enzymatic digestion. Digestion of the mutant type I collagen with trypsin and chymotrypsin at increasing temperatures sequentially generated three discrete collagenous fragments, approximately 90, 170, and 230 amino acids shorter than normal type I collagen. This incremental thermal denaturation is indicative of cooperative melting blocks within the type I collagen. This is the first demonstration of such cooperative blocks of melting in intact, essentially normal post-translationally modified type I collagen. This direct evidence for cooperative melting domains of uncut type I collagen suggests that discrete blocks of amino acids function as core sites stabilizing the collagen helix. The location of mutations of the alpha-chains of type I collagen relative to these discrete blocks of amino acids may influence the severity of the disease phenotype.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,NEW BRUNSWICK,NJ 08903; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,PHILADELPHIA,PA 19107	Rutgers State University New Brunswick; Rutgers State University Medical Center; Jefferson University	DEAK, SB (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT SURG,CARDIAC SURG SECT,NEW BRUNSWICK,NJ 08903, USA.		Deltas, Constantinos/J-9345-2013	Deltas, Constantinos/0000-0001-5549-9169				BATEMAN JF, 1988, J BIOL CHEM, V263, P11627; BATEMAN JF, 1987, J BIOL CHEM, V262, P7021; BONADIO J, 1985, NATURE, V316, P363, DOI 10.1038/316363a0; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; BYERS PH, 1990, ANN NY ACAD SCI, V580, P117; CONSTANTINOU CD, 1987, EUR J BIOCHEM, V163, P247, DOI 10.1111/j.1432-1033.1987.tb10794.x; CRISCITIELLO MG, 1965, CIRCULATION, V31, P255, DOI 10.1161/01.CIR.31.2.255; DEAK SB, 1985, COLLAGEN REL RES, V5, P305; DEAK SB, 1983, J BIOL CHEM, V258, P5192; DOLZ R, 1986, BIOPOLYMERS, V25, P1069, DOI 10.1002/bip.360250607; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HEPPNER RL, 1973, AM J CARDIOL, V31, P654, DOI 10.1016/0002-9149(73)90338-X; HORTOP J, 1986, CIRCULATION, V73, P54, DOI 10.1161/01.CIR.73.1.54; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LAMANDE SR, 1989, J BIOL CHEM, V264, P15809; PIERCE RA, 1987, J BIOL CHEM, V262, P1652; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; PRUCHNO CJ, 1991, HUM GENET, V87, P33, DOI 10.1007/BF01213088; RAO VH, 1989, J BIOL CHEM, V264, P1793; REMIGIO PA, 1970, AM J DIS CHILD, V119, P524, DOI 10.1001/archpedi.1970.02100050526014; TROMP G, 1988, BIOCHEM J, V253, P919, DOI 10.1042/bj2530919; TSUNEYOSHI T, 1990, AM J HUM GENET, V47, pA240; VETTER U, 1989, EUR J PEDIATR, V149, P184, DOI 10.1007/BF01958277; WALLIS GA, 1990, J BIOL CHEM, V265, P18628; WALLIS GA, 1990, AM J HUM GENET, V46, P1034; WEISINGER B, 1975, BRIT HEART J, V37, P475; WENSTRUP RJ, 1991, J BIOL CHEM, V266, P2590; WESTERHAUSEN A, 1990, J BIOL CHEM, V265, P13995; WHEELER V R, 1988, Pediatric Pathology, V8, P55	30	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21827	21832						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1718984				2022-12-25	WOS:A1991GP80400077
J	JENA, BP; PADFIELD, PJ; INGEBRITSEN, TS; JAMIESON, JD				JENA, BP; PADFIELD, PJ; INGEBRITSEN, TS; JAMIESON, JD			PROTEIN TYROSINE PHOSPHATASE STIMULATES CA2+-DEPENDENT AMYLASE SECRETION FROM PANCREATIC ACINI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DIFFERENT EXOCRINE GLANDS; HUMAN-PLACENTA; MAST-CELLS; POLYPEPTIDES OCCURS; GRANULE MEMBRANES; COMMON SPECTRUM; EXOCYTOSIS; BINDING	Eukaryotic cells respond to various stimuli by an increase or decrease in levels of phosphoproteins. Phosphotyrosine levels on eukaryotic cellular proteins are tightly regulated by the opposing actions of protein-tyrosine kinases and protein-tyrosine phosphatases (PTPases, EC 3.1.3.48). Studies on permeabilized mast cells suggest that the enabling reaction for exocytosis might involve protein dephosphorylation. In the present studies, a recombinant form of rat brain PTPase (rrbPTP-1) has been used to examine the potential role of PTPases in Ca2+-dependent amylase secretion from permeabilized rat pancreatic acini. Additionally, the concentrations and subcellular distributions of endogenous PTPase activity in rat pancreas were determined. The results from these experiments indicate that addition of exogenous PTPase stimulated Ca2+-dependent amylase secretion from pancreatic acinar cells and that endogenous PTPase activity was associated with the postgranule supernatant, zymogen granules, and in particular zymogen granule membranes. Our data suggest that protein tyrosine dephosphorylation is potentially involved in regulated secretion at a site(s) distal to receptor-mediated elevation of intracellular second messengers.	IOWA STATE UNIV SCI & TECHNOL,DEPT ZOOL & GENET,AMES,IA 50011	Iowa State University	JENA, BP (corresponding author), YALE UNIV,SCH MED,DEPT CELL BIOL,C222,SHM,333 CEDAR ST,NEW HAVEN,CT 06510, USA.				NCI NIH HHS [CA46128] Funding Source: Medline; NIDDK NIH HHS [DK17389] Funding Source: Medline; NIGMS NIH HHS [GM38415] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017389, R01DK017389] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038415] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONIW JF, 1976, EUR J BIOCHEM, V68, P44; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREW K, 1975, J BIOL CHEM, V250, P1434; BRUZZONE R, 1985, BIOCHEM J, V226, P621, DOI 10.1042/bj2260621; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHERNOFF J, 1990, P NATL ACAD SCI USA, V87, P2735, DOI 10.1073/pnas.87.7.2735; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; FINDLAY L, 1958, BIOCHEM J, V69, P469; GOMPERTS BD, 1988, COLD SPRING HARB SYM, V53, P983, DOI 10.1101/SQB.1988.053.01.113; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; INGEBRITSEN TS, 1989, ADV PROT PHOSPHATASE, V5, P121; INGEBRITSEN TS, IN PRESS METHODS ENZ; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; PADFIELD PJ, 1991, BIOCHEM BIOPH RES CO, V174, P600, DOI 10.1016/0006-291X(91)91459-P; ROSENZWEIG SA, 1983, J CELL BIOL, V96, P1288, DOI 10.1083/jcb.96.5.1288; SOTTOCASA GL, 1967, J CELL BIOL, V32, P417; TATHAM PER, 1989, BIOSCIENCE REP, V9, P99, DOI 10.1007/BF01117516; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TREADWAY JL, 1989, J BIOL CHEM, V264, P15136; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; WAGNER PD, 1990, J BIOL CHEM, V265, P10352	26	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17744	17746						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1717440				2022-12-25	WOS:A1991GG55300007
J	MARIN, O; DONELLADEANA, A; BRUNATI, AM; FISCHER, S; PINNA, LA				MARIN, O; DONELLADEANA, A; BRUNATI, AM; FISCHER, S; PINNA, LA			PEPTIDES REPRODUCING THE PHOSPHOACCEPTOR SITES OF PP60C-SRC AS SUBSTRATES FOR TPK-IIB, A SPLENIC TYROSINE KINASE DEVOID OF AUTOPHOSPHORYLATION ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; SYNTHETIC PEPTIDES; PARTICULATE-FRACTION; PHOSPHORYLATION; SPLEEN; SPECIFICITY; RECEPTOR; P56LCK; VIRUS	TPK-IIB, a spleen tyrosine protein kinase devoid of autophosphorylation activity (Brunati, A. M., and Pinna, L. A. (1988) Eur. J. Biochem. 172, 451-457), has been purified to near homogeneity and assayed for its ability to phosphorylate the synthetic peptides EDNEYTA and EPQYQPA reproducing the two conserved phosphoacceptor sites of pp60c-src (Tyr-416 and Tyr-527). While EPQYQPA was phosphorylated with low efficiency (K(m) = 16.7 mM, K(cat) = 14.4), EDNEYTA is an excellent substrate displaying a K(m) value of 58-mu-M and a K(cat) value of 31.2. The single substitution, in the latter peptide, of the glutamic acid adjacent to the tyrosine by alanine to give EDNAYTA caused a 6-fold increase in the K(m). The positive influence on the phosphorylation of the acidic residues at -3 and -4 relative to the tyrosine is indicated by comparison of the kinetic constants for peptides EDAAYAA (K(cat) = 4.6, K(m) 0.325 mM) and QNAAYAA (K(cat) 2.4, K(m) 1.7 mM). Furthermore, when residues in the peptide NEYTA were replaced by alanine, the phosphorylation of the peptides NAYTA and AAYAA, was almost negligible (in terms of K(cat)/K(m) ratio). However AEYTA, NEYAA and AEYAA were still phosphorylated, albeit less efficiently than NEYTA. The probability that these peptides will adopt a beta-turn is EDNAYTA = EDNEYTA, NAYTA > NEYTA, and no predicted beta-turn for AEYTA, NEYAA, and AEYAA. Therefore these results support the concept that an amino-terminal acidic residue(s) is strictly required by TPK-IIB, irrespective of peptide conformation, although a beta-turn may enhance the phosphorylation of those peptides that satisfy this requirement. Two other spleen tyrosine kinases, TPK-I/lyn and TPK-III, both related to the src family, also have a far greater preference for the peptide EDNEYTA over EPQYQPA. However, they can be distinguished from TPK-IIB by their lower affinity for the peptides ED-NEYTA and NEYTA and by their different specificity towards the substituted derivatives of NEYTA. TPK-I/lyn, accepts most of the substitutions that are detrimental to TPK-IIB, the triply substituted peptide AAYAA being actually preferred over the parent peptide NEYTA. The substitution of glutamic acid by alanine is also tolerated by TPK-III, although, in contrast to TPK-IIB, the phosphorylation efficiency is drastically decreased by the substitution of the asparagine at position -2. Taken together these data would indicate that the highly conserved phosphoacceptor site, homologous to pp60c-src Tyr-416, is optimally configured for the specificity requirements of TPK-IIB, suggesting that TPK-IIB or tyrosine protein kinases with similar specificity might be involved in the phosphorylation of the members of the src family.	UNIV PADUA,CTR STUDIO FISIOL MITOCONDRIALE NAZL RIC,I-35100 PADUA,ITALY; INSERM,U332,F-75005 PARIS,FRANCE	University of Padua; Institut National de la Sante et de la Recherche Medicale (Inserm)	MARIN, O (corresponding author), UNIV PADUA,DIPARTMENTO CHIM BIOL,I-35100 PADUA,ITALY.		Brunati, Anna Maria/I-8136-2018	Brunati, Anna Maria/0000-0002-3481-9503				BATZER AG, 1990, EUR J BIOCHEM, V194, P251, DOI 10.1111/j.1432-1033.1990.tb19450.x; BRUNATI AM, 1989, FEBS LETT, V254, P145, DOI 10.1016/0014-5793(89)81027-0; BRUNATI AM, 1988, EUR J BIOCHEM, V172, P451, DOI 10.1111/j.1432-1033.1988.tb13909.x; BRUNATI AM, 1991, BIOCHIM BIOPHYS ACTA, V1091, P123, DOI 10.1016/0167-4889(91)90232-M; CASNELLIE JE, 1984, ADV ENZYME REGUL, V22, P501, DOI 10.1016/0065-2571(84)90028-1; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COLA C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P191, DOI 10.1016/0167-4889(89)90095-5; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; FOULKES JG, 1985, J BIOL CHEM, V260, P8070; GEAHLEN RL, 1990, PEPT PROT PHOSPH, P239; KEMP BE, 1975, P NATL ACAD SCI USA, V72, P3448, DOI 10.1073/pnas.72.9.3448; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; MEGGIO F, 1976, ANAL BIOCHEM, V71, P283; OKADA M, 1989, J BIOL CHEM, V264, P20886; TINKER DA, 1988, J BIOL CHEM, V263, P5024; WONG TW, 1983, J BIOL CHEM, V258, P1022; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237	22	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17798	17803						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1717442				2022-12-25	WOS:A1991GG55300016
J	LOWE, JB; KUKOWSKALATALLO, JF; NAIR, RP; LARSEN, RD; MARKS, RM; MACHER, BA; KELLY, RJ; ERNST, LK				LOWE, JB; KUKOWSKALATALLO, JF; NAIR, RP; LARSEN, RD; MARKS, RM; MACHER, BA; KELLY, RJ; ERNST, LK			MOLECULAR-CLONING OF A HUMAN FUCOSYL-TRANSFERASE GENE THAT DETERMINES EXPRESSION OF THE LEWIS-X AND VIM-2 EPITOPES BUT NOT ELAM-1-DEPENDENT CELL-ADHESION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-L-FUCOSE; D-GALACTOSIDE 2-ALPHA-L-FUCOSYLTRANSFERASE; PERFORMANCE LIQUID-CHROMATOGRAPHY; MYELOGENOUS LEUKEMIA-CELLS; SIALYL-LEX DETERMINANT; HAMSTER OVARY CELLS; BLOOD GROUP-A; MONOCLONAL-ANTIBODY; EMBRYONIC ANTIGEN; MESSENGER-RNA	We have used the human Lewis blood group fucosyltransferase cDNA and cross-hybridization procedures to isolate a human gene that encodes a distinct fucosyltransferase. Its DNA sequence predicts a type II transmembrane protein whose sequence is identical to 133 of 231 amino acids at corresponding positions within the catalytic domain of the Lewis fucosyltransferase. When expressed by transfection in cultured cell lines, this gene determines expression of a fucosyltransferase capable of efficiently utilizing N-acetyllactosamine to form the Lewis x determinant (Gal-beta-1 --> 4[Fuc-alpha-1 --> 3]GlcNAc). By contrast, biochemical and flow cytometry analyses suggest that the enzyme cannot efficiently utilize the type II acceptor NeuNAc-alpha-2 --> 3Gal-beta-1 --> 4GlcNAc, to form the sialyl Lewis x determinant. In Chinese hamster ovary cells, however, the enzyme can determine expression of the alpha-2 --> 3-sialylated, alpha-1 --> 3-fucosylated structure known as VIM-2, a putative oligosaccharide ligand for ELAM-1. Cell adhesion assays using VIM-2-positive, sialyl Lewis x-negative transfected Chinese hamster ovary cells indicate that surface expression of the VIM-2 determinant is not sufficient to confer ELAM-1-dependent adhesive properties upon the cells. These results demonstrate that substantial structural similarities can exist between mammalian glycosyltransferases with closely related enzymatic properties, thus facilitating isolation of their cognate genes by cross-hybridization methods. The results further suggest that cell surface expression of the VIM-2 determinant is not necessarily sufficient to mediate ELAM-1-dependent cell adhesion.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,ANN ARBOR,MI 48109; SAN FRANCISCO STATE UNIV,DEPT CHEM & BIOCHEM,SAN FRANCISCO,CA 94132	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; California State University System; San Francisco State University	LOWE, JB (corresponding author), UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,MED SCI RES BLDG,RM 3510,1150 W MED CTR DR,ANN ARBOR,MI 48109, USA.				NATIONAL CANCER INSTITUTE [R01CA032826] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038482] Funding Source: NIH RePORTER; NCI NIH HHS [CA32826] Funding Source: Medline; NIDDK NIH HHS [DK38482] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENJAMIN C, 1990, BIOCHEM BIOPH RES CO, V171, P348, DOI 10.1016/0006-291X(90)91400-M; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; CAILLARD T, 1988, EXP CLIN IMMUNOGENET, V5, P15; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIA D, 1985, CANCER RES, V45, P435; COUILLIN P, 1991, CYTOGENET CELL GENET, V56, P108, DOI 10.1159/000133061; Dayhoff M.O., 1978, ATLAS PROTEIN SEQ ST; DERAPPE C, 1986, CARBOHYD RES, V150, P273, DOI 10.1016/0008-6215(86)80022-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUKUDA M, 1984, J BIOL CHEM, V259, P925; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; FUKUDA MN, 1986, J BIOL CHEM, V261, P2376; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GALTON J, 1985, 9TH P INT CONV IMM, P117; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; JOHNSON PH, 1981, BIOCHEM BIOPH RES CO, V100, P1611, DOI 10.1016/0006-291X(81)90703-8; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KOBATA A, 1972, METHOD ENZYMOL, V28, P262; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER BA, 1988, J BIOL CHEM, V263, P10186; Maniatis T., 1982, MOL CLONING; MELLIS SJ, 1983, ANAL BIOCHEM, V134, P442, DOI 10.1016/0003-2697(83)90320-2; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MONTREUIL J, 1960, B SOC CHIM BIOL, V42, P1399; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OATES DC, 1977, SOMAT CELL GENET, V3, P561, DOI 10.1007/BF01539066; PALCIC MM, 1989, CARBOHYD RES, V190, P1, DOI 10.1016/0008-6215(89)84141-2; PATTERSON TA, 1987, NUCLEIC ACIDS RES, V15, P6298, DOI 10.1093/nar/15.15.6298; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POTVIN B, 1990, J BIOL CHEM, V265, P1615; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SYMINGTON FW, 1985, J IMMUNOL, V134, P2498; TETTEROO PAT, 1987, J BIOL CHEM, V262, P15984; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; VANKEUREN ML, 1986, AM J HUM GENET, V38, P793; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; Watkins W M, 1980, Adv Hum Genet, V10, P1; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146	65	290	295	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17467	17477						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1716630				2022-12-25	WOS:A1991GF44500074
J	KLEPPEL, MM; FAN, WW; CHEONG, HI; MICHAEL, AF				KLEPPEL, MM; FAN, WW; CHEONG, HI; MICHAEL, AF			EVIDENCE FOR SEPARATE NETWORKS OF CLASSICAL AND NOVEL BASEMENT-MEMBRANE COLLAGEN - CHARACTERIZATION OF ALPHA-3(IV)-ALPORT ANTIGEN HETERODIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPORT FAMILIAL NEPHRITIS; IV COLLAGEN; GOODPASTURE ANTIGEN; HEREDITARY NEPHRITIS; GLOBULAR DOMAIN; CHAIN; IDENTIFICATION; PROTEINS; MONOMERS; TISSUE	The COOH-terminal non-collagenous domains (NC1) of type IV collagen from glomerular basement membranes (GBM), lens capsule basement membranes, and Descemet's membrane varied in the distribution of their NC1 subunits. All of these basement membranes (BMs) contained both classical (alpha-1(IV) and alpha-2(IV)) and novel collagen chains (alpha-3(IV), alpha-4(IV) and the Alport antigen). Whereas GBM had a predominance of disulfide-bonded subunits, the lens capsule and Descemet's membrane were primarily monomeric, differences that are likely related to the functional and structural diversity of collagen in various tissues. A heterodimer formed from monomeric subunits of alpha-3(IV) and the Alport antigen exists in human and bovine GBM. This dimer represents an important cross-link of the NC1 domain of novel collagen. Additionally, immunoaffinity methodology showed that the novel BM collagen hexamers segregate into populations containing only novel BM subunits without the participation of the classical subunits (alpha-1(IV) and alpha-2(IV)). These data provided evidence for the presence of two separate networks of BM collagen: one containing alpha-1(IV) and alpha-2(IV), and the other consisting of the novel collagen chains.	UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	KLEPPEL, MM (corresponding author), UNIV MINNESOTA,SCH MED,DEPT PEDIAT,BOX 491 UMHC,MINNEAPOLIS,MN 55455, USA.		Cheong, Hae Il/J-5652-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI010704, R37AI010704] Funding Source: NIH RePORTER; NIAID NIH HHS [AI10704] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BITTNER M, 1980, ANAL BIOCHEM, V102, P459, DOI 10.1016/0003-2697(80)90182-7; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1990, J LAB CLIN MED, V115, P365; BUTKOWSKI RJ, 1985, J BIOL CHEM, V260, P3739; FESSLER LI, 1980, J SUPRAMOL STRUCT S, V4, P178; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; HINGLAIS N, 1972, LAB INVEST, V27, P473; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; KASHTAN C, 1986, J CLIN INVEST, V78, P1035, DOI 10.1172/JCI112658; KIM Y, 1991, AM J PATHOL, V138, P413; KIM Y, 1991, IN PRESS AM J PATHOL; KLEPPEL MM, 1989, AM J PATHOL, V134, P813; KLEPPEL MM, 1990, AM J ANAT, V187, P165, DOI 10.1002/aja.1001870205; KLEPPEL MM, 1987, J CLIN INVEST, V80, P263, DOI 10.1172/JCI113057; KLEPPEL MM, 1989, LAB INVEST, V61, P278; KLEPPEL MM, 1986, J BIOL CHEM, V261, P6547; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; ORKIN RW, 1977, J EXP MED, V145, P204, DOI 10.1084/jem.145.1.204; PHIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; RISTELI J, 1980, EUR J BIOCHEM, V108, P239, DOI 10.1111/j.1432-1033.1980.tb04717.x; RUMPELT HJ, 1980, CLIN NEPHROL, V13, P203; SAUS J, 1988, J BIOL CHEM, V263, P13374; SCHWARZ U, 1986, EUR J BIOCHEM, V157, P49, DOI 10.1111/j.1432-1033.1986.tb09636.x; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SPEAR GS, 1972, AM J PATHOL, V69, P213; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; WEBER S, 1984, EUR J BIOCHEM, V139, P401, DOI 10.1111/j.1432-1033.1984.tb08019.x; WESTBERG G, 1970, BIOCHEMISTRY-US, V9, P3838; WIESLANDER J, 1984, P NATL ACAD SCI USA, V81, P3833; YOSHIKAWA N, 1981, J PATHOL, V135, P199, DOI 10.1002/path.1711350305; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z	35	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4137	4142						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740456				2022-12-25	WOS:A1992HE60700084
J	PISONI, RL; LINDLEY, ER				PISONI, RL; LINDLEY, ER			INCORPORATION OF [P-32] ORTHOPHOSPHATE INTO LONG CHAINS OF INORGANIC POLYPHOSPHATE WITHIN LYSOSOMES OF HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORT; NEUROSPORA-CRASSA; TRIMETAPHOSPHATASE; MEMBRANE; SYSTEM; CELLS; PHOSPHATASE; PROTEINS; POOLS	When isolated human fibroblast lysosomes are incubated with 4-mu-M [P-32]phosphate at pH 7.0, orthophosphate is transported into lysosomes and is rapidly incorporated into low and high molecular weight products. We have characterized the high molecular weight (HMW) lysosomal material into which [P-32]phosphate is incorporated and have found it to consist of long chains of inorganic polyphosphate based on the following observations. 1) > 97% of HMW P-32-lysosomal material is converted to [P-32]orthophosphate when incubated with 1 N HCl for 20 min at 100-degrees-C. 2) Incubation of HMW P-32-lysosomal material at pH 7.0 and 65-degrees-C for 96 h results in the formation of [P-32]trimetaphosphate, which is known to be produced only from linear chains of polyphosphate under these conditions. 3) HMW P-32-lysosomal material is resistant to degradation by proteinase K, ribonuclease, and deoxyribonuclease and extracts into the aqueous phase during phenol/chloroform extractions. 4) HMW P-32-lysosomal material displays heterogeneous mobility on polyacrylamide gels with most chains ranging in length from 100 to at least 600 phosphate residues. 5) HMW P-32-lysosomal material is partially hydrolyzed under alkaline conditions to yield a continuous ladder of polyphosphate species differing by one or several residues in length on polyacrylamide gels.			PISONI, RL (corresponding author), UNIV MICHIGAN,DEPT PEDIAT & COMMUNICABLE DIS,ANN ARBOR,MI 48109, USA.				NIDDK NIH HHS [DK40323] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040323] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERG GG, 1958, ANAL CHEM, V30, P213, DOI 10.1021/ac60134a015; BRIGHTWELL R, 1968, ARCH BIOCHEM BIOPHYS, V124, P333, DOI 10.1016/0003-9861(68)90335-4; CHRISTENSEN HN, 1988, BIOSCIENCE REP, V8, P121, DOI 10.1007/BF01116456; CLARK JE, 1987, ANAL BIOCHEM, V161, P280, DOI 10.1016/0003-2697(87)90452-0; CRAMER CL, 1984, J BIOL CHEM, V259, P5152; CRAMER CL, 1980, J BACTERIOL, V142, P945, DOI 10.1128/JB.142.3.945-952.1980; DOTY SB, 1977, J HISTOCHEM CYTOCHEM, V25, P1381, DOI 10.1177/25.12.200672; FORSTER S, 1988, BIOCHIM BIOPHYS ACTA, V947, P465, DOI 10.1016/0304-4157(88)90004-4; GABEL NW, 1971, J NEUROCHEM, V18, P1229, DOI 10.1111/j.1471-4159.1971.tb00222.x; GAHL WA, 1989, ANNU REV NUTR, V9, P39, DOI 10.1146/annurev.nu.09.070189.000351; GAHL WA, 1989, METABOLIC BASIS INHE, P2619; GRIFFIN JB, 1965, J BIOL CHEM, V240, P4427; HANES CS, 1949, NATURE, V164, P1107, DOI 10.1038/1641107a0; HEINRIKSON RL, 1969, J BIOL CHEM, V244, P299; IGARASHI M, 1968, J BIOL CHEM, V243, P6084; KOPFMAIER P, 1990, ACTA ANAT, V139, P164; KULAEV IS, 1979, BIOCH INORGANIC POLY, P8; KULAEV IS, 1979, BIOCH INORGANIC POLY, P17; KULAEV IS, 1979, BIOCH INORGANIC POLY, P9; KULAEV IS, 1983, ADV MICROB PHYSL, V24, P84; KULAEV IS, 1979, BIOCH INORGANIC POLY, P7; MANDECKI W, 1988, DNA-J MOLEC CELL BIO, V7, P57, DOI 10.1089/dna.1988.7.57; OFFENBACHER S, 1984, ARCH BIOCHEM BIOPHYS, V231, P114, DOI 10.1016/0003-9861(84)90368-0; OLIVER C, 1980, J HISTOCHEM CYTOCHEM, V28, P78, DOI 10.1177/28.1.6243325; PAYER AF, 1980, J HISTOCHEM CYTOCHEM, V28, P183, DOI 10.1177/28.2.6243682; PEPIN CA, 1986, BIOCHEM INT, V12, P111; PETTY HR, 1985, J ULTRA MOL STRUCT R, V90, P80, DOI 10.1016/0889-1605(85)90118-1; PISONI RL, 1989, J BIOL CHEM, V264, P4850; PISONI RL, 1991, J BIOL CHEM, V266, P979; PISONI RL, 1987, J BIOL CHEM, V262, P15011; PISONI RL, 1987, J BIOL CHEM, V262, P6010; RAO NN, 1985, J BACTERIOL, V162, P242, DOI 10.1128/JB.162.1.242-247.1985; ROBINSON NA, 1984, BIOCHEM INT, V8, P757; SCHNEIDER DL, 1983, J BIOL CHEM, V258, P1833; SMITH ML, 1987, J BIOL CHEM, V262, P1244; THILO E, 1957, Z ANORG ALLG CHEM, V291, P164, DOI 10.1002/zaac.19572910120; TIJSSEN JPF, 1983, BIOCHIM BIOPHYS ACTA, V760, P143, DOI 10.1016/0304-4165(83)90135-6; WIEMKEN A, 1973, PLANTA, V109, P293, DOI 10.1007/BF00387098	38	63	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3626	3631						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740414				2022-12-25	WOS:A1992HE60700015
J	BERNARDI, P; VASSANELLI, S; VERONESE, P; COLONNA, R; SZABO, I; ZORATTI, M				BERNARDI, P; VASSANELLI, S; VERONESE, P; COLONNA, R; SZABO, I; ZORATTI, M			MODULATION OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE - EFFECT OF PROTONS AND DIVALENT-CATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CA-2+-INDUCED MEMBRANE TRANSITION; HEART-MITOCHONDRIA; OXIDATIVE STRESS; INNER MEMBRANE; ION CHANNEL; CA-2+-DEPENDENT PORE; N-ETHYLMALEIMIDE; CALCIUM FLUXES; CA-2+ RELEASE	We have studied the induction of the mitochondrial cyclosporin A-sensitive permeability transition pore (PTP) by the bifunctional SH group reagent phenylarsine oxide (PhAsO). Addition of nanomolar concentrations of the electroneutral H+-K+ ionophore nigericin to nonrespiring mitochondria in sucrose medium determines a dramatic increase of the time required for PTP induction by PhAsO, while no effect of nigericin is apparent in KCl medium. Using mitochondria loaded with the internal pH indicator 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein, we show that the effect of nigericin is mediated by the ionophore-induced acidification of matrix pH(i) Indeed, experimental manipulation of pH(i) by a number of treatments indicates that PTP induction is directly related to matrix pH, in that the PTP induction process becomes slower as pH(i) decreases at constant pH(o). PTP induction by PhAsO in respiration-inhibited mitochondria is stimulated by Ca2+ and inhibited by a series of divalent cations. Since PhAsO induces the PTP even in the presence of excess EGTA and in the absence of respiration (Lenartowicz, E., Bernardi, P., and Azzone, G. F. (1991) J. Bioenerg. Biomembr. 23, 679-688), we have been able to study the Ca2+ dependence of the induction process. We show that the apparent K(m) for Ca2+ activation is about 10(-5) M and that Ca2+, cyclosporin A, and inhibitory Me2+ ions behave as if they were competing for the same binding site(s) on the pore. Since similar results are obtained from patch-clamp experiments on the mitochondrial mega-channel (Szabo, I., Bernardi, P., and Zoratti, M. (1992) J. Biol. Chem. 267, 2940-2946), we suggest that (i) the PTP and the mitochondrial mega-channel are the same molecular structures and (ii) the same factors affect both the process of pore induction and its open-closed orientation.	UNIV PADUA, INST GEN PATHOL, I-35121 PADUA, ITALY	University of Padua	BERNARDI, P (corresponding author), CNR, STUDY PHYSIOL MITOCHONDRIA UNIT, VIA TRIESTE 75, I-35121 PADUA, ITALY.		Bernardi, Paolo/C-3656-2008; Szabo, Ildiko/AAW-5972-2021; Padova, Ildiko/K-5344-2016	Bernardi, Paolo/0000-0001-9187-3736; Szabo, Ildiko/0000-0002-3637-3947; Vassanelli, Stefano/0000-0003-0389-8023				AKERMAN KEO, 1977, BIOCHIM BIOPHYS ACTA, V464, P287, DOI 10.1016/0005-2736(77)90004-9; BEATRICE MC, 1980, J BIOL CHEM, V255, P8663; BERNARDI P, 1979, EUR J BIOCHEM, V102, P555, DOI 10.1111/j.1432-1033.1979.tb04272.x; BERNARDI P, 1990, EUR J BIOCHEM, V188, P91, DOI 10.1111/j.1432-1033.1990.tb15375.x; BERNARDI P, 1982, FEBS LETT, V139, P9, DOI 10.1016/0014-5793(82)80475-4; BERNARDI P, 1989, J BIOL CHEM, V264, P18902; BERNARDI P, 1983, BIOCHIM BIOPHYS ACTA, V724, P212, DOI 10.1016/0005-2728(83)90140-8; BERNARDI P, 1983, EUR J BIOCHEM, V134, P377, DOI 10.1111/j.1432-1033.1983.tb07578.x; BERNARDI P, 1992, IN PRESS MECHANICS S; BRIERLEY GP, 1989, BIOCHEMISTRY-US, V28, P4347, DOI 10.1021/bi00436a034; BRIERLEY GP, 1978, MOL BIOL MEMBRANES, P295; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; BROEKEMEIER KM, 1989, BIOCHEM BIOPH RES CO, V163, P561, DOI 10.1016/0006-291X(89)92174-8; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V936, P139, DOI 10.1016/0005-2728(88)90261-7; CHAVEZ E, 1988, J BIOL CHEM, V263, P3582; CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915; CROMPTON M, 1988, EUR J BIOCHEM, V178, P489, DOI 10.1111/j.1432-1033.1988.tb14475.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Garlid K.D., 1988, INTEGRATION MITOCHON, P259; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; HUNTER FE, 1955, J BIOL CHEM, V216, P357; JUNG DW, 1988, ARCH BIOCHEM BIOPHYS, V263, P19, DOI 10.1016/0003-9861(88)90609-1; JUNG DW, 1977, ARCH BIOCHEM BIOPHYS, V183, P452, DOI 10.1016/0003-9861(77)90380-0; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; LEQUOC K, 1982, ARCH BIOCHEM BIOPHYS, V216, P639, DOI 10.1016/0003-9861(82)90254-5; LI XQ, 1990, J BIOL CHEM, V265, P15316; MASSARI S, 1972, J MEMBRANE BIOL, V9, P57, DOI 10.1007/BF01868043; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23, DOI 10.1016/0005-2728(72)90094-1; MCGUINNESS O, 1990, EUR J BIOCHEM, V194, P671, DOI 10.1111/j.1432-1033.1990.tb15667.x; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MITCHELL P, 1969, EUR J BIOCHEM, V9, P149, DOI 10.1111/j.1432-1033.1969.tb00588.x; NAKASHIMA RA, 1982, J BIOL CHEM, V257, P9252; NICOLLI A, 1991, J BIOL CHEM, V266, P9465; NOVGORODOV SA, 1987, J BIOENERG BIOMEMBR, V19, P191, DOI 10.1007/BF00762412; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PFEIFFER DR, 1979, J BIOL CHEM, V254, P1485; POTTER VR, 1947, J BIOL CHEM, V169, P17; POZZAN M, 1981, FEBS LETT, V127, P263; SARIS NEL, 1963, SOC SCI FENN COMMENT, V28, P1; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1989, J BIOENERG BIOMEMBR, V21, P485, DOI 10.1007/BF00762520; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; TEDESCHI H, 1955, ARCH BIOCHEM BIOPHYS, V58, P52, DOI 10.1016/0003-9861(55)90092-8; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; ZORATTI M, 1990, BIOCHEM BIOPH RES CO, V168, P443, DOI 10.1016/0006-291X(90)92341-V; ZORATTI M, 1984, BIOCHIM BIOPHYS ACTA, V767, P231, DOI 10.1016/0005-2728(84)90192-0; ZORATTI M, 1991, TRENDS BIOMEMBRANES, P263	59	407	418	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2934	2939						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737749				2022-12-25	WOS:A1992HD15400021
J	BRODY, LC; MITCHELL, GA; OBIE, C; MICHAUD, J; STEEL, G; FONTAINE, G; ROBERT, MF; SIPILA, I; KAISERKUPFER, M; VALLE, D				BRODY, LC; MITCHELL, GA; OBIE, C; MICHAUD, J; STEEL, G; FONTAINE, G; ROBERT, MF; SIPILA, I; KAISERKUPFER, M; VALLE, D			ORNITHINE DELTA-AMINOTRANSFERASE MUTATIONS IN GYRATE ATROPHY - ALLELIC HETEROGENEITY AND FUNCTIONAL CONSEQUENCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; NUCLEOTIDE-SEQUENCE; NONSENSE MUTATIONS; STRUCTURAL GENE; MOLECULAR-BASIS; MESSENGER-RNA; OAT LOCUS; DNA; DEFICIENCY; RETINA	Ornithine delta-aminotransferase is a nuclear-encoded mitochondrial matrix enzyme which catalyzes the reversible interconversion of ornithine and alpha-ketoglutarate to glutamate semialdehyde and glutamate. Inherited deficiency of ornithine delta-aminotransferase results in ornithine accumulation and a characteristic chorioretinal degeneration, gyrate atrophy of the choroid and retina. We have surveyed the ornithine delta-aminotransferase genes of gyrate atrophy patients for mutations. Using a variety of techniques, we discovered and molecularly characterized 21 newly recognized ornithine delta-aminotransferase alleles. We determined the consequences of these and three previously described mutations on ornithine delta-aminotransferase mRNA, antigen, and enzyme activity in cultured fibroblasts. The majority (20/24) of these alleles produce normal amounts of normally sized ornithine delta-aminotransferase mRNA. By contrast, only 2/24 had normal amounts of ornithine delta-aminotransferase antigen. Reproducing these mutations by site-directed mutagenesis and expressing the mutant ornithine delta-aminotransferase in Chinese hamster ovary cells confirms that several of these mutations inactivate ornithine delta-aminotransferase and cause gyrate atrophy in these patients.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,GENET LAB,PCTB 802,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; HOP ST JUSTINE,SERV GENET MED,MONTREAL H3T 1C5,QUEBEC,CANADA; CHILDRENS HOSP HELSINKI,DEPT PEDIAT,HELSINKI,FINLAND; NEI,BETHESDA,MD 20892	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)					NEI NIH HHS [EY02948] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002948] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARTSCH K, 1990, J BACTERIOL, V172, P7035, DOI 10.1128/jb.172.12.7035-7042.1990; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG J, 1990, Molecular and Cellular Biology, V10, P5215; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEGOLS G, 1987, EUR J BIOCHEM, V169, P193, DOI 10.1111/j.1432-1033.1987.tb13597.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIBBS RA, 1987, SCIENCE, V236, P303, DOI 10.1126/science.3563511; GIBBS RA, 1985, SCIENCE, V230, P1242; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAYASHI H, 1990, ANNU REV BIOCHEM, V59, P87, DOI 10.1146/annurev.biochem.59.1.87; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HONG CM, 1990, DNA CELL BIOL, V9, P233, DOI 10.1089/dna.1990.9.233; INANA G, 1988, INVEST OPHTH VIS SCI, V29, P1001; INANA G, 1986, P NATL ACAD SCI USA, V83, P1203, DOI 10.1073/pnas.83.5.1203; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KNOWLES JR, 1987, SCIENCE, V236, P1252; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKOVICHOUSLEY Z, 1987, EUR J BIOCHEM, V162, P345, DOI 10.1111/j.1432-1033.1987.tb10607.x; MCCLATCHEY AI, 1990, AM J HUM GENET, V47, P790; MICHAUD J, 1991, AM J HUM GENET, V49, pA2519; Miller JH., 1972, EXPT MOL GENETICS; MITCHELL GA, 1988, J CLIN INVEST, V81, P630, DOI 10.1172/JCI113365; MITCHELL GA, 1988, J BIOL CHEM, V263, P14288; MITCHELL GA, 1991, P NATL ACAD SCI USA, V88, P815, DOI 10.1073/pnas.88.3.815; MITCHELL GA, 1989, P NATL ACAD SCI USA, V86, P197, DOI 10.1073/pnas.86.1.197; MONONEN I, 1991, P NATL ACAD SCI USA, V88, P2941, DOI 10.1073/pnas.88.7.2941; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ORKIN SH, 1983, J CLIN INVEST, V71, P775, DOI 10.1172/JCI110826; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; RAMESH V, 1986, DNA-J MOLEC CELL BIO, V5, P493, DOI 10.1089/dna.1.1986.5.493; RAMESH V, 1988, P NATL ACAD SCI USA, V85, P3777, DOI 10.1073/pnas.85.11.3777; RAMESH V, 1990, Investigative Ophthalmology and Visual Science, V31, P310; Sambrook J, 1989, MOL CLONING LABORATO; SHULZ GE, 1979, PRINCIPLES PROTEIN S, P17; SIMARD L, 1986, AM J HUM GENET, V39, P38; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VALLE D, 1973, BIOCHEM BIOPH RES CO, V53, P1130, DOI 10.1016/0006-291X(73)90582-2; VALLE D, 1977, P NATL ACAD SCI USA, V74, P5159, DOI 10.1073/pnas.74.11.5159; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; WU J, 1988, CYTOGENET CELL GENET, V48, P126, DOI 10.1159/000132606; ZINTZ CB, 1990, EXP EYE RES, V50, P759, DOI 10.1016/0014-4835(90)90126-F	45	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3302	3307						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737786				2022-12-25	WOS:A1992HD15400076
J	KORANGY, F; JULIN, DA				KORANGY, F; JULIN, DA			A MUTATION IN THE CONSENSUS ATP-BINDING SEQUENCE OF THE RECD SUBUNIT REDUCES THE PROCESSIVITY OF THE RECBCD ENZYME FROM ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; DNA-POLYMERASE; SUBSTRATE-SPECIFICITY; EXONUCLEASE-V; PROTEINS; K-12; DEOXYRIBONUCLEASE; MECHANISM; GENE; RECONSTITUTION	We have constructed a mutant form of the RecBCD enzyme from Escherichia coli with a lysine to glutamine change in the consensus ATP-binding sequence in the RecD subunit (Korangy, F., and Julin, D. A. (1992a, 1992b) J. Biol. Chem., 1727-1732; 1733-1740). We compare here the kinetics of double-stranded DNA-dependent ATP hydrolysis by the mutant (RecBCD-K177Q) and wild-type enzymes. We included heparin to trap enzyme not bound to DNA, or the single-stranded DNA-binding (SSB) protein from Escherichia coli to prevent the enzyme from binding to single-stranded DNA products and partially single-stranded reaction intermediates. The ATP hydrolysis kinetics in either case show a rapid burst phase followed by a slower second phase. The wild-type enzyme hydrolyzes an amount of ATP about equal to the DNA nucleotide concentration in the rapid phase. The amount of ATP hydrolyzed by the RecBCD-K177Q enzyme in the burst is about 8-10-fold lower than the wild-type, in the presence of either heparin or SSB. The burst magnitude of the wild-type enzyme with heparin is proportional to the size of the DNA from about 1,420 to 22,400 base pairs whereas that of the mutant is independent of the DNA size. The wild-type enzyme completely degrades a 6,250-base pair DNA substrate with no partially degraded molecules visible on agarose gels. RecBCD-K177Q enzyme reaction mixtures in the presence of SSB protein contain a heterogeneous mixture of partially degraded molecules of 2,000-5,000 base pairs. These results indicate that the RecBCD-K177Q enzyme is less processive than the wild-type enzyme.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park					NIGMS NIH HHS [GM39777] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039777, R01GM039777] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8583, DOI 10.1093/nar/14.21.8583; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8573, DOI 10.1093/nar/14.21.8573; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; HICKSON ID, 1985, J BIOL CHEM, V260, P1224; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; ISHII K, 1987, BIOCHEM J, V241, P111, DOI 10.1042/bj2410111; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JULIN DA, 1987, J BIOL CHEM, V262, P9044; KARU AE, 1973, J BIOL CHEM, V248, P4874; KORANGY F, 1992, J BIOL CHEM, P1733; KORANGY F, 1992, J BIOL CHEM, P1727; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; LIEBERMAN RP, 1974, P NATL ACAD SCI USA, V71, P4816, DOI 10.1073/pnas.71.12.4816; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MACKAY V, 1976, J BIOL CHEM, V251, P3716; MACKAY V, 1974, J BIOL CHEM, V249, P4286; MANIATIS T, 1982, MOL CLONING LABORATO, P121; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; Muskavitch K. M. T., 1981, ENZYMES, V14, P233; MUSKAVITCH KMT, 1982, J BIOL CHEM, V257, P2641; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROSAMOND J, 1979, J BIOL CHEM, V254, P8646; RUYECHAN WT, 1976, BIOCHEMISTRY-US, V15, P5057, DOI 10.1021/bi00668a017; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SMITH GR, 1990, NUCLEIC ACIDS MOL BI, V4, P78; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER G, 1967, EUR J BIOCHEM, V3, P194, DOI 10.1111/j.1432-1033.1967.tb19515.x	41	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3088	3095						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737764				2022-12-25	WOS:A1992HD15400043
J	PAKDEL, F; KATZENELLENBOGEN, BS				PAKDEL, F; KATZENELLENBOGEN, BS			HUMAN ESTROGEN-RECEPTOR MUTANTS WITH ALTERED ESTROGEN AND ANTIESTROGEN LIGAND DISCRIMINATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACIDS; BREAST-CANCER-CELLS; DNA-BINDING DOMAIN; ANTI-ESTROGEN; GLUCOCORTICOID RECEPTORS; SEQUENCE HOMOLOGY; STEROID-BINDING; TRANSCRIPTION; HORMONE; IDENTIFICATION	A structural characteristic of many antiestrogens (AEs) is a bulky side chain with basic or polar functional groups that may interact with charged and polar amino acids near the hormone-binding site in the estrogen receptor. Recently, we have identified Cys530 as the residue of the human estrogen receptor that is the site of covalent labeling by aziridine analogs of estrogens (Es) and AEs (Harlow, K. W., Smith, D. N., Katzenellenbogen, J. A., Greene, G. L., and Katzenellenbogen, B. S. (1989) J. Biol. Chem. 264, 17476-17485). Since the aziridine function is on the bulky side chain of these ligands, Cys530 must be at or near the site of those side chain interactions. To probe these interactions, we have, by site-directed mutagenesis, made mutant human estrogen receptors in which charged and polar amino acids near Cys530 are changed (Glu523 to Gln, Lys529 and Lys531 to Gln, Asn532 to Asp, and Asp538 to Asn) so as to alter charge with minimal steric alteration. These receptors were expressed in mammalian (Chinese hamster ovary or COS-1) cells and assayed for their binding affinity for Es and AEs, their interaction with estrogen-responsive element DNA, and their ability to activate or suppress transcription of estrogen-responsive reporter genes. Two of the estrogen receptor mutants, KKN-QQD (mutation of LyS529, Lys531, and Asn532 to Gln529, Gln531, and Asp532, respectively) and KK-QQ (mutation of Lys529 and Lys531 to Gln529 and Gln531, respectively), in which the local charge is changed from +2 to -1 or 0, respectively, display an affinity for estradiol (E2) 5-10 times lower than that of the wild-type receptor, which is attributable to an enhanced rate of E2 dissociation. Although these mutant receptors have reduced affinity for a variety of Es, they retain unaltered affinity for AE. The profiles of transcriptional activation of reporter genes by various concentrations of E2 show that these two mutants (KKN-QQD and KK-QQ) require 40- and 15-fold higher E2 concentrations, respectively, to achieve half-maximal activity. In contrast, mutants E523Q and D538N, with changes at amino acids further from Cys530, were unaltered in their hormone binding and transactivation activity by E or AE. Interestingly, the AEs 4-hydroxytamoxifen, LY 117018, U 23469M, and ICI 164384 were 15-30-fold more effective in inhibiting E2-Stimulated transcription by mutants KKN-QQD and KK-QQ compared to the wild-type receptor. These mutants bind to estrogen-responsive element DNA as well as does the wild-type estrogen receptor, as demonstrated by gel retardation assays; but the mobilities of mutant receptor.E2.DNA and mutant receptor.AE.DNA complexes are different from that of the wild type receptor. These results show that changes of specific amino acids in the hormone-binding domain near Cys530 can result in changes in binding affinity of the receptor for one category of ligands (Es) but not for another (AEs), resulting in a greatly reduced potency of Es in transactivation and a greatly enhanced sensitivity to AEs in suppression of E-stimulated transcription. The findings suggest that these amino acids near Cys530 are involved in receptor discrimination between Es and AEs.	UNIV ILLINOIS,COLL MED,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	PAKDEL, F (corresponding author), UNIV ILLINOIS,DEPT PHYSIOL & BIOPHYS,URBANA,IL 61801, USA.		Pakdel, Farzad/K-1700-2015	Pakdel, Farzad/0000-0002-3067-3156	NCI NIH HHS [CA18119] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA018119, R01CA018119] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BROWN M, 1990, J BIOL CHEM, V265, P11238; BROWN TR, 1990, MOL ENDOCRINOL, V4, P1759, DOI 10.1210/mend-4-12-1759; CHANG TC, 1990, J BIOL CHEM, V265, P8176; ECKERT RL, 1982, J BIOL CHEM, V257, P8840; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1989, MOL ENDOCRINOL, V3, P1002, DOI 10.1210/mend-3-6-1002; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1989, CANCER RES, V49, pS2282; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENE GL, 1984, J STEROID BIOCHEM, V20, P51, DOI 10.1016/0022-4731(84)90188-2; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Ham J, 1989, CURR OPIN CELL BIOL, V1, P503, DOI 10.1016/0955-0674(89)90012-4; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KATZENELLENBOGEN BS, 1985, BREAST CANCER RES TR, V5, P231, DOI 10.1007/BF01806018; KATZENELLENBOGEN BS, 1983, J STEROID BIOCHEM, V19, P59, DOI 10.1016/S0022-4731(83)80007-7; KOIKE S, 1987, NUCLEIC ACIDS RES, V15, P2499, DOI 10.1093/nar/15.6.2499; KRUST A, 1986, EMBO J, V5, P891, DOI 10.1002/j.1460-2075.1986.tb04300.x; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; PAKDEL F, 1989, MOL ENDOCRINOL, V3, P44, DOI 10.1210/mend-3-1-44; PAKDEL F, 1991, ENDOCRINOLOGY S, V128, P120; PHAM TA, 1991, P NATL ACAD SCI USA, V88, P3125, DOI 10.1073/pnas.88.8.3125; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REESE JC, 1991, J BIOL CHEM, V266, P10880; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SEGNITZ B, 1990, J BIOL CHEM, V265, P2789; SIMONS SS, 1991, ENDOCRINOLOGY S, V128, P14; TATEE T, 1979, J MED CHEM, V22, P1509, DOI 10.1021/jm00198a015; WAKELING AE, 1988, J STEROID BIOCHEM, V30, P141, DOI 10.1016/0022-4731(88)90086-6; WEATHERILL PJ, 1988, J STEROID BIOCHEM, V30, P263, DOI 10.1016/0022-4731(88)90103-3; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEILER IJ, 1987, MOL ENDOCRINOL, V1, P355, DOI 10.1210/mend-1-5-355; WHITE R, 1987, MOL ENDOCRINOL, V1, P601; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893	56	130	132	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3429	3437						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737796				2022-12-25	WOS:A1992HD15400094
J	BEAUMONT, A; BARBE, B; LEMOUAL, H; BOILEAU, G; CRINE, P; FOURNIEZALUSKI, MC; ROQUES, BP				BEAUMONT, A; BARBE, B; LEMOUAL, H; BOILEAU, G; CRINE, P; FOURNIEZALUSKI, MC; ROQUES, BP			CHARGE POLARITY REVERSAL INVERSES THE SPECIFICITY OF NEUTRAL ENDOPEPTIDASE-24.11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SITE-DIRECTED MUTAGENESIS; 24.11 ENKEPHALINASE; ACTIVE-SITE; SUBSTRATE-SPECIFICITY; RETRO-THIORPHAN; ENZYME; THERMOLYSIN; CATALYSIS; BINDING	Attempts to change enzyme specificity by charge polarity reversal have so far met with little success, probably due to a destabilization of the resulting ion pair in an environment naturally optimized for the inverted pair. In the zinc metallopeptidase neutral endopeptidase-24.11 EC 3.4.24.11), Arg102, involved in substrate binding, is probably located at the edge of the active site (Bateman, R. C., Jr., Kim, Y.-A., Slaughter, C., and Hersh, L. B. (1990) J. Biol. Chem. 265, 8365-8368; Beaumont, A., Le Moual, H., Boileau, G., Crine, P., and Roques, B. P. (1991) J. Biol. Chem. 266, 214-220). This environment may be favorable for polarity reversal, as in water the energies of reverse ion pairs would be identical. We show here that, while mutating Arg102 to Glu reduces the specificity of a C-terminally negatively charged substrate 16-fold, it increases that of a substrate with an optimally positioned positive charge 29-fold. The concept of charge polarity reversal can be extended to other zinc metallopeptidases, and the mutated enzyme could also have applications in the enantiomeric separation of unnatural amino acids.	CNRS,UNITE FORMAT & RECH SCI PHARMACEUT & BIOL 498,INSERM,U266,F-75270 PARIS 06,FRANCE; UNIV MONTREAL,DEPT BIOCHIM,MONTREAL H3C 3J7,QUEBEC,CANADA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montreal								BATEMAN RC, 1990, J BIOL CHEM, V265, P8365; BATEMAN RC, 1989, J BIOL CHEM, V264, P6151; BEAUMONT A, 1991, J BIOL CHEM, V266, P214; BENCHETRIT T, 1988, BIOCHEMISTRY-US, V27, P592, DOI 10.1021/bi00402a014; CHARPENTIER B, 1988, PEPTIDES, V9, P835, DOI 10.1016/0196-9781(88)90130-1; CHOREV M, 1984, J ORG CHEM, V49, P821, DOI 10.1021/jo00179a014; CHRISTIANSON DW, 1985, P NATL ACAD SCI USA, V82, P6840, DOI 10.1073/pnas.82.20.6840; CRONIN CN, 1988, BIOCHEMISTRY-US, V27, P4572, DOI 10.1021/bi00412a052; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; DEVAULT A, 1988, FEBS LETT, V231, P54, DOI 10.1016/0014-5793(88)80701-4; GRAF L, 1987, BIOCHEMISTRY-US, V26, P2616, DOI 10.1021/bi00383a031; HWANG JK, 1988, NATURE, V334, P270, DOI 10.1038/334270a0; LELOUAL H, 1991, J BIOL CHEM, V266, P15670; LEMAY G, 1989, J BIOL CHEM, V264, P15620; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; RODERICK SL, 1989, BIOCHEMISTRY-US, V28, P1493, DOI 10.1021/bi00430a011; ROQUES BP, 1982, LIFE SCI, V31, P1749, DOI 10.1016/0024-3205(82)90201-6; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; ROQUES BP, 1983, P NATL ACAD SCI-BIOL, V80, P3178, DOI 10.1073/pnas.80.11.3178; SKIDGEL RA, 1987, NEUROPEPTIDES THEIR, P165; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P8386; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; THOMAS PG, 1985, NATURE, V318, P375, DOI 10.1038/318375a0; VIJAYARAGHAVAN J, 1990, BIOCHEMISTRY-US, V29, P8052, DOI 10.1021/bi00487a009; VOGEL Z, 1977, FEBS LETT, V80, P332, DOI 10.1016/0014-5793(77)80469-9; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007	26	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2138	2141						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733922				2022-12-25	WOS:A1992HB53200007
J	GARMENDIA, C; BERNAD, A; ESTEBAN, JA; BLANCO, L; SALAS, M				GARMENDIA, C; BERNAD, A; ESTEBAN, JA; BLANCO, L; SALAS, M			THE BACTERIOPHAGE-PHI-29 DNA-POLYMERASE, A PROOFREADING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE PHI-29 DNA; 5' EXONUCLEASE ACTIVITY; SPONTANEOUS MUTATION; TERMINAL PROTEIN; ESCHERICHIA-COLI; KLENOW FRAGMENT; REPLICATION; INITIATION; SITE; ACID	The bacteriophage phi-29 DNA polymerase, involved both in the protein-primed initiation and elongation steps of the viral DNA replication, displays a very processive 3',5'-exonuclease activity acting preferentially on single-stranded DNA. This exonucleolytic activity showed a marked preference for excision of a mismatched versus a correctly paired 3' terminus. These characteristics enable the phi-29 DNA polymerase to act as a proofreading enzyme. A comparative analysis of the wild-type phi-29 DNA polymerase and a mutant lacking 3',5'-exonuclease activity indicated that a productive coupling between the exonuclease and polymerase activities is necessary to prevent fixation of polymerization errors. Based on these data, the phi-29 DNA polymerase, a model enzyme for protein-primed DNA replication, appears to share the same mechanism for the editing function as that first proposed for T4 DNA polymerase and Escherichia coli DNA polymerase I on the basis of functional and structural studies.	UNIV AUTONOMA MADRID,CONSEJO SUPER INVEST CIENT,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Salas, Margarita/J-9873-2014; Esteban, Jose/L-4944-2014; Bernad, Antonio/P-8573-2017; Blanco, Luis/I-1848-2015	Salas, Margarita/0000-0001-5939-3441; Esteban, Jose/0000-0002-3759-3300; Bernad, Antonio/0000-0003-0620-9668	NIGMS NIH HHS [5R01 GM27242-11] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BESSMAN MJ, 1977, J MOL BIOL, V116, P115, DOI 10.1016/0022-2836(77)90122-X; BLANCO L, 1985, NUCLEIC ACIDS RES, V13, P1239, DOI 10.1093/nar/13.4.1239; BLANCO L, 1985, P NATL ACAD SCI USA, V82, P6404, DOI 10.1073/pnas.82.19.6404; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1986, VIROLOGY, V153, P179, DOI 10.1016/0042-6822(86)90021-8; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; CLAYTON LK, 1979, J BIOL CHEM, V254, P1902; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; MANIATIS T, 1982, MOL CLONING, P478; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; WATABE K, 1984, BIOCHEM BIOPH RES CO, V123, P1019, DOI 10.1016/S0006-291X(84)80235-1; WATABE K, 1984, P NATL ACAD SCI-BIOL, V81, P5374, DOI 10.1073/pnas.81.17.5374	25	90	97	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2594	2599						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733957				2022-12-25	WOS:A1992HB53200075
J	OGAWA, Y; SCHMIDT, DK; DASCH, JR; CHANG, RJ; GLASER, CB				OGAWA, Y; SCHMIDT, DK; DASCH, JR; CHANG, RJ; GLASER, CB			PURIFICATION AND CHARACTERIZATION OF TRANSFORMING GROWTH FACTOR-BETA-2.3 AND FACTOR-BETA-1.2 HETERODIMERS FROM BOVINE BONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; POLYACRYLAMIDE GELS; PROTEINS; CELLS; IDENTIFICATION; EXPRESSION; ANTIBODIES	A unique form of transforming growth factor-beta (TGF-beta), TGF-beta-2.3 heterodimer, has been purified from bovine bone extract. TGF-beta-2.3 migrated as a single 25-kDa band by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, whereas under reducing conditions it migrated as a 12.5 kDa band. The TGF-beta-2.3 reacted positively with anti-TGF-beta-2 and anti-TGF-beta-3 antibodies on immunoblots. Equal levels of TGF-beta-2 and TGF-beta-3 sequences were detected by N-terminal sequencing. TGF-beta-2.3 eluted as a single sharp peak by reverse-phase high performance liquid chromatography. However, prior reduction of the protein with dithiothreitol resulted in the protein eluting in two peaks, one containing predominantly TGF-beta-3 and the other containing predominantly TGF-beta-2. TGF-beta-2.3 inhibited proliferation of mink lung epithelial cells and promoted the formation of colonies of normal rat kidney fibroblasts in culture with specific biological activity similar to those of TGF-beta-1 and TGF-beta-2. These results demonstrate that the protein is TGF-beta-2.3 heterodimer, consisting of one polypeptide chain each of TGF-beta-2 and TGF-beta-3 linked by one or more disulfide bonds. In addition, TGF-beta-1.2 heterodimer, previously found only in porcine platelets, has also been purified from bovine bone extract.	BERLEX BIOSCI, S SAN FRANCISCO, CA 94080 USA		OGAWA, Y (corresponding author), CELTRIX LABS, 2500 FABER PL, PALO ALTO, CA 94303 USA.							ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BENTZ H, 1989, J BIOL CHEM, V264, P20805; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; DASCH JR, 1989, J IMMUNOL, V142, P1536; ELLINGSWORTH LR, 1986, J BIOL CHEM, V261, P2362; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; Harlow E., 1988, ANTIBODIES LABORATOR, P79; JAKOWLEW SB, 1988, MOL ENDOCRINOL, V2, P1186, DOI 10.1210/mend-2-12-1186; KSANDER GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1831, DOI 10.1177/38.12.2254647; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCPHERSON JM, 1989, BIOCHEMISTRY-US, V28, P3442, DOI 10.1021/bi00434a044; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OGAWA Y, 1991, METHOD ENZYMOL, V198, P317; ROBERTS AB, 1984, CELL CULTURE METHODS, V1, P181; Roberts AB, 1990, PEPTIDE GROWTH FACTO, P419; Roberts AB, 1990, GROWTH FACTORS, V2, P135, DOI 10.3109/08977199009071500; SEYEDIN SM, 1983, J CELL BIOL, V97, P1950, DOI 10.1083/jcb.97.6.1950; SEYEDIN SM, 1985, P NATL ACAD SCI USA, V82, P2267, DOI 10.1073/pnas.82.8.2267; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	21	63	69	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2325	2328						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733936				2022-12-25	WOS:A1992HB53200034
J	SHEFF, DR; RUBENSTEIN, PA				SHEFF, DR; RUBENSTEIN, PA			AMINO-TERMINAL PROCESSING OF ACTINS MUTAGENIZED AT THE CYS-1 RESIDUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ALPHA-ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; INITIATOR METHIONINE; NUCLEOTIDE-SEQUENCE; ALTERNATE PATHWAYS; IDENTIFICATION; REMOVAL; GENE; ACETYLMETHIONINE; MUTAGENESIS	Most actins examined to date undergo a unique posttranslational modification termed processing, catalyzed by the actin N-acetylaminopeptidase. Processing is the removal of acetylmethionine from the amino terminus in class I actins with Met-Asp(Glu) amino termini. For class II actins with Met-X-Asp(Glu) amino termini, processing is the removal of the second residue as an N-acetylamino acid. Other cytosolic proteins with these amino termini are not processed suggesting that the reaction may be specific for actins. In actin, X is usually cysteine. However, there are some class II actins in which this residue is other than cysteine, suggesting a broader substrate specificity for actin N-acetylaminopeptidase than acetylmethionine or acetylcysteine. We constructed mutant actins in which this cysteine was replaced with serine, asparagine, glycine, aspartic acid, histidine, phenylalanine, and tyrosine and used these to determine the substrate specificity of rat liver actin N-acetylaminopeptidase in vitro. Amino-terminal acetylmethionine was cleaved from adjacent aspartic acid, asparagine, or histidine, but not serine, glycine, phenylalanine, or tyrosine. Of the acetylated actin amino termini tested, only acetylmethionine and acetylcysteine were cleaved. Histidine was never N-acetylated and was not cleaved. When phenylalanine and tyrosine were adjacent to the initiator methionine, no initiator methionine was cleaved even though it was acetylated. These results suggest a narrow substrate specificity for the rat liver actin N-acetylaminopeptidase. They also demonstrate that the adjacent residue can affect actin N-acetylaminopeptidase specificity.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa				Rubenstein, Peter/0000-0003-1225-4414	NIGMS NIH HHS [T32GM07337, GM-33689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337, R01GM033689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRE E, 1988, J BIOL CHEM, V263, P722; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; BUTLER ET, 1982, J BIOL CHEM, V257, P5772; COOK RK, 1991, J BIOL CHEM, V266, P16825; COOPER TG, 1986, TOOLS BIOCH; GADE W, 1978, J BIOL CHEM, V253, P5012; HIGHTOWER RC, 1986, GENETICS, V114, P315; HIRONO M, 1987, J MOL BIOL, V194, P181, DOI 10.1016/0022-2836(87)90367-6; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; KAINE BP, 1982, NATURE, V295, P430, DOI 10.1038/295430a0; KOBAYASHI K, 1987, J BIOL CHEM, V262, P11435; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; LEE FJS, 1990, J BIOL CHEM, V265, P3603; LEE FJS, 1990, J BIOL CHEM, V265, P11576; MARTIN DJ, 1987, J BIOL CHEM, V262, P6350; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; RADHAKRISHNA G, 1986, J BIOL CHEM, V261, P9572; RADHAKRISHNA G, 1988, MOL BIOL INTRACELLUL, P109; REDMAN KL, 1985, J BIOL CHEM, V260, P4857; RUBENSTEIN P, 1980, J BIOL CHEM, V255, P7858; RUBENSTEIN PA, 1987, METHOD CELL BIOL, V28, P231; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHAH DM, 1982, P NATL ACAD SCI-BIOL, V79, P1022, DOI 10.1073/pnas.79.4.1022; SHEFF DR, 1989, J BIOL CHEM, V264, P11491; SOLOMON TL, 1988, J BIOL CHEM, V263, P19662; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P435, DOI 10.1021/bi00350a024; VANDEKERCKHOVE JS, 1989, J CELL BIOL, V109, P619, DOI 10.1083/jcb.109.2.619; YAMADA R, 1991, BIOCHEMISTRY-US, V30, P1017, DOI 10.1021/bi00218a019; YOSHIDA A, 1972, J BIOL CHEM, V247, P952	32	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2671	2678						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733964				2022-12-25	WOS:A1992HB53200086
J	YANG, J; ISENBERG, KE; ZORUMSKI, CF				YANG, J; ISENBERG, KE; ZORUMSKI, CF			VOLATILE ANESTHETICS GATE A CHLORIDE CURRENT IN POSTNATAL RAT HIPPOCAMPAL-NEURONS	FASEB JOURNAL			English	Note						GABA(A)-MIMETIC; VOLATILE ANESTHETICS; ISOFLURANE; HIPPOCAMPAL CULTURE	SPINAL NEURONS; GABA RECEPTOR; CULTURE; ISOFLURANE; CONDUCTANCE; PHARMACOLOGY	A volatile anesthetic-gated current was characterized in patch-clamped cultured postnatal rat hippocampal neurons. In this preparation, the major volatile anesthetics, isoflurane, halothane, and enflurane, open an anion-selective conductance. This volatile anesthetic-gated current exhibits anion selectivity with a chloride-to-acetate permeability ratio of 15, shows outward rectification well described by the constant field equation, and is activated in a dose-dependent fashion with half-maximal response to isoflurane at 0.8 mM (0.032 atm). The current persists in the absence of external Ca2+ and is not blocked by strychnine, a glycine antagonist. However, the gamma-aminobutyric acid(A) (GABA(A)) antagonists, bicuculline and picrotoxinin, and the non-specific anion channel blocker, 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS), completely block the response. These observations suggest that volatile anesthetics, like several other general anesthetics such as barbiturates, steroids, and etomidate, have a GABA-mimetic effect on vertebrate central neurons in culture. It is not clear whether this GABA(A)-gating property is a prerequisite for all general anesthetics. However, under normal physiological conditions of low intracellular Cl-, it is likely that drugs with both direct GABA agonist and GABA modulatory properties will produce overall depression of the central nervous system by increasing the normal inhibitory synaptic influence and by directly hyperpolarizing neurons.	UNIV MARYLAND,SCH MED,DEPT ANESTHESIOL,655 W BALTIMORE ST,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PHARMACOL & EXPTL THERAPEUT,BALTIMORE,MD 21201; WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Washington University (WUSTL); Washington University (WUSTL)					NIMH NIH HHS [MH00630, MH 00635] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K11MH000635, K11MH000630] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BARKER JL, 1987, J PHYSIOL-LONDON, V386, P485, DOI 10.1113/jphysiol.1987.sp016547; BARKER JL, 1978, J PHYSIOL-LONDON, V280, P355, DOI 10.1113/jphysiol.1978.sp012388; BERGJOHNSEN J, 1990, BRAIN RES, V507, P28, DOI 10.1016/0006-8993(90)90517-F; EGER EI, 1984, BRIT J ANAESTH, V56, pS71; EVANS RH, 1978, EXPERIENTIA, V34, P1325, DOI 10.1007/BF01981448; FRANKS NP, 1988, NATURE, V333, P662, DOI 10.1038/333662a0; FUJIWARA N, 1988, J PHYSIOL-LONDON, V402, P155, DOI 10.1113/jphysiol.1988.sp017198; INOUE M, 1986, NATURE, V324, P156, DOI 10.1038/324156a0; KRISHTAL OA, 1988, NEUROSCI LETT, V84, P271, DOI 10.1016/0304-3940(88)90519-8; LEDEZ KM, 1987, ANESTHESIOLOGY, V67, P301, DOI 10.1097/00000542-198709000-00004; MADISON DV, 1986, NATURE, V321, P695, DOI 10.1038/321695a0; MAYER ML, 1985, J PHYSIOL-LONDON, V364, P217, DOI 10.1113/jphysiol.1985.sp015740; MIU P, 1989, EXP BRAIN RES, V75, P354; MODY I, 1991, BRAIN RES, V538, P319, DOI 10.1016/0006-8993(91)90447-4; NAKAHIRO M, 1989, FASEB J, V3, P1850, DOI 10.1096/fasebj.3.7.2541038; NICOLL RA, 1980, BRAIN RES, V191, P225, DOI 10.1016/0006-8993(80)90325-X; NICOLL RA, 1982, SCIENCE, V217, P1055, DOI 10.1126/science.7112112; OBRIEN RJ, 1986, J NEUROSCI, V6, P3275; OWEN DG, 1984, NATURE, V311, P567, DOI 10.1038/311567a0; PROCTOR WR, 1986, J NEUROSCI, V6, P3164; RICHTER JJ, 1989, CLIN ANESTH, P281; SEGAL M, 1984, J NEUROPHYSIOL, V51, P500, DOI 10.1152/jn.1984.51.3.500; VLACHOVA V, 1987, J PHYSIOL-LONDON, V386, P425, DOI 10.1113/jphysiol.1987.sp016542; WALKER RJ, 1989, COMP BIOCHEM PHYS A, V93, P25, DOI 10.1016/0300-9629(89)90188-6; YANG J, 1989, Society for Neuroscience Abstracts, V15, P78; ZORUMSKI C F, 1988, Society for Neuroscience Abstracts, V14, P889	27	52	52	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					914	918		10.1096/fasebj.6.3.1740240	http://dx.doi.org/10.1096/fasebj.6.3.1740240			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740240				2022-12-25	WOS:A1992HE39000016
J	HARATA, K; MURAKI, M				HARATA, K; MURAKI, M			X-RAY STRUCTURAL EVIDENCE FOR A LOCAL HELIX-LOOP TRANSITION IN ALPHA-LACTALBUMIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							EGG-WHITE LYSOZYME; 3-STATE DENATURATION; RESOLUTION; MECHANISM	The three-dimensional structure of human alpha-lactalbumin for two crystal forms has been determined by x-ray analysis. One crystal (the form LT) was obtained at pH 4.2 and room temperature, while the other crystal (the form HT) was grown at pH 6.5 and 37-degrees-C. The backbone structure for Lys1-Ile95 residues is almost conserved between the two structures as indicated by the root mean square difference of 0.30 angstrom for the superposition of equivalent C(alpha) atoms. The calcium ion is surrounded by seven oxygen atoms of three carboxyl groups, two carbonyl groups, and two water molecules, which form a distorted pentagonal bipyramid in both structures. A large difference in polypeptide folding is found in the region of Leu96-Leu123 residues. Especially in the region of Trp104-Cys111 residues, a distorted alpha-helix is observed in the form HT while a loop structure is formed in the other crystal. The fact that the crystals of both forms appeared in the same batch at pH 6.5 and room temperature indicates that the human alpha-lactalbumin structure is highly fluctuated in solution and the folding and unfolding of the alpha-helix of Trp104-Cys111 residues are in equilibrium. Since the crystal of the form HT exclusively appeared around the physiological temperature, the structure of this form can be considered as the native structure. The partially unfolded structure in the form LT indicates that the local denaturation occurs even at room temperature.	NATL CHEM LAB IND, TSUKUBA, IBARAKI 305, JAPAN	National Institute of Advanced Industrial Science & Technology (AIST)	HARATA, K (corresponding author), RES INST POLYMERS & TEXT, 1-1-4 HIGASHI, TSUKUBA, IBARAKI 305, JAPAN.		Muraki, Michiro/C-9643-2011; muraki, michiro/AAU-7139-2021	Muraki, Michiro/0000-0003-4953-8007; muraki, michiro/0000-0003-4953-8007				ACHARYA KR, 1989, J MOL BIOL, V208, P99, DOI 10.1016/0022-2836(89)90091-0; ACHARYA KR, 1989, PROTEIN DATA BANK; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; ARTHYMUIK PJ, 1982, ACTA CRYSTALLOGR B, V38, P778; BERTHOU J, 1983, PROC R SOC SER B-BIO, V217, P471, DOI 10.1098/rspb.1983.0021; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BRADBURY JH, 1975, EUR J BIOCHEM, V53, P387, DOI 10.1111/j.1432-1033.1975.tb04078.x; BRUNGER AT, 1987, SCIENCE, V241, P71; FENNA RE, 1982, J MOL BIOL, V161, P211, DOI 10.1016/0022-2836(82)90288-1; GO N, 1983, ANNU REV BIOPHYS BIO, V12, P183, DOI 10.1146/annurev.bb.12.060183.001151; HALL L, 1982, NUCLEIC ACIDS RES, V10, P3503, DOI 10.1093/nar/10.11.3503; HOGLE J, 1981, ACTA CRYSTALLOGR B, V37, P591, DOI 10.1107/S0567740881003634; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KRONMAN MJ, 1967, BIOCHIM BIOPHYS ACTA, V133, P46, DOI 10.1016/0005-2795(67)90037-2; KRONMAN MJ, 1965, BIOCHEMISTRY-US, V4, P518, DOI 10.1021/bi00879a022; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1976, J MOL BIOL, V106, P359, DOI 10.1016/0022-2836(76)90091-7; KUWAJIMA K, 1977, J MOL BIOL, V114, P241, DOI 10.1016/0022-2836(77)90208-X; MOULT J, 1976, J MOL BIOL, V100, P179, DOI 10.1016/S0022-2836(76)80147-7; NOZAKA M, 1978, BIOCHEMISTRY-US, V17, P3753, DOI 10.1021/bi00611a013; STUART DI, 1986, NATURE, V324, P84, DOI 10.1038/324084a0; TAKESADA H, 1976, J BIOCHEM-TOKYO, V50, P969; [No title captured]	24	54	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1419	1421						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730691				2022-12-25	WOS:A1992HA48500005
J	SAKAC, D; ZACHOS, M; LINGWOOD, CA				SAKAC, D; ZACHOS, M; LINGWOOD, CA			PURIFICATION OF THE TESTICULAR GALACTOLIPID - 3'-PHOSPHOADENOSINE 5'-PHOSPHOSULFATE SULFOTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOCEREBROSIDE SULFOTRANSFERASE; PHENOL SULFOTRANSFERASE; ACTIVITY INVITRO; RAT-KIDNEY; ENZYME; SPERMATOGENESIS; BIOSYNTHESIS; INFERTILITY; MODULATION; PROTEIN	The rat testicular galactolipid sulfotransferase has been purified by affinity chromatography using 3'5'-adenosine diphosphate-agarose affinity chromatography. Both galactosyl glycerolipid and galactosyl ceramide were effective substrates with K(m) values of 4.8 and 1.1-mu-M respectively. A single protein of molecular mass 56 kDa was present in the purified sulfotransferase preparation as monitored by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and silver staining. Specific photoaffinity substrate labeling, using an azido derivative of galactosyl ceramide, was used to identify this protein, both in crude extracts and when purified. The protein was also selectively phosphorylated in the presence of the rat testicular galactolipid sulfotransferase stimulatory protein kinase.	UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT MICROBIOL,TORONTO M5S 1A1,ONTARIO,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								BARNES S, 1989, J LIPID RES, V30, P529; BORCHARDT RT, 1982, BIOCHIM BIOPHYS ACTA, V708, P272, DOI 10.1016/0167-4838(82)90437-X; FALANY CN, 1989, BIOCHEM J, V260, P641, DOI 10.1042/bj2600641; FLEISCHER B, 1974, J BIOL CHEM, V249, P5995; HOBKIRK R, 1990, BIOCHEM J, V268, P759, DOI 10.1042/bj2680759; KNAPP A, 1973, BIOCHEM BIOPH RES CO, V55, P179, DOI 10.1016/S0006-291X(73)80076-2; LAW H, 1988, J CELL PHYSIOL, V137, P462, DOI 10.1002/jcp.1041370310; LEE LMY, 1980, BIOCHEM J, V187, P437, DOI 10.1042/bj1870437; LEE TK, 1983, J BIOL CHEM, V258, P3166; LINGWOOD C, 1985, BIOCHEM J, V231, P401, DOI 10.1042/bj2310401; LINGWOOD C, 1991, J CELL PHYSIOL, V146, P258, DOI 10.1002/jcp.1041460210; LINGWOOD C, 1986, BIOCHEM CELL BIOL, V64, P631, DOI 10.1139/o86-087; LINGWOOD C, 1990, J CELL PHYSIOL, V142, P170, DOI 10.1002/jcp.1041420121; LINGWOOD CA, 1985, BIOCHEM J, V231, P393, DOI 10.1042/bj2310393; LINGWOOD CA, 1986, BIOCHEM CELL BIOL, V64, P984, DOI 10.1139/o86-131; LINGWOOD CA, 1985, J CELL SCI, V75, P329; LINGWOOD CA, 1985, CAN J BIOCHEM CELL B, V63, P1077, DOI 10.1139/o85-134; LINGWOOD CA, 1990, BIOL REPROD, V43, P694, DOI 10.1095/biolreprod43.4.694; Murry R. K., 1980, ACS SYM SER, V128, P105; OTTERNESS DM, 1989, MOL PHARMACOL, V36, P856; SADLER JE, 1981, J CHROMATOGR, V215, P181, DOI 10.1016/S0021-9673(00)81398-9; SAKAC D, 1989, BIOCHEM J, V261, P423, DOI 10.1042/bj2610423; SMITH PF, 1983, CRC CRIT R MICROBIOL, V11, P157; SUNDARAM KS, 1990, BIOCHEM BIOPH RES CO, V169, P927, DOI 10.1016/0006-291X(90)91982-X; TANIGUCHI N, 1982, J BIOL CHEM, V257, P631; TANIGUCHI N, 1985, J BIOL CHEM, V260, P4908; TAYLOR T, 1987, BIOCHIM BIOPHYS ACTA, V913, P131, DOI 10.1016/0167-4838(87)90321-9; TENNEKOON G, 1978, J NEUROCHEM, V31, P329, DOI 10.1111/j.1471-4159.1978.tb12466.x; TENNEKOON G, 1985, ARCH BIOCHEM BIOPHYS, V240, P932, DOI 10.1016/0003-9861(85)90102-X; TENNEKOON GI, 1981, J CELL BIOL, V91, P332, DOI 10.1083/jcb.91.2.332	30	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1655	1659						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730710				2022-12-25	WOS:A1992HA48500041
J	BULLERJAHN, AME; FREISHEIM, JH				BULLERJAHN, AME; FREISHEIM, JH			SITE-DIRECTED DELETION MUTANTS OF A CARBOXYL-TERMINAL REGION OF HUMAN DIHYDROFOLATE-REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOBACILLUS-CASEI; BINDING; MUTAGENESIS; RESIDUES; STEREOCHEMISTRY; TRIMETHOPRIM; METHOTREXATE; CONVERSION; ANTIBODIES	Substrate and inhibitor binding to dihydrofolate reductase (DHFR) primarily involves residues in the amino-terminal half of the enzyme; however, antibody binding studies performed in this laboratory suggested that the loop region located in the carboxyl terminus of human DHFR (hDHFR; residues 140-186) is involved in conformational changes that occur upon ligand binding and affect enzyme function (Ratnam, M., Tan, X., Prendergast, N.J., Smith, P.L. & Freisheim, J.H. (1988) Biochemistry 27, 4800-4804). To investigate this observation further, site-directed mutagenesis was used to construct deletion mutants of hDHFR missing 1 (del-1), 2 (del-2), 4 (del-4), and 6 (del-6) residues from loops in the carboxyl terminus of the enzyme. The del-1 mutant enzyme has a two-amino acid substitution in addition to the one-amino acid deletion. Deletion of only one amino acid resulted in a 35% decrease in the specific activity of the enzyme. The del-6 mutant enzyme was inactive. Surprisingly, the del-4 mutant enzyme retained a specific activity almost 33% that of the wild type. The specific activity of the del-2 mutant enzyme was slightly higher (38% wild-type activity) than that of the del-4 mutant. All three active deletion mutants were much less stable than the wild-type enzyme, and all three showed at least a 10-fold increase in K(m) values for both substrates. The del-1 and del-2 mutants exhibited a similar increase in K(D) values for both substrate and cofactor. The three active deletion mutants lost activity at concentrations of activating agents such as KCl, urea, and p-hydroxymercuribenzoate that continued to stimulate the wild-type enzyme. Antibody binding studies revealed conformational differences between the wild-type and mutant enzymes both in the absence and presence of bound folate. Thus, although the loops near the carboxyl terminus are far removed from the active site, small deletions of this region significantly affect DHFR function, indicating that the loop structure in mammalian DHFR plays an important functional role in its conformation and catalysis.			BULLERJAHN, AME (corresponding author), MED COLL OHIO,DEPT BIOCHEM & MOLEC BIOL,300 ARLINGTON AVE,BOX 10008,TOLEDO,OH 43699, USA.				NCI NIH HHS [CA08824, CA41461] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA008824, R01CA041461] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEMAN JR, 1989, J BIOL CHEM, V264, P2625; APPLEMAN JR, 1985, J BIOL CHEM, V263, P10304; BEVAN AW, 1983, P INT S PTERIDINES F, V7, P557; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BIRDSALL B, 1980, BIOCHEMISTRY-US, V19, P3732, DOI 10.1021/bi00557a014; BIRDSALL B, 1984, BIOCHEMISTRY-US, V23, P4733, DOI 10.1021/bi00315a032; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELCAMP TJ, 1983, BIOCHEMISTRY-US, V22, P633, DOI 10.1021/bi00272a017; FEENEY J, 1980, BIOCHEMISTRY-US, V19, P2316, DOI 10.1021/bi00552a006; FREISHEIM JH, 1984, FOLATE ANTAGONISTS T, V1, P69; GRONENBORN A, 1981, BIOCHEMISTRY-US, V20, P1717, DOI 10.1021/bi00510a003; HITCHINGS GH, 1984, FOLATE ANTAGONISTS T, V1, P151; HORECKER BL, 1948, J BIOL CHEM, V175, P385; HUANG SM, 1989, BIOCHEMISTRY-US, V28, P471, DOI 10.1021/bi00428a010; HUANG SM, 1990, BIOCHEMISTRY-US, V29, P8063, DOI 10.1021/bi00487a011; Kaufman B T, 1974, Methods Enzymol, V34, P272; KEMPTON RJ, 1982, J MED CHEM, V24, P475; MANIATIS T, 1982, MOL CLONING LABORATO, P90; MATTHEWS DA, 1985, J BIOL CHEM, V260, P392; MATTHEWS DA, 1979, J BIOL CHEM, V254, P4144; MATTHEWS DA, 1985, J BIOL CHEM, V260, P381; MONTGOMERY JA, 1984, FOLATE ANTAGONISTS T, V1, P219; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; OEFNER C, 1988, EUR J BIOCHEM, V174, P377, DOI 10.1111/j.1432-1033.1988.tb14108.x; PRENDERGAST NJ, 1988, BIOCHEMISTRY-US, V27, P3664, DOI 10.1021/bi00410a022; PRENDERGAST NJ, 1989, BIOCHEMISTRY-US, V28, P4645, DOI 10.1021/bi00437a020; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P5453, DOI 10.1021/bi00367a016; RATNAM M, 1988, BIOCHEMISTRY-US, V27, P4800, DOI 10.1021/bi00413a033; REYES P, 1967, BIOCHEMISTRY-US, V6, P3519, DOI 10.1021/bi00863a025; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHWEITZER BI, 1989, J BIOL CHEM, V264, P20786; SEEGER DR, 1949, J AM CHEM SOC, V71, P1753, DOI 10.1021/ja01173a061; TAN XH, 1990, J BIOL CHEM, V265, P8022; TAN XH, 1990, J BIOL CHEM, V265, P8027; THOMPSON PD, 1991, BIOCHEMISTRY-US, V30, P8124, DOI 10.1021/bi00247a005; WILLIAMS JW, 1981, BIOCHEMISTRY-US, V20, P6024, DOI 10.1021/bi00524a016; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021; 1984, DNA SYNTHESIZER USER, V13	41	7	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					864	870						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730674				2022-12-25	WOS:A1992GY96000030
J	CRUZ, MA; PETERSEN, E; TURCI, SM; HANDIN, RI				CRUZ, MA; PETERSEN, E; TURCI, SM; HANDIN, RI			FUNCTIONAL-ANALYSIS OF A RECOMBINANT GLYCOPROTEIN IB-ALPHA POLYPEPTIDE WHICH INHIBITS VONWILLEBRAND-FACTOR BINDING TO THE PLATELET GLYCOPROTEIN IB-IX COMPLEX AND TO COLLAGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BERNARD-SOULIER SYNDROME; VON-WILLEBRAND FACTOR; NATIVE MONOMERIC COLLAGEN; RATE-DEPENDENT DECREASE; COVALENT CROSS-LINKING; AMINO-ACID SEQUENCE; SHEAR RATE; MONOCLONAL-ANTIBODIES; IIIA COMPLEX; ADHESION	By deletion mutagenesis and transient expression in COS cells, a 96-amino acid hydrophilic sequence in the glycoprotein Ib-alpha-polypeptide located between L220 and L318 was identified which appeared to contain its von Willebrand factor- (vWF) binding site. The cDNA encoding this fragment was then expressed in Escherichia coli and purified from the bacterial cell lysate. The recombinant polypeptide, rGpIb-alpha-Q221-L318, was monomeric and had an apparent molecular weight of 14,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. It inhibited both ristocetin-induced binding of I-125-vWF to fixed washed platelets and ristocetin-induced platelet agglutination. The recombinant polypeptide also inhibited the binding of I-125-vWF to immobilized type I and III collagen. Inhibition of I-125-vWF binding to platelets and collagen was dose-dependent, with IC50 values of 500 and 200 nm rGpIb-alpha-Q221-L318, respectively. Fifty % inhibition of ristocetin-induced platelet agglutination required 500 nM rGpIb-alpha-Q221-L318. Although rGpIb-alpha-Q221-L318 inhibited vWF binding to collagen it did not, itself, bind to collagen-coated surfaces. Reduction of the disulfide bond between C248 and C264 abolished activity. I-125 rGpIb-alpha-Q221-L318 bound directly to GpIb/IX sites on multimeric vWF. These studies document that a portion of the sequence between Q221 and L318 is needed for recognition and binding to vWF and that binding requires an intact disulfide bond between C248 and C264 The binding of this recombinant polypeptide to vWF multimers inhibits vWF interaction with two important substrates, platelet GpIb/IX and collagen.	BRIGHAM & WOMENS HOSP,DIV HEMATOL ONCOL,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CHEM,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [5R37-HL34787, T32-HL07623] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034787, T32HL007623] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN JP, 1975, J LAB CLIN MED, V85, P318; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BOCKENSTEDT P, 1986, J CLIN INVEST, V78, P551, DOI 10.1172/JCI112608; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; CANFIELD VA, 1987, BIOCHEM BIOPH RES CO, V147, P526, DOI 10.1016/0006-291X(87)90963-6; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; COLLER BS, 1983, BLOOD, V61, P99; CRUZ M, 1991, IN PRESS BLOOD S1, V78; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FUJIMOTO T, 1982, NATURE, V297, P154, DOI 10.1038/297154a0; FUJIMURA Y, 1987, BLOOD, V70, P985; GRALNICK HR, 1981, BLOOD, V58, P387; GRALNICK HR, 1984, BLOOD, V64, P797; GREENBERG SM, 1988, BLOOD, V72, P1968; HANDA M, 1986, J BIOL CHEM, V261, P2579; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; KOUTTS T, 1979, PROG HAEMATOL, V2, P113; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MICHELSON AD, 1986, BLOOD, V67, P19; MILLER JL, 1990, BRIT J HAEMATOL, V74, P313, DOI 10.1111/j.1365-2141.1990.tb02589.x; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; NURDEN AT, 1975, NATURE, V255, P720, DOI 10.1038/255720a0; OKUMURA T, 1976, J BIOL CHEM, V251, P5944; OKUMURA T, 1976, J BIOL CHEM, V251, P5950; PARETI FI, 1987, J BIOL CHEM, V262, P13835; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SIXMA JJ, 1984, J CLIN INVEST, V74, P736, DOI 10.1172/JCI111489; SIXMA JJ, 1984, BLOOD, V63, P128; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; VICENTE V, 1990, J BIOL CHEM, V265, P274; WEISS HJ, 1974, AM J MED, V57, P920, DOI 10.1016/0002-9343(74)90170-3; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9	46	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1303	1309						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730650				2022-12-25	WOS:A1992GY96000097
J	OGAWA, W; SHII, K; YONEZAWA, K; BABA, S; YOKONO, K				OGAWA, W; SHII, K; YONEZAWA, K; BABA, S; YOKONO, K			AFFINITY PURIFICATION OF INSULIN-DEGRADING ENZYME AND ITS ENDOGENOUS INHIBITOR FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; MONOCLONAL-ANTIBODIES; SUBCUTANEOUS INSULIN; DEGRADATION; PROTEASE; PRODUCTS; IDENTIFICATION; HEPATOCYTES; MECHANISMS; RESISTANCE	A metallothiol protease called insulin-degrading enzyme (IDE) seems to be implicated in insulin metabolism to terminate the response of cells to hormone, as well as in other biological functions, including muscle differentiation, regulation of growth factor levels, and antigen processing. In order to obtain highly pure and biologically active IDE, we have developed an immunoaffinity method using a monoclonal antibody to this enzyme (9B12). When the cytosolic fraction of rat liver was first applied to a 9B12-coupled Affi-Gel 10 column, more than 97% of the insulin-degrading activity was absorbed. Among various kinds of buffers successfully eluting the enzyme, only the buffer with a high pH (pH 11) could retain the full biological activity of this enzyme. IDE was further purified via two steps of chromatography using Mono Q anion exchange and Superose 12 molecular sieve columns. The final preparation showed a single band at 110 kDa on reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). In the eluate from the immunoaffinity column, the inhibitory activity associated with the enzyme was also observed. To better recover this endogenous inhibitor, heat-treated cytosolic fraction was fractionated by ammonium sulfate precipitation and applied to the immunoaffinity column on which IDE had been adsorbed. Then, IDE and its inhibitor could be co-eluted with pH 11 as a complex form. After heat treatment of this fraction, the inhibitor was further purified using the same series of chromatography as IDE to more than 20,000-fold; it showed a 14 kDa band on SDS-PAGE. It inhibited both the insulin degradation by IDE in a competitive manner and the cross-linking of I-125-insulin to IDE. Highly purified IDE and the endogenous inhibitor will be useful tools for better understanding the various biological functions of this enzyme.	KOBE UNIV, SCH MED,DEPT INTERNAL MED 2, 5-1 KUSUNOKI CHO 7-CHOME,CHUO KU, KOBE 650, JAPAN; HYOGO INST CLIN RES, AKASHI 673, JAPAN	Kobe University			OGAWA, Wataru/AAQ-9586-2020					AFFHOLTER JA, 1988, SCIENCE, V242, P1415, DOI 10.1126/science.3059494; AKIYAMA H, 1988, BIOCHEM BIOPH RES CO, V155, P914, DOI 10.1016/S0006-291X(88)80583-7; AKIYAMA H, 1990, BIOCHEM BIOPH RES CO, V170, P1325, DOI 10.1016/0006-291X(90)90539-Y; ALHASHIMI I, 1988, J BIOL CHEM, V263, P9381; DUCKWORT.WC, 1972, P NATL ACAD SCI USA, V69, P3698, DOI 10.1073/pnas.69.12.3698; DUCKWORTH WC, 1988, J BIOL CHEM, V263, P1826; DUCKWORTH WC, 1981, ENDOCRINOLOGY, V108, P1142, DOI 10.1210/endo-108-4-1142; DUCKWORTH WC, 1988, ENDOCR REV, V9, P319, DOI 10.1210/edrv-9-3-319; DUCKWORTH WC, 1990, J BIOL CHEM, V265, P2984; FREIDENBERG GR, 1981, NEW ENGL J MED, V305, P363, DOI 10.1056/NEJM198108133050702; HARI J, 1987, ENDOCRINOLOGY, V120, P829, DOI 10.1210/endo-120-2-829; ISEMURA S, 1986, FEBS LETT, V198, P145, DOI 10.1016/0014-5793(86)81201-7; KAYALAR C, 1989, J BIOL CHEM, V264, P8928; KUO WL, 1990, MOL ENDOCRINOL, V4, P1580, DOI 10.1210/mend-4-10-1580; MCELDUFF A, 1980, AUST NZ J MED, V10, P56, DOI 10.1111/j.1445-5994.1980.tb03421.x; MCKENZIE RA, 1984, ARCH BIOCHEM BIOPHYS, V229, P604, DOI 10.1016/0003-9861(84)90193-0; MIRSKY A, 1949, ARCH BIOCHEM, V20, P1; MIRSKY IA, 1955, SCIENCE, V122, P559, DOI 10.1126/science.122.3169.559; NISHIURA I, 1978, J BIOCHEM-TOKYO, V84, P1657, DOI 10.1093/oxfordjournals.jbchem.a132296; PARKES C, 1986, PROTEINASE INHIBITOR, V12, P571; PAULSEN EP, 1979, DIABETES, V28, P640, DOI 10.2337/diabetes.28.7.640; ROTH RA, 1984, ENDOCR RES, V10, P101, DOI 10.3109/07435808409035411; RYAN MP, 1983, BIOCHEM BIOPH RES CO, V116, P195, DOI 10.1016/0006-291X(83)90400-X; SEMPLE JW, 1989, J IMMUNOL, V142, P4184; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; SHII K, 1985, J BIOL CHEM, V260, P6503; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; STENTZ FB, 1989, J BIOL CHEM, V264, P20275; STOPPELLI MP, 1988, P NATL ACAD SCI USA, V85, P3469, DOI 10.1073/pnas.85.10.3469; TITANI K, 1972, NATURE-NEW BIOL, V238, P35, DOI 10.1038/newbio238035a0; WAXMAN L, 1978, J BIOL CHEM, V253, P5888; YOKONO K, 1981, ENDOCRINOLOGY, V108, P1527, DOI 10.1210/endo-108-4-1527; YOKONO K, 1979, DIABETES, V28, P810, DOI 10.2337/diab.28.9.810; YOKONO K, 1980, DIABETES, V29, P856, DOI 10.2337/diabetes.29.10.856; YONEZAWA K, 1989, ENDOCRINOLOGY, V124, P496, DOI 10.1210/endo-124-1-496; YONEZAWA K, 1986, ENDOCRINOLOGY, V118, P1989, DOI 10.1210/endo-118-5-1989; YU SS, 1973, J BIOL CHEM, V248, P3753	37	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1310	1316						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730651				2022-12-25	WOS:A1992GY96000098
J	UCHIDA, Y; IZAI, K; ORII, T; HASHIMOTO, T				UCHIDA, Y; IZAI, K; ORII, T; HASHIMOTO, T			NOVEL FATTY-ACID BETA-OXIDATION ENZYMES IN RAT-LIVER MITOCHONDRIA .2. PURIFICATION AND PROPERTIES OF ENOYL-COENZYME-A (COA) HYDRATASE/3-HYDROXYACYL-COA DEHYDROGENASE/3-KETOACYL-COA THIOLASE TRIFUNCTIONAL PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL 3-KETOACYL-COA THIOLASE; 3-HYDROXYACYL-COA DEHYDROGENASE; ESCHERICHIA-COLI; BIFUNCTIONAL ENZYME; MULTIENZYME COMPLEX; HYDRATASE; SYSTEM; EXISTENCE; MEMBRANE; CDNA	Long-chain 3-hydroxyacyl-CoA dehydrogenase was extracted from the washed membrane fraction of frozen rat liver mitochondria with buffer containing detergent and then was purified. This enzyme is an oligomer with a molecular mass of 460 kDa and consisted of 4 mol of large polypeptide (79 kDa) and 4 mol of small polypeptides (51 and 49 kDa). The purified enzyme preparation was concluded to be free from the following enzymes based on marked differences in behavior of the enzyme during purification, molecular masses of the native enzyme and subunits, and immunochemical properties: enoyl-CoA hydratase, short-chain 3-hydroxyacyl-CoA dehydrogenase, peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase bifunctional protein, and mitochondrial and peroxisomal 3-ketoacyl-CoA thiolases. The purified enzyme exhibited activities toward enoyl-CoA hydratase and 3-ketoacyl-CoA thiolase together with the long-chain 3-hydroxyacyl-CoA dehydrogenase activity. The carbon chain length specificities of these three activities of this enzyme differed from those of the other enzymes. Therefore, it is concluded that this enzyme is not long-chain 3-hydroxyacyl-CoA dehydrogenase; rather, it is enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase trifunctional protein.	SHINSHU UNIV,SCH MED,DEPT BIOCHEM,MATSUMOTO,NAGANO 390,JAPAN	Shinshu University	UCHIDA, Y (corresponding author), GIFU UNIV,SCH MED,DEPT PEDIAT,GIFU 500,JAPAN.							BINSTOCK JF, 1977, P NATL ACAD SCI USA, V74, P492, DOI 10.1073/pnas.74.2.492; BREMER J, 1984, FATTY ACID METABOLIS, P113; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; El-Fakhri M, 1979, BIOCHEM SOC T, V7, P392, DOI 10.1042/bst0070392; ELFAKHRI M, 1982, BIOCHIM BIOPHYS ACTA, V713, P270, DOI 10.1016/0005-2760(82)90244-2; FREVERT J, 1980, EUR J BIOCHEM, V107, P79, DOI 10.1111/j.1432-1033.1980.tb04627.x; FURUTA S, 1980, J BIOCHEM, V88, P1059, DOI 10.1093/oxfordjournals.jbchem.a133057; FURUTA S, 1981, J BIOCHEM, V90, P1751, DOI 10.1093/oxfordjournals.jbchem.a133652; HALE DE, 1990, FATTY ACID OXIDATION, P503; HASHIMOTO T, 1982, ANN NY ACAD SCI, V386, P5, DOI 10.1111/j.1749-6632.1982.tb21403.x; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; IMAMURA S, 1990, J BIOCHEM, V107, P184, DOI 10.1093/oxfordjournals.jbchem.a123023; ISHII N, 1987, J BIOL CHEM, V262, P8144; IZAI K, 1992, J BIOL CHEM, V267, P1027; KOIKE M, 1971, METHOD ENZYMOL, V22, P339; Kunau W.-H., 1987, PEROXISOMES BIOL MED, P128; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Middleton B, 1975, Methods Enzymol, V35, P128, DOI 10.1016/0076-6879(75)35148-3; MIYAZAWA S, 1980, EUR J BIOCHEM, V103, P589, DOI 10.1111/j.1432-1033.1980.tb05984.x; MIYAZAWA S, 1981, J BIOCHEM, V90, P511, DOI 10.1093/oxfordjournals.jbchem.a133499; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; OSUMI T, 1984, TRENDS BIOCHEM SCI, V9, P317, DOI 10.1016/0968-0004(84)90301-3; OSUMI T, 1980, ARCH BIOCHEM BIOPHYS, V203, P372, DOI 10.1016/0003-9861(80)90189-7; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PAWAR S, 1981, J BIOL CHEM, V256, P3894; REDDY MK, 1987, P NATL ACAD SCI USA, V84, P3214, DOI 10.1073/pnas.84.10.3214; RYAN LD, 1974, ARCH BIOCHEM BIOPHYS, V160, P279, DOI 10.1016/S0003-9861(74)80035-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANDERS RJA, 1989, LANCET, V2, P52, DOI 10.1016/S0140-6736(89)90300-0; YANG SY, 1983, J BIOL CHEM, V258, P9780	33	299	306	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1034	1041						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730633				2022-12-25	WOS:A1992GY96000058
J	GRIFFITH, AJ; BLIER, PR; MIMORI, T; HARDIN, JA				GRIFFITH, AJ; BLIER, PR; MIMORI, T; HARDIN, JA			KU POLYPEPTIDES SYNTHESIZED INVITRO ASSEMBLE INTO COMPLEXES WHICH RECOGNIZE ENDS OF DOUBLE-STRANDED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN COMPLEX; AUTO-ANTIGEN; SEQUENCE; CDNA; AUTOANTIBODIES; PURIFICATION; CLONING; ELEMENT; SERA	The Ku protein is composed of two polypeptide subunits, p70 and p80, and binds DNA ends in vitro. Previous studies suggested that p70 and p80 are physically associated in vivo, although such an association may have been mediated by DNA. We have now utilized full-length Ku polypeptides synthesized in vitro to examine the association of p70, p80, and linear DNA to form a complex. In gel filtration chromatography, p70 migrates as a 70-kDa structure, whereas p80 migrates at 150 kDa. Co-translation of the two cDNAs yields complexes which migrate at 300 kDa and contain equimolar quantities of the p70 and p80 polypeptides, providing direct evidence that p70 and p80 assemble into a complex in the absence of DNA. To demonstrate that this recombinant protein complex binds DNA, we developed a radiolabeled protein electrophoretic mobility shift assay. When radiolabeled proteins synthesized in vitro were incubated with linear DNA and fractionated in a nonreducing, nondenaturing gel, a band representing a complex of p70, p80, and the DNA was seen. Formation of this Ku-DNA complex required free DNA ends, and binding to DNA ends was not observed with individual p70 or p80 subunits. DNA binding was not reconstituted by mixing the individual subunits together. These studies thus demonstrate that it is the complex of p70 and p80, not individual p70 or p80, which possesses the DNA binding properties previously described for native Ku protein. These results provide new information about the assembly, structure, and DNA binding properties of the Ku protein.	YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; KEIO UNIV,DEPT MED,TOKYO 160,JAPAN	Yale University; Yale University; Keio University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040072, R37AR040072, R01AR032549] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26853] Funding Source: Medline; NIAMS NIH HHS [AR32549, AR40072] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLAWAY GP, 1990, BIOCHEM BIOPH RES CO, V168, P747, DOI 10.1016/0006-291X(90)92385-D; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; CHAN JYC, 1989, J BIOL CHEM, V264, P3651; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FRANCOEUR AM, 1986, J IMMUNOL, V136, P1648; GRIFFITH A, 1990, Arthritis and Rheumatism, V33, pS50; GRIFFITH A J, 1990, Arthritis and Rheumatism, V33, pS79; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; Maniatis T., 1982, MOL CLONING; MAY G, 1991, J BIOL CHEM, V266, P3052; MERRICK WC, 1983, METHOD ENZYMOL, V101, P606; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MORISATO D, 1987, CELL, V51, P101, DOI 10.1016/0092-8674(87)90014-6; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REEVES WH, 1985, J EXP MED, V161, P18, DOI 10.1084/jem.161.1.18; ROBERTS MR, 1989, CELL REGUL, V1, P151, DOI 10.1091/mbc.1.1.151; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; YANEVA M, 1985, BIOCHIM BIOPHYS ACTA, V841, P22, DOI 10.1016/0304-4165(85)90270-3; YANEVA M, 1986, BIOCHEMISTRY-US, V25, P5057, DOI 10.1021/bi00366a013; YANEVA M, 1989, J BIOL CHEM, V264, P13407	25	95	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					331	338						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730599				2022-12-25	WOS:A1992GY43900055
J	JIN, SJ; HOPPEL, CL; TSERNG, KY				JIN, SJ; HOPPEL, CL; TSERNG, KY			INCOMPLETE FATTY-ACID OXIDATION - THE PRODUCTION AND EPIMERIZATION OF 3-HYDROXY FATTY-ACIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; BETA-OXIDATION; 3-HYDROXYDICARBOXYLIC ACIDURIA; DICARBOXYLIC ACIDURIA; EPIMERASE; PATHWAY; IDENTIFICATION; PEROXISOMES; RIBOFLAVIN; HYDRATASES	3-Hydroxydicarboxylic acids are major urinary metabolites derived from fatty acid metabolism. These compounds are produced from the omega-oxidation of 3-hydroxy fatty acids. The production of the precursor 3-hydroxy fatty acids from incomplete beta-oxidation of fatty acids in rat liver mitochondria was investigated. Independent of the chain length or the concentration of fatty acid substrates, the accumulation of 3-hydroxyacyl intermediates was relatively constant at the concentration of 3-5 nmol/mg of mitochondrial protein. The extent of the incomplete oxidation was the same in Percoll gradient-purified mitochondria. Rotenone treatment increased the production of 3-hydroxy fatty acids. 3-Hydroxy fatty acids did not exist as pure L-enantiomer as expected from beta-oxidation. Instead, these metabolites were epimerized to a n ar racemic mixture of D- and L-isomers with a slightly dominant D-isomer (58 +/- 3%). By using deuterium-isotope labeling, the mechanism of epimerizartion was shown to be a rapid dehydration-rehydration through trans-2-enoyl-CoA. In addition, cis-3 and trans-3 fatty acids were produced; these metabolites were derived from the isomerization of trans-2-enoyl-CoA. Epimerase and isomerase were thought to be enzymes involved in the oxidation of unsaturated fatty acids. Current data have shown that the metabolism of these acids is actually through NADPH-dependent reduction pathways. The activities of epimerase and isomerase detected in rat liver mitochondria possibly function mainly in the metabolism of saturated fatty acids in a reverse role to the conventional concept.	VET AFFAIRS MED CTR,MED RES SERV,10701 E BLVD,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT NUTR,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,CLEVELAND,OH 44106	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University								BRADY PS, 1985, BIOCHEM J, V229, P717, DOI 10.1042/bj2290717; BRASS EP, 1980, BIOCHEM J, V188, P451, DOI 10.1042/bj1880451; BREMER J, 1972, BIOCHIM BIOPHYS ACTA, V280, P515, DOI 10.1016/0005-2760(72)90131-2; CHU CH, 1985, FEBS LETT, V185, P129, DOI 10.1016/0014-5793(85)80755-9; CHU CH, 1984, BIOCHEM BIOPH RES CO, V118, P162, DOI 10.1016/0006-291X(84)91081-7; DICZFALUSY U, 1990, BIOCHIM BIOPHYS ACTA, V1043, P182, DOI 10.1016/0005-2760(90)90294-8; DRYSDALE GR, 1953, J BIOL CHEM, V202, P119; DURAN M, 1991, EUR J PEDIATR, V150, P190, DOI 10.1007/BF01963564; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; GARLAND PB, 1965, BIOCHEM J, V97, P587, DOI 10.1042/bj0970587; GOLMAN P, 1961, J BIOL CHEM, V236, P2620; HAGENFELDT L, 1990, J PEDIATR-US, V116, P387, DOI 10.1016/S0022-3476(05)82826-4; HALE DE, 1990, FATTY ACID OXIDATION, P503; HAMMARSTROM S, 1973, ANAL BIOCHEM, V52, P169, DOI 10.1016/0003-2697(73)90342-4; HILTUNEN JK, 1989, J BIOL CHEM, V264, P13536; HOPPEL C, 1979, J BIOL CHEM, V254, P4164; JIN SJ, 1990, BIOCHEMISTRY-US, V29, P8540, DOI 10.1021/bi00489a006; KELLEY RI, 1988, CLIN CHIM ACTA, V175, P19, DOI 10.1016/0009-8981(88)90031-9; KILPONEN JM, 1990, BIOCHEM J, V269, P223, DOI 10.1042/bj2690223; LAZAROW PB, 1978, J BIOL CHEM, V253, P1522; LOPESCARDOZO M, 1978, EUR J BIOCHEM, V83, P629, DOI 10.1111/j.1432-1033.1978.tb12132.x; MOORE KH, 1982, J CLIN INVEST, V69, P377, DOI 10.1172/JCI110461; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; POLLITT RJ, 1987, J INHERIT METAB DIS, V10, P266, DOI 10.1007/BF01811422; POLLTHE BT, 1988, J INHERIT METAB DIS, V11, P183, DOI 10.1007/BF01804230; RIUDOR E, 1986, J INHERIT METAB DIS, V9, P297, DOI 10.1007/BF01799734; SCHULZ H, 1987, TRENDS BIOCHEM SCI, V12, P403, DOI 10.1016/0968-0004(87)90196-4; SMELAND TE, 1989, BIOCHEM BIOPH RES CO, V160, P988, DOI 10.1016/S0006-291X(89)80098-1; STANLEY KK, 1975, BIOCHEM J, V150, P77, DOI 10.1042/bj1500077; TSERNG KY, 1991, J BIOL CHEM, V266, P11614; TSERNG KY, 1991, J BIOL CHEM, V266, P2924; TSERNG KY, 1991, BIOCHEMISTRY-US, V30, P2508, DOI 10.1021/bi00223a030; TSERNG KY, 1991, METABOLISM, V40, P676, DOI 10.1016/0026-0495(91)90083-9; WATMOUGH NJ, 1989, BIOCHEM J, V262, P261, DOI 10.1042/bj2620261	35	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					119	125						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730577				2022-12-25	WOS:A1992GY43900024
J	OTT, RJ; HUI, AC; GIACOMINI, KM				OTT, RJ; HUI, AC; GIACOMINI, KM			INHIBITION OF N-LINKED GLYCOSYLATION AFFECTS ORGANIC CATION-TRANSPORT ACROSS THE BRUSH-BORDER MEMBRANE OF OPOSSUM KIDNEY (OK) CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER-MEDIATED TRANSPORT; RABBIT PROXIMAL TUBULE; BASOLATERAL MEMBRANE; TETRAETHYLAMMONIUM TRANSPORT; ANTIPORT SYSTEM; LINE LLC-PK1; RENAL BBMV; VESICLES; OLIGOSACCHARIDES; SECRETION	Many organic cations are transported across the apical membrane of the proximal tubule by specific saturable mechanisms. The goal of this study was to determine if the transporter for tetraethylammonium (TEA) in the brush border membrane of an established opossum kidney (OK) cell line is glycosylated and to elucidate the function of this glycosylation. The uptake of TEA was determined in OK cell monolayers treated with tunicamycin (TM), a compound that prevents synthesis of the core oligosaccharide precursor molecules. TM exposure significantly decreased the incorporation of [H-3]mannose in OK cell proteins and significantly reduced TEA uptake in a time and a concentration dependent manner. No effect of TM exposure on cellular protein synthesis, DNA content, cell viability or on [H-3]proline uptake was observed. The transport of TEA in control cells was characterized by a K(m) of 26.9 +/- 16.4-mu-M and a V(max) of 378 +/- 39 pmol/mg of protein/min. TM treatment (1-mu-g/ml for 21 h) significantly increased the K(m) by over 4-fold to 111.5 +/- 18.4-mu-M while not affecting the V(max). The apparent K(I) values of other organic cations known to interact with this transport system were also significantly increased by TM exposure. Estimated K(I) values of N1-methylnicotinamide, cimetidine, and mepiperphenidol increased by 6-fold, 4-fold, and 2-fold, respectively, after exposure of OK cells to TM. An increased K(I) for protons was also observed. Additional inhibitors of the N-linked glycosylation pathway, castanospermine, deoxynojirimycin, and deoxymannojirimycin significantly decreased TEA transport, whereas swainsonine had no effect. Our results suggest that the organic cation transporter is glycosylated. The N-linked oligosaccharide side chain appears to be of the hybrid type, and it either directly or indirectly affects the binding site of the transporter for both organic cations and protons. This is the first report describing the importance of glycosylation in the function of the organic cation transporter in the apical membrane of OK cells.	UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	OTT, RJ (corresponding author), UNIV CALIF SAN FRANCISCO,SCH PHARM,S-926,BOX 0446,SAN FRANCISCO,CA 94143, USA.		Giacomini, Kathleen/AEF-2452-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036780] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36780] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKAKI RF, 1987, J BIOL CHEM, V262, P11886; BESSEGHIR K, 1990, J PHARMACOL EXP THER, V253, P452; BESSEGHIR K, 1990, J PHARMACOL EXP THER, V253, P444; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DANTZLER WH, 1989, AM J PHYSIOL, V256, pF290, DOI 10.1152/ajprenal.1989.256.2.F290; DEAS J, 1989, BRAIN RES, V483, P84, DOI 10.1016/0006-8993(89)90037-1; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; ELBEIN AD, 1987, METHOD ENZYMOL, V138, P661; FAUTH C, 1988, AM J PHYSIOL, V254, pF351, DOI 10.1152/ajprenal.1988.254.3.F351; FOUDA AK, 1990, J PHARMACOL EXP THER, V252, P286; GSTRAUNTHALER GJA, 1988, RENAL PHYSIOL BIOCH, V11, P1; HOLOHAN PD, 1981, J PHARMACOL EXP THER, V216, P294; HOLOHAN PD, 1980, J PHARMACOL EXP THER, V215, P191; HORI R, 1989, J BIOL CHEM, V264, P12232; HORI R, 1987, J PHARMACOL EXP THER, V241, P1010; HSYU PH, 1988, AM J PHYSIOL, V254, pF56, DOI 10.1152/ajprenal.1988.254.1.F56; HSYU PH, 1987, AM J PHYSIOL, V252, pF1065, DOI 10.1152/ajprenal.1987.252.6.F1065; HSYU PH, 1987, J BIOL CHEM, V262, P3964; INUI K, 1985, BIOCHEM J, V227, P199, DOI 10.1042/bj2270199; KABAKOFF B, 1990, J CELL BIOL, V111, P391, DOI 10.1083/jcb.111.2.391; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; MAEGAWA H, 1988, J BIOL CHEM, V263, P11150; MATTER K, 1989, J BIOL CHEM, V264, P13131; MCKINNEY TD, 1990, J AM SOC NEPHROL, V1, P902; MCKINNEY TD, 1988, J CELL PHYSIOL, V137, P513, DOI 10.1002/jcp.1041370317; MIYAMOTO Y, 1989, AM J PHYSIOL, V256, pF540, DOI 10.1152/ajprenal.1989.256.4.F540; MONTROSERAFIZADEH C, 1989, AM J PHYSIOL, V257, pF243, DOI 10.1152/ajprenal.1989.257.2.F243; OTT RJ, 1991, AM J PHYSIOL, V61, pF443; RAFIZADEH C, 1987, J PHARMACOL EXP THER, V240, P308; RENNICK BR, 1981, AM J PHYSIOL, V240, pF83, DOI 10.1152/ajprenal.1981.240.2.F83; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SAITO Y, 1989, J BIOCHEM, V106, P1035, DOI 10.1093/oxfordjournals.jbchem.a122960; SCHALI C, 1983, AM J PHYSIOL, V245, pF238, DOI 10.1152/ajprenal.1983.245.2.F238; SHA X, 1989, MOL ENDOCRINOL, V3, P1090, DOI 10.1210/mend-3-7-1090; SMITH MM, 1986, J BIOL CHEM, V261, P4825; SOKOL PP, 1986, J BIOL CHEM, V261, P3282; SPIRO RC, 1989, J BIOL CHEM, V264, P1779; TAKANO M, 1984, BIOCHIM BIOPHYS ACTA, V773, P113, DOI 10.1016/0005-2736(84)90556-X; VANDENBOSCH L, 1989, BIOCHIM BIOPHYS ACTA, V979, P91, DOI 10.1016/0005-2736(89)90527-0; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040; WRIGHT SH, 1988, J BIOL CHEM, V263, P19494; WUARIN F, 1989, BIOCHIM BIOPHYS ACTA, V981, P185, DOI 10.1016/0005-2736(89)90027-8; YUAN G, 1991, J BIOL CHEM, V266, P8978; YUSUFI ANK, 1988, J BIOL CHEM, V263, P13683; ZAMOFING D, 1989, AM J PHYSIOL, V256, pC958, DOI 10.1152/ajpcell.1989.256.5.C958; ZAMOFING D, 1988, J MEMBRANE BIOL, V104, P69, DOI 10.1007/BF01871903	47	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					133	139						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730580				2022-12-25	WOS:A1992GY43900026
J	WOJTCZAK, A; LUFT, J; CODY, V				WOJTCZAK, A; LUFT, J; CODY, V			MECHANISM OF MOLECULAR RECOGNITION - STRUCTURAL ASPECTS OF 3,3'-DIIODO-L-THYRONINE BINDING TO HUMAN SERUM TRANSTHYRETIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; MACROMOLECULAR STRUCTURES; PREALBUMIN; REFINEMENT	The three-dimensional structure of the thyroid hormone metabolite, 3,3'-diiodo-L-thyronine (3,3'-T2), complex with human serum transthyretin (TTR) has been refined to R = 18.5% for 8-2 A resolution data. This is the first detailed description of a thyroid hormone metabolite binding to a thyroid transport protein. The four TTR monomeric subunits form a tetramer in the same manner as the native transthyretin reported earlier (Blake, C. C. F., Geisow, M. J., Oatley, S. J., Rerat, B., and Rerat, C. (1978) J. Mol. Biol. 121, 339356). The two hormone binding sites of the TTR tetramer are occupied by 3,3'-T2. A statistical disorder model for the ligand was applied with a 50% occupancy to account for the discrepancy between the crystallographic 2-fold symmetry of the binding sites and the lack of such symmetry for 3,3'-T2. The bound metabolite has an overall transoid conformation with the etherbridge intermediate between skewed and perpendicular. The hormone metabolite is bound 3.5 angstrom deeper and with a different orientation in the channel than observed for thyroxine (T4), thereby revealing the presence of another set of halogen binding sites close to the center of the tetramer. When compared with the binding of T4, these data show that the 3-iodine of 3,3'-T2 occupies the same site as the 3'-iodine of T4, and the metabolite 3'-iodine occupies the water site observed in the T4 complex. The binding affinity of 3,3'-T2, which is 100-fold lower than that of T4, reflects the lack of the second pair of iodine atoms interacting in the channel. In order to understand the tighter binding of T4 observed in the Ala-109 --> Thr mutant, modeling studies were carried out that indicate that this modification could shorten the contacts between thyroid hormone iodines and residues 108-110 of the binding site.	MED FDN BUFFALO INC,73 HIGH ST,BUFFALO,NY 14203				Wojtczak, Andrzej/H-8130-2014	Wojtczak, Andrzej/0000-0001-8801-7728	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041009] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41009] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENSON MD, 1991, J MED GENET, V28, P73, DOI 10.1136/jmg.28.2.73; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BUSH BL, 1988, PS300 FRODO MOL GRAP; CAVALIERI RR, 1981, PHARMACOL REV, V33, P55; CODY V, 1988, ANN ENDOCRINOL-PARIS, V49, P188; Cody V, 1980, Endocr Rev, V1, P140; CODY V, 1984, J MOL STRUCT, V112, P189, DOI 10.1016/0022-2860(84)85061-9; CODY V, 1991, Journal of Cellular Biochemistry Supplement, V15, P21; DAVIS PJ, 1987, BIOCHEM PHARMACOL, V36, P3635, DOI 10.1016/0006-2952(87)90013-X; FERGUSON RN, 1975, BIOCHEMISTRY-US, V14, P282, DOI 10.1021/bi00673a014; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; Jorgensen E.C., 1978, Hormonal Proteins and Peptides, V6, P107; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KOHRLE J, 1989, ENDOCRINOLOGY, V125, P532, DOI 10.1210/endo-125-1-532; LARSEN PR, 1981, ENDOCR REV, V2, P87, DOI 10.1210/edrv-2-1-87; MOSES AC, 1990, CLIN RES, V38, pA476; MOSES AC, 1982, NEW ENGL J MED, V307, P824; ROSEN HN, 1991, 10 INT THYR C FEB 3, P231; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; TRITSCH GL, 1972, J MED, V3, P129	22	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					353	357						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730601				2022-12-25	WOS:A1992GY43900058
J	RUBEN, L; HUTCHINSON, A; MOEHLMAN, J				RUBEN, L; HUTCHINSON, A; MOEHLMAN, J			CALCIUM HOMEOSTASIS IN TRYPANOSOMA-BRUCEI - IDENTIFICATION OF A PH-SENSITIVE NONMITOCHONDRIAL CALCIUM POOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; BLOOD-STREAM FORMS; CA-2+ TRANSPORT; SARCOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; MEMBRANE-VESICLES; PROTEIN; ATPASE; H+; RHODESIENSE	The objective of this study was to characterize mechanisms which maintain intracellular calcium homeostasis in bloodstream forms of Trypanosoma brucei. The identification of homeostatic pathways is required to understand signal transduction in these organisms. The fluorescent probes Fura-2, 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein, and bisoxonol were used to measure intracellular calcium ([Ca2+]i), intracellular pH (pH(i)), and membrane potential, respectively. Homeostatic pathways maintained [Ca2+]i at 98 +/- 12 nM in the presence of 1.8 mM extracellular calcium despite a steady leak of calcium into the cell. The addition of 2.7-mu-M nigericin acidified the cytosol, depolarized the plasma membrane, and induced an approximate 3-fold increase in [Ca2+]i. The rise in [Ca2+]i could not be induced with valinomycin or gramicidin D under conditions where membrane depolarization occurred. By contrast, the proton ionophore, carbonyl cyanide p-trifluoromethoxyphenylhydrazone, elevated [Ca2+]i in a manner that was not additive with nigericin. Changes in pH(i) appeared to regulate [Ca2+]i since: 1) stepwise addition of K+ to nigericin-treated cells generated an incremental increase in pH(i) and concomitant decrease in [Ca]i; 2) addition of serum to nigericin-treated cells allowed simultaneous recovery of pH(i) and [Ca2+]i; and 3) addition of NH4Cl to untreated cells resulted in a biphasic change in pH(i) with corresponding biphasic change in [Ca2+]i. The rise in [Ca2+]i was derived from an intracellular pool which was not dependent on functional cytochrome oxidase, mitochondrial alternative oxidase, or the F0F1-ATPase. These data demonstrate that large quantities of calcium are reversibly stored in a non-mitochondrial pH-sensitive intracellular pool in T. brucei. We conclude that changes in pH(i) can serve to trigger calcium signals in these organisms.			RUBEN, L (corresponding author), SO METHODIST UNIV,DEPT BIOL SCI,DALLAS,TX 75275, USA.				NIAID NIH HHS [AI24627] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024627] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BABABUNMI E, 1982, ANN NY ACAD SCI, V402, P349; BAUM BJ, 1988, BIOCHEM J, V254, P649, DOI 10.1042/bj2540649; BENAIM G, 1990, BIOCHIM BIOPHYS ACTA, V1027, P79, DOI 10.1016/0005-2736(90)90051-O; BIENEN EJ, 1991, MOL BIOCHEM PARASIT, V45, P185, DOI 10.1016/0166-6851(91)90085-K; Carafoli E, 1978, Ann N Y Acad Sci, V307, P269, DOI 10.1111/j.1749-6632.1978.tb41957.x; CLARKSON AB, 1982, SCIENCE, V216, P1321, DOI 10.1126/science.6805075; CLARKSON AB, 1989, J BIOL CHEM, V264, P17770; DHONDT J, 1979, NATURE, V282, P613, DOI 10.1038/282613a0; DIXON DA, 1989, J MEMBRANE BIOL, V112, P169, DOI 10.1007/BF01871278; DOCAMPO R, 1989, J BIOL CHEM, V264, P108; DOCAMPO R, 1989, ARCH BIOCHEM BIOPHYS, V272, P122, DOI 10.1016/0003-9861(89)90202-6; GARCIASOTO J, 1987, DEV BIOL, V120, P112, DOI 10.1016/0012-1606(87)90109-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KEITH K, 1990, MOL BIOCHEM PARASIT, V43, P107, DOI 10.1016/0166-6851(90)90135-9; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LEE MG, 1990, NUCLEIC ACIDS RES, V18, P4252, DOI 10.1093/nar/18.14.4252; MCCORMACK JG, 1986, TRENDS BIOCHEM SCI, V11, P258, DOI 10.1016/0968-0004(86)90190-8; MCLAUGHLIN J, 1985, MOL BIOCHEM PARASIT, V15, P189, DOI 10.1016/0166-6851(85)90119-7; MICHELANGELI F, 1990, BIOCHEM J, V267, P423, DOI 10.1042/bj2670423; MINTA A, 1989, J BIOL CHEM, V264, P8171; MORENOSANCHEZ R, 1988, BIOCHEM J, V256, P403, DOI 10.1042/bj2560403; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1990, INTRACELLULAR CALCIU, P349; NOLAN DP, 1990, BIOCHEM SOC T, V18, P735, DOI 10.1042/bst0180735; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PHILOSOPH H, 1989, J BIOL CHEM, V264, P10420; RIGONI F, 1987, EUR J BIOCHEM, V169, P417, DOI 10.1111/j.1432-1033.1987.tb13628.x; ROSEN BP, 1987, BIOCHIM BIOPHYS ACTA, V906, P101, DOI 10.1016/0304-4157(87)90007-4; RUBEN L, 1991, MOL BIOCHEM PARASIT, V46, P123, DOI 10.1016/0166-6851(91)90206-L; RUBEN L, 1990, EXP PARASITOL, V70, P144, DOI 10.1016/0014-4894(90)90095-T; RUBEN L, 1987, J PROTOZOOL, V34, P367, DOI 10.1111/j.1550-7408.1987.tb03193.x; RUBEN L, 1990, CALCIUM INTRACELLULA, P317; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SCHUMAKER KS, 1986, J BIOL CHEM, V1261, P178; SCHUMAKER KS, 1986, J BIOL CHEM, V261, P178; SHOSHAN V, 1981, P NATL ACAD SCI-BIOL, V78, P4828, DOI 10.1073/pnas.78.8.4828; SISKIND MS, 1989, AM J PHYSIOL, V256, pC234, DOI 10.1152/ajpcell.1989.256.2.C234; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; THISSEN JA, 1991, EXP PARASITOL, V72, P243, DOI 10.1016/0014-4894(91)90143-K; VERCESI AE, 1990, MOL BIOCHEM PARASIT, V42, P119, DOI 10.1016/0166-6851(90)90119-7; WILLIAMSON J, 1981, J PROTOZOOL, V28, P460, DOI 10.1111/j.1550-7408.1981.tb05320.x	43	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24351	24358						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722203				2022-12-25	WOS:A1991GW84500021
J	HIRABAYASHI, J; KASAI, K				HIRABAYASHI, J; KASAI, K			EFFECT OF AMINO-ACID SUBSTITUTION BY SITE-DIRECTED MUTAGENESIS ON THE CARBOHYDRATE RECOGNITION AND STABILITY OF HUMAN 14-KDA BETA-GALACTOSIDE-BINDING LECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLACENTA; SEQUENCE; PROTEIN; CDNA; PURIFICATION; CLONING	The roles of selected amino acid residues of human 14-kDa beta-galactoside-binding lectin were studied by site-directed mutagenesis. Ten mutant lectin proteins were produced, in each of which one of the residues regarded as possibly related to the stability of the lectin (6 cysteine residues) or one of those highly conserved in the vertebrate beta-galactoside-binding lectin family (Asn46, Trp68, Glu71, and Arg73), was substituted. All the mutant lectins in which one of the cysteine residues had been substituted with serine (C2S, C16S, C42S, C60S, C88S, and C130S) proved to have sugar binding ability comparable with that of the wild-type lectin. In addition, one of the mutants in which Cys2 was substituted (C2S) was found to have become considerably more stable under non-reducing conditions. It retained asialofetuin binding activity for over a week in the absence of beta-mercaptoethanol, while the wild-type lectin lost it within a day. This suggests that oxidation of Cys2 could be a key process in the inactivation of human 14-kDa lectin. Substitution of highly conservative Trp68 to tyrosine (W68Y) slightly reduced lactose binding ability, but the mutant was still adsorbed strongly on asialofetuin-agarose. Other mutant lectins in which conservative hydrophilic amino acids were substituted (N46D, E71Q, and R73H) failed to bind to the asialofetuin agarose, with no sign of retardation. Thus, conservative hydrophilic residues proved to be more important in carbohydrate recognition than the cysteine and tryptophan residues, contrary to the widely accepted concept that these latter residues are essential.			HIRABAYASHI, J (corresponding author), TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAGAMIKO,KANAGAWA 19901,JAPAN.							ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ABBOTT WM, 1991, J BIOL CHEM, V266, P5552; ARBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; GITT M, 1991, BIOCHEMISTRY-US, V30, P823; Hirabayashi J, 1990, J Mol Recognit, V3, P204, DOI 10.1002/jmr.300030506; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P987, DOI 10.1093/oxfordjournals.jbchem.a121968; HIRABAYASHI J, 1989, FEBS LETT, V250, P161, DOI 10.1016/0014-5793(89)80711-2; HIRABAYASHI J, 1988, J BIOCHEM-TOKYO, V104, P1; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; JIA SH, 1988, J BIOL CHEM, V263, P6009; Kasai K., 1990, ADV LECTIN RES, V3, P10; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVI G, 1981, J BIOL CHEM, V256, P5735; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NOWAK TP, 1976, BIOCHEM BIOPH RES CO, V68, P650, DOI 10.1016/0006-291X(76)91195-5; ODA Y, 1983, BIOCHIM BIOPHYS ACTA, V761, P237, DOI 10.1016/0304-4165(83)90071-5; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SOMA GI, 1987, BIOCHEM BIOPH RES CO, V148, P629, DOI 10.1016/0006-291X(87)90923-5; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	30	175	188	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23648	23653						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721052				2022-12-25	WOS:A1991GV31900023
J	DOLAN, KM; OLIVER, DB				DOLAN, KM; OLIVER, DB			CHARACTERIZATION OF ESCHERICHIA-COLI SECA PROTEIN-BINDING TO A SITE ON ITS MESSENGER-RNA INVOLVED IN AUTOREGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATION ATPASE; PRECURSOR PROTEINS; PLASMA-MEMBRANE; EXPORT; INVITRO; SEQUENCE; LEADER; RECOGNITION; COMPONENT; VESICLES	In order to understand further the autogenous regulation of Escherichia coli secA translation, we have set up a purified system to study the binding of SecA protein to portions of its mRNA. Specific SecA protein-RNA binding was demonstrated by UV cross-linking, filter binding, and gel shift assays. Use of the filter binding assay allowed optimization of binding, which was influenced by Mg2+ and ATP concentrations, and a measurement of the affinity of this interaction. A nested series of RNAs lacking either 5' or 3' portions of geneX-secA sequences were used to localize the SecA protein binding site to sequences around the geneX-secA intergenic region. These studies imply that SecA protein directly regulates its own translation by a specific RNA binding activity that presumably blocks translational initiation.	SUNY STONY BROOK, DEPT MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Cabelli RJ, 1991, THESIS STATE U NEW Y; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KUMAMOTO CA, 1989, J BIOL CHEM, V264, P2242; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Maniatis T., 1982, MOL CLONING; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; NOMURA M, 1986, S SOC GENERAL MICROB, P199; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; ROMANIUK PJ, 1985, NUCLEIC ACIDS RES, V13, P5369, DOI 10.1093/nar/13.14.5369; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; TOKUDA H, 1990, EUR J BIOCHEM, V192, P583, DOI 10.1111/j.1432-1033.1990.tb19264.x; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978	31	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23329	23333						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1720780				2022-12-25	WOS:A1991GT48300083
J	GARCIA, R; PARIKH, NU; SAYA, H; GALLICK, GE				GARCIA, R; PARIKH, NU; SAYA, H; GALLICK, GE			EFFECT OF HERBIMYCIN-A ON GROWTH AND PP60C-SRC ACTIVITY IN HUMAN COLON-TUMOR CELL-LINES	ONCOGENE			English	Article							TYROSINE PROTEIN-KINASES; ROUS-SARCOMA VIRUS; SRC GENE-PRODUCT; RAT-KIDNEY CELLS; C-SRC; MITOGENIC RESPONSIVENESS; SIGNAL TRANSDUCTION; MUCOSAL CELLS; PHOSPHORYLATION; CARCINOMA	The effect of herbimycin A, an ansamycin antibiotic which inhibits cellular transformation by retroviral tyrosine kinases, on the monolayer growth of seven colon tumor cell lines and one cell line established from normal colonic mucosa, CCL239, was examined. Each colon tumor cell line tested showed dose-dependent growth inhibition in response to herbimycin A. A 125 ng ml-1 dose of the antibiotic caused > 40% growth inhibition in all colon tumor cell lines after two cell doublings. In contrast, at similar herbimycin A concentrations only 12% inhibition was observed in 'normal' CCL239 cells. No major morphologic changes were observed at the light microscopic level in any of the tumor cell lines or CCL239 cells in response to treatment with herbimycin A. Studies using the HT29 colon adenocarcinoma cell line showed dose-dependent inactivation of pp60c-src by herbimycin A, resulting in decreased autophosphorylation, enolase phosphorylation and steady-state levels, which correlated with cellular growth inhibition. Herbimycin A-induced reductions in pp60c-src kinase activity preceded changes in pp60c-src steady-state levels. Growth and pp60c-src inhibition were reversible following removal of herbimycin A from cell culture media. Our results suggest that regulation of pp60c-src tyrosine kinase activity may be important in growth control of colon tumor cells.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEUROONCOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Saya, Hideyuki/J-4325-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM013005] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13005-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SM, 1990, ONCOGENE, V5, P317; BARNEKOW A, 1987, CANCER RES, V47, P235; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DESEAU V, 1987, J CELL BIOCHEM, V35, P113, DOI 10.1002/jcb.240350205; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FOSS FM, 1989, ONCOGENE RES, V5, P13; GALLICK GE, 1984, VIROLOGY, V139, P366, DOI 10.1016/0042-6822(84)90382-9; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HONMA Y, 1989, CANCER RES, V49, P331; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1984, ADV CYCLIC NUCL PROT, V17, P443; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOH SWM, 1991, BIOCHEM BIOPH RES CO, V174, P452, DOI 10.1016/0006-291X(91)91437-H; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; LUTTRELL LM, 1989, ONCOGENE, V4, P317; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MAXWELL SA, 1987, CANCER RES, V47, P1731; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MURAKAMI Y, 1988, CANCER RES, V48, P1587; MUSER J, 1989, ONCOGENE, V4, P1433; OMURA S, 1979, TETRAHEDRON LETT, P4323; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PREIS PN, 1988, CANCER RES, V48, P6530; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; ROSEN N, 1986, J BIOL CHEM, V261, P3754; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAYA H, 1989, J CELL BIOCH UCL B S, V13, P111; SEFTON BM, 1986, CURR TOP MICROBIOL, V123, P39; SEFTON BM, 1984, ADV CYCLIC NUCL PROT, V18, P195; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUZUKAKETSUCHIYA K, 1989, J ANTIBIOT, V42, P1831, DOI 10.7164/antibiotics.42.1831; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UEHARA Y, 1988, J ANTIBIOT, V41, P831, DOI 10.7164/antibiotics.41.831; UMEZAWA K, 1987, EXPERIENTIA, V43, P614, DOI 10.1007/BF02126351; WASILENKO WJ, 1987, J CELL PHYSIOL, V131, P450, DOI 10.1002/jcp.1041310318; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU KT, 1985, J BIOL CHEM, V260, P5838	64	65	67	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					1983	1989						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719464				2022-12-25	WOS:A1991GX11900007
J	CHENG, HC; LITWIN, CME; HWANG, DM; WANG, JH				CHENG, HC; LITWIN, CME; HWANG, DM; WANG, JH			STRUCTURAL BASIS OF SPECIFIC AND EFFICIENT PHOSPHORYLATION OF PEPTIDES DERIVED FROM P34CDC2 BY A PP60SRC-RELATED PROTEIN TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; CELL-CYCLE; M-PHASE; SEQUENCE; MECHANISM; MEMBRANES	Cys-cdc2(8-20), a synthetic peptide derived from p34cdc2, was previously reported to be a specific and efficient substrate of a pp60c-src-related tyrosine kinase isolated from bovine spleen (the spleen tyrosine kinase) (Litwin, C.M.E., Cheng, H.-C., and Wang, J.H. (1991) J. Biol. Chem. 266, 2557-2566). The longer peptide, cdc2(1-24), was found to be phosphorylated by the kinase with similar efficiency, and Tyr15 was the only amino acid residue phosphorylated. This indicated that the amino acid sequence of cdc2(8-20) peptide, EKI-GEGTYGVVYK, contained the structural features important for protein tyrosine kinase substrate activity. A stepwise procedure using synthetic peptides was employed to investigate such structural features. First, a computer search of protein sequences homologous to cdc2(8-20) uncovered five protein kinases containing homologous sequence with tyrosine at a position corresponding to Tyr15 of p34cdc2. Second, a peptide derived from ribosomal S6 protein kinase (rsk(436-456)) was synthesized. The rsk(436-456) peptide contained a segment, ETIGVGSYSVCKR, which is highly homologous to that of cdc2(8-20). It was found to be a very poor substrate of the spleen tyrosine kinase. Third, peptide analogs of cdc2(6-20) with single substitutions of amino acid residues Lys9, Glu12, Thr14, Gly16, Val18, and Tyr19 by amino acid residues at corresponding positions of rsk were synthesized and tested as spleen tyrosine kinase substrates. Only Glu12 and Thr14 substituted peptide analogs showed decreased substrate activities. (The substrate activity of a peptide is the ability of the peptide to serve as the substrate of the spleen tyrosine kinase. It was determined either by the kinetic parameters (K(m) and V(max)) of phosphorylation of the peptide or by the initial phosphorylation rate of the peptide by the spleen tyrosine kinase.) An analog with double substitution at Glu12 and Thr14 was found to be almost as poor a substrate as the rsk peptide. In addition, peptide analogs with Tyr15 substituted by Phe or D-Tyr had poor substrate activities as well as weak inhibitory activities. Thus, Glu12, Thr14, and Tyr15 residues of p34cdc2 contained structural components essential for the efficient phosphorylation of the peptides derived from p34cdc2 by the pp60c-src-related spleen tyrosine kinase.			CHENG, HC (corresponding author), UNIV CALGARY,FAC MED,DEPT MED BIOCHEM,MRC,SIGNAL TRANSDUCT GRP,CALGARY T2N 4N1,ALBERTA,CANADA.			Cheng, Heung-Chin/0000-0002-4965-7148				ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BALDWIN GS, 1983, NATURE, V301, P435, DOI 10.1038/301435a0; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRAUN S, 1984, J BIOL CHEM, V259, P2051; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; DONELLADEANA A, 1990, EUR J BIOCHEM, V194, P773, DOI 10.1111/j.1432-1033.1990.tb19468.x; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOUSE C, 1984, EUR J BIOCHEM, V140, P363, DOI 10.1111/j.1432-1033.1984.tb08109.x; HUNTER T, 1982, J BIOL CHEM, V257, P4843; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1986, ENZYMES, V17, P192; KASUGA M, 1983, J BIOL CHEM, V258, P973; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KONG SK, 1987, J BIOL CHEM, V262, P2597; KREK W, 1990, J CELL BIOL, V111, P220; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PIKE LJ, 1982, P NATL ACAD SCI-BIOL, V79, P1443, DOI 10.1073/pnas.79.5.1443; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WONG TW, 1983, J BIOL CHEM, V258, P1022; YAMASHIRO D, 1973, J AM CHEM SOC, V95, P1310, DOI 10.1021/ja00785a049; YUAN CJ, 1990, J BIOL CHEM, V265, P16205	27	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17919	17925						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1717444				2022-12-25	WOS:A1991GG55300034
J	FUKAYAMA, M; KANNO, T; BRODY, SL; KIRBY, M; CRYSTAL, RG				FUKAYAMA, M; KANNO, T; BRODY, SL; KIRBY, M; CRYSTAL, RG			RESPIRATORY-TRACT GENE-TRANSFER - TRANSPLANTATION OF GENETICALLY MODIFIED LYMPHOCYTES-T DIRECTLY TO THE RESPIRATORY EPITHELIAL SURFACE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; RETROVIRAL EXPRESSION; CELLS; THERAPY; GROWTH; MOUSE; LINE; TUMORIGENICITY; TRANSDUCTION; MIGRATION	To evaluate the strategy for potentially treating respiratory disorders with genetically modified T-lymphocytes, the interleukin-2 (IL-2)-dependent murine T-cell line, CTLL2, was genetically altered with the Escherichia coli beta-galactosidase (beta-gal) gene (lacZ) in vitro with a retroviral vector and the modified T-cells were transplanted directly to the respiratory epithelial surface of syngeneic C57Bl/6 mice. Southern and Northern analyses confirmed that the neomycin-selected modified T-cells contained and expressed the lacZ gene. The fate of the modified T-cells (CTLL2/lacZ) was followed by flow cytometry with T-cell surface marker Thy1.2 and fluorescent beta-gal analysis. One day after transplantation (7.5 x 10(5) CTLL2/lacZ T-cells/g of body weight), 95 +/- 3% of the Thy1.2+ T-cells recovered from respiratory epithelial lining fluid (ELF) were beta-gal+. Importantly, the modified T-cells remained in the lung for some time; at 3 days, Thy1.2+ beta-gal+ T-cells represented 63 +/- 12% of ELF Thy1.2+ T-cells and 59 +/- 6% of Thy1.2+ T-cells recovered from the whole lung. At 7 days, 33 +/- 8% of the Thy 1.2+ cells in ELF and 75 +/- 6% of the Thy1.2+ cells in whole lung were Thy1.2+ beta-gal+. In contrast, the proportion of the Thy1.2+ beta-gal+ T-cells in the spleen, the major extrapulmonary lymphatic organ, never rose above 3 +/- 1% of the total Thy1.2+ cells. The number of Thy1.2+ beta-gal+ T-cells in the lung could be modified by the systemic administration of IL-2, with whole lung Thy1.2+ beta-gal+ T-cells increasing 4.6-fold 3 days after transplantation, compared with non-IL-2-treated animals. These studies suggest that direct transplantation of genetically modified T-cells into the lung is feasible and represents a viable strategy for lung-specific gene transfer.	NHLBI, PULM BRANCH, BLDG 10, RM 6D03, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								Anderson W French, 1990, Hum Gene Ther, V1, P331, DOI 10.1089/hum.1990.1.3-331; ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; AUGUSTIN A, 1989, NATURE, V340, P239, DOI 10.1038/340239a0; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BLANKENSTEIN T, 1990, EUR J IMMUNOL, V20, P935, DOI 10.1002/eji.1830200433; CULVER KW, 1990, UCLA SYM BI, V135, P129; CULVER KW, 1991, TRANSPLANT P, V23, P170; CULVER KW, 1990, HUM GENE THER, V1, P399, DOI 10.1089/hum.1990.1.4-399; DANNENBERG AM, 1981, METHODS STUDYING MON, P375; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; GILLIS S, 1978, J IMMUNOL, V120, P2027; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; HAMBLIN AS, 1987, LYMPHOCYTES PRACTICA, P209; KANNO T, 1991, American Review of Respiratory Disease, V143, pA325; KANTOFF PW, 1986, P NATL ACAD SCI USA, V83, P6563, DOI 10.1073/pnas.83.17.6563; KASID A, 1990, P NATL ACAD SCI USA, V87, P473, DOI 10.1073/pnas.87.1.473; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER AD, 1990, BLOOD, V76, P271; NISHIHARA K, 1988, CANCER RES, V48, P4730; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; PABST R, 1989, IMMUNOL REV, V108, P83, DOI 10.1111/j.1600-065X.1989.tb00014.x; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROTMAN B, 1961, P NATL ACAD SCI USA, V47, P1981, DOI 10.1073/pnas.47.12.1981; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SPIESS PJ, 1987, JNCI-J NATL CANCER I, V79, P1067; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; STRAIR RK, 1990, BLOOD, V76, P1201; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WILSON JM, 1990, SCIENCE, V248, P1413, DOI 10.1126/science.1972597; YAMADA G, 1987, EMBO J, V6, P2705, DOI 10.1002/j.1460-2075.1987.tb02563.x	36	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18339	18344						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1717448				2022-12-25	WOS:A1991GG55300094
J	UCKUN, FM; SCHIEVEN, GL; DIBIRDIK, I; CHANDANLANGLIE, M; TUELAHLGREN, L; LEDBETTER, JA				UCKUN, FM; SCHIEVEN, GL; DIBIRDIK, I; CHANDANLANGLIE, M; TUELAHLGREN, L; LEDBETTER, JA			STIMULATION OF PROTEIN TYROSINE PHOSPHORYLATION, PHOSPHOINOSITIDE TURNOVER, AND MULTIPLE PREVIOUSLY UNIDENTIFIED SERINE THREONINE-SPECIFIC PROTEIN-KINASES BY THE PAN-B-CELL RECEPTOR CD40/BP50 AT DISCRETE DEVELOPMENTAL STAGES OF HUMAN B-CELL ONTOGENY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; LIGAND-INDUCED DESENSITIZATION; MEDIATED CA-2+ MOBILIZATION; PHOSPHOLIPASE-C-GAMMA; LYMPHOCYTE-B; MONOCLONAL-ANTIBODY; SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; PC12 CELLS; SURFACE MOLECULES	CD40/Bp50 B-cell receptor has been implicated as having an important function for the regulation of human B-cell growth and maturation as well as antigen-driven selection of tonsillar B-cells in germinal centers. The purpose of the present study was to examine the biochemical events triggered by the engagement of the CD40 receptor in human B-lineage lymphoid cells corresponding to discrete developmental stages of human B-cell ontogeny. The engagement of the CD40 receptor on pro-B-, pre-pre-B-, pre-B-, or activated mature B-cells but not on resting mature B-cells with the agonistic anti-CD40 monoclonal antibody G28-5 resulted in enhanced tyrosine phosphorylation of four distinct phosphoproteins with molecular masses of 67, 72, 96, and 113 kDa and induced a rapid increase in the production of inositol 1,4,5-trisphosphate. Further, we have identified five electrophoretically distinct renaturable CD40-regulated serine/threonine-specific protein kinases (PK120, PK93, PK76, PK55, and PK48) that showed markedly increased in vitro activity after CD40 stimulation. Protein kinase C inhibitor 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H7) abrogated the stimulation of the in vitro activity of PK120, PK93, PK55, and PK48 and attenuated the stimulation of the in vitro activity of PK76 in response to the engagement of the CD40 receptor but did not influence the enhanced tyrosine phosphorylation of cellular substrates after CD40 stimulation. Notably, genistein and herbimycin A, two potent inhibitors of tyrosine-specific protein kinases, not only abrogated the CD40-induced enhanced tyrosine phosphorylation on the 67-, 72-, 96-, and 113-kDa substrates, but they also inhibited the CD40-induced stimulation of phosphoinositide turnover as well as the CD40-induced increase of the in vitro activity of renaturable serine/threonine-specific protein kinases. Taken together, these results demonstrate the following: (a) The CD40 receptor is active in signal transduction at multiple stages of B-cell ontogeny including the pro-B-, pre-pre-B-, and pre-B-cell stages before surface immunoglobulin expression as well as the later stages of B-cell differentiation in germinal centers; (b) The transmembrane signal triggered by engagement of the CD40 receptor is intimately linked to a functional protein tyrosine kinase/protein tyrosine phosphatase regulatory pathway, activates phospholipase C in immature B-cell precursors, early B-cells, and activated buoyant tonsillar B-cells but not in sIgM+ dense tonsillar B-cells with functional antigen receptors; (c) Tyrosine phosphorylation is an important and perhaps mandatory step in the generation of the CD40 receptor-linked transmembrane signal; (d) CD40 ligation induces activation by covalent modification of multiple previously unidentified serine/threonine-specific protein kinases.	UNIV MINNESOTA, HLTH SCI CTR, DEPT THERAPEUT RADIOL RADIAT ONCOL, CANC & LEUKEMIA BIOL SECT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, HLTH SCI CTR, DEPT PEDIAT, DIV HEMATOL ONCOL BONE MARROW TRANSPLANTAT, MINNEAPOLIS, MN 55455 USA; UNIV WASHINGTON, DEPT MICROBIOL, SEATTLE, WA 98195 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, SEATTLE, WA 98121 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle; Bristol-Myers Squibb				Uckun, Fatih M./0000-0001-9334-183X	NCI NIH HHS [R01-CA-51425] Funding Source: Medline; NIGMS NIH HHS [P01 GM-42508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM042508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BACKER JM, 1989, J BIOL CHEM, V264, P1694; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; CAIRNS J, 1988, EUR J IMMUNOL, V18, P349, DOI 10.1002/eji.1830180305; CAMBIER J, 1988, P NATL ACAD SCI USA, V85, P6493, DOI 10.1073/pnas.85.17.6493; CAMBIER JC, 1990, J IMMUNOL, V145, P13; CAMBIER JC, 1987, IMMUNOL REV, V95, P37, DOI 10.1111/j.1600-065X.1987.tb00499.x; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CLARK EA, 1989, ADV CANCER RES, V52, P81; CLARK EA, 1990, J IMMUNOL, V145, P1400; CLEMENT LT, 1986, J IMMUNOL, V136, P2375; COCHET C, 1984, J BIOL CHEM, V259, P2553; COGGESHALL KM, 1984, J IMMUNOL, V133, P3382; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; CREMINS J, 1986, J CELL BIOL, V103, P887, DOI 10.1083/jcb.103.3.887; DEAN NM, 1989, ANAL BIOCHEM, V183, P199, DOI 10.1016/0003-2697(89)90468-5; DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143; DHAR A, 1990, MOL PHARMACOL, V37, P519; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; EARP HS, 1985, J BIOL CHEM, V260, P4351; EARP HS, 1984, P NATL ACAD SCI-BIOL, V81, P2347, DOI 10.1073/pnas.81.8.2347; EVANS JPM, 1990, BLOOD, V75, P88; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; FRELINGER JA, 1975, SCIENCE, V188, P268, DOI 10.1126/science.1118728; GETTYS TW, 1990, RECEPTOR PHOSPHORYLA, P39; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GORDON J, 1987, EUR J IMMUNOL, V17, P1535, DOI 10.1002/eji.1830171026; GORDON J, 1988, J IMMUNOL, V140, P1425; GRUNBERGER G, 1984, P NATL ACAD SCI-BIOL, V81, P2762, DOI 10.1073/pnas.81.9.2762; HALEGOUA S, 1980, CELL, V22, P571, DOI 10.1016/0092-8674(80)90367-0; HAMA T, 1986, P NATL ACAD SCI USA, V83, P2353, DOI 10.1073/pnas.83.8.2353; HARRISON ML, 1984, J BIOL CHEM, V259, P9348; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KIM UH, 1991, J BIOL CHEM, V266, P1359; KNAPP W, 1989, IMMUNOL TODAY, V10, P253, DOI 10.1016/0167-5699(89)90135-7; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KURNICK JT, 1979, SCAND J IMMUNOL, V10, P563, DOI 10.1111/j.1365-3083.1979.tb01391.x; LANE PJL, 1990, J IMMUNOL, V144, P3684; LANE PJL, 1991, J IMMUNOL, V146, P715; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P1897, DOI 10.1073/pnas.85.6.1897; LEDBETTER JA, 1987, J IMMUNOL, V138, P788; LEDBETTER JA, 1991, BLOOD, V77, P1271; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDA Y, 1987, J BIOL CHEM, V262, P2832; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; NEL AE, 1985, J IMMUNOL, V135, P3448; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; PATEL MD, 1987, J BIOL CHEM, V262, P5831; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SHARON M, 1989, J IMMUNOL, V143, P2530; SHAWVER LK, 1989, J BIOL CHEM, V264, P1046; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P3589, DOI 10.1073/pnas.88.9.3589; UCKUN FM, 1990, BLOOD, V76, P2449; UCKUN FM, 1988, P NATL ACAD SCI USA, V85, P8603, DOI 10.1073/pnas.85.22.8603; UCKUN FM, 1987, BLOOD, V70, P1020; UCKUN FM, 1989, J CLIN INVEST, V84, P1595, DOI 10.1172/JCI114337; UCKUN FM, 1990, BLOOD, V76, P1908; UCKUN FM, 1988, BLOOD, V71, P13; VALENTINE MA, 1989, J BIOL CHEM, V264, P11282; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	77	151	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17478	17485						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1716631				2022-12-25	WOS:A1991GF44500075
J	HEYDUK, E; HEYDUK, T; LEE, JC				HEYDUK, E; HEYDUK, T; LEE, JC			GLOBAL CONFORMATIONAL-CHANGES IN ALLOSTERIC PROTEINS - A STUDY OF ESCHERICHIA-COLI CAMP RECEPTOR PROTEIN AND MUSCLE PYRUVATE-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE CYCLIC 3',5'-MONOPHOSPHATE; FLUORESCENCE ENERGY-TRANSFER; ASPARTATE CARBAMOYLTRANSFERASE; MONOPHOSPHATE RECEPTOR; THERMODYNAMIC LINKAGES; DOMAIN INTERACTION; LAC PROMOTER; ALPHA-CORE; BINDING; AMP	One of the basic features in allosteric regulation involves long range transduction of information. Based on crystallographic data on protein systems that are regulated by allosteric mechanisms, a global conformational change has always been observed. It is, therefore, important and useful to correlate the cooperativity of global structural change with the mode of binding of the regulatory ligand. Two systems were chosen for study, namely Escherichia coli cAMP receptor protein and muscle pyruvate kinase, which show negative and positive cooperativity in the binding of allosteric ligands, respectively. Quantitative titration of the global structural change, monitored by a high precision analytical gel chromatography technique, was conducted as a function of allosteric effector concentration. The results obtained for cAMP receptor protein show that the protein undergoes contraction upon binding of cAMP. The decreases in Stokes radius associated with complex formation are 0.1 +/- 0.1 and 0.7 +/- 0.1 angstrom when one and two cAMP-binding sites are filled, respectively. The results for the pyruvate kinase system show a concerted structural change that quantitatively match the predicted behavior based on equilibrium constants derived from the analysis of steady state kinetic data by a two-state model. Hence, for these two systems, these results show that negative and positive cooperativity are correlated with sequential and concerted modes of structural change, respectively.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045579] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-21489] Funding Source: Medline; NIGMS NIH HHS [GM-45579] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; ANDERSON WB, 1971, J BIOL CHEM, V246, P5929; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BERNHARDT R, 1983, BIOCHIM BIOPHYS ACTA, V745, P140, DOI 10.1016/0167-4838(83)90042-0; BOYER PD, 1962, ENZYMES, P695; BROMBERG S, 1990, J BIOCHEM BIOPH METH, V20, P143, DOI 10.1016/0165-022X(90)90073-L; BROWN AM, 1989, P NATL ACAD SCI USA, V76, P7387; CONSLER TG, 1989, BIOCHEMISTRY-US, V28, P8756, DOI 10.1021/bi00448a012; CONSLER TG, 1988, J BIOL CHEM, V263, P2794; CONSLER TG, 1988, J BIOL CHEM, V263, P2787; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; DEGRAZIA H, 1990, BIOCHEMISTRY-US, V29, P3557, DOI 10.1021/bi00466a019; EBRIGHT RH, 1985, J MOL BIOL, V182, P91, DOI 10.1016/0022-2836(85)90030-0; EILEN E, 1978, BIOCHEMISTRY-US, V17, P2469, DOI 10.1021/bi00606a001; EILEN E, 1977, BIOCHIM BIOPHYS ACTA, V493, P115, DOI 10.1016/0005-2795(77)90264-1; EVANS PR, 1986, J MOL BIOL, V191, P713, DOI 10.1016/0022-2836(86)90455-9; FISH WW, 1969, J BIOL CHEM, V244, P4989; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GARNER MM, 1982, BIOCHEMISTRY-US, V21, P6032, DOI 10.1021/bi00267a001; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; KE H, 1990, J MOL BIOL, V212, P513, DOI 10.1016/0022-2836(90)90329-K; KE HM, 1984, P NATL ACAD SCI-BIOL, V81, P4037, DOI 10.1073/pnas.81.13.4037; KE HM, 1991, BIOCHEMISTRY-US, V30, P4412, DOI 10.1021/bi00232a007; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KRAKOW JS, 1973, P NATL ACAD SCI USA, V70, P2529, DOI 10.1073/pnas.70.9.2529; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; KUMAR SA, 1980, FEBS LETT, V109, P121, DOI 10.1016/0014-5793(80)81324-X; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P111; LESLIE AGW, 1984, J MOL BIOL, V178, P743, DOI 10.1016/0022-2836(84)90250-X; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OBERFELDER RW, 1984, BIOCHEMISTRY-US, V23, P3813, DOI 10.1021/bi00312a004; OBERFELDER RW, 1984, BIOCHEMISTRY-US, V23, P3822, DOI 10.1021/bi00312a005; PERUTZ MF, 1970, NATURE, V228, P738; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TAFORD C, 1961, PHYSICAL CHEM MACROM, P306; TAKAHASHI M, 1980, BIOCHEMISTRY-US, V19, P5124, DOI 10.1021/bi00563a029; TAKASHI R, 1979, BIOCHEMISTRY-US, V18, P5164, DOI 10.1021/bi00590a021; TAN GS, 1991, BIOCHEMISTRY-US, V30, P5076, DOI 10.1021/bi00234a034; WINDHOLZ M, 1976, MERCK INDEX, P353	42	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3200	3204						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737775				2022-12-25	WOS:A1992HD15400061
J	PEJLER, G; SELJELID, R				PEJLER, G; SELJELID, R			INACTIVATION OF THROMBIN BY MURINE PERITONEAL-MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE PROCOAGULANT RESPONSE; BLOOD-COAGULATION; PLASMINOGEN-ACTIVATOR; HEPARIN COFACTOR; LYMPHOCYTES-T; CELL-SURFACE; THROMBOPLASTIN; INHIBITION; MECHANISM; COMPLEXES	We recently showed that murine peritoneal macrophages cultured in vitro express potent prothrombinase activity (Lindahl, U., Pejler, G., Bogwald, J., and Seljelid, R. (1989) Arch. Biochem. Biophys. 273, 180-188). In the present report, we demonstrate that the macrophages also express anticoagulant activity by inactivating the thrombin that is formed due to the action of the prothrombinase. Addition of exogenous purified thrombin to the macrophage cultures resulted in inactivation of the enzyme at a maximum rate of approximately 5-mu-g/h/1O(6) cells. The inactivation appeared to be specific for thrombin, since neither Factor Xa, chymotrypsin, nor trypsin, three serine proteases exhibiting homology with thrombin, were inactivated by the macrophages. Thrombin-inactivating activity was not secreted into the culture medium. Inhibitors of endocytosis did not decrease the rate by which thrombin was inactivated, suggesting that internalization of the coagulation factor was not required. In contrast, the thrombin-inactivating activity was strongly inhibited by the polycation Polybrene. Anion-exchange chromatography of extracts obtained after Triton X-100-solubilization of the macrophages demonstrated that the thrombin-inactivating activity exhibited a high negative charge. Incubation of the thrombin-inactivating activity recovered after anion-exchange chromatography with unlabeled thrombin, followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis, showed that thrombin was proteolytically cleaved into defined fragments. Similar proteolytic fragments were obtained when I-125-labeled thrombin was added to macrophage cultures. Degradation of thrombin was blocked by phenylmethanesulfonic fluoride, an inhibitor of serine proteases, but not by inhibitors of other classes of proteases. Thrombin that had been chemically modified at its active site was degraded at the same rate by the macrophages as active thrombin. Taken together, these findings indicate that the murine macrophages express surface-bound serine protease activity that specifically inactivates thrombin by proteolytic cleavage. The significance of thrombin-inactivating activity in relation to the involvement of macrophage procoagulant activity in the immune response is discussed.	UNIV TROMSO,INST MED BIOL,N-9001 TROMSO,NORWAY	UiT The Arctic University of Tromso	PEJLER, G (corresponding author), BIOMED CTR,DEPT VET MED CHEM,POB 575,S-75123 UPPSALA,SWEDEN.							BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BARSHAVIT R, 1986, INT REV EXP PATHOL, V29, P213; BARSHAVIT R, 1986, P NATL ACAD SCI USA, V83, P976, DOI 10.1073/pnas.83.4.976; BARSHAVIT R, 1983, J CELL BIOL, V96, P282, DOI 10.1083/jcb.96.1.282; BARSHAVIT R, 1983, SCIENCE, V220, P7285; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; CARNEY DH, 1978, CELL, V15, P1341, DOI 10.1016/0092-8674(78)90059-4; CLOHISY DR, 1990, J BIOL CHEM, V265, P7729; COHN ZA, 1965, J EXP MED, V121, P153, DOI 10.1084/jem.121.1.153; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; GECZY CL, 1983, LYMPHOKINES, V8, P201; GREGORY SA, 1986, J IMMUNOL, V137, P3231; GREGORY SA, 1989, MOL CELL BIOL, V9, P2752, DOI 10.1128/MCB.9.6.2752; GURWITZ D, 1990, J CELL PHYSIOL, V142, P155, DOI 10.1002/jcp.1041420119; HATTORI R, 1989, J BIOL CHEM, V264, P7768; HOPPER KE, 1981, J IMMUNOL, V126, P1052; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALOMBARDI VJ, 1983, BIOCHEM J, V211, P695; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; LINDAHL U, 1989, ARCH BIOCHEM BIOPHYS, V273, P180, DOI 10.1016/0003-9861(89)90177-X; LINDAHL U, 1982, BIOCHEM J, V206, P231, DOI 10.1042/bj2060231; LYBERG T, 1984, HAEMOSTASIS, V14, P430; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; OSTERUD B, 1984, HAEMOSTASIS, V14, P386; OSTERUD B, 1981, FEBS LETT, V127, P154, DOI 10.1016/0014-5793(81)80363-8; OSTERUD B, 1980, FEBS LETT, V120, P41, DOI 10.1016/0014-5793(80)81041-6; PARKER KA, 1985, J BIOL CHEM, V260, P3501; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PERDUE JF, 1981, J BIOL CHEM, V256, P2767; RAZIN E, 1985, EXP CELL RES, V160, P380, DOI 10.1016/0014-4827(85)90184-3; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; ROTHBERGER H, 1977, J CLIN INVEST, V59, P549, DOI 10.1172/JCI108670; RYAN J, 1988, J IMMUNOL, V141, P2110; SCHWARTZ BS, 1981, J CLIN INVEST, V67, P1650, DOI 10.1172/JCI110201; SCHWARTZ BS, 1982, J EXP MED, V155, P1464, DOI 10.1084/jem.155.5.1464; SHANDS JW, 1984, HAEMOSTASIS, V14, P373; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; TANAKA K, 1986, J BIOL CHEM, V261, P2610; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; TSAO BP, 1984, J EXP MED, V159, P1042, DOI 10.1084/jem.159.4.1042	42	9	9	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3136	3142						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737768				2022-12-25	WOS:A1992HD15400050
J	BUECHTER, DD; MEDZIHRADSZKY, KF; BURLINGAME, AL; KENYON, GL				BUECHTER, DD; MEDZIHRADSZKY, KF; BURLINGAME, AL; KENYON, GL			THE ACTIVE-SITE OF CREATINE-KINASE - AFFINITY LABELING OF CYSTEINE-282 WITH N-(2,3-EPOXYPROPYL)-N-AMIDINOGLYCINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; ADENYLATE KINASE; 3-DIMENSIONAL STRUCTURE; SUBSTRATE COMPLEXES; CATALYTIC MECHANISM; MAGNETIC-RESONANCE; SEQUENCE IONS; MUSCLE; PEPTIDES; BINDING	Epoxycreatine (N-(2,3-epoxypropyl)-N-amidino-glycine) is an affinity label of creatine kinase that irreversibly and completely inactivates the enzyme (Marletta, M. A., and Kenyon, G. L. (1979) J. Biol. Chem. 254, 1879-1886). To identify active site residues of rabbit muscle creatine kinase, the site of modification of it by epoxycreatine has been determined. Separation by high performance liquid chromatography of a tryptic digest of [C-14]epoxycreatine-modified creatine kinase yielded two radiolabeled peptides. The larger of these consisted of amino acids Ala-266 through Arg-291 and was labeled with epoxycreatine at Cys-282. Attempts to purify completely the other labeled peptide were not successful; however, it was possible to obtain, by tandem mass spectrometry, a collision-induced dissociation spectrum of it from a mixture of several peptides. This peptide was a fragment (amino acids Val-279 through Arg-291) of the previously identified peptide and was also labeled at Cys-282. Model studies with cysteine and epoxycreatine have demonstrated that opening of the oxirane ring occurs by attack of the cysteine thiolate at the terminal carbon of the epoxide. These results are consistent with previous studies on the base lability of the label; however, a carboxyl group in the active site is not labeled, as had been previously suggested. These results provide evidence that Cys-282 is located in or near the creatine-binding site and will also be important in identifying and delineating the boundaries of the active site of creatine kinase.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, BOX 0446, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NCRR NIH HHS [RR01614] Funding Source: Medline; NIAMS NIH HHS [AR 17323] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR017323, R37AR017323] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABBITT PC, 1986, J PROTEIN CHEM, V5, P1, DOI 10.1007/BF01025580; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BORDERS CL, 1975, BIOCHEMISTRY-US, V14, P4699, DOI 10.1021/bi00692a021; BUECHTER DD, 1990, THESIS U CALIFORNIA; BUECHTER DD, 1991, TECHNIQUES PROTEIN C, V2, P537; BURLINGAME AL, 1990, ANAL CHEM, V62, pR268, DOI 10.1021/ac00211a014; CHEN LH, 1991, J BIOL CHEM, V266, P12053; CHEN LH, 1990, FASEB J, V4, pA2119; CLARKE DE, 1979, BIOCHEM J, V181, P467, DOI 10.1042/bj1810467; COHN M, 1971, J BIOL CHEM, V246, P6037; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1204, DOI 10.1021/bi00508a023; DERTERROSSIAN E, 1976, EUR J BIOCHEM, V70, P623; DEWOLF WE, 1988, BIOCHEMISTRY-US, V27, P9093, DOI 10.1021/bi00426a005; DIEDERICHS K, 1990, BIOCHEMISTRY-US, V29, P8138, DOI 10.1021/bi00487a022; EGNER U, 1987, J MOL BIOL, V195, P649, DOI 10.1016/0022-2836(87)90188-4; FAWCETT AH, 1982, BIOCHEM BIOPH RES CO, V107, P302, DOI 10.1016/0006-291X(82)91704-1; FRY DC, 1985, BIOCHEMISTRY-US, V24, P4680, DOI 10.1021/bi00338a030; FRY DC, 1988, BIOCHEMISTRY-US, V27, P3588, DOI 10.1021/bi00410a009; GRUEMER HD, 1987, CLIN CHIM ACTA, V162, P1, DOI 10.1016/0009-8981(87)90227-0; HOOTON BT, 1968, BIOCHEMISTRY-US, V7, P2063, DOI 10.1021/bi00846a007; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; JAMES TL, 1976, BIOCHEMISTRY-US, V15, P4724, DOI 10.1021/bi00666a029; JAMES TL, 1974, J BIOL CHEM, V249, P2599; JOHNSON RS, 1988, INT J MASS SPECTROM, V86, P137, DOI 10.1016/0168-1176(88)80060-0; KASSAB R, 1968, BIOCHIM BIOPHYS ACTA, V167, P308, DOI 10.1016/0005-2744(68)90210-6; KAUR S, 1989, J BIOL CHEM, V264, P16981; KENYON GL, 1983, ADV ENZYMOL RAMB, V54, P367; KUBY SA, 1954, J BIOL CHEM, V209, P191; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGIO ET, 1977, J BIOL CHEM, V252, P1202; MAHOWALD TA, 1962, J BIOL CHEM, V237, P1535; MAHOWALD TA, 1965, BIOCHEMISTRY-US, V4, P732, DOI 10.1021/bi00880a019; MARKHAM GD, 1977, J BIOL CHEM, V252, P1197; MARLETTA MA, 1979, J BIOL CHEM, V254, P1879; MCLAUGHLIN AC, 1976, J BIOL CHEM, V251, P2777; MILDVAN AS, 1987, ADV ENZYMOL RAMB, V59, P241; MILLER J, 1982, CLIN CHIM ACTA, V118, P67, DOI 10.1016/0009-8981(82)90227-3; OSULLIVA.WJ, 1968, J BIOL CHEM, V243, P2737; OSULLIVAN WJ, 1966, BIOCHEMISTRY-US, V5, P2666, DOI 10.1021/bi00872a027; OSULLIVAN WJ, 1971, INT J PROT RES, V3, P139; POCKER Y, 1988, J AM CHEM SOC, V110, P6492, DOI 10.1021/ja00227a033; PUTNEY S, 1984, J BIOL CHEM, V259, P14317; QUEST AFG, 1989, ENZYME, V41, P33, DOI 10.1159/000469048; RABIN BR, 1960, NATURE, V188, P1163, DOI 10.1038/1881163a0; REDDY SRR, 1979, BIOCHIM BIOPHYS ACTA, V569, P109, DOI 10.1016/0005-2744(79)90086-X; REED GH, 1972, J BIOL CHEM, V247, P3073; REED GH, 1980, BIOCHEMISTRY-US, V19, P5472, DOI 10.1021/bi00565a002; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; ROSEVEAR PR, 1981, BIOCHEMISTRY-US, V20, P6155, DOI 10.1021/bi00524a038; ROSS WCJ, 1950, J CHEM SOC, P2257, DOI 10.1039/jr9500002257; ROUSTAN C, 1970, BIOPHYS BIOCH ACTA, V167, P326; SAKS VA, 1975, EUR J BIOCHEM, V57, P273, DOI 10.1111/j.1432-1033.1975.tb02299.x; SCHULZ GE, 1974, NATURE, V250, P120, DOI 10.1038/250120a0; SERAYDARIAN MW, 1976, J MOL CELL CARDIOL, V8, P741, DOI 10.1016/0022-2828(76)90081-X; SETTINERI CA, 1990, BIOMED ENVIRON MASS, V19, P665, DOI 10.1002/bms.1200191106; SHYY YJ, 1987, BIOCHEMISTRY-US, V26, P6411, DOI 10.1021/bi00394a017; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P766, DOI 10.1021/bi00675a019; SMITH DJ, 1974, J BIOL CHEM, V249, P3317; TANZER ML, 1959, J BIOL CHEM, V234, P3201; TAYLOR JS, 1969, P NATL ACAD SCI USA, V64, P219, DOI 10.1073/pnas.64.1.219; THOMSON AR, 1964, NATURE, V203, P267, DOI 10.1038/203267a0; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; VANDEST P, 1980, EUR J BIOCHEM, V104, P433, DOI 10.1111/j.1432-1033.1980.tb04445.x; VETTER IR, 1990, BIOCHEMISTRY-US, V29, P7459, DOI 10.1021/bi00484a015; WANG ZX, 1988, BIOCHEMISTRY-US, V27, P5095, DOI 10.1021/bi00414a022; WATTS DC, 1962, BIOCHEM J, V85, P507, DOI 10.1042/bj0850507; WU AHB, 1989, CLIN CHEM, V35, P7; WU H, 1989, BIOCHIM BIOPHYS ACTA, V997, P78, DOI 10.1016/0167-4838(89)90137-4; YAN HG, 1990, BIOCHEMISTRY-US, V29, P6385, DOI 10.1021/bi00479a007; ZHOU HM, 1987, BIOCHIM BIOPHYS ACTA, V911, P136, DOI 10.1016/0167-4838(87)90002-1	70	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2173	2178						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733925				2022-12-25	WOS:A1992HB53200012
J	CLINE, K; ETTINGER, WF; THEG, SM				CLINE, K; ETTINGER, WF; THEG, SM			PROTEIN-SPECIFIC ENERGY-REQUIREMENTS FOR PROTEIN-TRANSPORT ACROSS OR INTO THYLAKOID MEMBRANES - 2 LUMENAL PROTEINS ARE TRANSPORTED IN THE ABSENCE OF ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-EVOLVING COMPLEX; CHLOROPHYLL-A/B PROTEIN; COLI LEADER PEPTIDASE; PRECURSOR PROTEINS; ESCHERICHIA-COLI; TRANSIT PEPTIDE; MITOCHONDRIA REQUIRES; PROCESSING PEPTIDASE; BINDING PROTEIN; KDA POLYPEPTIDE	Cytosolically synthesized thylakoid proteins must be translocated across the chloroplast envelope membranes, traverse the stroma, and then be translocated into or across the thylakoid membrane. Protein transport across the envelope requires ATP hydrolysis but not electrical or proton gradients. The energy requirements for the thylakoid translocation step were studied here for the light-harvesting chlorophyll a/b protein (LHCP), an integral membrane protein, and for several thylakoid lumen-resident proteins: plastocyanin and OE33, OE23, and OE17 (the 33-, 23-, and 17-kDa subunits of the oxygen-evolving complex, respectively). Dissipation of the thylakoid protonmotive force during an in organello protein import assay partially inhibited the thylakoid localization of LHCP and OE33, totally inhibited localization of OE23 and OE17, and had no effect on localization of plastocyanin. We used reconstitution assays for LHCP insertion and for OE23 and OE17 transport into isolated thylakoids to investigate the energy requirements in detail. The results indicated that LHCP insertion absolutely requires ATP hydrolysis and is enhanced by a transthylakoid DELTA-pH and that transport of OE23 and OE17 is absolutely dependent upon a DELTA-pH. Surprisingly, OE23 and OE17 transport occurred maximally in the complete absence of ATP. These results establish the thylakoid membrane as the only membrane system in which a DELTA-pH can provide all of the energy required to translocate Proteins across the bilayer. They also demonstrate that the energy requirements for integration into or translocation across the thylakoid membranes are protein specific.	UNIV CALIF DAVIS,DEPT BOT,DAVIS,CA 95616	University of California System; University of California Davis	CLINE, K (corresponding author), UNIV FLORIDA,DEPT FRUIT CROPS,GAINESVILLE,FL 32611, USA.		Cline, Kenneth/J-6238-2013					ANDERSON CM, 1991, FEBS LETT, V280, P383, DOI 10.1016/0014-5793(91)80337-3; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BAUERLE C, 1991, J BIOL CHEM, V266, P5876; BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; CLINE K, 1988, PLANT PHYSIOL, V86, P1120, DOI 10.1104/pp.86.4.1120; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1989, J BIOL CHEM, V264, P14225; CLINE K, 1986, J BIOL CHEM, V261, P4804; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FLUGGE UI, 1986, EUR J BIOCHEM, V160, P563, DOI 10.1111/j.1432-1033.1986.tb10075.x; FULSON DR, 1988, PLANT PHYSIOL, V88, P1146, DOI 10.1104/pp.88.4.1146; GELLER BL, 1989, J BIOL CHEM, V264, P16465; GROSSMAN A, 1980, NATURE, V285, P625, DOI 10.1038/285625a0; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; JAGENDORF AT, 1990, PLANT SCI, V71, P137, DOI 10.1016/0168-9452(90)90001-5; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KALINICH JF, 1989, J BIOL CHEM, V264, P17979; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KIRWIN PM, 1987, J BIOL CHEM, V262, P16386; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KOHORN BD, 1989, PLANT CELL, V1, P159; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; LAMPPA GK, 1988, J BIOL CHEM, V263, P14996; LAST DI, 1989, PLANT MOL BIOL, V12, P655, DOI 10.1007/BF00044156; MOULD RM, 1991, J BIOL CHEM, V266, P12189; NELSON N, 1977, P NATL ACAD SCI USA, V74, P2375, DOI 10.1073/pnas.74.6.2375; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; PFANNER N, 1990, J BIOL CHEM, V265, P16324; Pichersky E., 1990, CURRENT RES PHOTOSYN, V3, P553; REED JE, 1990, EUR J BIOCHEM, V194, P33, DOI 10.1111/j.1432-1033.1990.tb19423.x; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHINDLER C, 1987, Z NATURFORSCH C, V42, P103; SEIDLER A, 1990, EMBO J, V9, P1743, DOI 10.1002/j.1460-2075.1990.tb08298.x; SIMPSON DJ, 1989, CARLSBERG RES COMMUN, V54, P55, DOI 10.1007/BF02907585; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; STEELE JA, 1978, BIOCHIM BIOPHYS ACTA, V504, P136, DOI 10.1016/0005-2728(78)90012-9; STEELE JA, 1976, P NATL ACAD SCI USA, V73, P2245, DOI 10.1073/pnas.73.7.2245; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; TAI PC, 1990, BACTERIA TREATISE ST, V12, P393; THEG SM, 1989, J BIOL CHEM, V264, P6730; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; VIITANEN PV, 1988, J BIOL CHEM, V263, P15000; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WAGNER R, 1989, EMBO J, V8, P2827, DOI 10.1002/j.1460-2075.1989.tb08429.x; WALES R, 1989, PLANT MOL BIOL, V12, P439, DOI 10.1007/BF00017583; WALES R, 1989, PLANT MOL BIOL, V13, P573, DOI 10.1007/BF00027317; WICKNER W, 1988, BIOCHEMISTRY-US, V27, P1081, DOI 10.1021/bi00404a001	57	229	231	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2688	2696						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733965				2022-12-25	WOS:A1992HB53200088
J	FLORES, O; LU, H; REINBERG, D				FLORES, O; LU, H; REINBERG, D			FACTORS INVOLVED IN SPECIFIC TRANSCRIPTION BY MAMMALIAN RNA POLYMERASE-II - IDENTIFICATION AND CHARACTERIZATION OF FACTOR-IIH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR; ACCURATE TRANSCRIPTION; FUNCTIONAL-ANALYSIS; BINDING-PROTEIN; PURIFICATION; PROMOTER; DNA; DOWNSTREAM; EXPRESSION; COMPLEXES	Two new factors required for transcription of class II genes have been identified. These factors, TFIIH and TFIIJ, were required together with the previously described general factors (TFIIA, TFIIB, TFIID, TFIIE, and TFIIF) and RNA polymerase II for transcription of different class II genes. TFIIH was extensively purified, and the activity appeared to coelute with polypeptides of 33 and 95 kDa. The role of TFIIH and TFIIJ in preinitiation complex assembly was analyzed using mobility shift assays. It was found that TFIIH and TFIIJ association with the preinitiation complex was ordered and required the previous assembly of a preinitiation complex intermediate containing factors IID, IIB, IIF, IIE, and RNA polymerase II. A model for the ordered assembly of the general factors and RNA polymerase II is presented.			FLORES, O (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.			Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037110] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 37110] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURKE C, 1990, NUCLEIC ACIDS RES, V18, P3611, DOI 10.1093/nar/18.12.3611; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CONAWAY JW, 1989, J BIOL CHEM, V264, P2357; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CORTES P, 1991, IN PRESS MOL CELL BI; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1990, J BIOL CHEM, V265, P5629; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; INOSTROZA J, 1991, J BIOL CHEM, V266, P9304; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KAWAGUCHI T, 1990, P NATL ACAD SCI USA, V87, P6619, DOI 10.1073/pnas.87.17.6619; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MERMELSTEIN FH, 1989, BIOCHIM BIOPHYS ACTA, V1009, P1, DOI 10.1016/0167-4781(89)90071-7; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; PETERSON MG, 1991, NATURE, V354, P369; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SOPTA M, 1985, J BIOL CHEM, V260, P353; SOPTA M, 1989, NATURE, V341, P4100; STONE N, 1991, PHARM TECHNOL, V15, P36; SUMIMOTO H, 1990, P NATL ACAD SCI USA, V87, P9158, DOI 10.1073/pnas.87.23.9158; USUDA Y, 1991, EMBO J, V10, P2305, DOI 10.1002/j.1460-2075.1991.tb07767.x; VANDYKE MW, 1989, MOL CELL BIOL, V9, P342, DOI 10.1128/MCB.9.1.342; ZHENG XM, 1990, NATURE, V344, P556, DOI 10.1038/344556a0; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	45	208	211	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2786	2793						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733973				2022-12-25	WOS:A1992HB53200100
J	LEE, JC; HOROWITZ, PM				LEE, JC; HOROWITZ, PM			SULFHYDRYL-GROUPS ON YEAST RIBOSOMAL PROTEIN-L7 AND PROTEIN-L26 ARE SIGNIFICANTLY MORE REACTIVE IN THE 80-S PARTICLES THAN IN THE 60-S SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRANSFER-RNA; INITIATION COMPLEX; RAT-LIVER; SACCHAROMYCES-CEREVISIAE; CROSS-LINKING; BINDING	The sulfhydryl-directed fluorescent reagent, 5-iodoacetamidofluorescein (IAF), reacts differently with proteins from the 60 S ribosomal subunit of Saccharomyces cerevisiae when this subunit is free as opposed to being contained within the 80 S ribosome. When the 80 S ribosomes and the free 60 S subunits were labeled with IAF, the specific fluorescence intensity (fluorescence intensity unit/A260 60 S subunit) of the subsequently derived 60 S was 16.3 and 5.4, respectively. Gel analysis showed that proteins L7 and L26 were selectively labeled and contained > 90% of the total fluorescent label, when 80 S ribosomes were labeled. When free 60 S subunits were labeled, six additional proteins were labeled. Both types of modified 60 S subunits were equally capable to support protein synthesis in vitro. Reassociation of the IAF-labeled derived and free 60 S subunits with unmodified 40 S subunits resulted in a maximum of 5-7% decrease and a 3-fold increase, respectively, in the fluorescence intensity without a shift in the emission maxima. The data suggest that ribosomal proteins L7 and L26 contain SH groups that respond to ribosomal subunit association and become more reactive in the intact ribosome than in the subunit. The environments of some or all of the additionally labeled proteins are also sensitive to subunit reassociation.			LEE, JC (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA.				NIGMS NIH HHS [GM-35851] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1975, J MOL BIOL, V93, P449, DOI 10.1016/0022-2836(75)90239-9; BOUBLIK M, 1983, EUR J CELL BIOL, V32, P136; BURMA DP, 1986, STRUCTURE FUNCTION G, P438; CHISTYAKOV PG, 1989, FEBS LETT, V246, P197, DOI 10.1016/0014-5793(89)80282-0; ERICSON G, 1989, J BIOL CHEM, V264, P540; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; KOESSEL H, 1990, Nucleic Acids Research, V18, P4083; LECLERC D, 1991, FEBS LETT, V279, P171, DOI 10.1016/0014-5793(91)80141-O; LEE JC, 1984, J BIOL CHEM, V259, P9971; LEE JC, 1983, J BIOL CHEM, V258, P854; LEE JC, 1987, BIOCHIM BIOPHYS ACTA, V908, P109, DOI 10.1016/0167-4781(87)90049-2; LEIBOWITZ MJ, 1991, METHOD ENZYMOL, V194, P536; MICHEL S, 1983, MOL GEN GENET, V191, P251, DOI 10.1007/BF00334822; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MURALIKRISHNA P, 1989, BIOCHEMISTRY-US, V28, P7505, DOI 10.1021/bi00445a002; OAKES M, 1986, STRUCTURE FUNCTION G, P47; PEREZGOSALBEZ M, 1978, MOL GEN GENET, V163, P29, DOI 10.1007/BF00268961; REBOUD AM, 1980, J BIOL CHEM, V255, P6954; REBOUD AM, 1984, NUCLEIC ACIDS RES, V12, P7889, DOI 10.1093/nar/12.20.7889; ROMBY P, 1990, BIOCHIM BIOPHYS ACTA, V1050, P84, DOI 10.1016/0167-4781(90)90146-S; SERDYUK IN, 1986, STRUCTURE FUNCTION G, P425; STEINERT PM, 1974, J MOL BIOL, V88, P895, DOI 10.1016/0022-2836(74)90406-9; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; WESTERMANN P, 1975, CHEM-BIOL INTERACT, V10, P429, DOI 10.1016/0009-2797(75)90073-3; XIANG RH, 1989, J BIOL CHEM, V264, P10542; YEH YC, 1986, J BIOL CHEM, V261, P14148	26	6	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2502	2506						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733947				2022-12-25	WOS:A1992HB53200060
J	BOTFIELD, MC; NAGUCHI, K; TSUCHIYA, T; WILSON, TH				BOTFIELD, MC; NAGUCHI, K; TSUCHIYA, T; WILSON, TH			MEMBRANE TOPOLOGY OF THE MELIBIOSE CARRIER OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; PEPTIDE-SPECIFIC ANTIBODY; HUMAN GLUCOSE TRANSPORTER; AMINO-ACID-SEQUENCES; RHODOPSEUDOMONAS-VIRIDIS; ALKALINE-PHOSPHATASE; PROTEIN EXPORT; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN; COOH TERMINUS	The minimum structural information necessary to formulate and assess mechanistic models of integral membrane protein function is that of membrane topology. This paper characterizes the topological structure of the melibiose carrier of Escherichia coli based on constraints provided by genetic fusions to the compartment-specific reporter protein alkaline phosphatase. Twenty-eight unique chimeras exhibiting either low alkaline phosphatase activity (cytoplasmic location of the fusion joint) or high alkaline phosphatase activity (periplasmic location of the fusion joint) were characterized and used in conjunction with Goldman-Engelman-Steitz hydropathy analysis to model topological structure. The melibiose carrier is predicted to have a cytoplasmic amino terminus, two sets of six transmembrane domains separated by an unusually large cytoplasmic loop ("six-loop-six" arrangement), and a 45-residue cytoplasmic carboxyl tail. Remarkably, the identical six-loop-six arrangement is predicted from the hydrophobicity plots of the H+-coupled lactose, arabinose, xylose, and citrate cotransporters of E. coli, the glucose transporter from rat brain, the family of glucose transporters isolated from various human tissues and cell lines, and the human, mouse, and hamster multidrug resistance transporters (Henderson, P. J. F. (1990) Res. Microbiol. 141, 316-328; Maloney, P. C. (1990) Res. Microbiol. 141, 374-383). Such a broad degree of conservation (or convergence) suggests a distinct structural and/or mechanistic advantage associated with the six-loop-six motif. The nature of this advantage is as yet unknown.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; OKAYAMA UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL,OKAYAMA 700,JAPAN	Harvard University; Harvard Medical School; Okayama University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK005736] Funding Source: NIH RePORTER; NIDDK NIH HHS [2-RO1-DKO5736] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN LC, 1975, P NATL ACAD SCI USA, V72, P4701, DOI 10.1073/pnas.72.12.4701; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLUMENTHAL R, 1980, NATURE, V288, P333, DOI 10.1038/288333a0; BOTFIELD MC, 1989, J BIOL CHEM, V264, P11649; BOTFIELD MC, 1990, THESIS ANN ARBOR MI, V3058; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; CHARBIT A, 1986, EMBO J, V5, P3029, DOI 10.1002/j.1460-2075.1986.tb04602.x; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; COHEN GN, 1956, ANN IN PASTEUR PARIS, V91, P683; COHN DE, 1980, BIOCHEMISTRY-US, V19, P4237, DOI 10.1021/bi00559a015; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEISENHOFER J, 1984, J MOL BIOL, V180, P385, DOI 10.1016/S0022-2836(84)80011-X; DONOVAN JJ, 1981, P NATL ACAD SCI-BIOL, V78, P172, DOI 10.1073/pnas.78.1.172; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; ENQUIST HG, 1981, EUR J BIOCHEM, V116, P227; Fersht AR., 1977, ENZYME STRUCTURE MEC; FORD RC, 1987, EMBO J, V6, P1581, DOI 10.1002/j.1460-2075.1987.tb02403.x; FUKOMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; GOLDKORN T, 1983, P NATL ACAD SCI-BIOL, V80, P3322, DOI 10.1073/pnas.80.11.3322; GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0; GUTIERREZ C, 1987, J MOL BIOL, V195, P289, DOI 10.1016/0022-2836(87)90650-4; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JOSEFSSON LG, 1981, J BIOL CHEM, V256, P2504; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; LOPILATO J, 1978, J BACTERIOL, V134, P147, DOI 10.1128/JB.134.1.147-156.1978; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MANOIL C, 1990, P NATL ACAD SCI USA, V87, P4937; MANOIL C, 1988, TRENDS GENET, V4, P333; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; MICHEL H, 1986, EMBO J, V5, P1149, DOI 10.1002/j.1460-2075.1986.tb04340.x; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; MUELLER M, 1984, Proceedings of the National Academy of Sciences of the United States of America, V81, P7421; NIIYA S, 1982, J BIOL CHEM, V257, P8902; RANDALL LL, 1984, MICROBIOL REV, V48, P290, DOI 10.1128/MMBR.48.4.290-298.1984; REYNOLDS CH, 1983, J BACTERIOL, V156, P1019, DOI 10.1128/JB.156.3.1019-1024.1983; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; ROSEMAN MA, 1988, J MOL BIOL, V200, P513, DOI 10.1016/0022-2836(88)90540-2; Rosen B P, 1979, Methods Enzymol, V56, P233; Rosen B.P., 1978, BACTERIAL TRANSPORT, P559; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSE J, 1987, CURRENT PROTOCOLS MO, P1061; SECKLER R, 1983, J BIOL CHEM, V258, P817; TAKAGAKI Y, 1983, J BIOL CHEM, V258, P9136; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; TSUCHIYA T, 1977, BIOCHEM BIOPH RES CO, V76, P26, DOI 10.1016/0006-291X(77)91663-1; TSUCHIYA T, 1978, J MEMBRANE BIOL, V42, P45, DOI 10.1007/BF01870393; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WILSON TH, 1980, J SUPRAMOL STR CELL, V13, P421, DOI 10.1002/jss.400130403; WILSON TH, 1982, MEMBRANES TRANSPORT, P33	71	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1818	1822						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730719				2022-12-25	WOS:A1992HA48500065
J	IIRI, T; OHOKA, Y; UI, M; KATADA, T				IIRI, T; OHOKA, Y; UI, M; KATADA, T			MODIFICATION OF THE FUNCTION OF PERTUSSIS TOXIN SUBSTRATE GTP-BINDING PROTEIN BY CHOLERA TOXIN-CATALYZED ADP-RIBOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; ALPHA ALTER STIMULATION; LEUKEMIC HL-60 CELLS; ADENYLYL CYCLASE; GS-ALPHA; SIGNAL TRANSDUCTION; BOVINE BRAIN; MEMBRANES; MUTATIONS; SITE	The alpha-subunit of G(i-2), in addition to that of G(s) (GTP-binding proteins involved in adenylate cyclase inhibition and stimulation, respectively) was ADP-ribosylated by cholera toxin in HL-60 cell membranes when a chemotactic receptor was stimulated by formyl-Met-Leu-Phe (fMLP), and the sites modified by cholera and pertussis toxins on the alpha-subunit of G(i-2) were different (Iiri, T., Tohkin, M., Morishima, N., Ohoka, Y., Ui, M., and Katada, T. (1989) J. Biol. Chem. 264, 21394-21400). In order to investigate how the functions of G(i-2) were modified by cholera toxin, the ADP-ribosylated and unmodified proteins were purified from HL-60 cell membranes that had been incubated in the presence and absence of cholera toxin, respectively. The modified G(i-2) displayed unique properties as follows. 1) The ADP-ribosylated alpha-subunit had a more acidic pI than the unmodified one, leading to a partial resolution of the modified G(i-2) trimer from the unmodified protein by an anion column chromatography. 2) When the purified proteins were incubated with [gamma-P-32] GTP, the radioactivity was more greatly retained in the modified G(i-2) than in the unmodified protein. 3) The actual catalytic rate (k(cat) of GTP hydrolysis was, indeed, markedly inhibited by cholera toxin-induced modification. 4) There was an increase in the apparent affinity of G(i-2) for GDP by cholera toxin-induced modification. 5) The modified G(i-2) exhibited a low substrate activity for pertussis toxin-catalyzed ADP-ribosylation. 6) A high-affinity fMLP binding to HL-60 cell membranes was more effectively reconstituted with the ADP-ribosylated G(i-2) than with the unmodified protein. These results suggested that the agonist-fMLP receptor complex was effectively coupled with the ADP-ribosylated G(i-2), resulting in the GTP-bound form, and that the hydrolysis of GTP on the modified alpha-subunit was selectively attenuated. Thus, cholera toxin ADP-ribosylated G(i-2) appeared to be not only a less sensitive pertussis toxin substrate but also an efficient signal transducer between receptors and effectors.	TOKYO INST TECHNOL, DEPT LIFE SCI, YOKOHAMA, KANAGAWA 227, JAPAN; UNIV TOKYO, FAC PHARMACEUT SCI, DEPT PHYSIOL CHEM, TOKYO 113, JAPAN	Tokyo Institute of Technology; University of Tokyo								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; DERETIC D, 1987, J BIOL CHEM, V262, P10839; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GIERSCHIK P, 1987, FEBS LETT, V224, P219, DOI 10.1016/0014-5793(87)80451-9; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HOLBROOK SR, 1989, P NATL ACAD SCI USA, V86, P1751, DOI 10.1073/pnas.86.6.1751; HOSHINO S, 1990, FEBS LETT, V276, P227, DOI 10.1016/0014-5793(90)80548-W; IIRI T, 1989, J BIOL CHEM, V264, P21394; JOHN J, 1988, J BIOL CHEM, V263, P11792; KATADA T, 1986, J BIOL CHEM, V261, P8182; KATADA T, 1986, J BIOL CHEM, V261, P5215; KIKUCHI A, 1986, J BIOL CHEM, V261, P1558; KLINZ FJ, 1989, BIOCHEM BIOPH RES CO, V165, P554, DOI 10.1016/S0006-291X(89)80002-6; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1986, PROTEIN ENG, V1, P47, DOI 10.1093/protein/1.1.47; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILLIGAN G, 1988, BIOCHEM J, V252, P369, DOI 10.1042/bj2520369; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; OINUMA M, 1987, J BIOL CHEM, V262, P8347; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; SHIBASAKI H, 1991, FEBS LETT, V285, P268, DOI 10.1016/0014-5793(91)80814-J; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TOHKIN M, 1991, EUR J BIOCHEM, V195, P527, DOI 10.1111/j.1432-1033.1991.tb15733.x; TOHKIN M, 1989, FEBS LETT, V255, P187, DOI 10.1016/0014-5793(89)81088-9; TOMITA U, 1991, J BIOCHEM-TOKYO, V109, P187; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UHING RJ, 1987, J BIOL CHEM, V262, P15575; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; VANDOP C, 1984, J BIOL CHEM, V259, P696; WEST RE, 1985, J BIOL CHEM, V260, P4428	41	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1020	1026						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730631				2022-12-25	WOS:A1992GY96000056
J	PHILIP, A; OCONNORMCCOURT, MD				PHILIP, A; OCONNORMCCOURT, MD			INTERACTION OF TRANSFORMING GROWTH FACTOR-BETA-1 WITH ALPHA-2-MACROGLOBULIN - ROLE IN TRANSFORMING GROWTH FACTOR-BETA-1 CLEARANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT COMPLEX; FACTOR TYPE-BETA; ALPHA-MACROGLOBULIN; EMBRYO FIBROBLASTS; HUMAN-PLATELETS; LATENT FORM; BINDING; INHIBITION; CELLS; PROTEINS	It has been widely assumed that the interaction of transforming growth factor-beta-1 (TGF-beta-1) with its serum-binding protein, alpha-2-macroglobulin (alpha-2M), mediates the rapid clearance of TGF-beta-1 from the circulation. To test this, we have analyzed the effect of TGF-beta-1 binding on the conformational state Of alpha-2M. Our results demonstrate that the binding of TGF-beta-1 to alpha-2M does not lead to the conformational change in the alpha-2M molecule that is required for the clearance of the alpha-2M.TGF-beta-1 complex via the alpha-2M receptor. Furthermore, endogenous TGF-beta-1 is associated with the conformationally unaltered slow clearance form of alpha-2M. Clearance studies in mice show that the half-life of I-125-TGF-beta-1 in the circulation (1.6 +/- 0.71 min) is not affected by blocking the alpha-2M receptor with excess conformationally altered alpha-2M. These results suggest that TGF-beta-1 is rapidly cleared from the circulation after injection by a pathway not involving alpha-2M.	NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, PROT ENGN SECT, 6100 ROYALMOUNT AVE, MONTREAL H4P 2R2, QUEBEC, CANADA	National Research Council Canada								ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BORTH W, 1989, J BIOL CHEM, V264, P5818; CENTRELLA M, 1988, FASEB J, V2, P3066, DOI 10.1096/fasebj.2.15.2903838; COFFEY RJ, 1987, J CLIN INVEST, V80, P750, DOI 10.1172/JCI113130; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GANROT PO, 1966, CLIN CHIM ACTA, V14, P493, DOI 10.1016/0009-8981(66)90037-4; GENTRY LE, 1987, MOL CELL BIOL, V7, P3418, DOI 10.1128/MCB.7.10.3418; GOEY H, 1989, J IMMUNOL, V143, P877; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; KOO PH, 1989, J NEUROSCI RES, V22, P247, DOI 10.1002/jnr.490220304; KRYCEVEMARTINERIE C, 1985, INT J CANCER, V35, P553, DOI 10.1002/ijc.2910350421; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARRE J, 1991, BIOCHIM BIOPHYS ACTA, V1091, P197, DOI 10.1016/0167-4889(91)90062-3; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; LAWRENCE D, 1985, BIOCHEM BIOPH RES CO, V133, P1026, DOI 10.1016/0006-291X(85)91239-2; LAWRENCE DA, 1984, J CELL PHYSIOL, V121, P184, DOI 10.1002/jcp.1041210123; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; MATSUDA T, 1989, J IMMUNOL, V142, P148; MCCAFFREY TA, 1989, J CELL BIOL, V109, P441, DOI 10.1083/jcb.109.1.441; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MUSTOE TA, 1987, SCIENCE, V237, P1333, DOI 10.1126/science.2442813; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PFEILSCHIFTER J, 1987, P NATL ACAD SCI USA, V84, P2024, DOI 10.1073/pnas.84.7.2024; RAINES EW, 1984, P NATL ACAD SCI-BIOL, V81, P3424, DOI 10.1073/pnas.81.11.3424; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RONNE H, 1979, BIOCHEM BIOPH RES CO, V87, P330, DOI 10.1016/0006-291X(79)91683-8; RUFF E, 1986, BIOCHEM BIOPH RES CO, V138, P714, DOI 10.1016/S0006-291X(86)80555-1; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWARDZIK DR, 1989, J NATL CANCER I, V81, P1182, DOI 10.1093/jnci/81.15.1182; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Wakefield LM, 1989, GROWTH FACTORS, V1, P203, DOI 10.3109/08977198908997997; WAKEFIELD LM, 1988, ANN NY ACAD SCI, V551, P290, DOI 10.1111/j.1749-6632.1988.tb22355.x; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965	46	81	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22290	22296						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1718991				2022-12-25	WOS:A1991GR56400038
J	BRODERICK, TL; QUINNEY, HA; LOPASCHUK, GD				BRODERICK, TL; QUINNEY, HA; LOPASCHUK, GD			CARNITINE STIMULATION OF GLUCOSE-OXIDATION IN THE FATTY-ACID PERFUSED ISOLATED WORKING RAT-HEART	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONICALLY DIABETIC RATS; BB WISTAR RATS; ENERGY-METABOLISM; P-31 NMR; MYOCARDIAL ISCHEMIA; LIVER-MITOCHONDRIA; LIPID-METABOLISM; MUSCLE; ACYLCARNITINE; QUANTITATION	The effects of L-carnitine on myocardial glycolysis, glucose oxidation, and palmitate oxidation were determined in isolated working rat hearts. Hearts were perfused under aerobic conditions with perfusate containing either 11 mM [2-H-3/U-C-14]glucose in the presence or absence of 1.2 mM palmitate or 11 mM glucose and 1.2 mM [1-C-14]palmitate. Myocardial carnitine levels were elevated by perfusing hearts with 10 mM L-carnitine. A 60-min perfusion period resulted in significant increases in total myocardial carnitine from 4376 +/- 211 to 9496 +/- 473 nmol/g dry weight. Glycolysis (measured as (H2O)-H-3 production) was unchanged in carnitine-treated hearts perfused in the absence of fatty acids (4418 +/- 300 versus 4547 +/- 600 nmol glucose/g dry weight.min). If 1.2 mM palmitate was present in the perfusate, glycolysis decreased almost 2-fold compared with hearts perfused in the absence of fatty acids. In carnitine-treated hearts this drop in glycolysis did not occur (glycolytic rates were 2911 +/- 231 to 4629 +/- 460 nmol glucose/g dry weight.min, in control and carnitine-treated hearts, respectively. Compared with control hearts, glucose oxidation rates (measured as (CO2)-C-14 production from [U-C-14]glucose) were unaltered in carnitine-treated hearts perfused in the absence of fatty acids (1819 +/- 169 versus 2026 +/- 171 nmol glucose/g dry weight.min, respectively ). In the presence of 1.2 mM palmitate, glucose oxidation decreased dramatically in control hearts (11-fold). In carnitine-treated hearts, however, glucose oxidation was significantly greater than control hearts under these conditions (158 +/- 21 to 454 +/- 85 nmol glucose/g dry weight-min, in control and carnitine-treated hearts, respectively). Palmitate oxidation rates (measured as (CO2)-C-14 production from [1-C-14]palmitate) decreased in the carnitine-treated hearts from 728 +/- 61 to 572 +/- 111 nmol palmitate/g dry weight.min. This probably occurred secondary to an increase in overall ATP production from glucose oxidation (from 5.4 to 14.5% of steady state myocardial ATP production). The results reported in this study provide direct evidence that carnitine can stimulate glucose oxidation in the intact fatty acid perfused heart. This probably occurs secondary to facilitating the intramitochondrial transfer of acetyl groups from acetyl-CoA to acetylcarnitine, thereby relieving inhibition of the pyruvate dehydrogenase complex.	UNIV ALBERTA,DEPT EXERCISE PHYSIOL,423 HERITAGE MED RES BLDG,EDMONTON T6G 2S2,ALBERTA,CANADA; UNIV ALBERTA,DEPT PEDIAT,EDMONTON T6G 2S2,ALBERTA,CANADA; UNIV ALBERTA,DEPT PHARMACOL,EDMONTON T6G 2S2,ALBERTA,CANADA	University of Alberta; University of Alberta; University of Alberta								FOLTS JD, 1978, AM J CARDIOL, V41, P1209, DOI 10.1016/0002-9149(78)90877-9; FRITZ IB, 1963, ADV LIPID RES, V1, P283; HANSFORD RG, 1978, ARCH BIOCHEM BIOPHYS, V191, P65, DOI 10.1016/0003-9861(78)90068-1; ICHIHARA K, 1985, AM J PHYSIOL, V249, pH492, DOI 10.1152/ajpheart.1985.249.3.H492; KERBEY AL, 1985, BASIC RES CARDIOL, V80, P93; KOBAYASHI K, 1979, CIRC RES, V44, P166, DOI 10.1161/01.RES.44.2.166; LIEDTKE AJ, 1979, J CLIN INVEST, V64, P440, DOI 10.1172/JCI109481; LOPASCHUK GD, 1988, CIRC RES, V63, P1036, DOI 10.1161/01.RES.63.6.1036; LOPASCHUK GD, 1990, CAN J PHYSIOL PHARM, V68, P462, DOI 10.1139/y90-065; LOPASCHUK GD, 1986, AM J PHYSIOL, V250, pH351, DOI 10.1152/ajpheart.1986.250.3.H351; LOPASCHUK GD, 1990, CIRC RES, V66, P546, DOI 10.1161/01.RES.66.2.546; LOPASCHUK GD, 1987, CIRC RES, V61, P853, DOI 10.1161/01.RES.61.6.853; LOPASCHUK GD, 1989, MOL CELL BIOL, V188, P175; LYSIAK W, 1986, J BIOL CHEM, V261, P3698; LYSIAK W, 1988, J BIOL CHEM, V263, P1151; MCGARRY JD, 1976, J LIPID RES, V17, P277; NAGEO B, 1987, JPN HEART J, V28, P243; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; NEWSHOLME EA, 1962, NATURE, V193, P270, DOI 10.1038/193270a0; PANDE SV, 1976, J BIOL CHEM, V251, P6683; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PAULSON DJ, 1984, METABOLISM, V33, P358, DOI 10.1016/0026-0495(84)90199-9; PEARSON DJ, 1967, BIOCHEM J, V105, P953, DOI 10.1042/bj1050953; PIEPER GM, 1984, BIOCHIM BIOPHYS ACTA, V803, P241, DOI 10.1016/0167-4889(84)90113-7; PIEPER GM, 1987, BIOCHEM MED METAB B, V38, P111, DOI 10.1016/0885-4505(87)90068-5; PIEPER GM, 1984, BIOCHIM BIOPHYS ACTA, V803, P229, DOI 10.1016/0167-4889(84)90112-5; RODRIGUES B, 1990, CAN J PHYSIOL PHARM, V68, P1085, DOI 10.1139/y90-163; RODRIGUES B, 1988, DIABETES, V37, P1358, DOI 10.2337/diabetes.37.10.1358; ROVETTO MJ, 1975, CIRC RES, V37, P742, DOI 10.1161/01.RES.37.6.742; SADDIK M, 1991, J BIOL CHEM, V266, P8162; SHUG AL, 1973, J LAB CLIN MED, V81, P214; SHUG AL, 1978, ARCH BIOCHEM BIOPHYS, V187, P25, DOI 10.1016/0003-9861(78)90003-6; SUZUKI Y, 1981, JPN CIRC J, V45, P552, DOI 10.1253/jcj.45.552; UZIEL G, 1988, MUSCLE NERVE, V11, P720, DOI 10.1002/mus.880110708; VARY TC, 1983, AM J PHYSIOL, V244, pH247, DOI 10.1152/ajpheart.1983.244.2.H247; VARY TC, 1982, AM J PHYSIOL, V242, pH585, DOI 10.1152/ajpheart.1982.242.4.H585; WALL SR, 1989, BIOCHIM BIOPHYS ACTA, V1006, P97, DOI 10.1016/0005-2760(89)90328-7; [No title captured]	38	167	167	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3758	3763						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740427				2022-12-25	WOS:A1992HE60700035
J	KINSELLA, BT; MALTESE, WA				KINSELLA, BT; MALTESE, WA			RAB GTP-BINDING PROTEINS WITH 3 DIFFERENT CARBOXYL-TERMINAL CYSTEINE MOTIFS ARE MODIFIED INVIVO BY 20-CARBON ISOPRENOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; LAMIN-B; FARNESYL; YEAST; P21RAS; IDENTIFICATION; ISOPRENYLATION; BIOSYNTHESIS; TRANSFERASE; INHIBITION	p21ras and several other ras-related GTP-binding proteins are modified post-translationally by addition of 15-carbon farnesyl or 20-carbon geranylgeranyl isoprenoids to cysteines within a conserved carboxyl-terminal sequence motif, Caa(M/S/L), where a is an aliphatic amino acid. Proteins ending with M or S are substrates for farnesyltransferase, whereas those ending with L are modifed preferentially by geranylgeranyltransferase. We recently reported that GTP-binding proteins encoded by rab1B (GGCC), rab2 (GGCC), and rab5 (CCSN) are modified by 20-carbon isoprenyl derivatives of [H-3]mevalonate when translated in vitro, despite having carboxyl-terminal sequences distinct from the Caa(M/S/L) motif. We now show that these proteins function as specific acceptors for geranylgeranyl in vitro and are modified by 20-carbon isoprenyl groups in COS cells metabolically labeled with [H-3]mevalonate. Proteins encoded by rab4 and rab6, with yet another distinct carboxyl-terminal motif (xCxC), are similarly modified by 20-carbon isoprenoids in vitro and in vivo. The geranylgeranyl modification of rab5 protein (CCSN) is catalyzed by an enzyme in brain cytosol but not by a purified geranylgeranyltransferase that modifies GTP-binding proteins with the CaaL motif. Unlike the prenylation of proteins with Caa(M/S/L) termini, the prenylation of rab5 protein is not inhibited by a synthetic peptide based on its carboxyl-terminal sequence (TRNQCCSN). When cellular isoprenoid synthesis is blocked by treatment of cells with lovastatin, rab proteins that are normally localized in membranes of the endoplasmic reticulum, Golgi apparatus, and endosomes accumulate in the cytosol. This change in rab protein localization is reversed by providing cells with mevalonate. These findings suggest that geranylgeranyl modification underlies the ability of rab GTP-binding proteins to associate with intracellular membranes, where they are postulated to function as mediators of vesicular traffic.	GEISINGER MED CLIN,WEIS CTR RES,N ACAD AVE,DANVILLE,PA 17822	Geisinger Medical Center				Kinsella, B. Therese/0000-0003-3072-941X	NCI NIH HHS [CA34569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GUILLY MN, 1987, EUR J CELL BIOL, V43, P266; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; KINSELLA BT, 1991, P NATL ACAD SCI USA, V88, P8934, DOI 10.1073/pnas.88.20.8934; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONARD S, 1990, J BIOL CHEM, V265, P5157; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; MOORES SL, 1991, J BIOL CHEM, V266, P14603; OHYA Y, 1991, J BIOL CHEM, V266, P12356; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REPKO EM, 1989, J BIOL CHEM, V264, P9945; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sambrook J, 1989, MOL CLONING LABORATO; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIELH E, 1989, NUCLEIC ACIDS RES, V17, P1770, DOI 10.1093/nar/17.4.1770; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	63	119	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3940	3945						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740442				2022-12-25	WOS:A1992HE60700061
J	SCAPIN, G; GORDON, JI; SACCHETTINI, JC				SCAPIN, G; GORDON, JI; SACCHETTINI, JC			REFINEMENT OF THE STRUCTURE OF RECOMBINANT RAT INTESTINAL FATTY ACID-BINDING APOPROTEIN AT 1.2-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN-STRUCTURE; MESSENGER-RNA; 3-DIMENSIONAL STRUCTURE; MOLECULAR-STRUCTURE; CRYSTAL-STRUCTURE; SEQUENCE; EXPRESSION; IDENTIFICATION; MODEL	The three-dimensional structure of the 131-residue rat intestinal fatty acid-binding protein, without bound ligand (apoI-FABP), has been refined with x-ray diffraction data to a nominal resolution of 1.19 angstrom. The final model has a conventional crystallographic R-factor of 16.9% for 34,290 unique reflections [a root mean square (r.m.s.) deviation for bond length of 0.012 angstrom and a r.m.s deviation of 2.368-degrees for bond angles]. Ninety-two residues are present as components of the protein's 10 anti-parallel beta-strands while 14 residues are part of its two short alpha-helices. The beta-strands and alpha-helices are organized into two nearly orthogonal beta-sheets. Particular attention has been placed in defining solvent structure and the structures of discretely disordered groups in this protein. Two hundred thirty-seven solvent molecules have been identified; 24 are located within apoI-FABP. The refined model includes alternate conformers for 228 protein atoms (109 main-chain, 119 side-chain) and 63 solvent molecules. We have found several aromatic side-chains with multiple conformations located near, or in, the protein's ligand binding site. This observation, along with the fact that these side-chains have a temperature factor that is relatively higher than that of other aromatic residues, suggests that they may be involved in the process of noncovalent binding of fatty acid. The absence of a true hydrophobic core in I-FABP suggests that its structural integrity may be maintained primarily by a hydrogen bonding network involving protein and solvent atoms.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)	SCAPIN, G (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30292] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; BOHMER FD, 1987, J BIOL CHEM, V262, P15137; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GORDON JI, 1983, J BIOL CHEM, V258, P3356; HEUCKEROTH RO, 1987, J BIOL CHEM, V262, P9709; HOLDEN HM, 1987, EMBO J, V6, P1565, DOI 10.1002/j.1460-2075.1987.tb02401.x; HUBER R, 1987, J MOL BIOL, V198, P499, DOI 10.1016/0022-2836(87)90296-8; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; ISHAQUE A, 1982, J BIOL CHEM, V257, P592; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCREE DE, 1989, P NATL ACAD SCI USA, V86, P6533, DOI 10.1073/pnas.86.17.6533; MILNERWHITE EJ, 1987, BIOCHIM BIOPHYS ACTA, V911, P261, DOI 10.1016/0167-4838(87)90017-3; MONACO HL, 1987, J MOL BIOL, V197, P695, DOI 10.1016/0022-2836(87)90476-1; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; OLINS PO, 1989, J BIOL CHEM, V264, P16973; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SACCHETTINI JC, 1989, P NATL ACAD SCI USA, V86, P7736, DOI 10.1073/pnas.86.20.7736; SACCHETTINI JC, 1990, MOL CELL BIOCHEM, V98, P81; SACCHETTINI JC, 1990, J BIOL CHEM, V265, P19199; SALEMME FR, 1985, METHOD ENZYMOL, V114, P140; SCAPIN G, 1990, MOL CELL BIOCHEM, V98, P95; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SMITH JL, 1988, ACTA CRYSTALLOGR A, V44, P357, DOI 10.1107/S0108767388000303; SUNDELIN J, 1985, J BIOL CHEM, V260, P6494; SUNDELIN J, 1985, J BIOL CHEM, V260, P6488; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALZ DA, 1988, J BIOL CHEM, V263, P14189	39	175	177	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4253	4269						17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740465				2022-12-25	WOS:A1992HE60700099
J	SUNDSETH, SS; ALBERTA, JA; WAXMAN, DJ				SUNDSETH, SS; ALBERTA, JA; WAXMAN, DJ			SEX-SPECIFIC, GROWTH HORMONE-REGULATED TRANSCRIPTION OF THE CYTOCHROME-P450 2C11 AND 2C12 GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOCHROME-P-450; INVITRO TRANSCRIPTION; BINDING-PROTEIN; C-FOS; EXPRESSION; PITUITARY; ALPHA-2U-GLOBULIN; HEPATOCYTES; SECRETION; GLAND	Growth hormone (GH) differentially regulates the expression of several male-specific and female-specific liver cytochrome P450 mRNAs as a function of its sex-dependent ultradian secretory pattern. Pulsatile GH release stimulates expression of the male-specific P450 2C11, while a continuous GH secretion pattern suppresses expression of 2C11 and stimulates the expression of the female-specific P450 2C12. To help define the level at which GH regulates the expression of 2C11 and 2C12 mRNA, liver nuclear RNA samples isolated from rats differing in GH status were analyzed for 2C11 and 2C12 hnRNAs by hybridization to 2C11 and 2C12 gene-specific exonic oligonucleotide probes, as well as exon/intron junction probes. The 2C11 and 2C12 hnRNAs were found to be responsive to circulating GH profiles in a manner indistinguishable from the corresponding mature, cytoplasmic mRNAs, with no 2C12 mRNA precursors found in untreated male or hypophysectomized female liver nuclei, and no 2C11 mRNA precursors in untreated female or hypophysectomized male liver nuclei. Thus, transport of 2C11 and 2C12 RNA to the cytoplasm and cytoplasmic mRNA stability are unlikely to be important GH-regulated control points for sex-specific P450 RNA expression. Run-on transcription analysis further established that GH regulates the sex-specific expression of the 2C11 and 2C12 genes at the level of transcript initiation. Transcription was also shown to be the major step for regulation of the male-specific P450 2A2 RNA, whose expression, unlike 2C11, is not obligatorily dependent on pulsatile GH release. In vitro footprinting analysis of 2C11 and 2C12 promoter fragments incubated with liver nuclear proteins isolated from rats differing in GH status revealed several sex- and GH-dependent differences in DNase cleavage patterns ("hypersensitivity sites"), demonstrating that GH can regulate specific protein-DNA interactions in the 5'-flanking sequences of these two genes. In vitro transcription assays driven by 2C11 and 2C12 5'-flanking DNA sequences fused to TATAA box-G-less cassette template constructs did not, however, faithfully mimic the sex-specific transcription of the 2C11 and 2C12 genes, indicating that additional cis-elements or trans-acting factors may be required to achieve the transcriptional regulation of these genes that occurs in vivo.	HARVARD UNIV, SCH MED,DANA FARBER CANC INST,JF-525,44 BINNEY ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Sundseth, Scott/0000-0002-3122-4862; Waxman, David/0000-0001-7982-9206	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33765, R01 DK033765] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; EDEN S, 1979, ENDOCRINOLOGY, V105, P555, DOI 10.1210/endo-105-2-555; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREENBERG ME, 1987, CURRENT PROTOCOLS; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; GUZELIAN PS, 1988, P NATL ACAD SCI USA, V85, P9783, DOI 10.1073/pnas.85.24.9783; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; ISGAARD J, 1988, ENDOCRINOLOGY, V123, P2605, DOI 10.1210/endo-123-6-2605; JANECZKO R, 1990, MOL ENDOCRINOL, V4, P295, DOI 10.1210/mend-4-2-295; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; JOHNSON RM, 1990, ENDOCRINOLOGY, V127, P2099, DOI 10.1210/endo-127-5-2099; KATO R, 1986, J BIOCHEM-TOKYO, V100, P895, DOI 10.1093/oxfordjournals.jbchem.a121802; KULKARNI AB, 1985, P NATL ACAD SCI USA, V82, P2579, DOI 10.1073/pnas.82.9.2579; LANDOLFI NF, 1989, BIOTECHNIQUES, V7, P500; LAPERCHE Y, 1983, CELL, V32, P453, DOI 10.1016/0092-8674(83)90465-8; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MACGEOCH C, 1985, ENDOCRINOLOGY, V117, P2085, DOI 10.1210/endo-117-5-2085; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MATSUNAGA T, 1990, BIOCHEMISTRY-US, V29, P1329, DOI 10.1021/bi00457a032; MCCLELLANGREEN PD, 1989, J BIOL CHEM, V264, P18960; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MODE A, 1989, MOL ENDOCRINOL, V3, P1142, DOI 10.1210/mend-3-7-1142; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; MORGAN ET, 1985, J BIOL CHEM, V260, P1895; MORISHIMA N, 1987, BIOCHEMISTRY-US, V26, P8279, DOI 10.1021/bi00399a039; MURTY CVR, 1987, ENDOCRINOLOGY, V121, P1819; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NORSTEDT G, 1984, CELL, V36, P805, DOI 10.1016/0092-8674(84)90030-8; NOSHIRO M, 1986, J BIOL CHEM, V261, P5923; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; SAMBROOK J, 1989, MOL CLONING LABORATO, V1; SARKAR P, 1989, MOL ENDOCRINOL, V3, P342, DOI 10.1210/mend-3-2-342; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SENEVIRATNE C, 1990, MOL ENDOCRINOL, V4, P1199, DOI 10.1210/mend-4-8-1199; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SUNDSETH R, 1990, DNA PROTEIN ENG TECH, V2, P57; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; THORNER MO, 1988, J CLIN INVEST, V82, P745, DOI 10.1172/JCI113673; TOLLET P, 1990, MOL ENDOCRINOL, V4, P1934, DOI 10.1210/mend-4-12-1934; TSUTSUMI K, 1989, MOL CELL BIOL, V9, P4923, DOI 10.1128/MCB.9.11.4923; UENO T, 1990, MOL CELL BIOL, V10, P4495, DOI 10.1128/MCB.10.9.4495; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WAXMAN DJ, 1985, BIOCHEMISTRY-US, V24, P4409, DOI 10.1021/bi00337a023; WAXMAN DJ, 1988, J BIOL CHEM, V263, P11396; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; WAXMAN DJ, 1991, METHODS ENZYMOL, V206, P249; WEN LP, 1990, P NATL ACAD SCI USA, V87, P8545, DOI 10.1073/pnas.87.21.8545; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; WRIGHT K, 1990, FEBS LETT, V271, P59, DOI 10.1016/0014-5793(90)80371-O; YAMAZOE Y, 1988, J BIOCHEM-TOKYO, V104, P785, DOI 10.1093/oxfordjournals.jbchem.a122550; ZANGER UM, 1991, J BIOL CHEM, V266, P11417; ZAPHIROPOULOS PG, 1989, TRENDS PHARMACOL SCI, V10, P149, DOI 10.1016/0165-6147(89)90167-3; ZAPHIROPOULOS PG, 1990, DNA CELL BIOL, V9, P49, DOI 10.1089/dna.1990.9.49; ZAPHIROPOULOS PG, 1988, P NATL ACAD SCI USA, V85, P4214, DOI 10.1073/pnas.85.12.4214	58	123	123	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3907	3914						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740438				2022-12-25	WOS:A1992HE60700057
J	LADANT, D; GLASER, P; ULLMANN, A				LADANT, D; GLASER, P; ULLMANN, A			INSERTIONAL MUTAGENESIS OF BORDETELLA-PERTUSSIS ADENYLATE-CYCLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CALMODULIN-BINDING; PROTEIN; IDENTIFICATION; PURIFICATION; EXPRESSION; TOXIN; CONSTRUCTION; RESIDUES; MOLECULE	We developed an improved method of linker insertion mutagenesis for introducing 2 or 16 codons into the Bordetella pertussis cyaA gene which encodes a calmodulin-dependent adenylate cyclase. A recombinant kanamycin resistance cassette, containing oligonucleotide linkers, was cloned in plasmids which carried a truncated cyaA gene, fused at its 3' end to the 5' end of the Escherichia coli lacZ gene, specifying the alpha-peptide. This construction permitted a double selection for in-frame insertions by using screening for kanamycin resistance and for lactose-positive phenotype, resulting from alpha-complementation. We showed that most of the two-amino acid insertions within the N-terminal moiety of the catalytic domain of adenylate cyclase abolished enzymatic activity and/or altered the stability of the protein. All two-amino acid insertions within the C-terminal part of adenylate cyclase resulted in fully stable and active enzymes. These results confirm the modular structure of the catalytic domain of adenylate cyclase, previously proposed on the basis of proteolytic studies. Two-amino acid insertions between residues 247-248 and 335-336 were shown to affect the calmodulin responsiveness of adenylate cyclase, suggesting that the corresponding region in the enzyme is involved in the binding of calmodulin or in the process of calmodulin activation. In addition, we have identified within the primary structure of adenylate cyclase several permissive sites which tolerate 16-amino acid insertions without interfering with the catalytic activity or calmodulin binding. By inserting foreign antigenic determinants into these permissive sites the resulting recombinant adenylate cyclase toxin could be used to deliver specific epitopes into antigen-presenting cells.	INST PASTEUR,UNITE REGULAT EXPRESS GENET,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	LADANT, D (corresponding author), INST PASTEUR,UNITE BIOCHIM REGULAT CELLULAIRES,F-75724 PARIS 15,FRANCE.		Glaser, Philippe/O-2641-2015	Glaser, Philippe/0000-0003-4156-2782; LADANT, Daniel/0000-0003-1955-548X				BARANY F, 1985, P NATL ACAD SCI USA, V82, P4202, DOI 10.1073/pnas.82.12.4202; BARANY F, 1985, GENE, V37, P111, DOI 10.1016/0378-1119(85)90263-X; BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BLONDEL A, 1991, NUCLEIC ACIDS RES, V19, P181, DOI 10.1093/nar/19.1.181; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHARBIT A, 1986, EMBO J, V5, P3029, DOI 10.1002/j.1460-2075.1986.tb04602.x; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; FREIMUTH PI, 1990, J BIOL CHEM, V265, P896; FREIMUTH PI, 1986, P NATL ACAD SCI USA, V83, P7816, DOI 10.1073/pnas.83.20.7816; GENTILE F, 1990, J BIOL CHEM, V265, P10686; GILLES AM, 1990, BIOCHEMISTRY-US, V29, P8126, DOI 10.1021/bi00487a020; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GLASER P, 1991, EMBO J, V10, P1683, DOI 10.1002/j.1460-2075.1991.tb07692.x; GO M, 1980, INT J PEPT PROT RES, V15, P211; GORDON VM, 1989, J BIOL CHEM, V264, P14792; GOYARD S, 1989, BIOCHEMISTRY-US, V28, P1964, DOI 10.1021/bi00431a002; HANSKI E, 1989, TRENDS BIOCHEM SCI, V14, P459, DOI 10.1016/0968-0004(89)90106-0; HEDEGAARD L, 1985, MOL GEN GENET, V201, P38, DOI 10.1007/BF00397984; HEFFRON F, 1978, P NATL ACAD SCI USA, V75, P6012, DOI 10.1073/pnas.75.12.6012; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; INOUYE S, 1983, P NATL ACAD SCI-BIOL, V80, P6829, DOI 10.1073/pnas.80.22.6829; KUMAR GB, 1991, J BIOL CHEM, V266, P1348; LADANT D, 1988, J BIOL CHEM, V263, P2612; LADANT D, 1989, J BIOL CHEM, V264, P4015; LADANT D, 1986, J BIOL CHEM, V261, P6264; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LOBEL LI, 1984, P NATL ACAD SCI-BIOL, V81, P4149, DOI 10.1073/pnas.81.13.4149; MONNERON A, 1988, BIOCHEMISTRY-US, V27, P536, DOI 10.1021/bi00402a005; MUNIER H, 1991, EUR J BIOCHEM, V196, P469, DOI 10.1111/j.1432-1033.1991.tb15838.x; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; ROBERTS DM, 1985, BIOCHEMISTRY-US, V24, P5090, DOI 10.1021/bi00340a020; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; STARZYK RM, 1989, BIOCHEMISTRY-US, V28, P8479, DOI 10.1021/bi00447a031; SWAN DG, 1987, NATURE, V329, P84, DOI 10.1038/329084a0; TOMA S, 1991, BIOCHEMISTRY-US, V30, P97, DOI 10.1021/bi00215a015; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661	43	63	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2244	2250						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733931				2022-12-25	WOS:A1992HB53200022
J	LENHARD, JM; MAYORGA, L; STAHL, PD				LENHARD, JM; MAYORGA, L; STAHL, PD			CHARACTERIZATION OF ENDOSOME-ENDOSOME FUSION IN A CELL-FREE SYSTEM USING DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEINS; RECEPTOR-MEDIATED ENDOCYTOSIS; YEAST SECRETORY MUTANTS; INVITRO FUSION; ACANTHAMOEBA PHAGOLYSOSOMES; ELECTRON-MICROSCOPE; VESICULAR TRANSPORT; INTRACELLULAR PH; VACUOLE FUSION; GOLGI STACK	An in vitro endosome fusion assay using Dictyostelium discoideum is described. The method requires endocytosis of anti-dinitrophenol (DNP) IgG or DNP-derivitized beta-glucuronidase into two sets of cells. After homogenizing the cells, the vesicles were mixed, and fusion was measured by quantitating immune complex formation between DNP-beta-glucuronidase and anti-DNP IgG. Fusion was dependent upon ATP, temperature, pH, ionic strength, and cytosol and sensitive to detergent, dilution, trypsin, N-ethylmaleimide, and guanosine 5'-3-O-(thio)triphosphate. Although weak bases, ionophores, hadacidin, [ethylenebis(oxyethylenenitrilo)] tetraacetic acid, and caffeine inhibit endocytosis in vivo, these reagents had no affect on in vitro endosome fusion. Comparison of Dictyostelium with mammalian cells showed differences in the temperature, pH, and salt requirements for fusion, possibly reflecting differences in the life-styles of various cell types. Like mammalian cells, Dictyostelium required GTP-binding protein(s) and an N-ethylmaleimide-sensitive factor for endosome fusion. Thus, the mechanism driving endosome fusion may have been conserved throughout evolution. Electron microscopic studies confirmed in vitro endosome fusion and revealed endosomes were being engulfed by other endosomes, resulting in formation of multivesicular elements (i.e. autophagic vesicles). This system may be useful for characterizing mutations, evolution, and developmental regulation along the endocytic pathway.	NATL UNIV CUYO,INST HISTOL & EMBRIOL,RA-5500 MENDOZA,ARGENTINA	University Nacional Cuyo Mendoza	LENHARD, JM (corresponding author), WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110, USA.		Stahl, Philip/D-6315-2012	Mayorga, Luis S/0000-0002-5995-0671	NIAID NIH HHS [AI20015] Funding Source: Medline; NIGMS NIH HHS [GM42259-19] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020015, R37AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BEAUMELLE BD, 1989, BIOCHEM J, V264, P137, DOI 10.1042/bj2640137; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRAELL WA, 1987, P NATL ACAD SCI USA, V84, P1137, DOI 10.1073/pnas.84.5.1137; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; COSSON P, 1989, J CELL BIOL, V108, P377, DOI 10.1083/jcb.108.2.377; DAVEY J, 1985, CELL, V43, P643, DOI 10.1016/0092-8674(85)90236-3; de Chastellier C, 1977, Journal Cell Biol, V75, P218, DOI 10.1083/jcb.75.1.218; DECHASTELLIER C, 1977, J CELL BIOL, V75, P200; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, J BIOL CHEM, V264, P13171; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DIAZ R, 1991, IN PRESS METHODS ENZ; DUNPHY WG, 1986, P NATL ACAD SCI USA, V83, P1622, DOI 10.1073/pnas.83.6.1622; EBERT DL, 1989, J CELL BIOL, V109, P1445, DOI 10.1083/jcb.109.4.1445; GONZALEZ C, 1990, J CELL PHYSIOL, V144, P408, DOI 10.1002/jcp.1041440307; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG JE, 1986, EMBO J, V5, P3091, DOI 10.1002/j.1460-2075.1986.tb04615.x; KELLER RK, 1975, J BIOL CHEM, V250, P4765; KINSELLA BA, 1986, DIFFERENTIATION, V31, P100, DOI 10.1111/j.1432-0436.1986.tb00389.x; KLEIN G, 1986, BIOCHEM BIOPH RES CO, V138, P1146, DOI 10.1016/S0006-291X(86)80402-8; LENHARD JM, 1991, BIOCHEM BIOPH RES CO, V174, P197, DOI 10.1016/0006-291X(91)90505-2; LENHARD JM, 1989, J CELL BIOL, V109, P2761, DOI 10.1083/jcb.109.6.2761; LENHARD JM, 1989, EXP CELL RES, V182, P242, DOI 10.1016/0014-4827(89)90295-4; LOOMIS WF, 1987, METHOD CELL BIOL, V28, P31; MAEDA Y, 1986, EXP CELL RES, V164, P516, DOI 10.1016/0014-4827(86)90049-2; MARIN FT, 1980, J CELL BIOL, V87, P823, DOI 10.1083/jcb.87.3.823; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; NORTH MJ, 1983, J GEN MICROBIOL, V129, P1381; OATES PJ, 1978, J CELL BIOL, V79, P217, DOI 10.1083/jcb.79.1.217; OATES PJ, 1976, J CELL BIOL, V68, P319, DOI 10.1083/jcb.68.2.319; OTSUKA FL, 1984, J NUCL MED, V25, P1343; PADH H, 1991, J BIOL CHEM, V266, P5514; RIEZMAN H, 1985, CELL, V40, P1001, DOI 10.1016/0092-8674(85)90360-5; Rodman JS, 1990, CURR OPIN CELL BIOL, V2, P664, DOI 10.1016/0955-0674(90)90108-Q; ROTH J, 1983, TECHNIQUES IMMUNOCYT, V2, P217; SATRE M, 1989, BIOCHIMIE, V71, P941, DOI 10.1016/0300-9084(89)90076-X; SCHEKMAN R, 1983, METHOD ENZYMOL, V96, P802; SHEPHERD VL, 1985, J BIOL CHEM, V260, P160; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; THILO L, 1985, BIOCHIM BIOPHYS ACTA, V822, P243, DOI 10.1016/0304-4157(85)90010-3; THILO L, 1980, P NATL ACAD SCI-BIOL, V77, P1015, DOI 10.1073/pnas.77.2.1015; TURNER R, 1979, BIOCHEM J, V180, P119, DOI 10.1042/bj1800119; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	51	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1896	1903						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730725				2022-12-25	WOS:A1992HA48500077
J	MITCHELL, MT; HOBSON, GM; BENFIELD, PA				MITCHELL, MT; HOBSON, GM; BENFIELD, PA			TATA BOX-MEDIATED POLYMERASE-III TRANSCRIPTION INVITRO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENE; CREATINE-KINASE PROMOTER; MAJOR LATE PROMOTER; SMALL NUCLEAR-RNA; C-MYC GENE; REGULATORY ELEMENTS; UPSTREAM PROMOTER; BINDING-PROTEIN; INITIATION; REGION	We have defined conditions whereby a functional TATA box can mediate efficient in vitro transcription by RNA polymerase III. A TATA box is absolutely required for this reaction as a single-point mutation in this sequence completely abolishes transcription. Two protein components are also required: a HeLa cell phosphocellulose fraction (fraction B) and at least one other factor that can be supplied by various crude nuclear extracts or by HeLa cell phosphocellulose fractions C and D. The order of addition is critical; fraction B must be preincubated with the template DNA for TATA box-dependent polymerase III transcription to occur. Various TATA sequences are quite similar in their ability to mediate transcription by polymerases II and III. Despite the similarity in sequence requirements, fraction B does not appear to contain any detectable transcription factor (TF) IID activity, and TATA box-mediated polymerase III transcription does not appear to require TFIID in the form contained in phosphocellulose fraction D. It was recently reported that TFIID is required for polymerase III transcription of the yeast and human U6 genes (Margottin, F., Dujardin, G., Gerard, M., Egly, J.-M., Huet, J., and Sentenac, A. (1991) Science 251, 424-426; Simmen, K. A., Bernues, J., Parry, H. D., Stunnenberg, H. G., Berkenstam, A., Cavallini, B., Egly, J.-M., and Mattaj, I. W. (1991) EMBO J. 10, 1853-1862). We propose that fraction B may contain TFIID in a modified form that is not functional for polymerase II transcription.			MITCHELL, MT (corresponding author), DUPONT CO,WILMINGTON,DE 19880, USA.							ABMAYR SM, 1988, GENE DEV, V2, P542, DOI 10.1101/gad.2.5.542; BENTLEY DL, 1989, GENE DEV, V3, P1179, DOI 10.1101/gad.3.8.1179; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; EISENMANN DM, 1989, CELL, V58, P1183, DOI 10.1016/0092-8674(89)90516-3; GARCIA AD, 1987, MOL CELL BIOL, V7, P2046, DOI 10.1128/MCB.7.6.2046; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; HOBSON GM, 1988, NUCLEIC ACIDS RES, V16, P8925, DOI 10.1093/nar/16.18.8925; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KLEINERT H, 1990, EMBO J, V9, P711, DOI 10.1002/j.1460-2075.1990.tb08164.x; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; LARSON D, 1983, P NATL ACAD SCI-BIOL, V80, P3416, DOI 10.1073/pnas.80.11.3416; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LEE BJ, 1989, J BIOL CHEM, V264, P9696; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MITCHELL MT, 1990, J BIOL CHEM, V265, P8259; MOENNE A, 1990, EMBO J, V9, P271, DOI 10.1002/j.1460-2075.1990.tb08105.x; MORTON DG, 1984, P NATL ACAD SCI USA, V8, P5519; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NAGWA F, 1985, P NATL ACAD SCI USA, V82, P8557; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NIELSEN DA, 1986, NUCLEIC ACIDS RES, V14, P5936, DOI 10.1093/nar/14.14.5936; OHSHIMA Y, 1981, NUCLEIC ACIDS RES, V9, P5145, DOI 10.1093/nar/9.19.5145; PARRY HD, 1990, EMBO J, V9, P1097, DOI 10.1002/j.1460-2075.1990.tb08215.x; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REDDY R, 1988, J BIOL CHEM, V263, P15980; REINBERG D, 1987, J BIOL CHEM, V262, P3310; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHARP SJ, 1985, CRC CR REV BIOCH MOL, V19, P107, DOI 10.3109/10409238509082541; SIMMEN KA, 1990, NUCLEIC ACIDS RES, V18, P5649, DOI 10.1093/nar/18.19.5649; SIMMEN KA, 1991, EMBO J, V10, P1853, DOI 10.1002/j.1460-2075.1991.tb07711.x; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; TALKINGTON CA, 1982, NATURE, V298, P192, DOI 10.1038/298192a0; WAIBEL F, 1990, NUCLEIC ACIDS RES, V18, P3451, DOI 10.1093/nar/18.12.3451; WASYLYK B, 1981, NUCLEIC ACIDS RES, V9, P1813, DOI 10.1093/nar/9.8.1813; WASYLYK B, 1980, P NATL ACAD SCI-BIOL, V77, P7024, DOI 10.1073/pnas.77.12.7024; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3	56	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1995	2005						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730731				2022-12-25	WOS:A1992HA48500091
J	COBB, JA; MANNING, D; KOLATKAR, PR; COX, DJ; RIGGS, AF				COBB, JA; MANNING, D; KOLATKAR, PR; COX, DJ; RIGGS, AF			DEOXYGENATION-LINKED ASSOCIATION OF A TETRAMERIC COMPONENT OF CHICKEN HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-AFFINITY; ORGANIC-PHOSPHATES; RANA-CATESBEIANA; BETA-CHAINS; BLOOD; EXPRESSION; BULLFROG; AGGREGATION; EVOLUTION; BINDING	Deoxygenation-dependent association of hemoglobin tetramers appears to be widespread among amphibians, reptiles, and possibly all or most birds. The evidence for this conclusion depends largely on oxygen equilibria of whole blood which have Hill coefficients that reach values as high as 5-7 at 80-90% oxygenation. Computer simulation of the sedimentation velocity behavior of the major components A and D of chicken hemoglobin shows that component D but not A self-associates to form dimers of tetramers. The gradient profiles at pH 7.5 were satisfactorily fitted with an association constant of 1.26 x 10(4) M-1 and sedimentation coefficients of 4.63 and 7.35 S for tetramer and (tetramer)2, respectively. Since components A and D share common beta-chains we conclude that tetramer-tetramer contacts must depend on surface residues of the alpha-chains. Comparison of the amino acid sequences of the alpha(D) and alpha(A) chains of the hemoglobins from 12 avian species ranging from sparrow to ostrich shows that 20 residues are conserved in the alpha(D) chains but not in the alpha(A) chains. Nine of these (45%) are clustered between positions E20 and FG2. Four of the latter, Lys71 (E20), Asn75(EF4), Gln78(EF7), and Glu82(F3) are conserved in all alpha(D) chains even though they do not appear to participate in intratetramer contacts. Molecular modeling indicates that residues Lys71, Gln78, and Glu82 of the alpha-chain are strong candidates for the primary tetramer-tetramer contacts.	KANSAS STATE UNIV AGR & APPL SCI,DEPT BIOCHEM,MANHATTAN,KS 66506; UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712; UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712	Kansas State University; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin				kolatkar, prasanna/0000-0003-4970-5944	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035847] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35847] Funding Source: Medline; PHS HHS [22243] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABBASI A, 1988, BIOL CHEM H-S, V369, P755, DOI 10.1515/bchm3.1988.369.2.755; ATHA DH, 1979, J BIOL CHEM, V254, P3393; BAUMANN R, 1984, BIOCHEM J, V217, P767, DOI 10.1042/bj2170767; BAUMANN R, 1982, J APPL PHYSIOL, V53, P1439, DOI 10.1152/jappl.1982.53.6.1439; BERNER NJ, 1988, J EXP BIOL, V140, P437; Cohn E. J., 1943, PROTEINS AMINO ACIDS; Cox D. J, 1978, METHOD ENZYMOL, V48F, P212; COX DJ, 1967, ARCH BIOCHEM BIOPHYS, V119, P230, DOI 10.1016/0003-9861(67)90450-X; CZELUSNIAK J, 1982, NATURE, V298, P297, DOI 10.1038/298297a0; FERMI G, 1981, ATLAS MOL STRUCTURES, P1; GIBSON QH, 1973, J BIOL CHEM, V248, P5976; Gilbert L M, 1973, Methods Enzymol, V27, P273; HIEBL I, 1987, BIOL CHEM H-S, V368, P1559, DOI 10.1515/bchm3.1987.368.2.1559; HIRSOWITZ LA, 1977, RESP PHYSIOL, V31, P51, DOI 10.1016/0034-5687(77)90064-0; HOLLOWAY RR, 1974, ARCH BIOCHEM BIOPHYS, V160, P595, DOI 10.1016/0003-9861(74)90436-6; HUBER K, 1988, BIOL CHEM H-S, V369, P1251, DOI 10.1515/bchm3.1988.369.2.1251; HUISMAN THJ, 1964, BIOCHIM BIOPHYS ACTA, V88, P352, DOI 10.1016/0926-6577(64)90190-1; ISAACKS RE, 1976, ARCH BIOCHEM BIOPHYS, V173, P114, DOI 10.1016/0003-9861(76)90240-X; JOHANSEN K, 1987, PHYSIOL ZOOL, V60, P269, DOI 10.1086/physzool.60.2.30158651; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KIRSHNER AG, 1964, BIOCHEMISTRY-US, V3, P291, DOI 10.1021/bi00891a002; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P579; LAPENNAS GN, 1983, RESP PHYSIOL, V52, P27, DOI 10.1016/0034-5687(83)90134-2; LUTZ PL, 1980, AM ZOOL, V20, P187; LUTZ PL, 1974, RESP PHYSIOL, V20, P325, DOI 10.1016/0034-5687(74)90029-2; MORROW JS, 1974, BIOCHEM BIOPH RES CO, V60, P1058, DOI 10.1016/0006-291X(74)90420-3; OBERTHUR W, 1986, BIOL CHEM H-S, V367, P507, DOI 10.1515/bchm3.1986.367.1.507; OCHIAI T, 1972, ARCH BIOCHEM BIOPHYS, V149, P316, DOI 10.1016/0003-9861(72)90327-X; Redfield AC, 1933, Q REV BIOL, V8, P31, DOI 10.1086/394424; RIGGS AF, 1988, ANNU REV PHYSIOL, V50, P181, DOI 10.1146/annurev.ph.50.030188.001145; RUCKNAGEL KP, 1984, H-S Z PHYSIOL CHEM, V365, P1163, DOI 10.1515/bchm2.1984.365.2.1163; SACK JS, 1978, HEMOGLOBIN, V2, P153, DOI 10.3109/03630267809074782; TAM LT, 1986, J BIOL CHEM, V261, P8290; TAM LT, 1984, J BIOL CHEM, V259, P2610; VANDECASSERIE C, 1971, EUR J BIOCHEM, V24, P284, DOI 10.1111/j.1432-1033.1971.tb19683.x; WASTL H, 1931, ARCH GES PHYSIOL, V227, P367; WEINGARTEN JP, 1978, PFLUG ARCH EUR J PHY, V377, P135, DOI 10.1007/BF00582843	37	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1183	1189						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730642				2022-12-25	WOS:A1992GY96000079
J	FLANAGAN, WM; CRABTREE, GR				FLANAGAN, WM; CRABTREE, GR			INVITRO TRANSCRIPTION FAITHFULLY REFLECTING T-CELL ACTIVATION REQUIREMENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T3-ANTIGEN RECEPTOR COMPLEX; LYMPHOCYTE-SPECIFIC FACTORS; CYTOPLASMIC FREE CALCIUM; HUMAN INTERLEUKIN-2 GENE; RNA POLYMERASE-II; PROTEIN KINASE-C; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; ADHESION RECEPTORS; OVERLAP EXTENSION	T-cell activation is a complex process mediated by cell membrane molecules including the T-cell antigen receptor (TCR), adhesive molecules, and cytokine receptors that collectively produce an increase in intracellular Ca2+, and activation of protein kinase C that initiate a genetic program resulting in immunologic function and irreversible differentiation. To understand how these cell membrane events are translated into a genetic regulatory cascade resulting in T-cell function, we have developed an in vitro transcription system, derived from Jurkat T-cells, which demonstrates inducible, cell-type-specific transcription following T-cell stimulation. Nuclear extracts from cells stimulated with phorbol 12-myristate 13-acetate and ionomycin, which activate protein kinase C and mimic physiological activation through the T-cell antigen receptor, transcribe an interleukin-2 (IL-2) enhancer (-326 to +24) template 5-fold more efficient than nuclear extracts from resting T-cells and several-fold more efficient than extracts from Jurkat cells treated with phorbol 12-myristate 13-acetate or ionomycin alone. Further results demonstrate that in vitro transcription of the IL-2 enhancer is T-cell specific since nuclear extracts from rat liver and stimulated HeLa cells are unable to induce IL-2 transcription. The activation-dependent, T-cell-specific in vitro transcription system described here should facilitate the dissection of signals that emanate from the T-cell surface resulting in IL-2 transcription and T-cell activation.	STANFORD UNIV, BECKMAN CTR, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University					NATIONAL CANCER INSTITUTE [R37CA039612, R01CA039612] Funding Source: NIH RePORTER; NCI NIH HHS [CA39612] Funding Source: Medline; NIAID NIH HHS [AI07290] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM RT, 1987, J BIOL CHEM, V262, P2719; ALEXANDER DR, 1989, IMMUNOL TODAY, V10, P200, DOI 10.1016/0167-5699(89)90325-3; Altman A, 1990, Adv Immunol, V48, P227, DOI 10.1016/S0065-2776(08)60756-7; ANGEL P, 1989, New Biologist, V1, P35; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BLACKMAN MA, 1986, CELL, V47, P609, DOI 10.1016/0092-8674(86)90625-2; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BURATOWSKI S, 1988, NATURE, V334, P37, DOI 10.1038/334037a0; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CORTHESY B, 1988, SCIENCE, V239, P1137, DOI 10.1126/science.2830672; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; CRABTREE GR, 1982, CELL, V31, P159, DOI 10.1016/0092-8674(82)90415-9; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; IMBODEN JB, 1985, IMMUNOL TODAY, V6, P328, DOI 10.1016/0167-5699(85)90129-X; IMBODEN JB, 1985, J IMMUNOL, V134, P663; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JOHNSON FB, 1990, GENE DEV, V4, P1044, DOI 10.1101/gad.4.6.1044; KAGONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20; KAMPS MP, 1990, MOL CELL BIOL, V10, P5464, DOI 10.1128/MCB.10.10.5464; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KUMAGAI N, 1987, J IMMUNOL, V139, P1393; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MANGER B, 1987, J IMMUNOL, V139, P2755; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MATSUNAMI N, 1986, NUCLEIC ACIDS RES, V14, P4779, DOI 10.1093/nar/14.12.4779; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MONOSTORI E, 1990, J IMMUNOL, V144, P1010; NABEL GJ, 1988, P NATL ACAD SCI USA, V85, P2934, DOI 10.1073/pnas.85.9.2934; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; RADLER-POHL A, 1990, New Biologist, V2, P566; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; SANDERS ME, 1988, IMMUNOL TODAY, V9, P195, DOI 10.1016/0167-5699(88)91212-1; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHIBUYA H, 1989, NUCLEIC ACIDS RES, V17, P9173, DOI 10.1093/nar/17.22.9173; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; WANG T, 1978, SCIENCE, V201, P155, DOI 10.1126/science.208147; Watson J, 1980, Immunol Rev, V51, P257, DOI 10.1111/j.1600-065X.1980.tb00324.x; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1989, FUNDAMENTAL IMMUNOLO, P359; WISKOCIL R, 1985, J IMMUNOL, V134, P1599	72	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					399	406						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730605				2022-12-25	WOS:A1992GY43900065
J	PRESTRELSKI, SJ; ARAKAWA, T; WU, CSC; ONEAL, KD; WESTCOTT, KR; NARHI, LO				PRESTRELSKI, SJ; ARAKAWA, T; WU, CSC; ONEAL, KD; WESTCOTT, KR; NARHI, LO			SOLUTION STRUCTURE AND DYNAMICS OF EPIDERMAL GROWTH-FACTOR AND TRANSFORMING GROWTH FACTOR-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE; CIRCULAR-DICHROISM; FACTOR RECEPTORS; CELLS; CONFORMATION; SPECTRA	Circular dichroism (CD) and Fourier transform infrared spectroscopic studies have shown that the secondary structure of transforming growth factor-alpha (TGF-alpha) is very similar to that of epidermal growth factor (EGF). The infrared spectra revealed a minor difference between the two proteins, in particular in the beta-sheet structure. A large difference was observed with CD between the two proteins in the apparent conformation each adopts when the disulfide bonds are reduced. Reduced TGF-alpha showed a distinct alpha-helical conformation only at a high trifluoroethanol concentration, whereas reduced EGF assumed an alpha-helical conformation in the absence of trifluoroethanol. This indicates that these two proteins adopt different secondary structures in the absence of disulfide bonds, although they assume similar folding structures in their presence. These data suggest that the disulfide bonds to a large degree dictate the conformation of these two proteins. Additionally, differences in the dynamic behavior between EGF and TGF-alpha were also observed. Infrared experiments showed that the hydrogen-deuterium exchange rate is much higher for TGF-alpha than for EGF, indicating that TGF-alpha is a more flexible molecule. The rate of reduction of the disulfide bonds by dithiothreitol was also faster for TGF-alpha. Therefore, it can be concluded that although EGF and TGF-alpha have a similar overall conformation, TGF-alpha is a more flexible molecule than EGF.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	PRESTRELSKI, SJ (corresponding author), AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320, USA.				NIGMS NIH HHS [GM-10880] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURGESS AW, 1989, BRIT MED BULL, V45, P401, DOI 10.1093/oxfordjournals.bmb.a072331; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; COHEN S, 1962, J BIOL CHEM, V237, P1555; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; COVINGTON AK, 1968, ANAL CHEM, V40, P700, DOI 10.1021/ac60260a013; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERCOLE AJ, 1976, EXCERPTA MED INTO C, V381, P190; ENGLANDER SW, 1972, ANNU REV BIOCHEM, V41, P903, DOI 10.1146/annurev.bi.41.070172.004351; HVIDT A., 1963, COMPT REND TRAV LAB CARLSBERG, V33, P475; JIRGENSONS B, 1982, INT J PEPT PROT RES, V20, P110; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; MARQUARDT H, 1983, P NATL ACAD SCI-BIOL, V80, P4684; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; PRESTRELSKI SJ, 1991, BIOCHEMISTRY-US, V30, P133, DOI 10.1021/bi00215a020; PRESTRELSKI SJ, 1991, ARCH BIOCHEM BIOPHYS, V285, P111, DOI 10.1016/0003-9861(91)90335-G; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SMITH JM, 1985, NATURE, V315, P515, DOI 10.1038/315515a0; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; TAMURA Y, 1980, ARCH BIOCHEM BIOPHYS, V199, P413, DOI 10.1016/0003-9861(80)90297-0; TAPPIN MJ, 1989, EUR J BIOCHEM, V179, P629, DOI 10.1111/j.1432-1033.1989.tb14594.x; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258	24	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					319	322						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730598				2022-12-25	WOS:A1992GY43900053
J	MCDONNELL, PC; KUMAR, S; RABSON, AB; GELINAS, C				MCDONNELL, PC; KUMAR, S; RABSON, AB; GELINAS, C			TRANSCRIPTIONAL ACTIVITY OF REL FAMILY PROTEINS	ONCOGENE			English	Article							NF-KAPPA-B; LONG TERMINAL REPEAT; AVIAN RETICULOENDOTHELIOSIS VIRUS; TRANSFORMED LYMPHOID-CELLS; V-REL; CYTOPLASMIC PROTEIN; CELLULAR PROTEINS; ONCOGENE ENCODES; BINDING PROTEINS; MAMMALIAN-CELLS	Our studies originally demonstrated that the v-rel oncoprotein repressed gene expression in chicken lymphoid cells, while it activated transcription in rodent fibroblasts. Here we report that the c-rel protein can activate expression of genes linked to kappa-B motifs when low levels of endogenous kappa-B-binding activity are present. In contrast v-rel, and to a lesser extent c-rel, inhibit NF-kappa-B-mediated activation of the human immunodeficiency virus long terminal repeat (HIV LTR) in phorbol ester-stimulated HeLa cells. Competition assays show that v-rel competitively inhibits both NF-kappa-B and c-rel-mediated transcriptional activation. Analysis of mutant HIV LTR-chloramphenicol acetyltransferase (CAT) constructs in which all Sp1 or both NF-kappa-B elements have been deleted shows that NF-kappa-B motifs are required for rel-mediated effects on gene expression. Transforming v-rel mutants compete efficiently with phorbol ester-activated kappa-B factors, whereas a transformation-defective mutant of v-rel is impaired in this activity. Taken together, these results strengthen the hypothesis that v-rel functions as a dominant interfering member of rel family proteins. These results also suggest that the ability of v- and c-rel to activate or repress gene expression in specific cells may result from their capacity to compete with endogenous rel family proteins whose expression and/or activity are cell-specific.	CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center								BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BHAT GV, 1990, ONCOGENE, V5, P625; BROWNELL E, 1987, MOL CELL BIOL, V7, P1304, DOI 10.1128/MCB.7.3.1304; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; EMBRETSON JE, 1987, J VIROL, V61, P3454, DOI 10.1128/JVI.61.11.3454-3462.1987; FRANKLIN RB, 1974, INTERVIROLOGY, V3, P342, DOI 10.1159/000149771; FRANZA BR, 1987, NATURE, V330, P391, DOI 10.1038/330391a0; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HERZOG NK, 1986, J VIROL, V57, P371, DOI 10.1128/JVI.57.1.371-375.1986; INOUE JI, 1991, P NATL ACAD SCI USA, V8, P3715; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOO HM, 1991, J VIROL, V65, P4769, DOI 10.1128/JVI.65.9.4769-4776.1991; LEONARD J, 1989, J VIROL, V63, P4919, DOI 10.1128/JVI.63.11.4919-4924.1989; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MORRISON LE, 1989, ONCOGENE, V4, P677; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PARROTT C, 1991, J VIROL, V65, P1414, DOI 10.1128/JVI.65.3.1414-1419.1991; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THEILEN GH, 1966, J NATL CANCER I, V37, P731; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; YAMAGUCHI Y, 1989, J VIROL, V63, P1040, DOI 10.1128/JVI.63.3.1040-1048.1989	47	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					163	170						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741161				2022-12-25	WOS:A1992HC22700022
J	PUOPOLO, K; KUMAMOTO, C; ADACHI, I; FORGAC, M				PUOPOLO, K; KUMAMOTO, C; ADACHI, I; FORGAC, M			A SINGLE GENE ENCODES THE CATALYTIC-A SUBUNIT OF THE BOVINE VACUOLAR H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; CHROMAFFIN-GRANULE MEMBRANES; CLATHRIN-COATED VESICLES; AMINO-ACID-SEQUENCE; SULFOLOBUS-ACIDOCALDARIUS; SACCHAROMYCES-CEREVISIAE; NEUROSPORA-CRASSA; MESSENGER-RNAS; BETA-SUBUNIT	We have previously demonstrated that the 73-kDa (A) subunit of the bovine coated vesicle (H+)-ATPase possesses a nucleotide binding site required for catalytic activity (Arai, H., Berne, M., Terres, G., Terres, H., Puopolo, K., and Forgac, M. (1987) Biochemistry 26, 6632-6638). Here we report the cDNA sequence of the coding region of the bovine brain A subunit. Comparison of the deduced amino acid sequence with those previously reported for the A subunits of vacuolar ATPases from lower eukaryotes, plants, and archaebacteria reveals significant homology, especially in sequences implicated in nucleotide binding. The message encoding the bovine brain A subunit is relatively large, approximately 4.6 kilobases; Northern blotting of RNA isolated from rat brain and human brain tumor cells reveals a message of similar size. Northern analysis of several bovine tissues indicates that only one message for this subunit is expressed. Southern blot analysis of bovine genomic DNA indicates that the bovine A subunit is encoded by a single gene.	TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts University; Tufts University			Puopolo, Karen/AAY-7748-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34478, R01 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; AOTA S, 1988, NUCLEIC ACIDS RES, V16, pR315, DOI 10.1093/nar/16.suppl.r315; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; ARAI H, 1988, J BIOL CHEM, V263, P8796; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERGER SL, 1987, METHODS ENZYMOL, V152; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1983, J BIOL CHEM, V258, P5238; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BOWMAN EJ, 1986, P NATL ACAD SCI USA, V83, P48, DOI 10.1073/pnas.83.1.48; BROWN D, 1987, J CELL BIOL, V105, P1637, DOI 10.1083/jcb.105.4.1637; CIDON S, 1986, J BIOL CHEM, V261, P9222; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEAN GE, 1984, J BIOL CHEM, V259, P9569; DENDA K, 1988, J BIOL CHEM, V263, P6012; DENDA K, 1988, J BIOL CHEM, V263, P17251; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GALLOWAY CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3334, DOI 10.1073/pnas.80.11.3334; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; HIRATA R, 1990, J BIOL CHEM, V265, P6726; INATOMI K, 1986, J BACTERIOL, V167, P837, DOI 10.1128/jb.167.3.837-841.1986; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; Innis MA, 1990, PCR PROTOCOLS GUIDE; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; KONISHI J, 1990, J BIOCHEM, V108, P554, DOI 10.1093/oxfordjournals.jbchem.a123241; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMAMOTO CA, 1986, J BIOL CHEM, V261, P37; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; MANDALA S, 1986, J BIOL CHEM, V261, P2850; Maniatis T., 1982, MOL CLONING; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MANOLSON MF, 1987, MEMBRANE PROTEINS; MARQUEZSTERLING N, 1991, IN PRESS EUR J CELL; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MOLLER W, 1985, FEBS LETT, V186, P1, DOI 10.1016/0014-5793(85)81326-0; MORIYAMA Y, 1986, BIOCHIM BIOPHYS ACTA, V854, P102, DOI 10.1016/0005-2736(86)90069-6; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON H, 1989, J BIOL CHEM, V264, P1775; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PERCY JM, 1985, BIOCHEM J, V231, P557, DOI 10.1042/bj2310557; RANDALL SK, 1986, J BIOL CHEM, V261, P1364; ROBERTIS EDP, 1987, CELL MOL BIOL; RUNSWICK MJ, 1983, J BIOL CHEM, V258, P3081; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER DL, 1981, J BIOL CHEM, V256, P3858; STONE DK, 1983, J BIOL CHEM, V258, P4059; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; YAFFE D, 1985, NUCLEIC ACIDS RES, V13, P3723, DOI 10.1093/nar/13.10.3723; YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929; ZHANG F, 1983, BIOCHEM BIOPH RES CO, V114, P620, DOI 10.1016/0006-291X(83)90825-2; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; [No title captured]	75	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24564	24572						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722207				2022-12-25	WOS:A1991GW84500051
J	HLA, T; MACIAG, T				HLA, T; MACIAG, T			CYCLOOXYGENASE GENE-EXPRESSION IS DOWN-REGULATED BY HEPARIN-BINDING (ACIDIC FIBROBLAST) GROWTH FACTOR-I IN HUMAN ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-H-SYNTHASE; SMOOTH-MUSCLE CELLS; PROSTACYCLIN SYNTHESIS; POTENT INHIBITOR; CLONING; INTERLEUKIN-1; RECOVERY; STIMULATION; ASPIRIN; INVITRO	The expression of cyclooxygenase (EC 1.14.99.1, Cox), a rate-limiting enzyme in the biosynthesis of inflammatory prostanoids, is regulated by growth factors and cytokines. We have shown previously that the cytokine interleukin-1, an inhibitor of endothelial growth in vitro and stimulator of prostacyclin production, induces the expression of the 3-kilobase Cox transcript in cultured human umbilical vein endothelial cells (HUVEC). In contrast, the endothelial cell mitogen, heparin-binding (acidic fibroblast) growth factor-1 (HBGF-1) inhibits the synthesis of prostacyclin in HUVEC. In this report, we describe the effect of HBGF-1 on Cox mRNA expression in HUVEC. Cells cultured in the presence of HBGF-1 express diminished Cox mRNA levels whereas quiescent cells maintained in serum expressed a 7-fold higher level of the transcript for Cox. Concomitantly, the level of the Cox translation product and prostacyclin synthesis are also reduced by HBGF-1. Further, HBGF-1, in the presence of heparin, down-regulates the levels of the Cox transcript in a dose- and time-dependent manner. The onset of action of HBGF-1 is slow, requiring up to 24 h to depress the level of Cox mRNA. Lastly, the effective dose of HBGF-1 to depress Cox mRNA levels is similar to that required for mitogenesis, suggesting that cell proliferation may be required for the reduction of Cox expression in vitro. Thus, Cox may belong to a class of genes that are reversibly down-regulated during periods of endothelial cell proliferation.			HLA, T (corresponding author), AMER RED CROSS,JEROME H HOLLAND LAB BIOMED SCI,MOLEC BIOL LAB,ROCKVILLE,MD 20855, USA.		Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, R01HL035627] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35627, HL32348] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY JM, 1985, J LIPID RES, V26, P54; BEVILACQUA MP, 1986, J CLIN INVEST, V78, P587, DOI 10.1172/JCI112613; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURGESS WH, 1986, P NATL ACAD SCI USA, V83, P7216, DOI 10.1073/pnas.83.19.7216; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DOCTROW SR, 1987, J CELL BIOL, V104, P679, DOI 10.1083/jcb.104.3.679; ENDO H, 1988, BIOCHEM BIOPH RES CO, V156, P1007, DOI 10.1016/S0006-291X(88)80944-6; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; FU JY, 1990, J BIOL CHEM, V265, P16737; GAY C, 1989, J BIOL CHEM, V265, P3284; GORODETSKY JS, 1985, PHARMACOL RES COMMUN, V17, P447, DOI 10.1016/0031-6989(85)90079-7; GRENFELL S, 1989, BIOCHEM J, V264, P813, DOI 10.1042/bj2640813; HASEGAWA N, 1988, J CELL PHYSIOL, V137, P603, DOI 10.1002/jcp.1041370331; HLA T, 1986, PROSTAGLANDINS, V32, P829, DOI 10.1016/0090-6980(86)90093-6; HLA T, 1990, J BIOL CHEM, V265, P9308; HLA TT, 1989, PROSTAG LEUKOTR ESS, V36, P175, DOI 10.1016/0952-3278(89)90059-8; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KONKLE BA, 1990, J BIOL CHEM, V265, P21867; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; Maciag T, 1990, Important Adv Oncol, P85; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; MONCADA S, 1977, LANCET, V1, P18; MONTESANO R, 1987, J CELL PHYSIOL, V130, P284, DOI 10.1002/jcp.1041300215; MORRIS PB, 1988, AM J PHYSIOL, V23, P6318; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NORIOKA K, 1987, BIOCHEM BIOPH RES CO, V145, P969, DOI 10.1016/0006-291X(87)91060-6; PASH JM, 1988, FASEB J, V2, P2613, DOI 10.1096/fasebj.2.10.2968288; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; RAZ A, 1988, J BIOL CHEM, V263, P3022; RISTIMAKI A, 1990, ARTERIOSCLEROSIS, V10, P653, DOI 10.1161/01.ATV.10.4.653; ROSSI V, 1985, SCIENCE, V229, P174, DOI 10.1126/science.2409598; RYAN U, 1988, ENDOTHELIAL CELL; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SMITH WL, 1990, ADV PROSTAG THROMB L, V20, P14; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1986, ANNU REV PHYSIOL, V48, P251; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; WEKSLER BB, 1990, J CELL PHYSIOL, V142, P514, DOI 10.1002/jcp.1041420310; WU KK, 1988, J BIOL CHEM, V263, P19043; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	50	84	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24059	24063						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721064				2022-12-25	WOS:A1991GV31900082
J	STROOP, SD; BEAVO, JA				STROOP, SD; BEAVO, JA			STRUCTURE AND FUNCTION STUDIES OF THE CGMP-STIMULATED PHOSPHODIESTERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; BINDING-SITES; CALF LIVER; CATALYTIC PROPERTIES; RAT-LIVER; IDENTIFICATION; SUBUNIT; LUNG; PURIFICATION	Studies of cGMP binding to both the native cyclic GMP-stimulated phosphodiesterase and to two unique isolated chymotryptic fragments lacking the catalytic domain suggest that the enzyme contains two noncatalytic cGMP-binding sites/homodimer. In the presence of high concentrations of ammonium sulfate, 2 mol of cGMP are bound/mol of cGMP-stimulated phosphodiesterase homodimer. Under these conditions, linear Scatchard plots of binding are obtained that give an apparent K(d) of approximately 2-mu-M. The inclusion of 3-isobutyl-1-methylxanthine produces a curvilinear plot. In the absence of ammonium sulfate, the dissociation of cGMP from the holoenzyme is rapid, having a t1/2 of less than 10 s, and addition of ammonium sulfate to the incubation greatly decreases this rate of dissociation. The native enzyme is resistant to degradation by chymotrypsin in the absence of cGMP; however, in its presence, chymotrypsin treatment produces several discrete fragments. Similarly, in the presence but not in the absence of cGMP, dicyclohexylcarbodiimide causes an irreversible activation of the enzyme without cross-linking the nucleotide to the phosphodiesterase. Both observations provide evidence that a different conformation in the enzyme results from cGMP binding. Only the conformation formed upon cGMP binding is easily attacked by chymotrypsin or permanently activated by treatment with dicyclohexylcarbodiimide. One major chymotryptic cleavage site exposed by cGMP binding is at tyrosine 553, implying that this region takes part in the conformational change. Limited proteolysis experiments indicate that these noncatalytic binding sites are located within a region of internal sequence homology previously proposed to include the cGMP-binding site(s) and that they retain a high affinity and specificity for cGMP independent of the catalytic domain of the enzyme. The products formed by partial proteolysis can be separated into individual catalytically active and cGMP-binding fractions by anion exchange chromatography. Gel filtration and electrophoresis analysis of the isolated fractions suggest that the cGMP-binding peak has a dimeric structure. Moreover, it can be further resolved by polyethyleneimine high performance liquid chromatography into two peaks (Peaks IIIA and IIIB). Peak IIIA binds 2 mol of cGMP/mol of dimer with an apparent K(d) of 0.2-mu-M. Peak IIIB, however, has greatly reduced cGMP binding. Further digestion of these fragments with cyanogen bromide show that the differences between Peaks IIIA and IIIB are due to one or more additional proteolytic nicks in IIIB that remove a few residues near its C terminus, most probably residues 523-550 or 534-550. This in turn suggests that this region is essential for cGMP-binding activity. Several of the amino acids in this area are highly conserved in all phosphodiesterases known to have high affinity noncatalytic cGMP-binding sites.	UNIV WASHINGTON, DEPT PHARMACOL, SJ-30, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	BEAVO, JA (corresponding author), UNIV WASHINGTON, DEPT PHARMACOL, SJ-30, SEATTLE, WA 98195 USA.				NHLBI NIH HHS [T32-HL07312] Funding Source: Medline; NIDDK NIH HHS [DK21723] Funding Source: Medline; NIGMS NIH HHS [GM15731] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BEAVO JA, 1971, J BIOL CHEM, V246, P3841; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BUECHLER JA, 1989, BIOCHEMISTRY-US, V28, P2065, DOI 10.1021/bi00431a015; BUECHLER JA, 1988, BIOCHEMISTRY-US, V27, P7356, DOI 10.1021/bi00419a027; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; CORBIN JD, 1983, J BIOL CHEM, V258, P1391; ERNEUX C, 1981, EUR J BIOCHEM, V115, P503; ERNEUX C, 1982, FEBS LETT, V142, P251, DOI 10.1016/0014-5793(82)80146-4; ERNEUX C, 1988, METHOD ENZYMOL, V159, P520; ERNEUX C, 1984, ADV CYCLIC NUCL PROT, V16, P107; ERNEUX C, 1982, BIOCH BIOPHYS, V218, P119; FISCHMEISTER R, 1987, J PHYSIOL-LONDON, V387, P453, DOI 10.1113/jphysiol.1987.sp016584; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETRONG H, 1990, BIOCHEMISTRY-US, V29, P10280; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; MACKENZIE CW, 1982, J BIOL CHEM, V257, P5589; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MIOT F, 1985, EUR J BIOCHEM, V149, P59, DOI 10.1111/j.1432-1033.1985.tb08893.x; MOSS J, 1988, MOL PHARMACOL, V34, P279; MUMBY MC, 1982, J BIOL CHEM, V257, P13283; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NARDELLA FA, 1985, J EXP MED, V162, P1811, DOI 10.1084/jem.162.6.1811; Segel I.H., 1975, ENZYME KINETICS; STROOP SD, 1989, J BIOL CHEM, V264, P13718; TANAKA T, 1991, IN PRESS CYCLIC NUCL; VANSANDE J, 1975, BIOCHEM BIOPH RES CO, V62, P168, DOI 10.1016/S0006-291X(75)80119-7; WADA H, 1987, J BIOL CHEM, V262, P13938; WADA H, 1987, J BIOL CHEM, V262, P5139; WADA H, 1987, BIOCHEMISTRY-US, V26, P6565, DOI 10.1021/bi00394a042; YAMAMOTO T, 1983, J BIOL CHEM, V258, P2526; YAMAMOTO T, 1983, J BIOL CHEM, V258, P4173; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619	38	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23802	23809						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721055				2022-12-25	WOS:A1991GV31900044
J	BAUMANN, H; SCHENDEL, P				BAUMANN, H; SCHENDEL, P			INTERLEUKIN-11 REGULATES THE HEPATIC EXPRESSION OF THE SAME PLASMA-PROTEIN GENES AS INTERLEUKIN-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE-STIMULATING FACTORS; CELLS; GLUCOCORTICOIDS; RAT; DNA	Treatment of rat hepatoma H-35 cells with purified human recombinant interleukin-11 (IL-11) resulted in the stimulated production of several major acute phase plasma proteins. The qualitative and quantitative changes were comparable to those mediated by IL-6 or leukemia inhibitor factor (LIF). Like IL-6, IL-11 acted synergistically with IL-1 on type 1 acute phase proteins. The combination of IL-11 and dexamethasone yielded a magnitude of stimulation which was more similar to the combination of LIF and dexamethasone than IL-6 and dexamethasone. IL-11 elicited in treatment of primary cultures of rat hepatocytes a qualitative change of plasma protein production which was similar to that in H-35 cells. Comparison of rat and human hepatoma cells indicated that the IL-11 response did not correlate with that of IL-6 or LIF, suggesting that the action of IL-11 was mediated by an IL-11-specific receptor system. However, the intracellular transduction of the IL-11, IL-6, and LIF signals to the acute phase protein genes seems to rely, in part, on common elements as judged from their stimulatory effects on the transfected expression vector containing the IL-6 response element of the rat beta-fibrinogen gene. The finding that IL-11 shares liver-regulating properties with IL-6 and LIF suggests that IL-11 has the potential of contributing to the control of systemic homeostasis and hepatic acute phase response.	GENET INST, CAMBRIDGE, MA 02140 USA		BAUMANN, H (corresponding author), NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NCI NIH HHS [CA26122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1988, METHOD ENZYMOL, V163, P566; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1984, J BIOL CHEM, V259, P7331; Fey G H, 1990, Prog Liver Dis, V9, P89; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; SEHGAL PB, 1990, MOL BIOL MED, V7, P117	14	189	202	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20424	20427						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1718962				2022-12-25	WOS:A1991GM03900081
J	HERBST, R; LAMMERS, R; SCHLESSINGER, J; ULLRICH, A				HERBST, R; LAMMERS, R; SCHLESSINGER, J; ULLRICH, A			SUBSTRATE PHOSPHORYLATION SPECIFICITY OF THE HUMAN C-KIT RECEPTOR TYROSINE KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; STEM-CELL FACTOR; GTPASE-ACTIVATING PROTEIN; GAP-ASSOCIATED PROTEINS; PDGF BETA-RECEPTOR; SPOTTING W LOCUS; PHOSPHOLIPASE-C; SI-LOCUS; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAINS	The chimeric EK-receptor (EK-R), consisting of the epidermal growth factor receptor (EGF-R) extracellular binding domain and p145c-kit cytoplasmic signal-generating sequences, was fully functional in forming high and low affinity EGF binding sites and in ligand-regulated receptor and substrate phosphorylation activities. Relative to EGF-R, EK-R activation stimulated kit-characteristic phosphorylation of human 293 fibroblast substrate polypeptides. Transient coexpression of EK-R with candidate substrates resulted in ligand-induced phosphorylation of phospholipase C-gamma and guanosine trisphosphatase-activating polypeptide. The RAF-1 serine/threonine kinase was shown to be associated with activated EK-R, but no tyrosine phosphorylation could be detected. The faithfulness of EK-R substrate phosphorylation specificity was confirmed with stem cell factor-stimulated p145c-kit.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,KLOPFERSPITZ 18A,W-8033 MARTINSRIED,GERMANY; NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	Max Planck Society; New York University								ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; DOWNING JR, 1989, EMBO J, V8, P3345, DOI 10.1002/j.1460-2075.1989.tb08496.x; EGHTEDARZADEH MK, 1986, NUCLEIC ACIDS RES, V19, P5115; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENDLY BM, 1990, CANCER RES, V50, P1550; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KUMJIAN DA, 1991, J BIOL CHEM, V266, P3973; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LEV S, 1990, MOL CELL BIOL, V10, P6064, DOI 10.1128/MCB.10.11.6064; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIBE S, 1989, J BIOL CHEM, V264, P10335; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REEDIJK M, 1990, MOL CELL BIOL, V10, P5601, DOI 10.1128/MCB.10.11.5601; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SULTZMAN L, 1991, MOL CELL BIOL, V11, P2018, DOI 10.1128/MCB.11.4.2018; THORPE GHG, 1985, CLIN CHEM, V31, P1335; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	58	68	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					19908	19916						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1718957				2022-12-25	WOS:A1991GM03900010
J	POWERS, MF; BEAVIS, AD				POWERS, MF; BEAVIS, AD			TRIORGANOTINS INHIBIT THE MITOCHONDRIAL INNER MEMBRANE ANION CHANNEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; HEART SUBMITOCHONDRIAL PARTICLES; ORGANOTIN COMPOUNDS; TRIPHENYLTIN COMPOUNDS; DIBUTYLCHLOROMETHYLTIN CHLORIDE; OXIDATIVE-PHOSPHORYLATION; TRIETHYLTIN BROMIDE; LIGHT-SCATTERING; CAT HEMOGLOBIN; ION CHANNEL	The inner membrane of liver and heart mitochondria possesses an anion uniport pathway, known as the inner membrane anion channel (IMAC). IMAC is inhibited by matrix Mg2+, matrix H+, N,N'-dicyclohexylcarbodiimide, mercurials and amphiphilic amines such as propranolol. Most of these agents react with a number of different mitochondrial proteins and, therefore, more selective inhibitors have been sought. In this paper, we report the discovery of a new class of inhibitors, triorganotin compounds, which block IMAC completely. One of the most potent, tributyltin (TBT) inhibits malonate uniport via IMAC 95% at 0.9 nmol/mg. The only other mitochondrial protein reported to react with triorganotins, the F1F0ATPase, is inhibited by about 0.75 nmol/mg. The potency of inhibition of IMAC increases with hydrophobicity in the sequence trimethyltin << triethyltin << tripropyltin < triphenyltin < tributyltin; which suggests that the binding site is accessible from the lipid bilayer. It has long been established that triorganotins are anionophores able to catalyze Cl-/OH- exchange; however, TBT is able to inhibit Cl- and NO3- transport via IMAC at doses below those required to catalyze rapid rates of Cl-/OH- exchange. Consistent with previous reports, the data indicate that about 0.8 nmol of TBT per mg of mitochondrial protein is tightly bound and not available to mediate Cl-/OH- exchange. We have also shown that the mercurials, p-chloromercuribenzene sulfonate and mersalyl, which only partially inhibit Cl- and NO3- transport can increase the IC50 for TBT 10-fold. This effect appears to result from a reaction at a previously unidentified mercurial reactive site. The inhibitory dose is also increased by raising the pH and inhibition by TBT can be reversed by S2- and dithiols but not by monothiols.			POWERS, MF (corresponding author), MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699, USA.				NHLBI NIH HHS [HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDRIDGE WN, 1970, BIOCHEM J, V118, P171, DOI 10.1042/bj1180171; ALDRIDGE WN, 1955, BIOCHEM J, V61, P406, DOI 10.1042/bj0610406; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; BEAVIS AD, 1990, BIOPHYS J, V57, pA179; BEAVIS AD, 1988, J BIOL CHEM, V263, P7574; BEAVIS AD, 1989, EUR J BIOCHEM, V185, P511, DOI 10.1111/j.1432-1033.1989.tb15143.x; BEAVIS AD, 1989, J BIOL CHEM, V264, P17148; BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1989, J BIOL CHEM, V264, P1508; BEAVIS AD, 1991, BIOCHIM BIOPHYS ACTA, V1063, P111, DOI 10.1016/0005-2736(91)90360-K; BEECHEY RB, 1966, BIOCHEM BIOPH RES CO, V23, P75, DOI 10.1016/0006-291X(66)90271-3; BRIERLEY GP, 1984, J BIOL CHEM, V259, P4672; BYINGTON KH, 1974, TOXICOL APPL PHARM, V27, P230, DOI 10.1016/0041-008X(74)90194-X; BYINGTON KH, 1971, BIOCHEM BIOPH RES CO, V42, P16, DOI 10.1016/0006-291X(71)90355-X; COSTA LG, 1985, TOXICOL APPL PHARM, V79, P471, DOI 10.1016/0041-008X(85)90144-9; DIWAN JJ, 1982, J BIOENERG BIOMEMBR, V14, P15, DOI 10.1007/BF00744076; DIWAN JJ, 1983, J BIOENERG BIOMEMBR, V15, P277, DOI 10.1007/BF00744525; DOCTOR SV, 1982, TOXICOLOGY, V25, P213, DOI 10.1016/0300-483X(82)90031-2; ELFERINK JGR, 1986, BIOCHEM PHARMACOL, V35, P3727, DOI 10.1016/0006-2952(86)90657-X; ELLIOT BM, 1977, BIOCHEM J, V103, P583; ELLIOTT BM, 1979, BIOCHEM J, V177, P461, DOI 10.1042/bj1770461; EMANUEL EL, 1984, BIOCHIM BIOPHYS ACTA, V766, P209, DOI 10.1016/0005-2728(84)90233-0; FARROW BG, 1978, EUR J BIOCHEM, V86, P85, DOI 10.1111/j.1432-1033.1978.tb12287.x; FONYO A, 1978, J BIOENERG BIOMEMBR, V10, P171, DOI 10.1007/BF00743106; GARLID KD, 1985, J BIOL CHEM, V260, P3434; GARLID KD, 1986, BIOCHIM BIOPHYS ACTA, V853, P187, DOI 10.1016/0304-4173(87)90001-2; GARLID KD, 1986, J BIOL CHEM, V261, P1529; KIEHL R, 1980, BIOCHEMISTRY-US, V19, P541, DOI 10.1021/bi00544a023; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; POWERS M F, 1991, Biophysical Journal, V59, p596A; ROSE MS, 1972, BIOCHEM J, V127, P51, DOI 10.1042/bj1270051; ROSE MS, 1968, BIOCHEM J, V106, P821, DOI 10.1042/bj1060821; ROSE MS, 1969, BIOCHEM J, V111, P129, DOI 10.1042/bj1110129; SELWYN MJ, 1970, EUR J BIOCHEM, V14, P120, DOI 10.1111/j.1432-1033.1970.tb00268.x; SELWYN MJ, 1972, BIOCHEM J, V130, pP65, DOI 10.1042/bj1300065P; SELWYN MJ, 1976, ORGANOTIN COMPOUNDS, P204; SIEBENLIST KR, 1986, BIOCHEM J, V233, P471, DOI 10.1042/bj2330471; SIEBENLIST KR, 1983, BIOCHEMISTRY-US, V22, P4642, DOI 10.1021/bi00289a005; SOLOMON R, 1989, TOXICOL APPL PHARM, V100, P307, DOI 10.1016/0041-008X(89)90316-5; SONE N, 1964, J BIOCHEM-TOKYO, V56, P151, DOI 10.1093/oxfordjournals.jbchem.a127972; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SORGATO MC, 1989, J BIOENERG BIOMEMBR, V21, P485, DOI 10.1007/BF00762520; UREN SC, 1983, MAR POLLUT BULL, V14, P303, DOI 10.1016/0025-326X(83)90540-4; VANDERKERK GJM, 1976, ORGANOTIN COMPOUNDS, P1; WATLING AS, 1970, FEBS LETT, V10, P139, DOI 10.1016/0014-5793(70)80437-9; WULF RG, 1975, ARCH BIOCHEM BIOPHYS, V167, P176, DOI 10.1016/0003-9861(75)90454-3	46	75	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17250	17256						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1716627				2022-12-25	WOS:A1991GF44500044
J	ODA, Y; KUO, MD; HUANG, SS; HUANG, JS				ODA, Y; KUO, MD; HUANG, SS; HUANG, JS			THE PLASMA-CELL MEMBRANE GLYCOPROTEIN, PC-1, IS A THREONINE-SPECIFIC PROTEIN-KINASE STIMULATED BY ACIDIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; FACTOR RECEPTOR; PURIFICATION; LIVER; BONDS	A P-32-labeled protein that co-purified with acidic fibroblast growth factor (aFGF) receptor from bovine liver proved to be a distinct membrane protein, which itself has kinase activity that is stimulated by aFGF. The protein was designated MAFP for major aFGF-stimulated phosphoprotein. MAFP was purified from bovine liver using immunoaffinity chromatography with monoclonal antibody to MAFP following Triton X-100 extraction of plasma membranes and wheat germ lectin-Sepharose 4B column chromatography. The purified MAFP showed molecular masses of 130 kDa and 260 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing and nonreducing conditions, respectively. Purified MAFP elicited aFGF-stimulated Thr-specific autophosphorylation activity and phosphorylation activity toward protein substrates (myelin basic protein and histone). Amino acid sequence analyses of 16 peptide fragments of MAFP, produced by endoproteinase Lys-C digestion followed by reduction and S-pyridylethylation, showed approximately 80-100% homology with the cDNA-deduced amino acid sequences of human and mouse plasma cell membrane glycoprotein, PC-1 (Buckley, M. F., Loveland, K. A., McKinstry, W. J., Garson, 0. M., and Goding, J. W. (1990) J. Biol. Chem. 265, 17506-17511), suggesting that MAFP is the bovine version of PC-1. The amino acid sequences of bovine MAFP, human and mouse PC-1 reveal a putative ATP binding site in their extracellular domains. These results suggest that MAFP(PC-1) is an ectoprotein kinase. In addition to the kinase activity, MAFP(PC-1) was also found to possess alkaline nucleotide phosphodiesterase activity. It is now clear that several of the unique properties previously attributed to the aFGF receptor kinase are actually properties of this novel Thr-specific ectoprotein kinase, which co-purifies with the aFGF receptor and is responsive to stimulation by aFGF.	ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,1402 S GRAND BLVD,ST LOUIS,MO 63104	Saint Louis University					NCI NIH HHS [CA38808] Funding Source: Medline; NHLBI NIH HHS [HL41782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; EVANS WH, 1973, BIOCHEM J, V135, P819, DOI 10.1042/bj1350819; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HIROSE M, 1988, ANAL BIOCHEM, V168, P193, DOI 10.1016/0003-2697(88)90028-0; HUANG JS, 1986, J BIOL CHEM, V261, P1600; HUANG SS, 1986, J BIOL CHEM, V261, P9568; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KUO MD, 1990, J BIOL CHEM, V265, P16455; LOKESHWAR VB, 1990, J BIOL CHEM, V265, P1665; RAZZELL WE, 1963, METHOD ENZYMOL, V6, P236, DOI 10.1016/0076-6879(63)06169-3; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; SKUBITZ KM, 1991, BIOCHEM BIOPH RES CO, V174, P49, DOI 10.1016/0006-291X(91)90483-N; SU L, 1985, ANN REV PHYSL, V47, P665; TAKAHASHI T, 1970, J EXP MED, V131, P1325, DOI 10.1084/jem.131.6.1325; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; VONDRIEL IR, 1987, J BIOL CHEM, V262, P4882; WOLD F, 1981, ANNU REV BIOCHEM, V50, P783, DOI 10.1146/annurev.bi.50.070181.004031	17	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16791	16795						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1715869				2022-12-25	WOS:A1991GD63500086
J	GRECO, NJ; TANDON, NN; JACKSON, BW; JAMIESON, GA				GRECO, NJ; TANDON, NN; JACKSON, BW; JAMIESON, GA			LOW STRUCTURAL SPECIFICITY FOR NUCLEOSIDE TRIPHOSPHATES AS ANTAGONISTS OF ADP-INDUCED PLATELET ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS ADENYLATE-CYCLASE; GRANULE SECRETION; BINDING; AGGREGATION; ADENOSINE; 5'-DIPHOSPHATE; RECEPTORS; DISTINCT	Although the platelet ADP receptor is thought to exhibit a high degree of structural selectivity, adenosine 5'-O-(thiotriphosphate) (ATP-alpha-S) is a potent inhibitor of ADP-induced platelet activation and has been recently shown to bind with high affinity (K(d) 3 +/- 0.1 nM) to formaldehyde-fixed platelets and to be photoincorporated into an 18-kDa fragment beginning at Tyr-198 of glycoprotein (GP) IIb-alpha (Greco, N. J., Yamamoto, N., Jackson, B. W., Tandon, N. N., Moos, M., Jr., and Jamieson, G. A. (1991) J. Biol. Chem. 266, 13627-13633). Further studies have now shown that guanosine 5'-O-(thiotriphosphate) (GTP-alpha-S) also binds to high affinity sites (K(d) 4.7 +/- 0.9 nM; 13,600 +/- 1,140 sites/platelet) and to low affinity sites (K(d) 470 +/- 85 nM; 135,900 +/- 19,400 sites/platelet). Competition binding studies showed that all GTP-alpha-S binding sites were accessible to ADP and vice versa. The corresponding pyrimidine nucleotide cytidine 5'-O-(thiotriphosphate) (CTP-alpha-S) was found to be similarly effective in competing in the binding of ADP and both 5'-O-(thiotriphosphates) as well as uridine 5'-O-(thiotriphosphate) (UTP-alpha-S) were potent inhibitors of platelet shape change and aggregation. Ultraviolet irradiation of platelets in the presence of either [S-35]GTP-alpha-S or [S-35]UTP-alpha-S resulted in their specific incorporation into the alpha-chain of GPIIb as previously shown with [S-35]ATP-alpha-S. These results show that the structure of the nucleotide base has little influence on its ability to occupy the ADP-binding site on platelets, to function as an inhibitor of ADP-induced activation or to be photoincorporated into GPIIb-alpha.	AMER RED CROSS,CELL BIOL LAB,15601 CRABBS BRANCH WAY,ROCKVILLE,MD 20855	American Red Cross					NHLBI NIH HHS [HL 39438] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL039438] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRAWAL AK, 1989, THROMB HAEMOSTASIS, V62, P1103; ANTONOFF RS, 1974, J BIOL CHEM, V249, P3319; AUTHI KS, 1987, THROMB HAEMOSTASIS, V58, P1715; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; BYLUND DB, 1980, RECEPTOR BINDING TEC, P70; COLMAN RW, 1988, PLATELET MEMBRANE RE, P263; CUSACK NJ, 1982, BRIT J PHARMACOL, V76, P221, DOI 10.1111/j.1476-5381.1982.tb09210.x; GRECO NJ, 1991, J BIOL CHEM, V266, P13627; Haslam R. J., 1981, PURINERGIC RECEPTORS, P223; JEFFERSON JR, 1987, J MED CHEM, V30, P2013, DOI 10.1021/jm00394a015; JEFFERSON JR, 1988, BLOOD, V71, P110; KRISHNAMURTHI S, 1988, BIOCHEM J, V250, P209, DOI 10.1042/bj2500209; MACFARLANE DE, 1982, BIOCHEMISTRY-US, V21, P544, DOI 10.1021/bi00532a020; MACFARLANE DE, 1975, BLOOD, V46, P309; MILLS DCB, 1985, J BIOL CHEM, V260, P8078; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OBRIG TG, 1975, BIOCHEM BIOPH RES CO, V66, P437, DOI 10.1016/S0006-291X(75)80347-0; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992	18	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2966	2970						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737752				2022-12-25	WOS:A1992HD15400026
J	RAM, PA; WAXMAN, DJ				RAM, PA; WAXMAN, DJ			THYROID-HORMONE STIMULATION OF NADPH P450 REDUCTASE EXPRESSION IN LIVER AND EXTRAHEPATIC TISSUES - REGULATION BY MULTIPLE MECHANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; RAT-LIVER; MALIC ENZYME; GROWTH-HORMONE; CYTOCHROME-P-450 REDUCTASE; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; BINDING-SITES; RNA LEVEL; TRIIODOTHYRONINE	The role of thyroid hormone in regulating the expression of the flavoprotein NADPH cytochrome P450 reductase was studied in adult rats. Depletion of circulating thyroid hormone by hypophysectomy, or more selectively, by treatment with the anti-thyroid drug methimazole led to a 75-85% depletion of hepatic microsomal P450 reductase activity and protein in both male and female rats. Thyroxine substantially restored P450 reductase activity at a dose that rendered the thyroid-depleted rats euthyroid. Microsomal P450 reductase activity in several extrahepatic tissues was also dependent on thyroid hormone, but to a lesser extent than in liver (30-50% decrease in kidney, adrenal, lung, and heart but not in testis from hypothyroid rats). Hepatic P450 reductase mRNA levels were also decreased in the hypothyroid state, indicating that the loss of P450 reductase activity is not a consequence of the associated decreased availability of the FMN and FAD cofactors of P450 reductase. Parallel analysis of S14 mRNA, which has been studied extensively as a model thyroid-regulated liver gene product, indicated that P450 reductase and S14 mRNA respond similarly to these changes in thyroid state. In contrast, while the expression of S14 and several other thyroid hormone-dependent hepatic mRNAs is stimulated by feeding a high carbohydrate, fat-free diet, hepatic P450 reductase expression was not increased by this lipogenic diet. Injection of hypothyroid rats with T3 at a supraphysiologic, receptor-saturating dose stimulated a major induction of hepatic P450 reductase mRNA that was detectable 4 h after the T3 injection, and peaked at approximately 650% of euthyroid levels by 12 h. However, this same treatment stimulated a biphasic increase in P450 reductase protein and activity that required 3 days to reach normal euthyroid levels. T3 treatment of euthyroid rats also stimulated a major induction of P450 reductase mRNA that was maximal (12-fold increase) by 12 h, but in this case no major increase in P450 reductase protein or activity was detectable over a 3-day period. Together, these studies establish that thyroid hormone regulates P450 reductase expression by pretranslational mechanisms. They also suggest that other regulatory mechanisms, which may involve changes in P450 reductase protein stability and/or changes in the translational efficiency of its mRNA, are likely to occur.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Waxman, David/0000-0001-7982-9206				BACK DW, 1986, J BIOL CHEM, V261, P2555; BERLIN V, 1981, J BIOL CHEM, V256, P4747; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; COOPER DS, 1984, ENDOCRINOLOGY, V114, P786, DOI 10.1210/endo-114-3-786; DAY R, 1989, ENDOCRINOLOGY, V125, P459, DOI 10.1210/endo-125-1-459; DOZIN B, 1985, BIOCHEMISTRY-US, V24, P5581, DOI 10.1021/bi00341a044; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; JUMP DB, 1984, J BIOL CHEM, V259, P2789; JUMP DB, 1988, J BIOL CHEM, V263, P7254; JUMP DB, 1989, J BIOL CHEM, V264, P4698; KAMINSKY LS, 1985, EUR J BIOCHEM, V149, P479, DOI 10.1111/j.1432-1033.1985.tb08950.x; KINLAW WB, 1989, J BIOL CHEM, V264, P19779; KUPFER D, 1988, ARCH BIOCHEM BIOPHYS, V261, P186, DOI 10.1016/0003-9861(88)90117-8; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LEE SS, 1985, ARCH BIOCHEM BIOPHYS, V237, P197, DOI 10.1016/0003-9861(85)90269-3; LIAW C, 1983, BIOCHEMISTRY-US, V22, P213, DOI 10.1021/bi00270a031; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; MIWA GT, 1978, J BIOL CHEM, V253, P1921; NG SF, 1990, CANCER RES, V50, P464; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; OPPENHEIMER JH, 1974, ENDOCRINOLOGY, V95, P897, DOI 10.1210/endo-95-3-897; OPPENHEIMER JH, 1977, J CLIN INVEST, V59, P517, DOI 10.1172/JCI108667; PETERSON J, 1988, CYTOCHROME P450 STRU, P89; PORTER TD, 1990, BIOCHEMISTRY-US, V29, P9814, DOI 10.1021/bi00494a009; PORTER TD, 1985, P NATL ACAD SCI USA, V82, P973, DOI 10.1073/pnas.82.4.973; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; RAM PA, 1990, J BIOL CHEM, V265, P19223; RAM PA, 1991, MOL ENDOCRINOL, V5, P13, DOI 10.1210/mend-5-1-13; RIVLIN RS, 1969, ENDOCRINOLOGY, V84, P584, DOI 10.1210/endo-84-3-584; SHIMADA T, 1989, CANCER RES, V49, P3218; SONG MKH, 1988, J BIOL CHEM, V263, P17970; STRAIT KA, 1989, J BIOL CHEM, V264, P19784; SUNDSETH SS, 1990, J BIOL CHEM, V265, P15090; TAO TY, 1986, ANN NY ACAD SCI, V478, P20, DOI 10.1111/j.1749-6632.1986.tb15518.x; WAXMAN DJ, 1991, METHOD ENZYMOL, V206, P249; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WAXMAN DJ, 1990, MOL ENDOCRINOL, V4, P447, DOI 10.1210/mend-4-3-447; WAXMAN DJ, 1989, MOL PHARMACOL, V35, P519; WONG NCW, 1986, J BIOL CHEM, V261, P387; YAMANO S, 1989, MOL PHARMACOL, V36, P83	42	83	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3294	3301						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737785				2022-12-25	WOS:A1992HD15400075
J	AVIRAM, M				AVIRAM, M			LOW-DENSITY-LIPOPROTEIN MODIFICATION BY CHOLESTEROL OXIDASE INDUCES ENHANCED UPTAKE AND CHOLESTEROL ACCUMULATION IN CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM; FAMILIAL HYPERCHOLESTEROLEMIA; CULTURED MACROPHAGES; OXIDATION; RECEPTOR; LDL; METABOLISM; MEMBRANE; PLASMA; ESTERIFICATION	Oxidation of low density lipoprotein (LDL) by cells of the arterial wall or in the presence of copper ions was shown to result in the peroxidation of its fatty acids as well as its cholesterol moiety. LDL incubation with cholesterol oxidase (CO) resulted in the conversion of up to 85% of the lipoprotein unesterified cholesterol (cholest-5-en-3-ol) to cholestenone (cholest-4-en-3-one) in a dose- and time-dependent pattern. Plasma very low density lipoprotein (VLDL) and high density lipoprotein (HDL) could be similarly modified by CO. In cholesterol oxidase-modified LDL (CO-LDL), unlike copper ion-induced oxidized LDL (Cu-Ox-LDL), there was no fatty acids peroxidation, and lipoprotein size or charge as well as LDL cholesteryl ester, phospholipids, and triglycerides content were not affected. CO-LDL, however, demonstrated enhanced susceptibility to oxidation by copper ions in comparison to native LDL. Upon incubation of CO-LDL with J-774 A.1 macrophage-like cell line, cellular uptake and degradation of the lipoprotein was increased by up to 62% in comparison to native LDL but was 15% lower than that of Cu-Ox-LDL. Similarly, the binding of CO-LDL to macrophages increased by up to 80%, and cellular cholesterol mass was increased 51% more than the mass obtained with native LDL. Several lines of evidence indicate that CO-LDL was taken up via the LDL receptor: 1) Excess amounts of unlabeled LDL, but not acetyl-LDL (Ac-LDL), effectively competed with I-125-CO-LDL for the uptake by cells. 2) The degradation of CO-LDL by various types of macrophages and by fibroblasts could be dissociated from that of Ac-LDL and was always higher than that of native LDL. 3) A monoclonal antibody to the LDL receptor (IgG-C7) and a monoclonal antibody to the LDL receptor binding domains on apoB-100 (B1B6) inhibited macrophage degradation of CO-LDL. The receptor for Cu-Ox-LDL, which is not shared with Ac-LDL, was also partially involved in macrophage uptake of CO-LDL, since Cu-Ox-LDL demonstrated some competition capability with CO-I-125-LDL for its cellular degradation. CO-LDL cellular degradation was inhibited by chloroquine, thus implying lysosomal involvement in the cellular processing of the lipoprotein. Incubation of macrophages with LDL in the presence of increasing concentrations of cholestenone resulted in up to 52% enhanced lipoprotein cellular degradation suggesting that the cholestenone in CO-LDL might be involved in the enhanced cellular uptake of the modified lipoprotein. Oxidation of LDL by incubation with macrophages resulted in the oxidation of both fatty acids and cholesterol including the formation of cholestenone. Thus, if CO-LDL is produced under certain pathological conditions, it can potentially lead to foam cell formation and to accelerated atherosclerosis.	TECHNION ISRAEL INST TECHNOL, FAC MED, HAIFA, ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	AVIRAM, M (corresponding author), RAMBAM MED CTR, RAPPAPORT FAMILY INST RES MED SCI, LIPID RES UNIT, HAIFA, ISRAEL.							AVIRAM M, 1990, ATHEROSCLEROSIS, V84, P141, DOI 10.1016/0021-9150(90)90084-V; AVIRAM M, 1989, THROMB RES, V53, P561, DOI 10.1016/0049-3848(89)90145-X; AVIRAM M, 1990, ARTERIOSCLEROSIS, V10, P559, DOI 10.1161/01.ATV.10.4.559; AVIRAM M, 1991, BIOCHEM BIOPH RES CO, V179, P359, DOI 10.1016/0006-291X(91)91378-P; AVIRAM M, 1983, BIOCHEM MED METAB B, V30, P111, DOI 10.1016/0006-2944(83)90013-3; AVIRAM M, 1986, ANN NUTR METAB, V30, P143, DOI 10.1159/000177187; AVIRAM M, 1988, J BIOL CHEM, V263, P15416; AVIRAM M, 1988, J BIOL CHEM, V263, P16842; AVIRAM M, 1991, J BIOL CHEM, V266, P11567; AVIRAM M, 1989, J CLIN CHEM CLIN BIO, V27, P3; AVIRAM M, 1989, ARTERIOSCLEROSIS, V9, P67, DOI 10.1161/01.ATV.9.1.67; AVIRAM M, 1991, BLOOD CELL BIOCH, V2, P179; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BENAMOTZ A, 1989, J NUTR, V119, P1013, DOI 10.1093/jn/119.7.1013; BERNHEIMER AW, 1987, BIOCHEM BIOPH RES CO, V148, P260, DOI 10.1016/0006-291X(87)91104-1; BHADRA S, 1991, BIOCHEM BIOPH RES CO, V176, P431, DOI 10.1016/0006-291X(91)90942-Z; BIERMAN EL, 1974, CIRC RES, V35, P136, DOI 10.1161/01.RES.35.1.136; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BROWN MS, 1980, J BIOL CHEM, V255, P9344; Buege J A, 1978, Methods Enzymol, V52, P302; CARPENTER KLH, 1990, ATHEROSCLEROSIS, V83, P217, DOI 10.1016/0021-9150(90)90167-H; CHAIT A, 1979, J CLIN INVEST, V64, P1309, DOI 10.1172/JCI109587; CHIAMORI N, 1959, AM J CLIN PATHOL, V31, P305; CHIN HP, 1968, CLIN CHIM ACTA, V20, P305, DOI 10.1016/0009-8981(68)90165-4; ELSAADANI M, 1989, J LIPID RES, V30, P627; ESTERBAUER H, 1989, FETT WISS TECHNOL, V91, P316, DOI 10.1002/lipi.19890910805; GRAY MF, 1971, LIPIDS, V6, P836, DOI 10.1007/BF02531214; HASHIM SA, 1966, AM J CLIN NUTR, V19, P137, DOI 10.1093/ajcn/19.2.137; HEINECKE JW, 1987, FREE RADICAL BIO MED, V3, P65, DOI 10.1016/0891-5849(87)90040-2; INNERARITY JG, 1986, METHOD ENZYMOL, V124, P542; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KANDUTSCH AA, 1978, SCIENCE, V201, P498, DOI 10.1126/science.663671; KEIDAR S, 1990, METABOLISM, V39, P281, DOI 10.1016/0026-0495(90)90048-H; LANGE Y, 1984, BIOCHIM BIOPHYS ACTA, V769, P551, DOI 10.1016/0005-2736(84)90053-1; LINDER R, 1984, BIOCHIM BIOPHYS ACTA, V779, P423, DOI 10.1016/0304-4157(84)90019-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAOR I, 1991, ATHEROSCLEROSIS, V88, P163, DOI 10.1016/0021-9150(91)90078-H; MARZETTA CA, 1986, J LIPID RES, V27, P753; MITCHINSON MJ, 1990, EUR HEART J, V11, P116, DOI 10.1093/eurheartj/11.suppl_E.116; MOORE NF, 1977, BIOCHEMISTRY-US, V16, P4708, DOI 10.1021/bi00640a027; MUSLINER TA, 1987, BIOCHIM BIOPHYS ACTA, V919, P97, DOI 10.1016/0005-2760(87)90196-2; RICHMOND W, 1973, CLIN CHEM, V19, P1350; SALEN G, 1983, METABOLIC BASIS INHE, P713; SLOTTE JP, 1990, J LIPID RES, V31, P2235; SMITH AG, 1976, J STEROID BIOCHEM, V7, P705, DOI 10.1016/0022-4731(76)90071-6; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TOLLESHAUG H, 1983, CELL, V32, P941, DOI 10.1016/0092-8674(83)90079-X; WIELAND O, 1957, BIOCHEM Z, V329, P313; ZHANG HF, 1990, J LIPID RES, V31, P1361	54	64	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					218	225						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730591				2022-12-25	WOS:A1992GY43900039
J	NAGAMATSU, S; KORNHAUSER, JM; BURANT, CF; SEINO, S; MAYO, KE; BELL, GI				NAGAMATSU, S; KORNHAUSER, JM; BURANT, CF; SEINO, S; MAYO, KE; BELL, GI			GLUCOSE TRANSPORTER EXPRESSION IN BRAIN - CDNA SEQUENCE OF MOUSE GLUT3, THE BRAIN FACILITATIVE GLUCOSE TRANSPORTER ISOFORM, AND IDENTIFICATION OF SITES OF EXPRESSION BY INSITU HYBRIDIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; RAT-BRAIN; TISSUE DISTRIBUTION; GENE LOCALIZATION; PRIMARY CULTURES; SKELETAL-MUSCLE; GLIAL-CELLS; PROTEIN; INSULIN; CLONING	Complementary DNAs encoding the mouse GLUT3/brain facilitative glucose transporter have been isolated and sequenced. The predicted amino acid sequence indicates that mouse GLUT3 is composed of 493 amino acids and has 83 and 89% identity and similarity, respectively, to the sequence of human GLUT3. In contrast to human GLUT3 mRNA, which can be readily detected by RNA blotting in all human tissues that have been examined, mouse GLUT3 mRNA was only present at significant levels in brain. In situ hybridization showed differential expression of GLUT3 mRNA in several regions of adult mouse brain. Specific expression was observed in the hippocampus, with GLUT3 mRNA levels being higher in areas CA1 to CA3 than in the dentate gyrus. It was also detected in the Purkinje cell layer of the cerebellum and in the cerebral cortex, with higher expression in the piriform cortex than in other regions of the cortex. Antisera to mouse GLUT3 immunoblotted a series of proteins of 45-50 kDa in mouse brain plasma membranes. These results are consistent with GLUT3 being a neuronal glucose transporter.	NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208; UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	Northwestern University; University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago			Burant, Charles/GPC-5690-2022	Burant, Charles/0000-0001-9189-5003	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086, P60DK020595] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-21921] Funding Source: Medline; NIDDK NIH HHS [DK-20595, DK-42086] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1989, NUCLEIC ACIDS RES, V17, P6386, DOI 10.1093/nar/17.15.6386; ASANO T, 1988, BIOCHEM BIOPH RES CO, V154, P1204, DOI 10.1016/0006-291X(88)90268-9; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BOADO RJ, 1990, BIOCHEM BIOPH RES CO, V166, P174, DOI 10.1016/0006-291X(90)91927-K; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FLIER JS, 1987, J CLIN INVEST, V79, P657, DOI 10.1172/JCI112864; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUKUMOTO H, 1988, DIABETES, V37, P657, DOI 10.2337/diabetes.37.5.657; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GERHART DZ, 1989, J NEUROSCI RES, V22, P464, DOI 10.1002/jnr.490220413; GOULD GW, 1990, TRENDS BIOCHEM SCI, V15, P18, DOI 10.1016/0968-0004(90)90125-U; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HARIK SI, 1990, J NEUROSCI, V10, P3862, DOI 10.1523/JNEUROSCI.10-12-03862.1990; HAWKINS RA, 1983, J NEUROCHEM, V40, P1013, DOI 10.1111/j.1471-4159.1983.tb08086.x; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P4937; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KALARIA RN, 1988, ANN NEUROL, V24, P757, DOI 10.1002/ana.410240610; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KAYANO T, 1990, J BIOL CHEM, V265, P13276; LAMANNA JC, 1985, BRAIN RES, V326, P299, DOI 10.1016/0006-8993(85)90039-3; MAHER F, 1991, IN PRESS MOL CELL NE; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OKA Y, 1988, J BIOL CHEM, V263, P13432; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; PELLIGRINO DA, 1990, AM J PHYSIOL, V259, pE729, DOI 10.1152/ajpendo.1990.259.5.E729; PILCH PF, 1990, ENDOCRINOLOGY, V126, P3, DOI 10.1210/endo-126-1-3; REED BC, 1990, ARCH BIOCHEM BIOPHYS, V279, P261, DOI 10.1016/0003-9861(90)90490-P; SADIQ F, 1990, ENDOCRINOLOGY, V126, P2417, DOI 10.1210/endo-126-5-2417; Sambrook J, 1989, MOL CLONING LABORATO; SIVITZ W, 1989, ENDOCRINOLOGY, V124, P1875, DOI 10.1210/endo-124-4-1875; SUHR ST, 1989, MOL ENDOCRINOL, V3, P1693, DOI 10.1210/mend-3-11-1693; SUZUE K, 1989, NUCLEIC ACIDS RES, V17, P10099, DOI 10.1093/nar/17.23.10099; TAKATA K, 1990, BIOCHEM BIOPH RES CO, V173, P67, DOI 10.1016/S0006-291X(05)81022-8; WALKER PS, 1988, J BIOL CHEM, V263, P15594; WEILERGUTTLER H, 1989, BIOL CHEM H-S, V370, P467, DOI 10.1515/bchm3.1989.370.1.467; WERNER H, 1989, ENDOCRINOLOGY, V125, P314, DOI 10.1210/endo-125-1-314; YANO H, 1991, BIOCHEM BIOPH RES CO, V174, P470, DOI 10.1016/0006-291X(91)91440-N	38	254	255	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					467	472						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730609				2022-12-25	WOS:A1992GY43900075
J	PITT, A; MAYORGA, LS; SCHWARTZ, AL; STAHL, PD				PITT, A; MAYORGA, LS; SCHWARTZ, AL; STAHL, PD			TRANSPORT OF PHAGOSOMAL COMPONENTS TO AN ENDOSOMAL COMPARTMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MEMBRANE-PROTEINS; PLASMA-MEMBRANE; MACROPHAGE ENDOSOMES; VACUOLAR SYSTEM; FUSION; ASIALOGLYCOPROTEIN; PATHWAYS; BINDING; LIGAND	The participation of phagosomes in interorganellar protein and membrane exchange is important to the maturation of phagosomes into phagolysosomes. To investigate this process, we have developed an assay to measure protein transport from phagosomes to other vesicle populations. J774-E clone macrophages phagocytosed I-125-anti-dinitrophenol IgG-coated Staphylococcus aureus for 3 min followed by chase for intervals of 0-30 min. Following cell fractionation, the intracellular distribution of radioiodinated protein was assayed. We observed a time-dependent increase radioiodinated protein in a non-phagosome vesicle fraction which displayed endosome characteristics. Concomitantly, radioiodinated protein within phagosomes decreased over the chase period. As assessed via Percoll density gradient fractionation, the phagocytosed radioiodinated protein migrated to both heavy (lysosome density) and light (endosome density) vesicle populations. Characterization of the fusogenic properties of the transport vesicles demonstrated that they are capable of in vitro fusion with early endosomes. Furthermore, this fusion event shares many of the biochemical requirements identified for phagosome-endosome and endosome-endosome fusion. Morphological analysis of phagosome maturation provides additional evidence for phagosome to endosome transport. These results suggest phagocytosed material is transferred from phagosomes to endosomes and then recycled out of the cell.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,4566 SCOTT AVE,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINKRODT DEPT PHARMACOL,ST LOUIS,MO 63110; NATL UNIV CUYO,CONSEJO NACL INVEST CIENT & TECN,INST HISTOL & EMBRIOL,RA-5500 MENDOZA,ARGENTINA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza			Stahl, Philip/D-6315-2012	Mayorga, Luis S/0000-0002-5995-0671	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020015, R01AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20015] Funding Source: Medline; NIGMS NIH HHS [GM38284, GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGELER J, 1982, J CELL BIOL, V94, P613, DOI 10.1083/jcb.94.3.613; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, J BIOL CHEM, V264, P13171; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; DIMENT S, 1985, J BIOL CHEM, V260, P5311; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GEUZE HJ, 1983, EUR J CELL BIOL, V32, P38; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HUBBARD AL, 1975, J CELL BIOL, V64, P461, DOI 10.1083/jcb.64.2.461; ISENMAN LD, 1989, J BIOL CHEM, V264, P21591; KELLER RK, 1975, J BIOL CHEM, V250, P4765; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LANG T, 1988, EUR J CELL BIOL, V46, P39; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; MULLER WA, 1980, J CELL BIOL, V86, P292, DOI 10.1083/jcb.86.1.292; MULLER WA, 1980, J CELL BIOL, V86, P304, DOI 10.1083/jcb.86.1.304; OTSUKA FL, 1984, J NUCL MED, V25, P1343; ROTH J, 1983, TECHNIQUES IMMUNOCYT, V2, P217; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; WERB Z, 1972, J BIOL CHEM, V247, P2439	31	102	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					126	132						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730578				2022-12-25	WOS:A1992GY43900025
J	HANNON, GJ; CHUBB, A; MARONEY, PA; HANNON, G; ALTMAN, S; NILSEN, TW				HANNON, GJ; CHUBB, A; MARONEY, PA; HANNON, G; ALTMAN, S; NILSEN, TW			MULTIPLE CIS-ACTING ELEMENTS ARE REQUIRED FOR RNA POLYMERASE-III TRANSCRIPTION OF THE GENE ENCODING H1 RNA, THE RNA COMPONENT OF HUMAN RNASE-P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PROMOTER ELEMENTS; UPSTREAM PROMOTER; INITIATION; SEQUENCES	In humans, the H1 RNA, the RNA subunit of RNase P, is synthesized by RNA polymerase III. We have used block replacement mutagenesis to identify the sequences necessary for in vitro transcription of H1 RNA. We find that multiple cis-acting elements located in the H1 RNA 5'-flanking region are necessary for H1 RNA synthesis; no internal sequences are essential. Required cis-acting elements include sequences resembling proximal sequence element, distal sequence element, and TATA motifs. In this respect, the H1 RNA promoter is similar in structure to the promoters of the genes encoding the U6 snRNA, the 7 SK RNA and the MRP RNA. However, our mutational analysis indicates that the H1 promoter is unexpectedly complex, with several additional cis-acting elements spanning nearly 70 base pairs of the H1 RNA gene 5'-flanking sequence.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,10900 EUCLID AVE,CLEVELAND,OH 44106; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	Case Western Reserve University; Yale University			Hannon, Gregory/AAB-3568-2019		NIGMS NIH HHS [GM19422, GM31528] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019422, R01GM031528, R01GM019422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAER M, 1990, NUCLEIC ACIDS RES, V18, P97, DOI 10.1093/nar/18.1.97; BOGENHAGEN DF, 1980, CELL, V19, P27, DOI 10.1016/0092-8674(80)90385-2; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HANNON GJ, 1990, EMBO J, V9, P1915, DOI 10.1002/j.1460-2075.1990.tb08318.x; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; KROL A, 1987, NUCLEIC ACIDS RES, V15, P2463, DOI 10.1093/nar/15.6.2463; KUNKEL GR, 1989, NUCLEIC ACIDS RES, V17, P7371, DOI 10.1093/nar/17.18.7371; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6986, DOI 10.1073/pnas.88.16.6986; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; LOBO SM, 1990, NUCLEIC ACIDS RES, V18, P2891, DOI 10.1093/nar/18.10.2891; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1989, TRENDS GENET, V5, P122, DOI 10.1016/0168-9525(89)90043-7; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; PARRY HD, 1989, TRENDS BIOCHEM SCI, V14, P15, DOI 10.1016/0968-0004(89)90083-2; SIMMEN KA, 1990, NUCLEIC ACIDS RES, V18, P5649, DOI 10.1093/nar/18.19.5649; STEINBERG TH, 1990, J BIOL CHEM, V265, P499; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; YUAN Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P33, DOI 10.1016/0167-4781(91)90081-V	25	42	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22796	22799						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1720774				2022-12-25	WOS:A1991GT48300006
J	CRUMLEY, G; BELLOT, F; KAPLOW, JM; SCHLESSINGER, J; JAYE, M; DIONNE, CA				CRUMLEY, G; BELLOT, F; KAPLOW, JM; SCHLESSINGER, J; JAYE, M; DIONNE, CA			HIGH-AFFINITY BINDING AND ACTIVATION OF A TRUNCATED FGF-RECEPTOR BY BOTH AFGF AND BFGF	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; EARLY XENOPUS EMBRYOS; CELL-GROWTH; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; FACTOR CDNA; ACIDIC FGF; GENE; EXPRESSION	We recently reported the cloning and overexpression of full-length forms of human fibroblast growth factor (FGF) receptors, bek and flg. These receptors contain three immunoglobulin (Ig)-like domains and an unusual acidic motif in the extracellular region, a single transmembrane segment and a protein tyrosine kinase cytoplasmic domain containing a 14 amino acid insert. Each of the related full-length gene products interacts at high affinity with both acidic FGF and basic FGF. We now report the isolation of cDNA clones encoding two variant forms of human bek. One variant form encodes a potentially secreted bek protein containing only the first Ig-like domain and acidic motif, whereas the other variant includes all of the full-length bek protein except the first Ig-like domain and acidic motif. Overexpression of the latter bek form in NIH3T3 cells has been used to demonstrate that the N-terminal Ig-like domain and acidic region are not required for binding or activation of bek by aFGF or bFGF.	NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	New York University	CRUMLEY, G (corresponding author), RHONE POULENC RORER CENT RES, 680 ALLENDALE RD, KING OF PRUSSIA, PA 19406 USA.							ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; BAUMBACH WR, 1989, GENE DEV, V3, P1199, DOI 10.1101/gad.3.8.1199; BELLOT F, 1991, IN PRESS EMBO J; BLAM SB, 1988, ONCOGENE, V3, P129; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; HUNKAPILLER T, 1989, ADV IMMUNOL, V44, P1, DOI 10.1016/S0065-2776(08)60639-2; ISACCHI A, 1990, NUCLEIC ACIDS RES, V18, P1906, DOI 10.1093/nar/18.7.1906; JAYE M, 1987, J BIOL CHEM, V262, P16612; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KAMHOLZ J, 1986, P NATL ACAD SCI USA, V83, P4962, DOI 10.1073/pnas.83.13.4962; KAN M, 1988, J BIOL CHEM, V263, P11306; KAPLOW JM, 1990, BIOCHEM BIOPH RES CO, V172, P107, DOI 10.1016/S0006-291X(05)80179-2; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LOBB RR, 1985, BIOCHEMISTRY-US, V24, P4969, DOI 10.1021/bi00340a001; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PETERSON PA, 1972, P NATL ACAD SCI USA, V69, P1697, DOI 10.1073/pnas.69.7.1697; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; TOGARI A, 1985, J NEUROSCI, V5, P307; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	63	58	59	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2255	2262						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1722570				2022-12-25	WOS:A1991GX73500012
J	JIRTLE, RL; CARR, BI; SCOTT, CD				JIRTLE, RL; CARR, BI; SCOTT, CD			MODULATION OF INSULIN-LIKE GROWTH FACTOR-II/MANNOSE 6-PHOSPHATE RECEPTORS AND TRANSFORMING GROWTH FACTOR-BETA-1 DURING LIVER-REGENERATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II MANNOSE-6-PHOSPHATE RECEPTOR; MOLECULAR-WEIGHT COMPLEX; RAT-LIVER; FACTOR-BETA; MANNOSE 6-PHOSPHATE; PARTIAL-HEPATECTOMY; TGF-BETA; INCREASED EXPRESSION; GENE-TRANSCRIPTION; BINDING-PROTEIN	Transforming growth factor-beta-1 (TGF-beta-1) is a potent mito-inhibiting substance that is thought to play an important function in regulating hepatocyte proliferation during liver regeneration. In this investigation, we have shown by immunohistochemistry that hepatocytes contain significant intracellular concentrations of TGF-beta-1 12 h after a two-thirds partial hepatectomy. This increase in hepatocyte TGF-beta-1 concentration was initially confined to those cells that resided in the periportal region of the liver. The elevation of intracellular TGF-beta-1 was, however, transient, and within 36 h, the hepatocytes positive for TGF-beta-1 had changed in a wavelike fashion from the periportal to the pericentral region of the liver lobules. By 48 h, most hepatocytes no longer contained TGF-beta-1. Interestingly, this temporary increase in TGF-beta-1 always preceded the onset of hepatocyte replication by approximately 3-6 h. Since TGF-beta-1 mRNA has been shown to be absent from hepatocytes normally and throughout liver regeneration, these results imply that the increase in intracellular TGF-beta-1 resulted from an augmented uptake. We have further shown that the insulin-like growth factor-II/mannose 6-phosphate (IGF-II/Man-6-P) receptors were up-regulated during liver regeneration and that the increased expression of this receptor co-localized in those hepatocytes containing elevated concentrations of TGF-beta-1. The latent TGF-beta-1 phosphomannosyl glycoprotein complex has been shown to bind to the IGF-II/Man-6-P receptor. Therefore, our data are consistent with the hypothesis that this latent complex is internalized through the IGF-II/Man-6-P receptor to the intracellular acidic prelysosomal/endosomal compartments where the mature TGF-beta-1 molecule could be activated by dissociation from the latent complex.	UNIV PITTSBURGH, DEPT SURG, PITTSBURGH, PA 15261 USA; ROYAL PRINCE ALFRED HOSP, DEPT ENDOCRINOL, CAMPERDOWN, NSW 2050, AUSTRALIA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Sydney	JIRTLE, RL (corresponding author), DUKE UNIV, MED CTR, DEPT RADIOL, BOX 3433, DURHAM, NC 27710 USA.		Scott, Carolyn/A-4544-2015	Scott, Carolyn/0000-0001-9363-1829; Carr, Brian/0000-0002-6111-5077	NATIONAL CANCER INSTITUTE [R01CA025951, R01CA040172] Funding Source: NIH RePORTER; NCI NIH HHS [CA25951, CA40172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALCORN JA, 1990, HEPATOLOGY, V11, P909, DOI 10.1002/hep.1840110602; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BONDY CA, 1990, MOL ENDOCRINOL, V4, P1386, DOI 10.1210/mend-4-9-1386; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; BRESLOW N, 1988, CANCER RES, V48, P1653; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; BURGUERA B, 1990, MOL ENDOCRINOL, V4, P1539, DOI 10.1210/mend-4-10-1539; CARR BI, 1986, CANCER RES, V46, P2330; CARR BI, 1989, J CELL BIOCHEM, V39, P477, DOI 10.1002/jcb.240390413; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRUISE JL, 1987, HEPATOLOGY, V7, P1189, DOI 10.1002/hep.1840070604; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DUBOIS RD, 1990, HEPATOLOGY, V11, P1079, DOI 10.1002/hep.1840110626; FAUSTO N, 1989, LAB INVEST, V60, P4; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GRISHAM JW, 1969, NORMAL MALIGNANT CEL, P28; GRUPPUSO PA, 1990, CANCER RES, V50, P1464; HARTSHORN MA, 1989, J ENDOCRINOL, V121, P221, DOI 10.1677/joe.0.1210221; Higgins GM, 1931, ARCH PATHOL, V12, P186; JIRTLE RL, 1991, DIGEST DIS SCI, V36, P659, DOI 10.1007/BF01297035; KOVACINA KS, 1989, BIOCHEM BIOPH RES CO, V160, P393, DOI 10.1016/0006-291X(89)91669-0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LEVY JR, 1987, ENDOCRINOLOGY, V121, P2075, DOI 10.1210/endo-121-6-2075; LINDROOS PM, 1991, HEPATOLOGY, V13, P743, DOI 10.1002/hep.1840130422; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCMAHON JB, 1986, CANCER RES, V46, P4665; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MIYAZONO K, 1989, NATURE, V338, P158, DOI 10.1038/338158a0; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; NAGY P, 1989, MOL CARCINOGEN, V2, P345, DOI 10.1002/mc.2940020609; NAKATSUKASA H, 1990, LAB INVEST, V63, P171; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; Sambrook J, 1989, MOL CLONING LABORATO; SCOTT CD, 1987, ENDOCRINOLOGY, V120, P1; SCOTT CD, 1990, ENDOCRINOLOGY, V126, P2543, DOI 10.1210/endo-126-5-2543; SCOTT CD, 1990, ENDOCRINOLOGY, V127, P2210, DOI 10.1210/endo-127-5-2210; SHA X, 1989, MOL ENDOCRINOL, V3, P1090, DOI 10.1210/mend-3-7-1090; SILVERMAN JA, 1989, MOL CARCINOGEN, V2, P63, DOI 10.1002/mc.2940020203; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646	55	109	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22444	22450						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1718994				2022-12-25	WOS:A1991GR56400062
J	JOSLIN, G; KRAUSE, JE; HERSHEY, AD; ADAMS, SP; FALLON, RJ; PERLMUTTER, DH				JOSLIN, G; KRAUSE, JE; HERSHEY, AD; ADAMS, SP; FALLON, RJ; PERLMUTTER, DH			AMYLOID-BETA PEPTIDE, SUBSTANCE-P, AND BOMBESIN BIND TO THE SERPIN-ENZYME COMPLEX RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN COFACTOR-II; HAMSTER OVARY CELLS; PROTEASE NEXIN-II; ALPHA-1-PROTEINASE INHIBITOR; NEUTROPHIL CHEMOATTRACTANT; MOLECULAR CHARACTERIZATION; PROTEINASE-INHIBITORS; INVIVO CATABOLISM; PRECURSOR PROTEIN; FUNCTIONAL CDNA	During the formation of an inhibitory complex with neutrophil elastase, a, antitrypsin (al AT) undergoes a structural rearrangement and the resulting alpha-1 AT-elastase complex becomes endowed with chemoattractant activities, mediates an increase in synthesis of alpha-1AT, and is rapidly cleared from the circulation. In previous studies we have provided evidence that these biological activities involve the recognition of a conformation-specific domain in the alpha-1 AT molecule by a cell surface receptor on human hepatoma HepG2 cells and human monocytes. The receptor has been termed the serpin-enzyme complex (SEC) receptor because it also recognizes complexes of serpins antithrombin III, alpha-1 antichymotrypsin, and C1 inhibitor with their cognate enzymes. Because a pentapeptide domain of alpha-1 AT (amino acids 370-374, Phe-Val-Phe-Leu-Met) is sufficient for binding to the SEC receptor and the sequence of this domain is remarkably similar to those of substance P, several other tachykinins, bombesin, and the amyloid-beta peptide, we have examined the possibility that these other ligands bind to the SEC receptor. The results indicate that substance P, several other tachykinins, and bombesin compete for binding to, and cross-linking of, the SEC receptor. The SEC receptor is distinct from the substance P receptor by several criteria. There is no substance P receptor mRNA in HepG2 cells; the SEC receptor is present in much higher density on receptor-bearing cells and binds its ligands at lower affinity than the substance P receptor; the SEC receptor is much less restricted in the specificity with which it recognizes ligand; ligands for the SEC receptor including peptide 105Y (based on alpha-1AT sequence 359374), alpha-1 AT-protease complexes, and bombesin do not compete for binding of substance P to a stable transfected cell line expressing the substance P receptor. Finally, we show here that the amyloid-beta peptide competes for binding to the SEC receptor but does not bind to the substance P receptor, therein raising the possibility that the SEC receptor is involved in certain biological activities, including the recently described neurotrophic and neurotoxic effects ascribed to the amyloid-beta-peptide.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	JOSLIN, G (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PEDIAT,400 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.		Hershey, Andrew D./K-1245-2019	Hershey, Andrew D./0000-0002-1598-7536	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021937, R55NS021937] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37784] Funding Source: Medline; NINDS NIH HHS [NS21937] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANDA MJ, 1988, J EXP MED, V167, P1608, DOI 10.1084/jem.167.5.1608; BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BARBEYMOREL C, 1991, PEDIATR RES, V29, P133, DOI 10.1203/00006450-199102000-00005; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JI TH, 1982, ANAL BIOCHEM, V121, P286, DOI 10.1016/0003-2697(82)90481-X; JOSLIN G, 1991, J BIOL CHEM, V266, P11282; KATZMAN R, 1991, FASEB J, V5, P278, DOI 10.1096/fasebj.5.3.2001787; LEE CM, 1989, BRAIN RES, V488, P328, DOI 10.1016/0006-8993(89)90724-5; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PAYAN DG, 1986, J BIOL CHEM, V261, P14321; PERLMUTTER DH, 1988, J CLIN INVEST, V81, P1774, DOI 10.1172/JCI113519; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; PERLMUTTER DH, 1989, AM J PHYSIOL, V257, pL147, DOI 10.1152/ajplung.1989.257.4.L147; PERLMUTTER DH, 1990, J BIOL CHEM, V265, P16713; PERLMUTTER DH, 1990, P NATL ACAD SCI USA, V87, P3753, DOI 10.1073/pnas.87.10.3753; PERLMUTTER DH, 1991, HEPATOLOGY, V13, P172, DOI 10.1002/hep.1840130125; PIZZO SV, 1988, BIOCHIM BIOPHYS ACTA, V967, P158, DOI 10.1016/0304-4165(88)90005-0; PRATT CW, 1988, ARCH BIOCHEM BIOPHYS, V262, P111, DOI 10.1016/0003-9861(88)90173-7; QUIRION R, 1988, REGUL PEPTIDES, V22, P18, DOI 10.1016/0167-0115(88)90245-5; SEGE RD, 1984, NATURE, V307, P742, DOI 10.1038/307742a0; SELKOE DJ, 1989, CELL, V58, P611, DOI 10.1016/0092-8674(89)90093-7; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SPINDEL E, 1986, TRENDS NEUROSCI, V9, P130, DOI 10.1016/0166-2236(86)90042-1; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TSUCHIDA K, 1990, EUR J BIOCHEM, V193, P751, DOI 10.1111/j.1432-1033.1990.tb19396.x; VANNOSTRAND WE, 1989, NATURE, V341, P546; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	32	113	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21897	21902						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1718986				2022-12-25	WOS:A1991GP80400086
J	WICKER, G; PRILL, V; BROOKS, D; GIBSON, G; HOPWOOD, J; VONFIGURA, K; PETERS, C				WICKER, G; PRILL, V; BROOKS, D; GIBSON, G; HOPWOOD, J; VONFIGURA, K; PETERS, C			MUCOPOLYSACCHARIDOSIS-VI (MAROTEAUX-LAMY SYNDROME) - AN INTERMEDIATE CLINICAL PHENOTYPE CAUSED BY SUBSTITUTION OF VALINE FOR GLYCINE AT POSITION-137 OF ARYLSULFATASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ACID-PHOSPHATASE; CULTURED HUMAN-FIBROBLASTS; SULFATASE; BIOSYNTHESIS; MATURATION; DIAGNOSIS; GENE; DNA; INHIBITORS; MUTATIONS	The Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI) is a lysosomal storage disease with autosomal recessive inheritance caused by deficiency of the enzyme arylsulfatase B. Severe, intermediate, and mild forms of the disease have been described. The molecular correlate of the clinical heterogeneity is not known at present. To identify the molecular defect in a patient with the intermediate form of the disease, arylsulfatase B mRNA from his fibroblasts was reverse-transcribed, amplified by the polymerase chain reaction, and subcloned. Three point mutations were detected by DNA sequence analysis, two of which, a silent A to G transition at nucleotide 1191 and a G to A transition at nucleotide 1126 resulting in a methionine for valine 376 substitution, were polymorphisms. A G to T transversion at nucleotide 410 causing a valine for glycine 137 substitution (G137V) was identified as the mutation underlying the Maroteaux-Lamy phenotype of the patient, who was homozygous for the allele. The kinetic parameters of the mutant arylsulfatase B enzyme toward a radiolabeled trisaccharide substrate were normal excluding an alteration of the active site. The G137V mutation did not affect the synthesis but severely reduced the stability of the arylsulfatase B precursor. While the wild type precursor is converted by limited proteolysis in late endosomes or lysosomes to a mature form, the majority of the mutant precursor was degraded presumably in a compartment proximal to the trans Golgi network and only a small amount escaped to the lysosomes accounting for the low residual enzyme activity in fibroblasts of a patient with the juvenile form of the disease.	ADELAIDE MED CTR WOMEN & CHILDREN,DEPT CHEM PATHOL,LYSOSOMAL DIS RES UNIT,ADELAIDE,SA 5006,AUSTRALIA	Womens & Childrens Hospital Australia	WICKER, G (corresponding author), UNIV GOTTINGEN,GOSSLERSTR 12D,W-3400 GOTTINGEN,GERMANY.		Brooks, Doug A/K-6714-2012	Brooks, Doug/0000-0001-9098-3626				BARKER D, 1984, CELL, V36, P131, DOI 10.1016/0092-8674(84)90081-3; BROOKS DA, 1991, AM J HUM GENET, V48, P710; CAUSIN C, 1988, BIOCHEM J, V252, P795, DOI 10.1042/bj2520795; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; GIBSON GJ, 1987, BIOCHEM J, V248, P755, DOI 10.1042/bj2480755; HASILIK A, 1980, J BIOL CHEM, V255, P4937; HOPWOOD JJ, 1986, BIOCHEM J, V234, P507, DOI 10.1042/bj2340507; KOBAYASHI K, 1990, J BIOL CHEM, V265, P11361; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; LEMANSKY P, 1985, J BIOL CHEM, V260, P9023; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATALON R, 1974, BIOCHEM BIOPH RES CO, V61, P1450, DOI 10.1016/S0006-291X(74)80446-8; MYEROWITZ R, 1981, J BIOL CHEM, V256, P3044; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; Neufeld EF, 1989, METABOLIC BASIS INHE, P1565; OBRIEN JF, 1974, BIOCHEM BIOPH RES CO, V60, P1170, DOI 10.1016/0006-291X(74)90435-5; PAW BH, 1990, J BIOL CHEM, V265, P9452; PETERS C, 1990, J BIOL CHEM, V265, P3374; POLTEN A, 1991, NEW ENGL J MED, V324, P18, DOI 10.1056/NEJM199101033240104; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUCHMAN EH, 1990, GENOMICS, V6, P149, DOI 10.1016/0888-7543(90)90460-C; STECKEL F, 1983, J BIOL CHEM, V258, P4322; TAYLOR JA, 1990, BIOCHEM J, V268, P379, DOI 10.1042/bj2680379; VONFIGURA K, 1983, P NATL ACAD SCI-BIOL, V80, P6066; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	29	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21386	21391						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1718978				2022-12-25	WOS:A1991GP80400014
J	MEYER, C; LEVIN, JM; ROUSSEL, JM; ROUZE, P				MEYER, C; LEVIN, JM; ROUSSEL, JM; ROUZE, P			MUTATIONAL AND STRUCTURAL-ANALYSIS OF THE NITRATE REDUCTASE HEME DOMAIN OF NICOTIANA-PLUMBAGINIFOLIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE; DEFICIENT MUTANTS; TOBACCO; GENES; DNA; MUTAGENESIS; PROTEOLYSIS; EXPRESSION	We have analyzed four Nicotiana plumbaginifolia null mutants presumably affected in the heme domain of nitrate reductase. The DNA sequence of this domain has been determined for each mutant and for the wild type. Two mutations were identified as single base changes leading to, respectively, the substitution of a histidine residue by an asparagine (mutant E56) and to the appearance of an ochre stop codon (mutant E64). Based on the amino acid sequence homology between the nitrate reductase heme domain and mammalian cytochrome b5, we have predicted the three-dimensional structure of this domain. This showed that the nitrate reductase heme domain is structurally very similar to cytochrome b5, and it also confirmed that the residue involved in E56 mutation is one of the two heme-binding histidines. The two other mutations (mutants A1 and K21) were found to be, respectively, -1 and +1 frameshift mutations resulting in the appearance of an opal stop codon. These sequence data confirmed previous genetic and biochemical hypotheses on nitrate reductase-deficient mutants. Northern blot analysis of these mutants indicated that mutant E56 overexpressed the nitrate reductase mRNA, whereas the nonsense mutations present in the other mutants led to reduced levels of nitrate reductase mRNA.	INRA, BATIMENT BIOTECHNOL, UNITE INGN PROT, F-78350 JOUY EN JOSAS, FRANCE	INRAE; UDICE-French Research Universities; Universite Paris Saclay	MEYER, C (corresponding author), INRA, BIOL CELLULAIRE LAB, F-78026 VERSAILLES, FRANCE.		Levin, Jonathan/N-3189-2018	Meyer, Christian/0000-0002-7994-5693				CABOCHE M, 1990, TRENDS GENET, V6, P187, DOI 10.1016/0168-9525(90)90175-6; CALZA R, 1987, MOL GEN GENET, V209, P552, DOI 10.1007/BF00331162; Campbell W. H., 1988, Current Topics in Plant Biochemistry and Physiology, V7, P1; CHAKRABARTI P, 1990, PROTEIN ENG, V4, P49, DOI 10.1093/protein/4.1.49; CHEREL I, 1986, PLANT PHYSIOL, V81, P376, DOI 10.1104/pp.81.2.376; CHEREL I, 1990, PLANT PHYSIOL, V92, P659, DOI 10.1104/pp.92.3.659; CHOI HK, 1989, PLANT MOL BIOL, V13, P731, DOI 10.1007/BF00016030; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; DOLFERUS R, 1990, MOL GEN GENET, V224, P297, DOI 10.1007/BF00271565; GABARD J, 1987, MOL GEN GENET, V209, P596, DOI 10.1007/BF00331169; GALANGAU F, 1988, PLANT PHYSIOL, V88, P383, DOI 10.1104/pp.88.2.383; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KAY CJ, 1989, BIOCHEM J, V263, P285, DOI 10.1042/bj2630285; KUBO Y, 1988, J BIOL CHEM, V263, P19684; LEVIN JM, 1988, BIOCHIM BIOPHYS ACTA, V955, P283, DOI 10.1016/0167-4838(88)90206-3; MATHEWS FS, 1971, COLD SPRING HARB SYM, V36, P387, DOI 10.1101/SQB.1972.036.01.050; MEYER C, 1987, BIOCHIMIE, V69, P735, DOI 10.1016/0300-9084(87)90194-5; MOUREAUX T, 1989, EUR J BIOCHEM, V179, P617, DOI 10.1111/j.1432-1033.1989.tb14591.x; NOTTON BA, 1989, PHYTOCHEMISTRY, V28, P2261, DOI 10.1016/S0031-9422(00)97964-0; PELSY F, 1991, GENETICS, V127, P199; PELSY F, 1984, CURR GENET, V8, P277, DOI 10.1007/BF00419725; POUTEAU S, 1989, PLANT CELL, V1, P1111, DOI 10.1105/tpc.1.11.1111; REDINBAUGH MG, 1985, J BIOL CHEM, V260, P3380; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SLIGAR SG, 1987, J AM CHEM SOC, V109, P7896, DOI 10.1021/ja00259a056; SOLOMONSON LP, 1990, ANNU REV PLANT PHYS, V41, P225, DOI 10.1146/annurev.pp.41.060190.001301; SOLOMONSON LP, 1987, J BIOL CHEM, V262, P8934; VANCANNEYT G, 1990, NUCLEIC ACIDS RES, V18, P2917, DOI 10.1093/nar/18.10.2917; VANGUNSTEREN WF, 1987, SPRINGER IMA SERIES; VAUCHERET H, 1989, PLANT MOL BIOL, V12, P597, DOI 10.1007/BF00036974; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; WRAY JL, 1986, GENETIC APPROACH PLA, V3, P101; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629	35	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20561	20566						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1718967				2022-12-25	WOS:A1991GM03900103
J	GUILLOTON, MB; KORTE, JJ; LAMBLIN, AF; FUCHS, JA; ANDERSON, PM				GUILLOTON, MB; KORTE, JJ; LAMBLIN, AF; FUCHS, JA; ANDERSON, PM			CARBONIC-ANHYDRASE IN ESCHERICHIA-COLI - A PRODUCT OF THE CYN OPERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIOXIDE HYDRATION ACTIVITY; GENE ENCODING CYANASE; PURIFICATION; EXPRESSION; INHIBITION; SEQUENCE; K-12; IDENTIFICATION; BICARBONATE; PROTEINS	The product of the cynT gene of the cyn operon in Escherichia coli has been identified as a carbonic anhydrase. The cyn operon also includes the gene cynS, encoding the enzyme cyanase. Cyanase catalyzes the reaction of cyanate with bicarbonate to give ammonia and carbon dioxide. The carbonic anhydrase was isolated from an Escherichia coli strain overexpressing t he cynT gene and characterized. The purified enzyme was shown to contain 1 Zn2+/subunit (24 kDa) and was found to behave as an oligomer in solution, the presence of bicarbonate resulted in partial dissociation of the oligomeric enzyme. The kinetic properties of the enzyme are similar to those of carbonic anhydrases from other species, including inhibition by sulfonamides and cyanate. The amino acid sequence shows a high degree of identity with the sequences of two plant carbonic anhydrases, but not with animal and algal carbonic anhydrases. Since carbon dioxide formed in the bicarbonate-dependent decomposition of cyanate diffuses out of the cell faster than it would be hydrated to bicarbonate, the apparent function of the induced carbonic anhydrase is to catalyze hydration of carbon dioxide and thus prevent depletion of cellular bicarbonate.	UNIV MINNESOTA,DEPT BIOCHEM,DULUTH,MN 55812; UNIV MINNESOTA,DEPT MOLEC BIOL,DULUTH,MN 55812; UNIV MINNESOTA,COLL BIOL SCI,DEPT BIOCHEM,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033842] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33842] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER L, 1972, BIOCHIM BIOPHYS ACTA, V284, P298, DOI 10.1016/0005-2744(72)90068-X; ANDERSON PM, 1990, FEMS MICROBIOL LETT, V87, P247, DOI 10.1016/0378-1097(90)90462-Y; ANDERSON PM, 1987, BIOCHEMISTRY-US, V26, P3938, DOI 10.1021/bi00387a029; ANDERSON PM, 1988, J BIOL CHEM, V263, P5674; ANDERSON PM, 1980, BIOCHEMISTRY-US, V19, P2882, DOI 10.1021/bi00554a010; ANDERSON PM, 1986, BIOCHEMISTRY-US, V25, P1621, DOI 10.1021/bi00355a026; BURNELL JN, 1990, PLANT PHYSIOL, V92, P37, DOI 10.1104/pp.92.1.37; CHIN CCQ, 1983, J BIOL CHEM, V258, P276; DODGSON SJ, 1986, ARCH BIOCHEM BIOPHYS, V251, P198, DOI 10.1016/0003-9861(86)90066-4; DODGSON SJ, 1991, CARBONIC ANHYDRASES, P297; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAWCETT TW, 1990, J BIOL CHEM, V265, P5414; GILL SR, 1984, ARCH MICROBIOL, V138, P113, DOI 10.1007/BF00413010; GUILLOTON M, 1987, J GEN MICROBIOL, V133, P645; GUILLOTON M, 1987, J GEN MICROBIOL, V133, P655; GUTKNECHT J, 1977, J GEN PHYSIOL, V69, P779; JOHNSON WV, 1987, J BIOL CHEM, V262, P9021; KANDEL M, 1978, J BIOL CHEM, V253, P679; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KIM KH, 1987, J MOL BIOL, V198, P137, DOI 10.1016/0022-2836(87)90465-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLE RM, 1987, J BIOL CHEM, V262, P10120; MAJEAU N, 1991, PLANT PHYSIOL, V95, P264, DOI 10.1104/pp.95.1.264; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NAFI BM, 1990, J MED MICROBIOL, V32, P1, DOI 10.1099/00222615-32-1-1; POCKER Y, 1973, BIOCHEMISTRY-US, V12, P5127, DOI 10.1021/bi00749a016; ROBYT JF, 1987, BIOCH TECHNIQUES THE, P340; SANYAL G, 1982, MOL PHARMACOL, V22, P211; SUNG YC, 1989, J BACTERIOL, V171, P4674, DOI 10.1128/jb.171.9.4674-4678.1989; SUNG YC, 1988, J BIOL CHEM, V263, P14769; SUNG YC, 1987, J BACTERIOL, V169, P2639, DOI 10.1128/jb.169.6.2639-2642.1987; SUNG YC, 1987, J BACTERIOL, V169, P5224, DOI 10.1128/jb.169.11.5224-5230.1987; TASHIAN RE, 1989, BIOESSAYS, V10, P186, DOI 10.1002/bies.950100603; TAUSSIG A, 1960, BIOCHIM BIOPHYS ACTA, V44, P510, DOI 10.1016/0006-3002(60)91605-X; TAUSSIG A, 1960, CAN J MICROBIOL, V6, P619, DOI 10.1139/m60-074; TU CK, 1987, PLANT PHYSIOL, V85, P72, DOI 10.1104/pp.85.1.72; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WESTLER J, 1960, BIOCHIM BIOPHYS ACTA, V40, P364, DOI 10.1016/0006-3002(60)91368-8	40	107	111	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3731	3734						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740425				2022-12-25	WOS:A1992HE60700031
J	KUZNETSOV, G; BROSTROM, MA; BROSTROM, CO				KUZNETSOV, G; BROSTROM, MA; BROSTROM, CO			DEMONSTRATION OF A CALCIUM REQUIREMENT FOR SECRETORY PROTEIN PROCESSING AND EXPORT - DIFFERENTIAL-EFFECTS OF CALCIUM AND DITHIOTHREITOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; CHAIN BINDING-PROTEIN; INTRACELLULAR-TRANSPORT; LINKED OLIGOSACCHARIDES; DISULFIDE-ISOMERASE; EUKARYOTIC CELLS; GOLGI; PERTURBATION; BIOSYNTHESIS; INHIBITORS	HepG2 cells were employed as model system to investigate potential relationships between early protein processing and Ca2+ storage by the endoplasmic reticulum. Ca2+ was required for glycoprotein processing and export by intact cells. The processing and export of alpha-1-antitrypsin and the secretion of complement factor 3, which are glycosylated proteins, were inhibited by the Ca2+ ionophore ionomycin whereas the export of albumin, a non-glycoprotein, was little affected. Ionomycin blocked processing of alpha-1-antitrypsin at the conversion from the high mannose to the complex glycosylated form without affecting ATP or GTP contents. Pre-existing inhibition of intracellular processing of alpha-1-antitrypsin by ionomycin was fully reversible upon removal of the ionophore with fatty acid-free bovine serum albumin. This reversal required Ca2+. After reversal the arrested form of alpha-1-antitrypsin was fully converted to the mature form and exported to the medium. Inhibitions of alpha-1-antitrypsin processing and complement factor 3 secretion by the metalloendoprotease antagonist Cbz-Gly-Phe-NH2, (where Cbz is benzyloxycarbonyl) were strongest at low extracellular Ca2+ but were reduced or prevented by high extracellular Ca2+. Processing and secretion of alpha-1-antitrypsin were reduced upon incubation in low Ca2+ medium. Exposure to dithiothreitol reduced albumin export while affecting alpha-1-antitrypsin export minimally. Suppression of amino acid incorporation into total cellular proteins of HepG2 cells accompanied inhibitions of protein processing by agents depleting sequestered Ca2+ stores or by dithiothreitol. Putative control of rates of translational initiation by the endoplasmic reticulum through linkage to rates of early protein processing is discussed.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NIDDK NIH HHS [DK 35393] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035393] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1986, BIOCHEMISTRY-US, V25, P3944, DOI 10.1021/bi00361a031; ALBERT PR, 1984, J BIOL CHEM, V259, P5350; ALBERT PR, 1986, AM J PHYSIOL, V251, pC887, DOI 10.1152/ajpcell.1986.251.6.C887; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BROSTROM CO, 1989, J BIOL CHEM, V264, P1644; BROSTROM CO, 1983, J BIOL CHEM, V258, P4390; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BROSTROM MA, 1991, J BIOL CHEM, V266, P7037; BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; CARLSON J, 1982, J BIOL CHEM, V257, P2987; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GROSS V, 1982, EUR J BIOCHEM, V129, P317, DOI 10.1111/j.1432-1033.1982.tb07054.x; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELKES PI, 1987, J BIOL CHEM, V262, P15496; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; MORRIS KM, 1982, SCIENCE, V215, P399, DOI 10.1126/science.7199205; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PAULIK M, 1988, J BIOL CHEM, V263, P17738; PFEIFFER DR, 1982, POLYETHER ANTIBIOTIC, V1, P103; PROSTKO CR, 1991, J BIOL CHEM, V266, P19790; REED PW, 1982, POLYETHER ANTIBIOTIC, V1, P185; REED PW, 1982, POLYETHER ANTIBIOTIC, V1, P369; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SCHUTZBACH JS, 1990, J BIOL CHEM, V265, P2546; STROUS GJ, 1988, J BIOL CHEM, V263, P18197; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; WHITE A, 1978, PRINCIPLES BIOCH, P136; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; Williamson J.R., 1969, METHOD ENZYMOL, V13, P434, DOI 10.1016/0076-687913072-4; WONG WL, 1991, INT J BIOCHEM, V23, P605	47	96	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3932	3939						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740441				2022-12-25	WOS:A1992HE60700060
J	GUIHARD, G; BOULANGER, P; LETELLIER, L				GUIHARD, G; BOULANGER, P; LETELLIER, L			INVOLVEMENT OF PHAGE-T5 TAIL PROTEINS AND CONTACT SITES BETWEEN THE OUTER AND INNER MEMBRANE OF ESCHERICHIA-COLI IN PHAGE-T5 DNA INJECTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL PROTEINS; IRREVERSIBLE BINDING; RECEPTOR PROTEIN; CROSS-RESISTANCE; CELL-ENVELOPE; LYSIS PROTEIN; ION CHANNELS; HOST-CELL; BACTERIOPHAGE-T5; T5	The penetration of phage T5 DNA into the Escherichia coli envelope takes place through ion channels (Boulanger, P., and Letellier, L. (1992) J. Biol. Chem. 267, 3168-3172). To identify putative phage protein(s) involved in the formation of these channels, E. coli cells were infected at 37-degrees-C with radioactively labeled phage and their envelopes were fractionated. After a flotation gradient, proteins belonging to the phage tail were recovered both in fractions containing the contact sites between the inner and outer membranes and in the outer membrane. The electrophoretic banding pattern of phage proteins indicates that the contact sites were enriched in the protein pb2. Moreover, infected cells were significantly enriched in contact sites as compared to intact cells. There was no enrichment of contact sites and very little radioactivity was found in this fraction and in the outer membrane when the cells were infected at 4-degrees-C (i.e. under conditions where the phage does not inject its DNA). These results suggest that both contact sites and pb2 may play a central role in the translocation of phage T5 DNA.	UNIV PARIS 11, BIOMEMBRANE LAB, CNRS, UA 116, BAT 433, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay								BAYERME, 1979, BACTERIAL OUTER MEMB, P167; BOEKE JD, 1982, MOL GEN GENET, V186, P185, DOI 10.1007/BF00331849; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOULANGER P, 1992, J BIOL CHEM, V267, P3168; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; BRADLEY DE, 1967, BACTERIOL REV, V31, P230, DOI 10.1128/MMBR.31.4.230-314.1967; BRAUN V, 1980, J BACTERIOL, V142, P162, DOI 10.1128/JB.142.1.162-168.1980; BRAUN V, 1973, BIOCHIM BIOPHYS ACTA, V323, P87, DOI 10.1016/0005-2736(73)90433-1; BREWER S, 1990, J MOL BIOL, V216, P883, DOI 10.1016/S0022-2836(99)80008-4; DAVIES JK, 1975, J BACTERIOL, V123, P102, DOI 10.1128/JB.123.1.102-117.1975; DAVIES JK, 1975, J BACTERIOL, V123, P96, DOI 10.1128/JB.123.1.96-101.1975; DUBERTRET C, 1978, FEMS MICROBIOL LETT, V4, P63; EICKHELMERICH K, 1989, J BACTERIOL, V171, P5117, DOI 10.1128/jb.171.9.5117-5126.1989; FEUCHT A, 1989, FEBS LETT, V255, P435, DOI 10.1016/0014-5793(89)81140-8; FEUCHT A, 1990, J BIOL CHEM, V265, P18561; HELLER K, 1979, J BACTERIOL, V139, P32, DOI 10.1128/JB.139.1.32-38.1979; HELLER KJ, 1985, J BACTERIOL, V162, P621, DOI 10.1128/JB.162.2.621-625.1985; HEPPEL LA, 1967, SCIENCE, V156, P1451, DOI 10.1126/science.156.3781.1451; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; JAKES KS, 1988, J BACTERIOL, V170, P4231, DOI 10.1128/jb.170.9.4231-4238.1988; KAPLAN RS, 1989, METHOD ENZYMOL, V172, P393; KELLENBERGER E, 1990, MOL MICROBIOL, V4, P697, DOI 10.1111/j.1365-2958.1990.tb00640.x; LABEDAN B, 1973, J MOL BIOL, V75, P213, DOI 10.1016/0022-2836(73)90017-X; LABEDAN B, 1976, VIROLOGY, V75, P368, DOI 10.1016/0042-6822(76)90035-0; LABEDAN B, 1974, J VIROL, V13, P1093, DOI 10.1128/JVI.13.5.1093-1100.1974; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANNI YT, 1960, VIROLOGY, V10, P501, DOI 10.1016/0042-6822(60)90132-X; LANNI YT, 1968, BACTERIOL REV, V32, P227, DOI 10.1128/MMBR.32.3.227-242.1968; LETELLIER L, 1989, BIOCHIMIE, V71, P167, DOI 10.1016/0300-9084(89)90147-8; LOPEZ J, 1985, J BACTERIOL, V163, P1270, DOI 10.1128/JB.163.3.1270-1274.1985; MCCORQUODALE DL, 1988, BACTERIOPHAGES, V1, P437; MUHLRADT PF, 1974, EUR J BIOCHEM, V43, P533, DOI 10.1111/j.1432-1033.1974.tb03440.x; SAIGO K, 1978, VIROLOGY, V85, P422, DOI 10.1016/0042-6822(78)90449-X; WALDERICH B, 1988, J BACTERIOL, V170, P5027, DOI 10.1128/jb.170.11.5027-5033.1988; WALDERICH B, 1989, J BACTERIOL, V171, P3331, DOI 10.1128/jb.171.6.3331-3336.1989; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7; ZWEIG M, 1973, VIROLOGY, V51, P443, DOI 10.1016/0042-6822(73)90443-1	37	36	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3173	3178						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737771				2022-12-25	WOS:A1992HD15400056
J	SAUER, UH; SUN, DP; MATTHEWS, BW				SAUER, UH; SUN, DP; MATTHEWS, BW			TOLERANCE OF T4-LYSOZYME TO PROLINE SUBSTITUTIONS WITHIN THE LONG INTERDOMAIN ALPHA-HELIX ILLUSTRATES THE ADAPTABILITY OF PROTEINS TO POTENTIALLY DESTABILIZING LESIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANT; SITE-SPECIFIC MUTAGENESIS; PHAGE-T4 LYSOZYME; BACTERIOPHAGE-T4 LYSOZYME; T4 LYSOZYME; PHENOTYPIC SELECTION; THERMAL-STABILITY; THERMOSTABILITY; CONFORMATIONS; REFINEMENT	To investigate the ability of a protein to accommodate potentially destabilizing amino acid substitutions, and also to investigate the steric requirements for catalysis, proline was substituted at different sites within the long alpha-helix that connects the amino-terminal and carboxyl-terminal domains of T4 lysozyme. Of the four substitutions attempted, three yielded folded, functional proteins. The catalytic activities of these three mutant proteins (Q69P, D72P, and A74P) were 60-90% that of wild-type. Their melting temperatures were 7-12-degrees-C less than that of wild-type at pH 6.5. Mutant D72P formed crystals isomorphous with wild-type allowing the structure to be determined at high resolution. In the crystal structure of wild-type lysozyme the interdomain alpha-helix has an overall bend angle of 8.5-degrees. In the mutant structure the introduction of the proline causes this bend angle to increase to 14-degrees and also causes a corresponding rotation of 5.5-degrees of carboxyl-terminal domain relative to the amino-terminal one. Except for the immediate location of the proline substitution there is very little change in the geometry of the interdomain alpha-helix. The results support the view that protein structures are adaptable and can compensate for potentially destabilizing amino acid substitutions. The results also suggest that the precise shape of the active site cleft of T4 lysozyme is not critical for catalysis.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, HOWARD HUGHES MED INST, EUGENE, OR 97403 USA; UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	University of Oregon; Howard Hughes Medical Institute; University of Oregon; University of Oregon					NIGMS NIH HHS [GM21967] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1988, SCIENCE, V239, P631, DOI 10.1126/science.3277275; ALBER T, 1987, METHOD ENZYMOL, V154, P511; ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; ANDERSON WF, 1981, J MOL BIOL, V147, P523, DOI 10.1016/0022-2836(81)90398-3; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BELL JA, 1991, PROTEINS, V10, P10, DOI 10.1002/prot.340100103; CONSLER TG, 1991, BIOCHEMISTRY-US, V30, P1291, DOI 10.1021/bi00219a019; DAOPIN S, 1991, J MOL BIOL, V221, P647, DOI 10.1016/0022-2836(91)80079-A; DAOPIN S, 1991, J MOL BIOL, V221, P873, DOI 10.1016/0022-2836(91)80181-S; DAOPIN S, 1990, PROTEINS, V7, P198, DOI 10.1002/prot.340070208; ELWELL M, 1975, BIOCHIM BIOPHYS ACTA, V386, P309, DOI 10.1016/0005-2795(75)90273-1; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; GRUTTER MG, 1979, NATURE, V277, P667, DOI 10.1038/277667a0; GRUTTER MG, 1987, J MOL BIOL, V197, P315, DOI 10.1016/0022-2836(87)90126-4; HAWKES R, 1984, J MOL BIOL, V175, P195, DOI 10.1016/0022-2836(84)90474-1; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KARLE IL, 1991, P NATL ACAD SCI USA, V88, P5307, DOI 10.1073/pnas.88.12.5307; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVITT M, 1974, J MOL BIOL, V82, P393, DOI 10.1016/0022-2836(74)90599-3; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MATTHEWS BW, 1987, BIOCHEMISTRY-US, V26, P6885, DOI 10.1021/bi00396a001; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NISHIKAWA K, 1972, J PHYS SOC JPN, V32, P1331, DOI 10.1143/JPSJ.32.1331; ONEIL K, 1900, SCIENCE, V250, P646; PJURA PE, 1990, BIOCHEMISTRY-US, V29, P2592, DOI 10.1021/bi00462a023; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; SONDEK J, 1990, PROTEINS, V7, P299, DOI 10.1002/prot.340070402; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; STREHLOW KG, 1991, BIOCHEMISTRY-US, V30, P5810, DOI 10.1021/bi00237a026; STREISINGER G, 1961, COLD SPRING HARB SYM, V26, P25, DOI 10.1101/SQB.1961.026.01.007; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSUGITA A, 1968, J BIOL CHEM, V243, P391; WEAVER LH, 1989, BIOCHEMISTRY-US, V28, P3793, DOI 10.1021/bi00435a025; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; WETZEL R, 1988, P NATL ACAD SCI USA, V85, P401, DOI 10.1073/pnas.85.2.401; YUN RH, 1991, PROTEINS, V10, P219, DOI 10.1002/prot.340100306; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001	44	52	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2393	2399						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733941				2022-12-25	WOS:A1992HB53200045
J	WALKER, JW; LU, Z; MOSS, RL				WALKER, JW; LU, Z; MOSS, RL			EFFECTS OF CA2+ ON THE KINETICS OF PHOSPHATE RELEASE IN SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN ATPASE ACTIVITY; RABBIT PSOAS FIBERS; X-RAY-DIFFRACTION; ADENOSINE-TRIPHOSPHATE; TROPONIN-TROPOMYOSIN; INORGANIC-PHOSPHATE; STRUCTURAL-CHANGES; PARTIAL EXTRACTION; CA-2+ SENSITIVITY; FORCE GENERATION	The process of phosphate dissociation during the muscle cross-bridge cycle has been investigated by photoliberation of inorganic phosphate (P(i)) within skinned fibers of rabbit psoas muscle. This permitted a test of the idea that Ca2+ controls muscle contraction by regulating the P(i) release step of the cycle. Photoliberation of P(i) from structurally distinct "caged" P(i) precursors initiated a rapid tension decline of up to 12% of active tension, and this was followed by a slower tension decline. The apparent rate constant of the fast phase, k(Pi), depended on both [P(i)] and [Ca2+], whereas the slow phase generally occurred at 2-4 s-1. At maximal Ca2+, k(Pi) increased in a nonlinear manner from 43 +/- 2 s-1 to 118 +/- 7 s-1, as P(i) was raised from 0.9 to 12 mM. This was analyzed in terms of a three-state kinetic model in which a force-generating transition is coupled to P(i) dissociation from the cross-bridge. As Ca2+-activated tension was reduced from maximal (P(max)) to 0.1 P(max), (i) k(Pi) decreased by up to 2.5-fold, (ii) the relative amplitude of the rapid phase increased 2-fold, and (iii) the relative amplitude of the slow phase increased about 6-fold. Changes in the rapid phase are compatible with Ca2+ influencing an apparent equilibrium constant for the force-generating transition. By comparison, k(Pi) was faster than the rate constant of tension redevelopment, k(tr), and was influenced less by Ca2+. Ca2+ effects on the caged P(i) transient cannot account for the large effects of Ca2+ on actomyosin ATPase rates or cross-bridge cycling kinetics but may be a manifestation of reciprocal interactions between the thin filament and force-generating cross-bridges, and may represent Ca2+ regulation of the distribution of cross-bridges between non-force- and force-generating states.			WALKER, JW (corresponding author), UNIV WISCONSIN, DEPT PHYSIOL, MADISON, WI 53706 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044114, R01HL025861] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44114, HL25861] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOWATER R, 1988, BIOCHEMISTRY-US, V27, P5314, DOI 10.1021/bi00414a055; BRANDT PW, 1982, J GEN PHYSIOL, V79, P997, DOI 10.1085/jgp.79.6.997; BREMEL RD, 1972, NATURE-NEW BIOL, V238, P97, DOI 10.1038/newbio238097a0; BRENNER B, 1988, P NATL ACAD SCI USA, V85, P3265, DOI 10.1073/pnas.85.9.3265; BRENNER B, 1990, MOL MECHANISMS MUSCU; BURTON K, 1988, BIOPHYS J, V53, pA564; BURTON K, 1989, J PHYSL, V428, pP66; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHALOVICH JM, 1981, J BIOL CHEM, V256, P575; Corson B.B., 1941, ORG SYNTH, V1, P336; DANTZIG JA, 1988, P NATL ACAD SCI USA, V85, P6716, DOI 10.1073/pnas.85.18.6716; DANTZIG JA, 1992, IN PRESS J PHYSL; Ebashi S, 1968, Prog Biophys Mol Biol, V18, P123, DOI 10.1016/0079-6107(68)90023-0; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; ELSALEH SC, 1986, J MUSCLE RES CELL M, V7, P387, DOI 10.1007/BF01753582; FABIATO A, 1989, METHOD ENZYMOL, V72, P387; FERENCZI MA, 1984, J PHYSIOL-LONDON, V352, P575, DOI 10.1113/jphysiol.1984.sp015311; GEEVES MA, 1991, BIOCHEM J, V274, P1; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; GOLDMAN YE, 1984, J PHYSIOL-LONDON, V354, P577, DOI 10.1113/jphysiol.1984.sp015394; GORDON AM, 1990, J GEN PHYSIOL, V96, P1013, DOI 10.1085/jgp.96.5.1013; GUTH K, 1987, J BIOL CHEM, V262, P13627; HASSELGROVE JC, 1973, COLD SPRING HARB SYM, V37, P341; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HIBBERD MG, 1985, SCIENCE, V228, P1317, DOI 10.1126/science.3159090; HOAR PE, 1987, PFLUG ARCH EUR J PHY, V410, P30, DOI 10.1007/BF00581892; HOMSHER E, 1990, ANNU REV PHYSIOL, V52, P875, DOI 10.1146/annurev.ph.52.030190.004303; HUXLEY HE, 1973, COLD SPRING HARB SYM, V37, P361, DOI 10.1101/SQB.1973.037.01.046; KAPLAN JH, 1978, BIOCHEMISTRY-US, V17, P1929, DOI 10.1021/bi00603a020; KAWAI M, 1991, BIOPHYS J, V59, P329, DOI 10.1016/S0006-3495(91)82227-5; KRESS M, 1986, J MOL BIOL, V188, P325, DOI 10.1016/0022-2836(86)90158-0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MILBURN T, 1989, BIOCHEMISTRY-US, V28, P49, DOI 10.1021/bi00427a008; MILLAR NC, 1990, J BIOL CHEM, V265, P20234; MOISESCU DG, 1976, NATURE, V262, P610, DOI 10.1038/262610a0; MOSS RL, 1986, J PHYSIOL-LONDON, V377, P487, DOI 10.1113/jphysiol.1986.sp016199; MOSS RL, 1985, J GEN PHYSIOL, V86, P585, DOI 10.1085/jgp.86.4.585; MOSS RL, 1986, J GEN PHYSIOL, V87, P761, DOI 10.1085/jgp.87.5.761; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; PATE E, 1989, PFLUG ARCH EUR J PHY, V414, P73, DOI 10.1007/BF00585629; RAPP G, 1988, PFLUG ARCH EUR J PHY, V411, P200, DOI 10.1007/BF00582315; ROSENFELD SS, 1987, J BIOL CHEM, V262, P9984; RUEGG JC, 1971, PFLUG ARCH EUR J PHY, V325, P359, DOI 10.1007/BF00592176; SWARTZ D R, 1991, Biophysical Journal, V59, p587A; WALKER J W, 1991, Biophysical Journal, V59, p418A; WALKER JW, 1990, BIOPHYS J, V57, pA538; WALKER JW, 1988, J AM CHEM SOC, V110, P7170, DOI 10.1021/ja00229a036; WALKER JW, 1989, METHOD ENZYMOL, V172, P288; WEBB MR, 1986, J BIOL CHEM, V261, P5557; WHITE HD, 1976, BIOCHEMISTRY-US, V15, P5818, DOI 10.1021/bi00671a020	51	89	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2459	2466						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733945				2022-12-25	WOS:A1992HB53200054
J	MAKI, A; BEREZESKY, IK; FARGNOLI, J; HOLBROOK, NJ; TRUMP, BF				MAKI, A; BEREZESKY, IK; FARGNOLI, J; HOLBROOK, NJ; TRUMP, BF			ROLE OF [CA2+]I IN INDUCTION OF C-FOS, C-JUN, AND C-MYC MESSENGER-RNA IN RAT PTE AFTER OXIDATIVE STRESS	FASEB JOURNAL			English	Note						GENE EXPRESSION; FREE RADICAL; PROTOONCOGENE; CALCIUM; PROXIMAL TUBULAR EPITHELIUM	OXYGEN FREE-RADICALS; SEQUENTIAL PROTOONCOGENE EXPRESSION; BRONCHIAL EPITHELIAL-CELLS; PROTEIN KINASE-C; HYDROGEN-PEROXIDE; XANTHINE-OXIDASE; CYTO-TOXICITY; DNA-SYNTHESIS; 3T3 CELLS; ACTIVATION	Oxidative stress plays an important role in various types of cell injury and tumor promotion. Cells respond to oxidative stress in many ways including changes in membrane organization, ion movements, and altered gene expression, all of which contribute to the subsequent fate of affected cells. In this study, we investigated the expression of the proto-oncogenes c-fos, c-myc, and c-jun, which play a key role in proliferation and differentiation, using primary cultures of rat proximal tubular epithelium exposed to oxidative stress generated by the xanthine/xanthine oxidase system. This system generates superoxide and H2O2 in the extracellular space stimulating the release of active oxygen species from inflammatory cells. c-fos mRNA was expressed within 15 min, peaked at 30 min, and returned to constitutive levels by 3 h. c-jun mRNA began to rise after 30 min, peaked at 120 min, and remained above the constitutive levels up to 180 min. c-myc mRNA expression was less affected by the treatment, with levels increasing gradually over the 180 min period. The expression of c-fos was inhibited by superoxide dismutase but not by catalase and was super-induced by cycloheximide. H2O2 alone did not induce any c-fos mRNA in this system. Chelation of extracellular ionized calcium by EGTA or of intracellular ionized calcium by Quin 2/AM resulted in a marked decrease of c-fos expression. Two protein kinase C inhibitors, H-7 and staurosporine, partly diminished the expression of c-fos, whereas a third, 2-aminopurine, which has a broader spectrum of inhibiting protein kinases, almost completely abolished it. A poly ADP-ribosylation inhibitor, 3-aminobenzamide, had no effect on c-fos expression in this system. Our results show that oxidative stress provokes sequential expression of c-fos, c-jun, and c-myc, mRNA in this order. This c-fos expression appears to be largely controlled by calcium ion movement, which could include protein kinase C activation. Another protein kinase or kinases also appear to play an important role.	UNIV MARYLAND,SCH MED,DEPT PATHOL,10 S PINE ST,BALTIMORE,MD 21201; MARYLAND INST EMERGENCY MED SERV SYST,BALTIMORE,MD 21201; NIA,MOLEC GENET LAB,BALTIMORE,MD 21224	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK015440] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK15440] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAKER GL, 1985, ANN SURG, V202, P628, DOI 10.1097/00000658-198511000-00016; BUSCHER M, 1988, ONCOGENE, V3, P301; CANTONI O, 1989, EUR J BIOCHEM, V182, P209, DOI 10.1111/j.1432-1033.1989.tb14819.x; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COWLEY BD, 1989, J BIOL CHEM, V264, P8389; CRAWFORD D, 1988, ONCOGENE, V3, P27; ELLIGET KA, 1991, CELL BIOL TOXICOL, V7, P263; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FORNACE AJ, 1988, MOL CELL BIOL, V8, P4716, DOI 10.1128/MCB.8.11.4716; FRANCESCHI D, 1990, SURGERY, V108, P292; FREEMAN BA, 1985, J BIOL CHEM, V261, P6590; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; GLAUMANN B, 1975, VIRCHOWS ARCH B, V19, P303; HERRLICH P, 1990, MOL BIOL CANCER GENE, P150; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; KOLBER MA, 1990, FASEB J, V4, P3021, DOI 10.1096/fasebj.4.12.2394319; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LINK EM, 1988, BIOCHEM J, V249, P391, DOI 10.1042/bj2490391; MILLER AD, 1984, CELL, V36, P51; MIYASHITA M, 1989, CANCER RES, V49, P63; MOORE JP, 1986, J BIOL CHEM, V261, P8158; NAKAMURA Y, 1988, CARCINOGENESIS, V9, P203, DOI 10.1093/carcin/9.2.203; NITTA N, 1989, CIRC SHOCK, V27, P333; OPIE LH, 1989, CIRCULATION, V80, P1049, DOI 10.1161/01.CIR.80.4.1049; OYANAGUI Y, 1977, BIOCHEM PHARMACOL, V26, P473; PALLER MS, 1984, J CLIN INVEST, V74, P1156, DOI 10.1172/JCI111524; PARKS DA, 1983, SURGERY, V94, P428; PARKS DA, 1983, SURGERY, V94, P415; PRASAD K, 1988, ANGIOLOGY, V39, P417, DOI 10.1177/000331978803900503; ROOTS R, 1975, RADIAT RES, V64, P306, DOI 10.2307/3574267; SCHACHTELE C, 1988, BIOCHEM BIOPH RES CO, V151, P542, DOI 10.1016/0006-291X(88)90628-6; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SMITH MW, 1991, P NATL ACAD SCI USA, V88, P4926, DOI 10.1073/pnas.88.11.4926; SWANN JD, 1991, TOXICOL PATHOL, V19, P128, DOI 10.1177/019262339101900207; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TAMURA M, 1988, J BIOL CHEM, V263, P17621; THOMPSON NL, 1986, CANCER RES, V46, P3111; TRUMP BF, 1989, COMMENTS TOXICOL, V3, P47; VERMA IM, 1985, CANCER CELL, V3, P275; WANG ZW, 1983, J CELL BIOL, V96, P1743, DOI 10.1083/jcb.96.6.1743; WHITFIELD JF, 1990, CALCIUM CELL CYCLES, P201; WILLEY JC, 1984, CANCER RES, V44, P5124; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	51	158	158	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					919	924		10.1096/fasebj.6.3.1740241	http://dx.doi.org/10.1096/fasebj.6.3.1740241			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740241				2022-12-25	WOS:A1992HE39000017
J	AXELSON, M; SHODA, J; SJOVALL, J; TOLL, A; WIKVALL, K				AXELSON, M; SHODA, J; SJOVALL, J; TOLL, A; WIKVALL, K			CHOLESTEROL IS CONVERTED TO 7-ALPHA-HYDROXY-3-OXO-4-CHOLESTENOIC ACID IN LIVER-MITOCHONDRIA - EVIDENCE FOR A MITOCHONDRIAL STEROL 7-ALPHA-HYDROXYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHENODEOXYCHOLIC ACIDS; CYTOCHROME-P-450; PATHWAYS	The metabolism of cholesterol in isolated intact pig liver mitochondria has been investigated. Six major cholesterol metabolites were identified by gas-liquid chromatography-mass spectrometry, the metabolic end product being 7-alpha-hydroxy-3-oxo-4-cholestenoic acid. Incubations with the synthesized intermediates suggested that the major pathway from cholesterol to this acid proceeds via the sequence of 26-hydroxylation, 7-alpha-hydroxylation, further oxidation of the side chain and oxidation/isomerization in the A-ring. The observed reactions prove that in addition to a sterol 26-hydroxylase, pig liver mitochondria contain significant amounts of a 7-alpha-hydroxylase active on side chain oxygenated 3-beta-hydroxy-DELTA-5-C27 steroids, an oxidoreductase active in the side chain of 26-hydroxylated steroids and a 3-beta-hydroxy-DELTA-5 steroid oxidoreductase active on 7-alpha-hydroxylated C27 steroids. Since 7-alpha-hydroxy-3-oxo-4-cholestenoic acid is believed to be an important precursor of chenodeoxycholic acid, this study shows that the first reactions in the biosynthesis of bile acids can be exclusively mitochondrial and thereby bypass microsomal cholesterol 7-alpha-hydroxylase as the rate-limiting enzyme.	KAROLINSKA INST,DEPT PHYSIOL CHEM,S-10401 STOCKHOLM 60,SWEDEN; UNIV UPPSALA,DEPT PHARMACEUT CHEM,S-75105 UPPSALA,SWEDEN	Karolinska Institutet; Uppsala University	AXELSON, M (corresponding author), KAROLINSKA HOSP,DEPT CLIN CHEM,S-10401 STOCKHOLM 60,SWEDEN.							ANDERSON KE, 1972, J CLIN INVEST, V51, P112, DOI 10.1172/JCI106780; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AXELSON M, 1990, J STEROID BIOCHEM, V36, P631, DOI 10.1016/0022-4731(90)90182-R; AXELSON M, 1991, J BIOL CHEM, V266, P17770; AXELSON M, 1988, J LIPID RES, V29, P629; BJORKHEM I, 1978, J BIOL CHEM, V253, P842; BJORKHEM I, 1974, J BIOL CHEM, V249, P2528; BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALI JJ, 1991, J BIOL CHEM, V266, P7774; DAHLBACK H, 1990, BIOCHEM BIOPH RES CO, V167, P391, DOI 10.1016/0006-291X(90)92034-W; DAHLBACK H, 1988, BIOCHEM BIOPH RES CO, V153, P267, DOI 10.1016/S0006-291X(88)81217-8; MITROPOULOS K A, 1972, Biochemical Journal, V130, P363; MITROPOULOS KA, 1967, BIOCHEM J, V103, P472, DOI 10.1042/bj1030472; SWELL L, 1980, J LIPID RES, V21, P455; WHITEHOUSE MW, 1959, J BIOL CHEM, V234, P276; WIKVALL K, 1984, J BIOL CHEM, V259, P3800	17	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1701	1704						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730713				2022-12-25	WOS:A1992HA48500048
J	BLANCO, L; BERNAD, A; ESTEBAN, JA; SALAS, M				BLANCO, L; BERNAD, A; ESTEBAN, JA; SALAS, M			DNA-INDEPENDENT DEOXYNUCLEOTIDYLATION OF THE PHI-29 TERMINAL PROTEIN BY THE PHI-29 DNA-POLYMERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE PHI-29; NUCLEOTIDE-SEQUENCE; REPLICATION INVITRO; INITIATION; PHAGE-PHI-29; COMPLEX; MOTIF; BACTERIOPHAGE-PHI-29; PURIFICATION; ELONGATION	In this paper, we show that the phi-29 DNA polymerase, in the absence of DNA, is able to catalyze the formation of a covalent complex between the phi-29 terminal protein (TP) and 5'-dAMP. Like the reaction in the presence of phi-29 DNA, TP.dAMP complex formation is strongly dependent on activating Mn2+ ions and on the efficient formation of a TP/DNA polymerase heterodimer. The nature of the TP-dAMP linkage was shown to be identical (a O-5'-deoxyadenylyl-L-serine bond) to that found covalently linking TP to the DNA of bacteriophage phi-29, indicating that this DNA-independent reaction actually mimics that occurring as the initiation step of phi-29 DNA replication. Furthermore, as in normal TP-primed initiation on the phi-29 DNA template, this novel reaction showed the same specificity for TP Ser232 as the OH donor and the involvement of the YCDTD amino acid motif, highly conserved in alpha-like DNA polymerases. However, unlike the reaction in the presence of phi-29 DNA, the DNA-independent deoxynucleotidylation of TP by the phi-29 DNA polymerase did not show dATP specificity, being possible to obtain any of the four TP.dNMP complexes with a similar yield. This lack of specificity together with the poor efficiency of this reaction at low deoxynucleoside triphosphate (dNTP) concentration reflect a weak, but similar stability of the four dNTPs at the phi-29 DNA polymerase dNTP-binding site. Thus, the presence of a director DNA would mainly contribute to stabilizing a complementary nucleotide, giving base specificity to the protein-primed initiation reaction. According to all these data, the novel DNA polymerase reaction described in this paper could be considered as a "non-DNA-instructed" protein-primed deoxynucleotidylation.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,CANTO BLANCO,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Salas, Margarita/J-9873-2014; Bernad, Antonio/P-8573-2017; Esteban, Jose/L-4944-2014; Blanco, Luis/I-1848-2015	Salas, Margarita/0000-0001-5939-3441; Esteban, Jose/0000-0002-3759-3300; Bernad, Antonio/0000-0003-0620-9668	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM27242-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BARTHELEMY I, 1986, J VIROL, V60, P874, DOI 10.1128/JVI.60.3.874-879.1986; BERNAD A, 1990, GENE, V94, P45, DOI 10.1016/0378-1119(90)90466-5; BERNAD A, 1987, EMBO J, V6, P4219, DOI 10.1002/j.1460-2075.1987.tb02770.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BERNAD A, 1990, P NATL ACAD SCI USA, V87, P4610, DOI 10.1073/pnas.87.12.4610; BLANCO L, 1985, P NATL ACAD SCI USA, V82, P6404, DOI 10.1073/pnas.82.19.6404; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1987, J VIROL, V61, P3983, DOI 10.1128/JVI.61.12.3983-3991.1987; BLANCO L, 1991, GENE, V100, P27, DOI 10.1016/0378-1119(91)90346-D; BLANCO L, 1988, J VIROL, V62, P4167, DOI 10.1128/JVI.62.11.4167-4172.1988; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; CLARK JM, 1987, J MOL BIOL, V198, P123, DOI 10.1016/0022-2836(87)90462-1; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; GARMENDIA C, 1990, GENE AMST, V94, P45; GARMENDIA C, 1988, NUCLEIC ACIDS RES, V13, P7715; HERMOSO JM, 1980, P NATL ACAD SCI-BIOL, V77, P6425, DOI 10.1073/pnas.77.11.6425; HERMOSO JM, 1985, NUCLEIC ACIDS RES, V13, P7715, DOI 10.1093/nar/13.21.7715; Kornberg A., 1980, DNA REPLICATION; MATSUMOTO K, 1984, MOL GEN GENET, V196, P381, DOI 10.1007/BF00436183; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; PRIETO I, 1984, P NATL ACAD SCI-BIOL, V81, P1639, DOI 10.1073/pnas.81.6.1639; REKOSH DMK, 1977, CELL, V11, P283, DOI 10.1016/0092-8674(77)90045-9; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; VLCEK C, 1986, GENE, V46, P215, DOI 10.1016/0378-1119(86)90406-3; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; YOSHIKAWA H, 1982, GENE, V17, P323; ZABALLOS A, 1989, NUCLEIC ACIDS RES, V17, P10353, DOI 10.1093/nar/17.24.10353	29	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1225	1230						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730646				2022-12-25	WOS:A1992GY96000085
J	LEIDIG, F; SHEPARD, AR; ZHANG, WG; STELTER, A; CATTINI, PA; BAXTER, JD; EBERHARDT, NL				LEIDIG, F; SHEPARD, AR; ZHANG, WG; STELTER, A; CATTINI, PA; BAXTER, JD; EBERHARDT, NL			THYROID-HORMONE RESPONSIVENESS IN HUMAN GROWTH HORMONE-RELATED GENES - POSSIBLE CORRELATION WITH RECEPTOR-INDUCED DNA CONFORMATIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY-TUMOR-CELLS; HUMAN CHORIONIC SOMATOMAMMOTROPIN; CIS-ACTING ELEMENTS; TRANSCRIPTION FACTOR; RESPONSE ELEMENTS; REGULATED EXPRESSION; ESCHERICHIA-COLI; PROMOTER; BINDING; PROTEIN	Triiodothyronine (T3) induces the transcription of the human chorionic somatomammotropin (hCS) promoter transfected into rat pituitary (GC) cells, but does not stimulate the homologous human growth hormone (hGH) promoter. As demonstrated by forward and reverse mutagenesis, this differential T3 responsiveness is due to subtle structural differences in a T3 response element located between nucleotides -64 and -44 of the 5'-flanking DNA of the hGH and hCS promoters. Synthetic hCS(-70/-40) DNA binds thyroid hormone receptors with a 4-fold higher affinity than the corresponding hGH T3 response element, indicating that small differences in receptor binding properties are reflected by major differences in T3 responsiveness. Analysis of circular permutation fragments containing the native hGH and hCS or mutated hCS(-70/-40) sequences demonstrates that the thyroid hormone receptor induces DNA bending. The extent of bending shows a possible correlation with the function of these sequences, suggesting that the receptor-induced changes in DNA conformation may be required for thyroid hormone receptor action.	MAYO CLIN & MAYO FDN,DEPT MED,ENDOCRINE RES UNIT,4-407 ALFRED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM MOLEC BIOL,ENDOCRINE RES UNIT,ROCHESTER,MN 55905; UNIV CALIF SAN FRANCISCO,DEPT MED,METAB RES UNIT,SAN FRANCISCO,CA 94143; UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG R3E 0W3,MANITOBA,CANADA	Mayo Clinic; Mayo Clinic; University of California System; University of California San Francisco; University of Manitoba					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041206, R01DK041842] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41842, DK41206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APRILETTI JW, 1988, J BIOL CHEM, V263, P9409; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARBALLO M, 1990, DNA CELL BIOL, V9, P519, DOI 10.1089/dna.1990.9.519; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CATTINI PA, 1988, MOL CELL ENDOCRINOL, V60, P217, DOI 10.1016/0303-7207(88)90181-5; CATTINI PA, 1986, J BIOL CHEM, V261, P3367; CATTINI PA, 1987, NUCLEIC ACIDS RES, V15, P1297, DOI 10.1093/nar/15.3.1297; CHEN EY, 1989, GENOMICS, V4, P479, DOI 10.1016/0888-7543(89)90271-1; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; EASTMAN A, 1987, BIOTECHNIQUES, V5, P731; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FLINK IL, 1990, J BIOL CHEM, V265, P11233; FLUG F, 1987, J BIOL CHEM, V262, P6373; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GOODMAN SD, 1989, NATURE, V341, P251, DOI 10.1038/341251a0; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HAWLEY DK, 1983, CELL, V32, P327, DOI 10.1016/0092-8674(83)90452-X; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HIRT H, 1987, DNA-J MOLEC CELL BIO, V6, P59, DOI 10.1089/dna.1987.6.59; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOGAN ME, 1987, NATURE, V329, P263, DOI 10.1038/329263a0; ISAACS RE, 1987, MOL ENDOCRINOL, V1, P569, DOI 10.1210/mend-1-8-569; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KOLB A, 1983, NUCLEIC ACIDS RES, V11, P7833, DOI 10.1093/nar/11.22.7833; LAVIN TN, 1988, J BIOL CHEM, V263, P9418; LAVIN TN, 1989, STEROID THYROID HORM, P69; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; LEIDIG F, 1990, T ASSOC AM PHYSICIAN, V103, P154; LEMAIGRE FP, 1989, EUR J BIOCHEM, V181, P555, DOI 10.1111/j.1432-1033.1989.tb14760.x; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NACHTIGAL MW, 1989, NUCLEIC ACIDS RES, V17, P4327, DOI 10.1093/nar/17.11.4327; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NICKEL BE, 1990, BIOCHEM J, V267, P653, DOI 10.1042/bj2670653; NICKEL BE, 1991, ENDOCRINOLOGY, V128, P2353, DOI 10.1210/endo-128-5-2353; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; PARK CS, 1982, J BIOL CHEM, V257, P6950; RIBEIRO RCJ, 1990, PROG ABS ENDO SOC AN, V72, P357; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SELBY MJ, 1984, J BIOL CHEM, V259, P3131; SHUEY DJ, 1986, NATURE, V323, P459, DOI 10.1038/323459a0; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YE ZS, 1988, J BIOL CHEM, V263, P7821; ZHANG WG, 1990, CLIN RES, V38, pA410	69	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					913	921						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730680				2022-12-25	WOS:A1992GY96000038
J	HOFF, HF; WHITAKER, TE; ONEIL, J				HOFF, HF; WHITAKER, TE; ONEIL, J			OXIDATION OF LOW-DENSITY-LIPOPROTEIN LEADS TO PARTICLE AGGREGATION AND ALTERED MACROPHAGE RECOGNITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERITABLE HYPERLIPIDEMIC RABBITS; MOUSE PERITONEAL-MACROPHAGES; ATHEROSCLEROTIC LESIONS; APOLIPOPROTEIN-B; CHOLESTEROL; RECEPTOR; DEGRADATION; METABOLISM; CLEAVAGE; PROTEINS	Oxidized (ox-) low density lipoproteins (LDL) is characterized by the formation of lipid peroxides and their decomposition to reactive aldehydes which covalently link to apoB in LDL. These chemical changes are believed to be responsible for the enhanced recognition of ox-LDL by receptors on macrophages in culture. When oxidation is extensive, particle aggregation also occurs. The aim of this study was to characterize aggregation formation and how this influences the interaction of ox-LDL with macrophages in culture. When LDL was oxidized by incubating at 500-mu-g of protein/ml with 10-mu-M Cu2+ at 20-degrees-C for up to 25 h, time-dependent increases in thiobarbituric acid reactive substances, conjugated diene content, electrophoretic mobility, and fluorescence at 360 excitation/430 emission were found. Particle aggregation increased in parallel with several parameters of oxidation and increased with increasing incubation temperatures and LDL concentrations used. When evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, apoB fragments of reproducible sizes and higher molecular weight species appeared after mild oxidation of LDL. The percent of total apoB remaining aggregated in sodium dodecyl sulfate was 50-80% at high degrees of oxidation, whereas it was far less in LDL that had been aggregated without chemical modification. This suggested that intermolecular cross-linking of apoB had occurred during oxidation of LDL at high concentrations. Degradation of ox-LDL in mouse peritoneal macrophages (MPM) increased in parallel with the degree of oxidation and with particle aggregation but reached a plateau after 12 h. Results from cross-competition studies in MPM with soluble and insoluble portions of extensively ox-LDL and with acetyl-LDL were consistent with uptake of soluble ox-LDL via both the scavenger receptor and another receptor on MPM, and uptake of the insoluble ox-LDL by an alternative mechanism.			HOFF, HF (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT VASC CELL BIOL & ATHEROSCLEROSIS,CLEVELAND,OH 44195, USA.				NHLBI NIH HHS [HL 29582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BON GB, 1983, ARTERY, V12, P74; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; ESTERBAUER H, 1989, FETT WISS TECHNOL, V91, P316, DOI 10.1002/lipi.19890910805; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FONG LG, 1987, J LIPID RES, V28, P1466; FRANK JS, 1989, J LIPID RES, V30, P967; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HATCH FT, 1968, ADV LIPID RES, V6, P2, DOI 10.1016/B978-1-4831-9942-9.50008-5; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HOFF H F, 1973, Biochimica et Biophysica Acta, V296, P653, DOI 10.1016/0005-2760(73)90130-6; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOFF HF, 1989, ARTERIOSCLEROSIS, V9, P538, DOI 10.1161/01.ATV.9.4.538; HOFF HF, 1982, ATHEROSCLEROSIS, V42, P273, DOI 10.1016/0021-9150(82)90157-5; HOFF HF, 1977, EXP MOL PATHOL, V26, P214, DOI 10.1016/0014-4800(77)90051-X; JURGENS G, 1986, BIOCHIM BIOPHYS ACTA, V875, P103, DOI 10.1016/0005-2760(86)90016-0; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCNALLY AK, 1990, J IMMUNOL, V145, P254; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MORTON RE, 1986, J LIPID RES, V27, P1124; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P3894, DOI 10.1073/pnas.87.10.3894; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P10098; ROESCHLAU P, 1974, Zeitschrift fuer Klinische Chemie und Klinische Biochemie, V12, P403; SCHUH J, 1978, P NATL ACAD SCI USA, V75, P3173, DOI 10.1073/pnas.75.7.3173; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YOKODE M, 1988, J CLIN INVEST, V81, P720, DOI 10.1172/JCI113377	41	134	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					602	609						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730620				2022-12-25	WOS:A1992GY43900094
J	FARSETTI, A; MITSUHASHI, T; DESVERGNE, B; ROBBINS, J; NIKODEM, VM				FARSETTI, A; MITSUHASHI, T; DESVERGNE, B; ROBBINS, J; NIKODEM, VM			MOLECULAR-BASIS OF THYROID-HORMONE REGULATION OF MYELIN BASIC-PROTEIN GENE-EXPRESSION IN RODENT BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC MOUSE-BRAIN; MYELINOGENESIS INVITRO; DEVELOPMENTAL EXPRESSION; MESSENGER-RNAS; CELLS; IDENTIFICATION; CULTURES; MICE; TRANSCRIPTION; ELEMENTS	Regulation of myelin basic protein (MBP) gene(~)expression by thyroid hormone has been investigated in rodent brain. Quantitation of the 4 major alternatively spliced transcripts by RNase protection assay showed that the individual mRNAs, corresponding to MBP isoforms 21.5, 18.5, 17, and 14 kDa, were decreased from 2- to 17-fold at all ages studied (4-60 days) in hypothyroid animals when compared to euthyroid, but the timing of onset of expression was not altered. MBP mRNA was also reduced in young adult rats thyroidectomized at the age of 5-6 weeks and was restored to normal by thyroxine administration. Nu-clear run-off assays showed that the rate of MBP gene transcription is dependent on thyroid state. Co-transfection of MBP (-256/+1)-chloramphenicol acetyltransferase chimeric gene with a plasmid expressing thyroid hormone receptor-alpha, and in the presence of 3,5,3'-triiodothyronine, into NIH3T3 or NG108-15, increased chloramphenicol acetyltransferase expression 4-fold. Using a footprinting technique and Spodoptera frugiperda 9 (Sf9) nuclear extract infected with baculovirus expressing TR-alpha, we have identified a single DNA-binding site (-186/-163) for the receptor. A part of this region contains the AGGACA sequence found in thyroid hormone-responsive elements of other 3,5,3'-triiodothyronine-regulated genes. Our finding of a specific hormone-receptor interaction with the MBP promoter region is the first direct demonstration of a thyroid hormone-responsive element in a brain-specific gene.	NIDDKD,CLIN ENDOCRINOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Mitsuhashi, Tomoko/A-6996-2012; Farsetti, Antonella/I-8710-2018; Desvergne, Beatrice/C-8892-2016	Farsetti, Antonella/0000-0002-8603-7925; Desvergne, Beatrice/0000-0001-5483-288X				BALAZS R, 1969, BRAIN RES, V15, P219, DOI 10.1016/0006-8993(69)90321-7; BARBARESE E, 1978, J NEUROCHEM, V31, P779, DOI 10.1111/j.1471-4159.1978.tb00110.x; BHAT NR, 1981, J BIOL CHEM, V256, P1167; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; CAMPAGNONI CW, 1978, ARCH BIOCHEM BIOPHYS, V190, P118, DOI 10.1016/0003-9861(78)90258-8; CARSON JH, 1983, DEV BIOL, V96, P485, DOI 10.1016/0012-1606(83)90185-9; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEESCOBAR GM, 1989, IODINE BRAIN, P187; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DOZIN B, 1985, BIOCHEMISTRY-US, V24, P5581, DOI 10.1021/bi00341a044; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOSTER HL, 1981, MOUSE BIOMEDICAL RES, V3; FOX JG, 1984, AM COLL LABORATORY A; Hamburgh M, 1969, Curr Top Dev Biol, V4, P109, DOI 10.1016/S0070-2153(08)60482-2; IZUMO S, 1988, NATURE, V334, P539, DOI 10.1038/334539a0; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; JORDAN C, 1989, J NEUROSCI, V9, P248; KAMHOLZ J, 1988, J NEUROSCI RES, V21, P62, DOI 10.1002/jnr.490210110; KAMHOLZ J, 1986, P NATL ACAD SCI USA, V83, P4962, DOI 10.1073/pnas.83.13.4962; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MALONE MJ, 1975, J NEUROL SCI, V26, P1, DOI 10.1016/0022-510X(75)90108-2; MIURA M, 1989, GENE, V75, P31; Morell, 1984, MYELIN; NEWMAN S, 1987, P NATL ACAD SCI USA, V84, P886, DOI 10.1073/pnas.84.3.886; NIKODEM VM, 1990, THYROID GLAND, P307; NUNEZ J, 1989, IODINE BRAIN, P103; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwartz HL, 1983, MOL BASIS THYROID HO, P413, DOI DOI 10.1016/B978-0-12-527560-6.50020-2; SHANKER G, 1987, J NEUROSCI RES, V17, P220, DOI 10.1002/jnr.490170304; SHANKER G, 1985, NEUROCHEM RES, V10, P617, DOI 10.1007/BF00964401; SHANKER G, 1987, BIOSCIENCE REP, V7, P159, DOI 10.1007/BF01121880; SHANKER G, 1984, J NEUROSCI RES, V11, P263, DOI 10.1002/jnr.490110306; SONG MKH, 1988, J BIOL CHEM, V263, P17970; TAKAHASHI N, 1985, CELL, V42, P139, DOI 10.1016/S0092-8674(85)80109-4; WALTERS SN, 1981, J NEUROCHEM, V36, P1792, DOI 10.1111/j.1471-4159.1981.tb00433.x; ZELLER NK, 1984, P NATL ACAD SCI-BIOL, V81, P18, DOI 10.1073/pnas.81.1.18; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	39	184	186	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23226	23232						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1720778				2022-12-25	WOS:A1991GT48300069
J	HEINZEL, T; VELLEMAN, M; SCHUSTER, H				HEINZEL, T; VELLEMAN, M; SCHUSTER, H			C1 REPRESSOR OF PHAGE-P1 IS INACTIVATED BY NONCOVALENT BINDING OF P1 COI PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B TRANSCRIPTION FACTOR; I-KAPPA-B; GEL-ELECTROPHORESIS; BACTERIOPHAGE-P1; GENES; DNA; EXPRESSION; SEQUENCE; OPERATOR; SYSTEM	The temperate phage P1 encodes two genes whose products antagonize the action of the phage's C1 repressor of lytic functions, namely a distantly linked antirepressor gene, ant, and a closely linked c1 inactivator gene, coi. Starting with an inducible coi-recombinant plasmid, Coi protein was overproduced and purified to near homogeneity. By using a DNA mobility shift assay we demonstrate that Coi protein inhibits the operator binding of the C1 repressors of the closely related P1 and P7 phages. Coi protein (M(r) = 7,600) exerts its C1-inactivating function by forming a complex with the C1 repressor (M(r) = 32,500) at a molar ratio of about 1:1, as shown by density gradient centrifugation and gel filtration. C1 repressor and Coi protein are recovered in active form from the complex, suggesting that noncovalent interactions are the sole requirements for complex formation. The interplay of repressor and antagonists operating in the life cycle of P1 is discussed.			HEINZEL, T (corresponding author), MAX PLANCK INST MOLEC GENET,IHNESTR 73,W-1000 BERLIN 33,GERMANY.		Heinzel, Thorsten/B-1013-2015					BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAUMSTARK BR, 1987, VIROLOGY, V156, P404, DOI 10.1016/0042-6822(87)90420-X; BAUMSTARK BR, 1990, VIROLOGY, V179, P217, DOI 10.1016/0042-6822(90)90291-X; CITRON M, 1989, J BIOL CHEM, V264, P3611; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DREISEIKELMANN B, 1988, J BIOL CHEM, V263, P391; ELIASON JL, 1987, J MOL BIOL, V198, P281, DOI 10.1016/0022-2836(87)90313-5; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GUSSIN GN, 1983, LAMBDA, V2, P93; HEINRICH J, 1989, NUCLEIC ACIDS RES, V17, P7681; HEINZEL T, 1990, J BIOL CHEM, V265, P17928; HEINZEL T, 1989, J MOL BIOL, V205, P127, DOI 10.1016/0022-2836(89)90370-7; OSBORNE FA, 1989, NUCLEIC ACIDS RES, V17, P7671, DOI 10.1093/nar/17.19.7671; Poteete A. R., 1988, BACTERIOPHAGES, V2, P647; SCHAEFER TS, 1990, J BACTERIOL, V172, P3269, DOI 10.1128/jb.172.6.3269-3277.1990; Scott J R, 1980, Curr Top Microbiol Immunol, V90, P49; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Sternberg N, 1979, Contrib Microbiol Immunol, V6, P89; STOFFLER G, 1971, P NATL ACAD SCI USA, V68, P2283, DOI 10.1073/pnas.68.9.2283; SUSSKIND MM, 1983, LAMBDA, V2, P347; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOUATISCHWARTZ D, 1979, MOL GEN GENET, V174, P189, DOI 10.1007/BF00268355; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VELLEMAN M, 1990, J BIOL CHEM, V265, P18511; VELLEMAN M, 1987, P NATL ACAD SCI USA, V84, P5570, DOI 10.1073/pnas.84.16.5570; WALSH MJ, 1988, BIOCHEMISTRY-US, V27, P6867, DOI 10.1021/bi00418a032; YARMOLINSKY M, 1990, GENETIC MAPS, P52; YARMOLINSKY MB, 1988, BACTERIOPHAGES, V1, P291; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	31	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4183	4188						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740459				2022-12-25	WOS:A1992HE60700091
J	JAIN, SK; INMAN, RB; COX, MM				JAIN, SK; INMAN, RB; COX, MM			PUTATIVE 3-STRANDED DNA PAIRING INTERMEDIATE IN RECA PROTEIN-MEDIATED DNA STRAND EXCHANGE - NO ROLE FOR GUANINE N-7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PARANEMIC JOINTS; BRANCH MIGRATION; DUPLEX DNA; HELICAL DNA; COMPLEXES; FILAMENTS; RECOMBINATION; VISUALIZATION; PURIFICATION	As an early step in DNA strand exchange reactions, the recA protein aligns homologous sequences within two DNA molecules to form a putative triple-stranded intermediate. In virtually all models for three-stranded DNA proposed to date, hydrogen bonds involving the N-7 position of guanine have played a prominent structural role. To determine whether the N-7 position of guanine is required for triple helix and heteroduplex formation in the recA protein-mediated DNA pairing reaction, guanine was completely replaced by the base analog 7-deazaguanine in both strands of the duplex DNA substrate using polymerase chain reaction. This' modified double-strand DNA was reacted with unmodified single-strand DNA in vitro. The 7-deazaguanine-substituted DNA functioned as well as the unsubstituted DNA in recA protein-mediated DNA three-strand exchange reactions. Strand exchange reactions involving four strands also proceeded normally when three of the four strands contained 7-deazaguanine rather than guanine. In fact, the rate of strand exchange improved somewhat when the modified DNA substrates were used. This indicates either that the N-7 position of guanine is not essential for the formation of the putative triple-stranded DNA pairing intermediate, or that a three-stranded (or four-stranded) structure is not an obligate intermediate in recA protein-mediated DNA strand exchange.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM032335, R01GM014711, R01GM032335] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-14711, GM-32335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; BORTNER C, 1990, J MOL BIOL, V215, P623, DOI 10.1016/S0022-2836(05)80173-1; CHIU SK, 1990, J BIOL CHEM, V265, P21262; CONLEY EC, 1990, J BIOL CHEM, V265, P10156; CONLEY EC, 1989, CELL, V56, P987, DOI 10.1016/0092-8674(89)90632-6; COX MM, 1990, UCLA SYM BI, V127, P375; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; DASGUPTA C, 1980, CELL, V22, P437, DOI 10.1016/0092-8674(80)90354-2; Davis R., 1980, ADV BACTERIAL GENETI; DICAPUA E, 1987, EMBO J, V6, P2493, DOI 10.1002/j.1460-2075.1987.tb02531.x; DOMBROSKI DF, 1983, NUCLEIC ACIDS RES, V11, P7487, DOI 10.1093/nar/11.21.7487; GRIFFITH J, 1990, UCLA SYM BI, V127, P105; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; HSIEH P, 1990, GENE DEV, V4, P1951, DOI 10.1101/gad.4.11.1951; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; INNIS MA, 1990, PCR PROTOCOLS, P54; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KHAN R, 1984, J BIOL CHEM, V259, P7495; LATIMER LJP, 1991, J BIOL CHEM, V266, P13849; LEAHY MC, 1986, J BIOL CHEM, V261, P6954; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MCGAVIN S, 1971, J MOL BIOL, V55, P293, DOI 10.1016/0022-2836(71)90201-4; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MULLER B, 1990, J MOL BIOL, V212, P97, DOI 10.1016/0022-2836(90)90307-8; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RADDING CM, 1989, BIOCHIM BIOPHYS ACTA, V1008, P131, DOI 10.1016/0167-4781(80)90001-9; RAO BJ, 1991, P NATL ACAD SCI USA, V88, P2984, DOI 10.1073/pnas.88.8.2984; REGISTER JC, 1987, J BIOL CHEM, V262, P12812; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE BC, 1988, BIOCHEMISTRY-US, V27, P7886, DOI 10.1021/bi00420a046; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; STASIAK A, 1984, COLD SPRING HARB SYM, V49, P561, DOI 10.1101/SQB.1984.049.01.063; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; TAKAHASHI M, 1989, J MOL BIOL, V205, P137, DOI 10.1016/0022-2836(89)90371-9; TAKAHASHI M, 1991, BIOCHIMIE, V73, P219, DOI 10.1016/0300-9084(91)90205-F; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WILSON JH, 1979, P NATL ACAD SCI USA, V76, P3641, DOI 10.1073/pnas.76.8.3641; WU AM, 1983, P NATL ACAD SCI-BIOL, V80, P1256, DOI 10.1073/pnas.80.5.1256; WU AM, 1982, CELL, V30, P37, DOI 10.1016/0092-8674(82)90009-5	54	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4215	4222						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740461				2022-12-25	WOS:A1992HE60700095
J	NADLER, SG; KAPOUCH, JL; ELLIOTT, JI; WILLIAMS, KR				NADLER, SG; KAPOUCH, JL; ELLIOTT, JI; WILLIAMS, KR			SHUFFLING OF AMINO-ACID-SEQUENCE - AN IMPORTANT CONTROL IN SYNTHETIC PEPTIDE STUDIES OF NUCLEIC ACID-BINDING DOMAINS - BINDING-PROPERTIES OF FRAGMENTS OF A CONSERVED EUKARYOTIC RNA-BINDING MOTIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; MESSENGER-RNA; PROTEIN CONFORMATION; ESCHERICHIA-COLI; RIBONUCLEOPROTEIN; DESIGN; GENE; IDENTIFICATION; EPSILON; LIGANDS	We have used synthetic peptides to study a conserved RNA binding motif in yeast poly(A)-binding protein. Two peptides, 45 and 44 amino acids in length, corresponding to amino and carboxyl halves of a 90-amino acid RNA-binding domain in the protein were synthesized. While the amino-terminal peptide had no significant affinity for nucleic acids, the carboxyl-terminal peptide-bound nucleic acids with similar characteristics to that for the entire 577 residue yeast poly(A)-binding protein. In 100 mM NaCl, the latter peptide retained over 50% of the intrinsic binding free energy of the protein, as well as, similar RNA versus DNA binding specificity. However, shuffling of the sequence of this 44 residue peptide had surprisingly little effect on its nucleic acid binding properties suggesting the overriding importance of amino acid composition as opposed to primary sequence. Deletion studies on the 44 residue peptide with the "correct" sequence succeeded in identifying amino acids important for conferring RNA specificity and for increasing our understanding of the molecular basis for nucleic acid binding by synthetic peptides. The shuffled peptide study, however, clearly indicates that considerable caution must be exercised before extrapolating results of structure/function studies on synthetic peptide analogues to the parent protein.	YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University			Williams, Kenneth/B-5986-2016	Williams, Kenneth/0000-0001-7792-9588				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; BRUIST MF, 1987, SCIENCE, V235, P777, DOI 10.1126/science.3027895; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHUNG S Y, 1986, Proteins Structure Function and Genetics, V1, P195, DOI 10.1002/prot.340010302; CROTHERS DM, 1971, BIOPOLYMERS, V10, P2147, DOI 10.1002/bip.360101110; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; FRIEDMAN LP, 1988, NATURE, V334, P543; GUTTE B, 1979, NATURE, V281, P650, DOI 10.1038/281650a0; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HELENE C, 1981, CRC CR REV BIOCH MOL, V10, P213, DOI 10.3109/10409238109113600; KOHWISHIGEMATSU T, 1978, P NATL ACAD SCI USA, V75, P4689, DOI 10.1073/pnas.75.10.4689; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; KRAKAUER H, 1968, BIOPOLYMERS, V6, P491, DOI 10.1002/bip.1968.360060406; LEDNEVA RK, 1978, NUCLEIC ACIDS RES, V5, P4225, DOI 10.1093/nar/5.11.4225; LENERT P, 1990, SCIENCE, V248, P1639, DOI 10.1126/science.2363051; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3522, DOI 10.1021/bi00556a017; MASCOTTI DP, 1990, P NATL ACAD SCI USA, V87, P3142, DOI 10.1073/pnas.87.8.3142; MCGHEE JD, 1976, J MOL BIOL, V103, P679; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MERRILL BM, 1990, EUKARYOTIC NUCLEUS M, P579; MULLEN GP, 1989, J BIOL CHEM, V264, P19637; NADLER SG, 1991, BIOCHEMISTRY-US, V30, P2968, DOI 10.1021/bi00225a034; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; REEVES R, 1990, J BIOL CHEM, V265, P8573; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SLUKA JP, 1987, SCIENCE, V238, P1129, DOI 10.1126/science.3120311; STEINER RF, 1973, BIOCHIM BIOPHYS ACTA, V294, P24, DOI 10.1016/0005-2787(73)90311-0; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; SWANSON MS, 1987, MOL CELL BIOL, V7, P1731, DOI 10.1128/MCB.7.5.1731; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TAN XH, 1990, J BIOL CHEM, V265, P8022; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; ZLOTNICK A, 1989, J MOL BIOL, V209, P447, DOI 10.1016/0022-2836(89)90009-0	45	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3750	3757						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740426				2022-12-25	WOS:A1992HE60700034
J	ENGLER, DA; CAMPION, SR; HAUSER, MR; COOK, JS; NIYOGI, SK				ENGLER, DA; CAMPION, SR; HAUSER, MR; COOK, JS; NIYOGI, SK			CRITICAL FUNCTIONAL REQUIREMENT FOR THE GUANIDINIUM GROUP OF THE ARGININE-41 SIDE-CHAIN OF HUMAN EPIDERMAL GROWTH-FACTOR AS REVEALED BY MUTAGENIC INACTIVATION AND CHEMICAL REACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEAR-MAGNETIC-RESONANCE; TYROSINE KINASE-ACTIVITY; FACTOR RECEPTOR; TERTIARY STRUCTURE; PROTEIN; RESIDUES; BINDING; DOMAIN	In a preliminary study we demonstrated that the formation of the epidermal growth factor (EGF) receptor-ligand complex requires the participation of the highly conserved arginine 41 side chain of the growth factor peptide (Engler, D. A., Montelione, G. T., and Niyogi, S. K. (1990) FEBS Lett. 271, 47-50). In an attempt to gain further insight into the nature of this interaction(s), we used both site-directed mutagenesis and chemical modification reagents to produce human EGF (hEGF) analogues with altered chemical properties of the residue 41 side chain. Eight mutant analogues of hEGF were generated, substituting arginine 41 with lysine, glutamine, isoleucine, tyrosine, glycine, alanine, aspartate, or glutamate. Although each of the mutant analogues was able to displace wild-type hEGF fully in receptor competition binding assays, affinity of the receptor for the mutants was substantially reduced, varying from 0.4 to < 0.01% of that observed for wild-type growth factor. At sufficiently high concentrations these mutants were able to stimulate DNA synthesis in mouse keratinocytes. Substitution of lysine for arginine 41 reduced the receptor affinity 250-fold from that observed for wild type, despite retention of the positive electrostatic charge. The lysine substitution leaves a reactive amine at position 41 and made it possible, using amine-specific chemical modification reagents, to produce selected arginine homologues that were tested for their effects on receptor binding, receptor tyrosine kinase activation, and stimulation of DNA synthesis in mouse keratinocytes. The reaction of lysine 41 with methyl acetimidate resulted in a lysine-acetamidine product which only partially restored activity of the lysine hEGF mutant. However, reaction with O-methylisourea resulted in generation of an arginine 41 homologue (homoarginine) which restored full activity. The results indicate that the chemical properties inherent in the guanidinium group of the arginine 41 side chain of hEGF are responsible for optimal receptor-ligand association.	UNIV TENNESSEE,OAK RIDGE GRAD SCH BIOMED SCI,OAK RIDGE NATL LAB,DIV BIOL,POB 2009,OAK RIDGE,TN 37831; OAK RIDGE NATL LAB,PROT ENGN & MOLEC MUTAGENESIS PROGRAM,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville; United States Department of Energy (DOE); Oak Ridge National Laboratory					NCI NIH HHS [CA 09104, CA 50735, CA 09336] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050735, T32CA009104] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1985, BIOCHEM BIOPH RES CO, V131, P422; AVRUCH J, 1971, BIOCHIM BIOPHYS ACTA, V233, P334, DOI 10.1016/0005-2736(71)90331-2; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARPENTER G, 1985, METHOD ENZYMOL, V109, P107; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DEFEOJONES D, 1989, MOL CELL BIOL, V9, P4083, DOI 10.1128/MCB.9.9.4083; DUDGEON TJ, 1990, FEBS LETT, V261, P392, DOI 10.1016/0014-5793(90)80600-N; ENGLER DA, 1990, FEBS LETT, V271, P47, DOI 10.1016/0014-5793(90)80368-S; ENGLER DA, 1988, J BIOL CHEM, V263, P12384; ENGLER DA, 1909, MOL CELL BIOL, V11, P2425; ENGLER DA, 1990, THESIS U TENNESSEE K; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Hsuan J J, 1989, Prog Growth Factor Res, V1, P23, DOI 10.1016/0955-2235(89)90039-2; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; Kimmel J., 1967, METH ENZYMOLOGY, V11, P584; KOHDA D, 1988, J BIOCHEM-TOKYO, V103, P741, DOI 10.1093/oxfordjournals.jbchem.a122338; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; Ludwig M.L., 1967, METHOD ENZYMOL, V11, P595; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; MATSUNAMI RK, 1990, FEBS LETT, V264, P105, DOI 10.1016/0014-5793(90)80776-F; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; RAY P, 1988, BIOCHEMISTRY-US, V27, P7289, DOI 10.1021/bi00419a017; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WILEY HS, 1989, J BIOL CHEM, V264, P18912; WU DG, 1990, P NATL ACAD SCI USA, V87, P3151, DOI 10.1073/pnas.87.8.3151	36	55	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2274	2281						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733935				2022-12-25	WOS:A1992HB53200027
J	HAGA, K; HAGA, T				HAGA, K; HAGA, T			ACTIVATION BY G-PROTEIN BETA-GAMMA-SUBUNITS OF AGONIST-DEPENDENT OR LIGHT-DEPENDENT PHOSPHORYLATION OF MUSCARINIC ACETYLCHOLINE-RECEPTORS AND RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; GTP-BINDING PROTEINS; FROG RETINAL RODS; ADRENERGIC-RECEPTOR; 48-KDA PROTEIN; ALPHA-2-ADRENERGIC RECEPTOR; PHOTOEXCITED RHODOPSIN; PHOSPHOLIPID-VESICLES; REGULATORY PROTEINS; ADENYLATE-CYCLASE	We have partially purified a protein kinase that phosphorylates muscarinic receptors (mAChR) in the presence of agonists and have shown that the phosphorylation is stimulated by the beta-gamma-subunits of the GTP binding protein G(o) (Haga, K., and Haga, T. (1990) FEBS Lett. 268, 43-47). We report here that rhodopsin is also phosphorylated in a light-dependent manner by the same kinase preparation and that beta-gamma-subunits derived from G(s), G(i), and G(o) stimulate the phosphorylation of both rhodopsin and mAChRs. The rhodopsin- and mAChR-phosphorylating activities were eluted in the same fractions using a purification procedure that is essentially the same as that used for the purification of beta-adrenergic receptor kinase (Benovic, J. L., Strasser, R. H., Caron, M. G., and Lefkowitz, R. J. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 2797-2801) and were inhibited by low concentrations of heparin, an inhibitor of beta-adrenergic receptor kinase, (IC50 = 15 nM), suggesting that both mAChR and rhodopsin are phosphorylated by the same or very similar kinase(s) belonging to the beta-adrenergic receptor kinase family. G protein beta-gamma-subunits increased the V(max) of the phosphorylation of rhodopsin 12-fold. Kinetic data were consistent with the assumptions that the protein kinase (mAChR kinase) binds rhodopsin and beta-gamma-subunits in a random order and that the reaction rate is proportional to concentration of the ternary complex. By contrast, the light-dependent phosphorylation of rhodopsin by the rhodopsin kinase was not stimulated by the beta-gamma-subunits. These results indicate that beta-gamma-subunits may interact with and activate the mAChR kinase but not rhodopsin kinase and suggest that the beta-gamma-subunit of G proteins may take part in the desensitization of G protein-linked receptors.			HAGA, K (corresponding author), UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT BIOCHEM,7-3-1 HONGO,TOKYO 113,JAPAN.							BENNETT N, 1988, BIOCHEMISTRY-US, V27, P1710, DOI 10.1021/bi00405a049; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; BERSTEIN B, 1990, CURRENT ASPECTS NEUR, P245; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA K, 1989, MOL PHARMACOL, V35, P286; HAGA K, 1989, BIOMED RES-TOKYO, V10, P293, DOI 10.2220/biomedres.10.293; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAGA K, 1985, J BIOL CHEM, V260, P7927; HArgrave PA, 1982, PROGR RET RES, V1, P1; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NISHIYAMA T, 1989, BIOMED RES-TOKYO, V10, P251, DOI 10.2220/biomedres.10.251; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; PALCZEWSKI K, 1988, BIOCHEMISTRY-US, V27, P2306, DOI 10.1021/bi00407a010; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PARKER EM, 1991, J BIOL CHEM, V266, P519; PFISTER C, 1983, EUR J BIOCHEM, V136, P489, DOI 10.1111/j.1432-1033.1983.tb07767.x; SCHIMERLIK MI, 1989, ANNU REV PHYSIOL, V51, P217, DOI 10.1146/annurev.ph.51.030189.001245; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SITARAMAYYA A, 1986, BIOCHEMISTRY-US, V25, P5460, DOI 10.1021/bi00367a017; SOKOLOVSKY M, 1989, ADV DRUG RES, V18, P431; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	45	188	190	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2222	2227						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733928				2022-12-25	WOS:A1992HB53200018
J	KELLEY, CA; SELLERS, JR; GOLDSMITH, PK; ADELSTEIN, RS				KELLEY, CA; SELLERS, JR; GOLDSMITH, PK; ADELSTEIN, RS			SMOOTH-MUSCLE MYOSIN IS COMPOSED OF HOMODIMERIC HEAVY-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOPLASMIC MYOSINS; MULTIGENE FAMILY; MESSENGER-RNAS; GENE; PROTEINS; INVITRO; CELLS; EXPRESSION; MOVEMENT; CHICKEN	Vertebrate smooth muscle myosin heavy chains (MHCs) exist as two isoforms with molecular masses of 204 and 200 kDa (MHC204 and MHC200) that are generated from a single gene by alternative splicing of mRNA (Nagai, R., Kuro-o, M., Babij, P., and Periasamy, M. (1989) J. Biol. Chem. 264, 9734-9737). A dimer of two MHCs associated with two pairs of myosin light chains forms a functional myosin molecule. To investigate the isoform composition of the MHCs in native myosin, antibodies specific for MHC204 were generated and used to immunoprecipitate purified bovine aortic smooth muscle myosin from a solution containing equal amounts of each isoform. MHC204 quantitatively removed from this mixture was completely free of MHC200. Immunoprecipitation of the supernatant with an antiserum that recognizes both isoforms equally well revealed that only MHC200 remained. We conclude that only homodimers of MHC204 and MHC200 exist under these conditions. A method is described for the purification of enzymatically active MHC204 and MHC200 homodimers by affinity chromatography of myosin on a protein G-agarose high performance liquid chromatography column containing immobilized MHC204 antibodies. We show, using an in vitro motility assay, that the movement of actin filaments by myosin containing 204-kDa heavy chains (0.435 +/- 0.115-mu-m/s) was not significantly different from that of myosin containing 200-kDa heavy chains (0.361 +/- 0.078-mu-m/s) or from myosin containing equal amounts of each heavy chain isoform (0.347 +/- 0.082-mu-m/s).	NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	KELLEY, CA (corresponding author), NHLBI,MOLEC CARDIOL LAB,BLDG 10,RM 8N-202,BETHESDA,MD 20892, USA.			Adelstein, Robert/0000-0002-8683-2144				BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BURRIDGE K, 1975, J MOL BIOL, V99, P1, DOI 10.1016/S0022-2836(75)80154-9; DECHESNE CA, 1987, J CELL BIOL, V105, P3031, DOI 10.1083/jcb.105.6.3031; EDDINGER TJ, 1988, BIOCHEMISTRY-US, V27, P3807, DOI 10.1021/bi00410a043; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HAMADA Y, 1990, BIOCHEM BIOPH RES CO, V170, P53, DOI 10.1016/0006-291X(90)91239-O; HOH JFY, 1979, FEBS LETT, V97, P330, DOI 10.1016/0014-5793(79)80115-5; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; KAWAMOTO S, 1987, J BIOL CHEM, V262, P7282; KELLEY CA, 1990, J BIOL CHEM, V265, P17876; KERWIN B, 1991, J CELL BIOL, V113, P311, DOI 10.1083/jcb.113.2.311; KROPP KE, 1987, J BIOL CHEM, V262, P16536; KUROO M, 1991, J BIOL CHEM, V266, P3768; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWEY S, 1991, J CELL BIOL, V113, P303, DOI 10.1083/jcb.113.2.303; MOHAMMAD MA, 1988, AUST J BIOL SCI, V41, P409; MURAKAMI N, 1991, FEBS LETT, V278, P23, DOI 10.1016/0014-5793(91)80074-D; NAGAI R, 1989, J BIOL CHEM, V264, P9734; NGUYEN HT, 1982, P NATL ACAD SCI-BIOL, V79, P5230, DOI 10.1073/pnas.79.17.5230; PERIASAMY M, 1984, J BIOL CHEM, V259, P3573; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; ROVNER AS, 1986, AM J PHYSIOL, V250, pC861, DOI 10.1152/ajpcell.1986.250.6.C861; SCHACHAT F, 1978, CELL, V15, P405, DOI 10.1016/0092-8674(78)90009-0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SELLERS JR, 1985, J CELL BIOL, V101, P1897, DOI 10.1083/jcb.101.5.1897; SELLERS JR, 1988, BIOCHEMISTRY-US, V27, P6977, DOI 10.1021/bi00418a046; SHEETZ MP, 1984, J CELL BIOL, V99, P1867, DOI 10.1083/jcb.99.5.1867; SHOHET RV, 1989, P NATL ACAD SCI USA, V86, P7726, DOI 10.1073/pnas.86.20.7726; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; WEYDERT A, 1987, CELL, V49, P121, DOI 10.1016/0092-8674(87)90762-8; ZWEIG SE, 1981, J BIOL CHEM, V256, P1847	37	78	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2127	2130						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733920				2022-12-25	WOS:A1992HB53200004
J	PERSSON, R; SCHNELL, CR; BORG, LAH; FRIES, E				PERSSON, R; SCHNELL, CR; BORG, LAH; FRIES, E			ACCUMULATION OF GOLGI-PROCESSED SECRETORY PROTEINS IN AN ORGANELLE OF HIGH-DENSITY UPON REDUCTION OF ATP CONCENTRATION IN RAT HEPATOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; IMMUNO-CYTOCHEMICAL LOCALIZATION; ENDOPLASMIC-RETICULUM; BREFELDIN-A; INTRACELLULAR-TRANSPORT; POLYACRYLAMIDE GELS; CELL-SURFACE; COMPLEX; COMPARTMENT; HAPTOGLOBIN	We have previously shown that when rat hepatocytes are incubated with 4 mm azide, which reduces the intracellular ATP concentration to about 30% of its normal level, secretory proteins are reversibly arrested within the cell. Analysis of haptoglobin after 150 min of azide incubation shows that its carbohydrates have been processed by Golgi enzymes (Persson, R., Ahlstrom, E., and Fries, E. (1988) J. Cell Biol. 107, 2503-2510). Here, we have further characterized the site of arrest. Subcellular fractionation by density gradient centrifugation showed that albumin and haptoglobin fractionated like a marker for the endoplasmic reticulum. Localization of albumin by immunoelectron microscopy showed, however, that it occurred in flattened cisternae and that the endoplasmic reticulum was devoid of the protein. A possible explanation for these results is that the azide treatment blocks transport through the Golgi complex, leading to an accumulation of secretory proteins in a pre- or early Golgi compartment of high density. This compartment could contain sufficient amounts of Golgi enzymes to carry out the observed carbohydrate processing upon prolonged incubation or possibly acquire them as an effect of the azide treatment.	UNIV UPPSALA, CTR BIOMED, DEPT MED & PHYSIOL CHEM, BOX 575, S-75123 UPPSALA, SWEDEN; UNIV UPPSALA, CTR BIOMED, DEPT MED CELL BIOL, S-75123 UPPSALA, SWEDEN	Uppsala University; Uppsala University								BALCH WE, 1986, J BIOL CHEM, V261, P4690; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BISCHOFF J, 1984, BIOCHEM BIOPH RES CO, V125, P324, DOI 10.1016/S0006-291X(84)80371-X; BREW K, 1975, J BIOL CHEM, V250, P1434; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; DUNPHY WG, 1985, CELL, V42, P13, DOI 10.1016/S0092-8674(85)80097-0; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FRIES E, 1986, BIOCHEM J, V237, P33, DOI 10.1042/bj2370033; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GROSS V, 1985, EUR J BIOCHEM, V150, P41, DOI 10.1111/j.1432-1033.1985.tb08985.x; HANLEY JM, 1983, J BIOL CHEM, V258, P7858; ISHIKAWA E, 1983, ANN NY ACAD SCI, V420, P74, DOI 10.1111/j.1749-6632.1983.tb22191.x; JAMIESON JD, 1968, J CELL BIOL, V39, P589, DOI 10.1083/jcb.39.3.589; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; Maizel JV, 1971, METHOD VIROL, V5, P179; MELLIS SJ, 1981, ANAL BIOCHEM, V114, P276, DOI 10.1016/0003-2697(81)90480-2; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; OGATA S, 1986, EUR J BIOCHEM, V161, P315, DOI 10.1111/j.1432-1033.1986.tb10449.x; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PERSSON R, 1988, J CELL BIOL, V107, P2503, DOI 10.1083/jcb.107.6.2503; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; REGGIO H, 1983, METHOD ENZYMOL, V98, P379; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SJOBERG M, 1991, EUR J BIOCHEM, V197, P61, DOI 10.1111/j.1432-1033.1991.tb15882.x; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; TULSIANI DRP, 1982, J BIOL CHEM, V257, P7936; WATSON ML, 1958, J BIOPHYS BIOCHEM CY, V4, P475, DOI 10.1083/jcb.4.4.475; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; YOKOTA S, 1981, P NATL ACAD SCI-BIOL, V78, P4970, DOI 10.1073/pnas.78.8.4970	53	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2760	2766						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733972				2022-12-25	WOS:A1992HB53200097
J	PRICE, LKH; CHOI, HU; ROSENBERG, L; STANLEY, ER				PRICE, LKH; CHOI, HU; ROSENBERG, L; STANLEY, ER			THE PREDOMINANT FORM OF SECRETED COLONY STIMULATING FACTOR-I IS A PROTEOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC GROWTH-FACTOR; DERMATAN SULFATE PROTEOGLYCANS; MOLECULAR-CLONING; FACTOR CSF-1; FACTOR-I; C-FMS; ELECTROPHORETIC TRANSFER; MACROPHAGE PRODUCTION; POLYACRYLAMIDE GELS; MESSENGER-RNA	Colony stimulating factor-1 (CSF-1) is a homodimeric glycoprotein that humorally regulates the proliferation and differentiation of mononuclear phagocytic cells and locally regulates cells of the female reproductive tract. Alternative splicing of the human CSF-1 mRNA leads to alternative expression of the CSF-1 homodimer as a secreted glycoprotein or as a membrane-spanning molecule with cell surface biological activity. In the present study, analysis of immunoaffinity-purified CSF-1 from mouse L929 cell medium by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) indicated that CSF-1 is predominantly secreted as highly sulfated species of 375- and 250-kDa with a smaller amount of a 100-kDa species. Analysis by gel filtration in 4 M guanidine HCl buffer, indicated that, in contrast to the 100-kDa species, the highly sulfated species exhibit anomalously high molecular weights and self-association on SDS-PAGE similar to the dermatan sulfate proteoglycan, biglycan. The three predominant CSF-1 species were shown to be an 80-kDa homodimer, an 80-kDa/50-kDa heterodimer, and a 50-kDa homodimer. The 80-kDa subunit contained a single 18-kDa chondroitin sulfate chain that was absent from the 50-kDa subunit. Furthermore, treatment of the 80- and 50-kDa subunits, synthesized in the presence of tunicamycin, with chondroitinase ABC, neuraminidase, and endo-alpha-N-acetyl galactosaminidase reduced their apparent molecular masses to 60 and 25 kDa, respectively. These results are consistent with intracellular proteolytic cleavage of the 80-kDa chondroitin sulfate containing subunits from the membrane spanning CSF-1 precursor at a point carboxyl-terminal to the single consensus sequence for glycosaminoglycan addition and cleavage of the 50-kDa glycoprotein subunit at a position amino-terminal to this site. The predominance of the proteoglycan form of secreted CSF-1, which represents only 3-4% of the total trichloroacetic acid-precipitable counts released from (SO42-)-S-35-labeled L cells, has important implications for regulation by this growth factor.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT DEV BIOL & CANC,1300 MORRIS PK AVE,BRONX,NY 10461; MONTEFIORE MED CTR,ORTHOPED RES LAB,BRONX,NY 10467	Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine					NATIONAL CANCER INSTITUTE [R01CA032551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR021498, R01AR034614] Funding Source: NIH RePORTER; NCI NIH HHS [CA 32551] Funding Source: Medline; NIAMS NIH HHS [AR 34614, AR 21498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABBOUD SL, 1991, BLOOD, V78, P103; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AUSTIN PE, 1971, J CELL PHYSIOL, V77, P121, DOI 10.1002/jcp.1040770202; BHAVANANDAN VP, 1976, BIOCHEM BIOPH RES CO, V70, P738, DOI 10.1016/0006-291X(76)90654-9; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; CHOI HU, 1989, J BIOL CHEM, V264, P2876; DAS SK, 1980, J CELL PHYSIOL, V104, P359, DOI 10.1002/jcp.1041040309; DAS SK, 1982, J BIOL CHEM, V257, P13679; DAS SK, 1981, BLOOD, V58, P630; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DUKSIN D, 1982, J BIOL CHEM, V257, P3105; ESKO JD, 1986, J BIOL CHEM, V261, P5725; HALENBECK R, 1988, J BIOTECHNOL, V8, P45, DOI 10.1016/0168-1656(88)90067-3; HEARD JM, 1987, ONCOGENE RES, V1, P423; HEINEGARD D, 1984, EXTRACELLULAR MATRIX, P227; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KLEIN R, 1988, ONCOGENE RES, V2, P311; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LADNER MB, 1988, P NATL ACAD SCI USA, V85, P6706, DOI 10.1073/pnas.85.18.6706; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUTZ A, 1988, J BIOL CHEM, V263, P3905; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LOPEZOTIN C, 1989, J BIOL CHEM, V264, P9107; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MANOS MM, 1988, MOL CELL BIOL, V8, P5035, DOI 10.1128/MCB.8.11.5035; MANOS MM, 1988, VIRAL VECTORS, P45; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NEUFELD G, 1986, J BIOL CHEM, V261, P5631; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; PAIETTA E, 1990, CANCER RES, V50, P2049; POLLARD JW, 1987, NATURE, V330, P484, DOI 10.1038/330484a0; RAJAVASHISTH TB, 1987, P NATL ACAD SCI USA, V84, P1157, DOI 10.1073/pnas.84.5.1157; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SHERR CJ, 1990, HDB EXPT PHARM, V95, P667; STANLEY ER, 1979, P NATL ACAD SCI USA, V76, P2969, DOI 10.1073/pnas.76.6.2969; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; STANLEY ER, 1985, METHOD ENZYMOL, V116, P564; STANLEY ER, 1971, P SOC EXP BIOL MED, V137, P1029; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STANLEY ER, 1976, J EXP MED, V143, P35; STEIN J, 1990, BLOOD, V76, P1308, DOI 10.1182/blood.V76.7.1308.bloodjournal7671308; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; THIEL HJ, 1984, VIROLOGY, V134, P138, DOI 10.1016/0042-6822(84)90279-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAHEED A, 1979, J LAB CLIN MED, V94, P180; WATERFIELD MD, 1983, NATURE, V304, P3539; WONG GG, 1987, SCIENCE, V235, P1504, DOI 10.1126/science.3493529; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	60	133	135	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2190	2199						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733926				2022-12-25	WOS:A1992HB53200014
J	TORREBLANCO, A; ADACHI, E; HOJIMA, Y; WOOTTON, JAM; MINOR, RR; PROCKOP, DJ				TORREBLANCO, A; ADACHI, E; HOJIMA, Y; WOOTTON, JAM; MINOR, RR; PROCKOP, DJ			TEMPERATURE-INDUCED POSTTRANSLATIONAL OVER-MODIFICATION OF TYPE-I PROCOLLAGEN EFFECTS OF OVER-MODIFICATION OF THE PROTEIN ON THE RATE OF CLEAVAGE BY PROCOLLAGEN N-PROTEINASE AND ON SELF-ASSEMBLY OF COLLAGEN INTO FIBRILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO TENDONS; PERINATAL OSTEOGENESIS IMPERFECTA; UNCLEAVED PRO-ALPHA-1(I) CHAIN; TRIPLE-HELICAL CONFORMATION; SIMILAR THERMAL-STABILITY; CULTURED FIBROBLASTS; STRUCTURAL MUTATIONS; SEQUENTIAL CLEAVAGE; PROTEOLYTIC-ENZYMES; A-FRAGMENTS	Previous observations suggested that incubating fibroblasts at elevated temperature caused over-modification of type I procollagen by post-translational enzymes because of a delay in folding of the collagen triple helix. Here, human skin fibroblasts were incubated at 40.5 instead of 37-degrees-C, and the type I procollagen secreted into the medium was isolated. Analysis of the protein indicated that there was an increase of about 5 residues of hydroxylysine/alpha-chain and about 1 residue of glycosylated hydroxylysine/alpha-chain. Assays with procollagen N-proteinase indicated that the N-propeptide of the over-modified collagen was cleaved at a decreased rate, apparently because the over-modification altered the conformation-dependent cleavage site for the enzyme. Assays in a system for assembly of collagen into fibrils demonstrated that the over-modified protein had a higher critical concentration for self-assembly. Also, the fibrils formed from the over-modified collagen at 31 and 29-degrees-C had smaller diameters than fibrils formed from normal type I collagen. The results provide direct evidence for earlier suggestions that post-translational over-modification of a fibrillar collagen can alter the morphology of the fibrils formed. The results also indicate that some of the biological consequences of the mutations in type I procollagen causing heritable disorders must be ascribed to the effects of post-translational over-modifications that frequently occur as secondary consequences of changes in the primary structure of the protein.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; CORNELL UNIV,SCH VET MED,DEPT PATHOL,ITHACA,NY 14853	Jefferson University; Cornell University					NIAMS NIH HHS [AR-39740, AR-38188] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038188, P01AR039740] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASKENASI RS, 1972, ANAL BIOCHEM, V47, P67, DOI 10.1016/0003-2697(72)90279-5; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BATEMAN JF, 1986, BIOCHEM J, V240, P669; BERGER J, 1985, BIOCHEMISTRY-US, V24, P600, DOI 10.1021/bi00324a009; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BUTLER WT, 1966, J BIOL CHEM, V241, P3882; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; CONSTANTINOU CD, 1987, EUR J BIOCHEM, V163, P247, DOI 10.1111/j.1432-1033.1987.tb10794.x; DOMBROWSKI KE, 1987, THESIS RUTGERS U NEW; DOMBROWSKI KE, 1989, J BIOL CHEM, V263, P16545; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FIEDLERNAGY C, 1982, J BIOL CHEM, V257, P9181; FISCHER T, 1987, THESIS SWISS FEDERAL; GRANT ME, 1972, J BIOL CHEM, V247, P3539; GRANT ME, 1968, BIOCHEM J, V108, P586; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOJIMA Y, 1985, J BIOL CHEM, V260, P11336; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; KADLER KE, 1991, BIOCHEMISTRY-US, V30, P5081, DOI 10.1021/bi00234a035; KIRSCH E, 1983, BIOCHEM J, V211, P599, DOI 10.1042/bj2110599; KIVIRIKKO KI, 1984, EXTRACELLULAR MATRIX, P83; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; MINOR RR, 1986, J BIOL CHEM, V261, P6; MIYAHARA M, 1984, J BIOL CHEM, V259, P9891; PELTONEN L, 1980, P NATL ACAD SCI-BIOL, V77, P162, DOI 10.1073/pnas.77.1.162; Prockop D.J., 1976, BIOCH COLLAGENS, P163; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; SPIRO RG, 1969, J BIOL CHEM, V244, P602; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; STEINMANN B, 1991, BIOCHEM J, V279, P747, DOI 10.1042/bj2790747; TRELSTAD RL, 1977, LAB INVEST, V36, P501; TUDERMAN L, 1978, BIOCHEMISTRY-US, V17, P2948, DOI 10.1021/bi00608a002; TUDERMAN L, 1982, EUR J BIOCHEM, V125, P545, DOI 10.1111/j.1432-1033.1982.tb06716.x; UITTO VJ, 1978, ARCH BIOCHEM BIOPHYS, V185, P214, DOI 10.1016/0003-9861(78)90161-3; VOGEL BE, 1987, J BIOL CHEM, V262, P14737; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	41	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2650	2655						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733961				2022-12-25	WOS:A1992HB53200083
J	GREEN, TL; HUNTER, DD; CHAN, W; MERLIE, JP; SANES, JR				GREEN, TL; HUNTER, DD; CHAN, W; MERLIE, JP; SANES, JR			SYNTHESIS AND ASSEMBLY OF THE SYNAPTIC CLEFT PROTEIN S-LAMININ BY CULTURED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; BASEMENT-MEMBRANE PROTEIN; PARIETAL ENDODERM CELLS; FIBER BASAL LAMINA; NEUROMUSCULAR-JUNCTION; MULTIDOMAIN PROTEIN; NIDOGEN COMPLEX; TUMOR LAMININ; GROWTH-FACTOR; COLLAGEN-IV	S-laminin, a homologue of the B1 chain of laminin, is concentrated in a subset of basal laminae (BLs), including the BL at the skeletal neuromuscular junction and bears an adhesive site for motoneuron-like cells. Here, we have begun to characterize the native form of the protein. We show that several muscle- and glia-like cell lines synthesize and secrete S-laminin as well as the A, B1, and B2 subunits of the conventional laminin trimer. Experiments using subunit-specific antibodies showed that S-laminin is complexed with the A and B2 subunits of laminin but not with B1, suggesting that S-laminin replaces B1 to form a novel laminin-like trimer. Comparison of material precipitated by different antibodies provided evidence for two immunochemically distinct forms of S-laminin, both of which associate with B2 and A-like subunits. Analysis of tunicamycin-treated cells indicated that N-linked glycosylation is required neither for the selective association of S-laminin with B2 and A subunits nor for the distinction between two forms of S-laminin. Finally, a full-length S-laminin cDNA was constructed and transfected into muscle and non-muscle cells. S-laminin was detected intracellularly in both cell types, in extracellular matrix of muscle cells, and in two immunochemically distinct forms. Thus, the cDNA contains sufficient information to permit assembly, secretion, and post-translational modification of S-laminin.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,660 S EUCLID AVE,BOX 8108,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								ARATANI Y, 1988, J BIOL CHEM, V263, P16163; ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BEERS RF, 1952, J BIOL CHEM, V195, P133; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; CARLIN BE, 1983, J BIOL CHEM, V258, P7729; CHIU AY, 1991, GLIA, V4, P11, DOI 10.1002/glia.440040103; CHUNG AE, 1990, AM J RESP CELL MOL, V3, P275, DOI 10.1165/ajrcmb/3.4.275; COOPER AR, 1981, EUR J BIOCHEM, V119, P189, DOI 10.1111/j.1432-1033.1981.tb05593.x; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; DURKIN ME, 1988, BIOCHEMISTRY-US, V27, P5198, DOI 10.1021/bi00414a038; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; EDGAR D, 1988, J CELL BIOL, V106, P1299, DOI 10.1083/jcb.106.4.1299; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; GALILEO DS, 1990, P NATL ACAD SCI USA, V87, P458, DOI 10.1073/pnas.87.1.458; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HOWE CC, 1983, DEV BIOL, V98, P385, DOI 10.1016/0012-1606(83)90367-6; HOWE CC, 1984, MOL CELL BIOL, V4, P1; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUNTER DD, 1991, IN PRESS J NEUROSCI; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEDBETTER SR, 1985, J BIOL CHEM, V260, P8106; LISSITZKY JCS, 1988, BIOCHEM J, V250, P843, DOI 10.1042/bj2500843; MANN K, 1988, EUR J BIOCHEM, V178, P71, DOI 10.1111/j.1432-1033.1988.tb14430.x; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MCGADEY J, 1970, HISTOCHEMISTRY, V23, P180, DOI 10.1007/BF00305851; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERRILL GF, 1989, IN VITRO CELL DEV B, V25, P471; MORITA A, 1985, BIOCHEM J, V229, P259, DOI 10.1042/bj2290259; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; OLSEN D, 1989, LAB INVEST, V60, P772; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PETERS BP, 1985, J BIOL CHEM, V260, P4732; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; RAO CN, 1982, ARCH BIOCHEM BIOPHYS, V219, P65, DOI 10.1016/0003-9861(82)90134-5; ROTHBARD JB, 1982, J BIOL CHEM, V257, P1064; SAMBROOK L, 1989, MOL CLONING LABORATO; SANES JR, 1990, COLD SH Q B, V55, P419; SANES JR, 1979, J CELL BIOL, V83, P357, DOI 10.1083/jcb.83.2.357; SANES JR, 1983, DEV BIOL, V97, P123, DOI 10.1016/0012-1606(83)90070-2; SANES JR, 1984, J NEUROSCI, V4, P464; SANES JR, 1983, COLD SPRING HARB SYM, V48, P667, DOI 10.1101/SQB.1983.048.01.070; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANES JR, 1978, J CELL BIOL, V78, P176, DOI 10.1083/jcb.78.1.176; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASKI M, 1988, J BIOL CHEM, V263, P16536; SHEPPARD JR, 1975, SCIENCE, V187, P179; SILBERSTEIN L, 1982, NATURE, V295, P143, DOI 10.1038/295143a0; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; WEST CM, 1986, MOL CELL BIOCHEM, V72, P3; WEWER U, 1982, DEV BIOL, V93, P416, DOI 10.1016/0012-1606(82)90128-2; WU CY, 1988, BIOCHEMISTRY-US, V27, P8780, DOI 10.1021/bi00424a014; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432-0436.1977.tb01507.x; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	69	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					2014	2022						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730732				2022-12-25	WOS:A1992HA48500093
J	MAZZONE, T; PUSTELNIKAS, L; REARDON, CA				MAZZONE, T; PUSTELNIKAS, L; REARDON, CA			POSTTRANSLATIONAL REGULATION OF MACROPHAGE APOPROTEIN-E PRODUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; APOLIPOPROTEIN-E SYNTHESIS; OVARIAN GRANULOSA-CELLS; CHOLESTEROL EFFLUX; MAMMALIAN-CELLS; RAT HEPATOCYTES; SECRETION; EXPRESSION; GENES	We have transfected the murine macrophage cell line, J774, which does not express its endogenous apoE gene, with a constitutively expressed human apoE cDNA in order to study post-transcriptional and post-translational control of apoE production in macrophages. Loading cells with cholesterol using preincubations in acetylated low density lipoprotein, previously shown to enhance macrophage apoE gene transcription and apoE synthesis, did not increase apoE synthesis or secretion in constitutively expressing transfected cells, suggesting that sterol control of macrophage apoE production occurs predominantly at a transcriptional locus. However, incubation in human high density lipoprotein (HDL3) stimulated apoE secretion and appeared to inhibit degradation of newly synthesized apoE. This effect could be entirely reproduced by incubation with phosphatidylcholine vesicles which increased apoE accumulation in the medium by 2-6-fold. Pulse-chase experiments indicated that the effect of HDL3 or phospholipid vesicles was very rapid (occurring within 15 min) and was independent of changes in apoE synthesis. Furthermore, the increased apoE which accumulated in the medium in the presence of phospholipid vesicles or HDL3 was not due to altered rates of reuptake of labeled apoE since this difference was completely preserved in the absence of extracellular calcium. These results indicate that alteration of sterol content does not regulate macrophage apoE production at a translational or post-translational locus but that incubation with HDL3 or phospholipid vesicles can enhance apoprotein E production independent of changes in apoE gene transcription or apoE synthesis. The nature of the signal generated by the phospholipid vesicles which leads to inhibition of intracellular apoE degradation and enhanced apoE secretion will require further investigation.	RUSH MED COLL,DEPT MED,CHICAGO,IL 60612; RUSH MED COLL,DEPT BIOCHEM,CHICAGO,IL 60612; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637	Rush University; Rush University; University of Chicago					NHLBI NIH HHS [HL39653, HL15062] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039653, P50HL015062] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; BAMBERGER MJ, 1988, J BIOL CHEM, V263, P11868; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1982, J BIOL CHEM, V257, P9788; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BERNARD DW, 1991, J BIOL CHEM, V266, P710; BERNARD DW, 1990, ARTERIOSCLEROSIS, V10, P135, DOI 10.1161/01.ATV.10.1.135; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; DAVIS RA, 1989, J LIPID RES, V30, P1185; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DORY L, 1991, J LIPID RES, V32, P783; DORY L, 1989, J LIPID RES, V30, P809; DRISCOLL DM, 1985, J BIOL CHEM, V260, P9031; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HAMILTON RL, 1990, J LIPID RES, V31, P1589; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KOO C, 1986, J BIOL CHEM, V261, P1194; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1989, J LIPID RES, V30, P1055; MAZZONE T, 1991, J LIPID RES, V32, P507; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; ORAM JF, 1981, J BIOL CHEM, V256, P8348; ROUIS M, 1989, EUR J BIOCHEM, V189, P447; SATO R, 1990, J BIOL CHEM, V265, P11880; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; VANLENTEN BJ, 1983, J BIOL CHEM, V258, P5151; WERB Z, 1983, J EXP MED, V158, P1272, DOI 10.1084/jem.158.4.1272; WERB Z, 1983, J CELL BIOL, V97, P1113, DOI 10.1083/jcb.97.4.1113; WERB Z, 1983, J BIOL CHEM, V258, P642; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS KJ, 1987, J CLIN INVEST, V79, P1466, DOI 10.1172/JCI112975; WYNE KL, 1989, J BIOL CHEM, V264, P981; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495; ZECHNER R, 1991, J BIOL CHEM, V266, P10583	37	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1081	1087						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730636				2022-12-25	WOS:A1992GY96000065
J	OSHEAGREENFIELD, A; SMALE, ST				OSHEAGREENFIELD, A; SMALE, ST			ROLES OF TATA AND INITIATOR ELEMENTS IN DETERMINING THE START SITE LOCATION AND DIRECTION OF RNA POLYMERASE-II TRANSCRIPTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; PREINITIATION COMPLEX; INVITRO FUNCTION; BINDING PROTEIN; BOX REGION; CAP SITE; GENE; SEQUENCES; ACTIVATION; UPSTREAM	Transcriptional initiator elements and TATA elements are functionally similar, in that both can act in concert with a Sp1-dependent activator element to direct high levels of accurately initiated transcription. In this study, we have used in vitro transcription experiments to elucidate the relative activities of TATA and initiator. By varying the locations of TATA and initiator elements within a simple promoter, we compared their abilities to localize transcription start sites and to mediate transcriptional activation by Sp1. In addition, we addressed the contributions of initiator and TATA towards determining the direction of transcription from a promoter. Finally, we addressed the prevalence of initiator elements by analyzing the start site regions of several genes. We found that many of these regions possess initiator activity, although an initiator consensus sequence could not be defined. Taken together, the data presented suggest that an initiator is a common element that can influence the direction of transcription as well as the location of a transcription start site. However, in general, an initiator was incapable of altering these activities of a TATA box within a promoter containing both core elements.	UNIV CALIF LOS ANGELES,SCH MED,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BIELINSKA A, 1989, J VIROL, V63, P4097, DOI 10.1128/JVI.63.9.4097-4100.1989; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; CONAWAY JW, 1990, J BIOL CHEM, V265, P7564; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CORDEN J, 1980, SCIENCE, V209, P1405; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HERMANSON G, 1988, B CELL DEV, P133; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; MCVEY JH, 1988, J BIOL CHEM, V263, P11111; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289, DOI 10.1073/pnas.87.11.4289; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; PERKINS KK, 1988, GENE DEV, V2, P1615, DOI 10.1101/gad.2.12a.1615; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; TALKINGTON CA, 1982, NATURE, V298, P192, DOI 10.1038/298192a0; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WU L, 1988, VIROLOGY, V167, P318, DOI 10.1016/0042-6822(88)90089-X	45	200	202	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1391	1402						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730658				2022-12-25	WOS:A1992GY96000110
J	SANCHEZ, ER				SANCHEZ, ER			HEAT-SHOCK INDUCES TRANSLOCATION TO THE NUCLEUS OF THE UNLIGANDED GLUCOCORTICOID RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTRACELLULAR-LOCALIZATION; PROGESTERONE RECEPTORS; MONOCLONAL-ANTIBODIES; MAMMALIAN-CELLS; DNA-BINDING; PROTEIN; HORMONE; PHOSPHOPROTEIN; TRANSFORMATION	There have been many reports demonstrating the specific association of several heat shock proteins with unliganded steroid hormone receptors. However, little evidence to date has been proposed to link steroid receptor action with the heat shock response in cells. In this paper, we demonstrate the effect of heat and chemical stress on glucocorticoid receptor subcellular localization in mouse L929 cells and in a stably transfected Chinese hamster ovary cell line (WCL2) which over-expresses the mouse glucocorticoid receptor. When WCL2 cells are exposed to 43-degrees-C, there is a time-dependent decrease in glucocorticoid receptor hormone-binding capacity in the cytosolic fraction of these cells that correlates with a decrease in amount of glucocorticoid receptor protein. Analysis of both cytosolic and nuclear fractions for glucocorticoid receptor protein via quantitative Western blotting reveals that the unliganded glucocorticoid receptor of non-shocked L929 and WCL2 cells is localized primarily in the cytosolic fraction, whereas unliganded receptor of heat-shocked cells is found almost exclusively in the nuclear fraction. A similar shift to nuclear localization for unliganded glucocorticoid receptor is noted in L929 and WCL2 cells subjected to chemical shock (sodium arsenite). As treatment of these cells with glucocorticoid hormone also results in glucocorticoid receptor that is tightly bound within the nuclear fraction, it is speculated that heat and chemical stress provide a hormone-independent mechanism by which glucocorticoid receptor is transformed to the high affinity nuclear-binding state characteristic of the hormone-bound, transcriptionally active receptor.			SANCHEZ, ER (corresponding author), MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699, USA.				NIDDK NIH HHS [R01 DK043867] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043867] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTAKLY T, 1984, ENDOCRINOLOGY, V115, P1984, DOI 10.1210/endo-115-5-1984; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CIDLOWSKI JA, 1990, MOL ENDOCRINOL, V4, P1427, DOI 10.1210/mend-4-10-1427; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; FISHER GA, 1986, J CELL PHYSIOL, V128, P127, DOI 10.1002/jcp.1041280119; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GASC JM, 1989, EXP CELL RES, V181, P492, DOI 10.1016/0014-4827(89)90106-7; HIRST MA, 1990, MOL ENDOCRINOL, V4, P162, DOI 10.1210/mend-4-1-162; HOWARD KJ, 1988, J BIOL CHEM, V263, P3474; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTINS VR, 1991, MOL ENDOCRINOL, V5, P217, DOI 10.1210/mend-5-2-217; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; MENDEL DB, 1986, NATURE, V324, P478, DOI 10.1038/324478a0; MESHINCHI S, 1990, J BIOL CHEM, V265, P4863; PERROTAPPLANAT M, 1985, ENDOCRINOLOGY, V116, P1473, DOI 10.1210/endo-116-4-1473; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; TIENRUNGROJ W, 1987, J BIOL CHEM, V262, P17342; WELCH WJ, 1986, J CELL BIOL, V103, P2035, DOI 10.1083/jcb.103.5.2035; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WIKSTROM AC, 1987, ENDOCRINOLOGY, V120, P1232, DOI 10.1210/endo-120-4-1232	27	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					17	20						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730584				2022-12-25	WOS:A1992GY43900005
J	CHEN, HC; STERN, DB				CHEN, HC; STERN, DB			SPECIFIC RIBONUCLEASE-ACTIVITIES IN SPINACH-CHLOROPLASTS PROMOTE MESSENGER-RNA MATURATION AND DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' INVERTED REPEATS; PLASTID GENE-EXPRESSION; BACTERIOPHAGE-T4 GENE-32; ENDONUCLEOLYTIC CLEAVAGE; CYTOSOLIC PROTEIN; STABILITY; TRANSCRIPTION; REGION; BINDING; INVITRO	We have used an in vitro system to characterize ribonuclease activities present in spinach chloroplasts. We show that 3' end maturation of petD mRNA, which encodes subunit IV of the cytochrome bg/f complex, is affected by a 33-kDa protein that binds to a hairpin structure at the 3' end of the mature mRNA. Binding of the 33-kDa protein to the petD hairpin structure decreases the efficiency of 3' end maturation, probably by impeding the progress of the processive 3'-5' exonuclease activity involved in chloroplast mRNA processing. A two-base mutation in the stem of the petD hairpin structure creates a novel recognition site for a ribonuclease which competes with the normal processing exonuclease activity. This mutation results in a very low 3' end processing efficiency for mutant petD transcripts, and instead generates a second processing product that lacks a complete hairpin structure. An endonuclease activity which is biochemically distinct from the previously characterized exonuclease activities has also been identified. This endonuclease activity is EDTA-insensitive, and cleaves petD RNA both at the termination codon and at the mature RNA 3' end. Cleavage of petD mRNA at the termination codon leads to rapid degradation of upstream RNA. The possible roles of these ribonuclease activities in chloroplast mRNA decay in vivo are discussed.			CHEN, HC (corresponding author), CORNELL UNIV, BOYCE THOMPSON INST PLANT RES, ITHACA, NY 14853 USA.							ADAMS CC, 1990, NUCLEIC ACIDS RES, V18, P6003, DOI 10.1093/nar/18.20.6003; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CANNISTRARO VJ, 1986, J MOL BIOL, V192, P257, DOI 10.1016/0022-2836(86)90363-3; CARPOUSIS AJ, 1989, MOL GEN GENET, V219, P39, DOI 10.1007/BF00261155; CHEN HC, 1991, MOL CELL BIOL, V11, P4380, DOI 10.1128/MCB.11.9.4380; DENG XW, 1987, CELL, V49, P379, DOI 10.1016/0092-8674(87)90290-X; FAUBLADIER M, 1990, J MOL BIOL, V212, P461, DOI 10.1016/0022-2836(90)90325-G; GICK O, 1986, EMBO J, V5, P1319, DOI 10.1002/j.1460-2075.1986.tb04362.x; GRUISSEM W, 1989, CELL, V56, P161, DOI 10.1016/0092-8674(89)90889-1; GRUISSEM W, 1988, TRENDS GENET, V4, P258, DOI 10.1016/0168-9525(88)90033-9; GRUISSEM W, 1986, METHOD ENZYMOL, V118, P253; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HEINEMEYER W, 1984, CURR GENET, V8, P543, DOI 10.1007/BF00410442; KLAFF P, 1991, PLANT CELL, V3, P517, DOI 10.1105/tpc.3.5.517; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; LI YQ, 1990, EMBO J, V9, P3059, DOI 10.1002/j.1460-2075.1990.tb07502.x; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MOWRY KL, 1987, MOL CELL BIOL, V7, P1663, DOI 10.1128/MCB.7.5.1663; MUDD EA, 1988, EMBO J, V7, P3601, DOI 10.1002/j.1460-2075.1988.tb03238.x; MULLET JE, 1987, EMBO J, V6, P1571, DOI 10.1002/j.1460-2075.1987.tb02402.x; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NICKELSEN J, 1989, NUCLEIC ACIDS RES, V17, P9637, DOI 10.1093/nar/17.23.9637; NURNBERGER T, 1990, PLANT PHYSIOL, V92, P970, DOI 10.1104/pp.92.4.970; PORTIER C, 1987, EMBO J, V6, P2165, DOI 10.1002/j.1460-2075.1987.tb02484.x; REGNIER P, 1991, J MOL BIOL, V217, P283, DOI 10.1016/0022-2836(91)90542-E; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SCHUSTER G, 1991, EMBO J, V10, P1493, DOI 10.1002/j.1460-2075.1991.tb07669.x; STERN DB, 1989, J BIOL CHEM, V264, P18742; STERN DB, 1987, CELL, V51, P1145, DOI 10.1016/0092-8674(87)90600-3; STERN DB, 1991, PLANT CELL, V3, P285; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; UZAN M, 1988, P NATL ACAD SCI USA, V85, P8895, DOI 10.1073/pnas.85.23.8895	34	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24205	24211						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721067				2022-12-25	WOS:A1991GV31900103
J	KLEINERT, H; ASSERT, R; BENECKE, BJ				KLEINERT, H; ASSERT, R; BENECKE, BJ			A SINGLE BASE PAIR DELETION FROM THE INACTIVE OCTAMER-LIKE MOTIF OF THE 7S-K DISTAL SEQUENCE ELEMENT BRINGS FULL FUNCTIONALITY INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; IMMUNOGLOBULIN HEAVY-CHAIN; ENHANCER-LIKE SEQUENCE; CELL-TYPE SPECIFICITY; UPSTREAM PROMOTER; SNRNA GENES; U2 SNRNA; EFFICIENT TRANSCRIPTION; INVITRO TRANSCRIPTION; CONSERVED SEQUENCE	Octamer sequence elements were analyzed for their capacity to induce the 7S K "core" promoter in vivo. The U6 distal sequence element (DSE) which contains a consensus sequence octamer, was able to support efficient 7S K expression in vivo. In contrast, no such function could be attributed to the octamer-like element alone, which is present within the 7S K DSE. However, conversion of this octamer-like element (ATTTaGCAT) to the octamer consensus sequence ATTTGCAT generated a potent DSE, even in the absence of the CACCC box, which constitutes the major functional element of the 7S K DSE. Both the consensus and the octamer-like sequences revealed no cooperativity with the CACCC box. Together, these results demonstrate that the octamer-like element of the wild-type 7S K DSE is definitely not functional in vivo. Furthermore, our experiments indicate that in contrast to the RNA polymerase II-transcribed small nuclear RNA genes, in intact cells a single functional DSE motif is necessary and sufficient for maximal transcription by RNA polymerase III of the 7S K RNA gene.	RUHR UNIV BOCHUM,FAC CHEM,DEPT BIOCHEM NC6,W-4630 BOCHUM 1,GERMANY	Ruhr University Bochum	BENECKE, BJ (corresponding author), RUHR UNIV BOCHUM,FAC CHEM,DEPT BIOCHEM NC6,W-4630 BOCHUM 1,GERMANY.		Kleinert, Hartmut/M-2988-2018	Kleinert, Hartmut/0000-0003-2202-3548				ARES M, 1987, GENE DEV, V1, P808, DOI 10.1101/gad.1.8.808; ATCHISON ML, 1990, EMBO J, V9, P3109, DOI 10.1002/j.1460-2075.1990.tb07508.x; BARK C, 1987, NATURE, V328, P356, DOI 10.1038/328356a0; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BOHMANN D, 1987, NATURE, V325, P268, DOI 10.1038/325268a0; BREDOW S, 1990, GENE, V86, P217, DOI 10.1016/0378-1119(90)90282-V; BREDOW S, 1990, NUCLEIC ACIDS RES, V18, P6779, DOI 10.1093/nar/18.23.6779; CARBON P, 1987, CELL, V51, P71, DOI 10.1016/0092-8674(87)90011-0; CILIBERTO G, 1987, NUCLEIC ACIDS RES, V15, P2403, DOI 10.1093/nar/15.6.2403; DALHBERG JE, 1988, STRUCTURE FUNCTION M, P38; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HOWE JG, 1989, CELL, V57, P825, DOI 10.1016/0092-8674(89)90797-6; KLEINERT H, 1988, NUCLEIC ACIDS RES, V16, P1319, DOI 10.1093/nar/16.4.1319; KLEINERT H, 1990, EMBO J, V9, P711, DOI 10.1002/j.1460-2075.1990.tb08164.x; KROL A, 1987, NUCLEIC ACIDS RES, V15, P2463, DOI 10.1093/nar/15.6.2463; KRUGER W, 1987, J MOL BIOL, V195, P31, DOI 10.1016/0022-2836(87)90325-1; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; LEBOWITZ JH, 1988, GENE DEV, V2, P1227, DOI 10.1101/gad.2.10.1227; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; MANGIN M, 1986, EMBO J, V5, P987, DOI 10.1002/j.1460-2075.1986.tb04313.x; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; MATTAJ IW, 1988, CELL, V55, P435, DOI 10.1016/0092-8674(88)90029-3; MATTAJ IW, 1985, NATURE, V316, P163, DOI 10.1038/316163a0; MURPHY JT, 1987, J BIOL CHEM, V262, P1795; MURPHY S, 1986, NUCLEIC ACIDS RES, V14, P9243, DOI 10.1093/nar/14.23.9243; MURPHY S, 1989, CELL, V59, P1071, DOI 10.1016/0092-8674(89)90763-0; MURPHY S, 1987, CELL, V51, P81, DOI 10.1016/0092-8674(87)90012-2; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; ROEBUCK KA, 1990, MOL CELL BIOL, V10, P341, DOI 10.1128/MCB.10.1.341; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFNER W, 1989, TRENDS GENET, V5, P37, DOI 10.1016/0168-9525(89)90017-6; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; WEIL PA, 1979, J BIOL CHEM, V254, P6163; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; ZIEVE G, 1977, BIOCHEMISTRY-US, V16, P4520, DOI 10.1021/bi00639a029	44	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23872	23877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721058				2022-12-25	WOS:A1991GV31900054
J	MALDONADO, D; SCHUMANN, M; NGHIEM, P; DONG, Y; GARDNER, P				MALDONADO, D; SCHUMANN, M; NGHIEM, P; DONG, Y; GARDNER, P			PROSTAGLANDIN-E1 ACTIVATES A CHLORIDE CURRENT IN JURKAT-T LYMPHOCYTES VIA CAMP-DEPENDENT PROTEIN-KINASE	FASEB JOURNAL			English	Article						CYCLIC AMP; CYSTIC FIBROSIS; ION CHANNEL; CHLORIDE CHANNEL	EPITHELIAL-CELL LINE; CYSTIC-FIBROSIS; CYCLIC-AMP; IMMUNE-RESPONSE; CHANNELS; CONDUCTANCE; CA-2+; PHOSPHORYLATION; MODULATION; INHIBITION	Patch-clamp studies have identified a cAMP-dependent Cl- conductance in lymphocytes that is defectively regulated in cystic fibrosis. In this study we used I-125 efflux and whole-cell patch-clamp studies to investigate whether prostaglandin E1 (PGE1), an agonist that generates intracellular cAMP in Jurkat T lymphocytes, activates a Cl- conductance. Stimulation of T cells by externally applied PGE, stimulated I-125 efflux and activated a slowly developing membrane current. When external and internal Cl- were about equal, the current reversed at about zero mV, but when external Cl- was lowered from 157 to 7 mM the reversal potential shifted 75 mV in the positive direction, demonstrating that the current carrier was Cl-. In addition, the current was blocked by 10-mu-M 5-nitro-2(3-phenylpropylamino) benzoic acid (NPPB), a potent Cl- channel blocker. A membrane-permeable cAMP analog mimicked the effect of PGE1, whereas intracellular application of a cAMP antagonist Rp-cAMP blocked the effect of PGE1. Addition of purified catalytic subunit of cAMP-dependent protein kinase (PKA) plus ATP to the recording pipette also activated a similar current, whereas internally applied Walsh inhibitor, the synthetic peptide inhibitor of PKA, blocked the PGE1 effect. These results suggest that PGE1, acting through PKA, activates a Cl- current in Jurkat T cells.	STANFORD UNIV, MED CTR,SCH MED,FALK CARDIOVASC RES CTR,DEPT MED, STANFORD, CA 94305 USA	Stanford University			Nghiem, Paul T/A-9210-2011	Nghiem, Paul T/0000-0003-2784-963X	NCI NIH HHS [CA09302] Funding Source: Medline; NIDDK NIH HHS [DK41324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BAKER PE, 1981, CELL IMMUNOL, V61, P52, DOI 10.1016/0008-8749(81)90353-1; Beavo J A, 1974, Methods Enzymol, V38, P299; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BUBIEN JK, 1990, SCIENCE, V248, P1416, DOI 10.1126/science.2162561; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHENG HC, 1986, J BIOL CHEM, V261, P989; CLANCY J P, 1989, FASEB Journal, V3, pA562; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DAILEY MO, 1988, J IMMUNOL, V140, P2931; DEMAREST JR, 1989, SCIENCE, V245, P402, DOI 10.1126/science.2474200; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; FRANCIOLINI F, 1990, BIOCHIM BIOPHYS ACTA, V1031, P247, DOI 10.1016/0304-4157(90)90009-2; GOODWIN JS, 1979, CELL IMMUNOL, V43, P150, DOI 10.1016/0008-8749(79)90158-8; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; GOODWIN JS, 1977, NEW ENGL J MED, V197, P263; GRAY LS, 1986, J IMMUNOL, V136, P3032; GREGER R, 1989, ANN NY ACAD SCI, V574, P403; GRINSTEIN S, 1984, AM J PHYSIOL, V246, pC204, DOI 10.1152/ajpcell.1984.246.3.C204; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HESCHELER J, 1987, PFLUG ARCH EUR J PHY, V410, P23, DOI 10.1007/BF00581891; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JENTSCH TJ, 1989, BIOCHEM J, V261, P155, DOI 10.1042/bj2610155; KAILA K, 1987, NATURE, V330, P163, DOI 10.1038/330163a0; KELLY RH, 1982, AGENTS ACTIONS, V12, P471, DOI 10.1007/BF01965929; KIRBY PJ, 1976, PROSTAGLANDINS, V11, P621, DOI 10.1016/0090-6980(76)90065-4; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KORCHAK HM, 1980, P NATL ACAD SCI-BIOL, V77, P2721, DOI 10.1073/pnas.77.5.2721; LEE SC, 1988, AM J PHYSIOL, V254, pC286, DOI 10.1152/ajpcell.1988.254.2.C286; LEVITAN IB, 1985, J MEMBRANE BIOL, V87, P177, DOI 10.1007/BF01871217; LEWIS RS, 1987, HESCJU, V51, pA397; LI M, 1989, SCIENCE, V244, P1353, DOI 10.1126/science.2472006; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MAKOUL GT, 1985, J IMMUNO, V133, P1283; MARY D, 1989, J BIOL CHEM, V264, P14498; NORDSTEDT C, 1987, FEBS LETT, V220, P57, DOI 10.1016/0014-5793(87)80875-X; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSOFF PM, 1988, J BIOL CHEM, V263, P19535; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WELSH MJ, 1987, PHYSIOL REV, V67, P657; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; WOLINSKY SI, 1980, CLIN IMMUNOL IMMUNOP, V17, P31, DOI 10.1016/0090-1229(80)90070-7; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	48	15	15	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	1991	5	14					2965	2970		10.1096/fasebj.5.14.1721593	http://dx.doi.org/10.1096/fasebj.5.14.1721593			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GP269	1721593				2022-12-25	WOS:A1991GP26900012
J	SEELAN, RS; GROSSMAN, LI				SEELAN, RS; GROSSMAN, LI			CYTOCHROME-C-OXIDASE SUBUNIT-VIIA ISOFORMS - CHARACTERIZATION AND EXPRESSION OF BOVINE CDNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX-IV; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL MYOPATHIES; NUCLEOTIDE-SEQUENCE; SKELETAL-MUSCLE; 2 ISOFORMS; DEFICIENCY; GENES; DNA; HEART	Subunit VIIa of bovine cytochrome c oxidase occurs in two forms, the so-called heart and liver isoforms, which have been shown by protein analysis to differ in 35% of their amino acids. We have isolated and characterized cDNAs for each isoform. The derived heart-type processed protein is 59 amino acids long, with a 21-residue presequence; the immediate C terminus differs from the established protein sequence. The liver-type processed protein is 60 residues long, with a 23-amino acid presequence. Both presequences are traditional in that they are positively charged and appear amphiphilic when helically arrayed. The presequences are only 22% identical, but they both contain conserved residues indicative of two-step processing of the precursor proteins. Southern blot analysis reveals that the bovine genome contains five to six copies of the liver-type gene as opposed to the presence of a single copy heart-type gene. Transcriptional analysis shows that heart-type message is detectable only in heart and skeletal muscle; the liver type is also seen in heart and muscle and, additionally, in the other tissues examined (liver, brain, and lung). The amino acid sequence EKQKLFQED is conserved in rat and in both isoforms in cow and human and may represent a domain of core subunit function.	WAYNE STATE UNIV, SCH MED, DEPT MOLEC BIOL & GENET, DETROIT, MI 48201 USA	Wayne State University				Seelan, Ratnam/0000-0002-8925-1070	NCRR NIH HHS [RR05384] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANTHONY G, 1990, FEBS LETT, V277, P97, DOI 10.1016/0014-5793(90)80817-3; AQUA MS, 1991, IN PRESS GENE AMST; Battey, 1986, BASIC METHODS MOL BI; BLAKELY M, 1989, STRATAGIES, V2, P7; BRESOLIN N, 1985, NEUROLOGY, V35, P802, DOI 10.1212/WNL.35.6.802; CALDER KM, 1990, NUCLEIC ACIDS RES, V18, P1632, DOI 10.1093/nar/18.6.1632; CAPALDI RA, 1987, CURR TOP BIOENERG, V15, P91; CAPALDI RA, 1986, FEBS LETT, V207, P11, DOI 10.1016/0014-5793(86)80004-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCARELLI RB, 1984, CANCER RES, V44, P3892; CUMSKY MG, 1987, MOL CELL BIOL, V7, P3511, DOI 10.1128/MCB.7.10.3511; DIMAURO S, 1986, ANN NY ACAD SCI, V488, P19; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; ENDERS C, 1990, NUCLEIC ACIDS RES, V18, P7143, DOI 10.1093/nar/18.23.7143; FABRIZI GM, 1989, NUCLEIC ACIDS RES, V17, P7107, DOI 10.1093/nar/17.17.7107; FABRIZI GM, 1989, NUCLEIC ACIDS RES, V17, P6409, DOI 10.1093/nar/17.15.6409; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROSSMAN LI, 1990, AM J HUM GENET, V46, P415; HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADENBACH B, 1989, ORGANELLES IN EUKARYOTIC CELLS, P143; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KADENBACH B, 1990, BIOCHIM BIOPHYS ACTA, V1015, P368, DOI 10.1016/0005-2728(90)90042-3; KADENBACH B, 1983, ANGEW CHEM INT EDIT, V22, P275, DOI 10.1002/anie.198302751; KADENBACH B, 1983, ANAL BIOCHEM, V129, P517, DOI 10.1016/0003-2697(83)90586-9; KENNAWAY NG, 1990, PEDIATR RES, V28, P529; LIGHTOWLERS R, 1990, J BIOL CHEM, V265, P2677; LOMAX MI, 1989, TRENDS BIOCHEM SCI, V14, P501, DOI 10.1016/0968-0004(89)90185-0; LOMBES A, 1991, NEUROLOGY, V41, P491, DOI 10.1212/WNL.41.4.491; MEINECKE L, 1986, BIOL CHEM H-S, V367, P67, DOI 10.1515/bchm3.1986.367.1.67; MERLE P, 1982, EUR J BIOCHEM, V125, P239, DOI 10.1111/j.1432-1033.1982.tb06674.x; MIRANDA AF, 1989, NEUROLOGY, V39, P697, DOI 10.1212/WNL.39.5.697; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RIZZUTO R, 1989, J BIOL CHEM, V264, P10595; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SEELAN RS, 1989, NUCLEIC ACIDS RES, V17, P6410, DOI 10.1093/nar/17.15.6410; SEELAN RS, 1991, BIOTECHNIQUES, V10, P186; SMITH EO, 1991, BIOCHIM BIOPHYS ACTA, V1089, P266, DOI 10.1016/0167-4781(91)90022-E; TRISCHLER HJ, 1991, NEUROLOGY, V41, P300; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; VANBEEUMEN JJ, 1990, FEBS LETT, V263, P213, DOI 10.1016/0014-5793(90)81376-Y; VANKUILENBURG ABP, 1988, FEBS LETT, V240, P127, DOI 10.1016/0014-5793(88)80353-3; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WAGNER M, 1986, TRENDS GENET, V2, P134, DOI 10.1016/0168-9525(86)90203-9; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1991, GENES BRAIN BEHAV, P101; WATERLAND RA, 1991, J BIOL CHEM, V266, P4180; WIKSTROM M, 1981, ANNU REV BIOCHEM, V50, P623, DOI 10.1146/annurev.bi.50.070181.003203; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; ZHENG X, 1989, NEUROLOGY, V39, P1203, DOI 10.1212/WNL.39.9.1203	53	51	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19752	19757						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717471				2022-12-25	WOS:A1991GK66700090
J	CRABB, JW; GAUR, VP; GARWIN, GG; MARX, SV; CHAPLINE, C; JOHNSON, CM; SAARI, JC				CRABB, JW; GAUR, VP; GARWIN, GG; MARX, SV; CHAPLINE, C; JOHNSON, CM; SAARI, JC			TOPOLOGICAL AND EPITOPE MAPPING OF THE CELLULAR RETINALDEHYDE-BINDING PROTEIN FROM RETINA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE RETINA; ANTIGENIC DETERMINANTS; MONOCLONAL-ANTIBODIES; VITAMIN-A; SEQUENCE; LOCALIZATION; ADSORPTION; MEMBRANES; SURFACE; CELLS	Cellular retinaldehyde-binding protein (CRALBP) carries 11-cis-retinol or 11-cis-retinaldehyde as endogenous ligands and may function as a substrate carrier protein that modulates interaction of these retinoids with visual cycle enzymes. As a first approach to identifying functional domains and protein recognition sites in CRALBP, a low resolution topological and epitope map has been developed using monoclonal and polyclonal antibodies and limited proteolysis. Fifteen peptides of 8-31 residues spanning 99% of the 316-residue bovine CRALBP were synthesized and used to prepare 13 anti-peptide polyclonal antibodies. Using a competitive ELISA procedure, peptide epitopes were classified as either accessible or inaccessible in the native protein based on the extent of their recognition by these site-specific antibodies. Use of the synthetic peptides to map the epitopes of a polyclonal antibody to intact CRALBP confirmed that the amino terminus and carboxyl terminus are immunodominate regions and hence likely to be exposed, at least in part. Limited tryptic proteolysis of native CRALBP produced three major fragments which were shown by microsequence and Western analysis to be derived from sequential loss of short peptides from the amino terminus. None of these major fragments reacted with four monoclonal antibodies (mAbs) to intact CRALBP although each mAb immunoprecipitated native CRALBP. These results and the lack of mAb recognition of any of the synthetic peptides indicates that the amino terminus of the protein is exposed and contains part of an assembly epitope recognized by the mAbs. Overall this study indicates that residues 1-30, 100-124, and 257-285 contain highly exposed segments in the native protein and therefore constitute potential interaction domains for CRALBP and visual cycle enzymes. Residues 30-99 and 176-229 are inaccessible in the native structure and may be involved with retinoid binding. These results provide a basis for a systematic higher resolution mutagenesis study directed toward correlating CRALBP structural domains with function.	W ALTON JONES CELL SCI CTR,PROT CHEM FACIL,LAKE PLACID,NY 12946; UNIV WASHINGTON,SCH MED,DEPT OPHTHALMOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL EYE INSTITUTE [P30EY001730, R01EY003523] Funding Source: NIH RePORTER; NEI NIH HHS [EY01730, EY02317, EY03523] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AMIT AG, 1985, NATURE, V313, P156, DOI 10.1038/313156a0; ANDERSON AB, 1987, PROTEINS INTERFACES, P306; BARLOW DJ, 1986, NATURE, V322, P747, DOI 10.1038/322747a0; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BUNTMILAM AH, 1983, J CELL BIOL, V97, P703, DOI 10.1083/jcb.97.3.703; CHAPLINE C, 1989, 3RD S PROT SOC SEATT; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CRABB JW, 1988, J BIOL CHEM, V263, P18678; CRABB JW, 1988, J BIOL CHEM, V263, P18688; CRABB JW, 1991, FASEB J, V5, pA1173; DAVIES DR, 1988, J BIOL CHEM, V263, P10541; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DOWLING JE, 1960, NATURE, V163, P144; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FAZEKAS S, 1980, J IMMUNOL METHODS, V35, P1; GAUR VP, 1988, J NEUROCYTOL, V17, P683, DOI 10.1007/BF01260995; GAUR VP, 1990, EXP EYE RES, V50, P505, DOI 10.1016/0014-4835(90)90039-W; GEYSEN HM, 1986, CIBA F SYMP, V119, P130; HARFORD J, 1984, NATURE, V311, P673, DOI 10.1038/311673a0; HOLLANDER Z, 1986, MOL IMMUNOL, V23, P927, DOI 10.1016/0161-5890(86)90122-7; INTRES R, 1990, Investigative Ophthalmology and Visual Science, V31, P113; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT BC, 1987, CHEM SCRIPTA, V27, P185; LION F, 1975, BIOCHIM BIOPHYS ACTA, V384, P282; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P226, DOI 10.1073/pnas.83.2.226; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RICHARDS FM, 1959, J BIOL CHEM, V234, P1459; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; SAARI J C, 1990, Investigative Ophthalmology and Visual Science, V31, P111; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SAARI JC, 1982, J BIOL CHEM, V257, P13329; SAARI JC, 1987, J BIOL CHEM, V262, P7618; SAARI JC, 1982, BIOCHIM BIOPHYS ACTA, V716, P266, DOI 10.1016/0304-4165(82)90277-X; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SORIA J, 1985, J COLLOID INTERF SCI, V107, P204, DOI 10.1016/0021-9797(85)90163-8; STANKER LH, 1985, J IMMUNOL METHODS, V76, P157, DOI 10.1016/0022-1759(85)90488-0; WEST KA, 1990, CURRENT RES PROTEIN, P37	41	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16674	16683						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1715867				2022-12-25	WOS:A1991GD63500070
J	SUNDSETH, SS; WAXMAN, DJ				SUNDSETH, SS; WAXMAN, DJ			SEX-DEPENDENT EXPRESSION AND CLOFIBRATE INDUCIBILITY OF CYTOCHROME-P450 4A FATTY-ACID OMEGA-HYDROXYLASES - MALE SPECIFICITY OF LIVER AND KIDNEY CYP4A2 MESSENGER-RNA AND TISSUE-SPECIFIC REGULATION BY GROWTH-HORMONE AND TESTOSTERONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; RAT-LIVER; ARACHIDONIC-ACID; GENE-EXPRESSION; LAURIC ACID; TRANSCRIPTIONAL REGULATION; PHENOBARBITAL INDUCTION; RENAL CYTOCHROME-P-450; COMPLEMENTARY-DNA; P-450 FORMS	The induction of liver cytochrome P450 4A-catalyzed fatty acid omega-hydroxylase activity by clofibrate and other peroxisome proliferators has been proposed to be causally linked to the ensuing proliferation of peroxisomes in rat liver. Since female rats are less responsive than males to peroxisome proliferation induced by clofibrate, the influence of gender and hormonal status on the basal and clofibrate-inducible expression of the 4A P450s was examined. Northern blot analysis using gene-specific oligonucleotide probes revealed that in the liver, P450 4A1 and 4A3 mRNAs are induced to a much greater extent in male as compared to female rats following clofibrate treatment, whereas P450 4A2 mRNA is altogether absent from female rat liver. Male-specific expression of P450 4A2 mRNA was also observed in kidney. Western blot analysis indicated that a similar sex dependence characterizes both the basal expression and the clofibrate inducibility of the corresponding P450 4A proteins. This suggests that the lower responsiveness of female rats to clofibrate-induced peroxisome proliferation may reflect the lower inducibility of the P450 4A fatty acid hydroxylase enzymes in this sex. Investigation of the contribution of pituitary-dependent hormones to the male-specific expression of 4A2 revealed that this P450 mRNA is fully suppressed in liver following exposure to the continuous plasma growth hormone profile that characterizes adult female rats; in this and other regards liver P450 4A2 is regulated in a manner that is similar, but not identical to, P450 3A2, a male-specific testosterone 6 beta-hydroxylase. In contrast, kidney 4A2 expression, although also male-specific, was not suppressed by continuous growth hormone treatment, but was regulated by pathways that, in part, involve testosterone as a positive regulator. The male-specific expression of liver and kidney P450 4A2 is thus under the control of distinct pituitary-dependent hormones acting in a tissue-specific manner.	HARVARD UNIV, SCH MED,DANA FARBER CANC INST,RM JF-525, 44 BINNEY ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Waxman, David/0000-0001-7982-9206; Sundseth, Scott/0000-0002-3122-4862	NIDDK NIH HHS [DK 33765, R01 DK033765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOYAMA T, 1990, J LIPID RES, V31, P1477; CHAN WK, 1991, FASEB J, V5, pA1158; CHENG HC, 1986, J STEROID BIOCHEM, V24, P1061, DOI 10.1016/0022-4731(86)90360-2; CLARKE L, 1989, CANCER RES, V49, P2344; FAHL WE, 1984, P NATL ACAD SCI-BIOL, V81, P7827, DOI 10.1073/pnas.81.24.7827; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; Graham P R, 1973, Environ Health Perspect, V3, P3, DOI 10.2307/3428023; GRAY RH, 1984, HEPATOLOGY, V4, P520, DOI 10.1002/hep.1840040328; GUSTAFSSON JA, 1983, ANNU REV PHYSIOL, V45, P51, DOI 10.1146/annurev.ph.45.030183.000411; HARDWICK JP, 1987, J BIOL CHEM, V262, P801; HENDERSON CJ, 1990, BIOCHEM J, V266, P675, DOI 10.1042/bj2660675; HONG JY, 1989, CANCER RES, V49, P2973; IMAOKA S, 1990, ARCH BIOCHEM BIOPHYS, V278, P168, DOI 10.1016/0003-9861(90)90245-T; IMAOKA S, 1989, BIOCHEM INT, V18, P731; IMAOKA S, 1990, BIOCHIM BIOPHYS ACTA, V1036, P18, DOI 10.1016/0304-4165(90)90208-E; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; IWAI N, 1991, HYPERTENSION, V17, P161, DOI 10.1161/01.HYP.17.2.161; KATO R, 1986, J BIOCHEM-TOKYO, V100, P895, DOI 10.1093/oxfordjournals.jbchem.a121802; KAWASHIMA Y, 1989, BIOCHEM J, V261, P595, DOI 10.1042/bj2610595; KIMURA S, 1989, DNA-J MOLEC CELL BIO, V8, P517, DOI 10.1089/dna.1.1989.8.517; LAPUERTA L, 1988, AM J MED SCI, V295, P275, DOI 10.1097/00000441-198804000-00010; LEBLANC GA, 1988, J BIOL CHEM, V263, P15732; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MARKWELL MA, 1973, J BIOL CHEM, V248, P3426; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MCCLELLANGREEN PD, 1989, J BIOL CHEM, V264, P18960; MILTON MN, 1990, BIOCHEM PHARMACOL, V40, P2727, DOI 10.1016/0006-2952(90)90594-B; MORGAN ET, 1985, J BIOL CHEM, V260, P1895; MURAYAMA N, 1991, MOL PHARMACOL, V39, P811; NEMALI MR, 1988, CANCER RES, V48, P5316; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OMIECINSKI CJ, 1985, J BIOL CHEM, V260, P3247; RAM PA, 1990, J BIOL CHEM, V265, P19223; RAM PA, 1991, MOL ENDOCRINOL, V5, P13, DOI 10.1210/mend-5-1-13; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1989, MUTAT RES, V214, P63, DOI 10.1016/0027-5107(89)90198-X; REDDY JK, 1979, J BIOCHEM, V85, P847; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; ROFFEY SJ, 1990, FOOD CHEM TOXICOL, V28, P403, DOI 10.1016/0278-6915(90)90086-3; SAVOY C, 1990, 12TH EUR WORKSH DRUG; SCHUETZ EG, 1990, J BIOL CHEM, V265, P1188; SCHWARTZMAN ML, 1990, KIDNEY INT, V37, P94, DOI 10.1038/ki.1990.13; SHAPIRO BH, 1988, TOXICOL LETT, V44, P315, DOI 10.1016/0378-4274(88)90171-3; SHARMA R, 1988, BIOCHEM PHARMACOL, V37, P1193, DOI 10.1016/0006-2952(88)90770-8; SONG BJ, 1986, J BIOL CHEM, V261, P6689; SQUIRES EJ, 1988, J BIOL CHEM, V263, P4166; SUNDSETH SS, 1990, J BIOL CHEM, V265, P15090; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; TIONG TS, 1989, BIOCHEM BIOPH RES CO, V158, P141, DOI 10.1016/S0006-291X(89)80189-5; WAXMAN DJ, 1986, ARCH BIOCHEM BIOPHYS, V247, P335, DOI 10.1016/0003-9861(86)90592-8; WAXMAN DJ, 1991, METHOD ENZYMOL, V206, P249; WAXMAN DJ, 1990, BIOCHEM J, V271, P113, DOI 10.1042/bj2710113; WAXMAN DJ, 1988, BIOCHEM PHARMACOL, V37, P71, DOI 10.1016/0006-2952(88)90756-3; WAXMAN DJ, 1990, MOL ENDOCRINOL, V4, P447, DOI 10.1210/mend-4-3-447; WAXMAN DJ, 1989, ENDOCRINOLOGY, V124, P2954, DOI 10.1210/endo-124-6-2954; WAXMAN DJ, 1988, J BIOL CHEM, V263, P11396; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; YAMAZOE Y, 1987, J BIOL CHEM, V262, P7423; ZAPHIROPOULOS PG, 1989, TRENDS PHARMACOL SCI, V10, P149, DOI 10.1016/0165-6147(89)90167-3	60	198	199	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3915	3921						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740439				2022-12-25	WOS:A1992HE60700058
J	IKEDA, RA; LIN, AC; CLARKE, J				IKEDA, RA; LIN, AC; CLARKE, J			INITIATION OF TRANSCRIPTION BY T7-RNA POLYMERASE AT ITS NATURAL PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T7 RNA-POLYMERASE; BACTERIOPHAGE-T7 LATE PROMOTERS; RIBONUCLEIC-ACID POLYMERASE; LAC UV5 PROMOTER; NUCLEOTIDE-SEQUENCE; ENZYMATIC-REACTION; POINT MUTATIONS; DNA; BINDING; EXPRESSION	A kinetic assay has been developed to measure the strength of natural T7 promoters. By determining the rate of appearance of initiation products in the presence of constant concentrations of T7 RNA polymerase, an incomplete mixture of ribonucleoside triphosphates, and increasing promoter concentrations, a maximum rate of product formation (V(max)) and a promoter concentration giving half of the maximal activity ([P]V(max/2)) can be determined for any cloned T7 promoter. On supercoiled plasmids, it was found that the [P]V(max/2) measured for the six promoters phi-1.1B, phi-1.3, phi-3.8, phi-6.5, phi-10, and phi-13 ranged from 3.4 +/- 1.1 to 12.0 +/- 2.4 nm while the V(max) values showed no significant trends. On plasmids that had been linearized by cleavage at a single site with a restriction endonuclease, the cloned T7 promoters assayed fell into two broad classes that appear to be characterized by the T7 class II and III promoters. Generally, the class II promoters required higher promoter concentrations to produce half of the maximum rates of initiation ([P] V(max/2) values) than the class III promoters. The [P]V(max/2) values for the class II promoters ranged from 20 +/- 2.7 to 23 +/- 3.6 nM, while the [P]V(max/2) values for the class III promoters phi-10 and phi-13 were 13 +/- 1.6 nM and 7.8 +/- 1.4 nM. The one exception is the class III promoter phi-6.5 whose [P] V(max/2) (17 +/- 5 nM) falls between the [P]V(max/2) values of the class II promoters and the strong class III promoters. The V(max) values measured on linear templates are variable, but it appears that phi-10 is more active than the other five promoters.			IKEDA, RA (corresponding author), GEORGIA INST TECHNOL,SCH CHEM & BIOCHEM,ATLANTA,GA 30332, USA.			Ikeda, Richard/0000-0003-4015-5528	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024905] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24905] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASU S, 1986, J MOL BIOL, V190, P425, DOI 10.1016/0022-2836(86)90013-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2235; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2245; CHAMBERLIN M, 1982, ENZYMES, V15, P92; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHAPMAN KA, 1982, NUCLEIC ACIDS RES, V10, P6331, DOI 10.1093/nar/10.20.6331; CHAPMAN KA, 1987, NUCLEIC ACIDS RES, V15, P5413, DOI 10.1093/nar/15.13.5413; CHAPMAN KA, 1988, NUCLEIC ACIDS RES, V16, P4511, DOI 10.1093/nar/16.10.4511; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; GOULOMB M, 1974, P NATL ACAD SCI USA, V71, P760; GUNDERSON SI, 1987, BIOCHEMISTRY-US, V26, P1539, DOI 10.1021/bi00380a007; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Johnston D. E., 1976, RNA POLYMERASE, P413; JOLLIFFE LK, 1982, NATURE, V299, P653, DOI 10.1038/299653a0; LING ML, 1989, NUCLEIC ACIDS RES, V17, P1605, DOI 10.1093/nar/17.4.1605; Maniatis T., 1982, MOL CLONING; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; MARTIN CT, 1989, BIOCHEMISTRY-US, V28, P2760, DOI 10.1021/bi00433a002; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCALLISTER WT, 1978, P NATL ACAD SCI USA, V75, P804, DOI 10.1073/pnas.75.2.804; MCALLISTER WT, 1980, NUCLEIC ACIDS RES, V8, P4821, DOI 10.1093/nar/8.20.4821; MCALLISTER WT, 1981, J MOL BIOL, V153, P527, DOI 10.1016/0022-2836(81)90406-X; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MOFFATT BA, 1984, J MOL BIOL, V173, P265, DOI 10.1016/0022-2836(84)90194-3; MOOKHTIAR KA, 1991, BIOCHEMISTRY-US, V30, P6305, DOI 10.1021/bi00239a032; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; MULLER DK, 1989, BIOCHEMISTRY-US, V28, P3306, DOI 10.1021/bi00434a028; NILES EG, 1975, J MOL BIOL, V98, P57, DOI 10.1016/S0022-2836(75)80101-X; OAKLEY JL, 1979, BIOCHEMISTRY-US, V18, P528, DOI 10.1021/bi00570a023; RABKIN SD, 1988, J MOL BIOL, V204, P903, DOI 10.1016/0022-2836(88)90050-2; RANDERATH K, 1964, J CHROMATOGR, V16, P111, DOI 10.1016/S0021-9673(01)82445-6; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; SCHENBORN ET, 1985, NUCLEIC ACIDS RES, V13, P6223, DOI 10.1093/nar/13.17.6223; SMEEKENS SP, 1986, NUCLEIC ACIDS RES, V14, P2811, DOI 10.1093/nar/14.6.2811; STAHL SJ, 1981, J MOL BIOL, V148, P481, DOI 10.1016/0022-2836(81)90187-X; STRANEY DC, 1985, CELL, V43, P449, DOI 10.1016/0092-8674(85)90175-8; STROTHKAMP RE, 1980, BIOCHEMISTRY-US, V9, P1074; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367; STUDIER FW, 1982, COLD SPRING HARB SYM, V47, P999, DOI 10.1101/SQB.1983.047.01.114; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	52	27	34	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2640	2649						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733960				2022-12-25	WOS:A1992HB53200082
J	FUJIOKA, H; KAIBUCHI, K; KISHI, K; YAMAMOTO, T; KAWAMURA, M; SAKODA, T; MIZUNO, T; TAKAI, Y				FUJIOKA, H; KAIBUCHI, K; KISHI, K; YAMAMOTO, T; KAWAMURA, M; SAKODA, T; MIZUNO, T; TAKAI, Y			TRANSFORMING AND C-FOS PROMOTER ENHANCER-STIMULATING ACTIVITIES OF A STIMULATORY GDP GTP EXCHANGE PROTEIN FOR SMALL GTP-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-RESPONSE ELEMENT; KINASE-C; RAS P21; GENE-EXPRESSION; MAMMALIAN-CELLS; GROWTH-FACTOR; SMG P21; ACTIVATION; DOMAIN; GAP	smg GDP dissociation stimulator (GDS) is a stimulatory GDP/GTP exchange protein for a group of ras p21-like small GTP-binding proteins (G proteins) including c-Ki-ras p21, smg p21A, smg p21B, and rhoA p21. smg GDS converts the GDP-bound inactive form to the GTP-bound active form of each small G protein by stimulating their GDP/GTP exchange reaction in a cell-free system. The point-mutated c-Ki-ras p21 (c-Ki-ras(val12) p21) is known to strongly transform NIH/3T3 cells and to markedly stimulate the c-fos promoter/enhancer in this cell line, whereas the normal c-Ki-ras p21 is weak in these activities. In the present study, we examined the effect of smg GDS on these activities to explore its physiological function. Overexpression of both smg GDS and c-Ki-ras p21 strongly transformed NIH/3T3 cells, whereas overexpression of either smg GDS or c-Ki-ras p21 alone weakly transformed the cells. Furthermore, overexpression of both smg GDS and c-Ki-ras p21 markedly stimulated the c-fos promoter/enhancer in NIH/3T3 cells, whereas overexpression of either smg GDS or c-Ki-ras p21 alone weakly stimulated it. These results indicate that smg GDS transforms NIH/3T3 cells and stimulates the c-fos promoter/enhancer in this cell line in cooperation with c-Ki-ras p21.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HATA Y, 1991, J BIOL CHEM, V266, P6571; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; ITOH T, 1991, BIOCHEM BIOPH RES CO, V177, P1319, DOI 10.1016/0006-291X(91)90685-Z; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAWATA M, 1989, J BIOL CHEM, V264, P15688; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; OKU N, 1990, FEBS LETT, V269, P148, DOI 10.1016/0014-5793(90)81141-A; REY I, 1991, ONCOGENE, V6, P347; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1988, FEBS LETT, V236, P185, DOI 10.1016/0014-5793(88)80311-9; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; TAKAI Y, 1991, IN PRESS INT REV CYT; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YOSHIDA K, 1988, CANCER RES, V48, P5503	32	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					926	930						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730682				2022-12-25	WOS:A1992GY96000040
J	ACCILI, D; KADOWAKI, T; KADOWAKI, H; MOSTHAF, L; ULLRICH, A; TAYLOR, SI				ACCILI, D; KADOWAKI, T; KADOWAKI, H; MOSTHAF, L; ULLRICH, A; TAYLOR, SI			IMMUNOGLOBULIN HEAVY CHAIN-BINDING PROTEIN BINDS TO MISFOLDED MUTANT INSULIN-RECEPTORS WITH MUTATIONS IN THE EXTRACELLULAR DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY LIPOPROTEIN RECEPTOR; INTRACELLULAR-TRANSPORT; IMPAIRS TRANSPORT; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; KINASE-ACTIVITY; CYSTEINE-RICH; CELL-SURFACE; FORMS; GLYCOSYLATION	Cell-surface proteins are transported through the endoplasmic reticulum and Golgi apparatus en route to the plasma membrane. Previously, we have identified three point mutations in the insulin receptor gene that impair transport of the mutant receptors to the cell surface: Asn15 --> Lys, His209 --> Arg, and Phe382 --> Val. Furthermore, these mutations impair post-translational processing steps that normally occur as the receptors are transported through the endoplasmic reticulum and Golgi apparatus. In this study, we have demonstrated that the unprocessed Arg209 and Val382 mutant proreceptors are bound to the immunoglobulin heavy chain-binding protein (BiP) in the endoplasmic reticulum. This was demonstrated by the fact that monoclonal anti-BiP antibody coimmunoprecipitated the mutant proreceptors. Moreover, when ATP was added to the immunoprecipitates, the mutant proreceptors were released from BiP. In contrast, neither the normal human insulin receptor nor the Lys15 mutant proreceptor was coimmunoprecipitated by anti-BiP antibody. It seems likely that the Lys 15 receptor also binds BiP, but that the affinity was too low to resist dissociation during the stringent washing of the immmunoprecipitate. In conclusion, these observation are consistent with the hypothesis that binding to BiP explains the impaired transport of mutant receptors through the endoplasmic reticulum and Golgi apparatus to the plasma membrane.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,W-8033 MARTINSRIED,GERMANY	Max Planck Society	ACCILI, D (corresponding author), NIDDKD,DIABET BRANCH,BLDG 10,RM 8S-243,BETHESDA,MD 20892, USA.							ACCILI D, 1991, J BIOL CHEM, V266, P434; ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BHAVANANDAN VP, 1979, J BIOL CHEM, V254, P4000; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CAMA A, 1987, DIABETOLOGIA, V30, P631; DEUTSCH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P133, DOI 10.1073/pnas.80.1.133; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ESSER V, 1988, J BIOL CHEM, V263, P13282; ESSER V, 1988, J BIOL CHEM, V263, P13276; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HEDO JA, 1981, P NATL ACAD SCI-BIOL, V78, P4791, DOI 10.1073/pnas.78.8.4791; HEDO JA, 1983, J BIOL CHEM, V258, P20; JACOBS S, 1983, P NATL ACAD SCI-BIOL, V80, P1228, DOI 10.1073/pnas.80.5.1228; KADOWAKI T, 1990, J CLIN INVEST, V86, P254, DOI 10.1172/JCI114693; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KADOWAKI T, 1990, J BIOL CHEM, V265, P19143; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RONNETT GV, 1983, J BIOL CHEM, V258, P283; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH J, 1983, HARVEY LECT, V22, P81; Taylor S I, 1990, Recent Prog Horm Res, V46, P185; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466	30	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					586	590						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730618				2022-12-25	WOS:A1992GY43900091
J	KIM, HK; STORCH, J				KIM, HK; STORCH, J			FREE FATTY-ACID TRANSFER FROM RAT-LIVER FATTY ACID-BINDING PROTEIN TO PHOSPHOLIPID-VESICLES - EFFECT OF LIGAND AND SOLUTION PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; UNILAMELLAR VESICLES; HEART; PURIFICATION; CHOLESTEROL; EXPRESSION; PALMITATE; INTESTINE; ADIPOCYTE; MECHANISM	Fatty acid binding proteins (FABP) are a family of 14-15-kDa proteins found in many mammalian cell types in high abundance. Although their precise physiological role remains hypothetical, the transfer of free fatty acids (ffa) to intracellular membrane sites is believed to be an important function of FABP. To better understand the role of FABP in this process, we have examined how the rate of ffa transfer from liver FABP (L-FABP) to model membranes is influenced by variations in ffa structure and properties of the aqueous phase. The rate of transfer of fluorescent anthroyloxy ffa to model acceptor membranes was monitored using a resonance energy transfer assay. The results show that a monounsaturated ffa transfers 2-fold more rapidly than a saturated ffa of equivalent chain length, and a two-carbon increase in acyl chain length results in a 3-fold decrease in transfer rate. The transfer rate decreases logarithmically with increasing ionic strength, suggesting that the aqueous solubility of the ffa is an important determinant of its dissociation rate from L-FABP. Fatty acid binding and the relative partition of n-(9-anthroloxy) ffa to L-FABP as compared with phospholipid membranes both decrease as pH decreases, indicating that ionized but not protonated ffa bind to L-FABP. The rate of ffa transfer from L-FABP to membranes increases approximately 4-fold with increasing pH, suggesting that ionization of the ffa carboxyl group is also an important determinant of the transfer process. Analysis of the dependence of the transfer rate on temperature demonstrates that the DELTA-G of the activated state for ffa transfer arises from both enthalpic and entropic processes. These studies demonstrate that the rate of transfer of long chain ffa from L-FABP to membranes is substantially affected by aqueous phase variables as well as properties of the ffa ligand itself.	HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,665 HUNTINGTON AVE,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health				Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038389, R29DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38389, R01 DK038389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASS NM, 1986, BIOCHEM BIOPH RES CO, V137, P929, DOI 10.1016/0006-291X(86)90314-1; BASS NM, 1985, J BIOL CHEM, V260, P1432; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; CHARLTON SC, 1982, BIOCHEMISTRY-US, V21, P4023, DOI 10.1021/bi00260a018; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; CISTOLA DP, 1989, BIOCHEMISTRY-US, V28, P3628, DOI 10.1021/bi00434a072; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P711, DOI 10.1021/bi00402a033; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; CRISMAN TS, 1987, J MOL CELL CARDIOL, V19, P423, DOI 10.1016/S0022-2828(87)80394-2; DAWIDOWICZ EA, 1987, CURR TOP MEMBR TRANS, V29, P175; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; GLASSTONE S, 1941, THEORY RATE PROCESSE; GLATZ JFC, 1984, J BIOL CHEM, V259, P4295; GLATZ JFC, 1985, INT J BIOCHEM, V17, P13, DOI 10.1016/0020-711X(85)90080-1; GLATZ JFC, 1985, BIOCHIM BIOPHYS ACTA, V837, P57, DOI 10.1016/0005-2760(85)90085-2; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; Gomori G, 1942, J LAB CLIN MED, V27, P955; HAQ RU, 1983, NUTR RES, V3, P329; HAUNERLAND N, 1984, HOPPESEYLERS Z PHYSL, V365, P367; HUANG C, 1974, METHOD ENZYMOL, V32, P212; JEFFERSON JR, 1991, J BIOL CHEM, V266, P5486; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KAWASHIMA Y, 1983, BIOCHIM BIOPHYS ACTA, V754, P21, DOI 10.1016/0005-2760(83)90077-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG FA, 1952, CHEM REV, V51, P119, DOI 10.1021/cr60158a004; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MASSEY JB, 1982, BIOCHEMISTRY-US, V21, P3630, DOI 10.1021/bi00258a016; MCLEAN LR, 1984, BIOCHIM BIOPHYS ACTA, V776, P21, DOI 10.1016/0005-2736(84)90246-3; MISHKIN S, 1972, BIOCHEM BIOPH RES CO, V47, P997, DOI 10.1016/0006-291X(72)90931-X; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; OFFNER GD, 1986, J BIOL CHEM, V261, P5584; POWNALL HJ, 1983, J AM CHEM SOC, V105, P2440, DOI 10.1021/ja00346a055; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SCHULENBERGSCHELL H, 1988, EUR J BIOCHEM, V170, P565, DOI 10.1111/j.1432-1033.1988.tb13735.x; STORCH J, 1990, J BIOL CHEM, V265, P7827; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P8708; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; WAGGONER DW, 1990, J BIOL CHEM, V265, P11417; WILKINSON TCI, 1987, BIOCHEM J, V247, P485, DOI 10.1042/bj2470485; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001	45	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					77	82						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730626				2022-12-25	WOS:A1992GY43900018
J	TAKAHARA, H; KUSUBATA, M; TSUCHIDA, M; KOHSAKA, T; TAGAMI, S; SUGAWARA, K				TAKAHARA, H; KUSUBATA, M; TSUCHIDA, M; KOHSAKA, T; TAGAMI, S; SUGAWARA, K			EXPRESSION OF PEPTIDYLARGININE DEIMINASE IN THE UTERINE EPITHELIAL-CELLS OF MOUSE IS DEPENDENT ON ESTROGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; ARGININE RESIDUE; PROTEINS; RAT; PURIFICATION; TRYPSIN; ENZYME; UTERUS; IDENTIFICATION; CHYMOTRYPSIN	The effects of the steroid hormones estrogen and progesterone on peptidylarginine deiminase protein-L-arginine iminohydrolase, EC 3.5.3.15) levels in adult ovariectomized mouse uterus were studied. The amount of the enzyme in the uterus was considerably diminished by ovariectomy. When the mice were injected with a variety of estrogenic compounds, 17-beta-estradiol-3-benzoate, which was the most potent stimulator of uterine cell proliferation among the estrogens tested, dramatically elevated the enzyme formation of the uterus in a dose- and time-dependent fashion. Results of immunohistochemistry with the antiserum against mouse peptidylarginine deiminase demonstrated that the induction of the enzyme by the estradiol exclusively occurred at the luminal and glandular epithelia, corresponding with the previous findings in the normal estrous cycle. Furthermore, administration of the estradiol significantly increased the content of mRNA coding for peptidylarginine deiminase in uterus, indicating the evidence of regulation in pretranslation. On the other hand, progesterone alone did not restore the enzyme level of the ovariectomized mouse, but moderated the action of estrogen when given in concert with estrogen. Thus, the expression of peptidylarginine deiminase in luminal and glandular epithelia of mouse uterus is controlled by the amount of the steroid hormones estrogen and progesterone.	IBARAKI UNIV, FAC AGR, ANIM REPROD LAB, AMI, IBARAKI 30003, JAPAN	Ibaraki University	TAKAHARA, H (corresponding author), IBARAKI UNIV, FAC AGR, DEPT RESOURCE BIOL, BIOCHEM LAB, AMI, IBARAKI 30003, JAPAN.		Kohsaka, Tetsuya/I-1377-2019	Kohsaka, Tetsuya/0000-0001-9093-8243; Takahara, Hidenari/0000-0003-2373-8588				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cook B., 1976, Reproductive physiology of mammals and birds, by A.V. Nalbandov., P181; DONOHUE TM, 1983, BIOCHIM BIOPHYS ACTA, V739, P148, DOI 10.1016/0167-4781(83)90024-6; INAGAKI M, 1989, J BIOL CHEM, V264, P18119; JAZIN EE, 1988, ENDOCRINOLOGY, V122, P500, DOI 10.1210/endo-122-2-500; KNEIFEL MA, 1982, ENDOCRINOLOGY, V111, P493, DOI 10.1210/endo-111-2-493; KUBILUS J, 1985, J INVEST DERMATOL, V85, P232, DOI 10.1111/1523-1747.ep12276694; KUBILUS J, 1983, BIOCHIM BIOPHYS ACTA, V745, P285, DOI 10.1016/0167-4838(83)90060-2; KUROKAWA T, 1987, J BIOCHEM-TOKYO, V101, P1361, DOI 10.1093/oxfordjournals.jbchem.a122004; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LYTTLE CR, 1977, P NATL ACAD SCI USA, V74, P3162, DOI 10.1073/pnas.74.8.3162; MARTIN L, 1973, J ENDOCRINOL, V56, P133, DOI 10.1677/joe.0.0560133; MURPHY LJ, 1988, ENDOCRINOLOGY, V122, P325, DOI 10.1210/endo-122-1-325; NELSON JD, 1975, ARCH BIOCHEM BIOPHYS, V169, P181, DOI 10.1016/0003-9861(75)90331-8; NILSSON O, 1959, J ULTRA MOL STRUCT R, V2, P331, DOI 10.1016/S0022-5320(59)80005-8; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; Sambrook J, 1989, MOL CLONING LABORATO; SENSHU T, 1989, ENDOCRINOLOGY, V124, P2666, DOI 10.1210/endo-124-6-2666; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; SUNDSTROM SA, 1989, J BIOL CHEM, V264, P16941; TAKAHARA H, 1983, J BIOCHEM, V94, P1945, DOI 10.1093/oxfordjournals.jbchem.a134548; TAKAHARA H, 1986, AGR BIOL CHEM TOKYO, V50, P1303, DOI 10.1080/00021369.1986.10867548; TAKAHARA H, 1989, J BIOL CHEM, V264, P13361; TAKAHARA H, 1987, AGR BIOL CHEM TOKYO, V51, P1657, DOI 10.1080/00021369.1987.10868246; TAKAHARA H, 1986, AGR BIOL CHEM TOKYO, V50, P2899, DOI 10.1080/00021369.1986.10867830; TAKAHARA H, 1985, J BIOL CHEM, V260, P8378; TAKEDA A, 1988, ENDOCRINOLOGY, V122, P105, DOI 10.1210/endo-122-1-105; TSUCHIDA M, 1991, AGR BIOL CHEM TOKYO, V55, P295, DOI 10.1080/00021369.1991.10870549; WATANABE K, 1988, BIOCHIM BIOPHYS ACTA, V966, P375, DOI 10.1016/0304-4165(88)90088-8; WHEELER C, 1987, ENDOCRINOLOGY, V120, P919, DOI 10.1210/endo-120-3-919	33	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					520	525						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730614				2022-12-25	WOS:A1992GY43900083
J	ASANO, K; MORIWAKI, H; MIZOBUCHI, K				ASANO, K; MORIWAKI, H; MIZOBUCHI, K			AN INDUCED MESSENGER-RNA SECONDARY STRUCTURE ENHANCES REPZ TRANSLATION IN PLASMID COLIB-P9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE-EXPRESSION; LEADER PEPTIDE; CLONING; DNA; INITIATION; SEQUENCE; PROTEIN; ACID; IDENTIFICATION	Translation of the repZ gene encoding a DNA replication initiation protein of plasmid ColIb-P9 depends on not only the translation of a transcribed leader sequence (repY) but also the specific intergenic base pairing within RepZ mRNA between two short complementary sequences located in the repY and inc gene regions. In addition, repZ translation can be negatively regulated by Inc RNA, the product of the inc gene and a countertranscript to RepZ mRNA. Here we present evidence indicating that a stable secondary structure of RepZ mRNA, designated as structure III, sequesters one of the complementary sequences and the ribosome-binding site, thereby preventing repZ translation. When site-directed mutagenesis was used to destabilize structure III without changing the ribosome-binding site, a significant level of repZ expression was observed even in the absence of repY translation. Under these conditions, however, repZ expression could be substantially reduced by additional mutations that directly diminished the intergenic base pairing at the mRNA level between the two complementary sequences. These results indicate that repY translation is essential for the disruption of structure III by inducing the formation of a new secondary structure through the intergenic base pairing, and more importantly, that this new structure enhances repZ translation. We also found that the site of repY translation termination played a critical role in the intramolecular conformational alteration of structure III.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN	University of Tokyo								APPLEYARD RK, 1954, GENETICS, V39, P429; ASANO K, 1991, J BIOL CHEM, V266, P3774; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; COUTURIER M, 1988, MICROBIOL REV, V52, P375, DOI 10.1128/MMBR.52.3.375-395.1988; FIRPO MA, 1990, POSTTRANSCRIPTIONAL, P185; GALLIE DR, 1989, P NATL ACAD SCI USA, V86, P129, DOI 10.1073/pnas.86.1.129; GEGENHEIMER P, 1981, MICROBIOL REV, V45, P502, DOI 10.1128/MMBR.45.4.502-541.1981; GOLD L, 1988, ANNU REV BIOCHEM, V57, P199, DOI 10.1146/annurev.bi.57.070188.001215; HAMA C, 1990, J BACTERIOL, V172, P1983, DOI 10.1128/jb.172.4.1983-1991.1990; HAMA C, 1990, J BIOL CHEM, V265, P10666; KOLTER R, 1982, ANNU REV GENET, V16, P113, DOI 10.1146/annurev.ge.16.120182.000553; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MAYFORD M, 1990, J BACTERIOL, V172, P3772, DOI 10.1128/jb.172.7.3772-3779.1990; MCCARTHY JEG, 1985, EMBO J, V4, P519, DOI 10.1002/j.1460-2075.1985.tb03659.x; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Miller J.H., 1972, EXPT MOL GENETICS; MURRAY NE, 1974, NATURE, V251, P476, DOI 10.1038/251476a0; NARAYANAN CS, 1987, J BIOL CHEM, V262, P1756; OLINS PO, 1989, J BIOL CHEM, V264, P16973; PHILIPPE C, 1990, J MOL BIOL, V211, P415, DOI 10.1016/0022-2836(90)90362-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBA K, 1990, J BACTERIOL, V172, P1992, DOI 10.1128/jb.172.4.1992-1997.1990; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SPRENGART ML, 1990, NUCLEIC ACIDS RES, V18, P1719, DOI 10.1093/nar/18.7.1719; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAGNER EGH, 1987, EMBO J, V6, P515, DOI 10.1002/j.1460-2075.1987.tb04783.x	30	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24549	24556						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722206				2022-12-25	WOS:A1991GW84500049
J	EKRYLANDER, B; BILL, P; NORGARD, M; NILSSON, S; ANDERSSON, G				EKRYLANDER, B; BILL, P; NORGARD, M; NILSSON, S; ANDERSSON, G			CLONING, SEQUENCE, AND DEVELOPMENTAL EXPRESSION OF A TYPE-5, TARTRATE-RESISTANT, ACID-PHOSPHATASE OF RAT BONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ULTRASTRUCTURAL-LOCALIZATION; NUCLEOTIDE TRIPHOSPHATASE; SIMILARITY SEARCHES; MOLECULAR-CLONING; PEPTIDE SEQUENCES; PURIFICATION; PROTEIN; MARKER; SPLEEN; ATPASE	Tartrate-resistant acid phosphatase (TRAP) is a characteristic constituent of osteoclasts and some mononuclear preosteoclasts and, therefore, used as a histochemical and biochemical marker for osteoclasts and bone resorption. We now report the isolation of a 1397-base pair (bp) full-length TRAP/tartrate-resistant acid ATPase (TrATPase) cDNA clone from a neonatal rat calvaria lambda-gt11 cDNA library. The cDNA clone consists of a 92-bp untranslated 5'-flank, an open reading frame of 981 bp and a 324-bp untranslated 3'-poly(A)-containing region. The deduced protein sequence of 327 amino acids contains a putative cleavable signal sequence of 21 amino acids. The mature polypeptide of 306 amino acids has a calculated M(r) of 34,350 Da and a pI of 9.18, and it contains two potential N-glycosylation sites and the lysosomal targeting sequence DKRFQ. At the protein level, the sequence displays 89-94% homology to TRAP enzymes from human placenta, beef spleen, and uteroferrin and identity to the N terminus of purified rat bone TRAP/TrATPase. An N-terminal amino acid segment is strikingly homologous to the corresponding region in lysosomal and prostatic acid phosphatases. The cDNA recognized a 1.5-kilobase mRNA in long bones and calvaria, and in vitro translation using, as template, mRNA transcribed from the full-length insert yielded an immunoprecipitated product of 34 kDa. In neonatal rats, TRAP/TrATPase mRNA was highly expressed in skeletal tissues, with much lower (< 10%) levels detected in spleen, thymus, liver, skin, brain, kidney, brain, lung, and heart. In situ hybridization demonstrated specific labeling of osteoclasts at endostal surfaces and bone trabeculae of long bones. Thus, despite the apparent similarity of this osteoclastic TRAP/TrATPase with type 5, tartrate-resistant and purple, acid phosphatases expressed in other mammalian tissues, this gene appears to be preferentially expressed at skeletal sites.	KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT PATHOL,F42,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,SCH DENT,DEPT ORAL PATHOL,S-14186 HUDDINGE,SWEDEN; KARO BIO AB,NOVUM,HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet								ALLEN SH, 1989, J BONE MINER RES, V4, P47; ANDERSON TR, 1986, ARCH BIOCHEM BIOPHYS, V247, P131, DOI 10.1016/0003-9861(86)90541-2; ANDERSSON G, 1984, ARCH BIOCHEM BIOPHYS, V228, P431, DOI 10.1016/0003-9861(84)90007-9; ANDERSSON G, 1989, CONNECT TISSUE RES, V20, P151, DOI 10.3109/03008208909023883; ANDERSSON GN, 1986, J HISTOCHEM CYTOCHEM, V34, P293, DOI 10.1177/34.3.3005390; ANDERSSON GN, 1989, J HISTOCHEM CYTOCHEM, V37, P115, DOI 10.1177/37.1.2461980; BARON R, 1986, AM J PATHOL, V122, P363; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SA, 1989, J BONE MINER RES, V4, P399; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; EFSTRATIADIS T, 1985, ENZYME, V33, P34, DOI 10.1159/000469401; EKRYLANDER B, 1991, J BONE MINER RES, V6, P365; EKRYLANDER B, 1989, BONE MINER, V5, P309, DOI 10.1016/0169-6009(89)90009-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HAMMARSTROM LE, 1971, CLIN ORTHOPAEDICS, V78, P151; HARA A, 1985, COMP BIOCHEM PHYS B, V82, P269, DOI 10.1016/0305-0491(85)90239-1; HARA A, 1984, J BIOCHEM, V95, P67, DOI 10.1093/oxfordjournals.jbchem.a134603; HAYMAN AR, 1989, BIOCHEM J, V261, P601, DOI 10.1042/bj2610601; HIMENO M, 1989, BIOCHEM BIOPH RES CO, V162, P1044, DOI 10.1016/0006-291X(89)90779-1; HUNT DF, 1987, BIOCHEM BIOPH RES CO, V144, P1154, DOI 10.1016/0006-291X(87)91432-X; KATO T, 1986, COMP BIOCHEM PHYS B, V83, P813, DOI 10.1016/0305-0491(86)90152-5; KETCHAM CM, 1989, J BIOL CHEM, V264, P557; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU KHW, 1987, J BIOL CHEM, V262, P1389; LINDUNGER A, 1990, BONE MINER, V10, P109, DOI 10.1016/0169-6009(90)90086-U; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LORD DK, 1990, EUR J BIOCHEM, V189, P287, DOI 10.1111/j.1432-1033.1990.tb15488.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252; NORSTEDT G, 1988, CARCINOGENESIS, V9, P209, DOI 10.1093/carcin/9.2.209; REINHOLT FP, 1990, J BONE MINER RES, V5, P1055; ROIKO K, 1990, GENE, V89, P223, DOI 10.1016/0378-1119(90)90009-G; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDELMEISER J, 1987, HISTOCHEMISTRY, V87, P13, DOI 10.1007/BF00518719; SIMMEN RCM, 1988, MOL ENDOCRINOL, V2, P253, DOI 10.1210/mend-2-3-253; STEPAN JJ, 1990, BIOCHEM BIOPH RES CO, V168, P792, DOI 10.1016/0006-291X(90)92391-C; SUSI FR, 1986, AM J PHYSIOL, V211, P959; VANDEWIJNGAERT FP, 1986, J HISTOCHEM CYTOCHEM, V34, P1317, DOI 10.1177/34.10.3745910; VINCENT JB, 1990, FASEB J, V4, P3009, DOI 10.1096/fasebj.4.12.2394317; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WEINREB M, 1990, J BONE MINER RES, V5, P831; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V159, P68, DOI 10.1016/0006-291X(89)92405-4	51	99	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24684	24689						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722212				2022-12-25	WOS:A1991GW84500069
J	BEAR, CE; DUGUAY, F; NAISMITH, AL; KARTNER, N; HANRAHAN, JW; RIORDAN, JR				BEAR, CE; DUGUAY, F; NAISMITH, AL; KARTNER, N; HANRAHAN, JW; RIORDAN, JR			CL- CHANNEL ACTIVITY IN XENOPUS OOCYTES EXPRESSING THE CYSTIC-FIBROSIS GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANSMEMBRANE CONDUCTANCE REGULATOR; CHLORIDE CHANNEL; TRANSPORT; PROTEINS; CELLS	The expression of the cystic fibrosis (CF) gene on its introduction into nonepithelial somatic cells has recently been shown to result in the appearance of distinctive low conductance chloride channels stimulated by cyclic AMP (Kartner, N., Hanrahan, J. W., Jensen, T. J., Naismith, A. L., Sun, S., Ackerley, C. A., Reyes, E. F., Tsui, L.-C., Rommens, J. M., Bear, C. E., and Riordan, J. R. (1991) Cell 64, 681-691; Anderson, M. P., Rich, D. P., Gregory, R. J., Smith, A. E., and Welsh, M. J. (1991) Science 251, 679-682). Since Xenopus oocytes provide a powerful system for ion channel characterization, we have examined whole cell and single channel currents in them after injection of cRNA to program the synthesis of the cystic fibrosis transmembrane conductance regulator (CFTR). This has enabled the direct demonstration that the cyclic AMP activation is mediated by protein kinase A and that CFTR is without effect on the endogenous calcium-activated chloride channels of the oocyte, which have been well characterized previously and widely used as reporters of the expression of G-protein-coupled receptors. These findings strengthen the argument that the CF gene codes for a novel regulated chloride channel rather than a regulatory protein which can modulate separate chloride channel molecules.	UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT BIOCHEM & CLIN BIOCHEM,TORONTO M5S 1A1,ONTARIO,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL H3G 1Y6,QUEBEC,CANADA	University of Toronto; University of Toronto; McGill University	BEAR, CE (corresponding author), HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ONTARIO,CANADA.		Hanrahan, John/AGG-1926-2022	Hanrahan, John/0000-0001-9080-2039				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; Hille B, 1984, IONIC CHANNELS EXCIT; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; LESTER HA, 1988, SCIENCE, V241, P1057, DOI 10.1126/science.2457947; LODISH HF, 1990, NATURE, V348, P489, DOI 10.1038/348489a0; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RINGE D, 1990, NATURE, V346, P312, DOI 10.1038/346312a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1991, IN PRESS BIOESSAYS; RIORDAN JR, 1991, IDENTIFICATION CF CY; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593	18	171	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19142	19145						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717461				2022-12-25	WOS:A1991GK66700005
J	FEYEN, JHM; EVANS, DB; BINKERT, C; HEINRICH, GF; GEISSE, S; KOCHER, HP				FEYEN, JHM; EVANS, DB; BINKERT, C; HEINRICH, GF; GEISSE, S; KOCHER, HP			RECOMBINANT HUMAN [CYS281]INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-2 INHIBITS BOTH BASAL AND INSULIN-LIKE GROWTH FACTOR-I-STIMULATED PROLIFERATION AND COLLAGEN-SYNTHESIS IN FETAL-RAT CALVARIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST-ENRICHED CULTURES; IGF-I; PARATHYROID-HORMONE; CARRIER PROTEINS; ORGAN-CULTURE; BONE; CELLS; ESTRADIOL; EXPRESSION; CORTISOL	It is recognized that insulin-like growth factors (IGFs) are bound to specific high-affinity insulin-like growth factor-binding proteins (IGFBPs). The role of IGFBPs in bone metabolism is not well established. The effect of recombinant human [Cys281]IGFBP-2 ([Cys281]rhIGFBP-2) on bone formation in 21-day-old fetal rat calvariae was investigated. [Cys281]rhIGFBP-2 was expressed in and purified from conditioned medium of a clonal Chinese hamster ovary cell line. IGFI-stimulated cell proliferation was inhibited dose dependently by [CyS281]rhIGFBP-2, with half-maximal inhibition observed at 2 x 10(-8) M. Suppression of the IGF-I-stimulated DNA synthesis was observed at an apparent dose ratio of 1:10. [Cys281]rhlGFBP-2 (10(-6) M) also inhibited the basal incorporation of [H-3]thymidine into DNA by up to 45%. Insulin-stimulated cell proliferation was not affected in the presence of the binding protein. In addition, [Cys281]rhlGFBP-2 inhibited bone collagen synthesis under basal and IGF-I-stimulated conditions. In contrast, [CyS281]rhIGFBP-2 did not alter the parathyroid hormone-stimulated bone cell proliferation rate. In conclusion, binding of hIGF-I to rhlGFBP-2 results in an inhibition of the actions of free IGF-I on bone cell replication and matrix synthesis. Parathyroid hormone-stimulated cell proliferation is not mediated by an increase in free IGFs.	SANDOZ PHARMA LTD,DEPT BIOTECHNOL,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz	FEYEN, JHM (corresponding author), SANDOZ PHARMA LTD,DEPT ENDOCRINOL,PRECLIN RES 360-406,CH-4002 BASEL,SWITZERLAND.							BAGLEY CJ, 1989, BIOCHEM J, V259, P665, DOI 10.1042/bj2590665; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BINGHAM PJ, 1974, CALC TISS RES, V14, P31, DOI 10.1007/BF02060281; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BLUM WF, 1989, ENDOCRINOLOGY, V125, P766, DOI 10.1210/endo-125-2-766; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; BVENBERG WA, 1990, MOL CELL ENDOCRINOL, V74, P45; CANALIS E, 1988, ENDOCRINOLOGY, V122, P22, DOI 10.1210/endo-122-1-22; CANALIS E, 1990, ENDOCRINOLOGY, V126, P1806, DOI 10.1210/endo-126-4-1806; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; CENTRELLA M, 1990, ENDOCRINOLOGY, V126, P39, DOI 10.1210/endo-126-1-39; CHEN TL, 1991, ENDOCRINOLOGY, V128, P73, DOI 10.1210/endo-128-1-73; CHENU C, 1990, BONE, V11, P81, DOI 10.1016/8756-3282(90)90054-3; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DUNPHY MJ, 1987, J CHROMATOGR-BIOMED, V420, P394, DOI 10.1016/0378-4347(87)80195-0; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; ERNST M, 1988, P NATL ACAD SCI USA, V85, P2307, DOI 10.1073/pnas.85.7.2307; ERNST M, 1990, ENDOCRINOLOGY, V127, P807, DOI 10.1210/endo-127-2-807; ERNST M, 1988, BIOCHEM BIOPH RES CO, V151, P142, DOI 10.1016/0006-291X(88)90570-0; ERNST M, 1987, CALCIFIED TISSUE INT, V40, P27, DOI 10.1007/BF02555725; GRAY TK, 1989, BIOCHEM BIOPH RES CO, V158, P407, DOI 10.1016/S0006-291X(89)80062-2; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; KNAUER DJ, 1980, P NATL ACAD SCI-BIOL, V77, P7252, DOI 10.1073/pnas.77.12.7252; KREAM BE, 1985, ENDOCRINOLOGY, V116, P296, DOI 10.1210/endo-116-1-296; LINKHART TA, 1989, ENDOCRINOLOGY, V125, P1484, DOI 10.1210/endo-125-3-1484; MCCARTHY TL, 1990, J BIOL CHEM, V265, P15353; MCCARTHY TL, 1990, ENDOCRINOLOGY, V126, P1569, DOI 10.1210/endo-126-3-1569; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P301, DOI 10.1210/endo-124-1-301; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MCCARTHY TL, 1989, CONNECT TISSUE RES, V20, P277, DOI 10.3109/03008208909023897; MOHAN S, 1988, BIOCHIM BIOPHYS ACTA, V966, P44, DOI 10.1016/0304-4165(88)90127-4; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; RITVOS O, 1988, ENDOCRINOLOGY, V122, P2150, DOI 10.1210/endo-122-5-2150; SCHMID C, 1989, FEBS LETT, V244, P328, DOI 10.1016/0014-5793(89)80556-3; SCHMID C, 1989, BIOCHEM BIOPH RES CO, V160, P788, DOI 10.1016/0006-291X(89)92502-3; SCHMID C, 1984, FEBS LETT, V173, P48, DOI 10.1016/0014-5793(84)81015-7; SCHMID C, 1990, 3RD P INT S OST DENM, P40; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRACKE H, 1984, ACTA ENDOCRINOL-COP, V107, P16, DOI 10.1530/acta.0.1070016; TOLLEFSEN SE, 1991, J CLIN INVEST, V87, P1241, DOI 10.1172/JCI115125; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VANDORSSELAER A, 1990, BIOMED ENVIRON MASS, V19, P692, DOI 10.1002/bms.1200191108; WALTON PE, 1989, P SOC EXP BIOL MED, V190, P315; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	44	90	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19469	19474						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717466				2022-12-25	WOS:A1991GK66700053
J	PEPINSKY, RB; CHEN, LL; MEIER, W; WALLNER, BP				PEPINSKY, RB; CHEN, LL; MEIER, W; WALLNER, BP			THE INCREASED POTENCY OF CROSS-LINKED LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-3 (LFA-3) MULTIMERS IS A DIRECT CONSEQUENCE OF CHANGES IN VALENCY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE LIGAND; ALTERNATIVE PATHWAY; CD2; RECEPTOR; ADHESION; GLYCOPROTEIN; MOLECULES; BINDING; RECOGNITION; ACTIVATION	We have used chemically cross-linked dimers, trimers, and tetramers of lymphocyte function-associated antigen-3 (LFA-3) to study the role of multivalency in the interaction of the protein with its receptor, CD2. The cross-linked adducts showed enhanced activity in systems where LFA-3 has been shown to (i) block LFA-3/CD2 interactions in a rosetting assay and (ii) provide through the CD2 on peripheral blood lymphocytes a trigger for T-cell proliferation. The level of increase was directly related to the valency state of the multimers. In the rosetting assay, the dimers, trimers, and tetramers, by weight, exhibited 15-, 150-, and 430-fold increases in activity over monomeric LFA-3. In the proliferation assay, the tetramer produced a 6-fold increase in thymidine incorporation at 0.06-mu-g/ml, the trimer was 100 times less active than the tetramer, and the dimer and monomer were inactive. The LFA-3 multimers were generated using a three-step cross-linking chemistry that was targeted at the carbohydrates on LFA-3. With this procedure over 60% of the starting protein was converted into multimers with no effect on function. The cross-linking approach should be applicable to other surface antigens, providing a simple method for analyzing multivalent interactions.			PEPINSKY, RB (corresponding author), BIOGEN INC,CAMBRIDGE,MA 02142, USA.							DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DENNING SM, 1988, J IMMUNOL, V141, P2980; DUSTIN ML, 1987, J EXP MED, V165, P677, DOI 10.1084/jem.165.3.677; DUSTIN ML, 1987, NATURE, V329, P846, DOI 10.1038/329846a0; DUSTIN ML, 1989, J EXP MED, V169, P503, DOI 10.1084/jem.169.2.503; EDIDIN M, 1991, J CELL BIOL, V112, P1143, DOI 10.1083/jcb.112.6.1143; HUNIG T, 1987, NATURE, V326, P298, DOI 10.1038/326298a0; KAUFMAN RJ, 1982, J MOL BIOL, V159, P601, DOI 10.1016/0022-2836(82)90103-6; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; KRENSKY AM, 1984, J IMMUNOL, V132, P2180; KRENSKY AM, 1983, J IMMUNOL, V131, P611; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MEUER SC, 1984, ANNU REV IMMUNOL, V2, P23, DOI 10.1146/annurev.immunol.2.1.23; PLUNKETT ML, 1987, J EXP MED, V165, P664, DOI 10.1084/jem.165.3.664; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; SPRINGER TA, 1987, ANNU REV IMMUNOL, V5, P223, DOI 10.1146/annurev.immunol.5.1.223; VOLLGER LW, 1987, J IMMUNOL, V138, P358; WALLNER BP, 1987, J EXP MED, V166, P923, DOI 10.1084/jem.166.4.923; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	22	25	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18244	18249						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1717445				2022-12-25	WOS:A1991GG55300080
J	JIANG, YP; MULLERESTERL, W; SCHMAIER, AH				JIANG, YP; MULLERESTERL, W; SCHMAIER, AH			DOMAIN-3 OF KININOGENS CONTAINS A CELL-BINDING SITE AND A SITE THAT MODIFIES THROMBIN ACTIVATION OF PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; WASHED HUMAN-PLATELETS; ENDOTHELIAL-CELLS; HUMAN-PLASMA; HAGEMAN-FACTOR; LIGHT CHAIN; FACTOR-XI; PROTEIN; PREKALLIKREIN; PURIFICATION	High and low molecular weight kininogens (HK and LK) are able to bind to platelets to inhibit thrombin binding to and activation of platelets. The heavy chain domain on the kininogens that contains these functions has been determined. Domain 3 (D3) but not domains 1 or 2, completely inhibited I-125-HK binding to platelets (K(i) = 24 +/- 7 nM, n = 4). I-125-D3 specifically bound to unstimulated platelets and human umbilical vein endothelial cells. On platelets, it was blocked by unlabeled D3 and HK but not prekallikrein, factor XII, C1s, or C1 inhibitor. Further, one monoclonal antibody (HKH13) directed to kininogens' D3 blocked I-125-HK and I-125-D3 binding to platelets. The binding of I-125-D3 to platelets was fully reversible by addition of 35 molar excess of unlabeled D3. D3 binding to platelets was saturable with an apparent K(d) of 39 +/- 8 nM (n = 4) and 1227 +/- 404 binding sites/platelet. D3, like HK and LK, inhibited thrombin-induced platelet activation by preventing thrombin binding to platelets. Another monoclonal antibody (HKH12), directed to D3, which did not block HK binding to platelets, reduced HK's ability to inhibit I-125-alpha-thrombin binding. This result suggests that the region on D3 that inhibits I-125-alpha-thrombin binding to platelets is different from that which directly binds to platelets. These studies indicate that D3 of the kininogens contains both a binding region for platelets and endothelial cells and another region that inhibits thrombin-induced platelet activation.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,THROMBOSIS RES CTR,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,HEMATOL SECT,PHILADELPHIA,PA 19140; UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,W-6500 MAINZ,GERMANY	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Johannes Gutenberg University of Mainz			Schmaier, Alvin/AAM-1063-2020	Schmaier, Alvin/0000-0002-3884-6234; Jiang, Yongping/0000-0001-6024-4187	NHLBI NIH HHS [HL35553, HL01615] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035553, K04HL001615] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; BRADFORD HN, 1990, BIOCHEM J, V270, P83, DOI 10.1042/bj2700083; CANELLAS PF, 1981, J IMMUNOL METHODS, V47, P375, DOI 10.1016/0022-1759(81)90294-5; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; GRIFFIN JH, 1977, P NATL ACAD SCI USA, V74, P4636; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HONG SL, 1980, THROMB RES, V18, P787, DOI 10.1016/0049-3848(80)90201-7; JIANG YP, 1991, THROMB HAEMOSTASIS, V65, P1248; KAKIZUKA A, 1990, J BIOL CHEM, V265, P10102; KAUFMANN J, 1990, THESIS U MUNICH GERM; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; MULLER R, 1983, METHOD ENZYMOL, V92, P589; MULLERESTERL W, 1987, METHOD ENZYMOL, V163, P240; NAITO K, 1991, J BIOL CHEM, V266, P7353; OKBUKO I, 1984, BIOCHEMISTRY-US, V23, P5691; PURI RN, 1991, BLOOD, V77, P500; RETZIOS AD, 1987, J BIOL CHEM, V262, P3074; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHMAIER AH, 1986, BLOOD, V67, P119; SCHMAIER AH, 1986, J CLIN INVEST, V77, P1565, DOI 10.1172/JCI112472; SCHMAIER AH, 1980, BLOOD, V56, P1013; SCHMAIER AH, 1984, THROMB RES, V33, P51, DOI 10.1016/0049-3848(84)90154-3; SCHMAIER AH, 1983, J CLIN INVEST, V71, P1477, DOI 10.1172/JCI110901; SCHMAIER AH, 1985, J CLIN INVEST, V75, P242, DOI 10.1172/JCI111680; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCOTT CF, 1979, EUR J BIOCHEM, V100, P77, DOI 10.1111/j.1432-1033.1979.tb02035.x; SCOTT CF, 1980, J CLIN INVEST, V65, P413, DOI 10.1172/JCI109684; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SMITH D, 1985, BLOOD, V66, P835; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; THOMPSON RE, 1978, J EXP MED, V147, P488, DOI 10.1084/jem.147.2.488; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VOGEL R, 1988, J BIOL CHEM, V263, P12661; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	47	81	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3712	3717						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740422				2022-12-25	WOS:A1992HE60700028
J	SCHATZLE, J; BUSH, J; CARDELLI, J				SCHATZLE, J; BUSH, J; CARDELLI, J			MOLECULAR-CLONING AND CHARACTERIZATION OF THE STRUCTURAL GENE CODING FOR THE DEVELOPMENTALLY REGULATED LYSOSOMAL-ENZYME, ALPHA-MANNOSIDASE, IN DICTYOSTELIUM-DISCOIDEUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; SIMILARITY SEARCHES; PROTEIN; ACID; PRECURSORS; SECRETION; BIOGENESIS; EXPRESSION; PATHWAYS; SEQUENCE	The gene coding for the Dictyostelium discoideum lysosomal enzyme, alpha-mannosidase, has been cloned and sequenced. To accomplish this, the mature 60- and 58-kDa subunits of the enzyme were purified and subjected to liquid-phase N-terminal amino acid sequencing. Sequence information was obtained for both of the mature subunits, and a 48-mer oligonucleotide was synthesized based on the determined amino acid sequence of the 58-kDa subunit. Using this oligonucleotide as a probe, an 8-kilobase HindIII fragment of genomic DNA was isolated and subjected to Sanger dideoxy DNA sequencing. The first 4400 nucleotides contained the complete alpha-mannosidase gene and 1100 nucleotides of 5'-flanking DNA. Primer extension analysis indicated that transcription begins at multiple sites -48 to -64 nucleotides upstream of the first nucleotide of the predicted translation initiation codon. A single open reading frame (ORF) of 3015 nucleotides was found that was interrupted by a single intron and that contained the amino acid sequences of the N termini of the two mature alpha-mannosidase subunits; a polyadenylation signal was also found just downstream of the termination codon. A potential cleavable signal sequence was identified in the first 22 amino acids of the predicted precursor protein, and two propeptide regions (Pro I and II) were identified that were immediately upstream of the N termini of the 60- and 58-kDa mature subunits, respectively. These propeptide regions are not present in the mature protein and are therefore predicted to be proteolytically removed as the membrane associated 140-kDa precursor is transported to lysosomes and processed to the soluble 60- and 58-kDa mature forms of the enzyme. In fact, potential proteolytic cleavage sites were identified flanking the Pro I and Pro II regions. Pro I, which immediately follows the signal sequence, consists of 18 amino acids, most of which are highly charged and hydrophilic residues, while Pro II, found in the central portion of the precursor, is very hydrophobic. While no obvious transmembrane regions were identified, several short hydrophobic amino acid stretches were found to be localized in and around the Pro II region, and these may be responsible for attachment of precursors to membranes.	LOUISIANA STATE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,1501 KINGS HWY,SHREVEPORT,LA 71130	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039232, R01DK039232] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39232] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BISCHOFF J, 1990, J BIOL CHEM, V265, P17110; BURNS RA, 1981, DEV BIOL, V84, P407, DOI 10.1016/0012-1606(81)90409-7; CARAS IW, 1989, J CELL BIOL, V108, P1387, DOI 10.1083/jcb.108.4.1387; Cardelli J.A., 1988, P363; CARDELLI JA, 1990, J BIOL CHEM, V265, P8847; CARDELLI JA, 1986, ARCH BIOCHEM BIOPHYS, V244, P338, DOI 10.1016/0003-9861(86)90122-0; CARDELLI JA, 1985, DEV BIOL, V110, P147, DOI 10.1016/0012-1606(85)90072-7; CARDELLI JA, 1990, DEV GENET, V11, P454, DOI 10.1002/dvg.1020110522; CARDELLI JA, 1986, J CELL BIOL, V102, P1264, DOI 10.1083/jcb.102.4.1264; CARDELLI JA, 1989, J BIOL CHEM, V264, P3454; CARDELLI JA, 1987, METHOD CELL BIOL, V28, P139; CARDELLI JA, 1992, IN PRESS ENDOSOMES L; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARKE M, 1988, DEV GENET, V9, P315, DOI 10.1002/dvg.1020090413; COHEN P, 1987, BIOCHIMIE, V69, P87, DOI 10.1016/0300-9084(87)90239-2; DIMENT S, 1988, J BIOL CHEM, V263, P6901; EBERT DL, 1989, ARCH BIOCHEM BIOPHYS, V273, P479, DOI 10.1016/0003-9861(89)90507-9; EBERT DL, 1989, J CELL BIOL, V109, P1445, DOI 10.1083/jcb.109.4.1445; FREEZE HH, 1989, J BIOL CHEM, V264, P19278; FREEZE HH, 1986, MOL CELL BIOCHEM, V72, P47; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRAHAM TR, 1988, J BIOL CHEM, V263, P16823; GRANT CE, 1990, NUCLEIC ACIDS RES, V18, P5457, DOI 10.1093/nar/18.18.5457; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; LIVI GP, 1985, DEV BIOL, V110, P514, DOI 10.1016/0012-1606(85)90110-1; LOOMIS WF, 1987, J BACTERIOL, V103, P375; MAHURAN DJ, 1988, J BIOL CHEM, V263, P4612; MANIATIS T, 1982, MOL CLONING LABORATO, P93; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; MCINTYRE GF, 1991, J BIOL CHEM, V266, P15438; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIERENDORF RC, 1985, J CELL BIOL, V100, P1777, DOI 10.1083/jcb.100.5.1777; MIERENDORF RC, 1983, J BIOL CHEM, V258, P53878; NELLEN W, 1984, MOL CELL BIOL, V4, P2890, DOI 10.1128/MCB.4.12.2890; OWADA M, 1982, BIOCHEM BIOPH RES CO, V105, P814, DOI 10.1016/0006-291X(82)91042-7; PANNELL R, 1982, J BIOL CHEM, V257, P9861; PORTNOY DA, 1986, J BIOL CHEM, V261, P4697; RICHARDSON JM, 1988, J CELL BIOL, V107, P2097, DOI 10.1083/jcb.107.6.2097; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; ROBINSON A, 1987, BIOCHEM J, V246, P249, DOI 10.1042/bj2460249; SCHATZLE J, 1991, MOL CELL BIOL, V11, P3339, DOI 10.1128/MCB.11.6.3339; SCHWARTZ TW, 1986, FEBS LETT, V200, P1, DOI 10.1016/0014-5793(86)80500-2; STORRIE B, 1988, INT REV CYTOL, V3, P53; TAGER JM, 1984, BIOCHEM SOC T, V12, P902, DOI 10.1042/bst0120902; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VAUTI F, 1990, MOL CELL BIOL, V10, P4080, DOI 10.1128/MCB.10.8.4080; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WAHEED A, 1982, BIOCHEM BIOPH RES CO, V105, P1052, DOI 10.1016/0006-291X(82)91076-2; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; WOOD L, 1985, J CELL BIOL, V101, P2063, DOI 10.1083/jcb.101.6.2063; WOYCHIK NA, 1986, J BIOL CHEM, V261, P9595; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5	63	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4000	4007						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740448				2022-12-25	WOS:A1992HE60700069
J	VERBURG, JG; SMITH, CE; LISEK, CA; HUYNH, QK				VERBURG, JG; SMITH, CE; LISEK, CA; HUYNH, QK			IDENTIFICATION OF AN ESSENTIAL TYROSINE RESIDUE IN THE CATALYTIC SITE OF A CHITINASE ISOLATED FROM ZEA-MAYS THAT IS SELECTIVELY MODIFIED DURING INACTIVATION WITH 1-ETHYL-3-(3-DIMETHYLAMINOPROPYL)-CARBODIIMIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL CARBOXYL GROUPS; EGG-WHITE LYSOZYME; BACTERIOPHAGE-T4 LYSOZYME; CHEMICAL MODIFICATION; ANTIFUNGAL HYDROLASES; CARBOXYPEPTIDASE-A; FUNGAL GROWTH; MESSENGER-RNA; PEA TISSUE; BINDING	Chitinase isolated from Zea mays seeds is inactivated by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) in the absence of exogenous nucleophiles. Oligomers of N-acetylglucosamine, N,N',N",N"'-tetra-N-acetylchitotetraose (GlcNAc4), and to a lesser extent, N,N',N"-tri-N-acetylchitotriose (GlcNAc3) and N,N'-di-N-acetylchitobiose (GlcNAc2) provide partial protection against inactivation by the reagent. An examination of the concentration dependence of the protection afforded by GlcNAc4 revealed direct competition between the substrate analog and the reagent for the same binding sites on the enzyme. Isolation and Edman degradation of a "new" tryptic fragment, observed after inactivation of chitinase with EDC, revealed the sequence G-P-L-Q-I-S-W-N-*-N-Y-G-P-A-G-R, where the asterisk represents a cycle in which no amino acid was detected, presumably as a consequence of derivatization with EDC. In basic chitinases from dicotyledonous plants such as Arabidopsis thaliana, Phaseolis vulgaris (bean), Nicotiana tabacum (tobacco), and Solanum tuberosum (potato), as well as in the chitinase isolated from the monocotyledonous plant Hordeum vulgare (barley), this position is invariably occupied by a tyrosine. However, in the Oryza sativa (rice) basic chitinase, this position is occupied by a phenylalanine. The following additional evidence supports identification of this residue as tyrosine in Z. mays chitinase. (a) Inactivation of chitinase with EDC is reversible by treatment with hydroxylamine. (b) Liquid secondary ion mass spectrometric analysis of the isolated derivatized peptide revealed the presence of a molecular ion with a mass to charge ratio consistent with the peptide containing a derivatized tyrosine residue. These results provide evidence for an essential tyrosine residue at or near the catalytic site of chitinase that is selectively modified during inactivation with EDC.	MONSANTO CO, MONSANTO CORP RES, DEPT PROT BIOCHEM, CHESTERFIELD, MO 63198 USA; MONSANTO CO, MONSANTO CORP RES, CTR PHYS SCI, CHESTERFIELD, MO 63198 USA	Monsanto; Monsanto								ABELES FB, 1970, PLANT PHYSIOL, V47, P129; ANAND NN, 1988, BIOCHEM BIOPH RES CO, V153, P862, DOI 10.1016/S0006-291X(88)81175-6; ANDERSON WF, 1981, J MOL BIOL, V147, P523, DOI 10.1016/0022-2836(81)90398-3; AULD DS, 1971, BIOCHEMISTRY-US, V10, P2892, DOI 10.1021/bi00791a015; BAIRD SD, 1990, BIOCHEM BIOPH RES CO, V169, P1035, DOI 10.1016/0006-291X(90)91998-8; BANERJEE SK, 1975, J BIOL CHEM, V250, P4355; BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; BELL AA, 1981, ANNU REV PLANT PHYS, V32, P21, DOI 10.1146/annurev.pp.32.060181.000321; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P365, DOI 10.1098/rspb.1967.0034; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; BOLLER T, 1983, PLANTA, V157, P22, DOI 10.1007/BF00394536; Boller T, 1985, CELLULAR MOL BIOL PL, P247; BOLLER T, 1987, PLANT MICROBE INTERA, V2, P385; Boller T, 1988, METHOD ENZYMOL, V161, P430; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; CABIB E, 1971, J BIOL CHEM, V246, P152; CANFIELD RE, 1965, J BIOL CHEM, V240, P1997; CARRAWAY KL, 1968, BIOCHIM BIOPHYS ACTA, V160, P272, DOI 10.1016/0005-2795(68)90102-5; CLARKE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1040, P145, DOI 10.1016/0167-4838(90)90069-R; DARVILL AG, 1984, ANNU REV PLANT PHYS, V35, P243, DOI 10.1146/annurev.pp.35.060184.001331; EBEL J, 1986, ANNU REV PHYTOPATHOL, V24, P235; EYL AW, 1971, J BIOL CHEM, V246, P738; FUKUDA Y, 1991, PLANT MOL BIOL, V16, P1, DOI 10.1007/BF00017912; GAYNOR JJ, 1988, NUCLEIC ACIDS RES, V16, P5210, DOI 10.1093/nar/16.11.5210; Guggenheim EA, 1926, PHILOS MAG, V2, P538; Hartsuck J. A., 1971, ENZYMES, V3, P1; HENRISSAT B, 1990, Protein Sequences and Data Analysis, V3, P523; HIRANO S, 1976, CARBOHYD RES, V47, P315, DOI 10.1016/S0008-6215(00)84198-1; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; INOUYE M, 1970, J BIOL CHEM, V245, P3479; INOUYE M, 1966, J MOL BIOL, V22, P193, DOI 10.1016/0022-2836(66)90192-6; KULIOPULOS A, 1987, BIOCHEMISTRY-US, V26, P3927, DOI 10.1021/bi00387a028; KUROSAKI F, 1987, PHYSIOL MOL PLANT P, V31, P201, DOI 10.1016/0885-5765(87)90064-6; LEAH R, 1991, J BIOL CHEM, V266, P1564; LIN TY, 1969, J BIOL CHEM, V244, P505; MAJEAU N, 1990, PLANT SCI, V68, P9, DOI 10.1016/0168-9452(90)90146-F; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; MATTHEWS BW, 1981, J MOL BIOL, V147, P545, DOI 10.1016/0022-2836(81)90399-5; MAUCH F, 1988, PLANT PHYSIOL, V87, P325, DOI 10.1104/pp.87.2.325; MAUCH F, 1988, PLANT PHYSIOL, V88, P936, DOI 10.1104/pp.88.3.936; MILDVAN AS, 1964, BIOCHIM BIOPHYS ACTA, V89, P393, DOI 10.1016/0926-6569(64)90065-3; MOLANO J, 1977, ANAL BIOCHEM, V83, P648, DOI 10.1016/0003-2697(77)90069-0; MOULT J, 1976, J MOL BIOL, V100, P179, DOI 10.1016/S0022-2836(76)80147-7; PAICE MG, 1979, ADV CHEM SER, V181, P361; PARSONS SM, 1972, BIOCHEMISTRY-US, V11, P1623, DOI 10.1021/bi00759a013; PERFETTI RB, 1976, BIOCHEMISTRY-US, V15, P1735, DOI 10.1021/bi00653a022; PETRA PH, 1971, BIOCHEMISTRY-US, V10, P3163, DOI 10.1021/bi00793a001; PETRA PH, 1971, BIOCHEMISTRY-US, V10, P3171; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; REEKE JN, 1967, P NATL ACAD SCI USA, V58, P2220; REISSIG JL, 1955, J BIOL CHEM, V217, P959; RING M, 1990, ARCH BIOCHEM BIOPHYS, V283, P342, DOI 10.1016/0003-9861(90)90652-F; RIORDAN JF, 1963, BIOCHEMISTRY-US, V2, P1460, DOI 10.1021/bi00906a045; ROBERTS JM, 1986, J PSYCHIAT EDUC, V10, P26; ROBERTS WK, 1986, BIOCHIM BIOPHYS ACTA, V880, P161, DOI 10.1016/0304-4165(86)90076-0; SAMAC DA, 1990, PLANT PHYSIOL, V93, P907, DOI 10.1104/pp.93.3.907; SCHLUMBAUM A, 1986, NATURE, V324, P365, DOI 10.1038/324365a0; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; SIMPSON RT, 1966, BIOCHEMISTRY-US, V5, P1760, DOI 10.1021/bi00869a045; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOKOLOVS.M, 1967, BIOCHEMISTRY-US, V6, P700, DOI 10.1021/bi00855a008; SVENSSON B, 1990, EUR J BIOCHEM, V188, P29, DOI 10.1111/j.1432-1033.1990.tb15367.x; VERBURG JG, 1991, PLANT PHYSIOL, V95, P450, DOI 10.1104/pp.95.2.450; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; ZHU Q, 1991, MOL GEN GENET, V226, P289, DOI 10.1007/BF00273615	67	52	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3886	3893						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740436				2022-12-25	WOS:A1992HE60700054
J	DAVIS, KD; LAZAR, MA				DAVIS, KD; LAZAR, MA			SELECTIVE ANTAGONISM OF THYROID-HORMONE ACTION BY RETINOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GENE-EXPRESSION; RESPONSE ELEMENT; NEGATIVE REGULATION; NUCLEAR RECEPTORS; GH3 CELLS; BETA-GENE; TRANSCRIPTION; IDENTIFICATION; ALPHA; BINDING	Thyroid hormone (T3) and retinoic acid (RA) regulate gene transcription by binding to similar nuclear receptors. We have investigated the effects of RA, alone and in combination with T3, on a number of T3-responsive genes expressed in rat pituitary adenoma cells. Like T3, RA increased growth hormone gene expression in GH3 as well as in GH1 cells, and the effects of the hormones were additive. In contrast, RA alone had little effect on the expression of the beta-2 form of T3 receptor (TR-beta-2), which is markedly decreased by T3. Remarkably, however, RA completely inhibited the down-regulation of TR-beta-2 mRNA by T3. RA alone also had little effect on TR-beta-1 mRNA, but its presence did not prevent the up-regulation of TR-beta-1 mRNA by T3. The target-gene-specific antagonism of T3 action by RA was observed in both GH cell lines. Nuclear run-on assays demonstrated that the effect occurred at the level of TR-beta-2 gene transcription, and the half-life of the TR-beta-2 mRNA was unchanged by RA in the presence or absence of T3. The half-maximal RA dose required for these effects suggested that they were mediated by one or more of the nuclear receptors for RA. Indeed, GH3 cells contain mRNAs encoding the three distinct RA receptor subtypes, alpha, beta, and gamma, as well as retinoid X receptors. These results demonstrate that the effects of RA and T3 on gene expression are dependent on the nature of the target gene as well as on hormonal interactions, probably at the level of the receptors.	UNIV PENN,SCH MED,DEPT MED,611 CRB,422 CURIE BLVD,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT HUMAN GENET,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			Lazar, Mitchell A/AAF-3738-2019		NIAMS NIH HHS [AR 07481] Funding Source: Medline; NIDDK NIH HHS [DK 43806] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043806, R37DK043806] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRENT G A, 1989, New Biologist, V1, P329; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARLING DS, 1989, MOL ENDOCRINOL, V3, P1359, DOI 10.1210/mend-3-9-1359; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; LAZAR MA, 1990, J BIOL CHEM, V265, P17474; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P479, DOI 10.1210/mend-2-6-479; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T., 1982, MOL CLONING; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; ODONNELL AL, 1991, MOL ENDOCRINOL, V5, P94, DOI 10.1210/mend-5-1-94; Oppenheimer J. H., 1983, MOL BASIS THYROID HO; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SPINDLER SR, 1982, J BIOL CHEM, V257, P1627; SPORN MB, 1983, CANCER RES, V43, P3034; STANLEY F, 1984, J BIOL CHEM, V259, P9768; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; THALLER C, 1987, NATURE, V327, P625, DOI 10.1038/327625a0; THOMPSON K, 1989, J BIOL CHEM, V7264, P3230; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; YAFFE BM, 1984, J BIOL CHEM, V259, P6284; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	51	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3185	3189						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737772				2022-12-25	WOS:A1992HD15400058
J	GUPTA, R; JENTOFT, N				GUPTA, R; JENTOFT, N			THE STRUCTURE OF TRACHEOBRONCHIAL MUCINS FROM CYSTIC-FIBROSIS AND CONTROL PATIENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; MUCUS GLYCOPROTEINS; MUCOUS GLYCOPROTEINS; CONFORMATION; SECRETIONS; KINETICS; PROTEINS; SULFATE; SPUTUM; TISSUE	Tracheobronchial mucin samples from control and cystic fibrosis patients were purified by gel filtration chromatography on Sephacryl S-1000 and by density gradient centrifugation. Normal secretions contained high molecular weight (approximately 10(7)) mucins, whereas the cystic fibrosis secretions contained relatively small amounts of high molecular weight mucin together with larger quantities of lower molecular weight mucin fragments. These probably represent products of protease digestion. Reducing the disulfide bonds in either the control or cystic fibrosis high molecular weight mucin fractions released subunits of approximately 2000 kDa. Treating these subunits with trypsin released glycopeptides of 300 kDa. Trypsin treatment of unreduced mucin also released fragments of 2000 kDa that could be converted into 300-kDa glycopeptides upon disulfide bond reduction. Thus, protease-susceptible linkages within these mucins must be cross-linked by disulfide bonds so that the full effects of proteolytic degradation of mucins remain cryptic until disulfide bonds are reduced. Since various combinations of protease treatment and disulfide bond reduction release either 2000- or 300-kDa fragments, these fragments must represent important elements of mucin structure. The high molecular weight fractions of cystic fibrosis mucins appear to be indistinguishable from control mucins. Their amino acid compositions are the same, and various combinations of disulfide bond reduction and protease treatment release products of identical size and amino acid composition. Sulfate and carbohydrate compositions did vary considerably from sample to sample, but the limited number of samples tested did not demonstrate a cystic fibrosis-specific pattern. Thus, tracheobronchial mucins from cystic fibrosis and control patients are very similar, and both share the same generalized structure previously determined for salivary, cervical, and intestinal mucins.	CASE WESTERN RESERVE UNIV,DEPT PEDIAT,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NIADDK NIH HHS [AM27651] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P30AM027651] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN A, 1983, TRENDS BIOCHEM SCI, V8, P169, DOI 10.1016/0968-0004(83)90166-4; BHASKAR KR, 1974, BIOCHEM J, V143, P669, DOI 10.1042/bj1430669; BOAT TF, 1976, ARCH BIOCHEM BIOPHYS, V177, P95, DOI 10.1016/0003-9861(76)90419-7; BRUCE MC, 1985, AM REV RESPIR DIS, V132, P529; CARLSTEDT I, 1985, ESSAYS BIOCHEM, V20, P40; CARLSTEDT I, 1984, CIBA F S, V109, P1457; CHACE KV, 1985, BIOCHEMISTRY-US, V24, P7334, DOI 10.1021/bi00346a047; CHENG PW, 1989, J CLIN INVEST, V84, P68, DOI 10.1172/JCI114171; CORTI P, 1988, J CHROMATOGR, V424, P147; CREETH JM, 1977, BIOCHEM J, V167, P557, DOI 10.1042/bj1670557; FRATES RC, 1983, PEDIATR RES, V17, P30, DOI 10.1203/00006450-198301000-00006; GOERKE J, 1974, BIOCHIM BIOPHYS ACTA, V344, P241, DOI 10.1016/0304-4157(74)90009-4; GOLDSTEIN W, 1986, AM REV RESPIR DIS, V132, P529; GUPTA R, 1989, J CHROMATOGR, V474, P411, DOI 10.1016/S0021-9673(01)93936-6; GUPTA R, 1989, BIOCHEMISTRY-US, V28, P6114, DOI 10.1021/bi00440a058; GUPTA R, 1990, BIOPOLYMERS, V29, P374; HENDERSON LE, 1979, ANAL BIOCHEM, V93, P153, DOI 10.1016/S0003-2697(79)80129-3; JENTOFT N, 1985, ANAL BIOCHEM, V148, P424, DOI 10.1016/0003-2697(85)90248-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANTLE M, 1990, BIOCHEM J, V266, P597; MANTLE M, 1978, Biochemical Society Transactions, V6, P607; MARIANNE T, 1987, BIOCHEM J, V248, P189, DOI 10.1042/bj2480189; MEYER FA, 1983, BIOCHEM J, V215, P701, DOI 10.1042/bj2150701; PONCZ L, 1988, INFECT IMMUN, V56, P703, DOI 10.1128/IAI.56.3.703-704.1988; ROBERTS WL, 1985, BIOCHEM BIOPH RES CO, V33, P621; ROSE MC, 1987, PEDIATR RES, V22, P545, DOI 10.1203/00006450-198711000-00015; ROSE MC, 1989, J BIOL CHEM, V264, P8193; SELLERS LA, 1988, BIOCHEM J, V256, P599, DOI 10.1042/bj2560599; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SHOGREN RL, 1984, J BIOL CHEM, V259, P4657; SHOGREN RL, 1987, CARBOHYD RES, V160, P317; SHOGREN RL, 1986, BIOPOLYMERS, V25, P1505, DOI 10.1002/bip.360250809; TABACHNIK NF, 1981, J BIOL CHEM, V256, P7161; THORNTON DJ, 1990, BIOCHEM J, V265, P179, DOI 10.1042/bj2650179; WAHEED A, 1978, ANAL BIOCHEM, V89, P550, DOI 10.1016/0003-2697(78)90384-6; ZAHLER WL, 1968, J BIOL CHEM, V243, P716	36	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3160	3167						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737770				2022-12-25	WOS:A1992HD15400054
J	KARDASSIS, D; ZANNIS, VI; CLADARAS, C				KARDASSIS, D; ZANNIS, VI; CLADARAS, C			ORGANIZATION OF THE REGULATORY ELEMENTS AND NUCLEAR ACTIVITIES PARTICIPATING IN THE TRANSCRIPTION OF THE HUMAN APOLIPOPROTEIN-B GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROMOTER ELEMENTS; BINDING PROTEINS; INTESTINAL TRANSCRIPTION; IMMUNOGLOBULIN GENES; OCTAMER MOTIF; C/EBP FAMILY; EXPRESSION; SEQUENCE; ENHANCER	The human apolipoprotein B (apoB) promoter region (-150 to +124) is transcriptionally active in HepG2 and CaCo-2 but not in HeLa cells. In the present study, we demonstrate that transcription of the human apoB gene in hepatic cells is achieved through the interaction of proteins that bind to five regulatory elements, I (-118 to -98), II (-112 to -94), III (-86 to -62), IV (-72 to -53), and V (-53 to -33). Elements I, IV, and V can bind to bacterially expressed enhancer-binding protein (C/EBP) although with different affinities. In addition, elements I, IV, and V interact with at least two other heat-stable nuclear factors, designated NF-BA2 and NF-BA3, that are distinct from C/EBP. These activities have been separated by ion exchange chromatography and shown to produce footprints in elements I, IV, and V that are similar to those obtained with C/EBP. Element II is recognized by three activities designated NF-BCB1, NF-BCB2, and NF-BCB3, which have been separated by heparin-Sepharose chromatography. Saturation mutagenesis of the region established that they belong to a family of proteins recognizing the same motif, 5'-AAAAGCAAACAG-3'. Substitution mutations in element II that abolish binding of all three activities in vitro also reduce hepatic transcription in vivo to 10% of control, indicating that the binding of NF-BCB1, NF-BCB2, and NF-BCB3 activities is required for efficient transcription of the apoB gene. Furthermore, element III is recognized by the previously characterized nuclear factor NF-BA1, the binding of which is essential for the transcriptional activation of the apoB gene in hepatic and intestinal cells.	BOSTON UNIV,MED CTR,HOUSMAN MED RES CTR,DEPT MED,INST CARDIOVASC,MOLEC GENET SECT,BOSTON,MA 02118; BOSTON UNIV,MED CTR,HOUSMAN MED RES CTR,DEPT BIOCHEM,BOSTON,MA 02118	Boston University; Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033952, R29HL043909] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33952, HL43909] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAKKER O, 1991, NUCLEIC ACIDS RES, V19, P1213, DOI 10.1093/nar/19.6.1213; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BLACKHART BD, 1986, J BIOL CHEM, V261, P5364; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSSON P, 1989, GENE, V77, P113, DOI 10.1016/0378-1119(89)90365-X; CARLSSON P, 1990, GENE, V94, P295, DOI 10.1016/0378-1119(90)90401-C; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; CLADARAS C, 1986, BIOCHEMISTRY-US, V25, P5351, DOI 10.1021/bi00367a001; CLADARAS C, 1991, CIRCULATION, V84, P109; DAS HK, 1988, J BIOL CHEM, V263, P11452; DEMMER LA, 1986, P NATL ACAD SCI USA, V83, P8102, DOI 10.1073/pnas.83.21.8102; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1982, METABOLIC BASIS INHE, P672; HARDMAN DA, 1986, METHOD ENZYMOL, V128, P262; HEISS G, 1982, 831266 NIH US DEP HL, P7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IMAGAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P293, DOI 10.1016/0006-291X(91)91368-M; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KARDASSIS D, 1990, J BIOL CHEM, V265, P21733; KARDASSIS D, 1990, MOL CELL BIOL, V10, P2653, DOI 10.1128/MCB.10.6.2653; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LAW SW, 1986, P NATL ACAD SCI USA, V83, P8142, DOI 10.1073/pnas.83.21.8142; LUDWIG EH, 1987, DNA-J MOLEC CELL BIO, V6, P363, DOI 10.1089/dna.1987.6.363; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; METZGER S, 1990, J BIOL CHEM, V265, P9978; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; OGAMI K, 1990, J BIOL CHEM, V265, P9808; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RUSTGI AK, 1990, P NATL ACAD SCI USA, V87, P8707, DOI 10.1073/pnas.87.22.8707; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SNIDERMAN A, 1980, P NATL ACAD SCI-BIOL, V77, P604, DOI 10.1073/pnas.77.1.604; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96	57	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2622	2632						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733959				2022-12-25	WOS:A1992HB53200080
J	MA, YH; BRUIN, T; TUZGOL, S; WILSON, BI; ROEDERER, G; LIU, MS; DAVIGNON, J; KASTELEIN, JJP; BRUNZELL, JD; HAYDEN, MR				MA, YH; BRUIN, T; TUZGOL, S; WILSON, BI; ROEDERER, G; LIU, MS; DAVIGNON, J; KASTELEIN, JJP; BRUNZELL, JD; HAYDEN, MR			2 NATURALLY-OCCURRING MUTATIONS AT THE 1ST AND 2ND BASES OF CODON ASPARTIC ACID-156 IN THE PROPOSED CATALYTIC TRIAD OF HUMAN LIPOPROTEIN-LIPASE - INVIVO EVIDENCE THAT ASPARTIC ACID-156 IS ESSENTIAL FOR CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PANCREATIC LIPASE; SERINE PROTEASE; GENE FAMILY; MISSENSE MUTATION; HEPATIC LIPASE; CDNA; DEFICIENCY; SEQUENCE; CLONING; POLYMORPHISMS	We are studying naturally occurring mutations in the gene for lipoprotein lipase (LPL) to advance our knowledge about the structure/function relationships for this enzyme. We and others have previously described 11 mutations in human LPL gene and until now none of these directly involves any of the residues in the proposed Asp156-His241-Ser132 catalytic triad. Here we report two separate probands who are deficient in LPL activity and have three different LPL gene haplotypes, suggesting three distinct mutations. Using polymerase chain reaction cloning and DNA sequencing we have identified that proband 1 is a compound heterozygote for a G --> A transition at nucleotide 721, resulting in a substitution of asparagine for aspartic acid at residue 156, and a T --> A transversion, resulting in a substitution of serine for cysteine at residue 216. Proband 2 is homozygous for an A --> G base change at nucleotide 722, leading to a substitution of glycine for aspartic acid at residue 156. The presence of these mutations in the patients and available family members was confirmed by restriction analysis of polymerase chain reaction-amplified DNA. In vitro site-directed mutagenesis and subsequent expression in COS cells have confirmed that all three mutations result in catalytically defective LPL. The two naturally occurring mutations, which both alter the same aspartic acid residue in the proposed Asp156-HiS241-Ser132 catalytic triad of human LPL, indicate that Asp156 plays a significant role in LPL catalysis. The Cys216 --> Ser mutation destroys a conserved disulfide bridge that is apparently critical for maintaining LPL structure and function.	UNIV BRITISH COLUMBIA, DEPT MED GENET, RM 416, 2125 EAST MALL, VANCOUVER V6T 1Z4, BC, CANADA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, QUEBEC, CANADA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; UNIV AMSTERDAM, ACAD MED CTR, LIPID RES GRP, 1105 AZ AMSTERDAM, NETHERLANDS	University of British Columbia; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Washington; University of Washington Seattle; University of Amsterdam; Academic Medical Center Amsterdam			Kastelein, John/AAF-7950-2020; Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419	NIDDK NIH HHS [DK-02456] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMEIS D, 1991, J CLIN INVEST, V87, P1165, DOI 10.1172/JCI115114; BABIRAK SP, 1989, ARTERIOSCLEROSIS, V9, P326, DOI 10.1161/01.ATV.9.3.326; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; DATTA S, 1988, J BIOL CHEM, V263, P1107; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; DICHEK HL, 1991, J BIOL CHEM, V266, P473; EMI M, 1990, J BIOL CHEM, V265, P5910; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P14418; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; FISHER KL, 1987, NUCLEIC ACIDS RES, V15, P7657, DOI 10.1093/nar/15.18.7657; FUNKE H, 1987, NUCLEIC ACIDS RES, V15, P9102, DOI 10.1093/nar/15.21.9102; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HATA A, 1990, AM J HUM GENET, V47, P721; Hayden M.R., 1991, CURRENT OPINION LIPI, V2, P104; HENDERSON HE, 1991, J CLIN INVEST, V87, P2005, DOI 10.1172/JCI115229; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; Kerfelec B, 1986, Pancreas, V1, P430, DOI 10.1097/00006676-198609000-00007; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOMAROMY MC, 1987, P NATL ACAD SCI USA, V84, P1526, DOI 10.1073/pnas.84.6.1526; LOWE ME, 1989, J BIOL CHEM, V264, P20042; MA YH, 1991, NEW ENGL J MED, V324, P1761, DOI 10.1056/NEJM199106203242502; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; MULLENBACH R, 1989, TRENDS GENET, V5, P391; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SENDA M, 1987, P NATL ACAD SCI USA, V84, P4369, DOI 10.1073/pnas.84.13.4369; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; YANG CY, 1989, J BIOL CHEM, V264, P16822	35	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1918	1923						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730727				2022-12-25	WOS:A1992HA48500080
J	SWEASY, JB; LOEB, LA				SWEASY, JB; LOEB, LA			MAMMALIAN DNA POLYMERASE-BETA CAN SUBSTITUTE FOR DNA-POLYMERASE-I DURING DNA-REPLICATION IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CONSTITUTIVE EXPRESSION; MUTANTS; EXONUCLEASES; PLASMIDS; REPAIR; CELLS	Mammalian DNA polymerase-beta is the smallest known eukaryotic polymerase and is expressed as an active protein in Escherichia coli harboring a plasmid containing its cDNA. Since some catalytic functions of DNA polymerase-beta and E. coli DNA polymerase I are similar, we wished to determine if DNA polymerase-beta could substitute for DNA polymerase I in bacteria. We found that the expression of mammalian DNA polymerase-beta in E. coli restored growth in a DNA polymerase I-defective bacterial mutant. Sucrose density gradient analysis revealed that DNA polymerase-beta complements the replication defect in the mutant by increasing the rate of joining of Okazaki fragments. These findings demonstrate that DNA polymerase-beta, believed to function in DNA repair in mammalian cells, can also function in DNA replication. Moreover, this complementation system will permit study of the in vivo function of altered species of DNA polymerase-beta, an analysis currently precluded by the difficulty in isolating mutants in mammalian cells.			SWEASY, JB (corresponding author), UNIV WASHINGTON,DEPT PATHOL,JOSEPH GOTTSTEIN MEM CANC RES LAB,SEATTLE,WA 98195, USA.				NATIONAL CANCER INSTITUTE [F32CA008923] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA-3990, CA08923] Funding Source: Medline; NIA NIH HHS [AG-00057] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BLANK A, 1983, ANAL BIOCHEM, V135, P423, DOI 10.1016/0003-2697(83)90705-4; CHANG LMS, 1971, J BIOL CHEM, V246, P5835; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; FRY M, 1983, ENZYMES NUCLEIC ACID, P135; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOWARDFLANDERS P, 1981, DNA REPAIR LABORATOR, P459; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; Kornberg A., 1992, DNA REPLICATION; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LONGLEY M J, 1989, Methods in Molecular and Cellular Biology, V1, P79; MCCALL JO, 1987, J BACTERIOL, V169, P728, DOI 10.1128/jb.169.2.728-734.1987; MCMACKEN R, 1987, ESCHERICHIA COLI SAL, P564; Miller J. H ., 1971, EXPT MOL GENETICS; MOSBAUGH DW, 1983, J BIOL CHEM, V258, P108; OGAWA T, 1984, MOL GEN GENET, V193, P231, DOI 10.1007/BF00330673; OKAZAKI R, 1968, P NATL ACAD SCI USA, V59, P598, DOI 10.1073/pnas.59.2.598; OKAZAKI R, 1971, P NATL ACAD SCI USA, V68, P2954, DOI 10.1073/pnas.68.12.2954; RANDAHL H, 1988, J BIOL CHEM, V263, P12228; REIN DC, 1990, EUKARYOTIC NUCLEUS M, P95; SPANOS A, 1981, NUCLEIC ACIDS RES, V9, P1825, DOI 10.1093/nar/9.8.1825; UYEMURA D, 1976, J BIOL CHEM, V251, P4078; UYEMURA D, 1976, J BIOL CHEM, V251, P4079; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WESTERGAARD O, 1973, J BIOL CHEM, V248, P1361; WITKIN EM, 1982, MOL GEN GENET, V185, P43, DOI 10.1007/BF00333788	28	103	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1407	1410						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730689				2022-12-25	WOS:A1992HA48500002
J	VERMA, R; CAMPBELL, JL				VERMA, R; CAMPBELL, JL			IDENTIFICATION AND PURIFICATION OF DBF-A, A DOUBLE-STRANDED DNA-BINDING PROTEIN FROM SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; LARGE-TUMOR-ANTIGEN; AUTONOMOUS REPLICATION; GEL-ELECTROPHORESIS; YEAST; SEQUENCE; ORIGIN; ARS1; PLASMIDS; INVITRO	Using oligonucleotide affinity chromatography with DNase I footprinting as an assay we have looked for proteins that interact with sequence elements within the yeast origin of replication, autonomously replicating sequence 1 (ARS1). In this work we describe a protein that binds with high affinity to DNA but displays only moderate sequence specificity. It is eluted at 0.7 M salt from an ARS1 oligonucleotide column. Footprinting analysis on ARS1 at a high protein concentration revealed at least three sites of protection flanking element A and its repeats. Element A itself is rendered hypersensitive to DNase I digestion upon protein binding. This pattern is also observed for the H4 and HMR-E ARSs, suggesting that the protein alters the DNA conformation at element A and its repeats. The affinity-purified fraction is also capable of supercoiling a relaxed, covalently closed plasmid in the presence of topoisomerase. Highly purified preparations of the protein are enriched in an 18-kDa polypeptide which can be renatured from a denaturing gel and shown to bind ARS1 DNA. We have designated this protein DBF-A, DNA-binding factor A.	CALTECH, BRAUN LABS, PASADENA, CA 91125 USA	California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025505] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25505] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; BAUR CP, 1988, J MOL BIOL, V203, P1009, DOI 10.1016/0022-2836(88)90125-8; BOUTON AH, 1986, MOL CELL BIOL, V6, P2354, DOI 10.1128/MCB.6.7.2354; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; CAMPBELL JL, 1991, IN PRESS MOL CELLULA; CARON F, 1979, P NATL ACAD SCI USA, V76, P4265, DOI 10.1073/pnas.76.9.4265; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P8981, DOI 10.1073/pnas.84.24.8981; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DIFFLEY JFX, 1988, CANCER CELLS EUKARYO, V6, P243; ECKDAHL TT, 1990, NUCLEIC ACIDS RES, V18, P1609, DOI 10.1093/nar/18.6.1609; ECKDAHL TT, 1987, NUCLEIC ACIDS RES, V15, P8531; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GORANSSON M, 1990, NATURE, V344, P682, DOI 10.1038/344682a0; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; HOLMES SG, 1989, MOL CELL BIOL, V9, P5464, DOI 10.1128/MCB.9.12.5464; HUISMAN O, 1989, J BACTERIOL, V171, P3704, DOI 10.1128/jb.171.7.3704-3712.1989; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KOLODRUBETZ D, 1991, YEAST, V7, P79, DOI 10.1002/yea.320070202; KUNO K, 1990, GENE, V95, P73, DOI 10.1016/0378-1119(90)90415-N; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; Maniatis T., 1982, MOL CLONING LABORATO, P156; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; POLACZEK P, 1990, New Biologist, V2, P265; SCHMID MB, 1990, CELL, V63, P451, DOI 10.1016/0092-8674(90)90438-K; SCHMIDT AMA, 1991, EMBO J, V10, P981, DOI 10.1002/j.1460-2075.1991.tb08032.x; SHORE D, 1987, EMBO J, V6, P461, DOI 10.1002/j.1460-2075.1987.tb04776.x; SIMPSON RT, 1990, NATURE, V343, P387, DOI 10.1038/343387a0; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; Stinchcomb D. T, 1981, INITIATION DNA REPLI, P473, DOI 10.1016/b978-0-12-583580-0.50036-4; STRICH R, 1986, YEAST, V2, P169, DOI 10.1002/yea.320020305; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; WADA M, 1988, J MOL BIOL, V204, P581, DOI 10.1016/0022-2836(88)90357-9; WEBER K, 1969, J BIOL CHEM, V244, P4406; WIEDERRECHT G, 1987, CELL, V48, P507, DOI 10.1016/0092-8674(87)90201-7; WINTER E, 1989, EMBO J, V8, P1867, DOI 10.1002/j.1460-2075.1989.tb03583.x; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643	51	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1648	1654						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730709				2022-12-25	WOS:A1992HA48500040
J	MODDERMAN, PW; ADMIRAAL, LG; SONNENBERG, A; BORNE, AEGKV				MODDERMAN, PW; ADMIRAAL, LG; SONNENBERG, A; BORNE, AEGKV			GLYCOPROTEIN-V AND GLYCOPROTEIN-IB-IX FORM A NONCOVALENT COMPLEX IN THE PLATELET MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BERNARD-SOULIER SYNDROME; FACTOR-BINDING DOMAIN; HUMAN-BLOOD PLATELETS; VONWILLEBRAND-FACTOR; SURFACE GLYCOPROTEINS; MONOCLONAL-ANTIBODIES; ALPHA-CHAIN; THROMBIN; RECEPTOR	Platelet glycoprotein (GP) V is a M(r) 82,000 plasma membrane protein of unknown function that is cleaved by the potent platelet agonist, thrombin, to yield a M(r) 69,500 fragment (GPV(f1)). Platelet GPIb, a disulfide-linked alpha-beta-heterodimer (M(r) 160,000) that forms a noncovalent complex with GPIX (M(r) 22,000), functions as the platelet adhesion receptor for surface-bound von Willebrand factor. Association between GPV and GPIb-IX has been suggested by the finding that both proteins are deficient in the Bernard-Soulier syndrome, a bleeding disorder characterized by giant platelets and defective interaction with von Willebrand factor. Here we report that GPV and GPIb-IX are coprecipitated by monoclonal antibodies (mAbs) against GPV, GPIb, or GPIX when platelets are solubilized in the mild detergent, digitonin. Treatment of digitonin immunopreciptates with the nonionic detergent, Nonidet P-40, released GPV from anti-GPIb and anti-GPIX mAb precipitates and GPIb-IX from the anti-GPV mAb precipitate. Removal of the M(r) 45,000 amino-terminal part of GPIb-alpha by treatment with elastase did not abrogate association of GPV with GPIb-IX, showing that the leucine-rich repeat sequences in GPIb-alpha are not required for complex formation. Binding studies with I-125-labeled mAbs showed the presence of 24,370 GPIb-IX complexes and 11, 170 molecules of GPV/platelet (n = 5). These data show that the leucine-rich glycoproteins GPV and GPIb-IX form a noncovalent complex in the platelet membrane. GPV may play a role in the interaction of platelets with von Willebrand factor.	UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT HAEMATOL,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	MODDERMAN, PW (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT IMMUNOHEMATOL,POB 9406,1006 AK AMSTERDAM,NETHERLANDS.							BERNDT MC, 1983, BLOOD, V62, P800; BIENZ D, 1986, BLOOD, V68, P720; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; COLLER BS, 1983, BLOOD, V61, P99; COLLER BS, 1977, J CLIN INVEST, V60, P302, DOI 10.1172/JCI108778; DROUIN J, 1989, BLOOD, V74, pA31; DU XP, 1987, BLOOD, V69, P1524; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GEORGE JN, 1986, J CLIN INVEST, V78, P340, DOI 10.1172/JCI112582; HANDA M, 1986, J BIOL CHEM, V261, P2579; HARMON JT, 1986, J BIOL CHEM, V261, P3224; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HOMBACH J, 1988, EMBO J, V7, P3451, DOI 10.1002/j.1460-2075.1988.tb03219.x; HOURDILLE P, 1990, BLOOD, V76, P1503; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; LEGRAND C, 1985, BIOCHIM BIOPHYS ACTA, V812, P802, DOI 10.1016/0005-2736(85)90275-5; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MCGOWAN EB, 1983, ARCH BIOCHEM BIOPHYS, V227, P287, DOI 10.1016/0003-9861(83)90373-9; MICHELSON AD, 1987, BLOOD, V70, P1673; MILLER JL, 1982, BLOOD, V60, P790; MODDERMAN PW, 1989, BRIT J HAEMATOL, V73, P514, DOI 10.1111/j.1365-2141.1989.tb00290.x; MOSHER DF, 1979, BLOOD, V53, P437; OETGEN HC, 1986, NATURE, V320, P272; PHILLIPS DR, 1977, BIOCHEM BIOPH RES CO, V75, P940, DOI 10.1016/0006-291X(77)91473-5; ROTH GJ, 1990, BIOCHEM BIOPH RES CO, V170, P153, DOI 10.1016/0006-291X(90)91253-O; ROTH GJ, 1991, BLOOD, V77, P5; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHIMOMURA T, 1990, BLOOD, V75, P2349; SONNENBERG A, 1988, J BIOL CHEM, V263, P14030; STEINER B, 1983, THROMB RES, V29, P43, DOI 10.1016/0049-3848(83)90124-X; TETTEROO PAT, 1983, BRIT J HAEMATOL, V55, P509, DOI 10.1111/j.1365-2141.1983.tb02166.x; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VONDEMBORNE AEG, 1989, LEUCOCYTE TYPING, V4, P951; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS HJ, 1982, NEW ENGL J MED, V306, P326, DOI 10.1056/NEJM198202113060603; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x	38	166	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					364	369						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730602				2022-12-25	WOS:A1992GY43900060
J	SMITH, AF; TSUCHIDA, K; HANNEMAN, E; SUZUKI, TC; WELLS, MA				SMITH, AF; TSUCHIDA, K; HANNEMAN, E; SUZUKI, TC; WELLS, MA			ISOLATION, CHARACTERIZATION, AND CDNA SEQUENCE OF 2 FATTY ACID-BINDING PROTEINS FROM THE MIDGUT OF MANDUCA-SEXTA LARVAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXPRESSION	Two abundant fatty acid-binding proteins (MFB1 and MFB2) were isolated from the midgut cytosol of larval Manduca sexta. As isolated, MFB1 and MFB2 were found to contain bound fatty acids in a 1:1 molar stoichiometric ratio. Immunological screening demonstrated that MFB1 and MFB2 were restricted to the midgut in a gradient distribution, with MFB1 more concentrated in the anterior two-thirds of the midgut and MFB2 more concentrated in the posterior two-thirds of the midgut. MFB1 exchanged fatty acid more readily than did MFB2. MFB1 was about 2% and MFB2 about 12% of the cytosolic protein in the midgut. cDNA clones for MFB1 and MFB2 both encode proteins of 131 amino acids that are rich in lysine and acidic residues. Analysis of the amino acid sequence alignment of the MFBs with six mammalian fatty acid-binding proteins revealed a number of shared features: 9 conserved glycines, presumably important in turns of the beta-strands; a basic amino acid in a position corresponding to the residue reported to participate in binding the carboxyl group of the fatty acid (Arg in MFB1 and Lys in MFB2); and conservation of many of the residues important in binding the aliphatic portion of the fatty acid.	UNIV ARIZONA,CTR INSECT SCI,TUCSON,AZ 85721	University of Arizona	SMITH, AF (corresponding author), UNIV ARIZONA,DEPT BIOCHEM,BIOSCI W,TUCSON,AZ 85721, USA.				NHLBI NIH HHS [HL39116] Funding Source: Medline; NIGMS NIH HHS [GM13656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1127; BERNIER I, 1987, BIOCHIMIE, V69, P1127, DOI 10.1016/0300-9084(87)90140-4; BURNETTE WN, 1981, ANAL BIOCHEM, V18, P5294; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FERNANDOWARNAKULASURIYA GJP, 1988, INSECT BIOCHEM, V18, P211, DOI 10.1016/0020-1790(88)90025-X; GLATZ JFC, 1990, MOL CELL BIOCHEM, V98, P237, DOI 10.1007/BF00231390; HAUNERLAND NH, 1990, BIOCHIM BIOPHYS ACTA, V1047, P233, DOI 10.1016/0005-2760(90)90521-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM KT, 1988, J BIOL CHEM, V263, P15762; MAATMAN RGHJ, 1991, BIOCHEM J, V273, P759, DOI 10.1042/bj2730759; MORROW FD, 1983, J LIPID RES, V24, P324; MOSER D, 1991, J BIOL CHEM, V266, P8447; OCKNER RK, 1990, MOL CELL BIOCHEM, V98, P3; PRASAD SV, 1986, J BIOL CHEM, V261, P558; SACCHETTINI JC, 1990, MOL CELL BIOCHEM, V98, P81; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAKIS C, 1986, DEV BIOL, V114, P194, DOI 10.1016/0012-1606(86)90395-7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C	21	58	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					380	384						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730603				2022-12-25	WOS:A1992GY43900062
J	LEVIN, JD; SHAPIRO, R; DEMPLE, B				LEVIN, JD; SHAPIRO, R; DEMPLE, B			METALLOENZYMES IN DNA-REPAIR - ESCHERICHIA-COLI ENDONUCLEASE-IV AND SACCHAROMYCES-CEREVISIAE APN1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION; ENZYME; DIESTERASE; SUBSTRATE; PROTEIN; REGULON; DAMAGE; GENE; K-12	Escherichia coli endonuclease IV and its Saccharomyces cerevisiae homologue Apn1, two DNA repair enzymes for free radical damages, were previously shown to be inactivated by metal-chelating agents. In the present study, atomic absorption spectrometry of endonuclease IV revealed the presence of 2.4 zinc and 0.7 manganese atoms, whereas Apn1 contained 3.3 zinc atoms and no significant manganese. EDTA-inactivated endonuclease IV retained 0.7 zinc atom but little detectable manganese. ZnCl2 reactivated 1,10-phenanthroline-treated Apn1, but was ineffective with endonuclease IV treated with either 1,10-phenanthroline or EDTA. In contrast, enzymatic activity was restored to both enzymes after EDTA treatment by incubation with CoCl2 and to a lesser extent by MnCl2. Endonuclease IV, reactivated with CoCl2 or MnCl2, regained all of the activities characteristic of the native enzyme. MnCl2 was as effective as CoCl2 at restoring activity to the 1,10-phenanthroline-treated enzymes. The results indicate that intrinsic metals play critical roles in both endonuclease IV and Apn1 and that manganese may perform a special function in endonuclease IV. Possible mechanistic roles for the metals in these DNA repair enzymes are discussed.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,665 HUNTINGTON AVE,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOCHEM & BIOPHYS SCI & MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NCI NIH HHS [CA37831] Funding Source: Medline; NIGMS NIH HHS [GM07598] Funding Source: Medline; PHS HHS [E503926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNELOTMOENS C, 1989, NUCLEIC ACIDS RES, V17, P587, DOI 10.1093/nar/17.2.587; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; COTTON FA, 1979, P NATL ACAD SCI USA, V76, P2551, DOI 10.1073/pnas.76.6.2551; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; CUNNINGHAM RP, 1986, J BACTERIOL, V168, P1120, DOI 10.1128/jb.168.3.1120-1127.1986; DEMPLE B, 1986, P NATL ACAD SCI USA, V83, P7731, DOI 10.1073/pnas.83.20.7731; GREENBERG JT, 1990, P NATL ACAD SCI USA, V87, P6181, DOI 10.1073/pnas.87.16.6181; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; JOHNSON AW, 1988, J BIOL CHEM, V263, P18017; JOHNSON AW, 1988, J BIOL CHEM, V263, P18009; KIM EE, 1989, CLIN CHIM ACTA, V186, P175; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; LEVIN JD, 1990, NUCLEIC ACIDS RES, V18, P5069, DOI 10.1093/nar/18.17.5069; LJUNGQUIST S, 1977, J BIOL CHEM, V252, P2808; MANIATIS T, 1982, MOL CLONING LABORATO, P468; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; RAMOTAR D, 1991, MOL MICROBIOL, V5, P149, DOI 10.1111/j.1365-2958.1991.tb01835.x; Rogers S G, 1980, Methods Enzymol, V65, P201; SAPORITO SM, 1988, J BACTERIOL, V170, P5141, DOI 10.1128/jb.170.11.5141-5145.1988; SILLEN LG, 1964, SPECIAL PUBLICATION, V17; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; TSANEVA IR, 1990, J BACTERIOL, V172, P4197, DOI 10.1128/jb.172.8.4197-4205.1990; ULMER DD, 1971, ADV CHEM SCI, V100, P187; VALLEE BL, 1991, P NATL ACAD SCI USA, V88, P999, DOI 10.1073/pnas.88.3.999; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; VALLEE BL, 1974, PROTEIN METAL INTERA, P33; WILLIAMS RJP, 1985, J MOL CATAL, V30, P1, DOI 10.1016/0304-5102(85)80013-4	31	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					22893	22898						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1720775				2022-12-25	WOS:A1991GT48300021
J	AGAWA, Y; LEE, S; ONO, S; AOYAGI, H; OHNO, M; TANIGUCHI, T; ANZAI, K; KIRINO, Y				AGAWA, Y; LEE, S; ONO, S; AOYAGI, H; OHNO, M; TANIGUCHI, T; ANZAI, K; KIRINO, Y			INTERACTION WITH PHOSPHOLIPID-BILAYERS, ION CHANNEL FORMATION, AND ANTIMICROBIAL ACTIVITY OF BASIC AMPHIPATHIC ALPHA-HELICAL MODEL PEPTIDES OF VARIOUS CHAIN LENGTHS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID BILAYERS; PERMEABLE CHANNELS; XENOPUS SKIN; MEMBRANES; FORMS; POLYPEPTIDE	Basic amphipathic alpha-helical peptides Ac-(Leu-Ala-Arg-Leu)3 or 4-NHCH3 (4(3) or 4(4)) and H-(Leu-Ala-Arg-Leu)3-(Leu-Arg-Ala-Leu)2 or 3-OH (4(5)or 4(6)) were synthesized and studied in terms of their interactions with phospholipid membranes, biological activity, and ion channel-forming ability. CD study of the peptides showed that they form alpha-helical structures in the presence of phospholipid liposomes and thus they have amphipathic distribution of the side chains along the axis of the helix. A leakage study of carboxyfluorescein encapsulated in phospholipid vesicles indicated that the peptides possess a highly potent ability to perturb the membrane structure. Membrane current measurements using the planar lipid bilayer technique revealed that the peptide 4(6), which was long enough to span the lipid bilayer in the alpha-helical structure, formed cation-selective ion channels at a concentration of 0.5-mu-M in a planar diphytanoylphosphatidylcholine bilayer. In contrast, other shorter peptides failed to form discrete and stable channels though they occasionally induced an increase in the membrane current with erratic conductance levels. The probability of detecting a conductance increase was in the order of 4(6) > 4(5) > 4(4) > 4(3), which corresponds to the order of the peptide chain lengths. Furthermore, 4(6) but not 4(5) showed an antimicrobial activity against both Gram-positive and -negative bacteria. The structure of ion channels formed by 4(6) and the relationship between the peptide chain length and biological activity of the synthetic peptides are discussed.	KYUSHU UNIV,FAC SCI,DEPT CHEM,BIOCHEM LAB,HIGASHI KU,FUKUOKA 812,JAPAN; KYUSHU UNIV,FAC PHARMACEUT SCI,HIGASHI KU,FUKUOKA 812,JAPAN	Kyushu University; Kyushu University			Anzai, Kazunori/C-8577-2009					ANZAI K, 1991, BIOCHIM BIOPHYS ACTA, V1064, P256, DOI 10.1016/0005-2736(91)90310-5; ANZAI K, 1989, J PHARMACOBIODYN S, V12, P122; BOMAN HG, 1981, CURR TOP MICROBIOL, V94-5, P75; CHRISTENSEN B, 1988, P NATL ACAD SCI USA, V85, P5072, DOI 10.1073/pnas.85.14.5072; DAVIS JH, 1983, BIOCHEMISTRY-US, V22, P5298, DOI 10.1021/bi00292a008; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FUJIWARA C, 1988, J BIOCHEM, V104, P344, DOI 10.1093/oxfordjournals.jbchem.a122471; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HALL JE, 1984, BIOPHYS J, V45, P233, DOI 10.1016/S0006-3495(84)84151-X; HLADKY SB, 1972, BIOCHIM BIOPHYS ACTA, V274, P294, DOI 10.1016/0005-2736(72)90178-2; IDE T, 1989, BIOCHEM BIOPH RES CO, V163, P155, DOI 10.1016/0006-291X(89)92113-X; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KAISER ET, 1987, ANNU REV BIOPHYS BIO, V16, P561; KONIG W, 1970, CHEM BER-RECL, V103, P788, DOI 10.1002/cber.19701030319; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LEE S, 1986, BIOCHIM BIOPHYS ACTA, V862, P211, DOI 10.1016/0005-2736(86)90485-2; MELLOR IR, 1988, BIOCHIM BIOPHYS ACTA, V942, P280, DOI 10.1016/0005-2736(88)90030-2; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; OIKI S, 1988, P NATL ACAD SCI USA, V85, P2393, DOI 10.1073/pnas.85.7.2393; REDWOOD WR, 1971, BIOCHIM BIOPHYS ACTA, V233, P1, DOI 10.1016/0005-2736(71)90351-8; SAKAKIBARA S, 1967, B CHEM SOC JPN, V40, P2164, DOI 10.1246/bcsj.40.2164; SHAI Y, 1988, FEBS LETT, V242, P161, DOI 10.1016/0014-5793(88)81007-X; SUENAGA M, 1989, BIOCHIM BIOPHYS ACTA, V981, P143, DOI 10.1016/0005-2736(89)90092-8; TAKAGI M, 1965, Annual Report of Biological Works Faculty of Science Osaka University, V13, P107; TOSTESON MT, 1989, P NATL ACAD SCI USA, V86, P707, DOI 10.1073/pnas.86.2.707; TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4; UMEDA A, 1986, ANTIMICROB AGENTS CH, V30, P398, DOI 10.1128/AAC.30.3.398; WEINSTEIN JN, 1977, SCIENCE, V195, P489, DOI 10.1126/science.835007; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	30	91	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20218	20222						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1718959				2022-12-25	WOS:A1991GM03900053
J	ORLANDO, RA; CHERESH, DA				ORLANDO, RA; CHERESH, DA			ARGININE-GLYCINE-ASPARTIC ACID BINDING LEADING TO MOLECULAR STABILIZATION BETWEEN INTEGRIN ALPHA-V-BETA-3 AND ITS LIGAND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; HUMAN-ENDOTHELIAL CELLS; SYNTHETIC PEPTIDES; VITRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; HAMSTER FIBROBLASTS; ADHESION RECEPTORS; MELANOMA-CELLS; BETA-SUBUNIT	Cell adhesion is characterized by an integrin-mediated ligand binding event followed by reorganization of the actin-cytoskeleton leading to cell spreading and/or migration. In this report we examine the role of integrin alpha-v-beta-3 in mediating cell attachment to vitronectin or a RGD-containing peptide in the presence of cytochalasin B to prevent actin polymerization. Under these conditions cell attachment to a RGD-containing peptide can be dissociated by excess soluble ligand whereas cells attached to vitronectin cannot. These results suggest that alpha-v-beta-3-mediated cell attachment to vitronectin results in a highly stabilized interaction that is independent of the actin-cytoskeleton. To investigate the molecular nature of this interaction alpha-v-beta-3 was purified to homogeneity, and its binding properties toward various ligands were measured in a solid-phase receptor assay. The data indicate that alpha-v-beta-3 binds to vitronectin or fibronectin in a nondissociable manner whereas a RGD-containing peptide derived from vitronectin binds specifically but is completely dissociable with a K(d) of 9.4 x 10(-7) M. Moreover, chemical modification of alpha-v-beta-3 with limited glutaraldehyde treatment allowed vitronectin to bind in a RGD-dependent and dissociable manner, suggesting that receptor conformational changes or specific amino acid residues proximal to the ligand binding site(s) are involved in the stabilization event. Thus, in the absence of cytoskeletal proteins or other cellular components, integrin alpha-v-beta-3-ligand binding involves recognition of the RGD sequence leading to a highly stabilized protein-protein association.	SCRIPPS CLIN & RES FDN, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NCI NIH HHS [CA50286, CA45726] Funding Source: Medline; NIAID NIH HHS [T32 AI 07244-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA050286, R01CA045726, R01CA050286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARSHAVIT R, 1991, J CELL BIOL, V112, P335, DOI 10.1083/jcb.112.2.335; BOUCAUT JC, 1984, J CELL BIOL, V99, P1822, DOI 10.1083/jcb.99.5.1822; BURRIDGE K, 1987, J CELL SCI, P211; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CARTER WG, 1981, J CELL BIOL, V88, P138, DOI 10.1083/jcb.88.1.138; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; DAVIDPFEUTY T, 1985, EUR J CELL BIOL, V36, P195; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GEHLSEN KR, 1988, J CELL BIOL, V106, P925, DOI 10.1083/jcb.106.3.925; GRINNELL F, 1974, ARCH BIOCHEM BIOPHYS, V165, P524, DOI 10.1016/0003-9861(74)90278-1; HUGHES RC, 1979, EXP CELL RES, V121, P307, DOI 10.1016/0014-4827(79)90009-0; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; LOTZ MM, 1989, J CELL BIOL, V109, P1795, DOI 10.1083/jcb.109.4.1795; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MCCARTHY JB, 1984, J CELL BIOL, V98, P1474, DOI 10.1083/jcb.98.4.1474; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PEERSCHKE EIB, 1985, AM J PHYSIOL, V248, pC466, DOI 10.1152/ajpcell.1985.248.5.C466; PHILLIPS DR, 1988, BLOOD, V71, P831; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; RAUB TJ, 1989, EXP CELL RES, V184, P407, DOI 10.1016/0014-4827(89)90340-6; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SINGER II, 1982, J CELL BIOL, V92, P398, DOI 10.1083/jcb.92.2.398; SINGER II, 1988, J CELL BIOL, V106, P2171, DOI 10.1083/jcb.106.6.2171; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1990, J BIOL CHEM, V265, P11008; SMITH JW, 1988, J BIOL CHEM, V263, P18726; TUSZYNSKI GP, 1984, J BIOL CHEM, V259, P5247; VIRTANEN I, 1982, NATURE, V298, P660, DOI 10.1038/298660a0; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WILEY HS, 1982, J BIOL CHEM, V257, P4222; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	41	100	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19543	19550						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717468				2022-12-25	WOS:A1991GK66700063
J	GUSTERSON, BA; ANBAZHAGAN, R; WARREN, W; MIDGELY, C; LANE, DP; OHARE, M; STAMPS, A; CARTER, R; JAYATILAKE, H				GUSTERSON, BA; ANBAZHAGAN, R; WARREN, W; MIDGELY, C; LANE, DP; OHARE, M; STAMPS, A; CARTER, R; JAYATILAKE, H			EXPRESSION OF P53 IN PREMALIGNANT AND MALIGNANT SQUAMOUS EPITHELIUM	ONCOGENE			English	Article							CARCINOMA CELL-LINES; MONOCLONAL-ANTIBODIES; LUNG-CANCER; PROTO-ONCOGENE; BREAST-CANCER; TUMOR-ANTIGEN; GENE; MUTATIONS; TRANSFORMATION; CHROMOSOME-17	Using three antibodies (JG8, CM-1 and 1081) directed to the p53 protein, strong positivity was found in 16/47 (34.0%) of mucosal squamous cell carcinomas of the head and neck and in two squamous carcinoma cell lines (LICR-LON- HN5 and HN6Rr). The presence of the mutant p53 was confirmed in the cell lines as substitutions in exon 7 (codon 238, TGT > AGT) and exon 5 (codon 152, CCG > CTG) respectively. Positive staining was seen only in the undifferentiated cells and progressively lost as the cells keratinized, both in the tumour specimens and in the cell lines. Similar results were seen in areas of dysplasia, well removed from the site of the primary tumour. Staining of epidermal lesions showed positivity in 2/12 (16.6%) cases of Bowen's disease, 0/12 (0.0%) cases of solar keratosis, 0/10 (0.0%) basal cell carcinomas and in 3/20 (15.0%) squamous cell carcinomas. These results are discussed in relation to the multifocal origin of squamous cell carcinomas, the role of p53 mutations in squamous cell carcinomas from different sites and the significance of the 'basal' distribution of p53 as a normal growth regulator. The possible significance of the distribution of p53 in squamous epithelium as it relates to papilloma virus infection is also considered.	INST CANC RES,HADDOW LABS,MOLEC CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND	University of London; Institute of Cancer Research - UK; University of Dundee	GUSTERSON, BA (corresponding author), INST CANC RES,HADDOW LABS,PATHOL SECT,COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		gusterson, barry a/D-3752-2009; Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BARTEK J, 1990, ONCOGENE, V5, P893; BERG L, 1986, CELL, V46, P753, DOI 10.1016/0092-8674(86)90351-X; BURMAN JF, 1988, HEAD NECK ONCOLOGY R, P11; CARTER RL, 1985, CRC CR REV CL LAB SC, V22, P275, DOI 10.3109/10408368509165845; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHIBA I, 1990, ONCOGENE, V5, P1603; CHOW LT, 1987, CANCER CELLS, V5, P57; Cowley GO, 1984, CANCER CELL, V1, P5; COWLEY GP, 1986, BRIT J CANCER, V53, P223, DOI 10.1038/bjc.1986.39; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EASTY DM, 1981, BRIT J CANCER, V43, P772, DOI 10.1038/bjc.1981.115; EASTY DM, 1981, BRIT J CANCER, V43, P363; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREAVES R, 1988, THESIS U LONDON; GUSTERSON BA, 1986, DIFFERENTIATION, V30, P102; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KNIGHT J, 1985, ULTRASTRUCT PATHOL, V7, P133; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; MACKAY J, 1988, LANCET, V2, P1384; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MCKEE PH, 1990, PATHOLOGY SKIN; MITCHELL D, 1985, J HISTOCHEM CYTOCHEM, V33, P491, DOI 10.1177/33.5.3921605; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PFISTER H, 1984, REV PHYSIOL BIOCH P, V99, P111, DOI 10.1007/BFb0027716; RAYTER Z, 1989, EXP CELL RES, V183, P443, DOI 10.1016/0014-4827(89)90403-5; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STYLES JM, 1990, INT J CANCER, V45, P320, DOI 10.1002/ijc.2910450219; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANDENBERG FM, 1989, J PATHOL, V157, P193, DOI 10.1002/path.1711570304; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252	49	269	272	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1785	1789						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1717923				2022-12-25	WOS:A1991GX11800010
J	ISHIZAKA, Y; KOBAYASHI, S; USHIJIMA, T; HIROHASHI, S; SUGIMURA, T; NAGAO, M				ISHIZAKA, Y; KOBAYASHI, S; USHIJIMA, T; HIROHASHI, S; SUGIMURA, T; NAGAO, M			DETECTION OF RETTPC PTC TRANSCRIPTS IN THYROID ADENOMAS AND ADENOMATOUS GOITER BY AN RT PCR METHOD	ONCOGENE			English	Article							CARCINOMA CELL-LINE; PROTO-ONCOGENE; PAPILLARY CARCINOMAS; TYROSINE KINASE; HIGH-FREQUENCY; II ONCOGENE; ACTIVATION; CLONING; REARRANGEMENT; EXPRESSION	A reverse transcriptase-polymerase chain reaction (RT-PCR) method was adopted for detecting transcripts specific for ret(TPC)/PTC, an activated form of the ret proto-oncogene reported to be found specifically in human papillary thyroid carcinomas. By this sensitive method ret(TPC)/PTC transcript could be detected in about 500 fg of total RNA of TPC-1, a ret(TPC)/PTC transcript-positive cell line. In Japanese patients, one of 11 papillary thyroid carcinomas, four of 19 follicular adenomas and one of two adenomatous goiters were positive for the transcript, indicating that the involvement of ret(TPC)/PTC is not specific to papillary thyroid carcinomas. In several independent RT-PCR experiments using different portions of the same positive carcinoma tissue, ret(TPC)/PTC transcript was always detected. On the other hand, the transcript was not always positive in different RNA samples from benign cases, suggesting that positive carcinomas are probably composed of clonal cell populations all expressing ret(TPC)/PTC, whereas adenomas and adenomatous goiter comprise heterogeneous populations: both positive and negative for ret(TPC)/PTC transcript. Activation of the ret proto-oncogene might therefore be involved in malignant conversion to thyroid carcinomas.	NAGOYA CITY UNIV,SCH MED,DEPT SURG,NAGOYA,AICHI 467,JAPAN; NATL CANC CTR,RES INST,DIV PATHOL,TOKYO 104,JAPAN	Nagoya City University; National Cancer Center - Japan	ISHIZAKA, Y (corresponding author), NATL CANC CTR,RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI 5,CHUO KU,TOKYO 104,JAPAN.		Ushijima, Toshikazu/AAP-5742-2021	Ushijima, Toshikazu/0000-0003-3405-7817				BONGARZONE I, 1989, ONCOGENE, V4, P1457; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONGHI R, 1989, ONCOGENE, V4, P521; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hedinger, 2012, HISTOLOGICAL TYPING; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LEMOINE NR, 1989, ONCOGENE, V4, P159; OSADA H, 1989, JPN J CANCER RES, V80, P711, DOI 10.1111/j.1349-7006.1989.tb01702.x; Sambrook J, 1989, MOL CLONING LABORATO; SAMPSON RJ, 1969, J AMER MED ASSOC, V209, P65; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1; YAGAWA K, 1966, 25 P JAP CANC ASS AN, P106; YAGAWA K, 1962, 25TH P JAP CANC ASS, P106; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; 1988, HISTOLOGICAL TYPING	27	123	125	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1667	1672						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1717926				2022-12-25	WOS:A1991GX27400023
J	WU, CA; ZECHNER, EL; REEMS, JA; MCHENRY, CS; MARIANS, KJ				WU, CA; ZECHNER, EL; REEMS, JA; MCHENRY, CS; MARIANS, KJ			COORDINATED LEADING-STRAND AND LAGGING-STRAND SYNTHESIS AT THE ESCHERICHIA-COLI DNA-REPLICATION FORK .5. PRIMASE ACTION REGULATES THE CYCLE OF OKAZAKI FRAGMENT SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; PROTEIN	Replication forks formed during rolling-circle DNA synthesis supported by a tailed form II DNA substrate in the presence of the primosome, the single-stranded DNA binding protein, and the DNA polymerase III holoenzyme (Pol III HE) that had been reconstituted from the purified subunits, beta, tau, and the gamma.delta complex, at limiting (with respect to nucleotide incorporation) concentrations of the Pol III core (alpha, epsilon, and theta) produced aberrantly small Okazaki fragments, while the synthesis of the leading strand was unperturbed. These small Okazaki fragments were not arrayed in tandem along the lagging-strand DNA template, but were separated by large gaps. Similarly structured synthetic products were not manufactured by replication forks reconstituted with higher, saturating concentrations of the Pol III core. Replication forks producing these small fragments could respond, by modulating the size of the Okazaki fragments produced, to variations in the concentration of NTPs or the primase, conditions that affect the frequency of priming on the lagging strand, but not to variation in the concentration of dNTPs, conditions that affect the frequency of utilization of the primers. Significantly longer Okazaki fragments (> 7 kilobases) could be produced in the presence of a limiting amount of Pol Ill core at low concentrations of the primase. These observations indicated that the production of small Okazaki fragments was not a result of a debilitated lagging-strand Pol Ill core, but rather a function of the time available for nascent strand synthesis during the cycle of events that are required for the manufacture of an Okazaki fragment and that it was the association of primase with the replication fork that keyed this cycle.	CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021; UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	Cornell University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	WU, CA (corresponding author), MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.			Zechner, Ellen L./0000-0003-2035-1898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; GEORGE J, 1980, J BIOL CHEM, V255, P6521; LEBOWITZ J, 1986, J BIOL CHEM, V261, P7438; MAKI S, 1988, J BIOL CHEM, V263, P6561; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ODONNELL ME, 1985, J BIOL CHEM, V260, P2884; SELICK H, 1987, ICN UCLA S MOL CELLU, V7, P183; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	14	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4074	4083						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740453				2022-12-25	WOS:A1992HE60700077
J	ZECHNER, EL; WU, CA; MARIANS, KJ				ZECHNER, EL; WU, CA; MARIANS, KJ			COORDINATED LEADING-STRAND AND LAGGING-STRAND SYNTHESIS AT THE ESCHERICHIA-COLI DNA-REPLICATION FORK .2. FREQUENCY OF PRIMER SYNTHESIS AND EFFICIENCY OF PRIMER UTILIZATION CONTROL OKAZAKI FRAGMENT SIZE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; PROTEIN; PRIMASE; PRIMOSOME; TEMPLATE; ATP	To investigate the role of the priming apparatus at the replication fork in determining Okazaki fragment size, the products of primer synthesis generated in vitro during rolling-circle DNA replication catalyzed by the DNA polymerase III holoenzyme, the single-stranded DNA binding protein, and the primosome on a tailed form II DNA template were isolated and characterized. The abundance of oligoribonucleotide primers and the incidence of covalent DNA chain extension of the primer population was measured under different reaction conditions known to affect the size of the products of lagging-strand DNA synthesis. These analyses demonstrated that the factors affecting Okazaki fragment length could be distinguished by either their effect on the frequency of primer synthesis or by their influence on the efficiency of initiation of DNA synthesis from primer termini. Primase and the ribonucleoside triphosphates were found to stimulate primer synthesis. The observed trend toward smaller fragment size as the concentration of these effectors was raised was apparently a direct consequence of the increased frequency of primer synthesis. The beta-subunit of the DNA polymerase III holoenzyme and the deoxyribonucleoside triphosphates did not alter the priming frequency; instead, the concentration of these factors influenced the ability of the lagging-strand DNA polymerase to efficiently utilize primers to initiate DNA synthesis. Maximum utilization of the available primers correlated with the lowest mean value of Okazaki fragment length. These data were used to draw general conclusions concerning the temporal order of enzymatic steps that operate during a cycle of Okazaki fragment synthesis on the lagging-strand DNA template.	CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Cornell University	ZECHNER, EL (corresponding author), MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.			Zechner, Ellen L./0000-0003-2035-1898	NIGMS NIH HHS [GM 34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; BACHMANN BJ, 1976, BACTERIOL REV, V40, P116, DOI 10.1128/MMBR.40.1.116-167.1976; BENZ EW, 1980, J BIOL CHEM, V255, P1096; BOUCHE JP, 1978, J BIOL CHEM, V253, P765; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; KITANI T, 1985, J MOL BIOL, V184, P45, DOI 10.1016/0022-2836(85)90042-7; KUROSAWA Y, 1979, J MOL BIOL, V135, P841, DOI 10.1016/0022-2836(79)90515-1; LEE MS, 1989, J BIOL CHEM, V264, P14531; MCMACKEN R, 1978, J BIOL CHEM, V253, P3313; MODRICH P, 1971, P NATL ACAD SCI USA, V68, P1002, DOI 10.1073/pnas.68.5.1002; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ROWEN L, 1978, J BIOL CHEM, V253, P758; ROWEN L, 1978, J BIOL CHEM, V253, P770; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; WICKNER S, 1977, P NATL ACAD SCI USA, V74, P2815, DOI 10.1073/pnas.74.7.2815; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P3679, DOI 10.1073/pnas.70.12.3679; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	25	80	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4045	4053						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740452				2022-12-25	WOS:A1992HE60700074
J	HWANG, DS; THONY, B; KORNBERG, A				HWANG, DS; THONY, B; KORNBERG, A			ICIA PROTEIN, A SPECIFIC INHIBITOR OF INITIATION OF ESCHERICHIA-COLI CHROMOSOMAL REPLICATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATES DNAA PROTEIN; ORIGIN; RNA; SEQUENCE; BINDING; HYBRID	Specific binding of IciA protein to the 13-mers in the origin of a minichromosome (oriC) inhibits initiation of replication in vitro by blocking the opening of this region effected by the initiator DnaA protein (Hwang, D. S., and Kornberg, A. (1990) Cell 63, 325-331). Isolation of the iciA gene (Thony, B., Hwang, D. S., Fradkin, L., and Kornberg, A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4066-4070) has made possible the construction of an IciA-overproducing strain, which in turn has simplified the isolation of a large quantity of the protein, indistinguishable from that of the wild-type strain. Based on sedimentation and gel filtration, the IciA protein is an elongated dimer of a 33.4-kDa subunit. The specific binding of IciA protein to the 13-mers was stable for 2 h at 30-degrees-C. The amounts of IciA protein, detected by immunoassays, increased 4-fold compared with levels (about 100 dimers) in log-phase cells whereas levels of DnaA protein decreased upon entry of cells into the stationary phase.	STANFORD UNIV,MED CTR,SCH MED,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University								BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P560; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; DIXON NE, 1984, P NATL ACAD SCI-BIOL, V81, P424, DOI 10.1073/pnas.81.2.424; HANSEN FG, 1991, J BACTERIOL, V173, P5194, DOI 10.1128/jb.173.16.5194-5199.1991; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1991, J BIOL CHEM, V266, P7537; HWANG DS, 1990, J BIOL CHEM, V265, P19244; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kornberg A., 1992, DNA REPLICATION; LEONARD AC, 1988, J BACTERIOL, V170, P1380, DOI 10.1128/jb.170.3.1380-1383.1988; LOW RL, 1984, J BIOL CHEM, V259, P4576; Maniatis T., 1982, MOL CLONING; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; OGAWA T, 1984, P NATL ACAD SCI-BIOL, V81, P1040, DOI 10.1073/pnas.81.4.1040; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; SAKAKIBARA Y, 1982, MOL GEN GENET, V186, P87, DOI 10.1007/BF00422917; SCHONER BE, 1990, METHOD ENZYMOL, V185, P94; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; THONY B, 1991, P NATL ACAD SCI USA, V88, P4066, DOI 10.1073/pnas.88.10.4066; VONMEYENBURG K, 1987, ESCHERICHIA COLI SAL, V2, P1555; YASUDA S, 1977, P NATL ACAD SCI USA, V74, P5458, DOI 10.1073/pnas.74.12.5458; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; ZYSKIND JW, 1983, P NATL ACAD SCI-BIOL, V80, P1164, DOI 10.1073/pnas.80.5.1164	33	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2209	2213						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733927				2022-12-25	WOS:A1992HB53200016
J	SARNESTO, A; KOHLIN, T; HINDSGAUL, O; THURIN, J; BLASZCZYKTHURIN, M				SARNESTO, A; KOHLIN, T; HINDSGAUL, O; THURIN, J; BLASZCZYKTHURIN, M			PURIFICATION OF THE SECRETOR-TYPE BETA-GALACTOSIDE ALPHA-1-]2-FUCOSYL-TRANSFERASE FROM HUMAN SERUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD GROUP-A; HUMAN-ERYTHROCYTE MEMBRANES; 2 FUCOSYL-TRANSFERASE; CARCINOMA CELL-LINE; SUB-MAXILLARY GLAND; MONOCLONAL-ANTIBODY; ANTIGENIC DETERMINANTS; VASCULAR ENDOTHELIUM; LEWIS ANTIGENS; H-GENE	The secretor-type beta-galactoside alpha-1 --> 2-fucosyltransferase from human serum was purified by hydrophobic chromatography on phenyl-Sepharose, ion-exchange chromatography on sulfopropyl-Sepharose, and affinity chromatography on GDP-hexanolamine-Sepharose. Final purification of the enzyme was achieved by high pressure liquid chromatography gel filtration and resulted in a homogeneous protein as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the radiolabeled protein. The native enzyme appears as a molecule of apparent M(r) 150,000 as determined by gel filtration high pressure liquid chromatography. The apparent M(r) of the enzyme resolved in the presence of beta-mercaptoethanol by sodium dodecyl sulfate-polyacrylamide gel electrophoresis was determined to be 50,000, indicating a multisubunit structure of the enzyme. Secretor-type alpha-1 --> 2-fucosyltransferase is a glycoprotein as determined by WGA binding properties. A comparison of the M(r) of the native blood group H gene encoded with the secretor-type beta-galactoside alpha-1 --> 2-fucosyltransferases as well as comparison of subunit M(r) for both enzymes suggests structural similarity. The alpha-1 --> 2 linkage formed between alpha-L-fucose and terminal beta-D-galactose by the purified H- and secretor-type alpha-1 --> 2-fucosyltransferases was determined by H-1 NMR homonuclear cross-irradiation analysis of the oligosaccharide products. The substrate specificity and K(m) values calculated from the initial rate using various oligosaccharide acceptors showed that purified enzymes differ primarily in affinity for phenyl-beta-D-galactopyranoside and GDP-fucose as well as type 1 (Gal-beta-1 --> 3GlcNAc), 2 (Gal-beta-1 --> 4GlcNAc), and 3 (Gal-beta-1 --> 3GalNAc) oligosaccharide acceptors. The secretor-type alpha-1 --> 2-fucosyltransferase shows significantly lower affinity than the H enzyme for phenyl-beta-D-galactopyranoside and GDP-fucose as well as for type 2 oligosaccharide acceptors. On the contrary, type 1 and 3 oligosaccharide acceptors are preferentially utilized by the secretor-type enzyme as compared with the H enzyme. The enzymes also differ in several physicochemical properties, implying nonidentity of the two enzymes (Sarnesto, A., Kohlin, T., Thurin, J., and Blaszczyk-Thurin, M. (1990) J. Biol. Chem. 265, 15067-15075).	WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA; UNIV ALBERTA, DEPT CHEM, EDMONTON T6G 2G2, ALBERTA, CANADA	The Wistar Institute; University of Alberta					NATIONAL CANCER INSTITUTE [R01CA045363, R01CA050542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI028679] Funding Source: NIH RePORTER; NCI NIH HHS [CA50542, CA45363] Funding Source: Medline; NIAID NIH HHS [AI28679] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE K, 1986, CANCER RES, V46, P2639; AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; BETTERIDGE A, 1985, BIOCHEM SOC T, V13, P1126, DOI 10.1042/bst0131126; BETTERIDGE A, 1985, GLYCOCONJUGATE J, V2, P61; BEYER TA, 1980, J BIOL CHEM, V255, P5364; BEYER TA, 1980, J BIOL CHEM, V255, P5373; BLASZCZYK M, 1985, P NATL ACAD SCI USA, V82, P3552, DOI 10.1073/pnas.82.11.3552; BLASZCZYKTHURIN M, 1988, BIOCHEM BIOPH RES CO, V151, P100, DOI 10.1016/0006-291X(88)90564-5; BLASZCZYKTHURIN M, 1987, J BIOL CHEM, V262, P372; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN A, 1984, INT J CANCER, V33, P727, DOI 10.1002/ijc.2910330604; CLAUSEN H, 1985, P NATL ACAD SCI USA, V82, P1199, DOI 10.1073/pnas.82.4.1199; CLAUSEN H, 1986, J BIOL CHEM, V261, P1388; CLAUSEN H, 1985, BIOCHEMISTRY-US, V24, P3578, DOI 10.1021/bi00335a028; CLAUSEN H, 1987, TRANSPLANT P, V29, P4408; CORDONCARDO C, 1986, INT J CANCER, V37, P667, DOI 10.1002/ijc.2910370505; CUATRECASAS P, 1970, J BIOL CHEM, V245, P3059; ERNST C, 1984, LAB INVEST, V50, P394; GARDAS A, 1971, VOX SANG, V20, P137, DOI 10.1111/j.1423-0410.1971.tb00546.x; HINDSGAUL O, 1982, CARBOHYD RES, V109, P109, DOI 10.1016/0008-6215(82)84034-2; IUPAC - Abbreviated Terminology of Oligosaccharide Chains - Recommendations - IUB-IUPAC, 1980, J BIOL CHEM, V257, P3347; KHARE DP, 1985, CARBOHYD RES, V136, P285, DOI 10.1016/0008-6215(85)85204-6; KUMAZAKI T, 1984, P NATL ACAD SCI-BIOL, V81, P4193, DOI 10.1073/pnas.81.13.4193; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIEUX RU, 1978, CHEM SOC REV, V7, P423, DOI 10.1039/cs9780700423; LEPENDU J, 1985, AM J HUM GENET, V37, P749; LEPENDU J, 1982, AM J HUM GENET, V34, P402; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; NUDELMAN E, 1986, J BIOL CHEM, V261, P1247; NUNEZ HA, 1981, CAN J CHEM, V59, P2086, DOI 10.1139/v81-304; ORIOL R, 1981, AM J HUM GENET, V33, P421; ORIOL R, 1984, LAB INVEST, V50, P514; ORIOL R, 1987, BIOCHEM SOC T, V15, P596, DOI 10.1042/bst0150596; ORNTOFT TF, 1991, GUT, V32, P287, DOI 10.1136/gut.32.3.287; ORNTOFT TF, 1987, 9 P INT S GLYC LILL; PACUSZKA T, 1976, EUR J BIOCHEM, V64, P499, DOI 10.1111/j.1432-1033.1976.tb10328.x; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; RYDBERG L, 1987, TRANSPLANT P, V19, P4528; SAKAMOTO J, 1986, CANCER RES, V46, P1553; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	42	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2737	2744						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733969				2022-12-25	WOS:A1992HB53200094
J	HORIE, Y; FAZIO, S; WESTERLUND, JR; WEISGRABER, KH; RALL, SC				HORIE, Y; FAZIO, S; WESTERLUND, JR; WEISGRABER, KH; RALL, SC			THE FUNCTIONAL-CHARACTERISTICS OF A HUMAN APOLIPOPROTEIN-E VARIANT (CYSTEINE AT RESIDUE-142) MAY EXPLAIN ITS ASSOCIATION WITH DOMINANT EXPRESSION OF TYPE-III HYPERLIPOPROTEINEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING ACTIVITY; HUMAN-E APOPROTEIN; ARGININE INTERCHANGE; LIPOPROTEINS; PROTEIN; SITE; PHENOTYPE-E3/3; COMPLEXES; SEQUENCE; GENE	Type III hyperlipoproteinemia typically is associated with homozygosity for apolipoprotein (apo) E2(Arg158 --> Cys). Dominant expression of type III hyperlipoproteinemia associated with apoE phenotype E3/3 is caused by heterozygosity for a human apoE variant, apoE3(Cys112 --> Arg, Arg142 --> Cys). However, this apoE3 variant was not separable from the normal apoE3 in these patients' plasma because the two proteins have identical amino acid composition, charge, and molecular weight. Therefore, to determine the functional characteristics of this protein, we used recombinant DNA techniques to produce this apoE variant in bacteria. We also produced a non-naturally occurring variant, apoE(Arg142 --> Cys), that had only the cysteine substituted at residue 142. These two apoE variants were purified from cell lysates of the transfected Escherichia coli by ultracentrifugal flotation in the presence of phospholipid, by gel filtration chromatography, and by heparin-Sepharose chromatography. Both Cys142 apoE variants bound to lipoprotein receptors on human fibroblasts with only about 20% of normal binding activity. Therefore, cysteine at residue 142, not arginine at residue 112, is responsible for the decreased receptor binding activity of the variants. Cysteamine treatment and removal of the carboxyl-terminal domain had little effect on the binding activity, whereas both modulate the receptor binding activity of apoE2(Arg158 --> Cys). The mutation at residue 142 decreased the binding activity of apoE to both heparin and the monoclonal antibody 1D7 (this antibody inhibits receptor binding of apoE), whereas apoE2(Arg158 --> Cys), which is associated with recessive expression of type III hyperlipoproteinemia, binds normally to both. The Arg112, Cys142 variant predominates 3:1 over normal apoE3 in the very low density lipoproteins of plasma from an affected subject, as assessed by differential reactivity with the antibody 1D7. The unique combination of functional properties of the Arg112, Cys142 variant provides a possible explanation for its association with dominant expression of type III hyperlipoproteinemia.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,GLADSTONE FDN LABS CARDIOVASC DIS,POB 40608,SAN FRANCISCO,CA 94140	University of California System; University of California San Francisco; The J David Gladstone Institutes					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGERBECK LP, 1988, J BIOL CHEM, V263, P6249; CHAPPELL DA, 1989, J CLIN INVEST, V84, P1906, DOI 10.1172/JCI114378; DEKNIJFF P, 1991, J CLIN INVEST, V88, P643, DOI 10.1172/JCI115349; HAVEL RJ, 1983, J CLIN INVEST, V72, P379, DOI 10.1172/JCI110978; HIXSON JE, 1990, J LIPID RES, V31, P545; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1984, J BIOL CHEM, V259, P7261; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; Mahley Jr RWRS, 1989, METABOLIC BASIS INHE, P1195; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; PAIK YK, 1985, P NATL ACAD SCI USA, V82, P3445, DOI 10.1073/pnas.82.10.3445; PITAS RE, 1980, J BIOL CHEM, V255, P5454; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SRINIVAS.SR, 1972, ATHEROSCLEROSIS, V16, P95, DOI 10.1016/0021-9150(72)90012-3; UTERMANN G, 1982, RES CLIN LAB, V12, P23; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WEISGRABER KH, 1990, J LIPID RES, V31, P1503; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WEISGRABER KH, 1988, BIOCHEM BIOPH RES CO, V157, P1212, DOI 10.1016/S0006-291X(88)81003-9; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; YAO ZM, 1988, J BIOL CHEM, V263, P2998; ZANNIS VI, 1981, BIOCHEMISTRY-US, V20, P1033, DOI 10.1021/bi00507a059; ZILVERSMIT DB, 1973, CIRC RES, V33, P633, DOI 10.1161/01.RES.33.6.633	28	79	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1962	1968						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730728				2022-12-25	WOS:A1992HA48500086
J	KUIPER, J; RIJKEN, DC; DEMUNK, GAW; VANBERKEL, TJC				KUIPER, J; RIJKEN, DC; DEMUNK, GAW; VANBERKEL, TJC			INVIVO AND INVITRO INTERACTION OF HIGH AND LOW-MOLECULAR-WEIGHT SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR WITH RAT-LIVER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-UROKINASE; THROMBOLYTIC PROPERTIES; BINDING-SITES; RECEPTOR; DEGRADATION; INHIBITOR; IDENTIFICATION; PURIFICATION; FORMS; EXPRESSION	The plasma clearance and the interaction of high (HMW) and low (LMW) molecular weight single-chain urokinase-type plasminogen activator (scu-PA) with rat liver cells was determined. I-125-Labeled HMW- and LMW-scu-PA were rapidly cleared from plasma with a half-life of 0.45 min and a maximal liver uptake of 55% of the injected dose. Liver uptake of scu-PA was mediated by parenchymal cells. Excess of unlabeled HMW-scu-PA reduced the liver uptake of I-125-HMW-scu-PA strongly. In vivo liver degradation of scu-PA was reduced by inhibitors of the lysosomal pathway. A high affinity binding site (K(d) 45 nM, B(max) 1.7 pmol/mg cell protein) for both HMW- and LMW-scu-PA was determined on isolated parenchymal liver cells. Cross-competition binding studies showed that LMW- and HMW-scu-PA bind to the same site. Tissue-type plasminogen activator, mannose- or galactose-terminated glycoproteins did not affect the scu-PA binding to parenchymal liver cells. It is concluded that LMW- and HMW-scu-PA are taken up in the liver by a common, newly identified recognition site on parenchymal liver cells and are subsequently degraded in the lysosomes. It is suggested that this site is important for the regulation of the turnover of scu-PA.	TNO,IVVO,GAUBIUS LAB,2300 AK LEIDEN,NETHERLANDS	Netherlands Organization Applied Science Research	KUIPER, J (corresponding author), LEIDEN UNIV,CTR BIOPHARMACEUT SCI,SYLVIUS LAB,DIV BIOPHARMACEUT,POB 9503,2300 RA LEIDEN,NETHERLANDS.		Van Berkel, Theo/ABD-7677-2021					BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BIESSEN EAL, 1988, BIOCHEM PHARMACOL, V37, P3959, DOI 10.1016/0006-2952(88)90080-9; BINNEMA DJ, 1986, THROMB RES, V43, P569, DOI 10.1016/0049-3848(86)90077-0; BLASI F, 1988, Fibrinolysis, V2, P73, DOI 10.1016/0268-9499(88)90370-0; CASTELEIJN E, 1986, FEBS LETT, V201, P193, DOI 10.1016/0014-5793(86)80607-X; COLLEN D, 1984, THROMB HAEMOSTASIS, V52, P24; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEMUNK GAW, 1990, FIBRINOLYSIS, V4, P1, DOI 10.1016/S0268-9499(05)80034-7; DEMUNK GAW, 1991, IN PRESS J CLIN INVE; EATON DL, 1984, J BIOL CHEM, V259, P6241; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; HAJJAR KA, 1990, J BIOL CHEM, V265, P2908; HIRAMATSU R, 1989, FIBRINOLYSIS, V3, P147, DOI 10.1016/0268-9499(89)90012-X; KASAI S, 1985, J BIOL CHEM, V260, P2377; KRAUSE J, 1990, BIOCHEM J, V267, P647, DOI 10.1042/bj2670647; KUIPER J, 1989, FEBS LETT, V245, P229, DOI 10.1016/0014-5793(89)80227-3; KUIPER J, 1988, J BIOL CHEM, V263, P18220; LIJNEN HR, 1990, FIBRINOLYSIS, V4, P211, DOI 10.1016/0268-9499(90)90016-D; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; PLOUG M, 1991, J BIOL CHEM, V266, P1926; QUAX PHA, 1990, J BIOL CHEM, V265, P15560; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SPRIGGS DJ, 1989, BLOOD, V73, P1207; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; STUMP DC, 1987, J PHARMACOL EXP THER, V242, P245; STUMP DC, 1986, J BIOL CHEM, V261, P7120; UENO T, 1979, THROMB HAEMOSTASIS, V42, P885; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANBERKEL TJC, 1987, BIOCHEM J, V243, P715, DOI 10.1042/bj2430715; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; WIJNGAARDS G, 1986, THROMB RES, V42, P749, DOI 10.1016/0049-3848(86)90111-8	34	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1589	1595						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730704				2022-12-25	WOS:A1992HA48500032
J	DECKER, SJ; ALEXANDER, C; HABIB, T				DECKER, SJ; ALEXANDER, C; HABIB, T			EPIDERMAL GROWTH-FACTOR (EGF)-STIMULATED TYROSINE PHOSPHORYLATION AND EGF RECEPTOR DEGRADATION IN CELLS EXPRESSING EGF RECEPTORS TRUNCATED AT RESIDUE-973	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-II; KINASE-ACTIVITY; SIGNAL TRANSDUCTION; HUMAN-FIBROBLASTS; TERMINAL DOMAIN; GAP; INTERNALIZATION; PHOSPHOTYROSINE; ASSOCIATION; METABOLISM	Epidermal growth factor (EGF)-stimulated tyrosine phosphorylation of proteins was examined in cells expressing wild-type (WT-EGFR) EGF receptors or EGF receptors truncated at residue 973 (973-EGFR). A much broader spectrum of tyrosine phosphorylated proteins was found following EGF treatment of 973-EGFR expressing cells compared with cells expressing wild-type receptors. Several additional ras (GTPase activating protein-associated tyrosine phosphorylated proteins were found in EGF-treated 973-EGFR cells relative to WT-EGFR cells. Additional tyrosine-phosphorylated proteins were also found to co-immunoprecipitate with phospholipase C-gamma-1 (PLC-gamma-1) following EGF treatment of cells expressing 973-EGFR relative to cells expressing WT-EGFR. EGF-stimulated tyrosine phosphorylation of PLC-gamma-1 was found in cells expressing WT-EGFR, but not in cells expressing 973-EGFR. WT-EGF receptor from EGF-treated cells bound well to bacterially expressed src homology (SH) regions of PLC-gamma-1 and to a lesser extent to bacterially expressed GTPase activating protein SH regions. No binding of 973-EGF receptor to SH regions of either protein could be detected. EGF treatment greatly reduced the half-life of WT-EGFR, but had relatively little effect on the half-life of 973-EGFR. EGF induced internalization of 973-EGFR at a slower rate than WT-EGFR and caused the appearance of discrete receptor degradation products for both cell types. The data indicate that truncation of the EGF receptor at residue 973 alters receptor substrate specificity, decreases the rate of receptor internalization, and has an inhibitory effect on receptor degradation.	UNIV MICHIGAN,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48104; ROCKEFELLER UNIV,NEW YORK,NY 10021	University of Michigan System; University of Michigan; Rockefeller University	DECKER, SJ (corresponding author), PARKE DAVIS & CO,DIV PHARMACEUT RES,2800 PLYMOUTH RD,ANN ARBOR,MI 48106, USA.				NATIONAL CANCER INSTITUTE [R01CA037754] Funding Source: NIH RePORTER; NCI NIH HHS [CA37754] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BERTICS PJ, 1985, J BIOL CHEM, V260, P4642; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DECKER SJ, 1989, J BIOL CHEM, V264, P17641; DECKER SJ, 1984, MOL CELL BIOL, V4, P1718, DOI 10.1128/MCB.4.9.1718; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HELIN K, 1991, J BIOL CHEM, V266, P8363; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P2832; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MAYES ELV, 1984, EMBO J, V3, P531, DOI 10.1002/j.1460-2075.1984.tb01842.x; MEISENHELDER J, 1989, CELL, V57, P1108; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; SORKIN A, 1991, J BIOL CHEM, V266, P8355; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; USHIRO H, 1980, J BIOL CHEM, V255, P8363; VELU T, 1989, MOL CELL BIOL, P1772; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	40	38	38	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1104	1108						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730638				2022-12-25	WOS:A1992GY96000069
J	KANAMORI, A; BROWN, DD				KANAMORI, A; BROWN, DD			THE REGULATION OF THYROID-HORMONE RECEPTOR BETA GENES BY THYROID-HORMONE IN XENOPUS-LAEVIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONGOING PROTEIN-SYNTHESIS; CHICK-EMBRYO HEPATOCYTES; MESSENGER-RNA; RESPONSE ELEMENT; AMPHIBIAN METAMORPHOSIS; LIPOGENIC ENZYMES; TRANSCRIPTION; TRIIODOTHYRONINE; ACID; IDENTIFICATION	The mRNA level of the two Xenopus laevis thyroid hormone receptor beta (TR-beta) genes is up-regulated in tadpoles and cultured cells by the addition of thyroid hormone (TH). Up-regulation of transcripts of the 5' most exon is detectable 2-3 h before that of full-length TR-beta mRNA, strongly suggesting that up-regulation is under transcriptional control. The TH-induced up-regulation in cultured cells is inhibited by cycloheximide when measured either by a transcription initiation assay that measures transcripts of the 5' most exon or by synthesis of full-length TR-beta mRNA. From this we conclude that in cultured cells protein synthesis is required for up-regulation of TR-beta mRNA. The up-regulation of TR-beta mRNA by TH in tadpoles is only partially inhibited by protein synthesis inhibitors. A survey of "thyroid response" genes in the literature reveals that the reported change in gene expression is, in most cases, sensitive to protein synthesis inhibition. This is true of genes with demonstrable thyroid hormone response elements. If an unknown protein must be synthesized to effect up-regulation of a thyroid hormone response gene, it calls into question assays that only take into account the binary reaction between thyroid hormone receptor and a putative thyroid hormone response element.			KANAMORI, A (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,BALTIMORE,MD 21210, USA.			KANAMORI, AKIRA/0000-0002-4311-8143				ATWATER JA, 1990, ANNU REV GENET, V24, P519; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BACK DW, 1986, J BIOL CHEM, V261, P2555; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLIFFORD JL, 1990, MOL ENDOCRINOL, V4, P1546, DOI 10.1210/mend-4-10-1546; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; ELLISON TR, 1985, DEV BIOL, V112, P329, DOI 10.1016/0012-1606(85)90403-8; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Gilbert L, 1981, METAMORPHOSIS PROBLE; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAMBLIN PS, 1987, MOL ENDOCRINOL, V1, P397, DOI 10.1210/mend-1-6-397; HAYASHI I, 1984, METHODS SERUM FREE C, P1; HAYWARD MA, 1982, NUCLEIC ACIDS RES, V10, P8273, DOI 10.1093/nar/10.24.8273; JACOBY DB, 1987, MOL CELL BIOL, V7, P1352, DOI 10.1128/MCB.7.4.1352; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; PAIN B, 1990, New Biologist, V2, P284; PETTY KJ, 1990, J BIOL CHEM, V265, P7395; SALATI LM, 1991, J BIOL CHEM, V266, P4010; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SANTOS A, 1987, J BIOL CHEM, V262, P16880; SAP J, 1990, EMBO J, V9, P887, DOI 10.1002/j.1460-2075.1990.tb08186.x; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHI YB, 1992, J BIOL CHEM, V267, P733; SHUPNIK MA, 1985, ENDOCRINOLOGY, V117, P1940, DOI 10.1210/endo-117-5-1940; SIMONET WS, 1988, J BIOL CHEM, V263, P12448; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILSON AP, 1986, ANIMAL CELL CULTURE, P183; WILSON SB, 1986, J BIOL CHEM, V261, P5179; WONG NCW, 1986, J BIOL CHEM, V261, P387; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; ZILZ ND, 1990, J BIOL CHEM, V265, P8136	45	127	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					739	745						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730665				2022-12-25	WOS:A1992GY96000013
J	LEE, E; TAUSSIG, R; GILMAN, AG				LEE, E; TAUSSIG, R; GILMAN, AG			THE G226A MUTANT OF GS-ALPHA HIGHLIGHTS THE REQUIREMENT FOR DISSOCIATION OF G-PROTEIN SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; ADENYLATE-CYCLASE; RAS P21; GTP HYDROLYSIS; TRIPHOSPHATE CONFORMATION; AFFINITY-CHROMATOGRAPHY; GUANINE-NUCLEOTIDES; ESCHERICHIA-COLI; COMPONENT; PURIFICATION	Adenylylcyclase cannot be activated by hormones or guanine nucleotide analogs in membranes from cells that express the G226A mutant form of G(s-alpha) instead of the wild-type protein. The mutant G(s-alpha) protein appears incapable of undergoing the conformational change necessary for guanine nucleotide-induced dissociation of the G protein alpha-subunit from the beta-gamma-subunit complex (Miller, R. T., Masters, S. B., Sullivan, K. A., Beiderman, B., and Bourne, H. R. (1988) Nature 334, 712715). G226A G(s-alpha) was synthesized in Escherichia coli, purified, and characterized. Examination of the kinetics of dissociation of guanosine 5'-3-O-(thio)triphosphate (GTP-gamma-S) suggests that G226A G(s-alpha) is incapable of assuming the conformation necessary for high affinity binding of Mg2+ to the alpha-subunit-GTP-gamma-S complex. Associated changes include the failure of Mg2+ and GTP-gamma-S to confer resistance to tryptic proteolysis upon the protein, to enhance intrinsic tryptophan fluorescence, or to cause dissociation of alpha from beta-gamma. However, the GTPase activity of the mutant protein is near normal (at high Mg2+ concentrations), and the protein is capable of activating adenylylcyclase. A similar defect is present in G49V G(s-alpha). Failure of G protein subunit dissociation appears to be the explanation for the phenotypic properties of cells that express G226A G(s-alpha), and this mutation thus highlights the crucial nature of this reaction as a component of G protein action.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,5323 HARRY HINES BLVD,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, R37GM034497, R01GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07062, GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE HR, 1982, MOL PHARMACOL, V22, P204; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1981, MOL PHARMACOL, V20, P435; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P3597; HOWLETT AC, 1980, J BIOL CHEM, V255, P2861; ITOH H, 1991, J BIOL CHEM, V266, P16226; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; SALOMON MR, 1981, MOL PHARMACOL, V19, P109; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STERNWEIS PC, 1981, ADV CYCLIC NUCL PROT, V14, P23; SUNYER T, 1984, J BIOL CHEM, V259, P5447; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TANG WJ, 1991, IN PRESS SCIENCE; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624	40	131	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1212	1218						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730644				2022-12-25	WOS:A1992GY96000083
J	AVRAHAM, S; AVRAHAM, H; AUSTEN, KF; STEVENS, RL				AVRAHAM, S; AVRAHAM, H; AUSTEN, KF; STEVENS, RL			NEGATIVE AND POSITIVE CIS-ACTING ELEMENTS IN THE PROMOTER OF THE MOUSE GENE THAT ENCODES THE SERINE GLYCINE-RICH PEPTIDE CORE OF SECRETORY GRANULE PROTEOGLYCANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; TISSUE-SPECIFIC EXPRESSION; LEUKEMIA HL-60 CELLS; RAT MAST-CELLS; MOLECULAR-CLONING; BONE-MARROW; HEPARIN; PROTEIN; CDNA; DNA	The gene that encodes a proteoglycan peptide core rich in serine and glycine (SG-PG) is selectively expressed by hematopoietic cells that store in their cytoplasmic granules negatively charged proteoglycans bound ionically to numerous positively charged proteins. With deletion analysis, a negative transcription regulatory element was located between residues -250 and -190 of the 5'-flanking region of the mouse SG-PG gene, and a positive regulatory element was located between residues -118 and -81. The negative regulatory element was dominantly active in fibroblasts that do not express the SG-PG gene whereas the positive regulatory element was dominantly active in hematopoietic cells that do express the SG-PG gene. Site-directed mutagenesis was used to demonstrate that the proximal element within the gene's atypical promoter resided between residues -40 and -20. As assessed by gel mobility shift analyses, the nuclei of rat basophilic leukemia-1 cells and rat-1 fibroblasts contain a number of trans-acting factors that interact with the positive and negative cis-acting regulatory elements of the SG-PG gene. Furthermore, some of these trans-acting factors appear to be different for the two cell types. These studies on cell types that do and do not express the SG-PG gene indicate that transcription of this proteoglycan peptide core gene is regulated constitutively by both positive and negative cis-acting elements located 5' of an atypical promoter.	BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA; NEW ENGLAND DEACONESS HOSP, DEPT ONCOL HEMATOL & EXPTL MED, BOSTON, MA 02215 USA	Harvard University; Brigham & Women's Hospital	AVRAHAM, S (corresponding author), HARVARD UNIV, SCH MED,DEPT MED,SEELEY G MUDD BLDG,RM 625, 250 LONGWOOD AVE, BOSTON, MA 02115 USA.			Avraham, Hava/0000-0002-7545-3640	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022531, R01AI023483, R37AI022531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR035907] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22531, AI-23483] Funding Source: Medline; NIAMS NIH HHS [AR-35907] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLIEL PM, 1988, FEBS LETT, V236, P123, DOI 10.1016/0014-5793(88)80298-9; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; AVRAHAM S, 1988, J BIOL CHEM, V263, P7292; AVRAHAM S, 1989, J BIOL CHEM, V264, P16719; AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; BOURDON MA, 1986, J BIOL CHEM, V261, P2534; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHU G, 1985, NUCLEIC ACIDS RES, V13, P2921, DOI 10.1093/nar/13.8.2921; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GHOSH D, 1990, NUCLEIC ACIDS RES, V18, P1749, DOI 10.1093/nar/18.7.1749; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KATZ HR, 1983, P NATL ACAD SCI-BIOL, V80, P5916, DOI 10.1073/pnas.80.19.5916; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; NICODEMUS CF, 1990, J BIOL CHEM, V265, P5889; RAZIN E, 1982, J BIOL CHEM, V257, P7229; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARID J, 1989, J BIOL CHEM, V264, P1022; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SCHWARTZ LB, 1981, J IMMUNOL, V126, P2071; SELDEN RF, 1987, SCIENCE, V236, P714, DOI 10.1126/science.3472348; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SELDIN DC, 1985, P NATL ACAD SCI USA, V82, P3871, DOI 10.1073/pnas.82.11.3871; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STELLRECHT CM, 1989, NUCLEIC ACIDS RES, V17, P7523, DOI 10.1093/nar/17.18.7523; STEVENS RL, 1985, J BIOL CHEM, V260, P4194; STEVENS RL, 1988, J BIOL CHEM, V263, P7287; STEVENS RL, 1988, CURR TOP MICROBIOL I, V140, P93; TANTRAVAHI RV, 1986, P NATL ACAD SCI USA, V83, P9207, DOI 10.1073/pnas.83.23.9207; VALENT P, 1989, BLOOD, V73, P1778; YURT RW, 1977, J BIOL CHEM, V252, P518; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	42	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					610	617						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730621				2022-12-25	WOS:A1992GY43900095
J	HOWARD, KJ; FRANK, KB; SIM, IS; LEGRICE, SFJ				HOWARD, KJ; FRANK, KB; SIM, IS; LEGRICE, SFJ			RECONSTITUTION AND PROPERTIES OF HOMOLOGOUS AND CHIMERIC HIV-1.HIV-2P66.P51 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DEPENDENT DNA POLYMERASE; ESCHERICHIA-COLI; HIV-1 REPLICATION; SARCOMA VIRUS; H ACTIVITY; RNA; PRIMER; PURIFICATION; INHIBITION	Metal chelate affinity chromatography has been used to follow reconstitution of the 66- and 51-kDa human immunodeficiency (HIV)-1 and HIV-2 reverse transcriptase (RT) subunits into heterodimer, as well as chimeric enzymes comprised of heterologous subunits. By adding a small N-terminal polyhistidine extension to the 51-kDa subunit of either enzyme, reconstituted RT could be recovered from a cell lysate by chromatography on Ni2+-nitrilotriacetic acid-Sepharose. Homologous RT subunits rapidly associated to form the respective heterodimers (1-p66.1-p51 and 2-p66.2-p51) when bacterial lysates containing the individual components were mixed. Under the same conditions, association of p66 HIV-2 and p51 HIV-1 RT was inefficient and could be improved slightly by prolonged incubation of the respective p66 and p51 subunits. In contrast, HIV-1 p66 RT rapidly associated with the 51-kDa subunit of the HIV-2 enzyme. RNA-dependent DNA polymerase activity was associated with all reconstituted enzymes, and the response of each chimeric RT to an inhibitor selective for the HIV-1 enzyme indicated that sensitivity to inhibition was determined by the source of its 66-kDa subunit.	CASE WESTERN RESERVE UNIV, SCH MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; HOFFMANN LA ROCHE INC, DEPT VIROL, NUTLEY, NJ 07110 USA	Case Western Reserve University; Roche Holding					NIAID NIH HHS [AI 31147-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BARAT C, 1991, NUCLEIC ACIDS RES, V19, P751, DOI 10.1093/nar/19.4.751; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; CERTA U, 1986, EMBO J, V5, P3051, DOI 10.1002/j.1460-2075.1986.tb04605.x; CHENG N, 1991, BIOCHEM BIOPH RES CO, V174, P785, DOI 10.1016/0006-291X(91)91486-V; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HANSEN J, 1987, J BIOL CHEM, V262, P12393; HIZI A, 1991, VIROLOGY, V180, P339, DOI 10.1016/0042-6822(91)90038-D; HIZI A, 1990, VIROLOGY, V175, P575, DOI 10.1016/0042-6822(90)90444-V; HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HUBER HE, 1990, J BIOL CHEM, V265, P10565; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LEGRICE SFJ, 1988, J VIROL, V62, P2525, DOI 10.1128/JVI.62.7.2525-2529.1988; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LEGRICE SFJ, 1989, J BIOL CHEM, V264, P14902; LEGRICE SFJ, 1991, GWUMC DEPT, P55; MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568; MIZRAHI V, 1989, ARCH BIOCHEM BIOPHYS, V273, P347, DOI 10.1016/0003-9861(89)90493-1; MOLLING K, 1971, NATURE-NEW BIOL, V234, P240, DOI 10.1038/newbio234240a0; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; RESTLE T, 1990, J BIOL CHEM, V265, P8986; SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHATZ O, 1990, ONCOGENESIS AIDS, P304; TAYLOR JM, 1975, J VIROL, V16, P553, DOI 10.1128/JVI.16.3.553-558.1975; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003	32	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23003	23009						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1720776				2022-12-25	WOS:A1991GT48300037
J	CHAN, GCK; HESS, P; MEENAKSHI, T; CARLSTEDTDUKE, J; GUSTAFSSON, JA; PAYVAR, F				CHAN, GCK; HESS, P; MEENAKSHI, T; CARLSTEDTDUKE, J; GUSTAFSSON, JA; PAYVAR, F			DELAYED SECONDARY GLUCOCORTICOID RESPONSE ELEMENTS - UNUSUAL NUCLEOTIDE MOTIFS SPECIFY GLUCOCORTICOID RECEPTOR-BINDING TO TRANSCRIBED REGIONS OF ALPHA-2U-GLOBULIN DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2U GLOBULIN GENE; MAMMARY-TUMOR VIRUS; RAT ALPHA-1-ACID GLYCOPROTEIN; GROWTH-HORMONE GENE; THYROID-HORMONE; REGULATORY ELEMENT; HETEROLOGOUS PROMOTER; SELECTIVELY INVITRO; 1ST INTRON; CELL LINE	Glucocorticoids stimulate the transcription of rat alpha-2u-globulin (RUG) genes. Because this induction occurs after a time lag of several hours and is blocked by inhibitors of protein synthesis, it exemplifies a delayed secondary response to steroid hormones. In this report, we show that a region of RUG-transcribed DNA (approximately +1800 to +2174) contains multiple footprint sites for glucocorticoid receptor that are, apparently, organized into at least three independent binding clusters. The DNA sequences bound by the receptor and the location of binding sites were determined. A family of sequences related to half-sites of the consensus primary glucocorticoid response element (GRE) is discernible at each cluster of sites. Compared to the consensus GRE, which contains two pseudo-palindromic hexanucleotides arranged in a tail-to-tail fashion and separated by three bases, the arrangements of hexanucleotides within this segment of RUG DNA are unusual and heterogeneous. Methylation interference of a binding cluster containing three receptor footprints demonstrates that certain guanines of the GRE-like hexanucleotides are essential for efficient receptor binding. A synthetic 29-base pair (bp) RUG element, containing one receptor footprint from this cluster, selectively binds the receptor. Within this 29-bp element, six nucleotides separate two directly repeated copies of GRE-like hexanucleotides. RUG DNA fragments containing all or part of the three binding clusters, including the 29-bp element, confer a delayed secondary hormone responsiveness upon a linked heterologous promoter and reporter gene in stably transfected cell lines. We speculate that the unusual DNA sequence motifs of the receptor-binding sites are crucial for the generation of certain delayed secondary responses.	HUDDINGE UNIV HOSP F60,NOVUM,KAROLINSKA INST,DEPT MED NUTR,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet	CHAN, GCK (corresponding author), ST LOUIS UNIV,SCH MED,EA DOISY DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104, USA.		Chan, Guy/B-1862-2009		NCRR NIH HHS [RR05388] Funding Source: Medline; NIDDK NIH HHS [DK36385] Funding Source: Medline; NIGMS NIH HHS [T32GM08109] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008109] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON WR, 1986, MOL CELL BIOL, V6, P2334, DOI 10.1128/MCB.6.7.2334; ADDISON WR, 1989, J BIOL CHEM, V264, P21891; Ashburner M, 1974, Cold Spring Harb Symp Quant Biol, V38, P655; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BAUMANN H, 1983, J BIOL CHEM, V258, P563; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CHALEPAKIS G, 1988, NUCLEIC ACIDS RES, V16, P10237, DOI 10.1093/nar/16.21.10237; CHALEPAKIS G, 1990, DNA CELL BIOL, V9, P355, DOI 10.1089/dna.1990.9.355; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; Chen C L, 1980, Ann N Y Acad Sci, V349, P28, DOI 10.1111/j.1749-6632.1980.tb29512.x; CHOY HA, 1989, J BIOL CHEM, V264, P1754; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CLEVER U, 1966, P NATL ACAD SCI USA, V56, P1470, DOI 10.1073/pnas.56.5.1470; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOLAN KP, 1982, J BIOL CHEM, V257, P13527; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GODOWSKI PJ, 1989, BIOCHEM PHARMACOL, V38, P3135, DOI 10.1016/0006-2952(89)90605-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRALLA JD, 1989, CELL, V57, P193, DOI 10.1016/0092-8674(89)90955-0; GRAUPNER G, 1991, MOL ENDOCRINOL, V5, P365, DOI 10.1210/mend-5-3-365; HAMADA H, 1986, MOL CELL BIOL, V6, P4179, DOI 10.1128/MCB.6.12.4179; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HAYES JJ, 1989, BIOCHEMISTRY-US, V28, P9521, DOI 10.1021/bi00450a041; HESS P, 1990, P NATL ACAD SCI USA, V87, P2564, DOI 10.1073/pnas.87.7.2564; HOECK W, 1989, J BIOL CHEM, V264, P14396; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KULKARNI AB, 1985, P NATL ACAD SCI USA, V82, P2579, DOI 10.1073/pnas.82.9.2579; KURTZ DT, 1982, COLD SPRING HARB SYM, V47, P985; LABAER J, 1989, THESIS U CALIFORNIA; MAGASANIK B, 1988, TRENDS BIOCHEM SCI, V13, P475, DOI 10.1016/0968-0004(88)90234-4; Maxam A M, 1980, Methods Enzymol, V65, P499; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MIESFELD RL, 1989, CRIT REV BIOCHEM MOL, V24, P101, DOI 10.3109/10409238909086395; MOORE DD, 1985, P NATL ACAD SCI USA, V82, P699, DOI 10.1073/pnas.82.3.699; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; ORTI E, 1989, J STEROID BIOCHEM, V34, P85, DOI 10.1016/0022-4731(89)90069-1; PAYVAR F, 1981, P NATL ACAD SCI-BIOL, V78, P6628, DOI 10.1073/pnas.78.11.6628; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PAYVAR F, 1982, J CELL BIOCHEM, V19, P241, DOI 10.1002/jcb.240190305; PAYVAR F, 1983, NOBEL S, V57, P267; PONGS O, 1988, EUR J BIOCHEM, V175, P199, DOI 10.1111/j.1432-1033.1988.tb14184.x; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; REINKE R, 1985, J BIOL CHEM, V260, P4397; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SARKAR P, 1989, MOL ENDOCRINOL, V3, P342, DOI 10.1210/mend-3-2-342; SCHEIDEREIT C, 1984, P NATL ACAD SCI-BIOL, V81, P3029, DOI 10.1073/pnas.81.10.3029; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SIEBENLIST U, 1980, CELL, V20, P269, DOI 10.1016/0092-8674(80)90613-3; SLATER EP, 1985, MOL CELL BIOL, V5, P2984, DOI 10.1128/MCB.5.11.2984; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; VANDIJCK P, 1987, BIOCHEM BIOPH RES CO, V149, P1099, DOI 10.1016/0006-291X(87)90521-3; WIDMAN LE, 1982, J CELL PHYSIOL, V112, P316, DOI 10.1002/jcp.1041120303; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WRANGE O, 1989, J BIOL CHEM, V264, P5253; WRANGE O, 1986, J BIOL CHEM, V261, P1770; YAMAMOTO KR, 1989, AM ZOOL, V29, P537; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YAMAMOTO KR, 1983, NOBEL S, V757, P285; YAMAMOTO M, 1989, BIOCHIM BIOPHYS ACTA, V1008, P322, DOI 10.1016/0167-4781(89)90023-7	72	61	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22634	22644						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1718998				2022-12-25	WOS:A1991GR56400088
J	MAHESWARAN, S; MCCORMACK, JE; SONENSHEIN, GE				MAHESWARAN, S; MCCORMACK, JE; SONENSHEIN, GE			CHANGES IN PHOSPHORYLATION OF MYC ONCOGENE AND RB ANTIONCOGENE PROTEIN PRODUCTS DURING GROWTH ARREST OF THE MURINE LYMPHOMA WEHI-231 CELL-LINE	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; C-MYC; EXPRESSION; IMMUNOGLOBULIN; CYCLE; TRANSLOCATION; ACTIVATION; SARCOMA; VIRUS; RNA	The expression of the protein products of the c-myc oncogene and retinoblastoma susceptibility gene (RB) was investigated during either goat anti-mouse immunoglobulin (GaMIg)- or phorbol ester (TPA)-induced growth arrest of the murine B-lymphoma cell line WEHI 231. Previously we have demonstrated that c-myc mRNA levels increase within 1-2 h of treatment, return to control levels by 4 h, and decline below these values by 24 h of treatment. Here we demonstrate that the level of c-myc protein synthesis and mRNA change in parallel. The predominant c-myc protein expressed during the time course is the one initiated at the AUG codon (P2). The myc protein synthesized following 1-2 h of anti-immunoglobulin or TPA treatment migrates more slowly in a polyacrylamide gel as a result of increased phosphorylation. This hyperphosphorylation was no longer detectable by 4-6 h of treatment. Furthermore, the hyper-phosphorylated myc protein appears to be more readily extractable with salt than the hypophosphorylated form. The product of the RB gene is present in multiple phosphorylation states in exponentially growing WEHI 231 cells. By 8 h of GaMIg or TPA treatment, a hypophosphorylated form begins to be detectable and significant levels were seen by 15 h. Thus post-translational control of both c-myc and RB expression occurs during the growth arrest of WEHI 231 cells. These changes in phosphorylation may play a role in mediating the cessation of proliferation of these cells.	BOSTON UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02118 USA	Boston University					NCI NIH HHS [CA 36355] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036355] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1982, P NATL ACAD SCI-BIOL, V79, P6966, DOI 10.1073/pnas.79.22.6966; BISTER K, 1980, J VIROL, V36, P617, DOI 10.1128/JVI.36.2.617-621.1980; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOYD AW, 1981, J IMMUNOL, V126, P2266; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1988, CELL, V56, P67; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; GUY GR, 1989, BIOCHEM J, V263, P57, DOI 10.1042/bj2630057; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HORNBECK P, 1986, J BIOL CHEM, V261, P4817; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PONTE PA, 1981, NATURE, V291, P594, DOI 10.1038/291594a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RALPH P, 1979, IMMUNOL REV, V48, P107, DOI 10.1111/j.1600-065X.1979.tb00300.x; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHEW JY, 1989, ONCOGENE RES, V4, P205; STRAUSS F, 1984, CELL, V33, P741; VARMUS HE, 1984, ANNU REV GENET, V18, P553; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; XU HJ, 1989, ONCOGENE, V4, P807	39	39	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1965	1971						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719463				2022-12-25	WOS:A1991GX11900004
J	CORMACK, RS; MACKIE, GA				CORMACK, RS; MACKIE, GA			MAPPING RIBOSOMAL PROTEIN-S20-16-S RIBOSOMAL-RNA INTERACTIONS BY MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EQUILIBRIUM BINDING; ACID INTERACTIONS; PROTEINS S4; 16-S RNA; S20; SEQUENCE; REGIONS; GENE; SITE	Specific ribonucleotides within the 5' domain of Escherichia coli 16 S rRNA were altered by deletion and/or substitution by site-directed mutagenesis of cloned DNA to assess the importance of these particular residues in defining the binding site for ribosomal protein S20. Gel filtration and sucrose gradient centrifugation were employed to measure the binding of ribosomal protein S20 to synthetic transcripts spanning the 5' domain of 16 S rRNA containing various alterations. In several cases, the apparent association constants for these interactions were also determined. Three essential results were obtained. First, RNA transcripts containing residues 1-402 are sufficient for high affinity S20 binding. Second, bulges at residues 250-251 and 278-280 in a stem-loop structure extending from residues 240 to 286 are critical for S20 binding, arguing that the "260 stem" directly interacts with S20 at these sites. Third, mutations in a hairpin structure spanning residues 316-337 demonstrate a strong requirement for both the specific A321*G332 bulge and for unpaired residues in the loop itself for proper S20 binding. Our results document the importance of unpaired residues in maintaining the interaction between S20 and 16 S rRNA.	UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON N6A 5C1, ONTARIO, CANADA	Western University (University of Western Ontario)								DONLY BC, 1988, NUCLEIC ACIDS RES, V16, P997, DOI 10.1093/nar/16.3.997; DONLY BC, 1988, THESIS U W ONTARIO; DRAPER DE, 1979, BIOCHEMISTRY-US, V18, P753, DOI 10.1021/bi00572a003; DRAPER DE, 1988, METHOD ENZYMOL, V164, P203; EHRESMANN B, 1977, FEBS LETT, V78, P261, DOI 10.1016/0014-5793(77)80319-0; EHRESMANN C, 1980, EUR J BIOCHEM, V103, P439, DOI 10.1111/j.1432-1033.1980.tb05967.x; FELLNER P, 1969, EUR J BIOCHEM, V11, P12, DOI 10.1111/j.1432-1033.1969.tb00733.x; GARRETT RA, 1972, MOL GEN GENET, V114, P112, DOI 10.1007/BF00332782; GUTELL RR, 1990, P NATL ACAD SCI USA, V87, P3119; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKIE GA, 1981, J BIOL CHEM, V256, P8177; MACKIE GA, 1978, J MOL BIOL, V121, P17, DOI 10.1016/0022-2836(78)90260-7; MACKIE GA, 1977, BIOCHEMISTRY-US, V16, P4497, DOI 10.1021/bi00639a026; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIZUSHIMA S, 1970, NATURE, V226, P1214, DOI 10.1038/2261214a0; PARSONS GD, 1988, J BACTERIOL, V170, P2485, DOI 10.1128/jb.170.6.2485-2492.1988; SAPAG A, 1990, BIOCHIM BIOPHYS ACTA, V1050, P34, DOI 10.1016/0167-4781(90)90137-Q; SCHULTE C, 1974, BIOCHEMISTRY-US, V13, P1032, DOI 10.1021/bi00702a031; SPICER E, 1977, NUCLEIC ACIDS RES, V4, P491, DOI 10.1093/nar/4.2.491; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; STERN S, 1986, J MOL BIOL, V192, P101, DOI 10.1016/0022-2836(86)90467-5; STERN S, 1988, J MOL BIOL, V200, P291, DOI 10.1016/0022-2836(88)90241-0; UNGEWICKELL E, 1975, EUR J BIOCHEM, V51, P165, DOI 10.1111/j.1432-1033.1975.tb03917.x; WITTMANN HG, 1986, STRUCTURE FUNCTION G, P1; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; Zimmermann R. A., 1980, RIBOSOMES STRUCTURE, P135; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411	28	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18525	18529						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1717450				2022-12-25	WOS:A1991GJ47200021
J	ZIZI, M; FISHER, RS; GRILLO, FG				ZIZI, M; FISHER, RS; GRILLO, FG			FORMATION OF CATION CHANNELS IN PLANAR LIPID BILAYERS BY BREFELDIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GOLGI; RECONSTITUTION; PROTEINS; MEMBRANE; EXCHANGE	Brefeldin A (BFA) is a novel agent with the unique property of effecting a rapid increase of Golgi cisternae volume and subsequent loss of a recognizable Golgi apparatus in treated cells. Although a receptor-mediated mechanism has been proposed, the molecular basis of BFA action remains unknown (Lippincott-Schwartz, J., Glickman, J., Donaldson, J. G., Robbins, J., Kreis, T. E., Seamon, K. B., Sheetz, M. P., and Klausner, R. D. (1991) J. Cell Biol. 112, 567-577). Since a variety of ionophores distort Golgi architecture by initially causing osmotic swelling of the cisternae (Mollenhauer, H. H., Morre, D. J., and Rowe, L. D. (1990) Biochim. Biophys. Acta 1031, 225-246), Golgi membrane permeabilization by BFA seemed possible. We examined the effects of BFA on the conductance of planar lipid bilayers bathed in several aqueous salt solutions. Addition of BFA (1-mu-g/ml) quickly augmented alkali cation conductance (K+ > Na+ >> Li+) but not anion conductance of the bilayer. Lower concentrations (1 ng/ml) indicated that BFA formed discrete, cation-selective channels in these bilayers. Given that Golgi cisternae volume increases immediately upon treatment with BFA, these findings suggest that alteration of ion gradients or Golgi membrane potential followed by an influx of water may be the mechanism by which BFA initiates disruption of Golgi structural integrity. Subsequent functional perturbations may then ensue either as a consequence of these initial structural changes or by a combination of several distinct mechanisms.	WALTER REED ARMY MED CTR, DEPT NEPHROL, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center								DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; HARRI E, 1963, HELV CHIM ACTA, V46, P1235, DOI 10.1002/hlca.19630460419; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; MIRAMOSER F, 1976, EUR J CLIN INVEST, V6, P103, DOI 10.1111/j.1365-2362.1976.tb00499.x; MOLLENHAUER HH, 1990, BIOCHIM BIOPHYS ACTA, V1031, P225, DOI 10.1016/0304-4157(90)90008-Z; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; ORCI L, 1991, CELL, V64, P1183; RABAN M, 1991, TETRAHEDRON LETT, V32, P35, DOI 10.1016/S0040-4039(00)71211-1; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SOMLYO AP, 1975, J CELL BIOL, V66, P425, DOI 10.1083/jcb.66.2.425; WALDMAN BC, 1990, BIOCHEMISTRY-US, V29, P44, DOI 10.1021/bi00453a006; WHETSELL WO, 1969, J CELL BIOL, V42, P490, DOI 10.1083/jcb.42.2.490	16	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18443	18445						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1717449				2022-12-25	WOS:A1991GJ47200009
J	LAMPHEAR, BJ; FAY, PJ				LAMPHEAR, BJ; FAY, PJ			FACTOR-IXA ENHANCES RECONSTITUTION OF FACTOR-VIIIA FROM ISOLATED A2 SUBUNIT AND A1/A3-C1-C2 DIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; ACTIVATED PROTEIN-C; FACTOR-X; PROTHROMBINASE COMPLEX; THROMBIN; INACTIVATION; BINDING; SENSITIVITY; COAGULANT; SURFACE	Heterotrimeric factor VIIIa was reconstituted from isolated A2 subunit and A1/A3-C1-C2 dimer of thrombin-activated human factor VIII in a reaction that was sensitive to pH. Maximal levels of reconstituted factor VIIIa at pH 6.0 were as much as 20-fold greater than were values observed at pH 7.5. The presence of factor IXa and phospholipid resulted in a marked increase in factor VIIIa reconstituted at physiologic pH. However, the resultant factor VIIIa was unstable due to slow proteolysis of the A1 subunit. Factor IXa modified by the active site-specific reagent dansyl-glutamyl-glycyl-arginyl-chloromethyl ketone (DEGR-IXa) increased the level of factor VIIIa reconstituted from subunits to a similar extent as was observed for unmodified factor IXa and yielded stable factor VIIIa. This enhancement was saturated above a 1:1 molar ratio of DEGR-IXa to factor VIIIa subunits and could be blocked by an anti-factor IX antibody, suggesting that the DEGR-IXa-dependent increase in factor VIIIa reconstitution correlated with assembly of the factor X-ase complex. At a saturating amount of DEGR-IXa, the level of factor VIIIa reconstitution at pH 7.5 approached values obtained at pH 6.0. Fluorescence polarization measurements indicated that factor VIIIa altered binding of DEGR-IXa to phospholipid. However, neither the A2 subunit nor the A1/A3-C1-C2 dimer alone produced this effect. This result suggested that both A2 and A1/A3-C1-C2 were necessary for association of the cofactor with factor IXa. These results suggest a model in which assembly of the intrinsic factor X-ase complex stabilizes factor VIIIa through inhibition of subunit dissociation.	UNIV ROCHESTER,SCH MED & DENT,DEPT MED,HEMATOL UNIT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NHLBI NIH HHS [HL-38199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN RF, 1969, PHYSICAL PRINCIPLES, P209; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FULCHER CA, 1984, BLOOD, V63, P486; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HULTIN MB, 1982, J CLIN INVEST, V69, P950, DOI 10.1172/JCI110534; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; MANN KG, 1990, BLOOD, V76, P1; MERTENS K, 1984, BIOCHEM J, V223, P599, DOI 10.1042/bj2230599; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; SKIPSKI VP, 1964, BIOCHEM J, V90, P374, DOI 10.1042/bj0900374; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANDIEIJEN G, 1985, THROMB HAEMOSTASIS, V53, P396; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1987, ARCH BIOCHEM BIOPHYS, V252, P322, DOI 10.1016/0003-9861(87)90037-3; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	34	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3725	3730						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740424				2022-12-25	WOS:A1992HE60700030
J	HORNICK, CA; THOURON, C; DELAMATRE, JG; HUANG, J				HORNICK, CA; THOURON, C; DELAMATRE, JG; HUANG, J			TRIACYLGLYCEROL HYDROLYSIS IN ISOLATED HEPATIC ENDOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; MULTIVESICULAR BODIES; TRIGLYCERIDE LIPASE; MACROPHAGE ENDOSOMES; DENSITY LIPOPROTEINS; CELLS; ACIDIFICATION; LYSOSOMES; PLASMA; IDENTIFICATION	Three endosomal compartments including the compartment for uncoupling receptor and ligand (CURL), multivesicular bodies (MVB), and a putative recycling fraction (retrosomes) were isolated from rat liver homogenates fifteen minutes after a bolus injection of very low density lipoprotein (VLDL) was delivered into a femoral vein. Assays for enzyme markers indicate a minimal contamination with either lysosomes or Golgi. The increase in specific activity of the radiolabeled ligand (VLDL) during the isolation procedure from homogenate to MVB, demonstrates a 200-250-fold purification of this organelle. All three fractions have the ability to catabolize triacylglycerol substrate both as triolein and as VLDL triacylglycerol. Furthermore, incubation of isolated endosomes following injection of endogenously labeled VLDL demonstrate their ability to hydrolyze VLDL triacylglycerol in situ. Three distinct lipolytic pH optima were found at pH 5.5, 7.1, and 8.6. The effects of serum, MgCl2, CaCl2, NaCl, sodium dodecyl sulfate, bile acids, and antibody to hepatic triacylglycerol lipase on the individual endosome fractions demonstrated distinct lipolytic activities in the different compartments. Results indicate that both an endosomal neutral lipase as well as hepatic triacylglycerol lipase make a significant contribution to lipolytic processing of endocytosed lipoproteins prior to their resecretion or further processing in hepatic lysosomes.	LOUISIANA STATE UNIV, MED CTR, DEPT PATHOL, NEW ORLEANS, LA 70112 USA	Louisiana State University System	HORNICK, CA (corresponding author), LOUISIANA STATE UNIV, MED CTR, DEPT PHYSIOL, 1542 TULANE AVE, NEW ORLEANS, LA 70112 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL025596] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 25596] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; APPLEBAUM DM, 1977, J CLIN INVEST, V59, P601, DOI 10.1172/JCI108677; BAGINSKY ML, 1979, J LIPID RES, V20, P548; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BELCHER JD, 1985, BIOCHEM J, V229, P343, DOI 10.1042/bj2290343; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BERGERON JJM, 1988, CELL FREE ANAL MEMBR, P391; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; DELAMATRE JG, 1990, J LIPID RES, V31, P191; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DIMENT S, 1985, J BIOL CHEM, V260, P5311; FAERGEMAN O, 1975, J CLIN INVEST, V55, P1210, DOI 10.1172/JCI108039; FINDLAY J, 1958, BIOCHEM J, V69, P467, DOI 10.1042/bj0690467; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GREENSPAN P, 1984, J BIOL CHEM, V259, P1703; HARRISON EH, 1988, BIOCHIM BIOPHYS ACTA, V963, P28, DOI 10.1016/0005-2760(88)90334-7; HO RJ, 1970, ANAL BIOCHEM, V36, P105, DOI 10.1016/0003-2697(70)90337-4; HORNICK CA, 1985, J CELL BIOL, V100, P1558, DOI 10.1083/jcb.100.5.1558; HUANG J, 1989, ANAL BIOCHEM, V179, P413, DOI 10.1016/0003-2697(89)90154-1; JACKSON RL, 1983, ENZYMES, V16, P141; JAHN CE, 1983, EUR J BIOCHEM, V131, P25, DOI 10.1111/j.1432-1033.1983.tb07227.x; JONES AL, 1984, J LIPID RES, V25, P1151; JOSTVU E, 1986, HISTOCHEMISTRY, V85, P457, DOI 10.1007/BF00508427; LAROSA JC, 1972, J LIPID RES, V13, P356; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MCCOY KL, 1989, J IMMUNOL, V143, P29; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; SAUAR J, 1979, CLIN CHIM ACTA, V92, P101, DOI 10.1016/0009-8981(79)90402-9; STEIN O, 1974, BIOCHIM BIOPHYS ACTA, V360, P205, DOI 10.1016/0005-2760(74)90170-2; VANDYKE RW, 1985, J BIOL CHEM, V260, P1021; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; VANTOL A, 1980, BIOCHIM BIOPHYS ACTA, V619, P156, DOI 10.1016/0005-2760(80)90251-9; WILEMAN T, 1984, BIOCHEM J, V220, P665, DOI 10.1042/bj2200665; WILEY HS, 1985, J BIOL CHEM, V260, P5290; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723	38	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3396	3401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737793				2022-12-25	WOS:A1992HD15400089
J	JACKMAN, HL; MORRIS, PW; DEDDISH, PA; SKIDGEL, RA; ERDOS, EG				JACKMAN, HL; MORRIS, PW; DEDDISH, PA; SKIDGEL, RA; ERDOS, EG			INACTIVATION OF ENDOTHELIN-I BY DEAMIDASE (LYSOSOMAL PROTECTIVE PROTEIN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOPEPTIDASE 24.11 ENKEPHALINASE; NEUTRAL ENDOPEPTIDASE; CONVERTING ENZYME; CATHEPSIN-B; CELLS	Deamidase cleaves ester and peptide bonds in various substrates and deamidates protected COOH-terminal amino acids. It preferentially hydrolyzes peptides which contain hydrophobic amino acids in the P1' and/or P1 position. Because the COOH-terminal end of endothelin I contains the hydrophobic sequence -Ile19-Ile20-Trp21-OH, we investigated whether human deamidase, purified from platelets, could inactivate this peptide. We found that deamidase readily cleaved off Trp21 with an acid pH optimum, a K(m) = 22-mu-M, a k(cat) of 1454 min-1, and a k(cat)/K(m) of 68-mu-M-1 min-1. We also found the enzyme to be present in target cells of endothelin, in vascular smooth muscle cells. Extracts of cultured vascular smooth muscle cells cleave both the synthetic fluorescent substrate 5-dimethylaminonaphthalene-1-sulfonyl(Dns)-Phe-Leu-Arg and endothelin I by releasing the COOH-terminal amino acid. The reaction was inhibited by diisopropyl fluorophosphate, benzyloxycarbonyl-Gly-Leu-Phe-CH2Cl, and p-chloromercuribenzenesulfonate, which inhibit the purified deamidase, but not by inhibitors of some other peptidases. The rate of hydrolysis of endothelin I in the soluble, 100,000 x g final supernatant of the homogenized smooth muscle cells was 2.1-mu-mol/h/mg and 3.1-mu-mol/h/mg for Dns-Phe-Leu-Arg. Thus, smooth muscles, platelets, and many other tissues which contain the deamidase can inactivate endothelin by cleaving the COOH-terminal tryptophan.	UNIV ILLINOIS, COLL MED, DEPT PHARMACOL MC 868, 835 S WOLCOTT AVE, CHICAGO, IL 60612 USA; UNIV ILLINOIS, COLL MED, PEPTIDE RES LAB, CHICAGO, IL 60612 USA; UNIV ILLINOIS, COLL MED, DEPT ANESTHESIOL, CHICAGO, IL 60612 USA; UNIV ILLINOIS, COLL MED, DEPT BIOCHEM, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NHLBI NIH HHS [HL 36082, HL 36473] Funding Source: Medline; PHS HHS [H36081] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036082, R01HL036473, R37HL036473] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DEDDISH PA, 1990, J BIOL CHEM, V265, P15083; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; ERDOS EG, 1963, ANN NY ACAD SCI, V104, P222, DOI 10.1111/j.1749-6632.1963.tb17666.x; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1983, BIOCHEM BIOPH RES CO, V111, P994, DOI 10.1016/0006-291X(83)91398-0; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1991, J BIOL CHEM, V266, P14754; GAMMELTOFT S, 1991, DEGRADATION BIOACTIV, P81; HIOKI Y, 1991, BIOCHEM BIOPH RES CO, V174, P446, DOI 10.1016/0006-291X(91)91436-G; HISAKI K, 1991, BIOCHEM BIOPH RES CO, V177, P1127, DOI 10.1016/0006-291X(91)90656-R; IGIC R, 1972, CIRC RES, V31, pII51; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V171, P669, DOI 10.1016/0006-291X(90)91198-2; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; JOHNSON AR, 1985, AM REV RESPIR DIS, V132, P564; JOHNSON AR, 1985, AM REV RESPIR DIS, V132, P1262; KIMURA S, 1988, BIOCHEM BIOPH RES CO, V156, P1182, DOI 10.1016/S0006-291X(88)80757-5; KONIG W, 1970, CHEM BER-RECL, V103, P788, DOI 10.1002/cber.19701030319; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MATSUMURA Y, 1991, BIOCHEM BIOPH RES CO, V178, P899, DOI 10.1016/0006-291X(91)90976-E; MCMAHON EG, 1991, P NATL ACAD SCI USA, V88, P703, DOI 10.1073/pnas.88.3.703; NAKAJIMA K, 1989, BIOCHEM BIOPH RES CO, V163, P424, DOI 10.1016/0006-291X(89)92153-0; POLLOCK DM, 1991, AM J PHYSIOL, V261, pR257, DOI 10.1152/ajpregu.1991.261.1.R257; SIMONSON MS, 1991, HYPERTENSION, V17, P856, DOI 10.1161/01.HYP.17.6.856; SKIDGEL RA, 1991, BIOCHEM PHARMACOL, V41, P1335, DOI 10.1016/0006-2952(91)90106-F; SKIDGEL RA, 1991, METHODS NEUROSCIENCE, V6, P373; SLOANE BF, 1990, BIOL CHEM H-S, V371, P193; SOKOLOVSKY M, 1991, TRENDS BIOCHEM SCI, V16, P261, DOI 10.1016/0968-0004(91)90100-A; SOKOLOVSKY M, 1990, P NATL ACAD SCI USA, V87, P4702, DOI 10.1073/pnas.87.12.4702; TAKADA J, 1991, BIOCHEM BIOPH RES CO, V176, P860, DOI 10.1016/S0006-291X(05)80265-7; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150; WEBB DJ, 1991, TRENDS PHARMACOL SCI, V12, P43, DOI 10.1016/0165-6147(91)90492-B; WEISS RE, 1990, J UROLOGY, V144, P798, DOI 10.1016/S0022-5347(17)39595-2; YANG HYT, 1970, BIOCHEM PHARMACOL, V19, P1201, DOI 10.1016/0006-2952(70)90380-1	34	99	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2872	2875						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737744				2022-12-25	WOS:A1992HD15400010
J	MAO, LF; MILLINGTON, DS; SCHULZ, H				MAO, LF; MILLINGTON, DS; SCHULZ, H			FORMATION OF A FREE ACYL ADENYLATE DURING THE ACTIVATION OF 2-PROPYLPENTANOIC ACID - VALPROYL-AMP - A NOVEL CELLULAR METABOLITE OF VALPROIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								A study of the activation of valproic acid (2-n-propylpentanoic acid) by a soluble extract of rat liver mitochondria in the presence of ATP, CoASH, and MgCl2 revealed that, in addition to valproyl-CoA, an unknown UV-absorbing compound is formed which is the sole product when CoASH is omitted from the incubation mixture. The unknown compound, which was purified by high performance liquid chromatography, was identified as valproyl adenylate (valproyl-AMP) by mass spectrometry and by its enzymatic conversion to valproyl-CoA in the presence of CoASH. Valproyl-AMP exists, at least partially, in a free, not-enzyme-bound form. Its rate of formation is linear with time and increases 5-fold when the pH is decreased from 8 to 6.8. Valproyl-AMP was also identified when the metabolism of valproate was investigated with rat liver mitochondria and rat hepatocytes. Since the synthesis of valproyl-AMP is inhibited by octanoate, medium-chain acyl-CoA synthetase (EC. 6.2.1.2) may be responsible for its formation. This study establishes that during the activation of valproic acid to valproyl-CoA free valproyl-AMP is formed which is a novel cellular metabolite of valproic acid.	DUKE UNIV,MED CTR,DIV PEDIAT GENET & METAB,DURHAM,NC 27710	Duke University	MAO, LF (corresponding author), CUNY CITY COLL,DEPT CHEM,NEW YORK,NY 10031, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030847, R01HL018089] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30847, HL 18089] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILLIE TA, 1989, VALPROATE BIOTRANSFO, P601; BERG P, 1956, J BIOL CHEM, V222, P991; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNE T R, 1980, New England Journal of Medicine, V302, P661; CHAPPELL JB, 1969, SUBCELLULAR COMPONEN, P77; Groot P H, 1976, Adv Lipid Res, V14, P75; LI JX, 1991, BIOCHEMISTRY-US, V30, P388, DOI 10.1021/bi00216a012; Moldeus P, 1978, Methods Enzymol, V52, P60; WEBSTER LT, 1962, J BIOL CHEM, V237, P1050	9	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3143	3146						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737769				2022-12-25	WOS:A1992HD15400051
J	SZWEDA, LI; STADTMAN, ER				SZWEDA, LI; STADTMAN, ER			IRON-CATALYZED OXIDATIVE MODIFICATION OF GLUCOSE-6-PHOSPHATE-DEHYDROGENASE FROM LEUCONOSTOC-MESENTEROIDES - STRUCTURAL AND FUNCTIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-FUNCTION OXIDATION; GLUTAMINE-SYNTHETASE; OXIDIZED PROTEINS; ESSENTIAL LYSINE; SEQUENCE; RESIDUES; PEPTIDE; SITE	As a variety of eukaryotic cells age, the specific activity of glucose-6-phosphate dehydrogenase (Glu-6-PDH) declines as much as 50%. Because of the central role of this enzyme in metabolism, it is important to define factors responsible for this loss in enzyme activity. We report that Glu-6-PDH from Leuconostoc mesenteroides is rapidly inactivated by micromolar concentrations of Fe2+ and H2O2. Inactivation correlated with the formation of one carbonyl functionality/enzyme subunit, indicating that inactivation is the result of site-specific oxidative modification. Our results suggest that Fe2+ binds to the glucose 6-phosphate binding site and that interaction of the enzyme-bound Fe2+ with H2O2 leads to the oxidative modification of amino acids essential for enzyme activity. Partially inactivated enzyme remained predominantly in the dimeric form, and no change in the apparent affinity of the remaining active subunits for substrate was observed. Partial inactivation did, however, lead to a decrease in the thermal stability of the remaining activity. This decrease in thermal stability could be largely overcome by the addition of glucose 6-phosphate. Thus, although exposure to H2O2 and Fe2+ results in the irreversible inactivation of Glu-6-PDH, the resulting modification is selective, leads to the formation of heterodimers of both active and inactive subunits, and does not appear to cause large scale structural changes. Our results demonstrate the inherent susceptibility of Glu-6-PDH from L. mesenteroides to modification by an oxidation system known to exist in vivo. An assessment of the physiological significance of Fe2+-catalyzed oxidation of Glu-6-PDH awaits extension of these studies to mammalian sources known to accumulate less active or inactive forms of the enzyme as a function of age.			SZWEDA, LI (corresponding author), NHLBI,BIOCHEM LAB,BLDG 3,RM 221,BETHESDA,MD 20892, USA.							AMICI A, 1989, J BIOL CHEM, V264, P3341; BHADBHADE MM, 1987, FEBS LETT, V211, P243, DOI 10.1016/0014-5793(87)81445-X; CLIMENT I, 1991, ARCH BIOCHEM BIOPHYS, V289, P371, DOI 10.1016/0003-9861(91)90425-I; CLIMENT I, 1989, ANAL BIOCHEM, V182, P226, DOI 10.1016/0003-2697(89)90584-8; COLOMBO G, 1986, J BIOL CHEM, V261, P587; FARBER JM, 1986, J BIOL CHEM, V261, P4574; Fenton H., 1894, J CHEM SOC T, V65, P899, DOI [10.1039/CT8946500899, DOI 10.1039/CT8946500899]; FORNAINI G, 1969, EUR J BIOCHEM, V7, P214, DOI 10.1111/j.1432-1033.1969.tb19594.x; GRONENBORN AM, 1984, EUR J BIOCHEM, V145, P365, DOI 10.1111/j.1432-1033.1984.tb08563.x; Haber F., 1934, P R SOC LOND A, V147, P332, DOI [10.1098/rspa.1934.0221, DOI 10.1098/RSPA.1934.0221, DOI 10.1098/rspa.1934.0221]; HAGHIGHI B, 1982, BIOCHEMISTRY-US, V21, P6415, DOI 10.1021/bi00268a015; HAGHIGHI B, 1982, BIOCHEMISTRY-US, V21, P6429, DOI 10.1021/bi00268a017; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HOLLIDAY R, 1972, NATURE, V238, P26, DOI 10.1038/238026a0; ISHAQUE A, 1974, BIOCHEM BIOPH RES CO, V59, P894, DOI 10.1016/S0006-291X(74)80063-X; JEFFERY J, 1989, BIOCHEM BIOPH RES CO, V1601, P1290; KAHN A, 1977, BIOCHEM BIOPH RES CO, V77, P760, DOI 10.1016/S0006-291X(77)80043-0; KAHN A, 1974, BIOCHIMIE, V56, P1395; LEE WT, 1991, J BIOL CHEM, V266, P13028; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; Levy H R, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P97; LEVY HR, 1977, J BIOL CHEM, V252, P3745; MILHAUSEN M, 1975, EUR J BIOCHEM, V50, P453, DOI 10.1111/j.1432-1033.1975.tb09823.x; OLIVE C, 1971, J BIOL CHEM, V246, P2043; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; OLIVER CN, 1987, J AM GERIATR SOC, V35, P947, DOI 10.1111/j.1532-5415.1987.tb02297.x; OLIVER CN, 1985, CELLULAR REGULATION, P320; Rothstein M., 1984, P209; ROTHSTEIN M, 1982, BIOCH APPROACHES AGI, P213; SAHAKIAN JA, 1991, FASEB J, V5, pA1177; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; WULF JH, 1975, EXP GERONTOL, V10, P101, DOI 10.1016/0531-5565(75)90040-6	34	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3096	3100						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737765				2022-12-25	WOS:A1992HD15400044
J	CAMMUE, BPA; DEBOLLE, MFC; TERRAS, FRG; PROOST, P; VANDAMME, J; REES, SB; VANDERLEYDEN, J; BROEKAERT, WF				CAMMUE, BPA; DEBOLLE, MFC; TERRAS, FRG; PROOST, P; VANDAMME, J; REES, SB; VANDERLEYDEN, J; BROEKAERT, WF			ISOLATION AND CHARACTERIZATION OF A NOVEL CLASS OF PLANT ANTIMICROBIAL PEPTIDES FROM MIRABILIS-JALAPA L SEEDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNNEL WEB SPIDER; FUNGAL GROWTH; ANTIFUNGAL PROPERTIES; PROTEINS; PURIFICATION; CHITINASES; INHIBITION; MEMBRANES	We have isolated from seeds of Mirabilis jalapa L. two antimicrobial peptides, designated Mj-AMP1 and Mj-AMP2, respectively. These peptides are highly basic and consist of 37 and 36 residues for Mj-AMP1 and Mj-AMP2, respectively. Both peptides contain three disulfide bridges and differ from one another only by 4 amino acids. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the reduced and unreduced peptides suggests that the peptides associate into dimers in their native form. The Mj-AMPs exhibit a broad spectrum of antifungal activity since they are active against all 13 tested plant pathogenic fungi. Concentrations required for 50% inhibition of fungal growth vary from 6 to 300-mu-g/ml for Mj-AMP1 and from 0.5 to 20-mu-g/ml for Mj-AMP2. These peptides were also active on two tested Gram-positive bacteria but were apparently nontoxic for Gram-negative bacteria and cultured human cells. Although the Mj-AMPs show sequence similarity to mu-agatoxins, a class of insecticidal neurotoxic peptides isolated from the venom of spiders, they do not affect pulse transmission in insect nerves.	CATHOLIC UNIV LEUVEN,REGA INST MED RES,B-3000 LOUVAIN,BELGIUM; ICI PLC,AGROCHEM,JEALOTTS HILL RES STN,BRACKNELL RG12 6EY,BERKS,ENGLAND	KU Leuven	CAMMUE, BPA (corresponding author), CATHOLIC UNIV LEUVEN,FA JANSSENS LAB GENET,WILLEM DE CROYLAAN 42,B-3001 HEVERLEE,BELGIUM.		Proost, Paul/V-3052-2017; Cammue, Bruno/M-9575-2013	Proost, Paul/0000-0002-0133-5545; 				ADAMS ME, 1989, J COMP PHYSIOL A, V164, P333, DOI 10.1007/BF00612993; ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; BOHLMANN H, 1991, ANNU REV PLANT PHYS, V42, P227, DOI 10.1146/annurev.pp.42.060191.001303; BROEKAERT WF, 1989, SCIENCE, V245, P1100, DOI 10.1126/science.245.4922.1100; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1988, PHYSIOL MOL PLANT P, V33, P319, DOI 10.1016/0885-5765(88)90001-X; Creighton T. E., 1989, PROTEIN STRUCTURE PR, P155; DEBOLLE MFC, 1991, ELECTROPHORESIS, V12, P442, DOI 10.1002/elps.1150120612; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KOVARIK A, 1987, FOLIA BIOL-PRAGUE, V33, P253; LAMBERT J, 1989, P NATL ACAD SCI USA, V86, P262, DOI 10.1073/pnas.86.1.262; LEAH R, 1991, J BIOL CHEM, V266, P1564; LEHRER RI, 1991, CELL, V64, P229, DOI 10.1016/0092-8674(91)90632-9; Mansfield J. W., 1982, Phytoalexins., P253; MAUCH F, 1988, PLANT PHYSIOL, V88, P936, DOI 10.1104/pp.88.3.936; PATTERSONDELAFIELD J, 1981, INFECT IMMUN, V31, P723, DOI 10.1128/IAI.31.2.723-731.1981; PEUMANS WJ, 1983, FEBS LETT, V177, P99; PICHON Y, 1974, INSECT NEUROBIOLOGY; REDMAN DG, 1969, J SCI FOOD AGR, V20, P427, DOI 10.1002/jsfa.2740200715; ROBERTS WK, 1986, BIOCHIM BIOPHYS ACTA, V880, P161, DOI 10.1016/0304-4165(86)90076-0; ROBERTS WK, 1990, J GEN MICROBIOL, V136, P1771, DOI 10.1099/00221287-136-9-1771; SCHEEL D, 1990, Z NATURFORSCH C, V45, P569; SCHLUMBAUM A, 1986, NATURE, V324, P365, DOI 10.1038/324365a0; SKINNER WS, 1989, J BIOL CHEM, V264, P2150; VANDAMME J, 1987, EUR J IMMUNOL, V17, P1, DOI 10.1002/eji.1830170102; VANPARIJS J, 1991, PLANTA, V183, P258, DOI 10.1007/BF00197797; VIGERS AJ, 1991, MOL PLANT MICROBE IN, V4, P315, DOI 10.1094/MPMI-4-315; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2	30	223	263	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2228	2233						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733929				2022-12-25	WOS:A1992HB53200019
J	ECK, MJ; ULTSCH, M; RINDERKNECHT, E; DEVOS, AM; SPRANG, SR				ECK, MJ; ULTSCH, M; RINDERKNECHT, E; DEVOS, AM; SPRANG, SR			THE STRUCTURE OF HUMAN LYMPHOTOXIN (TUMOR NECROSIS FACTOR-BETA) AT 1.9-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOLECULAR-CLONING; FACTOR-ALPHA; RECEPTOR; EXPRESSION; REFINEMENT; PROTEINS; FORM	The three-dimensional structure of recombinant human lymphotoxin (residues 24-171 of the mature protein) has been determined by x-ray crystallography at 1.9-angstrom resolution (R(cryst) = 0.215 for I > 3-sigma(I)). Phases were derived by molecular replacement using tumor necrosis factor (TNF-alpha) as a search model. Like TNF-alpha, lymphotoxin (LT) folds to form a "jellyroll" beta-sheet sandwich. Three-fold related LT subunits form a trimer stabilized primarily by hydrophobic interactions. A cluster of 6 basic residues around the 3-fold axis may account for the acid lability of the trimer. Although the structural cores of TNF-alpha and LT are similar, insertions and deletions relative to TNF-alpha occur in loops at the "top" of the LT trimer and significantly alter the local structure and the overall shape of the molecule. The structure of the "base" of the trimer is highly conserved. The sites of two mutations (Asp-50 and Tyr-108) that abolish the cytotoxicity of LT are contained within poorly ordered loops of polypeptide chain that flank the cleft between neighboring subunits at the base of the molecule, suggesting that the receptor recognizes an intersubunit binding site.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; GENENTECH INC,SAN FRANCISCO,CA 94080	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Roche Holding; Genentech								AGGARWAL BB, 1990, TUMOR NECROSIS FACTOR : STRUCTURE, MECHANISM OF ACTION, ROLE IN DISEASE AND THERAPY, P49; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, X PLOR VERSION 2 1 M; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; GOH CR, 1991, PROTEIN ENG, V4, P785; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; HAMLIN R, 1981, J APPL CRYSTALLOGR, V14, P85, DOI 10.1107/S0021889881008856; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES TA, 1990, O VERSION 5 6; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; PAUL NL, 1988, ANNU REV IMMUNOL, V6, P407, DOI 10.1146/annurev.iy.06.040188.002203; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Rossmann M. G., 1972, MOL REPLACEMENT METH; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHALABY MR, 1985, J IMMUNOL, V135, P2069; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH RA, 1987, J BIOL CHEM, V262, P6951; SPRANG SR, 1991, TUMOR NECROSIS FACTO, P11; STEIGEMANN W, 1989, PROTEIN PROGRAM SYST; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713	28	194	222	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2119	2122						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733919				2022-12-25	WOS:A1992HB53200002
J	MCCAULIFFE, DP; YANG, YS; WILSON, J; SONTHEIMER, RD; CAPRA, JD				MCCAULIFFE, DP; YANG, YS; WILSON, J; SONTHEIMER, RD; CAPRA, JD			THE 5'-FLANKING REGION OF THE HUMAN CALRETICULIN GENE SHARES HOMOLOGY WITH THE HUMAN GRP78, GRP94, AND PROTEIN DISULFIDE ISOMERASE PROMOTERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEIN; CHAIN-BINDING-PROTEIN; RO/SS-A AUTOANTIGEN; LUMINAL ER PROTEINS; HEAT-SHOCK; ENDOPLASMIC-RETICULUM; HYPERSENSITIVE REGION; SECRETORY PROTEINS; MOLECULAR-CLONING; STRESS PROTEINS	Calreticulin (CR) is a calcium binding protein that resides in the endoplasmic and sarcoplasmic reticulum and is reactive with human Ro/SS-A autoimmune sera. We have used human CR cDNA to isolate a human 6-kilobase genomic clone that contains 529 base pairs upstream of the presumed transcription start site, 9 exons, 8 introns, and several hundred base pairs 3' of a polyadenylation sequence. Analysis of the human CR promoter region reveals a number of potential regulatory sites also found in the human GRP78, GRP94, and protein disulfide isomerase promoters, including multiple Sp1 and CCAAT consensus sequences, an A-P2 recognition sequence (absent in protein disulfide isomerase), and multiple GC-rich areas. DNA footprint and gel shift analysis on the CR 5'-flanking region demonstrates an area that is bound by protein found in human but not murine nuclear extracts. This sequence is homologous with previously determined regulatory sequences of the human GRP78 and GRP94 promoters. These data indicate that CR, GRP78, GRP94, and protein disulfide isomerase may in part have similar transcriptional regulation and suggest that their gene products while structurally distinct may have similar functions or co-functions. These observations are of additional interest as all four of these genes encode acidic proteins that localize to the endoplasmic reticulum.	UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT DERMATOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIAID NIH HHS [AI 12127] Funding Source: Medline; NIAMS NIH HHS [AR 07341] Funding Source: Medline; NIGMS NIH HHS [GM 31689] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI012127, R37AI012127] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031689] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EMERSON BM, 1985, CELL, V41, P21, DOI 10.1016/0092-8674(85)90057-1; FLIEGEL L, 1989, J BIOL CHEM, V264, P21522; FREEDMAN R, 1987, NATURE, V329, P196, DOI 10.1038/329196a0; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FREEDMAN RB, 1980, ENZYMOLOGY POST TRAN, P167; FURUKAWA F, 1990, J INVEST DERMATOL, V94, P77, DOI 10.1111/1523-1747.ep12873930; HANKE JH, 1988, P NATL ACAD SCI USA, V85, P3560, DOI 10.1073/pnas.85.10.3560; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KEMPER B, 1987, MOL CELL BIOL, V7, P2059, DOI 10.1128/MCB.7.6.2059; KOCH GLE, 1990, BIOESSAYS, V12, P527, DOI 10.1002/bies.950121105; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LIN AY, 1986, MOL CELL BIOL, V6, P1235, DOI 10.1128/MCB.6.4.1235; LODISH HF, 1990, J BIOL CHEM, V265, P10893; MACER DRJ, 1988, J CELL SCI, V91, P61; Maniatis T, 1989, DECONTAMINATION DILU; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCAULIFFE DP, 1990, J CLIN INVEST, V86, P332, DOI 10.1172/JCI114704; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAKAKI T, 1989, MOL CELL BIOL, V9, P2233, DOI 10.1128/MCB.9.5.2233; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NICHOLSON RC, 1990, P NATL ACAD SCI USA, V87, P1159, DOI 10.1073/pnas.87.3.1159; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RIDDIHOUGH G, 1986, EMBO J, V5, P1653, DOI 10.1002/j.1460-2075.1986.tb04408.x; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; SMITH MJ, 1989, EMBO J, V8, P3581, DOI 10.1002/j.1460-2075.1989.tb08530.x; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; TASANEN K, 1988, J BIOL CHEM, V263, P16218; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; TRAUT TW, 1988, P NATL ACAD SCI USA, V85, P2944, DOI 10.1073/pnas.85.9.2944; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; WATSON JD, 1987, MOL BIOL GENE, P274; WINFIELD JB, 1989, ARTHRITIS RHEUM, V32, P1497, DOI 10.1002/anr.1780321202; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOUNG RA, 1989, CELL, V59, P5, DOI 10.1016/0092-8674(89)90861-1; ZARAINHERZBERG A, 1988, J BIOL CHEM, V263, P4807	54	86	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2557	2562						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733953				2022-12-25	WOS:A1992HB53200069
J	ZHAO, GS; XIA, TH; FISCHER, RS; JENSEN, RA				ZHAO, GS; XIA, TH; FISCHER, RS; JENSEN, RA			CYCLOHEXADIENYL DEHYDRATASE FROM PSEUDOMONAS-AERUGINOSA - MOLECULAR-CLONING OF THE GENE AND CHARACTERIZATION OF THE GENE-PRODUCT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-PHENYLALANINE; BIOCHEMICAL PATHWAYS; NUCLEOTIDE-SEQUENCE; OVERFLOW PATHWAY; L-TYROSINE; PHEA GENE; BIOSYNTHESIS; PRETYROSINE; BACTERIA; ESCHERICHIA-COLI-K12	The gene encoding cyclohexadienyl dehydratase (denoted pheC) was cloned from Pseudomonas aeruginosa by functional complementation of a pheA auxotroph of Escherichia coli. The gene was highly expressed in E. coli due to the use of the high-copy number vector pUC18. The P. aeruginosa cyclohexadienyl dehydratase expressed in E. coli was purified to electrophoretic homogeneity. The latter enzyme exhibited identical physical and biochemical properties as those obtained for cyclohexadienyl dehydratase purified from P. aeruginosa. The activity ratios of prephenate dehydratase to arogenate dehydratase remained constant (about 3.3-fold) throughout purification, thus demonstrating a single protein having broad substrate specificity. The cyclohexadienyl dehydratase exhibited K(m) values of 0.42 mM for prephenate and 0.22 mM for L-arogenate, respectively. The pheC gene was 807 base pairs in length, encoding a protein with a calculated molecular mass of 30,480 daltons. This compares with a molecular mass value of 29.5 kDa determined for the purified enzyme by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Since the native molecular mass determined by gel filtration was 72 kDa, the enzyme probably is a homodimer. Comparison of the deduced amino acid sequence of pheC from P. aeruginosa with those of the prephenate dehydratases of Corynebacterium glutamicum, Bacillus subtilis, E. coli, and Pseudomonas stutzeri by standard pairwise alignments did not establish obvious homology. However, a more detailed analysis revealed a conserved motif (containing a threonine residue known to be essential for catalysis) that was shared by all of the dehydratase proteins.	UNIV FLORIDA,DEPT MICROBIOL & CELL SCI,GAINESVILLE,FL 32611	State University System of Florida; University of Florida								AHMAD S, 1988, CURR MICROBIOL, V16, P295, DOI 10.1007/BF01568535; AHMAD S, 1990, J BACTERIOL, V172, P1051, DOI 10.1128/jb.172.2.1051-1061.1990; BALDWIN GS, 1981, ARCH BIOCHEM BIOPHYS, V211, P66, DOI 10.1016/0003-9861(81)90430-6; BENTLEY R, 1990, CRIT REV BIOCHEM MOL, V25, P307, DOI 10.3109/10409239009090615; BERRY A, 1987, J GEN MICROBIOL, V133, P3257; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYNG GS, 1983, ARCH MICROBIOL, V136, P163, DOI 10.1007/BF00409838; BYNG GS, 1982, CRC CR REV MICROBIOL, V9, P227, DOI 10.3109/10408418209104491; CARLSON CA, 1984, ARCH MICROBIOL, V140, P124; COTTON RGH, 1965, BIOCHIM BIOPHYS ACTA, V100, P76, DOI 10.1016/0304-4165(65)90429-0; Davis R W, 1980, Methods Enzymol, V65, P404; DAYAN J, 1970, METHOD ENZYMOL, V17, P559; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FISCHER RS, 1991, J GEN MICROBIOL, V137, P1293, DOI 10.1099/00221287-137-6-1293; FISKE MJ, 1983, J BACTERIOL, V154, P623, DOI 10.1128/JB.154.2.623-631.1983; FOLLETTIE MT, 1986, J BACTERIOL, V167, P695, DOI 10.1128/jb.167.2.695-702.1986; HOCH GLE, 1972, BIOCHIM BIOPHYS ACTA, V258, P719; HOLLOWAY BW, 1969, BACTERIOL REV, V33, P419, DOI 10.1128/MMBR.33.3.419-443.1969; HUDSON GS, 1984, J MOL BIOL, V180, P1023, DOI 10.1016/0022-2836(84)90269-9; HUMPHREYS GO, 1975, BIOCHIM BIOPHYS ACTA, V383, P457, DOI 10.1016/0005-2787(75)90318-4; HYDE E, 1979, BIOCHEMISTRY-US, V18, P2766; HYDE E, 1978, BIOCHEMISTRY-US, V17, P1573; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MOHR CD, 1990, J BACTERIOL, V172, P6252, DOI 10.1128/jb.172.11.6252-6260.1990; PATEL N, 1977, J BIOL CHEM, V252, P5839; PATEL N, 1978, J BIOL CHEM, V253, P2972; PROBER JM, 1987, SCIENCE, V238, P336, DOI 10.1126/science.2443975; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; STENMARK SL, 1974, NATURE, V247, P290, DOI 10.1038/247290a0; TRACH K, 1989, J BACTERIOL, V171, P1362, DOI 10.1128/jb.171.3.1362-1371.1989; WEST SEH, 1988, NUCLEIC ACIDS RES, V16, P9323, DOI 10.1093/nar/16.19.9323; WHITAKER RJ, 1982, J BIOL CHEM, V257, P13550; XIA TH, 1991, ARCH BIOCHEM BIOPHYS, V286, P461, DOI 10.1016/0003-9861(91)90066-R; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZAMIR LO, 1985, BIOCHEMISTRY-US, V24, P1607, DOI 10.1021/bi00328a006; ZAMIR LO, 1980, J AM CHEM SOC, V102, P4499, DOI 10.1021/ja00533a032	38	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2487	2493						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733946				2022-12-25	WOS:A1992HB53200058
J	INGLESE, J; GLICKMAN, JF; LORENZ, W; CARON, MG; LEFKOWITZ, RJ				INGLESE, J; GLICKMAN, JF; LORENZ, W; CARON, MG; LEFKOWITZ, RJ			ISOPRENYLATION OF A PROTEIN-KINASE - REQUIREMENT OF FARNESYLATION ALPHA-CARBOXYL METHYLATION FOR FULL ENZYMATIC-ACTIVITY OF RHODOPSIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROD OUTER SEGMENTS; CYSTEINE RESIDUE; GAMMA-SUBUNIT; BOVINE; IDENTIFICATION; TRANSFERASE; EXPRESSION; SEQUENCE; CLEAVAGE; ESTER	The primary structure of bovine rhodopsin kinase (RK), which phosphorylates light-activated rhodopsin (Rho*), terminates with the amino acid sequence Cys558-Val-Leu-Ser561, a motif that has been shown to direct the isoprenylation and alpha-carboxyl methylation of many proteins (e.g. p21Ha-ras). Transient expression of RK in COS-7 cells revealed the presence of two immunoreactive protein species. Consistent with RK being modified by isoprenylation, interconversion of these two species was dependent upon isoprenoid biosynthesis in the cells. Moreover, a serine substitution for Cys558 resulted in a single RK species whose migration on sodium dodecyl sulfate-polyacrylamide gels was identical to that of RK from cells treated with mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and, thus, of isoprenoid biosynthesis. This finding indicates that isoprenylation of RK requires Cys558. The electrophoretic mobility of isoprenylated RK synthesized in COS-7 cells was identical to that of RK from bovine rod outer segments, suggesting that RK is isoprenylated in vivo. RK was determined to be modified by a farnesyl moiety and alpha-carboxyl-methylated. A time course of Rho* phosphorylation revealed that non-processed RK is approximately 4-fold less active than wild-type RK. This is the first demonstration of isoprenylation/alpha-carboxyl methylation of a protein kinase, and suggests that these modifications markedly influence enzymatic activity in vivo.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709	Duke University; Howard Hughes Medical Institute; Duke University; Duke University; Burroughs Wellcome Fund	INGLESE, J (corresponding author), DUKE UNIV,MED CTR,DEPT MED,BOX 3821,DURHAM,NC 27710, USA.		Glickman, Joseph/H-3021-2013; Lefkowitz, Robert/AAW-2649-2021	Glickman, Joseph/0000-0002-6706-4039; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; FARNSWORTH C C, 1990, Methods (Orlando), V1, P231, DOI 10.1016/S1046-2023(05)80322-6; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GUTEIRREZ L, 1989, EMBO J, V8, P1093; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARGRAVE P A, 1972, Federation Proceedings, V31, P462; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P1049, DOI 10.1080/00021369.1979.10863559; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KISNELLA BT, 1991, J BIOL CHEM, V266, P8540; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; KUHN H, 1981, CURR TOP MEMBR TRANS, V15, P174; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; OTA IM, 1989, J BIOL CHEM, V264, P12879; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SWANSON RJ, 1983, J BIOL CHEM, V258, P599; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; XIE H, 1990, Methods (Orlando), V1, P276, DOI 10.1016/S1046-2023(05)80328-7; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	34	172	174	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1422	1425						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730692				2022-12-25	WOS:A1992HA48500006
J	WYNN, RM; CHUANG, JL; DAVIE, JR; FISHER, CW; HALE, MA; COX, RP; CHUANG, DT				WYNN, RM; CHUANG, JL; DAVIE, JR; FISHER, CW; HALE, MA; COX, RP; CHUANG, DT			CLONING AND EXPRESSION IN ESCHERICHIA-COLI OF MATURE E1-BETA-SUBUNIT OF BOVINE MITOCHONDRIAL BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE COMPLEX - MAPPING OF THE E1-BETA-BINDING REGION ON E2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOYL TRANSACYLASE COMPONENT; SYRUP-URINE-DISEASE; MULTI-SITE PHOSPHORYLATION; PYRUVATE-DEHYDROGENASE; SUBUNIT STRUCTURE; PROTEIN-X; TRANSACETYLASE COMPONENT; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; MESSENGER-RNA	A cDNA encoding the mature E1-beta subunit of the bovine branched-chain alpha-keto acid dehydrogenase complex was isolated from a lambda-ZAP expression library. The bovine E1-beta cDNA is 1,393 base pairs in length. It encodes the entire mature E1-beta subunit consisting of 342 amino acid residues and a partial mitochondrial targeting presequence of 26 residues. The calculated molecular mass of the mature bovine E1-beta subunit is 37,776 daltons, and the calculated isoelectric point is pI 5.04. The mature bovine E1-beta subunit was expressed in Escherichia coli via the pKK233-2 vector in the presence of isopropyl beta-D-thiogalactopyranoside (IPTG). When expression was induced by IPTG at 37-degrees-C, the soluble recombinant E1-beta subunit existed as a single high molecular weight form (M(r) congruent-to 3.5 x 10(5)), which sedimented during sucrose gradient ultracentrifugation at 2 x 10(5) x g. However, lowering the induction temperature to 25-degrees-C resulted in the occurrence of both high and low molecular weight forms of the recombinant E1-beta protein. The low molecular weight form (M(r) congruent-to 9.1 x 10(4)) remained soluble after sucrose gradient centrifugation and was utilized in binding studies with a series of truncated recombinant E2 proteins. The results showed that the E1-beta subunit bound to the region between Ala-115 and Lys-150 of the E2 chain, which lay within the putative E3-binding domain. In contrast, the recombinant E1-alpha subunit did not bind the E2 component. The data suggest an apparent binding order of E2-E1-beta-E1-alpha, which supports and extends the model of E2 inner core deduced previously from the data of scanning transmission electron microscopy (Hackert, M. L., Xu, W.-X., Oliver, R. M., Wall, J. S., Hainfeld, J. F., Mullinax, T. R., and Reed, L. J. (1989) Biochemistry 28, 6816-6821). The relatively inaccessible topology of E1-beta may explain the lack of antigenicity and resistance to limited proteolysis of this subunit as it exists in the complex.	UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SOUTHWESTERN MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Wynn, Richard/0000-0002-1879-2136; Davie, James/0000-0002-0420-6888	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037373, R01DK026758] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-37373, DK-26758] Funding Source: Medline; NIGMS NIH HHS [5-P32 GM-08014] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRERA CR, 1972, ARCH BIOCHEM BIOPHYS, V148, P343, DOI 10.1016/0003-9861(72)90152-X; BEHAL RH, 1989, P NATL ACAD SCI USA, V86, P8732, DOI 10.1073/pnas.86.22.8732; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; CHUANG DT, 1984, J BIOL CHEM, V259, P9277; CHUANG DT, 1985, J BIOL CHEM, V260, P3779; COOK KG, 1983, FEBS LETT, V164, P85, DOI 10.1016/0014-5793(83)80024-6; COOK KG, 1985, BIOCHEM J, V225, P731, DOI 10.1042/bj2250731; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DANNER DJ, 1989, J BIOL CHEM, V264, P7742; DEMARCUCCI O, 1985, EUR J BIOCHEM, V149, P641, DOI 10.1111/j.1432-1033.1985.tb08972.x; FATANIA HR, 1983, FEBS LETT, V158, P234, DOI 10.1016/0014-5793(83)80585-7; FERRER A, 1990, FEBS LETT, V266, P67, DOI 10.1016/0014-5793(90)81508-L; FISHER CW, 1989, J BIOL CHEM, V264, P3448; GECK P, 1983, ANAL BIOCHEM, V135, P264, DOI 10.1016/0003-2697(83)90681-4; GRIFFIN TA, 1988, J BIOL CHEM, V263, P14008; GRIFFIN TA, 1990, J BIOL CHEM, V265, P12104; GRIFFIN TA, 1990, J BIOL CHEM, V265, P13174; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; HACKERT ML, 1989, BIOCHEMISTRY-US, V28, P6816, DOI 10.1021/bi00443a006; HEFFELFINGER SC, 1983, BIOCHEMISTRY-US, V22, P5519, DOI 10.1021/bi00293a011; HEMILA H, 1990, J BACTERIOL, V172, P5052, DOI 10.1128/jb.172.9.5052-5063.1990; HU CWC, 1986, J BIOL CHEM, V261, P343; HU CWC, 1988, J BIOL CHEM, V263, P9007; JILKA JM, 1986, J BIOL CHEM, V261, P1858; LAU KS, 1982, FEBS LETT, V144, P57, DOI 10.1016/0014-5793(82)80568-1; LAU KS, 1983, FEBS LETT, V160, P149, DOI 10.1016/0014-5793(83)80955-7; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Maniatis T., 1982, MOL CLONING; NOBUKUNI Y, 1990, BIOCHEMISTRY-US, V29, P1154, DOI 10.1021/bi00457a009; NOBUKUNI Y, 1989, BIOCHEM BIOPH RES CO, V161, P1035, DOI 10.1016/0006-291X(89)91347-8; ODESSEY R, 1982, BIOCHEM J, V204, P353, DOI 10.1042/bj2040353; ONO K, 1987, BIOCHEM MED METAB B, V37, P133, DOI 10.1016/0885-4505(87)90019-3; PACKMAN LC, 1986, FEBS LETT, V206, P193, DOI 10.1016/0014-5793(86)80979-6; PACKMAN LC, 1988, BIOCHEM J, V252, P79, DOI 10.1042/bj2520079; PAXTON R, 1986, ARCH BIOCHEM BIOPHYS, V244, P187, DOI 10.1016/0003-9861(86)90108-6; PAXTON R, 1982, J BIOL CHEM, V257, P4433; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; POWERSGREENWOOD SL, 1989, J BIOL CHEM, V264, P3655; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; REED LJ, 1980, FEBS S, V60, P47; REINBERG AP, 1983, ANAL BIOCHEM, V132, P6; RUSSELL GC, 1991, BIOCHIM BIOPHYS ACTA, V1076, P225, DOI 10.1016/0167-4838(91)90271-Z; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1985, DNA NY, V4, P165; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SYKES PJ, 1987, J BACTERIOL, V169, P1619, DOI 10.1128/jb.169.4.1619-1625.1987; TAKAGI H, 1988, BIO-TECHNOL, V6, P948, DOI 10.1038/nbt0888-948; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WILLIAMS DC, 1982, SCIENCE, V215, P687, DOI 10.1126/science.7036343; ZHANG B, 1988, GENE, V69, P159, DOI 10.1016/0378-1119(88)90390-3; ZHANG B, 1990, J BIOL CHEM, V265, P2425; ZHANG B, 1987, J BIOL CHEM, V262, P15220	54	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1881	1887						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730724				2022-12-25	WOS:A1992HA48500075
J	BELTRAN, C; KOPECKY, J; PAN, YCE; NELSON, H; NELSON, N				BELTRAN, C; KOPECKY, J; PAN, YCE; NELSON, H; NELSON, N			CLONING AND MUTATIONAL ANALYSIS OF THE GENE ENCODING SUBUNIT-C OF YEAST VACUOLAR H+-ATPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICLE PROTON PUMP; SACCHAROMYCES-CEREVISIAE; CDNA SEQUENCE; GAMMA-SUBUNIT; MEMBRANES; EVOLUTION; PROTEINS; CHAIN; TRIPHOSPHATASE; POLYPEPTIDE	A DNA fragment containing the gene encoding subunit C of vaculor H+-ATPase (V-ATPase) was cloned from a yeast library. The predicted amino acid sequence indicated that the C subunit consists of 373 amino acids with a calculated molecular mass of 42,287 Da. The protein from yeast is 37% identical in its amino acid sequence to the C subunit of bovine V-ATPase. The DNA fragment that was cloned in this study contained two additional reading frames. At the 5' end an amino acid sequence that is homologous to Artemia elongation factor 1 was detected. At the 3' end the N-terminal part of a kinesin-like protein was observed. The gene encoding subunit C of the V-ATPase was interrupted, and the resulting mutant could not grow at high pH and was sensitive to low and high Ca" concentrations in the growth medium. Transformation of the mutant by a plasmid containing the gene encoding subunit C repaired the phenotype of the mutant. Substitution of more than half of the coding region by a corresponding DNA fragment encoding the bovine subunit C resulted in a phenotype indistinguishable from wild type. Immunological studies with the disruptant mutant revealed that subunit C is necessary for the assembly of the catalytic sector of the enzyme.	ROCHE INST MOLEC BIOL, ROCHE RES CTR, 340 KINGSLAND ST, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, DEPT PROT BIOCHEM, NUTLEY, NJ 07110 USA	Roche Holding; Roche Holding			Kopecky, Jan/B-8244-2012; Beylot-Barry, Marie/AHC-3163-2022	Kopecky, Jan/0000-0001-8072-2035; 				ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; BOWMAN BJ, 1986, J MEMBRANE BIOL, V94, P83, DOI 10.1007/BF01871190; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENOS AP, 1990, CELL, V60, P1019, DOI 10.1016/0092-8674(90)90350-N; FANGER BO, 1987, ANAL BIOCHEM, V162, P11, DOI 10.1016/0003-2697(87)90004-2; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FOURY F, 1990, J BIOL CHEM, V265, P18554; GILAM S, 1975, NUCLEIC ACIDS RES, V2, P625; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; ITOH H, 1983, J BACTERIOL, V153, P163; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; KANE PM, 1989, J BIOL CHEM, V264, P19236; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RV, 1980, ANAL BIOCHEM, V104, P153, DOI 10.1016/0003-2697(80)90291-2; MAESSEN GDF, 1987, FEBS LETT, V223, P181, DOI 10.1016/0014-5793(87)80532-X; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORIYAMA Y, 1989, J BIOL CHEM, V264, P18445; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1989, BIOCHIM BIOPHYS ACTA, V980, P241, DOI 10.1016/0005-2736(89)90405-7; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON H, 1990, J BIOL CHEM, V265, P20390; NELSON N, 1986, METHOD ENZYMOL, V118, P352; NELSON N, 1989, J BIOENERG BIOMEMBR, V21, P553, DOI 10.1007/BF00808113; NELSON N, 1988, PLANT PHYSIOL, V86, P1, DOI 10.1104/pp.86.1.1; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NELSON N, 1988, METHOD ENZYMOL, V157, P619; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PARRY RV, 1989, J BIOL CHEM, V264, P20025; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1983, METHODS YEAST GENETI; SMITH M, 1983, METHODS DNA RNA SEQU, P23; SUDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067, DOI 10.1073/pnas.86.16.6067; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; WU R, 1972, NATURE-NEW BIOL, V236, P198, DOI 10.1038/newbio236198a0; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	51	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					774	779						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730668				2022-12-25	WOS:A1992GY96000018
J	DATTA, A				DATTA, A			PURIFICATION AND CHARACTERIZATION OF A NOVEL PROTEASE FROM SOLID SUBSTRATE CULTURES OF PHANEROCHAETE-CHRYSOSPORIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN PEROXIDASE; LENTINUS-EDODES; ACID PROTEASES; DEGRADATION; SPECIFICITY; PROTEINASES	The white-rot basidiomycete Phanerochaete chrysosporium is mostly known for its extracellular ligninolytic enzymes. In this paper, the purification and characterization of a novel extracellular protease secreted by this fungus in solid substrate cultures under ligninolytic conditions are described. The purification steps included extraction of enzymes from the wood substrate, concanavalin A-Sepharose chromatography, anion-exchange chromatography (Mono Q), and size-exclusion chromatography (Superose 12). The purified protein migrates with M(r) = 40,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. It has an isoelectric point of 5.6 and a sharp pH optimum at 4.0. The protease is totally inhibited by Hg2+, p-hydroxymercuribenzoic acid, and N-bromosuccinimide, but is insensitive to phenylmethanesulfonyl fluoride, pepstatin A, and EDTA. Its amino acid composition and NH2-terminal sequence have also been determined. The sequence data and the binding of the protease to concanavalin A indicate that the protease is a glycoprotein. The protease differs in its physico-chemical properties and its response to inhibitors from other extracellular proteases previously found in another strain of P. chrysosporium. The data suggest that it has properties of both aspartate-type and thiol-type proteases.			DATTA, A (corresponding author), UNIV WISCONSIN,CTR BIOTECHNOL,MADISON,WI 53705, USA.				NCRR NIH HHS [RR-03326] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CHANG WJ, 1976, J BIOCHEM-TOKYO, V80, P975, DOI 10.1093/oxfordjournals.jbchem.a131385; DATTA A, 1991, APPL ENVIRON MICROB, V57, P1453, DOI 10.1128/AEM.57.5.1453-1460.1991; DOSORETZ CG, 1990, APPL ENVIRON MICROB, V56, P3429, DOI 10.1128/AEM.56.11.3429-3434.1990; DOSORETZ CG, 1990, APPL ENVIRON MICROB, V56, P395, DOI 10.1128/AEM.56.2.395-400.1990; Eriksson K.-E., 1990, MICROBIAL ENZYMATIC; ERIKSSON KE, 1982, EUR J BIOCHEM, V124, P635; FARRELL RL, 1989, ENZYME MICROB TECH, V11, P322, DOI 10.1016/0141-0229(89)90014-8; FRUTON JS, 1970, ADV ENZYMOL REL S BI, V33, P401; GOLD MH, 1989, ACS SYM SER, V389, P127; HAAB D, 1990, J BIOTECHNOL, V16, P187, DOI 10.1016/0168-1656(90)90035-A; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; KIRK TK, 1989, WORLD PULP PAPER TEC, P23; LACKNER R, 1991, CAN J MICROBIOL, V37, P665, DOI 10.1139/m91-113; LAMAR RT, 1990, APPL ENVIRON MICROB, V56, P3093, DOI 10.1128/AEM.56.10.3093-3100.1990; LEATHAM GF, 1981, J GEN MICROBIOL, V125, P147; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MORIHARA K, 1974, ADV ENZYMOL RAMB, V41, P179; MURAO S, 1978, AGR BIOL CHEM TOKYO, V42, P1343, DOI 10.1080/00021369.1978.10863163; NORTH MJ, 1982, MICROBIOL REV, V46, P308, DOI 10.1128/MMBR.46.3.308-340.1982; POPP JL, 1991, ARCH BIOCHEM BIOPHYS, V288, P145, DOI 10.1016/0003-9861(91)90176-J; RICKERT WS, 1974, BIOCHIM BIOPHYS ACTA, V336, P437, DOI 10.1016/0005-2795(74)90425-5; SCHALCH H, 1989, MOL CELL BIOL, V9, P2743, DOI 10.1128/MCB.9.6.2743; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; TAPIA G, 1981, FEBS LETT, V130, P205, DOI 10.1016/0014-5793(81)81120-9; TERASHITA T, 1981, AGR BIOL CHEM TOKYO, V45, P1929, DOI 10.1080/00021369.1981.10864820; TIEN M, 1987, CRIT REV MICROBIOL, V15, P141, DOI 10.3109/10408418709104456; TSUJITA Y, 1977, J BIOCHEM-TOKYO, V81, P1063, DOI 10.1093/oxfordjournals.jbchem.a131529	29	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					728	736						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730663				2022-12-25	WOS:A1992GY96000011
J	DOUGHERTY, KM; BRANDRISS, MC; VALLE, D				DOUGHERTY, KM; BRANDRISS, MC; VALLE, D			CLONING HUMAN PYRROLINE-5-CARBOXYLATE REDUCTASE CDNA BY COMPLEMENTATION IN SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUNCTIONAL COMPLEMENTATION; PYRROLINE 5-CARBOXYLATE; HUMAN-ERYTHROCYTES; REGION SEQUENCES; GENE; PROLINE; ACID; PURIFICATION; DELTA1-PYRROLINE-5-CARBOXYLATE	Pyrroline-5-carboxylate reductase (EC 1.5.1.2) catalyzes the NAD(P)H-dependent conversion of pyrroline-5-carboxylate to proline. We cloned a human pyrroline-5-carboxylate reductase cDNA by complementation of proline auxotrophy in a Saccharomyces cerevisiae mutant strain, DT1100. Using a HepG2 cDNA library in a yeast expression vector, we screened 10(5) transformants, two of which gained proline prototrophy. The plasmids in both contained similar 1.8-kilobase inserts, which when reintroduced into strain DT1100, conferred proline prototrophy. The pyrroline-5-carboxylate reductase activity in these prototrophs was 1-3% that of wild type yeast, in contrast to the activity in strain DT1100 which was undetectable. The 1810-base pair pyrroline-5-carboxylate reductase cDNA hybridizes to a 1.85-kilobase mRNA in samples from human cell lines and predicts a 319-amino acid, 33.4-kDa protein. The derived amino acid sequence is 32% identical with that of S. cerevisiae. By genomic DNA hybridization analysis, the human reductase appears to be encoded by a single copy gene which maps to chromosome 17.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,GENET LAB,PCTB 802,725 N WOLFE ST,BALTIMORE,MD 21205; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103	Howard Hughes Medical Institute; Johns Hopkins University; Rutgers State University New Brunswick; Rutgers State University Medical Center					NEI NIH HHS [5RO1EY02948] Funding Source: Medline; NIGMS NIH HHS [5RO1GM40751] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040751] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; BRANDRISS MC, 1983, MOL CELL BIOL, V3, P1846, DOI 10.1128/MCB.3.10.1846; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELAUNEY AJ, 1990, MOL GEN GENET, V221, P299, DOI 10.1007/BF00259392; DEUTSCH AH, 1982, NUCLEIC ACIDS RES, V23, P7701; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAMILTON PT, 1985, MOL GEN GENET, V200, P47, DOI 10.1007/BF00383311; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERZFELD A, 1977, BIOCHEM J, V166, P95, DOI 10.1042/bj1660095; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LORANS G, 1981, BIOCHEM BIOPH RES CO, V101, P1018, DOI 10.1016/0006-291X(81)91850-7; MATSUZAWA T, 1982, BIOCHIM BIOPHYS ACTA, V717, P215; McKusick VA, 1990, MENDELIAN INHERITANC; MERRILL MJ, 1989, J BIOL CHEM, V264, P9352; MEZL VA, 1976, ANAL BIOCHEM, V74, P430, DOI 10.1016/0003-2697(76)90223-2; MEZL VA, 1977, BIOCHEM J, V166, P105, DOI 10.1042/bj1660105; MINET M, 1990, CURR GENET, V18, P287, DOI 10.1007/BF00318209; MITCHELL GA, 1988, J BIOL CHEM, V263, P14288; MIXSON AJ, 1988, J BIOL CHEM, V263, P10720; MOHANDAS T, 1986, SOMAT CELL MOLEC GEN, V12, P89, DOI 10.1007/BF01560731; NADEAU JH, 1989, TRENDS GENET, V5, P82, DOI 10.1016/0168-9525(89)90031-0; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; PHANG JM, 1973, ANAL BIOCHEM, V55, P266, DOI 10.1016/0003-2697(73)90312-6; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; ROSE MD, 1990, METHODS YEAST GENETI, P128; Sambrook J, 1989, MOL CLONING LABORATO; SAVIOZ A, 1990, GENE, V86, P107, DOI 10.1016/0378-1119(90)90121-7; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SHIONO T, 1986, BIOCHIM BIOPHYS ACTA, V881, P72, DOI 10.1016/0304-4165(86)90098-X; SMITH RJ, 1978, METABOLISM, V27, P685, DOI 10.1016/0026-0495(78)90006-9; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; TOMENCHOK DM, 1987, J BACTERIOL, V169, P5364, DOI 10.1128/jb.169.12.5364-5372.1987; VAESSEN RTMJ, 1986, EMBO J, V5, P335, DOI 10.1002/j.1460-2075.1986.tb04217.x; VALLE D, 1976, J CLIN INVEST, V58, P598, DOI 10.1172/JCI108506; YEH GC, 1988, J BIOL CHEM, V263, P13083; YEH GC, 1981, J CLIN INVEST, V67, P1042, DOI 10.1172/JCI110115	43	34	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					871	875						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730675				2022-12-25	WOS:A1992GY96000031
J	WEISMAN, LS; WICKNER, W				WEISMAN, LS; WICKNER, W			MOLECULAR CHARACTERIZATION OF VAC1, A GENE REQUIRED FOR VACUOLE INHERITANCE AND VACUOLE PROTEIN SORTING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; YEAST; DNA; SEGREGATION; BIOGENESIS; DIVISION; DOMAINS	Cell division requires an accurate partitioning of cytoplasmic organelles. The segregation of vacuoles in the budding yeast Saccharomyces cerevisaie occurs at a specific time in the cell cycle and is spatially targeted to the small bud. Several yeast vac mutants have been isolated which are defective in this process. We have now cloned the VAC1 gene, corresponding to the first of these mutants, vac1-1. This gene encodes a protein of 515 amino acids, without homolog in the current data bases. It contains neither long hydrophobic stretches nor a classical leader peptide. The most notable aspect of the sequence is the presence of three zinc fingers. Yeast in which the VAC1 gene has been entirely deleted are viable. However, they grow more slowly than wild-type cells and only form microcolonies when grown on glycerol at 37-degrees-C. These yeast are defective in vacuole segregation at both the permissive and nonpermissive temperatures. The vac1 mutant was previously shown to mislocalize carboxypeptidase Y to the cell surface, suggesting that Vac1p is involved in more than one vesicular traffic pathway.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles	WEISMAN, LS (corresponding author), UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA.			Weisman, Lois/0000-0001-7740-9785				BANTA LM, 1990, MOL CELL BIOL, V10, P4638, DOI 10.1128/MCB.10.9.4638; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BIRKY CW, 1983, INT REV CYTOL, P49; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; DEMESQUITA DSG, 1991, IN PRESS J GEN MICRO; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FRANKEL AD, 1988, CELL, V53, P675, DOI 10.1016/0092-8674(88)90083-9; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; Higuchi R., 1989, PCR TECHNOLOGY, P61; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRESTON RA, 1987, J CELL BIOL, V105, P1981, DOI 10.1083/jcb.105.5.1981; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBINSON JS, 1991, IN PRESS MOL CELL BI; Rose MD., 1990, METHODS YEAST GENETI; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW JM, 1991, EMBO J, V10, P1741, DOI 10.1002/j.1460-2075.1991.tb07698.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; WADA Y, 1990, MOL CELL BIOL, V10, P2214, DOI 10.1128/MCB.10.5.2214; WARREN G, 1985, TRENDS BIOCHEM SCI, V10, P439, DOI 10.1016/0968-0004(85)90027-1; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539; WEISMAN LS, 1990, P NATL ACAD SCI USA, V87, P1076, DOI 10.1073/pnas.87.3.1076; WOOLFORD CA, 1990, GENETICS, V125, P739; [No title captured]	35	84	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					618	623						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730622				2022-12-25	WOS:A1992GY43900096
J	KYPRIANOU, N; TAYLORPAPADIMITRIOU, J				KYPRIANOU, N; TAYLORPAPADIMITRIOU, J			ISOLATION OF AZATYROSINE-INDUCED REVERTANTS FROM RAS-TRANSFORMED HUMAN MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article								Non-transformed revertant clones were isolated from the ras-transformed MTSV1-7 (ras) cell line, after treatment with the antibiotic azatyrosine. Azatyrosine significantly inhibited the growth of the ras-transformed cells but not of the normal MTSV1-7. After 7 days of azatyrosine treatment, approximately 30% of MTSV1-7 (ras) cells survived, and revertant cell lines were selected by random cloning. The azatyrosine-induced revertants (six clones) were considered non-transformed on the basis of (a) their substantially reduced ability to form colonies in soft agar, and (b) their inability to produce tumours in nude mice. Molecular analysis of the revertants revealed that each contains multiple copies of the v-H-ras gene and expresses high levels of v-H-ras mRNA, and all revertants sustain elevated levels of p21ras protein. Thus, the revertant phenotype induced by azatyrosine does not result from inactivation of v-H-ras oncogene or inhibition of its expression. In vivo guanine nucleotide binding to p21ras in the revertant cell lines demonstrated binding of both GTP and GDP, indicating that reversion to the non-transformed phenotype was not due to inability of p21ras to bind GTP. The expression of the human K-rev-1 gene, a known tumour-suppressor gene in ras-transformed NIH3T3 cells, was studied in the isolated azatyrosine revertants. All six revertants showed a significant increase in the K-rev-1 transcript levels compared with the ras-transformed MTSVI-7 cells. These results suggest that tumorigenic transformation of human mammary epithelial cells by v-H-ras may be influenced by the level of expression of the tumour-suppressor gene, K-rev-1.	IMPERIAL CANC RES FUND, POB 123, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BOS JL, 1989, CANCER RES, V49, P4682; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HSIAO WLW, 1985, MOL CELL BIOL, V5, P1800, DOI 10.1128/MCB.5.7.1800; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NAKAYASU M, 1988, P NATL ACAD SCI USA, V85, P9066, DOI 10.1073/pnas.85.23.9066; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; PATERSON H, 1989, CIBA F SYMP, V142, P134; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SAMID D, 1984, BIOCHEM BIOPH RES CO, V119, P21, DOI 10.1016/0006-291X(84)91612-7; SHINDOOKADA N, 1989, MOL CARCINOGEN, V2, P159, DOI 10.1002/mc.2940020309; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; TAYLORPAPADIMITRIOU J, 1977, J NATL CANCER I, V58, P1563, DOI 10.1093/jnci/58.6.1563; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YANAGIHARA K, 1990, ONCOGENE, V5, P1179	30	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					57	63						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741165				2022-12-25	WOS:A1992HC22700008
J	BUEHLER, LK; KUSUMOTO, S; ZHANG, H; ROSENBUSCH, JP				BUEHLER, LK; KUSUMOTO, S; ZHANG, H; ROSENBUSCH, JP			PLASTICITY OF ESCHERICHIA-COLI PORIN CHANNELS - DEPENDENCE OF THEIR CONDUCTANCE ON STRAIN AND LIPID ENVIRONMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEIN PORIN; OUTER-MEMBRANE; K-12; OMPF; PEPTIDOGLYCAN; MITOCHONDRIA; RESOLUTION; MUTANTS; CELLS; GENE	The conductance properties of three members of the porin family which form channels across the outer membrane of Gram-negative bacteria were compared. With their endogenous lipopolysaccharide (LPS) bound, the closely related porins F and C from Escherichia coli reveal significantly different conductance steps and closing potentials, with values of 0.82 nS (nanosiemens) and 89 mV for F-type channels, and 0.49 nS and 158 mV for C-type pores (1 M NaCl), respectively. On the basis of their closing potentials, the two channel types can be distinguished unequivocally. If reconstituted in asolectin and extraneous LPS, porin C forms F-type in addition to C-type channels. Substitution of asolectin by mitochondrial lipids yields the native C-type pores only. Both channel types can be induced to assume the mutually other channel configuration by variation of ionic strength. A multiplicity of channel subtypes is observed by variation of the pH of the medium. The three channels within a trimer are, however, consistently of the same type. Since structural studies have revealed a single channel per monomer, the several conductance steps observed are likely to reflect distinct configurations of the same channel. Best channel recoveries were observed if endogenous LPS remained associated to porin during purification. Significant yields could nevertheless be obtained also if LPS was removed from porin and replaced with various precursors or chemically synthesized analogues. As function requires the presence of glycolipids, yet crystallization is perturbed by heterodisperse endogenous LPS, the smallest monodisperse analogues yielding good channel recovery were determined. The minimal synthetic moiety is a monoglucosaminetetraacyl compound. The characteristics of porin B from E. coli B(E) are shown to be indistinguishable from those of porin F. The conductance properties of this porin, refolded from random coil configuration, are indistinguishable from those exhibited by native protein. The formation of channels is thus encoded by the sequence of the mature polypeptide alone.	UNIV BASEL, BIOCTR, CH-4056 BASEL, SWITZERLAND; OSAKA UNIV, FAC SCI, DEPT CHEM, TOYONAKA, OSAKA 560, JAPAN	University of Basel; Osaka University								ACHTMAN M, 1986, ANNU REV MICROBIOL, V40, P185, DOI 10.1146/annurev.micro.40.1.185; BENZ R, 1979, BIOCHIM BIOPHYS ACTA, V551, P238, DOI 10.1016/0005-2736(89)90002-3; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BUEHLER L, 1989, THESIS U BASEL BASEL; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; DAUM G, 1982, J BIOL CHEM, V257, P3028; DORSET DL, 1983, J MOL BIOL, V165, P701, DOI 10.1016/S0022-2836(83)80275-7; EISELE JL, 1989, J MOL BIOL, V206, P209, DOI 10.1016/0022-2836(89)90533-0; EISELE JL, 1990, J BIOL CHEM, V265, P10217; ENGEL A, 1985, NATURE, V317, P643, DOI 10.1038/317643a0; GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309; GARAVITO RM, 1983, J MOL BIOL, V164, P313, DOI 10.1016/0022-2836(83)90079-7; GEHRING KB, 1989, J BIOL CHEM, V264, P2810; IMOTO M, 1987, B CHEM SOC JPN, V60, P2205, DOI 10.1246/bcsj.60.2205; IMOTO M, 1987, B CHEM SOC JPN, V60, P2197, DOI 10.1246/bcsj.60.2197; INOKUCHI K, 1982, NUCLEIC ACIDS RES, V10, P6957, DOI 10.1093/nar/10.21.6957; JAP BK, 1989, J MOL BIOL, V205, P407, DOI 10.1016/0022-2836(89)90351-3; KAGAWA Y, 1966, J BIOL CHEM, V241, P2467; KAWAJI H, 1979, J BACTERIOL, V140, P843, DOI 10.1128/JB.140.3.843-847.1979; KUSUMOTO S, 1984, TETRAHEDRON LETT, V25, P3727, DOI 10.1016/0040-4039(84)80116-1; MIZUNO T, 1983, J BIOL CHEM, V258, P6932; NAKAE T, 1975, J BIOL CHEM, V250, P7359; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NIKAIDO H, 1983, J BACTERIOL, V153, P241, DOI 10.1128/JB.153.1.241-252.1983; PREHM P, 1976, EUR J BIOCHEM, V66, P369, DOI 10.1111/j.1432-1033.1976.tb10526.x; PUGSLEY AP, 1983, FEMS MICROBIOL LETT, V16, P143; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; SASS HJ, 1989, J MOL BIOL, V209, P171, DOI 10.1016/0022-2836(89)90180-0; SCHINDLER H, 1978, P NATL ACAD SCI USA, V75, P3751, DOI 10.1073/pnas.75.8.3751; SCHINDLER H, 1981, P NATL ACAD SCI-BIOL, V78, P2302, DOI 10.1073/pnas.78.4.2302; SCHINDLER H, 1989, METHOD ENZYMOL, V171, P225; SEN K, 1988, J BIOL CHEM, V263, P1182; WEISS MS, 1990, FEBS LETT, V267, P268, DOI 10.1016/0014-5793(90)80942-C; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2; WICKNER W, 1989, TRENDS BIOCHEM SCI, V14, P280, DOI 10.1016/0968-0004(89)90064-9; XU GZ, 1986, BIOCHIM BIOPHYS ACTA, V862, P57, DOI 10.1016/0005-2736(86)90468-2	39	90	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24446	24450						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722204				2022-12-25	WOS:A1991GW84500034
J	DABORA, JM; SANYAL, G; MIDDAUGH, CR				DABORA, JM; SANYAL, G; MIDDAUGH, CR			EFFECT OF POLYANIONS ON THE REFOLDING OF HUMAN ACIDIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; PROTEOLYTIC DEGRADATION; IMMUNOSUPPRESSANT FK506; FACTOR-I; PROTEIN; HEPARIN; INACTIVATION; DENATURATION; SEQUENCE; LYSOZYME	Acidic fibroblast growth factor (aFGF) is unstable at physiological temperatures in the absence of polyanions such as heparin. Therefore, the effect of temperature on the kinetics of refolding of aFGF has been examined in the presence and absence of several polyanions. The protein folds into its native state at temperatures up to 30-degrees-C without polyanions with an activation energy of approximately 14 kcal/mol, but does not acquire native structure above this temperature. When heparin, inositol hexasulfate, or sulfate ion are present, aFGF refolds below 30-degrees-C with a slightly reduced activation energy (10-11 kcal/mol). In addition, the protein now also renatures between 30 and 50-degrees-C with activation energies of 1-2 (heparin), 16 (inositol hexasulfate), and 7 (sulfate) kcal/mol. Trace heavy metals appear to inhibit the refolding process, but a molecular chaperone (bovine 70-kDa heat shock cognate protein) and a peptidylprolyl isomerase (the FK506-binding protein) have no effect. It is concluded that the rate of refolding of aFGF at physiological temperatures is probably controlled by the interaction of a native-like state of the protein with an unknown polyanionic species.	MERCK SHARP & DOHME LTD,DEPT PHARMACEUT RES,PHARMACEUT BIOPHYS GRP,W POINT,PA 19486	Merck & Company	MIDDAUGH, CR (corresponding author), MERCK SHARP & DOHME LTD,DEPT PHARMACEUT RES,PHARMACEUT BIOPHYS GRP,W POINT,PA 19486, USA.							BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHEN BL, 1989, BIOCHEMISTRY-US, V28, P691, DOI 10.1021/bi00428a042; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; GERSCHITZ J, 1978, EUR J BIOCHEM, V87, P591, DOI 10.1111/j.1432-1033.1978.tb12411.x; GIMENEZGALLEGO G, 1985, SCIENCE, V230, P1385, DOI 10.1126/science.4071057; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; Linemeyer DL, 1990, GROWTH FACTORS, V3, P287, DOI 10.3109/08977199009003671; POHL FM, 1968, EUR J BIOCHEM, V7, P146, DOI 10.1111/j.1432-1033.1968.tb19585.x; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SADIS S, 1990, BIOCHEMISTRY-US, V29, P8199, DOI 10.1021/bi00488a001; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SEGAWA SI, 1984, BIOPOLYMERS, V23, P2473; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; Thompson RW, 1990, GROWTH FACTORS, V3, P221, DOI 10.3109/08977199009043906; VLODAVSKY I, 1991, J CELL BIOCHEM, V45, P167, DOI 10.1002/jcb.240450208; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	26	50	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23637	23640						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721051				2022-12-25	WOS:A1991GV31900021
J	GRAZIANI, A; GRAMAGLIA, D; CANTLEY, LC; COMOGLIO, PM				GRAZIANI, A; GRAMAGLIA, D; CANTLEY, LC; COMOGLIO, PM			THE TYROSINE-PHOSPHORYLATED HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR RECEPTOR ASSOCIATES WITH PHOSPHATIDYLINOSITOL 3-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							C-MET PROTEIN; KINASE-ACTIVITY; MOLECULAR-CLONING; PDGF RECEPTOR; FIBROBLASTS; ACTIVATION; SEQUENCE; CELLS; CDNA; PP85	The receptor for hepatocyte growth factor, also known as scatter factor (HGF/SF), has recently been identified as the 190-kDa heterodimeric tyrosine kinase encoded by the MET proto-oncogene (p190MET). The signaling pathway(s) triggered by HGF/SF are unknown. In A549 cells, a lung epithelial cell line, nanomolar concentrations of HGF/SF induced tyrosine phosphorylation of the p190MET receptor. The autophosphorylated receptor coprecipitated with phosphatidylinositol 3-kinase (PI 3-kinase) activity. In GTL16 cells, a cell line derived from a gastric carcinoma, the p190MET receptor, overexpressed and constitutively phosphorylated on tyrosine, coprecipitated with PI 3-kinase activity and with the 85-kDa PI 3-kinase subunit. In these cells activation of protein kinase C or the increase of intracellular [Ca2+] inhibits tyrosine phosphorylation of the p190MET receptor as well as the association with both PI 3-kinase activity and the 85-kDa subunit of the enzyme. In an in vitro assay, tyrosine phosphorylation of the immobilized p190MET receptor was required for binding of PI 3-kinase from cell lysates. These data strongly suggest that the signaling pathway activated by the HGF/SF receptor includes generation of D-3-phosphorylated inositol phospholipids.	UNIV TURIN,SCH MED,DIPARTIMENTO SCI BIOMED & ONCOL,CORSO MASSIMO DAZEGLIO 52,I-10126 TURIN,ITALY; TUFTS UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02111	University of Turin; Tufts University			graziani, andrea/B-2554-2009; Graziani, Andrea/AAB-6301-2022; Cantley, Lewis C/D-1800-2014; GRAMAGLIA, DANIELA/A-6354-2012	graziani, andrea/0000-0002-6302-2317; Graziani, Andrea/0000-0002-6302-2317; Cantley, Lewis C/0000-0002-1298-7653; Gramaglia, Daniela/0000-0001-6259-0059; Comoglio, Paolo/0000-0002-7056-5328	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036624, R37GM041890, R01GM041890] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 41890, GM 36624, R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NALDINI L, 1991, MOL CELL BIOL, V4, P1793; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT MP, 1991, IN PRESS MOL CELL BI; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VARTIKOVSKI L, 1991, IN PRESS MOL CELL BI, V11; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165	35	259	263	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22087	22090						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1718989				2022-12-25	WOS:A1991GR56400006
J	SAWAMURA, D; LI, KH; CHU, ML; UITTO, J				SAWAMURA, D; LI, KH; CHU, ML; UITTO, J			HUMAN BULLOUS PEMPHIGOID ANTIGEN (BPAG1) - AMINO-ACID-SEQUENCES DEDUCED FROM CLONED CDNAS PREDICT BIOLOGICALLY IMPORTANT PEPTIDE SEGMENTS AND PROTEIN DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; HUMAN-SKIN; HUMAN KERATINOCYTES; HEMIDESMOSOMES; LOCALIZATION; EXPRESSION; AUTOANTIBODIES; JUNCTION; DNA	Bullous pemphigoid antigens are defined as the autoantigens in a blistering skin disease, bullous pemphigoid. One of them, a 230-kDa protein (BPAG1), is associated with hemidesmosomes, attachment complexes at the basal keratinocyte-lamina lucida interface within the dermal-epidermal basement membrane zone. The precise functions and cellular compartmentalization of BPAG1 are unknown. In this study, a human keratinocyte lambda-gt11 cDNA library was screened for clones corresponding to BPAG1. The composite of overlapping cDNAs delineated 8,930 base pairs of nucleotide sequences that contained an open reading frame encoding 2,649 amino acids. Analysis of the deduced amino acid sequences predicted a putative signal peptide of 43 amino acids and the presence of a membrane-associated sequence of 17 amino acids. Several potential sites for N-glycosylation, as well as for protein kinase C or cAMP- and cGMP-dependent protein kinase-mediated phosphorylation were identified. Three peptide segments were predicted to be highly antigenic, potentially serving as epitopes for the formation of autoantibodies. Eight repeat segments of 38 residues each with a high degree of homology with sequences in desmoplakin I, a component of desmosomal cytoplasmic plaques, were detected in the carboxyl-terminal end of the molecule. In addition, the presence of three subdomains characterized by heptad repeats predicted an alpha-helical coiled coil dimer structure in the central portion of the protein. These data suggest that BPAG1 may be a membrane-associated protein that plays a role in the attachment of basal keratinocytes to the underlying basement membrane.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL,233 S 10TH ST,BLSB 450,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR038923, T32AR007561] Funding Source: NIH RePORTER; NIAMS NIH HHS [T32AR7561, P01AR38923] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERNARD P, 1989, J INVEST DERMATOL, V92, P171, DOI 10.1111/1523-1747.ep12276689; BRIGGAMAN RA, 1982, J INVEST DERMATOL, V78, P1, DOI 10.1111/1523-1747.ep12497841; DIAZ LA, 1978, BRIT J DERMATOL, V98, P631, DOI 10.1111/j.1365-2133.1978.tb03581.x; DIAZ LA, 1990, J CLIN INVEST, V86, P1088, DOI 10.1172/JCI114812; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FINE JD, 1991, J AM ACAD DERMATOL, V24, P119, DOI 10.1016/0190-9622(91)70021-S; FINE JD, 1988, ARCH DERMATOL, V124, P713, DOI 10.1001/archderm.124.5.713; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; HOLUBAR K, 1975, J INVEST DERMATOL, V64, P220, DOI 10.1111/1523-1747.ep12510658; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; IKEDA S, 1990, J INVEST DERMATOL, V94, P336, DOI 10.1111/1523-1747.ep12874466; JONES JCR, 1986, CELL MOTIL CYTOSKEL, V6, P560, DOI 10.1002/cm.970060604; LABIB RS, 1986, J IMMUNOL, V136, P1231; LEVER WF, 1965, PEMPHIGUS PEMPHIGOID, P15; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MUELLER S, 1989, J INVEST DERMATOL, V92, P33, DOI 10.1111/1523-1747.ep13070476; MUTASIM DF, 1989, J INVEST DERMATOL, V92, P225, DOI 10.1111/1523-1747.ep12276753; MUTASIM DF, 1985, J INVEST DERMATOL, V84, P47, DOI 10.1111/1523-1747.ep12274684; NAKASHIMA H, 1986, J BIOCHEM-TOKYO, V99, P153, DOI 10.1093/oxfordjournals.jbchem.a135454; NORTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; OLSEN DR, 1988, J INVEST DERMATOL, V90, P734, DOI 10.1111/1523-1747.ep12560934; PARRY DAD, 1977, J MOL BIOL, V113, P449, DOI 10.1016/0022-2836(77)90153-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; REGNIER M, 1985, J INVEST DERMATOL, V85, P187, DOI 10.1111/1523-1747.ep12276656; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWAMURA D, 1990, GENOMICS, V8, P722, DOI 10.1016/0888-7543(90)90261-R; SAWAMURA D, 1991, J INVEST DERMATOL, V96, P908, DOI 10.1111/1523-1747.ep12475433; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STANLEY JR, 1984, J INVEST DERMATOL, V82, P108, DOI 10.1111/1523-1747.ep12259224; STANLEY JR, 1981, CELL, V24, P897, DOI 10.1016/0092-8674(81)90115-X; TAKAHASHI Y, 1985, J INVEST DERMATOL, V85, P309, DOI 10.1111/1523-1747.ep12276893; THIVOLET CH, 1984, J INVEST DERMATOL, V82, P329, DOI 10.1111/1523-1747.ep12260634; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TSURUMI C, 1990, BIOCHEM BIOPH RES CO, V169, P136, DOI 10.1016/0006-291X(90)91444-W; UITTO J, 1989, J INVEST DERMATOL, V92, pS61; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4783; WESTGATE GE, 1985, J INVEST DERMATOL, V84, P218, DOI 10.1111/1523-1747.ep12265229	42	210	211	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17784	17790						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1717441				2022-12-25	WOS:A1991GG55300014
J	CIUDAD, CJ; MORRIS, AE; JENG, C; CHASIN, LA				CIUDAD, CJ; MORRIS, AE; JENG, C; CHASIN, LA			POINT MUTATIONAL ANALYSIS OF THE HAMSTER DIHYDROFOLATE-REDUCTASE MINIMUM PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR SP1; GENE PROMOTER; CELL-CYCLE; EXPRESSION; INITIATION; SEQUENCE; MINIGENES; UPSTREAM; ENHANCER	We have shown previously that 48 base pairs (bp) of 5'-nanking sequence are necessary for correct initiation at the major transcriptional start site of the Chinese hamster dihydrofolate reductase (dhfr) gene (Ciudad et al., 1988). As an upstream element, this sequence alone confers 25% of maximum promoter activity. The 5' half of this sequence is particularly well conserved among mammalian species; it contains one Sp1 binding site (GC box) and one CAA element. In the present work, we have analyzed the role of this region by extensive point mutational analysis. Twenty-three dhfr minigene constructs containing 1- or 2-base substitutions in this region of the promoter were tested by measuring their ability to transfect DHFR-deficient Chinese hamster ovary cells to a DHFR+ growth phenotype. Eight mutants, all in or near the GC box, exhibited reduced transfection efficiency. Promoter disfunction in these mutants was confirmed by RNase protection analysis of stable transfectants. Gel retardation experiments showed that mutants affected in the consensus sequence for Sp1 binding were deficient in binding a protein found in nuclear extracts of Chinese hamster ovary cells. Purified human transcription factor Sp1 was also unable to bind a promoter sequence bearing one of these single base substitutions, suggesting that Sp1 itself is involved in dhfr transcription in vivo. We conclude that most single base mutations in the GC box severely cripple or eliminate promoter function by inhibiting binding of transcription factors to this regulatory sequence and that Sp1 is likely to be involved in dhfr transcription in vivo. We also found that the well conserved CAA element is not absolutely necessary for transcription.	COLUMBIA UNIV,DEPT BIOL SCI,912 FAIRCHILD,NEW YORK,NY 10027	Columbia University			Ciudad, Carlos J./D-7917-2014	Ciudad, Carlos J./0000-0002-7855-392X	NATIONAL CANCER INSTITUTE [F32CA008312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022629] Funding Source: NIH RePORTER; NCI NIH HHS [5-532-CA08312] Funding Source: Medline; NIGMS NIH HHS [GM22629] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BLUNDELL MC, 1989, J VIROL, V63, P4814, DOI 10.1128/JVI.63.11.4814-4823.1989; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHASIN LA, 1986, MOL CELL GENETICS CH, P449; CHEN MJ, 1984, J BIOL CHEM, V259, P3933; CIUDAD CJ, 1988, J BIOL CHEM, V263, P16274; CROUSE GF, 1983, MOL CELL BIOL, V3, P257, DOI 10.1128/MCB.3.2.257; CROUSE GF, 1989, NUCLEIC ACIDS RES, V16, P7025; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FARNHAM PJ, 1986, MOL CELL BIOL, V6, P365, DOI 10.1128/MCB.6.2.365; FEDER JN, 1990, J CELL BIOL, V111, P2693, DOI 10.1083/jcb.111.6.2693; FEDER JN, 1989, J BIOL CHEM, V264, P20583; GASSER CS, 1982, P NATL ACAD SCI-BIOL, V79, P6522, DOI 10.1073/pnas.79.21.6522; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; JANSON L, 1987, NUCLEIC ACIDS RES, V15, P4997, DOI 10.1093/nar/15.13.4997; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MEANS AL, 1990, MOL CELL BIOL, V10, P1390; MITCHELL PJ, 1986, MOL CELL BIOL, V5, P214; ORLOFSKY A, 1985, MOL CELL BIOL, V5, P214, DOI 10.1128/MCB.5.1.214; SMITH ML, 1990, MOL CELL BIOL, V10, P6003, DOI 10.1128/MCB.10.11.6003; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; VENOLIA L, 1987, SOMAT CELL MOLEC GEN, V13, P491, DOI 10.1007/BF01534491; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YANG JK, 1984, J MOL BIOL, V176, P169, DOI 10.1016/0022-2836(84)90419-4	33	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3650	3656						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740417				2022-12-25	WOS:A1992HE60700019
J	KAWAICHI, M; OKA, C; SHIBAYAMA, S; KOROMILAS, AE; MATSUNAMI, N; HAMAGUCHI, Y; HONJO, T				KAWAICHI, M; OKA, C; SHIBAYAMA, S; KOROMILAS, AE; MATSUNAMI, N; HAMAGUCHI, Y; HONJO, T			GENOMIC ORGANIZATION OF MOUSE J(KAPPA) RECOMBINATION SIGNAL BINDING-PROTEIN (RBP-J) GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINASES; IMMUNOGLOBULIN GENES; V(D)J RECOMBINATION; ANTIGEN RECEPTOR; NUCLEAR-PROTEIN; SEQUENCES; TRANSCRIPTION; DIVERSITY; REARRANGEMENT; PURIFICATION	We have isolated a cDNA clone (RBP-2) for the protein (RBP-J(kappa)) which binds to immunoglobulin recombination signals with 23-base pair spacers (Matsunami, N., Hamaguchi, Y., Yamamoto, Y., Kuze, K., Kangawa, K., Matsuo, H., Kawaichi, M., and Honjo, T. (1989) Nature 342, 934-937). During further screening of a cDNA library from the same mouse pre-B cell line (38B9), we have isolated a second cDNA clone (RBP-2N) which differs from RBP-2 in its 5' sequence. RNase protection assays indicated that the RBP-2N type mRNA was produced in 10-20 times the quantity as RBP-2 mRNA. To elucidate the relationship between these two mRNAs, we analyzed the genomic organization of the RBP-J(kappa) gene. Southern hybridization of mouse genomic DNA detected at least 7 EcoRI fragments hybridizing to an RBP-2 cDNA probe, suggesting a complex structure for the RBP-J(kappa) gene. Cloning of each EcoRI fragment revealed one functional RBP-J(kappa) gene and three related genes. The functional gene was composed of 11 exons and spanned at least 50 kilobase pairs. The sequence of exon 1 and its 5'-flanking region contained a GC-rich promoter-like region but no apparent TATA box. The initiation site of transcription was heterogeneous, and the two types of mRNA are produced from the same exon by transcription initiation at different sites and by different usage of splice signals. Two of the three related genes were processed pseudogenes with scattered stop codons. The other was also a processed gene with a sequence exactly the same as that of RBP-2, except that this gene lacked the sequence corresponding to the first exon of the functional gene.	KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Honjo, Tasuku/N-4470-2016					AGUILERA RJ, 1987, CELL, V51, P909, DOI 10.1016/0092-8674(87)90578-2; ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DESIDERIO S, 1984, NATURE, V308, P860, DOI 10.1038/308860a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FULOP GM, 1990, NATURE, V308, P425; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; HALLIGAN BD, 1987, P NATL ACAD SCI USA, V84, P7019, DOI 10.1073/pnas.84.20.7019; HAMAGUCHI Y, 1989, NUCLEIC ACIDS RES, V17, P9015, DOI 10.1093/nar/17.22.9015; HONJO T, 1985, ANNU REV BIOCHEM, V54, P803, DOI 10.1146/annurev.bi.54.070185.004103; HOPE TJ, 1986, SCIENCE, V231, P1141, DOI 10.1126/science.3003919; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; POYARTSALMERON C, 1989, EMBO J, V8, P2425, DOI 10.1002/j.1460-2075.1989.tb08373.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; SUN SC, 1990, SCIENCE, V250, P1929; THOMAS KR, 1986, CELL, V44, P419, DOI 10.1016/0092-8674(86)90463-0; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5	35	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4016	4022						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740450				2022-12-25	WOS:A1992HE60700071
J	ALBE, KR; WRIGHT, BE				ALBE, KR; WRIGHT, BE			SYSTEMS-ANALYSIS OF THE TRICARBOXYLIC-ACID CYCLE IN DICTYOSTELIUM-DISCOIDEUM .2. CONTROL ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE TREATMENT; GENERAL SENSITIVITY THEORY; METABOLIC CONTROL; ENZYMATIC CHAINS; IMPLICIT METHODS; SKELETAL-MUSCLE; FLUX; PATHWAYS; MITOCHONDRIA; MODEL	A steady-state computer model of the tricarboxylic cycle in Dictyostelium discoideum was analyzed using metabolic control theory. The steady state had variations of less than 0.04% over the last half of the simulation for both metabolite concentrations and fluxes. Metabolite and flux control coefficients were determined by varying enzymatic activities within 2% of their initial values and simulating the responses of metabolite concentrations and fluxes to these changes. Under these conditions, summation properties were met for most metabolite and all flux control coefficients. Maximum flux control coefficients were found for succinate dehydrogenase (0.35), malic enzyme (0.24), and malate dehydrogenase (-0.18). Comparable control was found for the reaction supplying pyruvate (0.14) and for the sum of the input amino acids (0.43), which serve as an energy source for D. discoideum. The time-dependent processes by which a new steady state was established were examined after increasing malic enzyme or malate dehydrogenase activities. This provided a method for an analysis of the mechanisms by which the observed control coefficients were generated. In addition, the effects of increasing the stimuli within 5-20% of the original enzyme activity were examined. Under these conditions, more typical of experimental stimuli and measurable responses, the metabolic model failed to return to steady state, and thus summation properties were not met. Whether ''true'' steady states ever occur or whether metabolic control theory can be applied in vivo is discussed.			ALBE, KR (corresponding author), UNIV MONTANA, DIV BIOL SCI, MISSOULA, MT 59812 USA.				NATIONAL INSTITUTE ON AGING [R01AG003884] Funding Source: NIH RePORTER; NIA NIH HHS [AG03884] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBE KR, 1990, J THEOR BIOL, V143, P163, DOI 10.1016/S0022-5193(05)80266-8; ATKINSON DE, 1990, NATO ASI SER, P3; BARRETT J, 1988, PARASITOLOGY, V97, P355, DOI 10.1017/S0031182000058558; BRAND MD, 1988, BIOCHEM J, V255, P535; BRINDLE KM, 1988, BIOCHEMISTRY-US, V27, P6187, DOI 10.1021/bi00416a054; CANELA EI, 1987, ARCH BIOCHEM BIOPHYS, V254, P142, DOI 10.1016/0003-9861(87)90090-7; CASCANTE M, 1989, MATH BIOSCI, V94, P271, DOI 10.1016/0025-5564(89)90067-9; CASCANTE M, 1989, MATH BIOSCI, V94, P289, DOI 10.1016/0025-5564(89)90068-0; CLARKE FM, 1975, BIOCHIM BIOPHYS ACTA, V381, P37, DOI 10.1016/0304-4165(75)90187-7; CORNISH A, 1988, J GEN MICROBIOL, V134, P3111; CRABTREE B, 1985, CURR TOP CELL REGUL, V25, P21; DYKHUIZEN DE, 1987, GENETICS, V115, P25; GROEN AK, 1982, J BIOL CHEM, V257, P2754; HEINRICH R, 1974, EUR J BIOCHEM, V42, P97, DOI 10.1111/j.1432-1033.1974.tb03319.x; HEINRICH R, 1974, EUR J BIOCHEM, V42, P89, DOI 10.1111/j.1432-1033.1974.tb03318.x; HIGGINS J, 1963, ANN NY ACAD SCI, V108, P305, DOI 10.1111/j.1749-6632.1963.tb13382.x; HOFMEYR JHS, 1986, COMPUT APPL BIOSCI, V2, P5; HOFMEYR JHS, 1986, EUR J BIOCHEM, V155, P631, DOI 10.1111/j.1432-1033.1986.tb09534.x; KACSER H, 1981, GENETICS, V97, P639; KACSER H, 1987, TRENDS BIOCHEM SCI, V12, P5, DOI 10.1016/0968-0004(87)90005-3; KAICSER H, 1973, RATE CONTROL BIOL PR, V27, P65; KEIGHTLEY PD, 1987, GENETICS, V117, P319; KELETI T, 1988, CURR TOP CELL REGUL, V29, P1; KELLY PJ, 1979, BIOCHEM J, V184, P589, DOI 10.1042/bj1840589; KELLY PJ, 1979, BIOCHEM J, V184, P581, DOI 10.1042/bj1840581; KHOLODENKO B, 1987, FEBS LETT, V223, P247, DOI 10.1016/0014-5793(87)80298-3; MIDDLETON RJ, 1983, GENETICS, V105, P633; NIMMO HG, 1987, BIOCHEM J, V247, P1; PARK D J M, 1973, Computer Programs in Biomedicine, V3, P10, DOI 10.1016/0010-468X(73)90010-X; PETRONILLI V, 1988, BIOCHIM BIOPHYS ACTA, V932, P306, DOI 10.1016/0005-2728(88)90167-3; RAPOPORT TA, 1974, EUR J BIOCHEM, V42, P107, DOI 10.1111/j.1432-1033.1974.tb03320.x; RIGOULET M, 1987, EUR J BIOCHEM, V168, P275, DOI 10.1111/j.1432-1033.1987.tb13417.x; RIGOULET M, 1988, BIOCHIM BIOPHYS ACTA, V932, P116, DOI 10.1016/0005-2728(88)90145-4; SAURO HM, 1987, EUR J BIOCHEM, V165, P215, DOI 10.1111/j.1432-1033.1987.tb11214.x; SAVAGEAU M A, 1976, P379; SHERWOOD P, 1979, COMPUT PROG BIOMED, V10, P66, DOI 10.1016/0010-468X(79)90053-9; SORRIBAS A, 1989, MATH BIOSCI, V94, P195, DOI 10.1016/0025-5564(89)90065-5; TORRES NV, 1988, FEBS LETT, V233, P83, DOI 10.1016/0014-5793(88)81360-7; TORRES NV, 1986, BIOCHEM J, V234, P169, DOI 10.1042/bj2340169; WALSH K, 1985, P NATL ACAD SCI USA, V82, P3577, DOI 10.1073/pnas.82.11.3577; Welch G.R., 1985, ORG MULTIENZYME SYST; Wright B.E., 1987, Basic Life Sciences, V42, P111; WRIGHT BE, 1981, CURR TOP CELL REGUL, V19, P103; WRIGHT BE, 1984, J THEOR BIOL, V110, P445, DOI 10.1016/S0022-5193(84)80186-1; WRIGHT BE, 1977, EUR J BIOCHEM, V74, P217, DOI 10.1111/j.1432-1033.1977.tb11384.x; WRIGHT BE, 1988, J BIOL CHEM, V263, P14906; WRIGHT BE, 1990, NATO ASI SER, P317	47	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3106	3114						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737767				2022-12-25	WOS:A1992HD15400046
J	VIDEEN, JS; MEZGER, MS; CHANG, YM; OCONNOR, DT				VIDEEN, JS; MEZGER, MS; CHANG, YM; OCONNOR, DT			CALCIUM AND CATECHOLAMINE INTERACTIONS WITH ADRENAL CHROMOGRANINS - COMPARISON OF DRIVING FORCES IN BINDING AND AGGREGATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID SECRETORY PROTEIN; BOVINE CHROMAFFIN GRANULES; SECRETOGRANIN-I; ENDOCRINE; TISSUES; STORAGE; CELLS; GLAND	The soluble core of catecholamine storage vesicles in the adrenal medulla contains high concentrations of the cations calcium (20 mM) and catecholamine (600 mM). Do these cations interact with the abundant vesicle core anionic proteins, the chromogranins? We investigated the binding of calcium and norepinephrine (NE) to bovine adrenal chromogranins by equilibrium dialysis. Both calcium and NE were bound saturably by chromogranins, with low affinity (K(d) values of 1.3 x 10(-4) M and 2.1 x 10(-3) M), but high capacity (17 and 32 mol of ligand/mol of chromogranin A). Both ligands bound maximally at a pH > 5.5 and were displaced by competing cations in a pattern (trivalent > divalent > monovalent) consistent with electrostatic components to the interactions. Binding of calcium and NE was not impaired by prior heat denaturation of the chromogranins, and chromogranin A was involved in both binding reactions. Calcium but not NE binding was enhanced by nonpolar solvents. Temperature dependence studies indicated that calcium binding to chromogranins was largely entropy-driven, while NE binding was driven by a significantly negative (favorable) change in enthalpy (5760 cal/mol), even in the face of an unfavorable entropy. Exposure of chromogranins to calcium or NE resulted in precipitation (aggregation) as analyzed by centrifugation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. NE was a more effective chromogranin precipitant than calcium, and in combination, the NE effect was antagonized by calcium. Precipitation of chromogranins by both calcium and NE was inhibited by NaCl at ionic strengths comparable with those of the ligands. These data suggest that chromogranins bind and are precipitated by calcium and NE at affinities compatible with their in situ concentrations, but that the interactions exhibit different thermodynamic driving forces. Furthermore, NE may trigger an enthalpy-driven conformational change in chromogranins, resulting in aggregation.	UNIV CALIF SAN DIEGO,DEPT MED,V-111-H,3350 LA JOLLA VILLAGE DR,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,SAN DIEGO,CA 92161; DEPT VET AFFAIRS MED CTR,SAN DIEGO,CA 92161	University of California System; University of California San Diego; University of California System; University of California San Diego								BARBOSA JA, 1991, ENDOCRINOLOGY, V128, P174, DOI 10.1210/endo-128-1-174; BELL HB, 1964, INTRO PHYSICAL BIOCH, V2; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; CETIN Y, 1989, HISTOCHEMISTRY, V92, P265, DOI 10.1007/BF00500540; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; GORR SU, 1988, BONE MINER, V4, P17; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; HELLE KB, 1990, ACTA PHYSIOL SCAND, V138, P565, DOI 10.1111/j.1748-1716.1990.tb08885.x; Hughes M. N, 1981, INORGANIC CHEM BIOL, V2nd; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; LEISER M, 1989, J BIOL CHEM, V264, P2792; LIMBIRD LE, 1986, CELL SURFACE RECEPTO; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; OCONNOR DT, 1984, J BIOL CHEM, V259, P3237; OCONNOR DT, 1986, NEW ENGL J MED, V314, P1145, DOI 10.1056/NEJM198605013141803; OCONNOR DT, 1986, QUANTITATIVE ANAL CA, P302; Perrin D. D., 2012, BUFFERS PH METAL ION; PHILLIPS JH, 1982, NEUROSCIENCE, V7, P1595, DOI 10.1016/0306-4522(82)90017-3; POLLARD HB, 1978, ANAL BIOCHEM, V86, P761, DOI 10.1016/0003-2697(78)90805-9; PRICE PA, 1983, METHOD ENZYMOL, V91, P13; REIFFEN FU, 1986, BIOCHEMISTRY-US, V25, P4402, DOI 10.1021/bi00363a034; SCHMID KW, 1989, HISTOCHEM J, V21, P365, DOI 10.1007/BF01798500; SEIDAH NG, 1987, FEBS LETT, V211, P144, DOI 10.1016/0014-5793(87)81425-4; SHARP RR, 1977, BIOCHIM BIOPHYS ACTA, V497, P14, DOI 10.1016/0304-4165(77)90135-0; SMITH AD, 1967, BIOCHEM J, V103, P483, DOI 10.1042/bj1030483; SMITH WJ, 1967, MOL PHARMACOL, V3, P52; STEINER HJ, 1990, J HISTOCHEM CYTOCHEM, V38, P845, DOI 10.1177/38.6.2139887; STULIK K, 1986, QUANTITATIVE ANAL CA, P137; TAKIYYUDDIN MA, 1990, HYPERTENSION, V15, P237, DOI 10.1161/01.HYP.15.3.237; TAMAMURA H, 1990, EUR J BIOCHEM, V191, P33, DOI 10.1111/j.1432-1033.1990.tb19090.x; WEILAND GA, 1980, MOL PHARMACOL, V18, P341; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; YOO SH, 1990, BIOCHIM BIOPHYS ACTA, V1040, P66, DOI 10.1016/0167-4838(90)90146-7; YOO SH, 1990, J BIOL CHEM, V265, P14414	35	99	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3066	3073						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737762				2022-12-25	WOS:A1992HD15400040
J	TAYLOR, ME; BEZOUSKA, K; DRICKAMER, K				TAYLOR, ME; BEZOUSKA, K; DRICKAMER, K			CONTRIBUTION TO LIGAND-BINDING BY MULTIPLE CARBOHYDRATE-RECOGNITION DOMAINS IN THE MACROPHAGE MANNOSE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PHOSPHATE RECEPTOR; LIVER; PROTEINS; GLYCOPROTEINS; CELLS; ENDOCYTOSIS; ADHESION; CONTAINS; LECTINS; CLONING	The extracellular portion of the macrophage mannose receptor is composed of several cysteine-rich domains, including a fibronectin type II repeat and eight segments related in sequence to Ca2+-dependent carbohydrate-recognition domains (CRDs) of animal lectins. Expression of portions of the receptor in vitro, in fibroblasts and in bacteria, has been used to determine which of the extracellular domains are involved in binding and endocytosis of ligand. The NH2-terminal cysteine-rich domain and the fibronectin type II repeat are not necessary for endocytosis of mannose-terminated glycoproteins. CRDs 1-3 have at most very weak affinity for carbohydrate, so the carbohydrate binding activity of the receptor resides in CRDs 4-8. CRD 4 shows the highest affinity binding and has multispecificity for a variety of monosaccharides. However, CRD 4 alone cannot account for the binding of the receptor to glycoproteins. At least 3 CRDs (4, 5, and 7) are required for high affinity binding and endocytosis of multivalent glycoconjugates. In this respect, the mannose receptor is like other carbohydrate-binding proteins, in which several CRDs, each with weak affinity for single sugars, are clustered to achieve high affinity binding to oligosaccharides. In the mannose receptor, these multiple weak interactions are achieved through several active CRDs in a single polypeptide chain rather than by oligomerization of polypeptides each containing a single CRD.	COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, 630 W 168TH ST, NEW YORK, NY 10032 USA	Columbia University				Taylor, Maureen/0000-0001-8300-4987	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; CHIACCHIA KB, 1984, J BIOL CHEM, V259, P5440; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; DRICKAMER K, 1989, CIBA F SYMP, V145, P45; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; DRICKAMER K, 1989, BIOCHEM SOC T, V17, P13, DOI 10.1042/bst0170013; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLLAND EC, 1986, J BIOL CHEM, V261, P1286; HSUEH EC, 1986, J BIOL CHEM, V261, P4940; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARGENT BL, 1984, J BIOL CHEM, V259, P1764; LENNARTZ MR, 1989, J BIOL CHEM, V264, P2385; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LOEB JA, 1987, J BIOL CHEM, V262, P3022; Maniatis T., 1982, MOL CLONING; MELLOW TE, 1988, J BIOL CHEM, V263, P5468; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; OTTER M, 1991, J BIOL CHEM, V266, P13931; PARISE ER, 1984, J LAB CLIN MED, V104, P908; QUESENBERRY MS, 1991, IN PRESS GLYCOBIOLOG; SHEPHERD VL, 1990, BIOCHEM J, V270, P771, DOI 10.1042/bj2700771; SMEDSROD B, 1990, BIOCHEM J, V271, P345, DOI 10.1042/bj2710345; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; STAHL PD, 1990, AM J RESP CELL MOL, V2, P317, DOI 10.1165/ajrcmb/2.4.317; STAHL PD, 1980, TRENDS BIOCHEM SCI, V5, P194, DOI 10.1016/0968-0004(80)90238-8; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1987, BIOCHIM BIOPHYS ACTA, V915, P60, DOI 10.1016/0167-4838(87)90125-7; TONG PY, 1989, J BIOL CHEM, V264, P7962; WARR GA, 1980, BIOCHEM BIOPH RES CO, V93, P737, DOI 10.1016/0006-291X(80)91139-0; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WILSON ME, 1986, J IMMUNOL, V136, P4681	41	283	297	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1719	1726						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730714				2022-12-25	WOS:A1992HA48500051
J	KEMPPAINEN, JA; LANE, MV; SAR, M; WILSON, EM				KEMPPAINEN, JA; LANE, MV; SAR, M; WILSON, EM			ANDROGEN RECEPTOR PHOSPHORYLATION, TURNOVER, NUCLEAR TRANSPORT, AND TRANSCRIPTIONAL ACTIVATION - SPECIFICITY FOR STEROIDS AND ANTIHORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; MESSENGER-RIBONUCLEIC-ACID; PROSTATE-CANCER-CELLS; NONSTEROIDAL ANTIANDROGEN; GLUCOCORTICOID RECEPTOR; DEPENDENT PHOSPHORYLATION; BINDING; HORMONE; LOCALIZATION; RAT	Nuclear transport, phosphorylation, ligand binding, and degradation rate of the recombinant androgen receptor (AR) were analyzed in transfected COS cells in the presence of various steroids and antiandrogens. Transcriptional activition was assessed in CV1 cells by cotransfection with an androgen-responsive chloramphenicol acetyltransferase (CAT) reporter vector. Hormone binding specificity of recombinant AR was essentially identical to endogenous AR. AR localized in the nucleus in the presence of methyltrienolone (R1881, a synthetic androgen), dihydrotestosterone, testosterone, hydroxyflutamide, cyproterone acetate, estradiol, progesterone, and RU486. In the absence of hormone or with the antiandrogen, flutamide, AR remained largely in the cytoplasm with a perinuclear distribution. AR was degraded rapidly (t1/2 = 1 h) except in the presence of androgen (t1/2 = 6 h) which accounted for an apparent 2-4-fold androgen-induced increase in AR phosphorylation, indicating that AR phosphorylation was not enhanced by androgen. CAT activity was stimulated by R1881, dihydrotestosterone, testosterone, cyproterone acetate, estradiol, progesterone, and RU486 in a dose-dependent manner. The antiandrogens, flutamide and hydroxyflutamide, lacked agonist activity and inhibited R1881-induced activation of CAT and androgen stabilization of AR. Steroids and antiandrogens with moderate to low affinity for AR promoted both nuclear transport and transcriptional activation but only at high hormone concentrations. Hydroxyflutamide acted as a true antiandrogen since it lacked agonist activity and was an inhibitor of androgen-induced transcriptional activation.	UNIV N CAROLINA,REPROD BIOL LABS,CB7500 MACNIDER BLDG,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016910, P30HD018968, R01HD016910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017479] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD18968, HD16910] Funding Source: Medline; NINDS NIH HHS [NS17479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARDIN CW, 1984, PHARMACOL THERAPEUT, V23, P443; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BONNE C, 1976, STEROIDS, V27, P497, DOI 10.1016/0039-128X(76)90084-2; BRANN DW, 1989, BIOL REPROD, V40, P1201, DOI 10.1095/biolreprod40.6.1201; BROWN TR, 1979, ENDOCRINOLOGY, V105, P1281, DOI 10.1210/endo-105-6-1281; BULLOCK LP, 1977, ANN NY ACAD SCI, V286, P321, DOI 10.1111/j.1749-6632.1977.tb29427.x; BULLOCK LP, 1978, ENDOCRINOLOGY, V103, P1768, DOI 10.1210/endo-103-5-1768; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HARRIS SE, 1991, MOLECULAR AND CELLULAR BIOLOGY OF PROSTATE CANCER, P315; HARRIS SE, 1990, END SOC ABSTR, P93; HOECK W, 1990, J BIOL CHEM, V265, P5403; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; KATCHEN B, 1975, J CLIN ENDOCR METAB, V41, P373, DOI 10.1210/jcem-41-2-373; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFEBVRE P, 1988, BIOCHEM BIOPH RES CO, V150, P1221, DOI 10.1016/0006-291X(88)90759-0; LIAO S, 1974, ENDOCRINOLOGY, V94, P1205, DOI 10.1210/endo-94-4-1205; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; MAINWARING WI, 1974, MOL CELL ENDOCRINOL, V1, P113, DOI 10.1016/0303-7207(74)90004-5; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MOGUILEWSKY M, 1984, J STEROID BIOCHEM, V20, P271, DOI 10.1016/0022-4731(84)90216-4; MOWSZOWICZ I, 1974, ENDOCRINOLOGY, V95, P1589, DOI 10.1210/endo-95-6-1589; NERI R, 1972, ENDOCRINOLOGY, V91, P427, DOI 10.1210/endo-91-2-427; NERI RO, 1972, INVEST UROL, V10, P123; NERI RO, 1977, ANDROGENS ANTIANDROG, P179; Neri R, 1979, BIOCHEM SOC T, V7, P565, DOI 10.1042/bst0070565; Neumann F, 1970, Recent Prog Horm Res, V26, P337; OJASOO T, 1978, CANCER RES, V38, P4186; ORTI E, 1989, J BIOL CHEM, V264, P9728; Philibert D, 1985, ANTIPROGESTIN STEROI, P49; PHILIBERT D, 1984, ADRENAL STEROID ANTA, P77; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; QI M, 1990, MOL ENDOCRINOL, V4, P455, DOI 10.1210/mend-4-3-455; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P22, DOI 10.1210/mend-4-1-22; QUARMBY VE, 1990, MOL ENDOCRINOL, V4, P1399, DOI 10.1210/mend-4-9-1399; SAR M, 1990, ENDOCRINOLOGY, V127, P3180, DOI 10.1210/endo-127-6-3180; SAR M, 1985, TECHNIQUES IMMUNOCYT, V3, P43; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SEGNITZ B, 1990, J BIOL CHEM, V265, P2789; SIMARD J, 1986, MOL CELL ENDOCRINOL, V44, P261, DOI 10.1016/0303-7207(86)90132-2; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; SYMS AJ, 1985, J BIOL CHEM, V260, P455; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; VANLAAR JH, 1991, J BIOL CHEM, V266, P3734; VARKARAKIS MJ, 1975, INVEST UROL, V12, P275; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WILDING G, 1989, PROSTATE, V14, P103, DOI 10.1002/pros.2990140204; WILSON EM, 1976, J BIOL CHEM, V251, P5620; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893	55	386	396	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					968	974						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730684				2022-12-25	WOS:A1992GY96000047
J	SHANMUGASUNDARAM, T; WOOD, HG				SHANMUGASUNDARAM, T; WOOD, HG			INTERACTION OF FERREDOXIN WITH CARBON-MONOXIDE DEHYDROGENASE FROM CLOSTRIDIUM-THERMOACETICUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CO DEHYDROGENASE; ACETOGENIC BACTERIA; ACETATE; PURIFICATION; COMPONENTS; PYRUVATE; PATHWAY; COMPLEX; ENZYME	Acetogenic bacteria, as determined with Clostridium thermoaceticum, synthesize acetate by the acetyl-CoA pathway which involves the reduction of CO2 to a methyl group and then combination of the methyl with CoA and a carbonyl group formed from CO or CO2 (Wood, H. G., Ragsdale, S. W., and Pezacka, E. (1986) Trends Biochem. Sci. 11, 14-18). Carbon monoxide dehydrogenase (CODH), the key enzyme in this pathway not only catalyzes the oxidation of CO to CO2 but also the final step, the synthesis of acetyl-CoA from a methyl group, CO, and CoA. Previously, it has been shown that ferredoxin can stimulate exchange of CO with (CH3COSCoA)-C-14 (Ragsdale, S. W., and Wood, H. G. (1985) J. Biol. Chem. 260, 3970-3977). In the present study, it has been observed that ferredoxin and CODH can form an electrostatically stabilized complex. In order to identify the ferredoxin binding region on CODH, the ferredoxin and CODH were cross-linked by using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The cross-linked CODH-ferredoxin adduct was enzymatically as active as the uncross-linked complex. The native CODH and cross-linked CODH-ferredoxin complex were subjected to cyanogen bromide cleavage. By comparison of the high-performance liquid chromatography peptide profiles, it was observed that the mobility of at least one peptide is altered in the CODH-ferredoxin cross-linked complex. The peptide was identified with residues 229-239 of the alpha-subunit of CODH.			SHANMUGASUNDARAM, T (corresponding author), CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106, USA.				NIGMS NIH HHS [GM-24913] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024913, R01GM024913] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURTON JW, 1970, J MOL BIOL, V52, P165; CHU JW, 1973, J BIOL CHEM, V248, P5183; DAVIS DJ, 1983, BIOCHEM BIOPH RES CO, V116, P1000, DOI 10.1016/S0006-291X(83)80241-1; DRAKE HL, 1980, J BIOL CHEM, V255, P7174; DRAKE HL, 1981, J BIOL CHEM, V256, P1137; ELLIOTT JI, 1978, ARCH BIOCHEM BIOPHYS, V190, P351, DOI 10.1016/0003-9861(78)90285-0; FUCHS G, 1986, FEMS MICROBIOL LETT, V39, P181, DOI 10.1111/j.1574-6968.1986.tb01859.x; Gros E., 1967, METHOD ENZYMOL, V11, P238; HUSAIN M, 1986, J BIOL CHEM, V261, P8577; LINDAHL PA, 1990, J BIOL CHEM, V265, P3880; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; LJUNGDAHL LG, 1986, ANNU REV MICROBIOL, V40, P415, DOI 10.1146/annurev.mi.40.100186.002215; LU WP, 1990, J BIOL CHEM, V265, P3124; MORTENSEN LE, 1962, BIOCHEM BIOPH RES CO, V7, P238; MORTON TA, 1991, IN PRESS J BIOL CHEM; NELSON N, 1969, J BIOL CHEM, V244, P1926; PEZACKA E, 1988, J BIOL CHEM, V263, P16000; PHILLIPS NFB, 1986, BIOCHEMISTRY-US, V25, P1644, DOI 10.1021/bi00355a030; RAGSDALE SW, 1982, BIOCHEM BIOPH RES CO, V108, P658, DOI 10.1016/0006-291X(82)90880-4; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; RAGSDALE SW, 1985, P NATL ACAD SCI USA, V82, P6811, DOI 10.1073/pnas.82.20.6811; SHANMUGASUNDARAM T, 1988, Biofactors, V1, P147; SHANMUGASUNDARAM T, 1989, BIOCHEMISTRY-US, V28, P7112, DOI 10.1021/bi00443a049; SHANMUGASUNDARAM T, 1988, BIOCHEMISTRY-US, V27, P6499, DOI 10.1021/bi00417a045; SHIN M, 1965, J BIOL CHEM, V240, P1405; THAUER RK, 1989, ANNU REV MICROBIOL, V43, P43, DOI 10.1146/annurev.mi.43.100189.000355; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; WOOD HG, 1991, FASEB J, V5, P156, DOI 10.1096/fasebj.5.2.1900793; WOOD HG, 1986, TRENDS BIOCHEM SCI, V14, P11; WOOD HG, 1990, VARIATIONS AUTOTROPH, P202; YANG SS, 1977, J BACTERIOL, V130, P1084, DOI 10.1128/JB.130.3.1084-1090.1977	31	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					897	900						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730678				2022-12-25	WOS:A1992GY96000035
J	ZHOU, D; KORZEKWA, KR; POULOS, T; CHEN, S				ZHOU, D; KORZEKWA, KR; POULOS, T; CHEN, S			A SITE-DIRECTED MUTAGENESIS STUDY OF HUMAN PLACENTAL AROMATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST; AROMATIZATION; MICROSOMES; PROTEINS	Aromatase, a cytochrome P-450, catalyzes the formation of aromatic C18 estrogenic steroids from C19 androgens. Using the x-ray structure of cytochrome P-450 cam as the model, seven mutants of human aromatase were designed and expressed in Chinese hamster ovary cells by a stable expression method. They are His-128 --> Gln, His-128 --> Ala, Cys-299 --> Ala, Glu-302 Leu, Asp-309 --> Asn, Asp-309 --> Ala, and Ser-312 --> Cys. The presence of the aromatase mutants in the transfected Chinese hamster ovary cells were confirmed by immunoprecipitation analysis. The kinetic parameters of these mutants using [1-beta, 2-beta-H-3] androstenedione (or [1-beta-H-3]androstenedione), and [1-beta, 2-beta-H-3]testosterone as substrates were determined. In addition, inhibition profiles for these mutants with two aromatase inhibitors, 4-hydroxyandrostenedione and aminoglutethimide were obtained. Furthermore, the reactions catalyzed by these mutants were examined by evaluating the levels of the product estrone, and two intermediates, 19-hydroxyandrostenedione and 19-oxoandrostenedione by reverse phase high performance liquid chromatography using [7-H-3]androstenedione as the substrate. Our results indicate that among the positions we modified, Asp-309 appears to be very important for the enzyme catalysis.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DIV IMMUNOL,DUARTE,CA 91010; NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892; UNIV CALIF IRVINE,DEPT MOLEC BIOL & BIOCHEM,IRVINE,CA 92717	City of Hope; Beckman Research Institute of City of Hope; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California Irvine					NCI NIH HHS [CA 44735, CA 33572] Funding Source: Medline; NIGMS NIH HHS [GM 33688] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044735, P30CA033572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033688] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GRAHAMLORENCE S, 1990, FASEB J, V4; KELLY WG, 1977, BIOCHEMISTRY-US, V16, P140, DOI 10.1021/bi00620a024; KILLINGER D W, 1987, Steroids, V50, P523, DOI 10.1016/0039-128X(87)90036-5; KORZEKWA KR, 1990, DRUG METAB DISPOS, V18, P974; KORZEKWA KR, 1991, BIOCHEMISTRY-US, V30, P6155, DOI 10.1021/bi00239a011; MACLUSKY N J, 1987, Steroids, V50, P459, DOI 10.1016/0039-128X(87)90032-8; MILLER W R, 1987, Steroids, V50, P537, DOI 10.1016/0039-128X(87)90037-7; NELSON DR, 1988, J BIOL CHEM, V263, P6038; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; REED MJ, 1989, INT J CANCER, V44, P233, DOI 10.1002/ijc.2910440208; SALHANICK HA, 1982, CANCER RES, V42, P3315; SHIMADA H, 1990, INT S OXYGENASES OXY, P133; SILVA MC, 1989, CANCER RES, V49, P2588; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; ZHOU D, 1990, CANCER RES, V50, P6949; ZHOU DJ, 1991, P NATL ACAD SCI USA, V88, P410, DOI 10.1073/pnas.88.2.410	19	67	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					762	768						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730667				2022-12-25	WOS:A1992GY96000016
J	BURDICK, D; SOREGHAN, B; KWON, M; KOSMOSKI, J; KNAUER, M; HENSCHEN, A; YATES, J; COTMAN, C; GLABE, C				BURDICK, D; SOREGHAN, B; KWON, M; KOSMOSKI, J; KNAUER, M; HENSCHEN, A; YATES, J; COTMAN, C; GLABE, C			ASSEMBLY AND AGGREGATION PROPERTIES OF SYNTHETIC ALZHEIMERS A4/BETA AMYLOID PEPTIDE ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN PRECURSOR; PLAQUE CORE PROTEIN; X-RAY-DIFFRACTION; NEURONAL ORIGIN; SENILE PLAQUES; MESSENGER-RNA; DISEASE; DEPOSITS; INVITRO; FIBRILS	The amyloid A4 or beta-peptide is a major component of extracellular amyloid deposits that are a characteristic feature of Alzheimer's disease. We synthesized a series of peptide analogs of the A4/beta-peptide which are progressively longer at their carboxyl termini, including 42- and 39-residue peptides which represent the major forms of the A4/beta-peptide in senile plaque and the hereditary cerebral hemorrhage with amyloidosis form, respectively. All peptides tested, beta-1-28 through beta-1-42, formed amyloid-like fibrils and previously unreported thin sheet-like structures which stained with thioflavin T and Congo Red. The solubility of beta-1-42 and shorter peptides was pH and concentration dependent, with a broad insolubility profile in the pH range of 3.5-6.5 and at concentrations above 0.75 mg/ml. Only peptides of 42 residues or longer were significantly insoluble at pH 7.4. beta-1-47, and beta-1-52 peptides are highly insoluble in aqueous media but are soluble at 40 mg/ml in the alpha-helix-promoting solvent, 1,1,1,3,3,3-hexafluoro-2-propanol. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed that the beta-1-42 peptide migrates as a series of higher molecular mass aggregates whereas shorter peptides migrate as monomers. Aggregation is also dependent on pH, peptide concentration, and time of incubation in aqueous medium. These results indicate that the length of the hydrophobic carboxyl terminus of the A4/beta-peptide is important in determining the solubility and aggregation properties of the A4/beta-peptide and that an acid pH environment, high peptide concentration, and long incubation time would be predicted to be important factors in promoting amyloid deposition.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA; UNIV CALIF IRVINE, DEPT PSYCHOBIOL, IRVINE, CA 92717 USA; CALTECH, CTR MOLEC BIOTECHNOL, DIV BIOL, PASADENA, CA 91125 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; California Institute of Technology					NIA NIH HHS [AG 07918] Funding Source: Medline; NICHD NIH HHS [HD 21379] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG007918] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BEYREUTHER K, 1986, DISCUSSIONS NEUROSCI, V3, P68; CANDY JM, 1986, LANCET, V1, P354; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; CATALDO AM, 1990, BRAIN RES, V513, P181, DOI 10.1016/0006-8993(90)90456-L; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FRANGIONE B, 1989, ANN MED, V21, P69, DOI 10.3109/07853898909149186; GLABE C G, 1990, Technique (Philadelphia), V2, P138; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1988, CELL, V52, P307, DOI 10.1016/S0092-8674(88)80021-7; GOREVIC PD, 1987, BIOCHEM BIOPH RES CO, V147, P854, DOI 10.1016/0006-291X(87)91008-4; HALVERSON K, 1990, BIOCHEMISTRY-US, V29, P2639, DOI 10.1021/bi00463a003; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; JOACHIM CL, 1989, AM J PATHOL, V135, P309; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MASTERS CL, 1987, CIBA F SYMP, V126, P49; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLERHILL B, 1989, ANNU REV BIOCHEM, V58, P287; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; PRELLI F, 1988, BIOCHEM BIOPH RES CO, V151, P1150, DOI 10.1016/S0006-291X(88)80486-8; ROHER A, 1986, P NATL ACAD SCI USA, V83, P2662, DOI 10.1073/pnas.83.8.2662; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; TANAKA S, 1988, BIOCHEM BIOPH RES CO, V157, P472, DOI 10.1016/S0006-291X(88)80273-0; TANZI RE, 1989, ANN MED, V21, P91, DOI 10.3109/07853898909149191; TOMICH JM, 1988, ANAL BIOCHEM, V174, P197, DOI 10.1016/0003-2697(88)90535-0; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WHITSON JS, 1990, NEUROSCI LETT, V110, P319, DOI 10.1016/0304-3940(90)90867-9; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; WISNIEWSKI HM, 1989, ACTA NEUROPATHOL, V78, P337, DOI 10.1007/BF00688170; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V76, P541, DOI 10.1007/BF00689591; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	45	920	992	0	86	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					546	554						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730616				2022-12-25	WOS:A1992GY43900086
J	SMIT, G; PUVANESARAJAH, V; CARLSON, RW; BARBOUR, WM; STACEY, G				SMIT, G; PUVANESARAJAH, V; CARLSON, RW; BARBOUR, WM; STACEY, G			BRADYRHIZOBIUM-JAPONICUM-NODD1 CAN BE SPECIFICALLY INDUCED BY SOYBEAN FLAVONOIDS THAT DO NOT INDUCE THE NODYABCSUIJ OPERON	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELILOTI NODULATION GENES; COMMON NOD GENES; RHIZOBIUM-MELILOTI; BRADYRHIZOBIUM-JAPONICUM; HOST-SPECIFICITY; PLANT FLAVONE; ALFALFA SEEDS; GLYCINE-MAX; LEGUMINOSARUM; EXPRESSION	Besides genistein and daidzein, which are active inducers of the nodYABCSUIJ operon in Bradyrhizobium japonicum, soybean seeds also excrete compounds that are not inducers of the nodYABCSUIJ genes but enhance induction of this operon in the presence of a suboptimal genistein concentration. This synergism was studied in detail, and specific compounds were identified in seed exudate which specifically induce the nodD1 gene but not the nodYABCSUIJ operon. Therefore, our current hypothesis is that the observed synergism is caused by a specific induction of nodD1. The specific nodD1 inducers from soybean seed extract have been purified and characterized chemically. They appear to be derivatives of genistein, glycitein, and daidzein with glucose, malonyl, and acetyl groups attached. Both root and seed exudate appear to contain these compounds, with the seed being the major source. No hydrolysis of these compounds to their aglycone forms was detected in the presence of B. japonicum. A model for nod gene induction in B. japonicum is discussed.	UNIV TENNESSEE, CTR LEGUME RES, M409 WALTERS LIFE SCI BLDG, KNOXVILLE, TN 37996 USA; UNIV TENNESSEE, COMPLEX CARBOHYDRATE RES CTR, KNOXVILLE, TN 37996 USA; UNIV TENNESSEE, DEPT MICROBIOL, KNOXVILLE, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville					NIGMS NIH HHS [GM 33494-04, GM 40183-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033494] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANFALVI Z, 1988, MOL GEN GENET, V214, P420, DOI 10.1007/BF00330475; BECK AB, 1971, AUST J CHEM, V24, P1509, DOI 10.1071/CH9711509; BISHOP PE, 1976, PLANT PHYSIOL, V57, P542, DOI 10.1104/pp.57.4.542; CAETANOANOLLES G, 1988, J BACTERIOL, V170, P3164, DOI 10.1128/jb.170.7.3164-3169.1988; ELDRIDGE AC, 1982, J AGR FOOD CHEM, V30, P353, DOI 10.1021/jf00110a035; FISHER RF, 1988, GENE DEV, V2, P282, DOI 10.1101/gad.2.3.282; GOTTFERT M, 1989, MOL GEN GENET, V215, P407, DOI 10.1007/BF00427037; GOTTFERT M, 1988, J PLANT PHYSIOL, V132, P394, DOI 10.1016/S0176-1617(88)80051-8; GRAHAM TL, 1990, MOL PLANT MICROBE IN, V3, P157, DOI 10.1094/MPMI-3-157; HALVERSON LJ, 1986, MICROBIOL REV, V50, P193, DOI 10.1128/MMBR.50.2.193-225.1986; Harborne J. B., 1988, FLAVONOIDS ADV RES; HARTWIG UA, 1989, PLANT PHYSIOL, V91, P1138, DOI 10.1104/pp.91.3.1138; HARTWIG UA, 1990, PLANT PHYSIOL, V92, P116, DOI 10.1104/pp.92.1.116; HONG GF, 1987, NUCLEIC ACIDS RES, V15, P9677, DOI 10.1093/nar/15.23.9677; HOROWITZ RM, 1989, PHYTOCHEMISTRY, V28, P2531, DOI 10.1016/S0031-9422(00)98028-2; JOHNSTON AWB, 1989, NATO ASI SERIES H, V36, P311; KOSSLAK RM, 1987, P NATL ACAD SCI USA, V84, P7428, DOI 10.1073/pnas.84.21.7428; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; Markham K.R., 1975, FLAVONOIDS, DOI 10.1007/978-1-4899-2909-9_2; MATHEWS A, 1989, MOL PLANT MICROBE IN, V2, P283, DOI 10.1094/MPMI-2-283; MAXWELL CA, 1989, PLANT PHYSIOL, V91, P842, DOI 10.1104/pp.91.3.842; Miller JH., 1972, EXPT MOL GENETICS; MORRIS JW, 1990, P NATL ACAD SCI USA, V87, P3614, DOI 10.1073/pnas.87.9.3614; MULLIGAN JT, 1985, P NATL ACAD SCI USA, V82, P6609, DOI 10.1073/pnas.82.19.6609; MULLIGAN JT, 1989, GENETICS, V122, P7; NIEUWKOOP AJ, 1987, J BACTERIOL, V169, P2631, DOI 10.1128/jb.169.6.2631-2638.1987; PETERS NK, 1986, SCIENCE, V233, P977, DOI 10.1126/science.3738520; RECOURT K, 1989, J BACTERIOL, V171, P4370, DOI 10.1128/JB.171.8.4370-4377.1989; RECOURT K, 1990, NITROGEN FIXATION AC, P271; ROSSEN L, 1985, EMBO J, V4, P3369, DOI 10.1002/j.1460-2075.1985.tb04092.x; SCHLAMAN HRM, 1989, J BACTERIOL, V171, P4686, DOI 10.1128/jb.171.9.4686-4693.1989; SMIT G, 1990, NITROGEN FIXATION AC, P273; SPAINK HP, 1987, NATURE, V328, P337, DOI 10.1038/328337a0; SPAINK HP, 1989, J BACTERIOL, V171, P4045, DOI 10.1128/jb.171.7.4045-4053.1989; SPAINK HP, 1990, ADV MOL GENETICS PLA, P142; VANBRUSSEL AAN, 1990, J BACTERIOL, V172, P5394, DOI 10.1128/jb.172.9.5394-5401.1990; WANG SP, 1991, J BACTERIOL, V173, P3356, DOI 10.1128/jb.173.11.3356-3365.1991; YORK WS, 1986, METHOD ENZYMOL, V118, P3; ZAAT SAJ, 1987, J BACTERIOL, V169, P3388, DOI 10.1128/jb.169.7.3388-3391.1987; ZAAT SAJ, 1987, J BACTERIOL, V169, P198, DOI 10.1128/jb.169.1.198-204.1987	41	73	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					310	318						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730597				2022-12-25	WOS:A1992GY43900052
J	CHARLES, CH; ABLER, AS; LAU, LF				CHARLES, CH; ABLER, AS; LAU, LF			CDNA SEQUENCE OF A GROWTH FACTOR-INDUCIBLE IMMEDIATE EARLY GENE AND CHARACTERIZATION OF ITS ENCODED PROTEIN	ONCOGENE			English	Note							EXPRESSION; CELLS; SET	We report the cDNA sequence of 3CH134, an immediate early gene whose transcription is rapidly and transiently stimulated by serum growth factors. 3CH134 encodes a 367 amino acid protein that does not share significant sequence similarity with any known protein. 3CH134 is inducible through multiple signal transduction pathways, and in the adult mouse is expressed predominantly in the lung. Using affinity-purified antibodies, we have identified the 3CH134 protein in serum-stimulated Balb/c 3T3 cells and determined that it has a short half-life.	UNIV ILLINOIS,COLL MED,DEPT GENET,808 S WOOD ST,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [R01 CA46565] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; HARLOW E, 1988, ANTIBODIES LABORATOR; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P115	15	239	247	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					187	190						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741163				2022-12-25	WOS:A1992HC22700025
J	LIU, C; PARK, M; TSAO, MS				LIU, C; PARK, M; TSAO, MS			OVEREXPRESSION OF C-MET PROTOONCOGENE BUT NOT EPIDERMAL GROWTH-FACTOR RECEPTOR OR C-ERBB-2 IN PRIMARY HUMAN COLORECTAL CARCINOMAS	ONCOGENE			English	Note							HUMAN GASTRIC-CARCINOMA; HUMAN-BREAST CANCER; EGF RECEPTOR; NEU ONCOGENE; TYROSINE KINASE; ENHANCED EXPRESSION; GENE AMPLIFICATION; HUMAN-COLON; CELL-LINE; PHOSPHORYLATION	The epidermal growth factor receptor (EGFR) and the protein products of c-erbB-2 and c-met proto-oncogenes belong to a family of growth factor receptors with tyrosine kinase activity. In human colonic carcinomas, the expression of the EGFR and c-erbB-2 have been studied at the protein level only, while c-met expression has not been reported. We have examined the mRNA expression of these genes in human normal colorectal mucosa and primary carcinomas. The results demonstrate that the normal mucosa shows highly variable levels of EGFR and c-erbB-2 mRNAs, but expresses consistently low amounts of c-met mRNA. Colorectal carcinomas did not express significantly higher levels of the EGFR and c-erbB-2 mRNAs than the normal mucosa. In contrast, c-met was consistently and significantly overexpressed (mean sixfold) in carcinomas as compared with normal mucosa. Seventy percent of paired normal-tumor specimens showed a tumor to normal c-met mRNA ratio of greater than 4. The expression of c-met mRNA was also enhanced in the adenomas, suggesting that overexpression of this proto-oncogene may have mechanistic significance in the early stages of human colorectal carcinogenesis.	MONTREAL GEN HOSP,DEPT PATHOL,1650 CEDAR AVE,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,MONTREAL H3G 1A4,QUEBEC,CANADA; LUDWIG INST CANC RES,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; McGill University; Ludwig Institute for Cancer Research			Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; 				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERGER MS, 1988, CANCER RES, V48, P1238; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; COHEN JA, 1989, ONCOGENE, V4, P81; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DEMILIA J, 1989, ONCOGENE, V4, P1233; Dukes CE, 1940, J PATHOL BACTERIOL, V50, P527, DOI 10.1002/path.1700500314; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLEY GG, 1989, ONCOGENE, V4, P963; GIORDANO S, 1988, J CELL BIOCHEM, V38, P229, DOI 10.1002/jcb.240380402; GREEN MR, 1985, J INVEST DERMATOL, V85, P239, DOI 10.1111/1523-1747.ep12276708; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; KAHN P, 1986, ONCOGENES GROWTH FAC; KERN JA, 1990, CANCER RES, V50, P5184; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KORETZ K, 1990, VIRCHOWS ARCH A, V416, P343, DOI 10.1007/BF01605295; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MAGUIRE HC, 1989, J INVEST DERMATOL, V89, P786; MCCLARE JT, 1988, STATISTICS; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; NANNEY LB, 1984, J INVEST DERMATOL, V82, P165, DOI 10.1111/1523-1747.ep12259731; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PARK M, 1986, CELL, V45, P894; PFEIFFER A, 1990, GASTROENTEROLOGY, V98, P961, DOI 10.1016/0016-5085(90)90020-2; ROTHBAUER E, 1989, KLIN WOCHENSCHR, V67, P518, DOI 10.1007/BF01719776; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TSAO MS, 1989, MOL CARCINOGEN, V2, P144, DOI 10.1002/mc.2940020307; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEIDNER U, 1990, CANCER RES, V50, P4504; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, CANCER RES, V46, P414; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YASUI W, 1988, INT J CANCER, V41, P211, DOI 10.1002/ijc.2910410209; YASUI W, 1988, CANCER RES, V48, P137; YONEMURA Y, 1989, ONCOLOGY, V46, P158	44	154	173	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					181	185						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741162				2022-12-25	WOS:A1992HC22700024
J	CHOU, JL; ROZMAHEL, R; TSUI, LC				CHOU, JL; ROZMAHEL, R; TSUI, LC			CHARACTERIZATION OF THE PROMOTER REGION OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TRANSCRIPTIONAL SILENCER; FUNCTIONAL-ANALYSIS; NEGATIVE CONTROL; MAMMALIAN-CELLS; DNA; IDENTIFICATION; EXPRESSION; ENHANCER; ELEMENTS	To identify the transcription regulatory elements of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, DNA fragments located in the 5'-upstream region were fused with the bacterial chloramphenicol acetyltransferase (CAT) reporter gene and transfected into various cell lines to test for promoter activity. The results of these studies suggested that there were at least two positive and one negative cisacting elements involved in CFTR transcription initiation. One of them was a proximal, positive element delimited by the 5' deletion constructs -226 base parts upstream of the transcription start site. This minimal promoter sequence (-226 to +98) alone seemed to be sufficient to direct cell-specific CAT expression. The sequences immediately upstream of -277, on the other hand, appeared to contain a negative regulatory element; inclusion of this sequence with the proximal element (e.g. a construct containing sequences -345 to +98) rendered the CFTR promoter inactive. This negative regulatory element could also suppress the activity of a heterologous promoter. In addition, the DNA transfection study suggested the existence of another positive regulatory element outside the CFTR promoter region examined, as the inability of this region (e.g. -658 to +98) to function in a CAT assay could be overcome by the presence of a viral enhancer element.	HOSP SICK CHILDREN,RES INST,DEPT GENET,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Tsui, Lap-chee/A-1081-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034944] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34944] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; BUCHANAN JA, 1990, J CELL SCI, V95, P109; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARRISON T, 1977, VIROLOGY, V77, P319, DOI 10.1016/0042-6822(77)90428-7; KADESCH T, 1986, NUCLEIC ACIDS RES, V14, P8209, DOI 10.1093/nar/14.20.8209; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KAZAZIAN HH, 1990, SEMIN HEMATOL, V27, P1; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM BS, 1989, AM J HUM GENET, V44, P827; LAIMINS L, 1986, P NATL ACAD SCI USA, V83, P3151, DOI 10.1073/pnas.83.10.3151; LARSEN PR, 1986, P NATL ACAD SCI USA, V83, P8283, DOI 10.1073/pnas.83.21.8283; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LOK S, 1989, NUCLEIC ACIDS RES, V17, P3563, DOI 10.1093/nar/17.9.3563; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T., 1982, MOL CLONING; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; MURAKAMI H, 1980, P NATL ACAD SCI-BIOL, V77, P3464, DOI 10.1073/pnas.77.6.3464; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROMMENS JM, 1991, IN PRESS P NATL ACAD, V88; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WINOTO A, 1989, CELL, V59, P649, DOI 10.1016/0092-8674(89)90010-X; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140; ZIELENSKI J, 1991, GENOMICS, V10, P214, DOI 10.1016/0888-7543(91)90503-7	41	95	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24471	24476						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722205				2022-12-25	WOS:A1991GW84500037
J	EDMONDSON, DG; BRENNAN, TJ; OLSON, EN				EDMONDSON, DG; BRENNAN, TJ; OLSON, EN			MITOGENIC REPRESSION OF MYOGENIN AUTOREGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FIBROBLAST GROWTH-FACTOR; CREATINE-KINASE GENE; TERMINAL DIFFERENTIATION; DNA-BINDING; MUSCLE DIFFERENTIATION; AUTO-REGULATION; MOUSE MUSCLE; MYOD FAMILY; FACTOR-BETA; CELL LINE	The muscle-specific helix-loop-helix proteins MyoD and myogenin have been shown to positively autoregulate their own expression and to cross-activate one another's expression following transfection into a variety of nonmyogenic cell lines. We show that the ability of an exogenous myogenin expression vector to activate the endogenous myogenin allele in 10T1/2 fibroblasts is dependent on serum withdrawal. Repression of myogenin autoregulation by serum can be observed with a reporter gene linked to myogenin upstream sequences, indicating that repression occurs at the level of transcription. Like MyoD, myogenin exhibits a short half-life (approximately 20 min), which may serve to maintain the autoregulatory loop without allowing excess accumulation of the protein.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center				Edmondson, Diane/0000-0003-3702-9715				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRAUN T, 1990, NATURE, V346, P663, DOI 10.1038/346663a0; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; HU JS, 1990, J BIOL CHEM, V265, P7914; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	35	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21343	21346						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1718977				2022-12-25	WOS:A1991GP80400005
J	ZHANG, DE; GE, X; RABEK, JP; PAPACONSTANTINOU, J				ZHANG, DE; GE, X; RABEK, JP; PAPACONSTANTINOU, J			FUNCTIONAL-ANALYSIS OF THE TRANS-ACTING FACTOR BINDING-SITES OF THE MOUSE ALPHA-FETOPROTEIN PROXIMAL PROMOTER BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; HUMAN ALPHA-1-ANTITRYPSIN GENE; CELL-SPECIFIC EXPRESSION; LIVER-SPECIFIC EXPRESSION; NUCLEAR FACTOR-I; ALBUMIN GENE; ALPHA-1-FETOPROTEIN GENE; TRANSCRIPTIONAL CONTROL; REGULATORY ELEMENTS; DNA ELEMENTS	The trans-acting factors of the mouse alpha-fetoprotein proximal promoter (-202 base pairs) are aligned as follows: regions Ia (HNF-1), Ib (C/EBP), II (NF-1 or C/EBP), II' (NF-1 or HNF-1), III (NP-III), IV (NP-IV), Va (NP-Va), and Vb (C/EBP). Site-specific mutation abolished protein binding to the corresponding mutated site with the exception of the NF-1 site, in which mutation causes partial protection. Transient expression analyses indicate that chloramphenicol acetyltransferase (CAT) activity is reduced by mutations in regions Ia, II', Ib, II, and IV. Mutation of region III causes an increased activity and mutation of regions Va and Vb shows a slight inhibitory effect. Linking alpha-fetoprotein enhancer I to the wild type promoter resulted in a 12-fold stimulation of CAT activity. The activity of promoters with mutated C/EBP-binding sites (Ib, II, and Vb), was slightly above controls, indicating that enhancer I can reverse the effect of these mutations. Inhibition or stimulation of promoter activity resulting from mutations of the HNF-1 or NP-III binding sites, respectively, persisted when enhancer I was linked to the promoters, indicating that enhancer I cannot rescue these mutations. Mutation of both HNF-1-binding sites resulted in greater than 90% inhibition of CAT expression with and without enhancer I, indicating these sites are essential for promoter activity. The stimulation of promoter activity by mutation of the NP-III site suggests that this site may be essential for repression or attenuation of the alpha-fetoprotein gene. Our studies indicate that regulation of the alpha-fetoprotein gene requires the combinatorial effect of multiple cis- and trans-acting elements in the proximal promoter and that enhancer I may provide a factor(s) that specifically rescue the promoter from the inhibitory effect of mutation in the C/EBP-binding sites.	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77550	University of Texas System; University of Texas Medical Branch Galveston			Papaconstantinou, John/E-3312-2010		NATIONAL CANCER INSTITUTE [R01CA031472] Funding Source: NIH RePORTER; NCI NIH HHS [CA31472] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABISS LE, 1986, MOL CELL BIOL, V6, P3798, DOI 10.1128/MCB.6.11.3798; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CILIBERTO G, 1985, CELL, V41, P531, DOI 10.1016/S0092-8674(85)80026-X; COSTA RH, 1986, MOL CELL BIOL, V6, P4697, DOI 10.1128/MCB.6.12.4697; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; GE X, 1990, FASEB J, V4, P2308; GODBOUT R, 1988, MOL CELL BIOL, V8, P1169, DOI 10.1128/MCB.8.3.1169; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERTIN M, 1983, BIOCHEMISTRY-US, V22, P4296, DOI 10.1021/bi00287a021; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KELSEY GD, 1987, GENE DEV, V1, P161, DOI 10.1101/gad.1.2.161; KRUMLAUF R, 1985, MOL CELL BIOL, V5, P1639, DOI 10.1128/MCB.5.7.1639; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MCVEY JH, 1989, REGULATION LIVER GEN, P21; MOLNE M, 1989, NUCLEIC ACIDS RES, V17, P3447, DOI 10.1093/nar/17.9.3447; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; MONTGOMERY KT, 1990, MOL CELL BIOL, V10, P2625, DOI 10.1128/MCB.10.6.2625; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; PANDURO A, 1987, GENE DEV, V1, P1172, DOI 10.1101/gad.1.10.1172; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RABEK JP, 1990, FASEB J, V4, P2310; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SHEN RF, 1987, NUCLEIC ACIDS RES, V15, P8399, DOI 10.1093/nar/15.20.8399; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; WIDEN SG, 1987, MOL CELL BIOL, V7, P2606, DOI 10.1128/MCB.7.7.2606; WIDEN SG, 1986, P NATL ACAD SCI USA, V83, P8196, DOI 10.1073/pnas.83.21.8196; ZHANG DE, 1990, J BIOL CHEM, V265, P3382	46	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21179	21185						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1718972				2022-12-25	WOS:A1991GN00100092
J	KOLE, HK; LENARD, J				KOLE, HK; LENARD, J			INSULIN-INDUCED STIMULATION OF PROTEIN-PHOSPHORYLATION IN NEUROSPORA-CRASSA CELLS	FASEB JOURNAL			English	Article						TYROSINE PROTEIN KINASE; PHOSPHOAMINO ACIDS; SIGNAL TRANSDUCTION PATHWAYS; NEUROSPORA-CRASSA MEMBRANE; 2-DIMENSIONAL GEL ELECTROPHORESIS	RECEPTOR TYROSINE KINASE; WALL-LESS STRAIN; EPIDERMAL GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; MAMMALIAN INSULIN; FACTOR-I; AUTOPHOSPHORYLATION; METABOLISM; SUBSTRATE; ACTIVATION	1) Insulin stimulated the phosphorylation of at least 14 discrete proteins in Neurospora crassa cells. Specific proteins were phosphorylated at serine, threonine, and tyrosine residues, as determined by phosphoamino acid analysis of discrete spots on two-dimensional gels. 2) Insulin stimulated the phosphorylation by [gamma-P-32]ATP of at least six discrete proteins in solubilized N. crassa membrane preparations at serine and tyrosine residues. 3) A phosphotyrosine-containing protein of 38 kDa, pI 7.0-7.2, reacted by both immunoblotting and immunoprecipitation with antiserum to P2, a peptide from the human insulin receptor that contains an autophosphorylated tyrosine residue. In N. crassa cells, therefore, as in mammalian cells, insulin induces a variety of protein phosphorylations, some of which may be part of an evolutionarily conserved signal transduction pathway.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHYSIOL & BIOPHYS,675 HOES LANE,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NIDDK NIH HHS [DK-39502] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039502] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DENTON RM, 1990, NATURE, V348, P286, DOI 10.1038/348286a0; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FAWELL SE, 1988, BIOCHEM BIOPH RES CO, V155, P59, DOI 10.1016/S0006-291X(88)81049-0; FAWELL SE, 1988, ENDOCRINOLOGY, V122, P518, DOI 10.1210/endo-122-2-518; FLAWIA MM, 1973, J BIOL CHEM, V248, P4517; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GREENFIELD NJ, 1988, BIOCHEMISTRY-US, V27, P8526, DOI 10.1021/bi00423a004; GREENFIELD NJ, 1990, BIOCHIM BIOPHYS ACTA, V1025, P15, DOI 10.1016/0005-2736(90)90185-Q; HARING HU, 1987, P NATL ACAD SCI USA, V84, P113, DOI 10.1073/pnas.84.1.113; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HERRERA R, 1986, J BIOL CHEM, V261, P1980; KADOWAKI T, 1987, J BIOL CHEM, V262, P7342; KAMATA T, 1987, BIOCHEM BIOPH RES CO, V144, P19, DOI 10.1016/S0006-291X(87)80469-2; KOKE HK, 1991, BIOCHEMISTRY-US, V30, P682; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROITH D, 1985, CAN J BIOCHEM CELL B, V63, P839, DOI 10.1139/o85-106; LEROITH D, 1980, P NATL ACAD SCI-BIOL, V77, P6184; LEVENSON RM, 1989, J BIOL CHEM, V264, P19984; MCKENZIE MA, 1988, ENDOCRINOLOGY, V122, P511, DOI 10.1210/endo-122-2-511; MERMELSTEIN FH, 1989, MOL PHARMACOL, V36, P848; MUTHUKUMAR G, 1991, UNPUB PREPROINSULIN; NAVARRO J, 1982, BIOCHEMISTRY-US, V21, P6138, DOI 10.1021/bi00267a018; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; PETRUZELLI LM, 1985, P NATL ACAD SCI USA, V83, P4710; PONZIO G, 1988, EMBO J, V7, P4111, DOI 10.1002/j.1460-2075.1988.tb03305.x; ROSEN OM, 1987, SCIENCE, V237, P1451; SALE EM, 1987, J CELL BIOCHEM, V33, P15, DOI 10.1002/jcb.240330103; SANDERS MM, 1980, ANAL BIOCHEM, V103, P157, DOI 10.1016/0003-2697(80)90250-X; SCARBOROUGH GA, 1985, EXP MYCOL, V9, P275; SCHULTE TH, 1975, J BACTERIOL, V122, P1076, DOI 10.1128/JB.122.3.1076-1080.1975; SHEMER J, 1987, J BIOL CHEM, V262, P15476; SOOS MA, 1989, P NATL ACAD SCI USA, V86, P5217, DOI 10.1073/pnas.86.14.5217; SUNG CK, 1989, J BIOL CHEM, V264, P18951; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2	38	10	10	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2728	2734		10.1096/fasebj.5.12.1717334	http://dx.doi.org/10.1096/fasebj.5.12.1717334			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1717334				2022-12-25	WOS:A1991GE81100015
J	ROGERS, SJ; PRATT, CW; WHINNA, HC; CHURCH, FC				ROGERS, SJ; PRATT, CW; WHINNA, HC; CHURCH, FC			ROLE OF THROMBIN EXOSITES IN INHIBITION BY HEPARIN COFACTOR-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; ANTITHROMBIN-III; NEUTROPHIL ELASTASE; CRYSTAL-STRUCTURE; REACTIVE SITE; HIRUDIN; BINDING; IDENTIFICATION; INACTIVATION; FIBRINOGEN	We determined the role of specific thrombin "exosites" in the mechanism of inhibition by the plasma serine proteinase inhibitors heparin cofactor II (HC) and antithrombin (AT) in the absence and presence of a glycosaminoglycan by comparing the inhibition of alpha-thrombin to epsilon- and gamma(T)-thrombin (produced by partial proteolysis of alpha-thrombin by elastase and trypsin, respectively). All of the thrombin derivatives were inhibited in a similar manner by AT, either in the absence or presence of heparin, which confirmed the integrity of both heparin binding abilities and serpin reactivities of epsilon- and gamma(T)-thrombin compared to alpha-thrombin. Anti-thrombin activities of HC in the absence of a glycosaminoglycan with alpha-, epsilon-, and gamma(T)-thrombin were similar with rate constants of 3.5, 2.4, and 1.2 x 10(4) M-1 min-1, respectively. Interestingly, in the presence of glycosaminoglycans the maximal inhibition rate constants by HC with heparin and dermatan sulfate, respectively, were as follows: 30.0 x 10(7) and 60.5 x 10(7) for alpha-thrombin, 14.6 x 10(7) and 24.3 x 10(7) for epsilon-thrombin, and 0.017 x 10(7) and 0.034 x 10(7) M-1 min-1 for gamma(T)- and thrombin. A hirudin carboxyl-terminal peptide, which binds to anion-binding exosite-I of alpha-thrombin, dramatically reduced alpha-thrombin inhibition by HC in the presence of heparin but not in its absence. We analyzed our results in relation to the recently determined X-ray structure of D-Phe-Pro-Arg-chloromethyl ketone-alpha-thrombin (Bode, W., Mayr, I., Baumann, U., Huber, R., Stone, S. R., and Hofsteenge, J. (1989) EMBO J. 8, 3467-3475). Our results suggest that the beta-loop region of anion-binding exosite-I in alpha-thrombin, which is not present in gamma(T)-thrombin, is essential for the rapid inhibition reaction by HC in the presence of a glycosaminoglycan. Therefore, alpha-thrombin and its derivatives would be recognized and inhibited differently by HC and AT in the presence of a glycosaminoglycan.	UNIV N CAROLINA, SCH MED,CTR THROMBOSIS & HEMOSTASIS,DIV HEMATOL, CAMPUS BOX 7035, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32656] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERLINER LJ, 1984, MOL CELL BIOCHEM, V61, P159; BEZEAUD A, 1985, EUR J BIOCHEM, V153, P491, DOI 10.1111/j.1432-1033.1985.tb09328.x; BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BROWER MS, 1987, BLOOD, V69, P813; CHANG JY, 1991, BIOCHEMISTRY-US, V30, P6656, DOI 10.1021/bi00241a004; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CHURCH FC, 1991, J BIOL CHEM, V266, P11975; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CHURCH FC, 1985, P NATL ACAD SCI USA, V82, P6431, DOI 10.1073/pnas.82.19.6431; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; FENTON JW, 1991, BLOOD COAGUL FIBRIN, V2, P69, DOI 10.1097/00001721-199102000-00011; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; GRIFFITH MJ, 1983, P NATL ACAD SCI-BIOL, V80, P5460, DOI 10.1073/pnas.80.18.5460; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P2144, DOI 10.1021/bi00406a049; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; KAWABATA S, 1985, J BIOCHEM, V97, P325, DOI 10.1093/oxfordjournals.jbchem.a135057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAO SJT, 1988, BIOCHEMISTRY-US, V27, P8170, DOI 10.1021/bi00421a027; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NOE G, 1988, J BIOL CHEM, V263, P11729; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON TA, 1986, ANN NY ACAD SCI, V485, P96, DOI 10.1111/j.1749-6632.1986.tb34571.x; PARKER KA, 1985, J BIOL CHEM, V260, P3501; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; PRATT CW, 1989, ANN NY ACAD SCI, V556, P104; PRATT CW, 1991, SEMIN HEMATOL, V28, P3; PRATT CW, 1990, J BIOL CHEM, V265, P6092; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1990, J BIOL CHEM, V265, P22386; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; STONE SR, 1987, BIOCHEMISTRY-US, V26, P4617, DOI 10.1021/bi00389a004; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WHINNA HC, 1991, J BIOL CHEM, V266, P8129	43	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3613	3617						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740413				2022-12-25	WOS:A1992HE60700013
J	SHAWLEE, R; LISSEMORE, JL; SULLIVAN, DT; TOLAN, DR				SHAWLEE, R; LISSEMORE, JL; SULLIVAN, DT; TOLAN, DR			ALTERNATIVE SPLICING OF FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE TRANSCRIPTS IN DROSOPHILA-MELANOGASTER PREDICTS 3 ISOZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; ALCOHOL-DEHYDROGENASE GENES; RAT PYRUVATE-KINASE; B-GENE; LINKAGE GROUPS; MESSENGER-RNA; GPDH-LOCUS; EXPRESSION; CDNA; DNA	The genes that encode fructose 1,6-bisphosphate aldolase of Drosophila melanogaster have been isolated and characterized. These genes exist in a single copy 8-kilobase pair locus in the Drosophila genome which is located at cytogenetic position 97A-B. The nucleotide sequence and transcript mapping suggest that three overlapping protein isozyme genes may be encoded at this locus. These isozyme genes all share a single promoter, a 5'-untranslated first exon, and two other protein coding exons. The isozyme-specific carboxyl-terminal amino acids are encoded by one of three alternatively utilized fourth exons: 4A, 4B, or 4C by alternative splicing. The transcript containing exon 4C, whose sequence has been reported previously, is abundant throughout development and has a developmental profile similar to other glycolytic gene transcripts; however, it shows developmental specificity in the alternative use of two polyadenylation signals which result in a 2.4-kilobase and a 1.9-kilobase transcript. The transcript containing exon 4B is 1.6 kilobases in size and is most abundant during the larval stages and during the time of eclosion. The transcript containing exon4A is in low abundance and found only during the adult stage. Sequence comparisons of the alternative fourth exons indicate that the duplication leading to the multiple exons is quite old and preceded the origin of the genus Drosophila.	BOSTON UNIV,DEPT BIOL,5 CUMMINGTON ST,BOSTON,MA 02215; SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13244	Boston University; Syracuse University				Lissemore, James/0000-0002-1418-2285; Tolan, Dean/0000-0002-0598-7241	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026830] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 38821] Funding Source: Medline; NIGMS NIH HHS [GM 26830] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSDEN AB, 1985, THESIS U CALIF, P83; BARR PJ, 1986, BIOTECHNIQUES, V4, P428; BENDER W, 1975, J MOL BIOL, V168, P7; BERTHIAUME L, 1991, J BIOL CHEM, V266, P17099; BLOSTEIN R, 1963, J BIOL CHEM, V238, P3280; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; BURGESS DG, 1985, J BIOL CHEM, V260, P4604; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; COMINGS DE, 1972, NATURE, V238, P455, DOI 10.1038/238455a0; CROUSE GF, 1983, METHOD ENZYMOL, V101, P77; DAVIS RW, 1980, ADV BACTERIAL GENET, P124; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; GODSON GN, 1973, BIOCHIM BIOPHYS ACTA, V299, P516, DOI 10.1016/0005-2787(73)90223-2; JOH K, 1986, J MOL BIOL, V190, P401, DOI 10.1016/0022-2836(86)90011-2; KELLEY PM, 1986, PLANT PHYSIOL, V82, P1076, DOI 10.1104/pp.82.4.1076; KUKITA A, 1988, EUR J BIOCHEM, V171, P471, DOI 10.1111/j.1432-1033.1988.tb13813.x; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LISSEMORE JL, 1987, PLANT MOL BIOL, V8, P485, DOI 10.1007/BF00017994; MALEK AA, 1985, BIOCHEM BIOPH RES CO, V126, P199, DOI 10.1016/0006-291X(85)90591-1; MANIATIS T, 1982, MOL CLONING LABORATO, P269; MESTEK A, 1987, NUCLEIC ACIDS RES, V15, P10595, DOI 10.1093/nar/15.24.10595; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; OBRIEN SJ, 1986, J HERED, V77, P374, DOI 10.1093/oxfordjournals.jhered.a110264; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OHNO S, 1973, NATURE, V244, P259, DOI 10.1038/244259a0; OHNO S, 1968, HEREDITAS-GENETISK A, V59, P169; PAOLELLA G, 1986, EUR J BIOCHEM, V156, P229, DOI 10.1111/j.1432-1033.1986.tb09572.x; PENHOET E, 1966, P NATL ACAD SCI USA, V56, P1275, DOI 10.1073/pnas.56.4.1275; PENHOET E, 1967, BIOCHEMISTRY-US, V6, P2940, DOI 10.1021/bi00861a039; PENHOET EE, 1969, BIOCHEMISTRY-US, V8, P4391, DOI 10.1021/bi00839a025; PENHOET EE, 1969, BIOCHEMISTRY-US, V8, P4396, DOI 10.1021/bi00839a026; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; ROSE IA, 1969, J BIOL CHEM, V244, P126; ROTTMANN WH, 1984, P NATL ACAD SCI-BIOL, V81, P2738, DOI 10.1073/pnas.81.9.2738; ROTTMANN WH, 1987, BIOCHIMIE, V69, P137, DOI 10.1016/0300-9084(87)90246-X; RUTTER WJ, 1963, ADV ENZYME REGUL, V1, P39, DOI 10.1016/0065-2571(63)90005-0; SAKAKIBARA M, 1985, BIOCHEM BIOPH RES CO, V131, P413, DOI 10.1016/0006-291X(85)91818-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKUSE GR, 1985, EMBO J, V4, P2275, DOI 10.1002/j.1460-2075.1985.tb03926.x; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STARMER WT, 1989, MOL BIOL EVOL, V6, P546; SULLIVAN DT, 1990, EVOL BIOL, V24, P107; SULLIVAN DT, 1985, J BIOL CHEM, V260, P4345; TAKENAKA M, 1989, J BIOL CHEM, V264, P2363; TOLAN DR, 1987, AM J HUM GENET, V41, P907; TOLAN DR, 1984, J BIOL CHEM, V259, P1127; TOLAN DR, 1986, MOL BIOL MED, V3, P245; TSUTSUMI K, 1985, J MOL BIOL, V181, P153, DOI 10.1016/0022-2836(85)90081-6; VOELKER RA, 1979, BIOCHEM GENET, V17, P769, DOI 10.1007/BF00502135; VONKALM L, 1989, P NATL ACAD SCI USA, V86, P5020; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	53	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3959	3967						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740444				2022-12-25	WOS:A1992HE60700064
J	ZIONCHECK, TF; ROY, S; VEHAR, GA				ZIONCHECK, TF; ROY, S; VEHAR, GA			THE CYTOPLASMIC DOMAIN OF TISSUE FACTOR IS PHOSPHORYLATED BY A PROTEIN KINASE-C-DEPENDENT MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ENDOTHELIAL-CELLS; PROCOAGULANT ACTIVITY; EXPRESSION; ENDOTOXIN; BINDING	Tissue factor (TF) is an integral membrane glycoprotein that serves as a cellular receptor and cofactor for the activation of the plasma protease factor VII. TF activity in both monocytes and endothelial cells is regulated by various cytokines and mitogens, including the protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA). Three TF constructs (full-length human, a cytoplasmic domain deletion mutant, and a human-rat TF chimera), expressed in a human kidney cell line, were used to examine the in vivo phosphorylation state of TF after PMA treatment. The cytoplasmic domains of both rat and human TF were rapidly phosphorylated after cells were treated with 10-100 nM PMA. This response was completely abolished by preincubating cells with staurosporine, the potent PKC inhibitor, prior to PMA treatment. Localization of the phosphorylation site(s) to the cytoplasmic domain was demonstrated using a deletion mutant of TF and by CNBr digestion at the single methionine residue (Met-210) in the TF sequence. The rat TF cytoplasmic domain was phosphorylated to a higher specific activity than the human TF cytoplasmic domain. Phosphoamino acid analysis of the chimeric TF revealed both phosphothreonine and phosphoserine, whereas human TF contained only phosphoserine. Thus both potential phosphoacceptor sites are phosphorylated in the rat TF cytoplasmic domain. Alignment of TF cDNA sequences ef mouse, rat, rabbit, and man revealed that the phosphoacceptor site (X-S*/T*-P-X, where asterisk indicates the phosphorylated residue) in the cytoplasmic domain has been conserved through evolution.			ZIONCHECK, TF (corresponding author), GENENTECH INC, 460 POINT SAN BRUNO BLVD, SAN FRANCISCO, CA 94080 USA.		Roy, Soumitra/B-9113-2008					ANDREWS BS, 1991, GENE, V98, P265, DOI 10.1016/0378-1119(91)90184-D; ARCHIPOFF G, 1991, BIOCHEM J, V273, P679, DOI 10.1042/bj2730679; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BACH R, 1990, P NATL ACAD SCI USA, V87, P6995, DOI 10.1073/pnas.87.18.6995; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BROX JH, 1984, BRIT J HAEMATOL, V57, P239, DOI 10.1111/j.1365-2141.1984.tb02892.x; BROZNA JP, 1988, BLOOD, V72, P456; CAR BD, 1990, INFLAMMATION, V14, P681, DOI 10.1007/BF00916371; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CONKLING PR, 1989, J BIOL CHEM, V264, P18440; CROSSMAN DC, 1990, J BIOL CHEM, V265, P9782; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HURLEY TR, 1989, SCIENCE, V245, P407, DOI 10.1126/science.2787934; JANCO RL, 1985, BLOOD, V65, P545; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LOW PS, 1987, J BIOL CHEM, V262, P4592; MASON AJ, 1989, MOL ENDOCRINOL, V3, P1352, DOI 10.1210/mend-3-9-1352; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; NEMERSON Y, 1988, BLOOD, V71, P1; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PABORSKY LR, 1990, PROTEIN ENG, V3, P547, DOI 10.1093/protein/3.6.547; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; PABORSKY LR, 1990, THROMB RES, V60, P367, DOI 10.1016/0049-3848(90)90219-3; ROY S, 1991, J BIOL CHEM, V266, P4665; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SHIN JY, 1991, J BIOL CHEM, V266, P10658; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	35	122	124	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3561	3564						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740409				2022-12-25	WOS:A1992HE60700003
J	CORBEIL, D; BOILEAU, G; LEMAY, G; CRINE, P				CORBEIL, D; BOILEAU, G; LEMAY, G; CRINE, P			EXPRESSION AND POLARIZED APICAL SECRETION IN MADIN-DARBY CANINE KIDNEY-CELLS OF A RECOMBINANT SOLUBLE FORM OF NEUTRAL ENDOPEPTIDASE LACKING THE CYTOSOLIC AND TRANSMEMBRANE DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-G-PROTEIN; MDCK CELLS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; INFLUENZA HEMAGGLUTININ; 24.11 ENKEPHALINASE; TIGHT JUNCTIONS; COS-1 CELLS; GLYCOPROTEIN; SURFACE	Neutral endopeptidase-24.11 (NEP; EC 3.4.24.11) is an abundant metalloendopeptidase of the brush border membrane of kidney proximal tubules. We have recently shown that NEP is delivered directly to the apical domain of the plasma membrane when expressed in polarized Madin-Darby canine kidney (MDCK) cells in culture (Jalal, F., Lemay, G., Zollinger, M., Berteloot, A., Boileau, G., and Crine, P. (1991) J. Biol. Chem. 266, 19826-19832). Here, a soluble form of NEP consisting of the signal peptide of pro-opiomelanocortin fused in-frame with the ectodomain of NEP has been expressed in MDCK cells. Enzymatic assays performed on apical and basolateral culture media of MDCK cells grown on semi-permeable supports indicated that the recombinant enzyme was predominantly released at the apical surface. In contrast, when the chimeric protein was expressed in NIH 3T3 cells or when pro-opiomelanocortin was expressed in MDCK cells, non-polarized secretion was observed into both the apical and basolateral compartments of the culture chamber. Our results suggest that the ectodomain of NEP is sufficient for directing the targeting of this protein to the apical membrane of polarized MDCK epithelial cells.	UNIV MONTREAL,FAC MED,DEPT BIOCHIM,CP 6128,SUCC A,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,FAC MED,DEPT MICROBIOL & IMMUNOL,MONTREAL H3C 3J7,QUEBEC,CANADA; UNIV MONTREAL,RECH TRANSPORT MEMBRAINE GRP,MONTREAL H3C 3J7,QUEBEC,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal			Corbeil, Denis/A-6519-2010; Corbeil, Denis/AFL-1008-2022; Lemay, Guy/B-2165-2008	Lemay, Guy/0000-0002-0402-1285; Corbeil, Denis/0000-0003-1181-3659				AUBRY M, 1988, BIOCHIM BIOPHYS ACTA, V967, P56, DOI 10.1016/0304-4165(88)90188-2; BENNETT HPJ, 1981, BIOCHEMISTRY-US, V20, P4530, DOI 10.1021/bi00519a004; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CEREIJIDO M, 1989, J MEMBRANE BIOL, V110, P1, DOI 10.1007/BF01870987; CHEVRIER D, 1991, BIOCHEM CELL BIOL, V69, P58, DOI 10.1139/o91-008; COMPTON T, 1989, P NATL ACAD SCI USA, V86, P4112, DOI 10.1073/pnas.86.11.4112; CRINE P, 1985, BIOCHEM BIOPH RES CO, V131, P255, DOI 10.1016/0006-291X(85)91796-6; DEVAULT A, 1988, J BIOL CHEM, V263, P4033; DEVAULT A, 1988, FEBS LETT, V231, P54, DOI 10.1016/0014-5793(88)80701-4; DEVAULT A, 1987, EMBO J, V6, P1317, DOI 10.1002/j.1460-2075.1987.tb02370.x; FULCHER IS, 1982, BIOCHEM J, V203, P519, DOI 10.1042/bj2030519; GONZALEZ A, 1987, P NATL ACAD SCI USA, V84, P3738, DOI 10.1073/pnas.84.11.3738; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; HERZ RE, 1989, J BIOL CHEM, V264, P4605; JALAL F, 1991, J BIOL CHEM, V266, P19826; KLAUSNER RD, 1989, CELL, V57, P703, DOI 10.1016/0092-8674(89)90783-6; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; LEMAY G, 1989, J BIOL CHEM, V264, P15620; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MCQUEEN NL, 1987, J BIOL CHEM, V262, P16233; MOSTOV KE, 1987, J CELL BIOL, V105, P2031, DOI 10.1083/jcb.105.5.2031; NOEL G, 1989, J NEUROCHEM, V52, P1050, DOI 10.1111/j.1471-4159.1989.tb01846.x; OJAKIAN GK, 1987, AM J PHYSIOL, V253, pC433, DOI 10.1152/ajpcell.1987.253.3.C433; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RICHARDSON JCW, 1979, FEBS LETT, V105, P201, DOI 10.1016/0014-5793(79)80611-0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VAN MEER G, 1986, NATURE, V322, P639, DOI 10.1038/322639a0; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; VONBONSDORFF CH, 1985, EMBO J, V4, P2781, DOI 10.1002/j.1460-2075.1985.tb04004.x	34	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2798	2801						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733974				2022-12-25	WOS:A1992HB53200102
J	MABJEESH, NJ; KANNER, BI				MABJEESH, NJ; KANNER, BI			NEITHER AMINO NOR CARBOXYL TERMINI ARE REQUIRED FOR FUNCTION OF THE SODIUM-COUPLED AND CHLORIDE-COUPLED GAMMA-AMINOBUTYRIC-ACID TRANSPORTER FROM RAT-BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN ANTIGENIC DETERMINANTS; GABA TRANSPORTER; RECONSTITUTION; PURIFICATION; QUANTITIES; SEQUENCE; CLONING	Antibodies were raised against synthetic peptides corresponding to several regions of the rat brain gamma-aminobutyric acid (GABA) transporter. According to our model, this glycoprotein has 12 transmembrane alpha-helices with both amino and carboxyl termini located in the cytoplasm. The antibodies recognized the intact transporter on Western blots. Upon papain treatment, a reconstitutively active transporter can be isolated upon lectin chromatography (Kanner, B. I., Keynan, S., and Radian, R. (1989) Biochemistry 28, 3722-3728). The papainized transporter runs on sodium dodecyl sulfate-polyacrylamide gels as a broad band with an apparent molecular mass between about 58 and 68 kDa as compared to 80 kDa for the untreated transporter. The transporter fragment was recognized by all the antibodies, except for that raised against the amino terminus. Pronase cleaves the transporter to a relatively sharp 60-kDa band, which reacts with the antibodies against the internal loops but not with either the amino- or the carboxyl-terminal. This pronase-treated transporter, upon isolation by lectin chromatography, was reconstituted. It exhibits full GABA transport activity. This activity exhibits the same features as the intact system including an absolute dependence on sodium and chloride as well as electrogenicity. We conclude that the amino- and carboxyl-terminal parts of the transporter, possibly including transmembrane alpha-helices 1, 2, and 12, are not required for the transport function.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,IL-91010 JERUSALEM,ISRAEL	Hebrew University of Jerusalem					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENNETT JP, 1974, LIFE SCI, V15, P1045, DOI 10.1016/S0024-3205(74)80002-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; FOLCH J, 1957, J BIOL CHEM, V226, P497; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARLOW E, 1988, ANTIBODIES LABORATOR, P78; HOPP TP, 1983, MOL IMMUNOL, V20, P483, DOI 10.1016/0161-5890(83)90029-9; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; IVERSEN LL, 1975, BIOCHEM PHARMACOL, V24, P933, DOI 10.1016/0006-2952(75)90422-0; IVERSEN LL, 1973, BRIT MED BULL, V29, P130, DOI 10.1093/oxfordjournals.bmb.a070982; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; KAGAWA Y, 1971, J BIOL CHEM, V246, P5477; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1989, BIOCHEMISTRY-US, V28, P3722, DOI 10.1021/bi00435a015; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN D, 1976, GABA NERVOUS SYSTEM, P357; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; RADIAN R, 1986, J BIOL CHEM, V261, P5437; RADIAN R, 1985, J BIOL CHEM, V260, P1859; TAKAGI T, 1991, ADV ELECTROPHORESIS, V4, P391; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	27	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2563	2568						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733954				2022-12-25	WOS:A1992HB53200070
J	MEHTA, RA; FAWCETT, TW; PORATH, D; MATTOO, AK				MEHTA, RA; FAWCETT, TW; PORATH, D; MATTOO, AK			OXIDATIVE STRESS CAUSES RAPID MEMBRANE TRANSLOCATION AND INVIVO DEGRADATION OF RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; LARGE SUBUNIT; CHLOROPLAST MEMBRANE; SPINACH-CHLOROPLASTS; PROTEOLYTIC ACTIVITY; DIFFERENTIAL CHANGES; THYLAKOID PROTEINS; ESCHERICHIA-COLI; LEAF SENESCENCE; PHOTOSYSTEM-II	We have studied the turnover of an abundant chloroplast protein, ribulose-1,5-bisphosphate carboxylase/oxygenase (Rbu-P2 carboxylase/oxygenase), in plants (Spirodela oligorrhiza and Triticum aestivum L.) and algae (Chlamydomonas reinhardtii and C. moewusii) induced to senesce under oxidative conditions. RbU-P2 carboxylase/oxygenase activity and stability in vivo were found to be highly susceptible to oxidative stress, resulting in intermolecular cross-linking of large subunits by disulfide bonds within the holoenzyme, rapid and specific translocation of the soluble enzyme complex to the chloroplast membranes, and finally protein degradation. The redox state of Cys-247 in Rbu-P2 carboxylase/oxygenase large subunit seems involved in the sensitivity of the holoenzyme to oxidative inactivation and cross-linking. However, this process did not drive membrane attachment or degradation of Rbu-P2 carboxylase/oxygenase in vivo. Translocation of oxidized Rbu-P2 carboxylase/oxygenase to chloroplast membranes may be a necessary step in its turnover, particularly during leaf senescence. Thus, processes that regulate the redox state of plant cells seem closely intertwined with cellular switches shifting the leaf from growth and maturation to senescence and death.	USDA ARS,BELTSVILLE AGR RES CTR,PLANT MOLEC BIOL LAB,BLDG 006,RM 200,10300 BALTIMORE AVE,BELTSVILLE,MD 20705; UNIV MARYLAND,CATONSVILLE,MD 21228	United States Department of Agriculture (USDA)			Mattoo, Autar/U-9751-2019; Mattoo, Autar/G-9863-2011	Mattoo, Autar/0000-0001-9226-7164; 				ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; AVNI A, 1989, EMBO J, V8, P1915, DOI 10.1002/j.1460-2075.1989.tb03594.x; BARTLETT SG, 1982, METHODS CHLOROPLAST, P985; BASZYNSKI T, 1982, Z PFLANZENPHYSIOL, V108, P385, DOI 10.1016/S0044-328X(82)80163-3; BENDAVID H, 1983, PLANT PHYSIOL, V73, P507, DOI 10.1104/pp.73.2.507; CALLAHAN FE, 1989, PLANT PHYSIOL, V91, P629, DOI 10.1104/pp.91.2.629; CAMP PJ, 1984, J EXP BOT, V35, P659, DOI 10.1093/jxb/35.5.659; CHAPMAN MS, 1987, NATURE, V329, P354, DOI 10.1038/329354a0; CRAFTSBRANDNER SJ, 1991, PLANTA, V183, P300, DOI 10.1007/BF00197802; DALLING MJ, 1986, PLANT PROTEOLYTIC EN, V2, P125; ELLIS RJ, 1985, MOL BIOL PHOTOSYNTHE, P339; FELLER U, 1979, Z PFLANZENPHYSIOL, V95, P413, DOI 10.1016/S0044-328X(79)80212-3; FERREIRA RB, 1989, PLANTA, V179, P448, DOI 10.1007/BF00397584; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HSU BD, 1988, PLANT PHYSIOL, V87, P116, DOI 10.1104/pp.87.1.116; HUDSON GS, 1990, J BIOL CHEM, V265, P808; Loneragan J.F., 1981, COPPER SOILS PLANTS; Mae T., 1987, Plant senescence: its biochemistry and physiology. Proceedings of the Tenth Annual Symposium in Plant Physiology, 8-10 January, 1987, University of California, Riverside, California, USA., P123; MARDER JB, 1986, METHOD ENZYMOL, V118, P384; MATTOO A, 1985, J PLANT PHYSL, V123, P193; MCRAE DG, 1983, PLANTA, V158, P185, DOI 10.1007/BF01075253; MIZIORKO HM, 1983, ANNU REV BIOCHEM, V52, P507, DOI 10.1146/annurev.bi.52.070183.002451; NEWMAN J, 1990, J BIOL CHEM, V265, P15154; NEWMAN SM, 1990, PHOTOSYNTH RES, V26, P69, DOI 10.1007/BF00047078; PAECH C, 1985, MOD METHOD PLANT, V1, P199; PENARRUBIA L, 1990, ARCH BIOCHEM BIOPHYS, V281, P319, DOI 10.1016/0003-9861(90)90450-D; PEOPLES MB, 1980, PLANTA, V149, P241, DOI 10.1007/BF00384560; PETERSON LW, 1975, PLANT PHYSIOL, V55, P1009, DOI 10.1104/pp.55.6.1009; POSNER HB, 1967, METHODS DEV BIOL, P301; RAGSTER L, 1979, PLANT PHYSIOL, V64, P857, DOI 10.1104/pp.64.5.857; RANTY B, 1991, EUR J BIOCHEM, V200, P353, DOI 10.1111/j.1432-1033.1991.tb16192.x; REISFELD A, 1982, EUR J BIOCHEM, V124, P125, DOI 10.1111/j.1432-1033.1982.tb05914.x; RINTAMAKI E, 1989, J EXP BOT, V40, P1305, DOI 10.1093/jxb/40.12.1305; ROBERTS DR, 1987, PLANT MOL BIOL, V9, P343, DOI 10.1007/BF00014909; SHIOI Y, 1978, PLANT CELL PHYSIOL, V19, P203; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STOREY R, 1977, PLANTA, V137, P37, DOI 10.1007/BF00394432; Thimann K, 1980, SENESCENCE PLANTS; WITTENBACH VA, 1978, PLANT PHYSIOL, V62, P604, DOI 10.1104/pp.62.4.604; YANG RCA, 1986, GENE, V50, P259, DOI 10.1016/0378-1119(86)90330-6	43	160	172	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2810	2816						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733975				2022-12-25	WOS:A1992HB53200104
J	STRACKE, ML; KRUTZSCH, HC; UNSWORTH, EJ; ARESTAD, A; CIOCE, V; SCHIFFMANN, E; LIOTTA, LA				STRACKE, ML; KRUTZSCH, HC; UNSWORTH, EJ; ARESTAD, A; CIOCE, V; SCHIFFMANN, E; LIOTTA, LA			IDENTIFICATION, PURIFICATION, AND PARTIAL SEQUENCE-ANALYSIS OF AUTOTAXIN, A NOVEL MOTILITY-STIMULATING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; RESOLUTION 2-DIMENSIONAL ELECTROPHORESIS; CANCER-PATIENT FIBROBLASTS; HUMAN-TUMOR CELLS; GROWTH-FACTOR; SCATTER FACTOR; HAPTOTACTIC MIGRATION; SIGNAL TRANSDUCTION; FACTOR RECEPTOR; CHEMOTAXIS	Autotaxin (ATX) is a potent human motility-stimulating protein that has been identified in the conditioned medium from A2058 melanoma cells. This protein has been purified to homogeneity utilizing a strategy involving five column steps. Homogeneity of ATX was verified by two-dimensional gel electrophoresis. The molecular size of ATX is 125 kDa, and it has an isoelectric point of 7.7 +/- 0.2. Purified ATX was digested with cyanogen bromide and trypsin, and the resulting ATX peptides were purified by reverse-phase high performance liquid chromatography. Eleven peptides were subjected to amino acid sequence analysis, and 114 residues were identified. The partial amino acid sequences and the amino acid composition obtained for ATX show that it does not exhibit any significant homology to known growth factors or previously described motility factors. At picomolar concentrations, ATX stimulates both random and directed migration of human A2058 melanoma cells. Pretreatment of the melanoma cells with pertussis toxin abolishes the response to purified ATX, indicating that ATX stimulates motility through a receptor acting via a pertussis toxin-sensitive G protein.			STRACKE, ML (corresponding author), NCI,PATHOL LAB,BLDG 10,RM 2A33,BETHESDA,MD 20892, USA.							ATNIP KD, 1987, BIOCHEM BIOPH RES CO, V146, P996, DOI 10.1016/0006-291X(87)90746-7; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; GREY AM, 1989, P NATL ACAD SCI USA, V86, P2438, DOI 10.1073/pnas.86.7.2438; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; KAHAN BW, 1987, CANCER RES, V47, P6324; KOHN EC, 1990, INT J CANCER, V46, P287, DOI 10.1002/ijc.2910460225; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIOTTA LA, 1988, CANCER SURV, V7, P631; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MCCARTHY JB, 1984, J CELL BIOL, V98, P1474, DOI 10.1083/jcb.98.4.1474; NABI IR, 1990, CANCER RES, V50, P409; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NEWELL PC, 1988, J CELL SCI, V89, P123; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OHNISHI T, 1990, J NEUROSURG, V73, P881, DOI 10.3171/jns.1990.73.6.0881; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROSEN EM, 1990, P SOC EXP BIOL MED, V195, P34; RUFF M, 1985, CLIN IMMUNOL IMMUNOP, V37, P387, DOI 10.1016/0090-1229(85)90108-4; SCHOR SL, 1988, J CELL SCI, V90, P391; SILLETTI S, 1991, CANCER RES, V51, P3507; SINGER SJ, 1986, ANNU REV CELL BIOL, V2, P337, DOI 10.1146/annurev.cb.02.110186.002005; STONE K, 1991, IN PRESS PROTEIN CHE, V3; STONE KL, 1989, PRACTICAL GUIDE PROT, P33; STRACKE ML, 1987, BIOCHEM BIOPH RES CO, V146, P339, DOI 10.1016/0006-291X(87)90730-3; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VARON S, 1967, P NATL ACAD SCI USA, V57, P1782, DOI 10.1073/pnas.57.6.1782; VERGHESE MW, 1985, BIOCHEM BIOPH RES CO, V127, P450, DOI 10.1016/S0006-291X(85)80181-9; WANG JM, 1990, BIOCHEM BIOPH RES CO, V169, P165, DOI 10.1016/0006-291X(90)91449-3; WATANABE H, 1991, J BIOL CHEM, V266, P13442; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	40	489	511	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2524	2529						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733949				2022-12-25	WOS:A1992HB53200064
J	SUGAI, M; HASHIMOTO, K; KIKUCHI, A; INOUE, S; OKUMURA, H; MATSUMOTO, K; GOTO, Y; OHGAI, H; MORIISHI, K; SYUTO, B; YOSHIKAWA, K; SUGINAKA, H; TAKAI, Y				SUGAI, M; HASHIMOTO, K; KIKUCHI, A; INOUE, S; OKUMURA, H; MATSUMOTO, K; GOTO, Y; OHGAI, H; MORIISHI, K; SYUTO, B; YOSHIKAWA, K; SUGINAKA, H; TAKAI, Y			EPIDERMAL-CELL DIFFERENTIATION INHIBITOR ADP-RIBOSYLATES SMALL GTP-BINDING PROTEINS AND INDUCES HYPERPLASIA OF EPIDERMIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GENE-PRODUCT; BOVINE BRAIN MEMBRANES; TERMINAL DIFFERENTIATION; MOLECULAR-WEIGHT; STAPHYLOCOCCUS-AUREUS; BOTULINUM; PURIFICATION; GROWTH; TOXIN; RIBOSYLTRANSFERASE	Epidermal cell differentiation inhibitor (EDIN) is a recently discovered protein which inhibits terminal differentiation of cultured keratinocytes (Sugai, M., Enomoto, T., Hashimoto, K., Matsumoto, K., Matsuo, Y., Ohgai, H., Hong, Y.-M., Inoue, S., Yoshikawa, K., and Suginaka, H. (1990) Biochem. Biophys. Res. Commun. 173, 92-98). The amino acid sequence deduced from the EDIN gene has revealed that EDIN shares high amino acid sequence homology with the exoenzyme C3 of Clostridium botulinum (Inoue, S., Sugai, M., Murooka, Y., Paik, S.-Y., Hong, Y.-M., Ohgai, H., and Suginaka, H. (1991) Biochem. Biophys. Res. Commun. 174, 459-464), which has been shown to ADP-ribosylate the rho/rac proteins (members of the small GTP-binding protein family). We show here that EDIN ADP-ribosylates rhoB p21 in time- and dose-dependent manners in a cell-free system. Kinetic studies of the ADP-ribosylation and peptide mapping of the reaction products of rhoB p21 by EDIN and C3 suggest that the mode of action of the ADP-ribosylation by EDIN is quite similar to that by C3 and that the ADP-ribosylation site of rhoB p21 by EDIN is presumably the same as that by C3. Proteins in epidermal membranes and keratinocyte homogenate with M(r) values of about 22,000 are ADP-ribosylated by EDIN or C3. Treatment of cultured human keratinocytes by EDIN or C3 results in an inhibition of terminal differentiation and a stimulation of growth of the cells. Moreover, EDIN and C3 injected into adult mouse skin induce hyperplasia of epidermis. These results suggest that EDIN and C3 affect growth and differentiation of keratinocytes by ADP-ribosylation of protein(s) with a M(r) of about 22,000, which may be the rho/rac proteins or related proteins.	HIROSHIMA UNIV,SCH DENT,DEPT MICROBIOL,HIROSHIMA 734,JAPAN; OSAKA UNIV,SCH MED,DEPT DERMATOL,OSAKA 553,JAPAN; KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; EARTH CHEM CO LTD,BIOMED RES INST,AKO 67802,JAPAN; HOKKAIDO UNIV,FAC VET MED,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	Hiroshima University; Osaka University; Kobe University; Hokkaido University			Moriishi, Kohji/I-4173-2019	Moriishi, Kohji/0000-0002-9542-5188				ABRSHAM H, 1989, MOL CELL BIOL, V9, P2058; AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COBURN J, 1989, J BIOL CHEM, V264, P9004; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GREEN H, 1978, CELL, V15, P801, DOI 10.1016/0092-8674(78)90265-9; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1981, BIOCHEM BIOPH RES CO, V102, P739, DOI 10.1016/S0006-291X(81)80194-5; INOUE S, 1991, BIOCHEM BIOPH RES CO, V174, P459, DOI 10.1016/0006-291X(91)91438-I; JAKEN S, 1988, CARCINOGENESIS, V9, P1033, DOI 10.1093/carcin/9.6.1033; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KULESZMARTIN MF, 1980, CARCINOGENESIS, V1, P995, DOI 10.1093/carcin/1.12.995; KUROKI T, 1981, P NATL ACAD SCI-BIOL, V78, P6958, DOI 10.1073/pnas.78.11.6958; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADUALE P, 1987, P NATL ACAD SCI USA, V84, P779; MATSUMOTO K, 1990, BIOCHEM BIOPH RES CO, V166, P916, DOI 10.1016/0006-291X(90)90898-W; MORIISHI K, 1990, J BIOL CHEM, V265, P16614; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OHMORI T, 1989, J BIOL CHEM, V264, P1877; OKUMURA H, 1991, EXP CELL RES, V192, P647, DOI 10.1016/0014-4827(91)90089-D; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STANLEY JR, 1983, J CELL BIOL, V96, P1809, DOI 10.1083/jcb.96.6.1809; SUGAI M, 1987, CELL STRUCT FUNCT, V12, P395, DOI 10.1247/csf.12.395; SUGAI M, 1990, BIOCHEM BIOPH RES CO, V173, P92, DOI 10.1016/S0006-291X(05)81026-5; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; WANG P, 1989, J BIOCHEM-TOKYO, V105, P461, DOI 10.1093/oxfordjournals.jbchem.a122687; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0; YUSPA SH, 1980, CANCER RES, V40, P4694; YUSPA SH, 1981, NATURE, V293, P72, DOI 10.1038/293072a0	38	103	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2600	2604						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733958				2022-12-25	WOS:A1992HB53200076
J	THOMPSON, SA				THOMPSON, SA			THE DISULFIDE STRUCTURE OF BOVINE PITUITARY BASIC FIBROBLAST GROWTH-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; SEQUENCE; BONDS; GENE; FGF; HST	Basic fibroblast growth factor has 4 cysteine residues in its amino acid sequence, two of which are perfectly conserved within the fibroblast growth factor family of proteins suggesting a disulfide bond at this position. Furthermore, thiol titration of bovine pituitary basic fibroblast growth factor (bFGF) indicates the presence of two free thiols, which is consistent with an intramolecular disulfide. Direct analysis of natural and recombinant fibroblast growth factor proteins have not confirmed the existence of such a disulfide. Instead, the two nonconserved cysteines of bFGF purified from bovine pituitaries are S-thiolated with glutathione. Inclusion of 75 mM N-ethylmaleimide during the homogenization of the pituitaries effectively blocks the S-thiolation, demonstrating that this modification is an artifact of the purification procedure. Analysis of the N-ethylmaleimide purified bovine pituitary bFGF suggests that the natural protein is in the correct redox state when all 4 cysteines are in the reduced form.	CALIF BIOTECHNOL INC, Mountain View, CA 94043 USA						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL039348, R44HL039348] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 39348-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHARYA AS, 1986, J PROTEIN CHEM, V5, P299, DOI 10.1007/BF01025959; BOHLEN P, 1984, P NATL ACAD SCI-BIOL, V81, P5364, DOI 10.1073/pnas.81.17.5364; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BROWNING JL, 1986, ANAL BIOCHEM, V155, P123, DOI 10.1016/0003-2697(86)90236-8; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; EAGLE H, 1960, J BIOL CHEM, V235, P1719; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOX GM, 1988, J BIOL CHEM, V263, P18452; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GOSPODAROWICZ D, 1985, J CELL PHYSIOL, V122, P323, DOI 10.1002/jcp.1041220223; GOSPODAROWICZ D, 1984, P NATL ACAD SCI-BIOL, V81, P6963, DOI 10.1073/pnas.81.22.6963; HARRAP KR, 1973, BIOCHIM BIOPHYS ACTA, V310, P104, DOI 10.1016/0005-2795(73)90012-3; HUISMAN THJ, 1962, J LAB CLIN MED, V60, P302; KING TP, 1961, J BIOL CHEM, V236, pPC5; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; Linemeyer DL, 1990, GROWTH FACTORS, V3, P287, DOI 10.3109/08977199009003671; MARICS I, 1989, ONCOGENE, V4, P335; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SIES H, 1987, ADV ENZYME REGUL, V26, P175, DOI 10.1016/0065-2571(87)90013-6; THOMPSON SA, 1991, METHOD ENZYMOL, V198, P96; UENO N, 1986, BIOCHEM BIOPH RES CO, V138, P580, DOI 10.1016/S0006-291X(86)80536-8; WETZEL R, 1987, TRENDS BIOCHEM SCI, V12, P478, DOI 10.1016/0968-0004(87)90234-9; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	29	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2269	2273						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733934				2022-12-25	WOS:A1992HB53200026
J	FERNANDEZCHECA, JC; TAKIKAWA, H; HORIE, T; OOKHTENS, M; KAPLOWITZ, N				FERNANDEZCHECA, JC; TAKIKAWA, H; HORIE, T; OOKHTENS, M; KAPLOWITZ, N			CANALICULAR TRANSPORT OF REDUCED GLUTATHIONE IN NORMAL AND MUTANT EISAI HYPERBILIRUBINEMIC RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC-ANIONS; MEMBRANE-VESICLES; CONJUGATED HYPERBILIRUBINEMIA; HEPATOBILIARY TRANSPORT; HEPATIC GLUTATHIONE; S-TRANSFERASES; EFFLUX; LIVER; BILE; HEPATOCYTES	We have characterized the transport of GSH and the mechanism for impaired GSH transport in mutant Eisai hyperbilirubinemic rats (EHBR) using isolated canalicular membrane-enriched vesicles (cLPM). In control animals, the transport of GSH is an electrogenic process and is trans-stimulated by preloading the vesicles with GSH and is not enhanced in the presence of ATP. GSH transport in cLPM is saturable with a single component having a K(m) of approximately 16 mM and a V(max) of 6.7 nmol/mg/15 s. EHBR is a Sprague-Dawley rat with hyperbilirubinemia due to impaired bile secretion of organic anions by the ATP-dependent organic anion/GSH-conjugate transporter. In cLPM from EHBR we confirmed the defective stimulation by ATP of the transport of LTC4 and GSSG. In the mutant cLPM, the characteristics and kinetics of GSH transport were the same as in the controls. 2,4-(dinitrophenyl)-glutathione (DNP-GSH), which is a substrate for the ATP-dependent canalicular organic anion carrier, in the absence of ATP, cis-inhibited the transport of GSH into cLPM vesicles; however, when the vesicles were preloaded with DNP-GSH, there was a dose-dependent trans-stimulation of GSH transport. In contrast, in the presence of ATP, DNP-GSH enhanced GSH transport in cLPM vesicles; at 0.25 mM DNP-GSH, a concentration which did not cis-inhibit GSH, addition of ATP resulted in accelerated GSH transport; at 1.0 mM DNP-GSH, cis-inhibition was completely reversed by the addition of ATP despite a negligible fall in the medium DNP-GSH. Interestingly, sulfobromophthalein-glutathione (BSP-GSH) neither cis-inhibited nor trans-stimulated GSH transport in cLPM. This contrasts with bLPM where BSP-GSH interacts with the GSH carrier. Therefore, GSH is transported into bile by a multispecific low affinity electrogenic carrier which is distinct from the multispecific high affinity ATP-driven organic anion transporter. Although both carriers have overlapping specificities, BSP-GSH and GSH are uniquely specific for only one of the carriers. The near absence of GSH in the bile of mutant rats can be best explained as a secondary defect due to cis-inhibition from retained substrates for the defective carrier and/or loss of trans-stimulation by these same substrates which normally are concentratively transported into the bile. Other possibilities such as change in GSH carrier activity upon isolation or loss of a negative protein regulator during membrane isolation, although theoretical alternatives are less easily reconciled with the defect in the ATP-driven organic anion transporter.	TEIKYO UNIV,SCH MED,DEPT MED,TOKYO 173,JAPAN; EISAI LAB,IBARAKI 30026,JAPAN	Teikyo University; Eisai Co Ltd	FERNANDEZCHECA, JC (corresponding author), UNIV SO CALIF,SCH MED,DIV GASTROINTESTINAL & LIVER DIS,MUDD BLDG,RM 401,LOS ANGELES,CA 90033, USA.		Fernández-Checa, José Carlos/L-8342-2014	Fernández-Checa, José Carlos/0000-0003-3422-2990	NIDDK NIH HHS [DK 30312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030312, R37DK030312] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AW TY, 1986, AM J PHYSIOL, V250, pG236, DOI 10.1152/ajpgi.1986.250.2.G236; AW TY, 1987, BIOCHEM BIOPH RES CO, V143, P377, DOI 10.1016/0006-291X(87)90676-0; AW TY, 1984, J BIOL CHEM, V259, P9355; AWASTHI YC, 1981, BLOOD, V58, P733; BALLATORI N, 1989, AM J PHYSIOL, V256, pG482, DOI 10.1152/ajpgi.1989.256.3.G482; BALLATORI N, 1989, AM J PHYSIOL, V256, pG22, DOI 10.1152/ajpgi.1989.256.1.G22; BALLATORI N, 1985, AM J PHYSIOL, V248, pG238, DOI 10.1152/ajpgi.1985.248.2.G238; BALLATORI N, 1986, J BIOL CHEM, V261, P7860; BOYLAND E, 1969, BIOCHEM J, V115, P985, DOI 10.1042/bj1150985; BUTLER J, 1976, ANAL BIOCHEM, V75, P674, DOI 10.1016/0003-2697(76)90129-9; EBERLE D, 1981, J BIOL CHEM, V256, P2115; ELFERINK RPJ, 1989, J CLIN INVEST, V84, P476, DOI 10.1172/JCI114189; ELFERINK RPJO, 1991, BIOCHEM J, V274, P281, DOI 10.1042/bj2740281; ELFERINK RPJO, 1990, AM J PHYSIOL, V258, pG699, DOI 10.1152/ajpgi.1990.258.5.G699; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1990, AM J PHYSIOL, V258, pG967, DOI 10.1152/ajpgi.1990.258.6.G967; FERNANDEZCHECA JC, 1989, J CLIN INVEST, V83, P1247, DOI 10.1172/JCI114008; FERNANDEZCHECA JC, 1988, AM J PHYSIOL, V255, pG403, DOI 10.1152/ajpgi.1988.255.4.G403; FERNANDEZCHECA JC, 1991, CLIN RES, V39, pA302; Fiske CH, 1925, J BIOL CHEM, V66, P375; HABIG WH, 1974, P NATL ACAD SCI USA, V71, P3879, DOI 10.1073/pnas.71.10.3879; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hatefi Y, 1978, Methods Enzymol, V53, P21; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; INOUE M, 1984, J BIOL CHEM, V259, P4998; INOUE M, 1983, EUR J BIOCHEM, V134, P467, DOI 10.1111/j.1432-1033.1983.tb07590.x; INOUE M, 1984, EUR J BIOCHEM, V138, P491, DOI 10.1111/j.1432-1033.1984.tb07943.x; ISHIKAWA T, 1990, TRENDS BIOCHEM SCI, V15, P219, DOI 10.1016/0968-0004(90)90032-7; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; JACOBY WB, 1976, GLUTATHIONE METABOLI, P189; JANSEN PLM, 1987, HEPATOLOGY, V7, P71, DOI 10.1002/hep.1840070116; JANSEN PLM, 1987, GASTROENTEROLOGY, V93, P1094, DOI 10.1016/0016-5085(87)90574-9; KAPLOWITZ N, 1983, J PHARMACOL EXP THER, V224, P141; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; LAUTERBURG BH, 1984, J CLIN INVEST, V73, P124, DOI 10.1172/JCI111182; LU SC, 1990, J BIOL CHEM, V265, P16088; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MIKAMI T, 1986, CONGENIT ANOM, V26, P250; OOKHTENS M, 1988, J CLIN INVEST, V82, P608, DOI 10.1172/JCI113639; OOKHTENS M, 1991, AM J PHYSIOL, V261, pG648, DOI 10.1152/ajpgi.1991.261.4.G648; OOKHTENS M, 1985, J CLIN INVEST, V75, P258, DOI 10.1172/JCI111682; SUGIMOTO M, 1985, BIOCHEM PHARMACOL, V34, P3643; SUGIYAMA Y, 1984, PHARMACOLOGY, V28, P61, DOI 10.1159/000137945; TAKIKAWA H, 1991, HEPATOLOGY, V14, P352, DOI 10.1002/hep.1840140223; WARREN L, 1959, J BIOL CHEM, V234, P1971	49	185	187	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1667	1673						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730711				2022-12-25	WOS:A1992HA48500043
J	GRABER, SG; FIGLER, RA; GARRISON, JC				GRABER, SG; FIGLER, RA; GARRISON, JC			EXPRESSION AND PURIFICATION OF FUNCTIONAL G-PROTEIN ALPHA-SUBUNITS USING A BACULOVIRUS EXPRESSION SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; BETA-GAMMA-SUBUNITS; ISLET-ACTIVATING PROTEIN; BOVINE CEREBRAL-CORTEX; MUSCARINIC K+-CHANNEL; REGULATORY PROTEINS; ADENYLATE-CYCLASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; PERTUSSIS TOXIN	The a subunits of the heterotrimeric guanine nucleotide-binding proteins G(i1), G(i2), G(i3), G0, and G(s) have been overexpressed in Sf9 cells using a baculovirus expression system. The G(i1-alpha), G(i2-alpha), G(i3-alpha), and G0-alpha have been purified to homogeneity from infected Spodoptera frugiperda (Sf9) cells and characterized. Yields of up to 1.8 mg of purified recombinant G(alpha) have been obtained from 300-ml cultures of infected cells. The recombinant alpha-subunits are myristoylated and are ADP-ribosylated by pertussis toxin only in the presence of beta-gamma-subunits. They bind guanosine 5'-3-O-(thio)triphosphate (GTP-gamma-S) with low nM dissociation constants and stoichiometries of 0.8 mol/mol or greater. The rG(i1-alpha), rG(i2-alpha), and rG(i3-alpha) are capable of interacting with angiotensin II receptors based on their ability to restore high affinity angiotensin II binding in rat liver membranes shifted to a low affinity state with GTP-gamma-S.	UNIV VIRGINIA,SCH MED,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,CANC RES CTR,SCH MED,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia	GRABER, SG (corresponding author), UNIV VIRGINIA,MED CTR,SCH MED,DEPT PHARMACOL,BOX 448,CHARLOTTESVILLE,VA 22908, USA.				NIDDK NIH HHS [DK-19952] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1985, J BIOL CHEM, V260, P2653; BAUER PH, 1991, MOL PHARMACOL, V39, P579; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BRAY P, 1986, P NATL ACAD SCI USA, V83, P8893, DOI 10.1073/pnas.83.23.8893; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CARTY DJ, 1990, J BIOL CHEM, V265, P6268; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; CRANE JK, 1982, J BIOL CHEM, V257, P4959; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FRASER MJ, 1989, IN VITRO CELL DEV B, V25, P225; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GAO B, 1987, J BIOL CHEM, V262, P17254; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HUFF RM, 1986, J BIOL CHEM, V261, P1105; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KATADA T, 1986, J BIOL CHEM, V261, P8182; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MAIORELLA B, 1988, BIO-TECHNOL, V6, P1406, DOI 10.1038/nbt1288-1406; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OLSON EN, 1985, J BIOL CHEM, V260, P3784; PANG IH, 1990, J BIOL CHEM, V265, P18707; PARKER EM, 1991, J BIOL CHEM, V266, P519; POBINER BF, 1991, MOL PHARMACOL, V40, P156; POBINER BF, 1985, J BIOL CHEM, V260, P6200; POHL SL, 1976, METHODS RECEPTOR RES, P159; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; SENOGLES SE, 1990, J BIOL CHEM, V265, P4507; SIMON MI, 1991, SCIENCE, V252, P804; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; SMITH GE, 1983, J VIROL, V46, P584, DOI 10.1128/JVI.46.2.584-593.1983; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAYLOR CW, 1990, BIOCHEM J, V272, P1; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	69	98	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1271	1278						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730649				2022-12-25	WOS:A1992GY96000092
J	MEIERDIETER, U; BARR, K; STARMAN, R; HATCH, L; RICK, PD				MEIERDIETER, U; BARR, K; STARMAN, R; HATCH, L; RICK, PD			NUCLEOTIDE-SEQUENCE OF THE ESCHERICHIA-COLI RFE-GENE INVOLVED IN THE SYNTHESIS OF ENTEROBACTERIAL COMMON ANTIGEN - MOLECULAR-CLONING OF THE RFE-RFF-GENE CLUSTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE N-ACETYLGLUCOSAMINE-1-PHOSPHATE TRANSFERASE; SALMONELLA-TYPHIMURIUM; POLYSACCHARIDE CHAIN; INVITRO SYNTHESIS; BIOSYNTHESIS; LIPOPOLYSACCHARIDE; ACID; MUTANTS; PROTEIN; YEAST	The genetic determinants of enterobacterial common antigen (ECA) include the rfe and rff genes located between ilv and cya near min 85 on the Escherichia coli chromosome. The rfe-rff gene cluster of E. coli K-12 was cloned in the cosmid pHC79. The cosmid clone complemented mutants defective in the synthesis of ECA due to lesions in the rfe, rffE, rffD, rffA, rffC, rffT, and rffM genes. Restriction endonuclease mapping combined with complementation studies of the original cosmid clone and six subclones revealed the order of genes in this region to be rfe-rffD/rffE-rffA/rffC-rffT-rffM. The rfe gene was localized to a 2.54-kilobase ClaI fragment of DNA, and the complete nucleotide sequence of this fragment was determined. The nucleotide sequencing data revealed two open reading frames, ORF-1 and ORF-2, located on the same strand of DNA. The putative initiation codon of ORF-1 was found to be 570 nucleotides downstream from the termination codon of rho. ORF-1 and ORF-2 specify putative proteins of 257 and 348 amino acids with calculated M, values of 29,010 and 39,771, respectively. ORF-1 was identified as the rfe gene since ORF-1 alone was able to complement defects in the synthesis of ECA and 08-side chain synthesis in rfe mutants of E. coli. Data are also presented which suggest the possibility that the rfe gene is the structural gene for the tunicamycin sensitive UDP-GlcNAc:undecaprenylphosphate GlcNAc-1-phosphate transferase that catalyzes the synthesis of GlcNAc-pyrophosphorylundecaprenol (lipid I, the first lipid-linked intermediate involved in ECA synthesis.	UNIFORMED SERV UNIV HLTH SCI, DEPT MICROBIOL, BETHESDA, MD 20814 USA; AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, DEPT BIOCHEM, CANBERRA, ACT 2601, AUSTRALIA	Uniformed Services University of the Health Sciences - USA; Australian National University; John Curtin School of Medical Research					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021309] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21309] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRIGHT CF, 1989, P NATL ACAD SCI USA, V86, P7366, DOI 10.1073/pnas.86.19.7366; BARR K, 1989, J BACTERIOL, V171, P1326, DOI 10.1128/jb.171.3.1326-1332.1989; BARR K, 1987, J BIOL CHEM, V262, P7142; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COVARRUBIAS L, 1981, GENE, V13, P25, DOI 10.1016/0378-1119(81)90040-8; COX GB, 1987, BIOCHIM BIOPHYS ACTA, V890, P195, DOI 10.1016/0005-2728(87)90020-X; HARTOG KO, 1987, NUCLEIC ACIDS RES, V15, P3627, DOI 10.1093/nar/15.8.3627; JANN K, 1971, J GEN MICROBIOL, V67, P289, DOI 10.1099/00221287-67-3-289; KISS P, 1978, EUR J BIOCHEM, V88, P211, DOI 10.1111/j.1432-1033.1978.tb12440.x; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KUHN HM, 1988, FEMS MICROBIOL LETT, V54, P195, DOI 10.1111/j.1574-6968.1988.tb02743.x; KUHN HM, 1983, INFECT IMMUN, V40, P696, DOI 10.1128/IAI.40.2.696-700.1983; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEW HC, 1986, J BACTERIOL, V168, P715, DOI 10.1128/jb.168.2.715-721.1986; LEW HC, 1978, J BACTERIOL, V136, P227, DOI 10.1128/JB.136.1.227-233.1978; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDERITZ O, 1971, MICROBIAL TOXINS, V4, P145; LUGOWSKI C, 1983, CARBOHYD RES, V118, P173, DOI 10.1016/0008-6215(83)88045-8; MAKELA PH, 1976, BACTERIOL REV, V40, P591; MAKELA PH, 1970, J GEN MICROBIOL, V60, P91; Maniatis T., 1982, MOL CLONING; MANNEL D, 1978, EUR J BIOCHEM, V86, P361, DOI 10.1111/j.1432-1033.1978.tb12318.x; Mayer H, 1979, Curr Top Microbiol Immunol, V85, P99; MEIER U, 1985, J BACTERIOL, V163, P756, DOI 10.1128/JB.163.2.756-762.1985; MEIERDIETER U, 1989, FEMS MICROBIOL LETT, V59, P215, DOI 10.1016/0378-1097(89)90489-8; MEIERDIETER U, 1990, J BIOL CHEM, V265, P13490; ORSKOV I, 1977, BACTERIOL REV, V41, P667, DOI 10.1128/MMBR.41.3.667-710.1977; PETERS H, 1985, INFECT IMMUN, V50, P459, DOI 10.1128/IAI.50.2.459-466.1985; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; PREHM P, 1976, EUR J BIOCHEM, V67, P53, DOI 10.1111/j.1432-1033.1976.tb10631.x; RESKE K, 1972, EUR J BIOCHEM, V31, P320, DOI 10.1111/j.1432-1033.1972.tb02536.x; RICK PD, 1985, J BACTERIOL, V162, P494, DOI 10.1128/JB.162.2.494-503.1985; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT G, 1976, J BACTERIOL, V127, P755, DOI 10.1128/JB.127.2.755-762.1976; SCOCCA JR, 1990, J BIOL CHEM, V265, P20621; ZHU XY, 1990, J BIOL CHEM, V265, P14250	38	143	147	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					746	753						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730666				2022-12-25	WOS:A1992GY96000014
J	SHI, YB; YAOITA, Y; BROWN, DD				SHI, YB; YAOITA, Y; BROWN, DD			GENOMIC ORGANIZATION AND ALTERNATIVE PROMOTER USAGE OF THE 2 THYROID-HORMONE RECEPTOR BETA GENES IN XENOPUS-LAEVIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC-ACID RECEPTOR; NUCLEAR RECEPTORS; EXPRESSION; FAMILY; TRANSCRIPTION; SEQUENCE; MEDIATE; PROTEIN; PRIMER; ERBA	Each of the two Xenopus laevis thyroid hormone receptor beta-genes is at least 70 kilobases in length with similar intron-exon organization. There are up to eight alternatively spliced exons in the 5'-untranslated region. Excluding the extreme amino terminus, each receptor is encoded by six exons spanning about 6 kilobases of the genome, in which each of the two zinc fingers that comprise the DNA-binding domain is encoded by a separate exon and the hormone-binding domain is split into three exons. The last exon of the coding region also contains at least 600 base pairs of the 3'-untranslated region, which is about 8 kilobases. Each of the receptor genes has two promoters and just one of them is up-regulated in tadpoles by the administration of thyroid hormone.	TOKYO METROPOLITAN INST NEUROSCI,DEPT MOLEC NEUROBIOL,FUCHU,TOKYO 183,JAPAN	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	SHI, YB (corresponding author), CARNEGIE INST WASHINGTON,DEPT EMBRYOL,BALTIMORE,MD 21210, USA.			Shi, Yun-Bo/0000-0002-6330-0639				Ausubel FM., 1988, CURRENT PROTOCOLS MO; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DODD MHI, 1976, PHYSIOLOGY AMPHIBIA, V3, P467; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Galton VA, 1983, MOL BASIS THYROID HO, P445; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HUCKABY CS, 1987, P NATL ACAD SCI USA, V84, P8380, DOI 10.1073/pnas.84.23.8380; JELTSCH JM, 1990, J BIOL CHEM, V265, P3967; KANAMORI A, 1992, J BIOL CHEM, V267, P739; KROTOSKI DM, 1985, J EXP ZOOL, V233, P443, DOI 10.1002/jez.1402330313; LAUDET V, 1991, NUCLEIC ACIDS RES, V19, P1105, DOI 10.1093/nar/19.5.1105; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LEHMANN JM, 1991, NUCLEIC ACIDS RES, V19, P573, DOI 10.1093/nar/19.3.573; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; Maniatis T., 1982, MOL CLONING; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; Nunez EA, 1989, CURR OPIN CELL BIOL, V1, P177, DOI 10.1016/0955-0674(89)90083-5; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PONGLIKITMONGKOL M, 1988, EMBO J, V7, P3385, DOI 10.1002/j.1460-2075.1988.tb03211.x; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SCHWARZ K, 1990, NUCLEIC ACIDS RES, V18, P1079, DOI 10.1093/nar/18.4.1079; SHI YB, 1990, GENE DEV, V4, P1107, DOI 10.1101/gad.4.7.1107; SHYAMALA V, 1989, GENE, V84, P1, DOI 10.1016/0378-1119(89)90132-7; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; White B.A., 1981, P363; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; ZAHRAOUI A, 1987, EUR J BIOCHEM, V166, P63, DOI 10.1111/j.1432-1033.1987.tb13484.x; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	39	84	85	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					733	738						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730664				2022-12-25	WOS:A1992GY96000012
J	WANG, HM; OGOROCHI, T; ARAI, K; MIYAJIMA, A				WANG, HM; OGOROCHI, T; ARAI, K; MIYAJIMA, A			STRUCTURE OF MOUSE INTERLEUKIN-3 (IL-3) BINDING-PROTEIN (AIC2A) - AMINO-ACID-RESIDUES CRITICAL FOR IL-3 BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; RECEPTOR GENE FAMILY; MYELOID CELL-LINES; TYROSINE PHOSPHORYLATION; CLONING; IDENTIFICATION; SUPERFAMILY; EXPRESSION; MEMBER	Despite the high degree of sequence homology between two mouse proteins AIC2A and AIC2B (91% at the amino acid level), only the AIC2A protein binds interleukin 3 (IL-3). Soluble AIC2A protein bound IL-3 with affinity similar to the membrane-bound AIC2A protein, indicating that binding of IL-3 to AIC2A was mediated by the external domain alone. The extracellular domain of the AIC2A protein has two repeats of the common motif shared by members of the cytokine receptor family. Neither one of these repeats alone bound IL-3. Hybrids of AIC2A and AIC2B revealed that the first domain of the cytokine receptor motif could be replaced with the AIC2B sequence without an affinity change, suggesting the importance of the second domain. By changing individual amino acid residues of AIC2A in the second domain which differ from those of AIC2B, we identified several amino acid residues critical for IL-3 binding. All these residues are located at the putative hinge region within the second domain.	DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT MOLEC BIOL,901 CALIF AVE,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.								ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; DEVOS R, 1991, EMBO J, V10, P2133, DOI 10.1002/j.1460-2075.1991.tb07747.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NICOLA NA, 1986, J CELL PHYSIOL, V128, P180, DOI 10.1002/jcp.1041280207; OGOROCHI T, 1992, IN PRESS BLOOD; PALASZYNSKI EW, 1984, J IMMUNOL, V132, P1872; PARK LS, 1986, J BIOL CHEM, V261, P205; SCHRADER JW, 1986, ANNU REV IMMUNOL, V4, P205, DOI 10.1146/annurev.iy.04.040186.001225; SCHREURS J, 1991, IN PRESS INT IMMUNOL; Schreurs J, 1990, GROWTH FACTORS, V2, P221, DOI 10.3109/08977199009071508; SHANAFELT AB, 1991, IN PRESS EMBO J; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; YONEHARA S, 1990, INT IMMUNOL, V2, P143, DOI 10.1093/intimm/2.2.143	30	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					979	983						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730686				2022-12-25	WOS:A1992GY96000049
J	BERG, MM; STERNBERG, DW; PARADA, LF; CHAO, MV				BERG, MM; STERNBERG, DW; PARADA, LF; CHAO, MV			K-252A INHIBITS NERVE GROWTH FACTOR-INDUCED TRK PROTOONCOGENE TYROSINE PHOSPHORYLATION AND KINASE-ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PC12 CELLS; PROTEINS; TRANSCRIPTION; EXPRESSION; INCREASE	The rat pheochromocytoma PC12 cell line differentiates into a sympathetic neuronal phenotype upon treatment with either nerve growth factor (NGF) or basic fibroblast growth factor. The alkaloid-like compound K-252a has been demonstrated to be a specific inhibitor of NGF-induced biological responses in PC12 cells (Koizumi, S., Contreras, M. L., Matsuda, Y., Hama, T., Lazarovici, P., and Guroff, G. (1988) J. Neurosci. Res. 8, 715-721). NGF interacts with the protein product of the proto-oncogene trk and rapidly stimulates the tyrosine phosphorylation of both p140prototrk and a number of cellular substrates. Here we show that these phosphorylation events are directly inhibited in PC12 cells by K252a in a dose-dependent manner, indicating that the site of action of this inhibitor is at the NGF receptor level. K-252a inhibits p140prototrk activity in vitro, demonstrating that K252a has a direct effect on the p140prtotrk tyrosine kinase. Though many of the biochemical responses to NGF in PC12 cells are mimicked by basic fibroblast growth factor and epidermal growth factor, K-252a has no effect on the action of these growth factors in PC12 cells, demonstrating that the initial biological events initiated by NGF are distinctive during neuronal differentiation.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021; NCI,FREDERICK CANC RES & DEV CTR,MOLEC EMBRYOL SECT,ADV BIOSCI LAB,BASIC RES PROGRAM,FREDERICK,MD 21702	Cornell University; Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	BERG, MM (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021, USA.		Parada, luis F/B-9400-2014	Chao, Moses/0000-0002-6969-3744	NCI NIH HHS [N01-CO-741101, CA44356-05] Funding Source: Medline; NINDS NIH HHS [NS21072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021072, R56NS021072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; COULIER F, 1989, MOL CELL BIOL, V9, P15, DOI 10.1128/MCB.9.1.15; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANKS SK, 1988, SCIENCE, V241, P58; HASHIMOTO S, 1988, J CELL BIOL, V107, P1531, DOI 10.1083/jcb.107.4.1531; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; LAZAROVICI P, 1989, J NEUROSCI RES, V23, P1, DOI 10.1002/jnr.490230102; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MAHER PA, 1989, J NEUROSCI RES, V24, P29, DOI 10.1002/jnr.490240106; MAHER PA, 1988, P NATL ACAD SCI USA, V85, P6788, DOI 10.1073/pnas.85.18.6788; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MIYASAKA T, 1990, J BIOL CHEM, V265, P4730; MIYASAKA T, 1991, P NATL ACAD SCI USA, V88, P2653, DOI 10.1073/pnas.88.7.2653; NIKODIJEVIC B, 1990, J NEUROSCI RES, V26, P288, DOI 10.1002/jnr.490260304; RYDEL RE, 1987, J NEUROSCI, V7, P3637; SMITH DS, 1989, J NEUROCHEM, V53, P800, DOI 10.1111/j.1471-4159.1989.tb11776.x; TISCHLER AS, 1990, J NEUROCHEM, V55, P1159, DOI 10.1111/j.1471-4159.1990.tb03120.x; TOGARI A, 1985, J NEUROSCI, V5, P307; TSAO H, 1990, J BIOL CHEM, V265, P15471	27	340	349	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					13	16						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730579				2022-12-25	WOS:A1992GY43900004
J	SCHEUERMANN, RH				SCHEUERMANN, RH			THE TETRAMERIC STRUCTURE OF NF-MU-NR PROVIDES A MECHANISM FOR COOPERATIVE BINDING TO THE IMMUNOGLOBULIN HEAVY-CHAIN MU ENHANCER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL LOOP ANCHORAGE; CELL-TYPE SPECIFICITY; HISTONE H2B GENE; NUCLEAR FACTOR-I; SEQUENCE ELEMENTS; TRANSCRIPTION FACTOR; CONSERVED SEQUENCE; ESCHERICHIA-COLI; GEL-ELECTROPHORESIS; DNA-POLYMERASE	We have analyzed the structure and DNA-binding characteristics of the IgH enhancer-binding regulatory protein NF-mu-NR. We estimate that there are at least 5000 molecules of NF-mu-NR protein/nucleus of non-B cells, based on the yield of active protein following purification. Purified NF-mu-NR exists as a tetramer of 40-kDa subunits, even in the absence of its DNA-binding substrate. The protein complex binds to four binding sites flanking the immunoglobulin heavy chain mu-enhancer core. Separately, individual sites bind to the tetrameric complex with affinities varying over a 100-fold range. However, when a low affinity site and a high affinity site are present on the same DNA molecule, both are occupied at the same NF-mu-NR concentration; thus, there is a strong cooperative interaction between binding sites. The tetrameric structure provides a mechanism for binding cooperativity in which initial binding is mediated through a high affinity site on the DNA molecule followed by the engagement of the low affinity site juxtaposed to adjacent protein subunits. The presence of multiple binding sites flanking the mu-enhancer core may reflect the influence of NF-mu-NR binding on enhancer three-dimensional structure, transcription factor binding, and/or nuclear matrix interactions for cell type-specific enhancer function.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND					Scheuermann, Richard H./0000-0003-1355-892X				AMATI B, 1990, EMBO J, V9, P4007, DOI 10.1002/j.1460-2075.1990.tb07622.x; AUGEREAU P, 1986, EMBO J, V5, P1791, DOI 10.1002/j.1460-2075.1986.tb04428.x; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BISWAS SB, 1984, J BIOL CHEM, V259, P7990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHURCH GM, 1985, NATURE, V313, P798, DOI 10.1038/313798a0; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; HARVEY RP, 1982, NUCLEIC ACIDS RES, V10, P7851, DOI 10.1093/nar/10.23.7851; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; IRANI MH, 1983, CELL, V32, P783, DOI 10.1016/0092-8674(83)90064-8; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; MAJUMDAR A, 1984, P NATL ACAD SCI-BIOL, V81, P6100, DOI 10.1073/pnas.81.19.6100; MANDAL N, 1990, GENE DEV, V4, P410, DOI 10.1101/gad.4.3.410; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARTINEZ E, 1989, EMBO J, V8, P3781, DOI 10.1002/j.1460-2075.1989.tb08555.x; MASON JO, 1985, CELL, V41, P479, DOI 10.1016/S0092-8674(85)80021-0; Maxam A M, 1980, Methods Enzymol, V65, P499; MEISTERERNST M, 1988, NUCLEIC ACIDS RES, V16, P4419, DOI 10.1093/nar/16.10.4419; MERCOLA M, 1983, SCIENCE, V221, P663, DOI 10.1126/science.6306772; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; NEUBERGER MS, 1983, EMBO J, V2, P1373, DOI 10.1002/j.1460-2075.1983.tb01594.x; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; PETERSON CL, 1986, MOL CELL BIOL, V6, P4168, DOI 10.1128/MCB.6.12.4168; PETERSON CL, 1989, MOL CELL BIOL, V9, P776, DOI 10.1128/MCB.9.2.776; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P355, DOI 10.1146/annurev.genet.19.1.355; ROBBINS PA, 1985, ROLE CIS TRANS ACTIN; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; SCHEUERMANN RH, 1990, IMMUNOL METHODS, V4, P75; SCHLOKAT U, 1986, EMBO J, V5, P3251, DOI 10.1002/j.1460-2075.1986.tb04636.x; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TAKAHASHI K, 1986, NATURE, V319, P121, DOI 10.1038/319121a0; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V176, P551, DOI 10.1016/S0006-291X(05)80219-0; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WEINBERGER J, 1986, NATURE, V322, P846, DOI 10.1038/322846a0; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975; YOUNG BD, 1989, CENTRIFUGATION PRACT, P127; ZABEL U, 1991, J BIOL CHEM, V266, P252; ZAMROD Z, 1990, NUCLEIC ACIDS RES, V18, P7323, DOI 10.1093/nar/18.24.7323	72	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					624	634						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730623				2022-12-25	WOS:A1992GY43900097
J	IOVANNA, J; ORELLE, B; KEIM, V; DAGORN, JC				IOVANNA, J; ORELLE, B; KEIM, V; DAGORN, JC			MESSENGER-RNA SEQUENCE AND EXPRESSION OF RAT PANCREATITIS-ASSOCIATED PROTEIN, A LECTIN-RELATED PROTEIN OVEREXPRESSED DURING ACUTE EXPERIMENTAL PANCREATITIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC CALCIFYING PANCREATITIS; PROTEOGLYCAN CORE PROTEIN; AMINO-ACID-SEQUENCE; STONE PROTEIN; CARTILAGE PROTEOGLYCAN; CDNA SEQUENCE; NUCLEIC-ACID; RECEPTOR; AMYLASE; LIVER	Rat pancreatitis-associated protein (PAP) is an additional protein appearing in pancreatic juice after induction of pancreatic inflammation. Its messenger RNA was cloned and sequenced from pancreas. The deduced amino acid sequence revealed that PAP was synthetized as a preprotein with, in its mature form, a predicted molecular weight of 16,630. A search in protein data bases revealed a marked homology with the carbohydrate binding region of animal lectins; no hemagglutination activity could be shown for PAP, but the protein induced extensive bacterial aggregation. In healthy rats, the very low level of PAP expression in pancreas could be increased up to 4-fold by physiological stimuli such as chronic hormonal or cholinergic stimulation of pancreatic secretion and adaptation of rats to a carbohydrate-rich diet. By contrast, induction of acute experimental pancreatitis by retrograde injection of sodium taurocholate resulted in dramatic overexpression. Pancreatic concentration of PAP mRNA increased more than 300 x within 12 h whereas concentrations of mRNAs encoding major secretory proteins such as amylase decreased. PAP overexpression persisted during the 2 days of the acute phase and then returned to the control level during pancreatic recovery. PAP mRNA could not be evidenced in liver, stomach, salivary glands, brain, kidney, or testis. Its pattern of expression during severe pancreatic aggression suggests that it might be a stress protein involved in the control of bacterial proliferation.	INSERM,U315,46 BLVD GAYE,F-13009 MARSEILLE,FRANCE; UNIV HEIDELBERG,MED KLIN 2,W-6800 MANNHEIM,GERMANY	Institut National de la Sante et de la Recherche Medicale (Inserm); Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf			Iovanna, Juan/M-9805-2017	Iovanna, Juan/0000-0003-1822-2237				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BARROWMAN JA, 1974, J PHYSL, V238, P73; BENSON B, 1985, P NATL ACAD SCI USA, V82, P6379, DOI 10.1073/pnas.82.19.6379; BERNARD JP, 1991, PANCREAS, V6, P162, DOI 10.1097/00006676-199103000-00006; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEYER EC, 1980, J BIOL CHEM, V255, P4236; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAGORN JC, 1986, BIOCHIMIE, V68, P329, DOI 10.1016/S0300-9084(86)80031-1; DOEGE K, 1986, J BIOL CHEM, V261, P8108; DRICKAMER K, 1981, J BIOL CHEM, V256, P5827; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; EZEKOWITZ RAB, 1988, J EXP MED, V167, P1034, DOI 10.1084/jem.167.3.1034; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUHLENDORFF J, 1987, BIOCHEMISTRY-US, V26, P6757, DOI 10.1021/bi00395a027; GIORGI D, 1984, EMBO J, V3, P1521, DOI 10.1002/j.1460-2075.1984.tb02005.x; GIORGI D, 1989, J CLIN INVEST, V84, P100, DOI 10.1172/JCI114128; GLIBETIC MD, 1986, J IMMUNOL, V137, P1616; GOAD WB, 1982, NUCLEIC ACIDS RES, V10, P247, DOI 10.1093/nar/10.1.247; HOLBERGT D, 1988, J BIOL CHEM, V263, P9486; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IOVANNA J, 1987, DIGESTION, V38, P25; KEIM V, 1984, DIGESTION, V29, P242, DOI 10.1159/000199041; KEIM V, 1986, CLIN PHYSIOL BIOCH, V4, P136; KEIM V, 1991, GASTROENTEROLOGY, V100, P775, DOI 10.1016/0016-5085(91)80025-5; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LANKISCH PG, 1974, SCAND J GASTROENTERO, V9, P725; LUTCKE H, 1989, NUCLEIC ACIDS RES, V17, P6736; MACDONALD RJ, 1980, NATURE, V287, P117, DOI 10.1038/287117a0; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MULTIGNER L, 1985, GASTROENTEROLOGY, V89, P387, DOI 10.1016/0016-5085(85)90341-5; NOWAK TP, 1976, BIOCHEM BIOPH RES CO, V68, P650, DOI 10.1016/0006-291X(76)91195-5; PETERSEN TE, 1988, FEBS LETT, V231, P51, DOI 10.1016/0014-5793(88)80700-2; REBOUD JP, 1962, BIOCHIM BIOPHYS ACTA, V58, P326, DOI 10.1016/0006-3002(62)91016-8; RENAUD W, 1986, BIOCHEM J, V235, P305, DOI 10.1042/bj2350305; RINDERKNECHT H, 1979, GUT, V20, P886, DOI 10.1136/gut.20.10.886; Rinderknecht H, 1986, EXOCRINE PANCREAS BI, P163; RINDERKNECHT HI, 1983, DIGEST DIS SCI, V28, P1003; ROUQUIER S, 1991, J BIOL CHEM, V266, P786; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHICK J, 1984, J CELL BIOL, V99, P1569, DOI 10.1083/jcb.99.5.1569; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STEER ML, 1987, NEW ENGL J MED, V316, P144; TAKAHASHI H, 1985, J BIOL CHEM, V260, P2228; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; VONHEIJNE G, 1984, EMBO J, V3, P2315, DOI 10.1002/j.1460-2075.1984.tb02132.x; WEN DZ, 1987, BIOCHEMISTRY-US, V26, P4350, DOI 10.1021/bi00388a025; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726	53	182	196	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24664	24669						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722211				2022-12-25	WOS:A1991GW84500066
J	ARAKAWA, T; YPHANTIS, DA; LARY, JW; NARHI, LO; LU, HS; PRESTRELSKI, SJ; CLOGSTON, CL; ZSEBO, KM; MENDIAZ, EA; WYPYCH, J; LANGLEY, KE				ARAKAWA, T; YPHANTIS, DA; LARY, JW; NARHI, LO; LU, HS; PRESTRELSKI, SJ; CLOGSTON, CL; ZSEBO, KM; MENDIAZ, EA; WYPYCH, J; LANGLEY, KE			GLYCOSYLATED AND UNGLYCOSYLATED RECOMBINANT-DERIVED HUMAN STEM-CELL FACTORS ARE DIMERIC AND HAVE EXTENSIVE REGULAR SECONDARY STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE RECEPTOR; C-KIT RECEPTOR; GROWTH-FACTOR; MUTANT MICE; SI-LOCUS; W-LOCUS; LIGAND; PROTEINS; MOUSE; IDENTIFICATION	We have recently described the identification, isolation, and characterization of a factor, termed stem cell factor (SCF), which acts on primitive hematopoietic progenitors of the marrow. A soluble form of the factor was isolated from the conditioned medium of a rat cell line (Zsebo, K. M., Wypych, J., McNiece, I. K., Lu, H. S., Smith, K. A., Karkare, S. B., Sachdev, R. K., Yuschenkoff, V. N., Birkett, N. C., Williams, L. R., Satyagal, V. N., Tung, W., Bosselman, R. A., Mendiaz, E. A., and Langley, K. E. (1990) Cell 63, 195-201) and rat and human cDNAs have been cloned (Martin, F. H., Suggs, S. V., Langley, K. E., Lu, H. S., Ting, J., Okino, K. H., Morris, C. F., McNiece, I. K., Jacobsen, F. W., Mendiaz, E. A., Birkett, N. C., Smith, K. A., Johnson, M. J., Parker, V. P., Flores, J. C., Patel, A. C., Fisher, E. F., Erjavec, H. O., Herrera, C. J., Wypych, J., Sachdev, R. K., Pope, J. A., Leslie, I., Wen, D., Lin, C.-H., Cupples, R. L., and Zsebo, K. M. (1990) Cell 63, 203-211). The cDNAs encode amino acids C-terminal to those found in the isolated natural form, including a putative transmembrane domain. This paper describes the structural characterization of soluble forms of recombinant human SCF purified from Escherichia coli (unglycosylated) and from Chinese hamster ovary (CHO) cells (glycosylated). Fluorescence emission spectra indicate that the single Trp residue is present in a hydrophobic environment. Circular dichroism and infrared spectroscopy indicate considerable secondary structure, including both alpha-helix and beta-sheet. Molecular weight determinations by sedimentation equilibrium show that the molecules are dimeric (noncovalently associated), and gel filtration analyses are consistent with this conclusion. The CHO cell-derived SCF is about 30% carbohydrate by weight, with both N-linked and O-linked sugar. The presence or absence of the carbohydrate does not influence the results of the various structural analyses.	AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320; UNIV CONNECTICUT,ANALYT ULTRACENTRIFUGE FACIL,STORRS,CT 06269; UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,STORRS,CT 06269; UNIV CRETE,DEPT BIOL,HERAKLION,GREECE; UNIV CRETE,INST MOLEC BIOL & BIOTECHNOL,HERAKLION,GREECE	Amgen; University of Connecticut; University of Connecticut; University of Crete; University of Crete								ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ANDREWS P, 1964, BIOCHEM J, V91, P222, DOI 10.1042/bj0910222; ANDREWS RG, 1991, IN PRESS BLOOD, V78; BERNSTEIN ID, 1991, BLOOD, V77, P2316; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Cohn E. J., 1943, PROTEINS AMINO ACIDS; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; CORREIA JC, 1981, THESIS U CONNECTICUT; CORREIA JJ, 1980, FED PROC, V39, P1604; DAS SK, 1982, J BIOL CHEM, V257, P13679; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FUJITA J, 1989, P NATL ACAD SCI USA, V86, P2888, DOI 10.1073/pnas.86.8.2888; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARY J, 1990, BIOPHYS J, V57, pA377; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; Lee J C, 1979, Methods Enzymol, V61, P26; LEVISCHAFFER F, 1985, J IMMUNOL, V135, P3454; LU HS, 1991, J BIOL CHEM, V266, P8102; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MCCULLOC.EA, 1965, BLOOD-J HEMATOL, V26, P399, DOI 10.1182/blood.V26.4.399.399; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MCNIECE IK, 1991, J IMMUNOL, V146, P3785; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PRESTRELSKI SJ, 1991, INT J PEPT PROT RES, V37, P508; PRESTRELSKI SJ, 1991, BIOCHEMISTRY-US, V30, P133, DOI 10.1021/bi00215a020; QUI F, 1988, EMBO J, V7, P1003; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUSI H, 1983, BIOCHEM BIOPH RES CO, V115, P391, DOI 10.1016/0006-291X(83)91016-1; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TRAUBE J, 1899, SAMML CHEM CHEM TECH, V4, P255; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; Westphal U, 1975, Methods Enzymol, V36, P91; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	53	91	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18942	18948						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1717457				2022-12-25	WOS:A1991GJ47200082
J	OLENDER, EH; SIMONI, RD				OLENDER, EH; SIMONI, RD			THE INTRACELLULAR TARGETING AND MEMBRANE TOPOLOGY OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG-COA REDUCTASE; STEROL-REGULATED DEGRADATION; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-SEQUENCE; SIGNAL SEQUENCE; PROTEIN; TRANSLOCATION; GLYCOPROTEIN; INSERTION	We present evidence that the amino-terminal 39 residue region of 3-hydroxy-3-methylglutaryl- (HMG) CoA reductase, which includes the putative first transmembrane span, is a signal sequence for targeting HMG-CoA reductase to the endoplasmic reticulum. This evidence is based upon fractionation, endoglycosidase-H sensitivity and protease protection assays on an in vitro transcription/translocation system programmed with a mutant cDNA of HMG-CoA reductase that is deleted for sequences coding for all of the putative transmembrane spans except the first. We show that the protein product of this mutant cDNA is associated with microsomes, glycosylated, or protected from proteolysis only in the presence of Signal Recognition Particle. Also, we present evidence for a topological model of HMG-CoA reductase that consists of eight transmembrane spans. This evidence is based upon a concanavalin A binding assay for in vivo glycosylation of an engineered glycosylation site in each of a series of mutants of the fusion protein, HMGal (Skalnik, D. G., Narita, H., Kent, C., and Simoni, R. D. (1988) J. Biol. Chem. 263, 6836-6841). This series of mutants was designed such that for each linker segment between transmembrane spans, a mutant was constructed with an engineered glycosylation site introduced into that linker segment. We show that only the mutants with glycosylation sites in the linker segments between transmembrane spans 1 and 2, 3 and 4, and 5 and 6 are glycosylated. These results support an eight transmembrane span model for the topology of HMG-CoA reductase and are inconsistent with a seven-transmembrane span model.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26502] Funding Source: Medline; NIGMS NIH HHS [GM07276] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BASSON ME, 1988, MOL CELL BIOL, V8, P3797, DOI 10.1128/MCB.8.9.3797; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN DA, 1984, P NATL ACAD SCI-BIOL, V81, P1674, DOI 10.1073/pnas.81.6.1674; BROWN MS, 1980, J LIPID RES, V21, P505; CHEN HJ, 1990, J BIOL CHEM, V265, P4622; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CHUN KT, 1992, J BIOL CHEM, V267, P4236; COLEMAN J, 1985, CELL, V43, P351, DOI 10.1016/0092-8674(85)90040-6; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; FINIDORI J, 1987, J CELL BIOL, V104, P1705, DOI 10.1083/jcb.104.6.1705; GERTLER FB, 1988, MOL CELL BIOL, V8, P2713, DOI 10.1128/MCB.8.7.2713; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARDEMAN EC, 1984, ARCH BIOCHEM BIOPHYS, V232, P549, DOI 10.1016/0003-9861(84)90572-1; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LISCUM L, 1985, J BIOL CHEM, V260, P522; LUSKEY KL, 1985, J BIOL CHEM, V260, P271; PARKER RA, 1989, J BIOL CHEM, V264, P4877; RAJKOVIC A, 1989, P NATL ACAD SCI USA, V86, P8217, DOI 10.1073/pnas.86.21.8217; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; Sambrook J, 1989, MOL CLONING LABORATO; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SKALNIK DG, 1985, DNA-J MOLEC CELL BIO, V4, P439, DOI 10.1089/dna.1985.4.439; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; WOODWARD HD, 1988, J BIOL CHEM, V263, P18411; ZERIAL M, 1987, CELL, V48, P147, DOI 10.1016/0092-8674(87)90365-5	39	110	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4223	4235						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740462				2022-12-25	WOS:A1992HE60700096
J	CLERCH, LB; MASSARO, D				CLERCH, LB; MASSARO, D			OXIDATION-REDUCTION-SENSITIVE BINDING OF LUNG PROTEIN TO RAT CATALASE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ANTIOXIDANT ENZYMES; IRON; STABILITY; SEQUENCE; CDNA	Air-breathing organisms experience an elevated concentration of oxygen mainly under two conditions. One occurs at birth when the O2 tension in the lung increases from approximately 25 torr present in utero to approximately 100 torr. The lungs, in particular, are also exposed to hyperoxia when oxygen is administered for therapeutic reasons. Under hyperoxic conditions, increased lung antioxidant enzyme activity is important for survival. The molecular basis for the increase in antioxidant enzyme gene expression under these circumstances is not well understood; in hyperoxia-exposed neonatal rats the elevation of lung catalase activity is not due to an increased rate of transcription but is associated with an increased concentration of catalase mRNA due to enhanced stability of the mRNA (Clerch, L. B., Iqbal, J., and Massaro, D. (1991) Am. J. Physiol. 260, L428-L433). We now show that neonatal rat lung protein forms specific complexes with catalase mRNA; this binding is redox-sensitive since when oxidizing agents are added binding is abolished but is restored by reducing agents. Our data also indicate lungs from hyperoxia-exposed rats have a larger proportion of catalase RNA-binding protein in oxidized form than lungs from air-breathing rats. This redox-sensitive binding of protein to catalase mRNA may be important in the control of catalase gene expression.	GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20007	Georgetown University	CLERCH, LB (corresponding author), GEORGETOWN UNIV,MED CTR,DEPT PEDIAT,LUNG BIOL LAB,PRECLIN SCI BLDG,GM12,3900 RESERVOIR RD NW,WASHINGTON,DC 20007, USA.				NHLBI NIH HHS [HL-20366] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL020366, R01HL020366] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; CLERCH LB, 1991, AM J PHYSIOL, V260, pL428, DOI 10.1152/ajplung.1991.260.6.L428; FRANK L, 1984, PEDIATR RES, V18, P240, DOI 10.1203/00006450-198403000-00004; FRANK L, 1987, J PEDIATR-US, V110, P106, DOI 10.1016/S0022-3476(87)80300-1; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; FRIDOVICH I, 1986, ANNU REV PHYSIOL, V48, P693; FURUTA S, 1986, P NATL ACAD SCI USA, V83, P313, DOI 10.1073/pnas.83.2.313; HALLIWELL B, 1985, FREE RADICAL BIO MED, P1; HASS MA, 1989, J CLIN INVEST, V83, P1241, DOI 10.1172/JCI114007; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10501; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; LIEBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; SAMOKYSZYN VM, 1988, DRUG METAB REV, V19, P283, DOI 10.3109/03602538808994137	18	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2853	2855						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737743				2022-12-25	WOS:A1992HD15400005
J	SARTOR, O; MORIUCHI, R; SAMESHIMA, JH; SEVERINO, M; GUTKIND, JS; ROBBINS, KC				SARTOR, O; MORIUCHI, R; SAMESHIMA, JH; SEVERINO, M; GUTKIND, JS; ROBBINS, KC			DIVERSE BIOLOGIC PROPERTIES IMPARTED BY THE C-FGR PROTOONCOGENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING GENE-PRODUCT; NIH 3T3 CELLS; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; CD4 RECEPTOR; VIRUS; ACTIVATION; PP60C-SRC; THROMBIN	The c-fgr proto-oncogene specifies a nonreceptor protein-tyrosine kinase, p55c-fgr, a member of the src family. In the present study, we have mutagenized c-fgr to mimic alterations found at the 3' end of the v-fgr oncogene and have investigated the biologic effects of normal and mutant p55c-fgr expression. Genes lacking 10 or 13 codons at the 3' end, as well as a gene encoding phenylalanine instead of tyrosine at codon 523, were potent oncogenes when transfected into NIH 3T3 cells. Specific enzymatic activities of the more highly transforming gene products were 3-4-fold greater than that of p55c-fgr. In vivo, the amount of tyrosine phosphorylation of cellular proteins was directly proportional to potency in focus-forming assays. These findings are the first to identify highly transforming mutations of the c-fgr proto-oncogene. The proto-oncogene was also active in transforming assays, demonstrably greater than that of a kinase-deficient mutant. Foci arising in c-fgr-transfected cultures expressed abundant enzyme that was normal by a number of criteria. In addition, growth rates for cells expressing p55c-fgr were restricted, as compared with cells expressing a kinase-deficient protein or cells transformed by proteins with high specific enzymatic activities. Thus, enzymatically active p55c-fgr can simultaneously activate transforming and growth inhibitory pathways.	NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482				AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; INOUE K, 1987, ONCOGENE, V1, P301; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KATAMINE S, 1988, MOL CELL BIOL, V8, P259, DOI 10.1128/MCB.8.1.259; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEY TJ, 1989, MOL CELL BIOL, V9, P92, DOI 10.1128/MCB.9.1.92; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; PATEL M, 1990, ONCOGENE, V5, P201; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RASHEED S, 1982, VIROLOGY, V117, P238, DOI 10.1016/0042-6822(82)90522-0; ROBBINS KC, 1985, EMBO J, V4, P1783, DOI 10.1002/j.1460-2075.1985.tb03851.x; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SARTOR O, 1991, J BIOL CHEM, V266, P6462; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WILLMAN CL, 1987, P NATL ACAD SCI USA, V84, P4480, DOI 10.1073/pnas.84.13.4480; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5; ZIEGLER SF, 1989, MOL CELL BIOL, V9, P2724, DOI 10.1128/MCB.9.6.2724	39	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3460	3465						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737799				2022-12-25	WOS:A1992HD15400098
J	ZHANG, ZJ; BAI, G; DEANSZIRATTU, S; BROWNER, MF; LEE, EYC				ZHANG, ZJ; BAI, G; DEANSZIRATTU, S; BROWNER, MF; LEE, EYC			EXPRESSION OF THE CATALYTIC SUBUNIT OF PHOSPHORYLASE-PHOSPHATASE (PROTEIN PHOSPHATASE-1) IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; PHOSPHOPROTEIN PHOSPHATASE; MOLECULAR-WEIGHT; OKADAIC ACID; KINASE-FA; CELLULAR-REGULATION; DIVALENT-CATIONS; TUMOR PROMOTER; RNA-POLYMERASE; ACTIVATION	The catalytic subunit of rabbit skeletal muscle protein phosphatase-1 was expressed in Escherichia coli. Expression of phosphatase-1 in the pET3a vector, which is based on the use of the T7 promoter, resulted in the expression of the enzyme as an insoluble aggregate. The insoluble enzyme could be renatured by high dilutions of the urea-solubilized protein in buffers containing dithiothreitol, Mn2+, and high NaCl concentrations. However, under all conditions tested, only partial (< 5%) renaturation was achieved. A second attempt was made using a vector with the trp-lac hybrid promoter. In this case it was possible to express the enzyme as a soluble protein at levels of 3-4% of the soluble E. coli protein. The recombinant enzyme was purified by DEAE-Sepharose and heparin-Sepharose chromatography. Approximately 20 mg of purified enzyme was reproducibly obtained from the cells derived from 2 liters of culture. The purified enzyme had a specific activity toward phosphorylase a comparable to that reported for the authentic protein and had an M(r) of 37,000 by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The recombinant enzyme displayed similar sensitivities to inhibition by inhibitor-2, okadaic acid, and microcystin-LR as for the protein isolated from rabbit muscle. At all stages of purification the recombinant phosphatase behaved as an essentially inactive enzyme that required the presence of mu-M Mn2+ for full expression of its activity.	UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOLEC BIOL R-629, POB 016129, MIAMI, FL 33101 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of Miami; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018512] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18512] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAI G, 1990, THESIS U MIAMI; BAI GE, 1988, FASEB J, V2, P3010, DOI 10.1096/fasebj.2.14.2846396; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; BALLOU LM, 1986, ENZYMES, V17, P311; BERNDT N, 1990, EUR J BIOCHEM, V190, P291, DOI 10.1111/j.1432-1033.1990.tb15575.x; BERNDT N, 1987, FEBS LETT, V223, P340, DOI 10.1016/0014-5793(87)80316-2; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT H, 1975, BIOCHEM BIOPH RES CO, V63, P950, DOI 10.1016/0006-291X(75)90661-0; BRANDT H, 1974, BIOCHEM BIOPH RES CO, V61, P598, DOI 10.1016/0006-291X(74)90999-1; BRANDT H, 1975, J BIOL CHEM, V250, P8038; BRAUTIGAN DL, 1980, BIOCHEMISTRY-US, V19, P5787, DOI 10.1021/bi00566a019; BRAUTIGAN DL, 1982, BIOCHEMISTRY-US, V21, P1977, DOI 10.1021/bi00538a001; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; COHEN PTW, 1988, FEBS LETT, V232, P17, DOI 10.1016/0014-5793(88)80378-8; CONNER GE, 1990, DNA CELL BIOL, V9, P1, DOI 10.1089/dna.1990.9.1; Cori GT, 1943, J BIOL CHEM, V151, P31; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; GRATECOS D, 1977, BIOCHEMISTRY-US, V16, P4812, DOI 10.1021/bi00641a009; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HSIAO KJ, 1978, J BIOL CHEM, V253, P6901; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; JOHNSON GL, 1987, MOL ENDOCRINOL, V1, P745, DOI 10.1210/mend-1-10-745; JURGENSEN S, 1984, J BIOL CHEM, V259, P5864; KATO K, 1974, BIOCHIM BIOPHYS ACTA, V358, P299, DOI 10.1016/0005-2744(74)90460-4; KHANDELWAL RL, 1976, J BIOL CHEM, V251, P4850; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee E Y, 1980, Adv Cyclic Nucleotide Res, V13, P95; LI HC, 1985, J BIOL CHEM, V260, P6416; LI HC, 1982, CURR TOP CELL REGUL, V21, P129; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MCNALL SJ, 1988, J BIOL CHEM, V263, P1893; MELLGREN RL, 1979, J BIOL CHEM, V254, P648; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SCHEIN CH, 1988, BIO-TECHNOL, V6, P291, DOI 10.1038/nbt0388-291; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TAKAGI H, 1988, BIO-TECHNOL, V6, P948, DOI 10.1038/nbt0888-948; VANDENHEEDE JR, 1985, J BIOL CHEM, V260, P512; VILLAMORUZZI E, 1984, J BIOL CHEM, V259, P5857; WADZINSKI BE, 1990, J BIOL CHEM, V265, P21504; YAN SCB, 1982, MOL CELL BIOCHEM, V42, P21	56	127	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1484	1490						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730696				2022-12-25	WOS:A1992HA48500017
J	GAMIAN, A; BEURRET, M; MICHON, F; BRISSON, JR; JENNINGS, HJ				GAMIAN, A; BEURRET, M; MICHON, F; BRISSON, JR; JENNINGS, HJ			STRUCTURE OF THE L2 LIPOPOLYSACCHARIDE CORE OLIGOSACCHARIDES OF NEISSERIA-MENINGITIDIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MENINGOCOCCAL LIPOPOLYSACCHARIDES; ANTIGENIC EXPRESSION; HUMAN-ERYTHROCYTES; LIPOOLIGOSACCHARIDES; HETEROGENEITY; EPITOPES; SPECTROSCOPY; GONORRHOEAE; METHYLATION; GLYCOLIPIDS	Three different oligosaccharides were identified following mild acid hydrolysis of the lipopolysaccharide obtained from Neisseria meningitidis serotype 2 and their structures elucidated by combined chemical and physical techniques. The use of 500 MHz H-1 nmr in both one- and two-dimensional modes as well as nuclear Overhauser effect experiments were employed. To assist in the structural assignments the oligosaccharides were also degraded by chemical and enzymatic procedures to smaller fragments. The oligosaccharides were all triantennary nonasaccharides in which the longest antenna terminates in lacto-N-neotetraose. Two of the nonasaccharides (major components), not separable by column chromatography, were distinguishable only by their different patterns of phosphorylethanolamine substitution and the third minor component by the absence of this substituent.	NATL RES COUNCIL CANADA,DIV BIOL SCI,OTTAWA K1A 0R6,ONTARIO,CANADA	National Research Council Canada				Gamian, Andrzej/0000-0002-2206-6591; Beurret, Michel/0000-0002-4623-8896				BAX A, 1985, J MAGN RESON, V61, P306, DOI 10.1016/0022-2364(85)90085-X; BAX A, 1981, J MAGN RESON, V44, P542, DOI 10.1016/0022-2364(81)90287-0; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; DELL A, 1990, CARBOHYD RES, V200, P59, DOI 10.1016/0008-6215(90)84182-T; DIFABIO JL, 1990, CAN J CHEM, V68, P1029, DOI 10.1139/v90-160; FEIZI T, 1985, TRENDS BIOCHEM SCI, V10, P24, DOI 10.1016/0968-0004(85)90012-X; FIEGE V, 1979, P INT S GLYCOCONJUGA, P12; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; GRIFFISS JM, 1987, INFECT IMMUN, V55, P1792, DOI 10.1128/IAI.55.8.1792-1800.1987; GRIFFISS M, 1988, REV INFECT DIS, V10, pS287; HAKOMORI SI, 1981, SEMIN HEMATOL, V18, P39; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; JENNINGS HJ, 1980, CAN J BIOCHEM CELL B, V58, P128, DOI 10.1139/o80-018; JENNINGS HJ, 1984, INFECT IMMUN, V43, P407, DOI 10.1128/IAI.43.1.407-412.1984; JENNINGS HJ, 1983, CARBOHYD RES, V121, P233, DOI 10.1016/0008-6215(83)84020-8; JENNINGS HJ, 1987, A VAN LEEUW J MICROB, V53, P519, DOI 10.1007/BF00415511; KINNS M, 1984, J MAGN RESON, V56, P518, DOI 10.1016/0022-2364(84)90315-9; LEONTEIN K, 1978, CARBOHYD RES, V62, P359, DOI 10.1016/S0008-6215(00)80882-4; MANDRELL RE, 1988, J EXP MED, V168, P107, DOI 10.1084/jem.168.1.107; MANDRELL RE, 1977, INFECT IMMUN, V16, P471, DOI 10.1128/IAI.16.2.471-475.1977; MICHON F, 1990, J BIOL CHEM, V265, P7243; NEUHAUS D, 1983, J MAGN RESON, V53, P109, DOI 10.1016/0022-2364(83)90076-8; POOLMAN JT, 1982, FEMS MICROBIOL LETT, V13, P339, DOI 10.1111/j.1574-6968.1982.tb08284.x; SCHNEIDER H, 1984, INFECT IMMUN, V45, P544, DOI 10.1128/IAI.45.3.544-549.1984; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; TSAI CM, 1987, INFECT IMMUN, V55, P1652, DOI 10.1128/IAI.55.7.1652-1656.1987; TSAI CM, 1983, J BACTERIOL, V155, P498, DOI 10.1128/JB.155.2.498-504.1983; VIRJI M, 1990, MICROB PATHOGENESIS, V9, P441, DOI 10.1016/0882-4010(90)90062-U; WAEGHE TJ, 1983, CARBOHYD RES, V123, P281, DOI 10.1016/0008-6215(83)88484-5; ZOLLINGER WD, 1980, INFECT IMMUN, V28, P451; ZOLLINGER WD, 1977, INFECT IMMUN, V158, P424	31	82	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					922	925						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730681				2022-12-25	WOS:A1992GY96000039
J	NICKEL, W; AUSTERMANN, S; BIALEK, G; GROSSE, F				NICKEL, W; AUSTERMANN, S; BIALEK, G; GROSSE, F			INTERACTIONS OF AZIDOTHYMIDINE TRIPHOSPHATE WITH THE CELLULAR DNA-POLYMERASES ALPHA, DELTA, AND EPSILON AND WITH DNA PRIMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; CALF THYMUS; SACCHAROMYCES-CEREVISIAE; NUCLEAR ANTIGEN; AUXILIARY PROTEIN; 3'-AZIDO-3'-DEOXYTHYMIDINE; CELLS; 5'-TRIPHOSPHATE; PHARMACOLOGY; PURIFICATION	The interactions of azidothymidine triphosphate, the metabolically active form of the anti-AIDS drug azidothymidine (zidovudine), with the cellular DNA polymerases-alpha, delta, and epsilon, as well as with the RNA primer-forming enzyme DNA primase were studied in vitro. DNA polymerase-alpha was shown to incorporate azidothymidine monophosphate into a growing polynucleotide chain. This occurred 2000-fold slower than the incorporation of natural dTTP. Despite the ability of polymerase-alpha to use azidothymidine triphosphate as an alternate substrate, this compound was only marginally inhibitory to the enzyme (K(i) > 1 mM). Furthermore, the DNA primase activity associated with DNA polymerase-alpha was barely inhibited by azidothymidine triphosphate (K(i) > 1 mM). Inhibition was more pronounced for DNA polymerases-delta and epsilon. The type of inhibition was competitive with respect to dTTP, with K(i) values of 250 and 320-mu-M, respectively. No incorporation of azidothymidine monophosphate was detectable with these two DNA polymerases because their associated 3'- to 5'-exonuclease activities degraded primer molecules prior to any measurable elongation. Template-primer systems with a preformed 3'-azidothymidine-containing primer terminus inhibited the three replicative polymerases rather potently. DNA polymerase-alpha was inhibited with a K(i) of 150 nM and polymerases-delta and epsilon with K(i) values of 25 and 20 nM, respectively. The type of inhibition was competitive with respect to the unmodified substrate poly(dA).oligo(dT) for all DNA polymerases tested. Preformed 3'-azidothymidine-containing primers hybridized to poly(dA) were rather resistant to degradation by the 3'- to 5'-exonuclease of DNA polymerases-epsilon and more susceptible to the analogous activity that copurified with DNA polymerase-delta. It is proposed that the repair of 3'-azidothymidine-containing primers might become rate-limiting for the process of DNA replication in cells that have been treated with azidothymidine triphosphate.	MAX PLANCK INST EXPTL MED, CHEM ABT, HERMANN REIN STR 3, W-3400 GOTTINGEN, GERMANY	Max Planck Society								AVRAMIS VI, 1989, AIDS, V3, P417, DOI 10.1097/00002030-198907000-00002; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BIALEK G, 1988, BIOCHIM BIOPHYS ACTA, V951, P290, DOI 10.1016/0167-4781(88)90099-1; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; Burgers P M, 1989, Prog Nucleic Acid Res Mol Biol, V37, P235; BURGERS PMJ, 1990, EUR J BIOCHEM, V191, P617, DOI 10.1111/j.1432-1033.1990.tb19165.x; DIXON M, 1958, ENZYMES, P171; Eadie GS, 1942, J BIOL CHEM, V146, P85; FOCHER F, 1989, NUCLEIC ACIDS RES, V17, P1805, DOI 10.1093/nar/17.5.1805; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GROSSE F, 1986, EUR J BIOCHEM, V160, P459, DOI 10.1111/j.1432-1033.1986.tb10062.x; GROSSE F, 1981, BIOCHEMISTRY-US, V20, P5470, DOI 10.1021/bi00522a019; HEIDENREICH O, 1990, EUR J BIOCHEM, V192, P621, DOI 10.1111/j.1432-1033.1990.tb19268.x; HOHN KT, 1987, BIOCHEMISTRY-US, V26, P2870, DOI 10.1021/bi00384a031; HUANG P, 1990, J BIOL CHEM, V265, P11914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; LUDWIG J, 1989, J ORG CHEM, V54, P631, DOI 10.1021/jo00264a024; MATTHES E, 1987, BIOCHEM BIOPH RES CO, V148, P78, DOI 10.1016/0006-291X(87)91078-3; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; NASHEUER HP, 1988, J BIOL CHEM, V263, P8981; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SCHOMBURG U, 1986, EUR J BIOCHEM, V160, P451, DOI 10.1111/j.1432-1033.1986.tb10061.x; SOMMADOSSI JP, 1989, MOL PHARMACOL, V36, P9; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; SYVAOJA J, 1989, J BIOL CHEM, V264, P2489; TALANIAN RV, 1989, BIOCHEMISTRY-US, V28, P8270, DOI 10.1021/bi00447a002; TAN CK, 1986, J BIOL CHEM, V261, P2310; WEISER T, 1991, J BIOL CHEM, V266, P10420; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106	34	62	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					848	854						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730673				2022-12-25	WOS:A1992GY96000028
J	PATEL, RC; JACOBSLORENA, M				PATEL, RC; JACOBSLORENA, M			CIS-ACTING SEQUENCES IN THE 5'-UNTRANSLATED REGION OF THE RIBOSOMAL PROTEIN-A1 MESSENGER-RNA MEDIATE ITS TRANSLATIONAL REGULATION DURING EARLY EMBRYOGENESIS OF DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TUBULIN GENES; IRON-RESPONSIVE ELEMENT; NUCLEOTIDE-SEQUENCE; UNTRANSLATED LEADER; XENOPUS DEVELOPMENT; BINDING-PROTEIN; MELANOGASTER; ACCUMULATION; LAEVIS; CDNA	The rate of ribosomal (r)-protein synthesis in the early Drosophila embryo is low despite the presence of abundant, maternally supplied r-protein mRNAs. This low rate is due to specific repression of r-protein mRNA translation. In contrast to r-protein mRNAs, most other mRNAs are efficiently translated in the early embryo. Here we report on the identification of cis-acting sequences that mediate translational repression of the r-protein A1 (rpA1) mRNA. Chimeric genes containing sequences from the translationally regulated rpA1 mRNA fused to the constitutively translated alpha-tubulin mRNA were constructed and transformed into the Drosophila germ line. Translation of the corresponding hybrid mRNAs was measured in ovaries and embryos of the transgenic flies. The results indicated that a 89-nucleotide sequence in the untranslated rpA1 mRNA leader is by itself sufficient to confer full translational regulation to a heterologous mRNA.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT GENET, CLEVELAND, OH 44106 USA	Case Western Reserve University			Patel, Rekha/M-7123-2015	Patel, Rekha/0000-0001-9434-4880				ABASTADO JP, 1991, MOL CELL BIOL, V11, P486, DOI 10.1128/MCB.11.1.486; AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; ALATIA GR, 1985, BIOCHEMISTRY-US, V24, P5798, DOI 10.1021/bi00342a017; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BROWN SJ, 1988, MOL CELL BIOL, V8, P4314, DOI 10.1128/MCB.8.10.4314; CAFFARELLI E, 1987, EMBO J, V6, P3493, DOI 10.1002/j.1460-2075.1987.tb02674.x; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FRUSCOLONI P, 1983, P NATL ACAD SCI-BIOL, V80, P3359, DOI 10.1073/pnas.80.11.3359; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; GRENS A, 1990, J BIOL CHEM, V265, P11810; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HONGO S, 1991, DEV BIOL, V145, P338, DOI 10.1016/0012-1606(91)90132-M; HOUGHEVANS BR, 1980, GENETICS, V95, P81; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; ITOH N, 1989, NUCLEIC ACIDS RES, V17, P441, DOI 10.1093/nar/17.1.441; ITOH N, 1989, NUCLEIC ACIDS RES, V17, P2121, DOI 10.1093/nar/17.5.2121; JACOBSLORENA M, 1987, TRANSLATIONAL REGULA, P63; KALFAYAN L, 1981, CELL, V24, P97, DOI 10.1016/0092-8674(81)90505-5; KALFAYAN L, 1982, CELL, V29, P91, DOI 10.1016/0092-8674(82)90093-9; KAY MA, 1985, MOL CELL BIOL, V5, P3583, DOI 10.1128/MCB.5.12.3583; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; LOYD JE, 1981, DEV BIOL, V86, P272, DOI 10.1016/0012-1606(81)90185-8; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MAICAS E, 1988, MOL CELL BIOL, V8, P169, DOI 10.1128/MCB.8.1.169; MAKI C, 1989, GENE, V79, P289, DOI 10.1016/0378-1119(89)90211-4; MARIOTTINI P, 1990, MOL CELL BIOL, V10, P816, DOI 10.1128/MCB.10.2.816; MARIOTTINI P, 1988, GENE, V67, P69, DOI 10.1016/0378-1119(88)90009-1; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; MCPHEETERS DS, 1988, J MOL BIOL, V201, P517, DOI 10.1016/0022-2836(88)90634-1; MERMOD JJ, 1980, DEV BIOL, V75, P177, DOI 10.1016/0012-1606(80)90153-0; MISMER D, 1987, GENETICS, V116, P565; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PIERANDREIAMALDI P, 1985, DEV BIOL, V107, P281, DOI 10.1016/0012-1606(85)90311-2; PIERANDREIAMALDI P, 1982, CELL, V30, P163, DOI 10.1016/0092-8674(82)90022-8; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; QIAN S, 1987, NUCLEIC ACIDS RES, V15, P987, DOI 10.1093/nar/15.3.987; RAFTI F, 1989, NUCLEIC ACIDS RES, V17, P456, DOI 10.1093/nar/17.1.456; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUDDELL A, 1983, ROUX ARCH DEV BIOL, V192, P189, DOI 10.1007/BF00848689; SAKOYAMA Y, 1981, DEV BIOL, V81, P361, DOI 10.1016/0012-1606(81)90301-8; SAVOINI A, 1981, ROUX ARCH DEV BIOL, V190, P161, DOI 10.1007/BF00867803; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; STANDART N, 1990, GENE DEV, V4, P2157, DOI 10.1101/gad.4.12a.2157; STEEL LF, 1987, NUCLEIC ACIDS RES, V15, P10285, DOI 10.1093/nar/15.24.10285; STEEL LF, 1991, DEV GENET, V12, P98, DOI 10.1002/dvg.1020120117; TAMATE HB, 1990, MOL GEN GENET, V221, P171, DOI 10.1007/BF00261717; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; THEIL EC, 1990, J BIOL CHEM, V265, P4771; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; TSAY YF, 1988, GENE DEV, V2, P664, DOI 10.1101/gad.2.6.664; WATERHOUSE P, 1990, J BIOL CHEM, V265, P5585; WEISS YC, 1981, DEV BIOL, V87, P330, DOI 10.1016/0012-1606(81)90156-1; WIGBOLDUS JD, 1987, NUCLEIC ACIDS RES, V15, P10064, DOI 10.1093/nar/15.23.10064	62	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1159	1164						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730640				2022-12-25	WOS:A1992GY96000076
J	DOIG, P; EMODY, L; TRUST, TJ				DOIG, P; EMODY, L; TRUST, TJ			BINDING OF LAMININ AND FIBRONECTIN BY THE TRYPSIN-RESISTANT MAJOR STRUCTURAL DOMAIN OF THE CRYSTALLINE VIRULENCE SURFACE ARRAY PROTEIN OF AEROMONAS-SALMONICIDA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; 3-DIMENSIONAL STRUCTURE; STREPTOCOCCUS-PYOGENES; ESCHERICHIA-COLI; A-LAYER; S-LAYER; HYDROPHILA; STRAINS; COLLAGEN; FISH	The surface of Aeromonas salmonicida is covered by a tetragonal paracrystalline array (A-layer) composed of a single protein (A-protein, M(r) = 50,778). This array is a virulence factor. Cells containing A-layer and isolated A-layer sheets specifically bound laminin and fibronectin with high affinity. Binding by cells was inactivated by selective removal of A-layer at pH 2.2, and neither isogenic A-layer-deficient A. salmonicida mutants nor tetragonal paracrystalline array producing Aeromonas hydrophila and Aeromonas sobria strains bound either matrix protein. Laminin binding was by a single class of high affinity interactions (cell K(d) 1.52 nM), whereas fibronectin bound via two classes of interactions, one being similar to that of laminin (cell Class 2 interaction K(d) = 6.6 nM). This interaction with both proteins was partly hydrophobic. The Class 1 fibronectin interaction was of lower affinity (cell K(d) = 218 nM) and distinct. Purified A-protein inhibited binding of both matrix proteins to A-layer, and trypsin cleavage localized the matrix-protein binding region to the N-terminal major trypsin-resistant structural domain of A-protein. Monoclonal antibody inhibition studies showed that A-protein was folded such that Fabs of only one of two antibodies with epitopes mapping C-terminal to this trypsin-resistant peptide was capable of blocking binding.	UNIV VICTORIA,DEPT BIOCHEM & MICROBIOL,VICTORIA V8W 3P6,BC,CANADA; UNIV VICTORIA,CANADIAN BACTERIAL DIS NETWORK,VICTORIA V8W 3P6,BC,CANADA; UNIV PECS,SCH MED,INST MICROBIOL,H-7622 PECS,HUNGARY	University of Victoria; University of Victoria; University of Pecs								AL-KARADAGHI S, 1988, J ULTRA MOL STRUCT R, V101, P92, DOI 10.1016/0889-1605(88)90084-5; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BELLAND RJ, 1985, J BACTERIOL, V163, P877, DOI 10.1128/JB.163.3.877-881.1985; BELLAND RJ, 1987, J BACTERIOL, V169, P4086, DOI 10.1128/jb.169.9.4086-4091.1987; CHU S, 1991, J BIOL CHEM, V266, P15258; DOIG P, 1988, INFECT IMMUN, V56, P1641, DOI 10.1128/IAI.56.6.1641-1646.1988; DOOLEY JSG, 1988, J BACTERIOL, V170, P2631, DOI 10.1128/jb.170.6.2631-2638.1988; DOOLEY JSG, 1989, J BACTERIOL, V171, P190, DOI 10.1128/jb.171.1.190-197.1989; DOOLEY JSG, 1988, J BACTERIOL, V170, P499, DOI 10.1128/jb.170.2.499-506.1988; EMODY L, 1989, J BACTERIOL, V171, P6674; ESPERSEN F, 1982, INFECT IMMUN, V37, P526, DOI 10.1128/IAI.37.2.526-531.1982; FITZGERALD TJ, 1984, BRIT J VENER DIS, V60, P357; FROMAN G, 1987, J BIOL CHEM, V262, P6564; HOOK M, 1988, FIBRONECTIN, P295; ISHIGURO EE, 1981, J BACTERIOL, V148, P333, DOI 10.1128/JB.148.1.333-340.1981; KAY WW, 1981, J BACTERIOL, V147, P1077, DOI 10.1128/JB.147.3.1077-1084.1981; KAY WW, 1984, CAN J BIOCHEM CELL B, V62, P1064, DOI 10.1139/o84-137; KAY WW, 1985, J BACTERIOL, V164, P1332, DOI 10.1128/JB.164.3.1332-1336.1985; KOKKA RP, 1990, J CLIN MICROBIOL, V28, P2240, DOI 10.1128/JCM.28.10.2240-2247.1990; KOSTRZYNSKA M, 1989, FEMS MICROBIOL LETT, V59, P229; KOVAL SF, 1988, CAN J MICROBIOL, V34, P407, DOI 10.1139/m88-072; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPES JD, 1985, SCIENCE, V229, P275, DOI 10.1126/science.3160113; Means G E, 1977, Methods Enzymol, V47, P469; Miles E W, 1977, Methods Enzymol, V47, P431; MUNN CB, 1982, INFECT IMMUN, V36, P1069, DOI 10.1128/IAI.36.3.1069-1075.1982; MURRAY RGE, 1988, J BACTERIOL, V170, P2625, DOI 10.1128/jb.170.6.2625-2630.1988; OLSEN A, 1989, NATURE, V338, P652, DOI 10.1038/338652a0; PEARSON TW, 1980, J IMMUNOL METHODS, V34, P141, DOI 10.1016/0022-1759(80)90168-4; PHIPPS BM, 1983, BIOCHEMISTRY-US, V22, P2934, DOI 10.1021/bi00281a023; PHIPPS BM, 1988, J BIOL CHEM, V263, P9298; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; Savige W E, 1977, Methods Enzymol, V47, P442; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SLEYTR UB, 1986, SYST APPL MICROBIOL, V7, P310; SPEZIALE P, 1982, FEBS LETT, V146, P55, DOI 10.1016/0014-5793(82)80704-7; STEWART M, 1986, J BACTERIOL, V166, P120, DOI 10.1128/jb.166.1.120-127.1986; SWITALSKI L, 1989, MOL MECHANISM MICROB; SWITALSKI LM, 1984, J BIOL CHEM, V259, P3734; SWITALSKI LM, 1987, J BACTERIOL, V169, P1095, DOI 10.1128/jb.169.3.1095-1101.1987; TRUST TJ, 1983, CURR MICROBIOL, V9, P315, DOI 10.1007/BF01588826; TRUST TJ, 1986, ANNU REV MICROBIOL, V40, P479, DOI 10.1146/annurev.mi.40.100186.002403; TRUST TJ, 1980, FEMS MICROBIOL LETT, V9, P35, DOI 10.1016/0378-1097(80)90107-X; VANALSTINE JM, 1986, APPL ENVIRON MICROB, V51, P1309, DOI 10.1128/AEM.51.6.1309-1313.1986	44	41	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					43	49						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730607				2022-12-25	WOS:A1992GY43900012
J	DIAZMECO, MT; QUINONES, S; MUNICIO, MM; SANZ, L; BERNAL, D; CABRERO, E; SAUS, J; MOSCAT, J				DIAZMECO, MT; QUINONES, S; MUNICIO, MM; SANZ, L; BERNAL, D; CABRERO, E; SAUS, J; MOSCAT, J			PROTEIN KINASE-C-INDEPENDENT EXPRESSION OF STROMELYSIN BY PLATELET-DERIVED GROWTH-FACTOR, RAS ONCOGENE, AND PHOSPHATIDYLCHOLINE-HYDROLYZING PHOSPHOLIPASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MESSENGER-RNA; 3T3 CELLS; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; COORDINATE REGULATION; ANTISENSE RNA; TRANSIN GENE; FOS; METALLOPROTEINASE	Changes in the expression of several genes play critical roles in cell growth and tumor transformation. A number of proteases are increased in some tumors, and the level of these enzymes correlates with the metastatic potential of several cancer cell lines. Stromelysin, with the widest substrate specificity, can degrade the extracellular matrix conferring metastatic potential to tumor cells. The mechanisms whereby growth factors and oncogenes control the expression of stromelysin are beginning to be characterized. In the study shown here we also identify a region in the stromelysin promoter which is involved in the induction of stromelysin in response to platelet-derived growth factor, phosphatidylcholine-hydrolyzing phospholipase C, and ras oncogene. Our results are consistent with the notion that platelet-derived growth factor/phosphatidylcholine-hydrolyzing phospholipase C induces stromelysin gene expression through a phorbol myristate acetate/protein kinase C-independent mechanism by acting through elements in the stromelysin promoter distinct from the 12-O-tetradecanoylphorbol-13-acetate-responsive element.	HOSP GEN GREGORIO MARANON,CALLE DR ESQUERDO 46,E-28007 MADRID,SPAIN; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MED,PISCATAWAY,NJ 08854; INST INVEST CITOLOGICAL CAJA AHORROS VALENCIA,E-46010 VALENCIA,SPAIN; UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC,E-28049 MADRID,SPAIN	General University Gregorio Maranon Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Moscat, Jorge/A-7011-2009; Bernal, Dolores/K-7769-2014	Bernal, Dolores/0000-0003-4627-8393; Saus, Juan/0000-0003-2082-1597; Diaz-Meco, Maria/0000-0003-0147-0998				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEHERREROS AG, 1991, J BIOL CHEM, V266, P6825; DIAZLAVIADA I, 1990, EMBO J, V9, P3907, DOI 10.1002/j.1460-2075.1990.tb07611.x; EXTON JH, 1990, J BIOL CHEM, V265, P1; FRISCH SM, 1987, P NATL ACAD SCI USA, V84, P2600, DOI 10.1073/pnas.84.9.2600; GOLDFARB RH, 1986, SEMIN THROMB HEMOST, V12, P294, DOI 10.1055/s-2007-1003570; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KRUJIER W, 1984, NATURE, V312, P711; LARRODERA P, 1990, CELL, V61, P1113, DOI 10.1016/0092-8674(90)90074-O; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LITTLE C, 1988, BIOCHEM SOC T, V17, P271; LOPEZBARAHONA M, 1990, J BIOL CHEM, V265, P9022; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MOSCAT J, 1989, BIOCHEM SOC T, V17, P988, DOI 10.1042/bst0170988; MURPHY G, 1985, BIOCHIM BIOPHYS ACTA, V831, P49, DOI 10.1016/0167-4838(85)90148-7; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OGITA K, 1990, P NATL ACAD SCI USA, V87, P5011, DOI 10.1073/pnas.87.13.5011; OKADA Y, 1986, J BIOL CHEM, V261, P14245; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; SAUS J, 1988, J BIOL CHEM, V263, P6742; SCHMID TM, 1986, J BIOL CHEM, V261, P4184; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	49	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22597	22602						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1718997				2022-12-25	WOS:A1991GR56400083
J	CHASTRE, E; DIGIOIA, Y; BARBRY, P; SIMONBOUY, B; MORNET, E; FANEN, P; CHAMPIGNY, G; EMAMI, S; GESPACH, C				CHASTRE, E; DIGIOIA, Y; BARBRY, P; SIMONBOUY, B; MORNET, E; FANEN, P; CHAMPIGNY, G; EMAMI, S; GESPACH, C			FUNCTIONAL INSERTION OF THE SV40 LARGE T-ONCOGENE IN CYSTIC-FIBROSIS INTESTINAL EPITHELIUM - CHARACTERIZATION OF CFI-3 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CHLORIDE CHANNELS; NEOPLASTIC TRANSFORMATION; GENE; IDENTIFICATION; EXPRESSION; MUTATIONS; TRANSPORT; IMMORTALIZATION; ACTIVATION	Intestinal epithelial cells were isolated from a fetus with cystic fibrosis (CF) and transfected with a plasmid vector recombined with the ori- mutant of SV40. A population of proliferative cells was then subcloned and designated as CFI-3. These cells had a doubling time of 24 h and were maintained in culture for up to 25 passages. At passage 8, CFI-3 cells did not produce any tumors in nude mice. Northern blot and immunofluorescence studies indicated that the extended life-span of CFI-3 cells results in genomic insertion of SV40 LT. Intestinal CFI-3 cells are epithelial, according to the expression of the human cytokeratin 18 gene and poorly differentiated by phase-contrast and electron microscopy. Functional membrane receptors activated by vasoactive intestinal peptide (VIP), its natural analogue pituitary adenylate cyclase activating peptide (PACAP-38), and isoproterenol were observed in CFI-3 cells. Restriction fragment length polymorphism analysis of the PstI KM19 site revealed that the cftr locus was identical in the chorionic villi and in CFI-3 cells. The manifestation of CF in this family was not related to the common mutation DELTA-F508, since this fetus was heterozygous for the substitutions S549N and N1303K. Chloride transport, assessed by the I-125 efflux, was induced in CFI-3 cells by the calcium ionophore ionomycin, but not by the adenylate cyclase activator forskolin, and was inhibited by the chloride channel blocker 5-nitro-2-(3-phenylpropylamino)benzoic acid. These results were confirmed in patch clamp studies in which the cpt cAMP analogue failed to stimulate membrane currents, while the calcium ionophore ionomycin stimulated inward currents. We conclude that intestinal CFI-3 cells retain the CF phenotype relating to defective regulation of Cl- channels, and therefore constitute a suitable model, 1) for elucidating the function of CFTR protein, 2) developing new therapeutic agents, and 3) correcting the CF defect by gene replacement therapy in vitro.	INSERM,U73,F-75016 PARIS,FRANCE; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE; CNRS,UPR411,F-06560 VALBONNE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)	CHASTRE, E (corresponding author), INSERM,U55,UNITE RECH PEPTIDES NEURODIGEST & DIABET,184 RUE FAUBOURG ST ANTOINE,F-75571 PARIS 12,FRANCE.		Barbry, Pascal/O-5021-2016; CHASTRE, Eric/L-8446-2018	Barbry, Pascal/0000-0001-9632-6483; CHASTRE, Eric/0000-0002-8993-1228; Fanen, Pascale/0000-0002-3273-5349				ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUE A, 1986, HUM GENET, V74, P288; BUCHANAN JA, 1990, J CELL SCI, V95, P109; CHASTRE E, 1989, LIFE SCI, V44, P1721, DOI 10.1016/0024-3205(89)90560-2; CHASTRE E, 1989, AM J PHYSIOL, V257, pG561, DOI 10.1152/ajpgi.1989.257.4.G561; CHASTRE E, 1990, PULMONOLOGY S, V5, P198; CHASTRE E, 1991, MED SCI, V4, pR17; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CRYSTAL RG, 1990, PULMONOLOGY S, V5, P103; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DONOWITZ M, 1987, PHYSL GASTROINTESTIN, P1351; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; EMAMI S, 1990, DIGESTION, V46, P74, DOI 10.1159/000200370; EMAMI S, 1989, P NATL ACAD SCI USA, V86, P3194, DOI 10.1073/pnas.86.9.3194; FRIZZELL RA, 1986, SCIENCE, V233, P558, DOI 10.1126/science.2425436; FRIZZELL RA, 1987, TRENDS NEUROSCI, V10, P190, DOI 10.1016/0166-2236(87)90144-5; Gluzman Y, 1980, Cold Spring Harb Symp Quant Biol, V44 Pt 1,, P293; GOLDSTEIN JL, 1988, AM J PHYSIOL, V254, pC719, DOI 10.1152/ajpcell.1988.254.5.C719; GRUENERT DC, 1988, P NATL ACAD SCI USA, V85, P5951, DOI 10.1073/pnas.85.16.5951; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; JEFFERSON DM, 1990, AM J PHYSIOL, V259, pL496, DOI 10.1152/ajplung.1990.259.6.L496; JETTEN AM, 1989, SCIENCE, V244, P1472, DOI 10.1126/science.2472008; JILLING T, 1990, AM J PHYSIOL, V259, pC1010, DOI 10.1152/ajpcell.1990.259.6.C1010; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIM KH, 1987, J CELL BIOL, V105, P3039, DOI 10.1083/jcb.105.6.3039; KNOWLTON RG, 1985, NATURE, V318, P380, DOI 10.1038/318380a0; LEMEUTH V, 1991, AM J PHYSIOL, V260, pG265, DOI 10.1152/ajpgi.1991.260.2.G265; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MCPHERSON MA, 1987, BIOSCIENCE REP, V7, P165; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MONTROSERAFIZADEH C, 1991, J BIOL CHEM, V266, P4495; MORNET E, 1988, LANCET, V1, P376; ORLANDO RC, 1989, GASTROENTEROLOGY, V96, P1041, DOI 10.1016/0016-5085(89)91621-1; OSBORNE L, 1991, AM J HUM GENET, V48, P608; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROCHETTEEGLY C, 1988, GUT, V29, P571, DOI 10.1136/gut.29.5.571; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; SCHOLTE BJ, 1989, EXP CELL RES, V182, P559, DOI 10.1016/0014-4827(89)90259-0; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; TAYLOR CJ, 1988, GUT, V29, P957, DOI 10.1136/gut.29.7.957; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TILLY BC, 1991, J BIOL CHEM, V266, P2036; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, pC358; VIDAUD M, 1990, HUM GENET, V85, P446, DOI 10.1007/BF02428305; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WELSH MJ, 1986, NATURE, V322, P467, DOI 10.1038/322467a0; WIDDICOMBE JH, 1985, P NATL ACAD SCI USA, V82, P6167, DOI 10.1073/pnas.82.18.6167	54	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21239	21246						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1718974				2022-12-25	WOS:A1991GN00100101
J	ZIEGLER, A; KNESEL, J; FABBRO, D; NAGAMINE, Y				ZIEGLER, A; KNESEL, J; FABBRO, D; NAGAMINE, Y			PROTEIN-KINASE-C DOWN-REGULATION ENHANCES CAMP-MEDIATED INDUCTION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR MESSENGER-RNA IN LLC-PK1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE CARDIAC-MUSCLE; CYCLIC-AMP ACCUMULATION; ADENYLATE-CYCLASE ACTIVITY; ACTIN GENE-TRANSCRIPTION; LIGHT CHAIN KINASE; CATALYTIC SUBUNIT; PHORBOL-ESTER; CARCINOMA-CELLS; TUMOR PROMOTER; GROWTH-FACTOR	Expression of the urokinase-type plasminogen activator (uPA) gene in LLC-PK1 cells can be induced by signals mediated by both cAMP-dependent protein kinase (PKA) and Ca2+- and phospholipid-dependent protein kinase (PKC). We have utilized the tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA) to down-regulate PKC, in order to test for an effect on the PKA-mediated induction of the uPA gene expression. Incubation of cells for 24 h with 100 ng/ml TPA caused a marked decrease of PKC protein, both in cytosolic and particulate fractions, and an 85% reduction of total PKC activity. After down-regulation of PKC, uPA mRNA accumulation induced by 8-Br-cAMP was 5-10-fold higher than in control cells. Both uPA mRNA stability and uPA gene transcription rates induced by 8-Br-cAMP were increased by PKC down-regulation (6- and 1.8-fold, respectively). Although total PKA activity was reduced by 20% in extracts from PKC-depleted cells, activation of PKA by 8-Br-cAMP was 2.5-fold higher than in control cells. This enhanced activation of PKA in PKC- depleted cells also occurred in response to other cAMP derivatives and to cAMP induced endogenously by the activation of adenylate cyclase with forskolin, but was not due to down-regulation-associated changes in the rate of cAMP synthesis. Our results demonstrate that in LLC-PK, cells, down-regulation of PKC results in an enhanced induction of uPA gene expression by cAMP-mediated signals without alterations in adenylate cyclase activity, suggesting a mechanism distal to adenylate cyclase.	FRIEDRICH MIESCHER INST, POSTFACH 2543, CH-4002 BASEL, SWITZERLAND; UNIV HOSP BASEL, SCH MED, TUMORBIOL LAB, CH-4031 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; University of Basel				Ziegler, Annemarie/0000-0003-0018-7031				AASHEIM LH, 1989, CELL SIGNAL, V1, P617, DOI 10.1016/0898-6568(89)90070-3; ABOUSAMRA AB, 1987, J BIOL CHEM, V262, P1129; AKASHI M, 1989, BLOOD, V74, P2383; ALTUS MS, 1987, BIOCHEM J, V242, P387, DOI 10.1042/bj2420387; ANDRUS L, 1988, J BIOL CHEM, V263, P6183; BAND V, 1989, J CELL PHYSIOL, V138, P106, DOI 10.1002/jcp.1041380115; BEAVO JA, 1982, HDB EXPT PHARM, V58, P363; BELIN D, 1984, EMBO J, V3, P1901, DOI 10.1002/j.1460-2075.1984.tb02065.x; BELL JD, 1985, J BIOL CHEM, V260, P2625; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHOI EJ, 1988, J BIOL CHEM, V263, P17167; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1982, NATURE, V296, P613, DOI 10.1038/296613a0; CRONIN MJ, 1986, J BIOL CHEM, V261, P13932; DAYER JM, 1981, J CELL BIOL, V91, P195, DOI 10.1083/jcb.91.1.195; DEGEN JL, 1985, J BIOL CHEM, V260, P2426; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FABBRO D, 1985, ARCH BIOCHEM BIOPHYS, V239, P102, DOI 10.1016/0003-9861(85)90816-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEDLANDER G, 1987, BIOCHIM BIOPHYS ACTA, V929, P311, DOI 10.1016/0167-4889(87)90258-8; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HEMMINGS BA, 1986, FEBS LETT, V196, P126, DOI 10.1016/0014-5793(86)80226-5; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HEYWORTH CM, 1984, FEBS LETT, V170, P38, DOI 10.1016/0014-5793(84)81364-2; HOLLINGSWORTH EB, 1986, FEBS LETT, V196, P131, DOI 10.1016/0014-5793(86)80227-7; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; IKEBE M, 1985, J BIOL CHEM, V260, P4547; INOUE Y, 1989, J BIOL CHEM, V264, P8504; JANS DA, 1987, BIOCHEM J, V243, P413, DOI 10.1042/bj2430413; KIM UH, 1989, J BIOL CHEM, V264, P20167; KISHIMOTO A, 1977, J BIOL CHEM, V252, P7449; LI Y, 1989, ONCOGENE, V4, P795; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MALLER JL, 1978, P NATL ACAD SCI USA, V75, P248, DOI 10.1073/pnas.75.1.248; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MCATEE P, 1989, J BIOL CHEM, V264, P11193; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; NAGAMINE Y, 1983, CELL, V32, P1181, DOI 10.1016/0092-8674(83)90301-X; NAGAMINE Y, 1991, EMBO J, V10, P117, DOI 10.1002/j.1460-2075.1991.tb07927.x; NAGAMINE Y, 1984, NUCLEIC ACIDS RES, V12, P9525, DOI 10.1093/nar/12.24.9525; NAGHSHINEH S, 1986, J BIOL CHEM, V261, P4534; NAKAGAWA J, 1988, J BIOL CHEM, V263, P2460; NARINDRASORASAK S, 1987, J BIOL CHEM, V262, P10497; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8808; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PARKER PJ, 1984, EMBO J, V3, P953, DOI 10.1002/j.1460-2075.1984.tb01913.x; RAJ NBK, 1981, P NATL ACAD SCI-BIOL, V78, P7426, DOI 10.1073/pnas.78.12.7426; RANGELALDAO R, 1977, J BIOL CHEM, V252, P7140; RANGELALDAO R, 1976, J BIOL CHEM, V251, P7526; RANGELALDAO R, 1976, J BIOL CHEM, V251, P3375; RANNELS SR, 1980, J BIOL CHEM, V255, P7085; ROZENGURT E, 1987, P NATL ACAD SCI USA, V84, P2282, DOI 10.1073/pnas.84.8.2282; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHOJI S, 1979, J BIOL CHEM, V254, P6211; STOPPELLI MP, 1986, J CELL BIOL, V102, P1235, DOI 10.1083/jcb.102.4.1235; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUGDEN D, 1985, NATURE, V314, P359, DOI 10.1038/314359a0; TAMM I, 1978, ADV VIRUS RES, V22, P188; TAPIAARANCIBIA L, 1988, J NEUROSCI RES, V20, P195, DOI 10.1002/jnr.490200208; UZUMAKI H, 1986, BIOCHEM PHARMACOL, V35, P835, DOI 10.1016/0006-2952(86)90252-2; WALSH DA, 1979, BIOCH ACTIONS HORM, V6, P1; WARTMANN M, 1991, CELL REGUL, V2, P491, DOI 10.1091/mbc.2.6.491; WOLF M, 1985, J BIOL CHEM, V260, P5718; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZIEGLER A, 1990, J BIOL CHEM, V265, P21194	79	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21067	21074						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1718970				2022-12-25	WOS:A1991GN00100076
J	CHOI, YC; CHAE, CB				CHOI, YC; CHAE, CB			DNA HYPOMETHYLATION AND GERM CELL-SPECIFIC EXPRESSION OF TESTIS-SPECIFIC H2B HISTONE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION REGULATORY ELEMENTS; THYMIDINE KINASE GENE; CHROMATIN STRUCTURE; METHYLATED CPGS; BINDING-FACTOR; MOUSE; PROTEIN; PROMOTER; CYCLE; RNA	Testis-specific H2B (TH2B) histone gene of rat is expressed during meiotic event of spermatogenic differentiation. The gene is unusual in that it has conserved the regulatory elements involved in the S phase-specific transcription of somatic H2B genes as well as the S phase-specific stabilization of histone mRNA. Genomic sequencing revealed that all analyzed CpG sites in the promoter region of TH2B gene are methylated in somatic tissues but not in testis. During spermatogenesis, these CpG sites are unmethylated as early as spermatogonia type A and up to sperm. Thus, there is a good correlation between DNA hypomethylation and germ cell-specific expression of TH2B gene. Results obtained from in vivo DNase footprinting and DNA mobility shift experiments are consistent with the hypothesis that DNA methylation inhibits gene activity by preventing the binding of transcription factors to their recognition sequences. The results show that (i) the binding of ubiquitous transcription factors to the promoter region of TH2B gene may be blocked in nuclei of liver, and (ii) DNA methylation can directly interfere with the binding of transcription factors recognizing a hexamer (ACGTCA) motif. In vitro DNA methylation and transfection experiments demonstrated that expression of TH2B gene is inhibited by DNA methylation in vivo. These findings indicate that DNA methylation may play a key role in the transcriptional repression of germ cell-specific TH2B gene.			CHOI, YC (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020136] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20136] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ARIEL M, 1991, P NATL ACAD SCI USA, V88, P2317, DOI 10.1073/pnas.88.6.2317; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; BUSCHHAUSEN G, 1985, NUCLEIC ACIDS RES, V13, P5503, DOI 10.1093/nar/13.15.5503; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU ML, 1985, ARCH BIOCHEM BIOPHYS, V236, P260, DOI 10.1016/0003-9861(85)90625-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE KD, 1986, J BIOL CHEM, V261, P7178; DANDREA RJ, 1985, MOL CELL BIOL, V5, P3108, DOI 10.1128/MCB.5.11.3108; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HERMANN R, 1989, J MOL BIOL, V210, P411, DOI 10.1016/0022-2836(89)90340-9; HWANG I, 1990, MOL CELL BIOL, V10, P585, DOI 10.1128/MCB.10.2.585; HWANG IH, 1989, MOL CELL BIOL, V9, P1005, DOI 10.1128/MCB.9.3.1005; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KIM YJ, 1987, DEV BIOL, V124, P23, DOI 10.1016/0012-1606(87)90455-6; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; LABELLA F, 1988, GENE DEV, V2, P32, DOI 10.1101/gad.2.1.32; Maxam A M, 1980, Methods Enzymol, V65, P499; MAXSON R, 1983, ANNU REV GENET, V17, P239, DOI 10.1146/annurev.ge.17.120183.001323; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEISTRICH M L, 1987, P333; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; MILLER JR, 1978, CELL, V13, P717; MONK M, 1987, DEVELOPMENT, V99, P371; OBRIEN DA, 1980, DEV BIOL, V75, P386, DOI 10.1016/0012-1606(80)90171-2; OHMORI H, 1978, NUCLEIC ACIDS RES, V8, P1479; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; SALUZ H, 1989, P NATL ACAD SCI USA, V86, P2602, DOI 10.1073/pnas.86.8.2602; SALUZ HP, 1987, LABORATORY GUIDE GEN; SCHUMPERLI D, 1988, TRENDS GENET, V4, P187, DOI 10.1016/0168-9525(88)90074-1; SHIURBA R, 1979, P NATL ACAD SCI USA, V76, P3947, DOI 10.1073/pnas.76.8.3947; SITTMAN DB, 1983, P NATL ACAD SCI-BIOL, V80, P1849, DOI 10.1073/pnas.80.7.1849; STAUBER C, 1986, EMBO J, V5, P3297, DOI 10.1002/j.1460-2075.1986.tb04643.x; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; WOLFE SA, 1989, BIOCHIM BIOPHYS ACTA, V1007, P140, DOI 10.1016/0167-4781(89)90032-8; WOLGEMUTH DJ, 1985, GAMETE RES, V12, P1, DOI 10.1002/mrd.1120120102; YOUNG PR, 1984, MOL CELL BIOL, V4, P898, DOI 10.1128/MCB.4.5.898	52	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20504	20511						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1718964				2022-12-25	WOS:A1991GM03900094
J	FARRAR, MA; FERNANDEZLUNA, J; SCHREIBER, RD				FARRAR, MA; FERNANDEZLUNA, J; SCHREIBER, RD			IDENTIFICATION OF 2 REGIONS WITHIN THE CYTOPLASMIC DOMAIN OF THE HUMAN INTERFERON-GAMMA RECEPTOR REQUIRED FOR FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; MURINE PERITONEAL-MACROPHAGES; IFN-GAMMA; EXPRESSION; CELLS; CDNA; CLONING; PURIFICATION; MOUSE; DNA	Functionally active human interferon-gamma (IFN-gamma) receptors require the presence of at least two polypeptides: the IFN-gamma receptor and an accessory molecule encoded by a gene on human chromosome 21. Here we have used a murine L cell line that stably contains human chromosome 21 (SCC16-5) to determine whether the receptor's cytoplasmic domain is important for receptor function. SCC16-5 stably transfected with the full-length human IFN-gamma receptor cDNA bound, internalized, and responded to human IFN-gamma. In contrast, SCC16-5 expressing human IFN-gamma receptors lacking a cytoplasmic domain bound human IFN-gamma but did not internalize or respond to it. Using a family of IFN-gamma receptor deletion mutants, two functionally important regions within the intracellular domain were identified: (a) a membrane proximal region (residues 256-303) required for ligand processing and biologic responsiveness and (b) the carboxyl-terminal 39 amino acids (residues 434-472) needed exclusively for biologic responses.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,BOX 8118,660 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)			Farrar, Michael A/M-7802-2013; Schreiber, Robert D/A-1276-2013; Schreiber, Robert/Q-7550-2019	Schreiber, Robert D/0000-0001-6311-0432; Farrar, Michael/0000-0002-5569-0366	NCI NIH HHS [CA43059] Funding Source: Medline; NIAID NIH HHS [AI24854] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043059, R37CA043059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024854] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUET M, 1987, J EXP MED, V165, P988, DOI 10.1084/jem.165.4.988; BASU MT, 1988, P NATL ACAD SCI USA, V85, P6282, DOI 10.1073/pnas.85.17.6282; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CALDERON J, 1988, P NATL ACAD SCI USA, V85, P4837, DOI 10.1073/pnas.85.13.4837; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CELADA A, 1985, J CLIN INVEST, V76, P2196, DOI 10.1172/JCI112228; CELADA A, 1986, J IMMUNOL, V137, P2373; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; COFANO F, 1990, J BIOL CHEM, V265, P4064; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FAN XD, 1988, P NATL ACAD SCI USA, V85, P5122, DOI 10.1073/pnas.85.14.5122; FIDLER IJ, 1985, J IMMUNOL, V135, P4289; FISCHER T, 1990, Cytokine, V2, P157, DOI 10.1016/1043-4666(90)90010-Q; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P1368; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; HAMILTON TA, 1985, J BIOL CHEM, V260, P1378; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HERSHEY GKK, 1989, J BIOL CHEM, V264, P11981; HERSHEY GKK, 1990, J BIOL CHEM, V265, P17868; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HORII Y, 1989, J IMMUNOL, V143, P3949; JANSSEN JWG, 1986, CYTOMETRY, V7, P411, DOI 10.1002/cyto.990070504; JUNG V, 1990, J BIOL CHEM, V265, P1827; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KOIDE Y, 1988, P NATL ACAD SCI USA, V85, P3120, DOI 10.1073/pnas.85.9.3120; KUMAR CS, 1989, J BIOL CHEM, V264, P17939; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LOTZ M, 1988, J EXP MED, V167, P1253, DOI 10.1084/jem.167.3.1253; MAO C, 1990, J IMMUNOL, V145, P3949; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; PRPIC V, 1989, SCIENCE, V244, P469, DOI 10.1126/science.2541500; REHBERG E, 1982, J BIOL CHEM, V257, P1497; SANCEAU J, 1987, P NATL ACAD SCI USA, V84, P2906, DOI 10.1073/pnas.84.9.2906; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEEHAN KCF, 1988, J IMMUNOL, V140, P4231; SMITH MR, 1990, J IMMUNOL, V144, P1777; SOMERS SD, 1986, J IMMUNOL, V136, P4199; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAN YH, 1973, J EXP MED, V137, P317, DOI 10.1084/jem.137.2.317; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; UCER U, 1986, CANCER RES, V46, P5339; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; VILCEK J, 1985, LYMPHOKINES, V11, P1	48	91	93	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19626	19635						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717469				2022-12-25	WOS:A1991GK66700073
J	CHANG, WC; NING, CC; LIN, MT; HUANG, JD				CHANG, WC; NING, CC; LIN, MT; HUANG, JD			EPIDERMAL GROWTH-FACTOR ENHANCES A MICROSOMAL 12-LIPOXYGENASE ACTIVITY IN A431 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; LIPOXYGENASE PRODUCTS; POLYMORPHONUCLEAR LEUKOCYTES; ENDOTHELIAL-CELLS; BLOOD-PLATELETS; CYTOCHROME-P-450; IDENTIFICATION; OXYGENATION; STIMULATION; ACTIVATION	12-Hydroxyeicosatetraenoic acid (12-HETE) is formed from arachidonic acid either by 12-lipoxygenase or by a cytochrome P450 monooxygenase. 12-Lipoxygenase is generally localized in the soluble cytosolic fraction, and the cytochrome P450 monooxygenase is a microsomal enzyme. In this study, 12-HETE biosynthesis and the regulation of 12-HETE biosynthesis by epidermal growth factor (EGF) in A431 cells were investigated. 12-HETE was biosynthesized from arachidonic acid by the microsomal fraction of A431 cells, but not by the cytosolic fraction. The formation of 12-HETE was inhibited by 5,8,11,14-eicosatetraynoic acid, nordihydroguaiaretic acid, and caffeic acid. Nordihydroguaiaretic acid at 10(-4) m and 5,8,11,14-eicosatetraynoic acid at 10(-5) M almost completely inhibited its formation. However, the formation of 12-HETE was not affected by the presence of an NADPH-generating system, carbon monoxide, or SKF 525A. The biosynthetic 12-HETE was analyzed by chiral stationary phase high performance liquid chromatography and was highly enriched in (12S)-HETE. We therefore concluded that the enzyme responsible for the formation of (12S)-HETE in the microsomes of A431 cells is a 12-lipoxygenase. The microsomal 12-lipoxygenase of A431 cells belongs to the "leukocyte-type" enzyme as determined by substrate specificity and enzyme kinetics studies. The microsomal 12-lipoxygenase oxygenated linoleic acid much faster than the cytosolic platelet 12-lipoxygenase and is a "self-catalyzed inactivation" enzyme. Treatment of cells with 50 ng/ml EGF significantly induced microsomal 12-lipoxygenase activity. The lag period for the expression of the stimulatory effect of EGF on 12-lipoxygenase activity was approximately 10 h. The stimulatory effect of EGF on 12-lipoxygenase activity was completely blocked by treatment with 35-mu-M cycloheximide, indicating a requirement for de novo protein biosynthesis. Furthermore, the presence of the endogenous inhibitor of 12-lipoxygenase (which masked (12S)-HETE biosynthesis in intact cells) was identified in the cytosolic fraction of A431 cells. The putative inhibitor was enzyme-selective. It inhibited the leukocyte-type 12-lipoxygenase, but not the "platelet-type" enzyme.	NATL CHENG KUNG UNIV,COLL MED,DEPT BIOCHEM,TAINAN,TAIWAN	National Cheng Kung University	CHANG, WC (corresponding author), NATL CHENG KUNG UNIV,COLL MED,DEPT PHARMACOL,TAINAN,TAIWAN.							BAILEY JM, 1988, BIOCHEM BIOPH RES CO, V157, P1159, DOI 10.1016/S0006-291X(88)80995-1; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CAPDEVILA J, 1986, BIOCHEM BIOPH RES CO, V141, P1007, DOI 10.1016/S0006-291X(86)80144-9; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CAREY ML, 1988, J BIOL CHEM, V263, P7846; CHANG WC, 1988, PROSTAG LEUKOTR ESS, V33, P159; CHANG WC, 1982, BIOCHEM J, V202, P771, DOI 10.1042/bj2020771; CHAPRON Y, 1989, BIOCHEM BIOPH RES CO, V158, P527, DOI 10.1016/S0006-291X(89)80081-6; CUNNINGHAM FM, 1987, PROSTAGLANDINS, V34, P71, DOI 10.1016/0090-6980(87)90264-4; DUNN JR, 1987, PROSTAGLANDINS CANCE, P257; FAGAN JM, 1986, P NATL ACAD SCI USA, V83, P2771, DOI 10.1073/pnas.83.8.2771; FALES HM, 1973, ANAL CHEM, V45, P2302, DOI 10.1021/ac60335a020; GEROZISSIS K, 1985, NEUROENDOCRINOLOGY, V40, P272, DOI 10.1159/000124084; GROSSI IM, 1989, CANCER RES, V49, P1029; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HANSBROUGH JR, 1990, J BIOL CHEM, V265, P1771; HO PPK, 1977, BIOCHEM BIOPH RES CO, V76, P398, DOI 10.1016/0006-291X(77)90738-0; HURST JS, 1991, J BIOL CHEM, V266, P6726; KOSHIHARA Y, 1984, BIOCHIM BIOPHYS ACTA, V792, P92; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU AYH, 1980, PHARMACOL REV, V31, P277; MAHLER HR, 1955, METHOD ENZYMOL, V2, P688, DOI 10.1016/S0076-6879(55)02284-2; MASFERRER JL, 1990, INVEST OPHTH VIS SCI, V31, P535; MASS RL, 1981, P NATL ACAD SCI USA, V78, P5523; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MORRISON AR, 1981, P NATL ACAD SCI-BIOL, V78, P7375, DOI 10.1073/pnas.78.12.7375; NAKAO J, 1982, ATHEROSCLEROSIS, V44, P339, DOI 10.1016/0021-9150(82)90008-9; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; OLIW EH, 1982, J BIOL CHEM, V257, P3771; SCHWARTZMAN ML, 1987, P NATL ACAD SCI USA, V84, P8125, DOI 10.1073/pnas.84.22.8125; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SHINJO F, 1986, J BIOL CHEM, V261, P3377; TAKAHASHI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P613, DOI 10.1016/0003-9861(88)90294-9; TURK J, 1983, BIOCHIM BIOPHYS ACTA, V750, P78, DOI 10.1016/0005-2760(83)90206-0; UEDA N, 1990, J BIOL CHEM, V265, P2311; WALSTRA P, 1987, BIOCHIM BIOPHYS ACTA, V921, P312, DOI 10.1016/0005-2760(87)90032-4; WOOLLARD PM, 1986, BIOCHEM BIOPH RES CO, V136, P169, DOI 10.1016/0006-291X(86)90891-0; WU KK, 1988, J BIOL CHEM, V263, P19043; YAMAMOTO S, 1991, FREE RADICAL BIO MED, V10, P149, DOI 10.1016/0891-5849(91)90008-Q; YAMAMOTO T, 1982, BIOCHIM BIOPHYS ACTA, V713, P638; YOKOTA K, 1986, J BIOL CHEM, V261, P5410	42	73	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3657	3666						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740418				2022-12-25	WOS:A1992HE60700020
J	ARAI, N; KAWASAKI, K; SHIBATA, T				ARAI, N; KAWASAKI, K; SHIBATA, T			A MULTICOMPONENT PROTEIN OF A FISSION YEAST THAT PROMOTES JOINT MOLECULE FORMATION FROM HOMOLOGOUS DNAS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED FRAGMENTS; COLI RECA PROTEIN; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; PARTIAL-PURIFICATION; SUPERHELICAL DNA; BINDING PROTEIN; MEIOTIC CELLS; D-LOOPS	We developed a quantitative assay (''homologous pairing gel assay'') adequate for the purification of the activity promoting the formation of joint molecules, an intermediate of homologous recombination (''homologous pairing''). With this assay, one can measure the extent of homologous pairing between a single-stranded DNA and a strand of H-3-labeled double-stranded DNA by crude enzyme preparations. Since the total activity did not significantly change during the sporulation process, we tried to purify the activity from a whole cell extract of mitotic cells of a fission yeast, (Schizosaccharomyces pombe). Through quantitative assaying of a single fraction or of mixed fractions, we obtained three fractions, all of which were required for the maximum level of the ATP-independent homologous pairing: Fractions 65, 100, and 30. In Fractions 100 and 30, polypeptides of approximately 100 and approximately 30 kDa (the 100- and 30-kDa polypeptides), respectively, were the sole detectable components. Fraction 65 contained a polypeptide of approximately 65 kDa (the 65-kDa polypeptide) as the major component and also small amounts of the 30- and 100-kDa polypeptides. Fraction 65 by itself promoted homologous pairing, but the reaction was saturated at a level of approximately 20% of the maximum level achieved with the recA protein. Even when added in excess, Fraction 30 or 100 alone did not promote detectable homologous pairing. A mixture of Fractions 65 and 100 at a rather strict optimum ratio only promoted homologous pairing, the level being 50-70% that with the recA protein, suggesting a stoichiometric complex of these polypeptides as the active form. Fraction 30 alone did not enhance the reaction with Fraction 65, but stimulated homologous pairing promoted by the optimum mixture of Fractions 65 and 100 to the maximum level achieved with the recA protein. Therefore, the homologous pairing-promoting protein from the fission yeast is likely to be a multicomponent protein.	SAITAMA UNIV,GRAD SCH SCI & ENGN,URAWA,SAITAMA 338,JAPAN	Saitama University	ARAI, N (corresponding author), RIKEN INST PHYS & CHEM RES,MICROBIOL,WAKO,SAITAMA 35101,JAPAN.							BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHOW SA, 1988, J BIOL CHEM, V263, P200; CLARK AJ, 1965, P NATL ACAD SCI USA, V53, P451, DOI 10.1073/pnas.53.2.451; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; EISEN A, 1988, P NATL ACAD SCI USA, V85, P7481, DOI 10.1073/pnas.85.20.7481; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HEYER WD, 1989, BIOCHEMISTRY-US, V28, P2856, DOI 10.1021/bi00433a017; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; HSIEH P, 1986, CELL, V44, P885, DOI 10.1016/0092-8674(86)90011-5; KOBAYASHI I, 1978, MOL GEN GENET, V166, P25, DOI 10.1007/BF00379725; KOCHOYAN M, 1987, J MOL BIOL, V196, P599, DOI 10.1016/0022-2836(87)90036-2; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LOVETT CM, 1985, J BIOL CHEM, V260, P3305; LOWENHAUPT K, 1989, J BIOL CHEM, V264, P20568; MCCARTHY JG, 1988, P NATL ACAD SCI USA, V85, P5854, DOI 10.1073/pnas.85.16.5854; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MERRIL CR, 1979, P NATL ACAD SCI USA, V76, P4335, DOI 10.1073/pnas.76.9.4335; MOORE SP, 1990, J BIOL CHEM, V265, P11108; OFARRELL PZ, 1973, J BIOL CHEM, V248, P5499; RADDING CM, 1978, ANNU REV BIOCHEM, V47, P847, DOI 10.1146/annurev.bi.47.070178.004215; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHIBATA T, 1983, METHOD ENZYMOL, V100, P197; SHIBATA T, 1982, J BIOL CHEM, V257, P3981; SHIBATA T, 1980, P NATL ACAD SCI-BIOL, V77, P2606, DOI 10.1073/pnas.77.5.2606; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; Whitehouse H. L. K., 1982, GENETIC RECOMBINATIO; YONESAKI T, 1985, EMBO J, V4, P3321, DOI 10.1002/j.1460-2075.1985.tb04083.x	37	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3514	3522						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737802				2022-12-25	WOS:A1992HD15400105
J	GREEN, A; MILLIGAN, G; DOBIAS, SB				GREEN, A; MILLIGAN, G; DOBIAS, SB			GI DOWN-REGULATION AS A MECHANISM FOR HETEROLOGOUS DESENSITIZATION IN ADIPOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A1 ADENOSINE RECEPTOR; ADENYLATE CYCLASE SYSTEM; RAT FAT-CELLS; MEDIATED INHIBITION; GUANINE-NUCLEOTIDE; INSULIN-RECEPTORS; NICOTINIC-ACID; MESSENGER-RNA; PROLONGED INCUBATION; RADIOLIGAND BINDING	Prolonged incubation of rat adipocytes with (-)N6-phenylisopropyl adenosine (PIA) (an A1 adenosine receptor agonist) leads to down-regulation of each of the three subtypes of G(i) (Green, A., Johnson, J. L., and Milligan, G. (1990) J. Biol. Chem. 265, 5206-5210). To determine whether other inhibitors of adenylylcyclase would have similar actions, we incubated adipocytes in primary culture with PIA, prostaglandin E1 (PGE1), or nicotinic acid. After various times cells were homogenized, and crude membrane fractions were analyzed on Western blots using antipeptide antisera to alpha- and beta-subunits of G-proteins (SG1 (which binds to alpha(i)1 and alpha(i)2), I3B (which binds to alpha(i)3), BN2 (binds to beta-subunits) and CS1 (recognizes forms of alpha(s))). PIA and PGE1 caused approximately 90% down-regulation of alpha(i)1 and alpha(i)3, and about 50% loss of alpha(i)2 and beta-subunits. In contrast, nicotinic acid at concentrations up to 1 mM had no effect on levels of any of these G(i) subtypes. None of the compounds altered levels of either a 43- or 47-kDa form of alpha(s). PIA caused about a 50% decrease in binding of [H-3]DPCPX (an A1 adenosine receptor antagonist), indicating adenosine receptor down-regulation; however, neither PGE1 nor nicotinic acid treatment altered [H-3]DPCPX binding. None of the treatments affected the activity of adenylylcyclase when measured in the presence of 100-mu-M forskolin and 10 mM Mn2+, indicating that the catalytic subunit of adenylylcyclase is not altered. To determine whether G(i) down-regulation results in heterologous desensitization, we incubated adipocytes with maximally effective concentrations of PIA (300 nM), PGE1 (3-mu-M), or nicotinic acid (1 mM) for 4 days. The cells were then washed and incubated for an additional 30 min with various concentrations of these compounds to determine their ability to inhibit lipolysis. PIA caused a (marked) decrease in the sensitivity of the cells to both PIA and PGE1, thus indicating heterologous desensitization. Similarly, PGE1 decreased the sensitivity of the cells to both PGE1 and PIA, again demonstrating heterologous desensitization. In contrast, prolonged incubation with nicotinic acid decreased the sensitivity of the cells to nicotinic acid but had no effect on the sensitivity of the cells to PIA. Adenylylcyclase in membranes from PGE1-treated cells showed decreased sensitivity to inhibition by PIA. In contrast, adenylylcyclase showed normal sensitivity to PIA in membranes from nicotinic acid-treated cells. Together with the finding that PGE1 has no effect on either A1 adenosine receptors nor on the catalytic subunit of adenylylcyclase, these findings suggest that heterologous desensitization of lipolysis is at least partly due to down-regulation of the G-protein(s) responsible for inhibition of adenylylcyclase.	UNIV GLASGOW,DEPT BIOCHEM,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,SCOTLAND; UNIV GLASGOW,DEPT PHARMACOL,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow; University of Glasgow	GREEN, A (corresponding author), UNIV TEXAS,MED BRANCH,DEPT INTERNAL MED,MED RES BLDG 3142,RT J-60,GALVESTON,TX 77550, USA.		Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040061] Funding Source: NIH RePORTER; NIDDK NIH HHS [R-01 DK 40061] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKTORIES K, 1980, N-S ARCH PHARMACOL, V312, P167, DOI 10.1007/BF00569726; AKTORIES K, 1983, FEBS LETT, V156, P88, DOI 10.1016/0014-5793(83)80254-3; ALVAREZ R, 1990, ANAL BIOCHEM, V187, P98, DOI 10.1016/0003-2697(90)90423-7; ATTALI B, 1989, J NEUROCHEM, V53, P1636, DOI 10.1111/j.1471-4159.1989.tb08562.x; BARBER R, 1989, MOL PHARMACOL, V36, P459; BELSHAM GJ, 1980, BIOCHEM J, V192, P457, DOI 10.1042/bj1920457; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; DALY JW, 1984, ADV CYCLIC NUCL PROT, V17, P81; GARVEY WT, 1986, DIABETES, V35, P258, DOI 10.2337/diabetes.35.3.258; GREEN A, 1986, FEBS LETT, V206, P130, DOI 10.1016/0014-5793(86)81354-0; GREEN A, 1984, DIABETES, V33, P1045, DOI 10.2337/diabetes.33.11.1045; GREEN A, 1986, BIOCHEM J, V238, P663, DOI 10.1042/bj2380663; GREEN A, 1987, J BIOL CHEM, V262, P15702; GREEN A, 1982, P NATL ACAD SCI-BIOL, V79, P427, DOI 10.1073/pnas.79.2.427; GREEN A, 1983, BIOCHEM J, V212, P189, DOI 10.1042/bj2120189; GREEN A, 1990, J BIOL CHEM, V265, P5206; GRIER CE, 1989, J BIOL CHEM, V264, P5384; HADCOCK JR, 1991, J BIOL CHEM, V266, P11915; HADCOCK JR, 1989, J BIOL CHEM, V264, P19928; HARAGUCHI K, 1990, P NATL ACAD SCI USA, V87, P1208, DOI 10.1073/pnas.87.3.1208; HO RJ, 1984, J BIOL CHEM, V259, P7630; HOFFMAN BB, 1986, J CLIN INVEST, V78, P185, DOI 10.1172/JCI112550; HOFFMAN BB, 1989, ENDOCRINOLOGY, V124, P2434, DOI 10.1210/endo-124-5-2434; KIRCHICK HJ, 1983, ENDOCRINOLOGY, V113, P1638, DOI 10.1210/endo-113-5-1638; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; LOHSE MJ, 1987, N-S ARCH PHARMACOL, V336, P204, DOI 10.1007/BF00165806; LONGABAUGH JP, 1989, MOL PHARMACOL, V36, P681; MARCUS C, 1989, PEDIATR RES, V26, P255, DOI 10.1203/00006450-198909000-00020; MARSHALL S, 1981, J BIOL CHEM, V256, P1464; MARSHALL S, 1984, J BIOL CHEM, V259, P6376; MARSHALL S, 1985, J BIOL CHEM, V260, P4128; MCGOWAN MW, 1983, CLIN CHEM, V29, P538; MCKENZIE FR, 1990, J BIOL CHEM, V265, P17084; MCKENZIE FR, 1990, BIOCHEM J, V267, P391, DOI 10.1042/bj2670391; MILLAR JBA, 1989, P NATL ACAD SCI USA, V86, P3204, DOI 10.1073/pnas.86.9.3204; MITCHELL FM, 1989, BIOCHEM J, V262, P403, DOI 10.1042/bj2620403; PARSONS WJ, 1987, J BIOL CHEM, V262, P841; PREMONT RT, 1989, ENDOCRINOLOGY, V125, P1151, DOI 10.1210/endo-125-3-1151; REBOURCET MC, 1988, BIOCHEM J, V252, P679, DOI 10.1042/bj2520679; REITHMANN C, 1989, EUR J PHARM-MOLEC PH, V172, P211, DOI 10.1016/0922-4106(89)90051-5; RODBELL M, 1964, J BIOL CHEM, V239, P375; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STEHLE RG, 1982, METHOD ENZYMOL, V86, P436; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; UKENA D, 1984, N-S ARCH PHARMACOL, V326, P241, DOI 10.1007/BF00505325; UKENA D, 1985, PHARMACOLOGY, V30, P153, DOI 10.1159/000138064; WIESER PB, 1975, ENDOCRINOLOGY, V96, P1221, DOI 10.1210/endo-96-5-1221	52	89	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3223	3229						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737778				2022-12-25	WOS:A1992HD15400064
J	SVENSSON, EC; CONLEY, PB; PAULSON, JC				SVENSSON, EC; CONLEY, PB; PAULSON, JC			REGULATED EXPRESSION OF ALPHA-2,6-SIALYLTRANSFERASE BY THE LIVER-ENRICHED TRANSCRIPTION FACTORS HNF-1, DBP, AND LAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; HAMSTER OVARY CELLS; ENHANCER BINDING-PROTEIN; MOUSE ALBUMIN PROMOTER; KINASE GENE PROMOTER; DNA-BINDING; TERMINAL GLYCOSYLATION; ANTIGEN RECEPTOR; SEQUENCE	Tissue-specific carbohydrate structures are thought to result from the selective expression of specific terminal glycosyltransferases responsible for their synthesis. However, little is known about the regulation of the expression of these enzymes. Previous analysis of the distribution of one such enzyme, beta-galactoside alpha-2,6-sialyltransferase, revealed that its expression is tissue restricted, with highest levels being found in the liver. Examination of the gene suggested that its expression is regulated at the level of transcription by multiple promoters, one of which is strongly active in the liver. In this present work, an analysis of the liver-restricted promoter was undertaken to identify the promoter elements necessary for liver-restricted expression. Footprinting studies, 5' deletion analysis, and site-directed mutagenesis identified two cis-elements which were potentially important in the tissue-specific expression of this promoter. One of these elements contains a consensus binding site for the liver-enriched transcription factor hepatocyte nuclear factor-1-alpha, while the other is a consensus binding site for the liver-specific factors D-binding protein and liver-enriched transcriptional activator protein. Expression vectors containing cDNAs of these factors are capable of trans-activating transcription of the alpha-2,6ST promoter, demonstrating their ability to regulate transcription of this promoter. Together, these results suggest that tissue-specific glycosylation can be regulated at the level of transcription by the same factors involved in the expression of a number of other tissue-specific genes.	STANFORD UNIV, MED CTR,SCH MED,HOWARD HUGHES MED INST, BECKMAN CTR MOLEC & GENET MED, STANFORD, CA 94305 USA; Scripps Res Inst, DEPT CHEM & MOLEC BIOL, SAN DIEGO, CA 92121 USA; CYTEL CORP, SAN DIEGO, CA 92121 USA	Howard Hughes Medical Institute; Stanford University; Scripps Research Institute	SVENSSON, EC (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA.		Paulson, James/AAG-3565-2019		NICHD NIH HHS [HD-07201] Funding Source: Medline; NIGMS NIH HHS [GM-08042, GM-27904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008042, R01GM027904] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BERGER SL, 1987, METHOD ENZYMOL, V152, P725; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORGMEYER U, 1984, NUCLEIC ACIDS RES, V12, P4295, DOI 10.1093/nar/12.10.4295; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DYNAN WS, 1987, TRENDS GENET, V3, P121, DOI 10.1016/0168-9525(87)90200-9; ERNST LK, 1989, J BIOL CHEM, V264, P3436; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HEARD JM, 1987, MOL CELL BIOL, V7, P2425, DOI 10.1128/MCB.7.7.2425; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; KARIN M, 1990, TRENDS GENET, V6, P92, DOI 10.1016/0168-9525(90)90100-K; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LAVINE M, 1988, CELL, V55, P537; LEE EU, 1989, J BIOL CHEM, V264, P13848; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; POTVIN B, 1990, J BIOL CHEM, V265, P1615; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WEN D, 1991, IN PRESS J BIOL CHEM; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	53	86	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3466	3472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737800				2022-12-25	WOS:A1992HD15400099
J	WALKER, MW; BOBAK, DA; TSAI, SC; MOSS, J; VAUGHAN, M				WALKER, MW; BOBAK, DA; TSAI, SC; MOSS, J; VAUGHAN, M			GTP BUT NOT GDP ANALOGS PROMOTE ASSOCIATION OF ADP-RIBOSYLATION FACTORS, 20-KDA PROTEIN ACTIVATORS OF CHOLERA-TOXIN, WITH PHOSPHOLIPIDS AND PC-12 CELL-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING-PROTEINS; ADENYLATE-CYCLASE; REGULATORY COMPONENT; GUANINE-NUCLEOTIDES; PLASMA-MEMBRANES; MESSENGER-RNA; BOVINE BRAIN; VESICLES; RAS; YEAST	ADP-ribosylation factors (ARFs) are a family of approximately 20-kDa guanine nucleotide-binding proteins initially identified by their ability to enhance cholera toxin ADP-ribosyltransferase activity in the presence of GTP. ARFs have been purified from both membrane and cytosolic fractions. ARF purified from bovine brain cytosol requires phospholipid plus detergent for high affinity guanine nucleotide binding and for optimal enhancement of cholera toxin ADP-ribosyltransferase activity. The phospholipid requirements, combined with a putative role for ARF in vesicular transport, suggested that the soluble protein might interact reversibly with membranes. A polyclonal antibody against purified bovine ARF (sARF II) was used to detect ARF by immunoblot in membrane and soluble fractions from rat pheochromocytoma (PC-12) cell homogenates. ARF was predominantly cytosolic but increased in membranes during incubation of homogenates with nonhydrolyzable GTP analogues guanosine 5'-O-(3-thiotriphosphate), guanylyl-(beta-gamma-imido)-diphosphate, and guanylyl-(beta-gamma-methylene)-diphosphate, and to a lesser extent, adenosine 5'-O-(3-thiotriphosphate). GTP, GDP, GMP, and ATP were inactive. Cytosolic ARF similarly associated with added phosphatidylserine, phosphatidylinositol, or cardiolipin in GTP-gamma-S-dependent fashion. ARF binding to phosphatidylserine was reversible and coincident with stimulation of cholera toxin-catalyzed ADP-ribosylation. These observations may reflect a mechanism by which ARF could cycle between soluble and membrane compartments in vivo.			WALKER, MW (corresponding author), NHLBI,CELLULAR METAB LAB,BLDG 10,RM 5N307,900 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALCH WE, 1989, J BIOL CHEM, V264, P16965; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BOBAK DA, 1990, ADP RIBOSYLATING TOX, P439; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DONATO R, 1990, FEBS LETT, V262, P72, DOI 10.1016/0014-5793(90)80157-E; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HAYDEN SM, 1990, J CELL BIOL, V111, P443, DOI 10.1083/jcb.111.2.443; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; Kirby CJ, 1984, LIPOSOME TECHNOLOGY, V1, P19; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB TD, 1988, J PHYSIOL-LONDON, V401, pP94; LEVITZKI A, 1984, RECEPTORS QUANTITATI, P9; MCCORMICK F, 1990, ONCOGENE, V5, P1281; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OTERO AD, 1990, BIOCHEM PHARMACOL, V39, P1399; OTERO AS, 1988, SCIENCE, V242, P443, DOI 10.1126/science.3051383; PENG Z, 1989, Biofactors, V2, P45; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; REGAZZI R, 1991, BIOCHEM J, V275, P639, DOI 10.1042/bj2750639; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SERAFINI T, 1990, J CELL BIOCHEM, V14, P64; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1991, J BIOL CHEM, V266, P8213; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WIEDENMANN B, 1988, FEBS LETT, V240, P71, DOI 10.1016/0014-5793(88)80342-9; WOLF M, 1990, BIOCHEM J, V269, P723, DOI 10.1042/bj2690723	48	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3230	3235						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737779				2022-12-25	WOS:A1992HD15400065
J	WANG, YC; RUBENSTEIN, PA				WANG, YC; RUBENSTEIN, PA			CHOICE OF 3' CLEAVAGE POLYADENYLATION SITE IN BETA-TROPOMYOSIN RNA PROCESSING IS DIFFERENTIATION-DEPENDENT IN MOUSE BC3H1 MUSCLE-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN-EMBRYO FIBROBLASTS; TISSUE-SPECIFIC EXPRESSION; MESSENGER-RNA; SMOOTH-MUSCLE; UNTRANSLATED REGION; GENE-EXPRESSION; SKELETAL-MUSCLE; RIBONUCLEIC-ACID; CODING REGION; SELECTIVE USE	The rodent beta-tropomyosin (TM) gene produces either a 1.2-kilobase (kb) skeletal muscle beta-TM mRNA or a 1.1-kb fibroblast/smooth muscle TM-1 mRNA through tissue-specific alternative exon splicing and 3' cleavage/polyadenylation at two alternative poly(A) sites. beta-TM mRNA contains exon 6b, 9a, and the poly(A) site immediately following exon 9a, whereas TM-1 mRNA contains exon 6a, 9b, and the poly(A) site following exon 9b. We isolated a novel 2.1-kb beta-TM cDNA clone, pUTM, from a cDNA library of 2-day differentiated mouse BC3H, muscle-like cells. This cDNA contains the entire sequence of mature beta-TM mRNA with a normal but unused poly(A) site associated with exon 9a. Instead, 3' cleavage/polyadenylation of this cDNA occurred at the exon 9b-associated distal poly(A) site, resulting in the retention of a 1-kb intron and the TM-1 exon 9b. We identified a 2.3-kb functional mRNA, UTM RNA, corresponding to pUTM. UTM RNA appeared early during BC3H1 cell differentiation and gradually decreased as the beta-TM mRNA increased. UTM RNA was also detected in mouse C2C12 muscle cells and in skeletal muscle tissue isolated from mouse leg. Thus, in the processing of beta-TM gene transcripts, selection of alternative terminal exons and alternative poly(A) sites are not necessarily linked as they appear to be in other gene systems.	UNIV IOWA, COLL MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, CARDIOVASC RES CTR, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa				Rubenstein, Peter/0000-0003-1225-4414	PHITPO CDC HHS [HK-14388] Funding Source: Medline	PHITPO CDC HHS		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; AMARA SG, 1984, MOL CELL BIOL, V4, P2151, DOI 10.1128/MCB.4.10.2151; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; CAPETANAKI YG, 1983, CELL, V35, P411, DOI 10.1016/0092-8674(83)90174-5; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUMMINS P, 1974, BIOCHEM J, V141, P43, DOI 10.1042/bj1410043; DANNER D, 1985, P NATL ACAD SCI USA, V82, P8658, DOI 10.1073/pnas.82.24.8658; DAVIS LG, 1986, BASIC METHODS MOL BI, P44; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITZGERALD M, 1981, CELL, V24, P251, DOI 10.1016/0092-8674(81)90521-3; FORRYSCHAUDIES S, 1990, J MOL BIOL, V211, P321, DOI 10.1016/0022-2836(90)90354-O; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1990, DEV BIOL, V138, P443, DOI 10.1016/0012-1606(90)90210-A; HELFMAN DM, 1984, J BIOL CHEM, V259, P4136; HELFMAN DM, 1986, MOL CELL BIOL, V6, P3582, DOI 10.1128/MCB.6.11.3582; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HUMPHREY T, 1988, TRENDS GENET, V4, P243, DOI 10.1016/0168-9525(88)90028-5; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LATHAM KE, 1989, MOL CELL BIOL, V9, P3203, DOI 10.1128/MCB.9.8.3203; LAZARIDES E, 1975, J CELL BIOL, V65, P549, DOI 10.1083/jcb.65.3.549; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEFF SE, 1987, CELL, V48, P517, DOI 10.1016/0092-8674(87)90202-9; LEGER J, 1976, PFLUG ARCH EUR J PHY, V362, P271, DOI 10.1007/BF00581181; LIBRI D, 1989, J BIOL CHEM, V264, P2935; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; LIN JJC, 1988, J CELL BIOL, V107, P563, DOI 10.1083/jcb.107.2.563; LIN JJC, 1984, CANCER CELL, V1, P57; MACLEOD AR, 1985, P NATL ACAD SCI USA, V82, P7835, DOI 10.1073/pnas.82.23.7835; MACLEOD AR, 1987, BIOESSAYS, V6, P208, DOI 10.1002/bies.950060504; Maniatis T., 1982, MOL CLONING LAB MANU, P191; MANLEY JL, 1989, GENE DEV, V3, P2218, DOI 10.1101/gad.3.12b.2218; MANLEY JL, 1988, BIOCHIM BIOPHYS ACTA, V950, P1, DOI 10.1016/0167-4781(88)90067-X; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MCINNES C, 1988, BIOCHIM BIOPHYS ACTA, V951, P117, DOI 10.1016/0167-4781(88)90031-0; MILCAREK C, 1985, MOL CELL BIOL, V5, P2514, DOI 10.1128/MCB.5.10.2514; MOORE CL, 1984, CELL, V36, P581, DOI 10.1016/0092-8674(84)90337-4; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; NADALGINARD B, 1986, MOL BIOL MUSCLE DEV, P387; PACHTER JS, 1987, CELL, V51, P283, DOI 10.1016/0092-8674(87)90155-3; PAYNE MR, 1984, TRENDS BIOCHEM SCI, V9, P361, DOI 10.1016/0968-0004(84)90061-6; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; Richardson C.C., 1981, ENZYMES A, V14, P299, DOI DOI 10.1016/S1874-6047(08)60342-X; ROEDER RG, 1974, J BIOL CHEM, V249, P241; SADOFSKY M, 1985, MOL CELL BIOL, V5, P2713, DOI 10.1128/MCB.5.10.2713; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STRAUCH AR, 1989, J BIOL CHEM, V264, P8345; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; TRAUT RR, 1964, J MOL BIOL, V10, P63, DOI 10.1016/S0022-2836(64)80028-0; WANG YC, 1988, J CELL BIOL, V106, P797, DOI 10.1083/jcb.106.3.797; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAWAKIKATAOKA Y, 1985, J BIOL CHEM, V260, P4440; YOUNG EM, 1979, DEV BIOL, V72, P24, DOI 10.1016/0012-1606(79)90095-2	66	106	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2728	2736						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733968				2022-12-25	WOS:A1992HB53200093
J	HEIDENREICH, O; ECKSTEIN, F				HEIDENREICH, O; ECKSTEIN, F			HAMMERHEAD RIBOZYME-MEDIATED CLEAVAGE OF THE LONG TERMINAL REPEAT RNA OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOROTHIOATE-MODIFIED DNA; HELIX-COIL TRANSITION; THERAPEUTIC AGENTS; KINETICS; SEQUENCE; INVIVO; THERMODYNAMICS; EXPRESSION; POLYMERASE; SUBSTRATE	Three ribozymes targeted against different sites of the long terminal repeat RNA (LTR RNA) of human immunodeficiency virus type 1 cleaved a LTR RNA transcript 1,000 x less efficiently than corresponding short synthetic oligoribonucleotide substrates. Varying the stem lengths of the ribozyme resulted in changes of the catalytic efficiency. Almost no cleavage was observed for a ribozyme forming only 10 base pairs instead of 14 with the LTR RNA. Increasing the base pairs to 16 or elongation of the stem formed within the ribozyme revealed only small changes in k(cat)/K(m). The influence of chemical modifications within the ribozyme on the cleavage of the LTR RNA was also examined. 2'-Fluorocytidine substitutions as well as four terminal phosphorothioate internucleotidic linkages influenced the catalytic efficiency of ribozymes only negligibly. However, substitution of uridine by 2'-fluorouridine resulted in a 5-fold decrease of k(cat)/K(m). A ribozyme containing all these modifications revealed only a 7-fold lower catalytic efficiency but a markedly increased stability in cell culture supernatant. These results demonstrate that it is possible to increase the stability of ribozymes toward nucleases without a serious loss in catalytic efficiency.	MAX PLANCK INST EXPTL MED, HERMANN REIN STR 3, W-3400 GOTTINGEN, GERMANY	Max Planck Society			Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483				BRUENING G, 1989, METHOD ENZYMOL, V180, P546; BUZAYAN JM, 1990, NUCLEIC ACIDS RES, V18, P4447, DOI 10.1093/nar/18.15.4447; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; COTTEN M, 1990, TRENDS BIOTECHNOL, V8, P174, DOI 10.1016/0167-7799(90)90168-W; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; COTTEN M, 1989, MOL CELL BIOL, V9, P4479, DOI 10.1128/MCB.9.10.4479; CRAIG ME, 1971, J MOL BIOL, V62, P383, DOI 10.1016/0022-2836(71)90434-7; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; FERSHT A, 1985, ENZYME STRUCTURE MEC, P98; Goodchild J, 1990, BIOCONJUGATE CHEM, V1, P165, DOI 10.1021/bc00003a001; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; KARN J, 1991, NUCLEIC ACIDS MOL BI, V5, P194; King P. V., 1986, FOCUS, V8, P1; LORENTZEN EU, 1991, VIRUS GENES, V5, P17, DOI 10.1007/BF00571727; MOORE GE, 1967, J AMER MED ASSOC, V199, P519, DOI 10.1001/jama.199.8.519; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; OLSEN DB, 1989, NUCLEIC ACIDS RES, V17, P9613, DOI 10.1093/nar/17.23.9613; OLSEN DB, 1991, BIOCHEMISTRY-US, V30, P9735, DOI 10.1021/bi00104a024; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; PORSCHKE D, 1973, BIOPOLYMERS, V12, P1313, DOI 10.1002/bip.1973.360120609; PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; ROSSI JJ, 1990, TRENDS BIOTECHNOL, V8, P179, DOI 10.1016/0167-7799(90)90169-X; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SAXENA SK, 1990, J BIOL CHEM, V265, P17106; SCHMIDT W, 1990, THESIS U GOTTINGENR; SEGEL IH, 1975, ENZYME KINETICS, P508; SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747; SHELDON CC, 1990, NUCLEIC ACIDS MOL BI, V4, P227; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TINOCO JI, 1990, NUCLEIC ACIDS MOL BI, V4, P205; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	41	154	172	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1904	1909						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730726				2022-12-25	WOS:A1992HA48500078
J	SUGAHARA, K; YAMADA, S; YOSHIDA, K; DEWAARD, P; VLIEGENTHART, JFG				SUGAHARA, K; YAMADA, S; YOSHIDA, K; DEWAARD, P; VLIEGENTHART, JFG			A NOVEL SULFATED STRUCTURE IN THE CARBOHYDRATE-PROTEIN LINKAGE REGION ISOLATED FROM PORCINE INTESTINAL HEPARIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWARM RAT CHONDROSARCOMA; CELL-GROWTH FACTOR; MAGNETIC-RESONANCE; PROTEOGLYCANS; SPECTROSCOPY; OLIGOSACCHARIDES; AFFINITY	A preparation of porcine stage 14 intestinal heparin, which contains Ser as a predominant amino acid, was used for isolation of the carbohydrate-protein linkage region of heparin. Two glycoserines were isolated in a molar ratio of 96:4 after an exhaustive digestion with a mixture of bacterial heparinase and heparitinases. Their structures were determined by composition analysis, heparitinase digestion, co-chromatography with an authentic glycoserine on high performance liquid chromatography, and by 500-MHz one- and two-dimensional H-1 NMR spectroscopy. The structure of the major one is DELTA-GlcA-beta-1-3Gal-beta-1-3Gal-beta-1-4Xyl-beta-1-O-Ser and that of the minor is DELTA-GlcA-beta-1-4GlcNAc(6-O-sulfate) alpha-1-4GlcA-beta-1-3Gal-beta-1-3Gal-beta-1-4Xyl-beta-1-O-Ser. The novel 6-O-sulfated GlcNAc residue was demonstrated to occur in the vicinity of the carbohydrate-protein linkage region. The Gal residues were nonsulfated, in contrast to the sulfated Gal structures recently discovered in the carbohydrate-protein linkage region of chondroitin sulfate proteoglycans. The structural features are discussed in relation to biosynthetic mechanisms of the heparin glycosaminoglycans.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAKYO KU,KYOTO 606,JAPAN; SEIKAGAKU KOGYO CO,TOKYO RES INST,HIGASHIYAMATO,TOKYO 189,JAPAN; UNIV UTRECHT,CTR BIJVOET,DEPT BIOORGAN CHEM,3508 TD UTRECHT,NETHERLANDS	Kyoto University; Utrecht University								BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; Ernst RR, 1966, ADV MAGN RESON, V2, P1; FOLKMAN J, 1989, HEPARIN, P317; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; HARRIS MJ, 1970, CARBOHYD RES, V15, P57, DOI 10.1016/S0008-6215(00)80294-3; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KRISHNA NR, 1990, J BIOL CHEM, V265, P18256; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1965, J BIOL CHEM, V240, P2821; LINDAHL U, 1966, BIOCHIM BIOPHYS ACTA, V130, P368, DOI 10.1016/0304-4165(66)90233-9; Lindahl U., 1989, HEPARIN, P159; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; LYON M, 1987, BIOCHEM J, V242, P493, DOI 10.1042/bj2420493; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MARCUM JA, 1989, HEPARIN, P275; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; RICE KG, 1985, ANAL BIOCHEM, V150, P325, DOI 10.1016/0003-2697(85)90518-4; ROSENFELD L, 1988, J BIOL CHEM, V263, P262; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; SUGAHARA K, 1989, 10TH P INT S GLYC JE, P322; SUGAHARA K, 1991, IN PRESS EUR J BIOCH; SUGAHARA K, 1990, 15TH INT CARB S YOK, P292; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; VANHALBEEK H, 1982, EUR J BIOCHEM, V127, P1; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; YOSHIDA K, 1989, 10TH P INT S GLYC JE, P330	32	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1528	1533						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730699				2022-12-25	WOS:A1992HA48500024
J	ANN, DK; LIN, HH; LEE, S; TU, ZJ; WANG, E				ANN, DK; LIN, HH; LEE, S; TU, ZJ; WANG, E			CHARACTERIZATION OF THE STATIN-LIKE S1 AND RAT ELONGATION FACTOR-1-ALPHA AS 2 DISTINCTLY EXPRESSED MESSAGES IN RAT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FACTOR 1-ALPHA EF-1-ALPHA; NUCLEOTIDE-SEQUENCE; BINDING PROTEIN; GENES; YEAST; IDENTIFICATION; CEREVISIAE; GLANDS	Previously, we reported a rat S1 protein that is antigenically related to statin, a nonproliferating cell-specific marker; however, it shares high homology with the known human elongation factor-1-alpha (EF-1-alpha). To differentiate S1 from rat EF-1-alpha and to study their respective regulation for expression, a rat EF-1-alpha cDNA clone was isolated and characterized. The nucleotide and deduced amino acid sequences of this partial rat EF-1-alpha cDNA are compared with that of human and mouse as well as with rat S1. Both their messages were detected in rat brain by EF-1-alpha- or S1-specific probes. However, the mRNA encoding EF-1-alpha is more abundant than that encoding S1. S1 and EF-1-alpha expression were investigated in the parotid and submandibular glands of untreated rats and those treated with isoproterenol, a proliferation-inducing catecholamine. Quantitative solution hybridization demonstrated a dramatic reduction (approximately 68%) in the S1 mRNA following isoproterenol injection in proliferation-responsive parotid glands and a mild reduction (approximately 20%) of S1 steady-state messages in the proliferation-refractile submandibular glands. A slight increase or no changes of EF-1-alpha levels in both parotid and submandibular glands following isoproterenol treatment are also observed. Therefore, the EF-1-alpha and S1 genes are different genes, both expressed and regulated in vivo, but in differential quantitative and qualitative patterns.	MCGILL UNIV,JEWISH GEN HOSP,LADY DAVIS INST MED RES,BLOOMFIELD CTR RES AGING,MONTREAL H3T 1E2,QUEBEC,CANADA; UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,MINNEAPOLIS,MN 55455; MCGILL UNIV,DEPT MED,MONTREAL H3T 1E2,QUEBEC,CANADA; MCGILL UNIV,DEPT ANAT,MONTREAL H3T 1E2,QUEBEC,CANADA	Lady Davis Institute; McGill University; University of Minnesota System; University of Minnesota Twin Cities; McGill University; McGill University					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [K04DE000292, R29DE009175] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K07AG000744] Funding Source: NIH RePORTER; NIA NIH HHS [AG 0744] Funding Source: Medline; NIDCR NIH HHS [R29-DE09175, K04-DE00292] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANN DK, 1988, J BIOL CHEM, V263, P3546; ANN DK, 1991, J BIOL CHEM, V266, P10429; ANN DK, 1991, IN PRESS J CELL SCI; COTTRELLE P, 1985, CURR GENET, V9, P693, DOI 10.1007/BF00449823; COTTRELLE P, 1985, J BIOL CHEM, V260, P3090; DEVER TE, 1989, J BIOL CHEM, V264, P20518; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; GREENBERG JR, 1987, FEBS LETT, V224, P54, DOI 10.1016/0014-5793(87)80421-0; HAYASHI Y, 1989, J BIOCHEM-TOKYO, V106, P560, DOI 10.1093/oxfordjournals.jbchem.a122895; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; HUMPHREYSBEHER MG, 1984, BIOCHEM J, V221, P15, DOI 10.1042/bj2210015; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; LU X, 1989, Nucleic Acids Research, V17, P442, DOI 10.1093/nar/17.1.442; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; MUENZER J, 1979, J BIOL CHEM, V254, P5623; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; OHTA K, 1990, J BIOL CHEM, V265, P3240; Sambrook J, 1989, MOL CLONING LABORATO; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; SCHNEYER CA, 1972, REGULATION ORGAN TIS, P211; SUNDSTROM P, 1990, J BACTERIOL, V172, P2036, DOI 10.1128/jb.172.4.2036-2045.1990; UETZUKI T, 1989, J BIOL CHEM, V10, P5781; VANHEMERT FJ, 1984, EMBO J, V3, P1103; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	25	35	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					699	702						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730661				2022-12-25	WOS:A1992GY96000006
J	COLLINS, H; NAJAFI, H; BUETTGER, C; ROMBEAU, J; SETTLE, RG; MATSCHINSKY, FM				COLLINS, H; NAJAFI, H; BUETTGER, C; ROMBEAU, J; SETTLE, RG; MATSCHINSKY, FM			IDENTIFICATION OF GLUCOSE RESPONSE PROTEINS IN 2 BIOLOGICAL MODELS OF BETA-CELL ADAPTATION TO CHRONIC HIGH GLUCOSE EXPOSURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GEL-ELECTROPHORESIS; INSULIN-SECRETION; NORMAL RATS; HYPERGLYCEMIA; INFUSIONS; ISLETS	High resolution 2-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) combined with computerized analysis of gel images was used to search for proteins whose biosynthesis was induced or repressed in pancreatic islet cells chronically exposed to high glucose in an in situ and a tissue culture model of islet cell adaptation to excessive fuel load. The in situ model involved a 4-day intravenous infusion of either 50% glucose or 0.45% saline solution, followed by islet isolation, [S-35]methionine labeling at 3 and 18 mM glucose for both groups, and protein analysis by 2-dimensional SDS-PAGE. The tissue culture model involved a 7-day culture of isolated rat islets in RPMI 1640 with 10% fetal calf serum containing either 3 or 30 mM glucose, followed by radiolabeling and 2-dimensional PAGE of proteins as in the in situ model. A small fraction of about 1.5% of the approximately 2000 identifiable proteins can be characterized as adaptive proteins. Of these altogether 58 proteins in the two models, 5 proteins were demonstrable in both models and two of these (proteins 1526 and 7622) are particularly noteworthy. Protein 1526 (M(r) 57,000; pI 5.09) showed the same response pattern in both models and its expression was most enhanced when islets from chronically glucose-infused animals or those cultured for 7 days at 30 mM were radiolabeled at 18 mM glucose. Protein 7622 (M(r) 68,000; pl 6.50) (also known as GSP-65; Collins, H. W., Buettger, C., and Matschinsky, F. M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5494-5498) showed a different labeling pattern in the two models: stimulation of [S-35]methionine incorporation by 18 mM glucose both in control and experimental islets from the infusion study, but lack of such stimulation of radiolabeling in islets cultured for 7 days at 30 mM glucose in contrast to islets cultured at 3 mM. The experimental strategy and the methodology are evaluated and the significance of the results is discussed. Potentials of the approach and plans for future experiments are considered.	UNIV PENN,DIABET RES CTR,SCH MED,501 STEMMLER HALL,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104; HOSP UNIV PENN,DEPT SURG,PHILADELPHIA,PA 19104; VET ADM MED CTR,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Collins, Hannah/GSD-5229-2022		PHS HHS [22122, 19525] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BEDOYA FJ, 1991, DIABETES, V40, P7, DOI 10.2337/diabetes.40.1.7; BERDANIER CD, 1991, FASEB J, V5, P2139, DOI 10.1096/fasebj.5.8.2022312; BONNERWEIR S, 1989, DIABETES, V38, P49, DOI 10.2337/diabetes.38.1.49; BURCH PT, 1984, J GERONTOL, V39, P2, DOI 10.1093/geronj/39.1.2; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; COLEMAN DL, 1970, DIABETOLOGIA, V6, P252; COLLINS HW, 1990, P NATL ACAD SCI USA, V87, P5494, DOI 10.1073/pnas.87.14.5494; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GARRELS JI, 1990, ELECTROPHORESIS, V11, P1114, DOI 10.1002/elps.1150111204; GARRELS JI, 1989, J BIOL CHEM, V264, P5269; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; LEAHY JL, 1988, DIABETES, V37, P217, DOI 10.2337/diabetes.37.2.217; LEAHY JL, 1986, J CLIN INVEST, V77, P908, DOI 10.1172/JCI112389; LEAHY JL, 1987, DIABETES, V36, P459, DOI 10.2337/diabetes.36.4.459; LEAHY JL, 1985, INSULIN SECRETION MO, P149; LIANG Y, 1990, J BIOL CHEM, V265, P16863; MICHAELIS OE, 1986, AM J PATHOL, V123, P398; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PIPELEERS DG, 1981, DIABETOLOGIA, V20, P654; Sambrook J, 1989, MOL CLONING LABORATO	20	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1357	1366						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730656				2022-12-25	WOS:A1992GY96000106
J	SUNG, CY; GENNITY, JM; POLLITT, NS; INOUYE, M				SUNG, CY; GENNITY, JM; POLLITT, NS; INOUYE, M			A POSITIVE RESIDUE IN THE HYDROPHOBIC CORE OF THE ESCHERICHIA-COLI LIPOPROTEIN SIGNAL PEPTIDE SUPPRESSES THE SECRETION DEFECT CAUSED BY AN ACIDIC AMINO TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING-PROTEIN; OUTER-MEMBRANE; SEQUENCE; MUTATIONS; MUTANTS; EXPORT; REGION; PROLIPOPROTEIN; DELETION; CHARGE	The signal peptide of secretory proteins requires a basic amino terminus followed by a stretch of hydrophobic residues to effect efficient translocation of precursor proteins. Replacement of the positively charged amino-terminal residues of prolipoprotein by acidic amino acids decreased the rate of precursor translocation (Inouye, S., Soberon, X., Franceschini, T., Nakamura, K., Itakura, K., and Inouye, M. (1982) Proc. Natl. Acad. Sci. U.S.A. 79, 3438-3441; Vlasuk, G. P., Inouye, S., Ito, H., Itakura, K., and Inouye, M. (1983) J. Biol. Chem. 258, 7141-7148). We demonstrate here that an arginine residue, but not an aspartate, when localized at position 9 of the hydrophobic region of the lipoprotein signal peptide, is able to suppress intramolecularly the processing defect caused by an acidic amino terminus. Furthermore, when present at position 14 of the signal peptide, this positive residue, but not aspartate, was able to support efficient translocation of unmodified prolipoprotein. This demonstrates that a positive residue can restore the function of a severely defective signal peptide and need not be localized at the amino terminus to do so. Both aspartate and arginine substitution at position 14 of the lipoprotein signal peptide stimulated prolipoprotein synthesis. This effect was position-specific, did not require precursor translocation, and was dominant to the inhibition of synthesis caused by an acidic amino terminus.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LA,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center								BEDOUELLE H, 1980, NATURE, V285, P78, DOI 10.1038/285078a0; BOSCH D, 1989, BIOCHIM BIOPHYS ACTA, V979, P69, DOI 10.1016/0005-2736(89)90524-5; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; IINO T, 1987, J BIOL CHEM, V262, P7412; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; INOUYE S, 1977, P NATL ACAD SCI USA, V74, P1004, DOI 10.1073/pnas.74.3.1004; INOUYE S, 1986, J BIOL CHEM, V261, P970; INOUYE S, 1986, SNTHESIS APPLICATION, P181; LEHNHARDT S, 1988, J BIOL CHEM, V263, P10300; LEHNHARDT S, 1987, J BIOL CHEM, V262, P1716; LINN JJC, 1978, P NATL ACAD SCI USA, V75, P4891; MASUI Y, 1983, EXPT MANIPULATION GE, P15; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; POLLITT S, 1985, J BIOL CHEM, V260, P7965; PUZISS JW, 1989, J BACTERIOL, V171, P2303, DOI 10.1128/jb.171.5.2303-2311.1989; RYAN JP, 1986, J BIOL CHEM, V261, P3389; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STADER J, 1986, J BIOL CHEM, V261, P5075; TANJI Y, 1991, J BACTERIOL, V173, P1997, DOI 10.1128/jb.173.6.1997-2005.1991; TOKUNAGA H, 1984, J BIOL CHEM, V259, P6098; VLASUK GP, 1983, J BIOL CHEM, V258, P7141	22	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					997	1000						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730688				2022-12-25	WOS:A1992GY96000052
J	BYRON, KL; BABNIGG, G; VILLEREAL, ML				BYRON, KL; BABNIGG, G; VILLEREAL, ML			BRADYKININ-INDUCED CA2+ ENTRY, RELEASE, AND REFILLING OF INTRACELLULAR CA2+ STORES - RELATIONSHIPS REVEALED BY IMAGE-ANALYSIS OF INDIVIDUAL HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; HUMAN-ENDOTHELIAL CELLS; SENSITIVE CALCIUM POOL; DIVALENT-CATION ENTRY; INOSITOL PHOSPHATES; CA-2+ ENTRY; PLASMA-MEMBRANE; INFLUX; RAT; ACTIVATION	Lys-Bradykinin (BK), a mitogen for human foreskin fibroblasts (HSWP cells) (Owen, N. E., and Villereal, M. L. (1983) Cell 32, 979-985), elicits a rapid, transient elevation of intracellular free Ca2+ concentration ([Ca 2+]i) in these cells. We have used image analysis of fura-2-loaded HSWP cells to examine the BK-induced [Ca2+]i changes in individual cells. BK-stimulated Ca2+ entry and release of intracellular Ca2+ stores can be distinguished by stimulating cells in the presence or absence of extracellular Ca2+, or by inhibiting Ca2+ entry with 5 mM NiCl2. BK-sensitive intracellular Ca2+ stores can be depleted by exposure of the cells to BK in Ca2+-free medium; refilling of the stores requires extracellular Ca2+. A component of BK-stimulated Ca2+ entry persists after removal of agonist, but inactivates with a t1/2 of approximately 5 min. Although previous studies have attributed the Ca2+ entry which persists after agonist removal to a "capacitative Ca2+ entry" pathway activated by the depletion of the intracellular Ca2+ stores, we find that a large component of this BK-stimulated Ca2+ entry is not due to capacitative Ca2+ entry since (1) ionomycin can deplete the BK-sensitive intracellular Ca2+ stores without appreciably stimulating Ca2+ entry and without inhibiting the BK-stimulated Ca2+ entry and (2) this Ca2+ entry pathway inactivates at a time when the Ca2+ pools are still empty and a capacitance entry pathway should still be open. On the other hand, refilling of the intracellular Ca2+ stores can occur after the noncapaeitative Ca2+ entry component has inactivated or when it is inhibited by Ni2+; in these cases refilling occurs without a detectable elevation of [Ca2+]i suggesting that refilling of internal Ca2+ pools might occur by a capacitative route.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,947 E 58TH ST,CHICAGO,IL 60637	University of Chicago				Byron, Kenneth/0000-0002-3875-9667	NCRR NIH HHS [S10-RR-03322] Funding Source: Medline; NIGMS NIH HHS [GM-28359, 5T32-GM-07151] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR003322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028359, T32GM007151] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUB DL, 1982, J PHYSIOL-LONDON, V331, P557, DOI 10.1113/jphysiol.1982.sp014391; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BYRON KL, 1989, J BIOL CHEM, V264, P18234; ETSCHEID BG, 1989, J CELL PHYSIOL, V140, P264, DOI 10.1002/jcp.1041400211; FOSKETT JK, 1989, P NATL ACAD SCI USA, V86, P167, DOI 10.1073/pnas.86.1.167; HAASE W, 1984, CELL TISSUE RES, V235, P683; HALLAM TJ, 1989, BIOCHEM J, V259, P125, DOI 10.1042/bj2590125; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JAMIESON GA, 1987, ARCH BIOCHEM BIOPHYS, V252, P478, DOI 10.1016/0003-9861(87)90054-3; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KWAN CY, 1990, J BIOL CHEM, V265, P678; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; MULDOON LL, 1985, AM J PHYSIOL, V249, pC140, DOI 10.1152/ajpcell.1985.249.1.C140; NEGULESCU PA, 1988, AM J PHYSIOL, V254, pC130, DOI 10.1152/ajpcell.1988.254.1.C130; OWEN NE, 1983, CELL, V32, P979, DOI 10.1016/0092-8674(83)90082-X; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; POGGIOLI J, 1985, J BIOL CHEM, V260, P3289; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1976, J PHARMACOL EXP THER, V198, P375; RINK TJ, 1989, CELL CALCIUM, V10, P385, DOI 10.1016/0143-4160(89)90064-X; ROSCHER AA, 1984, J CLIN INVEST, V74, P552, DOI 10.1172/JCI111452; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; SHUTTLEWORTH TJ, 1990, BIOCHEM J, V266, P719, DOI 10.1042/bj2660719; STAUDERMAN KA, 1989, J BIOL CHEM, V264, P18349; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAYLOR CW, 1990, TRENDS PHARMACOL SCI, V11, P269, DOI 10.1016/0165-6147(90)90003-Q; TSIEN RW, 1983, ANNU REV PHYSIOL, V45, P341, DOI 10.1146/annurev.ph.45.030183.002013; VICENTINI LM, 1984, BIOCHEM BIOPH RES CO, V123, P663, DOI 10.1016/0006-291X(84)90280-8	36	86	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					108	118						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730576				2022-12-25	WOS:A1992GY43900023
J	CHAPPELL, DA; FRY, GL; WAKNITZ, MA; BERNS, JJ				CHAPPELL, DA; FRY, GL; WAKNITZ, MA; BERNS, JJ			EVIDENCE FOR ISOMERIZATION DURING BINDING OF APOLIPOPROTEIN-B100 TO LOW-DENSITY-LIPOPROTEIN RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMENSIONAL HETEROGENEOUS LATTICE; MULTIVALENT IMMUNE-COMPLEXES; LARGE-LIGAND ADSORPTION; CELL-SURFACE RECEPTOR; MONOCLONAL-ANTIBODIES; HUMAN-FIBROBLASTS; STOICHIOMETRIC BINDING; COMPETITION KINETICS; DIFFERENT PROTEINS; FC-RECEPTORS	To determine the kinetics of human low density lipoproteins (LDL) interacting with LDL receptors, I-125-LDL binding to cultured human fibroblasts at 4-degrees-C was studied. Apparent association rate constants did not increase linearly as I-125-LDL concentrations were increased. Instead, they began to plateau which suggested that formation of initial receptor-ligand complexes is followed by slower rearrangement or isomerization to complexes with higher affinity. To test this, I-125-LDL were allowed to associate for 2, 15, or 120 min, then dissociation was followed. The dissociation was biphasic with the initial phase being 64-110-fold faster than the terminal phase. After binding for 2 min, a greater percentage of I-125-LDL dissociated rapidly (36%) than after association for 15 min (24%) or 120 min (11%). Neither the rate constants nor the relative amplitudes of the two phases were dependent on the degree of receptor occupancy. Thus, the duration of association, but not the degree of receptor occupancy affected I-125-LDL dissociation. To determine if binding by large LDL, which is predominantly via apolipoprotein (apo) E, also occurs by an isomerization mechanism, the d = 1.006-1.05 g/ml lipoproteins were fractionated by ultracentrifugation. In contrast to small LDL which bound via apoB-100 and whose dissociation was similar to that of unfractionated LDL, large LDL dissociation after 2, 15, or 120 min of binding did not show isomerization to a higher affinity. This suggests that large and small LDL bind by different mechanisms as a result of different modes of interaction of apoE and apoB-100 with LDL receptors.			CHAPPELL, DA (corresponding author), UNIV IOWA,COLL MED,DEPT INTERNAL MED,E318GH,IOWA CITY,IA 52242, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002024, P50HL014230] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02024, HL14230] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOEYNAEMS JM, 1975, J CYCLIC NUCL PROT, V1, P123; BROWN MS, 1978, J BIOL CHEM, V253, P1121; CHAPPELL DA, 1991, J BIOL CHEM, V266, P19296; CHAPPELL DA, 1989, J CLIN INVEST, V84, P1906, DOI 10.1172/JCI114378; CORIN RE, 1982, J BIOL CHEM, V257, P104; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DELISI C, 1979, BIOPHYSICS-USSR, V1, P117; DOWER SK, 1981, BIOCHEMISTRY-US, V20, P6326, DOI 10.1021/bi00525a007; DOWER SK, 1981, BIOCHEMISTRY-US, V20, P6335, DOI 10.1021/bi00525a008; EPSTEIN IR, 1979, BIOPOLYMERS, V18, P2037, DOI 10.1002/bip.1979.360180815; GIBSON QH, 1966, J BIOL CHEM, V241, P1969; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1976, CELL, V7, P85, DOI 10.1016/0092-8674(76)90258-0; HARDY MR, 1985, BIOCHEMISTRY-US, V24, P22, DOI 10.1021/bi00322a004; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; INNERARITY TL, 1990, J LIPID RES, V31, P1337; JARV J, 1979, J BIOL CHEM, V254, P5595; KLEINBAUM DG, 1988, APPLIED REGRESSION A, P124; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MILLER DM, 1983, J BIOL CHEM, V258, P3665; MILNE RW, 1982, FEBS LETT, V146, P97, DOI 10.1016/0014-5793(82)80712-6; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ORCI L, 1978, EXP CELL RES, V113, P1, DOI 10.1016/0014-4827(78)90081-2; PITAS RE, 1980, J BIOL CHEM, V255, P5454; PITAS RE, 1979, P NATL ACAD SCI USA, V76, P2311, DOI 10.1073/pnas.76.5.2311; POLAND D, 1991, LANGMUIR, V7, P514, DOI 10.1021/la00051a017; POLAND D, 1990, BIOPOLYMERS, V30, P1215, DOI 10.1002/bip.360301307; PORTER DJT, 1973, J BIOL CHEM, V248, P4400; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHREIBER G, 1985, J BIOL CHEM, V260, P8789; SCHREIBER G, 1985, J BIOL CHEM, V260, P8795; SCHWARZ KR, 1986, BIOCHEMISTRY-US, V25, P2697, DOI 10.1021/bi00357a062; STANKOWSKI S, 1983, BIOCHIM BIOPHYS ACTA, V735, P352, DOI 10.1016/0005-2736(83)90149-9; STANKOWSKI S, 1983, BIOCHIM BIOPHYS ACTA, V735, P341, DOI 10.1016/0005-2736(83)90148-7; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; STRICKLAND S, 1973, J BIOL CHEM, V248, P2944; STURM J, 1981, BIOPOLYMERS, V20, P765, DOI 10.1002/bip.1981.360200410; STURM J, 1982, BIOPOLYMERS, V21, P1189, DOI 10.1002/bip.360210613; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VANDRIEL IR, 1989, J BIOL CHEM, V264, P9533; WAKELIN LPG, 1980, J MOL BIOL, V144, P183, DOI 10.1016/0022-2836(80)90032-7; WEISGRABER KH, 1978, J BIOL CHEM, V253, P6281; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178	49	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					270	279						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730595				2022-12-25	WOS:A1992GY43900046
J	VANDERVORM, ER; VANDERZON, GCM; MOLLER, W; KRANS, HMJ; LINDHOUT, D; MAASSEN, JA				VANDERVORM, ER; VANDERZON, GCM; MOLLER, W; KRANS, HMJ; LINDHOUT, D; MAASSEN, JA			AN ARG FOR GLY SUBSTITUTION AT POSITION-31 IN THE INSULIN-RECEPTOR, LINKED TO INSULIN RESISTANCE, INHIBITS RECEPTOR PROCESSING AND TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE DOMAIN; MUTATION; PATIENT; GENE; FAMILY	In a patient with Leprechaunism, we have characterized a new mutation in the insulin receptor substituting Arg for Gly at position 31. The proband, the mother, and the maternal grandfather were heterozygous for the mutation. Fibroblasts of the proband show a strongly reduced number of high affinity insulin receptors on the cell surface, whereas fibroblasts of the healthy mother and grandfather show moderately reduced insulin receptor numbers. In the other family members neither the binding defect nor the Arg31 mutation was found. The Arg31-mutant receptor was overexpressed in Chinese hamster ovary cells. In these cells the mutant alpha-beta-proreceptor was not proteolytically cleaved and no transport to the cell surface took place. The proreceptor was unable to bind insulin and to undergo autophosphorylation. In addition, the proreceptor was not recognized by monoclonal antibodies directed against conformation-dependent epitopes. These findings suggest that the Gly31 to Arg31 mutant is involved in the insulin receptor dysfunction seen in the Leprechaun patient. The mutation seems to alter the conformation of the receptor in such way that the transport of the proreceptor to the Golgi compartment, where proteolytical processing occurs, is inhibited.	LEIDEN UNIV,DEPT MED BIOCHEM,SYLVIUS LAB,WASSENAARSEWEG 72,2333 AL LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT ENDOCRINOL & METAB DIS,2333 AL LEIDEN,NETHERLANDS; ERASMUS UNIV,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam			Lindhout, Dick/AAH-5765-2019	Lindhout, Dick/0000-0001-9580-624X				ACILLI D, 1989, EMBO J, V8, P2509; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; DEPREZ RHL, 1989, DIABETOLOGIA, V32, P740; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; HEDO JA, 1981, P NATL ACAD SCI-BIOL, V78, P4791, DOI 10.1073/pnas.78.8.4791; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KADOWAKI H, 1990, DIABETES, V40, pA112; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; KAOWAKI T, 1990, J BIOL CHEM, V265, P19143; KLINKHAMER MP, 1989, EMBO J, V8, P2503, DOI 10.1002/j.1460-2075.1989.tb08387.x; KUSARI J, 1991, J BIOL CHEM, V266, P5260; LANE MD, 1985, BIOCHIMIE, V67, P1069, DOI 10.1016/S0300-9084(85)80104-8; MAASSEN JA, 1988, EUR J BIOCHEM, V172, P725, DOI 10.1111/j.1432-1033.1988.tb13949.x; MAASSEN JA, 1991, IN PRESS BIOCHEMISTR; MANIATIS T, 1988, MOL CLONING; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SEINO S, 1990, DIABETES, V39, P123, DOI 10.2337/diabetes.39.1.123; TAIRA M, 1989, SCIENCE, V245, P63, DOI 10.1126/science.2544997; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOGT B, 1991, BIOCHEM BIOPH RES CO, V177, P1013, DOI 10.1016/0006-291X(91)90639-O; WHITE MF, 1986, ENZYMES, V17, P247; WILLIAMS JF, 1990, J BIOL CHEM, V265, P8463; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938	29	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					66	71						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730625				2022-12-25	WOS:A1992GY43900016
J	WILLEM, R; BIESEMANS, M; HALLENGA, K; LIPPENS, G; MALAISSELAGAE, F; MALAISSE, WJ				WILLEM, R; BIESEMANS, M; HALLENGA, K; LIPPENS, G; MALAISSELAGAE, F; MALAISSE, WJ			DUAL ANOMERIC SPECIFICITY AND DUAL ANOMERASE ACTIVITY OF PHOSPHOGLUCOISOMERASE QUANTIFIED BY 2-DIMENSIONAL PHASE-SENSITIVE C-13 EXSY NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TWO-DIMENSIONAL NMR; D-GLUCOSE METABOLISM; ALPHA-D-GLUCOSE; CHEMICAL-EXCHANGE; CROSS-RELAXATION; SPECTROSCOPY; KINETICS; GLUCOSE-6-PHOSPHATE; ISOMERIZATION; 6-PHOSPHATE	The reversible conversion between D-glucose 6-phosphate and D-fructose 6-phosphate catalyzed by yeast phosphoglucoisomerase was studied by phase sensitive two-dimensional C-13-{H-1} EXSY NMR spectroscopy at 150.869 and 125.759 MHz, using C-13-enriched substrates in the C2 position of the D-hexose 6-phosphates. The shape of the build-up curves of the cross-peaks associated with the C-13(2) resonances of the alpha- and beta-anomers of both D-[2-C-13]glucose 6-phosphate and D-[2-C-13]fructose 6-phosphate reveals that phosphoglucoisomerase selectively catalyzes the reversible conversion between alpha-D-[2-C-13]glucose 6-phosphate and beta-D-[2-C-13]fructose 6-phosphate. Quantitative analysis of the build-up curves by three different methods allowed us to conclude that phosphoglucoisomerase not only selectively channels the latter isomerization but also considerably accelerates the anomerization of both D-hexose 6-phosphates. The rate constants of anomerization were indeed much higher in the presence than in the absence of enzyme. The major finding in the present study consists in the anomeric specificity of phosphoglucoisomerase toward the beta-anomer of D-fructose 6-phosphate both as a substrate and a product, contrary to previous proposals. This finding supports recent evidence suggesting the direct channelling of beta-D-fructose 6-phosphate from phosphoglucoisomerase to phosphofructokinase.	UNIV LIBRE BRUXELLES,FAC MED,EXPTL MED LAB,ROUTE LENNIK 808,B-1070 BRUSSELS,BELGIUM; VRIJE UNIV BRUSSELS,CTR HIGH RESOLUT NMR,B-1050 BRUSSELS,BELGIUM; FREE UNIV BRUSSELS,B-1070 BRUSSELS,BELGIUM; VRIJE UNIV BRUSSELS,FAC ENGN,DEPT GEN & ORGAN CHEM,B-1050 BRUSSELS,BELGIUM; VRIJE UNIV BRUSSELS,FAC SCI,DEPT GEN CHEM,B-1050 BRUSSELS,BELGIUM; UNIV LIBRE BRUXELLES,FAC MED,CONFORMAT STUDIES BIOL MOLEC UNIT,B-1070 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Universite Libre de Bruxelles				Lippens, Guy/0000-0002-8236-0901				ALEXANDRESCU AT, 1990, J MAGN RESON, V87, P523, DOI 10.1016/0022-2364(90)90309-W; BALABAN RS, 1983, P NATL ACAD SCI-BIOL, V80, P1241, DOI 10.1073/pnas.80.5.1241; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; FISHBEIN R, 1974, J BIOL CHEM, V249, P6047; HUANG Y, 1981, J AM CHEM SOC, V103, P5327, DOI 10.1021/ja00408a008; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; LIPPENS G, 1990, J MAGN RESON, V88, P619, DOI 10.1016/0022-2364(90)90294-J; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MACURA S, 1986, J MAGN RESON, V70, P493, DOI 10.1016/0022-2364(86)90143-5; MALAISSE WJ, 1988, NETH J MED, V33, P247; MALAISSE WJ, 1976, J BIOL CHEM, V251, P5936; MALAISSE WJ, 1987, J BIOL CHEM, V262, P11746; MALAISSE WJ, 1985, J BIOL CHEM, V260, P4630; MALAISSE WJ, 1987, BRAIN RES, V419, P147, DOI 10.1016/0006-8993(87)90578-6; MALAISSE WJ, 1991, INT J BIOCHEM, V23, P1471, DOI 10.1016/0020-711X(91)90290-4; MALAISSE WJ, 1990, DIABETES OBESITY HYP, P3; MALAISSE WJ, 1990, DIABETIC COMPLICATIO, V69, P3; MALAISSELAGAE F, 1986, EUR J BIOCHEM, V158, P663, DOI 10.1111/j.1432-1033.1986.tb09804.x; PERRIN CL, 1984, J AM CHEM SOC, V106, P4036, DOI 10.1021/ja00326a027; PERRIN CL, 1990, J MAGN RESON, V90, P363, DOI 10.1016/0022-2364(90)90143-W; PERRIN CL, 1990, CHEM REV, V90, P935, DOI 10.1021/cr00104a002; PLESSER T, 1979, EUR J BIOCHEM, V98, P93, DOI 10.1111/j.1432-1033.1979.tb13165.x; RAMACHANDRAN R, 1985, J MAGN RESON, V65, P136, DOI 10.1016/0022-2364(85)90382-8; SALAS M, 1965, J BIOL CHEM, V240, P561; SCHRAY KJ, 1973, J BIOL CHEM, V248, P2219; SENER A, 1982, BIOCHEM BIOPH RES CO, V108, P1567, DOI 10.1016/S0006-291X(82)80086-7; SNYDER JR, 1989, J AM CHEM SOC, V111, P2681, DOI 10.1021/ja00189a050; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; WILLEM R, 1987, PROG NUCL MAG RES SP, V20, P1, DOI 10.1016/0079-6565(88)80008-6; WILLEM R, 1990, BIOCHEM J, V265, P519, DOI 10.1042/bj2650519	30	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					210	217						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730590				2022-12-25	WOS:A1992GY43900038
J	HART, CM; ROBERTS, JW				HART, CM; ROBERTS, JW			RHO-DEPENDENT TRANSCRIPTION TERMINATION - CHARACTERIZATION OF THE REQUIREMENT FOR CYTIDINE IN THE NASCENT TRANSCRIPT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA-PR PROMOTER; ESCHERICHIA-COLI; RNA-POLYMERASE; PROTEIN-RHO; GENE-EXPRESSION; ATPASE ACTIVITY; MESSENGER-RNA; PLASMID DNA; SITES; BINDING	By substituting template segments encoding AU-rich, GU-rich, and CA-rich transcripts for natural sequences upstream of the phage-lambda rho-dependent tR1 termination site, we demonstrate that cytidines are required in the upstream RNA for rho-dependent termination to occur. These results are extended through in vitro mutagenesis of a template encoding an inactive AU-rich upstream sequence: certain mutant templates encoding new cytidines are able to activate rho-dependent termination. Cytidines must be dispersed over a region of the transcript in order for rho to be activated, although no specific pattern of cytidines appears to be required. The results show that no local clustering or regular spacing of cytidines is necessary and that cytidines are not used as a "ruler" to determine the location of termination sites. Rho is somewhat sensitive to the relative positions of cytidines since slightly different nascent transcripts activate rho termination activity to various degrees. A model is presented in which hexameric rho binds 78 nucleotides of contiguous RNA in a primary site, such that each monomer interacts with at least one cytidine somewhere in the 13 nucleotides allotted to the monomeric primary site.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University	ROBERTS, JW (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853, USA.		Hart, Craig/B-4832-2016	Hart, Craig/0000-0002-9870-991X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021941, R01GM021941] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BERMAN J, 1986, P NATL ACAD SCI USA, V83, P3713, DOI 10.1073/pnas.83.11.3713; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRIAT JF, 1987, J MOL BIOL, V198, P43, DOI 10.1016/0022-2836(87)90456-6; BRIAT JF, 1984, P NATL ACAD SCI-BIOL, V81, P7373, DOI 10.1073/pnas.81.23.7373; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GALLUPPI G, 1976, RNA POLYM, P357; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GUO LH, 1983, METHOD ENZYMOL, V100, P60; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HOWARD BH, 1976, J BIOL CHEM, V251, P2520; LAU LF, 1983, J BIOL CHEM, V258, P9391; LAU LF, 1985, J BIOL CHEM, V260, P574; LAU LF, 1982, P NATL ACAD SCI-BIOL, V79, P6171, DOI 10.1073/pnas.79.20.6171; Lis J T, 1980, Methods Enzymol, V65, P347; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; LOWERY C, 1977, J BIOL CHEM, V252, P1381; LOWERYGO.C, 1974, P NATL ACAD SCI USA, V71, P2003, DOI 10.1073/pnas.71.5.2003; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCSWIGGEN JA, 1988, J MOL BIOL, V199, P609, DOI 10.1016/0022-2836(88)90305-1; MORGAN WD, 1984, J BIOL CHEM, V259, P8664; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; MORGAN WD, 1983, J BIOL CHEM, V258, P9553; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; MULLER PP, 1984, J MOL BIOL, V175, P431, DOI 10.1016/0022-2836(84)90178-5; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; ODA T, 1972, J MOL BIOL, V71, P799; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROSENTHAL ER, 1987, J MOL BIOL, V194, P443, DOI 10.1016/0022-2836(87)90673-5; SCHMIDT MC, 1987, J MOL BIOL, V195, P809, DOI 10.1016/0022-2836(87)90486-4; SHARP JA, 1983, J BIOL CHEM, V258, P3482; SHIGESADA K, 1988, NUCLEIC ACIDS RES, V8, P3355; SIGMUND CD, 1988, BIOCHEMISTRY-US, V27, P5628, DOI 10.1021/bi00415a035; STITT BL, 1988, J BIOL CHEM, V263, P11130; THALENFELD BE, 1980, J BIOL CHEM, V255, P6173; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217; YANG YJ, 1988, THESIS CORNELL U; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1	47	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24140	24148						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721066				2022-12-25	WOS:A1991GV31900095
J	ZACHARY, I; SINNETTSMITH, J; ROZENGURT, E				ZACHARY, I; SINNETTSMITH, J; ROZENGURT, E			STIMULATION OF TYROSINE KINASE-ACTIVITY IN ANTI-PHOSPHOTYROSINE IMMUNE-COMPLEXES OF SWISS 3T3 CELL LYSATES OCCURS RAPIDLY AFTER ADDITION OF BOMBESIN, VASOPRESSIN, AND ENDOTHELIN TO INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS MITOGENIC DESENSITIZATION; STRUCTURALLY RELATED PEPTIDES; AFFINITY CROSS-LINKING; PROTEIN-KINASE; DNA-SYNTHESIS; GROWTH-FACTOR; SIGNAL TRANSDUCTION; PHORBOL ESTERS; EARLY EVENTS; RECEPTOR	Treatment of quiescent Swiss 3T3 cells with the mitogenic peptides bombesin, vasopressin, endothelin/vasoactive intestinal contractor (VIC), and bradykinin strikingly increased the initial rate of tyrosine phosphorylation measured in anti-phosphotyrosine immunoprecipitates of a major band of M, 115,000 (p115) and two minor components of M, 90,000 and 75,000. Neuropeptides increased the labeling of p115 within seconds and with great potency; half-maximum concentrations were 0.1, 0.2 and 0.3 nm for bombesin, vasopressin, and VIC, respectively. Immunoblotting and peptide mapping showed that the pl 15 band phosphorylated in anti-phosphotyrosine immunoprecipitates is identical to a major M, 115,000 substrate for neuropeptide-stimulated tyrosine phosphorylation in intact Swiss 3T3 cells. Furthermore, bombesin, vasopressin, and VIC markedly increased the rate of phosphorylation of Raytide, a broad specificity tyrosine kinase peptide substrate, by decreasing (8 +/- 1.3-fold) the apparent K(m) of the kinase for the substrate. Phorbol 12,13-dibutyrate and the Ca" ionophore A23187 had a weaker effect on tyrosine protein kinase activity in immune complexes compared with bombesin. Furthermore, down-regulation of protein kinase C blocked the small effect of phorbol esters but did not impair bombesin-stimulated tyrosine kinase activity. These results provide direct evidence for neuropeptide activation of a tyrosine kinase in cell-free preparations and identify a novel event in the action of this class of growth factors in Swiss 3T3 cells.	IMPERIAL CANC RES FUND,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	ROZENGURT, E (corresponding author), IMPERIAL CANC RES FUND,POB 123,LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND.							ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COFFER A, 1990, FEBS LETT, V263, P80, DOI 10.1016/0014-5793(90)80710-Z; COLLINS MKL, 1984, J CELL PHYSIOL, V118, P133, DOI 10.1002/jcp.1041180205; COLLINS MKL, 1983, P NATL ACAD SCI-BIOL, V80, P1924, DOI 10.1073/pnas.80.7.1924; DICKEY BF, 1987, J BIOL CHEM, V262, P8738; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1989, J CELL PHYSIOL, V141, P253, DOI 10.1002/jcp.1041410204; FABREGAT I, 1990, BIOCHEM BIOPH RES CO, V167, P161, DOI 10.1016/0006-291X(90)91745-E; FISHMAN JB, 1987, J BIOL CHEM, V262, P14049; FORCE T, 1991, J BIOL CHEM, V266, P6650; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; HUNTER T, 1982, J BIOL CHEM, V257, P4843; ISSANDOU M, 1990, J BIOL CHEM, V265, P11890; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MENDOZA SA, 1986, J CELL BIOL, V102, P2223, DOI 10.1083/jcb.102.6.2223; MILLAR JBA, 1990, J BIOL CHEM, V265, P19973; MILLAR JBA, 1988, J CELL PHYSIOL, V137, P214, DOI 10.1002/jcp.1041370203; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; PIKE LJ, 1982, P NATL ACAD SCI-BIOL, V79, P1443, DOI 10.1073/pnas.79.5.1443; RODRIGUEZPENA A, 1986, J CELL PHYSIOL, V129, P124, DOI 10.1002/jcp.1041290117; RODRIGUEZPENA A, 1985, EMBO J, V4, P71, DOI 10.1002/j.1460-2075.1985.tb02319.x; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1979, P NATL ACAD SCI USA, V76, P1284, DOI 10.1073/pnas.76.3.1284; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; Rozengurt E, 1990, J Cell Sci Suppl, V13, P43; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SINNETTSMITH J, 1988, J CELL BIOCHEM, V38, P237, DOI 10.1002/jcb.240380403; SINNETTSMITH J, 1990, BIOCHEM J, V265, P485, DOI 10.1042/bj2650485; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STROSBERG AD, 1991, EUR J BIOCHEM, V196, P1, DOI 10.1111/j.1432-1033.1991.tb15778.x; TAKUWA N, 1989, J BIOL CHEM, V264, P7856; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; Woll PJ, 1988, GROWTH FACTORS, V1, P75, DOI 10.3109/08977198809000249; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	49	89	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					24126	24133						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721065				2022-12-25	WOS:A1991GV31900093
J	SHAULSKY, G; GOLDFINGER, N; TOSKY, MS; LEVINE, AJ; ROTTER, V				SHAULSKY, G; GOLDFINGER, N; TOSKY, MS; LEVINE, AJ; ROTTER, V			NUCLEAR-LOCALIZATION IS ESSENTIAL FOR THE ACTIVITY OF P53 PROTEIN	ONCOGENE			English	Article							TRANSFORMATION-RELATED PROTEIN; COLI BETA-GALACTOSIDASE; VIRUS-40 TUMOR-ANTIGENS; CELL-CYCLE CONTROL; LARGE-T-ANTIGEN; MONOCLONAL-ANTIBODY; WILD-TYPE; SV40-TRANSFORMED CELLS; SEQUENCE REQUIREMENTS; DNA-REPLICATION	p53 appears to be a growth regulator, the perturbation of which induces changes in normal cell proliferation. Wild-type p53 protein is thought to function as a growth arrest gene, whereas mutant p53, which accumulates in transformed cells, has been shown to enhance malignant transformation. Both wild-type and mutant p53 migrate into the cell nucleus by means of identical nuclear localization signals (NLS) inherent in their primary sequences. Results presented here show that the suppressive activity of wild-type p53 measured as the reduction of transformation of primary rat fibroblasts induced by cotransfection with ras and either E1A or mutant p53, as well as the transformation enhancement of mutant p53 estimated by cooperation with ras in transformation of primary rat fibroblasts, is dependent upon nuclear localization signals in p53 protein. While transfection of unmodified wild-type p53 significantly reduces the number of rat embryonic fibroblast-transformed foci induced by E1A and ras or mutant p53 and ras, the wild-type p53 protein without NLS has completely lost this suppressive activity. Partially defective NLS wild-type p53, with a reduced nuclear accumulation ability, still exhibits some suppressive activity. In addition, we found that plasmids coding for intact mutant p53 protein efficiently cooperate with the ras oncogene, whereas the corresponding plasmids without NLS are totally inert. On this basis we conclude that nuclear localization of both wild-type and mutant p53 is a fundamental feature for manifesting the activities of these proteins. Both the suppressor activity mediated by the wild-type p53 and enhancement of transformation mediated by the mutant p53 require nuclear localization of the proteins to function.	PRINCETON UNIV,DEPT MOLEC BIOL,LEWIS THOMAS LAB,PRINCETON,NJ 08544	Princeton University	ROTTER, V (corresponding author), WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL.			Shaulsky, Gad/0000-0002-0532-0551				ADDISON C, 1990, ONCOGENE, V5, P423; AHUJA H, 1989, P NATL ACAD SCI USA, V86, P6783, DOI 10.1073/pnas.86.17.6783; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BURGLIN TR, 1987, EMBO J, V6, P2617, DOI 10.1002/j.1460-2075.1987.tb02552.x; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DANG CV, 1989, J BIOL CHEM, V264, P18019; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KELMAN Z, 1989, BLOOD, V74, P2318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINGJUN Z, 1988, CELL, V55, P1005; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, ONCOGENE, V5, P973; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; MORIN N, 1989, MOL CELL BIOL, V9, P4372, DOI 10.1128/MCB.9.10.4372; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; ROTTER V, 1985, ADV CANCER RES, V43, P113, DOI 10.1016/S0065-230X(08)60944-6; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; ROTTER V, 1983, J IMMUNOL, V181, P329; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6567; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; STURZBECHER HW, 1990, ONCOGENE, V5, P795; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WYCHOWSKI C, 1986, EMBO J, V5, P2569, DOI 10.1002/j.1460-2075.1986.tb04536.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	63	204	206	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2055	2065						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719467				2022-12-25	WOS:A1991GX11900017
J	SUGIYAMA, A; MIYAGI, Y; SHIRASAWA, Y; KUCHINO, Y				SUGIYAMA, A; MIYAGI, Y; SHIRASAWA, Y; KUCHINO, Y			DIFFERENT USAGE OF 2 POLYADENYLYLATION SIGNALS IN TRANSCRIPTION OF THE N-MYC GENE IN RAT-TUMOR CELLS	ONCOGENE			English	Article							CASEIN KINASE-II; DNA-BINDING PROTEINS; LARGE T-ANTIGEN; C-MYC; NUCLEOTIDE-SEQUENCE; ADENOVIRUS E1A; CODING REGION; EXPRESSION; ELEMENTS; FAMILY	The complete nucleotide sequence of a rat genomic DNA fragment of 6.9 kbp containing the entire N-myc gene was determined. A unique structural feature of the rat N-myc gene is the presence of two polyadenylation signals in the exon 3 region resulting in formation of two poly(A)+ N-myc mRNAs of 2.9 and 2.2 kb length. Elevated expression of the 2.9 kb mRNA, which was not due to gene amplification, was observed in normal rat tissues such as brain, adrenal and testis, and in rat tumor cells such as ascites hepatoma AH130, AH70Btc and AH7974 cells, and pituitary tumor GH3 cells. In contrast, expression of 2.2 kb mRNA, for which transcription was terminated at the upstream polyadenylation site, was observed only in GH3 cells.	NATL CANC CTR,RES INST,DIV BIOPHYS,5-1-1 TSUKIJI,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan								ASSELIN C, 1989, ONCOGENE, V4, P549; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHELLAPPAN SP, 1990, P NATL ACAD SCI USA, V87, P5878, DOI 10.1073/pnas.87.15.5878; CHEN RP, 1990, NATURE, V346, P583, DOI 10.1038/346583a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORRAL M, 1988, EXP CELL RES, V174, P107, DOI 10.1016/0014-4827(88)90146-2; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FOUREL G, 1990, NUCLEIC ACIDS RES, V18, P4918, DOI 10.1093/nar/18.16.4918; HIRVONEN H, 1990, ONCOGENE, V5, P1787; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KATOH K, 1988, NUCLEIC ACIDS RES, V16, P3589, DOI 10.1093/nar/16.8.3589; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KUCHINO Y, 1990, GENETIC BASIS CARCIN, P239; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NISEN PD, 1986, CANCER RES, V46, P6217; PEERS B, 1990, MOL CELL BIOL, V10, P4690, DOI 10.1128/MCB.10.9.4690; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; ROSEN N, 1986, CANCER RES, V46, P4139; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SAWAI S, 1990, MOL CELL BIOL, V10, P2017, DOI 10.1128/MCB.10.5.2017; SCHWAB M, 1988, ONCOGENE HDB, P381; SHAW APW, 1988, ONCOGENE, V3, P143; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; SUGIYAMA A, 1989, P NATL ACAD SCI USA, V86, P9144, DOI 10.1073/pnas.86.23.9144; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; WEISINGER G, 1988, ONCOGENE, V3, P635; WEISS EA, 1991, EMBO J, V10, P215, DOI 10.1002/j.1460-2075.1991.tb07938.x; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	43	14	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2027	2032						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719466				2022-12-25	WOS:A1991GX11900013
J	HALMEKYTO, M; HYTTINEN, JM; SINERVIRTA, R; UTRIAINEN, M; MYOHANEN, S; VOIPIO, HM; WAHLFORS, J; SYRJANEN, S; SYRJANEN, K; ALHONEN, L; JANNE, J				HALMEKYTO, M; HYTTINEN, JM; SINERVIRTA, R; UTRIAINEN, M; MYOHANEN, S; VOIPIO, HM; WAHLFORS, J; SYRJANEN, S; SYRJANEN, K; ALHONEN, L; JANNE, J			TRANSGENIC MICE ABERRANTLY EXPRESSING HUMAN ORNITHINE DECARBOXYLASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; NUCLEOTIDE-SEQUENCE; COMPLEMENTARY-DNA; MYELOMA CELLS; MOUSE; RAT; GROWTH; REGION; DIFLUOROMETHYLORNITHINE; AMPLIFICATION	We have generated transgenic mice carrying human ornithine decarboxylase gene. Two different transgene constructs were used: (i) a 5'-truncated human ornithine decarboxylase gene and (ii) an intact human ornithine decarboxylase gene. Transgenic mice carrying the 5'-truncated gene did not express human ornithine decarboxylase-specific mRNA. Transgenic mice carrying the intact human ornithine decarboxylase gene expressed human-specific ornithine decarboxylase mRNA in all tissues studied. However, as indicated by actual enzyme assays, the expression pattern was highly unusual. In comparison with their wild-type littermates, the transgenic mice exhibited greatly elevated enzyme activity in almost every tissue studied. Ornithine decarboxylase activity was moderately elevated in parenchymal organs such as liver, kidney, and spleen. Tissues like heart, muscle, lung, thymus, testis, and brain displayed an enzyme activity that was 20 to 80 times higher than that in the respective tissues of nontransgenic animals. The offspring of the first transgenic male founder animal did not show any overt abnormalities, yet their reproductive performance was reduced. The second transgenic founder animal, showing similar aberrant expression of ornithine decarboxylase in all tissues studied, including an extremely high activity in testis, was found to be infertile. Histological examination of the tissues of the latter animal revealed marked changes in testicular morphology. The germinal epithelium was hypoplastic, and the spermatogenesis was virtually totally shut off. Similar examination of male members of the first transgenic mouse line revealed comparable, yet less severe, histological changes in testis.	UNIV KUOPIO,DEPT BIOCHEM & BIOTECHNOL,SF-70211 KUOPIO,FINLAND; UNIV KUOPIO,DEPT PATHOL,SF-70211 KUOPIO,FINLAND	University of Eastern Finland; University of Eastern Finland				Syrjanen, Kari/0000-0001-7180-7491; Wahlfors, Jarmo/0000-0003-2716-2870				ALHONENHONGISTO L, 1987, BIOCHEM J, V242, P205, DOI 10.1042/bj2420205; ALHONENHONGISTO L, 1985, BIOCHEM J, V229, P711, DOI 10.1042/bj2290711; ALSHAWI R, 1990, MOL CELL BIOL, V10, P1192, DOI 10.1128/MCB.10.3.1192; BLACKSHEAR PJ, 1989, MOL ENDOCRINOL, V3, P68, DOI 10.1210/mend-3-1-68; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BRABANT M, 1988, P NATL ACAD SCI USA, V85, P2200, DOI 10.1073/pnas.85.7.2200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFINO P, 1988, NUCLEIC ACIDS RES, V16, P2731, DOI 10.1093/nar/16.6.2731; EISENBERG LM, 1989, NUCLEIC ACIDS RES, V17, P2359, DOI 10.1093/nar/17.6.2359; FIZGERALD MC, 1989, DNA NY, V8, P623; HALMEKYTO M, 1989, BIOCHEM BIOPH RES CO, V162, P528, DOI 10.1016/0006-291X(89)92029-9; HAYASHI S, 1989, ORNITHINE DECARBOXYL, P1; HICKOK NJ, 1987, DNA-J MOLEC CELL BIO, V6, P179, DOI 10.1089/dna.1987.6.179; HICKOK NJ, 1990, GENE, V93, P257, DOI 10.1016/0378-1119(90)90233-H; Hogan B, 1986, MANIPULATING MOUSE E, P1; HOLTTA E, 1989, GENE, V83, P125, DOI 10.1016/0378-1119(89)90410-1; JANNE J, 1971, J BIOL CHEM, V246, P1725; JANNE J, 1978, BIOCHIM BIOPHYS ACTA, V473, P241, DOI 10.1016/0304-419X(78)90015-X; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KAIPIA A, 1990, MOL CELL ENDOCRINOL, V73, P45, DOI 10.1016/0303-7207(90)90043-8; KATZ A, 1989, EMBO J, V8, P1163, DOI 10.1002/j.1460-2075.1989.tb03487.x; KONTULA KK, 1984, P NATL ACAD SCI-BIOL, V81, P731, DOI 10.1073/pnas.81.3.731; LEINONEN P, 1987, BIOCHEM J, V242, P199, DOI 10.1042/bj2420199; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MUSTOFI FK, 1990, ANDERSONS PATHOLOGY, P871; POLVINEN K, 1988, BIOCHEM BIOPH RES CO, V155, P373, DOI 10.1016/S0006-291X(88)81095-7; RAUTH S, 1990, SOMAT CELL MOLEC GEN, V2, P129; SHUBHADA S, 1989, J ANDROL, V10, P45; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VANSTEEG H, 1989, NUCLEIC ACIDS RES, V17, P8855, DOI 10.1093/nar/17.21.8855; WEN L, 1989, J BIOL CHEM, V264, P9016; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; WINQVIST R, 1986, CYTOGENET CELL GENET, V42, P133, DOI 10.1159/000132266	33	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19746	19751						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717470				2022-12-25	WOS:A1991GK66700089
J	WALES, R; RICHARDSON, PT; ROBERTS, LM; WOODLAND, HR; LORD, JM				WALES, R; RICHARDSON, PT; ROBERTS, LM; WOODLAND, HR; LORD, JM			MUTATIONAL ANALYSIS OF THE GALACTOSE BINDING ABILITY OF RECOMBINANT RICIN-B CHAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN; COMMUNIS AGGLUTININ; ESCHERICHIA-COLI; XENOPUS-OOCYTES; ENZYME-ACTIVITY; ANTIBODY-RICIN; EXPRESSION; GLYCOSYLATION; IMMUNOTOXINS; CELLS	Ricin B chain (RTB) is an N-glycosylated galactose-specific lectin which folds into two globular domains. Each domain binds one galactoside. The x-ray crystallographic structure has shown that the two binding sites are structurally similar and contain key binding residues which hydrogen bond to the sugar, and a conserved tripeptide, Asp-Val-Arg. We have used oligonucleotide site-directed mutagenesis to change either the binding residues or the homologous tripeptide in one or other or in both of the sites. The 5' signal sequence and RTB coding region were excised from preproricin cDNA and fused in frame to generate preRTB cDNA. Transcripts synthesized in vitro from wild-type or mutant preRTB cloned into the Xenopus transcription vector pSP64T using SP6 RNA polymerase, were microinjected into Xenopus oocytes. The recombinant products were segregated into the oocyte rough endoplasmic reticulum and core-glycosylated, and the N-terminal signal peptide was removed. Mutating sugar binding sites individually did not abrogate the lectin activity of RTB. When both sites were changed simultaneously, RTB was produced which was soluble and stable but no longer able to bind galactose. Changing the Asn residues of the two RTB N-glycosylation sites to Gln showed that oligosaccharide side chains were essential for both the stability and biological activity of recombinant RTB.			WALES, R (corresponding author), UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND.							AIKAWA J, 1990, J BIOL CHEM, V265, P13955; ANDERSON CW, 1983, METHOD ENZYMOL, V101, P635; BLAKEY DC, 1986, BIOESSAYS, V4, P292, DOI 10.1002/bies.950040615; COLMAN A, 1981, EUR J BIOCHEM, V113, P339, DOI 10.1111/j.1432-1033.1981.tb05072.x; DEAN JW, 1990, J BIOL CHEM, V265, P12553; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; FISCHER T, 1990, J BIOL CHEM, V265, P1710; HOUSTON LL, 1982, J BIOL CHEM, V257, P4147; HOUSTON LL, 1982, J BIOL CHEM, V257, P1532; HUSSAIN K, 1989, FEBS LETT, V244, P383, DOI 10.1016/0014-5793(89)80568-X; KRETZ KA, 1990, P NATL ACAD SCI USA, V87, P2541, DOI 10.1073/pnas.87.7.2541; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAMBERT JM, 1991, BIOCHEMISTRY-US, V30, P3234, DOI 10.1021/bi00227a011; LORD JM, 1985, EUR J BIOCHEM, V146, P411, DOI 10.1111/j.1432-1033.1985.tb08667.x; MCINTOSH DP, 1983, FEBS LETT, V164, P17, DOI 10.1016/0014-5793(83)80009-X; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; NEVILLE DM, 1982, IMMUNOL REV, V62, P75, DOI 10.1111/j.1600-065X.1982.tb00390.x; OHARE M, 1987, FEBS LETT, V216, P73, DOI 10.1016/0014-5793(87)80759-7; Olsnes S., 1982, MOL ACTION TOXINS VI, P51; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PIATAK M, 1988, J BIOL CHEM, V263, P4837; RICHARDSON PT, 1988, BIO-TECHNOL, V6, P565, DOI 10.1038/nbt0588-565; RICHARDSON PT, 1988, BIOCHIM BIOPHYS ACTA, V950, P385, DOI 10.1016/0167-4781(88)90135-2; RICHARDSON PT, 1990, IN PRESS CARBOHYDRAT; ROBERTS LM, 1981, EUR J BIOCHEM, V119, P31, DOI 10.1111/j.1432-1033.1981.tb05573.x; ROTHMAN E, 1989, CELL, V49, P591; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; TAKEUCHI M, 1990, J BIOL CHEM, V265, P12127; THORPE PE, 1984, EUR J BIOCHEM, V140, P63, DOI 10.1111/j.1432-1033.1984.tb08067.x; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; VILLAFRANCA JE, 1981, J BIOL CHEM, V256, P554; VITETTA ES, 1986, J IMMUNOL, V136, P1880; VITETTA ES, 1984, J EXP MED, V160, P341, DOI 10.1084/jem.160.1.341; VITETTA ES, 1990, BIOCHIM BIOPHYS ACTA, V1049, P151, DOI 10.1016/0167-4781(90)90035-Z; VITETTA ES, 1985, ANNU REV IMMUNOL, V3, P197; YOULE RJ, 1982, J BIOL CHEM, V257, P1598; YOULE RJ, 1987, J BIOL CHEM, V262, P4676; ZENTZ C, 1978, BIOCHIM BIOPHYS ACTA, V536, P18, DOI 10.1016/0005-2795(78)90047-8	39	77	80	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19172	19179						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717462				2022-12-25	WOS:A1991GK66700012
J	WHITEHEAD, AS; DEBEER, MC; STEEL, DM; RITS, M; LELIAS, JM; LANE, WS; DEBEER, FC				WHITEHEAD, AS; DEBEER, MC; STEEL, DM; RITS, M; LELIAS, JM; LANE, WS; DEBEER, FC			IDENTIFICATION OF NOVEL MEMBERS OF THE SERUM AMYLOID-A PROTEIN SUPERFAMILY AS CONSTITUTIVE APOLIPOPROTEINS OF HIGH-DENSITY-LIPOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; NUCLEOTIDE-SEQUENCE; MESSENGER-RNAS; GENE FAMILY; SAA; MOUSE; INDUCTION; NITROCELLULOSE; INFLAMMATION; METABOLISM	A novel serum amyloid A protein (SAA) has been identified as a normal apolipoprotein component of non-acute phase high density lipoprotein. This novel SAA has been designated "constitutive" SAA (C-SAA) to distinguish it from "acute phase" SAA (A-SAA). C-SAA was partially sequenced, and immunochemical analyses indicated that it constitutes a distinct subclass of apolipoproteins within the SAA superfamily. A C-SAA cDNA clone was isolated from a human liver library and sequenced. The clone predicts a pre-C-SAA molecule of 130 residues from which an 18-residue leader peptide is cleaved. The 112-residue mature molecule is 8 residues longer than human A-SAA; the size difference is due to the presence of an octapeptide between positions 70 and 77 that is not found in the corresponding region of human A-SAA. Paradoxically, octapeptides of similar composition are found at similar positions in the A-SAAs of a number of other species. The C-SAA octapeptide specifies the first two residues of a NSS tripeptide, the only potential N-linked glycosylation site in the molecule. Studies indicate that approximately 50% of these sites are glycosylated, thereby giving rise to two size classes, 14 and 19 kDa, of C-SAA in vivo. Human acute phase liver contains little C-SAA mRNA relative to the levels of A-SAA mRNA, and the treatment of PLC/PRF/5 hepatoma cells with monocyte-conditioned medium does not induce C-SAA mRNA concentrations to detectable levels, in contrast to the massive induction of A-SAA mRNA observed. C-SAA is therefore not a major acute phase reactant.	UNIV KENTUCKY,ALBERT B CHANDLER MED CTR,DEPT MED,MN614,800 ROSE ST,LEXINGTON,KY 40536; CHILDRENS HOSP MED CTR,DEPT IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115; DEPT VET AFFAIRS MED CTR,LEXINGTON,KY 40511; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138; BETH ISRAEL HOSP,DEPT HEMATOL & ONCOL,BOSTON,MA 02215	University of Kentucky; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; Harvard University; Harvard University; Beth Israel Deaconess Medical Center					PHS HHS [2T32A107306] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAUSSERMAN LL, 1984, BIOCHIM BIOPHYS ACTA, V792, P186, DOI 10.1016/0005-2760(84)90221-2; BEACH CM, 1991, IN PRESS BIOCH J; BENSON MD, 1989, J LAB CLIN MED, V113, P67; BRISSETTE L, 1989, J BIOL CHEM, V264, P19327; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; DWULET FE, 1988, BIOCHEMISTRY-US, V27, P1677, DOI 10.1021/bi00405a044; ERIKSEN N, 1980, P NATL ACAD SCI-BIOL, V77, P6860, DOI 10.1073/pnas.77.11.6860; FOLCH J, 1957, J BIOL CHEM, V226, P497; GODENIR NL, 1985, J IMMUNOL METHODS, V83, P217, DOI 10.1016/0022-1759(85)90243-1; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HOFFMAN JS, 1982, J BIOL CHEM, V257, P510; HUSEBEKK A, 1985, SCAND J IMMUNOL, V21, P283, DOI 10.1111/j.1365-3083.1985.tb01431.x; KLUVEBECKERMAN B, 1989, COMP BIOCHEM PHYS B, V94, P175, DOI 10.1016/0305-0491(89)90030-8; KLUVEBECKERMAN B, 1988, J CLIN INVEST, V82, P1670, DOI 10.1172/JCI113779; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWELL CA, 1986, J BIOL CHEM, V261, P8442; MARHAUG G, 1990, J BIOL CHEM, V265, P10049; MCADAM KPWJ, 1976, J EXP MED, V144, P1121, DOI 10.1084/jem.144.4.1121; MITCHELL TI, 1991, J CLIN INVEST, V87, P1177, DOI 10.1172/JCI115116; PARKS JS, 1983, AM J PATHOL, V112, P243; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; PINCUS T, 1986, J RHEUMATOL, V13, P841; RAMADORI G, 1985, J EXP MED, V162, P930, DOI 10.1084/jem.162.3.930; RAMADORI G, 1989, EUR J CLIN INVEST, V19, P316, DOI 10.1111/j.1365-2362.1989.tb00236.x; SACK GH, 1989, GENE, V84, P509, DOI 10.1016/0378-1119(89)90528-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELLAR GC, 1991, J BIOL CHEM, V266, P3505; SIPE JD, 1985, BIOCHEMISTRY-US, V24, P2931, DOI 10.1021/bi00333a018; SLETTEN K, 1989, SCAND J IMMUNOL, V30, P117, DOI 10.1111/j.1365-3083.1989.tb01195.x; STEEL DM, 1991, BIOCHEM J, V277, P477, DOI 10.1042/bj2770477; STEINKASSERER A, 1990, BIOCHEM J, V268, P187, DOI 10.1042/bj2680187; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; STRACHAN AF, 1989, J BIOL CHEM, V264, P18368; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TATUM F, 1990, NUCLEIC ACIDS RES, V18, P7447, DOI 10.1093/nar/18.24.7447; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHITEHEAD AS, 1990, BIOCHEM J, V266, P283, DOI 10.1042/bj2660283; WOO P, 1987, J BIOL CHEM, V262, P15790; ZACHARIUS RM, 1969, ANAL BIOCHEM, V30, P148, DOI 10.1016/0003-2697(69)90383-2; ZAHEDI K, 1989, J IMMUNOL, V143, P2880	47	163	168	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3862	3867						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740433				2022-12-25	WOS:A1992HE60700050
J	WILSON, TE; DAY, ML; PEXTON, T; PADGETT, KA; JOHNSTON, M; MILBRANDT, J				WILSON, TE; DAY, ML; PEXTON, T; PADGETT, KA; JOHNSTON, M; MILBRANDT, J			INVIVO MUTATIONAL ANALYSIS OF THE NGFI-A ZINC FINGERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATORY PROTEINS; EARLY GROWTH-RESPONSE; DNA-BINDING DOMAIN; CULTURED-CELLS; FACTOR-IIIA; GENE; SEQUENCES; ACTIVATOR; ENCODES; SPECIFICITY	NGFI-A is a mammalian transcription factor that contains zinc fingers similar to those observed in several other proteins, including NGFI-C and Krox-20. To define precisely the DNA binding domain of NGFI-A, we selected mutants using a chimeric transcriptional activator that contains the NGFI-A zinc finger domain sandwiched between the lexA DNA binding domain and the GAL4 transcriptional activating domain. Expression of this lexA-NGFI-A-GAL4 (LAG) trimeric protein in yeast significantly retarded their growth, unlike an activator containing only the lexA and GAL4 components. This suggested that LAG inappropriately regulates genes in yeast that contain NGFI-A binding sites. Yeast that contained LAG reverted to wild-type growth at high frequency by inactivation of LAG. The mutations recovered from these revertants were specifically limited to the 83-residue NGFI-A zinc finger domain by requiring that the lexA and GAL4 portions of the LAG chimera remain functional. Nearly all of the 93 mutants obtained contained single missense mutations that mapped within the zinc fingers to residues thought to be important for zinc finger function. Deletion analysis of native NGFI-A verified that residues distant from the zinc fingers do not influence DNA binding, thus establishing the minimal functional DNA binding domain. Interestingly, many zinc finger residues ascribed specific functions by x-ray crystallography were never mutated in yeast, implying that the identity of these residues is not critical. Surprisingly, not all of the mutations tested significantly impaired NGFI-A-specific DNA binding, suggesting that the function of these zinc fingers is more diverse than previously recognized.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,DIV LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			Johnston, Mark/R-6156-2019	Milbrandt, Jeffrey/0000-0002-5477-7689; Johnston, Mark/0000-0002-4932-7229				BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BLUMBERG H, 1987, NATURE, V328, P443, DOI 10.1038/328443a0; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARR MD, 1990, EUR J BIOCHEM, V188, P455, DOI 10.1111/j.1432-1033.1990.tb15423.x; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; HARSHORNE TA, 1986, NATURE, V320, P283; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MACKOW ER, 1990, P NATL ACAD SCI USA, V87, P518, DOI 10.1073/pnas.87.2.518; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; NEUHAUS D, 1990, FEBS LETT, V262, P179, DOI 10.1016/0014-5793(90)80184-K; PADGETT KA, 1991, BIOTECHNIQUES, V11, P56; PAN T, 1991, BIOCHEMISTRY-US, V30, P4212, DOI 10.1021/bi00231a016; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SHERMAN F, 1986, LABORATORY COURSE MA; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; THUKRAL SK, 1989, MOL CELL BIOL, V9, P2360, DOI 10.1128/MCB.9.6.2360; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	46	41	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3718	3724						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740423				2022-12-25	WOS:A1992HE60700029
J	ASTERMARK, J; HOGG, PJ; BJORK, I; STENFLO, J				ASTERMARK, J; HOGG, PJ; BJORK, I; STENFLO, J			EFFECTS OF GAMMA-CARBOXYGLUTAMIC ACID AND EPIDERMAL GROWTH FACTOR-LIKE MODULES OF FACTOR-IX ON FACTOR-X ACTIVATION STUDIES USING PROTEOLYTIC FRAGMENTS OF BOVINE FACTOR-IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYASPARTIC ACID; COAGULATION FACTOR-IX; K-DEPENDENT PROTEIN; FACTOR-LIKE DOMAIN; BLOOD-COAGULATION; CALCIUM-BINDING; MONOCLONAL-ANTIBODY; CHRISTMAS FACTOR; EXPRESSION; REGION	Factor IX is a vitamin K-dependent zymogen of a serine protease. The NH2-terminal half of the molecule consists of a Ca2+-binding gamma-carboxyglutamic acid (Gla)-containing module and two modules homologous to the epidermal growth factor (EGF) precursor. To elucidate the role of these non-catalytic modules of factor IXa-beta in factor X activation, we have isolated and characterized fragments of bovine factor IX, containing one or both of the EGF-like modules as well as these modules linked to the Gla module. The fragments were used as inhibitors of factor IXa-beta-mediated factor X activation in a plasma clotting system and in systems with purified components of the Xase complex. Fragments consisting of either the two EGF-like modules of factor IX linked together or the NH2-terminal EGF-like module alone were found to inhibit factor Xa generation both in the presence and absence of the cofactor, factor VIIIa. Moreover, a fragment consisting of the corresponding modules of factor X had a similar effect. We therefore propose that factor IXa-beta and factor X interact directly through their EGF-like modules on or in the vicinity of a phospholipid surface. We have also found that the isolated Gla module of factor IX inhibits the formation of factor Xa both in the presence and absence of phospholipid but not in the absence of factor VIIIa. Our results are compatible with a model of the Xase complex, in which both the serine protease part and the Gla module of factor IXa-beta interact with factor VIIIa.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT VET MED CHEM,S-75123 UPPSALA,SWEDEN	Lund University; Swedish University of Agricultural Sciences				Hogg, Philip/0000-0001-6486-2863				ASTERMARK J, 1991, J BIOL CHEM, V266, P2430; ASTERMARK J, 1991, J BIOL CHEM, V266, P2438; BAJAJ SP, 1982, J BIOL CHEM, V257, P3726; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; BARON M, 1991, TRENDS BIOCHEM SCI, V16, P13, DOI 10.1016/0968-0004(91)90009-K; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CHATTOPADHYAY A, 1989, BLOOD S1, V74; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DRAKENBERG T, 1983, P NATL ACAD SCI-BIOL, V80, P1802, DOI 10.1073/pnas.80.7.1802; DUGGLEBY RG, 1984, COMPUT BIOL MED, V14, P447, DOI 10.1016/0010-4825(84)90045-3; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERNLUND P, 1980, VITAMIN K METABOLISM, P166; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1973, BIOCHEMISTRY-US, V12, P4938, DOI 10.1021/bi00748a019; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HARLOS K, 1987, NATURE, V330, P82, DOI 10.1038/330082a0; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; JACKSON CM, 1972, BIOCHEMISTRY-US, V11, P4873, DOI 10.1021/bi00776a001; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; LIN SW, 1990, J BIOL CHEM, V265, P144; LOLLAR P, 1984, ARCH BIOCHEM BIOPHYS, V233, P438, DOI 10.1016/0003-9861(84)90465-X; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Maizel JV, 1971, METHOD VIROL, V5, P179; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MCCORD DM, 1990, J BIOL CHEM, V265, P10280; MILLERANDERSSON M, 1974, THROMB RES, V5, P439, DOI 10.1016/0049-3848(74)90001-2; MORITA T, 1986, J BIOL CHEM, V261, P4015; MORITA T, 1984, J BIOL CHEM, V259, P5698; OHLIN AK, 1987, J BIOL CHEM, V262, P13798; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; OHLIN AK, 1990, BIOCHEMISTRY-US, V29, P644; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; ORTHNER CL, 1989, J BIOL CHEM, V264, P18751; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; OWEN WG, 1974, J BIOL CHEM, V249, P594; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PATTHY L, 1987, FEBS LETT, V214, P1, DOI 10.1016/0014-5793(87)80002-9; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PERSSON E, 1991, J BIOL CHEM, V266, P2444; PERSSON E, 1991, J BIOL CHEM, V266, P2453; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; RYAN J, 1989, J BIOL CHEM, V264, P20283; SAKAI T, 1990, J BIOL CHEM, V265, P1890; STENFLO J, 1991, BLOOD, V78, P1637; STENFLO J, 1976, J BIOL CHEM, V251, P355; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; THOMPSON AR, 1986, BLOOD, V67, P565; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; WOHL RC, 1980, J BIOL CHEM, V255, P2005	53	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3249	3256						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737781				2022-12-25	WOS:A1992HD15400068
J	FUJIMURA, T; WICKNER, RB				FUJIMURA, T; WICKNER, RB			INTERACTION OF 2 CIS SITES WITH THE RNA REPLICASE OF THE YEAST L-A VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; Q-BETA REPLICASE; SACCHAROMYCES-CEREVISIAE; INVITRO; POLYMERASE; PARTICLES; PROTEIN; BINDING; TRANSCRIPTASE; RECOGNITION	L-A is a 4.6-kilobase double-stranded RNA virus of Saccharomyces cerevisiae. The in vitro L-A replication reaction ((-)-strand synthesis) requires an internal site 400 bases from the 3' end in addition to the 3'-terminal 30 nucleotides of the L-A (+)-single-stranded RNA. Elimination of the internal site reduces the template activity 5-10-fold. Here we investigate how the internal site can stimulate the replication reaction which starts at the 3' end of the template. When these two sites are split into two distinct RNA molecules, the internal site can no longer stimulate replication (no trans-activation). However, establishment of an intermolecular hydrogen bonding between these RNAs restored the replication-enhancing activity of the internal site. This result is consistent with a model wherein L-A's RNA polymerase interacts first with the internal site and then with the 3' end site by either looping or by a local dissociation-reassociation mechanism. These results, however, clearly eliminate anchored tracking and sliding models which require continuity of the RNA molecule between these two cis sites.			FUJIMURA, T (corresponding author), NIDDKD,BIOCHEM PHARMACOL LAB,GENET SIMPLE EUKARYOTES SECT,BLDG 8,RM 207,BETHESDA,MD 20892, USA.		Fujimura, Tsutomu/K-5807-2014	Fujimura, Tsutomu/0000-0002-9457-6769				BRUENN J, 1980, NUCLEIC ACIDS RES, V8, P2985, DOI 10.1093/nar/8.13.2985; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DINMAN JD, 1991, P NATL ACAD SCI USA, V88, P174, DOI 10.1073/pnas.88.1.174; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; ESTEBAN R, 1989, EMBO J, V8, P947, DOI 10.1002/j.1460-2075.1989.tb03456.x; ESTEBAN R, 1988, J VIROL, V62, P1278, DOI 10.1128/JVI.62.4.1278-1285.1988; ESTEBAN R, 1988, P NATL ACAD SCI USA, V85, P4411, DOI 10.1073/pnas.85.12.4411; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; FUJIMURA T, 1986, P NATL ACAD SCI USA, V83, P4433, DOI 10.1073/pnas.83.12.4433; FUJIMURA T, 1988, J BIOL CHEM, V263, P454; FUJIMURA T, 1987, MOL CELL BIOL, V7, P420, DOI 10.1128/MCB.7.1.420; FUJIMURA T, 1989, J BIOL CHEM, V264, P10872; GEORGOPOULOS DE, 1986, EXTRACHROMOSOMAL ELE, P203; HERRING AJ, 1977, NATURE, V268, P464, DOI 10.1038/268464a0; HORWITZ RJ, 1987, CELL, V51, P631, DOI 10.1016/0092-8674(87)90132-2; ICHO T, 1989, J BIOL CHEM, V264, P6716; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; KNAUS R, 1988, EMBO J, V7, P2919, DOI 10.1002/j.1460-2075.1988.tb03150.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MEYER F, 1981, J MOL BIOL, V153, P631, DOI 10.1016/0022-2836(81)90411-3; NISHIHARA T, 1983, J BIOCHEM, V93, P669, DOI 10.1093/jb/93.3.669; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; STEINMETZ EJ, 1990, J BIOL CHEM, V265, P18408; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WELSH JD, 1980, NUCLEIC ACIDS RES, V8, P2365, DOI 10.1093/nar/8.11.2365; WICKNER RB, 1991, YEASTS, V6; WICKNER RB, 1991, MOL BIOL YEAST SACCH, V1, P263	29	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2708	2713						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733966				2022-12-25	WOS:A1992HB53200090
J	WELLSTEIN, A; FANG, WJ; KHATRI, A; LU, Y; SWAIN, SS; DICKSON, RB; SASSE, J; RIEGEL, AT; LIPPMAN, ME				WELLSTEIN, A; FANG, WJ; KHATRI, A; LU, Y; SWAIN, SS; DICKSON, RB; SASSE, J; RIEGEL, AT; LIPPMAN, ME			A HEPARIN-BINDING GROWTH-FACTOR SECRETED FROM BREAST-CANCER CELLS HOMOLOGOUS TO A DEVELOPMENTALLY REGULATED CYTOKINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-RESPONSIVE GENE; MOUSE EMBRYOGENESIS; DEVELOPING BRAIN; PROTEINS; SEQUENCE; MK; CARCINOMA; MEMBRANES; CLONING; FAMILY	We report purification of an 18-kDa heparin-binding growth factor secreted from human cancer cells which is homologous to a developmentally regulated, neurotrophic factor, heparin-binding growth-associated molecule/pleiotrophin (HB-GAM/PTN; Merenmies, J., and Rauvala, H. (1990) J. Biol. Chem. 265, 16721-16724; Li, Y. S., Milner, P. G., Chauhan, A. K., Watson, M. A., Hoffman, R. M., Kodner, C. M., Milbrandt, J., and Deuel, T. F. (1990) Science 250, 1690-1694). We have purified the protein from tissue culture supernatants of human breast cancer cells (MDA-MB 231) and have used soft agar cloning of an epithelial cell line (SW-13) to detect its growth stimulating activity. A 32,000-fold purification was achieved by isoelectric focusing, heparin affinity chromatography, and reversed phase high pressure liquid chromatography. The molecular mass of the protein was confirmed by gel filtration chromatography in the presence of detergent and bioassay of the fractions. The N-terminal sequence was homologous to HB-GAM/PTN, and polymerase chain reaction amplification and DNA sequencing confirmed that the respective transcript was present in the cancer cells. We conclude that HB-GAM/PTN can function as a tumor growth factor in addition to its role during neuronal development.	GEORGETOWN UNIV, DEPT PHARMACOL, WASHINGTON, DC 20007 USA; SHRINERS HOSP CRIPPLED CHILDREN, DEPT IMMUNOL, TAMPA, FL 33612 USA	Georgetown University	WELLSTEIN, A (corresponding author), GEORGETOWN UNIV, VT LOMBARDI CANC CTR, 3800 RESERVOIR RD, WASHINGTON, DC 20007 USA.			Swain, Sandra/0000-0002-1320-3830; Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [U01CA051908] Funding Source: NIH RePORTER; NCI NIH HHS [UO1 CA51908] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COURTY J, 1991, J CELL BIOCH F S, V15, P221; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; KOVESDI I, 1990, BIOCHEM BIOPH RES CO, V172, P850, DOI 10.1016/0006-291X(90)90753-A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIPPMAN ME, 1989, RECENT PROG HORM RES, V45, P383; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MILNER PG, 1989, BIOCHEM BIOPH RES CO, V165, P1096, DOI 10.1016/0006-291X(89)92715-0; RAULAIS D, 1991, BIOCHEM BIOPH RES CO, V174, P708, DOI 10.1016/0006-291X(91)91475-R; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; Sambrook J, 1989, MOL CLONING LABORATO; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; TSUTSUI J, 1991, BIOCHEM BIOPH RES CO, V176, P792, DOI 10.1016/S0006-291X(05)80255-4; URIOS P, 1991, BIOCHEM BIOPH RES CO, V175, P617, DOI 10.1016/0006-291X(91)91610-O; VIGNY M, 1989, EUR J BIOCHEM, V186, P733, DOI 10.1111/j.1432-1033.1989.tb15267.x; WADZINSKI MG, 1987, CLIN PHYSIOL BIOCH, V5, P200; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WELLSTEIN A, 1991, JNCI-J NATL CANCER I, V83, P716, DOI 10.1093/jnci/83.10.716; WELLSTEIN A, 1991, J BIOL CHEM, V266, P12234	29	124	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2582	2587						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733956				2022-12-25	WOS:A1992HB53200073
J	ABOULELA, F; BOWATER, RP; LILLEY, DMJ				ABOULELA, F; BOWATER, RP; LILLEY, DMJ			COMPETING B-Z AND HELIX-COIL CONFORMATIONAL TRANSITIONS IN SUPERCOILED PLASMID DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANDED Z-DNA; THEORETICAL-ANALYSIS; CRUCIFORM EXTRUSION; SUPERHELICAL DNA; OSMIUM-TETROXIDE; SEQUENCES; DEPENDENCE; NUMBER; REPLICATION; RESOLUTION	The formation of melted regions from A + T-rich sequences and left-handed Z-DNA by alternating purine-pyrimidine sequences will both be facilitated by negative supercoiling, and thus if the sequences are present within the same plasmid molecule they will compete for the free energy of supercoiling. We have studied a series of plasmids that contain either (CG)8 or (TG)12 sequences in either G + C or A + T-rich contexts, by means of two-dimensional gel electrophoresis and chemical modification. We observe both B-Z and helix-coil transitions in all plasmids at elevated temperatures and low ionic strength. The plasmids fall into a number of different classes, in terms of the conformational behavior. As the superhelix density is increased, pCG8/vec ((CG)8 in G + C-rich context) undergoes an initial B-Z transition, followed by melting transitions in sequences remote from the (CG)8 sequence. The two transitions are coupled through the topology of the molecule but are otherwise independent. When the (CG)8 sequence was placed in an A + T-rich context (pCG8/col), the helix-coil transition was perturbed by the presence of the Z-DNA segment. Replacement of the (CG)8 tracts by (TG)12 sequences resulted in a further level of interaction between the transitions. Statistical mechanical modeling of the transitions suggested that at intermediate levels of negative supercoiling the Z-DNA formed by the (TG)12 sequence has a lowered probability due to the helix-coil transition in the A + T-rich sequences. These studies illustrate the complexities of competing conformational equilibria in supercoiled DNA molecules.	UNIV DUNDEE, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND	University of Dundee			Bowater, Richard P/A-4227-2010; aboul-ela, fareed/C-2887-2011	Bowater, Richard P/0000-0002-2745-7807; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BENHAM CJ, 1990, J CHEM PHYS, V92, P6294, DOI 10.1063/1.458353; BENHAM CJ, 1981, J MOL BIOL, V150, P43, DOI 10.1016/0022-2836(81)90324-7; BIANCHI A, 1990, J BIOL CHEM, V265, P21789; BOLIVAR F, 1977, P NATL ACAD SCI USA, V74, P5265, DOI 10.1073/pnas.74.12.5265; BOWATER R, 1991, IN PRESS BIOCH; BOWATER R, 1991, IN PRESS METHODS ENZ; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; FURLONG JC, 1989, BIOCHEMISTRY-US, V28, P2009, DOI 10.1021/bi00431a008; GALAZKA G, 1986, J BIOL CHEM, V261, P7093; GELLERT M, 1979, COLD SPRING HARB SYM, V43, P35, DOI 10.1101/SQB.1979.043.01.007; GUERON M, 1987, NATURE, V328, P89, DOI 10.1038/328089a0; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; HERR W, 1985, P NATL ACAD SCI USA, V82, P8009, DOI 10.1073/pnas.82.23.8009; HOROWITZ DS, 1984, J MOL BIOL, V173, P75, DOI 10.1016/0022-2836(84)90404-2; JIMENEZRUIZ A, 1991, P NATL ACAD SCI USA, V88, P31, DOI 10.1073/pnas.88.1.31; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KELLEHER RJ, 1986, P NATL ACAD SCI USA, V83, P6342, DOI 10.1073/pnas.83.17.6342; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KMIEC EB, 1985, CELL, V40, P139, DOI 10.1016/0092-8674(85)90317-4; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; KOWALSKI D, 1988, P NATL ACAD SCI USA, V85, P9464, DOI 10.1073/pnas.85.24.9464; LEE FS, 1985, NUCLEIC ACIDS RES, V13, P1665, DOI 10.1093/nar/13.5.1665; LILLEY DMJ, 1984, EMBO J, V3, P1187, DOI 10.1002/j.1460-2075.1984.tb01949.x; LILLEY DMJ, 1980, P NATL ACAD SCI-BIOL, V77, P6468, DOI 10.1073/pnas.77.11.6468; Maxam A M, 1980, Methods Enzymol, V65, P499; NAYLOR LH, 1990, NUCLEIC ACIDS RES, V18, P1595, DOI 10.1093/nar/18.6.1595; NEJEDLY K, 1985, J BIOMOL STRUCT DYN, V3, P467, DOI 10.1080/07391102.1985.10508435; NORDHEIM A, 1983, P NATL ACAD SCI-BIOL, V80, P1821, DOI 10.1073/pnas.80.7.1821; PANAYOTATOS N, 1981, NATURE, V289, P466, DOI 10.1038/289466a0; PECK LJ, 1981, NATURE, V292, P375, DOI 10.1038/292375a0; PECK LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4560, DOI 10.1073/pnas.79.15.4560; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; RAJAGOPALAN M, 1990, J BIOL CHEM, V265, P17294; RHODES D, 1980, NATURE, V286, P573, DOI 10.1038/286573a0; SCHAEFFER F, 1989, BIOPOLYMERS, V28, P1449, DOI 10.1002/bip.360280810; SINGLETON CK, 1982, NATURE, V299, P312, DOI 10.1038/299312a0; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SOUMPASIS DM, 1987, NUCLEIC ACIDS MOL BI, V1, P85; SULLIVAN KM, 1986, CELL, V47, P817, DOI 10.1016/0092-8674(86)90524-6; SULLIVAN KM, 1988, J BIOL CHEM, V263, P13074; Szu S. C., 1985, Mathematics and computers in biomedical applications, P19; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; VINOGRAD J, 1965, P NATL ACAD SCI USA, V53, P1104, DOI 10.1073/pnas.53.5.1104; WALKER GT, 1988, J BIOMOL STRUCT DYN, V5, P1209, DOI 10.1080/07391102.1988.10506464; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011	51	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1776	1785						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730717				2022-12-25	WOS:A1992HA48500059
J	MCCAFFREY, PG; JAIN, J; JAMIESON, C; SEN, R; RAO, A				MCCAFFREY, PG; JAIN, J; JAMIESON, C; SEN, R; RAO, A			A T-CELL NUCLEAR FACTOR RESEMBLING NF-AT BINDS TO AN NF-KAPPA-B SITE AND TO THE CONSERVED LYMPHOKINE PROMOTER SEQUENCE CYTOKINE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-SPECIFIC FACTORS; STIMULATING FACTOR GENE; LONG TERMINAL REPEAT; RECEPTOR-ALPHA-GENE; DNA-BINDING; INTERLEUKIN-2 GENE; CYCLOSPORINE-A; REL ONCOGENE; TRANSCRIPTIONAL ACTIVATOR; MONOCLONAL-ANTIBODY	Nuclear extracts from a nontransformed murine T lymphocyte clone contained two inducible factors that bound to a nuclear factor kappa-B (NF-kappa-B) site. One factor was NF-kappa-B, and the other was differentiated from NF-kappa-B by its mobility in the electrophoretic mobility shift assay and its lack of sensitivity to protein kinase C depletion. Competition and methylation interference assays showed that the binding site for the novel factor was limited to nucleotides in the 3' half of the kappa-B site. This part of the kappa-B site resembled sequences in the binding site for a second inducible nuclear factor of T cells, NF-AT, as well as a conserved sequence found in several lymphokine genes, termed "cytokine-1" (CK-1). Competition and methylation interference analysis showed that both NF-AT and CK-1 sequences bound a factor similar to the novel kappa-B-binding factor and that binding involved a four-nucleotide sequence (TTCC) that the kappa-B, CK-1, and NF-AT sites have in common. The complexes that form with each site have characteristics of NF-AT: they are induced upon T cell receptor stimulation, are sensitive to protein synthesis inhibitors and cyclosporin A, and are not sensitive to protein kinase C depletion. Thus, a factor or factors similar to NF-AT can bind to three distinct promoter sequences which occur commonly in several T cell activation genes. These results raise the possibility that related factors binding to kappa-B, CK-1, and NF-AT sequences could play a role in the coordinate induction of T cell activation genes. In addition, our results suggest that kappa-B and CK-1 sites represent potential cyclosporin-sensitive promoter elements by virtue of their ability to bind an NF-AT-like factor.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,DEPT BIOL,WALTHAM,MA 02254	Harvard University; Harvard Medical School; Brandeis University	MCCAFFREY, PG (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,MAYER BLDG,ROOM 613,44 BINNEY ST,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R37CA042471, R01CA042471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038925, R01GM038925] Funding Source: NIH RePORTER; NCI NIH HHS [CA42471] Funding Source: Medline; NIGMS NIH HHS [GM38925] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; GRANELLIPIPERNO A, 1986, J EXP MED, V163, P922, DOI 10.1084/jem.163.4.922; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; JAMIESON C, 1991, J IMMUNOL; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUBO RT, 1989, J IMMUNOL, V142, P2736; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MAUXION F, 1989, MOL CELL BIOL, V9, P3548, DOI 10.1128/MCB.9.8.3548; Maxam A M, 1980, Methods Enzymol, V65, P499; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMIDT A, 1990, J VIROL, V64, P4037, DOI 10.1128/JVI.64.8.4037-4041.1990; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SERFLING E, 1989, EMBO J, V8, P465, DOI 10.1002/j.1460-2075.1989.tb03399.x; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; STARCICH B, 1985, SCIENCE, V227, P538, DOI 10.1126/science.2981438; TOCCI MJ, 1989, J IMMUNOL, V143, P718; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WELLS R D, 1970, Journal of Molecular Biology, V54, P465, DOI 10.1016/0022-2836(70)90121-X; ZABEL U, 1991, J BIOL CHEM, V266, P252	45	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1864	1871						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730723				2022-12-25	WOS:A1992HA48500073
J	POTTER, MD; POWERSLEE, SG				POTTER, MD; POWERSLEE, SG			LOCATION OF THE ATP GAMMA-PHOSPHATE-BINDING SITES ON RAT-LIVER CARBAMOYL-PHOSPHATE SYNTHETASE-I - STUDIES WITH THE ATP ANALOG 5'-PARA-FLUOROSULFONYLBENZOYLADENOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-L-GLUTAMATE; ESCHERICHIA-COLI; ACTIVE-SITE; SECONDARY-STRUCTURE; CYSTEINE RESIDUES; PROTEINS; IDENTIFICATION; ACTIVATION; MECHANISM; DOMAIN	The gamma-phosphate subsites of the MgATP sites of rat liver carbamoyl-phosphate synthetase I have been defined by use of the ATP analog 5'-p-fluorosulfonylbenzoyladenosine (FSBA). The synthetase utilizes two molecules of MgATP, apparently in mechanistically discrete steps and at separate MgATP sites. Sequence analysis has revealed internal duplication within the synthetase molecule (Nyunoya, H., Broglie, K. E., Widgren, E. E., and Lusty, C. J. (1985) J. Biol. Chem. 260, 9346-9356) and, based on sequence similarity with other nucleotide-binding proteins, potential ATP sites have been predicted for each of the duplicated sequences. The present FSBA studies have identified four peptides within carbamoyl-phosphate synthetase I that are involved in binding MgATP. Differential effects of N-acetylglutamate, a required allosteric activator, on the interaction of FSBA with the peptides were utilized to develop the following model for two distinct MgATP sites. Peptides 631-638 and 1327-1348 (with Cys1327 and/or Cys1337 modified by FSBA) apparently form part of the binding site for the MgATP involved in bicarbonate activation. Peptides 1310-1317 and 1445-1454 (with Tyr1450 modified by FSBA) apparently form part of the binding site for the MgATP involved in phosphorylation of enzyme-bound carbamate. Each of these MgATP sites contains a peptide from one of the internal duplicated regions of the enzyme molecule, which have previously been suggested as containing MgATP sites (Nyunoya, H., Broglie, K. E., Widgren, E. E., and Lusty, C. J. (1985) J. Biol. Chem. 260, 9346-9356; Powers-Lee, S. G., and Corina, K. (1987) J. Biol. Chem. 262,9052-9056), as well as a peptide from the flexible C-terminal region.	NORTHEASTERN UNIV,DEPT BIOL,BOSTON,MA 02115	Northeastern University					NIDDK NIH HHS [DK-33460, DK-1319] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033460, K04DK001319] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADEBODUN F, 1989, BIOCHEMISTRY-US, V28, P7524, DOI 10.1021/bi00445a005; ALLEN G, 1989, SEQUENCING PROTEINS, P85; ANNAMALAI AE, 1981, J BIOL CHEM, V256, P276; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITTON HG, 1988, EUR J BIOCHEM, V171, P615, DOI 10.1111/j.1432-1033.1988.tb13832.x; BRITTON HG, 1979, EUR J BIOCHEM, V102, P521, DOI 10.1111/j.1432-1033.1979.tb04268.x; BULLOUGH DA, 1986, J BIOL CHEM, V261, P5722; BULLOUGH DA, 1988, BIOCHIM BIOPHYS ACTA, V934, P397, DOI 10.1016/0005-2728(88)90097-7; CHEN S, 1986, J PROTEIN CHEM, V5, P133, DOI 10.1007/BF01025197; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Colman R F, 1977, Methods Enzymol, V46, P240; COLMAN RF, 1983, ANNU REV BIOCHEM, V52, P67, DOI 10.1146/annurev.bi.52.070183.000435; EVANS DR, 1988, BIOCHIM BIOPHYS ACTA, V953, P185, DOI 10.1016/0167-4838(88)90023-4; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GESCHWILL K, 1989, BIOCHEM J, V260, P573, DOI 10.1042/bj2600573; HARLOW KW, 1990, J BIOL CHEM, V265, P5487; KNIGHT KL, 1985, J BIOL CHEM, V260, P177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL M, 1988, ARCH BIOCHEM BIOPHYS, V262, P455, DOI 10.1016/0003-9861(88)90397-9; MARSHALL M, 1985, ARCH BIOCHEM BIOPHYS, V241, P200, DOI 10.1016/0003-9861(85)90376-5; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; OHTA T, 1986, P NATL ACAD SCI USA, V83, P2071, DOI 10.1073/pnas.83.7.2071; PANDEY VN, 1988, J BIOL CHEM, V263, P6068; PAULUS H, 1969, ANAL BIOCHEM, V32, P91, DOI 10.1016/0003-2697(69)90107-9; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; POST LE, 1990, J BIOL CHEM, V265, P7742; POWERS SG, 1983, J BIOL CHEM, V258, P7545; POWERS SG, 1981, J BIOL CHEM, V256, P1160; POWERSLEE SG, 1986, J BIOL CHEM, V261, P5349; POWERSLEE SG, 1987, J BIOL CHEM, V262, P9052; RATNER S, 1973, ADV ENZYMOL RAMB, V39, P1; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; RUBIO V, 1983, EUR J BIOCHEM, V134, P337, DOI 10.1111/j.1432-1033.1983.tb07572.x; RUBIO V, 1979, EUR J BIOCHEM, V93, P245, DOI 10.1111/j.1432-1033.1979.tb12817.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WYATT JL, 1977, BIOCHEMISTRY-US, V16, P1333, DOI 10.1021/bi00626a015	37	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					2023	2031						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730733				2022-12-25	WOS:A1992HA48500094
J	ROSALES, C; BROWN, EJ				ROSALES, C; BROWN, EJ			CALCIUM-CHANNEL BLOCKERS NIFEDIPINE AND DILTIAZEM INHIBIT CA2+ RELEASE FROM INTRACELLULAR STORES IN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; STIMULATED HUMAN-NEUTROPHILS; RESPIRATORY BURST; CA-2+; DISCRIMINATE; GENERATION; LEUKOCYTES; CURRENTS; INFLUX	We have undertaken a detailed study of the mechanisms of maintenance of intracellular Ca2+ homeostasis in human polymorphonuclear neutrophils (PMN) and its implications for phagocytosis and IgG Fc receptor (FcR) signaling. When PMN were incubated in Ca2+-free medium, cytoplasmic calcium concentration ([Ca2+]i) was markedly depressed and intracellular stores were depleted of calcium. [Ca2+]i in these depleted cells increased within 1 min when PMN were placed in medium containing Ca2+ and then decreased to a level close to the normal basal [Ca2+]i, replenishing the intracellular Ca2+ pools. LaCl3 prevented entry of Ca2+ into Ca2+-depleted PMN, but the calcium channel blockers nifedipine, diltiazem, and verapamil did not. Nifedipine and diltiazem but not verapamil inhibited the movement of Ca2+ from cytosol to intracellular stores. Nifedipine and diltiazem inhibited the normal increase in [Ca2+]i from aggregated IgG binding to FcR and also prevented formyl-methionyl-leucyl-phenylalanine (fMLP)-induced [Ca2+]i rise. Verapamil had no effect on either an fMLP- or IgG-mediated increase in [Ca2+]i. Consistent with this, nifedipine and diltiazem inhibited fMLP-stimulated phagocytosis (which is dependent on an increase in [Ca2+]i) when PMN had repleted intracellular stores. In contrast, LaCl3 inhibited fMLP-stimulated ingestion only in PMN which had intracellular stores depleted. None of these compounds had any effect on phorbol dibutyrate-stimulated ingestion (which is independent of a [Ca2+]i rise). In summary, these data show that Ca2+ is in rapid equilibrium between intracellular and extracellular compartments in PMN. Exchange of cytoplasmic Ca2+ with the extracellular space is inhibited by LaCl3, while exchange of Ca2+ between the cytosol and intracellular stores is inhibited by the dihydropyridine nifedipine and the benzothiazepine diltiazem. These data suggest that these drugs, which are known to regulate some plasma membrane Ca2+ channels in excitable cells, can also regulate Ca2+ release from intracellular stores in PMN and that this regulation may have significant effects on PMN function.	WASHINGTON UNIV,SCH MED,DIV INFECT DIS,BOX 8051,660 S EUCLID AVE,ST LOUIS,MO 63110	Washington University (WUSTL)			ROSALES, CARLOS/AAA-5206-2019	ROSALES, CARLOS/0000-0003-2568-5723	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038330] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 38330] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGNEW WS, 1988, NATURE, V324, P299; ANDERSSON T, 1986, MOL PHARMACOL, V30, P437; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHANG J, 1987, INFLAMMATION, V11, P353, DOI 10.1007/BF00915839; DASCAL N, 1990, BIOCHEM PHARMACOL, V40, P1171, DOI 10.1016/0006-2952(90)90380-4; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; GOULD RJ, 1982, P NATL ACAD SCI-BIOL, V79, P3656, DOI 10.1073/pnas.79.11.3656; GRESHAM HD, 1987, J IMMUNOL, V139, P4159; GRESHAM HD, 1988, J CLIN INVEST, V82, P1192, DOI 10.1172/JCI113716; GRESHAM HD, 1986, J IMMUNOL, V137, P868; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HURN BA, 1980, METHOD ENZYMOL, V74, P104; KUNO M, 1986, NATURE, V323, P269, DOI 10.1038/323269a0; LEW DP, 1985, NATURE, V315, P509, DOI 10.1038/315509a0; MALGAROLI A, 1990, J BIOL CHEM, V265, P3005; MCKENNA E, 1990, BIOCHEM PHARMACOL, V39, P1145, DOI 10.1016/0006-2952(90)90255-J; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MILLER RJ, 1990, FASEB J, V4, P3291, DOI 10.1096/fasebj.4.15.1979294; MONROE JG, 1989, J EXP MED, V169, P1059, DOI 10.1084/jem.169.3.1059; MONTERO M, 1991, BIOCHEM J, V277, P73, DOI 10.1042/bj2770073; NALINI K, 1990, MOL CELL BIOCHEM, V93, P27; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; ROSALES C, 1991, J IMMUNOL, V146, P3937; ROSSI F, 1985, FEBS LETT, V181, P253, DOI 10.1016/0014-5793(85)80270-2; SAWYER DW, 1985, SCIENCE, V230, P663, DOI 10.1126/science.4048951; SLISH DF, 1989, FEBS LETT, V250, P509, DOI 10.1016/0014-5793(89)80786-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMSON CM, 1981, CAN J PHYSIOL PHARM, V59, P335, DOI 10.1139/y81-052; TRUETT AP, 1988, P NATL ACAD SCI USA, V85, P1549, DOI 10.1073/pnas.85.5.1549; TSCHARNER V, 1986, NATURE, V324, P369; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; YOUNG JDE, 1984, P NATL ACAD SCI-BIOL, V81, P5430, DOI 10.1073/pnas.81.17.5430	38	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1443	1448						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730694				2022-12-25	WOS:A1992HA48500011
J	IZAI, K; UCHIDA, Y; ORII, T; YAMAMOTO, S; HASHIMOTO, T				IZAI, K; UCHIDA, Y; ORII, T; YAMAMOTO, S; HASHIMOTO, T			NOVEL FATTY-ACID BETA-OXIDATION ENZYMES IN RAT-LIVER MITOCHONDRIA .1. PURIFICATION AND PROPERTIES OF VERY-LONG-CHAIN ACYL-COENZYME-A DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER FLAVOPROTEIN; PEROXISOMAL DISORDERS; 3-HYDROXYACYL-COA DEHYDROGENASE; COA DEHYDROGENASES; CLOFIBRATE; THIOLASE; PROTEINS; OXIDASE; CDNA	Freeze-thawed rat liver mitochondria were extensively washed with potassium phosphate, pH 7.5, and the residue was extracted with 10 mM potassium phosphate, pH 7.5, 1% (w/v) sodium cholate, 0.5 M KCl. The four beta-oxidation enzyme activities of the washes and the last extract were assayed with substrates of various carbon chain lengths. Our data suggest that the last extract contains a novel acyl-CoA dehydrogenase and long-chain 3-hydroxyacyl-CoA dehydrogenase. A novel acyl-CoA dehydrogenase was purified. The molecular masses of the native enzyme and the subunit were estimated to be 150 and 71 kDa, respectively. One mole of enzyme contained 2 mole of FAD. These properties and immunochemical properties of the enzyme differed from those of three other acyl-CoA dehydrogenases: short-, medium-, and long-chain acyl-CoA dehydrogenases. Carbon chain length specificity of the enzyme differed from that of other acyl-CoA dehydrogenases. The enzyme was active toward CoA esters of long- and very-long-chain fatty acids, but not toward those of medium- and short-chain fatty acids. The specific enzyme activity was > 10 times that of long-chain acyl-CoA dehydrogenase when palmitoyl-CoA was used as substrate. We propose the name "very-long-chain acyl-CoA dehydrogenase" for this enzyme.	SHIMOSHIZU NATL HOSP & SANITORIUM, DEPT PEDIAT, YOTSUKAIDO, CHIBA 284, JAPAN; SHINSHU UNIV, SCH MED, DEPT BIOCHEM, MATSUMOTO, NAGANO 390, JAPAN	Shinshu University	IZAI, K (corresponding author), GIFU UNIV, SCH MED, DEPT PEDIAT, GIFU 500, JAPAN.							DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; FURUTA S, 1981, J BIOCHEM, V90, P1739, DOI 10.1093/oxfordjournals.jbchem.a133651; FURUTA S, 1980, J BIOCHEM, V88, P1059, DOI 10.1093/oxfordjournals.jbchem.a133057; GEAR ARL, 1974, J BIOL CHEM, V249, P6495; HIJIKATA M, 1987, J BIOL CHEM, V262, P8151; HUSAIN M, 1983, BIOCHEM J, V209, P541, DOI 10.1042/bj2090541; IKEDA Y, 1983, J BIOL CHEM, V258, P1066; ISHII N, 1987, J BIOL CHEM, V262, P8144; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LIPSKY NG, 1982, J BIOL CHEM, V257, P1473; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNEN F, 1958, BIOCHEM Z, V330, P269; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MIYAZAWA S, 1980, EUR J BIOCHEM, V103, P589, DOI 10.1111/j.1432-1033.1980.tb05984.x; MIYAZAWA S, 1987, J BIOL CHEM, V262, P8131; MOSER HW, 1987, DEV NEUROSCI-BASEL, V9, P1, DOI 10.1159/000111604; MOSER HW, 1989, METABOLIC BASIS INHE, P1511; OSUMI T, 1980, ARCH BIOCHEM BIOPHYS, V203, P372, DOI 10.1016/0003-9861(80)90189-7; OSUMI T, 1980, J BIOCHEM, V87, P1735, DOI 10.1093/oxfordjournals.jbchem.a132918; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; OZASA H, 1984, EUR J BIOCHEM, V144, P453, DOI 10.1111/j.1432-1033.1984.tb08487.x; SCHUTGENS RBH, 1986, EUR J PEDIATR, V144, P430, DOI 10.1007/BF00441734; SEUBERT W, 1968, BIOCHIM BIOPHYS ACTA, V164, P498, DOI 10.1016/0005-2760(68)90180-X; Steinman H M, 1975, Methods Enzymol, V35, P136, DOI 10.1016/0076-6879(75)35149-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA Y, 1992, J BIOL CHEM, V267, P1034; WANDERS RJA, 1988, J NEUROL SCI, V88, P1, DOI 10.1016/0022-510X(88)90203-1; WIELAND T, 1953, ANGEW CHEM-GER EDIT, V65, P186, DOI 10.1002/ange.19530650706	30	251	255	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1027	1033						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730632				2022-12-25	WOS:A1992GY96000057
J	LEWIS, EJ; ASNANI, LP				LEWIS, EJ; ASNANI, LP			SOLUBLE AND MEMBRANE-BOUND FORMS OF DOPAMINE BETA-HYDROXYLASE ARE ENCODED BY THE SAME MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN GRANULES; PHEOCHROMOCYTOMA CELL-LINE; SIGNAL SEQUENCE; MOLECULAR-CLONING; CYCLIC-AMP; MEDULLA; CDNA; MONOOXYGENASE; EXPRESSION; PEPTIDE	A full length cDNA clone for bovine dopamine beta-hydroxylase was expressed in rat pheochromocytoma PC12 cells by stable transformation of this cell line with a plasmid expression vector. The recombinant protein exhibited dopamine beta-hydroxylase enzyme activity and was found in both the soluble and membrane fractions of the secretory vesicle. Immunoprecipitation of cell extracts from recombinant cell lines with dopamine beta-hydroxylase antisera followed by fractionation on sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed two subunits, which migrated to relative molecular masses of 76 and 78 kDa. The recombinant protein co-fractionated with neurotransmitter when subcellular structures were separated by sucrose gradient density centrifugation, suggesting that the protein was routed to the secretory vesicles. Dopamine beta-hydroxylase immunoreactivity in those sucrose gradient fractions presumed to contain secretory vesicles was resistant to treatment with trypsin unless the non-ionic detergent Triton X-100 was also present to disrupt membrane structure. The 76- and 78-kDa isoform were each found in both the membrane and soluble fractions of the secretory vesicle. Treatment of cultured cells with nerve growth factor or 8-(4-chlorophenylthio)-cyclic AMP alters the relative distribution of the subunits such that the 76-kDa form predominates. The subcellular distribution of a dopamine beta-hydroxylase cDNA clone lacking the first 16 nucleotide residues was also determined. The predicted amino acid sequence of the protein encoded by this cDNA would be deleted of the first 13 residues of the signal sequence, which were reported to be present in the membrane-bound form, but not the soluble form, of native dopamine beta-hydroxylase (Taljanidisz, J., Stewart, L., Smith, A. J., and Klinman, J. P. (1989) Biochemistry 28, 10054-10061). Immunoprecipitable dopamine beta-hydroxylase derived from expression of the deleted cDNA was found in both the membrane-bound and soluble fractions of the secretory vesicle. These experiments demonstrate that the membrane-bound and soluble forms of dopamine beta-hydroxylase are derived from one primary translation product, which is also sufficient to produce enzyme activity. In addition, the amino-terminal amino acids encoding residues 1-13, which compose the hydrophilic region of the signal sequence, are not necessary for the biogenesis of membrane-bound dopamine beta-hydroxylase.	OREGON HLTH SCI UNIV,DEPT MOLEC BIOL,PORTLAND,OR 97212; REGON HLTH SCI UNIV,DEPT MED GENET,PORTLAND,OR 97212	Oregon Health & Science University	LEWIS, EJ (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM,PORTLAND,OR 97212, USA.				NIGMS NIH HHS [GM38696] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038696, R01GM038696] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BJERRUM OJ, 1979, BIOCHEM J, V181, P231, DOI 10.1042/bj1810231; FISCHERCOLBRIE R, 1982, J NEUROCHEM, V38, P725, DOI 10.1111/j.1471-4159.1982.tb08691.x; HAEUPTLE MT, 1989, J CELL BIOL, V108, P1227, DOI 10.1083/jcb.108.4.1227; KOBAYASHI K, 1989, NUCLEIC ACIDS RES, V17, P1089, DOI 10.1093/nar/17.3.1089; LAMOUROUX A, 1987, EMBO J, V6, P3931, DOI 10.1002/j.1460-2075.1987.tb02734.x; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1990, J BIOL CHEM, V265, P1021; LIPP J, 1986, CELL, V46, P1103, DOI 10.1016/0092-8674(86)90710-5; MCHUGH EM, 1985, J BIOL CHEM, V260, P4409; MCMAHON A, 1990, J NEUROSCI RES, V25, P395, DOI 10.1002/jnr.490250317; NAGATSU T, 1986, NEUROMETHODS, V5; OYARCE AM, 1989, J MOL NEUROSCI, V1, P171, DOI 10.1007/BF02918903; PH V, 1990, NEUROSCI RES COMMUN, V6, P77; RICHARD F, 1988, J NEUROCHEM, V51, P1140, DOI 10.1111/j.1471-4159.1988.tb03079.x; ROSENBERG RC, 1977, MOL PHARMACOL, V13, P652; SABBAN EL, 1983, J BIOL CHEM, V258, P7819; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SAXENA A, 1983, J BIOL CHEM, V258, P4147; SAXENA A, 1985, J BIOL CHEM, V260, P3386; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SKOTLAND T, 1977, BIOCHEM BIOPH RES CO, V74, P1483, DOI 10.1016/0006-291X(77)90609-X; SKOTLAND T, 1979, J NEUROCHEM, V32, P1861, DOI 10.1111/j.1471-4159.1979.tb02302.x; SLATER EP, 1981, ARCH BIOCHEM BIOPHYS, V211, P288, DOI 10.1016/0003-9861(81)90456-2; SOKOLOFF RL, 1985, J NEUROCHEM, V44, P411, DOI 10.1111/j.1471-4159.1985.tb05431.x; SPERK G, 1980, J NEUROCHEM, V35, P972, DOI 10.1111/j.1471-4159.1980.tb07096.x; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; TAYLOR CS, 1989, J BIOL CHEM, V264, P14; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; WALLACE EF, 1983, P NATL ACA SCI US, V70, P2253; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5; WU HJ, 1990, J NEUROCHEM, V55, P97, DOI 10.1111/j.1471-4159.1990.tb08826.x; ZAREMBA S, 1981, J BIOL CHEM, V256, P2310; [No title captured]	34	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					494	500						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730612				2022-12-25	WOS:A1992GY43900079
J	LONGSTAFF, C; CLOUGH, AM; GAFFNEY, PJ				LONGSTAFF, C; CLOUGH, AM; GAFFNEY, PJ			KINETICS OF PLASMIN ACTIVATION OF SINGLE CHAIN URINARY-TYPE PLASMINOGEN-ACTIVATOR (SCU-PA) AND DEMONSTRATION OF A HIGH-AFFINITY INTERACTION BETWEEN SCU-PA AND PLASMINOGEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-UROKINASE; 2-CHAIN UROKINASE; TISSUE-TYPE; FIBRIN; MECHANISM; CLEAVAGE; THROMBIN; BINDING; FORMS	The activation kinetics of single chain urinary-type plasminogen activator (scu-PA) by plasmin have been studied in detail. Nonstandard Michaelis-Menten kinetics were observed. To explain our results, we propose a model in which plasmin can exist in two conformations of lower activity (k(cat)/K(m) = 1.4 x 10(6) M-1 s-1) or higher activity (k(cat)/K(m) = 16.7 x 10(6) M-1 s-1) depending on whether a lysine binding site is occupied or free, respectively. These kinetic studies demonstrate that scu-PA interacts at this binding site (K(D), almost-equal-to 30 nM) and so is able to act as both a substrate and effector in this reaction. Binding was also demonstrated between scu-PA and Glu- or Lys-plasminogen at a high affinity site (K(D) almost-equal-to 65 nM), sensitive to the presence of lysine analogs. This suggests that scu-PA may be almost completely bound to plasminogen in plasma under normal physiological conditions and provides a possible explanation for the fibrin specificity of this activator, as discussed.			LONGSTAFF, C (corresponding author), NATL INST BIOL STAND & CONTROLS,DIV HAEMATOL,POTTERS BAR EN6 3QG,HERTS,ENGLAND.		Longstaff, Colin/D-2413-2013	Longstaff, Colin/0000-0001-7608-208X				[Anonymous], 1989, LANCET, V1, P863; BROCKWAY WJ, 1972, ARCH BIOCHEM BIOPHYS, V151, P194, DOI 10.1016/0003-9861(72)90488-2; CHIBBER BAK, 1985, BIOCHEMISTRY-US, V24, P3429, DOI 10.1021/bi00335a006; CHRISTENSEN U, 1988, BIOCHIM BIOPHYS ACTA, V957, P258, DOI 10.1016/0167-4838(88)90281-6; COLLEN D, 1988, ANNU REV MED, V39, P405, DOI 10.1146/annurev.me.39.020188.002201; Cornish-Bowden A., 1975, PRINCIPLES ENZYME KI; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DOLAN G, 1988, Fibrinolysis, V2, P26; ELLIS V, 1987, J BIOL CHEM, V262, P14998; FRY ETA, 1989, THROMB HAEMOSTASIS, V62, P909; GUREWICH V, 1988, SEMIN THROMB HEMOST, V14, P110, DOI 10.1055/s-2007-1002763; GUREWICH V, 1988, ENZYME, V40, P97, DOI 10.1159/000469151; GUREWICH V, 1989, SEMIN THROMB HEMOST, V15, P123, DOI 10.1055/s-2007-1002694; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; KASAI S, 1985, J BIOL CHEM, V260, P2377; KOSHLAND DE, 1970, ENZYMES, V0001, P00342; LEATHERBARROW RJ, 1987, ENZFITTER PROGRAM NO; LIJNEN HR, 1981, EUR J BIOCHEM, V120, P149, DOI 10.1111/j.1432-1033.1981.tb05682.x; LIJNEN HR, 1989, BLOOD, V73, P1864; LIJNEN HR, 1986, J BIOL CHEM, V261, P1253; LIJNEN HR, 1987, EUR J BIOCHEM, V169, P359, DOI 10.1111/j.1432-1033.1987.tb13620.x; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MARKUS G, 1978, J BIOL CHEM, V253, P733; NIEUWENHUIZEN W, 1989, THROMB HAEMOSTASIS, V61, P208; PANNELL R, 1987, BLOOD, V69, P22; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; SAKSELA O, 1985, BIOCHIM BIOPHYS ACTA, V823, P35, DOI 10.1016/0304-419X(85)90014-9; SCHNEIDER J, 1989, THROMB RES, V56, P59, DOI 10.1016/0049-3848(89)90008-X; SCULLY MF, 1989, ARCH BIOCHEM BIOPHYS, V268, P438, DOI 10.1016/0003-9861(89)90311-1; STUMP DC, 1987, BLOOD, V69, P592; STUMP DC, 1986, J BIOL CHEM, V261, P1267; URANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P222, DOI 10.1016/0003-9861(88)90588-7; WALTHER PJ, 1974, J BIOL CHEM, V249, P1173	33	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					173	179						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730585				2022-12-25	WOS:A1992GY43900032
J	OMAHONY, DJ; XIE, WQ; SMITH, SD; SINGER, HA; ROTHBLUM, LI				OMAHONY, DJ; XIE, WQ; SMITH, SD; SINGER, HA; ROTHBLUM, LI			DIFFERENTIAL PHOSPHORYLATION AND LOCALIZATION OF THE TRANSCRIPTION FACTOR UBF INVIVO IN RESPONSE TO SERUM DEPRIVATION - INVITRO DEPHOSPHORYLATION OF UBF REDUCES ITS TRANSACTIVATION PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNA POLYMERASE-I; ESCHERICHIA-COLI; RIBOSOMAL DNA; PROTEINS; COMPLEXES; PROMOTER; BINDING; SULFATE; CELLS; RDNA	We have analyzed the expression, phosphorylation, and localization of the ribosomal DNA transcription factors UBF1 and UBF2 in Chinese hamster ovary cells in response to serum deprivation. In vivo labeling experiments demonstrate that UBF1 and UBF2 are phosphoproteins. Phosphoamino acid analysis of the in vivo labeled proteins demonstrate that UBF is phosphorylated on serine residues. Following serum deprivation there is no alteration in the cellular levels of UBF1 and UBF2 as determined by Western blotting, but there is an 80% reduction in the level of phosphorylation of UBF compared with logarithmically growing cells. Following serum deprivation there is a redistribution of UBF between the nucleolus, the nucleus, and the cytoplasm. Phosphatase-treated UBF demonstrated a reduced ability to rescue transcription by RNA polymerase I from the rDNA spacer promoter in vitro. These findings suggest that pbosphorylation of UBF is a prerequisite for transactivation of RNA polymerase I.			OMAHONY, DJ (corresponding author), GEISINGER MED CLIN,SIGFRIED & JANET WEIS CTR RES,DANVILLE,PA 17822, USA.							BACHVAROV D, 1991, NUCLEIC ACIDS RES, V19, P2331, DOI 10.1093/nar/19.9.2331; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CHAN PK, 1985, EXP CELL RES, V161, P101, DOI 10.1016/0014-4827(85)90494-X; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HENDERSON SL, 1990, MOL CELL BIOL, V10, P4970, DOI 10.1128/MCB.10.9.4970; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P4631, DOI 10.1093/nar/19.17.4631; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; MAHAJAN PB, 1990, J BIOL CHEM, V265, P16244; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; OMAHONY DJ, 1991, P NATL ACAD SCI USA, V88, P3180, DOI 10.1073/pnas.88.8.3180; OMAHONY DJ, 1990, GENE, V91, P275, DOI 10.1016/0378-1119(90)90100-6; PAULE MR, 1984, NUCLEIC ACIDS RES, V12, P8161, DOI 10.1093/nar/12.21.8161; PIKAARD CS, 1990, MOL CELL BIOL, V10, P3810, DOI 10.1128/MCB.10.7.3810; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; Sambrook J, 1989, MOL CLONING LABORATO; SCHNAPP A, 1990, EMBO J, V9, P2857, DOI 10.1002/j.1460-2075.1990.tb07475.x; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SMITH S, 1990, NUCLEIC ACIDS RES, V19, P1677; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; XIE WQ, 1991, BIOTECHNIQUES, V11, P324	29	114	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					35	38						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730600				2022-12-25	WOS:A1992GY43900010
J	WIKSTROM, L; LODISH, HF				WIKSTROM, L; LODISH, HF			ENDOPLASMIC-RETICULUM DEGRADATION OF A SUBUNIT OF THE ASIALOGLYCOPROTEIN RECEPTOR INVITRO - VESICULAR TRANSPORT FROM ENDOPLASMIC-RETICULUM IS UNNECESSARY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							INTRACELLULAR DEGRADATION; GOLGI-COMPLEX; PRE-GOLGI; CELLS; SPECIFICITY; PROTEINS	The H2a subunit of the human asialoglycoprotein receptor is rapidly degraded from the endoplasmic reticulum (ER) when expressed in CHO15B cells. We have reconstituted ER degradation of H2a in semipermeable cells. At least the initial step in degradation (a proteolytic cleavage inhibited by N(alpha)-p-tosyl-L-lysine chloromethyl ketone and L-1-tosylamido-2-phenylethyl chloromethyl ketone) can occur in vitro in the presence of guanosine 5'-3-O-(thio)triphosphate or in the absence of ATP and postnuclear supernatant, conditions that do not allow vesicular transport of subunit H1 from the ER to the Golgi. We conclude that vesicular transport from the ER is not required for ER degradation of H2a to occur and thus that it takes place in the ER itself.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; LUDWIG INST CANC RES,S-10401 STOCKHOLM,SWEDEN	Massachusetts Institute of Technology (MIT); Ludwig Institute for Cancer Research	WIKSTROM, L (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NIGMS NIH HHS [GM 35012] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035012] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BISCHOFF J, 1988, J CELL BIOL, V106, P1067, DOI 10.1083/jcb.106.4.1067; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LE A, 1990, J BIOL CHEM, V265, P14001; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MIZUOCHI T, 1984, J BIOCHEM-TOKYO, V95, P1209, DOI 10.1093/oxfordjournals.jbchem.a134711; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; TAI T, 1975, J BIOL CHEM, V250, P8569; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973	17	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					5	8						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730613				2022-12-25	WOS:A1992GY43900002
J	PRITCHARDJONES, K; FLEMING, S				PRITCHARDJONES, K; FLEMING, S			CELL-TYPES EXPRESSING THE WILMS-TUMOR GENE (WT1) IN WILMS-TUMORS - IMPLICATIONS FOR TUMOR HISTOGENESIS	ONCOGENE			English	Article							TRANSLOCATION BREAKPOINTS; EPIDEMIOLOGICAL FEATURES; GENITOURINARY DYSPLASIA; HUMAN CHROMOSOME-11; BAND 11P13; ANIRIDIA; DELETION; LOCUS; HETEROZYGOSITY; MAP	Wilms' tumour (nephroblastoma), a childhood embryonal kidney tumour, is believed to arise from malignant transformation of abnormally persistent metanephric blastemal cells. At a histological level, tumours show a remarkable mimicry of the normal nephrogenic pathway. There is histological and epidemiological evidence for at least two pathogenetic groupings within Wilms' tumour which may reflect different timings of the tumorigenic insult in this pathway and/or involvement of different genes. Tumorigenesis is thought to result from loss of function of a so-called tumour-suppressor gene which has an essential role in control of normal genitourinary development. Such a candidate, Wilms' tumour gene (WT1) mapping to chromosome 11p13, has been isolated and is known to be mutated in some tumours. We have examined the cell types expressing this gene in 32 Wilms' tumours and in nephroblastomatosis by in situ mRNA hybridization. Our results show that WT1 is expressed only in neoplastic structures whose normal counterparts also express the gene and that abnormally persistent high levels of expression are common in both these lesions. Thus, WT1 expression is a good marker for tumour differentiation and reveals how the normal pattern of differentiation is disrupted in Wilms' tumours. We postulate that mutation of the WT1 gene at the 11p13 locus results in Wilms' tumours associated with intralobar nephrogenic rests, which frequently show stromal-predominant histology. We have used our results and ideas to reinterpret current theories on tumour histogenesis and propose a model which explains how patterns of epithelial differentiation are disrupted in Wilms' tumour 2nd how malignant stroma can result from mutation in WT1.	WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,DEPT PATHOL,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh; University of Edinburgh			Pritchard-Jones, Kathy/F-4286-2014	Pritchard-Jones, Kathy/0000-0002-2384-9475				BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BEHESHTI M, 1984, UROLOGY, V24, P130, DOI 10.1016/0090-4295(84)90413-8; BENNINGTON JL, 1975, ATLAS TUMOR PATHOLOG; BICKMORE WA, 1989, GENOMICS, V5, P685, DOI 10.1016/0888-7543(89)90109-2; Bove K E, 1976, Perspect Pediatr Pathol, V3, P185; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COMPTON DA, 1990, GENOMICS, V6, P309, DOI 10.1016/0888-7543(90)90571-B; DAO DD, 1987, AM J HUM GENET, V41, P202; DAVIDSON D, 1988, DEVELOPMENT, V104, P305; DAVIS LM, 1988, SCIENCE, V241, P840, DOI 10.1126/science.2841760; DELEMARRE JFM, 1982, PEDIATRIC ONCOLOGY, P261; DENYS P, 1967, ARCH FR PEDIATR, V24, P729; DRASH A, 1970, J PEDIATR-US, V76, P585, DOI 10.1016/S0022-3476(70)80409-7; EKBLOM P, 1981, MED BIOL, V59, P139; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FLEMING S, 1985, HISTOPATHOLOGY, V9, P729, DOI 10.1111/j.1365-2559.1985.tb02859.x; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLASER T, 1986, NATURE, V321, P882, DOI 10.1038/321882a0; GREENBERG F, 1988, AM J MED GENET, V29, P773, DOI 10.1002/ajmg.1320290406; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HOU LT, 1967, J PATHOL BACTERIOL, V93, P477; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; JONES KL, 1988, SMITHS RECOGNIZABLE, P136; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LANGDALEBROWN B, 1990, J PATHOL, V160, pA162; LEWIS W H, 1988, Genomics, V3, P25, DOI 10.1016/0888-7543(88)90154-1; MAKIN CA, 1984, J CLIN PATHOL, V37, P975, DOI 10.1136/jcp.37.9.975; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MANNENS M, 1990, CANCER RES, V50, P3279; MIERAU GW, 1987, ULTRASTRUCT PATHOL, V11, P313, DOI 10.3109/01913128709048329; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PASTORE G, 1988, MED PEDIATR ONCOL, V16, P7, DOI 10.1002/mpo.2950160103; PENDERGRASS TW, 1976, CANCER, V37, P403, DOI 10.1002/1097-0142(197601)37:1<403::AID-CNCR2820370152>3.0.CO;2-H; PERLMAN M, 1973, J PEDIATR-US, V83, P414, DOI 10.1016/S0022-3476(73)80264-1; PING AJ, 1989, AM J HUM GENET, V44, P720; PORTEOUS DJ, 1987, P NATL ACAD SCI USA, V84, P5355, DOI 10.1073/pnas.84.15.5355; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; RICCARDI VM, 1978, PEDIATRICS, V61, P604; ROSE EA, 1990, CELL, V60, P495, DOI 10.1016/0092-8674(90)90600-J; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHMIDT D, 1982, PATHOBIOL ANN, V12, P281; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; SHANNON RS, 1982, ARCH DIS CHILD, V57, P685, DOI 10.1136/adc.57.9.685; TURLEAU C, 1984, CLIN GENET, V26, P356; VANHEYNINGEN V, 1985, P NATL ACAD SCI USA, V82, P8592; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; WADEY RB, 1990, ONCOGENE, V5, P901	57	73	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2211	2220						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1722569				2022-12-25	WOS:A1991GX73500006
J	DIRENZO, MF; NARSIMHAN, RP; OLIVERO, M; BRETTI, S; GIORDANO, S; MEDICO, E; GAGLIA, P; ZARA, P; COMOGLIO, PM				DIRENZO, MF; NARSIMHAN, RP; OLIVERO, M; BRETTI, S; GIORDANO, S; MEDICO, E; GAGLIA, P; ZARA, P; COMOGLIO, PM			EXPRESSION OF THE MET HGF RECEPTOR IN NORMAL AND NEOPLASTIC HUMAN TISSUES	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; MOLECULAR-CLONING; SCATTER FACTOR; HEPATOPOIETIN-A; CELL-LINE; ONCOGENE; SEQUENCE; GENE; CDNA	The MET oncogene encodes a transmembrane tyrosine kinase receptor. Recently, hepatocyte growth factor (HGF), a potent growth factor for hepatocytes involved in liver regeneration, has been proposed as a ligand. In this paper, the physiological role of the human Met/HGF receptor is investigated by studying its specific distribution in normal and neoplastic tissues. Northern blot analysis has shown that the MET gene is selectively expressed in several epithelial tissues. High levels of MET mRNA have been found in liver, gastrointestinal tract, thyroid and kidney. Western blot analysis has shown that the levels of the Met protein generally correspond to those of the mRNA. However, in the thyroid, where there is a high level of MET mRNA, the protein was barely detectable, suggesting translational or post-translational regulation. The protein was also detected in the brain. Normal or increased levels of MET mRNA and Met protein were consistently found in fresh samples of carcinomas as well as in epithelial tumor cell lines. In thyroid carcinomas of a specific histiotype the amount of Met protein, almost undetectable in the normal counterpart, was found to be increased more than 100-fold. The tissue distribution of the Met/HGF receptor indicates that this molecule is involved in growth control of epithelial cells other than hepatocytes and suggests that its increased expression may confer a growth advantage to neoplastic cells.	S GIOVANNI HOSP,TURIN,ITALY		DIRENZO, MF (corresponding author), UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,SEZIONE ISTOL C MDAZEGLIO 52,I-10126 TURIN,ITALY.		Giordano, Silvia/J-9858-2018; olivero, martina/J-4811-2018; DI RENZO, Maria Flavia/B-6091-2012	Giordano, Silvia/0000-0003-1854-1086; olivero, martina/0000-0002-6815-3498; DI RENZO, Maria Flavia/0000-0002-5093-3373; Comoglio, Paolo/0000-0002-7056-5328				BONGARZONE I, 1989, ONCOGENE, V4, P1457; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1988, ONCOGENE, V2, P593; CHAN AML, 1987, ONCOGENE, V1, P229; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, IN PRESS INT J CANCE; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; STERN CD, 1990, DEVELOPMENT, V110, P1271; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TASHIRO K, 1990, P NATL ACAD SCI USA, V87, P3200, DOI 10.1073/pnas.87.8.3200; TEMPEST PR, 1988, BRIT J CANCER, V58, P3, DOI 10.1038/bjc.1988.150; TEMPEST PR, 1986, FEBS LETT, V209, P357, DOI 10.1016/0014-5793(86)81142-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEIDNER KM, 1990, J CELL BIOL, V111, P2907; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZHAO YH, 1990, ONCOGENE, V5, P1629	38	494	513	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1997	2003						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719465				2022-12-25	WOS:A1991GX11900009
J	POWELL, DR; SUWANICHKUL, A; CUBBAGE, ML; DEPAOLIS, LA; SNUGGS, MB; LEE, PDK				POWELL, DR; SUWANICHKUL, A; CUBBAGE, ML; DEPAOLIS, LA; SNUGGS, MB; LEE, PDK			INSULIN INHIBITS TRANSCRIPTION OF THE HUMAN GENE FOR INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; HUMAN CHROMOSOMAL GENE; CHRONIC-RENAL-FAILURE; HUMAN AMNIOTIC-FLUID; HEPATOMA-CELLS; IGF-I; DIABETES-MELLITUS; CHLORAMPHENICOL ACETYLTRANSFERASE; MULTIHORMONAL REGULATION; PROMOTER ACTIVITY	Insulin rapidly lowers serum insulin-like growth factor-binding protein-1 (IGFBP-1) levels in vivo. In studies reported here, HEP G2 cells were used as a model system to investigate how insulin achieves this effect. When HEP G2 cells were incubated with 100 nM insulin for 6, 14, or 24 h, IGFBP-1 protein levels in conditioned medium fell to approximately 50% of control values. This apparently was due to a fall in the rate of IGFBP-1 protein synthesis, since HEP G2 cells incorporated 46% less [S-35]methionine into IGFBP-1 during a 4-h incubation with 100 nM insulin. IGFBP-1 mRNA levels were similarly affected by 100 nM insulin, falling to 45% of control values after 2 h, and to 9% of control values after 4 h of incubation with this hormone. The fall in IGFBP-1 mRNA level is consistent with data from nuclear transcription assays. HEP G2 nuclei isolated from cells that were incubated with 100 nM insulin for 2 h synthesized only approximately 1/3 the number of IGFBP-1 transcripts as did control nuclei. Further evidence that insulin decreases IGFBP-1 gene transcription comes from transient transfections using chimeric IGFBP-1 promoter-chloramphenicol acetyltransferase reporter gene constructs. IGFBP-1 promoter activity fell to approximately 50% of control values when HEP G2 cells transfected with a construct containing the first 1205 base pairs of the IGFBP-1 promoter were incubated with 100 nM insulin for 6, 14, or 24 h. Insulin lowered both IGFBP-1 protein levels and promoter activity in a dose-dependent manner. A half-maximal effect was found at approximately 1 nM insulin and a maximal effect was found at approximately 10 nM insulin in each instance. Transfections with constructs containing smaller IGFBP-1 promoter fragments showed that the region spanning from 103 to 529 base pairs 5' to the IGFBP-1 mRNA cap site was necessary to demonstrate the inhibitory effect of insulin. These studies indicate that insulin lowers IGFBP-1 protein levels, at least in part, by rapidly decreasing the rate of IGFBP-1 gene transcription, and suggest that this insulin-mediated fall in transcription is conferred through a specific region of the IGFBP-1 promoter.			POWELL, DR (corresponding author), BAYLOR COLL MED, DIABET RES CTR, DEPT PEDIAT, 8080 N STADIUM DR, HOUSTON, TX 77054 USA.			Lee, Phillip/0000-0002-6856-4262	NIDDK NIH HHS [DK-38773] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038773, R01DK038773] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BAXTER RC, 1987, J CLIN ENDOCR METAB, V65, P432, DOI 10.1210/jcem-65-3-432; BRISMAR K, 1988, J ENDOCRINOL INVEST, V11, P599, DOI 10.1007/BF03350189; BURCH WM, 1990, J CLIN ENDOCR METAB, V70, P173, DOI 10.1210/jcem-70-1-173; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CONOVER CA, 1990, J CLIN ENDOCR METAB, V70, P1062, DOI 10.1210/jcem-70-4-1062; CONOVER CA, 1990, ENDOCRINOLOGY, V127, P2795, DOI 10.1210/endo-127-6-2795; CONOVER CA, 1990, DIABETES, V39, P1251, DOI 10.2337/diabetes.39.10.1251; COTTERILL AM, 1988, J CLIN ENDOCR METAB, V67, P882, DOI 10.1210/jcem-67-5-882; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; CUBBAGE ML, 1989, MOL ENDOCRINOL, V3, P846, DOI 10.1210/mend-3-5-846; DANI C, 1989, MOL CELL ENDOCRINOL, V63, P199, DOI 10.1016/0303-7207(89)90096-8; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DROP SLS, 1984, J CLIN ENDOCR METAB, V59, P908, DOI 10.1210/jcem-59-5-908; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FEHLMANN M, 1983, BIOCHEM J, V214, P845, DOI 10.1042/bj2140845; FRAUMAN AG, 1989, ENDOCRINOLOGY, V124, P2289, DOI 10.1210/endo-124-5-2289; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; HOLLY JMP, 1988, CLIN ENDOCRINOL, V29, P667, DOI 10.1111/j.1365-2265.1988.tb03715.x; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACOBY DB, 1989, J BIOL CHEM, V264, P17623; JEFFERSON LS, 1980, DIABETES, V29, P487, DOI 10.2337/diab.29.6.487; KELLY JH, 1989, IN VITRO CELL DEV B, V25, P217; LEE PDK, 1989, PEDIATR RES, V26, P308, DOI 10.1203/00006450-198910000-00005; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LEWITT MS, 1989, J CLIN ENDOCR METAB, V69, P246, DOI 10.1210/jcem-69-2-246; LIU F, 1990, J CLIN ENDOCR METAB, V70, P620, DOI 10.1210/jcem-70-3-620; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MOHAN S, 1989, P NATL ACAD SCI USA, V86, P8338, DOI 10.1073/pnas.86.21.8338; MOSS M, 1981, MOL CELL BIOL, V1, P289, DOI 10.1128/MCB.1.3.289; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OOI GT, 1990, MOL ENDOCRINOL, V4, P321, DOI 10.1210/mend-4-2-321; ORLOWSKI CC, 1990, MOL ENDOCRINOL, V4, P1592, DOI 10.1210/mend-4-10-1592; POWELL DR, 1989, INT CONGR SER, V881, P3; POWELL DR, 1987, J CHROMATOGR-BIOMED, V420, P163, DOI 10.1016/0378-4347(87)80168-8; PRAGER D, 1988, J BIOL CHEM, V263, P16580; RITVOS O, 1988, ENDOCRINOLOGY, V122, P2150, DOI 10.1210/endo-122-5-2150; ROESLER WJ, 1990, TRENDS ENDOCRIN MET, V1, P347, DOI 10.1016/1043-2760(90)90082-E; ROGHANI M, 1989, FEBS LETT, V255, P253, DOI 10.1016/0014-5793(89)81101-9; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SENEVIRATNE C, 1990, MOL ENDOCRINOL, V4, P1199, DOI 10.1210/mend-4-8-1199; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SUIKKARI AM, 1988, J CLIN ENDOCR METAB, V66, P266, DOI 10.1210/jcem-66-2-266; SUWANICHKUL A, 1990, J BIOL CHEM, V265, P21185; UNTERMAN TG, 1990, ENDOCRINOLOGY, V126, P2614, DOI 10.1210/endo-126-5-2614; YEOH SI, 1988, ACTA ENDOCRINOL-COP, V119, P465, DOI 10.1530/acta.0.1190465	50	195	201	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18868	18876						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1717456				2022-12-25	WOS:A1991GJ47200072
J	KRANTZ, DD; ZIDOVETZKI, R; KAGAN, BL; ZIPURSKY, SL				KRANTZ, DD; ZIDOVETZKI, R; KAGAN, BL; ZIPURSKY, SL			AMPHIPATHIC BETA-STRUCTURE OF A LEUCINE-RICH REPEAT PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEAR MAGNETIC-RESONANCE; LIPID-PROTEIN INTERACTIONS; PLATELET GLYCOPROTEIN-IB; CYTOCHROME-C-OXIDASE; RIBONUCLEASE INHIBITOR; TRANSMEMBRANE PROTEIN; CIRCULAR-DICHROISM; ADENYLATE-CYCLASE; PROTEOGLYCAN-II	Long tandem arrays of a characteristic leucine-rich repeat motif on the order of 24 amino acids in length have been found in the primary structure of an increasing number of proteins. The most striking feature of these repeats is an amphipathic sequence, with leucine as the predominant hydrophobic residue. Based on this amphipathic sequence and the function of the proteins in which they have been found, the repeats have been proposed to be involved in protein-protein and protein-lipid interactions. As a step toward elucidating the structure and biochemical properties of the leucine-rich repeat motif, we have studied a synthetic leucine-rich repeat peptide (LRP32) representing one of the repeats found in Drosophila chaoptin. We have shown that: (i) LRP32 is soluble in aqueous solution but will bind quantitatively to phospholipid vesicles; (ii) LRP32 has a partial beta-structure in aqueous solution and is predominantly a beta-structure in the presence of phospholipid; (iii) LRP32 integrates into lipid bilayers to form 60-angstrom intramembrane particles as seen using freeze-fracture electron microscopy (these putative oligomeric structures appear to contain a central aqueous core as indicated by their ability to generate conductances in planar lipid bilayers); and (iv) LRP32-lipid complexes generate H-2 NMR spectra characteristic of integral membrane proteins. This study is consistent with LRP32 forming an amphipathic beta-sheet. We propose that protein segments containing tandem arrays of leucine-rich repeats also may form amphipathic beta-sheets.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90024; W LOS ANGELES VET ADM HOSP,LOS ANGELES,CA 90024; UNIV CALIF RIVERSIDE,DEPT BIOL,RIVERSIDE,CA 92521	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Riverside			Kagan, Bruce/ABD-7389-2020	Zipursky, Stephen/0000-0001-5630-7181				BARANY G, 1987, INT J PEPT PROT RES, V30, P705; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Branton D, 1970, J CELL BIOL, V45, P598, DOI DOI 10.1083/JCB.45.3.598.PMID:4918216; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRISMA M, 1984, INT J PEPT PROT RES, V23, P411; DAVIS JH, 1979, BIOPHYS J, V27, P339, DOI 10.1016/S0006-3495(79)85222-4; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; Eisenberg D., 1982, FARADAY S CHEM SOC, V17, P109, DOI DOI 10.1039/FS9821700109; ERARD M, 1990, EUR J BIOCHEM, V191, P19, DOI 10.1111/j.1432-1033.1990.tb19088.x; FERRERO E, 1990, J IMMUNOL, V145, P331; FERRERO E, 1988, NUCLEIC ACIDS RES, V16, P41; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FOX RO, 1982, NATURE, V300, P325, DOI 10.1038/300325a0; FUKUSHIMA D, 1979, J AM CHEM SOC, V101, P3703, DOI 10.1021/ja00507a068; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; Hille B, 1984, IONIC CHANNELS EXCIT; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; HORWITZ J, 1987, BIOCHEMISTRY-US, V26, P8092, DOI 10.1021/bi00399a012; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KAISER ET, 1987, ANNU REV BIOPHYS BIO, V16, P561; KANG SY, 1979, BIOCHEMISTRY-US, V18, P3257, DOI 10.1021/bi00582a010; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KRANTZ DE, 1990, EMBO J, V9, P1969, DOI 10.1002/j.1460-2075.1990.tb08325.x; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; LEE FS, 1988, BIOCHEMISTRY-US, V27, P8545, DOI 10.1021/bi00423a007; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MASSON P, 1986, CURR GENET, V10, P343, DOI 10.1007/BF00418405; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; Montal M, 1974, Methods Enzymol, V32, P545; MORROW MR, 1988, BIOCHEMISTRY-US, V27, P2024, DOI 10.1021/bi00406a032; MULLER L, 1983, J CHEM PHYS, V78, P4341, DOI 10.1063/1.445328; NAEME PJ, 1989, J BIOL CHEM, V264, P8653; OIKI S, 1988, P NATL ACAD SCI USA, V85, P8703, DOI 10.1073/pnas.85.22.8703; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PADDY MR, 1981, BIOCHEMISTRY-US, V20, P3152, DOI 10.1021/bi00514a026; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROTH GJ, 1990, BIOCHEM BIOPH RES CO, V170, P153, DOI 10.1016/0006-291X(90)91253-O; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SCHNEIDER R, 1988, EMBO J, V7, P4151, DOI 10.1002/j.1460-2075.1988.tb03310.x; SEGREST JP, 1974, P NATL ACAD SCI USA, V71, P3294, DOI 10.1073/pnas.71.8.3294; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SETOGUCHI M, 1989, BIOCHIM BIOPHYS ACTA, V1008, P213, DOI 10.1016/0167-4781(80)90012-3; SHIMOMURA T, 1990, BLOOD, V75, P2349; SPARROW JT, 1982, CRC CR REV BIOCH MOL, V13, P87, DOI 10.3109/10409238209108710; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; TAMM LK, 1983, BIOCHEMISTRY-US, V22, P1474, DOI 10.1021/bi00275a023; TAN FL, 1990, J BIOL CHEM, V265, P13; TILLACK TW, 1970, J CELL BIOL, V45, P649, DOI 10.1083/jcb.45.3.649; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; WOODY RW, 1974, PEPTIDES POLYPEPTIDE, P339; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YAMAWAKIKATAOKA Y, 1989, P NATL ACAD SCI USA, V86, P5693, DOI 10.1073/pnas.86.15.5693; ZAMPIGHI G, 1982, J CELL BIOL, V93, P175, DOI 10.1083/jcb.93.1.175	72	62	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16801	16807						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1715870				2022-12-25	WOS:A1991GD63500088
J	ASHBY, MN; KUTSUNAI, SY; ACKERMAN, S; TZAGOLOFF, A; EDWARDS, PA				ASHBY, MN; KUTSUNAI, SY; ACKERMAN, S; TZAGOLOFF, A; EDWARDS, PA			COQ2 IS A CANDIDATE FOR THE STRUCTURAL GENE ENCODING PARA-HYDROXYBENZOATE - POLYPRENYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL PYROPHOSPHATE SYNTHETASE; MITOCHONDRIAL-MEMBRANE SYSTEM; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; RAT-LIVER; UBIQUINONE BIOSYNTHESIS; CAROTENOID BIOSYNTHESIS; MICROSOMAL FRACTION; ELECTRON-TRANSPORT; MOLECULAR-CLONING	Coenzyme Q functions as a lipid-soluble electron carrier in eukaryotes. In Saccharomyces cerevisiae, the enzymes responsible for the assembly of the polyisoprenoid side chain and subsequent transfer to parahydroxybenzoate (PHB) are encoded by the nuclear genes COQ1 and COQ2, respectively. Yeast mutants defective in coenzyme Q biosynthesis are respiratory defective and provide a useful tool to study this nonsterol branch of the isoprenoid biosynthetic pathway. We isolated a 5.5-kilobase genomic DNA fragment that was able to functionally complement a coq2 strain. Additional complementation analyses located the COQ2 gene within a 2.1-kilobase HindIII-BglII restriction fragment. Sequence analyses revealed the presence of a 1,116-base pair open reading frame coding for a predicted protein of 372 amino acids and a molecular mass of 41,001 daltons. The amino acid sequence exhibits a typical amino-terminal mitochondrial leader sequence and six potential membrane-spanning domains. Primer extension and Northern analyses indicate the gene is transcriptionally active. Transformation of a coq2 strain with the 2.1-kilobase HindIII-BglII genomic restriction fragment on a multicopy plasmid restores PHB:polyprenyltransferase activity to wild-type levels. Disruption of the chromosomal COQ2 gene indicates the gene is not essential for viability, yet is required for PHB:polyprenyltransferase activity and respiratory function. In addition, the deduced amino acid sequence of PHB:polyprenyltransferase contains a putative allylic polyprenyl diphosphate-binding site. The presence of this aspartaterich domain in a number of functionally distinct proteins which utilize polyprenyl diphosphate substrates is reported.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CARDIOL,LOS ANGELES,CA 90024; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Columbia University					NHLBI NIH HHS [R01 HL022174, HL 30568, HL 07386] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174, P01HL030568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MS, 1989, J BIOL CHEM, V264, P19176; ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; ARMSTRONG GA, 1990, P NATL ACAD SCI USA, V87, P9975, DOI 10.1073/pnas.87.24.9975; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; ASHBY MN, 1990, MOL BIOL ATHEROSCLER, P27; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BREMS DN, 1981, BIOCHEMISTRY-US, V20, P3711, DOI 10.1021/bi00516a007; CARATTOLI A, 1991, J BIOL CHEM, V266, P5854; CASEY J, 1978, BIOCHIM BIOPHYS ACTA, V530, P487, DOI 10.1016/0005-2760(78)90168-6; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; CLARKE CF, 1987, MOL CELL BIOL, V7, P3138, DOI 10.1128/MCB.7.9.3138; DEKOK J, 1975, BIOCHIM BIOPHYS ACTA, V376, P27, DOI 10.1016/0005-2728(75)90202-9; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FUJISAKI S, 1990, J BIOCHEM-TOKYO, V108, P995, DOI 10.1093/oxfordjournals.jbchem.a123327; GOLDBERG SB, 1984, NUCLEIC ACIDS RES, V12, P4665, DOI 10.1093/nar/12.11.4665; GOTOH T, 1988, BIOCHEM BIOPH RES CO, V156, P396, DOI 10.1016/S0006-291X(88)80854-4; GREEN DE, 1966, COMPREHENSIVE BIOCH, V4, P309; GUPTA A, 1984, BIOCHEM BIOPH RES CO, V119, P1109, DOI 10.1016/0006-291X(84)90889-1; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HILL JE, 1986, YEAST, V2, P1163; HOLLOWAY PW, 1967, BIOCHEM J, V104, P57, DOI 10.1042/bj1040057; JENNINGS SM, 1991, P NATL ACAD SCI USA, V88, P6038, DOI 10.1073/pnas.88.14.6038; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KALEN A, 1990, J BIOL CHEM, V265, P1158; KALEN A, 1987, BIOCHIM BIOPHYS ACTA, V926, P70, DOI 10.1016/0304-4165(87)90183-8; KANG DC, 1990, J BIOCHEM-TOKYO, V108, P893; KING HL, 1977, BIOCHEMISTRY-US, V16, P3815, DOI 10.1021/bi00636a015; KROGER A, 1973, EUR J BIOCHEM, V39, P313, DOI 10.1111/j.1432-1033.1973.tb03129.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MICHALOWSKI CB, 1991, J BIOL CHEM, V266, P11866; MOMOSE K, 1972, J BIOL CHEM, V247, P3930; NAJARIAN D, 1987, MOL CELL BIOL, V7, P185, DOI 10.1128/MCB.7.1.185; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; PARSON WW, 1964, P NATL ACAD SCI USA, V51, P444, DOI 10.1073/pnas.51.3.444; Pennock J. F., 1983, BIOSYNTHESIS ISOPREN, V2, P191; POPJAK G, 1969, BIOCHEM J, V111, P333, DOI 10.1042/bj1110333; POWELL GK, 1986, NUCLEIC ACIDS RES, V14, P2555, DOI 10.1093/nar/14.6.2555; RAMASARMA T, 1985, COENZYME Q BIOCH BIO, P67; RAY J, 1987, NUCLEIC ACIDS RES, V15, P1058; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEARES BT, 1989, BIOCHEMISTRY-US, V28, P8129, DOI 10.1021/bi00446a025; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; STRABALA TJ, 1989, MOL GEN GENET, V216, P388, DOI 10.1007/BF00334380; SUN IL, 1990, BIOCHEM BIOPH RES CO, V172, P979, DOI 10.1016/0006-291X(90)91542-Z; TERUYA JH, 1990, MOL CELL BIOL, V10, P2315, DOI 10.1128/MCB.10.5.2315; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; WILKIN DJ, 1990, J BIOL CHEM, V265, P4607; WINROW MJ, 1969, BIOCHEM BIOPH RES CO, V37, P833, DOI 10.1016/0006-291X(69)90967-X	57	159	168	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4128	4136						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740455				2022-12-25	WOS:A1992HE60700083
J	ORTEL, TL; DEVORECARTER, D; QUINNALLEN, MA; KANE, WH				ORTEL, TL; DEVORECARTER, D; QUINNALLEN, MA; KANE, WH			DELETION ANALYSIS OF RECOMBINANT HUMAN FACTOR-V - EVIDENCE FOR A PHOSPHATIDYLSERINE BINDING-SITE IN THE 2ND C-TYPE DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; BOVINE FACTOR-V; HUMAN FACTOR-VIII; PHOSPHOLIPID-VESICLES; HEAVY-CHAIN; FACTOR-XA; CONNECTING REGION; MEMBRANE-BINDING; PROTEIN-C; THROMBIN	Human coagulation factor V is an integral component of the prothrombinase complex. Rapid activation of prothrombin is dependent on the interactions of this nonenzymatic cofactor with factor Xa and prothrombin in the presence of calcium ions and a phospholipid or platelet surface. Factor V is similar structurally and functionally to the homologous cofactor, factor VIII, which interacts with factor IXa to accelerate factor X activation in the presence of calcium and phospholipids. Both of these cofactors, when activated, possess homologous heavy and light chains. Binding to anionic phospholipids is mediated by the light chains of these two cofactors. In bovine factor Va, a phosphatidylserine-specific binding site has been localized to the amino-terminal A3 domain of the light chain. In human factor VIII, on the other hand, a region within the carboxyl-terminal C2 domain of the light chain has been shown to interact with anionic phospholipids. We have constructed a series of recombinant deletion mutants lacking domain-size fragments of the light chain of human factor V (rHFV). These mutants are expressed and secreted as single-chain proteins by COS cells. Thrombin and the factor V activator from Russell's viper venom process these deletion mutants as expected. The light chain deletion mutants possess essentially no procoagulant activity, nor are they activated by treatment with factor V activator from Russell's viper venom. Deletion of the second C-type domain results in essentially complete loss of phosphatidylserine-specific binding whereas the presence of the C2 domain alone (rHFV des-A3C1 which lacks the A3 and C1 domains of the light chain) results in significant phosphatidylserine-specific binding. The presence of the A3 domain alone (rHFV des-C1C2) does not mediate binding to immobilized phosphatidylserine. Increasing calcium ion concentrations result in decreased binding of recombinant human factor V and the mutant rHFV des-A3C1 to phosphatidylserine, similar to previous studies with purified plasma factor V and phospholipid vesicles. These results indicate that human factor V, similar to human factor VIII, possesses a phosphatidylserine-specific binding site within the C2 domain of the light chain.	DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,DURHAM,NC 27710	Duke University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043106, T32HL007057] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32 HL-07057, HL43106] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANNAMALAI AE, 1987, BLOOD, V70, P139; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BARTLES JR, 1982, BIOCHIM BIOPHYS ACTA, V687, P129, DOI 10.1016/0005-2736(82)90538-7; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BLOOM JW, 1987, THROMB RES, V48, P439, DOI 10.1016/0049-3848(87)90401-4; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; ESMON CT, 1979, J BIOL CHEM, V254, P964; FOSTER PA, 1990, BLOOD, V75, P1999; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GITSCHIER J, 1986, SCIENCE, V232, P1415, DOI 10.1126/science.3012775; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; INABA H, 1989, HUM GENET, V81, P335, DOI 10.1007/BF00283686; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KALAFATIS M, 1990, J BIOL CHEM, V265, P21580; KANE WH, 1988, BLOOD, V71, P539; KANE WH, 1986, P NATL ACAD SCI USA, V83, P6800, DOI 10.1073/pnas.83.18.6800; KANE WH, 1990, BIOCHEMISTRY-US, V29, P6762, DOI 10.1021/bi00481a003; KANE WH, 1987, BIOCHEMISTRY-US, V26, P6508, DOI 10.1021/bi00394a033; KANE WH, 1981, J BIOL CHEM, V256, P1002; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KRIEG UC, 1987, BIOCHEMISTRY-US, V26, P103, DOI 10.1021/bi00375a015; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; LAROCCA D, 1991, CANCER RES, V51, P4994; LECOMPTE MF, 1987, J BIOL CHEM, V262, P1935; MAYER LD, 1983, BIOCHEMISTRY-US, V22, P6226, DOI 10.1021/bi00295a029; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; ORTEL TL, 1984, P NATL ACAD SCI-BIOL, V81, P4761, DOI 10.1073/pnas.81.15.4761; POOLE S, 1981, J MOL BIOL, V153, P273, DOI 10.1016/0022-2836(81)90278-3; PUSEY ML, 1982, BIOCHEMISTRY-US, V21, P5262, DOI 10.1021/bi00264a022; PUSEY ML, 1984, BIOCHEMISTRY-US, V23, P6202, DOI 10.1021/bi00320a048; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019	39	118	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4189	4198						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740460				2022-12-25	WOS:A1992HE60700092
J	LINHARDT, RJ; WANG, HM; LOGANATHAN, D; BAE, JH				LINHARDT, RJ; WANG, HM; LOGANATHAN, D; BAE, JH			SEARCH FOR THE HEPARIN ANTITHROMBIN-III-BINDING SITE PRECURSOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; FLAVOBACTERIUM-HEPARINUM; STRUCTURAL FEATURES; SEQUENCE-ANALYSIS; OLIGOSACCHARIDES; PROTEOGLYCAN; BIOSYNTHESIS; LOCATION; SULFATE; TETRASACCHARIDES	The last step of heparin biosynthesis is thought to involve the action of 3-O-sulfotransferase resulting in the formation of an antithrombin III (ATIII) binding site required for heparin's anticoagulant activity. The isolation of a significant fraction of heparin chains without antithrombin III-binding sites and having low affinity for ATIII suggests the presence of a precursor site, lacking the 3-O-sulfate group. Porcine mucosal heparin was depolymerized into a mixture of oligosaccharides using heparin lyase. One of these oligosaccharides was derived from heparin's ATIII-binding site. In an effort to find the ATIII-binding site precursor, the structures of several minor oligosaccharides were determined. A greater than 90% recovery of oligosaccharides (on a mole and weight basis) was obtained for both unfractionated and affinity-fractionated heparins. An oligosaccharide arising from the ATIII-binding site precursor was found that comprised only 0.8 mol % of the oligosaccharide product mixture. This oligosaccharide was only slightly enriched in heparin having a low affinity for ATIII and only slightly disenriched in high affinity heparin. The small number of these ATIII-binding site precursors, found in unfractionated and fractionated heparins, suggests the existence of a low ATIII affinity heparin may not simply be the result of the incomplete action of 3-O-sulfotransferase in the final step in heparin biosynthesis. Rather these data suggest that some earlier step, involved in the formation or placement of these precursor sites, may be primarily responsible for high and low ATIII affinity heparins.			LINHARDT, RJ (corresponding author), UNIV IOWA,COLL PHARM,DIV MED & NAT PROD CHEM,IOWA CITY,IA 52242, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038060] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 29797] Funding Source: Medline; NIAID NIH HHS [AI 22350] Funding Source: Medline; NIGMS NIH HHS [GM 38060] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; COHEN DM, 1990, BIOPOLYMERS, V30, P733, DOI 10.1002/bip.360300708; FRANSSON LA, 1990, BIOCHEM J, V269, P381, DOI 10.1042/bj2690381; GALLIHER PM, 1981, APPL ENVIRON MICROB, V41, P360, DOI 10.1128/AEM.41.2.360-365.1981; GATTI G, 1979, MACROMOLECULES, V12, P1001, DOI 10.1021/ma60071a044; GOOD TA, 1964, ANAL BIOCHEM, V9, P253, DOI 10.1016/0003-2697(64)90183-6; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; JACOBSSON KG, 1987, BIOCHEM J, V246, P409, DOI 10.1042/bj2460409; KIM YS, 1989, THROMB RES, V53, P55, DOI 10.1016/0049-3848(89)90115-1; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LANE DL, 1989, HEPARIN CHEM BIOL PR; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; Lindahl U., 1989, HEPARIN, P159; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; Linhardt R.J., 1990, NEW TRENDS HAEMOSTAS, P12, DOI [10.1007/978-3-642-84318-1 2., DOI 10.1007/978-3-642-84318-1]; LINHARDT RJ, 1986, J BIOL CHEM, V261, P4448; LINHARDT RJ, 1991, CHEM IND-LONDON, P45; LINHARDT RJ, 1990, BIOMIMETIC POLYMERS, P135; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LINHARDT RJ, 1989, BIOCHEMISTRY-US, V28, P2888, DOI 10.1021/bi00433a021; LINHARDT RJ, 1990, J MED CHEM, V33, P1639, DOI 10.1021/jm00168a017; LINHARDT RJ, 1988, BIOCHEM J, V254, P781, DOI 10.1042/bj2540781; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; LOGANATHAN D, 1990, BIOCHEMISTRY-US, V29, P2611; MALLIS LM, 1989, ANAL CHEM, V61, P1453, DOI 10.1021/ac00188a030; MERCHANT ZM, 1985, BIOCHEM J, V229, P369, DOI 10.1042/bj2290369; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; OSCARSSON LG, 1989, J BIOL CHEM, V264, P296; PEJLER G, 1987, J BIOL CHEM, V262, P11413; PETITOU M, 1988, J BIOL CHEM, V263, P8685; RADOFF S, 1984, J BIOL CHEM, V259, P166; RICE KG, 1989, CARBOHYD RES, V190, P219, DOI 10.1016/0008-6215(89)84127-8; RICE KG, 1985, ANAL BIOCHEM, V150, P325, DOI 10.1016/0003-2697(85)90518-4; RICE KG, 1987, BIOCHEM J, V244, P515, DOI 10.1042/bj2440515; Roden L., 1989, HEPARIN CHEM BIOL PR, P1; ROSENFELD L, 1988, J BIOL CHEM, V263, P262; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; TURNBULL JE, 1988, BIOCHEM J, V251, P567; YANG VC, 1985, J BIOL CHEM, V260, P1849	46	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2380	2387						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733939				2022-12-25	WOS:A1992HB53200043
J	WEN, DX; SVENSSON, EC; PAULSON, JC				WEN, DX; SVENSSON, EC; PAULSON, JC			TISSUE-SPECIFIC ALTERNATIVE SPLICING OF THE BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE BETA-1,4-GALACTOSYLTRANSFERASE; ADHESION MOLECULES; MESSENGER-RNA; EXPRESSION; CDNA; DNA; GLYCOSYLTRANSFERASES; GLYCOPROTEINS; GLYCOSYLATION; ORGANIZATION	The rat alpha-2,6-sialyltransferase gene produces three different sized mRNAs (4.7, 4.3, and 3.6 kilobases (kb)) which exhibit striking tissue-specific expression. Recently, we characterized the cDNA and genomic organization of the 4.3-kb mRNA which is unique to rat liver. In this report cDNAs of the 4.7-kb mRNA found in most tissues and the 3.6-kb mRNA(s) unique to kidney have been cloned and characterized as well as the corresponding genomic sequences which differed from those of the previously characterized 4.3-kb mRNA. The 4.7-kb mRNA was found to be identical to the 4.3-kb mRNA with the exception of two additional exons at the 5'-untranslated end of the transcript. The constitutively expressed 4.7-kb mRNA therefore codes for the same sialyltransferase as the liver-restricted 4.3-kb mRNA. The additional 5'-exons of the 4.7-kb mRNA are located at least 15-40 kb upstream of the promoter responsible for the production of the 4.3-kb liver message. The 3.6-kb mRNA of rat kidney was found to be comprised of three transcripts of similar size. They were only expressed in kidney and were found to be generated from the alpha-2,6-sialyltransferase gene by alternative splicing and alternative promoter utilization. The results reveal the complexity of the alpha-2,6-sialyltransferase gene which produces at least five transcripts via alternative splicing in a tissue-specific fashion.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Paulson, James/AAG-3565-2019					BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P136; DAVIS RW, 1980, MANUAL GENETIC ENG A; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAKOMORI S, 1984, MONOCLONAL ANTIBODIE, P67; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; Sadler J. E., 1984, BIOL CARBOHYDRATES, V2, P199; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STOOLMAN LM, 1989, CELL, V56, P907, DOI 10.1016/0092-8674(89)90620-X; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9	30	93	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2512	2518						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733948				2022-12-25	WOS:A1992HB53200062
J	YOSHIDA, N; HIRATA, H; MORIGAMI, Y; IMAOKA, S; MATSUDA, M; YAMAZUMI, K; ASAKURA, S				YOSHIDA, N; HIRATA, H; MORIGAMI, Y; IMAOKA, S; MATSUDA, M; YAMAZUMI, K; ASAKURA, S			CHARACTERIZATION OF AN ABNORMAL FIBRINOGEN OSAKA-V WITH THE REPLACEMENT OF GAMMA-ARGININE 375 BY GLYCINE - THE LACK OF HIGH-AFFINITY CALCIUM-BINDING TO D-DOMAINS AND THE LACK OF PROTECTIVE EFFECT OF CALCIUM ON FIBRINOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT DERIVATIVES; AMINO-ACID SUBSTITUTION; CONGENITAL DYSFIBRINOGENEMIA; DEGRADATION PRODUCTS; CHAIN VARIANT; FRAGMENT-D; DISULFIDE KNOT; POLYMERIZATION DEFECT; MONOMER AGGREGATION; PLASMIN DEGRADATION	Prolonged thrombin time was completely corrected by the addition of millimolar concentrations of calcium in a new abnormal fibrinogen, Osaka V. Analysis of lysyl endopeptidase digests of A-alpha-, B-beta-, or gamma-chains by high performance liquid chromatography, and the following amino acid sequence analysis of relevant peptides revealed that about 50% of the gamma-chain has a replacement of gamma-arginine 375 by glycine. When fibrinogen was digested with plasmin in the presence of millimolar concentration of calcium, the amount of fragment D1 was about 50% of the normal control, and the rest was further cleaved to fragment D2, D3, or D62 with an apparent M(r) of 62,000. Plasmic digestion of cross-linked fibrin in the presence of calcium resulted in the appearance of an abnormal fragment with an apparent M(r) of 123,000 as well as fragments D2, D3, and D62, concomitant with the decrease of D dimer. The gamma-remnant of the abnormal fragment proved to be a cross-linked complex of the normal D1 gamma-remnant and residues 374-406/411 of the abnormal gamma-chain. The number of high affinity Ca2+-binding sites for the normal fibrinogen and fibrinogen Osaka V obtained by equilibrium dialysis was 2.88 (about 3) and 1.85, respectively, and that for the abnormal molecules was calculated as 0.9 (about 1) from their relative amounts in the samples, suggesting the lack of two Ca2+-binding sites in the D-domains. These data suggest that the normal structure of the COOH-terminal portion of the gamma-chain including residue 375 is required for the full expression of high affinity calcium binding to D-domains, the ability to be protected by calcium against plasmic digestion, and fibrin polymerization. During these studies, we found that the NH2-terminal amino acid of the gamma-remnant in fragments D or D dimer which were obtained after prolonged digestion with plasmin is gamma-Met89.	JICHI MED SCH,INST HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; JICHI MED SCH,DEPT BIOCHEM 1,MINAMI KAWACHI,TOCHIGI 32904,JAPAN; OSAKA KAISEI HOSP,DEPT INTERNAL MED,OSAKA 531,JAPAN; CTR ADULT DIS,DEPT SURG,OSAKA 537,JAPAN	Jichi Medical University; Jichi Medical University								AOKI N, 1978, J CLIN INVEST, V61, P1186, DOI 10.1172/JCI109034; BANTIA S, 1990, BLOOD, V75, P1659; BANTIA S, 1990, BLOOD, V76, P2279; CARRELL N, 1983, BLOOD, V62, P439; CARRELL N, 1982, BRIT J HAEMATOL, V52, P35, DOI 10.1111/j.1365-2141.1982.tb03859.x; CAVINS JF, 1970, ANAL BIOCHEM, V35, P489, DOI 10.1016/0003-2697(70)90211-3; CIERNIEWSKI CS, 1986, J BIOL CHEM, V261, P9116; COLLEN D, 1975, J BIOL CHEM, V250, P5808; DANG CV, 1985, J BIOL CHEM, V260, P9713; EBERT RF, 1982, FED PROC, V41, P654; ENGESSER L, 1988, THROMB HAEMOSTASIS, V60, P113; FERNANDEZ FJ, 1989, CLIN CHIM ACTA, V179, P239, DOI 10.1016/0009-8981(89)90086-7; Fernandez J, 1986, FIBRINOGEN ITS DERIV, P25; FURLAN M, 1983, BIOCHIM BIOPHYS ACTA, V742, P25, DOI 10.1016/0167-4838(83)90354-0; FURLAN M, 1975, BIOCHIM BIOPHYS ACTA, V400, P95, DOI 10.1016/0005-2795(75)90130-0; FURLAN M, 1983, FIBRINOGEN STRUCTURE, V2, P49; GAFFNEY PJ, 1975, CLIN SCI MOL MED, V49, P149, DOI 10.1042/cs0490149; GRALNICK HR, 1971, J CLIN INVEST, V50, P1819, DOI 10.1172/JCI106673; HAVERKATE F, 1977, THROMB RES, V10, P803, DOI 10.1016/0049-3848(77)90137-2; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3146, DOI 10.1021/bi00741a002; HORWITZ BH, 1984, P NATL ACAD SCI-BIOL, V81, P5980, DOI 10.1073/pnas.81.19.5980; KOOPMAN J, 1989, THROMB HAEMOSTASIS, V62, P158; KOOPMAN J, 1991, J BIOL CHEM, V266, P13456; KOOPMAN J, 1991, THROMB HAEMOSTASIS, V65, P1260; KUYAS C, 1982, J BIOL CHEM, V257, P1107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDANO AP, 1981, SCIENCE, V212, P457, DOI 10.1126/science.7209542; LORAND L, 1981, METHOD ENZYMOL, V80, P333; MARDER VJ, 1972, J BIOL CHEM, V247, P4775; MARGUERIE G, 1982, BIOCHIM BIOPHYS ACTA, V701, P410, DOI 10.1016/0167-4838(82)90246-1; MARGUERIE G, 1977, BIOCHIM BIOPHYS ACTA, V490, P94, DOI 10.1016/0005-2795(77)90109-X; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIYATA T, 1989, J BIOCHEM, V105, P10, DOI 10.1093/oxfordjournals.jbchem.a122601; MOSESSON MW, 1973, J BIOL CHEM, V248, P7913; NIEUWENHUIZEN W, 1982, BIOCHIM BIOPHYS ACTA, V708, P313, DOI 10.1016/0167-4838(82)90442-3; NIEUWENHUIZEN W, 1979, FEBS LETT, V98, P257, DOI 10.1016/0014-5793(79)80194-5; NIEUWENHUIZEN W, 1981, THROMB RES, V22, P653, DOI 10.1016/0049-3848(81)90063-3; NIEUWENHUIZEN W, 1983, THROMB RES, V31, P81, DOI 10.1016/0049-3848(83)90009-9; NIEUWENHUIZEN W, 1982, BIOCHIM BIOPHYS ACTA, V707, P190, DOI 10.1016/0167-4838(82)90349-1; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLEXA SA, 1981, J BIOL CHEM, V256, P3544; OLEXA SA, 1979, BIOCHIM BIOPHYS ACTA, V576, P39, DOI 10.1016/0005-2795(79)90482-3; PROCYK R, 1987, THROMB HAEMOSTASIS, V58, P38; PURVES LR, 1978, THROMB RES, V12, P473, DOI 10.1016/0049-3848(78)90318-3; PURVES LR, 1978, S AFR J SCI, V74, P202; REBER P, 1986, BLOOD, V67, P1751; REBER P, 1986, THROMB HAEMOSTASIS, V56, P401; REINACH FC, 1986, NATURE, V322, P80, DOI 10.1038/322080a0; RIXON MW, 1985, BIOCHEMISTRY-US, V24, P2077, DOI 10.1021/bi00329a041; RUPP C, 1983, THROMB HAEMOSTASIS, V50, P202; RUPP C, 1982, FIBRINOGEN RECENT BI, P167; RUPP C, 1984, VARIANTS HUMAN FIBRI, P65; SCHMELZER CH, 1989, THROMB RES, V56, P307, DOI 10.1016/0049-3848(89)90172-2; SIEBENLIST KR, 1989, THROMB HAEMOSTASIS, V62, P875; SORIA J, 1983, BRIT J HAEMATOL, V53, P575, DOI 10.1111/j.1365-2141.1983.tb07309.x; SORIA J, 1987, THROMB HAEMOSTASIS, V57, P310; SOUTHAN C, 1985, J BIOL CHEM, V260, P3095; TAKAGI T, 1975, BIOCHEMISTRY-US, V14, P940, DOI 10.1021/bi00676a010; TERUKINA S, 1989, BLOOD, V74, P2681; TERUKINA S, 1988, J BIOL CHEM, V263, P13579; TERUKINA S, 1987, THROMB HAEMOSTASIS, V58, P515; VANRUIJVENVERMEER IAM, 1978, FEBS LETT, V93, P177, DOI 10.1016/0014-5793(78)80831-X; VARADI A, 1986, BIOCHEMISTRY-US, V25, P519, DOI 10.1021/bi00351a001; WEINGER RS, 1980, AM J HEMATOL, V9, P237, DOI 10.1002/ajh.2830090302; YAMAZUMI K, 1989, J CLIN INVEST, V83, P1590, DOI 10.1172/JCI114056; YAMAZUMI K, 1988, THROMB HAEMOSTASIS, V60, P476; YOSHIDA N, 1988, J BIOL CHEM, V263, P13848; YOSHIDA N, 1986, BLOOD, V68, P703; YOSHIDA N, 1988, BLOOD, V71, P480; YOSHIDA N, 1982, J BIOL CHEM, V258, P7168	70	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2753	2759						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733971				2022-12-25	WOS:A1992HB53200096
J	ZHOU, NE; KAY, CM; HODGES, RS				ZHOU, NE; KAY, CM; HODGES, RS			SYNTHETIC MODEL PROTEINS - POSITIONAL EFFECTS OF INTERCHAIN HYDROPHOBIC INTERACTIONS ON STABILITY OF 2-STRANDED ALPHA-HELICAL COILED-COILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; LEUCINE ZIPPER; QUATERNARY STRUCTURE; T4 LYSOZYME; TROPOMYOSIN; STABILIZATION; SEQUENCE; PACKING; MUTAGENESIS; SECONDARY	We have designed a model protein that consists of two identical 35-residue polypeptide chains, parallel and in-register arranged in a two-stranded alpha-helical coiled-coil structure. This structure is stabilized by interchain hydrophobic interactions between leucine residues at positions "a" and "d' of a repeating heptad sequence. To determine the positional effects of interchain hydrophobic interactions on the stability of the coiled-coil, a single leucine residue in each chain at position "a" (9, 16, 23, 30) and "d" (5, 12, 19, 26, 33) was systematically replaced by an alanine. All these proteins formed two-stranded alpha-helical coiled-coils in benign conditions (0.05 M phosphate, 0.1 M KCl, pH 7). The stability of each mutant protein was determined by guanidine hydrochloride denaturation experiments, where the decrease in ellipticity at 220 nm was monitored by circular dichroism. The single alanine replacements of a leucine residue at hydrophobic positions a and/or d are all shown to destabilize the coiled-coil structure. The non-equivalent hydrophobic positions a and d make an equivalent contribution to protein stability along the majority of the coiled-coil structure (positions 9-30). The small decrease in coiled-coil stability caused by Leu --> Ala substitution at either ends of the coiled-coil suggested that the Leu-Leu hydrophobic interactions are less important at the ends of the coiled-coil and the ends of the coiled-coil are more flexible. Analysis of the difference between the ellipticity in benign buffer and in 50% trifluoroethanol (DELTA-theta-220) and the slope term from a plot of the free energy of unfolding versus guanidine hydrochloride concentration also supported the conclusion that the leucine residues at the ends of the coiled-coil are much less buried than in the middle section of the coiled-coil.	UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA; UNIV ALBERTA,PROT ENGN NETWORK CTR EXCELLENCE,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Alberta; University of Alberta								ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BALDWIN R. L., 1987, PROTEIN ENG, P127; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; DEFRANCESCO R, 1991, BIOCHEMISTRY-US, V30, P143, DOI 10.1021/bi00215a021; EPSTEIN HF, 1991, SCIENCE, V251, P1039, DOI 10.1126/science.1998120; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; GANTER C, 1990, BIOCHEMISTRY-US, V29, P9395, DOI 10.1021/bi00492a013; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HODGES R S, 1990, Peptide Research, V3, P123; HODGES R S, 1988, Peptide Research, V1, P19; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; HODGES RS, 1981, J BIOL CHEM, V256, P1214; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HUGHSON FM, 1989, BIOCHEMISTRY-US, V28, P4415, DOI 10.1021/bi00436a044; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KELLIS JT, 1989, BIOCHEMISTRY-US, V28, P4914, DOI 10.1021/bi00437a058; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU SYM, 1984, J CHROMATOGR, V317, P129, DOI 10.1016/S0021-9673(01)91653-X; LAU SYM, 1984, J BIOL CHEM, V259, P3253; LIM IV, 1980, PROTEIN FOLDING, P149; Mackay D.H.J., 1989, PREDICTION PROTEIN S, P317; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, 1989, J BIOL CHEM, V264, P16059; MCKNIGHT SL, 1990, SCI AM, V6, P36; MERUTKA G, 1990, BIOCHEMISTRY-US, V29, P894, DOI 10.1021/bi00456a007; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; Pace C N, 1986, Methods Enzymol, V131, P266; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PTITSYN OB, 1980, PROTEIN FOLDING, P101; RADDING JA, 1987, BIOCHEMISTRY-US, V26, P3530, DOI 10.1021/bi00386a042; REIDHAAROLSON JF, 1988, SCIENCE, V241, P53, DOI 10.1126/science.3388019; RICHARDS FM, 1980, PROTEIN FOLDING, P117; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; SHORTLE D, 1989, J BIOL CHEM, V264, P5315; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SODEK J, 1972, P NATL ACAD SCI USA, V69, P3800, DOI 10.1073/pnas.69.12.3800; SODEK J, 1978, J BIOL CHEM, V253, P1129; STONE D, 1978, J BIOL CHEM, V253, P1137; STPIERRE SA, 1976, BIOCHEM BIOPH RES CO, V72, P581, DOI 10.1016/S0006-291X(76)80080-0; STPIERRE SA, 1977, CAN J BIOCHEM CELL B, V55, P636, DOI 10.1139/o77-092; SUN DP, 1990, PROTEINS, V7, P198; TALBOT JA, 1982, ACCOUNTS CHEM RES, V15, P224, DOI 10.1021/ar00079a006; TANFORD C, 1980, HYDROPHOBIC EFFECT; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441; ZHOU NE, 1980, PEPTIDE RES, V3, P8	52	302	305	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2664	2670						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733963				2022-12-25	WOS:A1992HB53200085
J	BASHEERUDDIN, K; RECHTORIS, C; MAZZONE, T				BASHEERUDDIN, K; RECHTORIS, C; MAZZONE, T			TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL CONTROL OF APOLIPOPROTEIN-E GENE-EXPRESSION IN DIFFERENTIATING HUMAN MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE THP-1; E MESSENGER-RNA; PHORBOL ESTER; POSTTRANSCRIPTIONAL REGULATION; LIPOPROTEIN-LIPASE; CHOLESTEROL; PROTEIN; RIBONUCLEASE; MACROPHAGES; SYNTHESIZE	The present studies examined the mechanisms responsible for the regulation of apolipoprotein (apo) E gene expression during human monocytic differentiation. Levels of apoE mRNA were low in undifferentiated THP1 cells, a human monocytic cell line. Addition of 12-O-tetradecanoylphorbol-13-acetate (PMA) induced differentiation of these cells to a macrophage-like phenotype and was associated with increased apoE mRNA abundance in a time-dependent fashion, up to 10-11-fold within 32 h. Results of nuclear run-on transcription assays demonstrated that the apoE gene was transcriptionally active in undifferentiated THP1 cells and that differentiation of monocytes with PMA was associated with a maximal increase of apoE gene transcription rate of only 2-3-fold at 6-12 h. Using actinomycin D as an inhibitor of new transcription, we could demonstrate a more rapid degradation of mature apoE mRNA in undifferentiated compared to differentiated cells, suggesting that the apoE mRNA species was more stable in differentiated THP1 cells. Primer extension assays performed using RNA extracts from undifferentiated and differentiated THP1 cells confirmed the increase of apoE mRNA abundance in the latter but failed to disclose heterogeneity in apoE gene transcription start site between these two phenotypes. These findings indicate that apoE gene expression is controlled at both transcriptional and post-transcriptional loci during human monocyte-macrophage differentiation.	RUSH MED COLL,DEPT MED,CHICAGO,IL 60612; RUSH MED COLL,DEPT BIOCHEM,CHICAGO,IL 60612	Rush University; Rush University			Basheeruddin, Khaja/AGQ-5149-2022		NHLBI NIH HHS [R01 HL 39653] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039653] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; AUWREX JH, 1989, P NATL ACAD SCI USA, V86, P1133; BACHS O, 1987, J BIOL CHEM, V262, P10786; BANKA CL, 1991, J LIPID RES, V32, P35; BASHEERUDDIN K, 1984, P NATL ACAD SCI USA, V84, P709; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1983, SCIENCE, V219, P871, DOI 10.1126/science.6823554; BRENNER DA, 1987, J BIOL CHEM, V262, P17690; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARNELL JE, 1982, NATURE, V297, P265; DAWSON PA, 1986, J BIOL CHEM, V261, P5681; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; GORDON V, 1983, J BIOL CHEM, V258, P6202; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HANUKOGLU I, 1983, J MOL BIOL, V163, P673, DOI 10.1016/0022-2836(83)90117-1; HORIGUCHI J, 1988, MOL CELL BIOL, V8, P3951, DOI 10.1128/MCB.8.9.3951; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Maniatis T, 1982, MOL CLONING LABORATO; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; MAZZONE T, 1989, J LIPID RES, V30, P1055; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; MAZZONE T, 1991, J LIPID RES, V32, P507; MCLEAN JW, 1984, J BIOL CHEM, V259, P6498; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NEWMAN TC, 1985, J BIOL CHEM, V260, P2452; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; SHELNESS GS, 1984, J BIOL CHEM, V259, P9929; TAJIMA S, 1985, BIOCHEM BIOPH RES CO, V126, P526, DOI 10.1016/0006-291X(85)90637-0; VIA DP, 1989, J LIPID RES, V30, P1515; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WYNE KL, 1989, J BIOL CHEM, V264, P981	38	56	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1219	1224						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730645				2022-12-25	WOS:A1992GY96000084
J	GULINO, D; BOUDIGNON, C; ZHANG, LY; CONCORD, E; RABIET, MJ; MARGUERIE, G				GULINO, D; BOUDIGNON, C; ZHANG, LY; CONCORD, E; RABIET, MJ; MARGUERIE, G			CA2+-BINDING PROPERTIES OF THE PLATELET GLYCOPROTEIN-IIB LIGAND-INTERACTING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; IIIA COMPLEX; DIVALENT-CATIONS; BINDING-SITE; FIBRINOGEN BINDING; ALPHA-SUBUNIT; RECEPTOR; CALCIUM; MEMBRANE; PEPTIDES	Glycoprotein (GP) IIb is the alpha-subunit of platelet integrin GPIIb-IIIa. Analysis of the primary structure of this subunit has indicated the presence of four stretches of amino acid residues that are highly conserved among various integrin a subunits and that have been suggested to be putative calcium-binding sites. To verify the Ca2+-binding capacity of these conserved domains and their implication in integrin adhesive functions, a fragment corresponding to the amino acid sequence of GPIIb from positions 171 to 464 was expressed. The nucleotide sequence coding for this GPIIb domain was generated by polymerase chain reaction, cloned into the pTG1924 expression vector, and expressed in Escherichia coli strain TGE901. The recombinant protein was purified by gel exclusion chromatography and used in equilibrium dialysis experiments. The results demonstrate that the four binding sites can be occupied by Ca2+. Two classes of binding sites can be detected, including two sites with a K(d) of 30-mu-m and two sites of lower affinity with a K(d) of 120-mu-m. Interaction of Ca2+ with these two classes of sites was inhibited by a large excess of Mg2+ or Mn2+, suggesting that these cations are competitive for the same sites on GPIIb. Thus, the four Ca2+-binding sites of GPIIb are not similar and exhibit different affinities for divalent ions. To verify the functional implication of these Ca2+-binding sites, the effect of Ca2+ on the binding of fibrinogen to the recombinant protein was analyzed using a solid-phase assay. The results indicate that optimal fibrinogen binding occurs when the four calcium-binding sites are occupied and establish the functional importance of this Ca2+-binding domain in the ligand-binding activity of GPIIb.			GULINO, D (corresponding author), CEN,DBMS,INSERM,U217,HEMATOL LAB,85X,F-38041 GRENOBLE,FRANCE.							ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; BRASS LF, 1982, J BIOL CHEM, V257, P4000; CHARO IF, 1991, J BIOL CHEM, V266, P1415; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FITZGERALD LA, 1985, J BIOL CHEM, V260, P1366; FRACHET P, 1990, MOL BIOL REP, V14, P27, DOI 10.1007/BF00422712; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GOLDSTEIN DA, 1979, BIOPHYS J, V26, P235, DOI 10.1016/S0006-3495(79)85247-9; GULINO D, 1990, J BIOL CHEM, V265, P9575; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; LAM SCT, 1987, J BIOL CHEM, V262, P947; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; MARGUERIE G, 1982, BIOCHIM BIOPHYS ACTA, V701, P410, DOI 10.1016/0167-4838(82)90246-1; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MOVIBROEK MJ, 1987, J BIOL CHEM, V262, P25; PARISE LV, 1985, J BIOL CHEM, V260, P698; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PONCZ M, 1987, J BIOL CHEM, V262, P8476; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STEINER B, 1989, J BIOL CHEM, V264, P13102; Szebenyi DME, 1981, NATURE, V294, P327, DOI 10.1038/294327a0; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; WATTERSON DM, 1980, J BIOL CHEM, V255, P962	37	114	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1001	1007						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730629				2022-12-25	WOS:A1992GY96000053
J	BRODBECK, RM; BROWN, JL				BRODBECK, RM; BROWN, JL			SECRETION OF ALPHA-1-PROTEINASE INHIBITOR REQUIRES AN ALMOST FULL LENGTH MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; ALPHA-1-ANTITRYPSIN DEFICIENCY; PIZ-ALPHA-1-ANTITRYPSIN VARIANT; INTRACELLULAR DEGRADATION; CRYSTAL-STRUCTURE; DIFFERENT RATES; CELL-SURFACE; SALT BRIDGE; PRE-GOLGI; PROTEINS	In the human disease alpha-1-proteinase inhibitor deficiency, some variants of human alpha-1-proteinase inhibitor are not secreted. These secretory variants contain frameshift mutations leading to products with normal amino acid sequences to the points of the mutations followed by short, aberrant C-terminal sequences and then premature termination (Nukiwa, T., Takahashi, H., Brantly, M., Courtney, M., and Crystal, R. (1987) J. Biol. Chem. 262, 11999-12004; Sifers, R. N., Brashears-Macatee, S., Kidd, V. J., Muensch, H., and Woo, S. L. C. (1988) J. Biol. Chem. 263, 7330-7335; Curiel, D., Brantly, M., Curiel, E., Stier, L., and Crystal, R. G. (1989) J. Clin. Invest. 83, 1144-1152). To examine possible causes for lack of secretion of these null variants, we have altered the alpha-1-proteinase inhibitor cDNA to encode a series of abbreviated forms of this protein that retain authentic sequences to the points of truncation. Examination of the fates of these shortened proteins in transiently transfected Cos 1 cells indicates that the aberrant C-terminal sequences in the naturally occurring variants are not responsible for their lack of secretion and show that truncation prior to Pro391 prevents movement from the endoplasmic reticulum to the Golgi apparatus and therefore secretion. These truncated forms of alpha-1-proteinase inhibitor do not form inclusion bodies in the endoplasmic reticulum, rather they are degraded, probably by the pre-Golgi pathway. Our results support the idea that a sequence of at least 391 of the normal 394 residues is essential for the secretion of alpha-1-proteinase inhibitor and suggest that residue 391 plays an especially important role, perhaps in allowing or directing proper folding or as part of a transport signal, in the secretion of this protein.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37128] Funding Source: Medline; NIDDK NIH HHS [DK34914] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BRANTLY M, 1988, AM J MED, V84, P13; COX DW, 1986, FEBS LETT, V205, P255, DOI 10.1016/0014-5793(86)80908-5; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CRYSTAL RG, 1989, TRENDS GENET, V5, P411, DOI 10.1016/0168-9525(89)90200-X; CURIEL D, 1989, J CLIN INVEST, V83, P1144, DOI 10.1172/JCI113994; Fagerhol M K, 1981, Adv Hum Genet, V11, P1; FITTING T, 1982, J BIOL CHEM, V257, P4011; FRIES E, 1984, EMBO J, V3, P147, DOI 10.1002/j.1460-2075.1984.tb01775.x; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JEPPSSON JO, 1976, FEBS LETT, V65, P195, DOI 10.1016/0014-5793(76)80478-4; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LE A, 1990, J BIOL CHEM, V265, P14001; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; MCCRACKEN AA, 1991, J BIOL CHEM, V266, P7578; MCCRACKEN AA, 1989, MOL CELL BIOL, V9, P1406, DOI 10.1128/MCB.9.4.1406; NUKIWA T, 1987, J BIOL CHEM, V262, P11999; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SATO R, 1990, J BIOL CHEM, V265, P11880; SHEEHAN JC, 1958, J AM CHEM SOC, V80, P1154, DOI 10.1021/ja01538a036; SIFERS RN, 1989, J BIOL CHEM, V264, P2997; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WRIGHT HT, 1990, J MOL BIOL, V213, P513	31	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					294	297						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730596				2022-12-25	WOS:A1992GY43900049
J	QURESHI, SA; RIM, M; ALEXANDROPOULOS, K; BERG, K; SUKHATME, VP; FOSTER, DA				QURESHI, SA; RIM, M; ALEXANDROPOULOS, K; BERG, K; SUKHATME, VP; FOSTER, DA			SUSTAINED INDUCTION OF EGR-1 BY V-SRC CORRELATES WITH A LACK OF FOS-MEDIATED REPRESSION OF THE EGR-1 PROMOTER	ONCOGENE			English	Article								Serum stimulation of quiescent fibroblasts leads to a transient induction of the transcription factor egr-1. However, the induction of egr-1 by v-src was found to be sustained rather than transient. The proto-oncogene fos has been reported to be co-regulated with egr-1 and to repress serum-induced egr-1 expression. We found that c-fos prevents v-src-induced gene expression regulated by the egr-1 promoter. Thus, the sustained induction of egr-1 by v-src could be explained by a lack of c-fos induction by v-src. Consistent with this hypothesis, egr-1 and c-fos were co-induced by serum, but not by v-src, in Balb/c 3T3 cells, v-src did not induce c-fos expression in these cells. We propose that sustained expression of egr-1 induced by v-src in Balb/c 3T3 cells is due to a lack of c-fos down-regulation of egr-1.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, 695 PARK AVE, NEW YORK, NY 10021 USA; CUNY HUNTER COLL, DEPT BIOL RES, NEW YORK, NY 10021 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); Howard Hughes Medical Institute; University of Chicago; University of Chicago			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; Battey, 1986, BASIC METHODS MOL BI; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1988, ONCOGENE HDB, P305; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GRAY GM, 1988, J BIOL CHEM, V263, P10714; HATCH CL, 1987, ANAL BIOCHEM, V162, P283, DOI 10.1016/0003-2697(87)90038-8; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; JAHNER D, 1991, ONCOGENE, V6, P1259; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KRIEGLER M, 1984, CELL, V38, P483, DOI 10.1016/0092-8674(84)90503-8; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PATWARDHAN S, 1991, ONCOGENE, V6, P917; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, ONCOGENE, V6, P995; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VOGT PK, 1988, ONCOGENE, V3, P3; WELHAM MJ, 1990, ONCOGENE, V5, P161; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x	48	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					121	125						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741159				2022-12-25	WOS:A1992HC22700016
J	SUBRAMANIAM, A; JONES, WK; GULICK, J; WERT, S; NEUMANN, J; ROBBINS, J				SUBRAMANIAM, A; JONES, WK; GULICK, J; WERT, S; NEUMANN, J; ROBBINS, J			TISSUE-SPECIFIC REGULATION OF THE ALPHA-MYOSIN HEAVY-CHAIN GENE PROMOTER IN TRANSGENIC MICE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOSIN; THYROID-HORMONE; MESSENGER-RNA; FUSION GENE; HEART-CELLS; ACTIN GENE; EXPRESSION; ELEMENTS; FETAL; IDENTIFICATION	The intergenic region between the mouse alpha-myosin heavy chain (MHC) and beta-MHC genes was analyzed in terms of its ability to drive gene expression in transgenic mice. Earlier, we reported that the entire intergenic region was sufficient to direct expression of the bacterial chloramphenicol acetyl transferase reporter gene in a tissue-specific and developmental stage-specific manner. Additional transgenic lines have been generated which include two deletions. The first deletion, alpha-3, which lacks the distal 2.5 kilobase pairs of the upstream region, is competent to direct tissue- and developmental-specific expression of the transgene. A larger deletion, in which only 138 base pairs upstream of the transcriptional start site remain, shows no chloramphenicol acetyltransferase activity in either muscle or non-muscle tissue. Tissue surveys of transgene expression indicated low levels of activity in the lung, and analyses via the polymerase chain reaction confirmed the presence of the endogenous alpha-MHC gene transcripts in this tissue. Subsequently, an alpha-MHC gene-specific riboprobe was used to detect the cognate transcripts in lung sections by in situ hybridization. The data show that, in the lung, the transcripts are localized to the thick intimal wall of the veins and venules.	UNIV CINCINNATI, COLL MED, DEPT PHARMACOL & CELL BIOPHYS, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT PEDIAT, DIV PULM BIOL, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati					NHLBI NIH HHS [HL22619, HL41496] Funding Source: Medline; NICHD NIH HHS [HD13225] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013225] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041496, P01HL022619] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BOUVAGNET PF, 1987, MOL CELL BIOL, V7, P4377, DOI 10.1128/MCB.7.12.4377; BURCH GE, 1954, AM HEART J, V47, P58, DOI 10.1016/0002-8703(54)90211-2; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; CHIZZONITE RA, 1984, J BIOL CHEM, V259, P5564; CHIZZONITE RA, 1984, J BIOL CHEM, V259, P2628; FAVARO G, 1910, INT MENSTACHR ANAT U, V27, P376; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GULICK J, 1991, J BIOL CHEM, V266, P9180; GULICK J, 1987, EUR J BIOCHEM, V169, P79, DOI 10.1111/j.1432-1033.1987.tb13583.x; GUSTAFSON TA, 1987, P NATL ACAD SCI USA, V84, P3122, DOI 10.1073/pnas.84.10.3122; GUSTAFSON TA, 1987, J BIOL CHEM, V262, P13316; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; HOGAN B, 1986, MANIPULATING MOUSE E, P152; HOH JFY, 1978, J MOL CELL CARDIOL, V10, P1053, DOI 10.1016/0022-2828(78)90401-7; IANNELLO RC, 1991, J BIOL CHEM, V266, P3309; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KARRER HE, 1959, J BIOPHYS BIOCHEM CY, V6, P383, DOI 10.1083/jcb.6.3.383; KLIKA E, 1976, MONOGRAPH MYOCARDIUM; KROPP KE, 1987, J BIOL CHEM, V262, P16536; KURABAYASHI M, 1990, J BIOL CHEM, V265, P19271; LIEW CC, 1986, P NATL ACAD SCI USA, V83, P3175, DOI 10.1073/pnas.83.10.3175; LITTEN RZ, 1982, CIRC RES, V50, P856, DOI 10.1161/01.RES.50.6.856; LOMPRE AM, 1981, DEV BIOL, V84, P286, DOI 10.1016/0012-1606(81)90396-1; LOMPRE AM, 1979, NATURE, V282, P105, DOI 10.1038/282105a0; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; LYONS GE, 1990, J CELL BIOL, V111, P2427, DOI 10.1083/jcb.111.6.2427; MACLEOD DP, 1967, CAN J PHYSIOL PHARM, V45, P463, DOI 10.1139/y67-055; MAHDAVI V, 1984, P NATL ACAD SCI-BIOL, V81, P2626, DOI 10.1073/pnas.81.9.2626; MAHDAVI V, 1982, NATURE, V297, P659, DOI 10.1038/297659a0; MAHDAVI V, 1986, UCLA S MOL CELL BIOL, V29, P345; MAHDAVI V, 1989, UCLA S MOL CELL BIOL, V93, P369; Maniatis T., 1982, MOL CLONING; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MARKHAM BE, 1987, J BIOL CHEM, V262, P12856; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; NG WA, 1991, CIRC RES, V68, P1742, DOI 10.1161/01.RES.68.6.1742; PAESDEALMEIDA O, 1975, J MORPHOL, V145, P409, DOI 10.1002/jmor.1051450403; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PETROPOULOS CJ, 1989, MOL CELL BIOL, V9, P3785, DOI 10.1128/MCB.9.9.3785; RAUSCHEL F, 1836, MONOGRAPH ARTERIARUM; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; ROBBINS J, 1989, GENE, V85, P541, DOI 10.1016/0378-1119(89)90449-6; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SAMUEL JL, 1986, AM J PHYSIOL, V250, pH333, DOI 10.1152/ajpheart.1986.250.3.H333; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; SCHWARTZ K, 1981, J MOL CELL CARDIOL, V13, P1071, DOI 10.1016/0022-2828(81)90297-2; SHANI M, 1986, MOL CELL BIOL, V6, P2624, DOI 10.1128/MCB.6.7.2624; SHANI M, 1988, MOL CELL BIOL, V8, P1006, DOI 10.1128/MCB.8.2.1006; SHEN RQ, 1991, MOL CELL BIOL, V11, P1676, DOI 10.1128/MCB.11.3.1676; SINHA AM, 1982, P NATL ACAD SCI-BIOL, V79, P5847, DOI 10.1073/pnas.79.19.5847; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; SPACH MS, 1972, AM J CARDIOL, V30, P844, DOI 10.1016/0002-9149(72)90009-4; STEIDA L, 1877, ARCH MIKROSK ANAT, V14, P243; TSIKA RW, 1990, P NATL ACAD SCI USA, V87, P379, DOI 10.1073/pnas.87.1.379; Walter C A, 1989, Biotechniques, V7, P1065; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; YAMAUCHITAKIHARA K, 1989, P NATL ACAD SCI USA, V86, P3504, DOI 10.1073/pnas.86.10.3504; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	63	426	450	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24613	24620						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722208				2022-12-25	WOS:A1991GW84500058
J	LUK, JMC; LIND, SM; TSANG, RSW; LINDBERG, AA				LUK, JMC; LIND, SM; TSANG, RSW; LINDBERG, AA			EPITOPE MAPPING OF 4 MONOCLONAL-ANTIBODIES RECOGNIZING THE HEXOSE CORE DOMAIN OF SALMONELLA LIPOPOLYSACCHARIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; POLYACRYLAMIDE GEL-ELECTROPHORESIS; ESCHERICHIA-COLI; CROSS-REACTIVITY; SEROGROUP-A; O-ANTIGENS; POLYSACCHARIDE; HETEROGENEITY; TYPHIMURIUM; ENDOTOXIN	Four murine monoclonal antibodies reactive with distinctive regions of the hexose core domain of Salmonella lipopolysaccharide (LPS) were generated and their epitope specificities were delineated. MAST 56 (IgG1) and MAST 50 (IgG3) antibodies elicited by immunizations with Salmonella typhimurium Rb1 and Rb2 mutants, reacted selectively in enzyme immunoassay with the LPS from rough mutants. In contrast, MATy 1 (IgM) and MATy 2 (IgG2b) antibodies raised by an attenuated Salmonella typhi 620 Ty strain were reactive with LPS from both smooth and rough Salmonellae. Immunoblotting analysis showed that MATy 1 distinguished only the bottom bands (naked LPS core) among the heterogeneous LPS populations, whereas MATy 2 gave a ladder pattern (reactive with both naked and O-chain-substituted LPS cores). Differential binding specificities of MATy 1 and MATy 2 antibodies to the naked and capped LPS cores were further analyzed utilizing S. typhimurium polysaccharide fractions with different O-chain:core ratios which were obtained after separation by Sephacryl S-200 chromatography. Steric effects on the antibody reactivity by the bulky O-polysaccharide chain were detected. The use of chemically defined native and synthetic saccharides as inhibitors, in combination with the conformation of the Salmonella core oligosaccharide, permitted the definition of antigenic determinants carried in the core domain recognized by each antibody: (i) the branches I and VIII are essential for MATy 1 recognition, (ii) the backbone III-IV-V for MATy 2, (iii) the backbone II-III-IV-V for MAST 56, and (iv) the backbone plus the branch III-IV-V-VIII for MAST 50. [GRAPHICS]	KAROLINSKA INST, HUDDINGE HOSP F82, DEPT CLIN BACTERIOL, S-14186 HUDDINGE, SWEDEN; UNIV HONG KONG, QUEEN MARY HOSP, DEPT MICROBIOL, HONG KONG, HONG KONG	Karolinska Institutet; University of Hong Kong			Luk, John/A-4085-2008	Luk, John/0000-0002-6323-7940				AYDINTUG MK, 1989, J INFECT DIS, V160, P846, DOI 10.1093/infdis/160.5.846; BAUMGARTNER JD, 1990, J EXP MED, V171, P889, DOI 10.1084/jem.171.3.889; BAUMGARTNER JD, 1985, LANCET, V2, P59; BOCK K, 1984, CARBOHYD RES, V130, P23, DOI 10.1016/0008-6215(84)85267-2; DUBOIS M, 1951, NATURE, V168, P167, DOI 10.1038/168167a0; DUNN DL, 1985, SURGERY, V98, P283; FEIFFER R, 1892, Z HYG INFEKTIONSKR, V11, P393; GALANOS C, 1975, EUR J BIOCHEM, V54, P603, DOI 10.1111/j.1432-1033.1975.tb04172.x; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; GAREGG PJ, 1990, CARBOHYD RES, V205, P125, DOI 10.1016/0008-6215(90)80133-N; GIGLIOTTI F, 1985, J INFECT DIS, V151, P1005, DOI 10.1093/infdis/151.6.1005; GREISMAN SE, 1988, J INFECT DIS, V157, P54, DOI 10.1093/infdis/157.1.54; HARLOW E, 1988, ANTIBODIES LABORATOR; HELLERQV.CG, 1971, CARBOHYD RES, V16, P39, DOI 10.1016/S0008-6215(00)86096-6; HEUMANN D, 1991, J INFECT DIS, V163, P762, DOI 10.1093/infdis/163.4.762; HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983; HOMANS SW, 1990, BIOCHEMISTRY-US, V29, P9110, DOI 10.1021/bi00491a003; JANN B, 1975, EUR J BIOCHEM, V60, P239, DOI 10.1111/j.1432-1033.1975.tb20996.x; Jansson P E, 1989, J Mol Recognit, V2, P25, DOI 10.1002/jmr.300020105; JANSSON PE, 1981, EUR J BIOCHEM, V115, P571; JORBECK HJA, 1979, J IMMUNOL, V123, P1376; LEIVE L, 1974, ANN NY ACAD SCI, V235, P109, DOI 10.1111/j.1749-6632.1974.tb43261.x; LIND SM, 1991, J IMMUNOL, V146, P3864; LIND SM, 1985, FEMS MICROBIOL LETT, V28, P45; LINDBERG AA, 1980, SCAND J INFECT DIS, P86; LINDBERG AA, 1983, ACS SYM SER, V231, P83; LUDERITZ O, 1982, CURR TOP MEMBR TRANS, V17, P79; LUK JMC, 1990, J IMMUNOL METHODS, V129, P243, DOI 10.1016/0022-1759(90)90445-2; LUK JMC, 1991, J CLIN MICROBIOL, V29, P2424, DOI 10.1128/JCM.29.11.2424-2433.1991; LUK MC, 1987, J CLIN MICROBIOL, V25, P2140, DOI 10.1128/JCM.25.11.2140-2144.1987; NELLES MJ, 1984, INFECT IMMUN, V46, P677, DOI 10.1128/IAI.46.3.677-681.1984; NORBERG T, 1988, J CARBOHYD CHEM, V7, P283, DOI 10.1080/07328308808058925; PALVA ET, 1980, EUR J BIOCHEM, V107, P137, DOI 10.1111/j.1432-1033.1980.tb04634.x; PETER G, 1982, INFECTION, V10, P228, DOI 10.1007/BF01666916; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; SCHLECHT S, 1971, ZBL BAKT PARASIT, V216, P472; SUBBAIAH TV, 1964, NATURE, V201, P1298, DOI 10.1038/2011298a0; TSANG RSW, 1987, INFECT IMMUN, V55, P211, DOI 10.1128/IAI.55.1.211-216.1987; TSUCHIDO T, 1985, APPL ENVIRON MICROB, V50, P298, DOI 10.1128/AEM.50.2.298-303.1985; WESTPHAL O, 1952, Z NATURFORSCH B, V7, P148, DOI 10.1515/znb-1952-0303; WILKINSON RG, 1968, NATURE, V217, P955, DOI 10.1038/217955a0; WOLLIN R, 1983, J BIOL CHEM, V258, P3769; YOUNG LS, 1982, CLIN RES, V30, pA522; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	46	20	21	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23215	23225						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1720777				2022-12-25	WOS:A1991GT48300068
J	KUMAR, R; POTVIN, B; MULLER, WA; STANLEY, P				KUMAR, R; POTVIN, B; MULLER, WA; STANLEY, P			CLONING OF A HUMAN ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE THAT ENCODES ELFT BUT DOES NOT CONFER ELAM-1 RECOGNITION ON CHINESE-HAMSTER OVARY CELL TRANSFECTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEX DETERMINANT; EMBRYONIC ANTIGEN; MONOCLONAL-ANTIBODY; ADHESION; FUCOSYL; DNA; GLYCOSPHINGOLIPIDS; CARBOHYDRATE; BIOSYNTHESIS; EXPRESSION	In previous studies, Chinese hamster ovary (CHO) cell genomic DNA transfectants that expressed a human alpha(1,3)-fucosyltransferase (alpha(1,3)Fuc-T) gene were isolated and shown to possess a common approximately 7.5-kilobase (kb) EcoRI fragment that hybridized to an Alu probe (Potvin, B., Kumar, R., Howard, D. R., and Stanley, P. (1990) J. Biol. Chem. 265, 1615-1622). One of these transfectants was used to make a genomic DNA library in lambda-ZAP-II from EcoRI-digested, size-selected (6-8 kb) DNA, and plaques that hybridized to an Alu probe were purified. After in vivo excision, two plasmids with DNA inserts greater-than-or-equal-to 6 kb were obtained and one of these (D2.1) conferred human alpha(1,3)-Fuc-T activity on CHO transfectants. A partial restriction map of this clone revealed an approximately 3.6-kb PstI fragment that contained an Alu sequence. This fragment was subcloned into pGEM-3Zf(+) and compared by restriction analyses with a previously described approximately 3.6-kb PstI DNA fragment isolated from a human peripheral blood lymphocyte library and shown to encode an alpha(1,3) Fuc-T gene (Lowe, J. B., Stoolman, L. M., Nair, R. P., Larsen, R. D., Berhend, T. L., and Marks, R. M. (1990) Cell 63, 475-484). Both approximately 3.6-kb fragments gave identical restriction patterns. In addition, they both caused CHO transfectants to synthesize the Le(x) determinant Gal-beta(1,4)[Fuc-alpha(1,3)]GlcNAc-beta-1 but not the alpha(2,3)-sialyl-Le(x) determinant. As expected, these transfectants did not bind to ELAM-1 on activated endothelial cells, since sialyl-Le(x) is a carbohydrate ligand recognized by ELAM-1. Surprisingly, however, an open reading frame encoded within the approximately 3.6-kb PstI fragment had a sequence identical to that of ELFT, an alpha(1,3)-Fuc-T previously reported to confer ELAM-1 binding on a CHO transfectant (Goelz, S. E., Hession, C., Goff, D., Griffiths, B., Tizard, R., Newman, B., Chi-Rosso, G., and Lobb, R., (1990) Cell 63, 1349-1356). Possible explanations for these apparently disparate results are discussed.	ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,1300 MORRIS PK AVE,BRONX,NY 10456; ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Yeshiva University; Albert Einstein College of Medicine; Rockefeller University				Stanley, Pamela/0000-0001-5704-3747	PHS HHS [P01 13330, R01 30645] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARSOUM J, 1990, DNA CELL BIOL, V9, P293, DOI 10.1089/dna.1990.9.293; BENJAMIN C, 1990, BIOCHEM BIOPH RES CO, V171, P348, DOI 10.1016/0006-291X(90)91400-M; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUMMING D A, 1991, Glycobiology, V1, P115, DOI 10.1093/glycob/1.2.115; DOBRINA A, 1989, IMMUNOLOGY, V67, P502; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FUKUDA M, 1985, J BIOL CHEM, V260, P2957; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231; HANISCH FG, 1988, CARBOHYD RES, V178, P23, DOI 10.1016/0008-6215(88)80099-5; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; JELNIK WR, 1980, P NATL ACAD SCI USA, V77, P1398; JOHNSON PH, 1989, BIOCHEM SOC T, V17, P133, DOI 10.1042/bst0170133; KANNAGI R, 1986, CANCER RES, V46, P2619; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; MURAMATSU T, 1988, J CELL BIOCHEM, V36, P1, DOI 10.1002/jcb.240360102; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POTVIN B, 1990, J BIOL CHEM, V265, P1615; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275	34	163	166	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21777	21783						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1718983				2022-12-25	WOS:A1991GP80400069
J	DINGUS, J; OBAR, RA; HYAMS, JS; GOEDERT, M; VALLEE, RB				DINGUS, J; OBAR, RA; HYAMS, JS; GOEDERT, M; VALLEE, RB			USE OF A HEAT-STABLE MICROTUBULE-ASSOCIATED PROTEIN CLASS-SPECIFIC ANTIBODY TO INVESTIGATE THE MECHANISM OF MICROTUBULE BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAU-PROTEIN; MECHANOCHEMICAL ENZYME; MOLECULAR-CLONING; REPEATED SEQUENCE; BRAIN; IDENTIFICATION; DOMAIN; MAP-2; TUBULIN; SUBUNIT	Members of the heat-stable family of microtubule-associated proteins (MAPs), MAP 2, tau, and MAP 4, contain three or four tandem imperfect repeated sequences close to their carboxyl termini. These sequences lie within the microtubule-binding domains of the MAPs; they have been proposed to be responsible for microtubule binding and the ability of these MAPs to lower the critical concentration for microtubule assembly. Their spacing may reflect that of the regularly arrayed tubulin subunits on the microtubule surface. We here characterize the 32- and 34-kDa chymotryptic microtubule-binding fragments of MAP 2 identified in earlier work. We identify the primary chymotryptic cleavage site in high molecular weight MAP 2 as between Phe1525 and Lys1526, within 13 amino acids of the known MAP 2 splice junction. We have raised a monoclonal antibody to the 32- and 34-kDa fragments and find that it reacts with all members of the heat-stable MAPs class. To determine where it reacts, we sequenced immunoreactive subfragments of the 32- and 34-kDa fragments, selected several cDNA clones with the antibody, and tested for antibody reactivity against a series of synthetic MAP 2 and tau peptides. We identify the epitope sequence as HHVPGGG (His-His-Val-Pro-Gly-Gly-Gly). The antibody also recognized several other MAP 2 and tau repeats. Despite reacting with this highly conserved element, we find that the antibody does not block microtubule binding, but binds to the MAPs and co-sediments with microtubules. These results suggest that there are other regions besides the repeated elements which are essential for microtubule binding.	UNIV LONDON UNIV COLL, DEPT BIOL, LONDON WC1E 6BT, ENGLAND; MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	University of London; University College London; MRC Laboratory Molecular Biology	DINGUS, J (corresponding author), WORCESTER FDN EXPTL BIOL INC, CELL BIOL GRP, SHREWSBURY, MA 01545 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026701] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07312] Funding Source: Medline; NIGMS NIH HHS [GM26701] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIZAWA H, 1990, J BIOL CHEM, V265, P13849; BLOOM GS, 1984, J CELL BIOL, V98, P320, DOI 10.1083/jcb.98.1.320; BLOOM GS, 1983, J CELL BIOL, V96, P1523, DOI 10.1083/jcb.96.6.1523; CHAPIN SJ, 1991, J CELL SCI, V98, P27; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; HAMMARBACK JA, 1991, NEURON, V7, P129, DOI 10.1016/0896-6273(91)90081-A; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KINDLER S, 1990, J BIOL CHEM, V265, P19679; KINDLER S, 1990, NUCLEIC ACIDS RES, V18, P2822, DOI 10.1093/nar/18.9.2822; LEE G, 1990, CELL MOTIL CYTOSKEL, V15, P199, DOI 10.1002/cm.970150402; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEGENDRE N, 1988, BIOTECHNIQUES, V6, P154; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; NOBLE M, 1989, J CELL BIOL, V109, P3367, DOI 10.1083/jcb.109.6.3367; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VALLEE RB, 1990, CELL MOTIL CYTOSKEL, V15, P204, DOI 10.1002/cm.970150403; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; WAXDAL MJ, 1968, BIOCHEMISTRY-US, V7, P1959, DOI 10.1021/bi00845a046; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	34	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18854	18860						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1717454				2022-12-25	WOS:A1991GJ47200070
J	CLAIRMONT, CA; DEMAIO, A; HIRSCHBERG, CB				CLAIRMONT, CA; DEMAIO, A; HIRSCHBERG, CB			TRANSLOCATION OF ATP INTO THE LUMEN OF ROUGH ENDOPLASMIC RETICULUM-DERIVED VESICLES AND ITS BINDING TO LUMINAL PROTEINS INCLUDING BIP (GRP-78) AND GRP-94	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; INTRACELLULAR-TRANSPORT; GOLGI VESICLES; HEAVY-CHAINS; MOUSE-LIVER; RAT-LIVER; SECRETION; GLYCOSYLATION; MEMBRANE; SIALOGLYCOPROTEINS	Rat liver and canine pancreas rough endoplasmic reticulum-derived vesicles, which were sealed and of the same topographical orientation as in vivo, were used in a system in vitro to demonstrate translocation of ATP into their lumen. Translocation of ATP is saturable (apparent K(m): 3-4-mu-M and V(max): 3-7 pmol/min/mg of protein) and protein mediated because treatment of intact vesicles with Pronase, N-ethylmaleimide, or 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid inhibit transport. The entire ATP molecule is being translocated; this was shown by high performance liquid chromatography analysis and the use of a nonhydrolyzable analog. Control experiments rule out that translocation of ATP attributed to rough endoplasmic reticulum-derived vesicles is due to contamination by mitochondria and Golgi vesicles. Following translocation of ATP into the lumen of the vesicles, binding to luminal proteins including BiP (immunoglobulin heavy chain-binding protein-glucose-regulated protein 78) and glucose-regulated protein 94 was observed. This binding appeared to be specific because similar experiments with GTP were negative. These studies strongly suggest that translocation of ATP into the rough endoplasmic reticulum lumen may serve as a mechanism for making ATP available in proposed energy requiring reactions within the lumen.			CLAIRMONT, CA (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655, USA.			Hirschberg, Carlos/0000-0003-2299-7721	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AARONSON NN, 1974, METHOD ENZYMOL, V31, P90; ARION WJ, 1976, J BIOL CHEM, V251, P4901; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CAPASSO JM, 1989, J BIOL CHEM, V264, P5233; CAPASSO JM, 1984, J BIOL CHEM, V259, P4263; CAREY DJ, 1981, J BIOL CHEM, V256, P989; CAREY DJ, 1980, J BIOL CHEM, V255, P4348; CAREY DJ, 1980, CELL, V19, P597, DOI 10.1016/S0092-8674(80)80036-5; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; Fleischer S, 1974, Methods Enzymol, V31, P6; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HASS IG, 1983, NATURE, V306, P387; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KASSENBROCK CK, 1989, EMBO J, V8, P1461, DOI 10.1002/j.1460-2075.1989.tb03529.x; KREIBICH G, 1975, METHOD ENZYMOL, V31, P215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AS, 1984, J BIOL CHEM, V259, P4616; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PEREZ M, 1986, J BIOL CHEM, V261, P6822; PEREZ M, 1986, METHOD ENZYMOL, V138, P709; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P833; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SHARMA S, 1985, EMBO J, V4, P1479, DOI 10.1002/j.1460-2075.1985.tb03806.x; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WICE BM, 1985, J BIOL CHEM, V260, P139; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; WU FS, 1981, J BIOL CHEM, V256, P5309	38	113	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3983	3990						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740446				2022-12-25	WOS:A1992HE60700067
J	SCALONI, A; JONES, WM; BARRA, D; POSPISCHIL, M; SASSA, S; POPOWICZ, A; MANNING, LR; SCHNEEWIND, O; MANNING, JM				SCALONI, A; JONES, WM; BARRA, D; POSPISCHIL, M; SASSA, S; POPOWICZ, A; MANNING, LR; SCHNEEWIND, O; MANNING, JM			ACYLPEPTIDE HYDROLASE - INHIBITORS AND SOME ACTIVE-SITE RESIDUES OF THE HUMAN ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-PEPTIDE HYDROLASE; ACID-RELEASING ENZYME; CELL LUNG-CANCER; RAT-LIVER; PANCREATIC LIPASE; EUKARYOTIC CELLS; SEQUENCE; PURIFICATION; PROTEIN; AMINOACYLASE-1	Acylpeptide hydrolase may be involved in N-terminal deacetylation of nascent polypeptide chains and of bioactive peptides. The activity of this enzyme from human erythrocytes is sensitive to anions such as chloride, nitrate, and fluoride. Furthermore, blocked amino acids act as competitive inhibitors of the enzyme. Acetyl leucine chloromethyl ketone has been employed to identify one active site residue as His-707. Diisopropylfluorophosphate has been used to identify a second active site residue as Ser-587. Chemical modification studies with a water-soluble carbodiimide implicate a carboxyl group in catalytic activity. These results and the sequence around these active site residues, especially near Ser-587, suggest that acylpeptide hydrolase contains a catalytic triad. The presence of a cysteine residue in the vicinity of the active site is suggested by the inactivation of the enzyme by sulfhydryl-modifying agents and also by a low amount of modification by the peptide chloromethyl ketone inhibitor. Ebelactone A, an inhibitor of the formyl amino-peptidase, the bacterial counterpart of eukaryotic acylpeptide hydrolase, was found to be an effective inhibitor of this enzyme. These findings suggest that acylpeptidase hydrolase is a member of a family of enzymes with extremely diverse functions.	ROCKEFELLER UNIV,NEW YORK,NY 10021; CNR,CTR BIOL MOLEC,I-00185 ROME,ITALY; UNIV ROME LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM A ROSSIFANELLI,I-00185 ROME,ITALY	Rockefeller University; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome			Barra, Donatella/D-1236-2011	Scaloni, Andrea/0000-0001-9362-8515	NCRR NIH HHS [507-RR-07065] Funding Source: Medline; NHLBI NIH HHS [HL-18819] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL018819, R01HL018819] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BOLDOG F, 1989, CANCER GENET CYTOGEN, V42, P295, DOI 10.1016/0165-4608(89)90098-8; BOND JS, 1989, PROTEOLYTIC ENZYMES, P232; BRADSHAW RA, 1989, TRENDS BIOCHEM SCI, V14, P276, DOI 10.1016/0968-0004(89)90063-7; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BREDDAM K, 1986, CARLSBERG RES COMMUN, V51, P83, DOI 10.1007/BF02907561; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; DOOLITTLE RF, 1986, URFS ORFS; ERLANDSSON R, 1990, ONCOGENE, V5, P1207; FARRIES TC, 1991, EUR J BIOCHEM, V196, P679, DOI 10.1111/j.1432-1033.1991.tb15865.x; GADE W, 1978, J BIOL CHEM, V253, P5012; Hartley BS, 1971, ENZYMES, V3, P323; JACKSON R, 1970, NATURE, V227, P672, DOI 10.1038/227672a0; JONES WM, 1991, P NATL ACAD SCI USA, V88, P2194, DOI 10.1073/pnas.88.6.2194; JONES WM, 1988, BIOCHIM BIOPHYS ACTA, V953, P357, DOI 10.1016/0167-4838(88)90045-3; JONES WM, 1985, BIOCHEM BIOPH RES CO, V126, P933, DOI 10.1016/0006-291X(85)90275-X; JONES WM, 1986, BIOCHEM BIOPH RES CO, V139, P244, DOI 10.1016/S0006-291X(86)80105-X; JONES WM, 1987, PROTEIN-STRUCT FUNCT, P675; KOBAYASHI K, 1987, J BIOL CHEM, V262, P11435; KOBAYASHI K, 1989, J BIOL CHEM, V264, P8892; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIAO DI, 1990, J BIOL CHEM, V265, P6528; MANNING JM, 1966, BIOCHEMISTRY-US, V5, P1154, DOI 10.1021/bi00868a007; MILLER YE, 1990, GENOMICS, V8, P149, DOI 10.1016/0888-7543(90)90237-O; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; MITTA M, 1989, J BIOCHEM-TOKYO, V106, P548, DOI 10.1093/oxfordjournals.jbchem.a122891; NAYLOR SL, 1989, GENOMICS, V4, P355, DOI 10.1016/0888-7543(89)90342-X; NEURATH H, 1989, PROTEOLYTIC ENZYMES, P1; PALMITER RD, 1978, P NATL ACAD SCI USA, V75, P94, DOI 10.1073/pnas.75.1.94; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; RADHAKRISHNA G, 1989, J BIOL CHEM, V264, P11076; RAWLINGS ND, 1991, BIOCHEM J, V279, P907, DOI 10.1042/bj2790907; RENNEX D, 1991, BIOCHEMISTRY-US, V30, P2195, DOI 10.1021/bi00222a025; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; STEINBERG N, 1990, BIOCHEM INT, V21, P1043; STONE SR, 1991, BIOCHEM J, V276, P837, DOI 10.1042/bj2760837; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TSUNASAWA S, 1975, J BIOCHEM, V77, P89; UMEZAWA H, 1980, J ANTIBIOT, V33, P1594, DOI 10.7164/antibiotics.33.1594; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; VERGER R, 1971, BIOCHIM BIOPHYS ACTA, V242, P580, DOI 10.1016/0005-2744(71)90151-3; WEBSTER RE, 1966, BIOCHEMISTRY-US, V5, P155; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WITHEILER J, 1972, J BIOL CHEM, V247, P2217; WOLD F, 1984, TRENDS BIOCHEM SCI, V9, P250	47	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3811	3818						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740429				2022-12-25	WOS:A1992HE60700043
J	CHAO, CCK				CHAO, CCK			A SINGLE AMINO-ACID DELETION AT THE AMINO TERMINUS OF INFLUENZA-VIRUS HEMAGGLUTININ CAUSES MALFOLDING AND BLOCKS EXOCYTOSIS OF THE MOLECULE IN MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ROUGH ENDOPLASMIC-RETICULUM; INTRACELLULAR-TRANSPORT; TUNICAMYCIN INHIBITION; PROTEIN TRANSLOCATION; MEMBRANE INSERTION; GOLGI-COMPLEX; CLEAVAGE SITE; FREE SYSTEM; GLYCOPROTEIN	I am investigating the role of protein folding in the transport of influenza virus hemagglutinin (HA), a membrane-bound protein, along the exocytotic pathway. From a previous work (Gething, M.-J., McCammon, K., and Sambrook, J. (1986) Cell 46, 939-950), it has been shown that a subset of alterations of the COOH-terminal sequences of the HA molecule inhibit folding and impede its transport to the cell surface. Current studies establish that the integrity of the NH2-terminal sequences of the HA is essential for assembly and transport of the molecule. Mutants lacking just 1 or 2 amino acids immediately COOH-terminal to the signal cleavage site are translocated and core glycosylated, but also incorrectly folded. The mutant molecules are not terminally glycosylated and are thus confined inside the cells. A hypothesis will be presented to explain why sequences at opposite ends of the HA molecule are essential for the assembly of native structures and why correct folding is necessary for transport along the exocytotic pathway of mammalian cells.	CHANG GUNG MED COLL, DEPT MED, TAOYUAN 33332, TAIWAN	Chang Gung University	CHAO, CCK (corresponding author), CHANG GUNG MED COLL, DEPT BIOCHEM, TUMOR BIOL LAB, TAOYUAN 33332, TAIWAN.							ASH JF, 1977, P NATL ACAD SCI USA, V74, P5584, DOI 10.1073/pnas.74.12.5584; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CHAO CCK, 1987, MOL CELL BIOL, V7, P3842, DOI 10.1128/MCB.7.10.3842; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; ELDER KT, 1979, VIROLOGY, V95, P343, DOI 10.1016/0042-6822(79)90489-6; GAROFF H, 1985, ANNU REV CELL BIOL, V1, P403, DOI 10.1146/annurev.cb.01.110185.002155; GETHING MJ, 1985, CURR TOP MEMBR TRANS, V23, P17; GETHING MJ, 1981, NATURE, V293, P620, DOI 10.1038/293620a0; GETHING MJ, 1982, NATURE, V300, P598, DOI 10.1038/300598a0; GETHING MJ, 1980, NATURE, V287, P301, DOI 10.1038/287301a0; GETHING MJ, 1978, P NATL ACAD SCI USA, V75, P2737, DOI 10.1073/pnas.75.6.2737; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GREEN J, 1981, J MOL BIOL, V152, P663, DOI 10.1016/0022-2836(81)90122-4; HARDWICK JM, 1986, J CELL BIOL, V103, P829, DOI 10.1083/jcb.103.3.829; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; INOUYE S, 1986, J BIOL CHEM, V261, P970; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1978, J BIOL CHEM, V253, P7771; LEHLE L, 1976, FEBS LETT, V71, P167, DOI 10.1016/0014-5793(76)80922-2; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MAURER RA, 1978, J BIOL CHEM, V253, P6315; MCCAULEY J, 1979, FEBS LETT, V108, P422, DOI 10.1016/0014-5793(79)80578-5; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; OWEN MJ, 1980, J BIOL CHEM, V255, P9678; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PIPAS JM, 1979, COLD SPRING HARB SYM, V44, P285, DOI 10.1101/SQB.1980.044.01.032; PLOEGH HL, 1979, P NATL ACAD SCI USA, V76, P2273, DOI 10.1073/pnas.76.5.2273; ROBBINS PW, 1977, CELL, V12, P893, DOI 10.1016/0092-8674(77)90153-2; ROTH MG, 1989, INFLUENZA VIRUSES; RUSSEL M, 1981, P NATL ACAD SCI-BIOL, V78, P1717, DOI 10.1073/pnas.78.3.1717; SAMBROOK J, 1985, EMBO J, V4, P91, DOI 10.1002/j.1460-2075.1985.tb02322.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; TARENTINO AL, 1974, MOL CELL BIOL, V4, P688; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WILEY DC, 1977, VIROLOGY, V79, P446, DOI 10.1016/0042-6822(77)90371-3; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	45	5	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2142	2148						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733923				2022-12-25	WOS:A1992HB53200008
J	ANTHONY, DD; MERRICK, WC				ANTHONY, DD; MERRICK, WC			ANALYSIS OF 40-S AND 80-S COMPLEXES WITH MESSENGER-RNA AS MEASURED BY SUCROSE DENSITY GRADIENTS AND PRIMER EXTENSION INHIBITION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION-FACTORS; MAMMALIAN PROTEIN-SYNTHESIS; 16S RIBOSOMAL-RNA; BINDING; TRANSLATION; ATP; SUBUNITS; SITE; MIGRATION; COMPONENT	The technique of primer extension inhibition has been adapted to analyze the eukaryotic ribosome-mRNA interaction. Formation of the ribosome-mRNA complex was performed in a nuclease-treated rabbit reticulocyte lysate. Before primer extension analysis, however, the complex is isolated by sucrose gradient centrifugation. Both 80 S- and 40 S-mRNA complexes can be individually analyzed because of this isolation step. 80 S ribosomes and 40 S ribosomal subunits could be localized at the initiation codon by a number of independent means where all complexes were formed in a manner consistent with the current understanding of the initiation pathway for translation in eukaryotes. Complexes were also isolated with the aid of the antibiotic edeine, where the 40 S ribosomal subunit was not located at the initiation codon, but 5' to the initiation codon. This extension inhibition assay was used to complement studies regarding the ATP dependence of the 40 S-mRNA interacting initiation steps that involve the mammalian RNA-interacting initiation factors eIF-4A, -4B, and -4F. A strong requirement for ATP was observed for 40 S-mRNA complex formation. A factor-mediated stimulation of complex formation by a combination of eIF-4A, -4B, and -4F was observed, and was one which required the presence of ATP. This factor-mediated ATP-dependent stimulation of complex formation was significantly inhibited by preincubating eIF-4A with the ATP analog 5'-p-fluorosulfonylbenzoyl adenosine. Finally, all complexes accumulated to a significant degree were analyzed by the primer extension assay. It was found that the 40 S ribosomal subunit was positioned at the initiation codon for all variations tested.			ANTHONY, DD (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT BIOCHEM, CLEVELAND, OH 44106 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM-07520, GM-26796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON RD, 1987, J BIOL CHEM, V262, P3826; ABRAMSON RD, 1987, THESIS CASE U RESERV; ADAMS SL, 1975, J BIOL CHEM, V250, P9083; ANTHONY DD, 1990, ARCH BIOCHEM BIOPHYS, V281, P157, DOI 10.1016/0003-9861(90)90426-Y; BENNE R, 1978, J BIOL CHEM, V253, P3078; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; ETCHISON D, 1987, MOL CELL BIOCHEM, V76, P15; GRIFO JA, 1982, J BIOL CHEM, V257, P5246; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; HUNT T, 1974, MODERN TRENDS HUMAN, P300; KOZAK M, 1978, J BIOL CHEM, V253, P6568; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1980, CELL, V22, P459, DOI 10.1016/0092-8674(80)90356-6; LAWSON TG, 1989, BIOCHEMISTRY-US, V28, P4729, DOI 10.1021/bi00437a033; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; ODOM OW, 1978, J BIOL CHEM, V253, P1807; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PETERSEN RB, 1984, J VIROL, V51, P722, DOI 10.1128/JVI.51.3.722-729.1984; PETERSON DT, 1979, J BIOL CHEM, V254, P7730; RAY BK, 1985, J BIOL CHEM, V260, P7651; RAY BK, 1986, J BIOL CHEM, V261, P1466; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SARKAR G, 1985, J BIOL CHEM, V260, P3831; SCHAEFER EM, 1989, J BACTERIOL, V171, P3901, DOI 10.1128/jb.171.7.3901-3908.1989; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; SEAL SN, 1983, P NATL ACAD SCI-BIOL, V80, P6562, DOI 10.1073/pnas.80.21.6562; STEITZ JA, 1969, NATURE, V224, P957, DOI 10.1038/224957a0; STEITZ JA, 1980, RIBOSOMES STRUCTURE, P479; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; WILLIAMS NP, 1989, P NATL ACAD SCI USA, V86, P7515, DOI 10.1073/pnas.86.19.7515; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x	37	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1554	1562						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730701				2022-12-25	WOS:A1992HA48500027
J	PUGH, CE; HARWOOD, JL; JOHN, RA				PUGH, CE; HARWOOD, JL; JOHN, RA			MECHANISM OF GLUTAMATE SEMIALDEHYDE AMINOTRANSFERASE - ROLES OF DIAMINO-INTERMEDIATES AND DIOXO-INTERMEDIATES IN THE SYNTHESIS OF AMINOLEVULINATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-SEMIALDEHYDE AMINOTRANSFERASE; DELTA-AMINOLEVULINATE; TRANSFER-RNA; BIOSYNTHESIS; BARLEY; ACID	Glutamate semialdehyde aminotransferase was purified to homogeneity from pea leaves. The enzyme has an absorption spectrum with maxima at 345 and 416 nm. These chromophores were attributed to pyridoxamine phosphate and to pyridoxal phosphate bound as an aldimine respectively. Treatment of the enzyme with increasing concentrations of diaminovalerate produced a rapid fall in the 416 nm chromophore and a simultaneous increase in the 345 nm chromophore in a manner that indicated a stoichiometric reaction between 4,5-diaminovalerate and the pyridoxaldimine form of the enzyme. Treatment with 4,5-dioxovalerate produced the reverse reaction. The enzyme catalyzed the formation of aminolevulinate when dioxovalerate and diaminovalerate were present together and the maximal rate was 40% of that observed when glutamate semialdehyde itself was used as substrate. Conversion of the enzyme from its pyridoxaldimine to pyridoxamine form produced a proportional increase in activity towards glutamate semialdehyde, whereas reduction of the pyridoxaldimine form with sodium borohydride produced no change in this catalytic activity. It was concluded, therefore, that only the pyridoxamine form of the enzyme is active in catalyzing conversion of glutamate semialdehyde to aminolevulinate and that the catalytic mechanism includes enzyme-bound diaminovalerate as a central intermediate.	UNIV WALES COLL CARDIFF,DEPT BIOCHEM,POB 903,CARDIFF CF1 1ST,WALES	Cardiff University			Harwood, John L/A-4308-2010	Harwood, John/0000-0003-2377-2612				BULL AD, 1990, ARCH MICROBIOL, V154, P56; DORNEMANN D, 1980, BIOCHIM BIOPHYS ACTA, V628, P35, DOI 10.1016/0304-4165(80)90349-9; GEHRING H, 1984, BIOCHEMISTRY-US, V23, P6335, DOI 10.1021/bi00321a007; GOUGH SP, 1989, CARLSBERG RES COMMUN, V54, P67; GRIMM B, 1989, CARLSBERG RES COMMUN, V54, P67, DOI 10.1007/BF02907586; GRIMM B, 1991, J BIOL CHEM, V266, P12495; ILAG LL, 1991, J BACTERIOL, V173, P3408, DOI 10.1128/jb.173.11.3408-3413.1991; JAHN D, 1991, J BIOL CHEM, V266, P161; JENKINS WT, 1985, TRANSAMINASES, P216; KAHN A, 1987, CARLSBERG RES COMMUN, V52, P73, DOI 10.1007/BF02910429; KALLEN RG, 1985, TRANSAMINASES, P37; KANNANGARA CG, 1985, CARLSBERG RES COMMUN, V50, P179, DOI 10.1007/BF02907144; KANNANGARA CG, 1988, TRENDS BIOCHEM SCI, V13, P139; NAIR SP, 1991, FEBS LETT, V283, P4, DOI 10.1016/0014-5793(91)80540-J; PUGH C, 1991, IN PRESS ANAL BIOCH; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; [No title captured]	17	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1584	1588						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730703				2022-12-25	WOS:A1992HA48500031
J	BARKOCYGALLAGHER, GA; BASSFORD, PJ				BARKOCYGALLAGHER, GA; BASSFORD, PJ			SYNTHESIS OF PRECURSOR MALTOSE-BINDING PROTEIN WITH PROLINE IN THE +1 POSITION OF THE CLEAVAGE SITE INTERFERES WITH THE ACTIVITY OF ESCHERICHIA-COLI SIGNAL PEPTIDASE-I INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEADER PEPTIDASE; INVITRO TRANSLOCATION; EXPORTED PROTEINS; MEMBRANE-VESICLES; BETA-LACTAMASE; OUTER-MEMBRANE; MUTATIONS; SEQUENCE; SECRETION; LOCALIZATION	The residues occupying the -3 and - 1 positions relative to the cleavage site of secretory precursor proteins are usually amino acids with small, neutral side chains that are thought to constitute the recognition site for the processing enzyme, signal peptidase. No restrictions have been established for residues positioned +1 to the cleavage site, although there have been several indications that mutant precursor proteins with a proline at +1 cannot be processed by Escherichia coli signal peptidase I (also called leader peptidase). A maltose-binding protein (MBP) species with proline at +1, designated MBP27-P, was translocated efficiently but not processed when expressed in E. coli cells. Unexpectedly, induced expression of MBP27-P was found to have an adverse effect on the processing kinetics of five different nonlipoprotein precursors analyzed, but not precursor Lpp (the major outer membrane lipoprotein) processed by a different enzyme, signal peptidase II. Cell growth also was inhibited following induction of MBP27-P synthesis. Substitutions in the MBP27-P signal peptide that blocked MBP translocation across the cytoplasmic membrane and, hence, access to the processing enzyme or that altered the signal peptidase I recognition site at position -1 restored both normal growth and processing of other precursors. Since overproduction of signal peptidase I also restored normal growth and processing to cells expressing unaltered MBP27-P, it was concluded that precursor MBP27-P interferes with the activity of the processing enzyme, probably by competing as a noncleavable substrate for the enzyme's active site. Thus, although signal peptidase I, like many other proteases, is unable to cleave an X-Pro bond, a proline at +1 does not prevent the enzyme from recognizing the normal processing site. When the RBP signal peptide was substituted for the MBP signal peptide of MBP27-P, the resultant hybrid protein was processed somewhat inefficiently at an alternate cleavage site and elicited a much reduced effect on cell growth and signal peptidase I activity. Although the MBP signal peptide also has an alternate cleavage site, the different properties of the RBP and MBP signal peptides with regard to the substitution of proline at +1 may be related to their respective secondary structures in the processing site region.	UNIV N CAROLINA, SCH MED, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017292] Funding Source: NIH RePORTER; NIAID NIH HHS [AI17292] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BANKAITIS VA, 1984, J BIOL CHEM, V259, P2193; BIEKER KL, 1989, P NATL ACAD SCI USA, V86, P968, DOI 10.1073/pnas.86.3.968; BILGIN N, 1990, EMBO J, V9, P2717, DOI 10.1002/j.1460-2075.1990.tb07458.x; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; COLLIER DN, 1990, J BACTERIOL, V172, P6875, DOI 10.1128/jb.172.12.6875-6884.1990; COLLIER DN, 1988, CELL, V53, P273, DOI 10.1016/0092-8674(88)90389-3; DALBEY RE, 1985, J BIOL CHEM, V260, P5925; DATE T, 1981, P NATL ACAD SCI-BIOL, V78, P6106, DOI 10.1073/pnas.78.10.6106; DATE T, 1983, J BACTERIOL, V154, P76, DOI 10.1128/JB.154.1.76-83.1983; DEAN DA, 1989, J BACTERIOL, V171, P503, DOI 10.1128/jb.171.1.503-510.1989; DEV IK, 1990, J BIOENERG BIOMEMBR, V22, P271, DOI 10.1007/BF00763168; DEV IK, 1990, J BIOL CHEM, V265, P20069; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; DUFFAUD GD, 1985, CURR TOP MEMBR TRANS, V24, P65; EMR SD, 1982, J BIOL CHEM, V257, P5852; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FIKES JD, 1987, J BACTERIOL, V169, P2352, DOI 10.1128/jb.169.6.2352-2359.1987; FIKES JD, 1990, J BIOL CHEM, V265, P3147; GASCUEL O, 1986, J MOL EVOL, V24, P130, DOI 10.1007/BF02099961; HILL ROBERT L., 1965, ADVANCE PROTEIN CHEM, V20, P37, DOI 10.1016/S0065-3233(08)60388-5; HUTCHISON CA, 1986, P NATL ACAD SCI USA, V83, P710, DOI 10.1073/pnas.83.3.710; INADA T, 1989, J BACTERIOL, V171, P585, DOI 10.1128/jb.171.1.585-587.1989; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; KOSHLAND D, 1982, CELL, V30, P903, DOI 10.1016/0092-8674(82)90295-1; KUHN A, 1985, J BIOL CHEM, V260, P5914; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Miller J. H., 1972, EXPT MOL GENETICS, P431; NOTHWEHR SF, 1990, J BIOL CHEM, V265, P21797; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; OLIVER DB, 1981, CELL, V25, P765, DOI 10.1016/0092-8674(81)90184-7; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PLUCKTHUN A, 1987, J BIOL CHEM, V262, P3951; RASMUSSEN BA, 1985, J BACTERIOL, V164, P665, DOI 10.1128/JB.164.2.665-673.1985; RYAN JP, 1985, J BIOL CHEM, V260, P4832; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; von Heijne G, 1987, Protein Seq Data Anal, V1, P41; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATANABE T, 1988, J BACTERIOL, V170, P4001, DOI 10.1128/jb.170.9.4001-4007.1988; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WEISMAN LS, 1986, J BIOL CHEM, V261, P2309; WEISS JB, 1989, J BIOL CHEM, V264, P3021; WICKNER W, 1987, J BACTERIOL, V169, P3821, DOI 10.1128/jb.169.8.3821-3822.1987; WOLFE PB, 1982, J BIOL CHEM, V257, P7898; WU HC, 1987, BACTERIAL OUTER MEMB, P37; YAMANE K, 1988, J BIOL CHEM, V263, P5368; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479; ZWIZINSKI C, 1981, J BIOL CHEM, V256, P3593	55	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1231	1238						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730647				2022-12-25	WOS:A1992GY96000086
J	LIN, TW; BRIDGER, WA				LIN, TW; BRIDGER, WA			SEQUENCE OF A CDNA CLONE ENCODING PIG-HEART MITOCHONDRIAL COA TRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A-TRANSFERASE; ACID; MECHANISM; CATALYSIS	We have isolated a full-length cDNA clone encoding the cytoplasmic precursor to pig heart mitochondrial CoA transferase (succinyl-CoA:3-ketoacid coenzyme A transferase (3-oxoacid CoA transferase, EC 2.8.3.5)), a key enzyme for ketone body catabolism. The deduced amino acid sequence indicates the presence of a 39-residue mitochondrial signal sequence and a 481-residue mature protein of molecular weight 52,197. CoA transferase is known to be susceptible to proteolytic cleavage to produce a nicked but active enzyme. We have identified the site of proteolysis, and analysis of the sequence in its vicinity suggests that the polypeptide may fold into two domains connected by a highly hydrophilic bridge.	UNIV ALBERTA,DEPT BIOCHEM,4-74 MED SCI BLDG,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Alberta								BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; BUCK D, 1985, BIOCHEMISTRY-US, V24, P6245, DOI 10.1021/bi00343a031; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FIERKE CA, 1986, J BIOL CHEM, V261, P7603; FUKAO T, 1989, J BIOCHEM-TOKYO, V106, P197, DOI 10.1093/oxfordjournals.jbchem.a122832; GROSSBERGER D, 1987, NUCLEIC ACIDS RES, V16, P2726; HERSH LB, 1967, J BIOL CHEM, V242, P3468; HERSH LB, 1967, J BIOL CHEM, V242, P3481; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOWARD JB, 1986, J BIOL CHEM, V261, P60; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; Jencks W. P., 1973, ENZYMES, V9, P483; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; Mason PJ, 1985, NUCLEIC ACID HYBRIDI, P113; MOORE SA, 1982, J BIOL CHEM, V257, P893; PICKART CM, 1979, J BIOL CHEM, V254, P9120; SHARP JA, 1978, BIOCHEM J, V173, P759, DOI 10.1042/bj1730759; SOLOMON F, 1969, J BIOL CHEM, V244, P1079; TABOR S, 1989, J BIOL CHEM, V264, P6447; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WHITE H, 1976, J BIOL CHEM, V251, P1688; WHITE H, 1976, J BIOL CHEM, V251, P1708	23	32	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					975	978						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730685				2022-12-25	WOS:A1992GY96000048
J	TANIGUCHISIDLE, A; ISENMAN, DE				TANIGUCHISIDLE, A; ISENMAN, DE			MUTAGENESIS OF THE ARG-GLY-ASP TRIPLET IN HUMAN-COMPLEMENT COMPONENT-C3 DOES NOT ABOLISH BINDING OF IC3B TO THE LEUKOCYTE INTEGRIN COMPLEMENT RECEPTOR TYPE-III (CR3, CD11B/CD18)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MEMBRANE GLYCOPROTEIN MO1; MONOCLONAL-ANTIBODIES; 3RD COMPONENT; BETA-SUBUNIT; LEISHMANIA PROMASTIGOTES; NUCLEOTIDE-SEQUENCE; FUNCTIONAL DOMAINS; CONTAINING REGION	The leukocyte integrin complement receptor type III (CR3, CD11b/CD18) binds the C3 cleavage product iC3b. Many other integrins bind their ligands via an Arg-Gly-Asp (RGD) triplet. Both the RGD-containing C3 peptide 1390TRYRGDQDATMS1401 (pro-C3 numbering) and the RGD-like fibrinogen peptide GGAKQAGDV, which binds to the platelet integrin glycoprotein IIb-IIIa, were shown to inhibit the iC3b-CR3 interaction, suggesting that this binding is also RGD-mediated (Wright, S. D., Weitz, J. I., Huang, A. J., Levin, S. M., Silverstein, S. C., and Loike, J. D. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7734-7738). However, unlike other integrin-ligand interactions, that of CR3 and iC3b is unaffected by the hexapeptide GRGDSP, and substitutions in the RGD triplet of C3 from other species appear to be tolerated. It was, therefore, proposed (Grossberger, D., Marcuz, A., du Pasquier, L., and Lambris, J. D. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 1323-1327) that the highly conserved DATMS portion of the inhibitory C3 peptide may have been responsible for its binding. To address these inconsistencies and directly assess the role of the 1390-1401 segment within the complete iC3b molecule in mediating binding to CR3, a human C3 cDNA was altered by site-directed mutagenesis and the expressed recombinant proteins were examined in a CR3-specific assay. Replacement of RGD by AAA did not abolish rosetting of the corresponding iC3b-coated erythrocytes to human CR3-bearing leukocytes. In addition, mutant iC3b molecules in which the positively charged R1391 (corresponding to K in the fibrinogen peptide) and the highly conserved 1397DATMS sequence were replaced by Q and NAAMA respectively, were still bound by CR3. We conclude that the iC3b-CR3 interaction is not mediated by the RGD triplet or its neighboring residues.	UNIV TORONTO,DEPT BIOCHEM,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto								ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; ARNAOUT MA, 1988, J CELL BIOL, V106, P2153, DOI 10.1083/jcb.106.6.2153; BAKER MD, 1988, P NATL ACAD SCI USA, V85, P6432, DOI 10.1073/pnas.85.17.6432; BEARD J, 1980, J IMMUNOL, V124, P1943; BECHERER JD, 1989, COMPLEMENT INFLAMMAT, V6, P142, DOI 10.1159/000463091; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BOLOTIN C, 1977, BIOCHEMISTRY-US, V16, P2008, DOI 10.1021/bi00628a039; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; BUTTON LL, 1990, J EXP MED, V171, P589; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COLE FS, 1985, J IMMUNOL, V134, P2610; COOPER NR, 1970, J EXP MED, V132, P775, DOI 10.1084/jem.132.4.775; COOPER NR, 1970, IMMUNOCHEMISTRY, V7, P341, DOI 10.1016/0019-2791(70)90237-5; COOPER NR, 1968, IMMUNOCHEMISTRY, V5, P155, DOI 10.1016/0019-2791(68)90100-6; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DANA N, 1984, J CLIN INVEST, V73, P153, DOI 10.1172/JCI111186; DANA N, 1986, J IMMUNOL, V137, P3259; DAVIES SG, 1981, BIOSCIENCE REP, V1, P461, DOI 10.1007/BF01121579; DEBRUIJN MHL, 1985, P NATL ACAD SCI USA, V82, P708; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; EDDY A, 1984, CLIN IMMUNOL IMMUNOP, V31, P371, DOI 10.1016/0090-1229(84)90090-4; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; GAITHER TA, 1987, IMMUNOLOGY, V62, P405; GAITHER TA, 1974, J IMMUNOL, V113, P574; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GORDON DL, 1987, IMMUNOLOGY, V60, P553; GROSSBERGER D, 1989, P NATL ACAD SCI USA, V86, P1323, DOI 10.1073/pnas.86.4.1323; HARLOW E, 1988, ANTIBODIES LAB MANUA, P586; HERMANOWSKIVOSATKA A, 1988, J BIOL CHEM, V263, P17822; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; INOUYE S, 1987, SYNTHESIS APPLICATIO, P181; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; KUSANO M, 1986, IMMUNOL INVEST, V15, P365, DOI 10.3109/08820138609052955; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIS JD, 1988, IMMUNOL TODAY, V9, P387, DOI 10.1016/0167-5699(88)91240-6; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LAW SKA, 1987, EMBO J, V6, P915, DOI 10.1002/j.1460-2075.1987.tb04838.x; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P556; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P2178, DOI 10.1093/nar/18.8.2178; NAGASAWA S, 1977, P NATL ACAD SCI USA, V74, P2998, DOI 10.1073/pnas.74.7.2998; NAGASAWA S, 1980, J IMMUNOL, V125, P578; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; POLLEY MJ, 1967, J EXP MED, V126, P1013, DOI 10.1084/jem.126.6.1013; RIZVI FS, 1988, EUR J IMMUNOL, V18, P473, DOI 10.1002/eji.1830180323; ROSEN H, 1989, CURR TOP MICROBIOL I, V153, P99; ROSS GD, 1987, COMPLEMENT INFLAMMAT, V4, P61, DOI 10.1159/000463010; ROSS GD, 1982, J EXP MED, V155, P96, DOI 10.1084/jem.155.1.96; ROSS GD, 1982, J IMMUNOL, V129, P2051; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RUSSELL DG, 1989, INFECT IMMUN, V57, P630, DOI 10.1128/IAI.57.2.630-632.1989; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCHREIBER RD, 1982, CLIN IMMUNOL IMMUNOP, V23, P335, DOI 10.1016/0090-1229(82)90119-2; SEKIZAWA A, 1984, J IMMUNOL, V133, P1436; SPANGLER BD, 1991, J IMMUNOL, V146, P1591; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; SUGGS SV, 1981, DEV BIOL USING PURIF, P683; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; WETSEL RA, 1984, J BIOL CHEM, V259, P3857; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147; WONG WW, 1987, METHOD ENZYMOL, V150, P579; WRIGHT SD, 1987, P NATL ACAD SCI USA, V84, P1965, DOI 10.1073/pnas.84.7.1965; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1986, J IMMUNOL, V136, P1759; WRIGHT SD, 1989, J EXP MED, V169, P175, DOI 10.1084/jem.169.1.175; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149	76	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					635	643						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730624				2022-12-25	WOS:A1992GY43900098
J	BARTEK, J; VOJTESEK, B; GRAND, RJA; GALLIMORE, PH; LANE, DP				BARTEK, J; VOJTESEK, B; GRAND, RJA; GALLIMORE, PH; LANE, DP			CELLULAR-LOCALIZATION AND T-ANTIGEN BINDING OF THE RETINOBLASTOMA PROTEIN	ONCOGENE			English	Article								Mutation of the retinoblastoma (Rb) gene is found frequently in human sarcomas, lung, bladder and breast carcinomas and is the molecular basis for hereditary predisposition to retinoblastoma. The Rb protein is a nuclear phosphoprotein that is differentially phosphorylated during the cell cycle. Its precise function is unknown but it has been suggested that it may act as a transcriptional regulator or as a regulator of cellular DNA synthesis. The Rb protein forms specific complexes with the oncogenes of three different groups of DNA tumour viruses. We have prepared a new monoclonal antibody to the Rb protein and used it to establish sensitive immunoassays for Rb complexed to T antigen. In SV40-infected and transformed cells these assays showed that Rb enters a trimolecular complex containing p53. Rb and T. A large panel of human tumour cell lines was tested for expression, cellular localization and T-binding activity of Rb using the new antibody.	UNIV DUNDEE, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; MASARYK INST ONCOL, CS-65653 BRNO, CZECHOSLOVAKIA; UNIV BIRMINGHAM, DEPT CANC STUDIES, CANC RES CAMPAIGN LABS, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND	University of Dundee; Masaryk Memorial Cancer Institute; University of Birmingham			Lane, David P/C-4920-2008; Bartek, Jiri/G-5870-2014	Lane, David/0000-0003-0551-3545				AKIYAMA T, 1990, ONCOGENE, V5, P179; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BARTEK J, 1990, ONCOGENE, V5, P893; BENEDICT WF, 1987, ADV VIRAL ONCOL, P19; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GRAND RJA, 1989, ONCOGENE, V4, P1291; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1987, ADV VIRAL ONCOL, V7, P1; LANE DP, 1981, J IMMUNOL METHODS, V47, P303, DOI 10.1016/0022-1759(81)90286-6; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; STRATTON MR, 1990, ONCOGENE, V5, P1297; STRATTON MR, 1989, BRIT J CANCER, V60, P202, DOI 10.1038/bjc.1989.251; SUMEGI J, 1990, CELL GROWTH DIFFER, V1, P247; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1989, ONCOGENE, V4, P401; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; VARLEY JM, 1989, ONCOGENE, V4, P725; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; XU HJ, 1991, ONCOGENE, V6, P1139; YOKOTA J, 1988, ONCOGENE, V3, P471	57	61	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					101	108						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741157				2022-12-25	WOS:A1992HC22700014
J	OKADA, M; NADA, S; YAMANASHI, Y; YAMAMOTO, T; NAKAGAWA, H				OKADA, M; NADA, S; YAMANASHI, Y; YAMAMOTO, T; NAKAGAWA, H			CSK - A PROTEIN-TYROSINE KINASE INVOLVED IN REGULATION OF SRC FAMILY KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PP60C-SRC; GENE; CELLS; EXPRESSION; BINDING; DEPHOSPHORYLATION; PHOSPHORYLATION; TRANSFORMATION; ACTIVATION; P60C-SRC	The functions of src family protein-tyrosine kinases are thought to be regulated negatively by the phosphorylation of highly conserved tyrosine residues close to their carboxyl termini. Recently we have purified and cloned a protein-tyrosine kinase (designated as CSK) that can specifically phosphorylate the negative regulatory site of p60c-src. To elucidate the relationship between CSK and other types of src family kinases, we investigated the tissue distribution of CSK and examined whether CSK could phosphorylate the negative regulatory sites of src family kinases other than p60c-scr. Western blot analysis indicated that CSK was enriched at the highest level in lymphoid tissues in which the expression of p60c-src is considerably lower than those of other types of src family kinases. CSK phosphorylated p56lyn and p59fyn, which are known to be expressed in lymphoid tissues at a relatively high level. The putative regulatory site, tyrosine 508, was found to be essential for phosphorylation in p56lyn, and the kinase activities of these src family kinases were repressed by phosphorylation with CSK. These findings raise the possibility that CSK might act as a universal regulator for src family kinases.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo	OKADA, M (corresponding author), OSAKA UNIV,INST PROT RES,DIV PROT METAB,3-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.							CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DYMECKI SM, 1990, SCIENCE, V247, P332, DOI 10.1126/science.2404338; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; OKADA M, 1989, J BIOL CHEM, V264, P20886; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	28	496	511	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24249	24252						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722201				2022-12-25	WOS:A1991GW84500005
J	RAWLINGS, SR; BERRY, DJ; LEONG, DA				RAWLINGS, SR; BERRY, DJ; LEONG, DA			EVIDENCE FOR LOCALIZED CALCIUM MOBILIZATION AND INFLUX IN SINGLE-RAT GONADOTROPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY GONADOTROPHS; CYTOSOLIC CA-2+; CHROMAFFIN CELLS; ACTIVE ZONES; CHANNELS; TRANSIENTS; SECRETION; OSCILLATIONS; CURRENTS; RELEASE	Dynamic video-imaging microscopy was used to investigate the spatial and temporal nature of Ca2+ mobilization and Ca2+ influx in acutely dissociated, fura-2-loaded, rat gonadotropes. Addition of luteinizing hormone-releasing hormone (LHRH) to an isolated gonadotrope stimulated a wave of Ca2+ originating from a specific locus of the cell. This probably reflects Ca2+ mobilization from an intracellular store, since this response was unaffected by the removal of extracellular Ca2+. Application of the dihydropyridine-sensitive Ca2+ channel agonist Bay K 8644 (Bay K) stimulated a rise in cytosolic free Ca2+ concentration in the rat gonadotrope. This response was blocked by the removal of extracellular Ca2+ and probably reflects the influx of Ca2+ across the cell membrane. High speed (30 frames.s-1) imaging of the Bay K-induced Ca2+ influx revealed a wave of Ca2+ originating from a localized part of the cell membrane, which, in general, was spatially distinct from the LHRH-induced Ca2+ wave produced in the same cell. This suggests that Ca2+ channels in the cell membrane may be clustered in a specific area of the cell membrane. The velocity of the LHRH-induced Ca2+ mobilization wave was faster (mean = 79 +/- 5-mu-m.s-1, n = 9) than the Bay K-induced Ca2+ influx wave (39 +/- 7-mu-m.s-1, n = 9) (p less-than-or-equal-to 0.01, Wilcoxon signed rank test) measured in the same cells. Thus, both Ca2+ mobilization from intracellular stores and Ca2+ influx through the cell membrane appear to be spatially localized in the rat gonadotrope. These findings may have important implications in the intracellular regulation of Ca2+-dependent cell functions such as hormone biosynthesis and secretion.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MED,BOX 511,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PHYSIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROSCI,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia					NICHD NIH HHS [HD-13197] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013197] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; CHEEK TR, 1989, J CELL BIOL, V109, P1219, DOI 10.1083/jcb.109.3.1219; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CROXTON TL, 1988, ENDOCRINOLOGY, V123, P1783, DOI 10.1210/endo-123-4-1783; DAVIDSON JS, 1988, MOL ENDOCRINOL, V2, P383; GARNER LL, 1981, BIOL REPROD, V24, P461, DOI 10.1095/biolreprod24.2.461; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERNANDEZCRUZ A, 1990, SCIENCE, V247, P858, DOI 10.1126/science.2154851; HUANG PL, 1990, BIOPHYS J, V57, pA530; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KEEFER DA, 1981, IRCS MED SCI-BIOCHEM, V9, P691; KIM KT, 1989, P NATL ACAD SCI USA, V86, P9881, DOI 10.1073/pnas.86.24.9881; Knobil E, 1980, Recent Prog Horm Res, V36, P53; KOKUBUN S, 1984, P NATL ACAD SCI-BIOL, V81, P4824, DOI 10.1073/pnas.81.15.4824; LAWSON D, 1978, J CELL BIOL, V79, P394, DOI 10.1083/jcb.79.2.394; LEONG DA, 1991, J BIOL CHEM, V266, P9016; LEONG DA, 1985, ENDOCRINOLOGY, V116, P1371, DOI 10.1210/endo-116-4-1371; LEONG DA, 1991, CELL CALCIUM, V12, P233; LIPSCOMBE D, 1988, NEURON, V1, P355, DOI 10.1016/0896-6273(88)90185-7; MASON WT, 1989, J PHYSIOL-LONDON, V415, P367, DOI 10.1113/jphysiol.1989.sp017726; MASUMOTO N, 1991, J BIOL CHEM, V266, P6485; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; NAOR Z, 1986, J BIOL CHEM, V261, P2506; PUMPLIN DW, 1981, P NATL ACAD SCI-BIOL, V78, P7210, DOI 10.1073/pnas.78.11.7210; RAWLINGS S R, 1991, Biophysical Journal, V59, p272A; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; SCHLEGEL W, 1987, NATURE, V329, P719, DOI 10.1038/329719a0; SHANGOLD GA, 1988, P NATL ACAD SCI USA, V85, P6566, DOI 10.1073/pnas.85.17.6566; SILVER RA, 1990, NATURE, V343, P751, DOI 10.1038/343751a0; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SMITH SJ, 1988, CALCIUM ION CHANNEL, P147; STOJILKOVIC SS, 1988, J BIOL CHEM, V263, P13054; STUTZIN A, 1989, AM J PHYSIOL, V257, pC865, DOI 10.1152/ajpcell.1989.257.5.C865; WALROND JP, 1985, J NEUROSCI, V5, P1118	35	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22755	22760						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1719000				2022-12-25	WOS:A1991GR56400102
J	LEE, KM; BERTLES, JF; BOUSSIOS, T				LEE, KM; BERTLES, JF; BOUSSIOS, T			TRANSLATIONAL CONTROL OF GLOBIN CHAIN ONTOGENY IN HAMSTER YOLK-SAC ERYTHROID-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA; HEMOGLOBINS; EXPRESSION	Prior research has demonstrated that globin ontogeny of hamster proceeds nearly to completion during the several days that yolk sac erythroid cells (YSEC) circulate in the embryo; synthesis of embryonic globin chains gives way to synthesis of adult globin chains in these primitive cells. In the present study, we translated total cell RNA extracted from YSEC on days 9-13 of gestation in wheat germ cell-free extract, expecting to observe the same progressive rise that occurs in vivo in rates of translation of alpha- and beta-globin mRNA during ontogeny. The opposite occurred; translation rates of both globins decreased sharply. This disparity between synthesis of alpha- and beta-globins in vivo and in vitro suggested an element of control of translation attributable to the YSEC cytoplasm. We therefore assayed the effect of RNA-free clarified YSEC cytoplasm on cell-free translation of YSEC RNA. A repression of translation was detected of alpha- and beta-globin mRNA (not of embryonic globin mRNA), exercised strongly by cytoplasm from YSEC early in ontogeny (gestational day 9), and weakening as ontogeny progressed. The same effect was noted on alpha- and beta-globin mRNA of adult hamster and of rabbit. Heat treatment of cytoplasm abolished the greater part of the translation regulation, suggesting that the active agent is protein. Further characterization of this translational regulator included: (a) it binds to globin poly(A) mRNA but not to poly(A), (b) it was not detected in cell lysate of adult hamster brain, lung, or erythrocytes, and (c) it did not inhibit translation of adult hamster brain and liver RNA. We conclude that hamster globin ontogeny is substantially modulated by this translational regulation of alpha- and beta-globin expression.	ST LUKES ROOSEVELT HOSP, MED SERV,DIV HEMATOL ONCOL,S&R 12, AMSTERDAM AVE & 114TH ST, NEW YORK, NY 10025 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA	Mount Sinai St. Luke's; Mount Sinai West; Columbia University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030942, R01DK039751] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 30942, DK 39751] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BOUSSIOS T, 1982, SCIENCE, V218, P1225, DOI 10.1126/science.6183746; BOUSSIOS T, 1985, P NATL ACAD SCI USA, V82, P2794, DOI 10.1073/pnas.82.9.2794; BOUSSIOS T, 1982, BRIT J HAEMATOL, V51, P99, DOI 10.1111/j.1365-2141.1982.tb07294.x; BOUSSIOS T, 1989, J BIOL CHEM, V264, P16017; BOUSSIOS T, 1988, EXP HEMATOL, V16, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; ENVER T, 1989, P NATL ACAD SCI USA, V86, P7033, DOI 10.1073/pnas.86.18.7033; FANTONI A, 1969, J BIOL CHEM, V244, P675; ILAN J, 1987, TRANSLATIONAL REGULA; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KWON YK, 1991, P NATL ACAD SCI USA, V88, P3584, DOI 10.1073/pnas.88.9.3584; Maniatis T., 1982, MOL CLONING; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; THEIL EC, 1990, J BIOL CHEM, V265, P4771; WANG MJ, 1990, NUCLEIC ACIDS RES, V18, P6625, DOI 10.1093/nar/18.22.6625; WULCZYN FG, 1991, CELL, V65, P259, DOI 10.1016/0092-8674(91)90160-Z	18	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20555	20560						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1718966				2022-12-25	WOS:A1991GM03900102
J	MIYAUCHI, K; MASAKI, R; TAKETANI, S; YAMAMOTO, A; AKAYAMA, M; TASHIRO, Y				MIYAUCHI, K; MASAKI, R; TAKETANI, S; YAMAMOTO, A; AKAYAMA, M; TASHIRO, Y			MOLECULAR-CLONING, SEQUENCING, AND EXPRESSION OF CDNA FOR RAT-LIVER MICROSOMAL ALDEHYDE DEHYDROGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-DISTRIBUTION; CYTOPLASMIC ISOENZYME; HEME OXYGENASE; HORSE LIVER; PROTEIN; CYTOCHROME-B5; BINDING; PURIFICATION; FORMS; SITE	The cDNA clone for rat liver microsomal aldehyde dehydrogenase (msALDH) was isolated and sequenced. The deduced amino acid sequence consisting of 484 amino acid residues revealed that the carboxyl-terminal region of msALDH has a hydrophobic segment, which is probably important for the insertion of this enzyme into the endoplasmic reticulum membrane. COS-1 cells transfected with the expression vector pcD containing the full-length cDNA showed that the active enzyme was expressed and localized mainly on the cytoplasmic surface of the endoplasmic reticulum membranes. It has been proposed that ALDH isozymes form a superfamily consisting of class 1, 2, and 3 ALDHs (Hempel, J., Harper, K., and Lindahl, R., (1989) Biochemistry 28, 1160-1167). Comparison of the amino acid sequence of rat liver msALDH with those of rat other class ALDHs showed that msALDH was 24.2, 24.0, and 65.5% identical to phenobarbital-inducible ALDH (variant class 1), mitochondrial ALDH (class 2), and tumor-associated ALDH (class 3), respectively. Several amino acid residues common to the other known ALDHs, however, were found to be conserved in msALDH. Based on these results, we proposed to classify msALDH as a new type, class 4 ALDH.	KANSAI MED UNIV,DEPT HYG,MORIGUCHI,OSAKA 570,JAPAN	Kansai Medical University	MIYAUCHI, K (corresponding author), KANSAI MED UNIV,DEPT PHYSIOL,MORIGUCHI,OSAKA 570,JAPAN.							ABRIOLA DP, 1987, BIOCHEMISTRY-US, V26, P5679, DOI 10.1021/bi00392a015; ANTONENKOV VD, 1985, EUR J BIOCHEM, V149, P159, DOI 10.1111/j.1432-1033.1985.tb08906.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAILEY HA, 1981, J BIOL CHEM, V256, P3951; DEITRICH RA, 1977, J BIOL CHEM, V252, P6169; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; FARRES J, 1989, EUR J BIOCHEM, V180, P67, DOI 10.1111/j.1432-1033.1989.tb14616.x; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; GUAN KL, 1988, ALCOHOL CLIN EXP RES, V12, P713, DOI 10.1111/j.1530-0277.1988.tb00270.x; HEMPEL J, 1982, BIOCHEMISTRY-US, V21, P6834, DOI 10.1021/bi00269a032; HEMPEL J, 1985, EUR J BIOCHEM, V153, P13, DOI 10.1111/j.1432-1033.1985.tb09260.x; HEMPEL J, 1989, BIOCHEMISTRY-US, V28, P1160, DOI 10.1021/bi00429a034; HEMPEL J, 1984, EUR J BIOCHEM, V141, P21, DOI 10.1111/j.1432-1033.1984.tb08150.x; HEMPEL J, 1989, ENZYMOLOGY MOL BIOL, V2, P3; HEMPEL J, 1987, ENZYMOLOGY MOL BIOL, P1; HORTON AA, 1975, ARCH BIOCHEM BIOPHYS, V167, P426, DOI 10.1016/0003-9861(75)90483-X; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JOHANSSON J, 1988, EUR J BIOCHEM, V172, P527, DOI 10.1111/j.1432-1033.1988.tb13920.x; JONES DE, 1988, P NATL ACAD SCI USA, V85, P1782, DOI 10.1073/pnas.85.6.1782; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KOIVULA T, 1975, BIOCHIM BIOPHYS ACTA, V397, P9, DOI 10.1016/0005-2744(75)90174-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; LINDAHL R, 1984, J BIOL CHEM, V259, P1986; LINDAHL R, 1982, CANCER RES, V42, P577; Maniatis T., 1982, MOL CLONING; MARJANEN L, 1972, BIOCHEM J, V127, P633, DOI 10.1042/bj1270633; MASAKI R, 1987, J CELL BIOL, V104, P1207, DOI 10.1083/jcb.104.5.1207; MASAKI R, 1990, Cell Structure and Function, V15, P444; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAKAYASU H, 1978, BIOCHEM BIOPH RES CO, V83, P697, DOI 10.1016/0006-291X(78)91045-8; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OKADA Y, 1982, EUR J BIOCHEM, V122, P393, DOI 10.1111/j.1432-1033.1982.tb05894.x; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OZOLS J, 1977, P NATL ACAD SCI USA, V74, P3725, DOI 10.1073/pnas.74.9.3725; RACHUBINSKI RA, 1980, J CELL BIOL, V84, P705, DOI 10.1083/jcb.84.3.705; ROBB RJ, 1978, J BIOL CHEM, V253, P5319; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBAHARA S, 1979, ARCH BIOCHEM BIOPHYS, V197, P607, DOI 10.1016/0003-9861(79)90285-6; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; TAKAGI Y, 1985, J BIOCHEM-TOKYO, V98, P1647, DOI 10.1093/oxfordjournals.jbchem.a135435; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOTTMAR SOC, 1973, BIOCHEM J, V135, P577, DOI 10.1042/bj1350577a; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; VONBAHRLINDSTROM H, 1985, BIOCHEMISTRY-US, V24, P5847, DOI 10.1021/bi00342a023; VONBAHRLINDSTROM H, 1984, EUR J BIOCHEM, V141, P37; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4	51	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19536	19542						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717467				2022-12-25	WOS:A1991GK66700062
J	MOTTRAM, JC; BELL, SD; NELSON, RG; BARRY, JD				MOTTRAM, JC; BELL, SD; NELSON, RG; BARRY, JD			TRANSFER-RNAS OF TRYPANOSOMA-BRUCEI - UNUSUAL GENE ORGANIZATION AND MITOCHONDRIAL IMPORTATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC ORGANIZATION; KINETOPLASTID PROTOZOA; DNA; TRANSCRIPTION; IDENTIFICATION; MAXICIRCLE; SEQUENCES; EVOLUTION; UNITS	In Trypanosoma brucei the U snRNA B gene (J. C. Mottram, K. L. Perry, P. M. Lizardi, R. Luhrmann, N. Agabian, and R. G. Nelson (1989) Mol. Cell. Biol. 9, 1212-1223) is very tightly linked with other small RNA genes coding for tRNA(ACG)Arg, tRNA(CUU)Lys, and a approximately 275-nucleotide RNA (RNA X) of unknown function. A similar genomic organization is found at the U6 snRNA locus, where the U6 gene is linked to tRNA(CGU)Thr and tRNA(GUA)Tyr genes. The tRNA(Lys) and tRNA(Arg) genes are members of a multigene family, whereas the tRNA(Thr) and tRNA(Tyr) genes are single copy. Two additional tRNA(CUU)Lys genes and one tRNA(UUU)Lys gene were also isolated and sequenced and, together with a sequence previously published (D. A. Campbell (1989) Nucleic Acids Res. 17, 9479), appear to represent the entire gene family. Probes for tRNA(Lys), tRNA(Arg), tRNA(Thr), and tRNA(Tyr) were found to hybridize with mitochondrial and cytoplasmic tRNAs but not with mitochondrial DNA. This supports the hypothesis that mitochondrial tRNAs may be nuclear-encoded and imported from the cytosol into the mitochondrion.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	MOTTRAM, JC (corresponding author), UNIV GLASGOW,INST GENET,WELLCOME UNIT MOLEC PARASITOL,CHURCH ST,GLASGOW G11 5JS,SCOTLAND.			Mottram, Jeremy/0000-0001-5574-3766; Bell, Stephen/0000-0002-8474-6592	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; AMSTUTZ H, 1985, CELL, V40, P879, DOI 10.1016/0092-8674(85)90347-2; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BENNE R, 1985, TRENDS GENET, V1, P117, DOI 10.1016/0168-9525(85)90044-7; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BORST P, 1979, BIOCHIM BIOPHYS ACTA, V565, P1, DOI 10.1016/0005-2787(79)90078-9; BUCKLAND RA, 1989, AM J HUM GENET, V45, P283; BUCKLAND RA, 1983, GENE, V22, P211, DOI 10.1016/0378-1119(83)90105-1; CAMPBELL DA, 1989, MOL BIOCHEM PARASIT, V37, P257, DOI 10.1016/0166-6851(89)90157-6; CAMPBELL DA, 1989, NUCLEIC ACIDS RES, V17, P9479, DOI 10.1093/nar/17.22.9479; DEVRIES BF, 1988, MOL BIOCHEM PARASIT, V27, P71, DOI 10.1016/0166-6851(88)90026-6; DIRHEIMER G, 1979, TRANSFER RNA STRUCTU, P19; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; HANCOCK K, 1990, J BIOL CHEM, V265, P19208; HAUKBER J, 1988, NUCLEIC ACIDS RES, V16, P10623; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; LENARDO MJ, 1985, GENE, V35, P131, DOI 10.1016/0378-1119(85)90165-9; Maniatis T., 1982, MOL CLONING; MICHELS PAM, 1986, J MOL EVOL, V24, P45, DOI 10.1007/BF02099950; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; MULLER F, 1987, NUCLEIC ACIDS RES, V11, P7695; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; SHIBUYA K, 1985, J BIOCHEM-TOKYO, V97, P1719, DOI 10.1093/oxfordjournals.jbchem.a135230; SIMPSON AM, 1989, NUCLEIC ACIDS RES, V17, P5427, DOI 10.1093/nar/17.14.5427; SIMPSON L, 1986, INT REV CYTOL, V99, P119; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; SIMPSON L, 1978, CELL, V14, P169, DOI 10.1016/0092-8674(78)90311-2; SIMPSON L, 1987, ANNU REV MICROBIOL, V41, P363, DOI 10.1146/annurev.mi.41.100187.002051; SPRINZL M, 1987, NUCLEIC ACIDS RES, V15, pR53, DOI 10.1093/nar/15.suppl.r53; SUTER B, 1988, MOL CELL BIOL, V8, P3322, DOI 10.1128/MCB.8.8.3322	30	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18313	18317						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1717447				2022-12-25	WOS:A1991GG55300090
J	PAJOR, AM; WRIGHT, EM				PAJOR, AM; WRIGHT, EM			CLONING AND FUNCTIONAL EXPRESSION OF A MAMMALIAN NA+ NUCLEOSIDE COTRANSPORTER - A MEMBER OF THE SGLT FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ESCHERICHIA-COLI; BRUSH-BORDER; NUCLEOTIDE-SEQUENCE; MEMBRANE-VESICLES; SYMPORT CARRIER; D-GLUCOSE; TRANSPORT; NA+/GLUCOSE; GENE; PROTEIN	Complementary DNAs encoding seven different proteins related to the rabbit intestinal Na+/glucose cotransporter, SGLT1, were isolated from a rabbit renal cDNA library at relatively high stringency. The messages for RK-B to RK-F were single mRNA species at 2.3 kilobases (kb) in heart and kidney. The message for RK-A was 4 kb and was found in brain, lung, intestine, liver, and kidney. RK-I mRNA was approximately 3 kb and was found in all tissues tested. The most abundant clone, RK-C, constituted nucleotides 66-2150 of the sodium-nucleoside cotransporter, SNST1. The 672-amino acid protein encoded by SNST1 is 61% identical and 80% similar in sequence to SGLT1. Expression of SNST1c in Xenopus oocytes resulted in nucleoside-stimulated Na-22 uptake and sodium-dependent [H-3]uridine uptake. The uptake of [H-3] uridine was inhibited by a range of nucleosides, including the anti-human immunodeficiency virus drug, dideoxycytidine. The results of this study show that there is a family of SGLT1-related proteins found in a wide variety of tissues and that one of these is a Na+/nucleoside cotransporter.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIDDK NIH HHS [DK19565] Funding Source: Medline; NINDS NIH HHS [NS09666] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009666] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BELARDINELLI L, 1989, PROG CARDIOVASC DIS, V32, P73, DOI 10.1016/0033-0620(89)90015-7; COADY MJ, 1990, ARCH BIOCHEM BIOPHYS, V283, P130, DOI 10.1016/0003-9861(90)90622-6; COADY MJ, 1990, AM J PHYSIOL, V259, pC605, DOI 10.1152/ajpcell.1990.259.4.C605; DEGUCHI Y, 1990, J BIOL CHEM, V265, P21704; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GELIEBTER J, 1989, FOCUS BRL, V9, P5; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; JARVIS SM, 1989, BIOCHIM BIOPHYS ACTA, V979, P132, DOI 10.1016/0005-2736(89)90533-6; KOZAK M, 1983, MICROBIOL REV, V47, P1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE CW, 1990, AM J PHYSIOL, V258, pF1203, DOI 10.1152/ajprenal.1990.258.5.F1203; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; TURNER RJ, 1982, AM J PHYSIOL, V242, pF406, DOI 10.1152/ajprenal.1982.242.4.F406; WILLIAMS TC, 1989, BIOCHEM J, V264, P223, DOI 10.1042/bj2640223; YAMATO I, 1990, J BIOL CHEM, V265, P2450; YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925	22	158	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3557	3560						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740408				2022-12-25	WOS:A1992HE60700002
J	BUTZ, H; STUHLSATZ, HW; MAIER, G; SCHWARTZALBIEZ, R				BUTZ, H; STUHLSATZ, HW; MAIER, G; SCHWARTZALBIEZ, R			SECRETED AND CELLULAR PROTEOCHONDROITIN SULFATES OF A HUMAN B-LYMPHOBLASTOID CELL-LINE CONTAIN DIFFERENT PROTEIN CORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVARIANT CHAIN; PROTEOGLYCAN SYNTHESIS; GRANULE PROTEOGLYCAN; LYMPHOCYTES-T; PEPTIDE CORE; CDNA; BIOSYNTHESIS; RECOGNITION; ENCODES	Proteoglycans of the human B lymphoblastoid cell line LICR-LON-HMy2 were metabolically labeled with [S-35]sulfate. High-density fractions of S-35-labeled material separated by CsCl gradient ultracentrifugation were further purified by anion exchange chromatography and gel filtration. Two proteoglycans, isolated from cell lysates and culture supernatants, were characterized by gel filtration and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in combination with enzymatic degradation. Treatment with chondroitinase AC completely degraded the glycosaminoglycan moiety of the proteoglycans. Three to 4 chondroitin sulfate chains (average molecular mass = 26 kDa) were estimated for each of the two proteoglycans. Differences between the proteochondroitin sulfates (CSPG) were observed in the content of N-linked oligosaccharides. After chondroitinase AC treatment the resulting band in SDS-PAGE of the secreted CSPG was sensitive to treatment with endoglycosidase F (Endo F) which further reduced the molecular mass from 30 to 21.5 kDa, whereas the band of the cellular CSPG after chondroitinase AC treatment (molecular mass = 30 kDa) remained resistant to Endo F treatment. The composition of amino acids was different in the protein cores, suggesting differences in the primary structure. Both CSPG contained a high percentage of glycine and serine. For both CSPG a molecular mass of approximately 135 kDa was deduced from the hydrodynamic sizes of the glycosaminoglycan chains obtained after alkaline/borohydride treatment and the migration of the protein/oligosaccharide complexes in SDS-PAGE. 75% of all [S-35]sulfate-labeled molecules were found in the culture supernatant and 25% in the cellular fraction. S-35-Labeled material in the culture supernatant consisted exclusively of intact CSPG, whereas S-35-labeled molecules in the cellular preparation consisted largely of free chondroitin sulfate chains. Only 8.3% of the cellular material, isolated from the microsomal fraction, was intact CSPG. In pulse-chase experiments maximal secretion of CSPG was found after 4 h, comprising approximately 40% of totally synthesized CSPG. From these experiments we tentatively conclude that a small proportion of CSPG synthesized by LICR-LON-HMy2 cells is membrane-associated, a larger portion is secreted, and another portion is intracellularly degraded.	GERMAN CANC RES CTR,INST IMMUNOL & GENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY; GERMAN CANC RES CTR,INST CELL & TUMORBIOL,W-6900 HEIDELBERG,GERMANY; RHEIN WESTFAL TH AACHEN,FAC MED,DEPT CLIN CHEM & PATHOBIOCHEM,W-5100 AACHEN,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); RWTH Aachen University								AVRAHAM S, 1988, J BIOL CHEM, V263, P7292; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BLAND CE, 1984, J IMMUNOL, V132, P1937; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOURDON MA, 1985, P NATL ACAD SCI USA, V82, P1321, DOI 10.1073/pnas.82.5.1321; CAPEAU J, 1978, BIOMEDICINE, V28, P124; EDWARDS PAW, 1982, EUR J IMMUNOL, V12, P641, DOI 10.1002/eji.1830120804; GIACOLETTO KS, 1986, J EXP MED, V164, P1422, DOI 10.1084/jem.164.5.1422; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HART GW, 1982, BIOCHEMISTRY-US, V21, P6088, DOI 10.1021/bi00267a010; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITT D, 1983, J CELL BIOL, V97, P351, DOI 10.1083/jcb.97.2.351; LEVITT D, 1987, CELL IMMUNOL, V110, P425, DOI 10.1016/0008-8749(87)90134-1; MACDERMOTT RP, 1985, J EXP MED, V162, P1771, DOI 10.1084/jem.162.6.1771; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MCQUILLAN DJ, 1989, J BIOL CHEM, V264, P13245; OEBEN M, 1987, BIOCHEM J, V248, P85, DOI 10.1042/bj2480085; RIDER CC, 1987, MOL IMMUNOL, V24, P963, DOI 10.1016/0161-5890(87)90007-1; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SCHWARTZALBIEZ R, 1988, BRIT J CANCER, V57, P569, DOI 10.1038/bjc.1988.130; SIVAK LE, 1987, J IMMUNOL, V138, P1319; STEVENS RL, 1988, J BIOL CHEM, V263, P7287; STEVENS RL, 1987, J IMMUNOL, V139, P22863; STEVENS RL, 1988, CURR TOP MICROBIOL I, V140, P93; STEWARD WP, 1990, BIOCHIM BIOPHYS ACTA, V1052, P416, DOI 10.1016/0167-4889(90)90151-3; STUHLSATZ HW, 1981, H-S Z PHYSIOL CHEM, V362, P841, DOI 10.1515/bchm2.1981.362.2.841	29	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3402	3408						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737794				2022-12-25	WOS:A1992HD15400090
J	SZANKASI, P; SMITH, GR				SZANKASI, P; SMITH, GR			A DNA EXONUCLEASE INDUCED DURING MEIOSIS OF SCHIZOSACCHAROMYCES-POMBE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUS MITOTIC RECOMBINATION; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; MEIOTIC RECOMBINATION; ESCHERICHIA-COLI; FISSION YEAST; RECBC ENZYME; DEFICIENT MUTANTS; ENDO-EXONUCLEASE	In meiotic cells of the fission yeast Schizosaccharomyces pombe, a DNA exonuclease activity increased approximately 5-fold after premeiotic S-phase and decreased to the initial level before the meiotic divisions. We have purified this activity, designated exonuclease I, to near homogeneity. The activity co-purified with a polypeptide with an apparent molecular weight of 36,000. With a linear double-stranded DNA substrate, exonuclease I degraded only the 5'-ended strand from each end to produce 3'-single-stranded tails. The enzyme also acted on nicked circular DNA with comparable affinity. The meiotic induction of exonuclease I and its mode of action, similar to that of recombination-promoting exonucleases from bacteria, suggest that exonuclease I is involved in meiotic homologous recombination in S. pombe.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center				Smith, Gerald/0000-0002-8747-1352	NIGMS NIH HHS [GM32194] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032194] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAHLER J, 1991, CURR GENET, V19, P445, DOI 10.1007/BF00312735; BARBOUR SD, 1970, P NATL ACAD SCI USA, V67, P128, DOI 10.1073/pnas.67.1.128; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BLAKESLEY RW, 1975, NATURE, V257, P421, DOI 10.1038/257421a0; BORTS RH, 1984, COLD SPRING HARB SYM, V49, P67, DOI 10.1101/SQB.1984.049.01.010; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CHOW TYK, 1988, MOL GEN GENET, V211, P41, DOI 10.1007/BF00338391; CHOW TYK, 1987, J BIOL CHEM, V262, P17659; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; DOLBERG M, 1991, EUR J BIOCHEM, V198, P783, DOI 10.1111/j.1432-1033.1991.tb16081.x; EISEN A, 1988, P NATL ACAD SCI USA, V85, P7481, DOI 10.1073/pnas.85.20.7481; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; FRASER D, 1953, J BIOL CHEM, V205, P291; GILLEN JR, 1981, J BACTERIOL, V145, P521, DOI 10.1128/JB.145.1.521-532.1981; GROSSENBACHERGRUNDER AM, 1985, CURR GENET, V10, P95, DOI 10.1007/BF00636473; GUTZ H, 1971, GENETICS, V69, P331; HALBROOK J, 1989, J BIOL CHEM, V264, P21403; IINO Y, 1985, P NATL ACAD SCI USA, V82, P2447, DOI 10.1073/pnas.82.8.2447; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; JOSEPH JW, 1983, J BIOL CHEM, V258, P418; JUCHERLAPATI R, 1988, GENETIC RECOMBINATIO, P575; KERR C, 1972, J BIOL CHEM, V247, P311; KERR C, 1975, VIROLOGY, V65, P281, DOI 10.1016/0042-6822(75)90031-8; KMIEC EB, 1983, CELL, V33, P857, DOI 10.1016/0092-8674(83)90028-4; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLE JW, 1967, J BIOL CHEM, V242, P679; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; MALONE RE, 1988, CURR GENET, V14, P211, DOI 10.1007/BF00376741; MALONE RE, 1991, GENETICS, V128, P79; MARYON E, 1991, MOL CELL BIOL, V11, P3268, DOI 10.1128/MCB.11.6.3268; MCLEOD M, 1986, EMBO J, V5, P3665, DOI 10.1002/j.1460-2075.1986.tb04697.x; MENEES TM, 1989, GENETICS, V123, P675; MITCHISON JMM, 1974, CELL CYCLE CONTROLS; Munz P, 1989, MOL BIOL FISSION YEA, P1; NIELSEN O, 1990, EMBO J, V9, P1401, DOI 10.1002/j.1460-2075.1990.tb08255.x; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PONTICELLI AS, 1989, GENETICS, V123, P45; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; RADDING CM, 1982, ANNU REV GENET, V16, P405, DOI 10.1146/annurev.ge.16.120182.002201; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; RESNICK MA, 1984, MOL CELL BIOL, V4, P2811, DOI 10.1128/MCB.4.12.2811; RESNICK MA, 1979, ADV RADIAT BIOL, V8, P175; Robinow C, 1989, MOL BIOL FISSION YEA, P273; Sambrook J, 1989, MOL CLONING LABORATO; SHULMAN MJ, 1970, J MOL BIOL, V52, P501, DOI 10.1016/0022-2836(70)90416-X; SMITH GR, 1984, COLD SPRING HARB SYM, V49, P485, DOI 10.1101/SQB.1984.049.01.055; STAHL FW, 1986, PROG NUCLEIC ACID RE, V33, P169, DOI 10.1016/S0079-6603(08)60023-9; STRATHERN JN, 1991, GENETICS, V127, P61; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WIEGAND RC, 1975, J BIOL CHEM, V250, P8848; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	58	104	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3014	3023						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737756				2022-12-25	WOS:A1992HD15400033
J	PETERSON, CB; SCHACHMAN, HK				PETERSON, CB; SCHACHMAN, HK			LONG-RANGE EFFECTS OF AMINO-ACID SUBSTITUTIONS IN THE CATALYTIC CHAIN OF ASPARTATE TRANSCARBAMOYLASE - LOCALIZED REPLACEMENTS IN THE CARBOXYL-TERMINAL ALPHA-HELIX CAUSE MARKED ALTERATIONS IN ALLOSTERIC PROPERTIES AND INTERSUBUNIT INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BISUBSTRATE ANALOG N-(PHOSPHONACETYL)-L-ASPARTATE; GLOBAL CONFORMATIONAL CHANGE; ESCHERICHIA-COLI; SCANNING CALORIMETRY; REGULATORY SUBUNITS; PROTEIN STABILITY; DOMAIN CLOSURE; SIMPLE-MODEL; BINDING; CARBAMOYLTRANSFERASE	A single alpha-helical polypeptide segment of 21 amino acids near the carboxyl terminus of the catalytic chain of aspartate transcarbamoylase from Escherichia coli has been shown recently to be important for the in vivo folding of the chains and assembly of the enzyme (Peterson, C. B., and Schachman, H. K. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 458-462). Calorimetric measurements on purified mutant enzymes showed that single amino acid replacements within this secondary structural element affect the overall thermal stability of the oligomeric enzyme and the energetics of the interactions between polypeptide chains within the holoenzyme. Studies presented here demonstrate that marked changes in cooperativity occur due to single amino acid substitutions. Replacement of Gln288 by either Ala or Glu leads to a striking increase in the Hill coefficient of the holoenzymes and a substantial increase in the aspartate concentration corresponding to one-half V(max). In contrast, the isolated catalytic trimers harboring these same substitutions were similar in activity to the wild-type subunit, with the same affinity for aspartate as indicated by the values of K(m). Substituting Ala for the only charged residue in the helix, Arg296, caused a marked reduction in enzyme activity, as well as a greatly reduced stability of the holoenzyme due to a substantial weakening of the interactions between the catalytic and regulatory subunits. A subunit exchange method was used to demonstrate the changes in interchain interactions resulting from the amino acid substitutions and to show the additional weakening upon the binding of the bisubstrate ligand, N-(phosphonacetyl)-L-aspartate, at the active sites. Taken together, the results on this series of mutant enzymes illustrate how the effects of single amino acid replacements in one element of secondary structure are propagated throughout the molecule to positions remote from the site of the substitution.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 WENDELL M STANLEY HALL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,VIRUS LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley					NIGMS NIH HHS [GM 11955, GM 12159] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM012159, R37GM012159, F32GM011955] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; BLACKBURN MN, 1977, BIOCHEMISTRY-US, V16, P5084, DOI 10.1021/bi00642a022; BOTHWELL MA, 1980, J BIOL CHEM, V255, P1971; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; BURNS DL, 1982, J BIOL CHEM, V257, P8648; BURNS DL, 1982, J BIOL CHEM, V257, P8638; BURZ DS, 1990, BIOPHYS CHEM, V37, P31, DOI 10.1016/0301-4622(90)88005-D; CHAN WWC, 1975, J BIOL CHEM, V250, P668; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; COMPTON JG, 1979, THESIS U CALIFORNIA; DAVIES GE, 1970, J BIOL CHEM, V245, P1175; EDGE V, 1988, BIOCHEMISTRY-US, V27, P8081, DOI 10.1021/bi00421a017; EDGE V, 1985, BIOCHEMISTRY-US, V24, P5899, DOI 10.1021/bi00342a032; EISENSTEIN E, 1990, BIOCHEMISTRY-US, V29, P3724, DOI 10.1021/bi00467a019; EISENSTEIN E, 1989, P NATL ACAD SCI USA, V86, P3094, DOI 10.1073/pnas.86.9.3094; EVANS DR, 1979, J BIOL CHEM, V254, P679; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; GERHART JC, 1968, BIOCHEMISTRY-US, V7, P538, DOI 10.1021/bi00842a600; GERHART JC, 1965, BIOCHEMISTRY-US, V4, P1054, DOI 10.1021/bi00882a012; HONZATKO RB, 1982, J MOL BIOL, V160, P219, DOI 10.1016/0022-2836(82)90175-9; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5091, DOI 10.1021/bi00642a023; JOVIN T, 1964, ANAL BIOCHEM, V9, P351, DOI 10.1016/0003-2697(64)90192-7; KE HM, 1988, J MOL BIOL, V204, P725, DOI 10.1016/0022-2836(88)90365-8; KIM KH, 1987, J MOL BIOL, V196, P853, DOI 10.1016/0022-2836(87)90410-4; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P268, DOI 10.1021/bi00401a041; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; MEIGHEN EA, 1970, P NATL ACAD SCI USA, V65, P234, DOI 10.1073/pnas.65.1.234; MIDDLETON SA, 1989, BIOCHEMISTRY-US, V28, P1617, DOI 10.1021/bi00430a029; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NEWELL JO, 1990, BIOPHYS CHEM, V37, P183, DOI 10.1016/0301-4622(90)88018-N; NEWELL JO, 1989, J BIOL CHEM, V264, P2476; NEWTON CJ, 1990, BIOCHEMISTRY-US, V29, P1444, DOI 10.1021/bi00458a015; PAKULA AA, 1989, ANNU REV GENET, V23, P289, DOI 10.1146/annurev.ge.23.120189.001445; PETERSON CB, 1991, P NATL ACAD SCI USA, V88, P458, DOI 10.1073/pnas.88.2.458; REIDHAAROLSON JF, 1990, PROTEINS, V7, P306, DOI 10.1002/prot.340070403; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; SUBRAMANI S, 1977, P NATL ACAD SCI USA, V74, P3777, DOI 10.1073/pnas.74.9.3777; VICKERS LP, 1984, J BIOL CHEM, V259, P1027; WENTE SR, 1991, J BIOL CHEM, V266, P20833; WERNER WE, 1989, J MOL BIOL, V206, P221, DOI 10.1016/0022-2836(89)90535-4; WILDE JA, 1988, BIOCHEMISTRY-US, V27, P4127, DOI 10.1021/bi00411a033; Yang Y R, 1978, Methods Enzymol, V51, P35; YANG YR, 1987, ANAL BIOCHEM, V163, P188, DOI 10.1016/0003-2697(87)90111-4	49	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2443	2450						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733944				2022-12-25	WOS:A1992HB53200052
J	KIMSEY, HH; KAISER, D				KIMSEY, HH; KAISER, D			THE OROTIDINE-5'-MONOPHOSPHATE DECARBOXYLASE GENE OF MYXOCOCCUS-XANTHUS - COMPARISON TO THE OMP DECARBOXYLASE GENE FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRBI OPERON EXPRESSION; ESCHERICHIA-COLI K-12; NUCLEOTIDE-SEQUENCE; OROTIDINE-5'-PHOSPHATE DECARBOXYLASE; TRANSCRIPTION TERMINATION; SALMONELLA-TYPHIMURIUM; MOLECULAR ANALYSIS; RNA SEQUENCES; UMP SYNTHASE; ACID	The nucleotide sequence of the Myxococcus xanthus orotidine-5'-monophosphate decarboxylase (OMP DCase) gene was determined. The derived protein sequence is not closely related to other prokaryotic OMP DCase sequences; nor is it closely related to any eukarYotic OMP DCase sequences. Progressive multiple alignment of the M. xanthus OMP DCase protein sequence with 19 other OMP DCase sequences revealed four conserved regions present in all 20 sequences. Ten entirely conserved residues were found in these four regions and one region contains a tight cluster of 5 conserved residues, certain of which may be catalytically active residues. A second open reading frame was found upstream of uraA and oriented in the same direction as uraA. A stretch of 21 consecutive pyrimidine (C or T) residues were found in the intercistronic region between the potential ribosome-binding site of uraA and the UGA stop codon of the upstream open reading frame. RNA directly upstream of the pyrimidine run, including the UGA stop codon of the upstream open reading frame, could be folded into a stable hairpin structure resembling Rho-independent terminators of Escherichia coli. Expression of the uraA gene may be regulated by an intercistronic transcription termination mechanism.	STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305	Stanford University					NIGMS NIH HHS [GM23441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023441, R37GM023441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BEAK P, 1976, J AM CHEM SOC, V98, P3601, DOI 10.1021/ja00428a035; BERGES T, 1990, NUCLEIC ACIDS RES, V18, P7183, DOI 10.1093/nar/18.23.7183; BIBB MJ, 1984, GENE AMST, V30, P1; BONEKAMP F, 1984, EMBO J, V3, P2857, DOI 10.1002/j.1460-2075.1984.tb02220.x; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; CANTORAL JM, 1988, NUCLEIC ACIDS RES, V16, P8177, DOI 10.1093/nar/16.16.8177; CARTER PW, 1985, J BACTERIOL, V162, P943, DOI 10.1128/JB.162.3.943-949.1985; CHRISTIE GE, 1981, P NATL ACAD SCI-BIOL, V78, P4180, DOI 10.1073/pnas.78.7.4180; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P1; DIAZMINGUEZ JM, 1990, MOL GEN GENET, V224, P269, DOI 10.1007/BF00271561; DOOLITTLE RF, 1987, URFS ORFS PRIMER ANA, P18; FARNHAM PJ, 1981, NUCLEIC ACIDS RES, V9, P563, DOI 10.1093/nar/9.3.563; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; FOX GE, 1980, SCIENCE, V209, P457, DOI 10.1126/science.6771870; FROELIGER EH, 1989, GENE, V83, P387, DOI 10.1016/0378-1119(89)90127-3; GOLD L, 1987, ESCHERICHIA COLI SAL, V2, P1654; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; HAGEN TJ, 1990, J BACTERIOL, V172, P15, DOI 10.1128/JB.172.1.15-23.1990; HEILMANN HJ, 1988, EUR J BIOCHEM, V174, P485, DOI 10.1111/j.1432-1033.1988.tb14124.x; JACQUET M, 1988, MOL GEN GENET, V211, P441, DOI 10.1007/BF00425698; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KIMSEY HH, 1991, J BACTERIOL, V173, P6790, DOI 10.1128/jb.173.21.6790-6797.1991; KRONSTAD JW, 1989, GENE, V79, P97, DOI 10.1016/0378-1119(89)90095-4; LAMPEL KA, 1986, J BACTERIOL, V166, P238, DOI 10.1128/jb.166.1.238-243.1986; LEVIN HL, 1985, P NATL ACAD SCI USA, V82, P4643, DOI 10.1073/pnas.82.14.4643; LIU CG, 1989, J BACTERIOL, V171, P3337, DOI 10.1128/jb.171.6.3337-3342.1989; LOSBERGER C, 1989, CURR GENET, V16, P153, DOI 10.1007/BF00391471; LUDWIG W, 1983, ARCH MICROBIOL, V135, P58, DOI 10.1007/BF00419483; LYNN SP, 1988, J BIOL CHEM, V263, P472; MCCLEARY WR, 1990, J BACTERIOL, V172, P4877, DOI 10.1128/jb.172.9.4877-4887.1990; MESBAH M, 1989, INT J SYST BACTERIOL, V39, P159, DOI 10.1099/00207713-39-2-159; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEI M, 1987, MOL EVOLUTIONARY GEN, P8; NEWBURY SF, 1986, GENE AMST, V43, P1; OAKLEY BR, 1987, GENE, V61, P385, DOI 10.1016/0378-1119(87)90201-0; OHMSTEDE CA, 1986, J BIOL CHEM, V261, P4276; OYAIZU H, 1985, SYST APPL MICROBIOL, V6, P257, DOI 10.1016/S0723-2020(85)80028-X; QUINN CL, 1991, J BIOL CHEM, V266, P9113; ROLAND KL, 1985, J BACTERIOL, V163, P991, DOI 10.1128/JB.163.3.991-999.1985; ROSELLI PL, 1984, J MOL LIQ, V29, P1, DOI 10.1016/0167-7322(84)80031-8; SALSER W, 1977, COLD SPRING HARB SYM, V42, P985; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUSTER JR, 1987, NUCLEIC ACIDS RES, V15, P8573, DOI 10.1093/nar/15.20.8573; SUTTLE DP, 1988, P NATL ACAD SCI USA, V85, P1754, DOI 10.1073/pnas.85.6.1754; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THEISEN M, 1987, EUR J BIOCHEM, V164, P613, DOI 10.1111/j.1432-1033.1987.tb11171.x; TURNBOUGH CL, 1983, P NATL ACAD SCI-BIOL, V80, P368, DOI 10.1073/pnas.80.2.368; TURNBOUGH CL, 1987, J BIOL CHEM, V262, P10239; VIAN A, 1989, NUCLEIC ACIDS RES, V17, P8874, DOI 10.1093/nar/17.21.8874; VIERA J, 1987, METHOD ENZYMOL, V153, P3; WILLIAMS S A, 1986, Biotechniques, V4, P138; WILSON LJ, 1988, NUCLEIC ACIDS RES, V16, P2339, DOI 10.1093/nar/16.5.2339; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	55	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					819	824						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730672				2022-12-25	WOS:A1992GY96000024
J	LANDRY, J; LAMBERT, H; ZHOU, M; LAVOIE, JN; HICKEY, E; WEBER, LA; ANDERSON, CW				LANDRY, J; LAMBERT, H; ZHOU, M; LAVOIE, JN; HICKEY, E; WEBER, LA; ANDERSON, CW			HUMAN HSP27 IS PHOSPHORYLATED AT SERINES-78 AND SERINES-82 BY HEAT-SHOCK AND MITOGEN-ACTIVATED KINASES THAT RECOGNIZE THE SAME AMINO-ACID MOTIF AS S6 KINASE-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN STRESS PROTEINS; EHRLICH ASCITES TUMOR; CHINESE-HAMSTER-CELLS; ALPHA-CRYSTALLIN; DROSOPHILA-MELANOGASTER; RIBOSOMAL PROTEIN-S6; GROWTH-FACTOR; RODENT CELLS; HELA-CELLS; 27 KDA	The intracellular concentration of the 27-kDa mammalian heat shock protein, HSP27, increases several-fold after heat and other metabolic stresses and is closely associated with the acquisition of thermotolerance. Posttranslational modifications may also affect the function of HSP27. Heat shock of HeLa cell cultures, or treatment with arsenite, phorbol ester, or tumor necrosis factor, caused a rapid phosphorylation of preexisting HSP27 and the appearance of three phosphorylated isoforms, HSP27 B, C, and D. Digestion with trypsin and fractionation of the peptides by reverse phase high performance liquid chromatography revealed three P-32-labeled phosphopeptides. Microsequence analysis identified peak I as Ala76-Leu77-Ser78-Arg79 and peak II as Gln80-Leu81-Ser82-Ser83-Gly84-Val85-Ser86-Glu87-Ile88-Arg89 peak III contained the undigested peptide pair Ala76-Arg89. Ser82 was the major site and Ser78 the minor site of phosphorylation. Mutant proteins with Ser78 or Ser82 altered to glycine or Ser78-Ser82 double mutants were phosphorylated to reduced extents in vivo after heat or arsenite treatment. Ser78 and Ser82 (and Ser15) occur in the sequence motif RXXS, which is recognized by ribosomal protein S6 kinase II. Mitogenic stimulation of serum-deprived, G(o)-arrested Chinese hamster cells with serum, thrombin, or fibroblast growth factor also stimulated phosphorylation of HSP27 Ser78 and Ser82, and mitogenic stimulation and heat shock activated protein kinase activities that phosphorylated HSP27 and protein S6 in vitro. These results suggest that HSP27 may exert phosphorylation-activated functions linked with growth signaling pathways in unstressed cells. A homeostatic function at this level could protect cells from adverse effects of signal transduction systems which may be activated inappropriately during stress.	UNIV NEVADA, DEPT BIOL, RENO, NV 89557 USA; BROOKHAVEN NATL LAB, DEPT BIOL, UPTON, NY 11973 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; United States Department of Energy (DOE); Brookhaven National Laboratory	LANDRY, J (corresponding author), UNIV LAVAL, HOTEL DIEU QUEBEC, CTR CANCEROL, 11 COTE DU PALAIS, QUEBEC CITY G1R 2J6, QUEBEC, CANADA.			Lavoie, Josee N/0000-0001-6912-1132	NIGMS NIH HHS [GM43167] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043167] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON CW, 1982, GENETIC ENG PRINCIPL, V4, P147; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; ARRIGO AP, 1991, HEAT SHOCK DEV, P106; BURGER M, 1989, EUR J BIOCHEM, V183, P255, DOI 10.1111/j.1432-1033.1989.tb14921.x; CALDERWOOD SK, 1987, J CELL PHYSIOL, V130, P369, DOI 10.1002/jcp.1041300309; CALDERWOOD SK, 1985, BIOCHEM BIOPH RES CO, V126, P911, DOI 10.1016/0006-291X(85)90272-4; CHAMBARD JC, 1983, J BIOL CHEM, V258, P1706; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHIESA R, 1987, BIOCHEM BIOPH RES CO, V144, P1340, DOI 10.1016/0006-291X(87)91457-4; CHRETIEN P, 1988, J CELL PHYSIOL, V137, P157, DOI 10.1002/jcp.1041370119; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CRETE P, 1990, RADIAT RES, V121, P320, DOI 10.2307/3577783; DARBON JM, 1990, BIOCHEM BIOPH RES CO, V168, P527, DOI 10.1016/0006-291X(90)92353-2; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DRUMMOND IAS, 1986, MOL CELL BIOL, V6, P1767, DOI 10.1128/MCB.6.5.1767; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; ERIKSON E, 1988, SEC MESS PHOSPHOPROT, V12, P135; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FORNACE AJ, 1986, NUCLEIC ACIDS RES, V14, P5793, DOI 10.1093/nar/14.14.5793; FUQUA SAW, 1989, CANCER RES, V49, P4126; GAESTEL M, 1991, J BIOL CHEM, V266, P14721; GAESTEL M, 1989, EUR J BIOCHEM, V179, P209, DOI 10.1111/j.1432-1033.1989.tb14542.x; GROSE JH, 1990, ADV PROSTAGLANDIN TH, V21, P145; HAASS C, 1990, J CELL SCI, V96, P413; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KIM YJ, 1984, MOL CELL BIOL, V4, P468, DOI 10.1128/MCB.4.3.468; KRAMPS JA, 1977, FEBS LETT, V74, P82, DOI 10.1016/0014-5793(77)80757-6; KRIEG J, 1988, METHOD ENZYMOL, V164, P575; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1982, CANCER RES, V42, P2457; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LARSSON R, 1988, J BIOL CHEM, V263, P17452; LAVOIE J, 1990, NUCLEIC ACIDS RES, V18, P1637, DOI 10.1093/nar/18.6.1637; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LEVIN EG, 1991, J BIOL CHEM, V266, P174; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; OESTERREICH S, 1990, BIOMED BIOCHIM ACTA, V49, P219; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAULI D, 1990, J CELL BIOL, V111, P817, DOI 10.1083/jcb.111.3.817; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; REGAZZI R, 1988, BIOCHEM BIOPH RES CO, V152, P62, DOI 10.1016/S0006-291X(88)80680-6; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBAYE B, 1989, BIOCHEM BIOPH RES CO, V163, P301, DOI 10.1016/0006-291X(89)92135-9; SCHUTZE S, 1989, J BIOL CHEM, V264, P3562; STRAHLER JR, 1991, BIOCHEM BIOPH RES CO, V175, P134, DOI 10.1016/S0006-291X(05)81211-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUBJECK JR, 1982, HEAT SHOCK BACTERIA, P405; TAS PWL, 1987, EUR J BIOCHEM, V163, P553, DOI 10.1111/j.1432-1033.1987.tb10903.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VITEK MP, 1984, J MOL BIOL, V178, P173, DOI 10.1016/0022-2836(84)90138-4; WELCH WJ, 1985, J BIOL CHEM, V260, P3058; WETTENHALL REH, 1982, FEBS LETT, V148, P207, DOI 10.1016/0014-5793(82)80809-0; WETTENHALL REH, 1983, FEBS LETT, V162, P171, DOI 10.1016/0014-5793(83)81072-2; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WISTOW G, 1985, FEBS LETT, V181, P1, DOI 10.1016/0014-5793(85)81102-9; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; ZANTEMA A, 1989, J VIROL, V63, P3368, DOI 10.1128/JVI.63.8.3368-3375.1989	68	425	441	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					794	803						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730670				2022-12-25	WOS:A1992GY96000021
J	SMITH, DF; STENSGARD, BA; WELCH, WJ; TOFT, DO				SMITH, DF; STENSGARD, BA; WELCH, WJ; TOFT, DO			ASSEMBLY OF PROGESTERONE-RECEPTOR WITH HEAT-SHOCK PROTEINS AND RECEPTOR ACTIVATION ARE ATP MEDIATED EVENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TRANSFORMING PROTEIN; GLUCOCORTICOID-RECEPTOR; BINDING-PROTEIN; MONOCLONAL-ANTIBODIES; 59-KILODALTON PROTEIN; STEROID-RECEPTORS; CHICKEN OVIDUCT; MOLYBDATE; RECONSTITUTION; COMPLEX	To better understand assembly mechanisms of progesterone receptor (PR) complexes, we have developed a cell-free system for studying PR interactions with the 90- and 70-kDa heat shock proteins (hsp90 and hsp70), and we have used this system to examine requirements for hsp90 binding to PR. Purified chick PR, free of hsp90 and immobilized on an antibody affinity resin, will rebind hsp90 in rabbit reticulocyte lysate when several conditions are met. These include: 1) absence of progesterone, 2) elevated temperature (30-degrees-C), 3) presence of ATP, and 4) presence of Mg2+. We have obtained maximal hsp90 binding to receptor when lysate is supplemented with 3 mm MgCl2 and an ATP-regenerating system. ATP depletion of lysate by dialysis or by enzymatic means blocks hsp90 binding to PR; likewise, addition of EDTA to lysate blocks hsp90 binding, but binding is restored by the addition of excess Mg2+. Addition to lysate of monoclonal antibody against hsp70 inhibits hsp90 binding to PR and destabilizes preformed complexes. Stabilization of hsp90-receptor complexes also requires ATP, indicating that ATP and hsp70 are needed to form and to maintain hsp90 complexes. Hormone-dependent activation of reconstituted receptor complexes was also examined. The addition of progesterone to the reticulocyte lysate promotes dissociation of hsp90 and hsp70 from the receptor. This also appears to require ATP and dissociation is most efficient in the presence of an ATP-regenerating system. In conclusion, these studies indicate that PR-hsp90 complexes do not self-assemble; instead, assembly is probably a multistep process requiring ATP and other cellular factors.	MAYO CLIN & MAYO GRAD SCH MED,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	Mayo Clinic; University of California System; University of California San Francisco; University of California System; University of California San Francisco					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD009140, R01HD018287] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 18287, HD 09140] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; DAHMER MK, 1981, J BIOL CHEM, V256, P9401; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DENIS M, 1989, J BIOL CHEM, V264, P6005; DENIS M, 1987, J BIOL CHEM, V262, P11803; Ellis R J, 1990, Semin Cell Biol, V1, P1; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; IANNOTTI AM, 1988, ARCH BIOCHEM BIOPHYS, V264, P54, DOI 10.1016/0003-9861(88)90569-3; INANO K, 1990, FEBS LETT, V267, P157, DOI 10.1016/0014-5793(90)80313-8; KANG HS, 1991, J BIOL CHEM, V266, P5643; KOST SL, 1989, MOL CELL BIOL, V9, P3829, DOI 10.1128/MCB.9.9.3829; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MENDEL DB, 1986, J BIOL CHEM, V261, P3758; NAKO K, 1985, CAN J BIOCHEM CELL B, V63, P33; NISHIGORI H, 1980, BIOCHEMISTRY-US, V19, P77, DOI 10.1021/bi00542a012; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRATT WB, 1987, J CELL BIOCHEM, V35, P51, DOI 10.1002/jcb.240350105; RENOIR JM, 1984, BIOCHEMISTRY-US, V23, P6016, DOI 10.1021/bi00320a018; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SANCHEZ ER, 1990, J BIOL CHEM, V265, P22067; SANCHEZ ER, 1987, J BIOL CHEM, V262, P6986; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SCHLESINGER MJ, 1990, J BIOL CHEM, V265, P12111; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; SULLIVAN WP, 1985, BIOCHEMISTRY-US, V24, P4214, DOI 10.1021/bi00336a060; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043	38	171	172	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1350	1356						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730655				2022-12-25	WOS:A1992GY96000105
J	BOHM, S				BOHM, S			IDENTIFICATION OF PROTEIN-BINDING SEQUENCES MEDIATING CONSTITUTIVE AND 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED VL30 TRANSCRIPTION IN CULTURED MOUSE AND HUMAN KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; LONG TERMINAL REPEATS; RAS ONCOGENE; TUMOR PROMOTERS; KINASE-C; BALB/MK KERATINOCYTES; MURINE KERATINOCYTES; GENE-EXPRESSION; PHORBOL ESTERS	A retrovirus-like 30S (VL30) gene induced in mouse epidermis after a single application of 12-O-tetradecanoylphorbol-13-acetate (TPA) was used as a model gene to define mechanisms of transcriptional regulation in keratinocytes. Sequences important for TPA and epidermal growth factor-induced transcription were found to be separated from each other within the long terminal repeat. Deletion mapping of the long terminal repeat region and linking short sequences to a heterologous promoter made it possible to identify a 28-base pair VL30 TPA-responsive element. VL30 TPA-responsive element mediated both basal and TPA-induced transcription in the mouse keratinocyte cell line Balb/MK and in normal human keratinocytes. Gel-retardation and transient transfection experiments indicated that two nuclear factors (VLX and VLY) bind independently to the VL30 TPA-responsive element in juxtaposed positions and that the binding sites collaborate functionally in constitutive and TPA-induced transcription. The sequence involved in VLY binding shows no homology to previously identified binding motifs. Two different sequences involved in mediating TPA-induced transcription of the urokinase plasminogen activator and of the c-jun gene, respectively, competed for proteins with affinity toward the VLX binding site. No competition was found with sequences containing the consensus AP-1 binding site.			BOHM, S (corresponding author), KAROLINSKA INST,CTR BIOTECHNOL,NOVUM,BLICKAGANGEN 6,S-14157 HUDDINGE,SWEDEN.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAILLEUL B, 1990, CELL, V62, P697, DOI 10.1016/0092-8674(90)90115-U; BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BERGHARD A, 1990, J BIOL CHEM, V265, P21086; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BOHM S, 1990, CANCER RES, V50, P1626; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNAN JK, 1975, IN VITRO CELL DEV B, V11, P354, DOI 10.1007/BF02616371; CARTER AT, 1988, BIOCHIM BIOPHYS ACTA, V951, P130, DOI 10.1016/0167-4781(88)90033-4; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFINO P, 1988, NUCLEIC ACIDS RES, V16, P2731, DOI 10.1093/nar/16.6.2731; EATON L, 1990, NUCLEIC ACIDS RES, V18, P2069, DOI 10.1093/nar/18.8.2069; FALCO JP, 1988, ONCOGENE, V2, P573; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HODGSON CP, 1983, MOL CELL BIOL, V3, P2221, DOI 10.1128/MCB.3.12.2221; HOROWITZ JM, 1987, J VIROL, V61, P701, DOI 10.1128/JVI.61.3.701-707.1987; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; ITIN A, 1986, MOL CELL BIOL, V6, P1276, DOI 10.1128/MCB.6.4.1276; JOHNSON LD, 1985, P NATL ACAD SCI USA, V82, P1896, DOI 10.1073/pnas.82.7.1896; KAWAJIRI K, 1986, EUR J BIOCHEM, V159, P219, DOI 10.1111/j.1432-1033.1986.tb09857.x; KESHET E, 1981, NATURE, V289, P83, DOI 10.1038/289083a0; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENORMAND P, 1990, CELL GROWTH DIFFER, V1, P627; LUCIBELLO F C, 1989, Methods in Molecular and Cellular Biology, V1, P9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MOSCAT J, 1988, MOL ENDOCRINOL, V2, P799, DOI 10.1210/mend-2-9-799; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PERL A, 1989, NUCLEIC ACIDS RES, V17, P6841, DOI 10.1093/nar/17.17.6841; PERSONS DA, 1991, CELL GROWTH DIFFER, V2, P7; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RAICK AN, 1973, CANCER RES, V33, P269; REINERS JJ, 1983, CELL, V32, P247, DOI 10.1016/0092-8674(83)90515-9; RODLAND KD, 1988, MOL CELL BIOL, V8, P2247, DOI 10.1128/MCB.8.5.2247; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; ROTMAN G, 1986, NUCLEIC ACIDS RES, V14, P645, DOI 10.1093/nar/14.2.645; SAKURAI M, 1988, P NATL ACAD SCI USA, V85, P6909, DOI 10.1073/pnas.85.18.6909; Sambrook J, 1989, MOL CLONING LABORATO; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; TIMMERS HT, 1990, NUCLEIC ACIDS RES, V18, P23, DOI 10.1093/nar/18.1.23; TSONIS PA, 1988, NUCLEIC ACIDS RES, V16, P7745, DOI 10.1093/nar/16.15.7745; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WEISSMAN B, 1985, MOL CELL BIOL, V5, P3386, DOI 10.1128/MCB.5.12.3386	55	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24834	24841						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722214				2022-12-25	WOS:A1991GW84500089
J	BOTHWELL, ALM; BALLARD, DW; PHILBRICK, WM; LINDWALL, G; MAHER, SE; BRIDGETT, MM; JAMISON, SF; GARCIABLANCO, MA				BOTHWELL, ALM; BALLARD, DW; PHILBRICK, WM; LINDWALL, G; MAHER, SE; BRIDGETT, MM; JAMISON, SF; GARCIABLANCO, MA			MURINE POLYPYRIMIDINE TRACT BINDING-PROTEIN - PURIFICATION, CLONING, AND MAPPING OF THE RNA-BINDING DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; 3' SPLICE-SITE; SEX-LETHAL; SEQUENCE; GENE; IDENTIFICATION; INTRONS; YEAST; EXPRESSION	A complex of nucleic acid binding proteins (100, 35, and 25 kDa) was purified to apparent homogeneity from nuclear extracts of the murine plasmacytoma J558L. Amino-terminal sequence analysis of the 25-kDa subunit enabled the isolation of a cDNA that encodes a 528-amino acid protein that is highly homologous to the human 62-kDa human polypyrimidine tract binding protein (PTB) (Garcia-Blanco, M. A., Jamison, S. F., and Sharp, P. A. (1989) Genes & Dev. 3, 1874-1886; Gil, A., Sharp, P. A., Jamison, S. F., and Garcia-Blanco, M. A. (1991) Genes & Dev. 5, 1224-1236; Patton, J. G., Mayer, S. A., Tempst, P., and Nadal-Ginard, B. (1991) Genes & Dev. 5, 1237-1251). Sequence comparison programs suggested the presence of domains related to the RNA recognition motif found in other RNA-binding proteins, and deletion analysis revealed that the carboxyl-terminal 195 amino acids of the recombinant PTB was sufficient for specific binding to pre-mRNAs. Cross-linking experiments identified a 25-kDa protein in crude nuclear extracts of J558L cells that possessed the RNA binding properties of PTB, while a approximately 60-kDa protein is detected in other murine cell lines tested. Thus, the 25-kDa protein found in J558L is likely a proteolytic product of the murine polypyrimidine tract binding protein. A probe derived from the PTB cDNA detected a ubiquitous 3.3-kb mRNA in murine cell lines and a 3.6-kb mRNA in human lines. Southern blot analysis revealed three strongly hybridizing DNA fragments and several more weakly hybridizing bands in mouse, human, and yeast DNA. The role of PTB in pre-mRNA splicing is discussed.	YALE UNIV, SCH MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; DUKE UNIV, MED CTR, DEPT MICROBIOL & IMMUNOL, CELL GROWTH REGULAT & ONCOGENESIS SECT, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA	Howard Hughes Medical Institute; Yale University; Duke University; Duke University	BOTHWELL, ALM (corresponding author), YALE UNIV, SCH MED, IMMUNOBIOL SECT, NEW HAVEN, CT 06510 USA.							ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; ANDERSON GJ, 1989, NATURE, V342, P819, DOI 10.1038/342819a0; BALLARD DW, 1988, J BIOL CHEM, V263, P8450; BALLARD DW, 1986, P NATL ACAD SCI USA, V83, P9626, DOI 10.1073/pnas.83.24.9626; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; Bothwell A., 1990, METHODS CLONING ANAL; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; FU XY, 1988, EMBO J, V7, P809, DOI 10.1002/j.1460-2075.1988.tb02879.x; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GARCIABLANCO MA, 1990, P NATL ACAD SCI USA, V87, P3082, DOI 10.1073/pnas.87.8.3082; GERKE V, 1986, CELL, V47, P973, DOI 10.1016/0092-8674(86)90812-3; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; JIN W, 1990, NUCLEIC ACIDS RES, V18, P5995, DOI 10.1093/nar/18.20.5995; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; MOUNT SM, 1981, NUCLEIC ACIDS RES, V9, P6351, DOI 10.1093/nar/9.23.6351; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PINOLROMA S, 1989, J CELL BIOL, V109, P2575, DOI 10.1083/jcb.109.6.2575; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; RUSKIN B, 1985, CELL, V43, P131, DOI 10.1016/0092-8674(85)90018-2; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; TAZI J, 1986, CELL, V47, P755, DOI 10.1016/0092-8674(86)90518-0; TOLLERVEY D, 1987, EMBO J, V6, P469, DOI 10.1002/j.1460-2075.1987.tb04777.x; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	42	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24657	24663						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722210				2022-12-25	WOS:A1991GW84500065
J	LEONE, AM; PALMER, RMJ; KNOWLES, RG; FRANCIS, PL; ASHTON, DS; MONCADA, S				LEONE, AM; PALMER, RMJ; KNOWLES, RG; FRANCIS, PL; ASHTON, DS; MONCADA, S			CONSTITUTIVE AND INDUCIBLE NITRIC-OXIDE SYNTHASES INCORPORATE MOLECULAR-OXYGEN INTO BOTH NITRIC-OXIDE AND CITRULLINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; L-ARGININE; GLUCOCORTICOIDS INHIBIT; MACROPHAGE OXIDATION; ENDOTHELIAL-CELLS; NITROGEN-OXIDES; MECHANISM; INDUCTION; ENDOTOXIN; NITRATE	Nitric oxide (NO) is synthesized by a number of cells from a guanidino nitrogen atom of L-arginine by the action of either constitutive or inducible NO synthases, both of which form citrulline as a co-product. We have determined the source of the oxygen in both NO and in citrulline formed by the constitutive NO synthase from the vascular endothelium and brain and by the inducible NO synthase from the murine macrophage cell line J774. All these enzymes incorporate molecular oxygen both into NO and into citrulline. Furthermore, activated J774 cells form NO from omega-hydroxyl-L-arginine, confirming the proposal that this compound is an intermediate in the biosynthesis of NO.	WELLCOME RES LABS, LANGLEY COURT, BECKENHAM BR3 3BS, KENT, ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories	MONCADA, S (corresponding author), WELLCOME RES LABS, LANGLEY COURT, BECKENHAM BR3 3BS, KENT, ENGLAND.							BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; DEMASTER EG, 1989, BIOCHEM BIOPH RES CO, V163, P527, DOI 10.1016/0006-291X(89)92169-4; FERGUSON JH, 1975, N NITROSO COMPOUNDS, P90; GRYGLEWSKI RJ, 1986, BRIT J PHARMACOL, V87, P685, DOI 10.1111/j.1476-5381.1986.tb14586.x; HIBBS JB, 1987, J IMMUNOL, V138, P550; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; HIBBS JB, 1990, INT CONGR SER, V897, P189; IYENGAR R, 1987, P NATL ACAD SCI USA, V84, P6369, DOI 10.1073/pnas.84.18.6369; KNOWLES RG, 1990, BIOCHEM J, V269, P207, DOI 10.1042/bj2690207; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; KWON NS, 1989, J BIOL CHEM, V264, P20496; KWON NS, 1990, J BIOL CHEM, V265, P13442; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCCALL TB, 1989, BIOCHEM J, V261, P293, DOI 10.1042/bj2610293; MCCALL TB, 1991, BRIT J PHARMACOL, V102, P234, DOI 10.1111/j.1476-5381.1991.tb12159.x; MULSCH A, 1989, N-S ARCH PHARMACOL, V340, P767; PALACIOS M, 1989, BIOCHEM BIOPH RES CO, V165, P802, DOI 10.1016/S0006-291X(89)80037-3; PALMER RMJ, 1989, BIOCHEM BIOPH RES CO, V158, P348, DOI 10.1016/S0006-291X(89)80219-0; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PUNDAK S, 1981, J ORG CHEM, V46, P808, DOI 10.1021/jo00317a033; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; REES DD, 1990, BRIT J PHARMACOL, V101, P746, DOI 10.1111/j.1476-5381.1990.tb14151.x; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; STUEHR DJ, 1990, BIOCHEM BIOPH RES CO, V168, P558, DOI 10.1016/0006-291X(90)92357-6; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; TAYEH MA, 1989, J BIOL CHEM, V264, P19654	35	255	260	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23790	23795						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721054				2022-12-25	WOS:A1991GV31900042
J	GENG, JG; MOORE, KL; JOHNSON, AE; MCEVER, RP				GENG, JG; MOORE, KL; JOHNSON, AE; MCEVER, RP			NEUTROPHIL RECOGNITION REQUIRES A CA2+-INDUCED CONFORMATIONAL CHANGE IN THE LECTIN DOMAIN OF GMP-140	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYASPARTIC ACID; GAMMA-CARBOXYGLUTAMIC ACID; NODE HOMING RECEPTOR; LEUKOCYTE ADHESION MOLECULE-1; GRANULE MEMBRANE-PROTEIN; BOVINE FACTOR-X; ACTIVATED PLATELETS; CALCIUM-BINDING; CELL-ADHESION; CA-2+ BINDING	GMP-140, a receptor for myeloid cells that is expressed on surfaces of thrombin-activated platelets and endothelial cells, is a member of the selectin family of adhesion molecules that regulate leukocyte interactions with the blood vessel wall. Each selectin contains an N-terminal domain homologous to Ca2+-dependent lectins and mediates cell-cell contact by binding to oligosaccharide ligands in a Ca2+-dependent manner. The mechanisms by which Ca2+ promotes selectin-dependent cellular interactions have not been defined. We demonstrate that purified GMP-140 contains two high affinity binding sites for Ca2+ as measured by equilibrium dialysis (K(d) = 22 +/- 2-mu-M). Occupancy of these sites by Ca2+ alters the conformation of the protein as detected by a reduction in intrinsic fluorescence emission intensity (K(d) = 4.8 +/- 0.2-mu-M). This Ca2+-dependent conformational change exposes an epitope spanning residues 19-34 of the lectin domain that is recognized by a monoclonal antibody capable of blocking neutrophil adhesion to GMP-140 (half-maximal antibody binding at approximately 20-mu-M Ca2+). Furthermore, a synthetic peptide encoding this epitope, CQNRYT-DLVAIQNKNE, inhibits neutrophil binding to GMP-140. Mg2+ also alters the conformation of the protein, but not in a manner that will support leukocyte recognition in the absence of Ca2+. There is a strong correlation between the Ca2+ levels required for neutrophil adhesion to GMP-140, for occupancy of the two Ca2+-binding sites, for the fluorescence-detected conformational change, and for exposure of the antibody epitope in the lectin domain. We conclude that binding of Ca2+ to high affinity sites on GMP-140 modulates the conformation of the lectin domain in a manner that is essential for leukocyte recognition.	UNIV OKLAHOMA, HLTH SCI CTR,ST FRANCIS MED RES INST,DEPT MED, 825 NE 13TH ST, OKLAHOMA CITY, OK 73104 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, HLTH SCI CTR, ST FRANCIS MED RES INST, DEPT BIOCHEM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, DEPT CHEM & BIOCHEM, NORMAN, OK 73019 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma - Norman			Johnson, Arthur E/G-3457-2012		NHLBI NIH HHS [HL 32934, HL 45510, HL 34363] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034363, R01HL032934, R01HL045510, R37HL034363] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN TT, 1982, J BIOL CHEM, V257, P8036; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BRASS LF, 1989, METHOD ENZYMOL, V169, P355; CORRAL L, 1990, BIOCHEM BIOPH RES CO, V172, P1349, DOI 10.1016/0006-291X(90)91598-M; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; GAMBLE JR, 1990, SCIENCE, V249, P414; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAMBURGER SA, 1990, BLOOD, V75, P550; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; JOHNSON AE, 1983, J BIOL CHEM, V258, P5554; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LOEB JA, 1988, J BIOL CHEM, V263, P9752; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MCEVER RP, 1984, J BIOL CHEM, V259, P9799; MCEVER RP, 1989, J CLIN INVEST, V84, P92, DOI 10.1172/JCI114175; MCEVER RP, 1991, THROMB HAEMOSTASIS, V65, P223; MCEVER RP, 1991, J CELL BIOCHEM, V45, P156, DOI 10.1002/jcb.240450206; MCMULLEN BA, 1983, BIOCHEMISTRY-US, V22, P2875, DOI 10.1021/bi00281a016; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MORITA T, 1984, J BIOL CHEM, V259, P5698; OHLIN AK, 1988, J BIOL CHEM, V263, P19240; PERSSON E, 1989, J BIOL CHEM, V264, P16897; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; SIEGELMAN MH, 1990, CELL, V61, P611, DOI 10.1016/0092-8674(90)90473-R; SKINNER MP, 1991, J BIOL CHEM, V266, P5371; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STENFLO J, 1988, J BIOL CHEM, V263, P21; SUGO T, 1984, J BIOL CHEM, V259, P5705; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TEDDER TF, 1989, J EXP MED, V170, P123, DOI 10.1084/jem.170.1.123; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; YEDNOCK TA, 1987, J CELL BIOL, V104, P713, DOI 10.1083/jcb.104.3.713; ZHOU Q, 1991, IN PRESS J CELL BIOL	45	67	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22313	22318						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1718992				2022-12-25	WOS:A1991GR56400042
J	MOORE, KS; BEVINS, CL; BRASSEUR, MM; TOMASSINI, N; TURNER, K; ECK, H; ZASLOFF, M				MOORE, KS; BEVINS, CL; BRASSEUR, MM; TOMASSINI, N; TURNER, K; ECK, H; ZASLOFF, M			ANTIMICROBIAL PEPTIDES IN THE STOMACH OF XENOPUS-LAEVIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNUSUAL REPETITIVE STRUCTURE; AMINO-ACID-SEQUENCE; MESSENGER-RNA; CERULEIN PRECURSOR; CDNA SEQUENCE; SKIN PEPTIDES; FROG-SKIN; MAGAININ; BIOSYNTHESIS; SECRETION	Antimicrobial peptides are widely distributed in nature and appear to play a role in the host defense of plants and animals. In this study we report the existence of antimicrobial peptides in the stomach of the vertebrate Xenopus laevis, an animal previously shown to store high concentrations of antimicrobial peptides in its skin. Antimicrobial activity was detected in extracts of X. laevis stomach tissue and nine antimicrobial peptides were then purified. A novel 24-amino acid peptide, designated PGQ, was isolated from these extracts, and has the following amino acid sequence: GVLSNVIGYLKKLGTGALNAVLKQ. PGQ is relatively basic and has the potential to form an amphipathic alpha-helix. The other peptides isolated are members of the magainin family of antimicrobial peptides, and include magainins I and II, PGLa, xenopsin precursor fragment, and four caerulein precursor fragments. None of these peptides had been previously identified in tissues other than the skin. The purification of the peptides from stomach extracts and subsequent protein sequence analysis reveals that the peptides have undergone the same processing as their dermal counterparts, and that they are stored in their processed forms. Northern blot analysis indicates that the magainin family of peptides are synthesized in the stomach, and immunohistochemical studies demonstrate that magainin is stored in a novel granular multinucleated cell in the gastric mucosa of Xenopus. This study demonstrates that the magainin family of antimicrobial peptides is found in the gastrointestinal system of X. laevis and offers an opportunity to further define the physiological role of these defense peptides.	CHILDRENS HOSP PHILADELPHIA,DIV HUMAN GENET & MOLEC BIOL,34TH ST & CIV CTR BLVD,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; MAGAININ SCI INC,PLYMOUTH MEETING,PA 19462	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania			Bevins, Charles L/P-4438-2015	Bevins, Charles L/0000-0003-2725-2622	NIGMS NIH HHS [5T32GM07170] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007170] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREU D, 1985, EUR J BIOCHEM, V149, P531, DOI 10.1111/j.1432-1033.1985.tb08957.x; BECHINGER B, 1991, Journal of Biomolecular NMR, V1, P167, DOI 10.1007/BF01877228; BESSALLE R, 1990, FEBS LETT, V274, P151, DOI 10.1016/0014-5793(90)81351-N; BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.bi.59.070190.002143; BEVINS CL, 1988, DNA PROT ENG TECH, V1, P1; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BRAUDE AI, 1986, INFECT DIS, P654; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DOCKRAY GJ, 1975, J CELL BIOL, V64, P724, DOI 10.1083/jcb.64.3.724; DUCLOHIER H, 1989, BIOPHYS J, V56, P1017, DOI 10.1016/S0006-3495(89)82746-8; ELMES ME, 1984, J CLIN PATHOL, V37, P1268, DOI 10.1136/jcp.37.11.1268; ERLANDSEN SL, 1972, J ULTRA MOL STRUCT R, V41, P296, DOI 10.1016/S0022-5320(72)90071-8; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLUCHER BE, 1986, J CELL BIOL, V103, P2299, DOI 10.1083/jcb.103.6.2299; FLUCHER BE, 1988, GEN COMP ENDOCR, V72, P54, DOI 10.1016/0016-6480(88)90179-7; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GIBSON BW, 1986, J BIOL CHEM, V261, P5341; GIOVANNINI MG, 1987, BIOCHEM J, V243, P113, DOI 10.1042/bj2430113; GREGORY RA, 1988, ADV METAB DISORD, V11, P163; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HOFFMANN W, 1983, EMBO J, V2, P111, DOI 10.1002/j.1460-2075.1983.tb01390.x; HOFFMANN W, 1983, EMBO J, V2, P711, DOI 10.1002/j.1460-2075.1983.tb01489.x; KHALILI K, 1984, J MOL BIOL, V175, P453, DOI 10.1016/0022-2836(84)90179-7; KUCHLER K, 1989, EUR J BIOCHEM, V179, P281, DOI 10.1111/j.1432-1033.1989.tb14552.x; LECHAGO J, 1978, GEN COMP ENDOCR, V36, P553, DOI 10.1016/0016-6480(78)90095-3; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEHRER RI, 1988, HEMATOL ONCOL CLIN N, V2, P159; Maniatis T., 1982, MOL CLONING; MARION D, 1988, FEBS LETT, V227, P21, DOI 10.1016/0014-5793(88)81405-4; MATSUZAKI K, 1989, BIOCHIM BIOPHYS ACTA, V981, P130, DOI 10.1016/0005-2736(89)90090-4; NAKAMURA T, 1988, J BIOL CHEM, V263, P16709; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OLSON T, 1972, ACTA CHEM SCAND, V26, P585, DOI 10.3891/acta.chem.scand.26-0585; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; OZAKI Y, 1980, J BIOCHEM, V87, P549, DOI 10.1093/oxfordjournals.jbchem.a132777; POULTER L, 1988, J BIOL CHEM, V263, P3279; RICHTER K, 1986, J BIOL CHEM, V261, P3676; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SAMAKOVLIS C, 1990, EMBO J, V9, P2969, DOI 10.1002/j.1460-2075.1990.tb07489.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCALISE FW, 1988, GEN COMP ENDOCR, V72, P303, DOI 10.1016/0016-6480(88)90213-4; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SORAVIA E, 1988, FEBS LETT, V228, P337, DOI 10.1016/0014-5793(88)80027-9; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; SURES I, 1984, P NATL ACAD SCI-BIOL, V81, P380, DOI 10.1073/pnas.81.2.380; TERRY AS, 1988, J BIOL CHEM, V263, P5745; VLASAK R, 1987, EUR J BIOCHEM, V169, P53, DOI 10.1111/j.1432-1033.1987.tb13579.x; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; WAKABAYASHI T, 1985, NUCLEIC ACIDS RES, V13, P1817, DOI 10.1093/nar/13.6.1817; WAKABAYASHI T, 1984, GENE, V31, P295, DOI 10.1016/0378-1119(84)90225-7; WILLIAMS RW, 1990, BIOCHEMISTRY-US, V29, P4490, DOI 10.1021/bi00470a031; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZASLOFF M, 1988, P NATL ACAD SCI USA, V85, P910, DOI 10.1073/pnas.85.3.910	56	137	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19851	19857						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717472				2022-12-25	WOS:A1991GK66700103
J	GEBERT, JF; MOGHAL, N; FRANGIONI, JV; SUGARBAKER, DJ; NEEL, BG				GEBERT, JF; MOGHAL, N; FRANGIONI, JV; SUGARBAKER, DJ; NEEL, BG			HIGH-FREQUENCY OF RETINOIC ACID RECEPTOR BETA ABNORMALITIES IN HUMAN LUNG-CANCER	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN HEPATOCELLULAR-CARCINOMA; TRACHEAL EPITHELIAL-CELLS; SQUAMOUS DIFFERENTIATION; T(15-17) TRANSLOCATION; RESPONSIVE ELEMENT; MESSENGER-RNAS; GENE; EXPRESSION; GAMMA	One of the three human retinoic acid receptors, RAR-beta, maps to a region on the short arm of chromosome 3 frequently deleted in lung cancer. Because retinoic acid is required for normal epithelial cell growth and regulation, and loss of a retinoic acid receptor might be expected to contribute to oncogenesis, we examined RAR-beta RNA and DNA in normal lung, 33 lung cancer cell lines and nine primary lung tumors. Normally, RAR-beta is expressed as two transcripts, of sizes 3.1 kb and 2.8 kb, which are strongly induced by retinoic acid. At least 50% of the cell lines and 30% of the tumor samples show altered RAR-beta expression and/or inducibility, including examples of absence or specific loss of one of the RAR-beta transcripts. Abnormalities in the expression patterns of RAR-alpha and RAR-gamma also are found, but at a lower frequency than RAR-beta abnormalities. Southern analysis reveals alteration of the RAR-beta gene in three of the cell lines. Our data suggest that abnormalities in structure and expression of the RAR-beta gene may be involved in the pathogenesis of lung cancer.	BETH ISRAEL HOSP,MOLEC MED UNIT,330 BROOKLINE AVE,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DIV THORAC SURG,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital					NATIONAL CANCER INSTITUTE [R01CA049152] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 49152-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DOLLE P, 1990, DEVELOPMENT, V110, P1133; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; IBSON JM, 1987, J CELL BIOCHEM, V33, P267, DOI 10.1002/jcb.240330405; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; JETTEN AM, 1989, ENVIRON HEALTH PERSP, V80, P149, DOI 10.2307/3430740; JETTEN AM, 1987, LAB INVEST, V56, P654; JETTEN AM, 1985, RETINOIDS DIFFERENTI, P61; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1989, CANCER RES, V49, P651; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LECHNER JF, 1981, CANCER RES, V41, P2294; LEMONS RS, 1990, GENE CHROMOSOME CANC, V2, P79, DOI 10.1002/gcc.2870020202; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maniatis T., 1982, MOL CLONING; MARTIN CA, 1990, P NATL ACAD SCI USA, V87, P4804, DOI 10.1073/pnas.87.12.4804; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; MATTEI MG, 1988, HUM GENET, V80, P186, DOI 10.1007/BF00702866; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REARICK JI, 1987, J CELL PHYSIOL, V133, P573, DOI 10.1002/jcp.1041330320; ROBERTS AB, 1984, RETINOIDS, V2, P209; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, EMBO J, V7, P3771, DOI 10.1002/j.1460-2075.1988.tb03261.x; TORA L, 1988, NATURE, V333, P15; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WU R, 1990, AM J RESP CELL MOL, V3, P467, DOI 10.1165/ajrcmb/3.5.467; WU R, 1982, IN VITRO CELL DEV B, V18, P800; WU R, 1986, IN VITRO MODELS RESP, P1; YOKOTA J, 1989, CANCER RES, V49, P3598; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; [No title captured]	60	220	224	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1859	1868						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1717924				2022-12-25	WOS:A1991GX11800019
J	JUST, M; HERBST, H; HUMMEL, M; DURKOP, H; TRIPIER, D; STEIN, H; SCHUPPAN, D				JUST, M; HERBST, H; HUMMEL, M; DURKOP, H; TRIPIER, D; STEIN, H; SCHUPPAN, D			UNDULIN IS A NOVEL MEMBER OF THE FIBRONECTIN-TENASCIN FAMILY OF EXTRACELLULAR-MATRIX GLYCOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ADHESION GLYCOPROTEIN; AMINO-ACID-SEQUENCE; VONWILLEBRAND-FACTOR; VI COLLAGEN; GLOBULAR DOMAINS; ALPHA-SUBUNIT; MESSENGER-RNA; IMMUNOGLOBULIN SUPERFAMILY; MOSAIC STRUCTURE; BINDING DOMAINS	We characterized cDNA clones specific for the extra-cellular matrix glycoprotein undulin. Two sets of cDNA clones were isolated from a human placental lambda-gt11 expression library and from a rhabdomyosarcoma cell line encoding two partially identical carboxyl-terminal polypeptides of 843 (Un1) and 443 (Un2) amino acids suggesting differential splicing of a single gene transcript. Northern blot analysis of human rhabdomyosarcoma cell poly(A) RNA with cDNA specific for Un1 identified transcripts of approximately 4.2, 6.5, and 8.5 kilobases, whereas a probe specific for Un2 detected a single mRNA of approximately 5 kilobases. Since a monoclonal antibody that is reactive with a sequence encoded by Un1 and not by Un2 detects the bands considered characteristic for undulin in Western blots, the mRNAs related to Un1 may code for the major part of the undulin molecule. The protein sequences deduced from Un1 and Un2 reveal an amino-terminal differentially spliced von Willebrand factor A domain, characteristic of proteins that interact with interstitial collagens, which is linked to fibronectin-like type III homology units by a unique sequence of 57 amino acids. Whereas Un2 encodes two complete and one incomplete type III homologies followed by a unique acidic carboxyl-terminal domain of 118 amino acids, Un1 codes for seven complete and one truncated type III homologies, followed by a short proline-rich carboxyl-terminal segment of 23 amino acids. Considering the 298 amino acids occurring in identical segments, the 989 different amino acid positions deduced from clones Un1 and Un2 represent an estimated 40% of the overall undulin sequence. In the context of 1) rotary shadowing electron microscopy data showing undulin as a structure composed of nodules that are interconnected by flexible rods of varying size, 2) the presence of three major bands of M(r) 270,000, 190,000, and 180,000 in sodium dodecyl sulfate-polyacrylamide gel electrophoresis, with 3) common antigenic epitopes and similar peptide maps (Schuppan, D., Cantaluppi, M. C., Becker, J., Veit, A., Bunte, T., Troyer, D., Schuppan, F., Schmid, M., Ackermann, R., and Hahn, E. G. (1990) J. Biol. Chem. 265, 8823-8832), our finding of differentially spliced type III homology units, as found in tenascin and fibronectin, suggests that undulin is another member of the fibronectin-tenascin family of extracellular matrix glycoproteins. Furthermore, as in fibronectin and tenascin, undulin bears an additional subset of interactive domains tailored to specific structural and functional roles in development and differentiation.	FREE UNIV BERLIN,KLINIKUM STEGLITZ,GASTROENTEROL LAB,HINDENBURGDAMM 30,W-1000 BERLIN 45,GERMANY; FREE UNIV BERLIN,KLINIKUM STEGLITZ,INST PATHOL,W-1000 BERLIN 45,GERMANY; HOECHST AG,PGE STOFFWECHSEL,W-6000 FRANKFURT,GERMANY	Free University of Berlin; Free University of Berlin; Sanofi-Aventis								ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BONALDO P, 1989, J BIOL CHEM, V264, P5575; BONALDO P, 1989, J BIOL CHEM, V264, P20235; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRUMMENDORF T, 1989, NEURON, V2, P1351, DOI 10.1016/0896-6273(89)90073-1; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CHIQUETEHRISMANN R, 1990, FASEB J, V4, P2598, DOI 10.1096/fasebj.4.9.1693347; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; CHUNG AE, 1979, CELL, V16, P277, DOI 10.1016/0092-8674(79)90005-9; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CORBI AL, 1988, J BIOL CHEM, V263, P12403; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUBLET B, 1989, J BIOL CHEM, V264, P13150; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GORDON MK, 1989, J BIOL CHEM, V264, P19772; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; JONES FS, 1988, P NATL ACAD SCI USA, V85, P2186, DOI 10.1073/pnas.85.7.2186; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; KOLLER E, 1989, EMBO J, V8, P1073, DOI 10.1002/j.1460-2075.1989.tb03475.x; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; RANSCHT B, 1988, J CELL BIOL, V107, P1561, DOI 10.1083/jcb.107.4.1561; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; SEKIGUCHI K, 1986, BIOCHEMISTRY-US, V25, P4936, DOI 10.1021/bi00365a032; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; YAMADA KM, 1977, BIOCHEMISTRY-US, V16, P5552, DOI 10.1021/bi00644a025	45	65	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17326	17332						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1716629				2022-12-25	WOS:A1991GF44500055
J	HERZ, JM; KOLB, SJ; ERLINGER, T; SCHMID, E				HERZ, JM; KOLB, SJ; ERLINGER, T; SCHMID, E			CHANNEL PERMEANT CATIONS COMPETE SELECTIVELY WITH NONCOMPETITIVE INHIBITORS OF THE NICOTINIC ACETYLCHOLINE-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICH MEMBRANE-FRAGMENTS; MULTIPLE AFFINITY STATES; ENDPLATE CHANNELS; TORPEDO-MARMORATA; LOCAL-ANESTHETICS; MONO-VALENT; <H-3>PHENCYCLIDINE BINDING; ACTIVATED CHANNELS; SODIUM-CHANNELS; ION PERMEATION	Previous work suggests that noncompetitive inhibitor (NCI) ligands and channel permeant cations bind to sites within the nicotinic acetylcholine receptor ion channel. We have used ethidium as a fluorescent probe of the NCI site to investigate interactions between NCI ligands and channel permeant cations. We found that ethidium can be completely displaced from the receptor by a variety of inorganic monovalent and divalent cations. The rank order of monovalent cation affinities was found to be Tl+ > Rb+ greater-than-or-equal-to K+ > Cs+ > Na+ > Li+. The monovalent cation K(d) values vary markedly over a 40-fold range, from 3 to 121 mM. The K(d) values and rank order correspond to values determined previously from electrophysiological data. Hill plots of the back titrations yield slopes of 1.0 for all monovalent cations, indicating a single class of independent sites, as shown previously for NCI ligands. Scatchard analysis of ethidium binding in the presence of Tl+ reveals a reduction in affinity and no changes in the maximal number of sites. In the presence of agonist the kinetics of ethidium dissociation induced by the addition of phencyclidine or cations alone or the simultaneous addition of both are nearly identical. The ethidium dissociation rate induced by either phencyclidine or cations is regulated by the occupation of the agonist sites in a similar manner. These results indicate that the effect of cations on NCI ligand binding occurs by mutually exclusive competition. We suggest that NCIs can regulate cation binding at a physiological cation recognition site that is likely part of the cation permeation path through the receptor channel.	UNIV TEXAS,CELL RES INST,AUSTIN,TX 78712	University of Texas System; University of Texas Austin	HERZ, JM (corresponding author), UNIV TEXAS,INST NEUROSCI,AUSTIN,TX 78712, USA.		Kolb, Stephen/E-3415-2011					ADAMS DJ, 1981, J GEN PHYSIOL, V78, P593, DOI 10.1085/jgp.78.6.593; ADAMS DJ, 1980, J GEN PHYSIOL, V75, P493, DOI 10.1085/jgp.75.5.493; ADAMS PR, 1981, J MEMBRANE BIOL, V58, P161, DOI 10.1007/BF01870902; ATHERTON SJ, 1984, PHOTOBIOCH PHOTOBIOP, V8, P103; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; COHEN JB, 1985, EFFECTS ANESTHESIA, P53; DANI JA, 1987, J GEN PHYSIOL, V89, P959, DOI 10.1085/jgp.89.6.959; DECKER ER, 1990, J NEUROSCI, V10, P3413; DIPAOLA M, 1990, J BIOL CHEM, V265, P11017; EARNEST JP, 1986, BIOCHEMISTRY-US, V25, P5809, DOI 10.1021/bi00367a070; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; ELLIOTT J, 1982, BIOCHEMISTRY-US, V18, P1868; GAGE PW, 1979, J PHYSIOL-LONDON, V288, P509; GREEN WN, 1987, J GEN PHYSIOL, V89, P873, DOI 10.1085/jgp.89.6.873; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P3112, DOI 10.1021/bi00282a014; HEIDMANN T, 1986, BIOCHEMISTRY-US, V25, P6109, DOI 10.1021/bi00368a041; HERZ JM, 1989, J BIOL CHEM, V264, P12439; HERZ JM, 1987, J BIOL CHEM, V262, P7238; HILLE B, 1984, IONIC CHANNELS EXCIT, P249; HOFFMANN HM, 1983, J GEN PHYSIOL, V81, P687, DOI 10.1085/jgp.81.5.687; HORN R, 1980, P NATL ACAD SCI-BIOL, V77, P6930, DOI 10.1073/pnas.77.11.6930; HUANG LYM, 1978, J GEN PHYSIOL, V71, P397, DOI 10.1085/jgp.71.4.397; HUGANIR RL, 1983, SOC NEUR ABSTR, V9, P578; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; OSWALD RE, 1983, J NEUROCHEM, V41, P1077, DOI 10.1111/j.1471-4159.1983.tb09054.x; OSWALD RE, 1984, MOL PHARMACOL, V25, P360; OSWALD RE, 1983, BIOCHEMISTRY-US, V22, P3128, DOI 10.1021/bi00282a015; PEDERSEN SE, 1990, BIOPHYS J, V57, P126; POSTMA SW, 1984, MOL PHARMACOL, V25, P219; REDMANN GA, 1982, BIOPHYS J, V37, P324; SAKMANN B, 1980, NATURE, V286, P71, DOI 10.1038/286071a0; SINE SM, 1987, J PHYSIOL-LONDON, V385, P325, DOI 10.1113/jphysiol.1987.sp016496; TAKEDA K, 1982, PROC R SOC SER B-BIO, V216, P225, DOI 10.1098/rspb.1982.0072; TANK DW, 1983, P NATL ACAD SCI-BIOL, V80, P5129, DOI 10.1073/pnas.80.16.5129; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029	36	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16691	16698						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1715868				2022-12-25	WOS:A1991GD63500072
J	BAGLIA, FA; JAMESON, BA; WALSH, PN				BAGLIA, FA; JAMESON, BA; WALSH, PN			FINE MAPPING OF THE HIGH-MOLECULAR-WEIGHT KININOGEN BINDING-SITE ON BLOOD-COAGULATION FACTOR-XI THROUGH THE USE OF RATIONALLY DESIGNED SYNTHETIC ANALOGS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA PREKALLIKREIN; LIGHT CHAIN; FUNCTIONAL-CHARACTERIZATION; MONOCLONAL-ANTIBODIES; HAGEMAN-FACTOR; HEAVY-CHAIN; ACTIVATION; MECHANISM; REGION	Using immunological and chemical cleavage techniques, we have previously identified a domain contained within residues Phe56-Ser86 in the first tandem repeat (A1) of the heavy chain of factor XI which binds high Mr kininogen (Baglia, F. A., Jameson, B. A., and Walsh, P. N. (1990) J. Biol. Chem. 265, 4149-4154). We have now chemically synthesized peptides from corresponding homologous regions in the second (A2), third (A3), and fourth (A4) tandem repeats of the heavy chain (A2: Asn145-Ala176; A3: Asn235-Arg266; and A4: Gly326-Lys357). These peptides had no effect on the binding of factor XI to high M(r) kininogen. Because of a lack of detailed structural information for the A1 domain, a molecular model of this region was constructed. This hypothetical model made distinct and testable predictions regarding potential surfaces and concomitant secondary structure. Specifically, the resulting structure depicted two juxtaposed beta-stranded stem-loops that, in conjunction with biological information, constitute a candidate surface for contact with high M(r) kininogen. The hypothetical A1 model was, consequently, used as a predictive template in the rational design of two synthetic peptides (Val59-Arg70 and Asn72-Lys83). When both these peptides were added together and the binding of factor XI to high M(r) kininogen was examined, a synergistic inhibitory effect was observed compared with each peptide added individually. Our data are consistent with the notion that the sequence of amino acids from Val59-Lys83 of the heavy chain of factor XI contains two antiparallel beta-strands connected by beta-turns that together comprise a continuous surface utilized for the binding of high M(r) kininogen.	TEMPLE UNIV, HLTH SCI CTR,SCH MED,THROMBOSIS RES CTR, 3400 N BROAD ST, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT MED & BIOCHEM, PHILADELPHIA, PA 19140 USA; THOMAS JEFFERSON UNIV, DEPT MED & BIOCHEM, PHILADELPHIA, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University					NHLBI NIH HHS [HL45486, HL46213, HL36579] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046213, P01HL036579, P50HL045486] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA H, 1986, J CLIN INVEST, V78, P1631, DOI 10.1172/JCI112756; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; BAGLIA FA, 1989, BLOOD, V74, P244; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GRIFFIN JH, 1976, P NATL ACAD SCI USA, V73, P2554, DOI 10.1073/pnas.73.8.2554; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HOCK J, 1990, J BIOL CHEM, V265, P12005; JAMESON BA, 1989, NATURE, V341, P465, DOI 10.1038/341465a0; KENT SBH, 1985, SYNTHETIC PEPTIDES B, P29; KERBIRIOU DM, 1979, J BIOL CHEM, V254, P2020; KURACHI K, 1980, BIOCHEMISTRY-US, V19, P1330, DOI 10.1021/bi00548a011; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; OHKUBO I, 1982, FED PROC, V41, P656; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; Quick AJ, 1935, AM J MED SCI, V190, P501, DOI 10.1097/00000441-193510000-00009; SCOTT CF, 1984, BLOOD, V63, P42; SINHA D, 1985, J BIOL CHEM, V260, P714; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VOGEL R, 1990, J BIOL CHEM, V265, P12494	26	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4247	4252						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740464				2022-12-25	WOS:A1992HE60700098
J	CHUN, KT; SIMONI, RD				CHUN, KT; SIMONI, RD			THE ROLE OF THE MEMBRANE DOMAIN IN THE REGULATED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; CRYSTALLOID ENDOPLASMIC-RETICULUM; STEROL-ENHANCED DEGRADATION; MEVALONATE-DERIVED PRODUCT; LOW-DENSITY LIPOPROTEIN; A REDUCTASE; RAT-LIVER; BOUND DOMAIN; PROTEIN; CELLS	We have constructed a series of mutations in the membrane and linker domains of Syrian hamster 3-hydroxy-3-methylglutaryl-(HMG) CoA reductase in order to determine the regions critical for the regulated degradation of the enzyme. In transfected Chinese hamster ovary cells, we have expressed a fusion protein, HMGal, which consists of the membrane and linker domains of the Syrian hamster HMG-CoA reductase fused to beta-galactosidase. Using this fusion protein, we have determined that a deletion of 64 amino acids from the central region of the membrane domain causes the protein to be degraded extremely rapidly. In addition, deletion of PEST sequences has little effect on degradation, but deletion of the linker domain makes the protein's degradation insensitive to sterols and mevalonate. In addition to deletion mutations, we have systematically replaced each hydrophobic, putative membrane spanning region of the membrane domain with the first transmembrane sequence from bacteriorhodopsin. Replacement of span 4 has no effect on degradation. Replacements of spans 5 or 6 result in a protein which has a normal basal rate of degradation, but this rate of degradation is not accelerated by mevalonate, low density lipoprotein, or 25-hydroxycholesterol. Replacement of span 3 results in a protein whose degradation is similarly not accelerated by sterols or mevalonte, but since this protein might be mislocalized, these results are inconclusive. Replacement of span 7 yields a short-lived protein which is degraded more rapidly in response to mevalonate but not in response to exogenous sterols. Replacement of span 8 extends both the basal and mevalonate-accelerated half-life about 5-fold. This work begins to define the critical regions for regulated degradation within the membrane domain of HMG-CoA reductase.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NHLBI NIH HHS [HL26502] Funding Source: Medline; NIGMS NIH HHS [GM07276] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEG ZH, 1984, P NATL ACAD SCI-BIOL, V81, P7293, DOI 10.1073/pnas.81.23.7293; BROWN DA, 1984, P NATL ACAD SCI-BIOL, V81, P1674, DOI 10.1073/pnas.81.6.1674; BROWN MS, 1980, J LIPID RES, V21, P505; CHANG TY, 1981, J BIOL CHEM, V256, P6174; CHEN HW, 1982, BIOCHIM BIOPHYS ACTA, V712, P484, DOI 10.1016/0005-2760(82)90275-2; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; EDWARDS PA, 1985, J BIOL CHEM, V260, P278; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARDEMAN EC, 1984, ARCH BIOCHEM BIOPHYS, V232, P549, DOI 10.1016/0003-9861(84)90572-1; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; LIENER IE, 1986, LECTINS PROPERTIES F, P56; LISCUM L, 1985, J BIOL CHEM, V260, P522; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PARKER RA, 1989, J BIOL CHEM, V264, P4877; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROITELMAN J, 1984, J BIOL CHEM, V259, P4029; ROSSER DSE, 1989, J BIOL CHEM, V264, P12653; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA RD, 1983, J BIOL CHEM, V258, P3331; URBANI L, 1990, J BIOL CHEM, V265, P1919	39	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4236	4246						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740463				2022-12-25	WOS:A1992HE60700097
J	PIERCE, A; LYON, M; HAMPSON, IN; COWLING, GJ; GALLAGHER, JT				PIERCE, A; LYON, M; HAMPSON, IN; COWLING, GJ; GALLAGHER, JT			MOLECULAR-CLONING OF THE MAJOR CELL-SURFACE HEPARAN-SULFATE PROTEOGLYCAN FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG FIBROBLASTS; LYMPHOCYTE RECOGNITION; MEMBRANE PROTEOGLYCAN; ENDOTHELIAL-CELLS; PROTEINS; BINDING; DOMAIN; ACID; RNA; GLYCOSAMINOGLYCANS	We have used an antiserum raised against a purified heparan sulfate proteoglycan (HSPG) preparation isolated from rat liver to screen a lambda-gt11 expression library and have obtained overlapping cDNA clones that contain the full-length coding sequence of an HSPG core protein capable of spanning the plasma membrane. The open reading frame of the rat cDNA encodes a protein of 211 amino acids. The predicted protein sequence (23 kDa) has a high degree of homology with the published partial sequence of the human lung fibroblast HSPG, fibroglycan. The deduced protein sequence contains a 24-amino acid transmembrane domain and a 33-amino acid cytoplasmic domain, both of which are identical with the corresponding regions of human fibroglycan and are highly homologous to the human, hamster, and mouse epithelial HSPG, syndecan. The putative ectodomain, which has 85%, homology to fibroglycan, contains three possible glycosaminoglycan attachment sites that may be occupied by heparan sulfate chains. The major 49-kDa core protein in the liver HSPG preparation was found to be reactive to an antibody that specifically recognizes the cytoplasmic domain of fibroglycan. We have used the full-length cDNA clone to analyze the expression of this transmembrane core protein gene in whole tissues and several epithelial and fibroblastoid lines. It hybridizes to three mRNA species in all cell and tissue types examined, but in liver, isolated hepatocytes, and kidney, an additional 0.8-kilobase mRNA was detected. The three common messages arise from differential use of alternative polyadenylation sites, whereas the fourth tissue-restricted RNA species represents a related gene transcript. The rat equivalent of human fibroglycan therefore appears to be the major transmembrane proteoglycan in liver, and its widespread expression in many diverse tissues and cells suggests that it plays an important role in cellular interactions.	CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, CANC RES CAMPAIGN, DEPT EXPTL HAEMATOL, MANCHESTER M20 9BX, ENGLAND; CHRISTIE HOSP NHS TRUST, PATERSON INST CANC RES, CANC RES CAMPAIGN, DEPT MED ONCOL, MANCHESTER M2O 9BX, ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research				Pierce, Andrew/0000-0001-5995-2469; Lyon, Malcolm/0000-0001-9575-6879				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BRANDAN E, 1989, J BIOL CHEM, V264, P10520; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CHURCH GM, 1984, P NATL ACAD SCI USA, V69, P1408; CISAR LA, 1989, J BIOL CHEM, V264, P1767; COLE GJ, 1986, J CELL BIOL, V102, P403, DOI 10.1083/jcb.102.2.403; COLE GJ, 1989, EXP CELL RES, V182, P44, DOI 10.1016/0014-4827(89)90278-4; CONYERS SM, 1991, ANAL BIOCHEM, V192, P207, DOI 10.1016/0003-2697(91)90208-B; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FARRELL DH, 1987, BIOCHEM J, V245, P543, DOI 10.1042/bj2450543; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; HAYASHI K, 1987, J HISTOCHEM CYTOCHEM, V35, P1079, DOI 10.1177/35.10.2957423; HEINEGARD D, 1989, FASEB J, V3, P2042, DOI 10.1096/fasebj.3.9.2663581; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KJELLEN L, 1981, P NATL ACAD SCI-BIOL, V78, P5371, DOI 10.1073/pnas.78.9.5371; KJELLEN L, 1980, J BIOL CHEM, V255, P407; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LORIES V, 1989, J BIOL CHEM, V264, P7009; LYON M, 1991, BIOCHEM J, V273, P415, DOI 10.1042/bj2730415; MALI M, 1990, J BIOL CHEM, V265, P6884; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1989, HEPARIN, P275; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SANDERSON RD, 1988, P NATL ACAD SCI USA, V85, P9562, DOI 10.1073/pnas.85.24.9562; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SOROKA CJ, 1991, J CELL BIOL, V113, P1231, DOI 10.1083/jcb.113.5.1231; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WOODS A, 1990, Journal of Cell Biology, V111, p19A; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	58	92	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3894	3900						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740437				2022-12-25	WOS:A1992HE60700055
J	YEN, PM; DARLING, DS; CARTER, RL; FORGIONE, M; UMEDA, PK; CHIN, WW				YEN, PM; DARLING, DS; CARTER, RL; FORGIONE, M; UMEDA, PK; CHIN, WW			TRIIODOTHYRONINE (T3) DECREASES BINDING TO DNA BY T3-RECEPTOR HOMODIMERS BUT NOT RECEPTOR-AUXILIARY PROTEIN HETERODIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							THYROID-HORMONE RECEPTOR; RAT GROWTH-HORMONE; RESPONSE ELEMENT; DOMAIN; IDENTIFICATION; RESISTANCE; MUTATION; MEDIATE; SITE; BETA	Thyroid hormone receptors (TRs) are ligand-dependent transcription factors that bind to thyroid hormone response elements (TREs) to mediate positive and negative regulation of transcription of thyroid hormone-responsive genes. TR binding to TREs can be enhanced by interaction with a nuclear protein, triiodothyronine (T3) receptor auxiliary protein (TRAP). There are two major isoforms of thyroid hormone receptors, TR-alpha-1 and TR-beta-1, which are encoded on two separate genes. We studied the binding of TR-alpha-1 and TR-beta-1 to several TREs: the chick lysozyme TRE (F2), which is positively regulated by T3; rabbit beta-myosin heavy chain TRE, which is negatively regulated by T3; and an idealized inverted palindrome, TRE(lap). We demonstrate the formation of homodimers, TR-alpha/TR-beta dimers, and TR/TRAP heterodimers when receptor is bound to these DNA sequences. Surprisingly, we found that T3 decreased TR-alpha-1 and TR-beta-1 homodimer binding in a dose-dependent manner to these TREs as well as TR-alpha/TR-beta dimer binding to F2. In contrast, T3 did not affect TR/TRAP heterodimer binding to TREs suggesting that this heterodimer may be the stable complex occupying TREs in the presence of ligand.	HOWARD HUGHES MED INST, BOSTON, MA USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; UNIV ALABAMA, DEPT MED, DIV CARDIOVASC DIS, BIRMINGHAM, AL 35294 USA	Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham	YEN, PM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED,DIV GENET,GW THORN RES BLDG,ROOM 917, 20 SHATTUCK ST, BOSTON, MA 02115 USA.		Yen, Paul M/V-9857-2019; Darling, Douglas S/D-4573-2009	Yen, Paul/0000-0002-3790-8114; Darling, Douglas/0000-0002-9039-1169				BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEEBE JS, 1991, MOL ENDOCRINOL, V5, P85, DOI 10.1210/mend-5-1-85; BRENT G A, 1989, New Biologist, V1, P329; BRENT GA, 1991, MOL ENDOCRINOL, V5, P542, DOI 10.1210/mend-5-4-542; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; CRIBBS LL, 1989, J BIOL CHEM, V264, P10672; DARLING DS, 1991, MOL ENDOCRINOL, V5, P73, DOI 10.1210/mend-5-1-73; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HOLLOWAY JM, 1990, P NATL ACAD SCI USA, V87, P8160, DOI 10.1073/pnas.87.20.8160; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KRISHNA V, 1991, J CLIN INVEST, V87, P1977, DOI 10.1172/JCI115225; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; RODRIGUEZ R, 1990, MOL ENDOCRINOL, V4, P1782, DOI 10.1210/mend-4-12-1782; SAKURAI A, 1989, P NATL ACAD SCI USA, V86, P8977, DOI 10.1073/pnas.86.22.8977; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UMEDA PK, 1990, DYNAMIC STATE OF MUSCLE FIBERS, P61; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; USALA SJ, 1990, J CLIN INVEST, V85, P93, DOI 10.1172/JCI114438; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YEN PY, 1992, IN PRESS ENDOCRINOLO; ZHANG XK, 1991, NEW BIOL, V3, P169	35	183	184	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3565	3568						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740410				2022-12-25	WOS:A1992HE60700004
J	PORTER, DJT; BOYD, FL				PORTER, DJT; BOYD, FL			REDUCED S-ADENOSYLHOMOCYSTEINE HYDROLASE - KINETICS AND THERMODYNAMICS FOR BINDING OF 3'-KETOADENOSINE, ADENOSINE, AND ADENINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM-BASED INHIBITORS; L-HOMOCYSTEINE HYDROLASE; NEPLANOCIN-A; NUCLEOSIDE ANALOGS; INACTIVATION; 2'-DEOXYADENOSINE; CELLS; POTENT; 3-DEAZANEPLANOCIN-A; COMPETENCE	S-Adenosylhomocysteine hydrolase (SAHase) was resolved into apoenzyme and NAD+ by acidic ammonium sulfate treatment. The apoenzyme was catalytically inactive, but could be reconstituted to active enzyme with NAD+. Reduced SAHase (E(NADH)) that was prepared by reconstitution of the apoenzyme with NADH was catalytically inactive. E(NADH) was oxidized by 3'-ketoadenosine to active SAHase. The recovery of activity paralleled the oxidation of enzyme-bound NADH. The association rate constant for E(NADH) and 3'-ketoadenosine was 6.1 x 10(2) M-1 s-1, and the dissociation rate constant was calculated to be 4 x 10(-7) s-1. This association rate constant was considerably smaller than the association rate constant for adenosine and SAHase (> 10(7) M-1 s-1). However, the observed pseudo first-order rate constant for reaction of 3'-ketoadenosine with E(NADH) (0.6 s-1 with 1 mM 3'-ketoadenosine) approached k(cat), for the hydrolytic reaction (1.2 s-1). Thus, bound 3'-ketoadenosine probably reacted sufficiently rapidly with E(NADH) to be considered a kinetically competent intermediate. The dissociation constants of SAHase for adenosine and 4',5'-dehydroadenosine, substrates for the enzyme, were 9 and 14-mu-M, respectively. In contrast, the dissociation constants of E(NADH) for 3'-ketoadenosine and 4',5'-dehydro-3'-ketoadenosine, intermediates of the catalytic reaction, were significantly lower with values of 600 and 300 pM, respectively. The equilibrium constant for reduction of enzyme-bound NAD+ in the absence of an adenosine analogue, as estimated from cyanide binding studies, was 10-fold more favorable than that for free NAD+. E(NADH) was highly fluorescent (emission maximum 428 nm, excitation 340 nm) with a quantum yield that was six times that of free NADH. Since SAHase reduced by adenosine was not highly fluorescent, enzyme-bound intermediates quenched the fluorescence of enzyme-bound NADH. Adenosine and adenine quenched the fluorescence of E(NADH). Cyanide formed a complex with SAHase that was analogous to E(NADH). Adenine stabilized this complex sufficiently that addition of 65-mu-M adenine and 25 mM cyanide to SAHase caused total complex formation with loss of over 95% of the catalytic activity.			PORTER, DJT (corresponding author), WELLCOME RES LABS,DIV EXPTL THERAPY,RES TRIANGLE PK,NC 27709, USA.							ABELES RH, 1980, BIOCHEM BIOPH RES CO, V95, P612, DOI 10.1016/0006-291X(80)90829-3; ABELES RH, 1982, BIOCHEMISTRY-US, V21, P5557, DOI 10.1021/bi00265a027; ANDERSON KS, 1990, J BIOL CHEM, V265, P5567; ASKONAS LJ, 1986, DISS ABSTR INT B, V47; BEVINGTONPR, 1969, DATA REDUCTION ERROR, P204; BORCHARDT RT, 1984, J BIOL CHEM, V259, P4353; BORCHERDING DR, 1988, J MED CHEM, V31, P1729, DOI 10.1021/jm00117a011; BURTON RM, 1955, METHOD ENZYMOL, V1, P397, DOI 10.1016/0076-6879(55)01064-1; CHIANG PK, 1981, ARCH BIOCHEM BIOPHYS, V207, P175, DOI 10.1016/0003-9861(81)90023-0; CLELAND WW, 1990, BIOCHEMISTRY-US, V29, P3194, DOI 10.1021/bi00465a006; CREWS RP, 1983, NUCLEOS NUCLEOT, V2, P275, DOI 10.1080/07328318308078861; DECLERCQ E, 1989, BIOCHEM PHARMACOL, V38, P1771, DOI 10.1016/0006-2952(89)90411-5; DELAHABA G, 1986, BIOCHEMISTRY-US, V25, P8337, DOI 10.1021/bi00373a031; GABRIEL O, 1978, INT REV BIOCHEM, V16, P1; GLAZER RI, 1986, BIOCHEM PHARMACOL, V35, P4523, DOI 10.1016/0006-2952(86)90774-4; GOMI T, 1989, BIOCHIM BIOPHYS ACTA, V994, P172, DOI 10.1016/0167-4838(89)90157-X; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1985, BIOCHEM J, V230, P43, DOI 10.1042/bj2300043; JENSEN JL, 1974, J ORG CHEM, V39, P2103, DOI 10.1021/jo00928a028; JENSEN JL, 1971, TETRAHEDRON LETT, P7; KIM IY, 1985, BIOCHIM BIOPHYS ACTA, V829, P150, DOI 10.1016/0167-4838(85)90183-9; MADHAVAN GVB, 1988, J MED CHEM, V31, P1798, DOI 10.1021/jm00117a021; MATUSZEWSKA B, 1987, J BIOL CHEM, V262, P265; MCCARTHY JR, 1989, J AM CHEM SOC, V111, P1127, DOI 10.1021/ja00185a052; MERTA A, 1983, COLLECT CZECH CHEM C, V48, P2701, DOI 10.1135/cccc19832701; NARAYANAN SR, 1988, J MED CHEM, V31, P500, DOI 10.1021/jm00398a002; PAISLEY SD, 1989, J MED CHEM, V32, P1415, DOI 10.1021/jm00127a001; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PORTER DJT, 1991, IN PRESS J BIOL CHEM; SANPOIETRO A, 1955, J BIOL CHEM, V230, P579; STIPANUK MH, 1986, ANNU REV NUTR, V6, P179, DOI 10.1146/annurev.nu.06.070186.001143; TSENG CKH, 1989, J MED CHEM, V32, P1442, DOI 10.1021/jm00127a007; WALLENFELS K, 1959, LIEBIGS ANN CHEM, V621, P166; WINER AD, 1959, J BIOL CHEM, V234, P1155; WOLFSON G, 1986, J BIOL CHEM, V261, P4492; 1961, OR18 PABST CIRC, V2	36	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3205	3213						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737776				2022-12-25	WOS:A1992HD15400062
J	FALLMAN, M; GULLBERG, M; HELLBERG, C; ANDERSSON, T				FALLMAN, M; GULLBERG, M; HELLBERG, C; ANDERSSON, T			COMPLEMENT RECEPTOR-MEDIATED PHAGOCYTOSIS IS ASSOCIATED WITH ACCUMULATION OF PHOSPHATIDYLCHOLINE-DERIVED DIGLYCERIDE IN HUMAN NEUTROPHILS - INVOLVEMENT OF PHOSPHOLIPASE-D AND DIRECT EVIDENCE FOR A POSITIVE FEEDBACK SIGNAL OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN-NEUTROPHILS; CYTOSOLIC FREE CALCIUM; FMET-LEU-PHE; HL-60 GRANULOCYTES; PHORBOL ESTER; INOSITOL 1,4,5-TRISPHOSPHATE; TEMPORAL RELATIONSHIP; LINKED DIGLYCERIDES; RESPIRATORY BURST; LYMPHOCYTES-T	Complement receptor (CR)-mediated phagocytosis is associated with an increased accumulation of diglyceride (sn-1,2-diacylglycerol and/or 1-O-alkyl-2-acyl-glycerol) in human neutrophils. The C3bi-mediated increase in diglyceride (5-20 min) was only partially impaired when phosphoinositide-specific phospholipase C (PLC) activity was abolished by reduction of cytosolic free Ca2+. At an early time point (1 min), however, diglyceride production was barely detectable in control cells, whereas production was considerable in cells with a reduced cytosolic free Ca2+ concentration. C3bi stimulation of P-32-labeled neutrophils caused a rapid and significant breakdown of [P-32]phosphatidylcholine (PC) which was not affected by inhibition of Ca2+-dependent phosphoinositide-specific PLC. Thus, PC hydrolysis could be involved in C3bi-induced diglyceride formation. Stimulation of cells labeled with [H-3]1-O-alkyl-lyso-PC ([H-3]alkyl-lyso-PC), resulted in an increased formation of [H-3]1-O-alkyl-phosphatidic acid ([H-3]alkyl-PA) and a later and slower formation of [H-3] 1-O-alkyl-diglyceride ([H-3]alkyl-diglyceride); this suggests activation of phospholipase D (PLD). When these labeled cells were stimulated in the presence of 0.5% ethanol a marked accumulation of [H-3]1-O-alkyl-phosphatidylethanol ([H-3] alkyl-PEt) was observed in both controls and calcium-reduced cells, further strengthening the suggested involvement of PLD activity. In parallel with the sustained increase in diglyceride formation, CR-mediated phagocytosis was also associated with phosphorylation of a cellular protein kinase C substrate (MARCKS). Therefore it seems reasonable to suggest a causal relationship between C3bi-induced PLD activation, which results in diglyceride formation, and activation of protein kinase C. In electropermeabilized cells which were incapable of ingesting particles, C3bi particles were still able to activate PLD and induce formation of diglyceride. This signaling event must therefore be triggered by binding of particles to the cell and not by the engulfment process. Most importantly, introduction of the protein kinase C inhibitor peptides, PKC(19-36) and PKC(19-31), into these permeabilized cells resulted in a clear reduction of the C3bi-induced production of diglyceride, indicating that CR-mediated activation of protein kinase C directly triggers a positive feedback mechanism for additional diglyceride formation. Taken together, these data further clarify the mechanisms of CR-mediated diglyceride formation and give added support to the concept that protein kinase C plays an important role in the phagocytic process.	UMEA UNIV,APPL CELL & MOLEC BIOL UNIT,S-90187 UMEA,SWEDEN	Umea University	FALLMAN, M (corresponding author), LINKOPING UNIV,DEPT CELL BIOL,S-58185 LINKOPING,SWEDEN.			Gullberg, Martin/0000-0002-3984-4572; Andersson, Tommy/0000-0003-4032-5769				ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; AGWU DE, 1989, J BIOL CHEM, V264, P1405; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; ALEXANDER DR, 1990, BIOCHEM J, V268, P303, DOI 10.1042/bj2680303; ALLING C, 1984, BIOCHIM BIOPHYS ACTA, V793, P119, DOI 10.1016/0005-2760(84)90060-2; ANDERSSON T, 1988, FEBS LETT, V239, P371, DOI 10.1016/0014-5793(88)80954-2; ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; BASS DA, 1988, J BIOL CHEM, V263, P19610; BENGTSSON T, 1988, J BIOL CHEM, V263, P17385; BENGTSSON T, 1990, P NATL ACAD SCI USA, V87, P2921, DOI 10.1073/pnas.87.8.2921; BERGMEYER HU, 1963, METHOD ENZYMAT AN, P737; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BURNHAM DN, 1989, ARCH BIOCHEM BIOPHYS, V269, P345, DOI 10.1016/0003-9861(89)90116-1; CABOT MC, 1988, FEBS LETT, V233, P153, DOI 10.1016/0014-5793(88)81374-7; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; COCKCROFT S, 1986, BIOCHEM J, V240, P503, DOI 10.1042/bj2400503; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DAWSON RMC, 1967, BIOCHEM J, V102, P205, DOI 10.1042/bj1020205; DELLABIANCA V, 1990, J IMMUNOL, V144, P1411; DIAZMECO MT, 1989, BIOCHEM J, V263, P115, DOI 10.1042/bj2630115; DIVIRGILIO F, 1988, J CELL BIOL, V106, P657, DOI 10.1083/jcb.106.3.657; DOUGHERTY RW, 1989, J BIOL CHEM, V264, P11263; EXTON JH, 1990, J BIOL CHEM, V265, P1; FALLMAN M, 1989, EXP CELL RES, V181, P217, DOI 10.1016/0014-4827(89)90195-X; FALLMAN M, 1990, BIOCHIM BIOPHYS ACTA, V1055, P173, DOI 10.1016/0167-4889(90)90118-W; FALLMAN M, 1989, J CLIN INVEST, V84, P886, DOI 10.1172/JCI114249; FORD DA, 1989, J BIOL CHEM, V264, P13818; FRIEDRICH B, 1989, EUR J IMMUNOL, V19, P17, DOI 10.1002/eji.1830190104; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUILLEMETTE G, 1987, J BIOL CHEM, V262, P1010; HARTWIG J H, 1990, Journal of Cell Biology, V111, p8A; HED J, 1982, IMMUNOLOGY, V45, P727; HONEYCUTT PJ, 1986, J BIOL CHEM, V261, P5900; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG CF, 1990, J BIOL CHEM, V265, P17468; HUANG R, 1991, J BIOL CHEM, V266, P1652; JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEW DP, 1985, NATURE, V315, P509, DOI 10.1038/315509a0; LOBAUGH LA, 1990, J BIOL CHEM, V265, P18393; MEGE JL, 1988, AM J PHYSIOL, V255, pC589, DOI 10.1152/ajpcell.1988.255.5.C589; MUID RE, 1987, BIOCHEM BIOPH RES CO, V143, P630, DOI 10.1016/0006-291X(87)91400-8; MUIR JG, 1987, J CELL PHYSIOL, V130, P382, DOI 10.1002/jcp.1041300311; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; NIEDEL JE, 1986, RECEPTOR BIOCH METHO, V7, P47; PAI JK, 1988, J BIOL CHEM, V263, P12472; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; PREISS J, 1986, J BIOL CHEM, V261, P8597; RIDER LG, 1987, J BIOL CHEM, V262, P5603; RIDER LG, 1988, J IMMUNOL, V140, P200; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROSEN A, 1989, J BIOL CHEM, V264, P9118; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SARNDAHL E, 1989, J CELL BIOL, V109, P2791, DOI 10.1083/jcb.109.6.2791; SHETERLINE P, 1984, EUR J CELL BIOL, V34, P80; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; STOSSEL TP, 1988, INFLAMMATION BASIC P, P325; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TATHAM PER, 1990, PEPTIDE HORMONES PRA, V2, P257; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THOMPSON NT, 1990, BIOCHEM J, V271, P209, DOI 10.1042/bj2710209	71	111	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2656	2663						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733962				2022-12-25	WOS:A1992HB53200084
J	SHEMSHEDINI, L; JI, JW; BROU, C; CHAMBON, P; GRONEMEYER, H				SHEMSHEDINI, L; JI, JW; BROU, C; CHAMBON, P; GRONEMEYER, H			INVITRO ACTIVITY OF THE TRANSCRIPTION ACTIVATION FUNCTIONS OF THE PROGESTERONE-RECEPTOR - EVIDENCE FOR INTERMEDIARY FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR LATE PROMOTER; HUMAN ESTROGEN-RECEPTOR; CELL-FREE SYSTEM; GLUCOCORTICOID RECEPTOR; NUCLEAR-LOCALIZATION; RNA-POLYMERASE; DEPENDENT TRANSCRIPTION; HORMONE RECEPTOR; STEROID-HORMONES; UPSTREAM ELEMENT	The human progesterone receptor (hPR) is a ligand-dependent transcription factor which contains two distinct transcription activation functions (TAFs). The full-length hPR and its individual TAFs were overexpressed in the baculovirus system and tested in a HeLa cell-derived in vitro transcription system. hPR stimulated transcription in a ligand-independent manner. When the two TAFs fused to the DNA-binding domain of GAL4 were tested, only the constitutive TAF-1 was functional in vitro, strongly suggesting that the transcriptional activity of baculovirus-expressed hPR comes solely from TAF-1. The GAL-TAF-1 activator was found to self-squelch without affecting basal transcription. A partially purified fraction relieved this self-squelching and, moreover, stimulated transcriptional activation by GAL-TAF-1, while having no influence on basal transcription. These results strongly suggest that the transcriptional activity of GAL-TAF-1 requires a factor(s) distinct from the general transcription factors.			SHEMSHEDINI, L (corresponding author), FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE.		Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/G-6240-2011	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				BAGCHI MK, 1990, NATURE, V345, P548; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; CORTHESY B, 1988, SCIENCE, V239, P1137, DOI 10.1126/science.2830672; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FREEDMAN LP, 1989, SCIENCE, V245, P298, DOI 10.1126/science.2473529; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; HEN R, 1982, P NATL ACAD SCI-BIOL, V79, P7132, DOI 10.1073/pnas.79.23.7132; HOROWITZ KB, 1983, ENDOCRINOLOGY, V113, P2195; KALFF M, 1990, NATURE, V344, P360, DOI 10.1038/344360a0; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LAUGHON A, 1982, P NATL ACAD SCI-BIOL, V79, P6827, DOI 10.1073/pnas.79.22.6827; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MIYAMOTO NG, 1984, NUCLEIC ACIDS RES, V12, P8779, DOI 10.1093/nar/12.23.8779; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1988, J BIOL CHEM, V263, P267; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SUMMERSMD, 1987, TEX AGR EXP STN B, V1555; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI SY, 1990, J BIOL CHEM, V265, P17055; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674	45	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1834	1839						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730721				2022-12-25	WOS:A1992HA48500068
J	HOLLENBACH, PW; ZILLI, DL; LASTER, SM				HOLLENBACH, PW; ZILLI, DL; LASTER, SM			INHIBITORS OF TRANSCRIPTION AND TRANSLATION ACT SYNERGISTICALLY WITH TUMOR-NECROSIS-FACTOR TO CAUSE THE ACTIVATION OF PHOSPHOLIPASE-A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MANGANOUS SUPEROXIDE-DISMUTASE; CYTO-TOXICITY; CELLS; LYMPHOTOXIN; MECHANISM; INDUCTION; INVITRO; STIMULATION; DESTRUCTION; INVOLVEMENT	In this report we have examined the ability of tumor necrosis factor-alpha (TNF) to induce the activity of phospholipase A2 (PLA2) in the cell line C3HA, a murine 3T3-like cell line which is normally resistant to TNF-induced cytolysis but can be sensitized with inhibitors of transcription and translation. Our results show that TNF is normally unable to induce the activity of PLA2 in this cell, as measured by the release of [H-3]arachidonic acid. We find, however, that in the presence of either actinomycin D (Act D) or cycloheximide (CHI), TNF is indeed able to induce phospholipase activity and that the TNF-induced activation of PLA2 occurs 2-4 h before the onset of Cr-51 release. The release of [H-3]arachidonic acid was inhibited by 40-50% by pretreatment with 1-mu-M dexamethasone. Treatment with dexamethasone also inhibited cytolysis by 40-50% indicating that the CHI-dependent, TNF-induced activation of PLA2 is a cause, not an effect of cytolysis. The ability of TNF to induce the activity of PLA2 was also tested in two other cell types which are resistant, to TNF except in the presence of Act D or CHI: SK-MEL-28, a human melanoma-derived cell line, and pVBETK-1cl15.2, an SV40-transformed murine L cell line. Our results were the same, treatment with a combination of Act D and TNF or CHI and TNF was required to cause activation of PLA2.	N CAROLINA STATE UNIV,DEPT MICROBIOL,RALEIGH,NC 27695	University of North Carolina; North Carolina State University					NCRR NIH HHS [RR7071] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ASOH K, 1989, BIOCHEM BIOPH RES CO, V162, P794, DOI 10.1016/0006-291X(89)92380-2; BEYAERT R, 1990, FEBS LETT, V262, P93, DOI 10.1016/0014-5793(90)80161-B; BOSS JM, 1991, IMMUNOLOGY, V73, P309; FITZGERALD MT, 1987, LYMPHOKINE RES, V6, P319; HEPBURN A, 1987, BIOCHEM BIOPH RES CO, V149, P815, DOI 10.1016/0006-291X(87)90440-2; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KULL FC, 1981, CANCER RES, V41, P4885; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEIGHTON JD, 1990, FEBS LETT, V259, P289, DOI 10.1016/0014-5793(90)80029-I; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OSTROVE JM, 1979, P SOC EXP BIOL MED, V160, P354; PALOMBELLA VJ, 1989, J BIOL CHEM, V264, P18128; REID TR, 1989, J BIOL CHEM, V264, P4583; SALMON JA, 1982, METHOD ENZYMOL, V86, P447; SUFFYS P, 1991, EUR J BIOCHEM, V195, P465, DOI 10.1111/j.1432-1033.1991.tb15727.x; TSUJIMOTO M, 1988, BIOCHEM BIOPH RES CO, V153, P109, DOI 10.1016/S0006-291X(88)81196-3; WATANABE N, 1988, IMMUNOPHARM IMMUNOT, V10, P479, DOI 10.3109/08923978809006450; WATANABE N, 1989, CANCER IMMUNOL IMMUN, V28, P157; WILLIAMSON BD, 1983, P NATL ACAD SCI-BIOL, V80, P5397, DOI 10.1073/pnas.80.17.5397; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAGISAWA H, 1982, IMMUNOLOGY, V47, P437	22	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					39	42						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730604				2022-12-25	WOS:A1992GY43900011
J	POT, DA; DIXON, JE				POT, DA; DIXON, JE			ACTIVE-SITE LABELING OF A RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5'-PARA-FLUOROSULFONYLBENZOYLADENOSINE; PURIFICATION; KINASE	The inactivation of the cytoplasmic domain of rat LAR, a receptor-like protein tyrosine phosphatase (PTPase), by iodoacetate and not by iodoacetamide suggested that iodoacetate interacts in a highly selective manner with the enzyme. The data indicate that iodoacetate binds at the active site of the enzyme with a stoichiometry of 0.8 mol of iodoacetate bound per mol of rat LAR. A single [C-14]iodoacetate-labeled peptide was isolated following endoproteinase Lys-C digestion of the radiolabeled PTPase. Sequence analysis of the active site labeled peptide demonstrates that Cys-1522 contains the radiolabel. This residue has been shown by site- directed mutagenesis to be essential for rat LAR activity (Pot, D. A., Woodford, T. A., Remboutsika, E., Haun, R. S., and Dixon, J. E. (1991) J. Biol. Chem. 266, 19688-19696). Iodoacetate reacts only with the first domain of this double domain PTPase. These results, for the first time, directly identify the highly reactive cysteine residue at the active site of a PTPase and highlight the ability of this residue to participate as a nucleophile in the hydrolysis of phosphate from tyrosine.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; PURDUE UNIV,WALTHER CANC INST,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Walther Cancer Institute				Pot, David/0000-0002-1480-9826	PHS HHS [18024] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALEXANDER D R, 1990, New Biologist, V2, P1049; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; DAUM G, 1991, J BIOL CHEM, V266, P12211; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FOSTER WB, 1981, J BIOL CHEM, V256, P882; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIXSON CS, 1979, J BIOL CHEM, V254, P7509; JONES SW, 1989, J BIOL CHEM, V264, P7747; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; OVERALL CM, 1987, ANAL BIOCHEM, V165, P208, DOI 10.1016/0003-2697(87)90221-1; POT DA, 1991, J BIOL CHEM, V266, P19688; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; SWARUP G, 1989, J BIOL CHEM, V264, P7801; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZANDER NF, 1991, BIOCHEMISTRY-US, V30, P6964, DOI 10.1021/bi00242a022	24	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					140	143						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730581				2022-12-25	WOS:A1992GY43900027
J	BANKA, CL; BONNET, DJ; BLACK, AS; SMITH, RS; CURTISS, LK				BANKA, CL; BONNET, DJ; BLACK, AS; SMITH, RS; CURTISS, LK			LOCALIZATION OF AN APOLIPOPROTEIN-A-I EPITOPE CRITICAL FOR ACTIVATION OF LECITHIN-CHOLESTEROL ACYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC PEPTIDE ANALOGS; HIGH-DENSITY LIPOPROTEINS; PERFORMANCE LIQUID-CHROMATOGRAPHY; IMMUNOCHEMICAL HETEROGENEITY; MONOCLONAL-ANTIBODIES; AMPHIPATHIC HELIX; ASSOCIATION	Apolipoprotein (apo) A-I, the major apoprotein of human high density lipoprotein, is a vital cofactor for lecithin-cholesterol acyltransferase (LCAT), the plasma enzyme responsible for esterification of free cholesterol associated with high density lipoprotein. This esterification is an important component of the reverse cholesterol transport process. An immunochemical approach was used to test the hypothesis that a discrete region of apoA-I was important for LCAT activation. Three human apoA-I-specific monoclonal antibodies were found to inhibit LCAT activation in vitro in a manner directly proportional to their ability to bind to apoA-I-proteoliposomes in fluid phase immunoassays. This relationship was not observed with another four apoA-I-specific antibodies that also were able to bind to the apoA-I proteoliposomes. The use of synthetic peptides representing short amino acid sequences of the apoA-I molecule facilitated the identification of discrete but overlapping apoA-I epitopes for those antibodies that interfered with LCAT-mediated cholesterol esterification. These epitopes spanned amino acid residues 95-121 of mature apoA-I. Therefore, this region is most likely involved in the activation of LCAT by apoA-I.	JOHNSON & JOHNSON BIOTECHNOL CTR INC, SAN DIEGO, CA 92121 USA	Johnson & Johnson	BANKA, CL (corresponding author), Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL-07195, HL-43815, HL-14197] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007195, P50HL014197, R01HL043815] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1976, METABOLISM, V25, P633, DOI 10.1016/0026-0495(76)90060-3; ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; BANKA CL, 1991, J LIPID RES, V32, P35; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; CHEN CH, 1982, J LIPID RES, V23, P680; CURTISS LK, 1982, J BIOL CHEM, V257, P5213; CURTISS LK, 1985, J BIOL CHEM, V260, P2982; CURTISS LK, 1988, J BIOL CHEM, V263, P13779; CURTISS LK, 1985, HYBRIDOMA TECHNOLOGY, P291; CURTISS LK, 1990, ATHEROSCLER REV, P217; CURTISS LK, 1987, NIH872646 PUBL, P363; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; EPAND RM, 1987, J BIOL CHEM, V262, P9389; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FUKUSHIMA D, 1980, J BIOL CHEM, V255, P651; Glomset J A, 1973, Adv Lipid Res, V11, P1; GLOMSET JA, 1968, J LIPID RES, V9, P155; JONAS A, 1990, J BIOL CHEM, V265, P22123; KINOSHITA M, 1983, J BIOCHEM-TOKYO, V94, P615, DOI 10.1093/oxfordjournals.jbchem.a134395; KOTTKE BA, 1986, MAYO CLIN PROC, V61, P313, DOI 10.1016/S0025-6196(12)61947-8; LEBLOND L, 1991, J BIOL CHEM, V266, P6058; LENARD J, 1967, J AM CHEM SOC, V89, P181, DOI 10.1021/ja00977a057; MARCEL YL, 1991, J BIOL CHEM, V266, P3644; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PAVLU B, 1986, J CHROMATOGR, V359, P449, DOI 10.1016/0021-9673(86)80098-X; PONSIN G, 1986, J BIOL CHEM, V261, P9202; POWNALL HJ, 1980, P NATL ACAD SCI-BIOL, V77, P3154, DOI 10.1073/pnas.77.6.3154; RALL SC, 1984, J BIOL CHEM, V259, P63; SEGREST JD, 1973, FEBS LETT, V38, P247; SPARROW JT, 1982, CRC CR REV BIOCH MOL, V13, P87, DOI 10.3109/10409238209108710; TSAO BP, 1982, J BIOL CHEM, V257, P5222; YOUNG SG, 1986, CLIN CHEM, V32, P1484	36	80	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23886	23892						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721059				2022-12-25	WOS:A1991GV31900056
J	BOWDITCH, RD; HALLORAN, CE; AOTA, S; OBARA, M; PLOW, EF; YAMADA, KM; GINSBERG, MH				BOWDITCH, RD; HALLORAN, CE; AOTA, S; OBARA, M; PLOW, EF; YAMADA, KM; GINSBERG, MH			INTEGRIN-ALPHA-IIB-BETA-3 (PLATELET GPIIB-IIIA) RECOGNIZES MULTIPLE SITES IN FIBRONECTIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING DOMAIN; GLYCOPROTEIN-IIB; PLASMA FIBRONECTIN; PROTEOLYTIC FRAGMENTS; MONOCLONAL-ANTIBODIES; FIBROBLASTIC CELLS; SYNTHETIC PEPTIDES; ADHESION; RECEPTOR; INTEGRINS	The binding of fibronectin (Fn) to several integrins involves the Arg-Gly-Asp (RGD) tripeptide sequence. However, linear synthetic RGD peptides do not completely mimic the cell attachment activity of intact Fn or certain large Fn fragments. This suggests that the integrin-Fn interaction involves a more extended surface of Fn than that provided by the RGD sequence. To test this possibility, three novel monoclonal anti-Fn antibodies that inhibit its binding to a purified integrin, alpha(IIb)beta-3, were developed. The epitopes of these three antibodies mapped to a region at least 55 residues amino-terminal of the RGD sequence. Further, recombinant fragments of Fn containing these epitopes and lacking the RGD site also inhibited the binding of Fn to purified alpha(IIb)beta-3. These fragments, which spanned Fn residues 1359-1436, bound to alpha(IIb)beta-3 in a divalent cation-dependent manner. In addition, this region of Fn bound specifically to alpha(IIb)beta-3 on thrombin-stimulated but not resting platelets. These results demonstrate the presence of additional sequences in Fn that interact with integrin alpha(IIb)beta-3 and suggest that multiple sites in Fn are involved in its recognition by this integrin.	SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; NIDR, DEV BIOL LAB, BETHESDA, MD 20892 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Yamada, Kenneth/0000-0003-1512-6805	NHLBI NIH HHS [HL 28235] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028235] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1985, J BIOL CHEM, V260, P4492; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; AOTA S, 1991, J BIOL CHEM, V266, P15938; BAUMANN P, 1985, J BACTERIOL, V163, P738, DOI 10.1128/JB.163.2.738-747.1985; BERKOWITZ SD, 1987, J CLIN INVEST, V79, P524, DOI 10.1172/JCI112843; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHARO IF, 1991, J BIOL CHEM, V266, P1415; DALE GL, 1991, BLOOD, V77, P1096; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1983, J CLIN INVEST, V71, P619, DOI 10.1172/JCI110808; GINSBERG MH, 1990, CELL DIFFER DEV, V32, P203, DOI 10.1016/0922-3371(90)90033-S; GUAN C, 1987, GENE, V67, P21; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Hynes RO, 1990, FIBRONECTINS; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KATAYAMA M, 1989, EXP CELL RES, V185, P229, DOI 10.1016/0014-4827(89)90051-7; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM SCT, 1987, J BIOL CHEM, V262, P947; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; NAGAI T, 1991, J CELL BIOL, V114, P1295, DOI 10.1083/jcb.114.6.1295; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; ODERMATT E, 1989, FIBRONECTIN, P1; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; PIERSCHBACHER MD, 1982, J BIOL CHEM, V257, P9593; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHOEN RC, 1982, HYBRIDOMA, V1, P99, DOI 10.1089/hyb.1.1982.1.99; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; STEINER B, 1988, CIRC S, V78; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS VL, 1986, J BIOL CHEM, V261, P5242; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	51	103	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23323	23328						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1720779				2022-12-25	WOS:A1991GT48300082
J	MELLSTROM, B; ACHAVAL, M; MONTERO, D; NARANJO, JR; SASSONECORSI, P				MELLSTROM, B; ACHAVAL, M; MONTERO, D; NARANJO, JR; SASSONECORSI, P			DIFFERENTIAL EXPRESSION OF THE JUN FAMILY MEMBERS IN RAT-BRAIN	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; IMMEDIATE EARLY GENES; DNA-BINDING DOMAINS; NERVE GROWTH-FACTOR; C-JUN; PROTO-ONCOGENE; LEUCINE ZIPPERS; V-JUN; FOS; INDUCTION	The transcription factor AP-1 is phorbol ester-regulated and, as such, is considered to be a nuclear target of the signal transduction pathway involving protein kinase C. AP-1 is constituted by the various products of the jun and fos gene family members. These genes belong to the early response class and are inducible in different ways by growth factors, phorbol esters and depolarization. We studied the transcript distribution of c-jun,junB and junD in the rat brain. Our results show that the transcripts for these three genes are differentially distributed in various neuronal tissues. We also provide evidence for developmentally regulated expression of jun genes in post-natal brain. The spatiotemporal pattern of expression of c-jun, junB and junD offers clues to the understanding of the links between gene regulation and neuronal processes.	CSIC,INST CAJAL NEUROCIENCIA,DOCTOR ARCE 37,E-28002 MADRID,SPAIN; FAC MED STRASBOURG,INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	Consejo Superior de Investigaciones Cientificas (CSIC); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			NARANJO, Jose R/K-1950-2014; Sassone-Corsi, Paolo/H-6182-2011	NARANJO, Jose R/0000-0002-0270-3469; 				AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BERRIDGE M, 1986, NATURE, V323, P294, DOI 10.1038/323294a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CURRAN T, 1987, BIOESSAYS, V7, P255, DOI 10.1002/bies.950070606; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; FREMEAU RT, 1986, SCIENCE, V234, P1265, DOI 10.1126/science.3775385; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; HERDEGEN T, 1990, 6TH P WORLD C PAIN; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; NARANJO JR, 1991, ONCOGENE, V6, P223; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SONNENBERG JL, 1989, NEURON, V3, P359, DOI 10.1016/0896-6273(89)90260-2; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; WU BY, 1989, J BIOL CHEM, V264, P9000	42	75	75	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					1959	1964						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719462				2022-12-25	WOS:A1991GX11900003
J	ZHANG, SS; GROSSE, F				ZHANG, SS; GROSSE, F			PURIFICATION AND CHARACTERIZATION OF 2 DNA HELICASES FROM CALF THYMUS NUCLEI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LARGE T-ANTIGEN; EUKARYOTIC INITIATION-FACTORS; ESCHERICHIA-COLI MUTANTS; GENE-PRODUCT; UNWINDING ACTIVITY; POLYMERASE-ALPHA; MESSENGER-RNA; REPLICATION; INVITRO; PROTEIN	Two DNA helicases from calf thymus nuclei have been purified and characterized. The two proteins, designated as nuclear DNA helicase I and II, were copurified on Bio-Rex 70, DEAE-Sepharose, phosphocellulose and subsequently separated from each other on a heparin-Sepharose column. Final purification of DNA helicase I was achieved on single-stranded DNA-cellulose and that of DNA helicase II on ATP-agarose. On denaturing polyacrylamide gels, nuclear DNA helicase I displayed two polypeptide bands of 170 and 200 kDa; nuclear DNA helicase II also consisted of two bands, in this case of 100 and 130 kDa. Both enzymes catalyzed the unwinding of a DNA primer from a single-stranded DNA template but had different nucleotide requirements for their energy supply. While nuclear DNA helicase I preferred to hydrolyze ATP or dATP to support its unwinding activity, nuclear DNA helicase II could utilize all four rNTPs or dNTPs, though ATP or dATP were still preferred to other nucleotides. ADP, AMP, or adenosine 5'-O-(thiotriphosphate) could not be used by either enzyme in the unwinding reactions. A divalent cation was essential for activity of both enzymes. Nuclear DNA helicase I required 3-5 mM Mg2+ or 1 mM Mn2+ for optimal unwinding. In contrast, nuclear DNA helicase II displayed high activity even at very low concentrations of Mg2+. Nuclear DNA helicase I was stimulated by NaCl, KCl, or potassium acetate up to concentrations of 150 mm; in contrast, nuclear DNA helicase II was strongly inhibited at salt concentrations over 75 mM. Both DNA helicases had an associated ATPase activity. However, while the ATPase activity of nuclear DNA helicase I was stimulated only in presence of single-stranded DNA, the ATPase activity of the nuclear DNA helicase II was stimulated by single-stranded DNA and, even more efficiently, by RNA. Finally, the translocation of both DNA helicases had a polarity from 3' to 5' with respect to the single-stranded DNA template to which the enzymes were bound. A comparison of these DNA helicases with the other reported mammalian DNA helicases will be given. The significance of the association of the two DNA helicases during the process of the purification will be discussed.	MAX PLANCK INST EXPTL MED,DEPT MED,W-3400 GOTTINGEN,GERMANY	Max Planck Society								ARIA K, 1981, J BIOL CHEM, V256, P5253; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BONHOEFFER F, 1966, Z VEREBUNGSL, V98, P141, DOI 10.1007/BF00897186; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CLAUDE A, 1991, J BIOL CHEM, V266, P10358; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DOWNEY KM, 1990, MOL MECHANISMS DNA R; FANGMAN WL, 1968, GENETICS, V60, P1; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; GROSSE F, 1984, EUR J BIOCHEM, V141, P109, DOI 10.1111/j.1432-1033.1984.tb08164.x; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HORITA Y, 1968, COLD SPRING HARB SYM, V33, P677; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Maniatis T., 1982, MOL CLONING; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; NASHEUER HP, 1987, BIOCHEMISTRY-US, V26, P8458, DOI 10.1021/bi00399a064; RAY BK, 1985, J BIOL CHEM, V260, P7651; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHOMBURG U, 1986, EUR J BIOCHEM, V160, P451, DOI 10.1111/j.1432-1033.1986.tb10061.x; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; STAHL H, 1985, J VIROL, V54, P473, DOI 10.1128/JVI.54.2.473-482.1985; TAN CK, 1986, J BIOL CHEM, V261, P2310; THOMMES P, 1990, J BIOL CHEM, V265, P14347; THOMMES P, 1990, FEBS LETT, V268, P325, DOI 10.1016/0014-5793(90)81279-W; TUTEJA N, 1990, NUCLEIC ACIDS RES, V18, P6785, DOI 10.1093/nar/18.23.6785; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; ZYSKIND JW, 1977, J BACTERIOL, V129, P1476, DOI 10.1128/JB.129.3.1476-1486.1977	34	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20483	20490						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1718963				2022-12-25	WOS:A1991GM03900091
J	PAINTER, GR; WRIGHT, LL; HOPKINS, S; FURMAN, PA				PAINTER, GR; WRIGHT, LL; HOPKINS, S; FURMAN, PA			INITIAL BINDING OF 2'-DEOXYNUCLEOSIDE 5'-TRIPHOSPHATES TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; KINETIC MECHANISM; SUBSTRATE; DOMAIN; KLENOW	Human immunodeficiency virus type 1 reverse transcriptase (EC 2.7.7.49), a heterodimer consisting of two polypeptide chains of molecular weights 66,000 and 51,000, fluoresces due to the presence of 36 tryptophan residues with an emission peak centered at 338 nm. The association of 2'-deoxynucleoside 5'-triphosphates with the enzyme results in a decrease in the intensity of the tryptophan emission spectrum, which can be used to calculate apparent dissociation constants. The K(d) values determined for binding of the four natural 2'-deoxynucleoside 5'-triphosphates to the free enzyme range from 36.7 +/- 1.8-mu-M for dTTP to 47.3 +/- 3.9-mu-M for dATP. The 5'-triphosphate of zidovudine has a K(d) of 54.1 +/- 1.3-mu-M. The enzyme shows no preference for purine or pyrimidine nucleotides. Hill coefficients and the results of dual ligand titration experiments demonstrate that the free enzyme possesses a single dNTP binding site for which the four natural substrates and the 5'-triphosphate of zidovudine compete. The presence of homopolymeric template-primers does not result in selective binding of the complementary 2'-deoxynucleoside 5'-triphosphate, indicating that Watson-Crick base pairing is not involved in the initial binding reaction. The major force driving the association of the ligands with the binding site is hydrophobic. Approximately 14% of the binding energy is derived from electrostatic interactions. Although Mg2+ is required for catalytic activity, it is not absolutely required for initial binding.	BURROUGHS WELLCOME CO, DIV VIROL, RES TRIANGLE PK, NC 27709 USA	Burroughs Wellcome Fund								BASU A, 1989, J BIOL CHEM, V264, P8746; CHA S, 1968, MOL PHARMACOL, V4, P621; CHENG N, 1991, BIOCHEM BIOPH RES CO, V174, P785, DOI 10.1016/0006-291X(91)91486-V; EDELHOCH H, 1968, BIOCHEMISTRY-US, V7, P3893, DOI 10.1021/bi00851a016; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; ENGLUND PT, 1969, J BIOL CHEM, V244, P3038; FERRIN LJ, 1986, BIOCHEMISTRY-US, V25, P5131, DOI 10.1021/bi00366a023; FERRIN LJ, 1987, DNA REPLICATION RECO, P75; FERSHT A, 1985, ENZYME STRUCTURE MEC, P272; FURMAN PA, 1991, IN PRESS P NATL ACAD; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HOPKINS S, 1989, BIOCHEM BIOPH RES CO, V163, P106, DOI 10.1016/0006-291X(89)92105-0; JOYCE CM, 1986, PROTEIN STRUCTURE FO, P197; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LARDER B, 1987, EMBO J, V6, P3133, DOI 10.1002/j.1460-2075.1987.tb02623.x; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LOWE DM, 1988, BIOCHEMISTRY-US, V27, P8884, DOI 10.1021/bi00425a002; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MILLER WH, 1982, BIOCHEM PHARMACOL, V31, P3879, DOI 10.1016/0006-2952(82)90305-7; PAINTER GR, 1991, GWUMC DEPT, P35; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SCOTT TG, 1970, J AM CHEM SOC, V92, P687, DOI 10.1021/ja00706a043; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; TEALE FWJ, 1957, BIOCHEM J, V65, P476, DOI 10.1042/bj0650476; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223	29	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19362	19368						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717463				2022-12-25	WOS:A1991GK66700040
J	FEDER, D; BISHOP, JM				FEDER, D; BISHOP, JM			IDENTIFICATION OF PLATELET MEMBRANE-PROTEINS THAT INTERACT WITH AMINO-TERMINAL PEPTIDES OF PP60C-SRC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; CELL SURFACE-ANTIGENS; BOVINE CARDIAC-MUSCLE; TYROSINE KINASE PP58; HUMAN LYMPHOCYTES-T; TRANSFORMING PROTEIN; PHOSPHOLIPASE-C; PHOSPHATIDYLINOSITOL KINASE; CATALYTIC SUBUNIT; PLASMA-MEMBRANES	Platelets contain exceptionally high levels of pp60c-src and, thus, provide a convenient system for investigating the physiological function of this protein-tyrosine kinase. We have employed chemical cross-linking of myristylated amino-terminal peptides of pp60c-src to platelet membranes in order to identify platelet membrane components that interact with pp60c-src to regulate or mediate its activity. We detected specific binding of radioiodinated peptides to platelet membrane proteins of 32, 50, 92, and 105 kDa. The 32-kDa protein may be related to the putative src receptor component recently identified in fibroblast membranes. The most reactive platelet protein, however, is the 50-kDa protein, which is either absent or nonreactive in fibroblast membranes. Binding of src peptides to this protein was saturable, and we estimate the presence of approximately 1 x 10(6) of the 50-kDa binding sites per platelet. The specificity of the peptide binding to the 50- and 32-kDa platelet proteins was analyzed by competition with different peptides. The binding sites displayed an absolute requirement for an N-myristoyl moiety and a strong preference for pp60c-src amino-terminal sequences. The identification of these src-interacting proteins may help to decipher the biochemical pathways in which platelet pp60c-src is involved.	UNIV CALIF SAN FRANCISCO, GEORGE WILLIAMS HOOPER FDN, BOX 0552, 1542 HSW, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44338] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER AJ, 1970, J BIOL CHEM, V245, P6357; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; COOPER JA, 1990, PEPTIDES PROTEIN PHO, P86; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; FEDER D, 1990, J BIOL CHEM, V265, P8205; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1990, ONCOGENE, V5, P1033; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; GODDARD C, 1989, J BIOL CHEM, V264, P15173; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HAWIGER J, 1989, METHOD ENZYMOL, V169, P191; HORAK ID, 1990, ONCOGENE, V5, P597; HUNTER T, 1986, ENZYMES, V17, P192; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KRUEGER JG, 1983, CURR TOP MICROBIOL, V107, P51; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINSON AD, 1981, P NATL ACAD SCI-BIOL, V78, P1624, DOI 10.1073/pnas.78.3.1624; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MERRIL CR, 1979, P NATL ACAD SCI USA, V76, P4335, DOI 10.1073/pnas.76.9.4335; NAIRN AC, 1985, ANNU REV BIOCHEM, V54, P931, DOI 10.1146/annurev.bi.54.070185.004435; NAKAMURA S, 1985, FEBS LETT, V184, P56, DOI 10.1016/0014-5793(85)80652-9; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; NAKAMURA S, 1988, EUR J BIOCHEM, V174, P471, DOI 10.1111/j.1432-1033.1988.tb14122.x; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PHANDINHTUY F, 1983, NATURE, V305, P435; Phillips D, 1986, BIOCH PLATELETS; PRESEK P, 1988, BIOCHIM BIOPHYS ACTA, V969, P271, DOI 10.1016/0167-4889(88)90062-6; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RENDU F, 1989, BLOOD, V73, P1545; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1988, MOL CELL BIOL, V8, P1896, DOI 10.1128/MCB.8.5.1896; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SHOJI S, 1981, P NATL ACAD SCI-BIOL, V78, P848, DOI 10.1073/pnas.78.2.848; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; VARSHNEY GC, 1986, FEBS LETT, V205, P97, DOI 10.1016/0014-5793(86)80873-0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	53	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					19040	19046						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1717459				2022-12-25	WOS:A1991GJ47200097
J	DOWD, TL; GUPTA, RK				DOWD, TL; GUPTA, RK			MULTINUCLEAR NMR-STUDIES OF INTRACELLULAR CATIONS IN PERFUSED HYPERTENSIVE RAT-KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC FREE CALCIUM; BLOOD-PRESSURE; PROXIMAL TUBULES; MAGNETIC-RESONANCE; PLASMA-MEMBRANE; NA+/H+ ANTIPORT; FREE MAGNESIUM; SODIUM; ACID; METABOLISM	We have investigated hypertension-associated alterations in intracellular cations in the kidney by measuring intracellular pH, free Mg2+, free Ca2+, and Na+ concentrations in perfused normotensive and hypertensive rat (8-14 weeks old) kidneys using P-31, F-19, and double quantum-filtered (DQ) Na-23 NMR. The effects of both anoxia and ischemia on the Na-23 DQ signal confirmed its ability to detect changes in intracellular Na+. However, there was a sizable contribution of the extracellular Na+ to the Na-23 DQ signal of the kidney. The intracellular free Ca2+ concentration, measured using F-19 NMR and 5,5' difluoro-1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid, also increased dramatically during ischemia; the increase could be partly reversed by reperfusion. No significant differences were found between normotensive and hypertensive kidneys in the ATP level, intracellular pH, intracellular free Mg2+, and the Na-23 DQ signal or in the extent of the extracellular contribution to the Na-23 DQ signal. Oxygen consumption rates were also similar for the normotensive (5.02 +/-0.46-mu-mol of O2/min/g) and hypertensive (5.47 +/- 0.42-mu-mol O2/min/g) rat kidneys. The absence of a significant difference in intracellular pH, Na+ concentration, and oxygen consumption between normotensive and hypertensive rat kidneys suggests that an alteration in the luminal Na+/H+ antiport activity in hypertension is unlikely. However, a highly significant increase (64%, p < 0.01) in free Ca2+ concentration was found in perfused kidneys from hypertensive rats (557 +/- 48 nM, blood pressure = 199 +/- 5 mmHg, n = 6) compared with normotensive rats (339 +/- 21 nM, blood pressure = 134 +/- 6, n = 4) indicating altered renal calcium homeostasis in essential hypertension. An increase in intracellular free Ca2+ concentration without an accompanying change in the intracellular Na+ suggests, among many possibilities, that the Ca2+/Mg2+-ATPase may be inhibited in the hypertensive renal tissue.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	DOWD, TL (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PHYSIOL & BIOPHYS, BRONX, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032030] Funding Source: NIH RePORTER; NCI NIH HHS [CA13330] Funding Source: Medline; NIDDK NIH HHS [DK32030] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED I, 1988, KIDNEY INT, V33, P291; ARENDSHORST WJ, 1979, AM J PHYSIOL, V237, pF38, DOI 10.1152/ajprenal.1979.237.1.F38; AVIV A, 1988, AM J HYPERTENS, V1, P410, DOI 10.1093/ajh/1.4.410; AVIV A, 1989, HYPERTENSION, V14, P584, DOI 10.1161/01.HYP.14.6.584; BADARGOFFER RS, 1990, J NEUROCHEM, V55, P878, DOI 10.1111/j.1471-4159.1990.tb04573.x; BAX A, 1984, 2 DIMENSIONAL NUCLEA, P129; BEIERWALTES WH, 1982, HYPERTENSION, V4, P908, DOI 10.1161/01.HYP.4.6.908; BIANCHI G, 1974, CLIN SCI MOL MED, V47, P435, DOI 10.1042/cs0470435; BLAUSTEIN MP, 1983, ANN INTERN MED, V98, P785, DOI 10.7326/0003-4819-98-5-785; BRAZY PC, 1989, AM J PHYSIOL, V250, pF451; CURTIS JJ, 1983, NEW ENGL J MED, V309, P1009, DOI 10.1056/NEJM198310273091702; DAHL LK, 1974, CIRC RES, V34, P94, DOI 10.1161/01.RES.34.1.94; DOWD T, 1989, RENAL PHYSIOL BIOCH, V12, P161; ENDRE ZH, 1989, MAGNET RESON MED, V11, P267, DOI 10.1002/mrm.1910110215; ERNE P, 1984, NEW ENGL J MED, V310, P1084, DOI 10.1056/NEJM198404263101705; ESCALANTE B, 1988, BIOCHEM BIOPH RES CO, V152, P1269, DOI 10.1016/S0006-291X(88)80422-4; ESCALANTE B, 1989, J PHARMACOL EXP THER, V248, P229; GARG LC, 1985, AM J PHYSIOL, V249, pF863, DOI 10.1152/ajprenal.1985.249.6.F863; GUPTA RK, 1980, P NATL ACAD SCI-BIOL, V77, P2487, DOI 10.1073/pnas.77.5.2487; HARRIS RC, 1986, AM J PHYSIOL, V251, pC815, DOI 10.1152/ajpcell.1986.251.5.C815; JACOBS WR, 1990, AM J PHYSIOL, V258, pF175, DOI 10.1152/ajprenal.1990.258.1.F175; JELICKS LA, 1991, AM J HYPERTENS, V4, P131, DOI 10.1093/ajh/4.2.131; JELICKS LA, 1990, J BIOL CHEM, V265, P1394; JELICKS LA, 1989, J MAGN RESON, V83, P146, DOI 10.1016/0022-2364(89)90298-9; KAWAGUCHI H, 1987, J HYPERTENS, V5, P299, DOI 10.1097/00004872-198706000-00006; LIVNE A, 1987, LANCET, V1, P533; LLIBRE J, 1988, HYPERTENSION, V12, P399, DOI 10.1161/01.HYP.12.4.399; LORENZEN M, 1984, AM J PHYSIOL, V247, pF93, DOI 10.1152/ajprenal.1984.247.1.F93; LYON RC, 1991, MAGNET RESON MED, V18, P80, DOI 10.1002/mrm.1910180110; LYON RC, 1990, SOC MAGN RES MED, P37; MORDUCHOWICZ GA, 1989, KIDNEY INT, V36, P576, DOI 10.1038/ki.1989.233; MORRILL GA, 1985, BIOCHIM BIOPHYS ACTA, V844, P377, DOI 10.1016/0167-4889(85)90140-5; MURPHY E, 1982, AM J PHYSIOL, V242, pC124, DOI 10.1152/ajpcell.1982.242.1.C124; NISHIITS.JM, 1967, BIOCHEM J, V103, P852, DOI 10.1042/bj1030852; PEKAR J, 1986, J MAGN RESON, V69, P582, DOI 10.1016/0022-2364(86)90180-0; PEKAR J, 1987, J MAGN RESON, V72, P159, DOI 10.1016/0022-2364(87)90182-X; POSTNOV YV, 1985, PHYSIOL REV, V65, P904, DOI 10.1152/physrev.1985.65.4.904; PURKERSON ML, 1986, HYPERTENSION, V8, P1113, DOI 10.1161/01.HYP.8.12.1113; RESNICK LM, 1987, P NATL ACAD SCI USA, V84, P7663, DOI 10.1073/pnas.84.21.7663; RESNICK LM, 1984, P NATL ACAD SCI-BIOL, V81, P6511, DOI 10.1073/pnas.81.20.6511; RETTIG R, 1989, AM J PHYSIOL, V257, pF197, DOI 10.1152/ajprenal.1989.257.2.F197; ROMAN RJ, 1985, AM J PHYSIOL, V248, pF199, DOI 10.1152/ajprenal.1985.248.2.F199; SACERDOTI D, 1989, SCIENCE, V243, P388, DOI 10.1126/science.2492116; SACERDOTI D, 1988, BIOCHEM PHARMACOL, V37, P521, DOI 10.1016/0006-2952(88)90223-7; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; SHINE N, 1987, ANN NY ACAD SCI, V508, P99, DOI 10.1111/j.1749-6632.1987.tb32898.x; SMITH GA, 1983, P NATL ACAD SCI-BIOL, V80, P7178, DOI 10.1073/pnas.80.23.7178; STEENBERGEN C, 1990, CIRC RES, V66, P135, DOI 10.1161/01.RES.66.1.135; THOMAS RD, 1975, CLIN SCI MOL MED, V48, pS169; YANG JM, 1988, AM J PHYSIOL, V255, pF787, DOI 10.1152/ajprenal.1988.255.4.F787; ZAVOICO GB, 1986, J BIOL CHEM, V261, P3160	51	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3637	3643						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740416				2022-12-25	WOS:A1992HE60700017
J	HOMANDBERG, GA; MEYERS, R; XIE, DL				HOMANDBERG, GA; MEYERS, R; XIE, DL			FIBRONECTIN FRAGMENTS CAUSE CHONDROLYSIS OF BOVINE ARTICULAR-CARTILAGE SLICES IN CULTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-BETA; ENDOTHELIAL-CELL GROWTH; IMMUNOELECTRON MICROSCOPIC DEMONSTRATION; RABBIT SYNOVIAL FIBROBLASTS; HEPARIN-BINDING FRAGMENTS; HUMAN DERMAL FIBROBLASTS; STEADY-STATE LEVELS; RHEUMATOID-ARTHRITIS; RECOMBINANT INTERLEUKIN-1; PROTEOGLYCAN SYNTHESIS	Elevated fibronectin (Fn) and Fn fragment concentrations are found in the synovial fluid of osteoarthritic and rheumatoid arthritic patients. Fn has been shown to affect expression of chondrocytic matrix proteins, and Fn fragments have been shown to elevate gene expression of neutral proteinases in synoviocytes. For these reasons, we tested the effects of Fn fragments on protease release and resultant proteoglycan release from cartilage in serum-free bovine articular cartilage explant cultures. We have found that 1-mu-M amino-terminal 29- and 50-kDa gelatin-binding Fn fragments caused over a 50-fold enhancement of gelatinolytic and collagenolytic proteinase release with a 23-fold enhancement of proteoglycan (PG) release. Release was significant at fragment concentrations as low as 20 nM. An integrin-binding 140-kDa fragment mixture was the least active fragment, whereas native Fn had little activity. The relative activities of the fragments correlated with their relative abilities to bind to cartilage. The RGDS integrin-recognition peptide also caused release, although sequence mutants did not. PG release was blocked by actinomycin D, cycloheximide, and deoxyglucose. Fn fragment-mediated PG release was decreased in 10% serum by over 10-fold but was still 2-fold greater than in controls. In the presence of insulin-like growth factor-1, PG release was as great as without serum. We suggest that Fn fragments, as found in diseased synovial fluid, may contribute to protease-mediated damage to cartilage.			HOMANDBERG, GA (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT BIOCHEM,1653 W CONGRESS PKWY,CHICAGO,IL 60612, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039239] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39239-03] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AGGELER J, 1984, J CELL BIOL, V98, P1662, DOI 10.1083/jcb.98.5.1662; ARNER EC, 1989, ARTHRITIS RHEUM, V32, P288, DOI 10.1002/anr.1780320310; BEEZHOLD DH, 1987, IMMUNOL INVEST, V16, P437, DOI 10.3109/08820138709087097; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BIRKEDALHANSEN H, 1982, BIOCHEM BIOPH RES CO, V107, P1173, DOI 10.1016/S0006-291X(82)80120-4; BOHNSACK JF, 1986, J IMMUNOL, V136, P3793; BROWN RA, 1990, J RHEUMATOL, V17, P65; BURTONWURSTER N, 1985, AM J VET RES, V46, P2542; BURTONWURSTER N, 1986, J RHEUMATOL, V13, P175; CARNEMOLLA B, 1984, ARTHRITIS RHEUM, V27, P913, DOI 10.1002/art.1780270811; CARSONS S, 1981, ARTHRITIS RHEUM, V24, P1261; CARSONS S, 1989, BIOL EXTRACELLULAR M, P327; CAWSTON TE, 1981, METHOD ENZYMOL, V80, P711; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CHANDRASEKHAR S, 1987, ANAL BIOCHEM, V161, P103, DOI 10.1016/0003-2697(87)90658-0; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CLEMMENSEN I, 1983, ARTHRITIS RHEUM, V26, P479, DOI 10.1002/art.1780260405; DAYER JM, 1986, J CLIN INVEST, V77, P645, DOI 10.1172/JCI112350; DESSAU W, 1978, J CELL BIOL, V79, P342, DOI 10.1083/jcb.79.2.342; EVEQUOZ V, 1984, EUR J IMMUNOL, V14, P490, DOI 10.1002/eji.1830140603; FRENZ DA, 1989, DEV BIOL, V136, P87, DOI 10.1016/0012-1606(89)90132-2; FRENZ DA, 1989, DEV BIOL, V136, P97, DOI 10.1016/0012-1606(89)90133-4; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; HARRISON R, 1989, ANAL BIOCHEM, V180, P110, DOI 10.1016/0003-2697(89)90096-1; HASCALL VC, 1983, J RHEUMATOL S, V11, P45; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; HOMANDBERG GA, 1989, CELL BIOL INT REP, V13, P891; HOMANDBERG GA, 1986, BIOCHEMISTRY-US, V25, P6917, DOI 10.1021/bi00370a027; HOMANDBERG GA, 1986, BIOCHIM BIOPHYS ACTA, V874, P61, DOI 10.1016/0167-4838(86)90102-0; JONES KL, 1987, ANN RHEUM DIS, V46, P809, DOI 10.1136/ard.46.11.809; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KRANE SM, 1985, COLLAGEN REL RES, V5, P99; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVIETES BB, 1985, ARTHRITIS RHEUM-US, V28, P1016, DOI 10.1002/art.1780280909; LOHR KM, 1990, BLOOD, V76, P2117; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MILLER DR, 1984, CONNECT TISSUE RES, V12, P267, DOI 10.3109/03008208409013689; MORALES TI, 1984, J BIOL CHEM, V259, P6720; NORRIS DA, 1982, J IMMUNOL, V129, P1612; PENNYPACKER JP, 1981, VISION RES, V21, P65, DOI 10.1016/0042-6989(81)90138-3; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; REES JA, 1987, ANN RHEUM DIS, V46, P816, DOI 10.1136/ard.46.11.816; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SCHALKWIJK J, 1989, ARTHRITIS RHEUM, V32, P66, DOI 10.1002/anr.1780320111; SCOTT DL, 1981, ANN RHEUM DIS, V40, P142, DOI 10.1136/ard.40.2.142; SCOTT DL, 1981, BRIT J EXP PATHOL, V62, P362; SCOTT DL, 1982, CLIN SCI, V62, P71, DOI 10.1042/cs0620071; SHIOZAWA S, 1983, ANN RHEUM DIS, V42, P254, DOI 10.1136/ard.42.3.254; SOMMARIN Y, 1989, EXP CELL RES, V184, P181, DOI 10.1016/0014-4827(89)90376-5; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; THOMPSON KL, 1988, J BIOL CHEM, V263, P19519; VARGA J, 1987, BIOCHEM BIOPH RES CO, V147, P1282, DOI 10.1016/S0006-291X(87)80209-7; WACHTFOGEL YT, 1988, J CLIN INVEST, V81, P1310, DOI 10.1172/JCI113456; WEISS RE, 1980, P NATL ACAD SCI-BIOL, V77, P2074, DOI 10.1073/pnas.77.4.2074; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WEST CM, 1979, CELL, V17, P491; WEST CM, 1984, DIFFERENTIATION, V27, P67, DOI 10.1111/j.1432-0436.1984.tb01409.x; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WRIGHT SD, 1985, J EXP MED, V162, P762, DOI 10.1084/jem.162.2.762; WURSTER NB, 1984, BIOCHIM BIOPHYS ACTA, V800, P52, DOI 10.1016/0304-4165(84)90093-X; WURSTER NB, 1985, DEGENERATIVE JOINTS, V2, P141; XIE DI, 1990, ORTHOP T, V36, P354; YARON I, 1989, ARTHRITIS RHEUM, V32, P173, DOI 10.1002/anr.1780320210	67	202	203	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3597	3604						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740411				2022-12-25	WOS:A1992HE60700011
J	TAYLOR, PM; MACKENZIE, B; LOW, SY; RENNIE, MJ				TAYLOR, PM; MACKENZIE, B; LOW, SY; RENNIE, MJ			EXPRESSION OF RAT-LIVER GLUTAMINE TRANSPORTERS IN XENOPUS-LAEVIS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; MESSENGER-RNA; SMALL-INTESTINE; SYSTEM; COTRANSPORTER; PURIFICATION; METABOLISM; CLONING	As a first step in attempting to isolate the Na+-dependent System N transporter from rat liver we have investigated the use of prophase-arrested oocytes from Xenopus laevis for the functional expression of rat liver glutamine transporters. Individual oocytes, defolliculated by collagenase treatment, were injected with 50 nl of a 1 mg.ml-1 solution of poly(A)+ RNA (mRNA) isolated from rat liver. 50-mu-M L-[H-3]glutamine uptake was measured 1-5 days post-injection: after 48 h, poly(A)+ RNA-injected oocytes showed a 60 +/- 12% increase in Na+-dependent glutamine uptake compared to controls. This increased uptake showed characteristic features of hepatic System N: that is, it tolerated Li+-for-Na+ substitution and was inhibited by the System N substrate L-histidine (5 mM) in Li medium, unlike endogenous Na+-dependent glutamine transport. In subsequent experiments rat liver poly(A)+ RNA, size-fractionated by density gradient fractionation, was injected into oocytes. Injection of poly(A)+ RNA of 1.9-2.8 kilobases (kb) in size resulted in a significant stimulation of Na+-dependent glutamine transport to 0.362 +/- 0.080 pmol.min-1/oocyte from 0.178 +/- 0.060 pmol.min-1/oocyte in vehicle-injected oocytes (p < 0.01). A lighter fraction, with poly(A)+ RNA of less than 1.9 kilobases size resulted in a similar increase in Na+-dependent glutamine uptake which was largely Li+-tolerant: Li+-stimulated glutamine uptake in oocytes injected with this fraction increased to 0.230 +/-0.070 pmol.min-1/oocyte from 0.098 +/- 0.029 pmol.min-1/oocyte in controls (p < 0.05). This enhanced rate of Li+-stimulated glutamine uptake was inhibited 28 and 70%, respectively, by 1 and 5 mM L-histidine. Na+-independent uptake of glutamine rose by 72 +/- 12% in oocytes injected with poly(A)+ RNA of 2.8-3.6 kb (p < 0.001). These results demonstrate that glutamine transporters, with characteristics associated with hepatic Systems N, L, and A (or ASC), can be expressed in X. laevis oocytes injected with specific size fractions of rat liver mRNA.			TAYLOR, PM (corresponding author), UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 4HN,SCOTLAND.		Taylor, Peter M/A-4667-2010	Mackenzie, Bryan/0000-0002-9661-8838	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AOSHIMA H, 1988, ARCH BIOCHEM BIOPHYS, V265, P73, DOI 10.1016/0003-9861(88)90372-4; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAILEY JM, 1976, ANAL BIOCHEM, V70, P75, DOI 10.1016/S0003-2697(76)80049-8; BRAKKE MK, 1970, ANAL BIOCHEM, V38, P56, DOI 10.1016/0003-2697(70)90155-7; CAMPA MJ, 1989, J CELL PHYSIOL, V141, P645, DOI 10.1002/jcp.1041410324; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1987, AMINO ACID TRANSPORT, P10; HAUSSINGER D, 1990, BIOCHEM J, V267, P281; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; ISHII T, 1991, ARCH BIOCHEM BIOPHYS, V289, P71, DOI 10.1016/0003-9861(91)90443-M; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JACOB R, 1986, AM J PHYSIOL, V251, pE509, DOI 10.1152/ajpendo.1986.251.5.E509; KAUR S, 1992, IN PRESS J PHYSL; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KILBERG MS, 1992, IN PRESS J PHYSL; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; LOW SY, 1991, BIOCHEM J, V278, P105, DOI 10.1042/bj2780105; PALACIN M, 1990, BIOCHEM J, V270, P189, DOI 10.1042/bj2700189; POGSON CI, 1991, REGULATION HEPATIC F, P262; SHAY NF, 1990, J BIOL CHEM, V265, P17844; SIGEL E, 1990, J MEMBRANE BIOL, V117, P201, DOI 10.1007/BF01868451; TARNUZZER RW, 1990, J BIOL CHEM, V265, P13914; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; TATE SS, 1989, ARCH BIOCHEM BIOPHYS, V275, P591, DOI 10.1016/0003-9861(89)90405-0; TAYLOR PM, 1989, J MEMBRANE BIOL, V112, P149, DOI 10.1007/BF01871276; TAYLOR PM, 1989, 17TH P INT UN PHYS S, P56; UCHIDA S, 1991, J BIOL CHEM, V266, P9605; VANWINKLE LJ, 1985, J BIOL CHEM, V260, P2118; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0	33	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3873	3877						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740435				2022-12-25	WOS:A1992HE60700052
J	PARSONS, MC; WEIL, PA				PARSONS, MC; WEIL, PA			CLONING OF TFC1, THE SACCHAROMYCES-CEREVISIAE GENE ENCODING THE 95-KDA SUBUNIT OF TRANSCRIPTION FACTOR TFIIIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; 2 FUNCTIONAL COMPONENTS; DNA-BINDING DOMAINS; XENOPUS 5S-RNA GENE; FACTOR-TAU; PURIFICATION; POLYPEPTIDE; PROTEINS; IDENTIFICATION; POLIOVIRUS	The yeast gene encoding the 95-kDa subunit of the class III gene transcription factor TFIIIC was cloned. This gene, termed TFC1 (transcription factor C, gene 1), was isolated by screening a lambda-gt11 yeast cDNA expression library using a polyclonal antiserum preparation which was previously shown to specifically recognize the 95-kDa subunit of yeast TFIIIC (Parsons, M. C., and Weil, P. A. (1990) J. Biol. Chem. 265, 5095-5103). TFC1 was found to be a single copy gene which contained a continuous open reading frame about 2 kilobases in length. TFC1 was shown to encode the 95-kDa subunit of TFIIIC by several criteria. Like the authentic yeast protein, the protein encoded by TFC1 had an apparent molecular weight of 95,000. In addition, the protein encoded by the TFC1 gene bound to the same antibody species as the yeast 95-kDa subunit of TFIIIC. Last, the sizes of the cleavage products of the Escherichia coli-expressed protein were indistinguishable from those of the cleavage products of the bona fide yeast 95-kDa protein.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040517] Funding Source: NIH RePORTER; NIDDK NIH HHS [P60 DK20593] Funding Source: Medline; NIGMS NIH HHS [GM 40517] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BERG JM, 1990, J BIOL CHEM, V265, P6513; BOULANGER PA, 1987, J BIOL CHEM, V262, P15098; CLARK ME, 1990, MOL CELL BIOL, V10, P5106, DOI 10.1128/MCB.10.10.5106; CROMLISH JA, 1989, J BIOL CHEM, V264, P18100; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRADKIN LG, 1987, MOL CELL BIOL, V7, P3880, DOI 10.1128/MCB.7.11.3880; GABRIELSEN OS, 1989, J BIOL CHEM, V264, P7505; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GIARDINA CA, 1990, J BIOL CHEM, V265, P9121; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; JOHNSON DL, 1989, MOL CELL BIOL, V9, P2018, DOI 10.1128/MCB.9.5.2018; KARNITZ L, 1989, MOL CELL BIOL, V9, P1929, DOI 10.1128/MCB.9.5.1929; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KELLER HJ, 1990, MOL CELL BIOL, V10, P5166, DOI 10.1128/MCB.10.10.5166; Landon, 1977, Methods Enzymol, V47, P145; MARZOUKI N, 1986, NATURE, V323, P176, DOI 10.1038/323176a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PARSONS MC, 1990, J BIOL CHEM, V265, P5095; REYNOLDS WF, 1989, NUCLEIC ACIDS RES, V17, P9381; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER HR, 1990, NUCLEIC ACIDS RES, V18, P4743, DOI 10.1093/nar/18.16.4743; SCHNEIDER HR, 1989, NUCLEIC ACIDS RES, V17, P5003, DOI 10.1093/nar/17.13.5003; SCHULTZ P, 1989, EMBO J, V8, P3815, DOI 10.1002/j.1460-2075.1989.tb08559.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SWANSON RN, 1991, P NATL ACAD SCI USA, V88, P4887, DOI 10.1073/pnas.88.11.4887; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; WINGENDER E, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P11; WOLFFE AP, 1988, EMBO J, V7, P1071, DOI 10.1002/j.1460-2075.1988.tb02915.x; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	42	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2894	2901						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737746				2022-12-25	WOS:A1992HD15400015
J	BRUNORI, M; ANTONINI, G; CASTAGNOLA, M; BELLELLI, A				BRUNORI, M; ANTONINI, G; CASTAGNOLA, M; BELLELLI, A			COOPERATIVE CYANIDE DISSOCIATION FROM FERROUS HEMOGLOBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APLYSIA-LIMACINA; DISTAL HISTIDINE; LIGAND-BINDING; MYOGLOBIN; KINETICS; RESOLUTION; ISOCYANIDES; OXYGEN; SPECTROSCOPY; DERIVATIVES	Rapid reduction of cyano-met hemoglobin (Hb+CN-) leads to the formation of an intermediate species, the cyanide derivative of ferrous hemoglobin, which dissociates to unliganded hemoglobin because of the extremely low affinity of the ligand for the ferrous heme iron. The properties of the intermediate were studied by transient spectroscopy in human hemoglobin and its isolated alpha and beta-chains, in the presence and absence of CO. When mixing with dithionite, the time courses of reduction of the heme iron and dissociation of cyanide overlap considerably; addition to the reaction mixture of the redox indicator methyl viologen considerably increases the rate of reduction and allows unequivocal determination of the spectroscopic and kinetic properties of the intermediate. The results show that (i) the dissociation of cyanide from the isolated alpha and beta-chains (as well as the (alpha-CO)2(beta+CN-)2 hybrid) is a simple process; (ii) the two chains display similar rate parameters, but show spectroscopic inequivalence, both in the Soret and the visible regions; (iii) cooperative effects are shown to control the rate of dissociation of cyanide from hemoglobin, similarly to what happens for oxygen; and (iv) allosteric effectors (typically inositol hexaphosphate) increase the overall rate of dissociation by stabilization of the T state. We have, therefore, shown for the first time that the dissociation of cyanide from ferrous hemoglobin is controlled by the quaternary state, thereby adding one more ligand to the analysis of the structure-function relationships in hemoglobin.	UNIV ROME LA SAPIENZA, CNR, CTR BIOL MOLEC, I-00185 ROME, ITALY; UNIV TOR VERGATA, DIPARTIMENTO MED SPERIMENTALE & SCI BIOCHIM, ROME, ITALY; UNIV CATTOLICA SACRO CUORE, IST CHIM, I-00168 ROME, ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Rome Tor Vergata; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	BRUNORI, M (corresponding author), UNIV ROME LA SAPIENZA, CNR, DIPARTIMENTO SCI BIOCHIM, PIAZZA ALDO MORO 5, I-00185 ROME, ITALY.		Bellelli, Andrea/D-2785-2009; Castagnola, Massimo/AAB-2825-2019; Castagnola, Massimo/AAM-6355-2021	Castagnola, Massimo/0000-0002-0959-7259; Antonini, Giovanni/0000-0002-2115-8961; Brunori, Maurizio/0000-0002-7795-1635				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BALDWIN JM, 1980, J MOL BIOL, V136, P103, DOI 10.1016/0022-2836(80)90308-3; BALTHAZARD V, 1926, ANN MED LEG CRIMINOL, V6, P137; Bateman H, 1910, P CAMB PHILOS SOC, V15, P423; BELLELLI A, 1990, J BIOL CHEM, V265, P18898; BOLOGNESI M, 1989, J MOL BIOL, V205, P529, DOI 10.1016/0022-2836(89)90224-6; BOLOGNESI M, 1990, J MOL BIOL, V213, P621, DOI 10.1016/S0022-2836(05)80249-9; BOYER PD, 1954, J AM CHEM SOC, V76, P4331, DOI 10.1021/ja01646a025; BRUNORI M, 1972, J MOL BIOL, V65, P423, DOI 10.1016/0022-2836(72)90199-4; BUCCI E, 1965, J BIOL CHEM, V240, pP551; COLLMAN J P, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1326, DOI 10.1073/pnas.71.4.1326; COX RP, 1977, EUR J BIOCHEM, V74, P575, DOI 10.1111/j.1432-1033.1977.tb11427.x; COX RP, 1977, BIOCHEM J, V167, P493, DOI 10.1042/bj1670493; DEATHERAGE JF, 1976, J MOL BIOL, V104, P687, DOI 10.1016/0022-2836(76)90129-7; GIACOMETTI GM, 1975, BIOCHEMISTRY-US, V14, P1584, DOI 10.1021/bi00679a006; GIBSON QH, 1986, J BIOL CHEM, V261, P228; GIBSON QH, 1973, P NATL ACAD SCI USA, V70, P1, DOI 10.1073/pnas.70.1.1; GIBSON QH, 1959, BIOCHEM J, V71, P293, DOI 10.1042/bj0710293; HEIDNER EJ, 1976, J MOL BIOL, V104, P707, DOI 10.1016/0022-2836(76)90130-3; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; HOPFIELD JJ, 1971, J MOL BIOL, V61, P425, DOI 10.1016/0022-2836(71)90391-3; ILGENFRITZ G, 1971, PROBES STRUCTURE FUN, V2, P399; KEILIN D, 1955, BIOCHEM J, V61, P153, DOI 10.1042/bj0610153; Mattevi A, 1991, J Mol Recognit, V4, P1, DOI 10.1002/jmr.300040102; MOORE EG, 1976, J BIOL CHEM, V251, P2788; OLIVAS E, 1977, J BIOL CHEM, V252, P4038; OLSON JS, 1988, NATURE, V336, P265, DOI 10.1038/336265a0; PERUTZ MF, 1987, ACCOUNTS CHEM RES, V20, P309, DOI 10.1021/ar00141a001; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; Press W., 1986, NUMERICAL RECIPES; REISBERG PI, 1980, J BIOL CHEM, V255, P4159; REISBERG PI, 1980, J BIOL CHEM, V255, P4144; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SHARMA VS, 1980, J BIOL CHEM, V255, P5879; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; Stitt F, 1939, J AM CHEM SOC, V61, P1263, DOI 10.1021/ja01874a075; SZABO A, 1978, P NATL ACAD SCI USA, V75, P2108, DOI 10.1073/pnas.75.5.2108; TALBOT B, 1971, J MOL BIOL, V58, P261, DOI 10.1016/0022-2836(71)90245-2; TENTORI L, 1973, INT J PEPT PROT RES, V5, P187	39	35	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2258	2263						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733933				2022-12-25	WOS:A1992HB53200024
J	KROZOWSKI, Z; OBEYESEKERE, V; SMITH, R; MERCER, W				KROZOWSKI, Z; OBEYESEKERE, V; SMITH, R; MERCER, W			TISSUE-SPECIFIC EXPRESSION OF AN 11-BETA-HYDROXYSTEROID DEHYDROGENASE WITH A TRUNCATED N-TERMINAL DOMAIN - A POTENTIAL MECHANISM FOR DIFFERENTIAL INTRACELLULAR-LOCALIZATION WITHIN MINERALOCORTICOID TARGET-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICOSTEROID 11-BETA-DEHYDROGENASE; MESSENGER-RNAS; RAT-KIDNEY; GENE; METABOLISM; RECEPTORS; SEQUENCE; CLONING; ENZYME; EXCESS	The enzyme 11-beta-hydroxysteroid dehydrogenase (11-HSD) is thought to confer specificity on the nonselective Type I adrenocorticoid receptor by converting glucocorticoids to receptor-inactive metabolites in mineralocorticoid target tissues. S1 nuclease analyses using a rat liver 11-HSD probe demonstrated tissue-specific expression of the 5' region of the 11-HSD gene in the liver, lung, and kidney not evident in previous studies. Renal tissue contained a unique protected species which mapped to a position within the coding region, consistent with a divergence in liver and kidney protein sequences. Screening of a rat kidney cDNA library resulted in the isolation of several clones (11-HSD1B) noncollinear in their 5' regions with the liver sequence (11-HSD1A). Nucleic acid sequence analysis showed that the divergent clones code for a protein lacking a 26-amino acid NH2-terminal putative membrane-spanning signal peptide. The deletion of the leader sequence from the microsomal 11-HSD1A protein may result in a nuclear localization of the 11-HSD1B isoform. The renal 11-HSD1A and 11-HSD1B species increased coordinately during ontogeny and in parallel with the developmental surge in glucocorticoids. At least three alternate sites of polyadenylation were found to be utilized by the 11-HSD gene. Southern blot analysis showed the presence of a single gene in the rat. This study shows the expression of a kidney-specific 11-HSD isoform which may protect the Type I adrenocorticoid receptor from occupation by glucocorticoids in the nucleus of a mineralocorticoid target cell.			KROZOWSKI, Z (corresponding author), BAKER MED RES INST,MOLEC HYPERTENS LAB,POB 348,PRAHRAN,VIC 3181,AUSTRALIA.							AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ALBISTON AL, 1990, MOL CELL ENDOCRINOL, V68, P121, DOI 10.1016/0303-7207(90)90184-A; BEAUMONT K, 1983, ENDOCRINOLOGY, V113, P2043, DOI 10.1210/endo-113-6-2043; BREM AS, 1989, AM J PHYSIOL, V257, pF700, DOI 10.1152/ajprenal.1989.257.4.F700; CARAS IW, 1987, NATURE, V325, P545, DOI 10.1038/325545a0; CHOBERT MN, 1990, J BIOL CHEM, V265, P2352; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; FRUNZIO R, 1986, J BIOL CHEM, V261, P7138; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; FUNDER JW, 1990, FASEB J, V4, P3234, DOI 10.1096/fasebj.4.14.2172062; GHRAF R, 1975, ACTA ENDOCRINOL-COP, V79, P192, DOI 10.1530/acta.0.0790192; GOWER HJ, 1988, CELL, V55, P955, DOI 10.1016/0092-8674(88)90241-3; HENNING SJ, 1978, AM J PHYSIOL, V235, pE451, DOI 10.1152/ajpendo.1978.235.5.E451; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; KOBAYASHI N, 1987, PFLUG ARCH EUR J PHY, V408, P46, DOI 10.1007/BF00581839; KROZOWSKI Z, 1990, ENDOCRINOLOGY, V127, P3009, DOI 10.1210/endo-127-6-3009; KROZOWSKI ZS, 1983, P NATL ACAD SCI-BIOL, V80, P6056, DOI 10.1073/pnas.80.19.6056; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LIN D, 1990, P NATL ACAD SCI USA, V87, P8516, DOI 10.1073/pnas.87.21.8516; Maniatis T., 1982, MOL CLONING; MERCER WR, 1992, IN PRESS ENDOCRINOLO; MONDER C, 1990, ENDOCRINOLOGY, V126, P2435, DOI 10.1210/endo-126-5-2435; MUKAI T, 1986, J BIOL CHEM, V261, P3347; RUNDLE SE, 1989, ENDOCRINOLOGY, V125, P1700, DOI 10.1210/endo-125-3-1700; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TANNIN GM, 1991, 73RD END SOC M WASH; THE VL, 1989, MOL ENDOCRINOL, V3, P1301, DOI 10.1210/mend-3-8-1301; ULICK S, 1979, J CLIN ENDOCR METAB, V49, P757, DOI 10.1210/jcem-49-5-757; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	34	57	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2569	2574						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733955				2022-12-25	WOS:A1992HB53200071
J	PILON, M; DEKRUIJFF, B; WEISBEEK, PJ				PILON, M; DEKRUIJFF, B; WEISBEEK, PJ			NEW INSIGHTS INTO THE IMPORT MECHANISM OF THE FERREDOXIN PRECURSOR INTO CHLOROPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT; INTACT CHLOROPLASTS; CYTOSOLIC FACTORS; ESCHERICHIA-COLI; TRANSLOCATION; BINDING; MITOCHONDRIA; TRANSPORT; MEMBRANE; PURIFICATION	We have investigated the import pathway of the nuclear-encoded chloroplast protein ferredoxin. By using purified precursor protein and washed intact chloroplasts in a defined in vitro uptake system, we show that preferredoxin is fully import-competent by itself. In addition, we show also that the in vitro, in a wheat germ lysate, synthesized preferredoxin is not stably associated with another protein. Import is dependent only on ATP and does not require the presence of cytosolic proteins. Translocation could be largely stimulated by the thiol reducing agent dithiothreitol (DTT). To determine whether DTT acts on the precursor or on the chloroplast, we modified the 5 cysteines in the precursor by a reaction with iodoacetamide, thereby preventing the formation of disulfide bridges in the precursor. The import of this modified precursor was still stimulated by the addition of DTT, indicating that DTT had a stimulating effect on the chloroplast import machinery. In the case of the modified precursor, the import must have taken place without iron-sulfur cluster attachment in the stroma. The modified precursor could be imported with a similar efficiency as the parent precursor showing that import takes place independently from cofactor assembly.	UNIV UTRECHT, DEPT MOLEC CELL BIOL, 3584 CH UTRECHT, NETHERLANDS; UNIV UTRECHT, CTR BIOMEMBRANES & LIPID ENZYMOL, 3584 CH UTRECHT, NETHERLANDS	Utrecht University; Utrecht University	PILON, M (corresponding author), UNIV UTRECHT, INST MOLEC BIOL, PADUALAAN 8, 3584 CH UTRECHT, NETHERLANDS.							ANDERSON CW, 1983, METHOD ENZYMOL, V101, P635; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUINSMA J, 1961, BIOCHIM BIOPHYS ACTA, V52, P576, DOI 10.1016/0006-3002(61)90418-8; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHUA NH, 1978, P NATL ACAD SCI USA, V75, P6110, DOI 10.1073/pnas.75.12.6110; CLINE K, 1985, J BIOL CHEM, V260, P3691; CROOKE E, 1988, CELL, V54, P1003, DOI 10.1016/0092-8674(88)90115-8; CSEKE C, 1986, BIOCHIM BIOPHYS ACTA, V853, P43, DOI 10.1016/0304-4173(86)90004-2; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FERNANDEZ MD, 1990, PLANT CELL, V2, P195, DOI 10.1105/tpc.2.3.195; FRIEDMAN AL, 1989, PLANT PHYSIOL, V89, P993, DOI 10.1104/pp.89.3.993; HAKVOORT TBM, 1990, P NATL ACAD SCI USA, V87, P4996, DOI 10.1073/pnas.87.13.4996; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HOWARDFLANDERS P, 1964, GENETICS, V49, P237; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; KNAFF DB, 1991, BIOCHIM BIOPHYS ACTA, V1056, P93, DOI 10.1016/S0005-2728(05)80277-4; KUSTERS R, 1989, J BIOL CHEM, V264, P20827; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1990, P NATL ACAD SCI USA, V87, P6748, DOI 10.1073/pnas.87.17.6748; LUBBEN TH, 1989, PLANT CELL, V1, P1223, DOI 10.1105/tpc.1.12.1223; Maniatis T., 1982, MOL CLONING; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURPHY DJ, 1986, BIOCHIM BIOPHYS ACTA, V864, P33, DOI 10.1016/0304-4157(86)90015-8; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; ONO H, 1990, ARCH BIOCHEM BIOPHYS, V280, P299, DOI 10.1016/0003-9861(90)90333-T; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; PILON M, 1990, J BIOL CHEM, V265, P3358; RAPOPORT TA, 1990, TRENDS BIOCHEM SCI, V15, P355, DOI 10.1016/0968-0004(90)90076-N; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1985, NUCLEIC ACIDS RES, V13, P3179, DOI 10.1093/nar/13.9.3179; TAKAHASHI Y, 1986, P NATL ACAD SCI USA, V83, P2434, DOI 10.1073/pnas.83.8.2434; THEG SM, 1989, J BIOL CHEM, V264, P6730; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; VANDERPLAS J, 1989, MOL MICROBIOL, V3, P275; WAEGEMANN K, 1990, FEBS LETT, V261, P89, DOI 10.1016/0014-5793(90)80643-W; WALKER DA, 1987, METHOD ENZYMOL, V148, P145; ZIMMERMANN R, 1988, EMBO J, V7, P2875, DOI 10.1002/j.1460-2075.1988.tb03144.x	49	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2548	2556						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733952				2022-12-25	WOS:A1992HB53200068
J	SATOH, T; UEHARA, Y; KAZIRO, Y				SATOH, T; UEHARA, Y; KAZIRO, Y			INHIBITION OF INTERLEUKIN-3 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR STIMULATED INCREASE OF ACTIVE RAS.GTP BY HERBIMYCIN-A, A SPECIFIC INHIBITOR OF TYROSINE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE ACTIVATING PROTEIN; MYELOID CELL-LINE; GROWTH-FACTOR; PC12 CELLS; RECEPTOR; RAS; PHOSPHORYLATION; DIFFERENTIATION; ONCOGENES; CLONING	Interleukin 3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulate the proliferation of several kinds of cultured hematopoietic cell lines. Growth signals from IL-3 and GM-CSF cause accumulation of active Ras.GTP complexes in PT18 mouse mast cell line (Satoh, T., Nakafuku, M., Miyajima, A., and Kaziro, Y. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3314-33 18). In this paper we describe the effect of herbimycin A, a tyrosine kinase-specific inhibitor, on the activation of Ras. The increase of Ras. GTP induced by IL-3 and GM-CSF diminished in cells treated with 0.5 approximately 1-mu-g/ml of herbimycin A for 24 h prior to the addition of the growth factors. Under this condition, the extent of phosphorylation on tyrosine residues of proteins decreased. However, the activity of cAMP-dependent protein kinase and protein kinase C did not change. Growth of cells in the presence of IL-3 or GM-CSF was also completely inhibited. These observations suggest that tyrosine kinases are involved in the pathways between IL-3 and GM-CSF receptors and Ras and that they are essential for the growth stimulated by these growth factors.	DNAX RES INST MOLEC & CELLULAR BIOL INC, 901 CALIF AVE, PALO ALTO, CA 94304 USA; NATL INST HLTH, DEPT ANTIBIOT, TOKYO 141, JAPAN	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; National Institute of Health Sciences - Japan			Satoh, Takaya/K-2628-2014					BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRAVES JD, 1991, J IMMUNOL, V146, P3709; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MUROYA K, 1991, IN PRESS ONCOGENE; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG HM, 1989, EMBO J, V8, P3677, DOI 10.1002/j.1460-2075.1989.tb08542.x; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	43	81	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2537	2541						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733950				2022-12-25	WOS:A1992HB53200066
J	FALETTO, MB; LINKO, P; GOLDSTEIN, JA				FALETTO, MB; LINKO, P; GOLDSTEIN, JA			A SINGLE AMINO-ACID MUTATION (SER180-]CYS) DETERMINES THE POLYMORPHISM IN CYTOCHROME-P450G (P4502C13) BY ALTERING PROTEIN STABILITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID 21-HYDROXYLASE DEFICIENCY; YEAST SACCHAROMYCES-CEREVISIAE; RAT-LIVER; MESSENGER-RNA; LUNG-CANCER; EXPRESSION; DEBRISOQUINE; CDNA; P-450G; ISOZYMES	Cytochrome P450g is polymorphic in the male rat. This polymorphism is characterized by a 20-40-fold difference in the hepatic content of P450g in the two phenotypes. Sequencing of cDNAs from high (+g) and low (-g) phenotype rats has shown that the low phenotype is due to a defective mRNA containing nine base mutations encoding 7 amino acid substitutions. To determine the role of these structural changes in the phenotypic expression of P450g, we altered each of these residues by site-directed mutagenesis in the present studies and expressed the normal and mutant cDNAs in Saccharomyces cerevisiae. P450+g protein was expressed at a level 4-6-fold higher than that of P450-g in yeast cells, despite the presence of identical mRNA levels. This difference in protein expression approaches the difference seen in the rat. A single amino acid change from Ser180 in P450+g to Cys in P450-g, in a highly conserved region in the P4502C subfamily, was found to be solely responsible for the phenotypic differences in expression of P450g. Protein half-life studies demonstrated that this mutation increases the degradation of P450g. This is the first example of a single amino acid substitution which alters the phenotypic expression of a P450 protein by affecting its stability.	NIEHS,BIOCHEM RISK ANAL LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Goldstein, Joyce/A-6681-2012					AMMERER G, 1983, METHOD ENZYMOL, V101, P192; AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; AYESH R, 1984, NATURE, V312, P169, DOI 10.1038/312169a0; BANDIERA S, 1985, ARCH BIOCHEM BIOPHYS, V240, P478, DOI 10.1016/0003-9861(85)90053-0; BANDIERA S, 1986, ARCH BIOCHEM BIOPHYS, V248, P658, DOI 10.1016/0003-9861(86)90521-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPORASO N, 1989, CANCER RES, V49, P3675; CHIOU SH, 1990, J BIOL CHEM, V265, P3549; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; DUMONT MD, 1990, J BIOL CHEM, V265, P2733; FALETTO MB, 1991, FASEB J, V5, pA1163; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0; Guengerich F. P., 1987, MAMMALIAN CYTOCHROME; GUENGERICH FP, 1989, TRENDS PHARMACOL SCI, V10, P107; GUENGERICH FP, 1988, CANCER RES, V48, P2946; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HARRIS CC, 1989, CARCINOGENESIS, V10, P1563, DOI 10.1093/carcin/10.9.1563; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IWASAKI M, 1991, J BIOL CHEM, V266, P3380; KAGIMOTO M, 1990, J BIOL CHEM, V265, P17209; KAISARY A, 1987, CANCER RES, V47, P5488; KEMPER B, 1989, DRUG METAB REV, V20, P811, DOI 10.3109/03602538909103580; KUPFER A, 1984, EUR J CLIN PHARMACOL, V26, P753, DOI 10.1007/BF00541938; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LUSTER MI, 1983, MOL PHARMACOL, V23, P252; MAHGOUB A, 1977, LANCET, V2, P584, DOI 10.1016/S0140-6736(77)91430-1; MCCLELLANGREEN P, 1987, ARCH BIOCHEM BIOPHYS, V253, P13, DOI 10.1016/0003-9861(87)90632-1; MCCLELLANGREEN PD, 1989, BIOCHEMISTRY-US, V28, P5832, DOI 10.1021/bi00440a020; MONIER S, 1988, J CELL BIOL, V107, P457, DOI 10.1083/jcb.107.2.457; NAGATA K, 1989, JPN J PHARMACOL, V51, P585, DOI 10.1254/jjp.51.585; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; NETER J, 1985, APPLIED LINEAR STATI, P60; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OMURA T, 1964, J BIOL CHEM, V239, P2370; PARKINSON A, 1983, ARCH BIOCHEM BIOPHYS, V225, P216, DOI 10.1016/0003-9861(83)90025-5; POMPON D, 1989, GENE, V83, P15, DOI 10.1016/0378-1119(89)90399-5; POULOS TL, 1989, NATURE, V339, P580, DOI 10.1038/339580a0; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAMPERSAUD A, 1987, ARCH BIOCHEM BIOPHYS, V252, P145, DOI 10.1016/0003-9861(87)90018-X; SAKAKI T, 1989, DNA-J MOLEC CELL BIO, V8, P409, DOI 10.1089/dna.1.1989.8.409; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TUSIELUNA MT, 1990, J BIOL CHEM, V265, P20916; WOLF CR, 1986, TRENDS GENET, V2, P209, DOI 10.1016/0168-9525(86)90232-5; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YEOWELL HN, 1985, ARCH BIOCHEM BIOPHYS, V243, P408, DOI 10.1016/0003-9861(85)90517-X; YEOWELL HN, 1990, BIOCHEMISTRY-US, V29, P713, DOI 10.1021/bi00455a018	54	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					2032	2037						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730734				2022-12-25	WOS:A1992HA48500095
J	KOPKE, AKE; LEGGATT, PA; MATHESON, AT				KOPKE, AKE; LEGGATT, PA; MATHESON, AT			STRUCTURE-FUNCTION-RELATIONSHIPS IN THE RIBOSOMAL STALK PROTEINS OF ARCHAEBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; METHANOCOCCUS-VANNIELII; SACCHAROMYCES-CEREVISIAE; SULFOLOBUS-SOLFATARICUS; MONOCLONAL-ANTIBODIES; RAT-LIVER; COMPLEX; SUBUNITS	The ribosomal L12 protein gene of Sulfolobus solfataricus (SsoL12) has been subcloned and overexpressed in Escherichia coli. Five protein L12 mutants were designed: two NH2-terminal and two COOH-terminal truncated mutants and one mutant lacking the highly charged part of the COOH-terminal region. The mutant protein genes were overexpressed in E. coli and the products purified. The amino acid composition was verified and the NH2 terminally truncated mutants were subjected to Edman degradation. The SsoL12 protein was selectively removed from entire S. solfataricus ribosomes by an ethanol wash. The remaining ribosomal core particles showed a substantial decrease in the in vitro translational activity. S. solfataricus L12 protein overexpressed in E. coli (SsoL12e) was incorporated into these ribosomal cores and restored their translational activity. Mutants lacking any part of the COOH-terminal region could be incorporated into these cores, as proven by two-dimensional polyacrylamide gels of the reconstituted particles. Mutant SsoL12 MC2 (residue 1-70) was sufficient for dimerization and incorporation into ribosomes. In contrast to the COOH terminally truncated mutants, L12 proteins lacking the 12 highly conserved NH2-terminal residues or the entire NH2-terminal region (44 amino acids) are unable to bind to ribosomes, suggesting that the SsoL12 protein binds with its NH2-terminal portion to the ribosome. None of the mutants could significantly increase the translational activity of the core particles suggesting that every deleted part of the protein was needed directly or indirectly for translational activity. Our results suggest that the COOH terminally truncated mutants were bound to ribosomes but not functional for translation. Cores preincubated with these COOH terminally truncated mutants regained activity when a second incubation with the entire overexpressed SsoL12e protein followed. This finding suggests that archaebacterial L12 proteins are freely exchanged on the ribosome.	UNIV VICTORIA, DEPT BIOCHEM & MICROBIOL, VICTORIA V8W 3P6, BC, CANADA; MAX PLANCK INST MOLEC GENET, W-1000 BERLIN 33, GERMANY	University of Victoria; Max Planck Society								AMONS R, 1979, FEBS LETT, V104, P85, DOI 10.1016/0014-5793(79)81089-3; AQUIST J, 1990, BIOPOLYMERS, V30, P205; BEAUCLERK AAD, 1984, J BIOL CHEM, V259, P6559; BOUBLIK M, 1979, ARCH BIOCHEM BIOPHYS, V198, P53, DOI 10.1016/0003-9861(79)90394-1; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CASIANO C, 1990, J BIOL CHEM, V265, P18757; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GEYL D, 1981, MOL GEN GENET, V181, P309, DOI 10.1007/BF00425603; GUDKOV AT, 1980, FEBS LETT, V109, P34, DOI 10.1016/0014-5793(80)81305-6; HAMEL E, 1972, J BIOL CHEM, V247, P805; ITOH T, 1981, BIOCHIM BIOPHYS ACTA, V671, P16, DOI 10.1016/0005-2795(81)90088-X; KOPKE AKE, 1989, FEBS LETT, V247, P167, DOI 10.1016/0014-5793(89)81326-2; KOPKE AKE, 1989, CAN J MICROBIOL, V35, P11; KOPKE AKE, 1991, NUCLEIC ACIDS RES, V19, P5169; KOPKE AKE, 1990, J BIOL CHEM, V265, P6436; KOPKE AKE, 1991, BIOCHIMIE, V73, P647, DOI 10.1016/0300-9084(91)90044-2; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; LILJAS A, 1991, INT REV CYTOL, V124, P103; LILJAS A, 1986, CHEM SCRIPTA, V26B, P109; Liljas A, 1986, STRUCTURE FUNCTION G, P379; LIN A, 1982, J BIOL CHEM, V257, P9189; LONDEI P, 1986, NUCLEIC ACIDS RES, V14, P2269, DOI 10.1093/nar/14.5.2269; MATHESON AT, 1990, RIBOSOME, P617; MATHESON AT, 1985, BACTERIA, V8, P345; MOLLER W, 1990, RIBOSOME, P380; Moller W., 1986, STRUCTURE FUNCTION G, P309; NAG B, 1987, BIOCHEMISTRY-US, V26, P461, DOI 10.1021/bi00376a018; Nierhaus K H, 1979, Methods Enzymol, V59, P443; OLSON HM, 1986, J BIOL CHEM, V261, P6924; OTAKA E, 1989, Protein Sequences and Data Analysis, V2, P395; PETTERSSON I, 1976, FEBS LETT, V64, P135, DOI 10.1016/0014-5793(76)80267-0; RAMIREZ C, 1989, CAN J MICROBIOL, V35, P234, DOI 10.1139/m89-036; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SAENZROBLES MT, 1988, EUR J BIOCHEM, V177, P531, DOI 10.1111/j.1432-1033.1988.tb14405.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID G, 1982, MOL GEN GENET, V185, P498, DOI 10.1007/BF00334147; STROBEL O, 1988, J BIOL CHEM, V263, P6538; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TERHORST C, 1973, EUR J BIOCHEM, V34, P138, DOI 10.1111/j.1432-1033.1973.tb02740.x; TSURUGI K, 1985, J BIOCHEM-TOKYO, V98, P1427, DOI 10.1093/oxfordjournals.jbchem.a135410; TSURUGI K, 1991, BIOCHEM BIOPH RES CO, V174, P1318, DOI 10.1016/0006-291X(91)91566-U; VANAGTHOVEN AJ, 1975, BIOCHEM BIOPH RES CO, V64, P1184, DOI 10.1016/0006-291X(75)90818-9; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; Wittmann-Liebold Brigitte, 1986, STRUCTURE FUNCTION G, P326; WITTMANNLIEBOLD B, 1990, RIBOSOME, P598; YAGUCHI M, 1980, GENETICS EVOLUTION R, P585; ZILLIG W, 1989, CAN J MICROBIOL, V35, P73, DOI 10.1139/m89-011	48	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1382	1390						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730657				2022-12-25	WOS:A1992GY96000109
J	LIN, TH; CHU, TM				LIN, TH; CHU, TM			ENHANCEMENT OF PROTEIN-KINASE-C IN MURINE LYMPHOKINE-ACTIVATED KILLER-CELLS BY RETINOIC ACID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER; VITAMIN-A; PHORBOL ESTER; RECEPTOR; DIFFERENTIATION; IDENTIFICATION; INDUCTION; GAMMA; HETEROGENEITY; QUANTITATION	We previously reported that retinoic acid (RA) augmented mouse (BALB/c) lymphokine (interleukin-2)activated killer (LAK) cell activity in a dose and time dependent manner. As evidence available has suggested the role of protein kinase C (PKC) in the regulation of cell mediated cytotoxicity, the present work was to investigate whether or not PKC may mediate the enhancement of LAK cell activity by RA. Accompanied with an augmented LAK cell activity, RA increased total PKC enzyme activity, [H-3]phorbol 12,13-dibutyrate binding activity, and the amount of immunoreactive PKC. A prolonged treatment (18 h) of LAK cells with 12-O-tetradecanoylphorbol-13-acetate resulted in the loss of both PKC and LAK cell activity. PKC inhibitors, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride and staurosporine, also drastically reduced LAK cell activity. Although most of the total PKC activity (97%) was detected in the cytosol fraction, the increase in PKC activity was attributed to an increased enzyme activity in both cytosol and membrane fractions, and shown to be RA dose-dependent. Kinetics study revealed that the increase in PKC was a time-dependent process and the enhancement was detectable as early as 8 h after the addition of RA to LAK cell culture. By immunoblotting, the cytosol PKC of LAK cells was shown to contain alpha and beta-isoforms, but not gamma. RA further increased the expression of PKC-alpha. The enhanced expression of alpha-isozyme of PKC by RA was also in a dose and time dependent manner. Taken together, these results indicate that the mechanism of the augmentation of LAK cell activity RA may in part result from the increase in PKC especially PKC-alpha-isozyme.	NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT DIAGNOST IMMUNOL RES & BIOCHEM,BUFFALO,NY 14263	Roswell Park Cancer Institute					NATIONAL CANCER INSTITUTE [R01CA037646] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BECKNER SK, 1988, J IMMUNOL, V140, P208; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAO T-Y, 1989, Molecular Biotherapy, V1, P318; CHAO TY, 1989, IN VITRO CELL DEV B, V25, P621; DENNERT G, 1978, EUR J IMMUNOL, V8, P23, DOI 10.1002/eji.1830080106; DENNERT G, 1985, CIBA F SYMP, V113, P117; ECCLES SA, 1985, BIOCHEM PHARMACOL, V34, P1599, DOI 10.1016/0006-2952(85)90623-9; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; HALTER SA, 1989, HUM PATHOL, V20, P205, DOI 10.1016/0046-8177(89)90124-X; HAVERSTICK DM, 1991, J IMMUNOL, V146, P3306; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUANG FL, 1987, BIOCHEM BIOPH RES CO, V149, P946, DOI 10.1016/0006-291X(87)90500-6; ISAKOV N, 1988, CELL IMMUNOL, V115, P288, DOI 10.1016/0008-8749(88)90182-7; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KOSAKA Y, 1988, BIOCHEM BIOPH RES CO, V151, P973, DOI 10.1016/S0006-291X(88)80461-3; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LIN TH, 1990, CANCER RES, V50, P3013; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; LOTAN R, 1979, CANCER RES, V39, P55; MAKOWSKE M, 1988, J BIOL CHEM, V263, P3402; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCRADY CW, 1988, CANCER RES, V48, P635; NILES RM, 1989, CANCER RES, V49, P4483; NISHIMURA T, 1987, J IMMUNOL, V139, P2888; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNISHI H, 1991, TUMOR BIOL, V12, P99, DOI 10.1159/000217694; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1987, FEBS LETT, V226, P125, DOI 10.1016/0014-5793(87)80564-1; OROSZ CG, 1983, J IMMUNOL, V130, P2499; ORTALDO JR, 1989, J IMMUNOL, V143, P366; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PROSS HF, 1981, J CLIN IMMUNOL, V1, P51, DOI 10.1007/BF00915477; RICHARDS AL, 1990, J IMMUNOL, V145, P3144; SHOYAB M, 1980, NATURE, V288, P451, DOI 10.1038/288451a0; SPORN MB, 1983, CANCER RES, V43, P3034; STEELE TA, 1988, J IMMUNOL, V141, P3164; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	44	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1335	1339						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730652				2022-12-25	WOS:A1992GY96000102
J	CHEN, MS; SUTTMANN, RT; WU, JC; PRISBE, EJ				CHEN, MS; SUTTMANN, RT; WU, JC; PRISBE, EJ			METABOLISM OF 4'-AZIDOTHYMIDINE - A COMPOUND WITH POTENT AND SELECTIVE ACTIVITY AGAINST THE HUMAN-IMMUNODEFICIENCY-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; HUMAN LYMPHOID-CELLS; THYMIDYLATE KINASE; REVERSE-TRANSCRIPTASE; NUCLEOSIDE ANALOG; HTLV-III/LAV; 3'-AZIDO-3'-DEOXYTHYMIDINE; INVITRO; PHOSPHORYLATION; INFECTIVITY	4'-Azidothymidine (ADRT) is a novel nucleoside analog, that selectively inhibits human immunodeficiency virus replication in human lymphocytes. Unlike the dideoxyribonucleoside analogs and 3'-azido-2',3'-dideoxythymidine (AZT), ADRT retains the 3'-hydroxy group. The pathways of ADRT metabolism were elucidated by determining: (i) the kinetics of the interactions of ADRT and its metabolites with enzymes of thymidine metabolic pathways, (ii) the pool sizes of phosphorylated metabolites, and (iii) the nature of ADRT incorporation into human DNA. ADRT is not a substrate for thymidine phosphorylase, but is metabolized by kinases. Thymidine kinase phosphorylates ADRT to ADRT monophosphate (ADRT-MP). For this enzyme, ADRT has a K(i) value of 5.2-mu-M, in comparison to a K(m) value of 0.7-mu-M for thymidine. The K(m) value of ADRT toward thymidine kinase is 8.3-mu-M and the rate of ADRT phosphorylation is 1.4% that of thymidine phosphorylation. ADRT-MP has a low affinity toward thymidylate kinase (a K(i) value of 28.9-mu-M versus a K(m) value of 0.56-mu-M for thymidylate), and toward thymidylate synthase (a K(i) value of 180-mu-M versus a K(m) value of 8-mu-M for deoxyuridylate). The results suggest that ADRT can be activated effectively by cellular kinases without significant interference of normal thymidine metabolism. In cultured human lymphocytes (A3.01, H9, and U937 cells), ADRT was phosphorylated efficiently to ADRT 5'-triphosphate (ADRT-TP), which is the major metabolite of ADRT. The intracellular concentrations of ADRT-TP ranged from 1 to 3.3-mu-M after 24 h of incubation with 2-mu-M of ADRT and the half-life of ADRT-TP varied from 3 to 6 h. Although ADRT-TP is a poor competitive inhibitor against dTTP toward DNA polymerases-alpha and beta with K(i) values of 62.5 and 150-mu-M, respectively, ADRT-MP was found to be internally incorporated into cellular DNA. The extent of ADRT-MP substitution for dTMP in DNA was 1 in 6979 for A3.01 cells incubated with 2.9-MU-M ADRT for 24 h. Internal incorporation of ADRT-MP contrasts with the mechanism of other 2',3'-dideoxynucleoside analogs (i.e. AZT, ddC, ddI, d4T...), which are DNA chain terminators. This finding indicates that a 3'-deoxy structure in a nucleoside analog is not a prerequisite for anti-human immunodeficiency virus activity.	SYNTEX INC,INST BIOORGAN CHEM,PALO ALTO,CA 94304	Syntex Corporation	CHEN, MS (corresponding author), SYNTEX INC,INST CANC & DEV BIOL,MAIL STOP S3-1,3401 HILLVIEW AVE,PALO ALTO,CA 94304, USA.							BALZARINI J, 1986, BIOCHEM BIOPH RES CO, V140, P735, DOI 10.1016/0006-291X(86)90793-X; BALZARINI J, 1989, J BIOL CHEM, V264, P6127; BONDOC LL, 1990, BIOCHEMISTRY-US, V29, P9839, DOI 10.1021/bi00494a013; CHEN MS, 1976, J BIOL CHEM, V251, P4833; CHEN MS, 1979, J BIOL CHEM, V254, P747; CHEN MS, 1984, MOL PHARMACOL, V25, P441; CHEN MS, 1978, J BIOL CHEM, V253, P1325; CHEN MS, 1986, ANAL BIOCHEM, V156, P300, DOI 10.1016/0003-2697(86)90256-3; CHEN MS, 1976, J BIOL CHEM, V251, P6555; CHEN MS, 1979, J BIOL CHEM, V254, P449; CHEN MS, 1991, 4TH INT C ANT RES NE, P87; CHENG YC, 1976, J BIOL CHEM, V251, P2605; FREITAS VR, 1985, ANTIMICROB AGENTS CH, V28, P240, DOI 10.1128/AAC.28.2.240; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; IMAI KI, 1969, J ORG CHEM, V34, P1547, DOI 10.1021/jo01258a004; JOHNSON MA, 1988, J BIOL CHEM, V263, P15354; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LIN TS, 1987, BIOCHEM PHARMACOL, V36, P311, DOI 10.1016/0006-2952(87)90287-5; MAAG H, 1991, 4TH INT C ANT RES NE, P43; MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911; MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096; PRISBE EJ, 1991, 1991 AM CANC SOC NAT; ROBERTS D, 1966, BIOCHEMISTRY-US, V5, P3546, DOI 10.1021/bi00875a022; SCHINAZI RF, 1987, J CELLULAR BIOCH D S, V11, P74; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; VINCE R, 1988, BIOCHEM BIOPH RES CO, V156, P1046, DOI 10.1016/S0006-291X(88)80950-1	27	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					257	260						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730594				2022-12-25	WOS:A1992GY43900044
J	CHENG, KC; CAHILL, DS; KASAI, H; NISHIMURA, S; LOEB, LA				CHENG, KC; CAHILL, DS; KASAI, H; NISHIMURA, S; LOEB, LA			8-HYDROXYGUANINE, AN ABUNDANT FORM OF OXIDATIVE DNA DAMAGE, CAUSES G -> T AND A -> C SUBSTITUTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; GENERATES G.C->T.A TRANSVERSIONS; APURINIC APYRIMIDINIC SITES; ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; BASE SUBSTITUTION; OXYGEN RADICALS; MUTATOR LOCUS; REPLICATION; POLYMERASE	Mutations caused by oxidative DNA damage may contribute to human disease. A major product of that damage is 8-hydroxyguanine (oh8Gua). Because of differences in experimental design, the base pairing specificity of oh8G in vivo is not completely resolved. Here, oh8dGTP and DNA polymerase were used in two complementary bacteriophage plaque color assays to examine the mutagenic specificity of oh8Gua in vivo. The first is a reversion assay that detects all three single-base substitutions caused by misreading of guanine analogues inserted at a specific site. oh8Gua at that site gave a mutation frequency of 0.7%. Twenty-two of the 23 mutations were G --> T substitutions. The second assay, a forward mutation assay, tests the mispairing potential of any altered nucleotide 1) during incorporation as substrate nucleotide, and 2) after multiple incorporations into a single-stranded DNA gap region of M13mp2. Substituting oh8dGTP for dGTP during polymerization produced 16% mutants; two classes of mutations were observed, both caused by pairing of oh8Gua with A. Seventy-six of 78 mutations were A --> C substitutions, and two were G --> T substitutions. These assays thus illustrate mutagenic replication of oh8Gua as template causing G --> T substitutions and misincorporation of oh8Gua as substrate causing A --> C substitutions, both caused by oh8Gua.A mispairs.	NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan	CHENG, KC (corresponding author), UNIV WASHINGTON, GOTTSTEIN MEM CANC RES LAB, SEATTLE, WA 98195 USA.		Cheng, Keith/B-6506-2011	Cheng, Keith/0000-0002-5350-5825	NATIONAL CANCER INSTITUTE [R35CA039903] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA-39903] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BHATNAGAR AK, 1991, J BIOL CHEM, V266, P9050; BOITEUX S, 1987, EMBO J, V6, P3177, DOI 10.1002/j.1460-2075.1987.tb02629.x; BOITEUX S, 1989, MOL GEN GENET, V215, P300, DOI 10.1007/BF00339732; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; CABRERA M, 1988, J BACTERIOL, V170, P5405, DOI 10.1128/jb.170.11.5405-5407.1988; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CHENG KC, 1991, IN PRESS P NATL ACAD; CHUNG MH, 1991, MUTAT RES, V254, P1, DOI 10.1016/0921-8777(91)90035-N; COTRAN RS, 1989, ROBBINS PATHOLOGIC B, P925; CULP SJ, 1989, CHEM RES TOXICOL, V2, P416, DOI 10.1021/tx00012a010; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DIZDAROGLU M, 1985, BIOCHEMISTRY-US, V24, P4476, DOI 10.1021/bi00337a032; EADIE JS, 1984, NATURE, V308, P201, DOI 10.1038/308201a0; ENGLER MJ, 1983, J BIOL CHEM, V258, P1165; FLOYD RA, 1986, BIOCHEM BIOPH RES CO, V137, P841, DOI 10.1016/0006-291X(86)91156-3; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUTCHINSON F, 1981, PROG NUCLEIC ACID RE, V32, P414; IKEHARA M, 1965, CHEM PHARM BULL, V13, P1140; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KUCHINO Y, 1987, NATURE, V327, P77, DOI 10.1038/327077a0; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNZ BA, 1991, MOL CELL BIOL, V11, P218, DOI 10.1128/MCB.11.1.218; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; MCBRIDE TJ, 1991, BIOCHEMISTRY-US, V30, P207, DOI 10.1021/bi00215a030; MICHAELS JL, 1991, NUCLEIC ACIDS RES, V19, P3629; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; ODA Y, 1991, NUCLEIC ACIDS RES, V19, P1407, DOI 10.1093/nar/19.7.1407; PRESTON BD, 1986, P NATL ACAD SCI USA, V83, P8501, DOI 10.1073/pnas.83.22.8501; PRYOR WA, 1986, ANNU REV PHYSIOL, V48, P657, DOI 10.1146/annurev.ph.48.030186.003301; REID TM, 1990, BIOCHEMISTRY-US, V29, P6153, DOI 10.1021/bi00478a007; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; Sambrook J, 1989, MOL CLONING LABORATO; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIGENAGA MK, 1989, P NATL ACAD SCI USA, V86, P9697, DOI 10.1073/pnas.86.24.9697; STRAUSS B, 1982, BIOCHIMIE, V64, P829, DOI 10.1016/S0300-9084(82)80138-7; TABOR S, 1989, J BIOL CHEM, V264, P6447; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TREFFERS HP, 1954, P NATL ACAD SCI USA, V40, P1064, DOI 10.1073/pnas.40.11.1064; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; ZAKOUR RA, 1984, NUCLEIC ACIDS RES, V12, P6615, DOI 10.1093/nar/12.16.6615	58	1648	1704	0	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					166	172						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730583				2022-12-25	WOS:A1992GY43900031
J	IMAJOHOHMI, S; TOKITA, K; OCHIAI, H; NAKAMURA, M; KANEGASAKI, S				IMAJOHOHMI, S; TOKITA, K; OCHIAI, H; NAKAMURA, M; KANEGASAKI, S			TOPOLOGY OF CYTOCHROME-B558 IN NEUTROPHIL MEMBRANE ANALYZED BY ANTIPEPTIDE ANTIBODIES AND PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; MICROBICIDAL OXIDASE; CHROMOSOMAL LOCATION; HUMAN GRANULOCYTES; RESPIRATORY BURST; PLASMA-MEMBRANE; LIGHT CHAIN; GENE; LOCALIZATION; SUBUNIT	Cytochrome b558 is an important constituent of the superoxide-generating system in neutrophils and B lymphocytes. In this paper, the topology of the cytochrome in human neutrophil membrane was studied using antibodies raised in rabbits against synthetic peptides corresponding to various regions in the large and small subunits of the cytochrome. The antibodies recognized the cytochrome subunits in immunoblots and the cytochrome in situ. An antibody raised against residues 150-172 in the large subunit (anti-L123) bound to intact neutrophils, indicating that this region is exposed to the outside of the cells. In contrast, antibodies raised against any of the carboxyl-terminal regions of the large and small subunits (anti-L(C) and anti-S(C), respectively) or the amino-terminal region of the small subunit (anti-S(N), bound to neutrophils only after the cells were made permeable by freezing and thawing. The region close to the carboxyl terminus of the large subunit was digested by extracellularly added papain and, as a result, an 18-kDa carboxyl-terminal fragment was detected. Thus the carboxyl-terminal region of the large subunit is cytoplasmic and/or buried in the membrane, and the region around residues 369-398 is exposed on the cell surface. In contrast to the large subunits, the small subunit in neutrophils was resistant to any of the proteinases tested, although the subunit in membrane or Triton-solubilized preparation was digestible with papain. These results indicate that the large subunit of cytochrome b558 is a transmembrane protein with at least two regions exposed on the cell surface and that the carboxyl terminus of this subunit and both termini of the small subunit are exposed to the cytoplasmic side.			IMAJOHOHMI, S (corresponding author), UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN.		Kanegasaki, Shiro/AAM-4921-2021					BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; CROSS AR, 1981, BIOCHEM J, V194, P599, DOI 10.1042/bj1940599; DINAUER MC, 1990, J CLIN INVEST, V86, P1729, DOI 10.1172/JCI114898; EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; GINSEL LA, 1990, BLOOD, V76, P2105; HATTORI HIROMI, 1961, NAGOYA JOUR MED SCI, V23, P362; IIZUKA T, 1985, J BIOL CHEM, V260, P2049; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; KOBAYASHI S, 1990, BLOOD, V75, P458; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MAKINO R, 1986, J BIOL CHEM, V261, P1444; MALY FE, 1989, J IMMUNOL, V142, P1260; NAKAMURA M, 1988, BLOOD, V72, P1550; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PARKOS CA, 1988, P NATL ACAD SCI USA, V85, P3319, DOI 10.1073/pnas.85.10.3319; Roos D, 1986, Methods Enzymol, V132, P250; ROTROSEN D, 1990, J BIOL CHEM, V265, P8745; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; SEGAL AW, 1987, NATURE, V326, P88, DOI 10.1038/326088a0; SEGAL AW, 1979, BIOCHEM J, V182, P181, DOI 10.1042/bj1820181; SEGAL AW, 1978, NATURE, V276, P515, DOI 10.1038/276515a0; SMITH RM, 1991, BLOOD, V77, P673; SUMIMOTO H, 1989, BIOCHEM BIOPH RES CO, V165, P902, DOI 10.1016/S0006-291X(89)80051-8; TANAKA T, 1988, J BIOL CHEM, V263, P13670; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; UENO I, 1991, FEBS LETT, V281, P130, DOI 10.1016/0014-5793(91)80375-D	29	108	108	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					180	184						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730586				2022-12-25	WOS:A1992GY43900033
J	LINDNER, D; GSCHWENDT, M; MARKS, F				LINDNER, D; GSCHWENDT, M; MARKS, F			PHORBOL ESTER-INDUCED DOWN-REGULATION OF THE 80-KDA MYRISTOYLATED ALANINE-RICH C-KINASE SUBSTRATE-RELATED PROTEIN IN SWISS 3T3 FIBROBLASTS - INHIBITION BY STAUROSPORINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CELLULAR SUBSTRATE; MOLECULAR-CLONING; GROWTH-FACTORS; PHOSPHORYLATION; PURIFICATION; CALCIUM; CELLS; BRAIN; INTERNALIZATION; EXPRESSION	A polyclonal antiserum raised against an oligopeptide with an amino acid sequence corresponding to a sequence of the myristoylated alanine-rich C-kinase substrate (MARCKS) from mouse macrophages and rat brain recognizes the 80-kDa C-kinase substrate from Swiss 3T3 fibroblasts. Using this antiserum for quantitative determination of the 80-kDa MARCKS-related protein, we found that the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) induces a rapid down-regulation of this protein in the fibroblasts. In accordance with earlier reports, TPA causes phosphorylation of the 80-kDa protein which can be inhibited by staurosporine. Staurosporine also suppresses the TPA-induced down-regulation, possibly indicating that the down-regulation of the MARCKS-related protein is dependent on its phosphorylation by protein kinase C.	GERMAN CANC RES CTR,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; BROOKS SF, 1990, FEBS LETT, V268, P291, DOI 10.1016/0014-5793(90)81030-R; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FEARN JC, 1985, CELL, V40, P991, DOI 10.1016/0092-8674(85)90359-9; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GRAFF JM, 1989, MOL ENDOCRINOL, V3, P1903, DOI 10.1210/mend-3-11-1903; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GSCHWENDT M, 1989, J CELL BIOCHEM, V40, P295, DOI 10.1002/jcb.240400306; HORN F, 1985, EUR J BIOCHEM, V148, P533, DOI 10.1111/j.1432-1033.1985.tb08872.x; HORNBECK P, 1989, MOL CELL BIOL, V9, P3727, DOI 10.1128/MCB.9.9.3727; JAMES G, 1989, J BIOL CHEM, V264, P20928; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LINDNER D, 1991, BIOCHEM BIOPH RES CO, V176, P1227, DOI 10.1016/0006-291X(91)90416-5; MAY WS, 1987, J BIOL CHEM, V262, P16710; MORRIS C, 1988, FEBS LETT, V231, P311, DOI 10.1016/0014-5793(88)80840-8; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROSEN J, 1991, J BIOL CHEM, V266, P3827; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; SMITH JB, 1985, BIOCHEM BIOPH RES CO, V131, P1109; SOLOMON DH, 1985, FEBS LETT, V190, P342, DOI 10.1016/0014-5793(85)81315-6; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253	30	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					24	26						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730592				2022-12-25	WOS:A1992GY43900007
J	MILLA, ME; CLAIRMONT, CA; HIRSCHBERG, CB				MILLA, ME; CLAIRMONT, CA; HIRSCHBERG, CB			RECONSTITUTION INTO PROTEOLIPOSOMES AND PARTIAL-PURIFICATION OF THE GOLGI-APPARATUS MEMBRANE UDP-GALACTOSE, UDP-XYLOSE, AND UDP-GLUCURONIC ACID TRANSPORT ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; RAT-LIVER GOLGI; CMP-SIALIC ACID; HEPARAN-SULFATE; RABBIT THROMBOMODULIN; FUNCTIONAL DOMAINS; VESICLE MEMBRANES; MUTANT DEFICIENT; PROTEOGLYCAN; PROTEIN	Previous studies in vitro on proteoglycan biosynthesis from our laboratory have shown that nucleotide sugar precursors of all the sugars of the linkage oligosaccharides (xylose, galactose, and glueuronic acid) and of the glycosaminoglycans (N-acetylglucosamine, N-galactosamine, and glucuronic acid) are transported by specific carriers into the lumen of Golgi vesicles. More recently, we also reported the reconstitution in phosphatidylcholine liposomes of detergent-solubilized Golgi membrane proteins containing transport activities of CMP-sialic acid and adenosine-3'-phosphate-5'-phosphosulfate. We have now completed the successful reconstitution into liposomes of the Golgi membrane transport activities of UDP-galactose, UDP-xylose, and UDP-glucuronic acid. Transport of these nucleotide sugars into Golgi protein proteoliposomes occurred with the same affinity, temperature dependence, and sensitivity to inhibitors as observed with intact Golgi vesicles. Preloading of proteoliposomes with UMP, the putative antiporter for Golgi vesicle transport of these nucleotide sugars, stimulated transport of the nucleotide sugars by 2-3-fold. Transport of UDP-xylose into Golgi protein proteoliposomes was dependent on the presence of endogenous Golgi membrane lipids while that of UDP-galactose and UDP-glucuronic acid was not. This suggests a possible stabilizing or regulatory role for Golgi lipids on the UDP-xylose translocator. Finally, we have also shown that detergent-solubilized Golgi membrane translocator proteins can be partially purified by an ion-exchange chromatographic step before successful reconstitution into liposomes, demonstrating that this reconstitution approach can be used for the biochemical purification of these transporters.			MILLA, ME (corresponding author), UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655, USA.			Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM 34396, GM 30365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030365, R01GM034396, R37GM030365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1987, J BIOL CHEM, V262, P4153; ARRUFFO A, 1990, CELL, V61, P1303; BOURIN MC, 1986, P NATL ACAD SCI USA, V83, P5924, DOI 10.1073/pnas.83.16.5924; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; CAREY DJ, 1981, J BIOL CHEM, V256, P989; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; JACKMAN RW, 1986, P NATL ACAD SCI USA, V83, P8834, DOI 10.1073/pnas.83.23.8834; KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688; KASAHARA M, 1976, P NATL ACAD SCI USA, V73, P396, DOI 10.1073/pnas.73.2.396; KEENAN TW, 1970, BIOCHEMISTRY-US, V9, P19, DOI 10.1021/bi00803a003; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LOHMANDER LS, 1986, ARCH BIOCHEM BIOPHYS, V250, P211, DOI 10.1016/0003-9861(86)90719-8; MIDURA RJ, 1990, J BIOL CHEM, V265, P15947; MILLA ME, 1989, P NATL ACAD SCI USA, V86, P1786, DOI 10.1073/pnas.86.6.1786; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; PEREZ M, 1986, J BIOL CHEM, V261, P6822; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLATT JL, 1990, DEV BIOL, V139, P338, DOI 10.1016/0012-1606(90)90303-Z; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; WILLIAMS MP, 1983, BIOCHIM BIOPHYS ACTA, V756, P83, DOI 10.1016/0304-4165(83)90027-2; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	32	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					103	107						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730575				2022-12-25	WOS:A1992GY43900022
J	REDEKER, V; LECAER, JP; ROSSIER, J; PROME, JC				REDEKER, V; LECAER, JP; ROSSIER, J; PROME, JC			STRUCTURE OF THE POLYGLUTAMYL SIDE-CHAIN POSTTRANSLATIONALLY ADDED TO ALPHA-TUBULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; MOUSE-BRAIN; BINDING-SITES; POLYMERIZATION; ACETYLATION; PROTEOLYSIS; COMMON; MAP2	Polyglutamylation, a new posttranslational modification of tubulin identified originally on the acidic alpha-variants by Edde et al. (Edde, B., Rossier, J., Le Caer, J. P., Desbruyeres, E., Gros, F., and Denoulet, P. (1990) Science 247, 83-85), consists of the successive addition of glutamyl units to the Glu445. To characterize their linkage mode mouse tubulin was posttranslationally labeled with [H-3]glutamate. After digestion of [H-3]tubulin with thermolysin, up to eight radioactive peaks were separated on an anion exchange column (DEAE). Combined use of Edman degradation sequencing and mass spectrometry analysis of the first 6 one indicated that they all correspond to the same COOH-terminal sequence 440VEGEGEEEGEE450 bearing one to six glutamyl units on the GLU445. The first glutamyl residue is amide-linked to the gamma-carboxyl group of Glu445, but the additional residues can be linked to the gamma- or alpha-carboxyl groups of the preceding one. All possible linkages for the biglutamylated tubulin peptides (gamma-1-alpha-2, gamma-1-gamma-2) and triglutamylated (gamma-1-alpha-2-alpha-3, gamma-1-alpha-2-gamma-3, gamma-1-alpha-2-gamma-2, gamma-1-gamma-2-alpha-3, gamma-1-gamma-2-gamma-3) were synthesized. These different peptides were successfully separated on a C18 5-mu-m reverse phase column. We found that the bi- and triglutamylated tubulin peptides behave as the gamma-1-alpha-2 and gamma-1-alpha-2-alpha-3 synthetic peptides, respectively. These results indicate that the second and third glutamyl residues of the polyglutamyl side chain are amide-linked to the alpha-carboxyl group of the preceding unit.	CNRS,CTR RECH BIOCHIM & GENET CELLULAIRES,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	REDEKER, V (corresponding author), CNRS,PHYSIOL NERVEUSE LAB,F-91198 GIF SUR YVETTE,FRANCE.		Redeker, Virginie/L-8929-2018	Redeker, Virginie/0000-0003-2694-8388				ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; BHATTACHARYYA B, 1985, J BIOL CHEM, V260, P208; CICHOWICZ DJ, 1987, BIOCHEMISTRY-US, V26, P504, DOI 10.1021/bi00376a024; DENOULET P, 1982, BIOCHIMIE, V64, P165, DOI 10.1016/S0300-9084(82)80466-5; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; EDDE B, 1991, J CELL BIOCHEM, V46, P134, DOI 10.1002/jcb.240460207; EDDE B, 1989, BIOL CELL, V65, P109; FERONE R, 1986, J BIOL CHEM, V261, P6356; LECAER JP, 1988, ANAL BIOCHEM, V169, P246, DOI 10.1016/0003-2697(88)90281-3; LEDIZET M, 1987, P NATL ACAD SCI USA, V84, P5720, DOI 10.1073/pnas.84.16.5720; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MEISTER A, 1973, SCIENCE, V180, P33, DOI 10.1126/science.180.4081.33; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; RAYBIN D, 1977, J CELL BIOL, V73, P492, DOI 10.1083/jcb.73.2.492; RINGEL I, 1984, BIOCHEMISTRY-US, V23, P5644, DOI 10.1021/bi00318a040; RODIONOV VI, 1990, J BIOL CHEM, V265, P5702; SACKETT DL, 1985, J BIOL CHEM, V260, P43; SACKETT DL, 1986, J BIOL CHEM, V261, P9070; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VERA JC, 1989, BIOCHEMISTRY-US, V28, P333, DOI 10.1021/bi00427a045; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; WEBER J, 1990, J BIOL CHEM, V265, P9664; WOLFF A, 1982, NEUROSCI LETT, V31, P323, DOI 10.1016/0304-3940(82)90041-6	26	57	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 5	1991	266	34					23461	23466						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GT483	1720781				2022-12-25	WOS:A1991GT48300102
J	HAHN, S; WODNARFILIPOWICZ, A; NAIR, APK; MORONI, C				HAHN, S; WODNARFILIPOWICZ, A; NAIR, APK; MORONI, C			RAS ONCOGENES AMPLIFY LYMPHOKINE (INTERLEUKIN-3, GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR) INDUCTION BY CALCIUM IONOPHORE	ONCOGENE			English	Article							CSF MESSENGER-RNA; GM-CSF; MAST-CELLS; GROWTH-FACTORS; EXPRESSION; GENE; TRANSFORMATION; TUMOR; ACTIVATION; TRANSCRIPTION	Interleukin 3 (IL-3) expression in PB-3c mastocytes is transiently induced in vitro by treatment with the drug A23187, a calcium ionophore, or constitutively following ras-dependent transformation in vivo. While the mechanism of oncogenically induced IL-3 expression is not clear, A23187-mediated lymphokine mRNA accumulation is primarily the result of calcium-dependent mRNA stabilization. We investigated whether the expression of various ras alleles influenced IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA induction by A23187. It was found that activated forms of ras potentiated ionophore-mediated lymphokine mRNA accumulation. This enhancement involves a post-transcriptional mechanism, as ionophore-induced lymphokine mRNAs are significantly more stable in ras oncogene-expressing lines than in the control line. We propose that one way by which ras genes exert their oncogenic potential is by extending the half-life of short-lived growth factor mRNAs.	UNIV BASEL, INST MED MIKROBIOL, CH-4003 BASEL, SWITZERLAND	University of Basel								ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GRIMALDI JC, 1989, BLOOD, V73, P2081; HOFSTETTER P, 1987, MOL CELL BIOL, V7, P4535, DOI 10.1128/MCB.7.12.4535; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; METCALF D, 1984, HEMOPOIETIC COLONIES; METZGER H, 1988, ADV IMMUNOL, V43, P277; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	28	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2327	2332						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1722572				2022-12-25	WOS:A1991GX73500022
J	DIMARCO, E; MARCHISIO, PC; BONDANZA, S; FRANZI, AT; CANCEDDA, R; DELUCA, M				DIMARCO, E; MARCHISIO, PC; BONDANZA, S; FRANZI, AT; CANCEDDA, R; DELUCA, M			GROWTH-REGULATED SYNTHESIS AND SECRETION OF BIOLOGICALLY-ACTIVE NERVE GROWTH-FACTOR BY HUMAN KERATINOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN KERATINOCYTES; HUMAN MELANOCYTE GROWTH; RAT SCIATIC-NERVE; EPIDERMAL-KERATINOCYTES; MONOCLONAL-ANTIBODIES; DEVELOPING SKIN; MESSENGER-RNA; FACTOR-ALPHA; BURN WOUNDS; CELLS	Nerve growth factor (NGF) transcripts were identified in normal human keratinocytes in primary and secondary culture. The expression of the NGF mRNA was strongly down-regulated by corticosteroids and was maximal when keratinocytes were in the exponential phase of growth. Immunofluorescence studies on growing keratinocytes colonies and on elutriated keratinocytes obtained from growing colonies and mature stratified epithelium showed specific staining of the Golgi apparatus only in basal keratinocytes in the exponential phase of growth. The keratinocyte-derived NGF was secreted in a biologically active form as assessed by neurite induction in sensory neurons obtained from chick embryo dorsal root ganglia. Based on these data we suggest that the basal keratinocyte is the cell synthesizing and secreting NGF in the human adult epidermis. The paracrine secretion of NGF by keratinocytes might have a major role in regulating innervation, lymphocyte function, and melanocyte growth and differentiation in epidermal morphogenesis as well as during wound healing.	UNIV TURIN, DIPARTIMENTO SCI BIOMED & ONCOL UMANA, I-10126 TURIN, ITALY; UNIV GENOA, IST ANAT UMANA NORMALE, I-16132 GENOA, ITALY	University of Turin; University of Genoa	DELUCA, M (corresponding author), IST NAZL RIC CANC, DIFFERENZIAMENTO CELLULARE LAB, IST, VIALE BENEDETTO 15, NO 10, I-16132 GENOA, ITALY.		De Luca, Michele/N-5883-2014	De Luca, Michele/0000-0002-0850-8445				BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; BIASSONI R, 1988, J IMMUNOL, V140, P1685; BLANTON RA, 1989, P NATL ACAD SCI USA, V86, P1273, DOI 10.1073/pnas.86.4.1273; CATTANEO A, 1988, J NEUROCHEM, V50, P1003, DOI 10.1111/j.1471-4159.1988.tb10565.x; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COMPTON CC, 1989, LAB INVEST, V60, P600; DANNA F, 1988, HISTOCHEM J, V20, P674, DOI 10.1007/BF01002747; DAVIES AM, 1987, NATURE, V326, P353, DOI 10.1038/326353a0; DELUCA M, 1989, BURNS, V15, P303, DOI 10.1016/0305-4179(89)90007-7; DELUCA M, 1988, J CELL BIOL, V107, P1919, DOI 10.1083/jcb.107.5.1919; DELUCA M, 1990, TRANSPLANTATION, V50, P454, DOI 10.1097/00007890-199009000-00019; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; EDWARDS RH, 1989, CELL, V58, P161, DOI 10.1016/0092-8674(89)90412-1; FENJVES ES, 1989, P NATL ACAD SCI USA, V86, P8803, DOI 10.1073/pnas.86.22.8803; FRIED RM, 1988, ENDOCRINOLOGY, V122, P2467, DOI 10.1210/endo-122-6-2467; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GORDON PR, 1989, J INVEST DERMATOL, V92, P565, DOI 10.1111/1523-1747.ep12709595; Green H, 1980, Harvey Lect, V74, P101; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HAEGERSTRAND A, 1989, P NATL ACAD SCI USA, V86, P5993, DOI 10.1073/pnas.86.15.5993; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; KANE CJM, 1990, J CELL PHYSIOL, V144, P144, DOI 10.1002/jcp.1041440119; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KORSCHING S, 1985, EMBO J, V4, P1389, DOI 10.1002/j.1460-2075.1985.tb03791.x; LANDRETH GE, 1985, J CELL BIOL, V100, P677, DOI 10.1083/jcb.100.3.677; LETOURNEAU PC, 1978, DEV BIOL, V66, P183, DOI 10.1016/0012-1606(78)90283-X; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LUGER TA, 1990, J INVEST DERMATOL, V95, pS100, DOI 10.1111/1523-1747.ep12874944; MARCHISIO PC, 1991, J CELL BIOL, V112, P761, DOI 10.1083/jcb.112.4.761; MERENDINO JJ, 1986, SCIENCE, V231, P388, DOI 10.1126/science.2417317; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PEACOCKE M, 1988, P NATL ACAD SCI USA, V85, P5282, DOI 10.1073/pnas.85.14.5282; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; ROHRER H, 1988, DEV BIOL, V128, P240, DOI 10.1016/0012-1606(88)90286-2; ROMAGNOLI G, 1990, NEW ENGL J MED, V323, P527, DOI 10.1056/NEJM199008233230806; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; ROSSINO P, 1990, EXP CELL RES, V189, P100, DOI 10.1016/0014-4827(90)90262-9; SCOTT J, 1983, NATURE, V302, P538, DOI 10.1038/302538a0; SIMINOSKI K, 1987, ENDOCRINOLOGY, V121, P1432, DOI 10.1210/endo-121-4-1432; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284	46	154	158	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21718	21722						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1718982				2022-12-25	WOS:A1991GP80400060
J	HERZ, J; GOLDSTEIN, JL; STRICKLAND, DK; HO, YK; BROWN, MS				HERZ, J; GOLDSTEIN, JL; STRICKLAND, DK; HO, YK; BROWN, MS			39-KDA PROTEIN MODULATES BINDING OF LIGANDS TO LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERCHOLESTEROLEMIA; LDL-RECEPTOR; MONOCLONAL-ANTIBODIES; MEDIATED ENDOCYTOSIS; HEYMANN NEPHRITIS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; APOLIPOPROTEIN-E; CULTURED-CELLS; PURIFICATION	A 39-kDa protein of unknown function has previously been reported to copurify with the low density lipoprotein receptor-related protein (LRP)/alpha-2-macroglobulin receptor. In this study we demonstrate that a recombinant 39-kDa fusion protein can reversibly bind to the 515-kDa subunit of the LRP/alpha-2-macroglobulin receptor. This interaction inhibits the binding and uptake of the receptor's two known ligands: 1) beta-migrating very low density lipoproteins activated by enrichment with apoprotein E and 2) alpha-2-macroglobulin activated by incubation with plasma proteases or methylamine. A potential in vivo role of the 39-kDa protein is to modulate the uptake of apoE-enriched lipoproteins and activated alpha-2-macroglobulin in hepatic and extrahepatic tissues.	AMER RED CROSS,BIOCHEM LAB,ROCKVILLE,MD 20855	American Red Cross	HERZ, J (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.				NHLBI NIH HHS [HL30200, HL20948] Funding Source: Medline; NIGMS NIH HHS [GM42581] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030200, P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042581] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; FURUKAWA T, 1990, J BIOCHEM-TOKYO, V108, P297, DOI 10.1093/oxfordjournals.jbchem.a123197; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1974, P NATL ACAD SCI USA, V71, P4288, DOI 10.1073/pnas.71.11.4288; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1990, J BIOL CHEM, V265, P21355; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; PIETROMONACO S, 1990, P NATL ACAD SCI USA, V87, P1811, DOI 10.1073/pnas.87.5.1811; RAYCHOWDHURY R, 1989, SCIENCE, V244, P1163, DOI 10.1126/science.2786251; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER WJ, 1985, METHOD ENZYMOL, V109, P405; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696	29	552	566	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21232	21238						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1718973				2022-12-25	WOS:A1991GN00100100
J	ROSS, TS; JEFFERSON, AB; MITCHELL, CA; MAJERUS, PW				ROSS, TS; JEFFERSON, AB; MITCHELL, CA; MAJERUS, PW			CLONING AND EXPRESSION OF HUMAN 7K-KDA INOSITOL POLYPHOSPHATE-5-PHOSPHATASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; HUMAN-PLATELETS; RAT-BRAIN; 1,4,5-TRISPHOSPHATE PHOSPHATASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; CDNA CLONING; PROTEIN; TRISPHOSPHATE; RECEPTOR	Inositol polyphosphate-5-phosphatase (5-phosphatase) hydrolyzes inositol 1,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate and thereby functions as a signal terminating enzyme in cellular calcium ion mobilization. A cDNA encoding human platelet 5-phosphatase has been isolated by screening for beta-galactosidase fusion proteins that bind to inositol 1,3,4,5-tetrakisphosphate. The sensitivity of the screening procedure was enhanced 50- to 100-fold by amplification of "sublibraries" prior to carrying out binding assays. The sequences derived from the "expression clone" were used to screen human erythroleukemia cell line and human megakaryocytic cell line cDNA libraries. We obtained two additional clones which together consist of 2381 base pairs. The amino-terminal amino acid sequence from the 75-kDa 5-phosphatase purified from platelets is identical to amino acids 38-56 predicted from the cDNA. This suggests that the platelet 5-phosphatase is formed by proteolytic processing of a larger precursor. The cDNA predicts that the mature enzyme contains 635 amino acids (M(r) 72, 891). Antibodies directed against recombinant TrpE fusion proteins of either an amino-terminal region or a carboxyl-terminal region immunoprecipitate the enzyme activity from a preparation of the 75-kDa form of platelet 5-phosphatase (Type II) but do not precipitate the distinct 47-kDa 5-phosphatase (Type I) also found in platelets. In addition, the recombinant protein expressed in Cos-7 cells has the same 5-phosphatase activity as the platelet 5-phosphatase.			ROSS, TS (corresponding author), WASHINGTON UNIV, SCH MED, DIV HEMATOL ONCOL, ST LOUIS, MO 63110 USA.			Ross, Theodora/0000-0002-9166-1802; Mitchell, Christina A/0000-0001-9372-3192	NHLBI NIH HHS [HLBI-16634, HLBI-14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, R37HL016634, P50HL014147] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baenziger N L, 1974, Methods Enzymol, V31, P149; BANSAL VS, 1990, ANNU REV CELL BIOL, V6, P41, DOI 10.1146/annurev.cellbio.6.1.41; BARKAS T, 1987, SCIENCE, V235, P77, DOI 10.1126/science.2432658; BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BRUNS RF, 1983, ANAL BIOCHEM, V132, P74, DOI 10.1016/0003-2697(83)90427-X; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CONNOLLY TM, 1986, J BIOL CHEM, V261, P122; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; DEWET JR, 1985, P NATL ACAD SCI USA, V82, P7870; DIEHL RE, 1990, J BIOL CHEM, V265, P5946; DONIE F, 1990, FEBS LETT, V268, P194, DOI 10.1016/0014-5793(90)81006-A; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; ERNEUX C, 1986, BIOCHEM BIOPH RES CO, V134, P351, DOI 10.1016/0006-291X(86)90570-X; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; HANSEN CA, 1986, J BIOL CHEM, V261, P8100; JOSEPH SK, 1985, FEBS LETT, V180, P150, DOI 10.1016/0014-5793(85)81061-9; KAUFMAN DL, 1986, SCIENCE, V232, P1138, DOI 10.1126/science.3518061; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIZ R, 1990, CIBA F SYMP, V150, P112; KUKITA M, 1986, BIOCHIM BIOPHYS ACTA, V885, P121, DOI 10.1016/0167-4889(86)90046-7; LACOMBE ML, 1987, GENE, V58, P29, DOI 10.1016/0378-1119(87)90026-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MOLINA LM, 1986, J BIOL CHEM, V261, P493; NORDQUIST DT, 1988, J NEUROSCI, V8, P4780; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RANA RS, 1986, J BIOL CHEM, V261, P5237; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROSS EM, 1980, ANNU REV BIOCHEM, V49, P553, DOI 10.1146/annurev.bi.49.070180.002533; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; SEYFRED MA, 1984, J BIOL CHEM, V259, P3204; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SPRAGUE J, 1983, J VIROL, V45, P773, DOI 10.1128/JVI.45.2.773-781.1983; STOREY DJ, 1984, NATURE, V312, P374, DOI 10.1038/312374a0; TANESE N, 1986, J VIROL, V59, P328, DOI 10.1128/JVI.59.2.328-340.1986; THEIBERT AB, 1990, BIOCHEM J, V267, P441, DOI 10.1042/bj2670441; WU Q, 1991, IN PRESS J BIOL CHEM, V266; YE RD, 1987, J BIOL CHEM, V262, P3718; YORK JD, 1990, P NATL ACAD SCI USA, V87, P9548, DOI 10.1073/pnas.87.24.9548; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	50	72	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20283	20289						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1718960				2022-12-25	WOS:A1991GM03900061
J	DHAR, A; SHUKLA, SD				DHAR, A; SHUKLA, SD			INVOLVEMENT OF PP60C-SRC IN PLATELET-ACTIVATING FACTOR-STIMULATED PLATELETS - EVIDENCE FOR TRANSLOCATION FROM CYTOSOL TO MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; RABBIT PLATELETS; PHOSPHOLIPASE-C; CYTOPLASMIC DOMAINS; PHOSPHORYLATION; RECEPTOR; THROMBIN; P56LCK; CD4; DESENSITIZATION	We have investigated the characteristics of platelet-activating factor (PAF)-stimulated protein tyrosine phosphorylation in rabbit platelets and its relationship to pp60c-src P-32-Labeled platelets were challenged with PAF (10(-7) M) for 15 s, the reaction was killed by lysis at 4-degrees-C, and samples were loaded onto a phosphotyrosine monoclonal antibody (Tyr(P)-mAb)-agarose column. The column was eluted with 10 mM phenyl phosphate, and the fractions were collected. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by autoradiography of the column fractions, showed that PAF increased the radioactivity of about a dozen protein bands with predominant ones of approximate molecular masses of 50, 60, 71, 82, and 300 kDa. When Tyr(P)-mAb-agarose column fractions were subjected to immunoblotting with pp60v-src mAb, it was observed that PAF treatment increased the reactivity of 50- and 60-kDa protein species. Immuno-precipitation with pp60v-src mAb further confirmed that PAF treatment increased phosphorylation of the 60- and 50-kDa proteins. Polyclonal antibody to G-protein (alpha-subunit) did not exhibit any reactivity to the column fractions and thus ruled out this protein as substrate for the tyrosine kinase. We next attempted to localize the pp60c-src. Platelet membrane particulate and cytosol fractions were separated from control and PAF-treated platelets, and it was observed that the immunoreactivity to pp60v-src mAb dramatically increased in the particulate membrane fraction from PAF-treated platelets. A concomitant decrease in the immunoreactivity in the cytosol fraction of PAF-treated platelets was also noted. It is concluded that PAF stimulates phosphorylation of pp60c-src tyrosine kinase and causes its rapid translocation from cytosol to membranes in rabbit platelets.	UNIV MISSOURI,SCH MED,DEPT PHARMACOL,M517B MED SCI BLDG,1 HOSP DR,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					NIDDK NIH HHS [1 K04 DK 01782, 5R01 DK 35170] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035170, K04DK001782] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DHAR A, 1990, MOL PHARMACOL, V37, P519; DHAR A, 1991, BIOCHIM BIOPHYS ACTA, V1091, P15, DOI 10.1016/0167-4889(91)90215-J; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEDER D, 1990, J BIOL CHEM, V265, P8205; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; GLAZER KB, 1990, J BIOL CHEM, V265, P8658; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HWANG SB, 1990, J LIPID MEDIATOR, V2, P123; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISON WJ, 1989, J PHARMACOL EXP THER, V250, P831; MORRISON WJ, 1989, LIFE SCI, V45, P333, DOI 10.1016/0024-3205(89)90143-4; MORRISON WJ, 1988, MOL PHARMACOL, V35, P409; NAKAMURA S, 1985, FEBS LETT, V184, P56, DOI 10.1016/0014-5793(85)80652-9; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; OKADA M, 1989, J BIOL CHEM, V264, P20886; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; RENDU F, 1989, BLOOD, V73, P1545; REUTER C, 1990, EUR J BIOCHEM, V190, P343, DOI 10.1111/j.1432-1033.1990.tb15581.x; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHUKLA SD, 1989, MOL PHARMACOL, V35, P409; SHUKLA SD, 1982, BIOCHEM BIOPH RES CO, V106, P697, DOI 10.1016/0006-291X(82)91767-3; SHUKLA SD, 1991, IN PRESS LIPIDS, V26; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; TAKAYAMA H, 1991, BIOCHEM BIOPH RES CO, V174, P922, DOI 10.1016/0006-291X(91)91506-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; TUY FPD, 1983, NATURE, V305, P435	37	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18797	18801						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1717453				2022-12-25	WOS:A1991GJ47200061
J	ROYCHOWDHURY, J; HUANG, TJ; KESARI, K; LEDERSTEIN, M; ARIAS, IM; ROYCHOWDHURY, N				ROYCHOWDHURY, J; HUANG, TJ; KESARI, K; LEDERSTEIN, M; ARIAS, IM; ROYCHOWDHURY, N			MOLECULAR-BASIS FOR THE LACK OF BILIRUBIN-SPECIFIC AND 3-METHYLCHOLANTHRENE-INDUCIBLE UDP-GLUCURONOSYLTRANSFERASE ACTIVITIES IN GUNN-RATS - THE 2 ISOFORMS ARE ENCODED BY DISTINCT MESSENGER-RNA SPECIES THAT SHARE AN IDENTICAL SINGLE BASE DELETION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID 21-HYDROXYLASE DEFICIENCY; LIVER; INDUCTION; MECHANISM; MUTATIONS; CDNA; DNA	Gunn rats lack UDP-glucuronosyltransferase (UDPGT) activity toward bilirubin. In addition, a UDPGT isoform which is active toward 4-nitrophenol and is induced by 3-methylcholanthrene (3-MC) in normal rats, is produced in a nonfunctional truncated form in Gunn rats due to the deletion of a single guanosine residue in the coding region of its mRNA. The hepatic concentration of bilirubin-UDPGT mRNA was lower in Gunn rats than in congenic normal rats. However, bilirubin-UDPGT mRNA was of apparently normal length and was induced by clofibrate, a known inducer of bilirubin-UDPGT activity. 3' regions of bilirubin- and 3-MC-inducible UDPGT mRNAs have identical nucleotide sequences; the single base deletion in the 3-MC-inducible UDPGT in Gunn rats occurs within this region. Using oligonucleotide primers corresponding to the identical and unique regions of the two mRNAs, and polymerase chain reaction, we amplified segments of mRNAs for the bilirubin- and 3-MC-inducible UDPGTs from normal and Gunn rat livers. Both amplified DNAs in Gunn rats lacked the restriction site for BstNI. Nucleotide sequence determination revealed that bilirubin- and 3-MC-inducible UDPGT mRNAs in Gunn rats contain an identical frame-shift deletion of a single guanosine residue within the common region of their coding sequences.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02155 USA; TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02155 USA	Howard Hughes Medical Institute; Rockefeller University; Tufts University; Tufts University	ROYCHOWDHURY, J (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, LIVER RES CTR, ULLMAN 625, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.				NIDDK NIH HHS [DK35652, DK34357, DK39137] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039137, R01DK035652, R37DK035652, R01DK034357] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; BOCK KW, 1988, BIOCHEM PHARMACOL, V37, P1439, DOI 10.1016/0006-2952(88)90004-4; BURCHELL B, 1981, REV BIOCHEM TOXICOL, V3, P1; CARBONE JV, 1957, P SOC EXP BIOL MED, V94, P461; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOWDHURY JR, 1986, BIOCHEM J, V233, P827, DOI 10.1042/bj2330827; CHOWDHURY NR, 1987, J CLIN INVEST, V79, P327, DOI 10.1172/JCI112816; DAAR IO, 1988, MOL CELL BIOL, V8, P802, DOI 10.1128/MCB.8.2.802; DRUCKER WD, 1968, P SOC EXP BIOL MED, V129, P308; Dutton G., 1980, GLUCURONIDATION DRUG, P3; ELAWADY M, 1990, J BIOL CHEM, V265, P10752; FALANY CN, 1986, BIOCHEM J, V238, P65, DOI 10.1042/bj2380065; Gunn CH, 1938, J HERED, V29, P137, DOI 10.1093/oxfordjournals.jhered.a104478; HARADA F, 1987, P NATL ACAD SCI USA, V84, P8091, DOI 10.1073/pnas.84.22.8091; HIGASHI Y, 1988, P NATL ACAD SCI USA, V85, P7486, DOI 10.1073/pnas.85.20.7486; IYANAGI T, 1989, J BIOL CHEM, V264, P21302; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; JANSEN PLM, 1977, J BIOL CHEM, V252, P2710; KIMURA H, 1989, J BIOL CHEM, V264, P2338; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; MACKENZIE PI, 1989, CLIN EXP PHARMACOL P, V16, P501, DOI 10.1111/j.1440-1681.1989.tb01595.x; MALOSIO ML, 1991, J BIOL CHEM, V266, P2048; ROYCHOWDHURY N, 1986, HEPATOLOGY, V6, P123; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO H, 1990, BIOCHEM BIOPH RES CO, V169, P260, DOI 10.1016/0006-291X(90)91462-2; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VAINIO H, 1974, BIOCHIM BIOPHYS ACTA, V362, P92, DOI 10.1016/0304-4165(74)90030-0; WATKINS JB, 1982, DRUG METAB DISPOS, V10, P590; WEATHERILL PJ, 1978, FEBS LETT, V87, P207, DOI 10.1016/0014-5793(78)80333-0	30	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					18294	18298						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1717446				2022-12-25	WOS:A1991GG55300087
J	GRAM, CD; BROOKER, RJ				GRAM, CD; BROOKER, RJ			AN ANALYSIS OF THE SIDE-CHAIN REQUIREMENT AT POSITION-177 WITHIN THE LACTOSE PERMEASE WHICH CONFERS THE ABILITY TO RECOGNIZE MALTOSE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CARRIER PROTEIN; LAC PERMEASE; DIRECTED MUTAGENESIS; ENHANCED RECOGNITION; TRANSPORT MALTOSE; ACTIVE-TRANSPORT; PLASMID DNA; MUTANTS; PROTON	In previous work (Brooker, R. J., and Wilson, T. H. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 3959-3963), lactose permease mutants were isolated which possessed an enhanced recognition for maltose. In some of these mutants, the wild-type alanine residue at position 177 was changed to valine or threonine. To gain further insight into the side chain requirement at position 177 that confers maltose recognition, further substitutions of isoleucine, leucine, phenylalanine, proline, and serine have been made via site-directed mutagenesis. Permeases containing alanine or serine exhibited poor maltose recognition whereas those containing isoleucine, leucine, phenylalanine, proline, or valine showed moderate or good recognition. As far as galactosides are concerned, the Val-177, Pro-177, and Ser-177 mutants were able to transport lactose as well as, or slightly better than, the wild-type strain. The other mutants displayed moderately reduced levels of lactose transport. For example, the Phe-177 mutant, which was the most defective, showed a level of downhill transport which was approximately 20% that of the wild-type strain. In uphill transport assays, all of the position 177 mutants were markedly defective in their ability to accumulate beta-D-thiomethylgalactopyranoside against a concentration gradient. Finally, the Position 177 mutants were analyzed for their ability to catalyze an H+ leak. Interestingly, even though the wild-type permease does not leak H+ across the bacterial membrane, all of the position 177 mutants were shown to transport H+ in the absence of sugars. For most of the mutants, this H+ leak was blocked by the addition Of beta-D-thiodigalactoside. Overall, these results are discussed with regard to the effects of position 177 substitutions on the sugar recognition site and H+ transport.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; UNIV MINNESOTA,INST ADV STUDIES BIOL PROC TECHNOL,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024204] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24204] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROOKER RJ, 1990, RES MICROBIOL, V141, P309, DOI 10.1016/0923-2508(90)90004-A; BROOKER RJ, 1985, P NATL ACAD SCI USA, V82, P3959, DOI 10.1073/pnas.82.12.3959; BROOKER RJ, 1985, J BIOL CHEM, V260, P6181; BROOKER RJ, 1990, J BIOL CHEM, V265, P4155; BROOKER RJ, 1991, J BIOL CHEM, V266, P4131; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; COLLINS JC, 1989, J BIOL CHEM, V264, P14698; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; CRANE RK, 1962, FED PROC, V21, P891; CRANE RK, 1960, PHYSIOL REV, V40, P784; EDDY AA, 1971, BIOCHEM J, V122, P701, DOI 10.1042/bj1220701; EELKEMA JA, 1991, J BIOL CHEM, V266, P4139; FASMAN GD, 1989, PREDICTION PROTEIN S, P232; FELLE H, 1980, BIOCHEMISTRY-US, V19, P3585, DOI 10.1021/bi00556a026; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1989, J BIOL CHEM, V264, P15988; FRANCO PJ, 1991, J BIOL CHEM, V266, P6693; Gabrovec S, 1974, ARHEOLO KI VESTNIK, V25, P287; KASHKET ER, 1969, BIOCHIM BIOPHYS ACTA, V193, P212, DOI 10.1016/0005-2736(69)90074-1; KING SC, 1991, BIOCHIM BIOPHYS ACTA, V1062, P177, DOI 10.1016/0005-2736(91)90390-T; KING SC, 1990, J BIOL CHEM, V265, P9645; KING SC, 1990, J BIOL CHEM, V265, P9638; KOMOR E, 1973, FEBS LETT, V38, P16, DOI 10.1016/0014-5793(73)80501-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Mandel M, 1970, J MOL BIOL, V53, P154; MARKGRAF M, 1985, MOL GEN GENET, V198, P473, DOI 10.1007/BF00332941; Miller J. H., 1972, EXPT MOL GENETICS, P433; Mitchell P., 1963, BIOCHEM SOC SYMP, V22, P142; RICKENBERG HV, 1956, ANN I PASTEUR PARIS, V91, P829; ROEPE PD, 1990, RES MICROBIOL, V141, P290, DOI 10.1016/0923-2508(90)90003-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUMAN HA, 1979, J BACTERIOL, V137, P365, DOI 10.1128/JB.137.1.365-373.1979; SLAYMAN CL, 1974, P NATL ACAD SCI USA, V71, P1935, DOI 10.1073/pnas.71.5.1935; SZKUTNICKA K, 1989, J BACTERIOL, V171, P4486, DOI 10.1128/JB.171.8.4486-4493.1989; TEATHER RM, 1978, MOL GEN GENET, V159, P239, DOI 10.1007/BF00268260; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; WEST IC, 1970, BIOCHEM BIOPH RES CO, V41, P655, DOI 10.1016/0006-291X(70)90063-X; WILSON TH, 1983, CELL MEMBR METH REV, V1, P1; WILSON TH, 1980, ANN NY ACAD SCI, V341, P465; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	45	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3841	3846						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740432				2022-12-25	WOS:A1992HE60700047
J	SIMON, SM; ADEREM, A				SIMON, SM; ADEREM, A			MYRISTOYLATION OF PROTEINS IN THE YEAST SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; ACID ACYLATED PROTEINS; FATTY-ACIDS; ANTIBIOTIC CERULENIN; TRANSPORT VESICLES; CELLULAR PROTEINS; MEMBRANE-FUSION; GOLGI CISTERNAE; PLASMA-MEMBRANE; COENZYME-A	Protein myristoylation was investigated in the yeast secretory pathway. Conditional secretory mutations were used to accumulate intermediaries in the pathway between the endoplasmic reticulum and Golgi (sec 18, 20), within the Golgi (sec 7), and between the Golgi and plasma membrane (sec 1, 3, 4, 5, 6, 8, 9). The accumulation of vesicles was paralleled by the enrichment of a defined subset of proteins modified either via ester or amide linkages to myristic acid: Myristoylated proteins of 21, 32, 49, 56, 75, and 136 kDa were enriched between the endoplasmic reticulum and Golgi; proteins of 21, 32, 45, 56, 75, 136 kDa were enriched by blocks within the Golgi; and proteins of 18, 21, 32, 36, 49, 68, and 136 kDa were trapped in a myristoylated form by blocks between the Golgi and plasma membrane. This enrichment of myristoylated proteins was reversed upon returning the cells to the permissive temperature for secretion. The fatty acid was linked to the 21-kDa protein via a hydroxylamine-resistant amide linkage (N-myristoylation) and to the proteins of 24, 32, 49, 56, 68, 136 kDa via hydroxylamine-labile ester linkage (E-myristoylation). In addition, myristoylated proteins of 21, 56, and 136 kDa were glycosylated via amino linkages to asparagine. This suggests they are exposed to the lumen of the secretory pathway. Three proteins (24, 32, and 56) were E-myristoylated in the presence of protein synthesis inhibitors, indicating this modification can occur posttranslationally. After using cycloheximide to clear protein passengers from the secretory pathway the 21-, 32-, and 56-kDa proteins continued to accumulate in a myristoylated form when vesicular transport was blocked between the Golgi and plasma membrane. These data suggest that myristoylation occurs on a component of the secretory machinery rather than on a passenger protein.	ROCKEFELLER UNIV,SIGNAL TRANSDUCT LAB,NEW YORK,NY 10021	Rockefeller University	SIMON, SM (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021, USA.			Simon, Sanford/0000-0002-8615-4224	NIAID NIH HHS [AIRO12503] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; AWAYA J, 1975, BIOCHIM BIOPHYS ACTA, V409, P267, DOI 10.1016/0005-2760(75)90022-3; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CROSS GAM, 1987, CELL, V48, P179, DOI 10.1016/0092-8674(87)90419-3; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; GLICK BS, 1987, NATURE, V326, P309, DOI 10.1038/326309a0; Goldstein A, 1975, Methods Enzymol, V42, P504; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KUKURUZINSKA MA, 1987, ANNU REV BIOCHEM, V56, P915, DOI 10.1146/annurev.biochem.56.1.915; LAMBRECHT B, 1986, FEBS LETT, V202, P127, DOI 10.1016/0014-5793(86)80662-7; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MAGEE AI, 1985, EMBO J, V4, P1137, DOI 10.1002/j.1460-2075.1985.tb03751.x; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; NAEVE CW, 1990, EMBO J, V9, P3857, DOI 10.1002/j.1460-2075.1990.tb07604.x; NGSEE JK, 1989, MOL CELL BIOL, V9, P3400, DOI 10.1128/MCB.9.8.3400; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OLSON EN, 1986, J BIOL CHEM, V261, P2458; OLSON EN, 1985, J BIOL CHEM, V260, P3784; OMURA S, 1976, BACTERIOL REV, V40, P681, DOI 10.1128/MMBR.40.3.681-697.1976; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PFANNER N, 1990, J CELL BIOL, V110, P955, DOI 10.1083/jcb.110.4.955; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROTHMAN JE, 1990, FASEB J, V4, P1460, DOI 10.1096/fasebj.4.5.2407590; ROTHMAN JH, 1989, J CELL BIOL, V109, P93, DOI 10.1083/jcb.109.1.93; SCHMIDT MFG, 1985, J GEN VIROL, V66, P2635, DOI 10.1099/0022-1317-66-12-2635; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WEN D, 1984, MOL CELL BIOL, V4, P688, DOI 10.1128/MCB.4.4.688; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	39	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3922	3931						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740440				2022-12-25	WOS:A1992HE60700059
J	WU, CA; ZECHNER, EL; MARIANS, KJ				WU, CA; ZECHNER, EL; MARIANS, KJ			COORDINATED LEADING-STRAND AND LAGGING-STRAND SYNTHESIS AT THE ESCHERICHIA-COLI DNA-REPLICATION FORK .1. MULTIPLE EFFECTORS ACT TO MODULATE OKAZAKI FRAGMENT SIZE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; GENE-PRODUCT; GAMMA-SUBUNIT; PHI-X174 DNA; PRIMING REPLICATION; PROTEIN MACHINES; RIBONUCLEIC-ACID; VIRAL-DNA; FACTOR-Y; INVITRO	The coordinated action Of many enzymatic activities is required at the DNA replication fork to ensure the error-free, efficient, and simultaneous synthesis of the leading and lagging strands of DNA. In order to define the essential protein-protein interactions and model the regulatory pathways that control Okazaki fragment synthesis, we have reconstituted the replication fork of Escherichia coli in vitro in a rolling circle-type DNA replication system. In this system, in the presence of the single-stranded DNA binding protein, the helicase/primase function on the lagging-strand template is provided by the primosome, and the synthesis of DNA strands is catalyzed by the DNA polymerase III holoenzyme. These reconstituted replication forks synthesize equivalent amounts of leading- and lagging-strand DNA, move at rates comparable to those measured in vivo (600-800 nucleotides/s at 30-degrees-C), and can synthesize leading strands in the range of 150-500 kilobases in length. Using this system, we have studied the cycle of Okazaki fragment synthesis at the replication fork. This cycle is likely to have several well defined decision points, steps in the cycle where incorrect execution by the enzymatic machinery will result in an alteration in the product of the reaction, i.e. in the size of the Okazaki fragments. Since identification of these decision points should aid in the determination of which of the enzymes acting at the replication fork control the cycle, we have endeavored to identify those reaction parameters that, when varied, alter the size of the Okazaki fragments synthesized. Here we demonstrate that some enzymes, such as the DnaB helicase, remain associated continuously with the fork while others, such as the primase, must be recruited from solution each time synthesis of an Okazaki fragment is initiated. We also show that variation of the concentration of the ribonucleoside triphosphates and the deoxyribonucleoside triphosphates affects Okazaki fragment size, that the control mechanisms acting at the fork to control Okazaki fragment size are not fixed at the time the fork is assembled but can be varied during the lifetime of the fork, and that alteration in the rate of the leading-strand DNA polymerase cannot account for the effect of the deoxyribonucleoside triphosphates.	CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Cornell University	WU, CA (corresponding author), MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.			Zechner, Ellen L./0000-0003-2035-1898	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, P241; ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; ALBERTS BM, 1985, TRENDS GENET, V1, P26, DOI 10.1016/0168-9525(85)90011-3; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; ARAI K, 1979, P NATL ACAD SCI USA, V76, P4308, DOI 10.1073/pnas.76.9.4308; ARAI K, 1981, J BIOL CHEM, V256, P5273; BACHMANN BJ, 1976, BACTERIOL REV, V40, P116, DOI 10.1128/MMBR.40.1.116-167.1976; BENZ EW, 1980, J BIOL CHEM, V255, P1096; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; BURGERS PMJ, 1981, P NATL ACAD SCI-BIOL, V78, P5391, DOI 10.1073/pnas.78.9.5391; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CHANDLER M, 1975, J MOL BIOL, V94, P127, DOI 10.1016/0022-2836(75)90410-6; DRAKE JW, 1969, NATURE, V221, P1128, DOI 10.1038/2211128a0; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; KUROSAWA Y, 1975, J MOL BIOL, V94, P229, DOI 10.1016/0022-2836(75)90080-7; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LIU CC, 1980, P NATL ACAD SCI-BIOL, V77, P5698, DOI 10.1073/pnas.77.10.5698; LIU CC, 1981, J BIOL CHEM, V256, P2821; MAKI S, 1988, J BIOL CHEM, V263, P6561; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; MARIANS KJ, 1990, ICN UCLA S MOL CELLU, V127, P289; MCMACKEN R, 1978, J BIOL CHEM, V253, P3313; MEYER RR, 1979, P NATL ACAD SCI USA, V76, P1702, DOI 10.1073/pnas.76.4.1702; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODRICH P, 1971, P NATL ACAD SCI USA, V68, P1002, DOI 10.1073/pnas.68.5.1002; MOK M, 1987, J BIOL CHEM, V262, P16644; MOK M, 1987, J BIOL CHEM, V262, P2304; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; NAKAI H, 1988, J BIOL CHEM, V263, P9819; NOSSAL NG, 1980, J BIOL CHEM, V255, P2176; NUSSLEIN V, 1971, NATURE-NEW BIOL, V234, P285, DOI 10.1038/newbio234285a0; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; ROMANO L, 1978, J BIOL CHEM, V254, P10483; ROMANO LJ, 1979, J BIOL CHEM, V254, P476; ROWEN L, 1978, J BIOL CHEM, V253, P770; SCHEKMAN R, 1975, J BIOL CHEM, V250, P5859; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SELICK H, 1987, REPLICATION RECOMBIN, P183; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SHLOMAI J, 1981, J BIOL CHEM, V256, P5233; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WECHSLER JA, 1971, MOL GEN GENET, V113, P273, DOI 10.1007/BF00339547; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WELCH MM, 1982, J BACTERIOL, V152, P351; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P783, DOI 10.1073/pnas.71.3.783; WICKNER S, 1977, P NATL ACAD SCI USA, V74, P2815, DOI 10.1073/pnas.74.7.2815; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P1053, DOI 10.1073/pnas.73.4.1053; WICKNER S, 1973, P NATL ACAD SCI USA, V70, P1613, DOI 10.1073/pnas.70.5.1613; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; WICKNER S, 1975, ICN UCLA S MOL CELLU, P227; WICKNER S, 1978, SINGLE STRANDED DNA, P255; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P3679, DOI 10.1073/pnas.70.12.3679; WRIGHT M, 1973, P NATL ACAD SCI USA, V70, P3120, DOI 10.1073/pnas.70.11.3120; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZAVITZ KH, 1991, J BIOL CHEM, V266, P13988; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	76	156	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4030	4044						15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740451				2022-12-25	WOS:A1992HE60700073
J	SHAYIQ, RM; AVADHANI, NG				SHAYIQ, RM; AVADHANI, NG			SEQUENCE COMPLEMENTARITY BETWEEN THE 5'-TERMINAL REGIONS OF MESSENGER-RNAS FOR RAT MITOCHONDRIAL CYTOCHROME P-450C27/25 AND A GROWTH HORMONE-INDUCIBLE SERINE PROTEASE INHIBITOR - A POSSIBLE GENE OVERLAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-MITOCHONDRIA; OPPOSITE STRAND; TRANSCRIPTION; LOCUS; DNA; 26-HYDROXYLATION; 25-HYDROXYLATION; PURIFICATION; VITAMIN-D3; EXPRESSION	Recently we reported that a P-450c27/25 cDNA probe hybridizes to two RNA species of about 1.9 and 2.3-2.4 kilobase pairs (kb) in some rat tissues. To understand the molecular relationship between the two mRNAs, we have isolated and characterized a cDNA for the larger, previously uncharacterized 2.3-kb mRNA species. The 2.3-kb cDNA is identical to the previously reported 1.9-kb P-450c27/25 cDNA excepting a 400-nucleotide-long 5' extension. The terminal 291 nucleotides of this extension exhibit 100% complementarity with the 5'-translated region of the mRNA belonging to a family of growth hormone-inducible serine protease inhibitors (SPI). Northern blot analysis, using strand-specific probes, and S1 nuclease protection revealed the presence of the 2.3-kb mRNA exhibiting the sequence characteristics of the larger cDNA. These results were further confirmed by polymerase chain reaction amplification of reverse transcribed RNA. Expression of the 2.3-kb cDNA in COS cells resulted in the correct mitochondrial targeting of a 52-kDa protein exhibiting the properties of P-450c27/25. Furthermore, both the 1.9- and 2.3-kb mRNAs appear to direct the synthesis of a similarly sized 55-kDa precursor protein in a reticulocyte lysate system. Restriction mapping, polymerase chain reaction amplification and partial sequencing of a 25-kb genomic DNA clone suggest the proximal location of the SPI and the P-450c27/25 protein coding regions in the rat genome on either side of a common overlap region. The results also show that the P-450c27/25 mRNAs are regulated by growth hormone in parallel to the SPI mRNAs. These results collectively suggest that a growth hormone-inducible SPI family mRNA and the P-450c27/25 mRNA are encoded by two closely linked, possibly overlapping genes.	UNIV PENN, SCH VET MED, DEPT ANIM BIOL, BIOCHEM LABS, PHILADELPHIA, PA 19104 USA	University of Pennsylvania					NATIONAL CANCER INSTITUTE [R37CA022762, R01CA022762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22762] Funding Source: Medline; NIGMS NIH HHS [GM-34883] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1991, BIOCHEMISTRY-US, V30, P8323, DOI 10.1021/bi00098a007; ADELMAN JP, 1987, SCIENCE, V235, P1514, DOI 10.1126/science.3547652; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDERSSON S, 1986, J BIOL CHEM, V261, P6932; BHAT KS, 1985, BIOCHEMISTRY-US, V24, P5818, DOI 10.1021/bi00342a020; BHAT NK, 1985, BIOCHEMISTRY-US, V24, P8107, DOI 10.1021/bi00348a041; BJORKHEM I, 1985, STEROLS BILE ACIDS, P231; BURKE JM, 1982, CELL, V31, P509, DOI 10.1016/0092-8674(82)90307-5; Carey M. C., 1982, LIVER BIOL PATHOBIOL, P429; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHLBACK H, 1988, BIOCHEM J, V252, P207, DOI 10.1042/bj2520207; DAHLBACK H, 1988, BIOCHEM BIOPH RES CO, V157, P30, DOI 10.1016/S0006-291X(88)80006-8; DELUCA HF, 1976, ANNU REV BIOCHEM, V45, P631, DOI 10.1146/annurev.bi.45.070176.003215; Flint S. J, 1981, DNA TUMOR VIRUSES; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; KINDY MS, 1987, MOL CELL BIOL, V7, P2857, DOI 10.1128/MCB.7.8.2857; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR MA, 1989, MOL CELL BIOL, V9, P1128, DOI 10.1128/MCB.9.3.1128; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; Maniatis T., 1982, MOL CLONING; MASUMOTO O, 1988, J BIOL CHEM, V263, P14256; MIZUNO T, 1984, P NATL ACAD SCI-BIOL, V81, P1966, DOI 10.1073/pnas.81.7.1966; MOREL Y, 1989, P NATL ACAD SCI USA, V86, P6582, DOI 10.1073/pnas.86.17.6582; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; OKUDA K, 1988, J BIOL CHEM, V263, P18138; PEDERSEN JI, 1979, J BIOL CHEM, V254, P6464; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sharp P A, 1980, Methods Enzymol, V65, P750; SHAYIQ RM, 1989, BIOCHEMISTRY-US, V28, P7546, DOI 10.1021/bi00445a008; SHAYIQ RM, 1991, METHOD ENZYMOL, V206, P587; SIMONS RW, 1983, CELL, V34, P683, DOI 10.1016/0092-8674(83)90401-4; SPENCER CA, 1986, NATURE, V322, P279, DOI 10.1038/322279a0; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; USUI E, 1990, FEBS LETT, V274, P175, DOI 10.1016/0014-5793(90)81357-T; WILLIAMS T, 1986, NATURE, V322, P275, DOI 10.1038/322275a0; YOON JB, 1987, J BIOL CHEM, V262, P4284; YOON JB, 1990, J BIOL CHEM, V265, P19947	41	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2421	2428						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733943				2022-12-25	WOS:A1992HB53200049
J	JIMENEZ, JJ; SAWAYA, ME; YUNIS, AA				JIMENEZ, JJ; SAWAYA, ME; YUNIS, AA			INTERLEUKIN-1 PROTECTS HAIR-FOLLICLES FROM CYTARABINE (ARA-C)-INDUCED TOXICITY INVIVO AND INVITRO	FASEB JOURNAL			English	Note						ALOPECIA; IL-1; IMUVERT; CHEMOTHERAPY; HAIR FOLLICLES; DNA SYNTHESIS		ImuVert, a biologic response modifier, and interleukin 1 (IL 1) have been shown to protect the young rat from alopecia induced by cytarabine (ARA-C). In the present study the inhibition by ARA-C of DNA synthesis in hair follicles (HFs) and the protective effect of ImuVert and IL 1 were investigated in vivo and in vitro. Both ImuVert and IL 1 were equally effective in protecting rats from ARA-C-induced alopecia. DNA synthesis in HFs isolated from ARA-C-treated animals was 10-20% of untreated controls. Follicles isolated from animals given either ImuVert or IL 1 before ARA-C exhibited normal DNA synthesis. In vitro, the incubation of normal rat HF with ARA-C resulted in 80% inhibition of [H-3]-thymidine uptake. Preincubation of the follicles for 1 hr with IL 1 before the addition of ARA-C completely blocked the inhibition. Preincubation with imuVert, however, was less effective in blocking the inhibition from ARA-C.	UNIV MIAMI,SCH MED,DEPT DERMATOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT ONCOL,MIAMI,FL 33101	University of Miami; University of Miami; University of Miami; University of Miami								BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; HASHIMOTO K, 1970, BRIT J DERMATOL, V83, P167, DOI 10.1111/j.1365-2133.1970.tb15041.x; HUSSEIN AM, 1990, SCIENCE, V249, P1564, DOI 10.1126/science.2218498; JAECKLE KA, 1990, J CLIN ONCOL, V8, P1408, DOI 10.1200/JCO.1990.8.8.1408; JIMENEZ JJ, 1991, FASEB J, V5, P2456, DOI 10.1096/fasebj.5.10.2065892; MCCALL CA, 1989, CYTOKINE, V1, P113; SANQUER S, 1990, J INVEST DERMATOL, V95, P700, DOI 10.1111/1523-1747.ep12514500; SAWAYA ME, 1988, J INVEST DERMATOL, V91, P101, DOI 10.1111/1523-1747.ep12463393; URBAN RW, 1836, Patent No. 57344; Warren R P, 1989, Mol Biother, V1, P145	11	13	13	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					911	913		10.1096/fasebj.6.3.1740239	http://dx.doi.org/10.1096/fasebj.6.3.1740239			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740239				2022-12-25	WOS:A1992HE39000015
J	BJORK, I; YLINENJARVI, K; OLSON, ST; BOCK, PE				BJORK, I; YLINENJARVI, K; OLSON, ST; BOCK, PE			CONVERSION OF ANTITHROMBIN FROM AN INHIBITOR OF THROMBIN TO A SUBSTRATE WITH REDUCED HEPARIN AFFINITY AND ENHANCED CONFORMATIONAL STABILITY BY BINDING OF A TETRADECAPEPTIDE CORRESPONDING TO THE P1 TO P14 REGION OF THE PUTATIVE REACTIVE BOND LOOP OF THE INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYZED PROTEASE INACTIVATION; HUMAN ANTI-THROMBIN; ALPHA-1-PROTEINASE INHIBITOR; CRYSTAL-STRUCTURE; ALPHA-THROMBIN; FACTOR-XA; TRANSIENT KINETICS; ACTIVE-SITE; FORM; CLEAVAGE	A synthetic tetradecapeptide having the sequence of the region of the antithrombin chain amino-terminal to the reactive bond, i.e. comprising residues P1 to P14, was shown to form a tight equimolar complex with antithrombin. A similar complex has previously been demonstrated between alpha-1-proteinase inhibitor and the analogous peptide of this inhibitor (Schulze, A. J., Baumann, U., Knof, S., Jaeger, E., Huber, R. and Laurell, C.-B. (1990) Eur. J. Biochem. 194, 51-56). The antithrombin-peptide complex had a conformation similar to that of reactive bond-cleaved antithrombin and, like the cleaved inhibitor, also had a higher conformational stability and lower heparin affinity than intact antithrombin. These properties suggest that the peptide bound to intact antithrombin at the same site that the P1 to P14 segment of the inhibitor occupies in reactive-bond-cleaved antithrombin, i.e. was incorporated as a sixth strand in the middle of the major beta-sheet, the A sheet. The extent of complex formation was reduced in the presence of heparin with high affinity for antithrombin, which is consistent with heparin binding and peptide incorporation being linked. Antithrombin in the complex with the tetradecapeptide had lost its ability to inactivate thrombin, but the reactive bond of the inhibitor was cleaved as in a normal substrate. These observations suggest a model, analogous to that proposed for alpha-1-proteinase inhibitor (Engh, R.A., Wright, H.T., and Huber, R. (1990) Protein Eng. 3, 469-477) for the structure of intact antithrombin, in which the A sheet contains only five strands and the P1 to P14 segment of the chain forms part of an exposed loop of the protein. The results further support a reaction model for serpins in which partial insertion of this loop into the A sheet is required for trapping of a proteinase in a stable complex, and complete insertion is responsible for the conformational change accompanying cleavage of the reactive bond of the inhibitor.	HENRY FORD HOSP, DIV BIOCHEM RES, DETROIT, MI 48202 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT PATHOL, NASHVILLE, TN 37232 USA	Henry Ford Health System; Henry Ford Hospital; Vanderbilt University	BJORK, I (corresponding author), SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT VET MED CHEM, BOX 575, S-75123 UPPSALA, SWEDEN.				NHLBI NIH HHS [HL-39888, HL-38779] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039888, R01HL039888, R01HL038779, R29HL038779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIACH M, 1985, THROMB RES, V39, P559, DOI 10.1016/0049-3848(85)90236-1; ASAKURA S, 1990, J BIOL CHEM, V265, P5135; BJORK I, 1982, J BIOL CHEM, V257, P2406; BJORK I, 1982, J BIOL CHEM, V257, P9487; BJORK I, 1981, FEBS LETT, V126, P257, DOI 10.1016/0014-5793(81)80255-4; BJORK I, 1986, PROTEINASE INHIBITOR, P489; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BOCK SC, 1982, NUCLEIC ACIDS RES, V10, P8113, DOI 10.1093/nar/10.24.8113; BORG JY, 1988, J CLIN INVEST, V81, P1292, DOI 10.1172/JCI113447; BRUCH M, 1988, J BIOL CHEM, V263, P16626; CARLSTROM AS, 1977, THROMB RES, V11, P785, DOI 10.1016/0049-3848(77)90107-4; CASO R, 1991, BRIT J HAEMATOL, V77, P87, DOI 10.1111/j.1365-2141.1991.tb07953.x; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; DEVRAJKIZUK R, 1988, BLOOD, V72, P1518; ENGH RA, 1990, PROTEIN ENG, V3, P469, DOI 10.1093/protein/3.6.469; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FISH WW, 1979, FEBS LETT, V98, P103, DOI 10.1016/0014-5793(79)80162-3; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P3634, DOI 10.1021/bi00410a017; HOOK M, 1976, FEBS LETT, V66, P90, DOI 10.1016/0014-5793(76)80592-3; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MILLERANDERSSON M, 1974, THROMB RES, V5, P439, DOI 10.1016/0049-3848(74)90001-2; MOLHOSABATIER P, 1989, J CLIN INVEST, V84, P1236, DOI 10.1172/JCI114290; MOUREY L, 1990, BIOCHIMIE, V72, P599, DOI 10.1016/0300-9084(90)90123-X; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; NORDENMAN B, 1978, EUR J BIOCHEM, V90, P1, DOI 10.1111/j.1432-1033.1978.tb12567.x; OLSON ST, 1986, J BIOL CHEM, V261, P3151; OLSON ST, 1982, J BIOL CHEM, V257, P4891; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OLSON ST, 1988, J BIOL CHEM, V263, P1698; OLSON ST, 1981, J BIOL CHEM, V256, P1065; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1991, THROMBIN STRUCTURE F; PEJLER G, 1987, J BIOL CHEM, V262, P11413; PERRY DJ, 1991, FEBS LETT, V285, P248, DOI 10.1016/0014-5793(91)80809-H; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; SUNDQVIST B, 1985, MASS SPECTROM REV, V4, P421, DOI 10.1002/mas.1280040403; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; WEBER K, 1969, J BIOL CHEM, V244, P4406; WRIGHT HT, 1990, J MOL BIOL, V213, P513	45	112	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1976	1982						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730729				2022-12-25	WOS:A1992HA48500088
J	IKUSHIRO, SI; KOMINAMI, S; TAKEMORI, S				IKUSHIRO, SI; KOMINAMI, S; TAKEMORI, S			ADRENAL P-450SCC MODULATES ACTIVITY OF P-45011-BETA IN LIPOSOMAL AND MITOCHONDRIAL-MEMBRANES - IMPLICATION OF P-450SCC IN ZONE SPECIFICITY OF ALDOSTERONE BIOSYNTHESIS IN BOVINE ADRENAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE VESICLES; ADRENOCORTICAL MITOCHONDRIA; PHOSPHOLIPID-VESICLES; CORTEX; CYTOCHROME-P-450; SYSTEM; ADRENODOXIN; REDUCTASE; P-45017-ALPHA,LYASE; STEROIDOGENESIS	Bovine adrenal P-450(11-beta) catalyzes the 11-beta- and 18-hydroxylation of corticosteroids as well as aldosterone synthesis. These activities of P-450(11-beta) were found to be modulated by another mitochondrial cytochrome P-450 species, P-450scc. The presence together of P-450(11-beta) and P-450scc in liposomal membranes was found to remarkably stimulate the 11-beta-hydroxylase activity of P-450(11-beta) and also stimulate the cholesterol desmolase activity of P-450scc. The stimulative effect of P-450scc on 11-beta-hydroxylase activity diminished by the addition of protein-free liposomes to proteoliposomes containing P-450(11-beta) and P-450scc, thus showing P-450scc to interact with P-450(11-beta) in the same membranes. Kinetic analysis of this effect indicated the formation of an equimolar complex between P-450(11-beta) and P-450scc on liposomal membranes. P-450(11-beta) in the complex had not only stimulated activity for 11-beta- and 18-hydroxylation of 11-deoxycorticosterone but also suppressed activity for production of 18-hydroxycorticosterone and aldosterone. When the inner mitochondrial membranes of zona fasciculata-reticularis from bovine adrenal were treated with anti-P-450scc IgG, aldosterone formation was stimulated to a greater extent than that of zona glomerulosa. This indicates the aldosterone synthesizing activity of P-450(11-beta) in the zona fasciculata-reticularis to be suppressed by interaction with P-450scc. The zone-specific aldosterone synthesis of P-450(11-beta) in bovine adrenal may possibly be induced by differences in interactions with P-450scc of mitochondrial membranes in each zone.	HIROSHIMA UNIV,FAC INTEGRATED ARTS & SCI,HIROSHIMA 730,JAPAN	Hiroshima University								ALSTON K, 1991, J BIOL CHEM, V266, P735; CHENG B, 1983, LIPIDS, V18, P577, DOI 10.1007/BF02534665; DHARIWAL MS, 1991, BIOCHEMISTRY-US, V30, P4940, DOI 10.1021/bi00234a015; Gower D.B., 1984, BIOCH STEROID HORMON, P117; GUT J, 1982, J BIOL CHEM, V257, P7030; HANUKOGLU I, 1981, J BIOL CHEM, V256, P4329, DOI 10.1016/S0021-9258(19)69437-8; HARKINS JB, 1974, ENDOCRINOLOGY, V94, P897, DOI 10.1210/endo-94-3-897; HARMON HJ, 1974, BIOCHIM BIOPHYS ACTA, V344, P119, DOI 10.1016/0304-4157(74)90002-1; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; IKUSHIRO S, 1989, BIOCHIM BIOPHYS ACTA, V984, P50, DOI 10.1016/0005-2736(89)90341-6; IKUSHIRO S, 1991, IN PRESS CYTOCHROME; KATAGIRI M, 1982, OXYGENASES OXYGEN ME, P391; KAWATO S, 1991, J BIOCHEM-TOKYO, V109, P587, DOI 10.1093/oxfordjournals.jbchem.a123424; KOMINAMI S, 1989, BIOCHIM BIOPHYS ACTA, V985, P293, DOI 10.1016/0005-2736(89)90415-X; KOMINAMI S, 1987, BIOCHIM BIOPHYS ACTA, V905, P143, DOI 10.1016/0005-2736(87)90018-6; KOMINAMI S, 1982, FLAVINS FLAVOPROTEIN, P715; LAMBETH JD, 1979, J BIOL CHEM, V254, P7255; LONG JA, 1975, HDB PHYSIOLOGY     7, V6, P13; MOCHIZUKI H, 1990, J STEROID BIOCHEM, V37, P133, DOI 10.1016/0960-0760(90)90382-U; NOSHIRO M, 1978, J BIOCHEM, V83, P61, DOI 10.1093/oxfordjournals.jbchem.a131913; OGISHIMA T, 1989, J BIOL CHEM, V264, P10935; OGISHIMA T, 1989, J BIOCHEM-TOKYO, V105, P497, DOI 10.1093/oxfordjournals.jbchem.a122694; OHNISHI T, 1984, BIOCHEM INT, V9, P715; OHNISHI T, 1988, J STEROID BIOCHEM, V31, P73; OHTA Y, 1991, J BIOCHEM-TOKYO, V109, P594, DOI 10.1093/oxfordjournals.jbchem.a123425; OMURA T, 1964, J BIOL CHEM, V239, P2370; ROSEMAN MA, 1977, J BIOL CHEM, V252, P4842; SATO H, 1978, ARCH BIOCHEM BIOPHYS, V190, P307, DOI 10.1016/0003-9861(78)90280-1; SEYVERT DW, 1979, J BIOL CHEM, V254, P12088; SHINZAWA K, 1988, J ENDOCRINOL, V119, P191, DOI 10.1677/joe.0.1190191; SHINZAWA K, 1985, BIOCHIM BIOPHYS ACTA, V833, P151; SUGANO S, 1989, ANAL BIOCHEM, V182, P327, DOI 10.1016/0003-2697(89)90603-9; SUHARA K, 1978, ARCH BIOCHEM BIOPHYS, V190, P290, DOI 10.1016/0003-9861(78)90278-3; SUHARA K, 1982, EUR J BIOCHEM, V125, P659, DOI 10.1111/j.1432-1033.1982.tb06733.x; SUHARA K, 1972, BIOCHIM BIOPHYS ACTA, V263, P272, DOI 10.1016/0005-2795(72)90079-7; TAKEMORI S, 1984, TRENDS BIOCHEM SCI, V9, P393, DOI 10.1016/0968-0004(84)90223-8; TUCKEY RC, 1982, J BIOL CHEM, V257, P2887; TULS J, 1989, J BIOL CHEM, V264, P16421; WADA A, 1985, J BIOCHEM-TOKYO, V98, P245, DOI 10.1093/oxfordjournals.jbchem.a135264; WADA A, 1984, BIOCHEM BIOPH RES CO, V119, P365, DOI 10.1016/0006-291X(84)91660-7	40	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1464	1469						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730695				2022-12-25	WOS:A1992HA48500014
J	KORANGY, F; JULIN, DA				KORANGY, F; JULIN, DA			ALTERATION BY SITE-DIRECTED MUTAGENESIS OF THE CONSERVED LYSINE RESIDUE IN THE ATP-BINDING CONSENSUS SEQUENCE OF THE RECD SUBUNIT OF THE ESCHERICHIA-COLI RECBCD ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; ADENYLATE KINASE; EXONUCLEASE-V; GENE; MUTATIONS; DOMAIN; DNA; PURIFICATION; PROTEINS; REGION	The RecD subunit of the RecBCD enzyme from Escherichia coli contains an amino acid sequence common to many enzymes which bind ATP or GTP (Gly-X-X-Gly-X-Gly-Lys-Thr). We have changed the conserved lysine residue (amino acid number 177) in the RecD protein to glutamine to investigate the role of RecD, and ATP-binding to RecD, in the enzymatic activities of RecBCD. The mutant RecD protein assembles with the RecB and RecC subunits and the mutant enzyme, designated RecBCD-K177Q, can be purified in the same way as the wild-type RecBCD enzyme. The mutant RecD subunit in RecBCD-K177Q is photolabeled to a lesser extent by the ATP analogue 8-azido-adenosine-5'-triphosphate than is the wild-type RecD subunit in RecBCD, suggesting that the mutation has reduced the affinity of RecD for ATP.	UNIV MARYLAND,DEPT CHEM & BIOCHEM,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park					NIGMS NIH HHS [GM39777] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039777, R29GM039777] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; ALSHAWI MK, 1989, J BIOL CHEM, V264, P15376; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAUDHURY AM, 1984, J BACTERIOL, V160, P788, DOI 10.1128/JB.160.2.788-791.1984; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; DREUSICKE D, 1988, J MOL BIOL, V199, P359, DOI 10.1016/0022-2836(88)90319-1; DYKSTRA CC, 1984, COLD SPRING HARB SYM, V49, P463, DOI 10.1101/SQB.1984.049.01.052; EICHLER DC, 1977, J BIOL CHEM, V252, P499; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8583, DOI 10.1093/nar/14.21.8583; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P4437, DOI 10.1093/nar/14.11.4437; FINCH PW, 1986, NUCLEIC ACIDS RES, V14, P8573, DOI 10.1093/nar/14.21.8573; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; HODGMAN TC, 1988, NATURE, V333, P578, DOI 10.1038/333578a0; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; JULIN DA, 1987, J BIOL CHEM, V262, P9044; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KORANGY F, 1992, J BIOL CHEM, V267, P1733; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIVNEH Z, 1983, P NATL ACAD SCI-BIOL, V80, P237, DOI 10.1073/pnas.80.1.237; Maniatis T., 1982, MOL CLONING; Muskavitch K. M. T., 1981, ENZYMES, V14, P233; MYLES GM, 1991, BIOCHEMISTRY-US, V30, P3824, DOI 10.1021/bi00230a004; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; REINSTEIN J, 1988, BIOCHEMISTRY-US, V27, P4712, DOI 10.1021/bi00413a020; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; SASAKI M, 1982, BIOCHEM BIOPH RES CO, V109, P414, DOI 10.1016/0006-291X(82)91737-5; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SMITH GR, 1990, NUCLEIC ACIDS MOL BI, V4, P78; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259	33	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1727	1732						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730715				2022-12-25	WOS:A1992HA48500052
J	NUREKAMAL, MSA; SIZELAND, A; DABACO, G; MARUTA, H				NUREKAMAL, MSA; SIZELAND, A; DABACO, G; MARUTA, H			ASPARAGINE-26, GLUTAMIC ACID-31, VALINE-45, AND TYROSINE-64 OF RAS PROTEINS ARE REQUIRED FOR THEIR ONCOGENICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GTPASE-ACTIVATING PROTEINS; SUPPRESSOR ACTIVITY; BINDING PROTEIN; R-RAS; GENE; IDENTIFICATION; DOMAIN; P21; PURIFICATION; GAP	Ras and Rap1 proteins are related GTP-dependent signal transducers which require Gly-12, the effector domain (residues 32-40), and Ala-59 for stimulation of their GTPase activities by GAP1 and GAP3, respectively. The replacement of Gly-12 by Val or Ala-59 by Thr potentiates the Ras oncogenicity and Rap1A anti-oncogenicity. However, the mutations in the effector domain, in particular the replacement of Thr-35 by Ala, abolish both Ras oncogenicity and Rap1A anti-oncogenicity, indicating that the effector domain is involved in interactions of these signal transducers with their targets as well as the GAPs. In this paper, we demonstrate that (i) replacement of Tyr-64 of the Ha-Ras protein or Phe-64 of the Rap1A protein by Glu or other non-hydrophobic amino acids reduces their intrinsic GTPase activities and abolishes their stimulation by GAP1 or GAP3, respectively, (ii) replacement of Tyr-64 by Gly and other non-hydrophobic amino acids results in complete loss of the oncogenicity of the v-Ha-Ras protein, indicating that the hydrophobic residue 64, in addition to the known effector domain, is essential for the Ras protein to interact with its target as well as GAP1. In addition we have found that Asn-26, Glu-31, and Val-45 of the v-Ha-Ras protein are required for its oncogenicity. Replacement of the Ras residues at either positions 26, 31, or 45 by the corresponding Rap1A residues abolishes the Ras oncogenicity.	PO ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE TUMOR BIOL BRANCH, VICTORIA 3050, AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital				D'ABACO, GIOVANNA MARISA/0000-0001-5793-4072				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HOLDEN JL, 1991, J BIOL CHEM, V266, P16992; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LOWE DG, 1988, P NATL ACAD SCI USA, V85, P1015, DOI 10.1073/pnas.85.4.1015; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MANIATIS T, 1982, MOL CLONING LABORATO, P185; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARUTA H, 1989, NATO ADV SCI I A-LIF, V170, P255; MARUTA H, 1991, J BIOL CHEM, V266, P11661; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SRIVASTAVA SK, 1990, MOL CELL BIOL, V9, P1779; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	28	56	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1415	1418						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730690				2022-12-25	WOS:A1992HA48500004
J	PERENTESIS, JP; PHAN, LD; GLEASON, WB; LAPORTE, DC; LIVINGSTON, DM; BODLEY, JW				PERENTESIS, JP; PHAN, LD; GLEASON, WB; LAPORTE, DC; LIVINGSTON, DM; BODLEY, JW			SACCHAROMYCES-CEREVISIAE ELONGATION FACTOR-II - GENETIC CLONING, CHARACTERIZATION OF EXPRESSION, AND G-DOMAIN MODELING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; FACTOR-II EF-2; DIPHTHERIA-TOXIN; 2 GENES; ESCHERICHIA-COLI; DROSOPHILA-MELANOGASTER; NUCLEOTIDE-SEQUENCE; 1-ALPHA EF-1-ALPHA; FACTOR-TU; DIPHTHAMIDE	The elongation factor 2 (EF-2) genes of the yeast Saccharomyces cerevisiae have been cloned and characterized with the ultimate goal of gaining a better understanding of the mechanism and control of protein synthesis. Two genes (EFT1 and EFT2) were isolated by screening a bacteriophage lambda-yeast genomic DNA library with an oligonucleotide probe complementary to the domain of EF-2 that contains diphthamide, the unique posttranslationally modified histidine that is specifically ADP-ribosylated by diphtheria toxin. Although EFT1 and EFT2 are located on separate chromosomes, the DNA sequences of the two genes differ at only four positions out of 2526 base pairs, and the predicted protein sequences are identical. Genetic deletion of each gene revealed that at least one functional copy of either EFT gene is required for cell viability. Messenger RNA levels of yeast EF-2 parallel cellular growth and peak in mid-log phase cultures. The EF-2 protein sequence is strikingly conserved through evolution. Yeast EF-2 is 66% identical to, and shares over 85% homology with, human EF-2. In addition, yeast and mammalian EF-2 share identical sequences at two critical functional sites: (i) the domain containing the histidine residue that is modified to diphthamide and (ii) the threonine residue that is specifically phosphorylated in vivo in mammalian cells by calmodulin-dependent protein kinase III, also known as EF-2 kinase. Furthermore, yeast EF-2 also contains the Glu-X-X-Arg-X-Ile-Thr-Ile "effector" sequence motif that is conserved among all known elongation factors, and its GTP-binding domain exhibits strong homology to the G-domain of Escherichia coli elongation factor Tu (EF-Tu) and other G-protein family members. Based upon these observations, we have modeled the G-domain of the deduced EF-2 protein sequence to the solved crystallographic structure for EF-Tu.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,RM 4-225,MILLARD HALL,435 DELAWARE ST SE,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities				Perentesis, John/0000-0002-4237-8226	NIAID NIH HHS [AI00793] Funding Source: Medline; NIGMS NIH HHS [GM13924, GM26832] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K11AI000793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026832] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1986, MOL CELL BIOL, V6, P3685, DOI 10.1128/MCB.6.11.3685; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHEN JYC, 1985, MOL CELL BIOL, V5, P3357, DOI 10.1128/MCB.5.12.3357; CHEN JYC, 1988, J BIOL CHEM, V263, P11692; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CIGAN AM, 1987, GENE, V59, P1; CLARK BFC, 1990, BIOCHIM BIOPHYS ACTA, V1050, P203, DOI 10.1016/0167-4781(90)90167-Z; COLLINS EJ, 1990, J BIOL CHEM, V265, P8665; COTTRELLE P, 1985, CURR GENET, V9, P693, DOI 10.1007/BF00449823; Dayhoff M., 1978, ATLAS PROTEIN SEQUEN; DUNLOP PC, 1983, J BIOL CHEM, V258, P4754; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRINBLAT Y, 1989, NUCLEIC ACIDS RES, V17, P7303, DOI 10.1093/nar/17.18.7303; Guthrie C., 1982, MOL BIOL YEAST SACCH, P487; HOVEMANN B, 1988, NUCLEIC ACIDS RES, V16, P3175, DOI 10.1093/nar/16.8.3175; ITOH T, 1989, EUR J BIOCHEM, V186, P213, DOI 10.1111/j.1432-1033.1989.tb15197.x; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KOHNO K, 1987, J BIOL CHEM, V262, P12298; KOHNO K, 1986, P NATL ACAD SCI USA, V83, P4978, DOI 10.1073/pnas.83.14.4978; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LECHNER K, 1988, NUCLEIC ACIDS RES, V16, P7817, DOI 10.1093/nar/16.16.7817; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Maniatis T., 1982, MOL CLONING; MILLER SP, 1991, NUCLEIC ACIDS RES, V19, P1657, DOI 10.1093/nar/19.7.1657; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOEHRING JM, 1988, J BIOL CHEM, V263, P3840; MOEHRING TJ, 1977, CELL, V11, P447, DOI 10.1016/0092-8674(77)90063-0; NAGASHIMA K, 1986, GENE, V45, P265; NAGATA S, 1984, EMBO J, V3, P1825, DOI 10.1002/j.1460-2075.1984.tb02053.x; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NYBORG J, 1989, GUANINE NUCLEOTIDE B, P3; OHTSUKA E, 1985, J BIOL CHEM, V260, P2605; OVCHINNIKOV LP, 1990, FEBS LETT, V275, P209, DOI 10.1016/0014-5793(90)81473-2; PAPPENHEIMER AM, 1983, J BACTERIOL, V153, P1342, DOI 10.1128/JB.153.3.1342-1347.1983; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; RAPP G, 1989, BIOL CHEM H-S, V370, P1071, DOI 10.1515/bchm3.1989.370.2.1071; RYAZANOV A G, 1990, New Biologist, V2, P843; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; RYAZANOV AG, 1987, FEBS LETT, V214, P331, DOI 10.1016/0014-5793(87)80081-9; SCHIRMAIER F, 1984, EMBO J, V3, P3311, DOI 10.1002/j.1460-2075.1984.tb02295.x; SELDEN RF, 1990, CURRENT PROTOCOLS MO; Sherman F., 1986, METHODS YEAST GENETI; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TODA K, 1989, J BIOL CHEM, V264, P15489; TRECO DA, 1990, CURRENT PROTOCOLS MO; VALENCIA A, 1991, P NATL ACAD SCI USA, V88, P5443, DOI 10.1073/pnas.88.12.5443; VANDOP C, 1984, J BIOL CHEM, V259, P696; VANNESS BG, 1980, FEBS LETT, V120, P4, DOI 10.1016/0014-5793(80)81032-5; VANNESS BG, 1980, J BIOL CHEM, V255, P717; VANNESS BG, 1978, J BIOL CHEM, V253, P8687; VELDMAN SA, 1990, ADP RIBOSYLATING TOX, P21; WALLDORF U, 1985, P NATL ACAD SCI USA, V82, P5795, DOI 10.1073/pnas.82.17.5795; WEBER IT, 1990, PROTEINS, V7, P172, DOI 10.1002/prot.340070206; ZENGEL JM, 1984, NUCLEIC ACIDS RES, V12, P2181, DOI 10.1093/nar/12.4.2181	59	72	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1190	1197						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730643				2022-12-25	WOS:A1992GY96000080
J	DEVOUGE, MW; MUKHERJEE, BB				DEVOUGE, MW; MUKHERJEE, BB			TRANSFORMATION OF NORMAL RAT-KIDNEY CELLS BY V-K-RAS ENHANCES EXPRESSION OF TRANSIN-2 AND AN S-100-RELATED CALCIUM-BINDING PROTEIN	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; EPIDERMAL GROWTH-FACTOR; COMPARATIVE BIOCHEMICAL-PROPERTIES; GUANINE NUCLEOTIDE-BINDING; MESSENGER-RNA; SIGNAL TRANSDUCTION; POLYACRYLAMIDE GELS; MOLECULAR-CLONING; GENE-PRODUCT; 3T3 CELLS	v-K-ras transformants of normal rat kidney cells (KNRK) exhibit cell surface-related, transformation-specific properties, including cell-surface fibronectin depletion, induction of anchorage- and density-independent growth, and increased synthesis of transforming growth factors-alpha and beta. To search for potential distal effectors of v-K-ras-mediated transformation, we prepared a rabbit antiserum directed against intact KNRK cells to immunoprecipitate and compare proteins from detergent lysates and conditioned media of labeled NRK, KNRK, B77-NRK (a v-src transformant) and ts-371-NRK cells (a Ki-MSV encoding a temperature-sensitive p21v-K-ras). Proteins with enhanced expression in both wild-type v-K-ras and v-src transformants included a cell-surface phosphoglycoprotein with apparent M(r) of 79 000 (79K) modified from an 85K protein observed in NRK cell lysates, a cytoplasmic 47K and a 10K protein, and a 57K secreted glycoprotein. A KNRK-specific 21K membrane-associated protein and secreted 59K and 36K secreted glycoproteins were also detected. The expression of the 36K and 59K proteins best correlated with temperature-dependent activation of the ts-371-NRK p21v-K-ras. Immunoselection of recombinant clones from a KNRK-specific lambda-gt11 cDNA library allowed identification of the 59K and 10K proteins as transin 2 and an S-100-related calcium-binding protein identified as p9Ka/42A but not previously associated with oncogenic transformation of rat cells. Transin 2 detection by a cell-derived antiserum may also suggest the presence of specific cell-surface binding sites for this enzyme.	MCGILL UNIV,CTR HUMAN GENET,MONTREAL H3A 1B1,QUEBEC,CANADA	McGill University	DEVOUGE, MW (corresponding author), MCGILL UNIV,DEPT BIOL,1205 AV DOCTEUR PENFIELD,MONTREAL H3A 1B1,QUEBEC,CANADA.							ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ANZANO MA, 1982, CANCER RES, V42, P4776; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1990, BIOCHEM BIOPH RES CO, V169, P660, DOI 10.1016/0006-291X(90)90381-V; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACK FM, 1990, BIOCHEM J, V267, P809, DOI 10.1042/bj2670809; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHARDIN P, 1988, BIOCHIMIE, V70, P865, DOI 10.1016/0300-9084(88)90226-X; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENHARDT DT, 1987, ONCOGENE, V2, P55; DER CJ, 1981, CELL, V26, P429, DOI 10.1016/0092-8674(81)90212-9; DEVOUGE MW, 1982, VIROLOGY, V121, P327, DOI 10.1016/0042-6822(82)90172-6; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; DURKIN JP, 1983, CANCER RES, V43, P5390; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GAL S, 1986, J BIOL CHEM, V261, P1760; GILLEN MF, 1987, J BIOL CHEM, V262, P5308; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDBERG AR, 1979, COLD SPRING HARB SYM, V44, P991; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GOTTESMAN MM, 1980, CELL, V19, P449, DOI 10.1016/0092-8674(80)90519-X; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; Marston F. A. O., 1987, DNA CLONING, P59; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MORRIS JDH, 1989, ONCOGENE, V4, P27; NEMIR M, 1989, J BIOL CHEM, V264, P18202; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAPAGEORGE A, 1982, J VIROL, V44, P509, DOI 10.1128/JVI.44.2.509-519.1982; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRICE BD, 1989, J BIOL CHEM, V264, P16638; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; Sambrook J, 1989, MOL CLONING LABORATO; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1987, J BIOL CHEM, V262, P10663; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SHIH TY, 1979, J VIROL, V31, P546, DOI 10.1128/JVI.31.2.546-546.1979; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; STEIN RB, 1986, J VIROL, V60, P782, DOI 10.1128/JVI.60.2.782-786.1986; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TODARO GJ, 1980, CONTROL MECHANISMS A, V1, P223; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; USHIRO H, 1980, J BIOL CHEM, V255, P8363; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	76	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					109	119						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741158				2022-12-25	WOS:A1992HC22700015
J	LAYTON, JE; MORSTYN, G; FABRI, LJ; REID, GE; BURGESS, AW; SIMPSON, RJ; NICE, EC				LAYTON, JE; MORSTYN, G; FABRI, LJ; REID, GE; BURGESS, AW; SIMPSON, RJ; NICE, EC			IDENTIFICATION OF A FUNCTIONAL DOMAIN OF HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR USING NEUTRALIZING MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; HUMAN INTERLEUKIN-6; BIOLOGICAL-ACTIVITY; GENE STRUCTURE; CHEMOTHERAPY; NEUTROPENIA; ESTABLISHMENT; MUTAGENESIS; RECEPTOR; ANTIGEN	Human granulocyte colony-stimulating factor (G-CSF) is a hemopoietic growth factor that is being used successfully to treat various forms of neutropenia. To define functionally important regions of G-CSF, we have prepared 37 monoclonal anti-G-CSF antibodies and mapped the regions of G-CSF recognized by different antibody groups. Antibodies recognizing similar epitopes were identified by competition assays, neutralization assays, conformation dependence and cross-reactivity with canine G-CSF. Seven of eight neutralizing antibodies fell into two related epitope groups and were conformation-dependent. The eighth was unrelated and conformation-independent. Peptides of GCSF were generated by chemical or enzymatic digestion and tested for antibody reactivity. One of the neutralizing antibodies (LMM351) recognized a small, disulfide-bonded peptide from the V8 protease digest (residues 34-46). A synthetic peptide (residues 20-58) was recognized by all the neutralizing antibodies, implicating this disulfide-bonded loop in receptor binding. The epitopes recognized by nonneutralizing antibodies were found throughout G-CSF. Thus, regions of G-CSF that are not involved in receptor binding have also been defined. A CNBr peptide (residues 1-121) had greatly reduced biological activity, indicating that the COOH terminus is required for receptor binding. We predict that residues 20-46 and the COOH terminus bind to the G-CSF receptor.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, LUDWIG INST CANC RES, JOINT PROT STRUCT LAB, PARKVILLE, VIC 3050, AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Walter & Eliza Hall Institute	LAYTON, JE (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, LUDWIG INST CANC RES, PARKVILLE, VIC 3050, AUSTRALIA.		Nice, Edouard C/B-1026-2011	Simpson, Richard/0000-0002-9834-0796; Reid, Gavin/0000-0002-9675-1444; fabri, louis/0000-0003-4033-3304				BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BEGG GS, 1989, TECHNIQUES PROTEIN C, P79; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BONILLA MA, 1989, NEW ENGL J MED, V320, P1574, DOI 10.1056/NEJM198906153202402; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRODSKY FM, 1980, TISSUE ANTIGENS, V16, P30; BRONCHUD MH, 1987, BRIT J CANCER, V56, P809, DOI 10.1038/bjc.1987.295; BURGESS AW, 1988, BIOCHEMISTRY-US, V27, P4977, DOI 10.1021/bi00414a005; COHEN AM, 1987, P NATL ACAD SCI USA, V84, P2484, DOI 10.1073/pnas.84.8.2484; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DEMPSEY PJ, 1990, HYBRIDOMA, V9, P545, DOI 10.1089/hyb.1990.9.545; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FIBI MR, 1991, BLOOD, V77, P1203; FULLMER CS, 1984, ANAL BIOCHEM, V142, P336, DOI 10.1016/0003-2697(84)90473-1; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; GREGO B, 1986, INT J PEPT PROT RES, V27, P201; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; HAMMARSTROM S, 1989, CANCER RES, V49, P4852; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; IDA N, 1989, BIOCHEM BIOPH RES CO, V165, P728, DOI 10.1016/S0006-291X(89)80027-0; KRUTTGEN A, 1990, FEBS LETT, V273, P95, DOI 10.1016/0014-5793(90)81059-W; KUGA T, 1989, BIOCHEM BIOPH RES CO, V159, P103, DOI 10.1016/0006-291X(89)92410-8; LU HS, 1989, ARCH BIOCHEM BIOPHYS, V268, P81, DOI 10.1016/0003-9861(89)90567-5; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MITCHELL AR, 1978, J ORG CHEM, V43, P2845, DOI 10.1021/jo00408a022; MORSTYN G, 1988, CANCER RES, V48, P5624; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; NAGATA S, 1986, EMBO J, V5, P575, DOI 10.1002/j.1460-2075.1986.tb04249.x; NAGATA S, 1989, BIOESSAYS, V10, P113, DOI 10.1002/bies.950100405; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; NICE EC, 1985, BIOCHEM INT, V11, P187; Nice E, 1990, GROWTH FACTORS, V3, P159, DOI 10.3109/08977199009108278; OHEDA M, 1990, J BIOL CHEM, V265, P11432; OHEDA M, 1988, J BIOCHEM-TOKYO, V103, P544, DOI 10.1093/oxfordjournals.jbchem.a122305; PARRY DAD, 1991, IN PRESS J MOL RECOG; SHERIDAN WP, 1989, LANCET, V2, P891; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; TAMURA M, 1987, BIOCHEM BIOPH RES CO, V142, P454, DOI 10.1016/0006-291X(87)90296-8; TSUCHIYA M, 1986, P NATL ACAD SCI USA, V83, P7633, DOI 10.1073/pnas.83.20.7633; WELTE K, 1987, J EXP MED, V165, P941, DOI 10.1084/jem.165.4.941	44	37	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 15	1991	266	35					23815	23823						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GV319	1721056				2022-12-25	WOS:A1991GV31900046
J	BARBOSA, P; WISTOW, GJ; CIALKOWSKI, M; PIATIGORSKY, J; OBRIEN, WE				BARBOSA, P; WISTOW, GJ; CIALKOWSKI, M; PIATIGORSKY, J; OBRIEN, WE			EXPRESSION OF DUCK LENS DELTA-CRYSTALLIN CDNAS IN YEAST AND BACTERIAL HOSTS - DELTA-2-CRYSTALLIN IS AN ACTIVE ARGININOSUCCINATE LYASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL PROPERTIES; STRUCTURAL PROTEIN; ENZYME-CRYSTALLINS; GENE; SEQUENCE; LIVER; RECRUITMENT; POLYMERASE; EVOLUTION; CLONING	The major soluble protein in the lenses of most birds and reptiles is delta-crystallin. In chickens and ducks the delta-crystallin gene has duplicated, and in the duck both genes contribute to the protein in the lens, while in the chicken lens there is a great preponderance of the delta-1 gene product. Purified delta-crystallin has previously been shown to possess the enzymatic activity of argininosuccinate lyase. In order to determine the enzymatic properties of the two duck delta-crystallins their corresponding cDNA molecules were placed in yeast and bacterial expression plasmids. In Saccharomyces cerevisiae, the activity of each crystallin was assessed by transformation of the expression plasmids into a strain deficient for argininosuccinate lyase activity. The ability of the resulting yeast to grow on arginine deficient medium was used as a measure of enzymatic activity. Yeast expressing the duck delta-2-crystallin protein grew rapidly, while those expressing delta-1-crystallin failed to grow. Enzyme activity measurements confirmed the presence of activity in the delta-2-crystallin-expressing yeast, and no detectable activity could be demonstrated in the delta-1-crystallin-expressing yeast. Northern blotting of RNA from the transformed yeast revealed equal levels of mRNA species from the two constructs. For further analysis, the delta-2-crystallin cDNA was placed in the bacterial expression plasmid, pET-3d. The delta-2-crystallin protein produced in Escherichia coli was purified to homogeneity and analyzed to determine the kinetic properties. A K(m) of 0.35 mM was determined for argininosuccinate and a V(m) of 3.5-mu-mol/min/mg was determined. These data demonstrate that, following duplication of the primordial argininosuccinate lyase gene, one of the genes maintained its role as an enzyme (delta-2-crystallin) while also serving as a crystallin and the other has evolved to specialize as a structural protein in the lens (delta-1-crystallin), presumably losing most or all of its catalytic capacity.	BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PLAZA,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; NEI,MOLEC & DEV BIOL LAB,BETHESDA,MD 20892	Baylor College of Medicine; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)					NEI NIH HHS [EY07612] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007612, R55EY007612] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAMSON RD, 1991, GENOMICS, V10, P126, DOI 10.1016/0888-7543(91)90492-W; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BARBOSA P, 1991, J BIOL CHEM, V266, P5286; BRAY RC, 1971, ARCH BIOCHEM BIOPHYS, V146, P531, DOI 10.1016/0003-9861(71)90158-5; CHIOU SH, 1991, BIOCHEM J, V273, P295, DOI 10.1042/bj2730295; DALES S, 1971, BIOCHIM BIOPHYS ACTA, V229, P771, DOI 10.1016/0005-2795(71)90295-9; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DOOLITTLE RF, 1988, NATURE, V336, P18, DOI 10.1038/336018a0; GARRARD LJ, 1985, J BIOL CHEM, V260, P5548; HAVIR EA, 1965, J BIOL CHEM, V240, P3079; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KONDOH H, 1991, GENE, V99, P267, DOI 10.1016/0378-1119(91)90137-Z; LAMBERT MA, 1986, MOL CELL BIOL, V6, P1722, DOI 10.1128/MCB.6.5.1722; MATSUBASA T, 1989, P NATL ACAD SCI USA, V86, P592, DOI 10.1073/pnas.86.2.592; MATUO S, 1988, FEBS LETT, V234, P395, DOI 10.1016/0014-5793(88)80124-8; MORI M, 1990, PROG CLIN BIOL RES, V344, P683; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURAKAMIMUROFUSHI K, 1979, ANAL BIOCHEM, V95, P139, DOI 10.1016/0003-2697(79)90197-0; NICKERSON JM, 1985, J BIOL CHEM, V260, P9100; NICKERSON JM, 1986, J BIOL CHEM, V261, P552; OBRIEN WE, 1981, BIOCHEMISTRY-US, V20, P2056, DOI 10.1021/bi00510a049; OBRIEN WE, 1986, P NATL ACAD SCI USA, V83, P7211, DOI 10.1073/pnas.83.19.7211; PARKER DS, 1988, DEV BIOL, V126, P375, DOI 10.1016/0012-1606(88)90147-9; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1981, BIOCHEMISTRY-US, V20, P6427, DOI 10.1021/bi00525a022; Ratner S, 1972, ENZYMES, P167; ROCHOVANSKY O, 1975, J BIOL CHEM, V250, P7225; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS G, 1990, New Biologist, V2, P903; TODD S, 1989, GENOMICS, V4, P53, DOI 10.1016/0888-7543(89)90314-5; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW G, 1990, P NATL ACAD SCI USA, V87, P6277, DOI 10.1073/pnas.87.16.6277; WISTOW GJ, 1990, GENE, V96, P263, DOI 10.1016/0378-1119(90)90262-P; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0; WISTOW GJ, 1988, J CELL BIOL, V107, P2729, DOI 10.1083/jcb.107.6.2729; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YEH LSL, 1988, COMP BIOCHEM PHYS B, V89, P433, DOI 10.1016/0305-0491(88)90247-7	43	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22319	22322						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1718993				2022-12-25	WOS:A1991GR56400043
J	MOLDAY, RS; MOLDAY, LL; DOSE, A; CLARKLEWIS, I; ILLING, M; COOK, NJ; EISMANN, E; KAUPP, UB				MOLDAY, RS; MOLDAY, LL; DOSE, A; CLARKLEWIS, I; ILLING, M; COOK, NJ; EISMANN, E; KAUPP, UB			THE CGMP-GATED CHANNEL OF THE ROD PHOTORECEPTOR CELL CHARACTERIZATION AND ORIENTATION OF THE AMINO TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GMP-SENSITIVE CONDUCTANCE; DEPENDENT CATION CHANNEL; OUTER SEGMENT DISK; CYCLIC-GMP; FUNCTIONAL RECONSTITUTION; PLASMA-MEMBRANE; MONOCLONAL-ANTIBODIES; PROTEIN; EXPRESSION; BINDING	The molecular properties and orientation of the cGMP-gated cation channel of bovine rod outer segment membranes were studied using biochemical and immunochemical methods. Western blots labeled with anti-channel monoclonal antibodies indicate that the channel has a subunit M(r) of 63,000 in bovine rod outer segment membranes prepared in the presence and absence of protease inhibitors and in rod outer segments from other mammalian retinas. The channel has an apparent M(r) of 78,000 in both COS-1 cells and Xenopus oocytes expressing the cloned cDNA. NH-2-terminal sequence analysis indicates that the lower M(r) of the channel in rod outer segments is caused by the absence of the first 92 amino acids predicted by cDNA sequence analysis. Immunofluoreseent and immunogold labeling has confirmed that the 63,000 form of the channel is present in rod outer segments. These results indicate that photoreceptor cell-specific co-translational or post-translational cleavage of the NH-2-terminal segment of the channel occurs prior or during the incorporation of the channel into the rod outer segment plasma membrane. Immunogold labeling studies using site-directed antibodies also indicate that the NH-2-terminal segment of the rod outer segment channel is exposed on the cytoplasmic side of the plasma membrane.	UNIV BRITISH COLUMBIA,DEPT BIOMED RES CTR,VANCOUVER V6T 1Z3,BC,CANADA; FORSCHUNGSZENTRUM JULICH,INST BIOL INFORMAT VERABEITUNG,W-5170 JULICH,GERMANY; MAX PLANCK INST BIOPHYS,MOLEK MEMBRANEBIOL ABT,W-6000 FRANKFURT 71,GERMANY	University of British Columbia; Helmholtz Association; Research Center Julich; Max Planck Society	MOLDAY, RS (corresponding author), UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA.				NEI NIH HHS [EY 02422] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD I, 1990, BIOCHEM BIOPH RES CO, V173, P463, DOI 10.1016/S0006-291X(05)81081-2; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; COLMAN A, 1984, TRANSCRIPTION TRANSL, P290; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; COOK NJ, 1986, PHOTOBIOCH PHOTOBIOP, V13, P331; COOK NJ, 1986, J BIOL CHEM, V261, P7033; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FESENKO EE, 1985, NATURE, V313, P310, DOI 10.1038/313310a0; HAYNES L, 1985, NATURE, V317, P61, DOI 10.1038/317061a0; JOHNSON LV, 1984, CURR EYE RES, V3, P969, DOI 10.3109/02713688409167215; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHT DB, 1989, SCIENCE, V243, P383, DOI 10.1126/science.2463673; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MACKENZIE D, 1982, J BIOL CHEM, V257, P7100; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; ROOF DJ, 1982, J CELL BIOL, V95, P487, DOI 10.1083/jcb.95.2.487; WOHLFART P, 1989, J BIOL CHEM, V264, P20934; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; YAU KW, 1985, NATURE, V317, P252, DOI 10.1038/317252a0	29	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	1991	266	32					21917	21922						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GP804	1718987				2022-12-25	WOS:A1991GP80400089
J	VEGA, MA; SEGUIREAL, B; GARCIA, JA; CALES, C; RODRIGUEZ, F; VANDERKERCKHOVE, J; SANDOVAL, IV				VEGA, MA; SEGUIREAL, B; GARCIA, JA; CALES, C; RODRIGUEZ, F; VANDERKERCKHOVE, J; SANDOVAL, IV			CLONING, SEQUENCING, AND EXPRESSION OF A CDNA-ENCODING RAT LIMP-II, A NOVEL 74-KDA LYSOSOMAL MEMBRANE-PROTEIN RELATED TO THE SURFACE-ADHESION PROTEIN-CD36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; GLYCOPROTEIN-IV CD36; GROWTH FACTOR-II; MONOCLONAL-ANTIBODY; CYTOPLASMIC TAIL; ACID-PHOSPHATASE; GOLGI-COMPLEX; CELLS; IDENTIFICATION; LOCALIZATION	LIMP II is a glycoprotein expressed in the membrane of lysosomes and secretory granules with lysosomal properties. Sequence analysis of a CNBr-cleaved peptide allowed the synthesis of a 47-mer oligonucleotide that was used to screen a rat liver cDNA library in lambda-gt11. This resulted in isolation of a 2-kilobase cDNA containing 1,434 bases encoding the entire protein. The deduced amino acid sequence indicates that LIMP II consists of 478 amino acid residues. The segment spanning residues 4-6 to 26 constitute an uncleavable signal peptide. LIMP II possesses a hydrophobic amino acid segment near the carboxyl end, that together with the uncleaved signal peptide may anchor the protein to the membrane through two distant segments. The major portion of the protein resides on the luminal side and displays 11 potential N-glycosylation sites and 5 cysteine residues. Two short cytoplasmic tails, 2-4 and 20-21 amino acids long, correspond to the NH2- and COOH-terminal ends of the protein, respectively. Transfection of COS cells with the cDNA of LIMP II resulted in expression of the protein and its transport to lysosomes. Comparison of the entire sequence to various data bases of known proteins revealed extensive homology between LIMP II and the cell surface protein CD36 involved in cell adhesion. No significant homology was detected with the two families of lysosomal membrane proteins A and B, recently described.	CSIC,CTR BIOMED,MADRID 6,SPAIN; STATE UNIV GHENT,GENET LAB,B-9000 GHENT,BELGIUM	Consejo Superior de Investigaciones Cientificas (CSIC); Ghent University	VEGA, MA (corresponding author), UNIV AUTONOMA MADRID,FAC CIENCIAS,CTR BIOL MOLEC,E-28049 MADRID,SPAIN.		Garcia, Juan Antonio/N-3723-2014; Calés, Carmela/AAB-1595-2019; Vega, Miguel A/M-1367-2016	Garcia, Juan Antonio/0000-0002-4861-9609; Vega, Miguel A/0000-0001-6151-4193; Rodriguez, Fernando/0000-0001-7361-8408; Cales, Carmela/0000-0002-6987-2259				ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; BERNSTEIN ID, 1982, J IMMUNOL, V128, P876; BONIFACINO JS, 1990, J CELL SCI, V92, P701; BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; CHA Y, 1990, J BIOL CHEM, V265, P5008; CHEN JW, 1985, ARCH BIOCHEM BIOPHYS, V239, P574, DOI 10.1016/0003-9861(85)90727-1; CHEN JW, 1988, J BIOL CHEM, V263, P8754; de Duve D, 1963, CIBA F S LYSOSOMES, P1; DSOUZA MP, 1986, ARCH BIOCHEM BIOPHYS, V249, P522, DOI 10.1016/0003-9861(86)90030-5; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; FUKUDA M, 1988, J BIOL CHEM, V263, P18920; GAROFF H, 1985, ANNU REV CELL BIOL, V1, P403, DOI 10.1146/annurev.cb.01.110185.002155; GEUZE HJ, 1988, J CELL BIOL, V107, P2491, DOI 10.1083/jcb.107.6.2491; GEUZE HJ, 1984, J CELL BIOL, V98, P2047, DOI 10.1083/jcb.98.6.2047; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOWE CL, 1988, P NATL ACAD SCI USA, V85, P7577, DOI 10.1073/pnas.85.20.7577; HUGHES EN, 1982, J BIOL CHEM, V257, P3970; JIN M, 1989, J BIOL CHEM, V264, P7675; KNOWLES DM, 1984, J IMMUNOL, V132, P2170; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LEWIS V, 1985, J CELL BIOL, V100, P1839, DOI 10.1083/jcb.100.6.1839; LIPPINCOTTSCHWARTZ J, 1986, J CELL BIOL, V102, P1593, DOI 10.1083/jcb.102.5.1593; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NOGUCHI Y, 1989, BIOCHEM BIOPH RES CO, V164, P1113, DOI 10.1016/0006-291X(89)91784-1; Nolan C M, 1987, Adv Exp Med Biol, V225, P199; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; PFEFFER SR, 1988, J MEMBRANE BIOL, V103, P7, DOI 10.1007/BF01871928; POHLMANN R, 1988, EMBO J, V7, P2343, DOI 10.1002/j.1460-2075.1988.tb03078.x; ROBBINS AR, 1988, PROTEIN TRANSFER ORG, P463; ROTH RA, 1988, SCIENCE, V239, P1269, DOI 10.1126/science.2964085; RUSSO AF, 1983, SCIENCE, V220, P1016, DOI 10.1126/science.6302843; SANDOVAL IV, 1989, ARCH BIOCHEM BIOPHYS, V271, P157, DOI 10.1016/0003-9861(89)90266-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKUDLAREK MD, 1984, LYSOSOM BIOL PATHOL, V7, P17; SLY WS, 1982, J CELL BIOCHEM, V18, P67, DOI 10.1002/jcb.1982.240180107; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TANDON NN, 1989, J BIOL CHEM, V264, P7576; VANDEKERCKHOVE J, 1985, EUR J BIOCHEM, V152, P9, DOI 10.1111/j.1432-1033.1985.tb09157.x; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WILLINGHAM MC, 1983, J HISTOCHEM CYTOCHEM, V31, P1	58	132	144	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16818	16824						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1715871				2022-12-25	WOS:A1991GD63500091
J	KHAN, WA; BLOBE, GC; HANNUN, YA				KHAN, WA; BLOBE, GC; HANNUN, YA			ACTIVATION OF PROTEIN-KINASE-C BY OLEIC-ACID - DETERMINATION AND ANALYSIS OF INHIBITION BY DETERGENT MICELLES AND PHYSIOLOGICAL MEMBRANES - REQUIREMENT FOR FREE OLEATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; PHORBOL ESTER BINDING; INDEPENDENT ACTIVATION; PHOSPHOLIPID-VESICLES; ALLOSTERIC REGULATION; PLATELET ACTIVATION; CELLULAR-REGULATION; KINETIC-ANALYSIS; MIXED MICELLES; CALCIUM	Sodium oleate is able to activate soluble protein kinase C (Murakami, K., Chan, S. Y., and Routtenberg, A. (1986) J. Biol. Chem. 261, 15424-15429) but is unable to activate membrane-bound enzyme (El Touny, S., Khan, W., and Hannun, Y. (1990) J. Biol. Chem. 265, 16437-16443). Because physiologic interactions of fatty acids with protein kinase C occur in the presence of membranes, the following studies were conducted to evaluate the effects of surfaces (detergent micelles or platelet membranes) on the activation of protein kinase C by oleate. At concentrations at or above the critical micellar concentration (CMC) of Triton X-100, oleate was present primarily in Triton X-100/oleate-mixed micelles, as determined by gel permeation chromatography and equilibrium dialysis binding studies. At concentrations slightly below the CMC for Triton X-100, the presence of oleate caused the formation of a limited number of mixed micelles. Studies of the dose-dependent activation of purified platelet protein kinase C by sodium oleate in the presence of different concentrations of Triton X-100 indicated that only unbound oleate was able to activate protein kinase C. Platelet protein kinase C was resolved into two major isoenzymes (types II (beta) and III (alpha)) which displayed nearly identical interaction with oleate. Activation of protein kinase C by oleate in a physiologic setting employing platelet substrates and endogenous platelet protein kinase C was investigated. Oleate potently activated protein kinase C in the cytosolic compartment. In platelet homogenates as well as in a reconstituted platelet cytosol and membrane system, the dose dependence of protein kinase C on oleate showed a significant shift to the right. Approximately 30% of oleate was associated with platelet cytosol and 70% was associated with platelet membranes. Partitioning of oleate into the two platelet compartments showed little change with pH, temperature, or duration of incubation. When corrected for free oleate concentration, activation of protein kinase C by oleate showed identical dose dependence in cytosol and homogenate. Arachidonate, a potential physiologic activator of protein kinase C, showed similar behavior as oleate although only 30% of arachidonate partitioned into platelet membranes with the majority of arachidonate (70%) remaining in the cytosolic fraction. These studies strongly suggest that only free fatty acids are able to activate soluble protein kinase C. It is proposed that physiologic activation of protein kinase C may occur in two compartments: soluble protein kinase C would be a primary target for cis-unsaturated fatty acids, especially arachidonate, while membrane-associated protein kinase C is a target for activation by diacylglycerols.	DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710	Duke University	KHAN, WA (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,POB 3355,DURHAM,NC 27710, USA.		Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901	NATIONAL CANCER INSTITUTE [P01CA047741] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NCI NIH HHS [CA-47741] Funding Source: Medline; NHLBI NIH HHS [HL-43707] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BONI LT, 1985, J BIOL CHEM, V260, P819; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; HANNUN YA, 1986, J BIOL CHEM, V261, P7184; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; Kitano T, 1986, Methods Enzymol, V124, P349; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LOFFELHOLZ K, 1989, BIOCHEM PHARMACOL, V38, P1543, DOI 10.1016/0006-2952(89)90299-2; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MURAKAMI K, 1986, J BIOL CHEM, V261, P5424; NAOR Z, 1988, MOL ENDOCRINOL, V2, P1043, DOI 10.1210/mend-2-11-1043; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIKAWA M, 1988, BIOCHEM PHARMACOL, V37, P3079, DOI 10.1016/0006-2952(88)90304-8; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RINK TJ, 1982, FEBS LETT, V148, P21, DOI 10.1016/0014-5793(82)81234-9; SANO K, 1983, J BIOL CHEM, V258, P2010; SEKIGUCHI K, 1987, BIOCHEM BIOPH RES CO, V145, P797, DOI 10.1016/0006-291X(87)91035-7; SHARKEY NA, 1985, BIOCHEM BIOPH RES CO, V133, P1051, DOI 10.1016/0006-291X(85)91242-2; SHEARMAN MS, 1989, FEBS LETT, V243, P177, DOI 10.1016/0014-5793(89)80125-5; SPOONER PJR, 1990, J BIOL CHEM, V265, P12650	26	116	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3605	3612						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740412				2022-12-25	WOS:A1992HE60700012
J	LUYTEN, FP; YU, YM; YANAGISHITA, M; VUKICEVIC, S; HAMMONDS, RG; REDDI, AH				LUYTEN, FP; YU, YM; YANAGISHITA, M; VUKICEVIC, S; HAMMONDS, RG; REDDI, AH			NATURAL BOVINE OSTEOGENIN AND RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2B ARE EQUIPOTENT IN THE MAINTENANCE OF PROTEOGLYCANS IN BOVINE ARTICULAR-CARTILAGE EXPLANT CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCTIVE PROTEIN; BETA FAMILY; DIFFERENTIATION; CHROMATOGRAPHY; PURIFICATION; METABOLISM; ASSAY; ACID	Osteogenin and related bone morphogenetic proteins are members of the transforming growth factor-beta superfamily, and were isolated by their ability to induce cartilage and bone formation in vivo. The influence of osteogenin, purified from bovine bone, and of recombinant human bone morphogenetic protein-2B (BMP-2B) has been examined in bovine articular cartilage explants. Both differentiation factors stimulated in a dose-dependent manner the synthesis of proteoglycans and decreased their rate of degradation. At a dose of 30 ng/ml, proteoglycan synthesis was increased to levels observed with either 20 ng/ml insulin-like growth factor 1, 10 ng/ml transforming growth factor-beta, or 20% fetal bovine serum. This increase of biosynthetic rates above basal medium levels was observed in young, adolescent, and adult tissues. Analysis of the size of the newly synthesized proteoglycans, the glycosaminoglycan chain size, and the glycosaminoglycan type of explants treated with osteogenin or BMP-2B were very comparable to each other, and to proteoglycans isolated from cartilage treated with either insulin-like growth factor I or fetal bovine serum. These results demonstrate that osteogenin and BMP-2B alone are capable of stimulating and maintaining the chondrocyte phenotype in vitro.	NIDR, PROTEOGLYCAN CHEM SECT, BETHESDA, MD 20892 USA; GENENTECH INC, DEPT DEV BIOL, S SAN FRANCISCO, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Roche Holding; Genentech	LUYTEN, FP (corresponding author), NIDR, BUNE CELL BIOL SECT, BLDG 30, ROOM 211, BETHESDA, MD 20892 USA.		Vukicevic, Slobodan/AEG-2646-2022; Luyten, Frank/GPS-7793-2022	Vukicevic, Slobodan/0000-0003-4076-0285; Hammonds, Glenn/0000-0003-0727-121X				CARLSON DM, 1968, J BIOL CHEM, V243, P616; CARRINGTON JL, 1991, DEV BIOL, V146, P406, DOI 10.1016/0012-1606(91)90242-U; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; CHEN P, 1991, EXP CELL RES, V195, P509, DOI 10.1016/0014-4827(91)90403-H; HAMMONDS RG, 1990, MOL ENDOCRINOL, V4, P149; HARRISON ET, 1991, EXP CELL RES, V192, P340, DOI 10.1016/0014-4827(91)90050-5; HASCALL VC, 1983, ARCH BIOCHEM BIOPHYS, V224, P206, DOI 10.1016/0003-9861(83)90205-9; HASCALL VC, 1991, METHODS CARTILAGE RE, P108; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAMMI M, 1988, ANAL BIOCHEM, V168, P352, DOI 10.1016/0003-2697(88)90329-6; LUYTEN FP, 1988, ARCH BIOCHEM BIOPHYS, V267, P416, DOI 10.1016/0003-9861(88)90047-1; LUYTEN FP, 1989, J BIOL CHEM, V264, P13377; MORALES TI, 1988, J BIOL CHEM, V263, P12828; OSBORN KD, 1989, J ORTHOP RES, V7, P35, DOI 10.1002/jor.1100070106; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; REDDI AH, 1972, P NATL ACAD SCI USA, V69, P1601, DOI 10.1073/pnas.69.6.1601; Rosenthal O, 1941, J CELL COMPAR PHYSL, V17, P221, DOI 10.1002/jcp.1030170207; SAMPATH TK, 1987, P NATL ACAD SCI USA, V84, P7109, DOI 10.1073/pnas.84.20.7109; SAMPATH TK, 1981, P NATL ACAD SCI-BIOL, V78, P7599, DOI 10.1073/pnas.78.12.7599; STOCKWELL RA, 1967, J ANAT, V101, P753; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; VUKICEVIC S, 1989, P NATL ACAD SCI USA, V86, P8793, DOI 10.1073/pnas.86.22.8793; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YANAGISHITA M, 1987, METHOD ENZYMOL, V138, P279; YANAGISHITA M, 1989, METHOD ENZYMOL, V179, P435; ZEBROWER ME, 1986, ANAL BIOCHEM, V157, P93, DOI 10.1016/0003-2697(86)90201-0	28	131	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3691	3695						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740421				2022-12-25	WOS:A1992HE60700025
J	BEACHAM, DA; WISE, RJ; TURCI, SM; HANDIN, RI				BEACHAM, DA; WISE, RJ; TURCI, SM; HANDIN, RI			SELECTIVE INACTIVATION OF THE ARG-GLY-ASP-SER (RGDS) BINDING-SITE IN VONWILLEBRAND-FACTOR BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON WILLEBRAND FACTOR; HUMAN-PLATELETS; CELL-ADHESION; FIBRONECTIN; EXPRESSION; RECEPTORS; SEQUENCE; COLLAGEN; DISTINCT; PROTEIN	In order to assess the requirement for the Arg-Gly-Asp-Ser (RGDS) consensus adhesion sequence in von Willebrand factor (vWF) for vWF binding to platelets and endothelial cells, point mutations were introduced into this sequence by site-directed mutagenesis. A glycine to alanine substitution yielded RADS-vWF, while an aspartate to glutamate substitution resulted in RGES-vWF. Recombinant RADS-vWF and RGES-vWF, purified from transformed Chinese hamster ovary cells, were compared with recombinant wild type vWF (WT-vWF) in functional assays with platelets and human umbilical vein endothelial cells (HUVECs). High molecular weight RADS-vWF and RGES-vWF multimers inhibited binding of I-125-vWF to a mixture of insolubilized native type I and III collagen and competed effectively with I-125-vWF for binding to formalin-fixed platelets in the presence of ristocetin, indicating functional collagen and platelet glycoprotein Ib binding. However, RADS-vWF and RGES-vWF were unable to displace the binding of I-125-vWF to thrombin or ADP-activated platelets. The attachment of HUVECs to either RADS-vWF or RGES-vWF coated surfaces was reduced and spreading was almost completely inhibited, compared with WT-vWF. We conclude that point mutations of the RGDS sequence in vWF selectively impair binding to platelet glycoprotein IIb/IIIa and the HUVEC vitronectin receptor.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV HEMATOL ONCOL,75 FRANCIS ST, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School					NHLBI NIH HHS [T32-HL07623, P01-HL33014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007623, P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCH AS, 1988, J CLIN INVEST, V81, P1600, DOI 10.1172/JCI113494; BEACHAM DA, 1990, EXP CELL RES, V189, P69, DOI 10.1016/0014-4827(90)90258-C; BOCKENSTEDT P, 1986, J CLIN INVEST, V77, P743, DOI 10.1172/JCI112369; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BOWDITCH RD, 1990, BLOOD, V46, pA448; DEJANA E, 1989, J CELL BIOL, V109, P367, DOI 10.1083/jcb.109.1.367; GIRMA JP, 1987, BLOOD, V70, P605; HANDIN RI, 1989, PROG HEMOST THROMB, V9, P233; HAVERSTICK DM, 1985, BLOOD, V66, P946; JACOBSON BS, 1988, ADV CELL BIOL, V2, P91; KAO KJ, 1979, J CLIN INVEST, V63, P656, DOI 10.1172/JCI109348; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MORISATO DK, 1980, BLOOD, V55, P9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; OKA JA, 1986, J CELL BIOL, V103, P1055, DOI 10.1083/jcb.103.3.1055; PHILLIPS DR, 1988, BLOOD, V71, P831; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; ROTH GJ, 1991, BLOOD, V77, P5; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RUNYAN RB, 1988, J CELL BIOL, V107, P1863, DOI 10.1083/jcb.107.5.1863; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, CELL, V52, P229; STREETER HB, 1987, J CELL BIOL, V105, P507, DOI 10.1083/jcb.105.1.507; TURITTO VT, 1987, HEMOSTASIS THROMBOSI, P1111; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9	31	73	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3409	3415						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737795				2022-12-25	WOS:A1992HD15400091
J	CHATRENET, B; CHANG, JY				CHATRENET, B; CHANG, JY			THE FOLDING OF HIRUDIN ADOPTS A MECHANISM OF TRIAL AND ERROR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; RECOMBINANT HIRUDIN; ANTITHROMBIN-III; AMINO-ACIDS; INTERMEDIATE; PROTEINS; HYDROLYSIS; THROMBIN; PATHWAY; DOMAIN	Reduced and denatured hirudin (65 amino acids and 3 disulfides) refolds in vitro to become an active molecule. The folding process adopts a mechanism of ''trial and error'' without predominant pathways. Throughout the entire folding process, the 6 cysteines were about equally involved in the disulfide shuffling. Among the first 20% of 3-disulfide species accumulated during the early phase of refolding, two-thirds were inactive and were reshuffled in the presence of thiol catalyst to regain correct disulfide pairing. When refolding was performed in the presence of strong denaturant (guanidinium chloride) without thiol catalyst, 8% of the active hirudin was obtained. This figure is close to the probability (6.7%) that would be expected from the random disulfide pairing of a molecule containing 6 sulfhydryl groups.	CIBA GEIGY AG,PHARMACEUT RES LABS,R-1056 309,CH-4002 BASEL,SWITZERLAND	Novartis								ANFINSEN CB, 1972, BIOCHEM J, V128, P737, DOI 10.1042/bj1280737; BALDWIN RL, 1989, TRENDS BIOCHEM SCI, V14, P291, DOI 10.1016/0968-0004(89)90067-4; BOERNSEN KO, 1990, CHIMIA, V44, P412; CHANG JY, 1991, ANAL BIOCHEM, V197, P52, DOI 10.1016/0003-2697(91)90354-V; CHANG JY, 1988, ANAL BIOCHEM, V170, P542, DOI 10.1016/0003-2697(88)90670-7; CHANG JY, 1990, J BIOL CHEM, V265, P22159; CHANG JY, 1991, J BIOL CHEM, V266, P10839; CHANG JY, 1983, FEBS LETT, V164, P307, DOI 10.1016/0014-5793(83)80307-X; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; FOLKERS PJM, 1989, BIOCHEMISTRY-US, V28, P2601, DOI 10.1021/bi00432a038; GRUETTER M, 1990, EMBO J, V9, P2361; HABER E, 1962, J BIOL CHEM, V237, P1839; HARRISON SC, 1985, P NATL ACAD SCI USA, V82, P4028, DOI 10.1073/pnas.82.12.4028; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; HENSCHEN A, 1986, ADV METHODS PROTEIN, P244; INGLIS AS, 1983, METHOD ENZYMOL, V91, P26, DOI 10.1016/S0076-6879(83)91007-8; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; KARAS M, 1990, TRAC-TREND ANAL CHEM, V9, P321, DOI 10.1016/0165-9936(90)85065-F; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KIM PS, 1982, ANNU REV BIOCHEM, V51, P459, DOI 10.1146/annurev.bi.51.070182.002331; KING J, 1986, BIO-TECHNOL, V4, P297, DOI 10.1038/nbt0486-297; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; KRSTENANSKY JL, 1987, FEBS LETT, V211, P10, DOI 10.1016/0014-5793(87)81264-4; LIGHT A, 1987, BIOCHEMISTRY-US, V26, P5556, DOI 10.1021/bi00391a051; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; MEYHACK B, 1987, THROMB RES S, V7, P33; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; Richards F. M., 1991, Scientific American, V264, P34; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SELA M, 1959, BIOCHIM BIOPHYS ACTA, V36, P471, DOI 10.1016/0006-3002(59)90188-X; SUN XJ, 1990, BIOCHEM J, V269, P665, DOI 10.1042/bj2690665; SUN XJ, 1989, J BIOL CHEM, V264, P11288; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	38	40	45	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3038	3043						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737759				2022-12-25	WOS:A1992HD15400036
J	MAHAUTSMITH, MP; SAGE, SO; RINK, TJ				MAHAUTSMITH, MP; SAGE, SO; RINK, TJ			RAPID ADP-EVOKED CURRENTS IN HUMAN PLATELETS RECORDED WITH THE NYSTATIN PERMEABILIZED PATCH TECHNIQUE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FURA-2-LOADED HUMAN-PLATELETS; POTASSIUM CHANNELS; LYMPHOCYTES-T; CALCIUM; MEMBRANE; CA-2+; CELLS; ACTIVATION; THROMBIN; ENTRY	''Whole-cell'' patch recordings using nystatin permeabilization were made from single human platelets during application of agonists from a ''puffer'' pipette. In platelets clamped near the resting potential and bathed in Na+ saline, 40-mu-M ADP activated a transient inward current within tens of milliseconds. At -73 mV the current lasted between 0.1 and 1 s and had a peak of between 13 and 31 pA in different cells. Ion substitution experiments indicated that the channel is permeable to Na+, K+, and Ba2+ and presumably also to Ca2+, but is not permeable to Cl-. The single channel conductance was 15 pS (near the resting potential) in nominally Ca2+-free saline and 11 picosiemens in BaCl2 saline. Thrombin, at 1 unit/ml, did not elicit detectable currents during a 3-s application in platelets bathed in 1 mM Ca2+, Na+ saline. Under the same conditions, in fura-2-loaded cells, thrombin-evoked Ca2+ entry (monitored by Mn2+ quench) was detectable after a delay of 1.4 s. This suggests that early thrombin-evoked Ca2+ entry occurs via small conductance channels, below the resolution of the patch clamp technique, or by an electroneutral pathway. The ADP-evoked channel has the requisite speed of activation to account for the rapid Ca2+ influx observed during stopped-flow studies of agonist-evoked changes in [Ca2+]i.	PHYSIOL LAB,CAMBRIDGE CB2 3EG,ENGLAND	University of Cambridge				Sage, Stewart/0000-0001-8578-3558				FALKE LC, 1989, FEBS LETT, V251, P167, DOI 10.1016/0014-5793(89)81448-6; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; HALLAM TJ, 1985, J PHYSIOL-LONDON, V368, P131, DOI 10.1113/jphysiol.1985.sp015850; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLZ R, 1970, J GEN PHYSIOL, V56, P125, DOI 10.1085/jgp.56.1.125; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; KUNO M, 1986, NATURE, V323, P269, DOI 10.1038/323269a0; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEVITAN ES, 1990, NATURE, V348, P545, DOI 10.1038/348545a0; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; MACINTYRE DE, 1982, THROMB HAEMOSTASIS, V47, P22; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MAHAUTSMITH MP, 1990, J PHYSIOL-LONDON, V428, P723, DOI 10.1113/jphysiol.1990.sp018237; MAHAUTSMITH MP, 1990, J MEMBRANE BIOL, V118, P69, DOI 10.1007/BF01872205; MAHAUTSMITH MP, 1991, J PHYSIOL-LONDON, V434, pP38; MARTY A, 1975, J GEN PHYSIOL, V65, P515, DOI 10.1085/jgp.65.4.515; Marty A., 1983, SINGLE CHANNEL RECOR, P107; MARUYAMA Y, 1987, J PHYSL, V4391, P467; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROBINSON RA, 1955, ELECTROLYTE SOLUTION; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SAGE SO, 1991, J PHYSIOL-LONDON, V441, P559, DOI 10.1113/jphysiol.1991.sp018767; SAGE SO, 1987, J BIOL CHEM, V262, P16364; ZSCHAUER A, 1988, NATURE, V334, P703, DOI 10.1038/334703a0	25	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3060	3065						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737761				2022-12-25	WOS:A1992HD15400039
J	MONONEN, I; HEISTERKAMP, N; KAARTINEN, V; MONONEN, T; WILLIAMS, JC; GROFFEN, J				MONONEN, I; HEISTERKAMP, N; KAARTINEN, V; MONONEN, T; WILLIAMS, JC; GROFFEN, J			ASPARTYLGLYCOSAMINURIA IN A NON-FINNISH PATIENT CAUSED BY A DONOR SPLICE MUTATION IN THE GLYCOASPARAGINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE; EXON	Aspartylglycosaminuria is a lysosomal storage disease caused by deficient activity of glycoasparaginase (EC 3.5.1.26), and it occurs with a high frequency among Finns. We have recently shown that the molecular defect in all Finnish aspartylglycosaminuria patients examined to date consists of two single base changes in the heavy chain of glycoasparaginase (Mononen, I., Heisterkamp, N., Kaartinen, V., Williams, J. C., Yates, J. R., III, Griffin, P. R., Hood, L. E., and Groffen, J. (1991) Proc. Natl. Acad. Sci U.S.A. 88, 2941-2945). This is the first report on the identification of the molecular defect causing aspartylglycosaminuria in a patient of non-Finnish origin. Total RNA from fibroblasts of a black American aspartylglycosaminuria patient was isolated, first-strand cDNA was synthesized, and the cDNA encoding glycoasparaginase was amplified by the polymerase chain reaction. The patient's mRNA nucleotide sequence was different from the normal sequence by a deletion of 134 nucleotides at positions 807-940. Nucleotide sequence analysis of the normal glycoasparaginase gene demonstrated that the deletion corresponded precisely to a 134-base pair exon. Moreover, analysis of the splice sites demonstrated a single base change, G to T, that altered the donor splice site of the exon deleted in the patient's mRNA. This change led to an exon-skipping event resulting in a frame shift and generation of a stop codon.	KUOPIO UNIV,CENT HOSP,DEPT CLIN CHEM,SF-70210 KUOPIO,FINLAND; CHILDRENS HOSP,DEPT PATHOL,MOLEC DIAGNOSIS SECT,LOS ANGELES,CA 90054; CHILDRENS HOSP,DIV MED GENET,LOS ANGELES,CA 90054; UNIV KUOPIO,DEPT CHEM,SF-70200 KUOPIO,FINLAND; AI VIRTANEN INST,CTR DIAGNOST BIOTECHNOL,SF-70210 KUOPIO,FINLAND	Kuopio University Hospital; University of Eastern Finland; Children's Hospital Los Angeles; Children's Hospital Los Angeles; University of Eastern Finland			Heisterkamp, Nora/C-1698-2012; Kaartinen, Vesa/AAU-5396-2021	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X				BEAUDET AL, 1989, METABOLIC BASIS INHE, P1603; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; FISHER KJ, 1990, FEBS LETT, V269, P440, DOI 10.1016/0014-5793(90)81211-6; HREIDARSSON S, 1983, CLIN GENET, V23, P427; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; KAARTINEN V, 1991, J BIOL CHEM, V266, P5860; KAARTINEN V, 1990, ANAL BIOCHEM, V190, P98, DOI 10.1016/0003-2697(90)90140-5; MARVIT J, 1987, NUCLEIC ACIDS RES, V15, P5613, DOI 10.1093/nar/15.14.5613; MONONEN I, 1984, BIOCHIM BIOPHYS ACTA, V788, P364, DOI 10.1016/0167-4838(84)90050-5; MONONEN I, 1991, P NATL ACAD SCI USA, V88, P2941, DOI 10.1073/pnas.88.7.2941; MONONEN T, 1991, HUM GENET, V87, P266; MORRIS C, 1991, IN PRESS HUM GENET; Norio R., 1981, BIOCULTURAL ASPECTS, P359; OLDEN K, 1985, TRENDS BIOCHEM SCI, V10, P78, DOI 10.1016/0968-0004(85)90238-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIF I, 1979, NUCLEIC ACIDS RES, V6, P3387, DOI 10.1093/nar/6.10.3387; TREISMAN R, 1982, CELL, V29, P903, DOI 10.1016/0092-8674(82)90452-4; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; WATKINS S, 1991, P NATL ACAD SCI USA, V88, P5959, DOI 10.1073/pnas.88.14.5959; WEIL D, 1988, J BIOL CHEM, V263, P8561	20	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3196	3199						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737774				2022-12-25	WOS:A1992HD15400060
J	TAMARAPPOO, BK; HANDLOGTEN, ME; LAINE, RO; SERRANO, MA; DUGAN, J; KILBERG, MS				TAMARAPPOO, BK; HANDLOGTEN, ME; LAINE, RO; SERRANO, MA; DUGAN, J; KILBERG, MS			IDENTIFICATION OF THE PROTEIN RESPONSIBLE FOR HEPATIC SYSTEM-N AMINO-ACID-TRANSPORT ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; RAT-LIVER; MONOCLONAL-ANTIBODIES; GLUTAMINE; METABOLISM; RECONSTITUTION; CELLS; HEPATOCYTES; GLUCAGON; CULTURES	In the liver, glutamine utilization may be limited by the rate of transport across the plasma membrane by the System N carrier. System N-mediated transport activity has been solubilized from rat liver plasma membrane, partially purified, and then reconstituted into proteoliposomes. To identify the System N carrier protein, monoclonal antibodies were generated against the protein fraction enriched for System N activity. Two antibodies, 3E1-2 and 1E7-3, inhibited System N activity in hepatocytes. These antibodies also immunoprecipitated System N activity from a mixture of solubilized proteins and were specific for antigen recognition in that neither immunoprecipitated System A activity. The antibody recognized a single protein of molecular size 100 kDa by immunoblot analysis. Recognition of this protein by the antibody increased in parallel with the enrichment of System N activity in solubilized membrane fractions. These data suggest that a 100-kDa plasma membrane protein mediates System N transport activity in rat hepatocytes.	UNIV FLORIDA, J HILLIS MILLER HLTH CTR, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida			SERRANO, MARIA A/A-9601-2017	SERRANO, MARIA A/0000-0001-6710-956X	NIDDK NIH HHS [DK-28374] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028374] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHANARAYANAN M, 1988, J BIOL CHEM, V263, P8338; BODE BP, 1991, J BIOL CHEM, V266, P7376; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FAFOURNOUX P, 1989, J BIOL CHEM, V264, P4805; GEBHARDT R, 1987, EUR J BIOCHEM, V166, P339, DOI 10.1111/j.1432-1033.1987.tb13520.x; HAUSSINGER D, 1983, EUR J BIOCHEM, V133, P269, DOI 10.1111/j.1432-1033.1983.tb07458.x; HAUSSINGER D, 1985, EUR J BIOCHEM, V152, P597, DOI 10.1111/j.1432-1033.1985.tb09237.x; HAUSSINGER D, 1984, J HEPATOL, V1, P3; JOSEPH SK, 1978, BIOCHEM J, V176, P827, DOI 10.1042/bj1760827; JOSEPH SK, 1978, BIOCHIM BIOPHYS ACTA, V543, P16, DOI 10.1016/0304-4165(78)90450-6; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; KOEPSELL H, 1988, J BIOL CHEM, V263, P18419; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAILLIARD ME, 1990, J BIOL CHEM, V265, P14321; MCCORMICK JI, 1988, P NATL ACAD SCI USA, V85, P7877, DOI 10.1073/pnas.85.21.7877; PRPIC V, 1984, J BIOL CHEM, V259, P1382; REMESY C, 1988, J NUTR, V118, P569, DOI 10.1093/jn/118.5.569; RUETZ S, 1987, J BIOL CHEM, V262, P11324; RUETZ S, 1988, P NATL ACAD SCI USA, V85, P6147, DOI 10.1073/pnas.85.16.6147; SCHENERMAN MA, 1986, BIOCHIM BIOPHYS ACTA, V856, P428, DOI 10.1016/0005-2736(86)90133-1; SCHMIDT UM, 1983, FEBS LETT, V161, P279, DOI 10.1016/0014-5793(83)81025-4; SILVERMAN M, 1991, ANNU REV BIOCHEM, V60, P757, DOI 10.1146/annurev.bi.60.070191.003545; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; TAMARAPPOO BK, 1991, BIOCHEM J, V274, P97, DOI 10.1042/bj2740097; VADGAMA JV, 1983, J BIOL CHEM, V258, P6422; VONDIPPE P, 1990, J BIOL CHEM, V265, P14812; WINDMUELLER HG, 1982, ADV ENZYMOL, V53, P202; WU JSR, 1989, J CELL BIOCHEM, V40, P83, DOI 10.1002/jcb.240400109; WU JSR, 1987, BIOCHEMISTRY-US, V26, P5783, DOI 10.1021/bi00392a030	33	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2370	2374						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733938				2022-12-25	WOS:A1992HB53200041
J	MIQUEL, M; BROWSE, J				MIQUEL, M; BROWSE, J			ARABIDOPSIS MUTANTS DEFICIENT IN POLYUNSATURATED FATTY-ACID SYNTHESIS - BIOCHEMICAL AND GENETIC-CHARACTERIZATION OF A PLANT OLEOYL-PHOSPHATIDYLCHOLINE DESATURASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCED THERMAL TOLERANCE; GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; CHLOROPLAST ULTRASTRUCTURE; PHOSPHOLIPID BIOSYNTHESIS; MICROSOMAL PREPARATIONS; SPINACH-CHLOROPLASTS; LIPID-METABOLISM; RAT-LIVER; SAFFLOWER; THALIANA	The overall fatty acid composition of leaf lipids in a mutant of Arabidopsis thaliana was characterized by reduced levels of polyunsaturated 18-carbon fatty acids and an increased proportion of oleate as a consequence of a single recessive nuclear mutation. Quantitative analysis of the fatty acid composition of individual lipids demonstrated that all the major phospholipids of the extrachloroplast membranes are affected by the mutation, whereas the chloroplast lipids show fatty acid compositions only slightly different from those of wild type plants. These results are consistent with the parallel operation of two pathways of lipid synthesis in plant leaf cells (the prokaryotic pathway in the chloroplast and the eukaryotic pathway in the endoplasmic reticulum) and with genetic evidence (Browse, J., Kunst, L., Anderson, S., Hugly, S., and Somerville, C. R. (1989) Plant Physiol 90, 522-529) that an independent 18:1/16:1 desaturase operates on chloroplast membrane lipids. Direct enzyme assays confirmed that the mutant plants are deficient in the activity of a microsomal oleoyl-phosphatidycholine desaturase and demonstrated that this desaturase is the major enzyme responsible for the synthesis of polyunsaturated phospholipids. Despite this deficiency in 18:1-desaturase activity, mutant plants contained relatively high levels of 18:3 in their leaf phospholipids. This finding is interpreted as additional evidence that considerable two-way exchange of lipid occurs between the chloroplast and endoplasmic reticulum and that this exchange allows the chloroplast desaturases to provide lipids containing 18:3 to the extrachloroplast compartment, thus partially alleviating the deficiency in 18:1 desaturase activity.	WASHINGTON STATE UNIV,INST BIOL CHEM,PULLMAN,WA 99164	Washington State University				Browse, John/0000-0002-2554-2821				BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWSE J, 1989, PLANT PHYSIOL, V90, P522, DOI 10.1104/pp.90.2.522; BROWSE J, 1986, PLANT PHYSIOL, V81, P859, DOI 10.1104/pp.81.3.859; BROWSE J, 1985, SCIENCE, V227, P763, DOI 10.1126/science.227.4688.763; BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; BROWSE J, 1988, PLANT SCI, V56, P15, DOI 10.1016/0168-9452(88)90179-3; BROWSE JA, 1981, FEBS LETT, V131, P111, DOI 10.1016/0014-5793(81)80899-X; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; DAWIDOWICZ EA, 1987, ANNU REV BIOCHEM, V56, P43, DOI 10.1146/annurev.bi.56.070187.000355; DONALDSON RP, 1991, PLANT PHYSIOL, V96, P669, DOI 10.1104/pp.96.3.669; DORNE AJ, 1990, P NATL ACAD SCI USA, V87, P71, DOI 10.1073/pnas.87.1.71; FRENTZEN M, 1983, EUR J BIOCHEM, V129, P629; FRENTZEN M, 1990, PLANT SCI, V69, P39, DOI 10.1016/0168-9452(90)90103-U; FUJIWARA Y, 1984, ARCH BIOCHEM BIOPHYS, V233, P402, DOI 10.1016/0003-9861(84)90461-2; HAJRA AK, 1974, LIPIDS, V9, P502, DOI 10.1007/BF02532495; HAUGHN GW, 1986, MOL GEN GENET, V204, P430, DOI 10.1007/BF00331020; HUGLY S, 1989, PLANT PHYSIOL, V90, P1134, DOI 10.1104/pp.90.3.1134; JAMES DW, 1990, THEOR APPL GENET, V80, P241, DOI 10.1007/BF00224393; KHAN MU, 1977, J CHROMATOGR, V140, P179, DOI 10.1016/S0021-9673(00)88412-5; KUNST L, 1988, P NATL ACAD SCI USA, V85, P4143, DOI 10.1073/pnas.85.12.4143; KUNST L, 1989, PLANT PHYSIOL, V91, P401, DOI 10.1104/pp.91.1.401; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; MCCOURT P, 1987, PLANT PHYSIOL, V84, P353, DOI 10.1104/pp.84.2.353; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; MOORE TS, 1982, ANNU REV PLANT PHYS, V33, P235, DOI 10.1146/annurev.pp.33.060182.001315; MUDD SH, 1989, PLANT PHYSIOL, V90, P306, DOI 10.1104/pp.90.1.306; Nichols B.W., 1964, NEW BIOCHEMICAL SEPA, P321; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; ROUGHAN PG, 1978, LIPIDS, V13, P497, DOI 10.1007/BF02533620; ROUGHAN PG, 1980, BIOCHEM J, V188, P17, DOI 10.1042/bj1880017; ROUGHAN PG, 1982, ANNU REV PLANT PHYS, V33, P97, DOI 10.1146/annurev.pp.33.060182.000525; ROUGHAN PG, 1979, BIOCHEM J, V184, P571, DOI 10.1042/bj1840571; SCHMIDT H, 1990, P NATL ACAD SCI USA, V87, P9477, DOI 10.1073/pnas.87.23.9477; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; SHIMAKATA T, 1982, P NATL ACAD SCI-BIOL, V79, P5808, DOI 10.1073/pnas.79.19.5808; SIEBERTZ HP, 1977, Z NATURFORSCH C, V32, P193; SLACK CR, 1976, BIOCHEM J, V155, P71, DOI 10.1042/bj1550071; SLACK CR, 1979, BIOCHEM J, V179, P649, DOI 10.1042/bj1790649; SMITH MA, 1990, BIOCHEM J, V272, P23, DOI 10.1042/bj2720023; SOMERVILLE CR, 1981, PLANT SCI LETT, V21, P89, DOI 10.1016/0304-4211(81)90073-0; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; STYMNE S, 1978, EUR J BIOCHEM, V90, P223, DOI 10.1111/j.1432-1033.1978.tb12594.x; VANDENBOOM T, 1989, ANNU REV MICROBIOL, V43, P317, DOI 10.1146/annurev.micro.43.1.317; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541	47	293	329	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1502	1509						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730697				2022-12-25	WOS:A1992HA48500020
J	KNUTSON, VP				KNUTSON, VP			LIGAND-INDEPENDENT INTERNALIZATION AND RECYCLING OF THE INSULIN-RECEPTOR - EFFECTS OF CHRONIC TREATMENT OF 3T3-C2 FIBROBLASTS WITH INSULIN AND DEXAMETHASONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DOWN-REGULATION; TYROSINE KINASE; CELL-SURFACE; RAT ADIPOCYTES; INACTIVATION; HEPATOCYTES; PRORECEPTOR; DEGRADATION; ENDOCYTOSIS; GENERATION	Upon binding insulin at the plasma membrane, the insulin receptor internalizes into the endosomal compartment of the cell with a half-time of approximately 10 min. Our earlier work demonstrated that receptor inactivation (loss of insulin binding capacity) is a regulated process. Long term treatment of cultured cells with insulin or the glucocorticoid dexamethasone increases or decreases, respectively, the rate constant for insulin receptor inactivation (Knutson, V. P., Ronnett, G. V., and Lane, M. D. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 2822-2826). In these studies, monolayer cultures of 3T3-C2 fibroblasts were chronically treated with insulin or dexamethasone. Subsequently, the surface receptors were labeled with the photoactivatable cross-linking agent I-125-labeled 2-(p-azidosalicylamido) ethyl-1,3'-dithiopropionate-insulin. Following equilibration of the radiolabeled receptor between the plasma membrane and internal pools, the steady-state rate constant for receptor recycling was determined by quantitating the rate at which internal radiolabeled receptor was inserted into the plasma membrane. The steady-state rate constant for this recycling process was the same in control, insulin-treated, or steroid-treated cells (t1/2 = 2 h). In contrast, the rate constant for receptor internalization was regulated; the half-times were 10 h for control cells, 5 h for insulin-treated cells, and 19 h for dexamethasone-treated cells. These changes in rate constants for internalization and inactivation lead to changes in the relative numbers of receptor molecules undergoing recycling versus inactivation. Therefore, whereas the recycling of the insulin receptor is not a regulated process, the internalization of surface receptor in the absence of bound ligand is a metabolically controlled step in receptor processing.			KNUTSON, VP (corresponding author), UNIV TEXAS,HLTH SCI CTR,SCH MED,DEPT PHARMACOL,6431 FANNIN,POB 20708,HOUSTON,TX 77225, USA.				NIDDK NIH HHS [DK35397] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035397] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1987, J BIOL CHEM, V262, P16186; CARPENTIER JL, 1986, J CELL BIOL, V102, P989, DOI 10.1083/jcb.102.3.989; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHVATCHKO Y, 1984, BIOCHEM J, V222, P111, DOI 10.1042/bj2220111; DEUTSCH PJ, 1983, P NATL ACAD SCI-BIOL, V80, P133, DOI 10.1073/pnas.80.1.133; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EZAKI O, 1986, J BIOL CHEM, V261, P3295; FEHLMANN M, 1982, J CELL BIOL, V93, P82, DOI 10.1083/jcb.93.1.82; FEHLMANN M, 1982, P NATL ACAD SCI-BIOL, V79, P5921, DOI 10.1073/pnas.79.19.5921; GOLDSTEIN BJ, 1988, J BIOL CHEM, V263, P12809; GORDEN P, 1982, DIABETES, V31, P659, DOI 10.2337/diabetes.31.7.659; HEDO JA, 1983, J BIOL CHEM, V258, P20; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; HSUAN JJ, 1989, BIOCHEM J, V259, P519, DOI 10.1042/bj2590519; HUECKSTEADT T, 1986, J BIOL CHEM, V261, P8655; KASUGA M, 1982, J BIOL CHEM, V257, P392; KNUTSON VP, 1986, J BIOL CHEM, V261, P306; KNUTSON VP, 1987, J BIOL CHEM, V262, P2374; KNUTSON VP, 1982, P NATL ACAD SCI-BIOL, V79, P2822, DOI 10.1073/pnas.79.9.2822; KNUTSON VP, 1985, J BIOL CHEM, V260, P4180; KNUTSON VP, 1983, J BIOL CHEM, V258, P2139; LEEF JW, 1987, J BIOL CHEM, V262, P14837; LUND KA, 1990, J BIOL CHEM, V265, P15713; MARSHALL S, 1985, J BIOL CHEM, V260, P4136; MAXFIELD FR, 1978, CELL, V14, P805, DOI 10.1016/0092-8674(78)90336-7; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PASTAN I, 1983, TRENDS BIOCHEM SCI, V8, P250, DOI 10.1016/0968-0004(83)90351-1; REED BC, 1984, J BIOL CHEM, V259, P8134; REED DK, 1989, J BIOL CHEM, V264, P12673; RONNETT GV, 1982, J BIOL CHEM, V257, P4285; THIES RS, 1990, J BIOL CHEM, V265, P10132; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0	32	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					931	937						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730683				2022-12-25	WOS:A1992GY96000041
J	SHINOMURA, T; KIMATA, K				SHINOMURA, T; KIMATA, K			PROTEOGLYCAN-LB, A SMALL DERMATAN SULFATE PROTEOGLYCAN EXPRESSED IN EMBRYONIC CHICK EPIPHYSEAL CARTILAGE, IS STRUCTURALLY RELATED TO OSTEOINDUCTIVE FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; CORE PROTEIN; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; IX COLLAGEN; PG-M; CDNA; CONTAINS; DECORIN	We have isolated cDNA clones encoding the core protein of PG-Lb, proteoglycan which has been shown to be preferentially expressed in the zone of flattened chondrocytes of the developing chick limb cartilage (Shinomura, T., Kimata, K., Oike, Y., Yano, S., and Suzuki, S. (1984) Dev. Biol. 103, 211-220). The deduced amino acid sequence from the cDNA analysis indicates the presence of consensus leucine-rich repeats which are present in other small proteoglycans, decorin, biglycan, and fibromodulin. However, the homology analysis revealed that chick PG-Lb showed a higher homology (about 50% in the region containing leucine-rich repeats) to human osteoinductive factor, OIF, rather than to the other small proteoglycans. Furthermore, 6 cysteine residues are detected in both PG-Lb and OIF with invariant relative positions. Therefore, such an evolutionarily conserved structure in the PG-Lb core protein might be involved in some important biological functions of this molecule. In close relation to the structural similarity to OIF, the unique expression of PG-Lb in the ossifying area of cartilage suggested the possible participation of this proteoglycan in osteogenic processes.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN	Aichi Medical University								BAUSE E, 1983, BIOCHEM J, V209, P331, DOI 10.1042/bj2090331; BENTZ H, 1989, J BIOL CHEM, V264, P20805; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BOURDON MA, 1987, P NATL ACAD SCI USA, V84, P3194, DOI 10.1073/pnas.84.10.3194; BOURDON MA, 1990, EXTRACELLULAR MATRIX, P157; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOEGE K, 1987, J BIOL CHEM, V262, P17757; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HENNESSY SW, 1989, J CELL BIOL, V108, P729, DOI 10.1083/jcb.108.2.729; HUBER S, 1988, J BIOL CHEM, V263, P752; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KIMURA JH, 1987, METHOD ENZYMOL, V144, P372; KIMURA JH, 1981, J BIOL CHEM, V256, P7890; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; MADISEN L, 1990, DNA CELL BIOL, V9, P303, DOI 10.1089/dna.1990.9.303; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; NICODEMUS CF, 1990, J BIOL CHEM, V265, P5889; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; NINOMIYA Y, 1990, EXTRACELLULAR MATRIX, P79; NORO A, 1983, J BIOL CHEM, V258, P9323; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SAI S, 1986, P NATL ACAD SCI USA, V83, P5081, DOI 10.1073/pnas.83.14.5081; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Seyedin S M, 1989, Oral Surg Oral Med Oral Pathol, V68, P527, DOI 10.1016/0030-4220(89)90232-6; SHINOMURA T, 1983, J BIOL CHEM, V258, P9314; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1984, DEV BIOL, V103, P211, DOI 10.1016/0012-1606(84)90022-8; SINGER RH, 1973, J MOL BIOL, V78, P321, DOI 10.1016/0022-2836(73)90119-8; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; YOUNG MF, 1984, NUCLEIC ACIDS RES, V12, P4207, DOI 10.1093/nar/12.10.4207; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	46	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1265	1270						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730648				2022-12-25	WOS:A1992GY96000091
J	BOURNE, Y; ROUGE, P; CAMBILLAU, C				BOURNE, Y; ROUGE, P; CAMBILLAU, C			X-RAY STRUCTURE OF A BIANTENNARY OCTASACCHARIDE-LECTIN COMPLEX REFINED AT 2.3-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; OCHRUS L DC; LATHYRUS-OCHRUS; BINDING-SITES; SACCHARIDE-BINDING; CRYSTAL-STRUCTURE; CONCANAVALIN-A; ISOLECTIN-I; PEA LECTIN; DATA-BANK	The structure and flexibility of saccharides have a profound and specific influence in several biological processes such as protein protection and the maintenance of conformational integrity, and in recognition events involving viruses, enzymes, and lectins. To establish the structural bases of these phenomena, we describe herein the extensively refined 2.3-angstrom resolution x-ray structure of a biantennary octasaccharide of the N-acetyllactosamine type, complexed to isolectin I from Lathyrus ochrus. The two octasaccharides are located in clefts at each end of the long axis of the lectin. The conformations of both the lectin and the saccharide are slightly modified upon binding. The complex is stabilized by numerous hydrogen bonds, many of them involving water molecules. It is also stabilized by van der Waals interactions, including some with aromatic residues. A more general model of a possible lectin-glycoprotein interaction is also proposed.	FAC MED SECTEUR NORD MARSEILLE, CRISTALLOG & CRISTALLISAT MACROMOLEC BIOL LAB, BD PIERRE DRAMARD, F-13326 MARSEILLE 15, FRANCE; UNIV TOULOUSE 3, FAC SCI PHARMACEUT, BIOL CELLULAIRE LAB, F-31062 TOULOUSE, FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Universite de Toulouse; Universite Toulouse III - Paul Sabatier			Rouge, Pierre/T-2059-2019; Bourne, Yves/AAC-4635-2022	Bourne, Yves/0000-0003-3850-0548				BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BOURNE Y, 1988, J MOL BIOL, V202, P685, DOI 10.1016/0022-2836(88)90299-9; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1990, J MOL BIOL, V213, P211, DOI 10.1016/S0022-2836(05)80180-9; BOURNE Y, 1990, J MOL BIOL, V214, P571, DOI 10.1016/0022-2836(90)90199-V; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CYGLER M, 1991, SCIENCE, V253, P442, DOI 10.1126/science.1713710; DEBRAY H, 1984, FEBS LETT, V176, P120, DOI 10.1016/0014-5793(84)80924-2; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DELBAERE LTJ, 1990, CAN J CHEM, V68, P1116, DOI 10.1139/v90-172; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; DIAZ CL, 1989, NATURE, V338, P579, DOI 10.1038/338579a0; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GETTINS P, 1981, BIOCHEMISTRY-US, V20, P7463, DOI 10.1021/bi00529a021; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; IMBERTY A, 1990, GLYCOCONJUGATE J, V7, P27, DOI 10.1007/BF01050401; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; LIS H, 1986, ANNU REV BIOCHEM, V55, P35, DOI 10.1146/annurev.bi.55.070186.000343; MONTREUIL J, 1975, PURE APPL CHEM, V42, P431, DOI 10.1351/pac197542030431; Montreuil J, 1980, Adv Carbohydr Chem Biochem, V37, P157; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REEKE GN, 1988, CURR TOP MICROBIOL, V139, P35; REEKE GN, 1986, SCIENCE, V234, P1108, DOI 10.1126/science.3775378; RICHARDSON M, 1984, FEBS LETT, V175, P76, DOI 10.1016/0014-5793(84)80573-6; RINI JM, 1986, J MOL BIOL, V189, P259, DOI 10.1016/0022-2836(86)90399-2; SHAANAN B, COMMUNICATION; SHAANAN B, 1989, INT S LECTINS; SPIK G, 1982, EUR J BIOCHEM, V121, P413, DOI 10.1111/j.1432-1033.1982.tb05803.x; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WALKER RA, 1988, LECTINS BIOL BIOCH C, V6, P591; WARIN V, 1979, CARBOHYD RES, V76, P11, DOI 10.1016/0008-6215(79)80002-6; WRIGHT CS, 1990, J MOL BIOL, V215, P635, DOI 10.1016/S0022-2836(05)80174-3; YARWOOD A, 1985, FEBS LETT, V184, P104, DOI 10.1016/0014-5793(85)80663-3	39	104	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					197	203						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730588				2022-12-25	WOS:A1992GY43900036
J	EVANS, DB; BRAWN, K; DEIBEL, MR; TARPLEY, WG; SHARMA, SK				EVANS, DB; BRAWN, K; DEIBEL, MR; TARPLEY, WG; SHARMA, SK			A RECOMBINANT RIBONUCLEASE-H DOMAIN OF HIV-1 REVERSE-TRANSCRIPTASE THAT IS ENZYMATICALLY ACTIVE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RNASE-H; ANTIBODY; ENZYME; ACID; DNA	We report here a human immunodeficiency virus type 1 (HIV-1) recombinant ribonuclease H (RNase H) domain engineered to contain an N-terminal tag for its isolation by affinity chromatography. The purified protein is active in hydrolyzing RNA-DNA hybrids in two separate in vitro assay systems. In light of recent reports of similar HIV-1 RNase H domains which were enzymatically inactive (Becerra, S. P., Clore, G. M., Gronenborn, A. M., Karlstrom, A. R., Stahl, S. J., Wilson, S. M., and Wingfield, P. T. (1990) FEBS Lett. 270, 76-80; Hostomsky, Z., Hostomska, Z., Hudson, G. O., Moomaw, E. W., and Nodes, B. R. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 1148-1152), our results suggest that a stretch of 20-30 residues immediately upstream of the polymerase-RNase H junction (residues 440-441 of HIV-1 reverse transcriptase) may be required for productive binding and alignment of the hybrid RNA-DNA substrate. The active HIV-1 RNase H domain is suitable for structural analysis, thereby providing a unique active molecule to better understand the structural basis for the functional organization of RNase associated with the HIV-1 reverse transcriptase.	UPJOHN CO,DEPT BIOCHEM,7240-267-117,KALAMAZOO,MI 49001; UPJOHN CO,DEPT CANC & INFECT DIS RES,KALAMAZOO,MI 49001	Pfizer; Pfizer								BECERRA SP, 1990, FEBS LETT, V270, P76, DOI 10.1016/0014-5793(90)81238-J; BRUTLAG D, 1972, J BIOL CHEM, V247, P241; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DEIBEL MR, 1990, AIDS RES HUM RETROV, V6, P329, DOI 10.1089/aid.1990.6.329; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; HANSEN J, 1988, EMBO J, V7, P239, DOI 10.1002/j.1460-2075.1988.tb02805.x; HOSTOMSKY Z, 1991, P NATL ACAD SCI USA, V88, P1148, DOI 10.1073/pnas.88.4.1148; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITSUYA H, 1987, NATURE, V325, P773, DOI 10.1038/325773a0; OMER CA, 1982, CELL, V30, P797, DOI 10.1016/0092-8674(82)90284-7; PANGANIBAN AT, 1988, SCIENCE, V241, P1064, DOI 10.1126/science.2457948; PRASAD VR, 1989, P NATL ACAD SCI USA, V86, P3104, DOI 10.1073/pnas.86.9.3104; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SHARMA SK, 1991, BIOTECHNOL APPL BIOC, V14, P69; TAN CK, 1991, BIOCHEMISTRY-US, V30, P2651, DOI 10.1021/bi00224a013; TISDALE M, 1988, J VIROL, V62, P3662, DOI 10.1128/JVI.62.10.3662-3667.1988	19	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					20583	20585						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1718968				2022-12-25	WOS:A1991GN00100002
J	KIKUTA, Y; SOGAWA, K; HANIU, M; KINOSAKI, M; KUSUNOSE, E; NOJIMA, Y; YAMAMOTO, S; ICHIHARA, K; KUSUNOSE, M; FUJIIKURIYAMA, Y				KIKUTA, Y; SOGAWA, K; HANIU, M; KINOSAKI, M; KUSUNOSE, E; NOJIMA, Y; YAMAMOTO, S; ICHIHARA, K; KUSUNOSE, M; FUJIIKURIYAMA, Y			A NOVEL SPECIES OF CYTOCHROME-P-450 (P-450IB) SPECIFIC FOR THE SMALL-INTESTINE OF RABBITS - CDNA CLONING AND ITS EXPRESSION IN COS CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; ENZYMATIC AMPLIFICATION; HYDROXYLASE-ACTIVITIES; OMEGA-HYDROXYLASE; PROSTAGLANDIN-A; GENE SUBFAMILY; MESSENGER-RNA; 2 FORMS	We have isolated a cDNA clone for a P-450, designated P-450ib (Ichihara, K., Kusunose, E., Kaku, M., Yamamoto, S., and Kusunose, M. (1985) Biochim. Biophys. Acta 831, 99-105), from a cDNA library of rabbit small intestine mucosa by using synthetic DNA fragment by the polymerase chain reaction, as a hybridization probe. The cDNA with a 1,829-base pair insert encodes a polypeptide of 501 amino acids. The deduced amino acid sequence contains all of the sequences of the NH2-terminal and 14 tryptic fragments from purified P-450ib. As the NH2-terminal methionine was not found in the sequence from the purified protein, the apoprotein of P-450ib is composed of 500 amino acids with a molecular weight of 57,193. P-450ib shows 35-41% sequence similarity with several members of 8 subfamilies in the P-450 II family, whereas it has a less than 30% sequence similarity with other P-450 families, suggesting that this P-450 is the first member of a novel subfamily within the P-450 II family. RNA blot analysis shows that mRNA hybridized to the cDNA is expressed in the small intestine, but not significantly in other tissues including liver, colon, kidney, lung, spleen, brain, stomach, and cecum, indicating that P-450ib is a P-450 specific to the small intestine. The protein expressed in COS-7 cells using the cDNA in an expression vector, pKCRH2, shows benzphetamine N-demethylase activity and gives a band identical with that of P-450ib in its mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis.	TOHOKU UNIV, FAC SCI,DEPT CHEM,AOBA KU, SENDAI, MIYAGI 980, JAPAN; OSAKA CITY UNIV, SCH MED,TONEYAMA INST TB RES, TOYONAKA, OSAKA 560, JAPAN; CITY HOPE NATL MED CTR, BECKMAN RES INT,DIV IMMUNOL, DUARTE, CA 91010 USA; KAWASAKI MED SCH, DEPT BIOCHEM, KURASHIKI, OKAYAMA 70101, JAPAN	Tohoku University; Osaka Metropolitan University; City of Hope; Beckman Research Institute of City of Hope; Kawasaki Medical School	KIKUTA, Y (corresponding author), FUKUYAMA UNIV, FAC ENGN, DEPT FOOD SCI & TECHNOL, FUKUYAMA, HIROSHIMA 72902, JAPAN.							AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; GONZALEZ FJ, 1987, DNA-J MOLEC CELL BIO, V6, P149, DOI 10.1089/dna.1987.6.149; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P7435; GOTOH O, 1983, J BIOCHEM, V93, P807, DOI 10.1093/jb/93.3.807; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARADA N, 1988, BIOCHEM BIOPH RES CO, V156, P725, DOI 10.1016/S0006-291X(88)80903-3; HEINEMANN FS, 1983, J BIOL CHEM, V258, P4195; HIGASHI Y, 1986, P NATL ACAD SCI USA, V83, P2841, DOI 10.1073/pnas.83.9.2841; HOBBS AA, 1986, J BIOL CHEM, V261, P9444; ICHIHARA K, 1979, J BIOCHEM-TOKYO, V86, P139; ICHIHARA K, 1981, J BIOCHEM, V89, P1821, DOI 10.1093/oxfordjournals.jbchem.a133383; ICHIHARA K, 1985, BIOCHIM BIOPHYS ACTA, V831, P99, DOI 10.1016/0167-4838(85)90155-4; ICHIHARA K, 1983, BIOCHEM INT, V7, P179; JOHNSON EF, 1987, J BIOL CHEM, V262, P5918; KAKU M, 1984, J BIOCHEM, V96, P1883, DOI 10.1093/oxfordjournals.jbchem.a135023; KHANI SC, 1987, P NATL ACAD SCI USA, V84, P638, DOI 10.1073/pnas.84.3.638; KUSUNOSE E, 1989, J BIOCHEM-TOKYO, V106, P194, DOI 10.1093/oxfordjournals.jbchem.a122831; Maniatis T, 1982, MOL CLONING LABORATO; MATSUBARA S, 1987, J BIOL CHEM, V262, P13366; MINOWA O, 1990, CELL STRUCT FUNCT, V15, P21, DOI 10.1247/csf.15.21; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; MOROHASHI K, 1984, P NATL ACAD SCI-BIOL, V81, P4647, DOI 10.1073/pnas.81.15.4647; MOROHASHI K, 1987, J BIOCHEM-TOKYO, V102, P559, DOI 10.1093/oxfordjournals.jbchem.a122089; NAGATA K, 1987, J BIOL CHEM, V262, P2787; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NEBERT DW, 1989, DNA-J MOLEC CELL BIO, V8, P1, DOI 10.1089/dna.1.1989.8.1; NEF P, 1989, J BIOL CHEM, V264, P6780, DOI 10.1016/S0021-9258(18)83497-4; NHAMBURO PT, 1990, BIOCHEMISTRY-US, V29, P5491, DOI 10.1021/bi00475a012; NOSHIRO M, 1989, FEBS LETT, V257, P97, DOI 10.1016/0014-5793(89)81795-8; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SOGAWA K, 1984, P NATL ACAD SCI-BIOL, V81, P5066, DOI 10.1073/pnas.81.16.5066; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNGER BP, 1986, J BIOL CHEM, V261, P1158; YOKOTANI N, 1989, J BIOL CHEM, V264, P21665; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	42	31	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17821	17825						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1717443				2022-12-25	WOS:A1991GG55300020
J	LAVOIE, L; TREMBLAY, A; MIRAULT, ME				LAVOIE, L; TREMBLAY, A; MIRAULT, ME			DISTINCT OXIDORESISTANCE PHENOTYPE OF HUMAN T47D CELLS TRANSFECTED BY RAT GLUTATHIONE-S-TRANSFERASE YC EXPRESSION VECTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; CU/ZN-SUPEROXIDE DISMUTASE; HYDROXYL RADICAL FORMATION; PEROXIDASE-ACTIVITY; LIPID-PEROXIDATION; TUMOR-CELLS; OXYGEN RADICALS; DNA DAMAGE; RESISTANCE; TOXICITY	We have investigated the role of a glutathione S-transferase (GST) with inherent peroxidase activity in the cellular defense against lipid peroxidation and free radical-mediated oxidative damage. Stable transfectants of human T47D cells were generated which express recombinant rat GST-Yc from a human cytomegalovirus promoter-based expression vector. Among several GST-Yc transfectants characterized, two of them contained, respectively, 2- and 3-fold higher GST activity than parental cells or control transfectants and, respectively, 4-5- and 8-10-fold higher selenium-independent glutathione peroxidase activity. Cellular growth kinetics and rates of [H-3]thymidine incorporation showed that both transfectants were more resistant to oxidative shocks mediated by cumene hydroperoxide or singlet oxygen generated by photo-sensitized rose bengal than were T47D cells and control transfectants. In contrast, a T47D transfectant, which expressed high levels of recombinant selenoglutathione peroxidase and showed enhanced resistance to cumene hydroperoxide (Mirault, M.-E., Tremblay, A., Beaudoin, N., and Tremblay, M. J. (1991) J. Biol. Chem. 266, 20752-20760), was as sensitive as parental cells to singlet oxygen. No difference was found in growth sensitivity to 1-h shock treatments with the quinonoid drug daunomycin, irrespective of GST-Yc or selenoglutathione peroxidase overexpression in these cells.	CHU LAVAL,RES CTR,QUEBEC CITY G1V 4G2,QUEBEC,CANADA; UNIV LAVAL,QUEBEC CITY G1V 4G2,QUEBEC,CANADA	Laval University; Laval University								ADELMAN R, 1988, P NATL ACAD SCI USA, V85, P2706, DOI 10.1073/pnas.85.8.2706; AKMAN SA, 1990, CANCER RES, V50, P1397; AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; Anderson ME, 1985, HDB METHODS OXYGEN R, P317; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BACHUR NR, 1979, P NATL ACAD SCI USA, V76, P954, DOI 10.1073/pnas.76.2.954; BATIST G, 1986, J BIOL CHEM, V261, P5544; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CATHCART R, 1984, P NATL ACAD SCI-BIOL, V81, P5633, DOI 10.1073/pnas.81.18.5633; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; DIMARCO A, 1975, CANCER CHEMOTH REP 3, V6, P91; DOROSHOW JH, 1986, BIOCHEM BIOPH RES CO, V135, P330, DOI 10.1016/0006-291X(86)90981-2; DOROSHOW JH, 1986, P NATL ACAD SCI USA, V83, P4514, DOI 10.1073/pnas.83.12.4514; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Gunzler WA, 1985, CRC HDB METHODS OXYG, P285; Habig W H, 1981, Methods Enzymol, V77, P398; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HORTON AA, 1987, CRC CR REV TOXICOL, V18, P27, DOI 10.3109/10408448709089856; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MANOHARAN TH, 1987, J BIOL CHEM, V262, P3739; MEYER DJ, 1985, FEBS LETT, V184, P139, DOI 10.1016/0014-5793(85)80670-0; MIRAULT ME, 1991, J BIOL CHEM, V266, P20752; MIRAULT ME, 1992, IN PRESS MOL BASIS O; MYERS CE, 1977, SCIENCE, P765; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PROHASKA JR, 1977, BIOCHEM BIOPH RES CO, V76, P437, DOI 10.1016/0006-291X(77)90744-6; PROHASKA JR, 1980, BIOCHIM BIOPHYS ACTA, V611, P87, DOI 10.1016/0005-2744(80)90045-5; PRYOR WA, 1977, FREE RADICAL BIO MED, V1, P1; SINHA BK, 1989, CANCER RES, V49, P3844; SINHA BK, 1987, BIOCHEM PHARMACOL, V36, P793, DOI 10.1016/0006-2952(87)90164-X; TAN KH, 1984, BIOCHEM J, V220, P243, DOI 10.1042/bj2200243; TELAKOWSKIHOPKINS CA, 1985, J BIOL CHEM, V260, P5820; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249	37	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3632	3636						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740415				2022-12-25	WOS:A1992HE60700016
J	DIFFLEY, JFX; STILLMAN, B				DIFFLEY, JFX; STILLMAN, B			DNA-BINDING PROPERTIES OF AN HMG1-RELATED PROTEIN FROM YEAST MITOCHONDRIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTONOMOUSLY REPLICATING SEQUENCE; MOBILITY GROUP PROTEIN-1; HISTONE-LIKE PROTEINS; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL-PROTEINS; TRANSCRIPTION FACTOR; CONSERVED SEQUENCE; PURIFICATION; GENES; HMG1	The DNA binding properties of ABF2, an abundant protein found in the mitochondria of the yeast Saccharomyces cerevisiae have been examined in detail. ABF2 is closely related to the vertebrate high mobility group protein HMG1 and like HMG1, ABF2 will introduce negative supercoils into a relaxed, double-stranded circular DNA molecule in cooperation with a DNA topoisomerase. Additionally, ABF2 binds approximately 5-10 times more tightly to negatively supercoiled DNA than to relaxed circular or linear DNA. Although ABF2 binds to most random double-stranded sequences with roughly equal affinity, its binding within certain key regulatory regions is qualitatively quite different. First, ABF2 binding induces a distinct pattern of DNA bending within the chromosomal origin of DNA replication, ARS1. Second, ABF2 binding to all nuclear replication origins tested, in addition to a critical mitochondrial promoter and replication origin, is clearly nonrandom as visualized by DNase1 footprinting. Analysis of the sequences found within these regions as well as competition experiments with synthetic DNA molecules suggest that site-specific DNA binding may be accomplished by the phased distribution of short stretches of poly(dA), which exclude ABF2 binding. These patterns of ABF2 DNA binding suggest a role for the protein in genome organization and site-specific regulation of transcription or DNA replication.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory	DIFFLEY, JFX (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,BLANCHE LANE,POTTERS BAR EN6 3LD,HERTS,ENGLAND.			Diffley, John/0000-0001-5184-7680; Stillman, Bruce/0000-0002-9453-4091	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020460, R37AI020460] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20460] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROACH JR, 1981, MOL BIOL YEAST SACCH, P445; BROYLES SS, 1986, J MOL BIOL, V187, P47, DOI 10.1016/0022-2836(86)90405-5; BUSTIN M, 1985, BIOCHEM BIOPH RES CO, V133, P633, DOI 10.1016/0006-291X(85)90952-0; CARON F, 1979, P NATL ACAD SCI USA, V76, P4265, DOI 10.1073/pnas.76.9.4265; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DIFFLEY JFX, 1986, MOL CELL BIOL, V6, P1363, DOI 10.1128/MCB.6.5.1363; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIFFLEY JFX, 1988, CANCER CELL, V6, P235; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; Dujon B., 1981, MOL BIOL YEAST SACCH, P505; DUNAWAY M, 1989, GENE DEV, V3, P1768, DOI 10.1101/gad.3.11.1768; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; FANGMAN WL, 1989, MOL CELL BIOL, V9, P1917, DOI 10.1128/MCB.9.5.1917; FISHER RP, 1992, J BIOL CHEM, V267, P3358; FISHER RP, 1991, J BIOL CHEM, V266, P9153; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; GRAY MW, 1989, ANNU REV CELL BIOL, V5, P25, DOI 10.1146/annurev.cb.05.110189.000325; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; HAGGREN W, 1988, MOL CELL BIOL, V8, P1282, DOI 10.1128/MCB.8.3.1282; HAMADA H, 1985, BIOCHEMISTRY-US, V24, P1428, DOI 10.1021/bi00327a022; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; JAVAHERIAN K, 1979, NUCLEIC ACIDS RES, V6, P3569, DOI 10.1093/nar/6.11.3569; KOLODRUBETZ D, 1988, FEBS LETT, V238, P175, DOI 10.1016/0014-5793(88)80251-5; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; PALZKILL TG, 1986, NUCLEIC ACIDS RES, V14, P6247, DOI 10.1093/nar/14.15.6247; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; Sambrook J, 1989, MOL CLONING LABORATO; SCHINKEL AH, 1988, EMBO J, V7, P3255, DOI 10.1002/j.1460-2075.1988.tb03192.x; SINGH J, 1990, BIOCHEMISTRY-US, V29, P6295, DOI 10.1021/bi00478a026; SNYDER M, 1986, NATURE, V324, P87, DOI 10.1038/324087a0; TSCHUMPER G, 1982, J MOL BIOL, V156, P293, DOI 10.1016/0022-2836(82)90330-8; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; van Holde KE., 1989, SPRINGER SERIES MOL	41	160	160	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3368	3374						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737791				2022-12-25	WOS:A1992HD15400085
J	FLOTOW, H; THOMAS, G				FLOTOW, H; THOMAS, G			SUBSTRATE RECOGNITION DETERMINANTS OF THE MITOGEN-ACTIVATED 70K-S6 KINASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN S6; EPIDERMAL GROWTH-FACTOR; SWISS 3T3 CELLS; PHOSPHORYLATION SITES; LATE PHASE; IDENTIFICATION; PURIFICATION; SERUM; CYCLOHEXIMIDE; DOMAINS	The mitogen-activated 70K S6 kinase has an apparent K(m) for 40 S ribosomal subunits of 0.25-mu-M. The apparent K(m) for a synthetic peptide derived from the carboxyl terminus of S6 and containing all of the in vivo sites of phosphorylation was 2.5-fold higher. A number of shorter peptides revealed that the substrate recognition determinants for the preferred site of phosphorylation, Ser236, reside in a seven-amino acid stretch of S6, residues 231-217. Critical to recognition is a block of 3 consecutive arginines, especially Arg231 and Arg233. In contrast, replacement of Ser235 or the preferred site of phosphorylation, Ser236, with alanine has little effect on the apparent K(m). Based on this data the consensus recognition sequence would be Arg-(Arg)-Arg-X-X-Ser-X. A number of kinases known to phosphorylate S6, including cAMP-dependent protein kinase and protein kinase C and the 92K S6 kinase II, were also tested for their ability to phosphorylate a decapeptide containing all the critical recognition determinants. Finally, a synthetic peptide containing a putative 70K S6 kinase autoinhibitory domain did not serve as a substrate for the enzyme but did inhibit its activity, although much less effectively than a synthetic peptide containing all the recognition determinants.	FRIEDRICH MIESCHER INST, POB 2543, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								AHN NG, 1990, J BIOL CHEM, V265, P11487; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7151; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P563; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1991, J BIOL CHEM, V266, P5249; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FERRARI S, 1991, J BIOL CHEM, V266, P22770; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; GRANOT J, 1980, J BIOL CHEM, V255, P4569; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JENO P, 1989, J BIOL CHEM, V264, P1293; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KOZMA SC, 1989, EMBO J, V8, P4125, DOI 10.1002/j.1460-2075.1989.tb08597.x; KOZMA SC, 1989, CELL SIGNAL, V1, P219, DOI 10.1016/0898-6568(89)90039-9; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KOZMA SC, 1992, IN PRESS REV PHYSL B; KRIEG J, 1988, J BIOL CHEM, V263, P11473; LANE HA, 1991, METHOD ENZYMOL, V200, P268; LEADER DP, 1991, BIOCHIM BIOPHYS ACTA, V1091, P426, DOI 10.1016/0167-4889(91)90210-O; MARTINPEREZ J, 1983, P NATL ACAD SCI-BIOL, V80, P926, DOI 10.1073/pnas.80.4.926; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; NOVAKHOFER I, 1984, J BIOL CHEM, V259, P5995; PARKER PJ, 1985, EUR J BIOCHEM, V148, P579, DOI 10.1111/j.1432-1033.1985.tb08879.x; PHILLIPS WF, 1976, J BIOL CHEM, V251, P2876; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; SUSA M, 1990, P NATL ACAD SCI USA, V87, P7040, DOI 10.1073/pnas.87.18.7040; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WETTENHALL R E H, 1991, Peptide Research, V4, P158; WETTENHALL REH, 1984, J BIOL CHEM, V259, P2084; WOOL IG, 1991, TRANSLATION EUKARYOT, P3	44	144	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3074	3078						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737763				2022-12-25	WOS:A1992HD15400041
J	FRITSCH, M; WELCH, RD; MURDOCH, FE; ANDERSON, I; GORSKI, J				FRITSCH, M; WELCH, RD; MURDOCH, FE; ANDERSON, I; GORSKI, J			DNA ALLOSTERICALLY MODULATES THE STEROID BINDING DOMAIN OF THE ESTROGEN-RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTORS; LIGAND-BINDING; ACTIVATION; ESTRADIOL; INVITRO; TRANSFORMATION; IDENTIFICATION; TRANSITION; KINETICS; GENE	The ability of DNA to allosterically alter the conformation of the estrogen receptor's (ER) steroid binding domain was investigated. Using dissociation kinetics we observed that when DNA was bound to the DNA binding domain of the rat uterine ER the rate of estrogen dissociation from the steroid binding domain increased almost 2-fold. This change in the rate of estrogen dissociation depended on the concentration of DNA used and correlated with the thermodynamic binding affinities (K(d)) of the ER for two different DNA sequences. We were unable to detect a DNA-induced change in the trypsin cleavage pattern of the amino terminal end of the ER. Using a whole cell dissociation kinetics assay with MCF-7 breast cancer cells we observed a 7-fold slower rate of estrogen dissociation from the ER within the cell than from the ER in vitro. This suggests that additional factors, other than DNA binding, may modify the steroid binding domain within the cell. We conclude that DNA can allosterically modulate the structure of the steroid binding domain of the ER, and we hypothesize that this conformational change may be necessary for the full transcriptional activity of the ER.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Welch, Roy/0000-0002-9946-108X; MURDOCH, FERN/0000-0001-5724-9681	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD008192, R37HD008192, T32HD007259] Funding Source: NIH RePORTER; NICHD NIH HHS [HD08192, HD07259] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BYLUND DB, 1985, 1980 SHORT COURSE SY, P70; CARSONJURICA MA, 1990, ENDOCR REV, V11, P201, DOI 10.1210/edrv-11-2-201; CURTIS SW, 1990, MOL ENDOCRINOL, V4, P276, DOI 10.1210/mend-4-2-276; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; GREEN S, 1989, CANCER RES, V49, pS2282; GREEN S, 1987, NATURE, V325, P75, DOI 10.1038/325075a0; GRODY WW, 1982, ENDOCR REV, V3, P141, DOI 10.1210/edrv-3-2-141; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P623, DOI 10.1021/bi00428a031; HANSEN JC, 1985, BIOCHEMISTRY-US, V24, P6078, DOI 10.1021/bi00343a008; HARLOW KW, 1989, J BIOL CHEM, V264, P17476; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KOIKE S, 1987, NUCLEIC ACIDS RES, V15, P2499, DOI 10.1093/nar/15.6.2499; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2331; LEE SJ, 1987, EMBO J, V6, P1129, DOI 10.1002/j.1460-2075.1987.tb04868.x; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIEBERMAN PM, 1962, MOL CELL BIOL, V11, P6391; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; MUROCH FE, 1991, BIOCHEMISTRY-US, V40, P10838; NELSON K, 1988, P85; NOTIDES AC, 1975, J BIOL CHEM, V250, P3945; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RIUH TS, 1973, ENDOCRINOLOGY, V92, P125; SABBAH M, 1991, P NATL ACAD SCI USA, V88, P390, DOI 10.1073/pnas.88.2.390; STUDITSKY VM, 1991, FEBS LETT, V280, P5, DOI 10.1016/0014-5793(91)80191-5; TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M; THEOFAN G, 1984, ENDOCRINOLOGY, V114, P1173, DOI 10.1210/endo-114-4-1173; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; WEICHMAN BM, 1977, J BIOL CHEM, V252, P8856; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; 1988, SAS STAT USERS GUIDE	41	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					1823	1828						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730720				2022-12-25	WOS:A1992HA48500066
J	HOHMANN, HP; REMY, R; AIGNER, L; BROCKHAUS, M; VANLOON, APGM				HOHMANN, HP; REMY, R; AIGNER, L; BROCKHAUS, M; VANLOON, APGM			PROTEIN-KINASES NEGATIVELY AFFECT NUCLEAR FACTOR-KAPPA-B ACTIVATION BY TUMOR-NECROSIS-FACTOR-ALPHA AT 2 DIFFERENT STAGES IN PROMYELOCYTIC HL-60 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1 SIGNAL TRANSDUCTION; DNA-BINDING SUBUNIT; FACTOR RECEPTORS; TRANSCRIPTION FACTOR; CYCLIC-AMP; DOWN-REGULATION; REL ONCOGENE; ENHANCER; CLONING; LIPOPOLYSACCHARIDE	HL60 and EL4 cells incubated with tumor necrosis factor-alpha (TNF-alpha) plus staurosporin, a potent inhibitor of protein kinases, showed at least 2-fold increased levels of nuclear factor-kappa-B (NF-kappa-B) activity compared with TNF-alpha alone both during rapid NF-kappa-B activation from the cytosolic pool and protein synthesis-dependent NF-kappa-B activation. NF-kappa-B activation by phorbol 12-myristate 13-acetate (PMA) and interleukin-1 was inhibited by staurosporin. Staurosporin treatment hardly affected the TNF-alpha-induced increase in mRNA for the p51 subunit of NF-kappa-B but interfered with any phorbol ester (PMA)-induced increase in p51 mRNA. Thus, induction of NF-kappa-B and p51 mRNA by TNF-alpha was not mediated by a staurosporin-sensitive factor, but NF-kappa-B activation by TNF-alpha was even reduced by action of a staurosporin-sensitive factor. Decreased levels of phosphorylation of TNF-R-alpha (TNF receptor type-alpha) after staurosporin-treatment correlated with increased induction of NF-kappa-B by TNF-alpha. Staurosporin-treatment did not affect TNF-R levels. Although protein kinase C stimulation by PMA inhibited NF-kappa-B activation by TNF-alpha, its action mechanism may be different from that of the staurosporin-sensitive factor. PMA induced disappearance of TNF-R-alpha by shedding into the surrounding medium, with kinetics similar to those of its inhibition of NF-kappa-B activation by TNF-alpha. Phosphorylation may not mediate receptor shedding, since PMA treatment did not detectably affect TNF-R-alpha phosphorylation.	F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES DEPT,NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,BIOTECHNOL,VITAMIN RES,CH-4002 BASEL,SWITZERLAND	Roche Holding; Roche Holding				Aigner, Ludwig/0000-0002-1653-8046				AGGARWAL BB, 1987, J BIOL CHEM, V262, P16450; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING AH, 1989, J BIOL CHEM, V264, P3924; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1991, MOL CELL BIOL, V11, P259, DOI 10.1128/MCB.11.1.259; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HOHMANN HP, 1991, MOL CELL BIOL, V11, P2315, DOI 10.1128/MCB.11.4.2315; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; JOHNSON SE, 1988, J BIOL CHEM, V263, P5686; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIZEL SB, 1990, IMMUNOL TODAY, V11, P390, DOI 10.1016/0167-5699(90)90154-2; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; ONEILL LAJ, 1990, IMMUNOL TODAY, V11, P392, DOI 10.1016/0167-5699(90)90155-3; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SCHEURICH P, 1986, BIOCHEM BIOPH RES CO, V141, P855, DOI 10.1016/S0006-291X(86)80251-0; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P959, DOI 10.1128/MCB.9.3.959; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; UNGLAUB R, 1987, J EXP MED, V166, P1788, DOI 10.1084/jem.166.6.1788; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WIGHTMAN PD, 1984, J BIOL CHEM, V259, P48; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	54	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1992	267	3					2065	2072						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HA485	1730737				2022-12-25	WOS:A1992HA48500099
J	ANDERSEN, KB; NILSSON, A; BLOMHOFF, HK; OYEN, TB; GABRIELSEN, OS; NORUM, KR; BLOMHOFF, R				ANDERSEN, KB; NILSSON, A; BLOMHOFF, HK; OYEN, TB; GABRIELSEN, OS; NORUM, KR; BLOMHOFF, R			DIRECT MOBILIZATION OF RETINOL FROM HEPATIC PERISINUSOIDAL STELLATE CELLS TO PLASMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CELLS; BINDING PROTEIN; VITAMIN-A; METABOLISM; STORAGE; RNA	We have studied the mechanism for mobilization of retinol from stellate cells. Our data show that perisinusoidal stellate cells isolated from liver contained retinol-binding protein (RBP) mRNA. By Western blot analysis we found that cultivated liver stellate cells secreted RBP into the medium. Cultivated stellate cells loaded in vitro with [H-3]retinyl ester mobilized radioactive retinol as a complex with RBP. Furthermore, exogenous RBP added to the medium of cultured stellate cells increased the secretion of retinol to the medium. These data suggest that liver stellate cells in vivo mobilize retinol directly to the blood and that a transfer to parenchymal cells for secretion as holo-RBP is not required. The direct mobilization of retinol from liver stellate cells as retinol-RBP to blood is indirectly supported by the demonstration of RBP mRNA production and RBP secretion by lung stellate cells. The data suggest that the same mechanism for retinol mobilization may exist in hepatic and extrahepatic stellate cells. This is, vitamin A-storing stellate cells in liver, lungs, and probably also in other organs may synthesize their own RBP (or alternatively use exogenous RBP) and mobilize holo-RBP directly to the blood.	UNIV OSLO,SCH MED,INST NUTR RES,POB 1046,N-0316 OSLO,NORWAY; NORWEGIAN RADIUM HOSP,INST CANC RES,IMMUNOL LAB,N-0310 OSLO,NORWAY; UNIV OSLO,INST BIOCHEM,N-0316 OSLO,NORWAY	University of Oslo; University of Oslo; University of Oslo								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BLANER WS, 1985, J LIPID RES, V26, P1241; BLOMHOFF R, 1984, EXP CELL RES, V150, P186, DOI 10.1016/0014-4827(84)90713-4; BLOMHOFF R, 1982, P NATL ACAD SCI-BIOL, V79, P7326, DOI 10.1073/pnas.79.23.7326; BLOMHOFF R, 1991, FASEB J, V5, P271, DOI 10.1096/fasebj.5.3.2001786; BLOMHOFF R, 1984, EXP CELL RES, V150, P194, DOI 10.1016/0014-4827(84)90714-6; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; BLOMHOFF R, 1990, METHOD ENZYMOL, V190, P58; BLOMHOFF R, 1988, P NATL ACAD SCI USA, V85, P3455, DOI 10.1073/pnas.85.10.3455; BLOMHOFF R, 1988, BRIT J NUTR, V60, P233, DOI 10.1079/BJN19880095; BLOMHOFF R, 1985, J BIOL CHEM, V260, P3560; GJOEN T, 1987, J BIOL CHEM, V262, P10926; Goodman DS, 1984, RETINOIDS, V2, P42; GREEN MH, 1985, J LIPID RES, V26, P806; GREEN MH, 1987, J NUTR, V117, P694, DOI 10.1093/jn/117.4.694; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MARINARI L, 1987, J LIPID RES, V28, P941; MARTONE RL, 1988, BIOCHEM BIOPH RES CO, V157, P1078, DOI 10.1016/S0006-291X(88)80984-7; SMITH JE, 1978, CELL, V15, P865, DOI 10.1016/0092-8674(78)90271-4; SOPRANO DR, 1986, J LIPID RES, V27, P166; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wake K, 1980, Int Rev Cytol, V66, P303; WISSE E, 1974, J ULTRA MOL STRUCT R, V46, P393, DOI 10.1016/S0022-5320(74)90064-1; YAMADA M, 1987, HEPATOLOGY, V7, P1224, DOI 10.1002/hep.1840070609	25	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1340	1344						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730653				2022-12-25	WOS:A1992GY96000103
J	FLANNERY, CR; LARK, MW; SANDY, JD				FLANNERY, CR; LARK, MW; SANDY, JD			IDENTIFICATION OF A STROMELYSIN CLEAVAGE SITE WITHIN THE INTERGLOBULAR DOMAIN OF HUMAN AGGRECAN - EVIDENCE FOR PROTEOLYSIS AT THIS SITE INVIVO IN HUMAN ARTICULAR-CARTILAGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST STROMELYSIN; SUBSTRATE-SPECIFICITY; PROTEOGLYCAN; METALLOPROTEINASE; TISSUE; PURIFICATION; COLLAGENASE; PROTEIN	Products generated by the digestion of human aggrecan with recombinant human stromelysin have been purified and analyzed-by N-terminal sequencing and C-terminal peptide isolation. N-terminal analysis of chondroitin sulfate-bearing fragments revealed a clearly identifiable sequence initiating at residue Phe342 of human aggrecan, providing evidence for a cleavage site at the Asn341-Phe342 bond located within the interglobular domain. This cleavage site, which separates the G1 domain from the remainder of the molecule, was confirmed by isolation from the liberated G1 domain of a C-terminal tryptic peptide with the sequence YDAICYTGEDFVDIPEN (in which the C-terminal residue is Asn341). This peptide was also isolated from tryptic digests of hyaluronan-binding proteins (A1D4 samples) prepared by CsCl gradient centrifugation of extracts of mature human articular cartilages. Since these A1D4 samples contain G1 domain which accumulates as a result of aggrecan catabolism in vivo, these results clearly indicate that stromelysin cleaves the Asn341-Phe342 bond of human aggrecan in situ.	SHRINERS HOSP CRIPPLED CHILDREN,12502 N PINE DR,TAMPA,FL 33612; MERCK SHARP & DOHME LTD,DEPT BIOCHEM & MOLEC PATHOL,RAHWAY,NJ 08520; UNIV S FLORIDA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33620	Merck & Company; State University System of Florida; University of South Florida					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038580] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 38580] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FARNDALE RW, 1982, CONNECT TISSUE RES, V9, P247, DOI 10.3109/03008208209160269; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; GALLOWAY WA, 1983, BIOCHEM J, V209, P741, DOI 10.1042/bj2090741; GUNJASMITH Z, 1989, BIOCHEM J, V258, P115, DOI 10.1042/bj2580115; HARDINGHAM T, 1990, SEMIN ARTHRITIS RHEU, V20, P12, DOI 10.1016/0049-0172(90)90044-G; Maniglia C. A., 1991, T ORTHOP RES SOC, V16, P193; MURPHY G, 1990, BIOCHEM SOC T, V18, P812, DOI 10.1042/bst0180812; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1986, COLLAGEN REL RES, V6, P351; NGUYEN Q, 1989, BIOCHEM J, V259, P61, DOI 10.1042/bj2590061; ROUGHLEY PJ, 1985, BIOCHEM J, V231, P129, DOI 10.1042/bj2310129; SANDY JD, 1991, J BIOL CHEM, V266, P8683; SANDY JD, 1991, J BIOL CHEM, V266, P8198; SHINICHI I, 1983, METHOD ENZYMOL, V91, P378; TEAHAN J, 1989, BIOCHEMISTRY-US, V28, P8497, DOI 10.1021/bi00447a034; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725; WU JJ, 1991, J BIOL CHEM, V266, P5625	19	259	264	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1008	1014						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730630				2022-12-25	WOS:A1992GY96000054
J	FLEMING, RE; GITLIN, JD				FLEMING, RE; GITLIN, JD			STRUCTURAL AND FUNCTIONAL-ANALYSIS OF THE 5'-FLANKING REGION OF THE RAT CERULOPLASMIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; ENHANCER BINDING-PROTEIN; ENRICHED TRANSCRIPTIONAL ACTIVATOR; ALPHA-FETOPROTEIN GENE; ALBUMIN GENE; PROMOTER ELEMENTS; MAMMALIAN-CELLS; DNA; LIVER; C/EBP	To characterize the mechanisms determining tissue-specific ceruloplasmin gene expression during development, the rat ceruloplasmin gene was isolated in a series of overlapping phage clones. The 5'-flanking region was characterized and the transcription initiation site was identified by primer extension and RNase protection. Nucleotide sequence analysis of this region revealed a typical eukaryotic promotor structure, but no obvious homology with cis-acting elements previously characterized as determining tissue-specific gene expression. Transient expression of chimeric ceruloplasmin-reporter gene constructs containing up to 5200 base pairs (bp) of the 5'-flanking region revealed that sequences 732 bp upstream of the start nucleotide were sufficient to confer hepatocyte-specific expression. The region from -393 to -348 was determined by deletion analysis to contain a positive-acting element, and includes sequence partially homologous to the rat albumin D site. Mobility shift analysis revealed that this region specifically binds a heat-labile nuclear protein from rat liver and from newborn but not adult rat lung. Binding to this region was competed by oligonucleotides corresponding to the albumin D site, but not by oligonucleotides corresponding to binding sites for the hepatocyte transcription factors HNF-1, HNF-3, HNF-4, and C/EBP. These data indicate that ceruloplasmin gene expression is determined in part by a cis-acting region 393 bp upstream of the transcription start site, which binds a previously uncharacterized nuclear protein. The tissue distribution of this nuclear protein suggests that it plays a role in directing ceruloplasmin gene expression in lung and liver during development.	WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL41536] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041536] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; COSTA R, 1990, P NATL ACAD SCI USA, V87, P6587; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DESIMONE V, 1988, OXFORD SURVEYS EUKAR; FLEMING RE, 1991, AM J PHYSIOL, V260, pL68, DOI 10.1152/ajplung.1991.260.2.L68; FLEMING RE, 1990, J BIOL CHEM, V265, P7701; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GITLIN JD, 1988, J BIOL CHEM, V263, P6281; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAVES BJ, 1986, CELL, V44, P545; GRAYSON D, 1982, SCIENCE, V239, P786; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GUILLOU F, 1991, J BIOL CHEM, V266, P9876; HAMMER RE, 1987, SCIENCE, V235, P53, DOI 10.1126/science.2432657; HIGUCHI K, 1988, J BIOL CHEM, V263, P18530; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; KINGSTON IB, 1977, P NATL ACAD SCI USA, V74, P5377, DOI 10.1073/pnas.74.12.5377; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KUO CF, 1990, DEVELOPMENT, V109, P473; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MANIATIS T, 1989, MOL CLONING, V2; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OGAMI K, 1990, J BIOL CHEM, V265, P9808; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; PICARD D, 1984, NATURE, V307, P80, DOI 10.1038/307080a0; QUEEN C, 1984, NUCLEIC ACIDS RES, V12, P581, DOI 10.1093/nar/12.1Part2.581; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RYDEN T, 1988, MOL CELL BIOL, V9, P1144; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMOKYSZYN VM, 1989, J BIOL CHEM, V264, P21; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1991, J BIOL CHEM, V266, P5128; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; van der Eb A J, 1980, Methods Enzymol, V65, P826; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807	52	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					479	486						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730611				2022-12-25	WOS:A1992GY43900077
J	SAIKI, H; CHAN, ET; WONG, E; YAMAMURO, W; OOKHTENS, M; KAPLOWITZ, N				SAIKI, H; CHAN, ET; WONG, E; YAMAMURO, W; OOKHTENS, M; KAPLOWITZ, N			ZONAL DISTRIBUTION OF CYSTEINE UPTAKE IN THE PERFUSED-RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE; HETEROGENEITY; HEPATOCYTES; TRANSPORT	When in situ perfused rat livers were administered tracer or physiologic concentrations of [S-35]cysteine, a zone III (perivenous) predominance of uptake was observed in either antegrade or retrograde single-pass perfusion, as determined by quantitative densitometry of autoradiographs of liver section. This pattern remained unchanged from 30 s to 5 min observed. At higher supraphysiologic doses a more uniform acinar distribution of cysteine uptake was observed. Uptake rates of cysteine in antegrade perfusion indicated an apparent saturable component at low but physiologic cysteine concentrations. That uptake rather than metabolic trapping accounts for this perivenular pattern was supported by finding identical zonal distribution under conditions in which GSH and protein synthesis were markedly inhibited. Furthermore, increasing or decreasing hepatic cysteine pool sizes did not affect the extraction or zonation. These results suggest that a low K(m) transport system for cysteine is localized in zone III of the hepatic acinus.	UNIV SO CALIF,SCH MED,DEPT MED,DIV GASTROINTESTINAL & LIVER DIS,LOS ANGELES,CA 90033; US DEPT VET AFFAIRS,OUTPATIENT CLIN,LOS ANGELES,CA 90013	University of Southern California; US Department of Veterans Affairs					NIDDK NIH HHS [DK30312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030312, R01DK030312] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AW TY, 1986, AM J PHYSIOL, V251, pG354, DOI 10.1152/ajpgi.1986.251.3.G354; BARON J, 1978, LIFE SCI, V23, P2627, DOI 10.1016/0024-3205(78)90380-6; BURGER HJ, 1989, HEPATOLOGY, V9, P22, DOI 10.1002/hep.1840090105; GAITONDE MK, 1967, BIOCHEM J, V104, P627, DOI 10.1042/bj1040627; GROOTHUIS GMM, 1982, AM J PHYSIOL, V243, pG455, DOI 10.1152/ajpgi.1982.243.6.G455; HAUSSINGER D, 1983, EUR J BIOCHEM, V133, P269, DOI 10.1111/j.1432-1033.1983.tb07458.x; HUDSON D, 1985, AM J PHYSIOL, V248, pG539, DOI 10.1152/ajpgi.1985.248.5.G539; Kaplowitz N, 1985, ANN REV PHARM TOXICO, V25, P714; KILBERG MS, 1981, J BIOL CHEM, V256, P3304; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MILLER DL, 1979, GASTROENTEROLOGY, V76, P965; PENTTILA KE, 1990, BIOCHEM J, V269, P659, DOI 10.1042/bj2690659; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; STOLL B, 1991, HEPATOLOGY, V13, P247, DOI 10.1002/hep.1840130208; TAKADA A, 1984, J BIOL CHEM, V259, P2441; TRABER PG, 1988, GASTROENTEROLOGY, V95, P1130, DOI 10.1016/0016-5085(88)90194-1	16	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					192	196						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730587				2022-12-25	WOS:A1992GY43900035
J	ELLISON, MJ; HOCHSTRASSER, M				ELLISON, MJ; HOCHSTRASSER, M			EPITOPE-TAGGED UBIQUITIN - A NEW PROBE FOR ANALYZING UBIQUITIN FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SHORT-LIVED PROTEIN; N-END RULE; MULTIUBIQUITIN CHAIN; CARRIER PROTEIN; GENE; DEGRADATION; PROTEOLYSIS; REPAIR; RAD6	In the present work, a method based on an epitope-tagged ubiquitin derivative is described that allows for the unambiguous detection of ubiquitin-protein conjugates formed in vivo or in vitro. Expression in the yeast Saccharomyces cerevisiae of ubiquitin that has been tagged at its amino terminus with a peptide epitope results in the formation of tagged ubiquitin-protein conjugates that are detectable by immunoblotting with a monoclonal antibody that recognizes the tag. The expression of tagged ubiquitin has no adverse effect on vegetative growth and, moreover, can suppress the stress-hypersensitive phenotype of yeast lacking the polyubiquitin gene UBI4. We also show that tagged ubiquitin is correctly conjugated in vivo and in vitro to a short-lived test protein and can be covalently extended into the multimeric ubiquitin chain that is normally required for the degradation of this protein. Surprisingly, however, conjugation of tagged ubiquitin inhibits proteolysis. These and related results suggest that the amino-terminal region of ubiquitin is important in protease-substrate recognition and that the multiubiquitin chain is a dynamic transient structure. The potential of tagged ubiquitin for the identification and isolation of ubiquitin-protein conjugates and ubiquitin-related enzymes, and as a tool in mechanistic studies is discussed.	UNIV CHICAGO,DEPT BIOCHEM & MOLEC BIOL,CHICAGO,IL 60637; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON T6G 2H7,ALBERTA,CANADA	University of Chicago; University of Alberta	ELLISON, MJ (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.			Hochstrasser, Mark/0000-0002-1131-5484	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039520, R01DK039520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008991] Funding Source: NIH RePORTER; NIA NIH HHS [AG08991] Funding Source: Medline; NIDDK NIH HHS [DK39520] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BRESLOW E, 1986, BIOCHEM BIOPH RES CO, V138, P437, DOI 10.1016/0006-291X(86)90300-1; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; ECKER DJ, 1987, J BIOL CHEM, V262, P14213; ECKER DJ, 1987, J BIOL CHEM, V262, P3524; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FRIEDBERG EC, 1988, MICROBIOL REV, V52, P70, DOI 10.1128/MMBR.52.1.70-102.1988; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GONDA DK, 1989, J BIOL CHEM, V264, P16700; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1987, J BIOL CHEM, V262, P345; HAAS AL, 1988, UBIQUITIN, P173; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOUGH R, 1986, J BIOL CHEM, V261, P2391; JENTSCH S, 1990, TRENDS BIOL SCI, V15, P105; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PICKART CM, 1988, UBIQUITIN, P77; Rechsteiner M., 1988, UBIQUITIN; REYNOLDS P, 1990, EMBO J, V9, P1423, DOI 10.1002/j.1460-2075.1990.tb08258.x; Rose I. A., 1988, UBIQUITIN, P135; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; Sherman F., 1981, METHODS YEAST GENETI; SULLIVAN ML, 1989, P NATL ACAD SCI USA, V86, P9861, DOI 10.1073/pnas.86.24.9861; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WILKINSON KD, 1988, UBIQUITIN, P5	34	187	213	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21150	21157						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1718971				2022-12-25	WOS:A1991GN00100088
J	RODRIGUEZLOPEZ, JN; TUDELA, J; VARON, R; GARCIACARMONA, F; GARCIACANOVAS, F				RODRIGUEZLOPEZ, JN; TUDELA, J; VARON, R; GARCIACARMONA, F; GARCIACANOVAS, F			ANALYSIS OF A KINETIC-MODEL FOR MELANIN BIOSYNTHESIS PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FROG EPIDERMIS TYROSINASE; COPPER ACTIVE-SITE; NEUROSPORA TYROSINASE; SUICIDE INACTIVATION; ENZYMATIC OXIDATION; MUSHROOM TYROSINASE; TRANSIENT-PHASE; L-SERINE; PRECURSORS; DOPA	The kinetic behavior of the melanin biosynthesis pathway from L-tyrosine up to dopachrome has been studied from experimental and simulation assays. The reaction mechanism proposed is based on a single active site of tyrosinase. The diphenolase and monophenolase activities of tyrosinase involve one single (oxidase) and two overlapped (hydroxylase and oxidase) catalytic cycles, respectively. The stoichiometry of the pathway implies that one molecule of tyrosinase must accomplish two turnovers in the hydroxylase cycle for each one in the oxidase cycle. Furthermore, the steady-state rates of dopachrome production and O2 consumption from tyrosine and L-dopa, also fulfill the stoichiometry of the pathway: V(O2)T/V(DC)T = 1.5 and V(O2)D/V(DC)D = 1.0, where T represents L-tyrosine, DC represents dopachrome, and D represents L-dopa. It has been ascertained by high performance liquid chromatography that in the steady-state, a quantity of dopa is accumulated ([D]ss) which fulfills the constant ratio [D]ss = R[T]0. Taking this ratio into account, an analytical expression has been deduced for the monophenolase activity of tyrosinase. In this expression k(cat)T, congruent-to (2/3)k3(K1/K2)R, revealing that k(cat)T is not a true catalytic constant, since it also depends on equilibrium constants and on the experimental R = 0.057. This low value explains the lower catalytic efficiency of tyrosinase on tyrosine than on dopa, (V(max)T/K(m)T)/(V(max)D/K(m)D) congruent-to (2/3) R, since a significant portion of tyrosinase is scavenged from the catalytic turnover as dead-end complex E(met)T in the steady-state of the monophenolase activity of tyrosinase.	UNIV MURCIA, FAC BIOL, DEPT BIOQUIM & BIOL MOLEC, E-30100 ESPINARDO, SPAIN; UNIV CASTILLA LA MANCHA, ESCUELA UNIV POLITECN ALBACETE, DEPT QUIM FIS, ALBACETE, SPAIN	University of Murcia; Universidad de Castilla-La Mancha			Garcia-Canovas, Francisco/M-1290-2014; Neptuno, Jose/F-5012-2016; Tudela, Jose/M-1278-2014; Garcia-Carmona, Francisco/K-6520-2017	Garcia-Canovas, Francisco/0000-0002-8869-067X; Tudela, Jose/0000-0002-5528-4296; Varon Castellanos, Ramon/0000-0002-4589-5376; Rodriguez-Lopez, Jose Neptuno/0000-0001-6863-1173				BELTRAMINI M, 1990, BIOCHIM BIOPHYS ACTA, V1040, P365, DOI 10.1016/0167-4838(90)90134-2; BRIGHT HJ, 1963, ANN NY ACAD SCI, V100, P965, DOI 10.1111/j.1749-6632.1963.tb42943.x; CABANES J, 1987, BIOCHIM BIOPHYS ACTA, V914, P190, DOI 10.1016/0167-4838(87)90063-X; CABANES J, 1987, BIOCHIM BIOPHYS ACTA, V923, P187, DOI 10.1016/0304-4165(87)90003-1; CABANES J, 1984, BIOCHIM BIOPHYS ACTA, V790, P101, DOI 10.1016/0167-4838(84)90212-7; CABANES J, 1987, PHYTOCHEMISTRY, V26, P917, DOI 10.1016/S0031-9422(00)82317-1; CANOVAS FG, 1982, J BIOL CHEM, V257, P8738; CANOVAS FG, 1987, BIOCHIM BIOPHYS ACTA, V912, P417, DOI 10.1016/0167-4838(87)90047-1; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P34; DEVI CC, 1989, PIGM CELL RES, V2, P8, DOI 10.1111/j.1600-0749.1989.tb00151.x; DEVI CC, 1987, EUR J BIOCHEM, V166, P705, DOI 10.1111/j.1432-1033.1987.tb13569.x; DUCKWORTH HW, 1970, J BIOL CHEM, V245, P1613; ESCRIBANO J, 1989, BIOCHEM J, V262, P597, DOI 10.1042/bj2620597; GALINDO JD, 1983, INT J BIOCHEM, V15, P1455, DOI 10.1016/0020-711X(83)90078-2; GARCIACARMONA F, 1982, BIOCHIM BIOPHYS ACTA, V717, P124, DOI 10.1016/0304-4165(82)90389-0; GARCIACARMONA F, 1987, BIOCHIM BIOPHYS ACTA, V914, P198, DOI 10.1016/0167-4838(87)90064-1; GARCIAMORENO M, 1991, ARCH BIOCHEM BIOPHYS, V288, P427, DOI 10.1016/0003-9861(91)90216-6; GERALD CF, 1978, APPLIED NUMERICAL AN; GUTTERIDGE S, 1975, EUR J BIOCHEM, V54, P107, DOI 10.1111/j.1432-1033.1975.tb04119.x; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HIMMELWRIGHT RS, 1980, J AM CHEM SOC, V102, P7339, DOI 10.1021/ja00544a031; JIMENEZ M, 1984, ARCH BIOCHEM BIOPHYS, V235, P438, DOI 10.1016/0003-9861(84)90217-0; JIMENEZ M, 1986, INT J BIOCHEM, V18, P39, DOI 10.1016/0020-711X(86)90006-6; JOLLEY RL, 1974, J BIOL CHEM, V249, P335; JOLLEY RL, 1972, BIOCHEM BIOPH RES CO, V46, P878, DOI 10.1016/S0006-291X(72)80223-7; KALYANARAMAN B, 1982, PHOTOCHEM PHOTOBIOL, V36, P5, DOI 10.1111/j.1751-1097.1982.tb04332.x; LAND EJ, 1986, PHOTOCHEM PHOTOBIOL, V44, P697, DOI 10.1111/j.1751-1097.1986.tb05526.x; LANGSTON JW, 1988, TRENDS PHARMACOL SCI, V9, P347, DOI 10.1016/0165-6147(88)90248-9; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; MAKINO N, 1973, J BIOL CHEM, V248, P5731; MAKINO N, 1974, J BIOL CHEM, V249, P6062; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MENON S, 1990, ARCH BIOCHEM BIOPHYS, V280, P27, DOI 10.1016/0003-9861(90)90513-X; OCHIAI E, 1985, QUIMICA BIOINORGANIC, P245; OCHIAI EI, 1973, INORG NUCL CHEM LETT, V9, P987, DOI 10.1016/0020-1650(73)80139-4; OSAKI S, 1963, ARCH BIOCHEM BIOPHYS, V100, P378, DOI 10.1016/0003-9861(63)90101-2; PENAFIEL R, 1984, BIOCHIM BIOPHYS ACTA, V788, P327, DOI 10.1016/0167-4838(84)90045-1; POMERANTZ SH, 1974, ARCH BIOCHEM BIOPHYS, V160, P73, DOI 10.1016/S0003-9861(74)80010-X; PROTA G, 1988, MED RES REV, V8, P525, DOI 10.1002/med.2610080405; ROBB DA, 1984, COPPER PROTEINS COPP, V2, P207; RODRIGUEZLOPEZ JN, 1991, BIOCHIM BIOPHYS ACTA, V1076, P379; Schoot Uiterkamp A. J., 1976, BIOCHIM BIOPHYS ACTA, V453, P200; SCHOOTUI.AJ, 1973, P NATL ACAD SCI USA, V70, P993; Serna Rodriguez P, 1990, Biochem J, V272, P459; SOLOMON EI, 1981, METAL IONS BIOL, V3, P41; THOMPSON A, 1985, BIOCHIM BIOPHYS ACTA, V843, P49, DOI 10.1016/0304-4165(85)90048-0; TRIPATHI RK, 1988, BIOCHEM J, V252, P481, DOI 10.1042/bj2520481; TUDELA J, 1987, BIOCHIM BIOPHYS ACTA, V912, P408, DOI 10.1016/0167-4838(87)90046-X; TUDELA J, 1988, BIOPHYS CHEM, V30, P303, DOI 10.1016/0301-4622(88)85025-7; Tudela J, 1987, J Enzyme Inhib, V2, P47, DOI 10.3109/14756368709030356; Vanneste W. H., 1974, MOL MECH OXYGEN ACTI, P371; VAUGHAN PFT, 1972, BIOCHEM J, V127, P641, DOI 10.1042/bj1270641; WICK MM, 1979, CANCER TREAT REP, V63, P991; WILCOX DE, 1985, J AM CHEM SOC, V107, P4015, DOI 10.1021/ja00299a043; YONG G, 1990, BIOCHEMISTRY-US, V29, P9684, DOI 10.1021/bi00493a025; 1989, SIGMAPLOT 4 0	57	194	198	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3801	3810						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740428				2022-12-25	WOS:A1992HE60700042
J	DOZIN, B; DESCALZI, F; BRIATA, L; HAYASHI, M; GENTILI, C; HAYASHI, K; QUARTO, R; CANCEDDA, R				DOZIN, B; DESCALZI, F; BRIATA, L; HAYASHI, M; GENTILI, C; HAYASHI, K; QUARTO, R; CANCEDDA, R			EXPRESSION, REGULATION, AND TISSUE DISTRIBUTION OF THE CH21-PROTEIN DURING CHICKEN EMBRYOGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN GENE-EXPRESSION; X COLLAGEN; RETINOIC ACID; GROWTH-FACTOR; INSITU HYBRIDIZATION; CELLS; CHONDROCYTES; EMBRYO; DIFFERENTIATION; LOCALIZATION	The Ch21 protein is one of the marker proteins whose synthesis and secretion by differentiating tibia chondrocytes is progressively increased during chicken embryogenesis (Descalzi-Cancedda, F., Manduca, P., Tacchetti, C., Fossa, P., Quarto, R. and Cancedda, R. (1988) J. Cell Biol. 107, 2455-2463). We report the corresponding full-length cDNA sequence and the complete primary structure of the protein, which contains a 20-residue signal peptide. The synthesis of the protein is directed by a 1450-base mRNA characterized by an unusually long 5'-untranslated leader sequence and is regulated only at the transcriptional level as shown by run-off transcription assays. During differentiation, maximal expression of the protein characterizes stage II hypertrophic chondrocytes. In situ hybridization on embryo sections reveals that the protein is expressed by several structures derived from the chondrogenic lineage and that, in addition, it is a major translational product in granulocytes. High cell density largely influences the expression of the Ch21 protein in chondrocyte cultures. When embryonic avian cells of different origin are grown to confluency, the expression of the Ch21 protein is observed in only some of the cell lines. Thus quiescence per se is not the primary factor determining the expression of the protein.	UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PATHOL, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	DOZIN, B (corresponding author), IST NAZL RIC CANC, DIFFERENZIAMENTO CELLULARE LAB, VIALE BENEDETTO 2510, I-16132 GENOA, ITALY.		dozin, beatrice/AAC-1717-2020; Quarto, Rodolfo/AAB-2182-2019; Gentili, Chiara/AAE-8046-2021	dozin, beatrice/0000-0002-0267-1735; GENTILI, CHIARA/0000-0001-6745-3782; Quarto, Rodolfo/0000-0002-1146-894X	NIA NIH HHS [AGO9199] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009199] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; CANCEDDA FD, 1988, J CELL BIOL, V107, P2455, DOI 10.1083/jcb.107.6.2455; CANCEDDA FD, 1990, J BIOL CHEM, V265, P19060; CAPASSO O, 1984, MOL CELL BIOL, V4, P1163, DOI 10.1128/MCB.4.6.1163; CASTAGNOLA P, 1986, J CELL BIOL, V102, P2310, DOI 10.1083/jcb.102.6.2310; CASTAGNOLA P, 1988, J CELL BIOL, V106, P461, DOI 10.1083/jcb.106.2.461; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DOZIN B, 1990, J BIOL CHEM, V265, P7216; GARDNER RC, 1981, NUCLEIC ACIDS RES, V9, P2871, DOI 10.1093/nar/9.12.2871; Gordon MK, 1990, CURR OPIN CELL BIOL, V2, P833, DOI 10.1016/0955-0674(90)90080-X; GORDON MK, 1989, CONNECT TISSUE RES, V20, P179, DOI 10.3109/03008208909023886; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAYASHI M, 1988, DEVELOPMENT, V103, P27; HAYASHI M, 1986, J CELL BIOL, V102, P2302, DOI 10.1083/jcb.102.6.2302; HEIDECKER G, 1980, GENE, V10, P69, DOI 10.1016/0378-1119(80)90145-6; KIELTY CM, 1985, BIOCHEM J, V227, P545, DOI 10.1042/bj2270545; KOSHER RA, 1983, CARTILAGE, V1, P59; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRYSTOSEK A, 1975, J BIOL CHEM, V250, P6077; MANDUCA P, 1989, EUR J CELL BIOL, V50, P154; Maniatis T., 1982, MOL CLONING; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; NAKAMAKI T, 1989, JPN J CANCER RES, V80, P1077, DOI 10.1111/j.1349-7006.1989.tb02262.x; OETTINGER HF, 1990, EXP CELL RES, V191, P292, DOI 10.1016/0014-4827(90)90017-5; Owen M., 1985, BONE MINERAL RES ANN, V1, P1; PFEFFERKORN ER, 1963, VIROLOGY, V20, P433, DOI 10.1016/0042-6822(63)90092-8; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID TM, 1985, DEV BIOL, V107, P373, DOI 10.1016/0012-1606(85)90319-7; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; SHROOT B, 1990, Nouvelle Revue Francaise d'Hematologie, V32, P26; WANG SY, 1989, LEUKEMIA RES, V13, P1091, DOI 10.1016/0145-2126(89)90154-9; WERNER H, 1989, P NATL ACAD SCI USA, V86, P7451, DOI 10.1073/pnas.86.19.7451; ZHONG R, 1983, NUCLEIC ACIDS RES, V11, P7409, DOI 10.1093/nar/11.21.7409	40	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					2979	2985						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737754				2022-12-25	WOS:A1992HD15400028
J	HIRSCH, AH; GLANTZ, SB; LI, Y; YOU, Y; RUBIN, CS				HIRSCH, AH; GLANTZ, SB; LI, Y; YOU, Y; RUBIN, CS			CLONING AND EXPRESSION OF AN INTRON-LESS GENE FOR AKAP-75, AN ANCHOR PROTEIN FOR THE REGULATORY SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE-II-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							FRIEND-ERYTHROLEUKEMIC CELLS; HIGH-AFFINITY BINDING; DIFFERENTIAL EXPRESSION; CAENORHABDITIS-ELEGANS; SECONDARY STRUCTURE; GLOBULAR-PROTEINS; DNA; RII; IDENTIFICATION; BRAIN	The A-Kinase Anchor Protein AKAP 75 (formerly designated bovine brain P75) is a particulate brain protein that avidly binds the regulatory subunit (RII-beta) of cAMP-dependent protein kinase II-beta (Bregman, D. B., Hirsch, A. H. and Rubin, C. S. (1991) J. Biol. Chem. 266, 7207-7213). The formation of stable AKAP 75.RII-beta complexes provides a potential mechanism for targeting physiological signals carried by cAMP to specific effector sites within neurons and other brain cells. We have now cloned and characterized the AKAP 75 gene. Its coding sequence is novel and unexpectedly short (1284 base pairs) and contains no introns. When the AKAP 75 gene was transfected into HEK 293 cells, a new RII-beta-binding protein with an apparent M(r) of 75,000 accumulated. A high proportion (approximately 65%) of the AKAP 75 gene product was excluded from the cytoplasm and was recovered in the 40,000 x g pellet derived from disrupted transfected cells. In contrast, cells transfected with a construct encoding 249 amino acids from the central and C-terminal regions of AKAP 75 produced an RII-beta-binding protein (apparent M(r) = 45,000) that was exclusively cytosolic. AKAP 75 is a novel protein composed of only 428 amino acid residues (M(r) = 47,878). A highly acidic C-terminal region mediates the binding of RII-beta (and cAMP-dependent protein kinase II-beta), whereas a positively charged N-terminal segment contains structural features that are essential for the association of AKAP 75 with the cytoskeleton and/or intracellular membranes.			HIRSCH, AH (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,ATRAN LABS,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1991, J BIOL CHEM, V266, P14188; EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GASCUEL O, 1988, COMPUT APPL BIOSCI, V4, P357; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Green MR, 1989, CURR OPIN CELL BIOL, V1, P519, DOI 10.1016/0955-0674(89)90014-8; GROSS RE, 1990, J BIOL CHEM, V265, P6896; GROSS RE, 1990, J BIOL CHEM, V265, P8152; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HU E, 1990, J BIOL CHEM, V265, P20609; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEISER M, 1986, J BIOL CHEM, V261, P1904; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU X, 1990, J BIOL CHEM, V265, P3292; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUBINO HM, 1989, NEURON, V3, P631, DOI 10.1016/0896-6273(89)90273-0; SAIKI RR, 1988, SCIENCE, V241, P487; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR D, 1984, J BIOL CHEM, V259, P9840; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; STEIN JC, 1987, J BIOL CHEM, V262, P3002; THEURKAUF WE, 1982, J BIOL CHEM, V257, P3284; VALLEE RB, 1984, J CELL BIOL, V99, pS38, DOI 10.1083/jcb.99.1.38s	34	96	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2131	2134						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733921				2022-12-25	WOS:A1992HB53200005
J	NAKANISHI, S; KAKITA, S; TAKAHASHI, I; KAWAHARA, K; TSUKUDA, E; SANO, T; YAMADA, K; YOSHIDA, M; KASE, H; MATSUDA, Y; HASHIMOTO, Y; NONOMURA, Y				NAKANISHI, S; KAKITA, S; TAKAHASHI, I; KAWAHARA, K; TSUKUDA, E; SANO, T; YAMADA, K; YOSHIDA, M; KASE, H; MATSUDA, Y; HASHIMOTO, Y; NONOMURA, Y			WORTMANNIN, A MICROBIAL PRODUCT INHIBITOR OF MYOSIN LIGHT CHAIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; DEPENDENT PROTEIN-KINASE; CHICKEN GIZZARD; SKELETAL-MUSCLE; PHOSPHORYLATION; PURIFICATION; POTENT; ACTIVATION; SECRETION; ANALOGS	We have found that a fungal strain, Talaromyces wortmannin KY12420, produces a potent inhibitor of smooth muscle myosin light chain kinase (MLCK). This active product, designated as MS-54, was isolated and purified from the culture broth of the fungus and identified as wortmannin. The inhibition of MLCK by wortmannin was prevented by a high concentration of ATP. The activity of the catalytic domain, which was disclosed by partial tryptic digestion, was also inhibited by wortmannin. These results suggest that wortmannin acts at or near to the catalytic site of the enzyme. It was shown clearly by kinetic analyses, preincubation studies, and dialysis experiments that the inhibitory action of wortmannin on MLCK was irreversible. Under the condition of preincubation for 3 min, 0.3-mu-M wortmannin inhibited the activity of MLCK, while 10-mu-M wortmannin had no effect on the activities of cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and had little effect on protein kinase C activity. These data expressed clearly the marked selectivity of the compound for MLCK. Furthermore, wortmannin also inhibited both the phosphorylation of myosin light chain and the contraction in rat thoracic aorta stimulated with KCl, which indicates the effectiveness of the compound in the cellular level as an MLCK inhibitor.	UNIV TOKYO,FAC MED,DEPT PHARMACOL 1,BUNKYO KU,TOKYO 113,JAPAN; KYOWA HAKKO KOGYO CO LTD,TOKYO RES LABS,TOKYO 194,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 1,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo; Kyowa Kirin Ltd; University of Tokyo								ABBAS HK, 1988, APPL ENVIRON MICROB, V54, P1268, DOI 10.1128/AEM.54.5.1268-1274.1988; ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; ADELSTEIN RS, 1980, CALCIUM CELL FUNCTIO, V1, P167; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIAN P. W., 1957, TRANS BRIT MYCOL SOC, V40, P365; DEWALD B, 1988, J BIOL CHEM, V263, P16179; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; GUTIERREZ LM, 1989, BIOCHEM J, V264, P589, DOI 10.1042/bj2640589; HAGIWARA M, 1988, BIOCHEM BIOPH RES CO, V152, P270, DOI 10.1016/S0006-291X(88)80710-1; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; HASHIMOTO Y, 1991, JPN J PHARM S1, V58, pP91; HASLAM RJ, 1977, BIOCHEM BIOPH RES CO, V77, P714, DOI 10.1016/S0006-291X(77)80037-5; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HATHAWAY DR, 1985, AM J PHYSIOL, V249, pC345; IKEBE M, 1987, J BIOL CHEM, V262, P13828; KASE H, 1986, J ANTIBIOT, V39, P1059, DOI 10.7164/antibiotics.39.1059; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KIKKAWA U, 1983, METHOD ENZYMOL, V99, P288; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; LINCOLN TM, 1983, METHOD ENZYMOL, V99, P62; MACMILLAN J, 1972, J CHEM SOC PERK T 1, P2898, DOI 10.1039/p19720002898; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MIYAMOTO E, 1969, J BIOL CHEM, V244, P6395; MOORE RL, 1984, AM J PHYSIOL, V247, pC462, DOI 10.1152/ajpcell.1984.247.5.C462; NAKANISHI S, 1988, J BIOL CHEM, V263, P6215; NAKANISHI S, 1990, MOL PHARMACOL, V37, P482; NAKANISHI S, 1991, ANAL BIOCHEM, V95, P313; NISHIKAWA M, 1980, NATURE, V287, P863, DOI 10.1038/287863a0; OZAKI H, 1989, BIOCHEM PHARMACOL, V38, P915; PEARSON RB, 1986, J BIOL CHEM, V261, P25; ROGERS JC, 1989, BIOCHEM BIOPH RES CO, V164, P419, DOI 10.1016/0006-291X(89)91736-1; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAITOH M, 1987, J BIOL CHEM, V262, P7796; SIMPSON TJ, 1979, J CHEM SOC PERK T 1, P931, DOI 10.1039/p19790000931; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P414, DOI 10.1073/pnas.87.1.414; Walsh M. P., 1985, CALCIUM CELL PHYSL, P170; WALSH MP, 1982, CALCIUM CELL FUNCTIO, V3, P223; WIESINGE.D, 1974, EXPERIENTIA, V30, P135, DOI 10.1007/BF01927691; YATOMI Y, 1990, SEIKAGAKU, V62, P919	43	451	460	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2157	2163						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733924				2022-12-25	WOS:A1992HB53200010
J	HUANG, TT; CARLSON, EJ; LEADON, SA; EPSTEIN, CJ				HUANG, TT; CARLSON, EJ; LEADON, SA; EPSTEIN, CJ			RELATIONSHIP OF RESISTANCE TO OXYGEN FREE-RADICALS TO CUZN-SUPEROXIDE DISMUTASE ACTIVITY IN TRANSGENIC, TRANSFECTED, AND TRISOMIC CELLS	FASEB JOURNAL			English	Note						MOUSE TRISOMY-16; DOWN SYNDROME; HUMAN TRISOMY-21; PARAQUAT; CUZN-SUPEROXIDE DISMUTASE	GLUTATHIONE-PEROXIDASE-ACTIVITY; PARAQUAT RESISTANCE; ESCHERICHIA-COLI; DOWNS-SYNDROME; TOXICITY; INHIBITION; MICE; DNA; OVEREXPRESSION; ENHANCEMENT	Although CuZn-superoxide dismutase (CuZnSOD) has been shown to reduce oxidative damage in several systems, the quantitative relationship between the degree of protection and CuZnSOD activity has not been well investigated. Therefore, the ability of cells to tolerate superoxide toxicity was assessed as a function of endogenous CuZnSOD activity in several mouse and human cell lines with progressively higher levels of CuZnSOD activity. In five lines of fetal fibroblasts derived from SOD1-transgenic mice, with CuZnSOD activities of 1.7- to 7.1-fold the nontransgenic level and no changes in the cellular glutathione peroxidase (GSHPx) activity, a direct relationship (r = 0.97) between the LD50 to paraquat and enzyme activity was observed, suggesting that CuZnSOD activity is the single most important factor in determining the paraquat LD50. Mouse trisomy 16 fetal fibroblasts and human trisomy 21 lung fibroblasts, both expressing a 1.5-fold increase in CuZnSOD activity, were 1.5-fold more tolerant to paraquat than were their diploid counterparts. Furthermore, the protective effect of CuZnSOD at the DNA level, as shown by reduced thymine glycol generation, was demonstrated in paraquat-treated transgenic fibroblasts. A direct relationship (r = 0.78) of paraquat LD50 and CuZnSOD activity was also observed with a panel of six lines of SOD1-transfected HeLa cells with 1.6- to 7.3-fold the basal CuZnSOD activity. Moreover, there was no correlation between resistance to paraquat toxicity and the cellular GSHPx and/or catalase activity. Taken together, these results demonstrate a consistently protective effect of endogenous CuZnSOD against superoxide toxicity in both primary and transformed cell lines.	UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,BOX 0748,SAN FRANCISCO,CA 94143; UNIV N CAROLINA,DEPT RADIAT ONCOL,CHAPEL HILL,NC 27599	University of California System; University of California San Francisco; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA040453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG008938] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40453] Funding Source: Medline; NIA NIH HHS [AG-08938] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AVRAHAM KB, 1991, J NEUROCYTOL, V20, P208, DOI 10.1007/BF01186993; AVRAHAM KB, 1988, CELL, V54, P823, DOI 10.1016/S0092-8674(88)91153-1; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; BOREK C, 1983, P NATL ACAD SCI-BIOL, V80, P1304, DOI 10.1073/pnas.80.5.1304; CEBALLOS I, 1988, BIOCHIM BIOPHYS ACTA, V949, P58, DOI 10.1016/0167-4781(88)90054-1; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Chow C.K., 1988, CELLULAR ANTIOXIDANT, P217; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; ELROYSTEIN O, 1988, CELL, V52, P259, DOI 10.1016/0092-8674(88)90515-6; Epstein C.J, 1986, CONSEQUENCES CHROMOS; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; EPSTEIN CJ, 1985, ISSUES REV TERATOLOG, V3, P171; EPSTEIN CJ, 1983, LYMPHOKINES, V8, P277; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fridovich I., 1982, SUPEROXIDE DISMUTASE, V1, P69; FRISCHER H, 1981, RED CELL, P269; GRONER Y, 1990, MOL GENETICS CHROMOS; GRUBER MY, 1990, P NATL ACAD SCI USA, V87, P2608, DOI 10.1073/pnas.87.7.2608; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Halliwell B., 1985, FREE RADICALS BIOL M, DOI 10.1016/0748-5514(85)90140-0; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; INOUE M, 1990, FEBS LETT, V269, P89, DOI 10.1016/0014-5793(90)81126-9; KELNER MJ, 1990, FREE RADICAL BIO MED, V9, P149, DOI 10.1016/0891-5849(90)90118-3; KELNER MJ, 1990, J BIOL CHEM, V265, P10872; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KRALL J, 1988, J BIOL CHEM, V263, P1910; KUJIRAI K, 1991, Society for Neuroscience Abstracts, V17, P812; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; LEADON SA, 1983, MUTAT RES, V112, P191, DOI 10.1016/0167-8817(83)90006-8; LOO DT, 1987, SCIENCE, V236, P200, DOI 10.1126/science.3494308; Luck H., 1974, ESTIMATION CATALASE, V885; MARKEY BA, 1990, FREE RADICAL BIO MED, V9, P307, DOI 10.1016/0891-5849(90)90005-4; MINAKAMI H, 1990, FASEB J, V4, P3239, DOI 10.1096/fasebj.4.14.2172063; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; PRZEDBORSKI S, 1992, IN PRESS J NEUROSCI; REVEILLAUD I, 1991, MOL CELL BIOL, V11, P632, DOI 10.1128/MCB.11.2.632; SAWADA M, 1988, MUTAT RES, V197, P133, DOI 10.1016/0027-5107(88)90149-2; SCHICKLER M, 1989, EMBO J, V8, P1385, DOI 10.1002/j.1460-2075.1989.tb03519.x; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; SETO NOL, 1990, P NATL ACAD SCI USA, V87, P4270, DOI 10.1073/pnas.87.11.4270; SINET PM, 1979, LIFE SCI, V24, P29, DOI 10.1016/0024-3205(79)90276-5; STARR J, 1986, SOMAT CELL MOLEC GEN, V12, P141, DOI 10.1007/BF01560661; STAVELEY BE, 1990, GENOME, V33, P867, DOI 10.1139/g90-130; Steinman H., 1982, SUPEROXIDE DISMUTASE, P11	44	51	55	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB 1	1992	6	3					903	910		10.1096/fasebj.6.3.1740238	http://dx.doi.org/10.1096/fasebj.6.3.1740238			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	HE390	1740238				2022-12-25	WOS:A1992HE39000014
J	LERNER, EA; SHOEMAKER, CB				LERNER, EA; SHOEMAKER, CB			MAXADILAN - CLONING AND FUNCTIONAL EXPRESSION OF THE GENE ENCODING THIS POTENT VASODILATOR PEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLY LUTZOMYIA-LONGIPALPIS; ENDOTHELIN RECEPTOR; CELLS	Maxadilan is a potent vasodilator peptide released into the skin when the sand fly Lutzomyia longipalpis, an important vector of leishmania, probes for a blood meal. As several lines of evidence suggest that this peptide may play a critical role in the enhancement of leishmania infectivity attributed to sand fly saliva, the peptide has been proposed as a candidate antigen for a leishmanial vaccine. Although maxadilan is the most potent vasodilator peptide known and shares several properties with calcitonin gene-related peptide (CGRP), studies of its structure, physiological effects, and biological roles have been limited by the miniscule quantities available. Here we report the isolation of cDNA and genomic DNA clones that encode maxadilan. The predicted translation product shows no significant homology with any previously isolated proteins. The coding DNA has been expressed in Escherichia coli and the purified recombinant peptide is biologically active with a specific activity comparable to the natural peptide. Recombinant maxadilan will be useful in studies of vascular biology and could lead to novel therapeutic and prophylactic agents.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT DERMATOL,DIV DERMATOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT TROP PUBL HLTH,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health								ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; BRAIN SD, 1985, NATURE, V313, P54, DOI 10.1038/313054a0; FULLER RW, 1987, BRIT J PHARMACOL, V92, P781, DOI 10.1111/j.1476-5381.1987.tb11381.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HAGERMARK O, 1974, ACTA DERM-VENEREOL, V54, P397; LERNER EA, 1991, J BIOL CHEM, V266, P11234; NONG YH, 1989, J IMMUNOL, V143, P45; RIBEIRO JMC, 1989, SCIENCE, V243, P212, DOI 10.1126/science.2783496; RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TESH RB, 1983, J MED ENTOMOL, V20, P199, DOI 10.1093/jmedent/20.2.199; THEODOS CM, 1991, INFECT IMMUN, V59, P1592, DOI 10.1128/IAI.59.5.1592-1598.1991; TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	16	88	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1062	1066						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730635				2022-12-25	WOS:A1992GY96000062
J	OHASHI, K; RUAN, KH; KULMACZ, RJ; WU, KK; WANG, LH				OHASHI, K; RUAN, KH; KULMACZ, RJ; WU, KK; WANG, LH			PRIMARY STRUCTURE OF HUMAN THROMBOXANE SYNTHASE DETERMINED FROM THE CDNA SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; PROSTAGLANDIN ENDOPEROXIDES; MESSENGER-RNAS; CYTOCHROME-P-450; PLATELETS; ENZYME; IDENTIFICATION; INHIBITORS; MICROSOMES; PROTEINS	Polymerase chain reaction techniques have been used to isolate a cDNA clone containing the entire protein coding region of thromboxane A, synthase (EC 5.3.99.5) from a human lung cDNA library. The cDNA clone hybridizes with a single 2.1-kilobase mRNA species in phorbol ester-induced human erythroleukemia and monocytic leukemia cell lines. A second cDNA, differing only by an insert of 163 base pairs near the 3'-end of the translated region, was also found to be present in the same library. The proteins predicted from both nucleic acid sequences include the three polypeptide sequences determined from amino acid sequencing of the purified human platelet enzyme, five potential sites for N-glycosylation, and a hydrophobic region that may serve to anchor the synthase in the endoplasmic reticulum membrane. The longer predicted protein, designated thromboxane synthase-1, contains 534 amino acids, with a M(r) of 60,684, whereas the shorter protein, designated thromboxane synthase-II, contains 460 amino acids and has a Mr of 52,408. Although thromboxane synthase-II lacks the conserved cysteine that serves as the proximal heme ligand in the other cytochromes, significant sequence similarities exist among thromboxane synthase-I and -II and several P450s, particularly those in family 3. The overall amino acid identity is considerably less than 40%, making it likely that thromboxane synthase represents a previously undefined family of cytochrome P450.	UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,DIV HEMATOL ONCOL,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,VASC DIS RES CTR,HOUSTON,TX 77030	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Wu, Kenneth Kun-Yu/B-1070-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35387] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FUKUMOTO S, 1983, PROSTA LEUKOTR MED, V11, P179, DOI 10.1016/0262-1746(83)90018-5; GOERIG M, 1987, J CLIN INVEST, V79, P903, DOI 10.1172/JCI112900; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HAURAND M, 1985, J BIOL CHEM, V260, P5059; HOCK CE, 1984, CIRC SHOCK, V14, P159; HONDA A, 1986, BIOCHIM BIOPHYS ACTA, V877, P423, DOI 10.1016/0005-2760(86)90208-0; JONES DA, 1990, J BIOL CHEM, V265, P20166; KIMURA S, 1987, P NATL ACAD SCI USA, V84, P5555, DOI 10.1073/pnas.84.16.5555; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAWRENCE CB, 1989, EUGENE SOFTWARE PACK; MORLEY J, 1979, Prostaglandins, V17, P730; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEEDLEMAN P, 1976, NATURE, V261, P558, DOI 10.1038/261558a0; NELSON DR, 1988, J BIOL CHEM, V263, P6038; NUSING R, 1990, ARCH BIOCHEM BIOPHYS, V280, P325, DOI 10.1016/0003-9861(90)90337-X; PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1985, J BIOL CHEM, V260, P6122; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SALMON JA, 1986, ADV DRUG RES, V15, P111; Sambrook J, 1989, MOL CLONING LABORATO; SANDUJA SK, 1991, IN PRESS BLOOD; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN RF, 1986, J BIOL CHEM, V261, P1592; SILVER MJ, 1974, SCIENCE, V183, P1085, DOI 10.1126/science.183.4129.1085; SVENSSON J, 1977, PROSTAGLANDINS, V14, P425, DOI 10.1016/0090-6980(77)90258-1; WANG LH, 1991, BIOCHEM BIOPH RES CO, V177, P286, DOI 10.1016/0006-291X(91)91980-Q; WOLD F, 1981, ANNU REV BIOCHEM, V50, P783, DOI 10.1146/annurev.bi.50.070181.004031; YAMASHITA T, 1991, J BIOL CHEM, V266, P3888; YOKOYAMA C, 1991, BIOCHEM BIOPH RES CO, V178, P1479, DOI 10.1016/0006-291X(91)91060-P; YOSHIMOTO T, 1977, J BIOL CHEM, V252, P5871	36	100	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					789	793						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730669				2022-12-25	WOS:A1992GY96000020
J	SEKO, A; KITAJIMA, K; INOUE, Y; INOUE, S				SEKO, A; KITAJIMA, K; INOUE, Y; INOUE, S			PEPTIDE-N-GLYCOSIDASE ACTIVITY FOUND IN THE EARLY EMBRYOS OF ORYZIAS-LATIPES (MEDAKA FISH) - THE 1ST DEMONSTRATION OF THE OCCURRENCE OF PEPTIDE-N-GLYCOSIDASE IN ANIMAL-CELLS AND ITS IMPLICATION FOR THE PRESENCE OF A DE-N-GLYCOSYLATION SYSTEM IN LIVING ORGANISMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED GLYCAN CHAIN; UNFERTILIZED EGGS; FREE SIALOOLIGOSACCHARIDES; CONCANAVALIN-A; ACETYLGLUCOSAMINIDASE; BIANTENNARY; HYOSOPHORIN; TRANSPORT; SEQUENCE; AMIDASE	The recent discovery of free oligosaccharides typical for the complex type of glycan chains terminating with a free di-N-acetylchitobiosyl structure in certain fish eggs and early embryos (Ishii, K., Iwasaki, M., Inoue, S., Kenny, P. T. M., Komura, H., and Inoue, Y. (1989) J. Biol. Chem. 264, 1623-1630; Seko, A., Kitajima, K., Iwasaki, M., Inoue, S., and Inoue, Y. (I 989) J. Biol. Chem. 264, 15922-15929; Inoue, S., lwasaki, M., Ishii, K., Kitajima, K., and Inoue, Y. (1989) J. Biol. Chem. 264, 18520-18526) led us to find an enzyme responsible for detachment of N-linked glycan chains from glycoproteins by hydrolyzing the beta-aspartyl-glucosylamine linkage in Oryzias latipes embryos. The enzyme, peptide-N4-(N-acetyl-beta-glucosaminyl) asparagine amidase or peptide:N-glycosidase (PNGase), was partially (2090-fold) purified, and the reaction site at which this enzyme acts was specified by analysis and identification of the reaction products. This is the first demonstration showing PNGase in animal sources, although the presence of PNGases was reported in a variety of plant extracts and bacteria. Thus, the commonality of this type of enzyme is now demonstrated, and the possible physiological role of PNGase in de-N-glycosylation as a basic biologic process is proposed.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,HONGO-7,TOKYO 113,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,TOKYO 142,JAPAN	University of Tokyo; Showa University								BOWLES DJ, 1986, J CELL BIOL, V102, P1284, DOI 10.1083/jcb.102.4.1284; BRASSART D, 1987, EUR J BIOCHEM, V169, P131, DOI 10.1111/j.1432-1033.1987.tb13589.x; CABACUNGAN JC, 1982, ANAL BIOCHEM, V124, P272, DOI 10.1016/0003-2697(82)90038-0; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FAYE L, 1987, PLANTA, V170, P217, DOI 10.1007/BF00397891; FOXWELL BMJ, 1985, BIOCHIM BIOPHYS ACTA, V840, P193, DOI 10.1016/0304-4165(85)90119-9; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; INOUE S, 1989, J BIOL CHEM, V264, P18520; ISHII K, 1989, J BIOL CHEM, V264, P1623; IWASAKI M, 1989, P ANN M JPN BIOCH SO, V61, P1150; KIMURA Y, 1989, P ANN M JPN BIOCH SO, V61, P1020; KITAJIMA K, 1989, DEV BIOL, V132, P544, DOI 10.1016/0012-1606(89)90249-2; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; PLUMMER TH, 1987, EUR J BIOCHEM, V163, P167, DOI 10.1111/j.1432-1033.1987.tb10751.x; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; SEKO A, 1989, J BIOL CHEM, V264, P15922; SEKO A, 1990, P ANN M JPN BIOCH SO, V62, P882; SHINSHI H, 1988, P NATL ACAD SCI USA, V85, P5541, DOI 10.1073/pnas.85.15.5541; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; TARENTINO AL, 1987, METHOD ENZYMOL, V138, P770; WILKINS TA, 1990, PLANT CELL, V2, P301, DOI 10.1105/tpc.2.4.301; YOSHITAKE S, 1978, AGR BIOL CHEM TOKYO, V42, P1267, DOI 10.1080/00021369.1978.10863144	24	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1991	266	33					22110	22114						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GR564	1718990				2022-12-25	WOS:A1991GR56400010
J	PAPAMARCAKI, T; KOUKLIS, PD; KREIS, TE; GEORGATOS, SD				PAPAMARCAKI, T; KOUKLIS, PD; KREIS, TE; GEORGATOS, SD			THE LAMIN B-FOLD - ANTIIDIOTYPIC ANTIBODIES REVEAL A STRUCTURAL COMPLEMENTARITY BETWEEN NUCLEAR LAMIN-B AND CYTOPLASMIC INTERMEDIATE FILAMENT EPITOPES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; MONOCLONAL-ANTIBODIES; AVIAN ERYTHROCYTES; DESMIN DERIVATIVES; SITE-SPECIFICITY; PROTEIN FAMILY; VIMENTIN; ENVELOPE; RECEPTOR; IDENTIFICATION	Previous studies have shown that nuclear lamin B binds specifically to the C-terminal domains of type III intermediate filament (IF) proteins under in vitro conditions. To further explore such site-specific interactions, we have used a two-step anti-idiotypic antibody approach. First, a monoclonal antibody disrupting the cytoplasmic IF network organization of living cells (mAb7A3) (Matteoni, R., and Kreis, T. E. (1987) J. Cell Biol. 105, 1253-1265) was characterized. Epitope mapping demonstrated that this antibody recognized a site located in the C-terminal domains of vimentin and peripherin (type III IF proteins). mAb7A3 was able to inhibit more than 80% of the in vitro binding of nuclear lamin B to PI, a synthetic peptide modeled after the C-terminal domain of peripherin that comprises a lamin B-binding site (Djabali, K., Portier, M. M., Gros, F., Blobel, G., and Georgatos, S. D. (1991) Cell 64, 109-121). In a second step, animals were immunized with mAb7A3 and the resulting anti-idiotypic sera were screened. Two of these antisera reacted specifically with nuclear lamin B but not with type A lamins or cytoplasmic IF proteins. The anti-lamin B activity of one of the antisera was isolated by affinity chromatography using a lamin B-agarose matrix. The reaction of these affinity-purified antibodies with lamin B was inhibited by mAb7A3. Furthermore, the anti-lamin B antibodies reacted with Fab fragments of mAb7A3 and abolished binding of lamin B to PI. From these data we conclude that anti-idiotypic antibodies against the paratope of mAb7A3 recognize specific epitopes of the lamin B molecule that have shapes complementary to the one of the C-terminal domain of type III IF proteins. We speculate that these (regional) conformations, which we term the "lamin B-fold," may also occur in non-lamin proteins that mediate the anchorage of IFs to various membranous organelles.	EUROPEAN MOLEC BIOL LAB,PROGRAM CELL BIOL,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)				Kouklis, Panos/0000-0003-0378-5619; Georgatos, Spyros/0000-0002-2078-7467				CARMO-FONSECA M, 1987, European Journal of Cell Biology, V45, P282; CARTAUD A, 1989, J CELL BIOL, V109, P1745, DOI 10.1083/jcb.109.4.1745; CARTAUD A, 1990, J CELL BIOL, V111, P581, DOI 10.1083/jcb.111.2.581; Chothia C, 1991, CURR OPIN STRUC BIOL, V1, P53, DOI 10.1016/0959-440X(91)90011-H; CLEVELAND WL, 1983, NATURE, V305, P56, DOI 10.1038/305056a0; DJABALI K, 1991, CELL, V64, P109, DOI 10.1016/0092-8674(91)90213-I; DUNIA I, 1990, EUR J CELL BIOL, V53, P59; ESCURAT M, 1990, J NEUROSCI, V10, P764; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; FUJITANI Y, 1989, J ELECTRON MICROSC, V38, P34; GEISLER N, 1982, CELL, V30, P277, DOI 10.1016/0092-8674(82)90033-2; GEORGATOS SD, 1985, J CELL BIOL, V100, P1955, DOI 10.1083/jcb.100.6.1955; GEORGATOS SD, 1987, J CELL BIOL, V105, P117, DOI 10.1083/jcb.105.1.117; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; GEORGATOS SD, 1985, J CELL BIOL, V100, P1962, DOI 10.1083/jcb.100.6.1962; GEORGATOS SD, 1987, J CELL BIOL, V105, P105, DOI 10.1083/jcb.105.1.105; GOLDMAN R, 1985, ANN NY ACAD SCI, V455, P1, DOI 10.1111/j.1749-6632.1985.tb50400.x; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JERNE NK, 1985, EMBO J, V4, P847, DOI 10.1002/j.1460-2075.1985.tb03709.x; JONES JCR, 1982, CELL MOTIL CYTOSKEL, V2, P197, DOI 10.1002/cm.970020302; KATSUMA Y, 1987, BIOL CELL, V59, P193, DOI 10.1111/j.1768-322X.1987.tb00531.x; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY RC, 1985, J CELL BIOCHEM, V30, P101; LEHNER CF, 1986, J BIOL CHEM, V261, P3293; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MERDES A, 1991, IN PRESS J CELL BIOL; NELSON WJ, 1982, J BIOL CHEM, V257, P5536; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PERIDES G, 1987, EUR J CELL BIOL, V43, P450; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; RAMAEKERS FCS, 1982, P NATL ACAD SCI-BIOL, V79, P3208, DOI 10.1073/pnas.79.10.3208; RIVAS CI, 1988, P NATL ACAD SCI USA, V85, P6092, DOI 10.1073/pnas.85.16.6092; SHECHTER Y, 1984, J BIOL CHEM, V259, P6411; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; VORBURGER K, 1989, J MOL BIOL, V208, P405, DOI 10.1016/0022-2836(89)90505-6; WICHE G, 1991, J CELL BIOL, V14, P83; 1989, PIERCE HDB GENERAL C	39	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	1991	266	31					21247	21251						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GN001	1718975				2022-12-25	WOS:A1991GN00100102
J	BAUMANN, H; JAHREIS, GP; MORELLA, KK; WON, KA; PRUITT, SC; JONES, VE; PROWSE, KR				BAUMANN, H; JAHREIS, GP; MORELLA, KK; WON, KA; PRUITT, SC; JONES, VE; PROWSE, KR			TRANSCRIPTIONAL REGULATION THROUGH CYTOKINE AND GLUCOCORTICOID RESPONSE ELEMENTS OF RAT ACUTE PHASE PLASMA-PROTEIN GENES BY C/EBP AND JUNB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ACID GLYCOPROTEIN GENE; HEPATOCYTE-STIMULATING FACTORS; ENHANCER BINDING-PROTEIN; HUMAN HAPTOGLOBIN GENE; C-REACTIVE PROTEIN; B VIRUS ENHANCER; NUCLEAR-PROTEIN; DNA-BINDING; ALPHA-2-MACROGLOBULIN GENE; DEPENDENT EXPRESSION	Independent of de novo protein synthesis, interleukin-1, interleukin-6, and dexamethasone caused immediate stimulation of transcriptional activity of most major acute phase plasma protein genes in the rat hepatoma H-35 cells. However, activation of alpha-2-macroglobulin and alpha-1-acid glycoprotein genes were delayed by 2-4 h and required ongoing protein synthesis. The hormones also increased transiently the transcription of the junB gene and the amounts of JunB, C/EBP, and C/EBP-like mRNA. To identify whether JunB and C/EBP have the ability to control both the early and late acute phase reactants, expression vectors for mouse C/EBP and JunB together with reporter gene constructs containing recognized hormone-specific regulatory elements were introduced into hepatoma cells. C/EBP displayed prominent transactivation activity with the interleukin-1 and glucocorticoid regulatory elements of alpha-1-acid glycoprotein, the interleukin-1 regulatory element of haptoglobin gene, and the interleukin-6 regulatory element of beta-fibrinogen. The interleukin-6 regulatory elements of the first two genes and the glucocorticoid response element of the third gene were not affected by C/EBP. These data suggest that normal hormone activation of these three acute phase reactant genes might involve, in part, C/EBP-related factors which have a broad range of specificity. H-35 cells stably transformed with a mouse C/EBP expression vector showed an elevated basal level as well as cytokine inducible expression of some but not all acute phase reactants. Cotransfected JunB resulted in reduced activity of cytokine-responsive constructs and in lower transactivation by C/EBP. JunB appears to function as a modulator of plasma protein expression during the course of acute phase response.			BAUMANN, H (corresponding author), ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263, USA.				NCI NIH HHS [CA26122] Funding Source: Medline; NICHD NIH HHS [HD25419] Funding Source: Medline; NIDDK NIH HHS [DK33886] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025419] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033886] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ARCONE R, 1988, NUCLEIC ACIDS RES, V16, P3195, DOI 10.1093/nar/16.8.3195; BAUMANN H, 1990, MOL BIOL MED, V7, P147; BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1986, J CELL BIOL, V102, P370, DOI 10.1083/jcb.102.2.370; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1986, MOL CELL BIOL, V6, P2551, DOI 10.1128/MCB.6.7.2551; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHENG J, 1990, NUCLEIC ACIDS RES, V18, P4261, DOI 10.1093/nar/18.14.4261; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P4427, DOI 10.1128/MCB.10.8.4427; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; Fey G H, 1990, Prog Liver Dis, V9, P89; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; HUBER P, 1990, J BIOL CHEM, V265, P5695; JAN GR, 1990, CELL, V62, P1189; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KLEIN ES, 1987, J BIOL CHEM, V262, P520; KLEIN ES, 1988, MOL ENDOCRINOL, V2, P1343, DOI 10.1210/mend-2-12-1343; KOJ A, 1974, STRUCTURE FUNCTION P, V1; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; LAMERS WH, 1982, P NATL ACAD SCI-BIOL, V79, P5137, DOI 10.1073/pnas.79.17.5137; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LI SP, 1990, J BIOL CHEM, V265, P4136; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARINKOVIC S, 1990, MOL CELL BIOL, V10, P1573, DOI 10.1128/MCB.10.4.1573; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; OLIVIERO S, 1987, EMBO J, V6, P1905, DOI 10.1002/j.1460-2075.1987.tb02450.x; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; PROWSE KR, 1990, J BIOL CHEM, V261, P10201; PRUITT SC, 1988, GENE, V66, P121, DOI 10.1016/0378-1119(88)90230-2; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; RON D, 1990, MOL CELL BIOL, V10, P1023, DOI 10.1128/MCB.10.3.1023; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHIELS BR, 1987, J BIOL CHEM, V262, P12826; SHUTTE J, 1989, CELL, V59, P987; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILSON DR, 1990, MOL CELL BIOL, V10, P6181, DOI 10.1128/MCB.10.12.6181; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; WON KA, 1991, MOL CELL BIOL, V11, P3001, DOI 10.1128/MCB.11.6.3001; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	63	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1991	266	30					20390	20399						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GM039	1718961				2022-12-25	WOS:A1991GM03900076
J	CHING, GY; LIEM, RKH				CHING, GY; LIEM, RKH			STRUCTURE OF THE GENE FOR THE NEURONAL INTERMEDIATE FILAMENT PROTEIN ALPHA-INTERNEXIN AND FUNCTIONAL-ANALYSIS OF ITS PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEIGHT NEUROFILAMENT PROTEIN; CELL-SPECIFIC EXPRESSION; AMINO-ACID-SEQUENCE; NF-M; DNA-BINDING; TRANSCRIPTION INVITRO; REGULATORY ELEMENTS; MOUSE EMBRYOGENESIS; TRANSGENIC MICE; NERVOUS TISSUES	We have isolated the gene encoding the neuronal intermediate filament protein alpha-internexin using low stringency hybridization conditions and an NF-M (neurofilament middle molecular weight subunit) cDNA probe. This gene consists of three exons and two introns. The sequence data and the exon-intron organization of the gene establish its classification as a type IV intermediate filament gene. Transient transfection experiments showed that up to 5 kilobases of the alpha-internexin promoter region transcribed equally well in both the alpha-internexin-expressing and -nonexpressing cell lines. The results also demonstrated that the region from -77 to +73 relative to the transcription start site was sufficient for accurate basal transcription, but inclusion of the -254 to -78 region was required for efficient transcription. Sequence analysis shows that the -254 to -78 region contains several potential positive regulatory elements.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,630 W 168 ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Columbia University; Columbia University					NINDS NIH HHS [NS151812] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE GW, 1989, P NATL ACAD SCI USA, V86, P5473, DOI 10.1073/pnas.86.14.5473; CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU FC, 1989, NEURON, V2, P1435, DOI 10.1016/0896-6273(89)90189-X; COMB M, 1988, EMBO J, V7, P3793, DOI 10.1002/j.1460-2075.1988.tb03264.x; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FARRELL FX, 1990, MOL CELL BIOL, V10, P2349, DOI 10.1128/MCB.10.5.2349; FLIEGNER KH, 1990, EMBO J, V9, P749, DOI 10.1002/j.1460-2075.1990.tb08169.x; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HIRSCH MR, 1990, MOL CELL BIOL, V10, P1959, DOI 10.1128/MCB.10.5.1959; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; JULIEN JP, 1990, J PHYSIOLOGY PARIS, V84, P50; JULIEN JP, 1988, GENE, V68, P307, DOI 10.1016/0378-1119(88)90033-9; JULIEN JP, 1987, BIOCHIM BIOPHYS ACTA, V909, P10, DOI 10.1016/0167-4781(87)90041-8; JULIEN JP, 1987, GENE DEV, V1, P1085, DOI 10.1101/gad.1.10.1085; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KAPLAN MP, 1990, J NEUROSCI, V10, P2735; LASEK RJ, 1983, COLD SPRING HARB SYM, V8, P41; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LEONARD DGB, 1988, J CELL BIOL, V106, P181, DOI 10.1083/jcb.106.1.181; LEVY E, 1987, EUR J BIOCHEM, V166, P71, DOI 10.1111/j.1432-1033.1987.tb13485.x; LEWIS SA, 1986, MOL CELL BIOL, V6, P1529, DOI 10.1128/MCB.6.5.1529; Liem RKH, 1990, CURR OPIN CELL BIOL, V2, P86, DOI 10.1016/S0955-0674(05)80036-5; LIEM RKH, 1978, J CELL BIOL, V79, P637, DOI 10.1083/jcb.79.3.637; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAEDA H, 1987, NUCLEIC ACIDS RES, V15, P2851, DOI 10.1093/nar/15.7.2851; MALOUF AT, 1984, J BIOL CHEM, V259, P2756; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERMOD N, 1988, NATURE, V332, P557, DOI 10.1038/332557a0; Miller JH., 1972, EXPT MOL GENETICS; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MIURA M, 1990, J NEUROCHEM, V55, P1180, DOI 10.1111/j.1471-4159.1990.tb03123.x; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NELSON C, 1990, GENE DEV, V4, P1035, DOI 10.1101/gad.4.6.1035; NELSON P, 1976, P NATL ACAD SCI USA, V73, P123, DOI 10.1073/pnas.73.1.123; OBLINGER MM, 1989, J NEUROSCI, V9, P3766; OLMSTED JB, 1970, P NATL ACAD SCI USA, V65, P129, DOI 10.1073/pnas.65.1.129; PACHTER JS, 1985, J CELL BIOL, V101, P1316, DOI 10.1083/jcb.101.4.1316; PARYSEK LM, 1988, J NEUROSCI, V8, P555; PIEPER FR, 1987, EMBO J, V6, P3611, DOI 10.1002/j.1460-2075.1987.tb02692.x; PLEASURE SJ, 1990, J NEUROSCI, V10, P2428; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; SAX CM, 1988, NUCLEIC ACIDS RES, V16, P8057, DOI 10.1093/nar/16.16.8057; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; THOMPSON MA, 1989, NEURON, V2, P1043, DOI 10.1016/0896-6273(89)90228-6; TROY CM, 1990, BRAIN RES, V529, P232, DOI 10.1016/0006-8993(90)90832-V; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	73	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19459	19468						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717465				2022-12-25	WOS:A1991GK66700052
J	BRAND, SH; LAURIE, SM; MIXON, MB; CASTLE, JD				BRAND, SH; LAURIE, SM; MIXON, MB; CASTLE, JD			SECRETORY CARRIER MEMBRANE-PROTEINS 31-35 DEFINE A COMMON PROTEIN-COMPOSITION AMONG SECRETORY CARRIER MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL-SPECIFIC PHOSPHOPROTEIN; ADRENAL CHROMAFFIN GRANULES; RABBIT PAROTID-GLAND; CELL-FREE SYSTEM; ENDOCRINE-CELLS; SUCCESSIVE COMPARTMENTS; MONOCLONAL-ANTIBODIES; PLASMA-MEMBRANE; ELECTRIC ORGAN; VESICLES	A novel compositional overlap between membranes of exocrine and endocrine granules, synaptic vesicles, and a liver Golgi fraction has been identified using a monoclonal antibody (SG7C12) raised against parotid secretion granule membranes. This antibody binds secretory carrier membrane proteins with apparent M(r) 31,000, 33,000 and 35,000 (designated SCAMPs 31, 33, 35). The proteins are nonglycosylated integral membrane components, and the epitope recognized by SG7C12 is on the cytoplasmic side of the granule membrane. SCAMP 33 is found in all secretory carrier membranes studied so far while SCAMP 35 is found in exocrine and certain endocrine granules and liver Golgi membranes and SCAMP31 only in exocrine granules. They are not related to other similar-sized proteins that have been studied previously in relation to vesicular transport and secretion. Immunocytochemical staining shows that these SCAMPs are highly concentrated in the apical cytoplasm of exocrine cells. Antigens are present not only on exocrine granules and synaptic vesicles but also on other smooth membrane vesicles of exocrine and neural origin as revealed by immunolocalization in subcellular fractions and immunoadsorption to antibody-coated magnetic beads. The wide tissue distribution and localization to secretory carriers and related membranes suggest that SCAMPs 31-35 may be essential components in vesicle-mediated transport/secretion.	UNIV VIRGINIA, HLTH SCI CTR, DEPT ANAT & CELL BIOL, BOX 439 MED CTR, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, INST MOLEC BIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NCRR NIH HHS [5-S07-RR05431] Funding Source: Medline; NIDCR NIH HHS [DE09655] Funding Source: Medline; NIDDK NIH HHS [DK29868] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029868] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVAN P, 1986, J CELL BIOL, V103, P1257, DOI 10.1083/jcb.103.4.1257; ARVAN P, 1982, J CELL BIOL, V95, P8, DOI 10.1083/jcb.95.1.8; ARVAN P, 1987, J CELL BIOL, V104, P243, DOI 10.1083/jcb.104.2.243; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BARTLES JR, 1985, J BIOL CHEM, V260, P2792; BAUMERT M, 1990, J CELL BIOL, V110, P1285, DOI 10.1083/jcb.110.4.1285; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAELL WA, 1984, CELL, V39, P511, DOI 10.1016/0092-8674(84)90458-6; BRAND SH, 1990, J CELL BIOL, V111, P319; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CAMERON RS, 1986, J CELL BIOL, V103, P1299, DOI 10.1083/jcb.103.4.1299; CAMERON RS, 1984, J MEMBRANE BIOL, V79, P127, DOI 10.1007/BF01872117; CAMERON RS, 1989, HDB PHYSL, P107; CARTY SE, 1980, ANAL BIOCHEM, V106, P438, DOI 10.1016/0003-2697(80)90545-X; CASTLE JD, 1985, J MEMBRANE BIOL, V87, P13; CASTLE JD, 1975, J CELL BIOL, V64, P182, DOI 10.1083/jcb.64.1.182; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; CREUTZ CE, 1983, J BIOL CHEM, V258, P4664; CREUTZ CE, 1987, J BIOL CHEM, V262, P1860; DECAMILLI P, 1987, ANN NY ACAD SCI, V493, P461; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; DRUST DS, 1991, J NEUROCHEM, V56, P469, DOI 10.1111/j.1471-4159.1991.tb08174.x; DUONG LT, 1984, J BIOL CHEM, V259, P4885; Engvall E, 1980, Methods Enzymol, V70, P419; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GLUCK S, 1987, J BIOL CHEM, V262, P15780; HELL JW, 1988, EMBO J, V7, P3023, DOI 10.1002/j.1460-2075.1988.tb03166.x; HOOPER JE, 1980, J CELL BIOL, V87, P104, DOI 10.1083/jcb.87.1.104; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAH JJ, 1990, J CELL BIOL, V111, P81; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MELDOLESI J, 1971, J CELL BIOL, V49, P109, DOI 10.1083/jcb.49.1.109; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; OBENDORF D, 1988, NEUROSCIENCE, V25, P343, DOI 10.1016/0306-4522(88)90030-9; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; SMITH AD, 1967, BIOCHEM J, V103, P480, DOI 10.1042/bj1030480; SPITZ M, 1986, METHOD ENZYMOL, V121, P33; Tartakoff A M, 1974, Methods Enzymol, V31, P41; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; VOLKNANDT W, 1990, EMBO J, V9, P2465, DOI 10.1002/j.1460-2075.1990.tb07424.x; VONZASTROW M, 1987, J CELL BIOL, V105, P2675, DOI 10.1083/jcb.105.6.2675; WATTIAUX R, 1978, J CELL BIOL, V78, P349, DOI 10.1083/jcb.78.2.349; WEILER R, 1989, FEBS LETT, V257, P457, DOI 10.1016/0014-5793(89)81595-9; YAMASHITA S, 1989, ACTA HISTOCHEM CYTOC, V22, P517, DOI 10.1267/ahc.22.517; YURKO MA, 1987, J BIOL CHEM, V262, P15770	59	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18949	18957						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1717458				2022-12-25	WOS:A1991GJ47200083
J	CHANG, PC; LEE, YHW				CHANG, PC; LEE, YHW			EXTRACELLULAR AUTOPROCESSING OF A METALLOPROTEASE FROM STREPTOMYCES-CACAOI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; LYSOSTAPHIN GENE; PRO-SEQUENCE; ZINC ENZYMES; PROTEASE; SUBTILISIN; PROTEINS; THERMOLYSIN	We have previously demonstrated that the extracellular neutral metalloprotease (Npr) of Streptomyces cacaoi is synthesized as a 60-kDa preproenzyme (P60), then processed to the 35-kDa mature form (P35) (Chang, P. C., Kuo, T.-C., Tsugita, A., and Lee, Y.H. W. (1990) Gene (Amst.) 88, 87-95). In this study, we investigated the active site and the mechanism involved in the maturation of the protease. Site-specific mutations at the putative zinc-binding ligands and active site of Npr at His202, Glu203, His206, and Glu240 led to complete abolishment of Npr activity and concomitant accumulation of a 57-kDa inactive protein (P57) which was secreted. Sequence analysis of the NH2 terminus indicated that P57 was derived from P60 after removal of the signal peptide and represented the proenzyme form of Npr (pro-Npr). Analysis of the zinc content of purified mutant P57 proteins revealed a dramatic loss of zinc atom as compared with the wild-type P35 protein. In vitro with the aid of exogenous active Npr, the mutant P57 protein could be converted to the mature inactive P35 with an identical NH2-terminal sequence and a molecular mass the same as that of the wild-type P35. From these studies, we conclude that these highly conserved residues (His202, Glu203, His206, and Glu240) are indispensable for zinc binding and protease activity, as well as processing of Npr. In addition, we have clearly demonstrated that maturation of Npr occurs extracellularly via an autocatalytic cleavage of the pro-Npr propeptide. This is the first report of such a maturation mechanism for an extracellular protease in streptomycetes which can serve as a model for further studies on the mechanism of secretion and processing of proteases from Gram-positive bacteria.	NATL YANG MING MED COLL,INST BIOCHEM,TAIPEI 112,TAIWAN	National Yang Ming Chiao Tung University				Lee Wu, Yan-Hwa/0000-0001-7299-7354				BEVER RA, 1988, J BACTERIOL, V170, P4309, DOI 10.1128/jb.170.9.4309-4314.1988; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG PC, 1990, GENE, V88, P87, DOI 10.1016/0378-1119(90)90063-W; DELEPELAIRE P, 1989, J BIOL CHEM, V264, P9083; EGNELL P, 1991, GENE, V97, P49, DOI 10.1016/0378-1119(91)90008-Y; EPSTEIN DM, 1988, J BIOL CHEM, V263, P16586; FALCHUK KH, 1988, METHOD ENZYMOL, V158, P422, DOI 10.1016/0076-6879(88)58073-4; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; HEINRICH P, 1987, MOL GEN GENET, V209, P563, DOI 10.1007/BF00331163; HOLMQUIST B, 1974, J BIOL CHEM, V249, P4601; HOPWOOD DA, 1985, GENETIC MANIPULATION, P70; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC, P30; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEWS BW, 1974, J BIOL CHEM, V249, P8030; Narahashi Y., 1970, METHOD ENZYMOL, V19, P651, DOI DOI 10.1016/0076-6879(70)19052-5; OLSEN J, 1988, FEBS LETT, V238, P307, DOI 10.1016/0014-5793(88)80502-7; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; POHLNER J, 1987, NATURE, V325, P458, DOI 10.1038/325458a0; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; RECSEI PA, 1987, P NATL ACAD SCI USA, V84, P1127, DOI 10.1073/pnas.84.5.1127; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sarath G., 1989, PROTEOLYTIC ENZYMES, P25; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; TITANI K, 1972, NATURE-NEW BIOL, V238, P35, DOI 10.1038/newbio238035a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VALLEE BL, 1989, FEBS LETT, V257, P138, DOI 10.1016/0014-5793(89)81805-8; WANDERSMAN C, 1989, MOL MICROBIOL, V3, P1825, DOI 10.1111/j.1365-2958.1989.tb00169.x; WONG SL, 1986, J BIOL CHEM, V261, P176; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	35	19	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3952	3958						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740443				2022-12-25	WOS:A1992HE60700063
J	KIM, YU; CARROLL, MC; ISENMAN, DE; NONAKA, M; PRAMOONJAGO, P; TAKEDA, J; INOUE, K; KINOSHITA, T				KIM, YU; CARROLL, MC; ISENMAN, DE; NONAKA, M; PRAMOONJAGO, P; TAKEDA, J; INOUE, K; KINOSHITA, T			COVALENT BINDING OF C3B TO C4B WITHIN THE CLASSICAL COMPLEMENT PATHWAY C5 CONVERTASE - DETERMINATION OF AMINO-ACID-RESIDUES INVOLVED IN ESTER LINKAGE FORMATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL THIOLESTER BOND; 3RD COMPONENT; 4TH COMPONENT; C-4; PURIFICATION; CLEAVAGE; DNA	C5 convertase of the classical complement pathway is a protein complex consisting of C4b, C2a, and C3b. Within this complex C3b binds to C4b via an ester linkage. We now present evidence that the covalent C3b-binding site on human C4b is Ser at position 1217 of C4. We also show that formation of the covalently linked C4b . C3b complex occurs in the mouse complement system and that the C3b-binding site on mouse C4b is Ser at position 1213 which is homologous to Ser-1217 of human C4. Therefore, covalent binding of C3b to a single specific site on C4b within the classical pathway C5 convertase is likely a common phenomenon in the mammalian complement system. Specific noncovalent association of metastable C3b with C4b would occur first, leading to reaction of the thioester with a specific hydroxy group. This is supported by two lines of experimental evidence, one which shows that a mutant C4 that does not make a covalent linkage with C3b is still capable of forming C5 convertase and a second in which the C4b . C3b complex has been demonstrated by cross-linking erythrocytes bearing this C5 convertase.	OSAKA UNIV, MICROBIAL DIS RES INST, DEPT IMMUNOREGULAT, 3-1 YAMADA OKA, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT BACTERIOL, SUITA, OSAKA 565, JAPAN; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02138 USA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A1, ONTARIO, CANADA; KANAZAWA UNIV, CANC RES INST, DEPT IMMUNOBIOL, KANAZAWA, ISHIKAWA 920, JAPAN	Osaka University; Osaka University; Harvard University; Harvard Medical School; University of Toronto; Kanazawa University			Kinoshita, Taroh/C-7353-2009; NONAKA, MASARU/G-4929-2014		NIAID NIH HHS [AI-22537] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022537] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; BARRIO E, 1991, EUR J IMMUNOL, V21, P343, DOI 10.1002/eji.1830210215; BOLOTIN C, 1977, BIOCHEMISTRY-US, V16, P2008, DOI 10.1021/bi00628a039; CARROLL MC, 1990, P NATL ACAD SCI USA, V87, P6868, DOI 10.1073/pnas.87.17.6868; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HONG KS, 1991, J IMMUNOL, V146, P1868; HSIUNG LM, 1987, MOL IMMUNOL, V24, P91; ISENMAN DE, 1980, J IMMUNOL, V124, P326; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; KINOSHITA T, 1989, BIOCHEM J, V261, P743, DOI 10.1042/bj2610743; KINOSHITA T, 1984, J IMMUNOL METHODS, V71, P247, DOI 10.1016/0022-1759(84)90071-1; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KOZONO H, 1990, J BIOL CHEM, V265, P14444; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAW SKA, 1983, ANN NY ACAD SCI, V421, P246, DOI 10.1111/j.1749-6632.1983.tb18113.x; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NAGASAWA S, 1977, P NATL ACAD SCI USA, V74, P2998, DOI 10.1073/pnas.74.7.2998; NELSON RA, 1966, IMMUNOCHEMISTRY, V3, P111, DOI 10.1016/0019-2791(66)90292-8; NONAKA M, 1985, J BIOL CHEM, V260, P936; OGATA RT, 1989, J BIOL CHEM, V264, P16565; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPINELLA D G, 1984, Complement, V1, P187; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764; TAKATA Y, 1987, J EXP MED, V165, P1494, DOI 10.1084/jem.165.6.1494; THOMAS ML, 1982, P NATL ACAD SCI-BIOL, V79, P1054, DOI 10.1073/pnas.79.4.1054; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOGT W, 1978, IMMUNOLOGY, V34, P29; VOLANAKIS JE, 1990, CURR TOP MICROBIOL, V153, P1	31	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					4171	4176						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740458				2022-12-25	WOS:A1992HE60700089
J	SADDIK, M; LOPASCHUK, GD				SADDIK, M; LOPASCHUK, GD			MYOCARDIAL TRIGLYCERIDE TURNOVER DURING REPERFUSION OF ISOLATED RAT HEARTS SUBJECTED TO A TRANSIENT PERIOD OF GLOBAL-ISCHEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED WORKING HEARTS; FREE FATTY-ACIDS; CANINE MYOCARDIUM; TRIACYLGLYCEROL METABOLISM; MEMBRANE INTERACTIONS; LIPID-METABOLISM; OXIDATION; CARNITINE; PALMITATE; GLUCOSE	Triglyceride turnover in reperfused/ischemic rat hearts was investigated. Hearts were initially perfused under aerobic conditions for a 1-h "pulse" perfusion with 1.2 mM [1-C-14]palmitate to label the endogenous lipid pools, followed by a 30-min period of no-flow ischemia or a 10-min period of retrograde perfusion (control). Hearts were then reperfused under aerobic conditions with buffer containing 1.2 mM [9, 10-H-3] palmitate. All buffers contained 11 mM glucose and 500 microunits/ml insulin. Rates of endogenous triglyceride lipolysis and synthesis were measured during reperfusion, whereas rates of exogenous palmitate oxidation were measured both prior to ischemia and during reperfusion following ischemia. During reperfusion of ischemic hearts, a 20% increase in exogenous fatty acid oxidation rates was seen compared with preischemic rates. Despite an initial burst of endogenous fatty acid oxidation, no acceleration of steady state endogenous triglyceride lipolysis was seen compared with their nonischemic hearts. In contrast, a significant increase in triglyceride synthesis was observed. Triglyceride turnover was also measured in a series of hearts reperfused following ischemia in the absence of exogenous fatty acids. A significant enhancement of functional recovery was seen compared with hearts reperfused with 1.2 mM palmitate. In addition, a significant increase in fatty acid oxidation from endogenous triglyceride lipolysis was observed. We conclude that the heart quickly recovers its ability to oxidize exogenous fatty acids during reperfusion and that although triglyceride lipolysis is not accelerated during reperfusion of ischemic hearts in the presence of 1.2 mM palmitate, a significant increase in triglyceride synthesis does occur.	UNIV ALBERTA, CARDIOVASC DIS RES GRP, 423 HERITAGE MED RES BLDG, EDMONTON T6G 2S2, ALBERTA, CANADA; UNIV ALBERTA, DEPT PEDIAT, LIPID & LIPOPROT RES GRP, EDMONTON T6G 2S2, ALBERTA, CANADA; UNIV ALBERTA, DEPT PHARMACOL, EDMONTON T6G 2S2, ALBERTA, CANADA	University of Alberta; University of Alberta; University of Alberta								BOWYER DE, 1977, J CHROMATOGR, V143, P473, DOI 10.1016/S0378-4347(00)81794-6; CHATELAIN P, 1986, CIRCULATION, V74, P67; CHATZIDAKIS C, 1987, LIPIDS, V22, P620, DOI 10.1007/BF02533939; CORR PB, 1984, CIRC RES, V55, P135, DOI 10.1161/01.RES.55.2.135; CORR PB, 1982, J MOL CELL CARDIOL, V14, P619, DOI 10.1016/0022-2828(82)90159-6; CRASS MF, 1975, AM J PHYSIOL, V229, P885; CRASS MF, 1977, FED PROC, V36, P1995; FOX KAA, 1985, CIRC RES, V57, P232, DOI 10.1161/01.RES.57.2.232; GRIFFITHS EJ, 1990, J MOL CELL CARDIOL, V22, P303, DOI 10.1016/0022-2828(90)91463-H; HEATHERS GP, 1985, J MOL CELL CARDIOL, V17, P907, DOI 10.1016/S0022-2828(85)80104-8; JESMOK GJ, 1978, CARDIOVASC RES, V12, P659, DOI 10.1093/cvr/12.11.659; KATZ AM, 1981, CIRC RES, V48, P1; LARSEN TJ, 1990, J MOL CELL CARDIO S3, V22, pL55; LIEDTKE AJ, 1988, CIRC RES, V62, P535, DOI 10.1161/01.RES.62.3.535; LIEDTKE AJ, 1981, PROG CARDIOVASC DIS, V23, P321, DOI 10.1016/0033-0620(81)90019-0; LIEDTKE AJ, 1988, J MOL CELL CARDIOL, V20, P65, DOI 10.1016/0022-2828(88)90333-1; LOPASCHUK GD, 1988, CIRC RES, V63, P1036, DOI 10.1161/01.RES.63.6.1036; LOPASCHUK GD, 1990, CIRC RES, V66, P546, DOI 10.1161/01.RES.66.2.546; LOPASCHUK GD, 1989, CIRC RES, V65, P378, DOI 10.1161/01.RES.65.2.378; LOPASCHUK GD, 1987, CIRC RES, V61, P853, DOI 10.1161/01.RES.61.6.853; MCDONOUGH KH, 1988, J MOL CELL CARDIOL, V20, P31, DOI 10.1016/0022-2828(88)90330-6; MCDONOUGH KH, 1979, FED PROC, V38, P894; MCMILLINWOOD J, 1977, BIOCHEM BIOPH RES CO, V74, P677; MCVEIGH JJ, 1990, AM J PHYSIOL, V259, pH1079, DOI 10.1152/ajpheart.1990.259.4.H1079; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; NIMMO H G, 1981, Biochemical Society Transactions, V9, p238P; OLIVER MF, 1968, LANCET, V1, P710; OPIE LH, 1976, AM J CARDIOL, V38, P310, DOI 10.1016/0002-9149(76)90173-9; OWENS K, 1982, AM J PHYSIOL, V242, pH456, DOI 10.1152/ajpheart.1982.242.3.H456; PAULSON DJ, 1986, BASIC RES CARDIOL, V81, P180, DOI 10.1007/BF01907382; PAULSON DJ, 1982, AM J PHYSIOL, V242, P1084, DOI 10.1152/ajpheart.1982.242.6.H1084; PAULY DF, 1991, CIRC RES, V68, P1085, DOI 10.1161/01.RES.68.4.1085; PIPER HM, 1983, BIOCHIM BIOPHYS ACTA, V732, P193, DOI 10.1016/0005-2736(83)90203-1; PRINZEN FW, 1984, AM J PHYSIOL, V247, pH264, DOI 10.1152/ajpheart.1984.247.2.H264; RIDER MH, 1983, BIOCHEM J, V214, P235, DOI 10.1042/bj2140235; SADDIK M, 1991, J BIOL CHEM, V266, P8162; SCHOONDERWOERD K, 1989, MOL CELL BIOCHEM, V88, P129, DOI 10.1007/BF00223434; SCHWAIGER M, 1985, J AM COLL CARDIOL, V6, P336, DOI 10.1016/S0735-1097(85)80169-8; SCHWAIGER M, 1985, J AM COLL CARDIOL, V6, P311, DOI 10.1016/S0735-1097(85)80166-2; SEVERSON DL, 1982, J MOL CELL CARDIOL, V14, P467, DOI 10.1016/0022-2828(82)90153-5; VANBILSEN M, 1989, CIRC RES, V64, P304, DOI 10.1161/01.RES.64.2.304; VANDERVUSSE GJ, 1982, CIRC RES, V50, P538, DOI 10.1161/01.RES.50.4.538; VEERKAMP JH, 1986, BIOCHEM MED METAB B, V35, P248, DOI 10.1016/0885-4505(86)90080-0; WHITMER JT, 1978, J BIOL CHEM, V253, P4305; WILLIAMSON JR, 1964, J BIOL CHEM, V239, P2721	45	80	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1992	267	6					3825	3831						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HE607	1740430				2022-12-25	WOS:A1992HE60700045
J	GRIEP, MA; MCHENRY, CS				GRIEP, MA; MCHENRY, CS			FLUORESCENCE ENERGY-TRANSFER BETWEEN THE PRIMER AND THE BETA SUBUNIT OF THE DNA POLYMERASE-III HOLOENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BINDING-PROTEIN; ESCHERICHIA-COLI THIOREDOXIN; ACID REPLICATION INVITRO; LARGE KLENOW FRAGMENT; INITIATION COMPLEX; EXONUCLEASE ACTIVITY; T7-DNA POLYMERASE; ATP ACTIVATION; SIZE CLASSES; BACTERIOPHAGE-T7	We report here our initial success in using fluorescence energy transfer to map the position of the subunits of the DNA polymerase III holoenzyme within initiation complexes formed on primed DNA. Using primers containing a fluorescent derivative 3 nucleotides from the 3'-terminus and acceptors of fluorescence energy transfer located on Cys333 of the beta-subunit, a donor-acceptor distance of 65 angstrom was measured. Coupling this distance with other information enabled us to propose a model for the positioning of beta-within initiation complexes. Examination of the fluorescence properties of a labeled primer with the unlabeled beta-subunit and other assemblies of DNA polymerase III holoenzyme subunits allowed us to distinguish all of the known intermediates of the holoenzyme-catalyzed reaction. Specific fluorescence changes could be assigned for primer annealing, Escherichia coli single-stranded DNA-binding protein binding, 3' --> 5' exonucleolytic hydrolysis of the primer, DNA polymerase III* binding, initiation complex formation upon the addition of beta in the presence of ATP, and DNA elongation. These fluorescence changes are sufficiently large to support future detailed kinetic studies. Particularly interesting was the difference in fluorescence changes accompanying initiation complex formation as compared to binding of DNA polymerase III holoenzyme subunit assemblies. Initiation complex formation resulted in a strong fluorescence enhancement. Binding of DNA polymerase III* led to a fluorescence quenching, and transfer of beta to primed DNA by the gamma-delta complex did not change the fluorescence. This demonstrates a rearrangement of subunits accompanying initiation complex formation. Monitoring fluorescence changes with labeled beta, we have determined that beta-binds with a stoichiometry of one monomer/primer terminus.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NIGMS NIH HHS [R01 GM35695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOR S, 1987, P NATL ACAD SCI USA, V84, P4767; ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P9586, DOI 10.1021/bi00451a006; ALLEN DJ, 1989, BIOCHEMISTRY-US, V28, P4601, DOI 10.1021/bi00437a014; BERKOWITZ SA, 1971, BIOCHEMISTRY-US, V13, P4825; BUJALOWSKI W, 1986, BIOCHEMISTRY-US, V25, P7799, DOI 10.1021/bi00372a003; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; CATALANO CE, 1990, BIOCHEMISTRY-US, V29, P3612, DOI 10.1021/bi00467a004; DOSREMEDIOS CG, 1987, J MUSCLE RES CELL M, V8, P97, DOI 10.1007/BF01753986; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; GIBSON KJ, 1987, NUCLEIC ACIDS RES, V15, P6455, DOI 10.1093/nar/15.16.6455; GLIKIN GC, 1983, NATURE, V303, P770, DOI 10.1038/303770a0; GRIEP MA, 1990, BIOCHEMISTRY-US, V29, P9006, DOI 10.1021/bi00490a018; GRIEP MA, 1988, BIOCHEMISTRY-US, V27, P5210, DOI 10.1021/bi00414a040; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; GRIEP MA, 1990, J BIOL CHEM, V265, P20356; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; JOHANSON KO, 1982, J BIOL CHEM, V257, P2310; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; KUWABARA N, 1981, P NATL ACAD SCI-BIOL, V78, P5764, DOI 10.1073/pnas.78.9.5764; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LANGOWSKI J, 1985, BIOCHEMISTRY-US, V24, P4022, DOI 10.1021/bi00336a033; LASKEN RS, 1987, J BIOL CHEM, V262, P1720; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P1; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6561; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MODRICH P, 1975, J BIOL CHEM, V250, P5508; MOK M, 1987, J BIOL CHEM, V262, P16644; MOLINEUX IJ, 1975, NUCLEIC ACIDS RES, V2, P1821, DOI 10.1093/nar/2.10.1821; MYERS TW, 1988, J BIOL CHEM, V263, P17006; OBERFELDER R, 1987, J BIOL CHEM, V262, P4190; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1989, J BIOL CHEM, V264, P6447; TOMASIEWICZ HG, 1987, J BACTERIOL, V169, P5735, DOI 10.1128/jb.169.12.5735-5744.1987; WEBER G, 1957, T FARADAY SOC, V53, P646, DOI 10.1039/tf9575300646; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P3679, DOI 10.1073/pnas.70.12.3679; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	52	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3052	3059						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737760				2022-12-25	WOS:A1992HD15400038
J	TIFFT, CJ; PROIA, RL; CAMERINIOTERO, RD				TIFFT, CJ; PROIA, RL; CAMERINIOTERO, RD			THE FOLDING AND CELL-SURFACE EXPRESSION OF CD4 REQUIRES GLYCOSYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; N-LINKED OLIGOSACCHARIDE; CHAIN BINDING-PROTEIN; INTRACELLULAR-TRANSPORT; LYMPHOCYTES-T; HIV; HEMAGGLUTININ; DOMAIN; SITES; GLYCOPROTEIN	Human CD4, a monomeric T cell surface glycoprotein, is required for T helper cell activation and is also the receptor for the human immunodeficiency virus. There have been conflicting reports as to whether glycosylation of CD4 is required for its cell surface expression. To clarify the effect of glycosylation on surface expression, folding, and intracellular sorting of CD4, we generated a series of mutant cDNAs in which one, the other, or both glycosylation recognition sites were eliminated. Using in vitro transcription and translation we confirmed that both potential glycosylation sites of CD4 were utilized. Transient expression of the mutants in HeLa cells demonstrated that glycosylation at either site was necessary and sufficient for cell surface expression. Finally, we showed that unglycosylated CD4 produced in HeLa cells was incorrectly folded and retained intracellularly, probably in the endoplasmic reticulum.			TIFFT, CJ (corresponding author), NIDDKD, GENET & BIOCHEM BRANCH, BLDG 10, RM 9D 15, BETHESDA, MD 20892 USA.		Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270				ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; BALTIMORE D, 1988, NATURE, V335, P395, DOI 10.1038/335395a0; BASCH RS, 1990, P NATL ACAD SCI USA, V87, P8085, DOI 10.1073/pnas.87.20.8085; BEDINGER P, 1988, NATURE, V334, P162, DOI 10.1038/334162a0; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BUONOCORE L, 1990, NATURE, V345, P625, DOI 10.1038/345625a0; DOYLE C, 1989, IMMUNOL REV, V109, P17, DOI 10.1111/j.1600-065X.1989.tb00018.x; EAGLE H, 1971, SCIENCE, V174, P500, DOI 10.1126/science.174.4008.500; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; KLATZMANN D R, 1990, Immunodeficiency Reviews, V2, P43; KONIG R, 1988, J BIOL CHEM, V263, P9502; KONIG R, 1989, BIOENGINEERED MOL BA, P57; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; LUCEY DR, 1989, J EXP MED, V169, P327, DOI 10.1084/jem.169.1.327; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NG DTW, 1990, MOL CELL BIOL, V10, P1989, DOI 10.1128/MCB.10.5.1989; NICHOLSON JKA, 1986, J IMMUNOL, V137, P323; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOSAGUADO J, 1987, MOL CELL BIOL, V7, P982, DOI 10.1128/MCB.7.3.982; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SONDERFELDFRESKO S, 1988, J BIOL CHEM, V263, P13463; STEWART SJ, 1986, J IMMUNOL, V136, P3773; VIDAL S, 1989, J VIROL, V63, P892, DOI 10.1128/JVI.63.2.892-900.1989; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WELLINGHAM MC, 1990, FOCUS, V12, P62	38	41	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 15	1992	267	5					3268	3273						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HD154	1737783				2022-12-25	WOS:A1992HD15400071
J	LIU, F; DONG, Q; FROMM, HJ				LIU, F; DONG, Q; FROMM, HJ			SITE-DIRECTED MUTAGENESIS OF THE PHOSPHATE-BINDING CONSENSUS SEQUENCE IN ESCHERICHIA-COLI ADENYLOSUCCINATE SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; NUCLEOTIDE-SEQUENCE; PROTEIN-KINASE; MESSENGER-RNA; ATP-BINDING; FAMILY; TRANSDUCERS; MODEL; GENE; DNA	Adenylosuccinate synthetases from different sources contain an N-terminal glycine-rich sequence GDEGKGK, which is homologous to the conserved sequence GXXXXGK found in many other guanine nucleotide-binding proteins or enzymes. To determine the role of this sequence in the structure and function of Escherichia coli adenylosuccinate synthetase, site-directed mutagenesis was performed to generate five mutant enzymes: G12V (Gly12 --> Val), G15V (Gly15 --> Val), G17V (Gly17 --> Val), K18R (Lys18 --> Arg), and I19T (Ile19 --> Thr). Comparison of the kinetic properties of the wild-type enzyme and those of the mutant enzymes revealed that the sequence is critical for enzyme activity. Replacement of Gly12, Gly15, or Gly17 with Val, or replacement of Lys18 with Arg, resulted in significant decreases in the k(cat)/K(m) values of the enzyme. Because the consensus sequence GXXXXGK(T/S) has been found in many GTP-binding proteins, isoleucine at position 19 in the E. coli adenylosuccinate synthetase was changed to threonine to produce the sequence GDEGKGKT. This mutation, which more closely resembles the consensus sequence, resulted in a 160-fold increase in the K(m) value for substrate GTP; however, there were no great changes for the other two substrates, IMP and aspartate. Based on these data, we suggest that the N-terminal glycine-rich sequence in E. coli adenylosuccinate synthetase plays a more important role in enzyme catalysis than in substrate binding. In addition, a hydrophobic amino acid residue such as isoleucine, leucine, or valine, rather than threonine, may play a critical role in GTP binding in adenosuccinate synthetase. These findings suggest that the glycine-rich sequence in adenylosuccinate synthetase functions differently relative to those in other GTP binding proteins or enzymes.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BEALE EG, 1985, J BIOL CHEM, V260, P748; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COOK JS, 1986, P NATL ACAD SCI USA, V83, P7583, DOI 10.1073/pnas.83.20.7583; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DONG Q, 1991, J BIOL CHEM, V266, P12228; DONG Q, 1990, J BIOL CHEM, V265, P6235; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HIGGINS CF, 1988, BIOESSAYS, V8, P111, DOI 10.1002/bies.950080406; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P283; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TAYLOR SS, 1989, J BIOL CHEM, V264, P8443; TOMASSELLI AG, 1986, FEBS LETT, V202, P303, DOI 10.1016/0014-5793(86)80706-2; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WOLFE SA, 1988, J BIOL CHEM, V263, P19147	31	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2388	2392						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733940				2022-12-25	WOS:A1992HB53200044
J	MORONI, MC; WILLINGHAM, MC; BEGUINOT, L				MORONI, MC; WILLINGHAM, MC; BEGUINOT, L			EGF-R ANTISENSE RNA BLOCKS EXPRESSION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR AND SUPPRESSES THE TRANSFORMING PHENOTYPE OF A HUMAN CARCINOMA CELL-LINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTO-ONCOGENE; FACTOR-ALPHA; OLIGOMER COMPLEMENTARY; INHIBITS PROLIFERATION; TRANSLATION INVIVO; GENE-EXPRESSION; 3T3 CELLS; KB CELLS; INVITRO	We have used an antisense approach to investigate the role of overexpression of the normal human epidermal growth factor (EGF) receptor in the transformed phenotype of KB cells, which are a tumor derived human cell line. Initial experiments performed in vitro, showed that antisense RNA complementary to the entire coding region (AS-FL) or to parts of the EGF-R mRNA (AS-3', AS-5', and AS-K) effectively blocked translation of EGF-R mRNA. In addition, upon microinjection into KB cells, the in vitro synthesized antisense RNAs were able to inhibit transiently the synthesis of EGF-R. Inhibition was concentration-dependent, both in vitro and in cells, and the most effective constructs were those complementary to the entire coding region (ASFL) or to the 3'-coding end of the mRNA (AS-3'). Transfection of the same EGF-R antisense RNA constructs into the human epidermoid carcinoma KB cell line gave rise to several clones stably expressing elevated levels of antisense RNA and resulting in low residual levels of EGF receptor. The most reduced clones exhibited a totally restored serum-dependent growth and were severely impaired in colony formation and growth in agar. In addition the severity of the phenotype was directly proportional to the residual amount of EGF-R expressed. We conclude that over-expression of normal EGF-R plays a direct primary role in the development of the transformed phenotype of this human cancer cell line.	UNIV COPENHAGEN,INST MICROBIOL,DK-1353 COPENHAGEN,DENMARK; NIH,MOLEC BIOL LAB,BETHESDA,MD 20892	University of Copenhagen; National Institutes of Health (NIH) - USA			Moroni, Maria Cristina/H-7044-2018	Moroni, Maria Cristina/0000-0003-2409-5764				ABOUDPIRAK E, 1988, J NATL CANCER I, V80, P1605, DOI 10.1093/jnci/80.20.1605; AMANO F, 1988, J CELL PHYSIOL, V135, P502, DOI 10.1002/jcp.1041350319; AMINI S, 1986, MOL CELL BIOL, V6, P2305, DOI 10.1128/MCB.6.7.2305; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BEGUINOT L, 1985, P NATL ACAD SCI USA, V82, P2774, DOI 10.1073/pnas.82.9.2774; BEGUINOT L, 1986, J BIOL CHEM, V261, P1801; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUSS JE, 1982, P NATL ACAD SCI-BIOL, V79, P2574, DOI 10.1073/pnas.79.8.2574; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK AJL, 1986, BIOCHIM BIOPHYS ACTA, V867, P244, DOI 10.1016/0167-4781(86)90040-0; CLARK AJL, 1985, P NATL ACAD SCI USA, V82, P8374, DOI 10.1073/pnas.82.24.8374; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HALEY JD, 1989, ONCOGENE, V4, P273; HELIN K, 1991, ONCOGENE, V6, P825; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IZANT JG, 1985, SCIENCE, V229, P346; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LYALL RM, 1987, CANCER RES, V47, P2961; Maniatis T, 1989, DECONTAMINATION DILU; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P144, DOI 10.1073/pnas.82.1.144; MENDEHLSON J, 1988, T AM CLIN CLIMAT ASS, V100, P131; MERLINO GT, 1985, MOL CELL BIOL, V5, P1722, DOI 10.1128/MCB.5.7.1722; NICHOLSON S, 1988, INT J CANCER, V42, P36, DOI 10.1002/ijc.2910420108; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1447; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WEHLAND J, 1981, CELL, V25, P105; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YAMAMOTO T, 1986, CANCER RES, V46, P414	54	95	107	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2714	2722						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733967				2022-12-25	WOS:A1992HB53200091
J	ZENZIEGREGORY, B; OSHEAGREENFIELD, A; SMALE, ST				ZENZIEGREGORY, B; OSHEAGREENFIELD, A; SMALE, ST			SIMILAR MECHANISMS FOR TRANSCRIPTION INITIATION MEDIATED THROUGH A TATA BOX OR AN INITIATOR ELEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; MAJOR LATE PROMOTER; FUNCTIONAL STEPS; BINDING; SITE; SP1; IDENTIFICATION; ACTIVATION; SEQUENCES; UPSTREAM	Previous studies have identified several biochemical parameters that resolve promoter-specific transcription initiation by RNA polymerase II into distinct steps. We have employed these parameters to compare the mechanisms of initiation mediated through either a TATA box or a transcriptional initiator element. Time course experiments revealed that initiator-mediated transcription in a cell-free extract does not display the lag period typically found with TATA-mediated transcription. Titration experiments with increasing amounts of extract revealed further differences between TATA- and initiator-mediated transcription, again suggesting that different steps are rate-limiting. In contrast, experiments with the detergent Sarkosyl, which is believed to define later steps in the initiation process, revealed a striking degree of similarity between TATA- and initiator-mediated transcription. Additional similarities were found using dinucleotide priming experiments, which are believed to measure the flexibility of initiation after RNA polymerase II is positioned over the transcription start site region. Taken together, these results suggest that the location of a preinitiation complex can be determined by core promoter recognition through either a TATA box or an initiator element. However, following these distinct template recognition events, the steps leading to initiation may be very similar and may proceed in a DNA sequence-independent manner.	UNIV CALIF LOS ANGELES,SCH MED,HOWARD HUGHES MED INST,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								AYER DE, 1988, MOL CELL BIOL, V8, P2021, DOI 10.1128/MCB.8.5.2021; BEAUPAIN D, 1990, NUCLEIC ACIDS RES, V18, P6509, DOI 10.1093/nar/18.22.6509; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Carey M, 1991, CURR OPIN CELL BIOL, V3, P452, DOI 10.1016/0955-0674(91)90073-8; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; FIRE A, 1984, J BIOL CHEM, V259, P2509; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT MC, 1989, MOL CELL BIOL, V9, P3299, DOI 10.1128/MCB.9.8.3299; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285	27	88	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1992	267	4					2823	2830						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	HB532	1733976				2022-12-25	WOS:A1992HB53200106
J	LAMORTE, VJ; GOLDSMITH, PK; SPIEGEL, AM; MEINKOTH, JL; FERAMISCO, JR				LAMORTE, VJ; GOLDSMITH, PK; SPIEGEL, AM; MEINKOTH, JL; FERAMISCO, JR			INHIBITION OF DNA-SYNTHESIS IN LIVING CELLS BY MICROINJECTION OF GI2 ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PERTUSSIS TOXIN; FACTOR-II; PROTEIN; GROWTH; IDENTIFICATION; SERUM; ACID	Heterotrimeric guanine nucleotide binding proteins function in the coupling of a diverse span of cell surface receptors to a variety of intracellular signaling pathways, some of which stimulate cellular proliferation. With the recent discovery that mutated forms of G proteins are present in specific tumors, there has been an increased interest in the determination of the role of specific subtypes of G proteins in the regulation of cellular growth. We have attempted to determine which subtypes of G proteins are directly involved in serum-stimulated DNA synthesis through microinjection of inhibitory antibodies into living cells. Inhibitory rabbit polyclonal antibodies directed against specific G(i) alpha-subunits were introduced into living Balb/c 3T3 fibroblasts by microinjection, and the effect upon serum-stimulated DNA synthesis was examined. Results of these experiments indicate that G(i2) plays a direct role in serum-stimulated DNA synthesis in living cells and suggest that G proteins may function in a variety of mitogenic signaling pathways initiated by serum growth factors.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093; NIDDKD,MOLEC PATHOPHYSIOL BRANCH,BETHESDA,MD 20892	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LAMORTE, VJ (corresponding author), UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093, USA.		Meinkoth, Judy L/G-2900-2010					BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOURNE HR, 1991, FASEB J, V5, pA699; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GUPTA SK, 1991, FASEB J, V5, pA884; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KOGIMA I, 1988, J BIOL CHEM, V263, P16561; LETTERIO JJ, 1986, SCIENCE, V234, P1117, DOI 10.1126/science.3465038; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809	18	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					691	694						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730660				2022-12-25	WOS:A1992GY96000004
J	LEE, RM; COBB, MH; BLACKSHEAR, PJ				LEE, RM; COBB, MH; BLACKSHEAR, PJ			EVIDENCE THAT EXTRACELLULAR SIGNAL-REGULATED KINASES ARE THE INSULIN-ACTIVATED RAF-1 KINASE KINASES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; RIBOSOMAL-PROTEIN S6; 3T3-L1 ADIPOCYTES; PHOSPHORYLATION; RECEPTOR; TYROSINE; CELLS; PROTOONCOGENE; TRANSDUCTION; INVITRO	The Raf-1 proto-oncogene protein kinase can be phosphorylated and activated after stimulation of cells with insulin and a variety of other growth factors and mitogens. We recently presented evidence that insulin and certain other growth factors activated one or more Raf-1 kinase kinase activities (Lee, R. M., Rapp, U. R., and Blackshear, P. J. (1991) J. Biol. Chem. 266, 10351-10357). In the present study, four peaks of Raf-1 kinase kinase activity were identified after anion-exchange chromatography of cell lysates, and two of these were activated by insulin. Further chromatographic characterization of these two peaks of insulin-activated kinase activity indicated that they contained three apparently distinct kinase activities. Two of these activities comigrated with immunoreactive extracellular signal-regulated kinases (ERK) 1 and 2 (mitogen-activated protein kinase) through three different chromatographic separations. Both ERK1 and ERK2 phosphorylated Raf-1 with reasonably high affinity (K(m) for ERK1 = 90 nM; K(m) for ERK2 = 120 nM), and produced similar, complex phosphopeptide maps; both kinases also phosphorylated myelin basic protein. The third kinase activity also phosphorylated Raf-1 and myelin basic protein but did not comigrate exactly with either immunoreactive ERK1 or ERK2. We conclude that two and possibly three insulin-activated Raf-1 kinase kinases are members of the ERK family.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST LABS,BOX 3897,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV ENDOCRINOL METAB & GENET,DIABET & METAB SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Duke University; Duke University; Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529; Cobb, Melanie/0000-0003-0833-5473				AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11495; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; COBB MH, 1986, J BIOL CHEM, V261, P2994; CZECH MP, 1988, J BIOL CHEM, V263, P11017; HAYSTEAD TA, 1991, J BIOL CHEM, V266, P16571; IZUMI T, 1991, J BIOL CHEM, V266, P7933; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LEE RM, 1991, J BIOL CHEM, V266, P10351; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RAY LB, 1988, J BIOL CHEM, V263, P12721; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SEIGEL JN, 1990, J BIOL CHEM, V265, P18472; SMITH CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2641, DOI 10.1073/pnas.77.5.2641; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	40	101	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1088	1092						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730637				2022-12-25	WOS:A1992GY96000066
J	YAO, ZM; BLACKHART, BD; JOHNSON, DF; TAYLOR, SM; HAUBOLD, KW; MCCARTHY, BJ				YAO, ZM; BLACKHART, BD; JOHNSON, DF; TAYLOR, SM; HAUBOLD, KW; MCCARTHY, BJ			ELIMINATION OF APOLIPOPROTEIN-B48 FORMATION IN RAT HEPATOMA-CELL LINES TRANSFECTED WITH MUTANT HUMAN APOLIPOPROTEIN-B CDNA CONSTRUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; STOP CODON; INTESTINE; EXPRESSION; LIVER	Rat hepatoma McA-RH7777 cell lines transfected with full-length human apolipoprotein (apo) B constructs produce mostly human apoB48 and only small amounts of apoB100, as a result of mRNA editing at codon 2153 (C to U conversion at nucleotide 6666). To abolish the formation of apoB48 and increase the yield of apoB100 and other forms of apoB longer than apoB48, site-specific mutations were introduced at or near the site of apoB mRNA editing. Among four mutations examined, only that in which codon 2153 was converted from CAA (Gln) to CTA (Leu) effectively precluded the formation of apoB48. In this mutant, a stop codon would not be generated even if the C to U conversion occurred. The three other mutations were introduced to disrupt the proposed stem-loop structure encompassing the editing site. Changes made in the third positions of five codons on the 5' side of the edited base or of four codons 3' of the edited base failed to eliminate the production of a protein with the approximate size of apoB48. A construct in which codon 2153 was changed from CAA to GAT (Asp) also failed to eliminate the production of a protein the size of apoB48. Analysis of the region between nucleotides 6200 and 6900 of the cDNA did not detect any prevalent alternate editing sites. Immunoblot analysis using polyclonal antibodies raised against synthetic peptides of human apoB100 indicated that the carboxyl terminus of the apoB48-like proteins probably resides between amino acid residues 2068 and 2129 of apoB100. These results provide some insight into the mechanism of apoB mRNA editing and will facilitate further studies on apoB-containing lipoproteins.			YAO, ZM (corresponding author), UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,GLADSTONE FDN,CARDIOVASC DIS LABS,POB 40608,SAN FRANCISCO,CA 94140, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOSTROM K, 1989, J BIOL CHEM, V264, P15701; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIDSON NO, 1988, J BIOL CHEM, V263, P13482; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; HODGES PE, 1991, NUCLEIC ACIDS RES, V19, P1197, DOI 10.1093/nar/19.6.1197; INNERARITY TL, 1987, J CLIN INVEST, V80, P1794, DOI 10.1172/JCI113273; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MILNE R, 1989, J BIOL CHEM, V264, P19754; NAVARATNAM N, 1991, NUCLEIC ACIDS RES, V19, P1741, DOI 10.1093/nar/19.8.1741; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SCOTT J, 1989, GUT, V30, P35, DOI 10.1136/gut.30.Spec_No.35; TENNYSON GE, 1989, P NATL ACAD SCI USA, V86, P500, DOI 10.1073/pnas.86.2.500; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1991, J BIOL CHEM, V266, P3300	21	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1992	267	2					1175	1182						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY960	1730641				2022-12-25	WOS:A1992GY96000078
J	LEYH, TS; SUO, Y				LEYH, TS; SUO, Y			GTPASE-MEDIATED ACTIVATION OF ATP SULFURYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; RHIZOBIUM-MELILOTI; ESCHERICHIA-COLI; ELONGATION; PROTEIN; CHROMATOGRAPHY; SULFATION; PANCREAS; SEQUENCE; DOMAIN	GTP stimulates the synthesis of APS (adenosine 5'-phosphosulfate) by the enzyme ATP sulfurylase (ATP:sulfate adenylyltransferase, EC 2.7.7.4) via a GTPase mechanism. The activation of the enzyme, purified from Escherichia coli, is titratable with GTP. The initial rate of APS formation is increased 116-fold at a saturating concentration of GTP. The enzyme exhibits a GTPase activity that is stimulated by ATP and further enhanced by SO4; however, SO4 alone does not significantly stimulate GTP hydrolysis. The larger subunit of ATP sulfurylase, encoded by cysN, contains a GTP-binding consensus sequence common to other known GTP-binding proteins. This is the first evidence that the sulfate activation pathway is a metabolic target for regulation by a GTPase.			LEYH, TS (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043003] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43003-01] Funding Source: Medline; DRS NIH HHS [BRSG 613-4743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DRS NIH HHS		ARAI K, 1980, P NATL ACAD SCI-BIOL, V77, P1326, DOI 10.1073/pnas.77.3.1326; BADDILEY J, 1957, J CHEM SOC, P1067, DOI 10.1039/jr9570001067; BEAUERLE PA, 1984, EMBO J, V3, P2209; BEAUERLE PA, 1987, J CELL BIOL, V105, P2655; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND SJ, 1984, NATURE, V309, P456, DOI 10.1038/309456a0; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; BRANDT DR, 1985, J BIOL CHEM, V260, P266; Cleland W W, 1979, Methods Enzymol, V63, P103; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DEVERED D, 1986, CIBA F S, V124; GODCHAUX W, 1979, J BIOL CHEM, V254, P7874; HERZOG V, 1985, European Journal of Cell Biology, V39, P399; HUNTSBERGER DV, 1970, STATISTICAL INFERENC, P167; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; JEVONS FR, 1963, BIOCHEM J, V89, P621, DOI 10.1042/bj0890621; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KARP DR, 1983, J BIOL CHEM, V258, P2745; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LEYH TS, 1988, J BIOL CHEM, V263, P2409; MORITA T, 1986, J BIOL CHEM, V261, P4008; NYE L, 1988, AM BIOTECHNOL LAB, V6, P18; OVCHINNIKOV YA, 1982, FEBS LETT, V139, P130, DOI 10.1016/0014-5793(82)80503-6; PLOWMAN KM, 1965, BIOCHEMISTRY-US, V4, P2809, DOI 10.1021/bi00888a035; ROBBINS PW, 1958, J BIOL CHEM, V233, P686; SCHWEDOCK J, 1990, NATURE, V348, P644, DOI 10.1038/348644a0; SCHWEDOCK J, 1989, Molecular Plant-Microbe Interactions, V2, P181, DOI 10.1094/MPMI-2-181; SIEGEL LM, 1975, METABOLIC PATHWAYS, V7, P217; TRAYER IP, 1974, BIOCHEM J, V139, P609, DOI 10.1042/bj1390609; UNSWORTH CD, 1982, NATURE, V295, P519, DOI 10.1038/295519a0	34	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1992	267	1					542	545						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GY439	1730615				2022-12-25	WOS:A1992GY43900085
J	MCGREW, BR; NICHOLS, DW; STANTON, VP; CAI, H; WHORF, RC; PATEL, V; COOPER, GM; LAUDANO, AP				MCGREW, BR; NICHOLS, DW; STANTON, VP; CAI, H; WHORF, RC; PATEL, V; COOPER, GM; LAUDANO, AP			PHOSPHORYLATION OCCURS IN THE AMINO TERMINUS OF THE RAF-1 PROTEIN	ONCOGENE			English	Article								The ability of the Raf-1 protein to morphologically transform murine fibroblasts can be activated by amino-terminal deletions or substitutions. We have compared the phosphorylation states of full-length and representative transforming and non-transforming amino-terminal deletion mutants of the Raf-1 protein using phosphoamino acid analysis and tryptic phosphopeptide mapping. Several [P-32]orthophosphate-labeled tryptic phosphopeptides that were present in the full-length Raf-1 protein were absent from the highly transforming 22W Raf-1 mutant (lacking 305 amino-terminal residues). Peptide-specific antisera localized Raf-1 phosphorylation sites to several amino-terminal cyanogen bromide and tryptic peptides that are deleted from the 22W protein. A major phosphorylated tryptic peptide of the Raf-1 protein was immunoprecipitated by antiserum directed against amino acid residues 257-275, a highly conserved region of the raf family. This tryptic peptide is entirely deleted from the highly transforming 22W protein. Subtractive Edman degradation and electrophoretic analysis of the immunoprecipitated tryptic peptide indicated that phosphorylation of the Raf-1 protein occurs at serine 259. Multiple phosphorylated tryptic peptide forms were immunoprecipitated by antiserum directed against Raf-1 residues 283-309. The majority of this tryptic peptide is also deleted from the highly transforming Raf-1 mutant 22W.	UNIV NEW HAMPSHIRE, DEPT BIOCHEM, SPAULDING LIFE SCI BLDG, DURHAM, NH 03824 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	University System Of New Hampshire; University of New Hampshire; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Stanton, Vincent/0000-0002-2205-6000	NCI NIH HHS [CA18689, K08 CA01052] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018689, K08CA001052] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; FIOL CJ, 1987, J BIOL CHEM, V262, P14042; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GRAY WR, 1970, ANAL BIOCHEM, V33, P36, DOI 10.1016/0003-2697(70)90436-7; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; ISHIKAWA F, 1988, ONCOGENE, V3, P653; KAGAN A, 1979, METHOD HORM RADIOIMM, P328; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MITSUNOBU F, 1989, ONCOGENE, V4, P437; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; OSHIMA RG, 1981, J BIOL CHEM, V256, P8124; PANTAZIS P, 1981, J BIOL CHEM, V256, P4669; PERCY ME, 1972, ANAL BIOCHEM, V45, P60, DOI 10.1016/0003-2697(72)90007-3; PICTON C, 1982, FEBS LETT, V150, P191, DOI 10.1016/0014-5793(82)81332-X; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1988, HDB ONCOGENES, P213; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Stewart JM, 1984, SOLID PHASE PEPTIDE; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247	42	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					33	42						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741164				2022-12-25	WOS:A1992HC22700005
J	TRAUB, LM; SAGIEISENBERG, R				TRAUB, LM; SAGIEISENBERG, R			PURIFICATION OF P100, A PROTEIN ANTIGENICALLY RELATED TO THE SIGNAL TRANSDUCING-G PROTEINS GT AND GI - EVIDENCE FOR AN ADAPTIN-LIKE PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DECAPEPTIDE; NUCLEOTIDE-BINDING-PROTEINS; SYNTHETIC PEPTIDES; ADENYLYL CYCLASE; ALPHA-SUBUNITS; DYE-BINDING; IDENTIFICATION; ANTIBODIES; RECEPTOR; CLATHRIN	A 100-kDa protein, termed p100, cross-reacts with antisera raised against a synthetic peptide corresponding to the carboxyl-terminal decapeptide of the alpha-subunit of the retinal G protein G(t). p100 is abundantly expressed in liver and, on subcellular fractionation of rat liver homogenates, is distributed between the cytosolic and microsome fractions (Traub, L. M., Evans, W. H., and Sagi-Eisenberg, R. (1990) Biochem. J. 272, 453-458; Udrisar, D., and Rodbell, M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 6321-6325). We have now purified p100 to near-homogeneity from rat liver microsomes. The protein was purified approximately 500-fold by ATP extraction followed by a series of four chromatographic steps. Similar to partially purified p100, on two-dimensional electrophoresis, the final preparation contained a major series of five immunoreactive 100-kDa charge isoforms. Partial amino terminus amino acid sequencing of the purified protein revealed that p100 is a previously unidentified protein. Further analysis of the soluble form of p100 showed the protein migrated with an apparent molecular weight of approximately 110,000 on gel filtration, indicating that the soluble protein occurs as a monomeric polypeptide. The soluble form of p100 was also partially purified from rat liver cytosol and amino acid sequencing yielded the same amino-terminal sequence as obtained from the microsome-associated form. The amino-terminal sequence of p100 exhibits significant similarity to the deduced amino-terminal amino acid sequences of both alpha- and gamma-adaptins. Using the amino-terminal sequence from p100, we have raised antipeptide polyclonal antisera. The antisera reacted specifically with the purified 100-kDa protein on immunoblots. With the purified protein and specific antisera now available, it will be possible to explore the physiological role of p100.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science				Traub, Linton/0000-0002-1303-0298				AHLE S, 1989, J BIOL CHEM, V264, P20089; BECK KA, 1991, J BIOL CHEM, V266, P4442; BECK KA, 1991, J BIOL CHEM, V266, P4437; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; CHEUNG AH, 1989, MOL PHARMACOL, V35, P132; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNCAN R, 1984, ANAL BIOCHEM, V138, P144, DOI 10.1016/0003-2697(84)90783-8; GERSHONI JM, 1988, METHOD BIOCHEM ANAL, V33, P1; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HAWKES R, 1982, ANAL BIOCHEM, V119, P142, DOI 10.1016/0003-2697(82)90677-7; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KEEN JH, 1990, ADV CELL BIOL, V3, P153; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; RALL T, 1987, FEBS LETT, V224, P365, DOI 10.1016/0014-5793(87)80486-6; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROBINSON MS, 1989, J CELL BIOL, V108, P883; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SIMONDS WF, 1989, FEBS LETT, V249, P189, DOI 10.1016/0014-5793(89)80622-2; Speicher D.W., 1989, TECHNIQUES PROTEIN C, P24; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; TRAUB LM, 1990, BIOCHEM J, V272, P453, DOI 10.1042/bj2720453; TRAUB LM, 1991, IN PRESS BIOCH J; UDRISAR D, 1990, P NATL ACAD SCI USA, V87, P6321, DOI 10.1073/pnas.87.16.6321; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VANDOP C, 1984, J BIOL CHEM, V259, P23; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	47	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 25	1991	266	36					24642	24649						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GW845	1722209				2022-12-25	WOS:A1991GW84500063
J	QUIGLEY, JP; IKAI, A; ARAKAWA, H; OSADA, T; ARMSTRONG, PB				QUIGLEY, JP; IKAI, A; ARAKAWA, H; OSADA, T; ARMSTRONG, PB			REACTION OF PROTEINASES WITH ALPHA-2-MACROGLOBULIN FROM THE AMERICAN HORSESHOE-CRAB, LIMULUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN ALPHA-MACROGLOBULINS; LYSYL AMINO-GROUPS; COMPLEX-FORMATION; CLEAVAGE SITES; CROSS-LINKING; THIOL-ESTER; COVALENT; BINDING; INHIBITION; TRYPSIN	The products generated by the reaction of Limulus alpha-2-macroglobulin with trypsin were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. Unreacted Limulus alpha-2-macroglobulin had a subunit molecular mass of 185 kDa. Trypsin-reacted samples contained two prominent peptides smaller (85 and 100 kDa) and three peptides larger (200, 250, and 300-350 kDa) than the unreacted subunit. Reaction of methylamine-treated Limulus alpha-2-macroglobulin with trypsin resulted in the same two prominent reaction products smaller than 185 kDa, but all of the reaction products larger than 185 kDa were absent. The covalent binding of biotinylated trypsin with Limulus alpha-2-macroglobulin was detected by probing Western blots with horseradish peroxidase-avidin. Surprisingly, the only reaction products that contained trypsin were bands at 100 and 120 kDa. The staining of these bands with horseradish peroxidase-avidin was weak: most of the biotinylated trypsin that remained associated with alpha-2-macroglobulin during gel filtration chromatography was located at the dye front following reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The reaction products larger than 185 kDa did not contain trypsin. Methylamine-reacted Limulus alpha-2-macroglobulin failed to bind any biotinylated trypsin. In contrast to the reaction of trypsin with Limulus alpha-2-macroglobulin, all high molecular mass bands generated by the reaction of human alpha-2-macroglobulin with biotinylated trypsin stained intensely with horseradish peroxidase-avidin. Thus, Limulus alpha-2-macroglobulin forms thiol ester-dependent, high molecular mass products involving isopeptide bonding between trypsin-generated fragments, without the incorporation of trypsin into the complexes. Most of the alpha-2-macroglobulin-associated trypsin is non-covalently trapped rather than covalently cross-linked.	MARINE BIOL LAB,WOODS HOLE,MA 02543; TOKYO INST TECHNOL,BIODYNAM LAB,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN; UNIV CALIF DAVIS,DEPT ZOOL,CELL BIOL LAB,DAVIS,CA 95616	Marine Biological Laboratory - Woods Hole; Tokyo Institute of Technology; University of California System; University of California Davis	QUIGLEY, JP (corresponding author), SUNY STONY BROOK,HLTH SCI CTR,DEPT PATHOL,STONY BROOK,NY 11794, USA.				NIGMS NIH HHS [GM 38185] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKAWA H, 1989, J BIOL CHEM, V264, P2350; ARMSTRONG PB, 1990, BIOL BULL, V178, P137, DOI 10.2307/1541972; ARMSTRONG PB, 1985, J EXP ZOOL, V236, P1, DOI 10.1002/jez.1402360102; ARMSTRONG PB, 1991, J BIOL CHEM, V266, P2526; ARMSTRONG PB, 1987, BIOCHEM J, V248, P703, DOI 10.1042/bj2480703; ARMSTRONG PB, 1991, IN PRESS IMMUNOLOGY; ARMSTRONG PB, 1985, BLOOD CELLS MARINE I, P253; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BJORK I, 1984, BIOCHEM J, V217, P303; BJORK I, 1985, BIOCHEMISTRY-US, V24, P2653; BJORK I, 1982, BIOCHEM J, V207, P347; BOYDE TRC, 1968, CLIN CHIM ACTA, V21, P9, DOI 10.1016/0009-8981(68)90003-X; CHRISTENSEN U, 1989, BIOCHEMISTRY-US, V28, P9324, DOI 10.1021/bi00450a012; CREWS BC, 1987, BIOCHEMISTRY-US, V26, P5963, DOI 10.1021/bi00393a003; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; ENGHILD JJ, 1990, BIOCHEMISTRY-US, V29, P10070, DOI 10.1021/bi00495a009; FEINMAN RD, 1983, ANN NY ACAD SCI, V421, P178, DOI 10.1111/j.1749-6632.1983.tb18108.x; FEINMAN RD, 1985, BIOCHEM J, V231, P417, DOI 10.1042/bj2310417; FEINMAN RD, 1983, CHEM BIOL ALPHA2 MAC; FELDMAN SR, 1985, P NATL ACAD SCI USA, V82, P5700, DOI 10.1073/pnas.82.17.5700; GANROT PO, 1966, CLIN CHIM ACTA, V14, P493, DOI 10.1016/0009-8981(66)90037-4; GONIAS SL, 1983, BIOCHEMISTRY-US, V22, P536, DOI 10.1021/bi00272a003; GONIAS SL, 1983, BIOCHEMISTRY-US, V22, P4933, DOI 10.1021/bi00290a009; GONIAS SL, 1983, J BIOL CHEM, V258, P14628; HALL PK, 1978, BIOCHEM J, V173, P27, DOI 10.1042/bj1730027; HARPEL PC, 1983, ANN NY ACAD SCI, V421, P1, DOI 10.1111/j.1749-6632.1983.tb18088.x; HOWARD JB, 1981, P NATL ACAD SCI-BIOL, V78, P2235, DOI 10.1073/pnas.78.4.2235; HOWELL JB, 1983, ARCH BIOCHEM BIOPHYS, V221, P261, DOI 10.1016/0003-9861(83)90143-1; HUANG JS, 1989, AM J RESP CELL MOL, V1, P169, DOI 10.1165/ajrcmb/1.3.169; IKAI A, 1990, J BIOL CHEM, V265, P8280; JAMES K, 1990, IMMUNOL TODAY, V11, P163, DOI 10.1016/0167-5699(90)90067-J; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RP, 1989, CURR TOP MICROBIOL I, V153, P73; LONBERGHOLM K, 1987, J BIOL CHEM, V262, P4844; MCPHERSON TA, 1970, IMMUNOLOGY, V19, P929; MEIJERS JCM, 1987, BIOCHEMISTRY-US, V26, P5932, DOI 10.1021/bi00392a053; NAGASE H, 1983, J BIOL CHEM, V258, P7490; NELLES LP, 1980, BIOCHIM BIOPHYS ACTA, V623, P677; OSADA T, 1986, J ULTRA MOL STRUCT R, V96, P136, DOI 10.1016/0889-1605(86)90014-5; PETERSON CGB, 1987, BIOCHEM J, V245, P781, DOI 10.1042/bj2450781; PIZZO SV, 1986, BIOL CHEM H-S, V367, P1177, DOI 10.1515/bchm3.1986.367.2.1177; POCHON F, 1987, FEBS LETT, V217, P101, DOI 10.1016/0014-5793(87)81251-6; POCHON F, 1981, J BIOL CHEM, V256, P547; QUIGLEY JP, 1983, J BIOL CHEM, V258, P7903; QUIGLEY JP, 1985, J BIOL CHEM, V260, P2715; SALVESEN GS, 1981, BIOCHEM J, V195, P453, DOI 10.1042/bj1950453; SALVESEN GS, 1980, BIOCHEM J, V187, P695, DOI 10.1042/bj1870695; SANTAMBROGIO P, 1989, BRIT J HAEMATOL, V71, P281, DOI 10.1111/j.1365-2141.1989.tb04268.x; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P127, DOI 10.1016/0014-5793(81)81097-6; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1990, J BIOL CHEM, V265, P17727; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P393; SOTTRUPJENSEN L, 1990, COMP BIOCHEM PHYS B, V96, P621, DOI 10.1016/0305-0491(90)90066-3; SOTTRUPJENSEN L, 1981, FEBS LETT, V128, P123, DOI 10.1016/0014-5793(81)81096-4; STOLLAR BD, 1978, ARCH BIOCHEM BIOPHYS, V190, P398, DOI 10.1016/0003-9861(78)90292-8; TACK BF, 1983, SPRINGER SEMIN IMMUN, V6, P259, DOI 10.1007/BF02116276; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERGRAAF F, 1984, BIOCHEMISTRY-US, V23, P1760, DOI 10.1021/bi00303a027; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9023; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; VANLEUVEN F, 1984, MOL CELL BIOCHEM, V58, P121, DOI 10.1007/BF00240611; WALLER EK, 1983, BIOCHEM J, V215, P123, DOI 10.1042/bj2150123; WANG D, 1981, ARCH BIOCHEM BIOPHYS, V211, P500, DOI 10.1016/0003-9861(81)90483-5; WANG D, 1984, BIOCHEMISTRY-US, V23, P2807, DOI 10.1021/bi00307a042; WU K, 1981, J BIOL CHEM, V256, P409	68	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 15	1991	266	29					19426	19431						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GK667	1717464				2022-12-25	WOS:A1991GK66700048
J	BATES, RC; RANKIN, LM; LUCAS, CM; SCOTT, JL; KRISSANSEN, GW; BURNS, GF				BATES, RC; RANKIN, LM; LUCAS, CM; SCOTT, JL; KRISSANSEN, GW; BURNS, GF			INDIVIDUAL EMBRYONIC FIBROBLASTS EXPRESS MULTIPLE BETA-CHAINS IN ASSOCIATION WITH THE ALPHA-V INTEGRIN SUBUNIT - LOSS OF BETA-3 EXPRESSION WITH CELL CONFLUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-BETA; VITRONECTIN RECEPTOR; ADHESION RECEPTORS; VONWILLEBRAND-FACTOR; FIBRONECTIN; ATTACHMENT; ANTIGEN; FAMILY; IDENTIFICATION; SYNTHESIZE	The alpha-chain of the vitronectin receptor, alpha-v, has been found in association with the integrin subunits beta-1, beta-3, or beta-5 on different cell types. We show here that cultured embryonic fibroblasts simultaneously display alpha-v-beta-3, alpha-v-beta-1, and alpha-v in association with two other beta-subunits, one of which is probably beta-5. Polymerase chain reaction analysis of single cells isolated by micromanipulation identified mRNA for alpha-v, beta-1, beta-3, and beta-5 in six of eight clones. Immunoprecipitation of iodinated cell surface proteins with a monoclonal antibody to alpha-v indicated that the relative proportions of the different beta-chains in association with alpha-v varied, particularly between two different cell lines. The cytokines platelet-derived growth factor, transforming growth factor-beta-1, and tumor necrosis factor-alpha did not appear to alter this ratio although tumor necrosis factor-alpha increased the surface expression of the alpha-v-associated integrins; but overnight culture in basic fibroblast growth factor caused a lower expression of alpha-v-beta-1 and alpha-v-beta-5 with no reduction in alpha-v-beta-3 expression. When the cell cultures were grown to complete confluence, surface expression of beta-3 was abolished, and the expression of an unknown beta-chain (beta-u) became more prominent. This effect was not overcome by culturing confluent cells with basic fibroblast growth factor. Affinity column chromatography showed that alpha-v-beta-5 bound to vitronectin but alpha-v-beta-1 did not, whereas alpha-v-beta-1 but not alpha-v-beta-5 bound to fibronectin. These results suggest that, on individual cells, the beta-subunits found in association with alpha-v may vary according to the proliferative capacity of the cell and that the promiscuous beta-3 subunit is progressively replaced by beta-subunits of individual ligand specificity.	UNIV NEWCASTLE,FAC MED,CANC RES UNIT,NEWCASTLE,NSW 2308,AUSTRALIA; UNIV AUCKLAND,SCH MED,DEPT MOLEC MED,AUCKLAND,NEW ZEALAND	University of Newcastle; University of Auckland								BODARY SC, 1990, J BIOL CHEM, V265, P5938; BOURDON MA, 1989, J CELL BIOL, V108, P1149, DOI 10.1083/jcb.108.3.1149; BURNS GF, 1982, CELL IMMUNOL, V71, P12, DOI 10.1016/0008-8749(82)90492-0; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DEDHAR S, 1990, J CELL BIOL, V110, P2185, DOI 10.1083/jcb.110.6.2185; DUNN SM, 1988, TRANSPLANT P, V21, P31; FINGERMAN E, 1988, EXP CELL RES, V177, P132, DOI 10.1016/0014-4827(88)90031-6; FREED E, 1989, EMBO J, V8, P2955, DOI 10.1002/j.1460-2075.1989.tb08445.x; GANI JS, 1990, LIFE SCI, V2, P32; HEINO J, 1989, J BIOL CHEM, V264, P380; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P615; KRISSANSEN GW, 1990, J BIOL CHEM, V265, P823; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; KRISSANSEN GW, 1990, INT IMMUNOL, V2, P267, DOI 10.1093/intimm/2.3.267; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MCLEAN JW, 1990, J BIOL CHEM, V265, P17126; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RAMASWAMY H, 1990, EMBO J, V9, P1561, DOI 10.1002/j.1460-2075.1990.tb08275.x; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; RUAN CG, 1987, BLOOD, V69, P570; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STAMATOGLOU SC, 1990, J CELL BIOL, V111, P2117, DOI 10.1083/jcb.111.5.2117; SUZUKI S, 1990, P NATL ACAD SCI USA, V87, P5354, DOI 10.1073/pnas.87.14.5354; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; VANKUPPEVELT THMSM, 1989, P NATL ACAD SCI USA, V86, P5415; VANNOESEL C, 1988, NATURE, V333, P850, DOI 10.1038/333850a0; VOGEL BE, 1990, J BIOL CHEM, V265, P5934; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P218	34	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18593	18599						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1717451				2022-12-25	WOS:A1991GJ47200032
J	SIHAG, RK; NIXON, RA				SIHAG, RK; NIXON, RA			IDENTIFICATION OF SER-55 AS A MAJOR PROTEIN KINASE-A PHOSPHORYLATION SITE ON THE 70-KDA SUBUNIT OF NEUROFILAMENTS - EARLY TURNOVER DURING AXONAL-TRANSPORT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL GANGLION-CELLS; TERMINAL HEAD DOMAIN; INTERMEDIATE FILAMENTS; MITOTIC CELLS; MEMBRANE INTERACTIONS; DESMIN DERIVATIVES; TRIPLET PROTEINS; PLASMA-MEMBRANE; NF-L; VIMENTIN	The 70-kDa neurofilament protein subunit (NF-L) is phosphorylated in vivo on at least three sites (L1 to L3) (Sihag, R. K., and Nixon, R. A. (1989) J. Biol. Chem. 264, 457-464). The turnover of phosphate groups on NF-L during axonal transport was determined after the neurofilaments in retinal ganglion cells were phosphorylated in vivo by injecting mice intravitreally with [P-32]orthophosphate. Two-dimensional phosphopeptide maps of NF-L from optic axons of mice 10 to 90 h after injection showed that radiolabel decreased faster from peptides L2 and L3 than from L1 as neurofilaments were transported. To identify phosphorylation sites on peptide L2, axonal cytoskeletons were phosphorylated by protein kinase A in the presence of heparin. After the isolated NF-L subunits were digested with alpha-chymotrypsin, P-32-peptides were separated by high performance liquid chromatography on a reverse-phase C8 column. Two-dimensional peptide mapping showed that the alpha-chymotrypsin P-32-peptide accepting most of the phosphates from protein kinase A migrated identically with the in vivo-labeled phosphopeptide L2. The sequence of this peptide (S-V-R-R-S-Y) analyzed by automated Edman degradation corresponded to amino acid residues 51-56 of the NF-L sequence. A synthetic 13-mer (S-L-S-V-R-R-S-Y-S-S-S-S-G) corresponding to amino acid residues 49-61 of NF-L was also phosphorylated by protein kinase A. alpha-Chymotryptic digestion of the 13-mer generated a peptide which contained most of the phosphates and co-migrated with the phosphopeptide L2 on two-dimensional phosphopeptide maps. Edman degradation of the phosphorylated 13-mer identified serine residue 55 which is located within a consensus phosphorylation sequence for protein kinase A as the major site of phosphorylation. Since protein kinase A-mediated phosphorylation influences intermediate filament assembly/disassembly in vitro, we propose that the phosphopeptide L2 region is a neurofilament-assembly domain and that the cycle of phosphorylation and dephosphorylation of Ser-55 on NF-L, which occurs relatively early after subunit synthesis in vivo, regulaaes a step in neurofilament assembly or initial interactions during axonal transport.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	SIHAG, RK (corresponding author), MCLEAN HOSP,MAILMAN RES CTR,MOLEC NEUROSCI LABS,115 MILL ST,BELMONT,MA 02178, USA.				NATIONAL INSTITUTE ON AGING [R37AG005604, R01AG005604, P01AG002126] Funding Source: NIH RePORTER; NIA NIH HHS [AG05604, AG02126] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGELIDES KJ, 1989, J CELL BIOL, V108, P1495, DOI 10.1083/jcb.108.4.1495; BLACK MM, 1988, J NEUROSCI, V8, P3296; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CELIS JE, 1983, J CELL BIOL, V97, P1429, DOI 10.1083/jcb.97.5.1429; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; EVANS RM, 1984, J BIOL CHEM, V259, P5372; FRANKE WW, 1987, CELL, V48, P38; FRAPPIER T, 1987, EUR J BIOCHEM, V109, P651; GEISLER N, 1985, FEBS LETT, V182, P475, DOI 10.1016/0014-5793(85)80357-4; Geisler N., 1986, P41; GEISLER N, 1988, EMBO J, V7, P15, DOI 10.1002/j.1460-2075.1988.tb02778.x; GEISLER N, 1987, FEBS LETT, V221, P403, DOI 10.1016/0014-5793(87)80964-X; GEORGATOS SD, 1987, P NATL ACAD SCI USA, V84, P6780, DOI 10.1073/pnas.84.19.6780; GEORGATOS SD, 1985, J CELL BIOL, V100, P1962, DOI 10.1083/jcb.100.6.1962; GILL SR, 1990, J CELL BIOL, V111, P2005, DOI 10.1083/jcb.111.5.2005; GONDA Y, 1990, BIOCHEM BIOPH RES CO, V167, P1316, DOI 10.1016/0006-291X(90)90667-C; HISANAGA S, 1990, CELL REGUL, V1, P237, DOI 10.1091/mbc.1.2.237; INAGAKI M, 1989, J BIOL CHEM, V264, P18119; INAGAKI M, 1988, J BIOL CHEM, V263, P5970; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETERRIER JF, 1982, J CELL BIOL, V95, P982, DOI 10.1083/jcb.95.3.982; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; NAKAMURA Y, 1990, BIOCHEM BIOPH RES CO, V169, P744, DOI 10.1016/0006-291X(90)90394-3; NIXON RA, 1980, BRAIN RES, V200, P69, DOI 10.1016/0006-8993(80)91095-1; NIXON RA, 1986, J BIOL CHEM, V261, P6298; NIXON RA, 1989, MOL BRAIN RES, V5, P93, DOI 10.1016/0169-328X(89)90001-6; NIXON RA, 1991, IN PRESS TRENDS NEUR; PAPPIN DJC, 1990, CURRENT RES PROTEIN, P191; SHARP GA, 1982, EXP CELL RES, V137, P403, DOI 10.1016/0014-4827(82)90042-8; SHAW G, 1990, J NEUROSCI RES, V25, P561, DOI 10.1002/jnr.490250414; SHAW G, 1982, NATURE, V298, P277, DOI 10.1038/298277a0; SIHAG R K, 1987, Journal of Cell Biology, V105, p207A; SIHAG R K, 1990, Journal of Cell Biology, V111, p433A; SIHAG RK, 1988, FEBS LETT, V233, P181, DOI 10.1016/0014-5793(88)81380-2; SIHAG RK, 1989, J BIOL CHEM, V264, P457; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; SIHAG RK, 1989, J CELL BIOL, V107, pA463; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; TOLLE HG, 1987, EUR J CELL BIOL, V43, P35; TRAUB P, 1984, J CELL SCI, V65, P1; WILLARD M, 1983, CELL, V35, P551, DOI 10.1016/0092-8674(83)90189-7	46	115	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 5	1991	266	28					18861	18867						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GJ472	1717455				2022-12-25	WOS:A1991GJ47200071
J	WANG, CC; SPREMULLI, LL				WANG, CC; SPREMULLI, LL			CHLOROPLAST TRANSLATIONAL INITIATION FACTOR-III - PURIFICATION AND CHARACTERIZATION OF MULTIPLE FORMS FROM EUGLENA-GRACILIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; FACTOR-III; NUCLEAR LOCATION; FACTOR IF-3; START-SITE; BINDING; GENE; RNA; IDENTIFICATION	The chloroplast translational initiation factor 3 (IF-3chl) has been purified by a combination of gravity and high pressure liquid chromatographic steps. IF-3chl activity has been resolved into three forms designated alpha, beta, and gamma. Analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis indicates that the alpha-form corresponds to a single polypeptide with a molecular mass of approximately 34 kDa. The beta and gamma-forms have been purified to near homogeneity, and both forms appear to function as monomers with molecular masses of about 39-42 kDa. All three forms are heat stable. All the forms of IF-3chl detected enhance the poly (A,U,G)-dependent binding of the initiator tRNA to chloroplast 30 S ribosomal subunits in the presence of Escherichia coli IF-1 and IF-2. the chloroplast factor, unlike the corresponding bacterial factor, does not have a strong RNA binding activity.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024963] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24963] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; BOYNTON JE, 1980, RIBOSOMES STRUCTURE, P903; BRAUER D, 1977, FEBS LETT, V79, P269, DOI 10.1016/0014-5793(77)80801-6; BREITENBERGER CA, 1979, ARCH BIOCHEM BIOPHYS, V194, P265, DOI 10.1016/0003-9861(79)90617-9; CIGAN AM, 1988, SCIENCE, V242, P93, DOI 10.1126/science.3051379; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; EBERLY SL, 1986, ARCH BIOCHEM BIOPHYS, V245, P338, DOI 10.1016/0003-9861(86)90224-9; EHRESMANN C, 1986, NUCLEIC ACIDS RES, V14, P4803, DOI 10.1093/nar/14.12.4803; FAKUNDING JL, 1973, J BIOL CHEM, V248, P4206; FOX L, 1981, J BIOL CHEM, V256, P7796; FOX L, 1980, J BIOL CHEM, V255, P6018; GOLD JC, 1985, J BIOL CHEM, V260, P4897; GRAVES MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P192, DOI 10.1016/0003-9861(83)90516-7; Gualerzi C, 1981, STRUCTURAL ASPECTS R, P805; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; HERSHEY JWB, 1977, ARCH BIOCHEM BIOPHYS, V182, P626, DOI 10.1016/0003-9861(77)90543-4; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; KAY AC, 1976, BIOCHIMIE, V58, P183, DOI 10.1016/S0300-9084(76)80369-0; KOZAK M, 1983, MICROBIOL REV, V47, P1; KRAUS BL, 1986, J BIOL CHEM, V261, P4781; KRAUS BL, 1988, PLANT PHYSIOL, V88, P993, DOI 10.1104/pp.88.4.993; KRAUS BL, 1987, THESIS U N CAROLINA, P26; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFFLER S, 1974, J BIOL CHEM, V249, P1458; MA L, 1990, J BIOL CHEM, V265, P13560; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; SCHLEICH T, 1980, BIOCHEMISTRY-US, V19, P4486, DOI 10.1021/bi00560a016; SCHMIDT BF, 1985, ARCH BIOCHEM BIOPHYS, V240, P217, DOI 10.1016/0003-9861(85)90026-8; SCHMIDT BF, 1985, ARCH BIOCHEM BIOPHYS, V240, P207, DOI 10.1016/0003-9861(85)90025-6; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SPREMULLI LL, 1982, ARCH BIOCHEM BIOPHYS, V214, P734, DOI 10.1016/0003-9861(82)90080-7; WANG CC, 1989, NUCLEIC ACIDS RES, V17, P9735, DOI 10.1093/nar/17.23.9735	33	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17079	17083						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1716626				2022-12-25	WOS:A1991GF44500020
